<SEC-DOCUMENT>0000885590-20-000060.txt : 20201103
<SEC-HEADER>0000885590-20-000060.hdr.sgml : 20201103
<ACCEPTANCE-DATETIME>20201103170838
ACCESSION NUMBER:		0000885590-20-000060
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201103
DATE AS OF CHANGE:		20201103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bausch Health Companies Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14956
		FILM NUMBER:		201284331

	BUSINESS ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8
		BUSINESS PHONE:		514-744-6792

	MAIL ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Valeant Pharmaceuticals International, Inc.
		DATE OF NAME CHANGE:	20100928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bhc-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:52525664-5cd4-4495-a34d-b14e0c25a97b,g:cfe4b6e8-8eeb-4675-b5cb-546679211f6a,d:e8b2716e216c4586bfedb14835ff92cc--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:bhc="http://www.bauschhealth.com/20200930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhc-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y18zLTEtMS0xLTA_71e2265b-e0e3-43ad-8ac2-db84ee316a98">0000885590</ix:nonNumeric><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y180LTEtMS0xLTA_39d28950-a424-41f0-9d15-6c3512834380">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y181LTEtMS0xLTA_bb81f688-5059-4577-b2ae-f0be5031ef2d">2020</ix:nonNumeric><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y182LTEtMS0xLTA_6eb15814-f4c7-49d2-ab29-147025273cd7">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y183LTEtMS0xLTA_25041103-031f-4868-8e22-05b0cdd15fc3">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjQtMC0xLTEtMA_f74c8ce8-3b2b-4446-b674-801bf69a03f8">us-gaap:AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ0Nw_fc60b351-a915-4b1e-a9cf-8bbc63693281">us-gaap:AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i6d1265def2fe4e2daba508971d3b269a_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183MC9mcmFnOmU4OTA5NGU3Yjg4ZjRkMzQ4MGRmYmVlZmU3ZmJmMjllL3RhYmxlOjcwOGZlZGJkMmI2OTQ0NWNhNjliNjc1NDliMGU3YzNiL3RhYmxlcmFuZ2U6NzA4ZmVkYmQyYjY5NDQ1Y2E2OWI2NzU0OWIwZTdjM2JfMy0xLTEtMS0w_4267d429-dfe6-4215-bc35-e5db56b625b7">0.5</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhc-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i58165bdb49574b6aa695effb47a3b6fd_I20201029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9da4fed668814346810326af9b4d6598_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644a5c6073d342b280ceb7503b40fffc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bf79c1fea774ba78e8ae4e67f3aae19_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie19134db53624c3dbe16d17f7a2c887b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397ad4497f454ed4b5c8ed511d657a01_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c3faa5394c4efa803b0d07a332d877_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a193aab3454c7c8df01544d3d5234a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e26a204cce2408c8c2b0e4eeba1bd23_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f203fd5d2ce4c9287eab1215ce4afc0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id4b4cd54f5e342ecaa9c703653b2eca2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b183b5868ef437cbfabaff430ddb177_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb91d49706df4bceb73a8b27d4b2cadf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b51462eae944b27b08ebf45591f45d4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54958c2a43bd4549bdafae413e7d07d5_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d717e4e6074467bd481358cfd95ccf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eba536ebee74aa3ac183442a212ee35_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c66878a6b314d1c8fa41e056f0e38a6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb63cfcaabb846eb9475e1a816a4cfd5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i496cdf76600d4d3b8075d83c64d87524_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec221254f7246e5ac168ac3177d8dc2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992ce3be69be4136b963377397c88687_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d1a74a2f6d479e80e6da708c4c0ea9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i614bd8e75e8b483b836943e11a8cff8c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b09d66e5904f00bdfc6d7dcac58e24_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6469a3085b415b81023abb0f50fd08_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i129921e9b4d049ed8ee7f90c0ac8ebcb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eeabd830b4744f9a609670edfae6e15_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i412d37633553439b9d65c47d77b03846_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0aee1138db3436cad68141f33b4b0eb_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95cdd8bdc8a642d58cfe7370d8001f2a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdda6c0d36a84d3592d9e9418514b1fc_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8fffeeb09e4491b53ff8013f59e0f8_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f1cd9b31f0a4d949e1701489137acd5_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e4bd8ca4ffe403ea5a27d2506365172_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6042397c7cfb490393cbd31597df38f8_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8935c278faab48a1946ca3d3bf7e95a3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898150194c8a49858946a480cb32bcd1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7ff222b1e2f4984a09b68fa09674122_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e79eda62004863b250270a4ac6e2e2_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76b9993210a745b9b43f1f5d49bc5f63_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0679fbabd2d543829b45838f2d32c8b1_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d9736297cfb443ab15742dc0bb31bba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1e4834a7c874cc1827742f22e88673d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45390232e74c44a99af3ec366a6470bf_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550ff3adb4da4b33b8c7b447a74a6ef0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0724670b830242fcb80b31e2447ea7a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee8d639acfc34aeab0f9340f2ef71914_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7807cd27ff842ef98aaf27968fece25_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida4e60de3b154f7395827c52cfbe8a3c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5629ad6776d5426ba54b6e7f66992f37_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d07813deb7b4c7a8b32656f580c213d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba3122b39dd4ec2976cc26a4121ca76_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9388a44254d042458ac025d5a3287ff3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf713c297ba443efac779956ff34bb58_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19280811252b4ca18390037dfc0e63f5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a25f11c2bfe443ea2f446aca2bb3794_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i292d75e4b4024bed95e33679bcebcbe2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia713159518cb42a0b248bc95796377b4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cfbeac78f9548d18d3b871368be2ee1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911bb2eff7e84f7cbb8079fd03ee877f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i326aa3bfc5ee4f3daab3236db5b49940_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85916a34835d4e4fae8f2fdf0dcf8c27_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa4a0c3396e645879bc46329d323ac1b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45afbb8c565241ff8ad164f429208ab3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95828f039eb46b1833d2a857454ec2c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cc32bfd1c3d470cbe8ccec2d8c006a7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28e8de9d52f4b1fb26013832875c24a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e72b076a70a45c584feaa8d3245efbd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90695475f3742f7bc22d422180c86a9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i626ac4778b4748438a325abd1b9e0d84_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>bhc:country</xbrli:measure></xbrli:unit><xbrli:context id="ib9975f10d37a4b9f8ab190b71f48d126_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926e8404d24b4f67a639801625df9821_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60746b3a7f484dad99381c010e94f132_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie229cebfd8564ef69cc3b87b8cca2163_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2ec754640b47e3bc475ba39e2f15b3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4865f0c8877843d2a74d4a34949d8990_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64e6b19fad9e422cbb35846a705746dc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4544171997534f44b301068e2ca91ee1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2a7fc687b364d7b91dd305f5f2c2a47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0d9b898b4dd4de4afef0d16544c30e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9396aa2e3a194b7d88a01028c2d8726f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcb4b2fb825447fba3ebaf7786b43dc7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b21a7ff737c4ce9bcf3101d1496b9e8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05ef307c522049b29a69292368af3288_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id29dfca8902e4b9ca9b215022329120a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563d7e65dd4f4fd3a57a525126385f71_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06448dd5b9c4a5a8833d7aeb0462adc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84a1548bc2b4290bf923185b9809a3c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5fc05eca2d45039ef1c66ddd5fd5bb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if87d338bc71847cbaa721c2e753719df_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b081d921d2542fab60f3ee0f92c0b0c_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbb36916236a49af8aabec568346f93f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ef27070c30b49c1a8b37fca2d781143_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba58938db3e44a8ab10e6ad34541726a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d0d96c365941de8f6f60a38bcb3768_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5216708cf09e4690887e64359dfa0177_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9935a6414aaa4e8e9a55fa03b280060c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d75e8d917347f5beaf038cb1a07543_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4767169b3e8b4b7f9c14e03ce1450592_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d9912296e4423eb2f0c58b058f3d53_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ab9e834c5043c3b3c019c844bf6906_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251db7175d9c4d7498e6bbc45a12b1a7_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43ca4779d36d4db0a4416740976e51df_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e68a168c934bf0b76363ae269a8dd4_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if477ae61fd124d7aac6ae9ddab03f3cf_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f26ca1233014e19a4813bfb570654cc_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22581c99ab8945728931a540b016ef35_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b5ad55c3114bbb9e240bd272663878_I20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea55888e199a4f30aa6537db612f8d50_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id525861ca12645cbbfa8004f60ba9429_D20190306-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-06</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if407461ef48547d3adc0e65ccd56a10c_I20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic76a9522ae624b31ba4b70987bd03b75_D20190306-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-06</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib738e1928e864b82b2984cc187349f0d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5183e10738b0469fafeab79f0c1a49bd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85e9f322f6594cb29a915174676fb28d_D20200921-20200921"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:AssetAcquisitionAxis">bhc:AllegroOphthalmicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-21</xbrli:startDate><xbrli:endDate>2020-09-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i596976330b084b2083ea00b7d8939d1e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bhc:AssetAcquisitionAxis">bhc:AllegroOphthalmicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>bhc:product</xbrli:measure></xbrli:unit><xbrli:context id="ied8b6d4a32f24bef886f050abd26218d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc655cb9eb649d7ab9cd303e9abe56d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a7193c3b1a346ab8b76b004d6fab3b0_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a254f3c123b4ca1bd8ea40230250dde_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9aec834c676489bb24751c37138f0ae_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4358fb6f74742fdb0a980244f01c440_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i630d2760251f4bf096f3e18b26d2c348_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46838e1d7a4a42c3a16733f85f00c538_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5238086c98844119970f8779efb8724d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie79caecdf5264091b27165fac0949180_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5703e3dc34b5445690b680201a721c40_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7ba393fb386441abbb663abd8248a98_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17077f1b6f0d4339a06e1372d84405db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7213b15a279a460cb57c398f93e64324_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id041afe2abf047cc82ee51281520ae03_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia07ebc37151443b8a5b057c7a3cfc60a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i188c7aa31f4846398b02780a637146ca_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b34ec25e124642a594402f4d39fd61_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2392471a1d8d4ca9aff058dfa66f23a9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ca7375bec54df1831d5ec1bb7ce35f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55a91dd3637642f194adf2e407393f51_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i639cfded29ff480cac614d7849308b01_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9b592bb3c924615aeffe086aa4dcc11_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c2fa48fde14cd796cde7eac723cdc9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf5b3db7d10d49d98b2d4ef9c94455ad_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id74922aa0e2c416dab84eaa66f9f5e9b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fbc708e24684f8c9c6e746a68d8705c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ided937c13e414b9f9a600c9abd30c643_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie382e8171db64a9b8b111fb4def54606_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07084c19d2c84f91a4a467900df34873_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4442b581e9fb476e88434975a33029ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676ba929c33c424d9ab4a59672a49177_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2d18c502e914148abcdf8a1c2043e91_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb95a9cbc524e899e63d817b3d8db10_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecc04b34723745959d6941b061c3195b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d60cf3b5dd4469bb5e47f010bbf50d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d3c9eab53e34f758a889ff1b9eef4af_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia73ddeb398ad40a697491174c66a253e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1d2c2593af94b8e894e62f71bab9723_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc55d9233fce40c7825223f6de02ff68_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8497a03630a4de5833e5a80958dbce4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3d471827df64e0fbd5711fd783ab1e9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1512c924cb094c078074e4aa0ffe4a40_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7093ac6fc1334022aa3265c9294c3e7a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13118f68b4df41a393ca9750e6026f86_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8202bf5ca3346e7b18cf85e6d73a250_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e77a2db2998441c921cc42c8c4a50c8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c0052b44d34257a40d70925ddf626c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b552f30645f4c44b3ed3df8ec2d60cf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38cb6a98dc8e41d69bdbcc7404a2eb8e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b5b7c7ce56466d86e248603302e40d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2cf0cf8e00c24e43afee18043d34a006_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i134b8d5216ea4c389549e0da9a4a0aae_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a85fa3c7eea46178ce2c429ccf9dc45_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5402810168f441a989e311c9910ffff_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa9d2b6c03b4436ab40680ad98a02f2a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if76287d4ad9248b093a21f0f369b5af6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d02c0d1ca7046cc873ad6dc780a7de5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb0bbb2a96944d2281f1f89a0ad18937_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90eeaa1d0b8e49aa8bf06da2ebbe726c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c91ac833ae4d6a85617b9307192c5d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8e52c2f7344bd9aaac24f3c709799e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d4e7897d68043b2ac3bba1cb881d410_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57206313b8ad44a69c438d9a2d26e856_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60b628768eab4646b40e4bdaf0246e63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5c8146e6c714086b4e9c25c3c92eed0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60de702a35f848f989e520b9af116415_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7d5353c4a04e4bab13e493b248f929_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1b9f564f7684ff0b786ed6ee60bbc93_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a9c4ec0dda0434ead7d7e333f7c0370_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e98dbf115d34eb7a1ad3c065774fa63_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1219c91340a14f5bad320111435c4733_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f288455ff543adb3dba8d444c258df_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62565a11ef494521b8f3aa6a1473a264_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d948a6f072e4f7b8c8b385b727ebcd0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7532691dd59d4bdeb91fcdaa78acc1ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90067b409ecb46e7a0730f1885ddd46a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5eb558f1acd4fa3890d17ea839f934f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1524d6d70de47e4bf378c17d3a6fb88_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98aa749670ef4cb2bcbe79c1b3f35d01_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f3c80353f4a458e9cf3e5ea8ee4bb86_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88876a23cdf3417d8234422eedf815f1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic084d62da2994e0b8eac7d247b4df526_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf690e4cf1844b909f7af94cd53ff788_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df44c5814334fcb9850108f2c45d7d7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37e1d6d0d86b4260a9dafbceb3ca67b3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ce595b55e84cc1b6036ed5e3783ef7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a82463a67ee4a98aebdb33bda1870ee_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff834d7d5db945ffb10479e4d06e77d1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60250601219a4629a0ff2f0c1dc4062f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbf24fa76f6a402bb9e6156b05d6b5f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c4612f6b4d649079848c866b406b98b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45b5cf1e2a7748d998e39be96bdcffe8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ddb02b4b9240f4a9c623f147564d77_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ac25e181e840fcba249ad8ca572ded_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02972067b44c4ebbb40b0dce231c9b74_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5788f2e64d25455ab4cc8ee55962643c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c98652fcf224ee890fa8c7644b8f148_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3901dd0ca3ae42fba60b944fd1072d67_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7242e85fe1ed4cbc935e2d4c982c7f86_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7796cbaae34c4708bf7e612f118984d4_D20191001-20191001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49d1b68c815f41ad8f89064d1e9fc9da_I20191001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d706dfc2e941c7aceac6173927bd08_I20191001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab0c68ed13d4af2b182ef303b0fe3ad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bfb00e0e8444c42bf506fb600021040_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a13f2e9033b495d9444dd5e982f843f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i497e92548eac4239bd07de80e571194e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie43ad075e98f4dd89ef32cfaff2d61e7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c5435fc465e4452bd424177d30f58bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica7020a01b884f0db71be5081d3f6c00_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2717ecbbb85c46189233254a15f62cb8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98399a1cca534743bbf269f1fb3a7bd3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf8b907b90fb44f7aaa306fa87dcc261_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i316ad5c435e840ef90de3b77001a0859_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf3f33246acf4dbca28fc09e8480089e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d696c5338494267913e8de2e88aa076_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4174779ec8e4c1ca5559035fd373586_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i497f5686edd647cda52dac088120c9ef_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f354431d8b04f3bb3386e747317da6f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87368b9b19074dd5bcef3473b1da76c9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa57f23b3f05469cb9fb7459da7dafe2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae95739a04e4d7e98f843bed573f29d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6a7be2d30645a2aa38edcdea6ea2d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16f95753426e401589837076426992c3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2400aa7f3799471ba8c54285606aa32b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6324b2addc314c438452dc1212149f94_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes450DueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i460140edb8e84ba8a14c588b51b5c03b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes450DueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ec30846b9da42938cce5010c3a35bcd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad32b98d9b574350bd3358b9c05d9ce6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53587a104f1b4a54a2d8ff9c9b6bd142_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id810e7631eea4dff84546da8b682136d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e1cfc4864b4b47939f26aad6d97167_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9962ff5f6e1a4381b06b75c4fe70b3cf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb407c4dee97479aaed7d0a54af5a221_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4435aa298394060ac34998db6d5518a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a207b5e7c8f4f558db12a478c0a5d91_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b37d1f5b4f444890c50f2aabcafde2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id04297c5b7e24c3baf8e9267fbf3225d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d7ec9f615434b68bcfe0abda5733b00_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01dddd98cd27486db73e8eb05dad1238_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i708265c3841641feae11212bbe24bd13_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50ef442c17d9418f8c9a539cb1195ec0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac1907fe5d474e3b8211ac9e30f9be82_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72ff37863f94b4283e88af507ae245a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib31dccdddcfb4000b0c308332ce9f610_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc75983ef66546d6bddf3613cff7f8a4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05453b6c881c458a820a5ac7d0ef7dfe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic43b82b77a204cbfb726e9c81f307b6e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb8e2769d544690be3abd9e969d7f6f_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31ba7f21ed03439b841008aab77cae59_D20180601-20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53bbc40a99854970b78201ecfae1f0b0_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d6f3842a7cc43d0b05b379a3197003c_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i776fc34ad45242c7b664a96b5697cafc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395e8b6493b243d785d218551ad6bc95_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84316338b21741c5b5edb758134470bd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c920ee5bc74d47b13bdda58721672a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cfbb77dee664f9f9fafde904ea66301_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i680f1d5e868b46d9b7570e6c1901ea09_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c27340fb9c6435297c9931c627217e6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89d453429494c1db0f7a576c7b8b619_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica05a2309e6e49efa816d3d0e6070d96_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b43c4704f924701a890d5f962a8caa7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c8b8449c734458ebb0e65b656a6f94b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eaf4c3ede854933aa1ae74e0977f05f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c735278fc854ebcad677441f39d21a3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59f859e9860470f84bad3c7b6b2ddad_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00c24c309eb54c4f804c01312f186da1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idde9534012fd4b75b3ce796e32bc14a2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaafc5c0d6e0c425db5de7640999583ad_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebbc28b6be8d43069e00894b8781bf0e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i084e681a0032449983710ed54eb3ad01_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2af09f0132c5448bab7483f939d8c584_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d8578871b7406b986dbb995cb8af67_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf7cc4e25d7482581fa9522ffd8054c_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i756c2741402c442dbf8d5d9b6d2b0761_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf372dafcdc4256a52a45555ce48252_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2e689cc9bc45aea09d11c8f10fbdc2_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a835f93c3841ec9faa2b983380dc84_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26953919345a48ac8c4fc7b3d9f771e5_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b0bf33724f4f958b89a4381b10a2a7_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7225129913c342a3996cf248b001bd71_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotesAndSeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b169ebb131842c7b5dab7380388dbb9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556544584b844001980693b54a079641_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i422f3d2912d24190bc5966214fdc77d5_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i156e9d3804a244b6a29b74a3e3e52c7b_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b8d1168c7204d658dfb66babf4ccc26_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b42858a98247d79b9bcf64d8e4cae8_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa041cac555c42fba824f78513336e7f_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9330108a6824e37b8217d2a11ded672_D20200116-20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-16</xbrli:startDate><xbrli:endDate>2020-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7907ded04dab4554a0ef907fa261b6f7_D20191216-20191216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7b866fe620404c9be6000f21284d31_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc5ee50d3e974a62ba9571a1f2f84fc0_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35061b0459224831a5dd5ee11d9692a9_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025AndNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4927b0e336fe4ef1b1ffb40e143d6d6f_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1fd33b8ea2042dfb42c2639a2b086ab_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id782e23cbd724954b6368623a4d54175_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f1c7ed275704247962d8203458ab574_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e190fe005974b5ea0fe1ade4aa15972_D20201029-20201029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-29</xbrli:startDate><xbrli:endDate>2020-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b698175e9eb43f389d1012167ab199d_D20201029-20201029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-29</xbrli:startDate><xbrli:endDate>2020-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d1265def2fe4e2daba508971d3b269a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f844286327848db87c6c0846469186e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31f5ab3c2924d3b8c230faa96e03243_I20140531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1234c5878b345c3be0c7887e84c8c4b_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f9e1c5bb0d428cb4b9c7514e892230_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonemployeeDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ebdf9ce1ce47ce953dd272b4116d9f_D20200428-20200428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-28</xbrli:startDate><xbrli:endDate>2020-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bcdb72d89d2453a81215c5d89199ddb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5e06f512ef41418fe077ef11562faa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if47991fff46a44fa8907b87f6e475934_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1f53d1c1fd4dd699f102722ad4ab30_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb6705ae1cc944e9b0c9948e2cc52937_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d204a1b39c34ebf957a3002d5e89825_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i106b3eee455e4af59474ab03ba414fb7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e61c443cd46403f897e0842ba3f568e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie657a420eece4d10b6860b72c457aaab_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife7d401df9e9436187d1434bcf9382ca_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a7f83031f2049529b19147c57eb7ff0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9987cef2d1d4602aa101e2592aabc48_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0418ceeffa1443e9802453c68467828b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdf089cab8914facba6578b77bebb264_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide4414ac166c4b98b170244eb491149f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f757f31530c45ddaa86c86406b50a0c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7333dc2ff308421588477f444d77526f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffd6ad7504a94a299b44307bf31e726b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b3127099e704d8e902e5069aa1e0b13_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472ae620787344d6baf50d96060d90ab_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898bb6c7930c478587dd044061b9d2a2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i741bd4dd7c0149f6b7ffc048b13bc0ee_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic862f703a2734648bf7d042a71301d5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57608adce9004fa8829f1bf5a0f4c66c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d1c6b9142d4a759b71dc4abddbb243_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie07c162ca742405c98233c58abdd8aac_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd54993dd634b0e82dc598e88544ff5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i762b42904b7d4c47b7d9c94632f27fd6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70173b7267ae47adacd4ad3ca61345b6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfc0abb71864f4a8d26e6f9694c6f5f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i563b2181888e4e4ebcc9b80b5cc2f344_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b05369642d5468d80a1713347b981b1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>bhc:case</xbrli:measure></xbrli:unit><xbrli:context id="i5aaed5342aab4e6ab0cdebeb807e227b_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="group"><xbrli:measure>bhc:group</xbrli:measure></xbrli:unit><xbrli:context id="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9761d415100240bda346f87cf5e43c87_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>bhc:action</xbrli:measure></xbrli:unit><xbrli:context id="if22f2ae279114a87892281886f95c6b6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="id21158059b994e63a17e72acde64ae62_D20200804-20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>bhc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i15509ff699a54e30814d181db390b519_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf179bff49a0406f8a4e9ebf6c739aa8_D20160527-20160916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-27</xbrli:startDate><xbrli:endDate>2016-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4b754682f144667ad815ed4518db769_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5b12e58e9e44f8ac5eb07d4df04f45_I20190913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="insurance_policy_period"><xbrli:measure>bhc:insurance_policy_period</xbrli:measure></xbrli:unit><xbrli:context id="ideecfb512d4a4ea28fd5ec735471c964_D20171207-20171207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-07</xbrli:startDate><xbrli:endDate>2017-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic882bdf321904c1a8e0bb5f1007fe242_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d3c5867e5e41f8914f1ce2d2dbfc1e_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e5ff05a4c0418eb2417e345fc2103d_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab043430936d464bb3fafd27f4d9e799_D20191125-20191125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-25</xbrli:startDate><xbrli:endDate>2019-11-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib845c8cc5de943d88c90123be7710ee5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="healthplan"><xbrli:measure>bhc:healthPlan</xbrli:measure></xbrli:unit><xbrli:context id="i5e0b356ae3324301ab3aeacbefbdc8b4_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GenericPricingAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2988c46f79404f97bf0bb7d6d8a49295_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GenericPricingAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia09727ee9461493e9f4e2df94a1f1591_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e734b47f6ad4ad984cd62d97f81a208_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id819c010b7eb43699a500c0115cc5647_D20190128-20190128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce77ea687ee470cace2bc7c9451c86d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SECInvestigationLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cf776ee426f4162b6f648f87bccf843_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InvestigationbytheStateofTexasStatesMedicaidProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i897313242ab641dc9046ace39af16263_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id12cb1b6cda347f9967513c7742fcb23_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80d7bbb8cfa04946a18339b2648304fd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d197803d96f4ffcbd4159fa39ebc261_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7932c3cbe2342548eee1258aa49347e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idafc86557cbe4d14b4c893a64ca76cf9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7fe2b7d367f4dae834989f4487131d7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74f4f9fe18664f5683fa137fff600592_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9630fad3411d4ecdbb4e6cecfef710ee_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fff547485ae43d2968ff0cc7028a326_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353913d5fc9242c18667b11e98757190_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a7b69b1fdb4a07b595627842521754_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96a2f7723254ec5a9f11c4c934d4889_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9c0c48d8f5d49e0a298cb9e6244ac8a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945442a1ab3a4f6fb3811c26a1bab0bc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961d00fe6e394e0097042fdf55f1f75b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8298bc44b8d4fa9a438061d2df01a40_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992e52a4d5fb436e95fb7cfa4b72df3d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c51a36d127d44c9946fde415735fe2c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c46aa3b1cd4b5789f0ca5a453ed7b5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f73a15d2634d3a8c0cca7a35b9ff85_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fcb52bae97844d694512c2bb87bdf17_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85eae108232242838086f4642eb70b08_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84c3fed40d05492ba7b7087a16d03b78_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief0221b682984fa68ee492bfa59a5d75_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12293851b1144e018c4c9985157b6af8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie45707f6b6bd4627847a810f8a92f826_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51df325c7f5b40f7a71d8a18b3dcdb9d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29ce34cdc90749658459a53d39ce83a0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib99f5f97c68d4eafb2e79dfd4f048b96_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i094e6cb87ab042c69be51aa8c8116f04_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5be2becb71a48feaf9761c4c7541a2f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib990d0233da244b0972eca21ff43328a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5062980ba6b7479fb407d0f9cd02aa37_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead2ba6fee0a4fb5b5d850fb95ea9e74_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i314220a4165d4110a6c992a829224748_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id732816e0fe14e848ad4ed7bcec29df9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7720a5e8447f4e1381a984683f37f801_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31809eee74c441e785284208908b1f6e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ac2fb975044cb48922c5f545218179_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64afb07c58eb4178b97dc69e29d5361b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7daf0166ae784d4dacd516d2bd1ccfb3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icef91f1f0ee3457e970eccecfdf34433_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd9b71a39574ae1b4eb9b5b3a159df7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94726a2e6540441193932a85a2d2cc8e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0e74417efd54c5fb043305c8ecdd0b5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7132aba1acc24050873b3abeb89f87fd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b45b1049375405a9881452df1db8885_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1eba4cc97be4881bf868d652d2c87f5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1195d51db05e405381373f1b2ed59c87_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d8c27663374e2881ba2608476c974d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579b7b5f0e22488caa4243c078316934_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7396b7657687421eb28bc8e668bf24f1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd8079e095cb462d8a0027725dbbbf9d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28e935d66b524719955d26d4a15f28b7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda25f4386fa403f9d99a5596c2399a8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fe7793dda5457b86b9bdaa7e2b4a3b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f08c50efaef40919b09f698d45f387f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic915105196dc4a20b1ba1cd55527b01f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b4872d17e0e4ba9800e4027b125c7d6_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25793ee653304f0aa6306ddf6ef5b8de_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59b022ef9b644f1996fe90ee1d0db81_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8648caf684ff4103860761d13f0a4022_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide34d3ab6c14458cbfef1276056d1463_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if93bc6d99c624444a2dd857bc569b178_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a664e5247e946dc82a303af2757e881_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c11c3e047f45a8adce344026ef9adf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868cfdaa81514efeb8f0a0de1e553842_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ed423758174f5d8bebe48cf827f4ad_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c702359f3d476aae3c6070536997d3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4dc2eddb6b41afba1498f1b41eb3af_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6bfdb0ca114a3a8781da2f91c440dd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f1c56b5e7db49989979d7e8ab238911_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a10616d5c494d258d21007f1d4ffe1d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica0936b4182347c0ba81f792a94fb471_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c8c78d6fd8848b4959e510c9f80474c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i663dfd024395400792b600237c407f71_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bfe83d14ce24791a3d5132de0b09aac_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6f9e05033db4fbeadb4c0989ca169b4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57f934afe4f64ccf8f499b8522d5d316_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72cef8d89cc3414c9c3e300be0a5e506_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77e2e17f2af240a08bb7068b4295f5c2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i831dca10038f44b7aba289500a72d53e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic04ff547f0df4e0896495412b8e3aad8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c2d87d9fe043c1ace3fe783ed9d84e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc10941479946efa1ee8c411876db52_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a85a453134467498de7319fa2fd19d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370c9e50384c49a68b916ab0f055e398_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ed869b702741d29a4ebbc97df0ebaf_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49df4ed56dce435c94526ec4c09c1c2f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id17680b424174ddb8afb72789e7a072c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia00b7a96dc7c4c748b6fc009269bf96b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e1bdf848e27419782e283160a6e7641_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8106cbd6b8fd4566bf0bb4e848d2fee0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cdf8fc7e882466b8e513669a8181321_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib806f0a34d7f41cc8b031f6eebdb460e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56662828b4c14cdaa652dc064c47d1a8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c5373b0b2e49bd9e26811bcb5264d6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8358f514f3b4ffda10dd8a1dde466f9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b46b63623c4a798936bae68871eb7f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0816679b5f144948af03427be4bb31d5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i786b9c0d86944563927834ab30da4a64_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72b229547ad046528b0cd05c36cf6248_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie62332dea55b46b8954d57e7ba3dc9f2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0e7f99a52e43e48893dceaa0497adb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62f195e557e04786bec86a970774242c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b960aeb700f41daa129bb69d64f7f80_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b601a52f89407f99c32a3569b6cd90_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68bed0a8366846bca633f75f6ce317bf_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bc889ba7d354ed0a200fac110801a10_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc89498ee0a490bbbf373ea6031e5d4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfb0d8e06b70439093e5b2e57f467fbd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice49f702f91540afa6e04bac724e0f16_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7ad86ee09244ffa6a3158acbdb9e91_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide576ffb75654cfeb9e83e3cf858df8f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6869bdf9417e4259950f8ca43e04a5bb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i169f654e818c4d728fa7590a5cc9e306_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67120e7176db4b1883ff589a8f3f08e7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d41709f1fc4926a6fb326d3fe3ba3d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5602fb5d32ec4b2382470ba9e6490b80_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i468251afcacf4241a879487d7f54a848_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de78745671b495ab8a2e476e94c3894_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79496248f2784fc4aaefcbc556fa23ba_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i100bb87dcfcf4840a8fecbd84eb6c20b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f857d233d64f27abaa8c813fb2a7d9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2eb21ef8614e1da439f89a40feb4a7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21a3c7c318944c1bb5d18c5f1f1e809c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ed07bae93244349ef6061cab4695fb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied4647195db84913b150f83d6b75649e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icecc5176f338476fadf188689a0d0f68_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2afc3f9dccba4cd1820e8c7514dcd21e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b6efa686104cbb8083a6040e07a9e2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4e98e35c504f19af4f7f6f7f90aa99_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd721943ada444938c0d07fde3a6cc26_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifee8da0bfabc4a0c9e458c09a7305cc3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7174942dd2a84a72be602fdbd7377d7b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd7f0a0d16e745bfae02ba539c5e89d8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56b60056c744cfdb5d527a6fe378f4f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1062e5544f2849cd93a2b26f2aa99d36_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67fafda9e64f435ab86b3c470ccd987e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b658a083e346888a69fe6190860bd5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b54d06035d4aad967bc1fe46878888_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e0f0ac6ffaa46f4a17dc33321f25e38_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa6a46c3ea345c5a6bd0ff77c6ab9da_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f07775356c46c28fa094499e05be60_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d30a915ca464a4ebf4fbbb5194076e0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02c96794f6994ca0923eb04b451e6f05_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef026f34c88467cacd0c7e88c3b10c4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i796193ce9afc4d12b6379f979c427b32_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f7be92a538f410c806913c3950dc54f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14c7ebc09514fa29a41b6fe5a2836f8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ebbbb3cbe22449e808dbfaf4d1e174a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf506968c6f545d189921bdd9e912182_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7e8c38f3f154fb49bb310a1dcb6fd83_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1618b6d63a4ef9bccc4d597fd44d7d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95891e4c7e3e457580e75965a1382082_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d66aef5c9743df9092cc861ecc3cf6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie36ad9ac246b4dd0bf391aa521396851_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577cd70d30de44d98818fb4178e165de_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342f9146a8194fbf8362fe186beb1150_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac25f9c6e9594c37a2bc71cd2f9ac2f7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id57036c953dd4ecd9a2259ce4d2a664d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59b54efdf337413095503da19334d74f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d0676dcb034bed9b3ac2d108318bfd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2342292213084417ab197a7ec39e2b32_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c453b5fedc64ccb8be26bdd2dbce3f8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic899b1ac11d94d5f912e083ac00a9925_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02bb5c4f94dc483eac3113fa75769620_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i208fbc90ac92433891048e7b267b2c4e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i263314b31684477a858ce1870a2e2935_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i518266816f6142088c1cd572e0b2e809_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3810d5f192614d9e904b2333976b6d3e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib90335586b5244348e2bb80b34efb485_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed3660f61d54acaa7f0f86779347965_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bc7e5aff7cc4ff89c60f1e3e20b5914_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92707ddce02f4496b1a61598b20a9fa3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ec6e666dbd4225ba98fddbddb193e8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib838e1722e0e4d97a13e8bf28d909626_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbcd2550da3f4409b5137f5be1419151_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id92405cf9f6e4d37a4052058cf207929_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i711aaaa53fba4ac29293979ceec66046_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida52154f667f4dc8a7f3ff3a48088ca3_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefc5f79887314486bdc0ac6a2c93b5f8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5dd515351d49189d4ea130cb854c26_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ede38bb8cc4a18b46ced535622b166_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c7c731a4d7b4bf69d3798a82bd76fdd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59f176c51ad42579aa28217a7a898fd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be82f95757f4dcbbd90b7b2c038ad94_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b5d0d8f5834a3db8a3fcc9475f9cbb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a61a4c91bff4480a041bd2adb0a40b0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55062b8f73664b389c95dbdb8d84eaf8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dde1c7051314b9aa3cda5a9a878059e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173c07ccf3334f6d87290a617f2f61e2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id597c4b3289e490a8b7183707736dfff_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87f54aacbd14ddb9195134667720744_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea718c704e394d629a0bb52b758793a4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a8f2aed6a0439783600917b76ae723_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74b9314e78a044d0b3e782173dfe569e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4caac1fc03db442481ef398991140fe8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8c67a640b5458da2fe72d26d0b549d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie8b2716e216c4586bfedb14835ff92cc_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 45.00pt 36.00pt 45.00pt"><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc3_a55c6123-632c-4d50-836c-ecc0d8ae04f1">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.798%"><tr><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YWE5M2RjNzRjZDBjNDI3ZTllZmQwODBkNTkwMGYwODUvdGFibGVyYW5nZTphYTkzZGM3NGNkMGM0MjdlOWVmZDA4MGQ1OTAwZjA4NV8wLTAtMS0xLTA_63f43dd6-98a2-405e-b734-62757acd1b42">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:right;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Quarterly Period Ended</span></div></td><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YWE5M2RjNzRjZDBjNDI3ZTllZmQwODBkNTkwMGYwODUvdGFibGVyYW5nZTphYTkzZGM3NGNkMGM0MjdlOWVmZDA4MGQ1OTAwZjA4NV8xLTItMS0xLTA_f0e45347-c373-4c61-bb0b-40e6636da09a">September 30, 2020</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YWE5M2RjNzRjZDBjNDI3ZTllZmQwODBkNTkwMGYwODUvdGFibGVyYW5nZTphYTkzZGM3NGNkMGM0MjdlOWVmZDA4MGQ1OTAwZjA4NV8zLTAtMS0xLTA_5edd564e-f6f4-434f-b842-7b2702c21ab4">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the transition period from&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTgw_18e360ba-600d-4d72-9e2e-8208504a9724">001-14956</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTgx_16af0fb4-f0be-4e9c-a5fb-b6a91db2af1c">Bausch Health Companies Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.816%"><tr><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6ZDNhNDk2OTZkYzZiNDZhYmJmYTE4YmNjYWQ3MTY4M2YvdGFibGVyYW5nZTpkM2E0OTY5NmRjNmI0NmFiYmZhMThiY2NhZDcxNjgzZl8wLTAtMS0xLTA_bcd81431-5115-4202-9c55-46654872c7bb">British Columbia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6ZDNhNDk2OTZkYzZiNDZhYmJmYTE4YmNjYWQ3MTY4M2YvdGFibGVyYW5nZTpkM2E0OTY5NmRjNmI0NmFiYmZhMThiY2NhZDcxNjgzZl8wLTQtMS0xLTA_ad880aac-be60-4d9d-b561-a4bb931ddaa4">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6ZDNhNDk2OTZkYzZiNDZhYmJmYTE4YmNjYWQ3MTY4M2YvdGFibGVyYW5nZTpkM2E0OTY5NmRjNmI0NmFiYmZhMThiY2NhZDcxNjgzZl8wLTctMS0xLTA_8673f230-0f77-48eb-a743-edf0ad92d376">98-0448205</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTgy_9dc8e9cb-feb4-4ee8-833d-d1d254334833">2150 St. Elz&#233;ar Blvd. West</ix:nonNumeric>, <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTgz_8fa9e64a-89b5-4c06-bd62-4ac79e2d4867">Laval</ix:nonNumeric>, <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc0_ee65cb7d-f8e0-4f99-bcb0-f0c7410c5551">Qu&#233;bec</ix:nonNumeric>, <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTg2_9272e2c3-f814-47f2-aec7-5ff26cae642e">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTg3_5d41e7a3-d628-47a1-ba8e-477677d03175">H7L 4A8</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc4_cc9cd1e5-3247-472a-af1d-ad1e293b0312">514</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc1_7289f567-0872-4194-818a-46a3c8073bb8">744-6792</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.522%"><tr><td style="width:1.0%"></td><td style="width:29.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6NDM2MTJiYTk2NzFiNDAwNmIxMTU1NTNlYTdlOGNiMTEvdGFibGVyYW5nZTo0MzYxMmJhOTY3MWI0MDA2YjExNTU1M2VhN2U4Y2IxMV8xLTAtMS0xLTA_183b2cf9-cc86-4594-86c7-7f8e380786ac">Common Shares, No Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6NDM2MTJiYTk2NzFiNDAwNmIxMTU1NTNlYTdlOGNiMTEvdGFibGVyYW5nZTo0MzYxMmJhOTY3MWI0MDA2YjExNTU1M2VhN2U4Y2IxMV8xLTEtMS0xLTA_879242a5-8bc6-422c-8159-0c7bd2593417">BHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6NDM2MTJiYTk2NzFiNDAwNmIxMTU1NTNlYTdlOGNiMTEvdGFibGVyYW5nZTo0MzYxMmJhOTY3MWI0MDA2YjExNTU1M2VhN2U4Y2IxMV8xLTItMS0xLTA_c13769bb-3e04-45b0-b381-3b1a38a26b5f">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Toronto Stock Exchange</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or&#160;15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc2_1285478a-5ceb-4211-917a-1d8d0c78dcfd">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTg0_ee82dd3d-8c4d-4aa1-9d6a-49cc692f5510">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YjFjNGZmZDk5ODcwNDBjMDhhZDc3MDU4YTI4MGQzZTMvdGFibGVyYW5nZTpiMWM0ZmZkOTk4NzA0MGMwOGFkNzcwNThhMjgwZDNlM18wLTAtMS0xLTA_009efea8-0a0d-4f09-bb33-6a5aaa5ee664">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YjFjNGZmZDk5ODcwNDBjMDhhZDc3MDU4YTI4MGQzZTMvdGFibGVyYW5nZTpiMWM0ZmZkOTk4NzA0MGMwOGFkNzcwNThhMjgwZDNlM18wLTctMS0xLTA_5cc012d7-7c16-41e6-8427-9b7b82e62c21">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YjFjNGZmZDk5ODcwNDBjMDhhZDc3MDU4YTI4MGQzZTMvdGFibGVyYW5nZTpiMWM0ZmZkOTk4NzA0MGMwOGFkNzcwNThhMjgwZDNlM18wLTktMS0xLTA_87666884-cc0a-4729-b794-711dc085d0fd">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as&#160;defined in Rule&#160;12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc5_ba380940-2f62-4ebf-bbe6-5533f8b407dc">&#9744;</ix:nonNumeric> No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable&#160;date.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares, no par value&#160;&#8212; <ix:nonFraction unitRef="shares" contextRef="i58165bdb49574b6aa695effb47a3b6fd_I20201029" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTMw_5182cd31-eec8-4c8b-a094-2ffed00a5f80">355,151,002</ix:nonFraction> shares outstanding as of October 29,&#160;2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED SEPTEMBER&#160;30, 2020 </span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;I.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_19">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_22">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_22"> 30, 2020 and December&#160;31, 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_25">Consolidated Statements of Operations for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_25">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_25"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_28">Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_31">Consolidated Statements of Shareholders' Equity for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_31">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_31"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_31">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_31"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_34">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_34">nine </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_34">months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_34">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_34"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_34">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_37">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_37">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_106">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_106">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_184">Quantitative and&#160;Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:right;text-indent:-27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_184">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_187">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_187">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part&#160;II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_196">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_196">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_199">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_199">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_202">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt;text-align:right;text-indent:-40.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_202">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_205">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_205">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_208">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_208">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_211">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_211">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_214">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_214">91</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ie8b2716e216c4586bfedb14835ff92cc_217">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ie8b2716e216c4586bfedb14835ff92cc_217">92</a></span></div></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED SEPTEMBER&#160;30, 2020 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introductory Note</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, all references in this Quarterly Report on Form&#160;10-Q for the quarterly period ended September&#160;30, 2020 (this &#8220;Form&#160;10-Q&#8221;) to&#160;the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or similar words or phrases are to Bausch Health Companies&#160;Inc. and its subsidiaries, taken together. In this Form&#160;10-Q, references to&#160;&#8220;$&#8221; are to United&#160;States (&#8220;U.S.&#8221;) dollars and references to &#8220;&#8364;&#8221; are to euros. Unless otherwise indicated, the statistical and financial data contained in this Form&#160;10-Q are presented as of September&#160;30, 2020.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_13"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-Q contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, product development and future performance and results of current and anticipated products; anticipated revenues for our products; anticipated growth in our Ortho Dermatologics business; expected research and development ("R&amp;D") and marketing spend; our expected primary cash and working capital requirements for 2020 and beyond; the Company's plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to meet the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement (the "Restated Credit Agreement"), and senior notes indentures; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income&#160;taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; and the Company&#8217;s plan to separate its eye-health business, including the structure and timing of completing such separation transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the statements in this Form&#160;10-Q that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the rapidly evolving reaction of governments, private sector participants and the public to that pandemic and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed separation of the Company&#8217;s eye-health business, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the separation transaction, the expected timing of completion of the separation transaction and its terms, the Company&#8217;s ability to complete the separation transaction considering the various conditions to the completion of the separation transaction (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other conditions are no longer favorable to completing the transaction, that any shareholder, stock exchange, regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the separation transaction, diversion of management time on the separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from either or both of the Canada Revenue Agency and the Internal Revenue Service will be sought or obtained), potential dissynergy costs resulting from the separation transaction, the impact of the separation transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC ("Philidor")), including pending investigations by the U.S. Attorney's Office for the District of Massachusetts and the&#160;U.S. Attorney's Office for the Southern District of New York, the investigation order issued by the Company from the Autorit&#233; des march&#233;s financiers (the &#8220;AMF&#8221;) (the Company&#8217;s principal securities regulator in Canada), a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the recently settled securities class action, (which is subject to final court approval, and remains subject to the risk and uncertainty that the U.S. District Court for the District of New Jersey may not approve the $1,210 million settlement agreement)) and certain opt-out actions in Canada relating to the recently settled class action in Canada (which is subject to court approval) and purported class actions under the federal RICO statute and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing (including the investigations by the&#160;U.S. Attorney's Offices for the District of Massachusetts&#160;and the Southern District of New York), and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s commitment that the average annual price increase for our branded prescription pharmaceutical products will be set at no greater than single digits, or any future pricing actions we may take following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the "FDA") and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to meet the financial and other covenants contained in our Restated Credit Agreement, senior notes indentures, 2023 Revolving Credit Facility (as defined below) and other current or future debt agreements and the limitations, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2023 Revolving Credit Facility and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or Restated Credit Agreement and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in the filing of any future financial statements or other filings and any default under the terms of our senior notes indentures or Restated Credit Agreement as a result of such delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2020 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in our Restated Credit Agreement and/or senior notes indentures and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, including, but not limited to, our ability to provide the time, resources, expertise and costs required for the commercial launch of new products, the acceptance and demand for new pharmaceutical products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit executives and other key&#160;employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated growth in our Ortho Dermatologics business, including the success of recently launched products (such as Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">), the ability to successfully implement and operate our new cash-pay prescription program for certain of our Ortho Dermatologics branded products, and the ability of such program to achieve the anticipated goals respecting patient access and fulfillment, the approval of pending and pipeline products (and the timing of such approvals), expected geographic expansion, changes in estimates on market potential for dermatology products and continued investment in and success of our sales force;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our Restated Credit Agreement, senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers ("PBMs") and other third-party payors; the impact our distribution, pricing and other practices (including as it relates to our current relationship with Walgreen Co. ("Walgreens")) may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; and the impact of obtaining or maintaining such reimbursement on the price and sales of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company, including the impact to the Company of our former relationship with Philidor and any alleged legal or contractual non-compliance by Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) and any potential changes to other trade agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the final outcome and impact of Brexit negotiations; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the United States and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">any additional divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements, including the impact of our arrangements with Walgreens;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreens, including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptance and success of our new cash-pay prescription program for certain of our Ortho Dermatologics branded products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;Health Care Reform Act&#8221;) and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its business and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vi</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken following the election of the next administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed on February 19, 2020, risks in Item 1A. &#8220;Risk Factors&#8221; of Part II of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, filed on May 7, 2020, risks in Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q and risks detailed from time to time in our other filings with the SEC and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;), as well as our ability to anticipate and manage the risks associated with the&#160;foregoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed on February 19, 2020, under Item&#160;1A. &#8220;Risk Factors&#8221;, in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, filed on May 7, 2020, under Item&#160;1A. &#8220;Risk Factors&#8221; of Part II, under Item&#160;1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q and in the Company&#8217;s other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vii</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_19"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:14pt;margin-top:5pt;padding-left:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMy0xLTEtMS0w_6b74a35f-70e1-40b5-82a4-cb9b359cc3f5">977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMy0zLTEtMS0w_b2d5ea94-7b58-445a-b300-8a34afa2b4e8">3,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNC0xLTEtMS0w_3d3c8053-3a48-4c18-82e1-64a7d1c02ab0">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNC0zLTEtMS0w_a7c14ec5-53b0-4727-ac38-d140be0c7473">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNS0xLTEtMS0w_d2aa71e2-687e-447a-97a3-f4ad746db3e1">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNS0zLTEtMS0w_9c38822c-efe3-459a-a041-6fc46f87acff">1,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNi0xLTEtMS0w_b2cd88d2-3f81-4bc3-863b-963f705d2d85">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNi0zLTEtMS0w_0565fd26-db62-4822-ba87-454bd8ab764e">1,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNy0xLTEtMS0w_245ecd22-d845-4b99-be3f-a3adec4c6309">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNy0zLTEtMS0w_aee5ff7e-8b0d-4216-ab70-1198627701be">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfOC0xLTEtMS0w_4db5c4fe-d67e-4f86-b6c3-0238bbfbcae2">5,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfOC0zLTEtMS0w_a0506b18-4f60-454d-b804-ef62e01ae46c">6,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfOS0xLTEtMS0w_5c7928b7-1e6c-435a-b905-c91e509cc08f">1,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfOS0zLTEtMS0w_2a78c76c-e467-4662-a507-41482de21893">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTAtMS0xLTEtMA_a1ffdbe4-37ec-4854-99ff-274a8a07431a">8,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTAtMy0xLTEtMA_1e6a4635-f2a1-471b-9f1f-d2cc9ef2de80">10,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTEtMS0xLTEtMA_bcbadd75-8103-44ab-a8d8-f3ce9a1d29ef">13,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTEtMy0xLTEtMA_57443242-dce2-4db7-8971-cba309efdb8e">13,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTItMS0xLTEtMA_535af6e3-d7ff-468b-84ca-bd5e131561b0">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTItMy0xLTEtMA_b0280887-8632-49b3-8b52-d64d5c14261a">1,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTMtMS0xLTEtMA_a4a73d0c-a5fc-4747-b219-8a44fdc8db57">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTMtMy0xLTEtMA_a85c16e9-7d06-44c6-b2c8-8a29ccd8db40">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTQtMS0xLTEtMA_8254b89d-c986-42e2-8f4c-645ae2ed3c6f">31,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTQtMy0xLTEtMA_759b6745-671d-449e-91d1-9f2a054e2424">33,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTctMS0xLTEtMA_dc866677-7c0b-471c-bf02-04890a742236">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTctMy0xLTEtMA_d7b95dd7-110e-42a4-89e4-a070b3a1c184">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTgtMS0xLTEtMA_81abf809-c5c9-4cc7-b74f-edb1580c61e7">4,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTgtMy0xLTEtMA_de6eea64-9a3b-41c8-952d-cc99c33df0f0">4,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTktMS0xLTEtMA_1a7bb015-c7b7-45e2-b5bd-58ea6b8f062f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTktMy0xLTEtMA_3f5a7c67-4bf9-4145-8018-6e6b77b2a2ff">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjAtMS0xLTEtMA_2ba996d1-18f6-438d-b228-e420da41b46d">4,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjAtMy0xLTEtMA_27e9e6d1-e904-406d-9ccf-06e816813aa7">6,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjEtMS0xLTEtMA_32dc226b-a6fd-40d2-b7c3-f188690c740f">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjEtMy0xLTEtMA_eb7a87ab-f27e-4836-b42c-b695c0b67e2c">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjItMS0xLTEtMA_e7e46d8b-b7f3-4daa-aaf6-b5cdad2ebd99">24,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjItMy0xLTEtMA_11755010-adcf-436b-8f74-f0872c1db4fc">24,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjMtMS0xLTEtMA_2ab31a26-58d7-414c-8b04-bee683eb0fc0">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjMtMy0xLTEtMA_1f5bbd55-2be8-4c29-86e6-7d7366cb5cb9">705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjQtMS0xLTEtMA_50c2ac96-5a94-40e7-9435-9aa34b125e2d">907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjQtMy0xLTEtMA_56dcfff2-e28a-4a56-9b16-e87b389b4a87">851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjUtMS0xLTEtMA_6c8bc39c-5b99-4e9b-84a0-d1e2c55996d0">30,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjUtMy0xLTEtMA_9756d990-13d9-4350-9791-979cd123ca7b">32,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjYtMS0xLTEtMA_d836edd4-55dc-4262-8e67-84eb845b948f"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjYtMy0xLTEtMA_55156f16-4381-443b-8f24-f6276d04995d"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNmYzUxZTJiOGM5MTQ5OTg4NDUxZjI1ZDRlYjE1ZWY2XzYz_2a32524f-0510-4a7e-918d-fc205a9a971e"><ix:nonFraction unitRef="shares" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNmYzUxZTJiOGM5MTQ5OTg4NDUxZjI1ZDRlYjE1ZWY2XzYz_796a1f39-79db-454d-94bf-f3ee72d75cf4">355,026,950</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNmYzUxZTJiOGM5MTQ5OTg4NDUxZjI1ZDRlYjE1ZWY2Xzcw_859899c9-9e4d-48bd-83fc-51b55be0c542"><ix:nonFraction unitRef="shares" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNmYzUxZTJiOGM5MTQ5OTg4NDUxZjI1ZDRlYjE1ZWY2Xzcw_b28f5530-b63d-4498-8e54-383d66c2b7d5">352,562,636</ix:nonFraction></ix:nonFraction> issued and outstanding at September 30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMS0xLTEtMA_2ef356b9-0940-4b50-b14c-e9179c3de267">10,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMy0xLTEtMA_82bccfba-b7b2-4411-b930-b019c695ea10">10,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjktMS0xLTEtMA_b037c78b-3139-4f9e-9828-4eac267a20bf">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjktMy0xLTEtMA_b6b83749-4475-47b7-9fac-13bf3197ca31">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzAtMS0xLTEtMA_bae629bf-7467-4166-a0f2-7034eddb09d1">7,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzAtMy0xLTEtMA_dccc5e74-2461-4d5f-8bba-9afe8e3dfe76">7,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzEtMS0xLTEtMA_d0bd8c8a-dcdb-4e4b-937a-024481bb0f26">2,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzEtMy0xLTEtMA_9ed8a57a-6797-466f-a357-efe9063820f2">2,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bausch Health Companies Inc. shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzItMS0xLTEtMA_b63dd2ec-df3b-4c52-802a-06da229835f2">587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzItMy0xLTEtMA_22b8d954-97c6-4ff0-a151-678f2291eacf">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzMtMS0xLTEtMA_30a10165-ce4a-4ff9-aba4-08901c992ce9">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzMtMy0xLTEtMA_fce3ef31-de30-4585-aafb-f6c3f1b085fb">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzQtMS0xLTEtMA_a835e8d5-e446-4947-95f0-a12a548170d6">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzQtMy0xLTEtMA_68ba0fb0-fe75-4394-9c9f-4b80be3bc6c5">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzUtMS0xLTEtMA_778e6ac6-20ca-478e-a17f-464a36036690">31,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzUtMy0xLTEtMA_cebc088e-546e-41b2-b8de-fbd156898672">33,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644a5c6073d342b280ceb7503b40fffc_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMy0xLTEtMS0w_d4448441-72ea-4c5c-8f98-12608b29f47b">2,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf79c1fea774ba78e8ae4e67f3aae19_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMy0zLTEtMS0w_44cdf530-cc3c-4fb5-bbfc-4559922d85d7">2,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19134db53624c3dbe16d17f7a2c887b_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMy01LTEtMS0w_5aa9c379-3962-424b-8516-2221c72a6e31">5,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i397ad4497f454ed4b5c8ed511d657a01_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMy03LTEtMS0w_9e819772-aa89-40a8-bd64-3b574ea0d89b">6,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c3faa5394c4efa803b0d07a332d877_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNC0xLTEtMS0w_d8a793d5-2b67-4e70-8991-e6fc14bf388a">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a193aab3454c7c8df01544d3d5234a_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNC0zLTEtMS0w_27596646-f89e-4b2e-bba8-c8c9c3df8930">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e26a204cce2408c8c2b0e4eeba1bd23_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNC01LTEtMS0w_9b09e782-aeaf-416f-994e-e55c32c09cc8">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f203fd5d2ce4c9287eab1215ce4afc0_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNC03LTEtMS0w_37c1d5ac-acd0-4bcc-9c85-6df6204ebcbf">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNS0xLTEtMS0w_344bd34d-520e-4d37-bb34-a82428efd1ca">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNS0zLTEtMS0w_df42d1a3-717e-4f46-9ecb-f884ec3702b9">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNS01LTEtMS0w_de66e8e9-737e-4aab-921a-30289ad0732c">5,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNS03LTEtMS0w_bb58abc5-e454-4e1a-9e7f-39e37f7f488f">6,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(excluding amortization and impairments of intangible assets)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644a5c6073d342b280ceb7503b40fffc_D20200701-20200930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNy0xLTEtMS0w_b215eac7-a6e0-47a7-ad42-5b9bb851bf3a">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf79c1fea774ba78e8ae4e67f3aae19_D20190701-20190930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNy0zLTEtMS0w_cb0e5b36-2810-4c3c-9a2e-dacdca10d7b0">571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19134db53624c3dbe16d17f7a2c887b_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNy01LTEtMS0w_1ab520e0-5791-4f45-a497-fa7f9cc3f308">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i397ad4497f454ed4b5c8ed511d657a01_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNy03LTEtMS0w_7d03ea7b-c249-4072-9d90-412aa2659cba">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c3faa5394c4efa803b0d07a332d877_D20200701-20200930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOC0xLTEtMS0w_254d7015-e279-4d78-bc4e-8ba8cb304b69">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a193aab3454c7c8df01544d3d5234a_D20190701-20190930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOC0zLTEtMS0w_342b07c3-9848-414a-adb0-13866ce80f38">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e26a204cce2408c8c2b0e4eeba1bd23_D20200101-20200930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOC01LTEtMS0w_aaebbe57-d711-4931-8a83-4394d64d2d01">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f203fd5d2ce4c9287eab1215ce4afc0_D20190101-20190930" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOC03LTEtMS0w_4f6860ee-d14c-4e5b-9a36-67d76349a546">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOS0xLTEtMS0w_31796805-6164-4c07-9b37-f5fe9f8bd6ac">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOS0zLTEtMS0w_0bbe461f-4f9b-469c-bbcb-f0a46f01bbb6">648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOS01LTEtMS0w_512e7998-a12c-427a-be2c-b16f86920a88">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOS03LTEtMS0w_7e670db8-757e-4b2a-80fd-3f1a83157fc4">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTAtMS0xLTEtMA_42090460-b958-4962-99de-3427e6ffd1cd">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTAtMy0xLTEtMA_4dbc3fe1-09a1-4877-ad35-966dbb27b35d">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTAtNS0xLTEtMA_05211246-3e96-4d44-bb44-1cc4a7bc3023">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTAtNy0xLTEtMA_3493a12e-f547-4b03-a4f3-91631c7c426c">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTEtMS0xLTEtMA_99f3d960-205c-49a0-9dcc-c7d9b50064c1">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTEtMy0xLTEtMA_55488ef5-d86f-47c9-a495-d19e3f6c5015">475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTEtNS0xLTEtMA_14588fad-bdba-4094-8052-cd6cdac6041e">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTEtNy0xLTEtMA_71f2c5f7-c139-41a8-8229-c726a5c393c1">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTItMS0xLTEtMA_33ef9d94-1755-452b-b42a-542ef78b1526">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTItMy0xLTEtMA_b4ab8a8b-8fad-4915-851a-46ff51e9cf76">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTItNS0xLTEtMA_b3d6b38e-1e86-4f41-90cc-bececbf8df90">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTItNy0xLTEtMA_f28a9d0f-fee0-450e-9f6a-4da1a6285d19">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration and separation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTMtMS0xLTEtMA_9ed79b1f-28ea-4343-80e9-7d6c50510618">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTMtMy0xLTEtMA_8ea96e68-ec6e-4c49-8b13-e202925afea0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTMtNS0xLTEtMA_eb23e368-e03b-4236-a921-54e04c66df57">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTMtNy0xLTEtMA_22c02771-d2c4-455a-a887-0a23087ce6c8">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTQtMS0xLTEtMA_c866e507-d155-42f1-9516-2507a0350d4d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTQtMy0xLTEtMA_87f52c44-301a-43af-981e-c55f6f6d7805">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTQtNS0xLTEtMA_bde9f472-967a-4a5c-9d77-3b0653316f3c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTQtNy0xLTEtMA_fee3d4c7-7a2a-4552-9791-a0f9dc037bb0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTUtMS0xLTEtMA_3015180b-a5dc-496f-8bf0-c8d5ad7c7582">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTUtMy0xLTEtMA_73c69c66-d782-4dc0-a692-3a93941c89c2">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTUtNS0xLTEtMA_68d0d713-aef8-41de-b27a-4a07e0d3aea7">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTUtNy0xLTEtMA_7f616b56-b9e5-4a92-af6a-877c476c8430">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTYtMS0xLTEtMA_2af577ad-d4df-43c1-b97f-af64670336a6">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTYtMy0xLTEtMA_91972cc9-34fc-450b-8d56-d6638e7e7c4c">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTYtNS0xLTEtMA_89d3ac6c-5d5d-46e8-a700-0cc591f63a72">5,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTYtNy0xLTEtMA_0a2f1ca6-0490-4f6b-9ba4-d3089d20a722">5,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTctMS0xLTEtMA_505e68de-33c9-401d-825d-751633514f20">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTctMy0xLTEtMA_44b10611-036d-4b20-bdf0-70c43db67e61">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTctNS0xLTEtMA_72b3b1c5-a796-4ef9-9863-347bff137658">681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTctNy0xLTEtMA_e0127e7d-213e-43e4-b002-659792540b4f">873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTgtMS0xLTEtMA_ac5388ec-05c6-404d-ad52-ff62656a054e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTgtMy0xLTEtMA_8a8422ec-f5e2-494e-bf75-98803329dd5c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTgtNS0xLTEtMA_874d4b9c-cac1-4008-a70b-736449b9f6c0">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTgtNy0xLTEtMA_4140b070-17d7-4599-ab5c-a6f57a732375">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTktMS0xLTEtMA_a124cf1a-aa99-42c7-ab98-f98bff52b509">374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTktMy0xLTEtMA_ae76d258-ebda-4e3d-a9cd-0216c7c91461">406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTktNS0xLTEtMA_32188f8b-3020-468e-ab6c-5e859f3eaa06">1,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTktNy0xLTEtMA_cde5b3ae-e578-47ac-a10e-771963ff6588">1,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjAtMS0xLTEtMA_e4a1e289-d4df-4ee7-8e9b-82d8361fb2a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjAtMy0xLTEtMA_73578cc2-8a88-4cbc-a05d-9d1cb396586c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjAtNS0xLTEtMA_d718b0b3-bc02-49c6-8997-cd263b0d041f">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjAtNy0xLTEtMA_ef69c169-e734-4ebe-817a-2484a19cc0dd">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjEtMS0xLTEtMA_11891486-f4a0-42d7-a6a6-1c82aba39c09">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjEtMy0xLTEtMA_f5dd09b4-fa3a-4670-97ce-16f9cd58003a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjEtNS0xLTEtMA_c09d0919-3ecc-485b-8b0c-62b8bf2c787c">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjEtNy0xLTEtMA_6e71dcad-f1c7-4084-a04e-3c2dfd1d45fb">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before (provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjItMS0xLTEtMA_660b6144-0ff0-4eb1-906f-4ec2ebc758f6">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjItMy0xLTEtMA_623eee78-466b-4ef3-9dc0-1c48dbf8b538">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjItNS0xLTEtMA_d99a3cbd-7869-4bd1-86f1-7f6f92d91b90">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjItNy0xLTEtMA_fe8a374a-f7a9-4467-a9e2-dce0ff92412d">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjMtMS0xLTEtMA_35a1e77f-8c2d-4be2-8490-c0c6cd1deaf6">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjMtMy0xLTEtMA_d77f4f36-de0e-4fc4-996e-cb150f11a5df">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjMtNS0xLTEtMA_87b0b14c-1ab7-47e5-8de3-511a3344bbb0">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjMtNy0xLTEtMA_df99febe-8bab-45a9-a639-a2424b6db713">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjQtMS0xLTEtMA_f2699f8c-a55c-4f50-9d55-93d81f771f14">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjQtMy0xLTEtMA_abbd3006-c542-4498-9279-8d0fc9c7f289">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjQtNS0xLTEtMA_f6cc09f4-5dc9-48e6-a649-c3c1655132b4">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjQtNy0xLTEtMA_0ccd7228-f338-4adb-8e1e-4b14f3cf8de8">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjUtMS0xLTEtMA_bfeb0b48-2040-4701-8664-f2e1963ec55d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjUtMy0xLTEtMA_e5843f9e-3fbd-45e8-84ef-8e07bd55ec72">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjUtNS0xLTEtMA_0f529a32-48d0-4eec-af43-2a3936d448c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjUtNy0xLTEtMA_f97dcdae-4e5a-4003-87ee-b25cf355b0eb">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjYtMS0xLTEtMA_b6086910-f9fa-4855-9a23-c1adcdb28912">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjYtMy0xLTEtMA_92c9e6cd-ed94-4acc-bab9-8921814b7024">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjYtNS0xLTEtMA_bed0149c-cc18-4932-be57-21feda5a0f79">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjYtNy0xLTEtMA_0f6154c1-7584-4e46-aaaa-ff12ae1e32e6">272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (loss) per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjktMS0xLTEtNDA4NQ_f2c4b984-4702-478e-bb77-f2b4767b2de2">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjktMy0xLTEtNDA4NQ_c8b027cc-696c-434d-9373-2511a36c8436">0.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjktNS0xLTEtNDA4NQ_f35c9ab4-c4bd-4b8a-9313-c7cba7a65944">1.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjktNy0xLTEtNDA4NQ_7c6f0f80-69a4-4d07-9f86-4c57f7f8f475">0.77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzAtMS0xLTEtNDEwNA_d49b7381-dfed-463e-a45c-50952168b0f5">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzAtMy0xLTEtNDEwNA_e4c59e56-5fce-4c80-8bf3-c734919ad25e">0.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzAtNS0xLTEtNDEwNw_eba0cb46-7d86-4ce3-9397-9624fb78dd8a">1.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzAtNy0xLTEtNDEwNw_f3bbbb2b-739b-4551-9bfc-724dea74734d">0.77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzEtMS0xLTEtNDAxOA_5db1c38a-5b69-4381-99a3-655b918ba269">355.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzEtMy0xLTEtNDAxOA_10fe2e1b-ea77-409a-9289-0885eee2dc43">352.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzEtNS0xLTEtNDAxOA_56dbbc9c-beb0-4411-a7f8-2b0805614bfe">354.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzEtNy0xLTEtNDAxOA_d4b3ace7-b112-4c57-934c-f395649beebf">351.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzItMS0xLTEtNDAyMQ_f5e1a83d-8317-4826-9301-fa0d9d171666">357.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzItMy0xLTEtNDAyMQ_ff73c632-5e4f-4c41-b9ac-f6de18a04c87">352.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzItNS0xLTEtNDAyMQ_46f268a8-ce17-4e73-93aa-a75b5120b0b2">354.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzItNy0xLTEtNDAyMQ_b2ec8888-54eb-4c9a-a14d-4065fdbff4d7">351.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfMi0xLTEtMS0w_7e2a2b22-048f-43be-9e98-63472710f137">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfMi0zLTEtMS0w_f945f142-b03c-4a7a-a3ae-a18378393b21">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfMi01LTEtMS0w_52e96380-7e72-41b1-918c-425679815aae">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfMi03LTEtMS0w_fd7e627c-7830-4ad8-85e3-467e6cabcbc1">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNC0xLTEtMS0w_649cdcb9-a78f-450b-abd7-787cd677b6d6">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNC0zLTEtMS0w_86ee870d-bfe3-4800-b01a-139c79738fd3">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNC01LTEtMS0w_98dfd2d4-67e2-43f9-8d16-d4a863d4de18">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNC03LTEtMS0w_abab72e5-c971-4302-9365-ba44be77c2dc">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNS0xLTEtMS0w_f5460575-4454-454c-acea-2f0378ac1009">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNS0zLTEtMS0w_fede19f0-eead-4287-9653-55b558b7feeb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNS01LTEtMS0w_2adafff4-e477-41d2-b2a0-370e400ad2b5">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNS03LTEtMS0w_bf8fc491-afb2-4ba0-91ef-da076dd28104">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNi0xLTEtMS0w_b058bf96-8c38-4354-abec-d714bed3d70a">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNi0zLTEtMS0w_64ddc255-4177-4d28-800b-3f9df7037eb8">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNi01LTEtMS0w_944ed985-f289-455e-b25f-ffd79d072940">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNi03LTEtMS0w_fa5484b5-4abc-4dfd-bc40-354f673915f9">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNy0xLTEtMS0w_81ef848f-7779-4d96-b60f-3ec9ed16913e">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNy0zLTEtMS0w_4ace5ba1-0fae-4a86-8e26-5a1369d6e07c">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNy01LTEtMS0w_31b58289-4ab4-425a-a8ce-ebe0b4a1e6c9">527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNy03LTEtMS0w_b366967f-823a-430e-b3a6-a1b6cd580494">287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive (income) loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOC0xLTEtMS0w_ae0e140b-44a9-4071-acc3-396f73bdad6e">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOC0zLTEtMS0w_41618b4e-609b-4408-ad12-0deee8cf64bf">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOC01LTEtMS0w_de547e5f-d29a-4c34-b0af-62864efd089a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOC03LTEtMS0w_631ae174-92da-47e1-947e-83c68deb9b53">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income (loss) attributable to Bausch Health <br/>Companies Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOS0xLTEtMS0w_e050a761-263c-4860-91de-65949ad4922f">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOS0zLTEtMS0w_849bbc11-0cde-47c8-91a2-0bb897987b4e">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOS01LTEtMS0w_d8d590ec-4464-4e64-85d1-27b67cadb1cc">528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOS03LTEtMS0w_bef1b4a5-8e10-4856-a915-0c0eedd4bdd1">291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies&#160;Inc. Shareholders' Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Bausch Health<br/>Companies&#160;Inc.<br/>Shareholders'<br/>Equity</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, July 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4b4cd54f5e342ecaa9c703653b2eca2_I20200630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0yLTEtMS0w_e9cf9fb9-dd73-421e-8cd6-e135d6ffb985">354.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b4cd54f5e342ecaa9c703653b2eca2_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC00LTEtMS0w_65294f79-cb06-4758-8b7d-999364904c07">10,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b183b5868ef437cbfabaff430ddb177_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC02LTEtMS0w_e841349d-8d1c-4fb9-9766-f7ef9edf26d5">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb91d49706df4bceb73a8b27d4b2cadf_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC04LTEtMS0w_581db994-3094-4848-8ba7-b40ac8282f5f">7,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b51462eae944b27b08ebf45591f45d4_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0xMC0xLTEtMA_581f291b-1247-4ac4-b1f7-693cd3e4e3d6">2,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54958c2a43bd4549bdafae413e7d07d5_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0xMi0xLTEtMA_ce27b87e-4a07-4b15-a27b-4190d4ce7665">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d717e4e6074467bd481358cfd95ccf_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0xNC0xLTEtMA_c5596f06-e212-4b3c-8540-4ed741edc2c3">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eba536ebee74aa3ac183442a212ee35_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0xNi0xLTEtMA_38edbdaa-9b40-4df6-94e8-ee40c26433c9">546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c66878a6b314d1c8fa41e056f0e38a6_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS0yLTEtMS0w_66ec4ab4-0a29-47ed-83ce-ef255ad09ae5">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c66878a6b314d1c8fa41e056f0e38a6_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS00LTEtMS0w_ecd6a05d-9c11-449d-9c7a-31343770732f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb63cfcaabb846eb9475e1a816a4cfd5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS02LTEtMS0w_a700bf65-63ab-46c8-8fde-264357081926">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS0xMi0xLTEtMA_64c71f76-80df-4e00-b82a-422246c099ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS0xNi0xLTEtMA_cb31ab09-08e6-48c5-878e-8dc011a0ddd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb63cfcaabb846eb9475e1a816a4cfd5_D20200701-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNi02LTEtMS0w_95a33f19-3689-4e3c-b60e-6911587e1cdb">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNi0xMi0xLTEtMA_c47bab62-bb0e-49bb-8fc4-c892b82795c5">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNi0xNi0xLTEtMA_ce898cd6-61a1-4cc3-a358-98c70c99d5f1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb63cfcaabb846eb9475e1a816a4cfd5_D20200701-20200930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNy02LTEtMS0w_14340d96-303e-4883-b993-c6016310f0a0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNy0xMi0xLTEtMA_a45d6735-2ccb-41a1-9eb5-dcc3bf3869da">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNy0xNi0xLTEtMA_c1736d97-7045-4f8d-979d-90b8875aab02">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i496cdf76600d4d3b8075d83c64d87524_D20200701-20200930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOC0xNC0xLTEtNzU5Mg_c43ff654-65c4-4c9f-8af3-4392a4d0d85e">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOC0xNi0xLTEtNzU5NA_6f1bb8eb-df35-44b3-84c0-9822aeec8e59">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec221254f7246e5ac168ac3177d8dc2_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOS04LTEtMS0w_2784979f-097a-412c-aa98-e5472d8426d9">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOS0xMi0xLTEtMA_75e7b866-680e-474f-9163-3f20f114a062">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i496cdf76600d4d3b8075d83c64d87524_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOS0xNC0xLTEtMA_a278ad4f-4be4-4835-967f-41293fe83f5b">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOS0xNi0xLTEtMA_6fb0c385-b959-4cd9-952c-da9fd0dc8581">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992ce3be69be4136b963377397c88687_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTAtMTAtMS0xLTA_6a9cac0e-be63-42c9-9b05-d5e22564beb8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTAtMTItMS0xLTA_1e57ebbf-184e-440b-b68f-d6c9f86f4481">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i496cdf76600d4d3b8075d83c64d87524_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTAtMTQtMS0xLTc1OTY_205f29b4-9c7b-4f0b-95b2-a6e016cbaecc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTAtMTYtMS0xLTA_a8da3f70-54f2-4240-a4c0-01ec8e8e8b35">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMi0xLTEtMA_898ac5f5-98f2-432e-9a98-7d3519a592f1">355.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtNC0xLTEtMA_0806fb92-3916-4d3e-8c21-9e6c41c2730c">10,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d1a74a2f6d479e80e6da708c4c0ea9_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtNi0xLTEtMA_f5c9c7a1-acca-4d7d-b0f1-a9a1129f7ff4">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i614bd8e75e8b483b836943e11a8cff8c_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtOC0xLTEtMA_9434e083-9240-4793-a12b-3adecfac2a93">7,860</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86b09d66e5904f00bdfc6d7dcac58e24_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMTAtMS0xLTA_2febc636-56ad-4867-8b7c-3e6890497ce1">2,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6469a3085b415b81023abb0f50fd08_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMTItMS0xLTA_889b5615-09a2-4eab-bda2-3286aba825b7">587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129921e9b4d049ed8ee7f90c0ac8ebcb_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMTQtMS0xLTA_01e56249-e697-4307-9ffe-14d52b6a56b0">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMTYtMS0xLTA_476ceb97-2299-4006-989a-04e12070a763">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="45" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, July 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7eeabd830b4744f9a609670edfae6e15_I20190630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMi0xLTEtMA_b520c7e9-0573-4999-84ea-17ce99421003">352.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eeabd830b4744f9a609670edfae6e15_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtNC0xLTEtMA_75dc06da-90d4-4fab-a639-81edf3f0f047">10,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412d37633553439b9d65c47d77b03846_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtNi0xLTEtMA_3ec422d0-135e-47c2-b272-e08784369c76">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0aee1138db3436cad68141f33b4b0eb_I20190630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtOC0xLTEtMA_874320e1-c004-45b0-b21d-adbaf8aab737">5,887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95cdd8bdc8a642d58cfe7370d8001f2a_I20190630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMTAtMS0xLTA_9ae1e310-43c5-4514-a385-e491d7a97400">2,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdda6c0d36a84d3592d9e9418514b1fc_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMTItMS0xLTA_824868b7-e69e-4e7d-afca-94db5a746d61">2,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec8fffeeb09e4491b53ff8013f59e0f8_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMTQtMS0xLTA_52ecb345-4bc9-4f78-8fda-a38790731282">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1cd9b31f0a4d949e1701489137acd5_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMTYtMS0xLTA_6cd4e5ea-413d-4049-9a1e-5439efe24abd">2,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e4bd8ca4ffe403ea5a27d2506365172_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtMi0xLTEtMA_624e9c8a-abe7-49cc-97ac-8096af186810">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e4bd8ca4ffe403ea5a27d2506365172_D20190701-20190930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtNC0xLTEtMA_bc317494-7740-4f3c-8836-698a4909d91d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6042397c7cfb490393cbd31597df38f8_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtNi0xLTEtMA_0124ab85-8bdf-4117-9151-2349391d1d4b">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtMTItMS0xLTA_950580b5-c1da-41df-a446-eb296f2508ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtMTYtMS0xLTA_6ed1fe0e-136a-4a6d-9998-6fd2cfd4adc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6042397c7cfb490393cbd31597df38f8_D20190701-20190930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTYtNi0xLTEtMA_eb57e7ad-e361-46e5-b7a0-e18f860d4005">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTYtMTItMS0xLTA_833c8b51-0106-422f-89ab-d576dcddd7c8">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTYtMTYtMS0xLTA_2ec48db3-8cae-45b6-b5aa-99f7e7752c98">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6042397c7cfb490393cbd31597df38f8_D20190701-20190930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTctNi0xLTEtMA_73377b93-4cf1-4d68-989e-5fb3b4223e2f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTctMTItMS0xLTA_7e19c186-241e-4299-a95f-68b165757428">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTctMTYtMS0xLTA_137a1b88-abac-45ec-8ef9-5f99f49c8423">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8935c278faab48a1946ca3d3bf7e95a3_D20190701-20190930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTQtMS0xLTMxMDc_62891a35-7149-4cb3-af5d-fa181960bf59">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTYtMS0xLTMxMDc_5377104e-5ae4-4652-a92e-ace69cd0e271">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i898150194c8a49858946a480cb32bcd1_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtOC0xLTEtMA_778d8f2a-e110-494a-9e32-7a41ac8ec574">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTItMS0xLTA_244d82a4-926a-46b2-9028-863fcb258678">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8935c278faab48a1946ca3d3bf7e95a3_D20190701-20190930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTQtMS0xLTA_00a639de-45cc-4b36-8a5b-6db60fc37a63">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTYtMS0xLTA_b1e70608-1e8f-4469-89b3-409f6f43ca62">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7ff222b1e2f4984a09b68fa09674122_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTktMTAtMS0xLTA_b5208f67-aa3d-44a6-90f9-7fa8dd18bb7b">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTktMTItMS0xLTA_3394b741-5a04-424d-9115-4ebf521782eb">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8935c278faab48a1946ca3d3bf7e95a3_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTQtMS0xLTMxMTM_f8dcd0d0-4f43-4fa2-af7a-8c2b76695af4">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTktMTYtMS0xLTA_78ffd9d5-8a68-4f36-900d-6d79c1b8a33b">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, September 30, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMi0xLTEtMA_be931eb1-e7c6-4f3f-b06b-c8a160ed9f54">352.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtNC0xLTEtMA_1987399f-a2cd-4f70-b558-3b7b5e96e1a5">10,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e79eda62004863b250270a4ac6e2e2_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtNi0xLTEtMA_216e086b-695a-44d3-b258-ecdd121c7ed1">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76b9993210a745b9b43f1f5d49bc5f63_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtOC0xLTEtMA_63b359fb-f589-4c46-8aba-24b78a898645">5,936</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0679fbabd2d543829b45838f2d32c8b1_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTAtMS0xLTA_812652a0-24f7-4f03-a151-afecf2133842">2,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d9736297cfb443ab15742dc0bb31bba_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTItMS0xLTA_dd125d45-ee27-44ef-9b42-982191ef5eec">2,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e4834a7c874cc1827742f22e88673d_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTQtMS0xLTA_ec6c50cb-b7c2-41c7-a617-09141ab1246e">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTYtMS0xLTA_9b6842f5-2a78-4385-b7d8-768240486edf">2,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="45" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i550ff3adb4da4b33b8c7b447a74a6ef0_I20191231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMi0xLTEtMA_7a0a89b0-c9df-4124-93f2-847212990125">352.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i550ff3adb4da4b33b8c7b447a74a6ef0_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtNC0xLTEtMA_a677f2ec-db9e-4d92-b712-9d583eb73bb8">10,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0724670b830242fcb80b31e2447ea7a9_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtNi0xLTEtMA_b1716fb1-d96b-4fcb-8697-d65a6948961e">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee8d639acfc34aeab0f9340f2ef71914_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtOC0xLTEtMA_5726a07d-ab06-4ad8-9dbe-2c31e118b76b">7,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7807cd27ff842ef98aaf27968fece25_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMTAtMS0xLTA_5bc93ee4-491c-4821-9f7a-e07e2073e200">2,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4e60de3b154f7395827c52cfbe8a3c_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMTItMS0xLTA_2f9ca242-4858-4127-8b41-a99766d4069c">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5629ad6776d5426ba54b6e7f66992f37_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMTQtMS0xLTA_21470e20-7216-4026-948c-535dbf1828e0">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMTYtMS0xLTA_ac2c38be-4521-4590-b95f-2128060506cb">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjQtMC0xLTEtMA_f74c8ce8-3b2b-4446-b674-801bf69a03f8">Effect of application of new accounting standard: financial instruments - credit losses</span></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d07813deb7b4c7a8b32656f580c213d_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjQtOC0xLTEtMA_89861307-7054-4a2b-a051-d0fc298fc367">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibba3122b39dd4ec2976cc26a4121ca76_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjQtMTItMS0xLTA_79b4a4de-6fb6-4885-9c56-d38d3e94a514">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9388a44254d042458ac025d5a3287ff3_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjQtMTYtMS0xLTA_6d8d9530-5efe-42fb-9aa7-366ed248f53b">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf713c297ba443efac779956ff34bb58_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtMi0xLTEtMA_5d36b08c-4a8d-472c-a0ce-eeed4e1cb4aa">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf713c297ba443efac779956ff34bb58_D20200101-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtNC0xLTEtMA_411b8829-8954-4a35-8303-4e9d1cb49751">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19280811252b4ca18390037dfc0e63f5_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtNi0xLTEtMA_8ba1b95f-46b8-4c09-9e42-c5ae4c938948">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtMTItMS0xLTA_4fd11ab8-ae4f-4962-b140-668f5e16d79c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtMTYtMS0xLTA_6366655b-003d-4b85-b964-8ac55c1e973f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19280811252b4ca18390037dfc0e63f5_D20200101-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjYtNi0xLTEtMA_2190f3dc-4203-4eef-999e-dfe5daaf4e2b">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjYtMTItMS0xLTA_10b463ff-c02d-4593-bdc5-8a7512ce9480">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjYtMTYtMS0xLTA_4d327492-752b-4250-af7d-93c448dfcfe2">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19280811252b4ca18390037dfc0e63f5_D20200101-20200930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjctNi0xLTEtMA_02b0d842-3950-4568-85d9-0ef236552998">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjctMTItMS0xLTA_271be536-6fd1-43d5-8898-e42604766676">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjctMTYtMS0xLTA_ede11bc3-8d60-4f68-a1d5-1d1e41bd3bbb">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a25f11c2bfe443ea2f446aca2bb3794_D20200101-20200930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTQtMS0xLTU4Nzg_a2e98968-3edb-400f-b5eb-14318f987018">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTYtMS0xLTU4Nzg_fc4d2e76-8d62-4880-a8cc-be8d107c84e9">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i292d75e4b4024bed95e33679bcebcbe2_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjgtOC0xLTEtMA_0f5de52c-eff6-46b1-869f-b77c465322ff">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjgtMTItMS0xLTA_9b2d9643-8563-4a78-a3d8-0efcc05c70dc">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjgtMTYtMS0xLTA_52e7f2f3-7d8d-41d8-8e30-cb0943705792">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia713159518cb42a0b248bc95796377b4_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTAtMS0xLTA_9ddd2885-8b4e-4813-b2c2-6156a3bdac4f">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTItMS0xLTA_e030a94b-6d98-43eb-946e-a22dbe139133">121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a25f11c2bfe443ea2f446aca2bb3794_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTQtMS0xLTA_7f27ca57-2482-4901-9b97-384d2a0475ac">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTYtMS0xLTA_9e7639eb-fa2f-45ae-837b-07357d9040c0">120</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMi0xLTEtMA_6e354808-0c4c-4b2a-afc6-e6c4599ca3af">355.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtNC0xLTEtMA_0a8ff72e-0572-4ce8-8a15-a0a639437dd0">10,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d1a74a2f6d479e80e6da708c4c0ea9_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtNi0xLTEtMA_4332f835-8145-418c-8b59-d55dd04a1128">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i614bd8e75e8b483b836943e11a8cff8c_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtOC0xLTEtMA_92d083dc-bad1-4ee7-bdf8-3bb3da2fae45">7,860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86b09d66e5904f00bdfc6d7dcac58e24_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMTAtMS0xLTA_7fe439c6-9de7-4a14-b5e1-86211f1888cf">2,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6469a3085b415b81023abb0f50fd08_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMTItMS0xLTA_e3dbc869-f631-4779-820d-50eceadf2c40">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i129921e9b4d049ed8ee7f90c0ac8ebcb_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMTQtMS0xLTA_ca53c320-7a09-4a69-b707-1855d923a485">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMTYtMS0xLTA_3dde98f8-e03a-4fad-833c-a6c28eb3fc77">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="45" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, January 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0cfbeac78f9548d18d3b871368be2ee1_I20181231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMi0xLTEtMA_e0748139-bb3e-4134-919a-60be233936e1">349.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cfbeac78f9548d18d3b871368be2ee1_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtNC0xLTEtMA_7b5c9645-cdf2-4409-90f3-00746e61b364">10,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911bb2eff7e84f7cbb8079fd03ee877f_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtNi0xLTEtMA_3d30b3c6-7bc3-40d1-b7de-a90e79a30857">413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i326aa3bfc5ee4f3daab3236db5b49940_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtOC0xLTEtMA_387d13a5-2174-4f06-9a0e-94fe334e49c8">5,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85916a34835d4e4fae8f2fdf0dcf8c27_I20181231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMTAtMS0xLTA_d05a1bd5-6a4b-4370-b20b-c317a2e9b39b">2,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4a0c3396e645879bc46329d323ac1b_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMTItMS0xLTA_a30f68d9-9c7b-48c5-b4bd-b8e778fcd818">2,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45afbb8c565241ff8ad164f429208ab3_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMTQtMS0xLTA_183bf575-5151-4c21-914e-6a42650e9db6">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMTYtMS0xLTA_2ac79043-7f92-4c0a-860d-e17e91649a2d">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cc32bfd1c3d470cbe8ccec2d8c006a7_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtMi0xLTEtMA_35598b3c-f4ea-49bd-8942-6c0a46832eee">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc32bfd1c3d470cbe8ccec2d8c006a7_D20190101-20190930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtNC0xLTEtMA_9c4576e4-ef2c-4651-8669-6dc4b35ea42c">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if28e8de9d52f4b1fb26013832875c24a_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtNi0xLTEtMA_4ef57697-1e20-46e5-8dde-996659a8397c">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtMTItMS0xLTA_e7cbb693-9a2f-4c39-acbb-c593b16fc6fb">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtMTYtMS0xLTA_05416ad6-a928-4c0b-8802-b5312a62fb02">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28e8de9d52f4b1fb26013832875c24a_D20190101-20190930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzUtNi0xLTEtMA_4e477b96-1239-4f52-90bf-92241ec177af">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzUtMTItMS0xLTA_7d174c42-68e6-43f3-a6d4-4c8416cbf63c">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzUtMTYtMS0xLTA_6ab1f8af-a80c-45f3-96e0-a30072d0993a">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if28e8de9d52f4b1fb26013832875c24a_D20190101-20190930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzYtNi0xLTEtMA_ee909d40-30d9-4ca5-bb09-a9312933cd91">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzYtMTItMS0xLTA_f84c71e5-4003-4c0d-aa6c-db962905a5c7">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzYtMTYtMS0xLTA_a3bfde90-e01e-4c5d-8eac-bf9f4127f8da">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e72b076a70a45c584feaa8d3245efbd_D20190101-20190930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTQtMS0xLTMxMDk_f54d07c6-52fc-437d-8a30-bdf8de1b0018">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTYtMS0xLTMxMDk_d78dabeb-8bc3-4eb2-8f2b-c444152eabc4">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic90695475f3742f7bc22d422180c86a9_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzctOC0xLTEtMA_2fab2eb2-26d2-46e7-8192-a10078c05226">272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzctMTItMS0xLTA_b6bb75cf-1be3-4a90-ab63-72ae5525aa63">272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e72b076a70a45c584feaa8d3245efbd_D20190101-20190930" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzctMTQtMS0xLTA_e4fa7b40-a2ba-41e4-8847-90ca36342d19">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzctMTYtMS0xLTA_341eeaec-3077-4add-b630-d6dd0daa89e2">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i626ac4778b4748438a325abd1b9e0d84_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTAtMS0xLTA_522670ce-53e3-455d-8286-6ab5138abcb7">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTItMS0xLTA_23c0a0d3-4357-45dd-9873-5a29598daccb">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e72b076a70a45c584feaa8d3245efbd_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNDAtMTQtMS0xLTMxMTE_3d6ae2fc-d992-4708-a0a4-3ab6a8fb0453">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTYtMS0xLTA_84c255cc-d445-438f-8f58-48118db3a1a4">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMi0xLTEtMA_18a87327-3e82-4005-b621-49028d94d09d">352.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktNC0xLTEtMA_61ca538b-6a12-46af-9690-b04a0a9353f2">10,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e79eda62004863b250270a4ac6e2e2_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktNi0xLTEtMA_b17b6bd5-2a44-4f83-afb3-6e7d576ce058">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76b9993210a745b9b43f1f5d49bc5f63_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktOC0xLTEtMA_6c6cc80e-00c3-4dd3-bb49-f4659881a53c">5,936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0679fbabd2d543829b45838f2d32c8b1_I20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMTAtMS0xLTA_443521a3-890c-4a19-9df1-47e3fe8050fa">2,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d9736297cfb443ab15742dc0bb31bba_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMTItMS0xLTA_aaeefbe1-252e-4df2-9b96-9e5f17d217f5">2,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e4834a7c874cc1827742f22e88673d_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMTQtMS0xLTA_c3097550-884e-40c1-8fa9-54e41b67834a">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMTYtMS0xLTA_ec6eba8b-ab99-404b-a09b-0bf799b705f1">2,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 22.50pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.699%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMy0xLTEtMS0w_52e96380-7e72-41b1-918c-425679815aae">407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMy0zLTEtMS0w_fd7e627c-7830-4ad8-85e3-467e6cabcbc1">266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNS0xLTEtMS0w_ad46fb66-225c-47b2-842a-efe8d3bccf29">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNS0zLTEtMS0w_15210dec-2832-4a9f-9cca-3378b877bdda">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and write-off of debt premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNi0xLTEtMS0w_25615016-beb4-4c27-87a5-2943b60478a6">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNi0zLTEtMS0w_2893bb90-124a-4b82-91a9-33aa181564a7">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNy0xLTEtMS0w_b3d6b38e-1e86-4f41-90cc-bececbf8df90">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNy0zLTEtMS0w_f28a9d0f-fee0-450e-9f6a-4da1a6285d19">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfOC0xLTEtMS0w_cd5eaa53-087d-49bc-af7a-45cec68f1c45">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfOC0zLTEtMS0w_3e66351b-04da-4430-bc54-1eaa2e7437f0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowances for losses on trade receivable and inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfOS0xLTEtMS0w_48115e8a-8bf3-4473-883f-06cfccaf8dc1">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfOS0zLTEtMS0w_ae19ef5f-3f89-4281-b948-e2e41b1c6419">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTAtMS0xLTEtMA_9cc15706-8bb1-41fa-ae72-8ae325e3b9a5">213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTAtMy0xLTEtMA_919b799d-90ec-4e0c-9d7a-3dbe2ca580da">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTEtMS0xLTEtMA_9eccb6e1-6e28-4333-8b9a-a85617d9fd57">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTEtMy0xLTEtMA_864d4084-1c2d-448c-b3ea-30cf6542984f">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to accrued legal settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTItMS0xLTEtMA_e6bd0861-686b-4bf6-9632-b5a445bb270a">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTItMy0xLTEtMA_0d1b63d1-29fa-4f7a-a519-eb9ae4ea6a06">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of accrued legal settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTMtMS0xLTEtMA_5d0ffedc-9e67-4520-8229-701d8141fbdf">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTMtMy0xLTEtMA_c8d76899-4090-413d-90c2-4d59d25ec00d">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTQtMS0xLTEtMA_58e253de-25f1-4f07-aeb0-e6a38d227360">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTQtMy0xLTEtMA_b0e45881-0f6c-4ed1-99bd-03280850476b">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTUtMS0xLTEtMA_2e6f3c61-b1ab-4efc-8266-e7858e05c52b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTUtMy0xLTEtMA_72d77a11-0043-4840-a9ea-411e07eb57a9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain excluded from hedge effectiveness</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTYtMS0xLTEtMA_5d376686-3727-4baa-93d8-3c86627fb44d">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTYtMy0xLTEtMA_9a6778d9-984c-4efa-8af6-110aac76ff01">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTctMS0xLTEtMA_4a459ddc-7a48-46b6-a4a7-fe3a54735660">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTctMy0xLTEtMA_b2857638-8ece-489e-a405-2dc8d38a1683">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of contingent consideration adjustments, including accretion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="bhc:PaymentOfAccretedInterestOnContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTgtMS0xLTEtMA_3b85b7e9-3610-4fc8-9bb5-df17f5904a80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="bhc:PaymentOfAccretedInterestOnContingentConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTgtMy0xLTEtMA_7bb77de5-4e00-4726-a6a3-fc773f75611d">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTktMS0xLTEtMA_2e770609-5c6e-4220-af3f-c57957d89374">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTktMy0xLTEtMA_d7c6576f-d0b3-4c6e-ab18-2083334775b2">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjEtMS0xLTEtMA_b41870c4-6d40-43b4-ad96-54512b4efcd0">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjEtMy0xLTEtMA_003a3009-711d-47f4-aeac-01924348c440">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjItMS0xLTEtMA_70114cdf-e02b-410b-a2a6-1881cd3d88ae">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjItMy0xLTEtMA_b6d2bf71-cd84-430e-9f55-8abd2b78333f">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjMtMS0xLTEtMA_f8f913c4-1cd4-4e9b-bb4c-720684078deb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjMtMy0xLTEtMA_eb4a5c07-ea0e-44ad-b357-4151cb9b6dfa">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjQtMS0xLTEtMA_6b3a54d4-b50e-425b-880d-547aecf19fc6">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjQtMy0xLTEtMA_b1c45be8-581c-456d-9927-e878053bcf5a">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjUtMS0xLTEtMA_810d616c-1908-4a19-9a92-4308604f607c">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjUtMy0xLTEtMA_943a5c62-75b4-427e-9eae-f98b02f570bb">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjctMS0xLTEtMA_dbb0222c-df61-42d0-a1d8-561c453ca35b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjctMy0xLTEtMA_97ca7d8b-2b71-4470-829a-eb081c432175">180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjgtMS0xLTEtMA_b46e4778-504c-4fe7-9b74-3d1fe205aa25">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjgtMy0xLTEtMA_c83c507e-007f-46c1-b837-a38a8e5eadbe">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for intangible and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjktMS0xLTEtMA_ccb885b5-80ba-4a9c-a6e0-b5039535ef35">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjktMy0xLTEtMA_3e7c2248-bd65-49f6-a65f-4e4cd96314b9">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzAtMS0xLTEtMA_eebb8e78-5c77-4a58-8dc3-172c628019c8">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzAtMy0xLTEtMA_2c462f28-88eb-4913-9c8a-00e0d30a2e40">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzEtMS0xLTEtMA_26a707d4-81f9-4f6b-a838-6913f7e6d2ed">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzEtMy0xLTEtMA_fc4b464a-70ec-4882-8744-c553076a5cf7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of assets and businesses, net of costs to sell</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzItMS0xLTEtMA_be261086-fe99-43ca-b486-0b5556a495b4">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzItMy0xLTEtMA_2054b76b-9ffa-437a-bd33-ec19276c7f0b">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest settlements from cross-currency swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzMtMS0xLTEtMA_1f649321-385d-4362-a267-da880d7167a8">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzMtMy0xLTEtMA_b9ef6442-2b36-44f0-b1a7-a8832fac4582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzQtMS0xLTEtMA_63aba4a3-f1d3-47af-8836-4428b8d1f77a">177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzQtMy0xLTEtMA_b9256a47-52b7-40b9-84a8-037e1193b973">334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of long-term debt, net of discounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzYtMS0xLTEtMA_910e04a2-250c-4757-a1f0-5b1e12759f3a">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzYtMy0xLTEtMA_59d2c1fb-9a9e-46ee-b18c-bf047fa486f0">3,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzctMS0xLTEtMA_42a0530b-0b49-4f8c-8e29-213cb2d7b517">3,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzctMy0xLTEtMA_e88d437d-44ba-421c-8b21-15afd59b3b38">3,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the issuances of short-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzgtMS0xLTEtMA_d10b47cd-d5f5-4524-b5fe-dbd7e061e0b2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzgtMy0xLTEtMA_14a098e8-0124-4ff9-adf7-bf9bb8c95ee9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of short-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzktMS0xLTEtMA_9c4fa155-5de1-487f-b9dd-ec289785dfff">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzktMy0xLTEtMA_37ebfa34-000b-4e56-b158-32af76a176d2">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of employee withholding taxes related to share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDAtMS0xLTEtMA_f5211f20-db7f-4517-989c-1c4c4bfb66fd">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDAtMy0xLTEtMA_06e26e3b-8579-489f-bbcd-6579ee70269d">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDEtMS0xLTEtMA_212f3eb6-ae0e-40cb-923b-f91872650301">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDEtMy0xLTEtMA_b4de7a77-2f7c-42a3-b915-91b6e78a8adf">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDItMS0xLTEtMA_6e690148-f0d5-44de-b61e-72053e6853ad">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDItMy0xLTEtMA_3f1c8478-68a4-4079-a696-9f35df5b5353">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDMtMS0xLTEtMA_b72e24b2-2da6-435b-afee-0d680ee21640">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDMtMy0xLTEtMA_2b02da7b-c523-4585-b7b3-a743c7821ccc">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDQtMS0xLTEtMA_47052671-aaa1-4f10-8573-9da26252dc93">1,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDQtMy0xLTEtMA_58b732c1-a430-4846-a23d-eb9c1c78ff24">812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDUtMS0xLTEtMA_bdbb4ebb-b488-41dc-be76-b548952ae180">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDUtMy0xLTEtMA_6ac9f254-f03c-4d9d-80f0-f16e2bd51de2">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDYtMS0xLTEtMA_5379881a-3f90-436e-9ff4-19eeb339ee7e">1,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDYtMy0xLTEtMA_d7537893-483c-437a-8caa-80f5c525d359">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDctMS0xLTEtMA_03241e46-1530-4f23-a983-6f1596d9f7e3">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDctMy0xLTEtMA_74739041-6bb3-4fa4-9a4d-15a0dd4d98d5">723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDgtMS0xLTEtMA_17b75c73-0584-49f7-b4cc-f25940c79b0a">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDgtMy0xLTEtMA_8ac5a72a-f7e2-41bd-a9a2-f21ff712f131">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDktMS0xLTEtMA_7866c4e4-4734-4e64-8ab7-ac33c3d7920d">977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDktMy0xLTEtMA_d46db9ec-ddbf-4a1e-a3ff-bece870d7da4">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNTAtMS0xLTEtMA_9db44b13-2c69-4174-a5a1-d9acaf4a5b1e">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNTAtMy0xLTEtMA_59b729b0-77ea-470e-9ba6-0c2487727033">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNTEtMS0xLTEtMA_60dfbe10-db9c-4aec-b39e-1aa70058689b">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNTEtMy0xLTEtMA_4eafb6e9-c1b2-4a44-a8f5-5c7be15f8c93">827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180MC9mcmFnOmEwOTkyMTkyZWI0MTRhNmZhNzg4MTJhNzc0ZDQ5ZTA4L3RleHRyZWdpb246YTA5OTIxOTJlYjQxNGE2ZmE3ODgxMmE3NzRkNDllMDhfNTkx_5425cfda-c574-4fce-9c16-dd2b997dd22b" continuedAt="i9288ce598b104d74b049f1c6c3937c01" escape="true">DESCRIPTION OF BUSINESS </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9288ce598b104d74b049f1c6c3937c01">Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or "Bausch Health") is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately <ix:nonFraction unitRef="country" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-2" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180MC9mcmFnOmEwOTkyMTkyZWI0MTRhNmZhNzg4MTJhNzc0ZDQ5ZTA4L3RleHRyZWdpb246YTA5OTIxOTJlYjQxNGE2ZmE3ODgxMmE3NzRkNDllMDhfNTc0_a25c53ad-a43c-4e65-b9ea-a567865dfbb9">100</ix:nonFraction> countries.</ix:continuation></span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_43"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQzMg_3af0b913-9134-45e2-9f1e-3aba6eb75bb8" continuedAt="i7149e3f1a76647dca37aaa7a3b627c8b" escape="true">SIGNIFICANT ACCOUNTING POLICIES </ix:nonNumeric></span></div><ix:continuation id="i7149e3f1a76647dca37aaa7a3b627c8b" continuedAt="icb930ccbfa2e4ffc9e9aa503c19c1146"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfOTg5NTYwNDY2MDg4NA_cb545697-8b90-46ee-b583-c8b9213c0a82" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators on February&#160;19, 2020. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2019, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;Separation&#8221;). The Separation will establish two separate companies that include: (i) a fully integrated eye-health company which will consist of the Company&#8217;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Rx businesses and (ii) a diversified pharmaceutical company which will include the Company&#8217;s Salix, International Rx, Solta, neurology and medical dermatology pharmaceutical businesses. The anticipated separation is subject to regulatory approvals and certain conditions, including final approval by the Company&#8217;s Board of Directors and any shareholder vote requirements that may be applicable. These unaudited Consolidated Financial Statements do not include any adjustments to give effect to the Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has begun addressing the internal organizational design and structure of the new entity which it anticipates having substantially completed in late 2021. Management is also exploring various capitalization structures and the form of the Separation transaction in order to properly capitalize both entities post-separation. As of the date of the issuance of these financial statements, the Company is in the planning phase of the Separation. As such, there are considerations, approvals and conditions that will determine the ultimate timing and structure of the Separation and there can be no assurance that a transaction will occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. The COVID-19 pandemic has also significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, elective medical procedures and travel. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence, if any, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="icb930ccbfa2e4ffc9e9aa503c19c1146" continuedAt="i42b9449c03dc409087677d613451520f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing.   Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfOTg5NTYwNDY2MDg4NQ_539ac518-4c12-4bdf-a7fe-249c75afab4a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ1NQ_135ff645-a548-4531-8e84-4be971a75950" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ0Mw_4c509346-e058-467a-931e-0386a19f9a6b" continuedAt="i84deec42f81c4a9abd788e763f330546" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Guidance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued guidance on the impairment of financial instruments requiring an <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ0Nw_fc60b351-a915-4b1e-a9cf-8bbc63693281">impairment model based on expected losses</span> rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to accumulated deficit of less than $<ix:nonFraction unitRef="usd" contextRef="ib9975f10d37a4b9f8ab190b71f48d126_I20200101" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNDkyNQ_eb883b8e-faf8-4b27-96a6-317930d93e58">1</ix:nonFraction> million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.&#160; The guidance was effective for the Company beginning January 1, 2020.&#160; The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During the nine months ended September 30, 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Adopted as of September&#160;30, 2020 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on its disclosures.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42b9449c03dc409087677d613451520f"><ix:continuation id="i84deec42f81c4a9abd788e763f330546">In December 2019, the FASB issued guidance simplifying the accounting for income taxes.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on the Company's financial position, results of operations and cash flows.</ix:continuation></ix:continuation></span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTU2NQ_e58a2f6b-66f5-4826-aa9a-90ea6d02de25" continuedAt="i9abac71768b547b8aeb5a9101dcb1867" escape="true"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTU5MA_c925f730-e740-4dfb-b159-388e16127893" continuedAt="ia0974792e377496ab4b16a8089b98404" escape="true">REVENUE RECOGNITION </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i9abac71768b547b8aeb5a9101dcb1867" continuedAt="ib8365914d78648ca9d43763d6d1695ff"><ix:continuation id="ia0974792e377496ab4b16a8089b98404"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities.  All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for the nine months ended September 30, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i926e8404d24b4f67a639801625df9821_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNjA0NzMxMzk2MjI4OQ_4248a727-413f-492b-a219-f73cb6c314d5">71</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i60746b3a7f484dad99381c010e94f132_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTQ5NzU1ODE0ODI4OQ_198c2304-e9d6-4b80-a59c-76356abf9ac3">50</ix:nonFraction>&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $<ix:nonFraction unitRef="usd" contextRef="ie229cebfd8564ef69cc3b87b8cca2163_D20200701-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDM5ODA0NjUyMDY1OA_1ec2b961-de10-40dc-a5ed-16cd9f16681a">38</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7d2ec754640b47e3bc475ba39e2f15b3_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTQ5NzU1ODE0ODI3Ng_b140316e-8912-4c17-a61e-b2e0a0bbb5f3">80</ix:nonFraction>&#160;million for the three months ended September 30, 2020 and 2019, respectively.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ib8365914d78648ca9d43763d6d1695ff"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTU2NA_50578ff4-41a1-453b-97ab-326d7dd5c262" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the nine months ended September 30, 2020 and 2019.</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4865f0c8877843d2a74d4a34949d8990_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi0yLTEtMS0w_a7c56802-71e6-443a-972d-61f1410f6bac">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64e6b19fad9e422cbb35846a705746dc_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi00LTEtMS0w_90770b8a-20a3-42de-99b4-c524aec974cd">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4544171997534f44b301068e2ca91ee1_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi02LTEtMS0w_7c99e0fc-ee50-411a-9246-9ca2d6b545e0">927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a7fc687b364d7b91dd305f5f2c2a47_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi04LTEtMS0w_90678e4a-b320-41aa-bff7-3eeb2a7d934c">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d9b898b4dd4de4afef0d16544c30e4_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi0xMC0xLTEtMA_6c054241-e6de-4aca-9407-fe22e866c46b">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi0xMi0xLTEtMA_f910167b-383a-4943-a534-b8aa842c94e0">2,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9396aa2e3a194b7d88a01028c2d8726f_D20200101-20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy0yLTEtMS0w_b0a59229-2011-4c07-8282-09e27e1d9973">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926e8404d24b4f67a639801625df9821_D20200101-20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy00LTEtMS0w_4248a727-413f-492b-a219-f73cb6c314d5">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb4b2fb825447fba3ebaf7786b43dc7_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy02LTEtMS0w_c7ec3a05-e55b-4f2d-afee-d4efcf9eb9de">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b21a7ff737c4ce9bcf3101d1496b9e8_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy04LTEtMS0w_76874f2b-108a-4051-82a9-0a97e8017a12">1,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ef307c522049b29a69292368af3288_D20200101-20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy0xMC0xLTEtMA_76e7ab63-1ccd-4f06-b673-ea1d4f6b7d6c">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy0xMi0xLTEtMA_d0e84e1e-98f2-4261-afeb-c1de8200f95d">3,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9396aa2e3a194b7d88a01028c2d8726f_D20200101-20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC0yLTEtMS0w_f6210a16-8455-42a3-aad1-bdd3be269ae7">454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i926e8404d24b4f67a639801625df9821_D20200101-20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC00LTEtMS0w_1d489f44-0013-4826-8f85-f883a5f99ac2">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcb4b2fb825447fba3ebaf7786b43dc7_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC02LTEtMS0w_76541a0e-dfd8-456e-b2ab-8eeb4209712f">1,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b21a7ff737c4ce9bcf3101d1496b9e8_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC04LTEtMS0w_9ac0ea02-a8d2-4afd-8368-f1a2ccf9e8a2">1,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05ef307c522049b29a69292368af3288_D20200101-20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC0xMC0xLTEtMA_c2ab1eea-a5d5-4e2e-aeca-f5fd8fe9dae5">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC0xMi0xLTEtMA_5543ebe9-f8c7-458c-a353-0ef2fc698273">3,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29dfca8902e4b9ca9b215022329120a_I20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS0yLTEtMS0w_3440b139-9d74-457e-bac3-ac227378cf75">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563d7e65dd4f4fd3a57a525126385f71_I20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS00LTEtMS0w_80c3d3b5-0d06-40b1-b588-509df56f4325">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06448dd5b9c4a5a8833d7aeb0462adc_I20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS02LTEtMS0w_a631cd4d-e929-4f7f-91fa-bb010965f3cd">909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia84a1548bc2b4290bf923185b9809a3c_I20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS04LTEtMS0w_2347b503-e974-4d79-9c26-d6333e323da4">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d5fc05eca2d45039ef1c66ddd5fd5bb_I20200930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS0xMC0xLTEtMA_5bcd5766-ef6e-49e3-9d83-153d1fd8e41e">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS0xMi0xLTEtMA_f503be33-a37a-4238-8bc6-204aa57e1375">1,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="if87d338bc71847cbaa721c2e753719df_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfMzg2OA_d96bfbab-a574-46ce-96eb-54b2ac726dc1">33</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4b081d921d2542fab60f3ee0f92c0b0c_I20200101" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfMzg3NQ_336b70e8-dfd3-4445-9718-ef4192a0f0fd">29</ix:nonFraction>&#160;million as of September 30, 2020 and January 1, 2020, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. Included as a reduction of Distribution Fees in the table above are price appreciation credits of approximately $<ix:nonFraction unitRef="usd" contextRef="ibbb36916236a49af8aabec568346f93f_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDEyNQ_0c063207-e805-46da-b441-38db5979c905">4</ix:nonFraction> million during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef27070c30b49c1a8b37fca2d781143_I20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi0yLTEtMS0w_662db892-e4d9-4c67-9781-81cee123b790">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba58938db3e44a8ab10e6ad34541726a_I20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi00LTEtMS0w_33992278-4eae-43a6-98c3-cfcd4db458d2">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d0d96c365941de8f6f60a38bcb3768_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi02LTEtMS0w_b96cd33a-e3ec-4f47-b1b6-246b30061c53">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5216708cf09e4690887e64359dfa0177_I20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi04LTEtMS0w_507e8c03-d91b-4a9c-a907-e7b8c611de35">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9935a6414aaa4e8e9a55fa03b280060c_I20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi0xMC0xLTEtMA_fa622b29-0494-48f2-90a0-af97037218f2">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi0xMi0xLTEtMA_80613c4e-2c5f-477c-b85f-6acc43f2da02">2,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Synergy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d75e8d917347f5beaf038cb1a07543_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy0yLTEtMS0w_953c9e60-1d97-4635-a6c9-240366f2af13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60746b3a7f484dad99381c010e94f132_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy00LTEtMS0w_67d0177e-b3be-45c9-b960-9762af7ae3b8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4767169b3e8b4b7f9c14e03ce1450592_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy02LTEtMS0w_0baa0902-7b7e-4727-814a-0daae041b4e8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9912296e4423eb2f0c58b058f3d53_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy04LTEtMS0w_677de5f7-eddd-4a76-b1fb-df3680a4fbbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10ab9e834c5043c3b3c019c844bf6906_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy0xMC0xLTEtMA_1c19a9c3-38af-46ab-9397-04b9ad7326c5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy0xMi0xLTEtMA_91d8a8e7-e8ea-4b8d-aced-a1f322b21c17">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d75e8d917347f5beaf038cb1a07543_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC0yLTEtMS0w_6413770a-e8d3-4d68-ba4d-326b25daf7a2">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60746b3a7f484dad99381c010e94f132_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC00LTEtMS0w_b178f36b-43a8-4abf-b95a-c61e75967ea4">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4767169b3e8b4b7f9c14e03ce1450592_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC02LTEtMS0w_b11df698-9478-4ba4-b1d1-7f7ae940f1a1">1,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d9912296e4423eb2f0c58b058f3d53_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC04LTEtMS0w_1375a2b7-cd4d-45fd-a12f-94af50734592">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10ab9e834c5043c3b3c019c844bf6906_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC0xMC0xLTEtMA_579a4bb8-e96b-456c-8b7b-9a6e9c030488">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC0xMi0xLTEtMA_1b0c2f3b-e2cb-4be8-9439-ea3a09488783">3,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08d75e8d917347f5beaf038cb1a07543_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS0yLTEtMS0w_ab7dda91-6423-489d-b153-03bc404a8a41">583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60746b3a7f484dad99381c010e94f132_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS00LTEtMS0w_b2314cfb-5a70-4da8-bb6f-2c9c73e508c4">187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4767169b3e8b4b7f9c14e03ce1450592_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS02LTEtMS0w_7a76b653-866f-4cab-b432-9e972d741862">1,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00d9912296e4423eb2f0c58b058f3d53_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS04LTEtMS0w_c78e7e3e-9b6d-45d9-95fd-518d247b8ea0">1,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10ab9e834c5043c3b3c019c844bf6906_D20190101-20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS0xMC0xLTEtMA_be94c93d-20c6-4c1f-903c-a12a5170495e">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS0xMi0xLTEtMA_53e7a20d-697f-423e-819c-ecd3812d9685">4,104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i251db7175d9c4d7498e6bbc45a12b1a7_I20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi0yLTEtMS0w_75c7c041-f7b6-4c65-8006-2ad11bfb7902">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43ca4779d36d4db0a4416740976e51df_I20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi00LTEtMS0w_914ea82c-9cd0-484a-9be9-42af1b8ca491">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90e68a168c934bf0b76363ae269a8dd4_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi02LTEtMS0w_f53d3f1c-141f-4f84-908a-22a223806eeb">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if477ae61fd124d7aac6ae9ddab03f3cf_I20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi04LTEtMS0w_3359708b-eb1c-4eef-9708-45997c5faf34">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f26ca1233014e19a4813bfb570654cc_I20190930" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi0xMC0xLTEtMA_3418b98e-5763-49e6-af82-2e6fa1ec2b1b">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi0xMi0xLTEtMA_2ed68237-64a3-4add-9e8a-e7af33aa9134">2,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="i22581c99ab8945728931a540b016ef35_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDI1NA_29fd2d94-5afd-4377-8c3d-12157c7d4250">26</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i53b5ad55c3114bbb9e240bd272663878_I20190101" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDI2MQ_0b7df582-57f3-42d2-966b-76575d09a7d2">26</ix:nonFraction>&#160;million as of September 30, 2019 and January 1, 2019, respectively. There were <ix:nonFraction unitRef="usd" contextRef="iea55888e199a4f30aa6537db612f8d50_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDMxMw_bd37f609-69cc-4438-b037-7baf2f4c8df2">no</ix:nonFraction> price appreciation credits during the nine months ended September 30, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTU3Mw_5598f9e1-6b15-42d0-8285-166105d76ca7" continuedAt="iecb84f8c5736406fb74045c0ab40e473" escape="true">The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2020 is as follows.</ix:nonNumeric></span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><ix:continuation id="iecb84f8c5736406fb74045c0ab40e473"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfMS0xLTEtMS0w_762ada39-807c-4ec1-99b8-32f22da608c7">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfMi0xLTEtMS0w_22608d95-b134-4376-a337-3a982418c83c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfMy0xLTEtMS0w_daf5f938-7388-44c0-820f-f5980a10f974">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfNC0xLTEtMS0w_821f53b8-804d-4f15-9c84-099faaef9394">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfNS0xLTEtMS0w_5bc5d4ed-5286-4816-bb96-986bee71ff99">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfNi0xLTEtMS0w_9b6f43c4-63cd-4fc7-8d58-a27db5e924d8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfNy0xLTEtMS0w_a3a6e6e8-2c3f-49c4-9c28-0619be14f11a">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_49"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfNDE2Mw_f06af6e6-0ac0-49ef-b18d-1a3a7101f608" continuedAt="idb4f2d7264854e848c2a432a83192720" escape="true">ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE</ix:nonNumeric></span></div><ix:continuation id="idb4f2d7264854e848c2a432a83192720" continuedAt="i6c68c23a177f4e10b4245dc897a70783"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of Certain Assets of Synergy Pharmaceuticals Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of&#160;approximately $<ix:nonFraction unitRef="usd" contextRef="id525861ca12645cbbfa8004f60ba9429_D20190306-20190306" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMjY4_bcc00371-607e-4fc1-9d50-8a485df4bf73">180</ix:nonFraction> million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired were the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and has, to date, resulted in additional revenues and certain business synergies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting as: (i) substantially all the fair value of the assets acquired is not&#160;concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfNDE2Nw_4f528711-c3bd-41ed-841f-de35ef6b7bb3" continuedAt="if60fa6cbef8a4e58ba51b4dcaa4e70f8" escape="true">The following table summarizes the fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:</ix:nonNumeric></span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><ix:continuation id="if60fa6cbef8a4e58ba51b4dcaa4e70f8"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.829%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfMS0xLTEtMS0w_028891a2-b8f1-4f5a-bedc-0e598dbddc67">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfMi0xLTEtMS0w_98b8f601-245b-44b7-9e9e-a0c432ec24c4">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfMy0xLTEtMS0w_8a886233-1ea9-4930-bd17-00219f1418c2">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life - <ix:nonNumeric contextRef="id525861ca12645cbbfa8004f60ba9429_D20190306-20190306" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNC0wLTEtMS0wL3RleHRyZWdpb246YzA4NDRmOWJhOWQ0NDJmMzg3ZmJiYjJlODZiYzU0MDRfNjE_71618cfc-41e0-4b49-9bc9-386b18c9cb7e">7</ix:nonNumeric> years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNC0xLTEtMS0w_a558a7ea-482d-42ee-96c5-330620c985d7">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNS0xLTEtMS0w_13b59df0-1fbf-4821-ac02-00cc9080f705">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306" decimals="-6" name="bhc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNi0xLTEtMS0w_614a5599-2d65-47d2-95ae-64e503ba3d8a">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNy0xLTEtMS0w_abf4ccd2-d132-4036-b2c0-3433e3b94295">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfOC0xLTEtMS0w_882ef03c-67af-4a22-a8bb-20a83576e14b">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfOS0xLTEtMS0w_90e6fbec-9f8a-421e-8f17-c39ebebbe125">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Results </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $<ix:nonFraction unitRef="usd" contextRef="ic76a9522ae624b31ba4b70987bd03b75_D20190306-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTY1OQ_b663d7f0-3e82-4cc3-b5ae-ba45beff6526">55</ix:nonFraction>&#160;million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the nine months ended September 30, 2019 and the year 2019 were <ix:nonFraction unitRef="usd" contextRef="ib738e1928e864b82b2984cc187349f0d_D20190101-20191231" decimals="-6" format="ixt-sec:numwordsen" name="bhc:BusinessAcquisitionProFormaOperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_51c80e5f-ad42-4e8f-8394-72ffa5c8be41"><ix:nonFraction unitRef="usd" contextRef="i5183e10738b0469fafeab79f0c1a49bd_D20190101-20190930" decimals="-6" format="ixt-sec:numwordsen" name="bhc:BusinessAcquisitionProFormaOperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_6f4d4898-4196-4c49-8844-3573ff00b375"><ix:nonFraction unitRef="usd" contextRef="ic76a9522ae624b31ba4b70987bd03b75_D20190306-20191231" decimals="-6" format="ixt-sec:numwordsen" name="bhc:BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_9a82669f-598a-4f0b-af1e-9f6257e087a7"><ix:nonFraction unitRef="usd" contextRef="ib738e1928e864b82b2984cc187349f0d_D20190101-20191231" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_ba1e81e0-9bdf-428f-b558-1f5d1c590952"><ix:nonFraction unitRef="usd" contextRef="i5183e10738b0469fafeab79f0c1a49bd_D20190101-20190930" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:BusinessAcquisitionsProFormaRevenue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_f217488e-15a4-4e17-8bb7-97f485326d9a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t material. Included in Other expense, net during the nine months ended September 30, 2019 are acquisition-related costs of $<ix:nonFraction unitRef="usd" contextRef="i5183e10738b0469fafeab79f0c1a49bd_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTk2OQ_67d97e0b-e42e-46a3-8b88-08957beda054">8</ix:nonFraction> million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC ("Allegro")</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2020, the Company announced that it entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option is exercised, is the worldwide rights to risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration ("AMD"). A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. The aggregate payments to acquire the Option are $<ix:nonFraction unitRef="usd" contextRef="i85e9f322f6594cb29a915174676fb28d_D20200921-20200921" decimals="INF" format="ixt:numdotdecimal" name="bhc:PotentialAssetAcquisitionAggregatePurchasePrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTA5OTUxMTYzMDE5MDc_03d323bb-f3d4-487f-abd3-3c81153af961">50</ix:nonFraction>&#160;million and include an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i85e9f322f6594cb29a915174676fb28d_D20200921-20200921" decimals="INF" format="ixt:numdotdecimal" name="bhc:PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTA5OTUxMTYzMDE5MjA_d9c962a9-35a0-4bbd-b65b-5c9206f42bdd">10</ix:nonFraction>&#160;million and a second payment of $<ix:nonFraction unitRef="usd" contextRef="i85e9f322f6594cb29a915174676fb28d_D20200921-20200921" decimals="INF" format="ixt:numdotdecimal" name="bhc:PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMjc0ODc3OTA3NTE0OA_01763962-40cd-4abe-8460-e4e2455cc1a1">40</ix:nonFraction>&#160;million should Allegro raise additional funding. During the three months ended September 30, 2020, the Company made and expensed the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i596976330b084b2083ea00b7d8939d1e_D20200701-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTA5OTUxMTYzMDE5MzM_760ca55e-26b5-4bb4-91c3-79682c83e0b0">10</ix:nonFraction>&#160;million as acquired in-process research and development ("IPR&amp;D") included in Other expense, net. If the Option is exercised, additional payments to acquire all ophthalmology assets of Allegro will be due.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i6c68c23a177f4e10b4245dc897a70783"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred.  Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company identified certain products in the Bausch + Lomb/International segment and <ix:nonFraction unitRef="product" contextRef="ied8b6d4a32f24bef886f050abd26218d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="bhc:DisposalGroupNumberOfProductsForDisposal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzE5MA_bf29eaa7-fdd4-4377-a817-8e4c7a9825e0">one</ix:nonFraction> product in the Diversified Products segment for disposal. The products and the related assets and liabilities of this disposal group qualified as a business. Revenues associated with this business were $<ix:nonFraction unitRef="usd" contextRef="i5bc655cb9eb649d7ab9cd303e9abe56d_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzM5NQ_987bede9-772e-4de9-951b-b373e37e1506">14</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2a7193c3b1a346ab8b76b004d6fab3b0_D20180101-20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzQwMg_c7366162-22bb-4c9b-9df8-f3f65cc441a2">19</ix:nonFraction> million for the years 2019 and 2018, respectively. The carrying value of the business, including inventories, intangible assets, goodwill and deferred income taxes, was adjusted to its estimated fair value less costs to sell and reclassified as held for sale as of September 30, 2019 and an impairment of $<ix:nonFraction unitRef="usd" contextRef="i9a254f3c123b4ca1bd8ea40230250dde_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzcwMg_7a7730e6-6cc0-40af-833f-9ce575532046">8</ix:nonFraction> million associated with this business was recognized during the three months ended September 30, 2019. As a result of changing business dynamics, during the three months ended March 31, 2020, the Company decided not to sell these assets and reclassified $<ix:nonFraction unitRef="usd" contextRef="id9aec834c676489bb24751c37138f0ae_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzk1MQ_72720392-31c5-4f46-aa63-c860ad7779a6"><ix:nonFraction unitRef="usd" contextRef="id9aec834c676489bb24751c37138f0ae_I20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzk1MQ_791143cb-b772-4a91-af6d-c86e3005f8a6">39</ix:nonFraction></ix:nonFraction> million of held for sale assets as assets held and used at their respective fair values at the date of the decision not to sell. This reclassification did not impact the Consolidated Statement of Operations for the nine months ended September 30, 2020.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_52"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMTE3MA_3fdcb211-fa90-4280-9ac2-7346595df92c" continuedAt="id7b91305fa8248619417fdf0aeb7d54f" escape="true">RESTRUCTURING, INTEGRATION AND SEPARATION COSTS </ix:nonNumeric></span></div><ix:continuation id="id7b91305fa8248619417fdf0aeb7d54f"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of September 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ic4358fb6f74742fdb0a980244f01c440_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNjE2_b08033ca-5c16-4b3a-a609-c0c276ba4073">25</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNjU2_4f615802-866a-45a5-bdb8-dc8b919dd907">12</ix:nonFraction> million of restructuring and integration costs. These costs included: (i) $<ix:nonFraction unitRef="usd" contextRef="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNzI1_cd0d2f23-a667-46ce-805b-71da289ab00b">7</ix:nonFraction> million of facility closure costs and (ii) $<ix:nonFraction unitRef="usd" contextRef="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNzYz_631c2376-1e1a-4cc8-8ae2-84e55574b37d">5</ix:nonFraction> million of severance costs. The Company made payments of $<ix:nonFraction unitRef="usd" contextRef="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfODE1_65b76fd6-f3e4-4cb0-8b04-7b6984323c76">14</ix:nonFraction>&#160;million for the nine months ended September 30, 2020.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2019, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfODY4_9d0c837e-6430-410b-b59c-ba834933ff19">28</ix:nonFraction> million of restructuring and integration costs. These costs included: (i) $<ix:nonFraction unitRef="usd" contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfOTM3_1186d165-aca3-4c8b-9e6f-e3a26c49cec4">11</ix:nonFraction> million of severance and other costs associated with the acquisition of certain assets of Synergy, (ii) $<ix:nonFraction unitRef="usd" contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMTAzNg_8cdf8a00-0d6b-4902-adba-8a06e89648b5">9</ix:nonFraction>&#160;million of facility closure costs and (iii) $<ix:nonFraction unitRef="usd" contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMTA3MQ_dceddedf-d8cb-4281-8ac6-7efb31d7ae36">8</ix:nonFraction> million of other severance costs. The Company made payments of $<ix:nonFraction unitRef="usd" contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMTE1Nw_c8a677e9-f922-4a88-8cd2-a0fa67ca21bf">27</ix:nonFraction> million for the nine months ended September 30, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation costs and separation-related costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. Included in Restructuring, integration and separation costs for the three and nine months ended September 30, 2020 is $<ix:nonFraction unitRef="usd" contextRef="i630d2760251f4bf096f3e18b26d2c348_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMzI5ODUzNDg5MjkxOA_10d53c6b-a176-4eda-909a-5603942aa4fc"><ix:nonFraction unitRef="usd" contextRef="i46838e1d7a4a42c3a16733f85f00c538_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMzI5ODUzNDg5MjkxOA_b3e8aaeb-b63a-4cf3-b8b9-f1b6002ef9c6">1</ix:nonFraction></ix:nonFraction>&#160;million of separation costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and will incur, separation-related costs which are incremental costs indirectly related to the Separation. Separation-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative expenses for the three and nine months ended September 30, 2020 is $<ix:nonFraction unitRef="usd" contextRef="i46838e1d7a4a42c3a16733f85f00c538_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNDM5ODA0NjUyMDQ3MQ_b6eb7bc8-b4ff-4f25-ad67-bb94c0f3e6a2"><ix:nonFraction unitRef="usd" contextRef="i630d2760251f4bf096f3e18b26d2c348_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNDM5ODA0NjUyMDQ3MQ_bfc47b65-ca98-42df-8d73-adf1bbc8462b">4</ix:nonFraction></ix:nonFraction>&#160;million of separation-related costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the planning phase of the Separation and the extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_55"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNDM5ODA0NjUyMjI1OA_0313fb2d-b3f8-43f5-9ceb-31d814cd185b" continuedAt="i78209e479a274c33b794311e633b67a1" escape="true">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i78209e479a274c33b794311e633b67a1" continuedAt="ic67c67564b544eadae59d1668200e9e4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ic67c67564b544eadae59d1668200e9e4" continuedAt="i2328023533524d1d8fc7decd43214ff7"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODIyMQ_71013458-42fe-4255-ba2e-6ac4f7052c03" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5238086c98844119970f8779efb8724d_I20200930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0yLTEtMS0w_0b2446f2-d04f-4f35-b348-a7ea7d6bf9bc">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79caecdf5264091b27165fac0949180_I20200930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy00LTEtMS0w_50858658-9223-4361-9122-7b8019959588">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5703e3dc34b5445690b680201a721c40_I20200930" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy02LTEtMS0w_f5758650-eff1-495c-ba12-cbd5a5e0a0cd">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ba393fb386441abbb663abd8248a98_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy04LTEtMS0w_cc374fea-f5e5-4092-9ae4-1c7ffe4c8cb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17077f1b6f0d4339a06e1372d84405db_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0xMC0xLTEtMA_4749384e-0ea3-4bc6-a53f-5f067a45f971">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7213b15a279a460cb57c398f93e64324_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0xMi0xLTEtMA_4cbe8603-81dd-4e01-ac91-5069294d55c2">2,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id041afe2abf047cc82ee51281520ae03_I20191231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0xNC0xLTEtMA_5c485a0b-1981-45a4-9d50-08d5ca114531">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07ebc37151443b8a5b057c7a3cfc60a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0xNi0xLTEtMA_2dc46820-ffed-4ad5-8718-dd4e5f0da8c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5238086c98844119970f8779efb8724d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0yLTEtMS0w_0357a7d5-e801-4997-a64b-a88ccd334884">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79caecdf5264091b27165fac0949180_I20200930" decimals="-6" format="ixt:numdotdecimal" name="bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC00LTEtMS0w_bc346a91-551f-43e9-9490-6e51d0185ce3">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5703e3dc34b5445690b680201a721c40_I20200930" decimals="-6" format="ixt:zerodash" name="bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC02LTEtMS0w_f3f8ce19-8066-4b7f-a78a-ab6c16c84cbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ba393fb386441abbb663abd8248a98_I20200930" decimals="-6" format="ixt:zerodash" name="bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC04LTEtMS0w_3b785ffa-8e94-497f-9437-6c2d83019ebe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17077f1b6f0d4339a06e1372d84405db_I20191231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0xMC0xLTEtMA_c01e95f0-dd39-424c-85bd-de00f950f455">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7213b15a279a460cb57c398f93e64324_I20191231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0xMi0xLTEtMA_cddebd84-cefc-4274-a469-1733ee000f4c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id041afe2abf047cc82ee51281520ae03_I20191231" decimals="-6" format="ixt:zerodash" name="bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0xNC0xLTEtMA_3dc240a8-0047-4c56-82ba-6d82c784d136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07ebc37151443b8a5b057c7a3cfc60a_I20191231" decimals="-6" format="ixt:zerodash" name="bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0xNi0xLTEtMA_55037714-e066-4bdf-b008-888c1ad8119e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i188c7aa31f4846398b02780a637146ca_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0yLTEtMS0w_fe0fe334-5843-4503-8a25-486c4290e55e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b34ec25e124642a594402f4d39fd61_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi00LTEtMS0w_631334d6-c3a8-4b64-b378-7662c9786bb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2392471a1d8d4ca9aff058dfa66f23a9_I20200930" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi02LTEtMS0w_4884d117-b830-4226-9f9f-2e21c01174c9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ca7375bec54df1831d5ec1bb7ce35f_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi04LTEtMS0w_14db03ce-b3ed-456e-995b-2d04a65f280f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a91dd3637642f194adf2e407393f51_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0xMC0xLTEtMA_d148ae1b-adb1-4506-9d85-62dab4a96a16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639cfded29ff480cac614d7849308b01_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0xMi0xLTEtMA_8dc747ec-98ca-408f-97c5-46a08f7e0f71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b592bb3c924615aeffe086aa4dcc11_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0xNC0xLTEtMA_e576fc88-20e8-4292-ad07-7147479d2fc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c2fa48fde14cd796cde7eac723cdc9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0xNi0xLTEtMA_ccdbb2db-5df2-4406-9723-feb2fcf21ce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5238086c98844119970f8779efb8724d_I20200930" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0yLTEtMS0w_f1dbf323-b896-43bc-93c7-b2d8914d552c">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79caecdf5264091b27165fac0949180_I20200930" decimals="-6" format="ixt:zerodash" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC00LTEtMS0w_4b38397b-5638-4357-b1b0-6c88ece70ae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5703e3dc34b5445690b680201a721c40_I20200930" decimals="-6" format="ixt:zerodash" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC02LTEtMS0w_cfc63258-da7c-4d16-aa14-97bf83ba0e6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ba393fb386441abbb663abd8248a98_I20200930" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC04LTEtMS0w_8a423910-b796-4340-9e89-da781f904941">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17077f1b6f0d4339a06e1372d84405db_I20191231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0xMC0xLTEtMA_bcc54f0d-899a-47a1-9ee7-a6492c4bc0d0">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7213b15a279a460cb57c398f93e64324_I20191231" decimals="-6" format="ixt:zerodash" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0xMi0xLTEtMA_2be3c651-389b-459c-a2f6-b9eb142591cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id041afe2abf047cc82ee51281520ae03_I20191231" decimals="-6" format="ixt:zerodash" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0xNC0xLTEtMA_5a32209b-9c14-4c11-ab2c-a2a9ce198216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia07ebc37151443b8a5b057c7a3cfc60a_I20191231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0xNi0xLTEtMA_71203c41-08d4-4be6-9601-4e8927406a3d">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf5b3db7d10d49d98b2d4ef9c94455ad_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0yLTEtMS0w_1d0e6013-f6b3-4437-8f3e-222d1c85ed40">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id74922aa0e2c416dab84eaa66f9f5e9b_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS00LTEtMS0w_610c1c1b-8824-476e-96b1-13cdb3fcb748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fbc708e24684f8c9c6e746a68d8705c_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS02LTEtMS0w_2128ca06-2cca-4c74-ac58-3fd18050c008">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided937c13e414b9f9a600c9abd30c643_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS04LTEtMS0w_06e92589-279d-4834-9b5a-5088e3eeb05e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie382e8171db64a9b8b111fb4def54606_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0xMC0xLTEtMA_244802d5-a5bf-457e-893d-5fc2cbb69e2e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07084c19d2c84f91a4a467900df34873_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0xMi0xLTEtMA_a85e5c30-b6ef-4be1-aa45-dfefea9697ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4442b581e9fb476e88434975a33029ed_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0xNC0xLTEtMA_0bed43d6-7c46-442f-a3ba-a87632e7df4b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676ba929c33c424d9ab4a59672a49177_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0xNi0xLTEtMA_9e305cd5-e983-43b1-98b7-d82e7dafc6ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i188c7aa31f4846398b02780a637146ca_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMi0xLTEtMA_57715f66-643d-4a93-8f10-be9fb01112ac">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b34ec25e124642a594402f4d39fd61_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtNC0xLTEtMA_1a325c78-ce86-4ecc-b2f2-524dbd800f6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2392471a1d8d4ca9aff058dfa66f23a9_I20200930" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtNi0xLTEtMA_e3b8df2b-c079-4ab7-97d9-fa6d52f9f038">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ca7375bec54df1831d5ec1bb7ce35f_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtOC0xLTEtMA_e13a07cc-0ebc-4a59-bce8-6d62fe832a09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a91dd3637642f194adf2e407393f51_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMTAtMS0xLTA_408d7022-9820-4c05-b343-6b96e06d998a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639cfded29ff480cac614d7849308b01_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMTItMS0xLTA_abcdff8f-8eb9-4f10-9184-17aea8aee2c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b592bb3c924615aeffe086aa4dcc11_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMTQtMS0xLTA_a315ecd7-5747-4dfb-bb24-881ce56af9f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c2fa48fde14cd796cde7eac723cdc9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMTYtMS0xLTA_fa9be649-70bb-4cc1-a4e3-6d68cedc7e4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:durwordsen" name="bhc:HighlyLiquidInvestmentsMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTQyOA_8fd2bf45-529a-4282-827f-11f0e53b8936">three months</ix:nonNumeric> or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, Restricted cash includes $<ix:nonFraction unitRef="usd" contextRef="ib2d18c502e914148abcdf8a1c2043e91_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTA5OTUxMTYzNzg1MQ_e023ec10-5ea7-4005-b6a0-5d7b35266090">1,010</ix:nonFraction>&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation, subject to final court approval, and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature.  These payments will remain in escrow until final approval of the settlement as discussed in Note 18, "LEGAL PROCEEDINGS".</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="icfb95a9cbc524e899e63d817b3d8db10_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMjIyNA_0229cc62-2f44-489d-b4ae-d9b7b2e4f7c8">1,250</ix:nonFraction> million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is the Company&#8217;s investment in certain euro-denominated subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values.  The fair value is determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs may include: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective and remain in Accumulative other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the nine months ended September 30, 2020 and 2019. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s cross-currency swaps liability as of September 30, 2020 and December 31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="iecc04b34723745959d6941b061c3195b_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMzkzNQ_25a99b8e-f35c-4385-9751-7c30407ed823">18</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icfb95a9cbc524e899e63d817b3d8db10_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTA5OTUxMTYzODE1Nw_09dbd726-90c1-4c36-b76d-298fc257ea0c">13</ix:nonFraction>&#160;million, respectively. Included in Other non-current liabilities is $<ix:nonFraction unitRef="usd" contextRef="if2d60cf3b5dd4469bb5e47f010bbf50d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMzk4MA_5422a834-c081-48e0-b250-8b940fadaefa">21</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d3c9eab53e34f758a889ff1b9eef4af_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTA5OTUxMTYzODE0NA_e67ae605-b6b1-412e-9ad3-279167c4377b">22</ix:nonFraction>&#160;million of cross-currency swaps and included in Prepaid expenses and other current assets is $<ix:nonFraction unitRef="usd" contextRef="ia73ddeb398ad40a697491174c66a253e_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNDA2OA_ef62d63c-1436-4445-9228-8a82b20b3ea0">3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic1d2c2593af94b8e894e62f71bab9723_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTA5OTUxMTYzODE3MA_056c338e-d3b8-4758-a394-b1648869a3ee">9</ix:nonFraction>&#160;million of earned interest within the Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019, respectively.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i2328023533524d1d8fc7decd43214ff7" continuedAt="i2502f16dc64946c2a2fb0c705f7b67f7"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODIxNA_3c4f6039-6153-4b82-9577-cb117e19af91" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Gain recognized in Other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc55d9233fce40c7825223f6de02ff68_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMS0xLTEtMS0w_42bbc31f-6324-46bd-b85a-b4857788407f">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8497a03630a4de5833e5a80958dbce4_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMS0zLTEtMS0w_d8916664-ef1f-4a27-af8a-9266aae66d38">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d471827df64e0fbd5711fd783ab1e9_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMi01LTEtMS0zMDg1_19dcb074-a053-4e55-bedd-7abedc92ffb5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1512c924cb094c078074e4aa0ffe4a40_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMi03LTEtMS0zMDg3_5e97b51b-3c0b-4709-9a4d-c04421f361ec">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7093ac6fc1334022aa3265c9294c3e7a_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMi0xLTEtMS0w_e7fc4fe7-22cc-42af-8a02-4dc3e6224892">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13118f68b4df41a393ca9750e6026f86_D20190701-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMi0zLTEtMS0w_f89a0c4c-b455-4ee3-a399-a12703825982">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8202bf5ca3346e7b18cf85e6d73a250_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMy01LTEtMS0zMDg1_52760cbe-65ea-4075-be05-2e2c5f64259f">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e77a2db2998441c921cc42c8c4a50c8_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMy03LTEtMS0zMDg3_73aeaed4-df17-4de9-84b4-a9f1dbae7c4f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of the Company's cross-currency swaps occur in February and August each year. During the nine months ended September 30, 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNDQ3MA_b69416c3-973c-4844-93c6-7031d62e27e3">23</ix:nonFraction> million in settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company entered into foreign currency exchange contracts, with an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i99c0052b44d34257a40d70925ddf626c_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNDcyNw_010edae7-dabd-4937-b5b5-79a2264bbf25">187</ix:nonFraction>&#160;million. The Company had no foreign currency exchange contracts during 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company's foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's foreign currency exchange contracts liability as of September 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i99c0052b44d34257a40d70925ddf626c_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTQ3Ng_afff2d30-fb1a-4993-9fa3-5f24890bbb23">1</ix:nonFraction>&#160;million. Included in Accrued and other current liabilities are $<ix:nonFraction unitRef="usd" contextRef="i99c0052b44d34257a40d70925ddf626c_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTUzNA_5c375bc7-e9d7-42d3-8e50-9afcfbddf818">2</ix:nonFraction>&#160;million and included in Prepaid expenses and other current assets are $<ix:nonFraction unitRef="usd" contextRef="i99c0052b44d34257a40d70925ddf626c_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTU5OQ_7bad7fed-a95a-4b1c-9733-4e386d001f3d">1</ix:nonFraction>&#160;million of foreign currency exchange contracts within the Consolidated Balance Sheets. During the three and nine months ended September 30, 2020, the net change in fair value was $<ix:nonFraction unitRef="usd" contextRef="i0b552f30645f4c44b3ed3df8ec2d60cf_D20200701-20200930" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTc0OQ_9f34c3e1-5528-4655-8ca5-72ce1437846f">0</ix:nonFraction> and a loss of $<ix:nonFraction unitRef="usd" contextRef="i38cb6a98dc8e41d69bdbcc7404a2eb8e_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTc2Ng_aca45e61-94ef-4765-b1ec-7695a7de9aad">1</ix:nonFraction>&#160;million, respectively. Settlements of the Company's foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. During the nine months ended September 30, 2020, the Company reported a realized loss of $<ix:nonFraction unitRef="usd" contextRef="i85b5b7c7ce56466d86e248603302e40d_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNjA3Nw_8924ad2f-1cca-4503-9901-5b312173199b">1</ix:nonFraction>&#160;million related to settlements of the Company's foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At September&#160;30, 2020, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from <ix:nonFraction unitRef="number" contextRef="i2cf0cf8e00c24e43afee18043d34a006_I20200930" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNjk5NA_7d3465d4-05a6-4dda-8cfa-ff4a47fbdf4a">5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i134b8d5216ea4c389549e0da9a4a0aae_I20200930" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNzAwMA_22eed1dd-93aa-446d-9313-c1e9445e6a6e">25</ix:nonFraction>%, and a weighted average risk-adjusted discount rate of <ix:nonFraction unitRef="number" contextRef="i8a85fa3c7eea46178ce2c429ccf9dc45_I20200930" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNzA1OA_df81f532-81dc-4554-8f40-649f2da5ebf1">8</ix:nonFraction>%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at September&#160;30, 2020.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i2502f16dc64946c2a2fb0c705f7b67f7"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODIzMw_e1c575dd-0d62-4396-b61c-69cbfb9178a3" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.194%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfMi00LTEtMS0w_8068900a-8aa8-44b7-ac2d-a0fc736331d7">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfMi04LTEtMS0w_2be82f4d-cf3f-48c3-b6fe-562de38f8521">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5402810168f441a989e311c9910ffff_D20200101-20200930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNC0yLTEtMS0w_4273bb9a-ed91-45a6-81b2-b8ec6d93396b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9d2b6c03b4436ab40680ad98a02f2a_D20190101-20190930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNC02LTEtMS0w_b2e526ca-f340-4adc-bcec-af75b91c5539">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if76287d4ad9248b093a21f0f369b5af6_D20200101-20200930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNS0yLTEtMS0w_eab3decf-29f5-415e-985a-b7e89989b3ad">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d02c0d1ca7046cc873ad6dc780a7de5_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNS02LTEtMS0w_b8cf70c7-a89a-4269-9ab1-0f92aba473a0">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNi00LTEtMS0w_5696a808-f3ff-4578-a03e-b4aa27c50bb4">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNi04LTEtMS0w_98c708e6-084b-44e9-8776-7e582c1c7cba">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNy00LTEtMS0w_eca9f807-4b7e-4c36-a6c9-eff0e51960dd">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNy04LTEtMS0w_29c241cd-5e1f-4a63-a48c-170cb0d871af">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfOC00LTEtMS0w_47d17850-67be-460a-a46c-fc074ee2a2cf">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfOC04LTEtMS0w_1c52744e-cf80-48c7-9bb1-9ae94bb2efc9">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfOS00LTEtMS0w_2e9411c7-4cb1-4aa0-a03d-1be04160d83b">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfOS04LTEtMS0w_1e5f6ba7-1a4f-4e75-af90-c66a0c848284">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfMTAtNC0xLTEtMA_18872e4c-c5d8-415b-90fd-ae9f86d81869">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfMTAtOC0xLTEtMA_d80917d4-a92b-4581-988b-6a325efdcda5">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODIyNA_216305de-d535-4a64-88bf-aebe3d462783" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.493%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb0bbb2a96944d2281f1f89a0ad18937_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0yLTEtMS0w_5f31231e-d24c-4e64-b355-df939c17caec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90eeaa1d0b8e49aa8bf06da2ebbe726c_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy00LTEtMS0w_118f7381-95e6-47e4-9c19-9bc1698e87eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c91ac833ae4d6a85617b9307192c5d_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy02LTEtMS0w_6d9590f1-22ce-4669-99c3-7b975452d42d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8e52c2f7344bd9aaac24f3c709799e_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy04LTEtMS0w_0332262f-4820-437d-9bb2-39dc03a2d3b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4e7897d68043b2ac3bba1cb881d410_I20191231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0xMC0xLTEtMA_b96afbe2-73d9-45e4-b4cc-928d5c39c8d2">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57206313b8ad44a69c438d9a2d26e856_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0xMi0xLTEtMA_ef96e143-dd85-4bb7-8edf-c6ae017e1aae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b628768eab4646b40e4bdaf0246e63_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0xNC0xLTEtMA_bfcd1c71-2534-413b-a5a5-a1df533a9408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c8146e6c714086b4e9c25c3c92eed0_I20191231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0xNi0xLTEtMA_875ab9e2-6b20-4770-8526-ef7017508761">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current assets held for sale of $<ix:nonFraction unitRef="usd" contextRef="i9d4e7897d68043b2ac3bba1cb881d410_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNzYzMg_ac960ee3-fe0a-4792-b59f-8d3a9248ffed">39</ix:nonFraction> million included in the Consolidated Balance Sheets as of December 31, 2019 were remeasured to their estimated fair values less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. As discussed in Note 4, "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE", due to changing business dynamics, the Company decided not to sell these assets during the three months ended March 31, 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of September&#160;30, 2020 and December&#160;31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="i78c91ac833ae4d6a85617b9307192c5d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODA5MQ_9fff14a2-552f-4405-ac01-8baeadc72c17">25,258</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i60b628768eab4646b40e4bdaf0246e63_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODA5OA_a5a8ecb5-db59-4417-8834-0c44b9a46f44">27,520</ix:nonFraction> million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_58"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RleHRyZWdpb246OWU4MTU1OTc1MTVhNGJmMzkwMTU2OGYyZWEyODFjMzRfODI_62b6ead5-b410-4485-8887-a221aff6435d" continuedAt="i42ce5a140f50494c893ab5dbf3120bc9" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i42ce5a140f50494c893ab5dbf3120bc9"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RleHRyZWdpb246OWU4MTU1OTc1MTVhNGJmMzkwMTU2OGYyZWEyODFjMzRfODU_b5c58bb7-58e7-45b3-af5c-53c0a116e1fa" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net of allowances for obsolescence consist of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMS0yLTEtMS0w_ca522a84-77ab-4b31-8ecd-fe579a3211d0">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMS00LTEtMS0w_6c5a59cd-268a-47af-87d5-ec9a4030f253">319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMi0yLTEtMS0w_dfdd638c-9e0e-4e27-8b0a-3fc95bdae4fc">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMi00LTEtMS0w_0f867e4c-6263-4e60-907a-742635914676">149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMy0yLTEtMS0w_9c8913d1-b866-4ddf-b9cd-687d6cde5161">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMy00LTEtMS0w_17564992-2ab0-4341-a48a-165e568a732c">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfNC0yLTEtMS0w_c0260dce-3263-4366-b3a5-2e2aec8987e4">1,224</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfNC00LTEtMS0w_4d706e59-dfb2-4934-a4b6-609c19b4993e">1,107</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_61"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMTk_d763e032-56e7-457c-9ac7-1741dc9d84a5" continuedAt="i68805c3da1104486ad0a8fa9291365ee" escape="true">INTANGIBLE ASSETS AND GOODWILL </ix:nonNumeric></span></div><ix:continuation id="i68805c3da1104486ad0a8fa9291365ee" continuedAt="i681c242e5c41458a85375ddcc56a3c17"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMDM_bad93be6-ae39-4c2a-9d86-417a467a739f" escape="true"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMTM_95759182-35fc-4696-b9fb-37990b2f1dfe" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60de702a35f848f989e520b9af116415_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy0yLTEtMS0w_0b81b270-5eef-4705-841c-90b5ad5456fe">21,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60de702a35f848f989e520b9af116415_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy00LTEtMS0w_b177aa89-8f43-44c2-9b0d-8ee6a9d2bbde">14,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60de702a35f848f989e520b9af116415_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy02LTEtMS0w_b47a56b8-9d9e-4ce8-8000-b21d75ad903f">6,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7d5353c4a04e4bab13e493b248f929_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy04LTEtMS0w_930a6bf0-4ae1-4703-b316-89d00a0582db">21,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a7d5353c4a04e4bab13e493b248f929_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy0xMC0xLTEtMA_70ed3a09-d514-412b-9267-c40598977543">13,544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7d5353c4a04e4bab13e493b248f929_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy0xMi0xLTEtMA_627b438e-c59b-49c7-ade4-f590f34f6f0d">7,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b9f564f7684ff0b786ed6ee60bbc93_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC0yLTEtMS0w_aec730fa-2cdb-4865-81bb-1650fd1fac46">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1b9f564f7684ff0b786ed6ee60bbc93_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC00LTEtMS0w_f9689712-a27a-4d43-91d1-3f824d0c6288">388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1b9f564f7684ff0b786ed6ee60bbc93_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC02LTEtMS0w_10fb7e29-6d6c-4eae-85e2-8b67d34a1119">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a9c4ec0dda0434ead7d7e333f7c0370_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC04LTEtMS0w_6afc0c28-ab1e-410d-80cb-9bde40372030">930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a9c4ec0dda0434ead7d7e333f7c0370_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC0xMC0xLTEtMA_42ccf664-72db-4b2a-98db-ac3d1ca9f6c7">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a9c4ec0dda0434ead7d7e333f7c0370_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC0xMi0xLTEtMA_203c1fc8-0f5d-4ae9-b4e2-340533a582cd">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e98dbf115d34eb7a1ad3c065774fa63_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS0yLTEtMS0w_f72670d6-0f86-4c7a-90d2-9980e1d64752">3,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e98dbf115d34eb7a1ad3c065774fa63_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS00LTEtMS0w_6848dcbf-8a21-4791-a940-8c0f8c7b95fa">3,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e98dbf115d34eb7a1ad3c065774fa63_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS02LTEtMS0w_d18017f1-e59a-462d-a6e9-97b0732a53ab">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1219c91340a14f5bad320111435c4733_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS04LTEtMS0w_0fafaa14-b24e-4a0b-8f81-81e35a579be6">3,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1219c91340a14f5bad320111435c4733_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS0xMC0xLTEtMA_39c1c1ac-6659-4b4e-9165-e47ae8ce6d27">2,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1219c91340a14f5bad320111435c4733_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS0xMi0xLTEtMA_cb143701-411c-41dc-aa4b-6d3d2661a4f2">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f288455ff543adb3dba8d444c258df_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi0yLTEtMS0w_8779c5bb-0068-457b-87a7-b96f65b1d890">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32f288455ff543adb3dba8d444c258df_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi00LTEtMS0w_7533843d-7e68-47b0-93c2-55f7dce032fd">163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f288455ff543adb3dba8d444c258df_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi02LTEtMS0w_a0d8198c-aa53-4c44-8550-93952a301f49">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62565a11ef494521b8f3aa6a1473a264_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi04LTEtMS0w_c85a9390-0c47-45b0-a0bd-fd95a5d62bfb">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62565a11ef494521b8f3aa6a1473a264_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi0xMC0xLTEtMA_80c21a67-01ef-4c96-826b-4f438c47c202">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62565a11ef494521b8f3aa6a1473a264_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi0xMi0xLTEtMA_0d7ca736-9b8f-4c58-a649-d923b89b9106">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d948a6f072e4f7b8c8b385b727ebcd0_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy0yLTEtMS0w_d3ac4d22-59e8-4bde-9dc3-6680e38d96d8">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d948a6f072e4f7b8c8b385b727ebcd0_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy00LTEtMS0w_84971e0b-a571-487e-bb5d-ed68c9134175">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d948a6f072e4f7b8c8b385b727ebcd0_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy02LTEtMS0w_b07c0e9d-c89d-4728-bc21-0918b2a245df">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7532691dd59d4bdeb91fcdaa78acc1ea_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy04LTEtMS0w_f09604d3-5790-42b3-b000-b1eb8347cd33">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7532691dd59d4bdeb91fcdaa78acc1ea_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy0xMC0xLTEtMA_7b8ebf4a-fd73-4469-a744-7f68883f7b16">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7532691dd59d4bdeb91fcdaa78acc1ea_I20191231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy0xMi0xLTEtMA_ac77878f-9a4f-4893-b141-c1d973ec79ea">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC0yLTEtMS0w_5713e6b8-18b2-4e76-ab6d-7e8df2d22db1">25,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC00LTEtMS0w_2f08778b-47af-40e1-8b56-26c6cbb474c3">18,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC02LTEtMS0w_ccdf0361-8378-4ed5-b08d-f2c0c6e2a23e">7,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC04LTEtMS0w_1cbbd834-5dcb-4306-90b5-e664fb549bf1">25,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC0xMC0xLTEtMA_683a9342-cd76-47cf-a415-b47b47c5bfc2">17,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC0xMi0xLTEtMA_bd937fd6-25b5-47da-8e4c-b49a18526a5a">8,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90067b409ecb46e7a0730f1885ddd46a_I20200930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOS0yLTEtMS0w_8303e0fe-a106-4495-92a8-04a3d29c3409">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90067b409ecb46e7a0730f1885ddd46a_I20200930" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOS02LTEtMS0w_913e256c-a928-4675-b531-308a72a8c9af">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5eb558f1acd4fa3890d17ea839f934f_I20191231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOS04LTEtMS0w_c32f5772-a67c-47bc-857a-3e6a690aab1e">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5eb558f1acd4fa3890d17ea839f934f_I20191231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOS0xMi0xLTEtMA_8ae8a382-9396-469b-9cc9-823e945aa795">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1524d6d70de47e4bf378c17d3a6fb88_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTAtMi0xLTEtMA_8b3aa41d-0caf-47f8-bdb2-1fc09dcd2e8d">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1524d6d70de47e4bf378c17d3a6fb88_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTAtNi0xLTEtMA_4017e783-d953-46ab-b757-dd16b4313d26">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98aa749670ef4cb2bcbe79c1b3f35d01_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTAtOC0xLTEtMA_fa76fe5d-51ee-422c-af4d-82124b03306b">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98aa749670ef4cb2bcbe79c1b3f35d01_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTAtMTItMS0xLTA_d71cbdaf-9709-4aa8-aca6-7756f07f2cbb">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtMi0xLTEtMA_908d1dff-8dad-4f18-aa18-15cc8dbf7d6e">27,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtNC0xLTEtMA_239f4b9c-0cb1-403e-a2bc-fd2b92e5d06f">18,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtNi0xLTEtMA_a221a219-bbf5-436d-995c-ab6fffd91a83">8,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtOC0xLTEtMA_9d7d692c-4b23-41e1-89ef-4022cbbf928a">27,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtMTAtMS0xLTA_d3cdf615-4ddf-42f5-ad87-e0020abac648">17,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtMTItMS0xLTA_2828f27b-8e5c-49ac-9f2e-3542897d4ea7">10,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments for the nine months ended September 30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNjI3_cca0c65f-7107-4f81-8e89-ad279eed20a9">17</ix:nonFraction>&#160;million and include impairments of: (i) $<ix:nonFraction unitRef="usd" contextRef="i2f3c80353f4a458e9cf3e5ea8ee4bb86_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNjYy_473c2e25-4ba3-4089-b4f8-0d04cceeb0b9">16</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) $<ix:nonFraction unitRef="usd" contextRef="i88876a23cdf3417d8234422eedf815f1_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNzM3_acbe30e4-fab6-4c88-a78a-791b0bd0369c">1</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments for the nine months ended September 30, 2019 were $<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfOTA1_c92db02d-a61e-4384-892e-d4ba752f4d99">49</ix:nonFraction>&#160;million and include impairments of: (i) $<ix:nonFraction unitRef="usd" contextRef="ic084d62da2994e0b8eac7d247b4df526_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfOTQw_6ef752e4-1060-48c3-aba4-75a476c442eb">38</ix:nonFraction>&#160;million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $<ix:nonFraction unitRef="usd" contextRef="icf690e4cf1844b909f7af94cd53ff788_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfOTg5NTYwNDY3NTg4Mg_acb17949-3fd9-49cb-b48e-17305f2d8c1f">8</ix:nonFraction>&#160;million related to assets being classified as held for sale and (iii) $<ix:nonFraction unitRef="usd" contextRef="i4df44c5814334fcb9850108f2c45d7d7_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTA0Ng_b5239c1d-5682-41f5-baac-3cda86e9c0e0">3</ix:nonFraction> million due to the discontinuance of specific product lines not aligned with the focus of the Company's core businesses.</span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMzI_03290997-c1b5-4eee-a459-b0c8b15ae0a5" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2020 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0yLTEtMS0w_caade619-2f3d-466a-aa8f-a8c940445870">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS00LTEtMS0w_1fd86f3b-18ea-471e-8707-6fc8c351278c">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS02LTEtMS0w_8d2ba600-543f-48d7-ab5f-7bf92185fc77">1,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS04LTEtMS0w_e68f4c30-b8dd-47c0-8c62-4065771aeeee">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0xMC0xLTEtMA_9afd49fb-4ed8-46d0-9ad7-398cf00df8f1">925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0xMi0xLTEtMA_98712df5-cdbd-4901-99af-bd02714b889f">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0xNC0xLTEtMA_9164bbea-3c1d-4f8e-9f04-e3fead3dcdd2">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0xNi0xLTEtMA_566cb719-9448-4fc7-b883-711e87571514">7,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMDA_16b4250e-04d1-42f5-9747-955f2caa1b3c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the nine months ended September 30, 2020 and the year ended December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37e1d6d0d86b4260a9dafbceb3ca67b3_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS0yLTEtMS0w_ec4713f2-a06a-444b-bc5c-82b3168b1aa2">5,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ce595b55e84cc1b6036ed5e3783ef7_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS00LTEtMS0w_f03a2c57-714f-4f3f-99da-9ec5bef3f7a7">3,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a82463a67ee4a98aebdb33bda1870ee_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS02LTEtMS0w_b2c65c03-222a-4c4e-8386-3697fa6ec726">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff834d7d5db945ffb10479e4d06e77d1_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS04LTEtMS0w_0e808717-8e61-45e7-9972-55fa36e11167">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS0xMC0xLTEtMA_e7a8c0d1-198d-4e01-b89e-d03003a7ade4">13,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60250601219a4629a0ff2f0c1dc4062f_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMi00LTEtMS0w_e52aed55-d1b3-4e4b-b3ed-3cf0c992e916">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMi0xMC0xLTEtMA_c7812dd1-f291-4fd8-aec2-baea553c53c3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbf24fa76f6a402bb9e6156b05d6b5f0_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMy0yLTEtMS0w_76be00cf-8e18-4c78-b3c8-cc544decbb22">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMy0xMC0xLTEtMA_d815b406-63fd-451f-82f5-78e59e00a2cf">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbf24fa76f6a402bb9e6156b05d6b5f0_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNC0yLTEtMS0w_f9450315-2432-433b-873b-d753ceeb08f7">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNC0xMC0xLTEtMA_d810d522-9840-4989-aa9f-092ef550d701">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c4612f6b4d649079848c866b406b98b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS0yLTEtMS0w_777bf8b6-7074-42fd-ba53-106e518a49c4">5,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45b5cf1e2a7748d998e39be96bdcffe8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS00LTEtMS0w_07013301-144f-4952-8061-1200739684f3">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ddb02b4b9240f4a9c623f147564d77_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS02LTEtMS0w_acb8cbb1-f71c-4aad-aba3-f8e447702765">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ac25e181e840fcba249ad8ca572ded_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS04LTEtMS0w_6fc9eaef-d308-4b8c-ae13-3785189507c1">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS0xMC0xLTEtMA_c360cbfe-8964-4cd6-b721-db9ffb97de2c">13,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill (Note 4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02972067b44c4ebbb40b0dce231c9b74_D20200101-20200930" decimals="-6" name="bhc:GoodwillReclassifiedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNi0yLTEtMS0w_01f2b004-f3cd-4aed-b929-5dd85742f18c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="bhc:GoodwillReclassifiedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNi0xMC0xLTEtMA_0fd82929-5c51-45c4-9052-136700fbd74e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02972067b44c4ebbb40b0dce231c9b74_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNy0yLTEtMS0w_17853935-07f9-4204-a8a8-15a0abfcc479">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNy0xMC0xLTEtMA_ad5dfefe-ecc8-499d-9106-65d63c376937">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5788f2e64d25455ab4cc8ee55962643c_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC0yLTEtMS0w_b8129203-3526-4ca8-b07e-abea85d3c3d0">5,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c98652fcf224ee890fa8c7644b8f148_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC00LTEtMS0w_15b18880-c0d1-4162-9842-c90a92e1f547">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3901dd0ca3ae42fba60b944fd1072d67_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC02LTEtMS0w_a5e5f127-81fc-4de2-b3e4-1f3fcc8ae3ce">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7242e85fe1ed4cbc935e2d4c982c7f86_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC04LTEtMS0w_e58d8922-4cf1-40c4-809a-8f238c3564ff">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC0xMC0xLTEtMA_44f80a28-0f1a-4feb-aec7-db89ac8c12e1">13,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i681c242e5c41458a85375ddcc56a3c17" continuedAt="idaa2955decef4e09a3d93121b0e80480"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of all reporting units using a discounted cash flow model which utilizes Level 3 unobservable inputs.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The Company performed its annual impairment test as of October 1, 2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount (Step 0). Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit (Step 1). The quantitative fair value test was performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company forecasts cash flows for each reporting unit and takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts were based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such charges could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Goodwill Impairment Testing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2019, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value and therefore, no impairments were recorded. The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was <ix:nonFraction unitRef="usd" contextRef="i7796cbaae34c4708bf7e612f118984d4_D20191001-20191001" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTM1NQ_ebce36b2-15be-4f11-a57d-105ec2236629">no</ix:nonFraction> impairment to the goodwill of any reporting unit. The Company performed quantitative fair value tests for the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of October 1, 2019, utilizing long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i49d1b68c815f41ad8f89064d1e9fc9da_I20191001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTYwMQ_c0be2b3d-52e1-42e9-9b8e-1b712eca37c4">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i46d706dfc2e941c7aceac6173927bd08_I20191001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTYwOA_c0a257b3-eefa-40c5-872e-57375350ddfd">1.5</ix:nonFraction>%, and discount rates of <ix:nonFraction unitRef="number" contextRef="i49d1b68c815f41ad8f89064d1e9fc9da_I20191001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTYzNA_0b107570-a0bc-40ab-b19d-7de57aceceef">9.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i46d706dfc2e941c7aceac6173927bd08_I20191001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTY0MQ_0efa800a-31f2-4e21-b233-7f7497994128">9.0</ix:nonFraction>%, respectively, in estimation of the fair value of these reporting units.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessments </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, the Company has taken actions to protect its employees, customers and other stakeholders and mitigate the negative impact of the COVID-19 pandemic on its operations and operating results. These and additional actions can increase the costs of doing business during the pandemic and, in the periods that follow, may include the costs of idling and reopening certain facilities in affected areas.  Further, social restrictions and other precautionary measures taken by customers, health care patients and consumers in response to the pandemic are expected to impact the timing and amount of revenues during the COVID-19 pandemic. Although the Company's revenues for the nine months ended September 30, 2020 were less than those forecasted on the date goodwill was last tested for impairment (October 1, 2019) and additional pandemic-related declines in revenues may occur for the remainder of 2020, there are no indications that these trends are materially related to developments other than the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative impacts of the COVID-19 pandemic on the global economy were not existing conditions on the date goodwill was last tested for impairment (October 1, 2019) and have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows.  In performing its assessment, the Company considered the possible affects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts as of October 1, 2019 (the date goodwill was last tested for impairment) for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="idaa2955decef4e09a3d93121b0e80480" continuedAt="i028aa4474f394b01934f0b7a82754f87"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the pandemic, the public has been advised to engage in certain "social restrictions" such as: (i) remaining at home or shelter-in-place, (ii) limiting social interaction, (iii) closing non-essential businesses and (iv) postponing certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, these factors negatively impacted, most notably, the revenues of the Company's Global Vision Care and Global Surgical businesses in Asia where the COVID-19 pandemic originated. Beginning in March 2020, and throughout most of the second quarter of 2020, the Company experienced steeper declines in these revenues and the revenues of other businesses as social restrictions expanded worldwide, particularly in the U.S. and Europe. Social restrictions negatively impacted the Company's revenues for contact lenses, intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of its Global Ophtho Rx business, medical aesthetics and therapeutic products of its Global Solta business, and certain branded pharmaceutical products of its Salix, Ortho Dermatologics and Dentistry businesses, as the offices of many health care providers were closed and certain surgeries and elective medical procedures were deferred.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues for the nine months ended September 30, 2020 were negatively impacted by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic earlier in the year. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize.  Presuming there is no material resurgence of the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020. The Company therefore believes that its revenues for the year 2020 will be most impacted by the COVID-19 pandemic in its second quarter, although the Company experienced additional COVID-19 pandemic related declines in the year-over-year revenues in its third quarter, and expects additional COVID-19 pandemic related declines in the fourth quarter of 2020, in many of its businesses and geographies. Presuming any reenactment of social restrictions is not significant, the Company anticipates that its affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's latest forecasts of cash flows gives consideration to the nature and timing of the expected revenue losses disclosed above.  The changes in the amounts and timing of these revenues as presented in the latest forecasts include a range of potential outcomes and, with the exception of the Ortho Dermatologics reporting unit as discussed below, are not substantial enough to materially adversely affect the recoverability of any of the associated reporting units&#8217; assets and are not material enough to indicate that the fair values of those reporting units might be below their respective carrying values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results of the October 1, 2019 annual goodwill impairment test, the Company continues to assess the performance of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit and performs quarterly qualitative assessments of their respective carrying values and fair values to determine if quantitative fair value testing is warranted. As part of these qualitative assessments, management considers the totality of all relevant events or circumstances that effect the carrying amount and fair value of each reporting unit, including comparing actual operating results to the forecast used to test the goodwill of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of October 1, 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neuro and Other Reporting Unit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believed that based on its qualitative assessments as of March 31, 2020, June 30, 2020 and September 30, 2020, it was more likely than not that the carrying amount of the Neuro and Other reporting unit was less than its fair value and, therefore, concluded a quantitative assessment was not required at March 31, 2020, June 30, 2020 and September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics Reporting Unit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the operating results for the Ortho Dermatologics reporting unit were less than those forecasted at October 1, 2019 for that period. As part of its qualitative assessment as of March 31, 2020, the Company revised its forecasts for the year 2020, for among other matters, the lower than originally forecasted operating results for the three months ended March 31, 2020 and the range of potential impacts of the COVID-19 pandemic, including longer than expected launch cycles for certain new products. Management believed that the revisions to its forecasts for the year 2020 were indicators that there was less headroom as of March 31, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2019).  Therefore, a quantitative test for the Ortho Dermatologics reporting unit was performed at March 31, 2020. Based on the quantitative test, the fair value of the Ortho Dermatologics </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i028aa4474f394b01934f0b7a82754f87"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting unit continued to be greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i3ab0c68ed13d4af2b182ef303b0fe3ad_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNDM5ODA0NjU0NDM1Mw_522644c4-49c8-4d16-96d8-aa604a43a1f9">no</ix:nonFraction> impairment to the goodwill of the reporting unit at March 31, 2020.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2020, the Company identified certain Ortho Dermatologics&#8217; products that were experiencing longer launch cycles than originally anticipated due to the COVID-19 pandemic and, as a direct result, took actions to mitigate the impact of these matters, including right-sizing its Ortho Dermatologics&#8217; sales force. As part of its qualitative assessment as of June 30, 2020, the Company revised its long-term forecasts for, among other matters, the decrease in forecasted revenues of the identified products, the reduction in sales force and related costs and a range of potential impacts of COVID-19 pandemic related matters.  Management believes that these events are indicators that there is less headroom as of June 30, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (March 31, 2020). Therefore, a quantitative test for the Ortho Dermatologics reporting unit was performed. The quantitative test utilized the Company's most recent cash flow projections, including a range of potential outcomes, along with a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i9bfb00e0e8444c42bf506fb600021040_I20200630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ3OTA_d5613b5a-65fc-460f-af79-c22f96d39af6">2.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i4a13f2e9033b495d9444dd5e982f843f_I20200630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ4MzE_2d503e8c-a172-4eab-8dae-e003d746e75e">9.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i497e92548eac4239bd07de80e571194e_I20200630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ4Mzg_a7a9623f-feba-4cee-9580-60e08dbd49f2">10.0</ix:nonFraction>%. Based on the quantitative test, the fair value of the Ortho Dermatologics reporting unit was <ix:nonFraction unitRef="number" contextRef="i4a13f2e9033b495d9444dd5e982f843f_I20200630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ5MzU_ccaa2b19-b857-41a9-be9f-9dc5595726d6">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i497e92548eac4239bd07de80e571194e_I20200630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ5NDE_03c3b84e-fee2-453a-94e6-d10c990e58e6">15</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="ie43ad075e98f4dd89ef32cfaff2d61e7_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTUwMDI_17ba7059-5301-4b11-9149-552c9c041769">no</ix:nonFraction> impairment to the goodwill of the reporting unit at June 30, 2020.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believed that based on its qualitative assessments as of September 30, 2020, it was more likely than not that the carrying amount of the Ortho Dermatologics reporting unit was less than its fair value and, therefore, concluded a quantitative assessment was not required at September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit and Neuro and Other reporting unit including: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for new products and (iv) ongoing pricing pressures, which could negatively impact the reporting units' results over the long term. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If market conditions further deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#8217;s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges can be material.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No other events occurred or circumstances changed during the period October 1, 2019 (the date goodwill was last tested for impairment) through September&#160;30, 2020 that indicate it is more likely than not the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit may be below its carrying value. The Company will perform its annual impairment test as of October 1, 2020. In addition, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021, and as a result the Company may need to perform an impairment test upon realignment of its operating segments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through September&#160;30, 2020 were $<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYxOTI_be0934a4-32a0-4c5b-9e38-fc613d25ff61">3,711</ix:nonFraction> million.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RleHRyZWdpb246MTU1NGMzMWMxYWQ0NGMzMmJhNzA4NjVlMDBiYmI0OTRfOTU_9cba617b-7f81-4b9b-99c4-aa6b1441eda7" continuedAt="i92744122abcf4ab8a85b0ae295b2458e" escape="true">ACCRUED AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i92744122abcf4ab8a85b0ae295b2458e"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RleHRyZWdpb246MTU1NGMzMWMxYWQ0NGMzMmJhNzA4NjVlMDBiYmI0OTRfMTAx_f745ca6a-3ef1-42d8-85a4-bccaf8c9aeab" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="bhc:Legalsettlementsandrelatedfees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMS0yLTEtMS0w_79cfedcf-70a9-4a78-ab4b-2f0b4c5458d9">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="bhc:Legalsettlementsandrelatedfees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMS00LTEtMS0w_1333fd15-fce1-4573-b927-42a7677ca65e">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMi0yLTEtMS0w_9a38944c-6319-4a54-bb8d-21c56c37b337">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMi00LTEtMS0w_fb1aaf78-5471-4290-8d2b-bfe5054378df">898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMy0yLTEtMS0w_50c74908-312c-45ed-9a99-2d2def8b5d14">577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMy00LTEtMS0w_354b7283-0e7f-41b4-aa08-832cc40ab24e">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNC0yLTEtMS0w_cd0065d3-a103-444e-8f60-b28ab693b390">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNC00LTEtMS0w_e9ed9578-313c-4bd9-8302-aec9acdd7478">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNS0yLTEtMS0w_c611d9b9-0974-4bf7-9d46-fe2ef6a2d707">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNS00LTEtMS0w_9a22b603-9ca8-4cf2-b9b9-98f532556405">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNi0yLTEtMS0w_035021ae-a92a-4777-9559-b266bb4fc402">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNi00LTEtMS0w_ad803188-cf41-4a86-b9be-4d965fa410d9">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNy0yLTEtMS0w_fd68610c-b207-49dc-bd10-8435f3d4c027">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNy00LTEtMS0w_4527fbe7-aa7c-4df8-84a0-6f0d68821699">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfOC0yLTEtMS0w_b3bdcd4e-70f4-4ac7-aa51-e643d941c1d0">4,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfOC00LTEtMS0w_77a90edf-32d0-4827-80e3-b5be54817d94">4,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_67"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNDM5ODA0NjUyOTY0OQ_11790faa-aca6-4a99-8183-9d141d626bad" continuedAt="ie095f76651aa494493c7e2e19ed5aa16" escape="true">FINANCING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="ie095f76651aa494493c7e2e19ed5aa16" continuedAt="i8b963c82480546a7917d32ba551c73a7"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTg0Njk_b444bdda-63f4-4e07-983d-c6f7f8aded0d" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMy00LTEtMS0w_29c3b1f0-ef10-440c-b270-bfc8c844b089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMy02LTEtMS0w_9bde65c0-75fd-4305-92a7-7d304a00625b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5435fc465e4452bd424177d30f58bd_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMy04LTEtMS0w_6f73f234-ff75-43b9-9532-e958b11339e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5435fc465e4452bd424177d30f58bd_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMy0xMC0xLTEtMA_a5a50ca3-ad15-437f-b9a3-e853f9309ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7020a01b884f0db71be5081d3f6c00_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNC00LTEtMS0w_78cd4c84-dae0-43b5-bf8a-7c883ed816f8">3,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7020a01b884f0db71be5081d3f6c00_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNC02LTEtMS0w_98b569d6-4a04-497a-b898-95316cc6c0f9">3,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2717ecbbb85c46189233254a15f62cb8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNC04LTEtMS0w_dddc085d-fb51-4176-b6cb-c9c13eaece6d">3,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2717ecbbb85c46189233254a15f62cb8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNC0xMC0xLTEtMA_d14e8dec-fb3f-46fe-9f16-6f1d8ce30afb">3,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98399a1cca534743bbf269f1fb3a7bd3_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNS00LTEtMS0w_6f68bdf7-087b-44ce-a188-66eff3cbadd4">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98399a1cca534743bbf269f1fb3a7bd3_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNS02LTEtMS0w_8ea2add5-0149-4dc0-bdbc-54aab1dbaa0f">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8b907b90fb44f7aaa306fa87dcc261_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNS04LTEtMS0w_13eb6b20-3a2c-465b-95ee-d06a6dc7768f">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8b907b90fb44f7aaa306fa87dcc261_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNS0xMC0xLTEtMA_6b3c07a3-985d-4c7a-9042-137bba9fd196">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i316ad5c435e840ef90de3b77001a0859_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy0wLTEtMS0wL3RleHRyZWdpb246ODgwMGNiOTExMjc0NDQwOWE5ZDg2OWY0ZGE3ZTY5MDFfNA_bc6c98f0-c600-47f0-be20-20cd0f0c6bbf">6.50</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i316ad5c435e840ef90de3b77001a0859_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy00LTEtMS0w_80e24bb6-ee20-4347-8ab1-b0de9695a1f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i316ad5c435e840ef90de3b77001a0859_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy02LTEtMS0w_2b64433d-fb42-4e9a-b443-5febb9737ab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3f33246acf4dbca28fc09e8480089e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy04LTEtMS0w_9912a63e-6bfe-414f-97fe-ba8b9371c412">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3f33246acf4dbca28fc09e8480089e_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy0xMC0xLTEtMA_ab269bae-81b3-4e14-a1a5-e48a9456ca56">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d696c5338494267913e8de2e88aa076_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC0wLTEtMS0wL3RleHRyZWdpb246NjBkY2RkOTIxNmRjNGUzNTk4MTljOGVjNDUwMjBmYWZfNA_9b175bd0-5930-473c-8e1e-97d6fcd79e77">7.00</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d696c5338494267913e8de2e88aa076_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC00LTEtMS0w_ed7add89-1b74-4fc7-aa62-71677e20f2ed">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d696c5338494267913e8de2e88aa076_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC02LTEtMS0w_0b413df9-b7fd-42d5-81c4-69f127776009">1,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4174779ec8e4c1ca5559035fd373586_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC04LTEtMS0w_9ad719f1-7cd9-4253-8936-7f6382ebe86d">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4174779ec8e4c1ca5559035fd373586_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC0xMC0xLTEtMA_a21a36f9-8a75-4e60-a01d-daed3e8236e9">1,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i497f5686edd647cda52dac088120c9ef_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS0wLTEtMS0wL3RleHRyZWdpb246MGNiODhlNmU1YmI3NDc4YTkxNjgwMGYyM2JlZWQzNWNfNA_e376a7cb-b155-4a3c-99f8-eac1e5f34037">5.50</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i497f5686edd647cda52dac088120c9ef_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS00LTEtMS0w_8a233c12-ca66-468b-830a-0cbd5b154af3">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i497f5686edd647cda52dac088120c9ef_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS02LTEtMS0w_44cd15ac-902f-4121-b583-510757f61bc2">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f354431d8b04f3bb3386e747317da6f_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS04LTEtMS0w_70005462-1823-4353-b9ae-9de36149517f">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f354431d8b04f3bb3386e747317da6f_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS0xMC0xLTEtMA_d3e404ef-8cb6-471e-acd7-dea38233aece">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i87368b9b19074dd5bcef3473b1da76c9_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmRkZTM3N2JmODZlZjRmOTVhMGMwZjJhYTk5YTUxMjkzXzQ_953084bf-3c47-4849-ada8-5eb264c299f3">5.75</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87368b9b19074dd5bcef3473b1da76c9_I20200930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtNC0xLTEtMA_4e04f346-37f0-4757-897d-af6f49c43b06">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87368b9b19074dd5bcef3473b1da76c9_I20200930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtNi0xLTEtMA_a99f0097-2d3c-46d6-a728-903c91020375">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa57f23b3f05469cb9fb7459da7dafe2_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtOC0xLTEtMA_735dfa22-94d9-47a2-b8ef-58e1b030d3e7">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa57f23b3f05469cb9fb7459da7dafe2_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtMTAtMS0xLTA_12a3eebb-0d62-46ae-ab15-8508914e234f">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icae95739a04e4d7e98f843bed573f29d_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjYzOTU4MzY4ZjM2ZTRjMDk4OWM5ZjFiZmMxNjliMTVhXzQ_6b60bc35-37c8-4a6e-852e-c3e90a531238">5.50</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae95739a04e4d7e98f843bed573f29d_I20200930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItNC0xLTEtMA_3a60a678-7b95-4b6e-8f0d-aa586d72c27d">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icae95739a04e4d7e98f843bed573f29d_I20200930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItNi0xLTEtMA_9f376ecf-9793-49ce-abec-db9ea3162462">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6a7be2d30645a2aa38edcdea6ea2d8_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItOC0xLTEtMA_85b0c9ca-74ff-4824-8d63-8747134bd19e">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6a7be2d30645a2aa38edcdea6ea2d8_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItMTAtMS0xLTA_d91cd166-231e-4428-99c6-64bcc631d2f4">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16f95753426e401589837076426992c3_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjFkNTIwMjBjZDdiZjQzN2Q5ZWFhYTE2NGY1YWE1ZmIwXzQ_7e927b73-f29a-4fd2-967b-b20a06f216f4">5.875</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f95753426e401589837076426992c3_I20200930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtNC0xLTEtMA_4584eba4-f178-4580-9266-a142d68a60d5">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f95753426e401589837076426992c3_I20200930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtNi0xLTEtMA_5921b1c1-804d-4d41-bf80-9d905b2189e9">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2400aa7f3799471ba8c54285606aa32b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtOC0xLTEtMA_a22667eb-4d99-46f5-a88d-3b9cca7c2d55">1,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2400aa7f3799471ba8c54285606aa32b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtMTAtMS0xLTA_0139faba-8bff-49b6-b16f-648a68626a78">1,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6324b2addc314c438452dc1212149f94_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMjllNmU2NGVhNTQ0OGQ4YjYzOGRkYjdkMzJlZTVhXzQ_8ef96e44-b4a3-4607-9567-1fe3d61add2e">4.50</ix:nonFraction>% euro-denominated debt</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6324b2addc314c438452dc1212149f94_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtNC0xLTEtMA_f8130cc5-e628-4971-9e6c-5781e546bf2b">1,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6324b2addc314c438452dc1212149f94_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtNi0xLTEtMA_9ce79e0a-1e33-49d6-81d5-ef798d89a1f9">1,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i460140edb8e84ba8a14c588b51b5c03b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtOC0xLTEtMA_963d7b68-3a7f-4af1-ab9e-e9847a096334">1,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i460140edb8e84ba8a14c588b51b5c03b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtMTAtMS0xLTA_ddc0141b-7389-4f13-bc88-a48102b47a3b">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ec30846b9da42938cce5010c3a35bcd_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtMC0xLTEtMC90ZXh0cmVnaW9uOmYzMTA5ZTMzYzZmMzRkOTU4MjRkOTJkMTIxMDc1ODYyXzQ_ef868129-4f2c-4826-8b96-1833355d88ae">6.125</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec30846b9da42938cce5010c3a35bcd_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtNC0xLTEtMA_629d97d7-0e7f-4aa1-9e67-e8fac7393aba">3,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec30846b9da42938cce5010c3a35bcd_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtNi0xLTEtMA_e8d21f0c-62d1-429e-a51b-b928371cb149">3,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad32b98d9b574350bd3358b9c05d9ce6_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtOC0xLTEtMA_35f12811-2136-4650-913e-bb5f0614ef70">3,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad32b98d9b574350bd3358b9c05d9ce6_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtMTAtMS0xLTA_c09446c4-1f38-4174-a1a2-fd533e074f3a">3,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53587a104f1b4a54a2d8ff9c9b6bd142_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtMC0xLTEtMC90ZXh0cmVnaW9uOjM1YmM1MGQwYWEzNDRlNTliMjgwNGZhZTk5MzFiOGZjXzQ_5b2d53c5-d895-491c-9905-c7f12672aa19">9.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53587a104f1b4a54a2d8ff9c9b6bd142_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtNC0xLTEtMA_3f568345-8e8a-4e77-820d-f0804dbf0c1b">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53587a104f1b4a54a2d8ff9c9b6bd142_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtNi0xLTEtMA_2dab3d32-5562-442d-a172-24604c4b01be">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id810e7631eea4dff84546da8b682136d_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtOC0xLTEtMA_44d96c4e-e056-45a2-b948-a58c7ac43be5">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id810e7631eea4dff84546da8b682136d_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtMTAtMS0xLTA_4a0b75f9-bd28-4901-b288-52cde47ecb6a">1,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50e1cfc4864b4b47939f26aad6d97167_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctMC0xLTEtMC90ZXh0cmVnaW9uOmNjZGVmMDRjY2MxNjRhYjBhN2Q2MzZjZDU3Y2I3OTFlXzQ_dea8d4a9-2779-4082-8715-3789e2381171">9.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e1cfc4864b4b47939f26aad6d97167_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctNC0xLTEtMA_c477dca8-9e52-4d44-bc1e-52e8f8d06626">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e1cfc4864b4b47939f26aad6d97167_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctNi0xLTEtMA_a04a93d0-8120-4d78-9fbf-b4060abca2dc">1,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9962ff5f6e1a4381b06b75c4fe70b3cf_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctOC0xLTEtMA_9aba713b-9952-40e1-9d1e-54f8ea6fba49">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9962ff5f6e1a4381b06b75c4fe70b3cf_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctMTAtMS0xLTA_884d1b62-78f2-4e30-b42e-2804c6e2de73">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb407c4dee97479aaed7d0a54af5a221_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NDAzOWE3NjAxNDQ1NTRhZjA1MmU4OTc2ZTg3NDRjXzQ_0941c101-dbc3-4ca4-8001-196bfa3da2f7">8.50</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb407c4dee97479aaed7d0a54af5a221_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtNC0xLTEtMA_61e70667-4f68-473a-83c8-787405eaf023">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb407c4dee97479aaed7d0a54af5a221_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtNi0xLTEtMA_26326908-f36d-4eac-899e-e14c5cf2fcbf">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4435aa298394060ac34998db6d5518a_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtOC0xLTEtMA_a4fc098e-b39d-45cf-a68e-2cee10780a7d">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4435aa298394060ac34998db6d5518a_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtMTAtMS0xLTA_f37f835f-cd91-4a77-a981-5b661fd2eb58">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a207b5e7c8f4f558db12a478c0a5d91_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktMC0xLTEtMC90ZXh0cmVnaW9uOmEwNTFlNWM3NzhjOTRhNDQ4YTBkYjJhNDA2OTQ0N2MwXzQ_8a9cd470-e676-4736-a0e9-86acad2b6114">7.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a207b5e7c8f4f558db12a478c0a5d91_I20200930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktNC0xLTEtMA_9e341abb-298f-4adc-8ea8-0a7f063c0738">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a207b5e7c8f4f558db12a478c0a5d91_I20200930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktNi0xLTEtMA_169b11df-9a49-445a-bdf3-a7105c2ff4a8">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b37d1f5b4f444890c50f2aabcafde2_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktOC0xLTEtMA_d5893ece-d5dc-4382-9311-54b68dad1b01">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b37d1f5b4f444890c50f2aabcafde2_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktMTAtMS0xLTA_4ff82337-7cff-4261-84ba-f73309cafaad">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id04297c5b7e24c3baf8e9267fbf3225d_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmY1MGU1MzBmZjM1MDRjODM4Yzc1MzZmNjM3OWQyYWQ0XzQ_6b11aa6f-ab41-49fc-ad80-8b5442e1a356">5.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04297c5b7e24c3baf8e9267fbf3225d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtNC0xLTEtMA_c5aebfe4-7dd7-454a-b4c4-30afcc0a41b4">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04297c5b7e24c3baf8e9267fbf3225d_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtNi0xLTEtMA_8f616bb6-9b22-48b6-8757-9ed850aafe1b">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7ec9f615434b68bcfe0abda5733b00_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtOC0xLTEtMA_ad275036-e7a8-4e90-b74f-3c524314bb38">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7ec9f615434b68bcfe0abda5733b00_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtMTAtMS0xLTA_e1b742ef-15df-4d77-b30b-c7ed2f6f7ecb">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01dddd98cd27486db73e8eb05dad1238_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjA0M2MyMjQwYzgxYjQ2YmZiYzBjY2E2MzVkMWNiOWU0XzQ_9e6b25b9-e092-486a-9a44-d31e4aea9750">6.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01dddd98cd27486db73e8eb05dad1238_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtNC0xLTEtMA_e0608dab-b2c7-4af5-9c3f-d43a6e3370b1">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01dddd98cd27486db73e8eb05dad1238_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtNi0xLTEtMA_1cd108d4-2f01-4613-8b04-1f8c4dd5b254">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708265c3841641feae11212bbe24bd13_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtOC0xLTEtMA_6e2d3891-b44e-4bee-ac61-7cd3c51177c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i708265c3841641feae11212bbe24bd13_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtMTAtMS0xLTA_a360b086-22bb-465a-a702-9189eedd7383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50ef442c17d9418f8c9a539cb1195ec0_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItMC0xLTEtMC90ZXh0cmVnaW9uOjY0MDI3MzhmZGI0OTQ2YWI4YjIyNGVhYmRiZDk1YWNhXzQ_daabd3e0-255a-47d2-952d-9020ccb99dad">7.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ef442c17d9418f8c9a539cb1195ec0_I20200930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItNC0xLTEtMA_39a65776-5d89-4873-8ba6-78111fee4fde">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50ef442c17d9418f8c9a539cb1195ec0_I20200930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItNi0xLTEtMA_e25bb200-cd9a-4cef-a3a3-9d9e4a1e5d83">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac1907fe5d474e3b8211ac9e30f9be82_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItOC0xLTEtMA_bcb5b5f8-b344-401f-b5da-2e90cd2ad731">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac1907fe5d474e3b8211ac9e30f9be82_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItMTAtMS0xLTA_5dd18f23-6108-4ef7-ab23-6e63beb7df1d">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie72ff37863f94b4283e88af507ae245a_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOjA0NDViZTBmYmIwNTRjNTBiYTQ2ZjNmY2FhMGVkMzRkXzQ_80fb1c38-669a-4335-97d7-c442487289c7">5.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72ff37863f94b4283e88af507ae245a_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtNC0xLTEtMA_17b6c9a4-382d-4cee-a40e-e1c2ca77ad68">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72ff37863f94b4283e88af507ae245a_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtNi0xLTEtMA_a7e02388-0c39-43e9-8b6d-a354c37f7539">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31dccdddcfb4000b0c308332ce9f610_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtOC0xLTEtMA_fbfee038-a5d3-476a-9bbc-05f89130164f">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31dccdddcfb4000b0c308332ce9f610_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtMTAtMS0xLTA_c63d0242-70bb-401b-8983-3e4fe2a36832">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75983ef66546d6bddf3613cff7f8a4_I20200930" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjQtNC0xLTEtMA_dda268f0-f968-442b-9b73-9c5d275efc1d">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc75983ef66546d6bddf3613cff7f8a4_I20200930" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjQtNi0xLTEtMA_fa5fe651-4834-4ebb-b990-8f8bc155acb3">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05453b6c881c458a820a5ac7d0ef7dfe_I20191231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjQtOC0xLTEtMA_1be6449b-2c9e-4efb-80e8-56558e1fb508">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05453b6c881c458a820a5ac7d0ef7dfe_I20191231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjQtMTAtMS0xLTA_d55dc8be-7886-4c26-847b-c6f87e5857b2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjUtNC0xLTEtMA_841863dc-b531-4806-b6cc-dcbe1fdf82b1">24,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjUtNi0xLTEtMA_94f01093-a71d-4b11-944b-9db994608987">24,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjUtOC0xLTEtMA_c9043a37-4c8c-4227-8c92-8571c38973aa">26,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjUtMTAtMS0xLTA_6c353933-73a4-4834-bdb0-d5e498b0e753">25,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjYtNi0xLTEtMA_1a7bb015-c7b7-45e2-b5bd-58ea6b8f062f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjYtMTAtMS0xLTA_3f5a7c67-4bf9-4145-8018-6e6b77b2a2ff">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjctNi0xLTEtMA_f54a3a50-9632-4dfe-972e-262bd43c4407">24,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjctMTAtMS0xLTA_110d1997-87ca-4fa5-9274-6f41152eb4dd">24,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of September&#160;30, 2020, the amount available for restricted payments under the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $<ix:nonFraction unitRef="usd" contextRef="ic43b82b77a204cbfb726e9c81f307b6e_I20200930" decimals="-6" format="ixt:numdotdecimal" name="bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTA5OTUxMTY0NjM1Mw_1991d110-e568-4fa9-8336-096c4d3503c2">12,600</ix:nonFraction>&#160;million. The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930" decimals="INF" name="bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM4Mw_e5be68de-d311-4fc4-9a95-3bacf44a0b2c">4.00</ix:nonFraction>:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. As the global economic landscape changes, there is a wide range of possible outcomes regarding the nature and timing of events and reactions to the COVID-19 pandemic, each of which are highly dependent on variables that are difficult to predict at this time.  While there are a number of standard borrowing conditions that must be met to make borrowings under the 2023 Revolving Credit Facility, the Company has considered the economy's impact on its non-financial and financial maintenance covenants and </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i8b963c82480546a7917d32ba551c73a7" continuedAt="i8fa859b845fc4f5e8e795cc4277808f6"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believes the current state of the economy does not limit its access to capital under the 2023 Revolving Credit Facility at this time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast as adjusted for the potential impacts of the COVID-19 pandemic, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of these financial statements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018, and as further amended (the &#8220;Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i2fb8e2769d544690be3abd9e969d7f6f_I20180601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzYyOA_4c7aebe8-6d8a-4367-a9d0-7497437a09c3">1,225</ix:nonFraction> million, which matures on the earlier of June 1, 2023 and the date that is <ix:nonNumeric contextRef="i31ba7f21ed03439b841008aab77cae59_D20180601-20180601" format="ixt-sec:durday" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzY5OA_90e03f99-9851-4d0e-ab3c-f5dfeaf9f624">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. ("BHA") in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="i2fb8e2769d544690be3abd9e969d7f6f_I20180601" decimals="INF" format="ixt:numdotdecimal" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzg4NA_678699d0-9dc1-48ba-8511-2d562aad65cf">1,000</ix:nonFraction> million (the "2023 Revolving Credit Facility") and term loan facilities of original principal amounts of $<ix:nonFraction unitRef="usd" contextRef="i53bbc40a99854970b78201ecfae1f0b0_I20180601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzk4NA_3c86027a-494c-4c11-80e3-5bd351dcb452">4,565</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7d6f3842a7cc43d0b05b379a3197003c_I20180601" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzk5MQ_b1d40d7e-716a-4d6e-9174-e64f3a17c32c">1,500</ix:nonFraction> million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the "November 2025 Term Loan B Facility"), respectively. Both the Company and BHA are borrowers under the 2023 Revolving Credit Facility, borrowings under which may be made in U.S. dollars, Canadian dollars or euros.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Description of Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus <ix:nonFraction unitRef="number" contextRef="i776fc34ad45242c7b664a96b5697cafc_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNDc3OA_4dcd0fc2-8c7f-47a3-a4df-148f1551d9d5">1.00</ix:nonFraction>% (or if such eurocurrency rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="i776fc34ad45242c7b664a96b5697cafc_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNDgzOQ_c295ce53-ff43-4307-b12e-5b480c23164e">1.00</ix:nonFraction>%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i395e8b6493b243d785d218551ad6bc95_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNTEwNw_c05363e2-d2fe-474d-a914-a51a7c023e78">0.00</ix:nonFraction>% per annum), in each case plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i84316338b21741c5b5edb758134470bd_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNTQ1Mg_7a746a9b-deba-4fc4-a048-4396f556af57">0.00</ix:nonFraction>% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus <ix:nonFraction unitRef="number" contextRef="ib4c920ee5bc74d47b13bdda58721672a_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjAwOQ_2505242b-1b6a-4a3b-bacd-6f2eaf0376f0">1.00</ix:nonFraction>% (provided however, that the prime rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i7cfbb77dee664f9f9fafde904ea66301_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjA4MQ_0cb8ced3-9b06-4937-8f16-495365c98c6b">0.00</ix:nonFraction>%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i7cfbb77dee664f9f9fafde904ea66301_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjMxNg_4a336abd-8b9a-40f7-9e4d-65818a22fa84">0.00</ix:nonFraction>% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;<ix:nonFraction unitRef="number" contextRef="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930" decimals="INF" name="bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjYyNg_bf5c87c8-cee4-452c-aff8-721ceb1ba429">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii)&#160;<ix:nonFraction unitRef="number" contextRef="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930" decimals="INF" name="bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjc4OA_1068ff05-8ab6-4708-abbf-cae1f763f252">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;<ix:nonFraction unitRef="number" contextRef="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930" decimals="INF" name="bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjkyNQ_3e8c558c-0c51-424a-a49e-18555e4ad844">50</ix:nonFraction>% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;<ix:nonFraction unitRef="number" contextRef="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930" decimals="INF" name="bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzA4Mg_54f7ded8-48bb-48ab-96e9-f9338a6a0231">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are <ix:nonFraction unitRef="number" contextRef="i680f1d5e868b46d9b7570e6c1901ea09_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzI5Mg_7c55299a-0603-46c2-b139-5315ec96e420">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1c27340fb9c6435297c9931c627217e6_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzI5OQ_2b85caa1-161c-490d-9cdf-bfeff1893ad8">1.75</ix:nonFraction>%, respectively, with respect to base rate and prime rate borrowings and <ix:nonFraction unitRef="number" contextRef="ia89d453429494c1db0f7a576c7b8b619_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzM3Mw_6886d111-b73b-4484-9364-b5bf1a70250a">3.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ica05a2309e6e49efa816d3d0e6070d96_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzM4MA_16b7c3d9-67f0-4728-88e0-abab1f75dbc2">2.75</ix:nonFraction>%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of September 30, 2020, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were <ix:nonFraction unitRef="number" contextRef="ica7020a01b884f0db71be5081d3f6c00_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzU0Ng_05ee7dbd-4204-4746-bc57-4dc79fd5e9bb">3.15</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i98399a1cca534743bbf269f1fb3a7bd3_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzU1Mw_d3d934a3-da86-4136-b2be-6792720881aa">2.90</ix:nonFraction>% per annum, respectively.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i8fa859b845fc4f5e8e795cc4277808f6" continuedAt="ie23f632d1684476584fed4bd585d9dd5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="ica7020a01b884f0db71be5081d3f6c00_I20200930" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzYzMw_4b563c28-7890-48bd-860e-f7a49736bb8d"><ix:nonFraction unitRef="number" contextRef="i98399a1cca534743bbf269f1fb3a7bd3_I20200930" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzYzMw_4cbed7be-1353-486e-a588-302ebb987bb0">5.00</ix:nonFraction></ix:nonFraction>% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of September 30, 2020, the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities were $<ix:nonFraction unitRef="usd" contextRef="i4b43c4704f924701a890d5f962a8caa7_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzg2Ng_792ebf86-9b40-4122-b6c0-747c827ec747">680</ix:nonFraction> million through November 1, 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are <ix:nonFraction unitRef="number" contextRef="i9c8b8449c734458ebb0e65b656a6f94b_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzk5Mg_fc8cf1be-2d1e-4fb3-a169-d3f219c941ff">1.50</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i7eaf4c3ede854933aa1ae74e0977f05f_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzk5NQ_cee45379-7955-4bf7-b2e9-42dd1410aec2">2.00</ix:nonFraction>% with respect to base rate or prime rate borrowings and <ix:nonFraction unitRef="number" contextRef="i0c735278fc854ebcad677441f39d21a3_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODA1Mw_a145d4b8-b831-4cd0-8657-cccb8e8b7eeb">2.50</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="id59f859e9860470f84bad3c7b6b2ddad_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODA1Ng_6b98b65b-5240-4f85-8153-1db39d8df7a3">3.00</ix:nonFraction>% with respect to eurocurrency rate or BA rate borrowings.&#160; As of September 30, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODE5MQ_ba3ec2c3-8aa2-41b4-897c-59bb71ddf71b">3.15</ix:nonFraction>% per annum. As of September&#160;30, 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODIzMQ_9d0b4ca9-a8a4-4d2f-8db2-25f75e93cb3c">no</ix:nonFraction> outstanding borrowings, $<ix:nonFraction unitRef="usd" contextRef="i00c24c309eb54c4f804c01312f186da1_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODI1OA_7ff1e6d5-e903-4cf0-91ea-17e7e9a5f5aa">107</ix:nonFraction> million of issued and outstanding letters of credit and remaining availability of $<ix:nonFraction unitRef="usd" contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODMzNQ_f93a8953-28c1-4c86-849c-d0aaf6083dfc">1,118</ix:nonFraction> million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="idde9534012fd4b75b3ce796e32bc14a2_D20200101-20200930" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODQ0Mw_10cc3b78-4d25-46e8-9465-a96846467b52">0.25</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="iaafc5c0d6e0c425db5de7640999583ad_D20200101-20200930" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODQ0Ng_170ffd0e-2080-4d5c-8747-ae5ea57c557f">0.50</ix:nonFraction>% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $<ix:nonFraction unitRef="usd" contextRef="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930" decimals="INF" format="ixt:numdotdecimal" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTA5Ng_0dca49af-bf1c-4b8e-8e48-cd70e968d407">1,000</ix:nonFraction> million and <ix:nonFraction unitRef="number" contextRef="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTEwMw_aa61e2f4-3f4f-4940-ae13-056bbc06fbb9">28.5</ix:nonFraction>% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="iebbc28b6be8d43069e00894b8781bf0e_I20200930" decimals="INF" name="bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTM2Mw_79f914b6-3900-4e38-8ed2-b9902dd20912">3.50</ix:nonFraction>:1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i084e681a0032449983710ed54eb3ad01_I20200930" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTQ0OQ_cab894ae-9c3f-4a0d-8455-19593f607e0a">6.50</ix:nonFraction>:1.00 or an interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930" decimals="INF" name="bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTUwMg_61de89f6-cfe6-4e83-b649-dcbdbf4e438f">2.00</ix:nonFraction>:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE0Nzk_c6226dfc-5805-43cd-beb2-a3b4fe214014">101</ix:nonFraction>% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i2af09f0132c5448bab7483f939d8c584_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE1NDg_c979d9f9-039b-46a2-a734-d4690ffe5446">5.75</ix:nonFraction>% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019, BHA and the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="ib9d8578871b7406b986dbb995cb8af67_I20190308" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE2Njk_d6ef278c-0cd3-4997-8d42-d6a1e2adc0ab">1,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ib9d8578871b7406b986dbb995cb8af67_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE3MDI_35eee638-471f-41da-af71-ebe7398e67ff">8.50</ix:nonFraction>% Senior Unsecured Notes due January 2027 (the "January 2027 Unsecured Notes") and (ii) $<ix:nonFraction unitRef="usd" contextRef="i2af09f0132c5448bab7483f939d8c584_I20190308" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE3OTE_1992c040-9012-452a-a5fd-d23fd7ac6d35">500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i2af09f0132c5448bab7483f939d8c584_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE4MjQ_d4f237c6-f87c-4d09-a27c-73f4f9762e1b">5.75</ix:nonFraction>% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds, and cash on hand, were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="ifaf7cc4e25d7482581fa9522ffd8054c_D20190308-20190308" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIwMTE_3dde00b6-2137-4323-a3a6-c3c428fcbf5b">584</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i756c2741402c442dbf8d5d9b6d2b0761_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIwMTc_8f24abc1-6dce-4ed4-b051-5bea8147baa6">5.875</ix:nonFraction>% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $<ix:nonFraction unitRef="usd" contextRef="i0cf372dafcdc4256a52a45555ce48252_D20190308-20190308" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIxMDI_757e2eb5-3937-4b9e-9bf3-21e433597821">518</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i6f2e689cc9bc45aea09d11c8f10fbdc2_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIxMDg_6c11d647-c079-4c67-b10d-f2937cd2a870">5.625</ix:nonFraction>% Senior Unsecured Notes due 2021 (the &#8220;December 2021 Unsecured Notes&#8221;), (iii) repurchase $<ix:nonFraction unitRef="usd" contextRef="i62a835f93c3841ec9faa2b983380dc84_D20190308-20190308" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIxOTk_f45b2934-07cf-44cd-a5cb-a5eb8d1fd28e">216</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i26953919345a48ac8c4fc7b3d9f771e5_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIyMDU_7259abb2-72ae-4c3a-97b5-6d2424dde76c">5.50</ix:nonFraction>% Senior Unsecured Notes due 2023 (the &#8220;March 2023 Unsecured Notes&#8221;) and (iv) pay all fees and expenses associated with these transactions (collectively, the &#8220;March 2019 Refinancing Transactions&#8221;). During April 2019, the Company redeemed $<ix:nonFraction unitRef="usd" contextRef="i24b0bf33724f4f958b89a4381b10a2a7_D20190401-20190430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTI0NDQ_e1fe33af-d579-4c74-b813-036d39672a68">182</ix:nonFraction> million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $<ix:nonFraction unitRef="usd" contextRef="i7225129913c342a3996cf248b001bd71_I20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTI2MTM_b82a2a26-d0de-4a6a-9a5c-5003c5817cf9">1,500</ix:nonFraction> million of debt in connection with the March 2019 Refinancing Transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ie23f632d1684476584fed4bd585d9dd5" continuedAt="ide2db1fbcc1241dd98bb5922b3196f72"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i1b169ebb131842c7b5dab7380388dbb9_D20200101-20200930" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM1NDQ_13d85847-cdc6-4542-84aa-cd0db6c7281c">101</ix:nonFraction>% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="ifb407c4dee97479aaed7d0a54af5a221_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM2NTg_1bf70b51-8b55-4ada-879c-aa3fc50d75a1">8.50</ix:nonFraction>% Senior Unsecured Notes due 2027 - March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the March 2019 Refinancing Transactions described above, BHA issued $<ix:nonFraction unitRef="usd" contextRef="ib9d8578871b7406b986dbb995cb8af67_I20190308" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM4MTA_d6ef278c-0cd3-4997-8d42-d6a1e2adc0ab">1,000</ix:nonFraction> million aggregate principal amount of January 2027 Unsecured Notes. These are additional notes and form part of the same series as BHA&#8217;s existing January 2027 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i556544584b844001980693b54a079641_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM5ODE_5d018957-422f-440e-93ef-b7873ebab9b5">7.00</ix:nonFraction>% Senior Unsecured Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="i422f3d2912d24190bc5966214fdc77d5_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQwMjA_b2212213-a800-41f9-b568-9eec0de0cf1f">7.25</ix:nonFraction>% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="i556544584b844001980693b54a079641_I20190523" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQxMzI_f506e8d0-6467-476f-856b-a1d963253a3d">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i556544584b844001980693b54a079641_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQxNjU_5d018957-422f-440e-93ef-b7873ebab9b5">7.00</ix:nonFraction>% Senior Unsecured Notes due January 2028 (the "<ix:nonFraction unitRef="number" contextRef="i556544584b844001980693b54a079641_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQyMTQ_5d018957-422f-440e-93ef-b7873ebab9b5">7.00</ix:nonFraction>% January 2028 Unsecured Notes") and (ii) $<ix:nonFraction unitRef="usd" contextRef="i422f3d2912d24190bc5966214fdc77d5_I20190523" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQyNTc_09a324ab-a307-4a81-bd79-0171690d6a7e">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i422f3d2912d24190bc5966214fdc77d5_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQyOTA_b2212213-a800-41f9-b568-9eec0de0cf1f">7.25</ix:nonFraction>% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement. The proceeds and cash on hand, were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="i156e9d3804a244b6a29b74a3e3e52c7b_I20190523" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ0NjE_0679cab7-c237-40d5-87ff-2473b2cd50e9">1,118</ix:nonFraction> million of May 2023 Unsecured Notes, (ii) repurchase $<ix:nonFraction unitRef="usd" contextRef="i0b8d1168c7204d658dfb66babf4ccc26_I20190523" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ1MDk_0efdb761-fea2-4037-a562-3b5a1558a2dd">382</ix:nonFraction> million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2019 Refinancing Transactions&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i38b42858a98247d79b9bcf64d8e4cae8_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ2NzA_d8a85269-bae9-4454-93d8-0af91d37983f">5.00</ix:nonFraction>% Senior Unsecured Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="iaa041cac555c42fba824f78513336e7f_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ3MDk_e59427cc-5508-46aa-936a-e09b8ead4687">5.25</ix:nonFraction>% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="i38b42858a98247d79b9bcf64d8e4cae8_I20191230" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ4NDU_169d8ad1-e900-4375-a6c1-22ee09168fa8">1,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i38b42858a98247d79b9bcf64d8e4cae8_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ4Nzg_d8a85269-bae9-4454-93d8-0af91d37983f">5.00</ix:nonFraction>% Senior Unsecured Notes due January 2028 (the "<ix:nonFraction unitRef="number" contextRef="i38b42858a98247d79b9bcf64d8e4cae8_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ5Mjc_d8a85269-bae9-4454-93d8-0af91d37983f">5.00</ix:nonFraction>% January 2028 Unsecured Notes") and (ii) $<ix:nonFraction unitRef="usd" contextRef="iaa041cac555c42fba824f78513336e7f_I20191230" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ5NzA_d8548a87-ab18-4aa9-86c1-2733669e1a7d">1,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iaa041cac555c42fba824f78513336e7f_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTUwMDM_e59427cc-5508-46aa-936a-e09b8ead4687">5.25</ix:nonFraction>% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) redeem $<ix:nonFraction unitRef="usd" contextRef="ic9330108a6824e37b8217d2a11ded672_D20200116-20200116" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTUxNjI_c985841e-d531-421c-87f0-8187dd54ec9f">1,240</ix:nonFraction> million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the $<ix:nonFraction unitRef="usd" contextRef="i7907ded04dab4554a0ef907fa261b6f7_D20191216-20191216" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTUyMzE_536b031b-bf41-4527-ad30-980a36ecae44">1,210</ix:nonFraction> million settlement of certain U.S. securities litigation, subject to final court approval, as discussed in Note 18, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions").</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="iba7b866fe620404c9be6000f21284d31_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU0ODM_a0237ac6-9f41-4bc0-8682-8aa7cd23a028">6.25</ix:nonFraction>% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="iba7b866fe620404c9be6000f21284d31_I20200526" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU1OTA_9bf5aa64-eaab-4869-b758-c1dd0d46d70c">1,500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iba7b866fe620404c9be6000f21284d31_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU2MjM_f58bfaa7-d834-4d4a-8c42-75f642cb50cf">6.25</ix:nonFraction>% Senior Unsecured Notes due February 2029 (the "February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="ifc5ee50d3e974a62ba9571a1f2f84fc0_I20200526" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU3ODg_ed6e94d8-9c70-414b-bf79-e75e7f272da3">1,250</ix:nonFraction>&#160;million aggregate principal amount of outstanding <ix:nonFraction unitRef="number" contextRef="ifc5ee50d3e974a62ba9571a1f2f84fc0_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU4MzM_761c4ffa-9170-40a8-a82c-d2b58c50cbf7">6.50</ix:nonFraction>% Senior Secured Notes due March 2022, (ii) prepay $<ix:nonFraction unitRef="usd" contextRef="i35061b0459224831a5dd5ee11d9692a9_D20200526-20200526" decimals="-6" format="ixt:numdotdecimal" name="bhc:PaymentForDebtAmortizationPrepaymentCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU4ODU_fa7e712b-57c4-4017-8062-22ea4cc0a939">303</ix:nonFraction>&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions"). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i4927b0e336fe4ef1b1ffb40e143d6d6f_D20200526-20200526" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTYyOTA_11748946-bc9d-4d47-8d8e-061256b26700">27</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The February 2029 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="iba7b866fe620404c9be6000f21284d31_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTY0ODY_92ac7b87-2e42-41d5-9cae-eb74a70c74c2">6.25</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to <ix:nonFraction unitRef="number" contextRef="ib1fd33b8ea2042dfb42c2639a2b086ab_D20200526-20200526" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTY3MDc_1a18c83e-25b6-42eb-8da4-29687bd0d76f">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="id782e23cbd724954b6368623a4d54175_D20200526-20200526" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTY5MjE_34d6781f-c120-434c-b1c5-86e39e17c97d">40</ix:nonFraction>% of the aggregate principal amount of the outstanding February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the February 2029 Unsecured Notes at the applicable redemption prices set forth in the February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company's outstanding debt obligations as of September&#160;30, 2020 and December&#160;31, 2019 was <ix:nonFraction unitRef="number" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTc1NzQ_566c1cba-15af-4561-90e6-63da545bc4e8">5.94</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTc1ODE_4f52bc45-47a6-4e2a-b38b-2ded881c7289">6.21</ix:nonFraction>%, respectively.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ide2db1fbcc1241dd98bb5922b3196f72"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to reduce future cash interest payments, as well as future maturities and mandatory payments, the Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. During the nine months ended September 30, 2020, the Company repurchased and retired, outstanding senior unsecured notes with an aggregate par value of $<ix:nonFraction unitRef="usd" contextRef="i1f1c7ed275704247962d8203458ab574_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTgxNDc_416248d1-8dc7-4c05-b052-798436e0b9e3">27</ix:nonFraction> million in the open market, for an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="i1b169ebb131842c7b5dab7380388dbb9_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTgxOTU_c2b67f3f-2b5b-4072-b2f9-8a78181432bc">26</ix:nonFraction> million.  In connection with these repurchases, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="i1b169ebb131842c7b5dab7380388dbb9_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTgyNzE_84c054ee-89b8-44a6-8125-3b944927a370">1</ix:nonFraction> million included in Loss on extinguishment of debt. </span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTg0NjY_7bb87fa7-ad06-4c22-8bed-0863ddd3cd39" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the remainder of 2020, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfMS0xLTEtMS0w_2a25206d-dbbd-4454-a171-16a71c8aeec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfMi0xLTEtMS0w_5e654750-2bc5-4d10-b517-020f1dce2385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfMy0xLTEtMS0w_19312461-9130-48d5-8665-ecdfdac9f3dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfNC0xLTEtMS0w_56eb29fa-9de6-4087-b3ea-d6bf3cfd51bb">2,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfNS0xLTEtMS0w_c6366527-5e01-4846-9b79-9333112cff3f">2,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfNi0xLTEtMS0w_076f2a94-6584-4bfb-a9b5-57ba669af331">10,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfNy0xLTEtMS0w_7a005991-f899-438b-a1c9-82eb07df5a81">9,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfOC0xLTEtMS0w_8b56cbeb-e652-4e62-be56-8c8697aad18e">24,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfOS0xLTEtMS0w_6ec5ef86-eba2-4b90-a3d1-96aa1edc9537">258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfMTAtMS0xLTEtMA_94f01093-a71d-4b11-944b-9db994608987">24,343</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 29, 2020, the Company issued an unconditional notice of redemption to redeem: (i) $<ix:nonFraction unitRef="usd" contextRef="i3e190fe005974b5ea0fe1ade4aa15972_D20201029-20201029" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTA5OTUxMTY0NzE3OQ_a1111ac6-84e5-4b92-9101-e97cadeb9aad">99</ix:nonFraction>&#160;million of May 2023 Unsecured Notes, representing the remaining outstanding principal balance of the May 2023 Unsecured Notes and (ii) $<ix:nonFraction unitRef="usd" contextRef="i9b698175e9eb43f389d1012167ab199d_D20201029-20201029" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTA5OTUxMTY0NzE5Mg_d5b59b13-98d1-486f-aeda-1ee2ceac2d90">51</ix:nonFraction>&#160;million of March 2023 Unsecured Notes, on November 30, 2020.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_73"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RleHRyZWdpb246ODRlYjQ3OTVlYWNkNDAzYmJhYzY0OWQ2YmVjNmYxNTZfMzk1_d402203a-5c05-49e5-bc30-4f72f5d091f1" continuedAt="idbd85dc833d44ef6959de58b74929779" escape="true">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="idbd85dc833d44ef6959de58b74929779"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RleHRyZWdpb246ODRlYjQ3OTVlYWNkNDAzYmJhYzY0OWQ2YmVjNmYxNTZfNDA0_c9451297-d408-4b5e-b923-123b097f6cd5" continuedAt="iec4039368a4546dfb0ad865a285a9d93" escape="true">Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2020 and 2019 consists of: </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="iec4039368a4546dfb0ad865a285a9d93"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.980%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 3.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy0yLTEtMS0w_87136ba7-0bb5-433b-a230-a30279b70132">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy00LTEtMS0w_71b9741b-e1af-47ae-85dc-488980447780">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy02LTEtMS0w_8cbe6e45-3cea-4d6e-b469-d2840b918fb5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy04LTEtMS0w_f828d7ff-9eb9-4621-9c2e-6073a0a84331">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy0xMC0xLTEtMA_9e0c2254-ca0f-4e54-a174-0c6eb2cf1bed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy0xMi0xLTEtMA_54e3f6da-6499-4b81-a155-1ce6259cf536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC0yLTEtMS0w_8007d542-fb8c-4a65-b846-0d8def2bae3c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC00LTEtMS0w_f39b50a8-3ee8-4ee9-a26f-5b11f54e84df">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC02LTEtMS0w_bdb7fc3a-e4fb-48db-89a8-c05c796491c0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC04LTEtMS0w_0bf4449b-073b-4dd8-9270-9183744df48c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC0xMC0xLTEtMA_e5540bb2-ac49-4948-bea0-6a91edb80b71">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC0xMi0xLTEtMA_c7de34ec-b58d-474c-9075-27a416770bff">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS0yLTEtMS0w_ae038fbb-9c71-4266-beb5-fd8672609792">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS00LTEtMS0w_b167181f-ed81-4eee-9d10-3b52a68abd0d">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS02LTEtMS0w_7559ef04-5b84-440e-a6d5-d5916881187e">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS04LTEtMS0w_17f27906-04cd-45b1-88cd-e53209ac581a">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS0xMC0xLTEtMA_4b631084-ef80-43d8-9607-f684b08c671d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS0xMi0xLTEtMA_511bf920-baea-4fca-8049-c0c5ebcda84f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi0yLTEtMS0w_7a5b4232-f1c6-4db4-ac96-53c67ee57430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi00LTEtMS0w_25e8242f-9693-44d7-be1d-de77f34f401a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi02LTEtMS0w_8fedcd53-ccdd-438d-a7ad-9d71ffb70613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi04LTEtMS0w_3456fdc7-acfa-4c3a-adc5-5c0e773a4491">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi0xMC0xLTEtMA_15829af4-082e-4fbb-8e8e-b1a66a472956">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi0xMi0xLTEtMA_3d22e801-4d96-45a0-8c74-ba87e6ed34fc">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0yLTEtMS03MjU_0d216bc7-d272-493c-8d65-d76a427b6474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy00LTEtMS0zMTcy_b2b0f36d-6d57-4d8e-b9cf-e4396f183a7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy02LTEtMS03Mjk_ec03c79a-a075-419b-accb-f2a21af7d9c8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy04LTEtMS0zMTcy_cdaf4de6-ae56-4b40-8558-764598284cdd">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0xMC0xLTEtNzMz_2f513b0a-2e4d-440a-98d9-303c7bb41c50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0xMi0xLTEtMzE3Mg_2ee1e9d8-4a8d-47c6-b5b3-88db61715e24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0yLTEtMS0w_f842ea77-34c4-4695-b50a-8479075cb3cb">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy00LTEtMS0w_54c39a90-d6e3-4a78-b04e-c0c8de8c2ecf">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy02LTEtMS0w_ff53dcae-9d81-4529-8a2a-6a5b9f3b4c18">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy04LTEtMS0w_1e505db8-0147-4d8a-ba5c-56897e8fa8a3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0xMC0xLTEtMA_9ca68843-02cd-4cec-a452-d8df03de5c08">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0xMi0xLTEtMA_1c1230bb-beef-44f5-9e87-cd0f5b79bece">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQ1NQ_b56e3751-9af4-4a6c-995d-8aebacde2495" continuedAt="id3f3129ff10042a5a03e787b947473a1" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="id3f3129ff10042a5a03e787b947473a1" continuedAt="i293fa468788c48faa0cd7bbde3059fbd"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to <ix:nonFraction unitRef="shares" contextRef="ie31f5ab3c2924d3b8c230faa96e03243_I20140531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQ0_1d3a830f-c6f4-4e22-b22d-4cca58315da2">18,000,000</ix:nonFraction> common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered <ix:nonFraction unitRef="shares" contextRef="ie31f5ab3c2924d3b8c230faa96e03243_I20140531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfODA0_ee69f985-bc64-43d7-a822-07997aebbe25">20,000,000</ix:nonFraction> common shares of common stock for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#8220;Amended and Restated 2014 Plan&#8221;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i293fa468788c48faa0cd7bbde3059fbd" continuedAt="i11a0d5c3d2214f49acb91f405ddf7ebf"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance under the Amended and Restated 2014 Plan has been increased by an additional <ix:nonFraction unitRef="shares" contextRef="if1234c5878b345c3be0c7887e84c8c4b_D20180430-20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfMTE4OA_0abc975f-d837-4f46-9cb4-355f30e126c2">11,900,000</ix:nonFraction> common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 30, 2018, (ii) introduction of a $<ix:nonFraction unitRef="usd" contextRef="id1f9e1c5bb0d428cb4b9c7514e892230_D20180430-20180430" decimals="INF" format="ixt:numdotdecimal" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfMTM0NQ_79c0d203-7cfb-46a7-b41e-fd6690c415b1">750,000</ix:nonFraction> aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#8217;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional <ix:nonFraction unitRef="shares" contextRef="i37ebdf9ce1ce47ce953dd272b4116d9f_D20200428-20200428" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfMjIzNA_5220048a-4915-4cfe-9c1c-7b1481c4a8af">13,500,000</ix:nonFraction> common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="i5bcdb72d89d2453a81215c5d89199ddb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfMzA0MQ_6271b1b0-70a3-4039-86fc-1624c4b1d7ec">17,067,000</ix:nonFraction> common shares were available for future grants as of September&#160;30, 2020. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term.  The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;) and (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;).   </span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQ1OA_79f77136-631c-4d94-abf2-677afca94288" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of share-based compensation expense related to stock options and RSUs for the three and nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:11pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5e06f512ef41418fe077ef11562faa_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMi0xLTEtMS0w_5b287845-e824-40a7-9f82-ae423dc83c63">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if47991fff46a44fa8907b87f6e475934_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMi0zLTEtMS0w_f864c36d-d7d5-4793-94aa-cdc108bee137">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMi01LTEtMS0w_0abd357b-87bb-4b75-b76b-d964d6dac261">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMi03LTEtMS0w_c03511af-e4bd-46ad-972c-53a4d3276e4b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1f53d1c1fd4dd699f102722ad4ab30_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMy0xLTEtMS0w_21e913e4-327f-4a5e-8bb7-a46d1b1b6e43">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6705ae1cc944e9b0c9948e2cc52937_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMy0zLTEtMS0w_07fc2651-0fa9-4c54-aa56-05d19e41eded">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d204a1b39c34ebf957a3002d5e89825_D20200101-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMy01LTEtMS0w_7dd31e87-2d15-433b-8426-45f6a86d43b8">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106b3eee455e4af59474ab03ba414fb7_D20190101-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMy03LTEtMS0w_ae7b22cd-1344-433f-8074-9c06c6ccc862">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNC0xLTEtMS0w_ea9cc6b9-df1b-49cd-b132-ffbe4888efbc">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNC0zLTEtMS0w_6c790cf2-03ed-4051-bc38-9997f2d71a1c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNC01LTEtMS0w_424475d8-15cf-4e33-9bb8-a36286421ed4">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNC03LTEtMS0w_2e045b18-4674-4773-b858-8291e770b96a">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e61c443cd46403f897e0842ba3f568e_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNi0xLTEtMS0w_cdd94197-c532-4a27-b28f-e219152a2f78">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie657a420eece4d10b6860b72c457aaab_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNi0zLTEtMS0w_fbed6538-d4fc-4315-a1e9-d98223e080a6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife7d401df9e9436187d1434bcf9382ca_D20200101-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNi01LTEtMS0w_fadbeb7e-d823-4bcd-b22e-f3fa530d4f20">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a7f83031f2049529b19147c57eb7ff0_D20190101-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNi03LTEtMS0w_1e76774a-fa67-49b3-8466-04e4b2bbb2e7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9987cef2d1d4602aa101e2592aabc48_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNy0xLTEtMS0w_3bf62ed9-9635-4c78-a1db-3ef496f454b4">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0418ceeffa1443e9802453c68467828b_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNy0zLTEtMS0w_7160bf29-5d79-45ac-863f-f03ee42864fd">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf089cab8914facba6578b77bebb264_D20200101-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNy01LTEtMS0w_21d724ef-a854-46a4-af75-6811e5930785">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide4414ac166c4b98b170244eb491149f_D20190101-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNy03LTEtMS0w_c8eb226b-554b-4b8b-8bd5-d232fa15b99b">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfOC0xLTEtMS0w_ebfe71be-1953-41a0-a24b-82363f60d6c3">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfOC0zLTEtMS0w_2d9f037d-89ba-454e-90ab-17c017ceb2ef">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfOC01LTEtMS0w_7f8d0458-223d-494d-9b16-59233687c619">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfOC03LTEtMS0w_61258ecb-fcc2-4a09-8e35-ffc4c0038000">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i11a0d5c3d2214f49acb91f405ddf7ebf"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQ1MA_f9acff0d-183e-4d62-9afb-b5efec2a83da" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMy0xLTEtMS0w_be8c9765-3302-4a9d-831e-7a7f622b9c55">2,269,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMy0zLTEtMS0w_c43da226-2479-41d6-8581-a278f6e95d8d">1,725,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfNC0xLTEtMS0w_ff9792e7-b746-468d-92fe-10184caf9b59">24.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfNC0zLTEtMS0w_24cbba63-8992-4119-9a26-f640ecfa794c">23.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfNS0xLTEtMS0w_38650105-6f2d-421e-81c2-16a6cd11b559">6.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfNS0zLTEtMS0w_872c241b-3882-418f-96f1-8e74f0b20c13">8.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f757f31530c45ddaa86c86406b50a0c_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfOC0xLTEtMS0w_f1226e01-2007-4f04-891a-de5f6839ba97">3,084,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7333dc2ff308421588477f444d77526f_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfOC0zLTEtMS0w_3ece06a4-8889-4658-86a8-57335baecf57">2,895,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f757f31530c45ddaa86c86406b50a0c_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfOS0xLTEtMS0w_4c2f9547-04f5-4dfc-91c2-228fbe972157">22.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7333dc2ff308421588477f444d77526f_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfOS0zLTEtMS0w_c95b61cf-bf25-418d-806e-d596b0e898bf">23.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffd6ad7504a94a299b44307bf31e726b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTItMS0xLTEtMA_966910e7-0958-4501-bfff-4fc529b4b501">425,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b3127099e704d8e902e5069aa1e0b13_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTItMy0xLTEtMA_d30147e2-209f-4fee-b1dd-171678bbc6de">454,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffd6ad7504a94a299b44307bf31e726b_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTMtMS0xLTEtMA_def8a59d-11ac-4292-9313-46fc0ae92179">26.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b3127099e704d8e902e5069aa1e0b13_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTMtMy0xLTEtMA_075996e3-07ca-4158-b8c8-0f8bbfa459dd">34.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i472ae620787344d6baf50d96060d90ab_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTYtMS0xLTEtMA_5f8b677e-9739-4beb-9834-3671ef8d0437">472,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i898bb6c7930c478587dd044061b9d2a2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTYtMy0xLTEtMA_ae08f0ca-da55-455e-ab9e-4205d84f879b">505,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i472ae620787344d6baf50d96060d90ab_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTctMS0xLTEtMA_20c92d4e-36a0-49e5-af68-8001b2106745">27.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i898bb6c7930c478587dd044061b9d2a2_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTctMy0xLTEtMA_476cb488-05e4-4459-a490-da6f8003650d">25.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the remaining unrecognized compensation expense related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDM3NA_f03181f5-785a-4258-b7bc-16712f61a304">116</ix:nonFraction> million, which will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQzNg_93c3c005-7fe8-4dd9-8ef6-3cb695690c35">1.59</ix:nonNumeric> years.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_79"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RleHRyZWdpb246NjUyYjFlOGUwMzg2NGI4NzhhYTc3YWE0ZWMxZjAyNWJfNjE5_1890b1c3-a72d-4718-84e5-39458ad82b34" continuedAt="i2141a3afeccb462fa5e73ae0d9daf782" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="i2141a3afeccb462fa5e73ae0d9daf782"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RleHRyZWdpb246NjUyYjFlOGUwMzg2NGI4NzhhYTc3YWE0ZWMxZjAyNWJfNjEy_076df75d-fb85-41ef-b723-800f8493b28c" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:69.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i741bd4dd7c0149f6b7ffc048b13bc0ee_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMS0yLTEtMS0w_71e9ec1d-e96d-4aab-9849-4d01968d88d4">2,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic862f703a2734648bf7d042a71301d5d_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMS00LTEtMS0w_5946a62e-f206-42f7-a165-d5b02ecc4b5f">2,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57608adce9004fa8829f1bf5a0f4c66c_I20200930" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMi0yLTEtMS0w_9debba7b-244e-4f24-b36f-67d850de300d">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21d1c6b9142d4a759b71dc4abddbb243_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMi00LTEtMS0w_1a26fad5-2b81-4759-9544-124c3aa20de8">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86b09d66e5904f00bdfc6d7dcac58e24_I20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMy0yLTEtMS0w_e48ef5d0-16fa-4a75-876a-d317fd3290b9">2,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7807cd27ff842ef98aaf27968fece25_I20191231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMy00LTEtMS0w_c6a89831-45ff-457e-99ae-b0bab89637b4">2,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, amounts reclassified from Accumulated other comprehensive loss into the Company's operating results were <ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RleHRyZWdpb246NjUyYjFlOGUwMzg2NGI4NzhhYTc3YWE0ZWMxZjAyNWJfNTk4_15f989b9-8f31-4863-b5c4-d643e6be07ba"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RleHRyZWdpb246NjUyYjFlOGUwMzg2NGI4NzhhYTc3YWE0ZWMxZjAyNWJfNTk4_a5292e37-aaa7-4229-bf44-cc67212fb6fe">no</ix:nonFraction></ix:nonFraction>t material.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_82"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RleHRyZWdpb246N2JjNjJkNjQ0YzFkNDcxMThmNjUxNjdhNjNmMzZiZjNfMjM0_dee05da5-073d-4617-9f4e-0fba5bc83c75" continuedAt="ic9ab51df17d64b68bcce88d43d1c393c" escape="true">RESEARCH AND DEVELOPMENT</ix:nonNumeric></span></div><ix:continuation id="ic9ab51df17d64b68bcce88d43d1c393c"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. <ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RleHRyZWdpb246N2JjNjJkNjQ0YzFkNDcxMThmNjUxNjdhNjNmMzZiZjNfMjM3_fd7fb91e-d03f-4c57-9205-28dc6cdb6c95" continuedAt="i8705d3246d9048b8af427c504a8cab52" escape="true">Research and development costs consist of:</ix:nonNumeric></span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><ix:continuation id="i8705d3246d9048b8af427c504a8cab52"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMi0yLTEtMS0w_4674b5cf-a64c-4592-b102-ea7018ca74f9">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMi00LTEtMS0w_acbeaf82-4aa0-4e81-8b22-43e1287bed13">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMi02LTEtMS0w_1b9df7a9-1d3c-4970-9e85-ffee3436943f">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMi04LTEtMS0w_e9fcab0c-27ad-467c-8f63-6c69bb5f89d4">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMy0yLTEtMS0w_1f142541-37dd-4162-8b4f-1d44e1577699">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMy00LTEtMS0w_e179e273-0d4d-4c47-9ec1-f4e38a515b69">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMy02LTEtMS0w_7e210f7f-84dc-414d-9b50-86a63aa3e1dc">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMy04LTEtMS0w_18a8f9d9-233e-4a69-9886-5a0c92ef9e9b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfNC0yLTEtMS0w_697af62a-b242-4749-a34a-0829f85d4926">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfNC00LTEtMS0w_36900f7c-d618-47c6-b5d8-67e5aba43b94">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfNC02LTEtMS0w_4b802918-0468-4230-b859-4975f928178a">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfNC04LTEtMS0w_5b7fb719-336b-4248-8aba-d71129db6b5c">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_85"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RleHRyZWdpb246NWNiOWY5YWU0Yjg0NDEwOWEyZWUxODY0ZjI2MzgzODNfNDUz_2ab35b8a-f5c3-4467-94e2-1051508c09ac" continuedAt="i0719931fe1fc42c5948ede691db24fb5" escape="true">OTHER EXPENSE, NET</ix:nonNumeric></span></div><ix:continuation id="i0719931fe1fc42c5948ede691db24fb5"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RleHRyZWdpb246NWNiOWY5YWU0Yjg0NDEwOWEyZWUxODY0ZjI2MzgzODNfNDU1_acca34af-e329-48c9-b4f5-2d903af75dc8" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of:</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMi0yLTEtMS0w_a9760a66-3d60-482f-b82f-d85d812d87a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMi00LTEtMS0w_4ee0fe35-6958-4d9b-af39-2be37f1e76f7">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMi02LTEtMS0w_ce421253-c05b-4165-9e50-448ae91e593b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMi04LTEtMS0w_1e887c5b-6158-4826-b942-aab16c94aa4a">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMy0yLTEtMS0w_c4a441bb-91e0-4242-97c0-8e1f9fe72957">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMy00LTEtMS0w_7f35e1d2-5ca8-4e9e-bd35-c7501a3371e8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMy02LTEtMS0w_83227e31-30f1-424b-87f9-0f6f97eadf73">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMy04LTEtMS0w_4f33b40d-12d9-457a-bebb-32e7b26ef732">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNC0yLTEtMS0w_3f4ace4a-7ab7-481f-80a9-931e27b1f95d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNC00LTEtMS0w_707154f2-f308-4993-a146-ee7d55aeeeda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNC02LTEtMS0w_3a140ffd-1c65-4c35-b330-999dddb18cff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNC04LTEtMS0w_8fafb168-d98c-4ae4-9a2a-c61da4e63e43">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNS0yLTEtMS0w_6036faac-e7bc-4c02-8289-ec97a23a3d66">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNS00LTEtMS0w_1d5774e7-e809-4a7d-8524-c21bb32c044c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNS02LTEtMS0w_6f4754c5-81b2-4a79-8ab7-158c39478a1b">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNS04LTEtMS0w_52beb311-ae20-4d8a-8bba-dbc81b834bc8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="bhc:OtherMiscellaneousNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNi0yLTEtMS0w_dfad94e6-ee5e-47a5-8110-065ce31d3d27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="bhc:OtherMiscellaneousNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNi00LTEtMS0w_a2127add-c650-46a7-86a1-c953945b7ae8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="bhc:OtherMiscellaneousNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNi02LTEtMS0w_519c0ed6-3f0b-4e0d-ba6b-ff06e8cf6fcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="bhc:OtherMiscellaneousNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNi04LTEtMS0w_3c64420c-b3bb-4b7b-bf4c-a43068d4740b">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNy0yLTEtMS0w_e7a2c7cc-2a57-439d-a876-e3bbd43da8b5">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNy00LTEtMS0w_194bd1f6-950e-4ce3-b1af-dea5a7369d3a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNy02LTEtMS0w_83fbd9c6-e1e6-4c8f-a6c4-dcfb68706b29">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNy04LTEtMS0w_8d14333b-5043-49fe-b32b-072ada5743ef">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, Litigation and other matters includes adjustments related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. Litigation and other matters also includes an insurance recovery related to a certain litigation matter.  See Note 18, "LEGAL PROCEEDINGS" for further details regarding these and other litigation matters.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfNDM5ODA0NjUxODEwMg_ff3832aa-483f-4260-b598-db2b910dfc19" continuedAt="i527813a7b6af4332b3e074fbfef76862" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="i527813a7b6af4332b3e074fbfef76862" continuedAt="ifba1c12c8aa641f997994d3da105b96d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company's ordinary income, subject to certain limitations on the benefit of losses. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company's income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company's estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefit from income taxes for the nine months ended September 30, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfNzY0_87b0b14c-1ab7-47e5-8de3-511a3344bbb0">133</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfNzg1_c1293aac-9365-4e64-a0a3-f1de3b4e98bf">105</ix:nonFraction> million of net income tax benefit for discrete items, which includes: (a) $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfODU0_2e1cdf57-a248-4c73-990c-42a4ea349fd6">63</ix:nonFraction>&#160;million in net tax benefits related to the release of a valuation allowance, (b) $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTY0OTI2NzQ0ODU1OA_ad898e0f-19c4-44f1-809b-80fac2be12ed">36</ix:nonFraction>&#160;million in tax benefits associated with law changes in the United States, (c) $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfOTMw_b6374249-8aee-439c-b59c-c9d8ecbb141c">10</ix:nonFraction> million in tax benefits recognized for changes in uncertain tax positions, (d) a $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTA3MQ_0bdce8de-d85f-467f-86e9-48f38ed8ae49">7</ix:nonFraction> million tax benefit related to a deduction for stock compensation and (e) $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTE0MA_1632dfa8-ad74-4309-beb8-fc962dcbddc9">11</ix:nonFraction> million of net tax expense associated with filing certain tax returns and (ii) $<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTIxNA_66dedf89-eee9-4ee8-a6bf-32c2bcb94e48">28</ix:nonFraction> million of income tax benefit for the Company's ordinary loss for the nine months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes for the nine months ended September 30, 2019 was $<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTMxNA_df99febe-8bab-45a9-a639-a2424b6db713">101</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTMzNQ_9e13e0b7-174f-4280-96e4-43b8335c2ee5">46</ix:nonFraction> million of net income tax benefit for discrete items, which includes: (a) $<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="bhc:EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTQwNA_d4b8fe4c-0970-49cf-855b-b5aa02da04de">32</ix:nonFraction> million of tax benefit recognized upon a ruling from the Polish tax authorities confirming the deductibility of royalty payments by an affiliate, (b) $<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="bhc:EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTU0OQ_add6c00c-996c-4725-9617-ee30e2c9522a">13</ix:nonFraction> million of net tax benefits associated with filing certain tax returns and (c) $<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTYyMw_3a59639c-ef80-4be5-96be-19d7b44b9e57">1</ix:nonFraction> million of net tax charges related to other changes in uncertain tax positions and (ii) $<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTcwNg_f1f6925f-bb08-4e88-b2d0-0b1c2e064f35">55</ix:nonFraction>&#160;million of income tax benefit for the Company's ordinary loss for the nine months ended September 30, 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made except that, as a result of the 2018 adoption of guidance regarding intra-entity transfers, any change in valuation allowance surrounding the adoption of the intra-entity transfer resulting from this adoption was recorded within equity. The valuation allowance against deferred tax assets was $<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMjQ1Ng_02843538-931e-4361-ba63-885aa9afc61a">2,756</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMjQ2Mw_797e9d08-3ba3-4410-aebe-4d75a954bb71">2,831</ix:nonFraction> million as of September&#160;30, 2020 and December&#160;31, 2019, respectively.  The decrease was primarily due to: (i) the change in the expected realizability of previously established losses in Germany, recorded discretely and (ii) income in Canada. The Company will continue to assess the need for a valuation allowance on a go-forward basis.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2020, the U.S. Treasury Department and the Internal Revenue Service (the "IRS") released final regulations under the Global Intangible Low Taxed Income ("GILTI") and Subpart F income provisions of the Internal Revenue Code regarding the treatment of income that is subject to a high rate of foreign tax. The final regulations allow taxpayers to exclude certain high-taxed income of a controlled foreign corporation from their GILTI computation on an elective basis. The Company has evaluated the effects of these final regulations and has discretely recorded a $<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="bhc:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTA5OTUxMTYzNDc2Mg_26a322cf-0018-4ed1-996a-85c320c75e96">19</ix:nonFraction>&#160;million tax benefit during the three months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December&#160;31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzUwNg_e8c29c84-e71f-4602-b0a7-c33c750cf20b">1,009</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzUxMw_18cea1cf-e444-4670-83c9-c231b2034ae2">1,002</ix:nonFraction> million of unrecognized tax benefits, which included $<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzU2MQ_23589fa6-00f5-4a85-b03a-ea93c468fa14">51</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzU2OA_b39c4cc1-d023-438e-aa52-93c7383f0fc0">45</ix:nonFraction> million of interest and penalties, respectively. Of the total unrecognized tax </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ifba1c12c8aa641f997994d3da105b96d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits as of September&#160;30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzY2MQ_0a093e51-772f-40ab-b6a0-18930d726871">363</ix:nonFraction> million would reduce the Company&#8217;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at September&#160;30, 2020 could decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzg2Nw_0a7622f9-2be2-4534-9a3b-ff0c74167aed">141</ix:nonFraction> million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. The Company&#8217;s position as of September&#160;30, 2020 with regard to proposed audit adjustments has not changed and the proposed adjustments continue to result primarily in a loss of tax attributes that are subject to a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations.  The 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the IRS has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. At this time, the Company does not expect that proposed adjustments, if any, for these periods would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2010 through 2011 and 2015 through 2017.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2011 through 2015. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTIwMQ_52168956-0db5-45f8-a70b-27cf5d50d3db" continuedAt="ib39e053bf0bd4910bbb3434f8ab93678" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ib39e053bf0bd4910bbb3434f8ab93678"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTIxNA_2fbb5d75-16f8-4fea-993c-e8043619daf5" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMi0xLTEtMS0w_1110133a-ffd4-4eca-b168-868b79b0053c">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMi0zLTEtMS0w_3d2da526-41cd-43ee-aa97-166d8ecf79e9">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMi01LTEtMS0w_4fc29f87-e041-4050-82e2-764189962967">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMi03LTEtMS0w_b879c12c-1fa7-4320-8293-ad7c366811a7">272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNC0xLTEtMS00NDQ4_5db1c38a-5b69-4381-99a3-655b918ba269">355.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNC0zLTEtMS00NDQ4_10fe2e1b-ea77-409a-9289-0885eee2dc43">352.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNC01LTEtMS00NDQ4_56dbbc9c-beb0-4411-a7f8-2b0805614bfe">354.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNC03LTEtMS00NDQ4_d4b3ace7-b112-4c57-934c-f395649beebf">351.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted effect of stock options and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMy0xLTEtMS0w_3faaf2bb-c228-4e14-a8c3-8255359ac6e6">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMy0zLTEtMS0w_2f1d2d50-6d50-4413-b6de-89043eff9b18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMy01LTEtMS0w_bdd2923e-41c7-448d-b6a5-9971dece40ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMy03LTEtMS0w_f68b79a3-a85f-4180-a17e-a464630e8351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNi0xLTEtMS00NDUx_f5e1a83d-8317-4826-9301-fa0d9d171666">357.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNi0zLTEtMS00NDUx_ff73c632-5e4f-4c41-b9ac-f6de18a04c87">352.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNi01LTEtMS00NDUx_46f268a8-ce17-4e73-93aa-a75b5120b0b2">354.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNi03LTEtMS00NDUx_b2ec8888-54eb-4c9a-a14d-4065fdbff4d7">351.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (loss) per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfOS0xLTEtMS00NDY3_f2c4b984-4702-478e-bb77-f2b4767b2de2">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfOS0zLTEtMS00NDY3_c8b027cc-696c-434d-9373-2511a36c8436">0.14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfOS01LTEtMS00NDY3_f35c9ab4-c4bd-4b8a-9313-c7cba7a65944">1.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfOS03LTEtMS00NDY3_7c6f0f80-69a4-4d07-9f86-4c57f7f8f475">0.77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMTAtMS0xLTEtNDQ2Nw_d49b7381-dfed-463e-a45c-50952168b0f5">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMTAtMy0xLTEtNDQ2Nw_e4c59e56-5fce-4c80-8bf3-c734919ad25e">0.14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMTAtNS0xLTEtNDQ2Nw_eba0cb46-7d86-4ce3-9397-9624fb78dd8a">1.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMTAtNy0xLTEtNDQ2Nw_f3bbbb2b-739b-4551-9bfc-724dea74734d">0.77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020 and the three and nine months ended September 30, 2019, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive.  The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately <ix:nonFraction unitRef="shares" contextRef="ie07c162ca742405c98233c58abdd8aac_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTA5OTUxMTYyOTM1Mg_c4551944-3003-4c2a-9fbf-43c54e2486c5">3,144,000</ix:nonFraction> common shares for the nine months ended September 30, 2020, and approximately <ix:nonFraction unitRef="shares" contextRef="i1dd54993dd634b0e82dc598e88544ff5_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTA5OTUxMTYyOTM0MQ_06e375a5-02cf-466c-b676-0a303bbc472d">4,453,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i762b42904b7d4c47b7d9c94632f27fd6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfNTY0_47283e01-fe76-443c-a3a9-21fa051d41e0">4,589,000</ix:nonFraction> common shares for the three and nine months September 30, 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, time-based RSUs, performance-based RSUs and stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="i70173b7267ae47adacd4ad3ca61345b6_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfNzE2_c827c1aa-1d65-454c-b038-fddcb0eda6ce">10,489,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ibcfc0abb71864f4a8d26e6f9694c6f5f_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfNzIz_ea967be3-e585-4e20-a962-e4370dbecb7a">10,604,000</ix:nonFraction> common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2019, time-based RSUs, performance-based RSUs and stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="i563b2181888e4e4ebcc9b80b5cc2f344_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTAxMw_c66d45aa-7fe2-4335-aa77-2043dcc84132">5,363,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6b05369642d5468d80a1713347b981b1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTAyMA_80a7c0d0-b917-407c-84e5-d12e29204473">5,363,000</ix:nonFraction> common shares, respectively were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_94"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNDM5ODA0NjU3NTg1OA_e41dcccd-81ee-470f-9626-41573c69fb3e" continuedAt="i4d25e94bdf634573bd1a2ce4b88dd023" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><ix:continuation id="i4d25e94bdf634573bd1a2ce4b88dd023" continuedAt="if521121fbbb14aa6b1bdb310d1785a1a"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued.  As of September 30, 2020, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $<ix:nonFraction unitRef="usd" contextRef="i9da4fed668814346810326af9b4d6598_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationReserveCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTM2Nw_1e5b6ddd-f6f5-4e27-a335-194f12ac3b99">1,462</ix:nonFraction> million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome -of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Governmental and Regulatory Inquiries&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the District of Massachusetts - re Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation.  The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, <ix:nonFraction unitRef="case" contextRef="i5aaed5342aab4e6ab0cdebeb807e227b_D20151001-20151031" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzQ5Mg_c3d805c5-6d22-4aa0-933f-c31dbe66ec0d">four</ix:nonFraction> putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the <ix:nonFraction unitRef="case" contextRef="i5aaed5342aab4e6ab0cdebeb807e227b_D20151001-20151031" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNDAzMw_0fc3c455-b967-4962-9c29-d635662756b2">four</ix:nonFraction> actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $<ix:nonFraction unitRef="usd" contextRef="i7907ded04dab4554a0ef907fa261b6f7_D20191216-20191216" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNDMzMw_e8dc9a06-f9d4-40dd-854f-86ea8b9534db">1,210</ix:nonFraction> million, subject to final court approval.  Once approved by the court, the settlement will resolve and discharge all claims against the Company in the class action.  As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. On January 27, 2020 the court preliminarily approved the settlement. A final settlement approval hearing was held on May 27, 2020 and the settlement remains subject to final court approval. In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payment is being paid in accordance with the payment schedule outlined in the settlement agreement. The opt-out litigations discussed below remain ongoing.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="if521121fbbb14aa6b1bdb310d1785a1a" continuedAt="i924e42408b754f1f8df73247f6387a46"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#8220;Timber Hill&#8221;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016.  On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658).  On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, <ix:nonFraction unitRef="group" contextRef="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNjM2MQ_6130fb1d-8a33-43be-b5b7-a82cde008a88">thirty-seven</ix:nonFraction> groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. In addition to the matters captioned Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (&#8220;Maverick&#8221;), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (&#8220;Templeton&#8221;), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (&#8220;USAA&#8221;), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (&#8220;GIC&#8221;), these actions were captioned previously in the Company&#8217;s Annual Report on Form 10K for the year ended December 31, 2019, filed on February 19, 2020. <ix:nonFraction unitRef="case" contextRef="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNzI4MQ_db6538f2-cf08-4f6f-b5df-0283a0c0a3e1">Seven</ix:nonFraction> of the <ix:nonFraction unitRef="group" contextRef="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNzI5MQ_6130fb1d-8a33-43be-b5b7-a82cde008a88">thirty-seven</ix:nonFraction> opt out actions have been dismissed; and the total number of remaining opt out actions pending in the District of New Jersey is <ix:nonFraction unitRef="group" contextRef="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNzQyMg_c76cca73-72e5-4f1e-bfba-95f65b2cf4fc">thirty</ix:nonFraction> actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case.  On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions.  On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, <ix:nonFraction unitRef="case" contextRef="i9761d415100240bda346f87cf5e43c87_D20150101-20151231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfOTMyNQ_b6b35997-b999-468b-819e-b0690f8b52d4">six</ix:nonFraction> putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of <ix:nonFraction unitRef="action" contextRef="if22f2ae279114a87892281886f95c6b6_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="bhc:LossContingencyNewClaimsFiledButNotYetServedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfOTU0Mw_9012afea-0f0a-44cc-be02-2e0e6a7a61bb">two</ix:nonFraction> additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, has been discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding.  On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD <ix:nonFraction unitRef="cad" contextRef="id21158059b994e63a17e72acde64ae62_D20200804-20200804" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTA5NjE_d6dca385-4f86-4aa6-ab5c-7257eac07a22">94,000,000</ix:nonFraction> plus payment of an additional amount to cover notice and settlement administration costs and disbursements.  As part of the settlement, the Company and </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i924e42408b754f1f8df73247f6387a46" continuedAt="i9c33ca39358b45a5908b0a96f7a4b739"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement agreement is subject to court approval. If court approval is granted, the Catucci action will be dismissed against the Company, its current and former directors and officers, its underwriters and its insurers. The hearing to approve the settlement is scheduled for November 16, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action.  On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, <ix:nonFraction unitRef="entity" contextRef="i15509ff699a54e30814d181db390b519_I20190215" decimals="INF" format="ixt-sec:numwordsen" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTIzODQ_a0a8caab-17e5-476d-b431-0a3294a9607f">one</ix:nonFraction> of the entities which exercised its opt-out rights (&#8220;CalSTRS&#8221;) served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> during the period covered by the claims. The Company has notified CalSTRS of its intention to oppose the amendments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, <ix:nonFraction unitRef="action" contextRef="ibf179bff49a0406f8a4e9ebf6c739aa8_D20160527-20160916" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTA5OTUxMTY3NTgwMw_018e5056-3401-403a-8693-860b3ba62168">three</ix:nonFraction> actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160; The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;A special master appointed by the Court has recommended that the Company&#8217;s motion to dismiss be denied, but a final decision is still pending with the Court. The Company believes these claims are without merit and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Securities and RICO Class Actions and Related Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. Such matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Lawsuits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019 and September 13, 2019, <ix:nonFraction unitRef="action" contextRef="if4b754682f144667ad815ed4518db769_I20190910" decimals="INF" format="ixt-sec:numwordsen" name="bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTM3MTI_94bff517-f26b-476e-a5ae-2460be50e9bb"><ix:nonFraction unitRef="action" contextRef="iee5b12e58e9e44f8ac5eb07d4df04f45_I20190913" decimals="INF" format="ixt-sec:numwordsen" name="bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTM3MTI_b5942670-bed8-45fc-867b-49e71dc98bb8">two</ix:nonFraction></ix:nonFraction> alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i9c33ca39358b45a5908b0a96f7a4b739" continuedAt="i8de22f78ec2e4760921048bc9ad0a621"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complaint was filed, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Case No. 19-cv-17833). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. The consolidated complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases are based on the same purported conduct that is at issue in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Valeant Pharmaceuticals International, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint.  Briefing on this motion concluded on August 3, 2020. The Company disputes these claims and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during <ix:nonFraction unitRef="insurance_policy_period" contextRef="ideecfb512d4a4ea28fd5ec735471c964_D20171207-20171207" decimals="INF" format="ixt-sec:numwordsen" name="bhc:LossContingencyNumberOfInsurancePolicyPeriods" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTU4NDk_33831d09-c440-4628-a0bf-e475219ab88c">two</ix:nonFraction> distinct policy periods, (i) 2013-14 and (ii) 2015-16.&#160; The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).&#160; In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in&#160;In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and certain of the investigations described above (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act.  This matter is currently stayed pending the completion of discovery in one of the above-noted federal opt-out cases. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, <ix:nonFraction unitRef="case" contextRef="ic882bdf321904c1a8e0bb5f1007fe242_D20190801-20200730" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTg4Mzk_78108d12-1162-4ba7-a784-4b2070909b60">eight</ix:nonFraction> (8) putative antitrust class actions and <ix:nonFraction unitRef="case" contextRef="i45d3c5867e5e41f8914f1ce2d2dbfc1e_D20190801-20200730" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTg4ODM_607fe60c-215f-4619-8ae6-3ebb0958b2ea">four</ix:nonFraction> (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. <ix:nonFraction unitRef="case" contextRef="i69e5ff05a4c0418eb2417e345fc2103d_D20190801-20200730" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTkyNzc_3abeec3c-ecb0-44c0-9816-c9d34b4f96c2">Three</ix:nonFraction> (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020.  The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. <ix:nonFraction unitRef="case" contextRef="iab043430936d464bb3fafd27f4d9e799_D20191125-20191125" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTk2NzA_e1af007f-6358-41a3-99c8-41aba6b2e8fb">Three</ix:nonFraction> (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020.  The Company&#8217;s motion to dismiss the insurer plaintiff&#8217;s amended complaint is pending. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions, <ix:nonFraction unitRef="case" contextRef="ib845c8cc5de943d88c90123be7710ee5_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTA5OTUxMTY3OTg4OA_696f7a1f-5f64-4a07-9a89-f1004b96657a">five</ix:nonFraction> (5) of which remain pending, have been consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA. The lawsuits allege that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints allege that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs seek damages under federal antitrust laws for claims based on direct purchases. The insurer plaintiff also seeks damages and equitable relief under various state laws for claims based on indirect purchases. The Company disputes the claims against it and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this subsection, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i8de22f78ec2e4760921048bc9ad0a621" continuedAt="i1aaff54470654cda80b5647ef1a20281"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16-MD-2724).  The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals.  The initial lawsuit to which the Company was added as a defendant in June 2018 was filed by a putative class of direct purchaser plaintiffs.  In December 2018, certain direct purchaser plaintiffs that had opted out of this putative class filed an amended complaint in the MDL that added the Company, alleging similar claims as the direct purchaser plaintiffs&#8217; putative class action complaint.  In February 2019, the Company filed a motion to dismiss the individual claims brought against it and that motion remains pending.  In October 2019, an end payer plaintiff that had opted out of the putative end payer class filed a complaint against the Company in the Eastern District of Pennsylvania alleging similar claims.  In December 2019, end payer opt-out complaints also were filed against the Company in the Eastern District of Pennsylvania and in the Northern District of California.  In December 2019, separate putative class action complaints were filed against the Company in the Eastern District of Pennsylvania by end payer and indirect reseller plaintiffs.  In February 2020, a putative class action complaint was filed against the Company in the Eastern District of Pennsylvania by direct purchaser plaintiffs.  In June 2020, an opt-out complaint raising both direct purchaser and end payer claims was filed against the Company in the Eastern District of Pennsylvania.  Also in June 2020, State Attorneys General filed a Complaint against the Company in the District of Connecticut. In July 2020, a direct purchaser opt-out complaint was filed against the Company in the Eastern District of Pennsylvania. In August 2020, a complaint was filed against the Company by Suffolk County, New York in the Eastern District of New York.  In September 2020, a direct purchaser opt-out complaint was filed against the Company in the Eastern District of Pennsylvania.  The cases have been or will be consolidated into the MDL.  There are also additional, separate complaints by other plaintiffs which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant.  In July 2019, <ix:nonFraction unitRef="healthplan" contextRef="i5e0b356ae3324301ab3aeacbefbdc8b4_D20190701-20190731" decimals="INF" name="bhc:LossContingencyNumberOfHealthPlansFiledLawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMjM3ODY_af719e76-ef04-417a-bd08-19ae9470e53d">87</ix:nonFraction> health plans commenced an action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed and the case has been put in deferred status.  In May 2020, <ix:nonFraction unitRef="healthplan" contextRef="i2988c46f79404f97bf0bb7d6d8a49295_D20200501-20200531" decimals="INF" format="ixt-sec:numwordsen" name="bhc:LossContingencyNumberOfHealthPlansFiledLawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMjQwNDg_3371796d-58ce-431a-b422-3b17d347ec9e">seven</ix:nonFraction> health plans commenced an additional action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed.  The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Plenvu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada, or other similar suits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (&#8220;Perrigo&#8221;), in which Perrigo asserted that certain U.S. patents, each of which is listed in the U.S.&#160;Food and Drug Administration's (the "FDA") Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo&#8217;s generic lotion, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Perrigo.  On August 28, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described below, regarding Perrigo&#8217;s ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo, in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo&#8217;s generic halobetasol propionate lotion, for which an ANDA has been filed by Perrigo.  On May 1, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described above, regarding Perrigo&#8217;s ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. ("Alfasigma") received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA's Orange </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i1aaff54470654cda80b5647ef1a20281" continuedAt="i45e03079c3134da8a535a06ac162e6fb"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an ANDA has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 23 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company and Alfasigma commenced litigation against Sun Pharmaceutical Industries Ltd. (&#8220;Sun&#8221;), alleging patent infringement by Sun&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution.&#160; IPR challenges have been brought against patents covering the Company's branded pharmaceutical products.&#160; For example, following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board ("PTAB"), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continues to be covered by eleven other Orange Book-listed patents owned by the Company and its licensor, which expire in the years 2028 through 2035.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;Product Liability&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, only twelve (<ix:nonFraction unitRef="case" contextRef="ia09727ee9461493e9f4e2df94a1f1591_I20200930" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzEwMTI_9098c11e-2995-40f6-9704-98338166d2e7">12</ix:nonFraction>) of such product liability suits currently remain pending. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company, and legal fees and costs will be paid by Johnson &amp; Johnson. Ten of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer or mesothelioma. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages.  The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; </span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i45e03079c3134da8a535a06ac162e6fb" continuedAt="i8e1c1ef8962347c08b27ede50beec84e"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. In accordance with the indemnification agreement, Johnson &amp; Johnson will continue to vigorously defend the Company in each of the remaining actions that are not voluntarily dismissed or subject to a grant of summary judgment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Graham v. Bausch Health Companies, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gutierrez, et al. v. Johnson &amp; Johnson, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted.  In August 2020, Plaintiffs filed the Fifth Amended Complaint and the Company&#8217;s motion to dismiss that complaint is pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower&#174; and its alleged causal link to mesothelioma and other cancers.  In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US expects to file its Answer in November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;General Civil Actions&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019), filed with the SEC on February 19, 2020. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $<ix:nonFraction unitRef="usd" contextRef="i4e734b47f6ad4ad984cd62d97f81a208_D20180401-20180430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzcxNTA_2fee9498-91b8-491a-a953-e29dcb758bc7">23</ix:nonFraction> million. The Company has asserted counterclaims against Doctors Allergy.&#160;</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i8e1c1ef8962347c08b27ede50beec84e" continuedAt="ife9dbcbbf65e40fe97770bc8480adaf8"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief.  The lawsuit arises out of the contractual termination of approximately $<ix:nonFraction unitRef="usd" contextRef="id819c010b7eb43699a500c0115cc5647_D20190128-20190128" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzc1MDk_132a575e-310d-4613-bcc1-02d96ebf29fa">30</ix:nonFraction> million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd.  Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Completed or Dormant Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since July 1, 2020 or the Company anticipates that no further material activity will take place with respect thereto, or the matters have been dormant for several quarters. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in November 2015, the Company received from the staff of the Los Angeles Regional Office of the SEC ("the Staff") subpoenas for documents, as well as various document, testimony and interview requests, related to its investigation of the Company, including requests concerning the Company's former relationship with Philidor Rx Services, LLC ("Philidor"), its accounting practices and policies, its public disclosures and other matters. On March 27, 2020, the Staff  issued a Wells Notice informing the Company that they had reached a preliminary determination to recommend that the SEC bring charges against the Company for violating the federal securities laws as a result of SEC filings and other statements made by Valeant and its former executives in 2014-2015 concerning Philidor, as well as other accounting and disclosure matters, including the Company&#8217;s disclosure of certain price appreciation credits in 2015 - 2016. The Company has entered into a settlement with the SEC that has resolved all allegations by the SEC against the Company. Under the terms of the settlement, the Company neither admitted nor denied the SEC&#8217;s allegations and agreed to pay a $<ix:nonFraction unitRef="usd" contextRef="i7ce77ea687ee470cace2bc7c9451c86d_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzk5NDk_eb90aea5-b9d9-4f19-a5ff-7f4a795fc283">45</ix:nonFraction>&#160;million civil monetary penalty.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMF Investigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2016, the Company received a letter from the Autorit&#233; des march&#233;s financiers (the &#8220;AMF&#8221;) requesting documents concerning the work of the Company&#8217;s ad hoc committee of independent directors, the Company&#8217;s former relationship with Philidor, the Company's accounting practices and policies and other matters. In July 2018, the Company was advised by the AMF that it had issued a formal investigation order against it. On September 30, 2020, the AMF confirmed that it had closed its investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the State of Texas</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2014, the State of Texas served Bausch &amp; Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) with a Civil Investigative Demand (&#8220;CID&#8221;) concerning various price reporting matters relating to the State's Medicaid program and the amounts the State paid in reimbursement for B&amp;L products for the period from 1995 to the date of the CID.&#160; B&amp;L Inc. and the State agreed to settle the matter for $<ix:nonFraction unitRef="usd" contextRef="i8cf776ee426f4162b6f648f87bccf843_D20200401-20200401" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNDA4Mzc_c5ae58c0-750e-4618-b450-96fac91ace7f">10</ix:nonFraction> million. The Company made the payment on April 1, 2020. On July 1, 2020, the State moved to dismiss the case by filing a notice that it was taking a nonsuit, with prejudice to refiling, effective immediately.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the District of Massachusetts regarding patient assistance and pricing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015 and June 2016, the Company received two subpoenas from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents and witness interviews with respect to the Company&#8217;s patient assistance programs and contributions to patient assistance organizations that provide financial assistance to Medicare patients taking products sold by the Company, and the Company&#8217;s pricing of its products.  The Company is cooperating with this investigation. There has been no material activity for several quarters on the part of the Company with respect to this matter nor has the Company had recent contact from the U.S. Attorney's Office for the District of Massachusetts with respect to this matter. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="ife9dbcbbf65e40fe97770bc8480adaf8"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the Southern District of New York</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the Southern District of New York, requesting materials including documents and witness interviews with respect to the Company&#8217;s patient assistance programs; its former relationship with Philidor and other pharmacies; the Company&#8217;s accounting treatment for sales by specialty pharmacies; information provided to the Centers for Medicare and Medicaid Services; the Company&#8217;s pricing (including discounts and rebates), marketing and distribution of its products; the Company&#8217;s compliance program; and employee compensation. The Company is cooperating with this investigation. There has been no material activity for several quarters on the part of the Company with respect to this matter. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div></ix:continuation><div id="ie8b2716e216c4586bfedb14835ff92cc_100"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyOTE_9748f319-ed92-4c8f-95ff-1e4702512400" continuedAt="i4119093654a249c98bf553366bb50c1c" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i4119093654a249c98bf553366bb50c1c" continuedAt="i5587d37c96f14cfda397c1d293e53f89"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Executive Officer ("CEO"), who is the Company&#8217;s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company&#8217;s CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports.&#160;The Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb/International segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Ortho Dermatologics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Acquired in-process research and development costs, Restructuring, integration and separation costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun addressing the internal organizational design and structure of the new entity, which it anticipates having substantially complete in late 2021. As of the date of the issuance of these financial statements, these matters are in the planning phase. In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021.  Accordingly, the Company expects to begin reporting its segment results to reflect the proposed realignment of its operating segments on a retrospective basis beginning with its first quarter of 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i5587d37c96f14cfda397c1d293e53f89" continuedAt="i0d5cd0fd3f104d02896ea081e0dbcab3"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyNjU_aba9a717-2891-4ea9-9fb5-95b55c14dbb8" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897313242ab641dc9046ace39af16263_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzMtMS0xLTEtMA_5530b3d3-fb29-4e18-b9ba-07b07ed23efd">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12cb1b6cda347f9967513c7742fcb23_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzMtMy0xLTEtMA_a5a39e46-572e-4fcc-9ea6-173c7184eda0">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d7bbb8cfa04946a18339b2648304fd_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzMtNS0xLTEtMA_b759965b-50b2-46b4-80c0-ba4381bad822">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d197803d96f4ffcbd4159fa39ebc261_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzMtNy0xLTEtMA_95617793-0138-416a-836d-f3786114de6a">3,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7932c3cbe2342548eee1258aa49347e_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzQtMS0xLTEtMA_7d54586f-2451-45fb-a7d9-7a3386a44ad9">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafc86557cbe4d14b4c893a64ca76cf9_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzQtMy0xLTEtMA_3113684e-18b9-45a6-b710-7068db71cf3b">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7fe2b7d367f4dae834989f4487131d7_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzQtNS0xLTEtMA_7b493132-8065-47bf-9e1b-36c9f2f7d10b">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f4f9fe18664f5683fa137fff600592_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzQtNy0xLTEtMA_305e2ad7-4d46-4e65-9b68-1558f83273dc">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9630fad3411d4ecdbb4e6cecfef710ee_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzUtMS0xLTEtMA_3ecc13ee-b994-4186-87e9-ba3a103c42c6">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fff547485ae43d2968ff0cc7028a326_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzUtMy0xLTEtMA_7bca7fdd-63fa-4f6e-915d-11aa39b87807">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353913d5fc9242c18667b11e98757190_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzUtNS0xLTEtMA_6cd1edad-654e-489c-807b-2d93b02cb1b3">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7b69b1fdb4a07b595627842521754_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzUtNy0xLTEtMA_bc411ab2-4bbf-4725-a9b7-fa677b6d8af7">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96a2f7723254ec5a9f11c4c934d4889_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzYtMS0xLTEtMA_66aad1f8-f505-44df-a125-7d0161380d28">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c0c48d8f5d49e0a298cb9e6244ac8a_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzYtMy0xLTEtMA_aa666936-0883-4f0e-9e0e-183487650480">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i945442a1ab3a4f6fb3811c26a1bab0bc_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzYtNS0xLTEtMA_f3948e85-1452-4ce6-afc1-ad1c866a38cb">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961d00fe6e394e0097042fdf55f1f75b_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzYtNy0xLTEtMA_58c7c77d-30d7-4100-b4bc-57e65985ea3c">964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8298bc44b8d4fa9a438061d2df01a40_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzctMS0xLTEtMA_46dd45f1-e414-4cb1-859c-d5e222c0b1f5">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992e52a4d5fb436e95fb7cfa4b72df3d_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzctMy0xLTEtMA_06b59886-0eb0-4303-9114-5540cfae742a">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c51a36d127d44c9946fde415735fe2c_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzctNS0xLTEtMA_d8d310fa-4b22-432e-98b2-de3e56f4b894">5,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c46aa3b1cd4b5789f0ca5a453ed7b5_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzctNy0xLTEtMA_b5983dbe-96c1-4f29-945c-99b72847b067">6,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i897313242ab641dc9046ace39af16263_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEwLTEtMS0xLTA_ae90b1d7-d30e-4679-9417-a97304946424">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12cb1b6cda347f9967513c7742fcb23_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEwLTMtMS0xLTA_c8f66e6d-ad70-49ba-80fa-b5083e1c597d">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d7bbb8cfa04946a18339b2648304fd_D20200101-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEwLTUtMS0xLTA_d137f316-5249-4077-ba58-be39b2995231">830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d197803d96f4ffcbd4159fa39ebc261_D20190101-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEwLTctMS0xLTA_9f043741-7e26-4ebf-a70b-7c7ebd1041b4">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7932c3cbe2342548eee1258aa49347e_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzExLTEtMS0xLTA_8bc56fe7-cce8-4838-86fb-6ccf41c26b77">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idafc86557cbe4d14b4c893a64ca76cf9_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzExLTMtMS0xLTA_2f932a3b-a18b-4b3b-9746-3b89e9a12cd2">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7fe2b7d367f4dae834989f4487131d7_D20200101-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzExLTUtMS0xLTA_77eae22e-0927-4f1d-b6af-0f4c207c1f2e">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74f4f9fe18664f5683fa137fff600592_D20190101-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzExLTctMS0xLTA_8119a27a-34e4-45c5-aee5-1a815564646c">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9630fad3411d4ecdbb4e6cecfef710ee_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEyLTEtMS0xLTA_21727fa8-d9ff-4ef4-b5ad-ce859c01d8ac">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fff547485ae43d2968ff0cc7028a326_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEyLTMtMS0xLTA_4e5b69ca-48b1-4ae8-b79b-8d8a3ee30f82">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353913d5fc9242c18667b11e98757190_D20200101-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEyLTUtMS0xLTA_e30cd823-cb3d-4d40-8d13-c57e0743111a">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a7b69b1fdb4a07b595627842521754_D20190101-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEyLTctMS0xLTA_7571c6bf-7d26-4eaa-8199-ae672e5f45db">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96a2f7723254ec5a9f11c4c934d4889_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEzLTEtMS0xLTA_07cf0fa9-0d41-4c77-837a-9a5e1b243880">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c0c48d8f5d49e0a298cb9e6244ac8a_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEzLTMtMS0xLTA_7ef62a57-2a3a-4511-8993-2e27b18d01c2">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i945442a1ab3a4f6fb3811c26a1bab0bc_D20200101-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEzLTUtMS0xLTA_01d60a51-3d82-409f-a0c6-c078a8e597c3">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i961d00fe6e394e0097042fdf55f1f75b_D20190101-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEzLTctMS0xLTA_c5c6b65d-f081-46dd-a79c-ec3658fb6364">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8298bc44b8d4fa9a438061d2df01a40_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE0LTEtMS0xLTA_13f94505-f8ba-485f-a2d4-6787e0b83aa4">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i992e52a4d5fb436e95fb7cfa4b72df3d_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE0LTMtMS0xLTA_a28b96b0-e140-450d-b2e5-1aef28ae6b38">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c51a36d127d44c9946fde415735fe2c_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE0LTUtMS0xLTA_8e603057-a419-4887-81e9-09537fba84d2">2,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c46aa3b1cd4b5789f0ca5a453ed7b5_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE0LTctMS0xLTA_86235591-8f9a-4c64-bd23-e5a13911f5b0">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f73a15d2634d3a8c0cca7a35b9ff85_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE1LTEtMS0xLTA_b2c4bcba-a7dc-4975-b7f0-ff8f28f186eb">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fcb52bae97844d694512c2bb87bdf17_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE1LTMtMS0xLTA_4e95077f-8586-4f60-ad0e-145bcd9fc993">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85eae108232242838086f4642eb70b08_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE1LTUtMS0xLTA_4241e9d4-9bc8-47e8-a0b2-11c1c727f03f">442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84c3fed40d05492ba7b7087a16d03b78_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE1LTctMS0xLTA_3a405689-e805-4578-8d6e-38852b0b6d2c">435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE2LTEtMS0xLTA_d0466226-82f4-405b-8b39-46125f007f27">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE2LTMtMS0xLTA_cb3cfc1b-1693-4d51-b362-10a241aa5b0b">475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE2LTUtMS0xLTA_874e6aa0-eeac-403d-82ce-e315838bbe45">1,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE2LTctMS0xLTA_083bcdc5-8b0c-45f6-a6b7-edd2ad9bceb3">1,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE3LTEtMS0xLTA_00b223a0-1d15-46f0-b648-546a659c64bc">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE3LTMtMS0xLTA_11d5c681-475c-493d-be96-d54dbde83076">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE3LTUtMS0xLTA_521afbbd-34e6-4ff5-a186-4235ca9383dc">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE3LTctMS0xLTA_117afb85-fff4-4e5f-977e-75906726fae5">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration and separation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE4LTEtMS0xLTA_cf1f41b7-c5f7-4055-85cf-2bb448abcbf0">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE4LTMtMS0xLTA_f97a6227-79d5-4e76-bb5b-e8006a13d174">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE4LTUtMS0xLTA_8c330888-6eed-4306-ae75-4860900f0c2b">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE4LTctMS0xLTA_9767b429-e434-44cc-b539-353e029c20b3">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE5LTEtMS0xLTA_87dfd17c-1468-4bfb-ab95-8da9256c4766">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE5LTMtMS0xLTA_b14c19c3-8daf-4904-8d7a-4e01b5b13b5b">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE5LTUtMS0xLTA_f6275f9a-fadd-4f14-9c7b-8311ca223c11">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE5LTctMS0xLTA_ca34344c-9f7b-4696-9768-990bc6dcdf88">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIwLTEtMS0xLTA_0455468a-45de-4688-ad04-0c8d622d47e5">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIwLTMtMS0xLTA_c1f9f638-ff27-4346-9814-9eabe54e67ab">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIwLTUtMS0xLTA_cf13a1ee-0dcb-4808-8f53-e31d44cc38d1">146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIwLTctMS0xLTA_b4791451-c7fd-43a7-817f-a7ca7923c4e3">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIxLTEtMS0xLTA_2f1c14d5-cd73-445b-8f48-32a147530219">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIxLTMtMS0xLTA_b4c871ea-6e69-4d3e-9b52-7ef070a927c8">329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIxLTUtMS0xLTA_438a301e-182c-49c8-9a26-9cfc2978fa78">681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIxLTctMS0xLTA_bc456c67-56d8-4a03-9142-c5f763ac8bd7">873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIyLTEtMS0xLTA_edaa993c-2a90-4440-9d40-cfe7c5cce932">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIyLTMtMS0xLTA_d202a0ec-9cfb-4353-9955-4c935d1d3668">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIyLTUtMS0xLTA_01db22eb-674f-4520-9e2e-220ceeddf569">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIyLTctMS0xLTA_358d65b7-dc0d-463b-91cc-e91e327bd6f7">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:InterestAndDebtExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIzLTEtMS0xLTA_c678cfe1-c810-4bd9-886c-e5ad21679a2b">374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:InterestAndDebtExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIzLTMtMS0xLTA_c3e2018a-8f34-4c03-98f9-c4090a74afd2">406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestAndDebtExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIzLTUtMS0xLTA_49d6dac3-cacb-4082-8975-ee5399c7bf38">1,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestAndDebtExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIzLTctMS0xLTA_d791219d-6780-4f96-8047-23c4e38a4f92">1,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI0LTEtMS0xLTA_4423089e-56f4-45d3-b63d-6661bf2950aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI0LTMtMS0xLTA_dbc8e14d-8d4d-496f-a8f8-b7bb0d0e3d5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI0LTUtMS0xLTA_f252a8f4-b4e0-4576-b83a-159d454291df">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI0LTctMS0xLTA_d0ef2cb3-4bab-4eaa-bc6c-57a1daac5926">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI1LTEtMS0xLTA_d29b6c9e-14ea-4089-8db9-75fd30ff1c32">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI1LTMtMS0xLTA_020e5fac-9f52-4744-a954-62c5a2b5c7b8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI1LTUtMS0xLTA_2c06cffb-cbfa-4a53-ab21-b3b7e3df572e">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI1LTctMS0xLTA_3b5bb004-6892-4490-8ee7-b6e9e8ec0409">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before (provision for) benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI2LTEtMS0xLTA_15464da8-6223-4291-882a-109cc45f96a7">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI2LTMtMS0xLTA_a14affee-98b0-4d23-b470-563f50170b83">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI2LTUtMS0xLTA_67f0645f-9ad9-490b-bbbd-9516ecd2d400">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI2LTctMS0xLTA_8ccdc5b4-86e5-49c2-8b57-b3c533a4ba5c">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyNzY_dec5e302-084f-461f-be5f-554b0f904f46" continuedAt="i744987e3762347819e0ea5e376827ee4" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows: </span></div><div style="margin-bottom:5pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief0221b682984fa68ee492bfa59a5d75_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMS0xLTEtMA_8163ec69-e851-478b-86b4-9b93d38ee140">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12293851b1144e018c4c9985157b6af8_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMy0xLTEtMA_5ccf53ce-79a6-4b2a-82e3-50036c99138f">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45707f6b6bd4627847a810f8a92f826_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItNS0xLTEtMA_f5f1dd56-d68e-416c-9226-7f686baeec1c">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51df325c7f5b40f7a71d8a18b3dcdb9d_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItNy0xLTEtMA_26a0cc8a-b7ec-4b9d-89ba-d5b949cdf8d2">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ce34cdc90749658459a53d39ce83a0_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItOS0xLTEtMA_fcabf783-c010-4a0f-8bae-57ba1d1ccea9">976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib99f5f97c68d4eafb2e79dfd4f048b96_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTEtMS0xLTA_9cc88017-4f18-4659-88e6-c2f4e04f869d">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i094e6cb87ab042c69be51aa8c8116f04_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTMtMS0xLTA_ee9cba5a-fd26-45d0-90c7-effc6677cd42">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5be2becb71a48feaf9761c4c7541a2f_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTUtMS0xLTA_194743f1-fbf2-4ca6-9088-a14c69451ed3">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib990d0233da244b0972eca21ff43328a_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTctMS0xLTA_9233ac27-6bd1-48c8-a4e2-3fe32f58f6f6">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5062980ba6b7479fb407d0f9cd02aa37_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTktMS0xLTA_86ff3409-45d5-44ca-b6df-033f56572d16">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead2ba6fee0a4fb5b5d850fb95ea9e74_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMS0xLTEtMA_4bd23bd6-3562-442d-8b5d-df42533f158b">360</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314220a4165d4110a6c992a829224748_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMy0xLTEtMA_50cf2d7c-08eb-4cf5-a66b-44a60117034d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id732816e0fe14e848ad4ed7bcec29df9_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtNS0xLTEtMA_04c5544b-36e2-4081-9d79-6b496545b628">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7720a5e8447f4e1381a984683f37f801_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtNy0xLTEtMA_bcbc737e-fda1-4a01-91bf-7c0a726f1b26">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31809eee74c441e785284208908b1f6e_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtOS0xLTEtMA_dd94f9de-8bca-434f-b0c2-2227aa2c0dbe">432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79ac2fb975044cb48922c5f545218179_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTEtMS0xLTA_c2bc9a33-d123-4a1e-a7d1-8447d87c3085">375</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64afb07c58eb4178b97dc69e29d5361b_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTMtMS0xLTA_2ab2cb18-528a-4a7a-9ebb-1614f7883f27">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7daf0166ae784d4dacd516d2bd1ccfb3_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTUtMS0xLTA_c2e00ca0-a16d-4f0b-b552-003bad5d4a56">46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icef91f1f0ee3457e970eccecfdf34433_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTctMS0xLTA_95332be5-b18a-48e1-9c50-28ba27bab411">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd9b71a39574ae1b4eb9b5b3a159df7_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTktMS0xLTA_8c97adb1-7aab-4364-857b-edb173cc4560">421</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94726a2e6540441193932a85a2d2cc8e_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMS0xLTEtMA_0b103782-739d-447f-be64-8652d1be4a65">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e74417efd54c5fb043305c8ecdd0b5_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMy0xLTEtMA_4fcaf462-899d-41ac-985a-2effb82f29aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7132aba1acc24050873b3abeb89f87fd_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtNS0xLTEtMA_aef31675-1bc4-4d91-908e-4499a358e08d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b45b1049375405a9881452df1db8885_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtNy0xLTEtMA_77c6e585-9e12-4529-b375-618766f94385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1eba4cc97be4881bf868d652d2c87f5_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtOS0xLTEtMA_32c31e35-d4f1-4649-b561-82cd46fa7e46">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1195d51db05e405381373f1b2ed59c87_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTEtMS0xLTA_9b24366e-a5ef-4c90-a9ba-8e7966eabcbe">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7d8c27663374e2881ba2608476c974d_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTMtMS0xLTA_fee4190d-5f80-447e-b42e-997306c69907">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579b7b5f0e22488caa4243c078316934_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTUtMS0xLTA_039c480a-12a0-4784-a98d-2b3594bbe51d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7396b7657687421eb28bc8e668bf24f1_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTctMS0xLTA_0d96abf9-9d9a-41ba-be3c-3ab39c62231d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8079e095cb462d8a0027725dbbbf9d_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTktMS0xLTA_706ed4c1-3940-47bd-b930-f32b0ce7a121">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e935d66b524719955d26d4a15f28b7_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMS0xLTEtMA_2b8d88b5-1070-4434-9887-301423080e1c">219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda25f4386fa403f9d99a5596c2399a8_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMy0xLTEtMA_f4132b34-c409-4bc8-b670-399ee466bd2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fe7793dda5457b86b9bdaa7e2b4a3b_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtNS0xLTEtMA_3b7d7b74-2f68-4b70-9a38-980664475d34">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f08c50efaef40919b09f698d45f387f_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtNy0xLTEtMA_73c7b07e-d355-41b6-9815-8e240bf06b0f">110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic915105196dc4a20b1ba1cd55527b01f_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtOS0xLTEtMA_b06e44c9-2145-4e96-b929-8c3c58a16bdc">329</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b4872d17e0e4ba9800e4027b125c7d6_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTEtMS0xLTA_7bbafeb3-7b1e-484e-b2d9-d58ba87bf7dc">197</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25793ee653304f0aa6306ddf6ef5b8de_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTMtMS0xLTA_12ac7587-c7dd-493f-abb0-7f8c5757d28a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59b022ef9b644f1996fe90ee1d0db81_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTUtMS0xLTA_26f78bd3-0026-4cab-ab3d-97b90c1cd58b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8648caf684ff4103860761d13f0a4022_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTctMS0xLTA_1c055c60-bf2d-4734-8496-5d4a8c881bf1">119</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide34d3ab6c14458cbfef1276056d1463_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTktMS0xLTA_f9f80864-61fa-49be-9ece-10c3a9eca4b6">316</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93bc6d99c624444a2dd857bc569b178_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMS0xLTEtMA_ed74e05a-1702-4403-8fa6-72630eaba351">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a664e5247e946dc82a303af2757e881_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMy0xLTEtMA_7cc2a994-f7e2-44fd-bf7b-1ffebd2d20d1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c11c3e047f45a8adce344026ef9adf_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtNS0xLTEtMA_2e5f467a-9bfb-4ae1-8812-8ce442cbc6d1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i868cfdaa81514efeb8f0a0de1e553842_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtNy0xLTEtMA_42606f71-0a00-4897-a9a4-d3ade58168e3">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ed423758174f5d8bebe48cf827f4ad_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtOS0xLTEtMA_8a560660-6081-4b14-a292-3b5366aec1e9">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c702359f3d476aae3c6070536997d3_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTEtMS0xLTA_c238b0ae-3775-4e59-908f-515ba64a321d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4dc2eddb6b41afba1498f1b41eb3af_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTMtMS0xLTA_d8c0080d-c8ef-46de-80a5-72c9ab49c180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a6bfdb0ca114a3a8781da2f91c440dd_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTUtMS0xLTA_bb157371-4362-4e14-ab97-043ca5cdcefb">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f1c56b5e7db49989979d7e8ab238911_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTctMS0xLTA_4024b5fe-2adc-45dd-a156-812016b5b1c4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a10616d5c494d258d21007f1d4ffe1d_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTktMS0xLTA_ec49680c-a0d9-44c3-a36f-9a17c9d67c64">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica0936b4182347c0ba81f792a94fb471_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMS0xLTEtMA_70a211ea-4a05-47f4-a6c9-3f9004a463dd">1,169</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c8c78d6fd8848b4959e510c9f80474c_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMy0xLTEtMA_4889bd66-a416-44a5-aecf-d535e81fe2f1">496</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i663dfd024395400792b600237c407f71_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctNS0xLTEtMA_39b67a60-2eeb-463e-a33d-085a4b70f955">144</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfe83d14ce24791a3d5132de0b09aac_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctNy0xLTEtMA_2b88220e-8d56-4fb0-8f60-35fde374fb0f">329</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctOS0xLTEtMA_6caf8dc5-f1f6-4cca-bc92-33d93bf14d61">2,138</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6f9e05033db4fbeadb4c0989ca169b4_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTEtMS0xLTA_cafa2d81-e981-4c5c-9503-f2911c615bfd">1,175</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f934afe4f64ccf8f499b8522d5d316_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTMtMS0xLTA_cd77b560-e3d4-40a8-9161-692ac0e7c536">551</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72cef8d89cc3414c9c3e300be0a5e506_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTUtMS0xLTA_6ff398d6-c589-409e-93b3-6fdb75f0faff">147</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e2e17f2af240a08bb7068b4295f5c2_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTctMS0xLTA_ec963003-cd17-428a-8e84-32711c75e8f4">336</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTktMS0xLTA_1c752666-e2d5-4ec7-aec1-d2afdcde2d7f">2,209</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><ix:continuation id="i0d5cd0fd3f104d02896ea081e0dbcab3"><div style="margin-bottom:8pt;margin-top:8pt"><ix:continuation id="i744987e3762347819e0ea5e376827ee4"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831dca10038f44b7aba289500a72d53e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMS0xLTEtMA_2aafdc56-8b69-4a8c-a0da-d36369cfb5d5">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04ff547f0df4e0896495412b8e3aad8_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMy0xLTEtMA_8fbbaa34-759c-466c-8649-185140201f3b">1,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6c2d87d9fe043c1ace3fe783ed9d84e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItNS0xLTEtMA_fe422b9b-62e6-4269-8e98-38b053928244">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc10941479946efa1ee8c411876db52_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItNy0xLTEtMA_2567d284-b338-4444-9da5-b3ba8be6f9c4">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a85a453134467498de7319fa2fd19d_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItOS0xLTEtMA_3a1f666b-098a-494a-bb04-3fca54c44e0d">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370c9e50384c49a68b916ab0f055e398_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTEtMS0xLTA_733af1e4-0b85-4e3b-a477-a7078e764a47">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ed869b702741d29a4ebbc97df0ebaf_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTMtMS0xLTA_51ca6bd2-7c0a-4956-848c-f8659ac8c3af">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49df4ed56dce435c94526ec4c09c1c2f_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTUtMS0xLTA_897e3fde-a2a8-4644-89cb-e22e57a16d86">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17680b424174ddb8afb72789e7a072c_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTctMS0xLTA_8e390a60-4559-4709-83c9-387110b01c48">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00b7a96dc7c4c748b6fc009269bf96b_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTktMS0xLTA_9caebee6-3bf0-4f97-bc0c-1fbcb92052a9">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1bdf848e27419782e283160a6e7641_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMS0xLTEtMA_e413d4af-67a9-4219-960d-401ae0be941c">921</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8106cbd6b8fd4566bf0bb4e848d2fee0_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMy0xLTEtMA_dcc7f393-5bb1-448f-8699-6ebd4b6a9630">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cdf8fc7e882466b8e513669a8181321_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtNS0xLTEtMA_0c484642-2540-4d22-bab0-c73ee05ea076">165</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib806f0a34d7f41cc8b031f6eebdb460e_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtNy0xLTEtMA_30dbc0e2-7893-400a-8cbf-725e2f26ee71">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56662828b4c14cdaa652dc064c47d1a8_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtOS0xLTEtMA_a790071f-14ce-4abb-856b-11e3c9e667f5">1,086</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c5373b0b2e49bd9e26811bcb5264d6_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTEtMS0xLTA_e6a720a8-be07-4db6-8dbe-52ada427b029">1,127</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8358f514f3b4ffda10dd8a1dde466f9_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTMtMS0xLTA_008aa0ad-5644-4a3a-af9c-fb8f0edc1f8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b46b63623c4a798936bae68871eb7f_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTUtMS0xLTA_27de551e-f1a5-4965-bc07-cf01bf983bf4">130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0816679b5f144948af03427be4bb31d5_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTctMS0xLTA_1957f6d7-0d59-46f7-b157-5201c7ec894a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786b9c0d86944563927834ab30da4a64_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTktMS0xLTA_4cf64040-903b-4e78-9ec5-ec4c990f6f8b">1,257</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72b229547ad046528b0cd05c36cf6248_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMS0xLTEtMA_ea5e7e20-bd34-48ae-8682-1dccf138bbbe">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62332dea55b46b8954d57e7ba3dc9f2_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMy0xLTEtMA_62a8689b-0a38-4f1a-b2f8-82a7a8b95d0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c0e7f99a52e43e48893dceaa0497adb_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtNS0xLTEtMA_ccc90897-abb4-4d39-af29-105af3bccec0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f195e557e04786bec86a970774242c_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtNy0xLTEtMA_625c83bb-8349-4ed7-b393-60c11dc77973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b960aeb700f41daa129bb69d64f7f80_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtOS0xLTEtMA_305f0926-d05b-4cb9-a22e-fcf94c1701ff">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b601a52f89407f99c32a3569b6cd90_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTEtMS0xLTA_62a69072-eb3e-4e87-82b9-20fbbb62800c">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68bed0a8366846bca633f75f6ce317bf_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTMtMS0xLTA_5118cd70-33d3-4512-9b84-87beef36db2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc889ba7d354ed0a200fac110801a10_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTUtMS0xLTA_06c672f0-a115-4e25-a798-928c77307e8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc89498ee0a490bbbf373ea6031e5d4_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTctMS0xLTA_c5179c73-1807-46b8-8c76-3ef0b9ec1e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb0d8e06b70439093e5b2e57f467fbd_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTktMS0xLTA_4024d004-6d7a-4982-9064-fbf71d79965b">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice49f702f91540afa6e04bac724e0f16_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMS0xLTEtMA_fb7328bd-e8ce-4591-b3ef-7008374f0a2d">597</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7ad86ee09244ffa6a3158acbdb9e91_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMy0xLTEtMA_dbc982bd-88af-480a-9fb8-0959a23785e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide576ffb75654cfeb9e83e3cf858df8f_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtNS0xLTEtMA_aa499027-4a50-4ded-8212-a033810cbf92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6869bdf9417e4259950f8ca43e04a5bb_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtNy0xLTEtMA_ffcda8ff-5f37-4f2a-870c-35029f026a48">312</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169f654e818c4d728fa7590a5cc9e306_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtOS0xLTEtMA_864a0c3a-0c81-418a-a3f5-ed030348f1a8">909</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67120e7176db4b1883ff589a8f3f08e7_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTEtMS0xLTA_97870a85-e851-4d9a-97a2-65ca96c6d192">582</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d41709f1fc4926a6fb326d3fe3ba3d_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTMtMS0xLTA_4da19e24-d599-414a-8060-ef3dc8dcedaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5602fb5d32ec4b2382470ba9e6490b80_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTUtMS0xLTA_e8d1de64-8f14-4f36-841b-9cd7d04e246b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468251afcacf4241a879487d7f54a848_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTctMS0xLTA_e24156b3-08ab-4286-aa32-dcf5cda4611d">332</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7de78745671b495ab8a2e476e94c3894_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTktMS0xLTA_c5bc1922-2bd4-4af8-b515-256052bfc37c">914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79496248f2784fc4aaefcbc556fa23ba_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMS0xLTEtMA_284cc4e1-fe6e-4655-90fe-52d2f317d116">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i100bb87dcfcf4840a8fecbd84eb6c20b_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMy0xLTEtMA_445ff007-0dbf-48f8-9b60-63e772e4b0f2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f857d233d64f27abaa8c813fb2a7d9_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtNS0xLTEtMA_650e785b-22ab-4e2a-a9c0-0c8faca1a9ec">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b2eb21ef8614e1da439f89a40feb4a7_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtNy0xLTEtMA_5b94a3bd-9245-48bb-9a72-63c82ee98f9b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a3c7c318944c1bb5d18c5f1f1e809c_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtOS0xLTEtMA_8cc32766-e8aa-429f-9075-bfc892a3cf9c">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ed07bae93244349ef6061cab4695fb_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTEtMS0xLTA_ade0aba5-605c-4ea3-826a-d4bf4f23de4b">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied4647195db84913b150f83d6b75649e_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTMtMS0xLTA_4f7ad249-08cc-4779-bb4f-c02d6826690a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icecc5176f338476fadf188689a0d0f68_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTUtMS0xLTA_160fe15e-cb47-4815-a5d8-b4207cd23e69">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2afc3f9dccba4cd1820e8c7514dcd21e_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTctMS0xLTA_b9af2c51-346c-4543-89db-bbd2caeffca9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b6efa686104cbb8083a6040e07a9e2_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTktMS0xLTA_7695b502-64bf-4ff6-85bf-9a339edef156">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb4e98e35c504f19af4f7f6f7f90aa99_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMS0xLTEtMA_5a1a0a59-cf9e-4a3e-b52a-9331e829c10d">3,166</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd721943ada444938c0d07fde3a6cc26_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMy0xLTEtMA_62231e3a-95b6-4198-a427-b686d4633d93">1,377</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifee8da0bfabc4a0c9e458c09a7305cc3_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctNS0xLTEtMA_7f9381af-089c-4d3f-93c7-fb3953187dec">393</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7174942dd2a84a72be602fdbd7377d7b_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctNy0xLTEtMA_a4b4b014-79b5-4e9e-bcdb-a71c66b2c155">878</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctOS0xLTEtMA_b30806ab-dd2e-48ca-987c-cbb40a612a29">5,814</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd7f0a0d16e745bfae02ba539c5e89d8_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTEtMS0xLTA_dbb9a13a-9ec9-420a-bf15-a9c910e2ddcb">3,501</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id56b60056c744cfdb5d527a6fe378f4f_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTMtMS0xLTA_b4d22c77-e877-4976-bf6c-f85be3e2ef7d">1,505</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1062e5544f2849cd93a2b26f2aa99d36_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTUtMS0xLTA_e996069e-aa41-429c-a9b4-6de8630f9cef">407</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67fafda9e64f435ab86b3c470ccd987e_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTctMS0xLTA_6f9291d4-673f-4f3b-b489-c295f2d83c7b">964</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTktMS0xLTA_1c4cbfb3-5499-424b-8709-853e4d3a8972">6,377</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top <ix:nonFraction unitRef="product" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="bhc:ConcentrationRiskNumberOfProducts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzI5NDA_148ac1f9-0255-47ca-b424-52bdc56ca51a"><ix:nonFraction unitRef="product" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="bhc:ConcentrationRiskNumberOfProducts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzI5NDA_bc5ec9a1-cc4c-411a-b4fc-eb8142c59755">ten</ix:nonFraction></ix:nonFraction> products for the nine months ended September 30, 2020 and 2019 represented <ix:nonFraction unitRef="number" contextRef="ia3b658a083e346888a69fe6190860bd5_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzI5NzU_7db1b860-fa0e-42bc-98ba-edbc6192f6b3">41</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i73b54d06035d4aad967bc1fe46878888_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzI5ODI_fc397c80-183e-457f-a7a0-8740f9d5eb95">38</ix:nonFraction>% of total revenues for the nine months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyOTI_965e2bf2-a47f-4a9e-9bd0-8337d54ec629" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e0f0ac6ffaa46f4a17dc33321f25e38_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzItMS0xLTEtMA_aeb2f64b-eb10-4221-83a0-4f9082ce8673">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa6a46c3ea345c5a6bd0ff77c6ab9da_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzItMy0xLTEtMA_55b25d97-d92a-4483-acc2-e7cfac8d10a9">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f07775356c46c28fa094499e05be60_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzItNS0xLTEtMA_cf1d800e-afb1-4ceb-a894-fc0cdc9e30e4">3,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d30a915ca464a4ebf4fbbb5194076e0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzItNy0xLTEtMA_248fb07c-3aea-430c-8f86-3ba62cb09778">3,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02c96794f6994ca0923eb04b451e6f05_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzMtMS0xLTEtMA_668a772d-832b-4961-a65e-dd8cf3f8707f">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef026f34c88467cacd0c7e88c3b10c4_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzMtMy0xLTEtMA_31a30e48-3b98-4a2e-a002-2c5c6f4bd0d7">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796193ce9afc4d12b6379f979c427b32_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzMtNS0xLTEtMA_1e58ba67-ab3f-4a16-952c-15edba7e21bd">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7be92a538f410c806913c3950dc54f_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzMtNy0xLTEtMA_035aa4fe-7e15-4eb6-a52e-8b8d4b666734">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14c7ebc09514fa29a41b6fe5a2836f8_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzQtMS0xLTEtMA_22ac8646-9504-4591-913e-42799c8adca0">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebbbb3cbe22449e808dbfaf4d1e174a_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzQtMy0xLTEtMA_8a70d072-3f5b-4276-b473-6fbd6405d3dc">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf506968c6f545d189921bdd9e912182_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzQtNS0xLTEtMA_d2d8f218-b727-4d3d-b259-f3fc51794bc2">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e8c38f3f154fb49bb310a1dcb6fd83_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzQtNy0xLTEtMA_2758a2fe-616c-4cb1-a861-777fc932d330">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1618b6d63a4ef9bccc4d597fd44d7d_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzUtMS0xLTEtMA_ed9190d8-3269-4f2f-b655-44653535072d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95891e4c7e3e457580e75965a1382082_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzUtMy0xLTEtMA_460f19ae-170e-44da-b3e9-cf96981a4bb7">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d66aef5c9743df9092cc861ecc3cf6_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzUtNS0xLTEtMA_d74a16b6-fee2-4811-b526-df3046d692e2">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie36ad9ac246b4dd0bf391aa521396851_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzUtNy0xLTEtMA_bae6e769-606f-4a71-ac37-861759b20dea">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i577cd70d30de44d98818fb4178e165de_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzYtMS0xLTEtMA_b471a3e0-115b-479e-b8c8-096cdbd2f44a">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342f9146a8194fbf8362fe186beb1150_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzYtMy0xLTEtMA_42176b5b-8ea7-4d4a-aa2c-4489698cb3d6">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac25f9c6e9594c37a2bc71cd2f9ac2f7_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzYtNS0xLTEtMA_a2653657-c09a-4efc-95bf-dcbc58487620">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57036c953dd4ecd9a2259ce4d2a664d_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzYtNy0xLTEtMA_0837dd4f-1f41-425a-ad28-bab4e078f27f">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59b54efdf337413095503da19334d74f_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzctMS0xLTEtMA_e0c7d577-3f2e-43cb-ad30-acbd3ca7d51f">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d0676dcb034bed9b3ac2d108318bfd_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzctMy0xLTEtMA_f35d70a8-0f5f-4445-9103-5c4f9bfc9e07">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2342292213084417ab197a7ec39e2b32_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzctNS0xLTEtMA_b2edac0c-d1f6-49a8-bb40-12810d4302ad">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c453b5fedc64ccb8be26bdd2dbce3f8_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzctNy0xLTEtMA_96447271-6d0a-4958-8aad-224b4c01c0c4">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic899b1ac11d94d5f912e083ac00a9925_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzgtMS0xLTEtMA_d5c910d5-ecd1-461a-b846-36537d13f383">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02bb5c4f94dc483eac3113fa75769620_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzgtMy0xLTEtMA_411ae2aa-d573-4df8-bd6e-e2e69f590338">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208fbc90ac92433891048e7b267b2c4e_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzgtNS0xLTEtMA_61d4656a-d673-47af-a00c-fd22a258b893">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263314b31684477a858ce1870a2e2935_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzgtNy0xLTEtMA_4bd3cdb3-a4e4-4f5f-ad41-fac5f3de49ae">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i518266816f6142088c1cd572e0b2e809_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzktMS0xLTEtMA_33fac381-ae8d-4c08-b7d4-c8030bcf9944">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3810d5f192614d9e904b2333976b6d3e_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzktMy0xLTEtMA_b816e7dd-1836-4225-9236-418c923b3810">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90335586b5244348e2bb80b34efb485_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzktNS0xLTEtMA_3cadb654-eda4-4b7e-bace-ed52b1a083f0">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed3660f61d54acaa7f0f86779347965_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzktNy0xLTEtMA_5c7e2446-380e-4960-b3ca-9ad4d80ae4e5">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc7e5aff7cc4ff89c60f1e3e20b5914_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEwLTEtMS0xLTA_64721c73-81fc-41f2-aef8-76506aa32c50">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92707ddce02f4496b1a61598b20a9fa3_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEwLTMtMS0xLTA_b9d7a155-66ae-40dc-aaf4-3d28dd9a603d">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ec6e666dbd4225ba98fddbddb193e8_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEwLTUtMS0xLTA_9751973d-cf9b-4c0e-88f0-ca6e67febf09">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib838e1722e0e4d97a13e8bf28d909626_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEwLTctMS0xLTA_dcd1cee7-5130-4d4c-938a-67c36a3147c8">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbcd2550da3f4409b5137f5be1419151_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzExLTEtMS0xLTA_14ca24cb-c35c-4e32-8d35-10e670adc31a">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92405cf9f6e4d37a4052058cf207929_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzExLTMtMS0xLTA_b5b61a6d-d98b-4895-940e-97f739d45e71">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i711aaaa53fba4ac29293979ceec66046_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzExLTUtMS0xLTA_8b32fa13-1136-4fbe-8a58-72045bde1336">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida52154f667f4dc8a7f3ff3a48088ca3_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzExLTctMS0xLTA_8fe83a41-3e77-4cbc-b83c-6b6e41b8fefa">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefc5f79887314486bdc0ac6a2c93b5f8_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEyLTEtMS0xLTA_6986462c-ab33-4ff1-abb3-e37192b5a958">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5dd515351d49189d4ea130cb854c26_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEyLTMtMS0xLTA_1a311e13-540c-44a3-92a5-6f5ecdc7dca5">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ede38bb8cc4a18b46ced535622b166_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEyLTUtMS0xLTA_6cd337b6-0af6-4531-bede-f364df6f3b21">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7c731a4d7b4bf69d3798a82bd76fdd_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEyLTctMS0xLTA_dcde7fb1-cac2-473a-84e9-8ad4ec0a9687">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59f176c51ad42579aa28217a7a898fd_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTEtMS0xLTU4MzQ_8d84af11-a1ae-4014-acf6-1697d5d6de49">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be82f95757f4dcbbd90b7b2c038ad94_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTMtMS0xLTU4MzQ_ed51b0da-6ef9-45b8-b9a5-3816607eefbd">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03b5d0d8f5834a3db8a3fcc9475f9cbb_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTUtMS0xLTU4MzQ_6a8e8331-3c36-4302-a1d5-d34b3b46c9c1">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a61a4c91bff4480a041bd2adb0a40b0_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTctMS0xLTU4MzQ_12fdb791-7b49-47a4-97ef-1692ae988d4c">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55062b8f73664b389c95dbdb8d84eaf8_D20200701-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTEtMS0xLTA_741e0588-5fb6-480f-aa46-3f49e2e8dd45">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dde1c7051314b9aa3cda5a9a878059e_D20190701-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTMtMS0xLTA_321d2d53-b7b6-4a8d-8d50-b279e790d5bb">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i173c07ccf3334f6d87290a617f2f61e2_D20200101-20200930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTUtMS0xLTA_f0fc29eb-887f-4080-9be4-e4a2cf5146a5">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id597c4b3289e490a8b7183707736dfff_D20190101-20190930" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTctMS0xLTA_e9bc6b00-d45b-4a95-b1f9-e27f264a684f">782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzE0LTEtMS0xLTA_c87d4c4f-6d77-4957-a111-4869c4a01698">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzE0LTMtMS0xLTA_4d01856d-a99f-4630-8816-c20f1a18ade2">2,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzE0LTUtMS0xLTA_bab8ef72-2be5-4044-b34a-e2db0e2a8a7b">5,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzE0LTctMS0xLTA_3fbb7583-5fb2-45cc-ae9f-4d9f417d25a9">6,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><ix:nonNumeric contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyOTk_d5c53669-5697-4746-a3bd-b86b3efae596" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows: </span></div><div style="margin-bottom:13pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id87f54aacbd14ddb9195134667720744_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzItMS0xLTEtMA_b17fe241-669f-4050-8ed4-4162ee442e9f">17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea718c704e394d629a0bb52b758793a4_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzItMy0xLTEtMA_fdc67091-aa59-40af-b1a9-a71c2fcf5e52">17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6a8f2aed6a0439783600917b76ae723_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzMtMS0xLTEtMA_6689c7c9-a254-4887-8909-03438a80096e">17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74b9314e78a044d0b3e782173dfe569e_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzMtMy0xLTEtMA_cecd94b6-c2eb-4bbe-a21c-a41289b7340d">17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4caac1fc03db442481ef398991140fe8_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzQtMS0xLTEtMA_b7533050-cf78-4ff7-bef5-e2d5f6961eeb">13</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b8c67a640b5458da2fe72d26d0b549d_D20190101-20190930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzQtMy0xLTEtMA_cb156b37-a7b6-47b7-9dd0-4ec57f363d27">14</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_106"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of&#160;Operations</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context otherwise indicates, as used in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; and similar terms refer to Bausch Health Companies Inc. and its subsidiaries. This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; has been updated through November&#160;3, 2020 and should be read in conjunction with the unaudited interim Consolidated Financial Statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended September&#160;30, 2020 (this &#8220;Form 10-Q&#8221;). The matters discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain certain forward-looking statements within the meaning of Section 27A of The Securities Act of 1993, as amended, and Section 21E of The Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;Forward-Looking Statements&#8221;). See &#8220;Forward-Looking Statements&#8221; at the end of this discussion. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our accompanying unaudited interim Consolidated Financial Statements as of September&#160;30, 2020 and for the three and nine months ended September 30, 2020 and 2019 have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements, and should be read in conjunction with our Consolidated Financial Statements for the year ended December&#160;31, 2019, which were included in our Annual Report on Form 10-K filed on February&#160;19, 2020. In our opinion, the unaudited interim Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations and cash flows for the periods indicated. Additional company information is available on SEDAR at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and on the SEC website at&#160;</span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  All currency amounts are expressed in U.S.&#160;dollars, unless otherwise noted.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_112"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global company whose mission is to improve people&#8217;s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology, a broad range of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (&#8220;OTC&#8221;) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to focus our business on core therapeutic classes that offer attractive growth opportunities. Within our chosen therapeutic classes, we prioritize durable products which we believe have the potential for strong operating margins and evidence of growth opportunities. We believe this strategy has reduced complexity in our operations and maximizes the value of our: (i) eye-health, (ii) GI and (iii) dermatology businesses, which collectively now represent a substantial portion of our revenues. We have found and continue to believe there is significant opportunity in these businesses and we believe our existing portfolio, commercial footprint and pipeline of product development projects position us to successfully compete in these markets and provide us with the greatest opportunity to build value for our shareholders. We identify these businesses as &#8220;core&#8221;, meaning that we believe we are best positioned to grow and develop them.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reportable Segments and Strategies</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into four operating and reportable segments: (i) Bausch + Lomb/International, (ii) Salix, (iii) Ortho Dermatologics and (iv) Diversified Products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Bausch + Lomb/International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - consists of our Global Bausch + Lomb eye-health business and our International Rx business. Our Global Bausch + Lomb eye-health business includes our Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx products, which in aggregate accounted for approximately 40%, 42% and 43% of our Company's revenues for the nine months ended September 30, 2020 and the years 2019 and 2018, respectively.  Our International Rx business, with the exception of our Solta products, includes sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products and OTC products, which in aggregate accounted for approximately 14%, 13% and 13% of our Company's revenues for the nine months ended September 30, 2020 and the years 2019 and 2018, respectively.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Bausch + Lomb business is a fully-integrated eye-health business, which we believe is critical to maintaining and developing our position in the global eye-health market. As a fully integrated eye-health business with a 165-year legacy, Bausch + Lomb has an established line of contact lenses, intraocular lenses and other medical devices, surgical systems and devices, vitamin and mineral supplements, lens care products, prescription eye-medications and other consumer products that positions us to compete in all areas of the eye-health market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our global Bausch + Lomb business strategy, we continually look for key trends in the eye-health market to meet changing consumer/patient needs and identify areas for investment and growth. For instance, one of these trends is the increasing rate of myopia, and importantly, myopia as a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye-health products that address conditions brought on by factors, such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population for example, as more and more baby-boomers in the U.S. are reaching the age of 65. To supplement our well-established Bausch + Lomb product lines, we continue to identify new products tailored to address these key trends, which we develop internally with our own research and development (&#8220;R&amp;D&#8221;) team to generate organic growth. We also license selective molecules or technology in leveraging our own R&amp;D expertise through development, as well as seek out external product development opportunities. Recent product launches include Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lenses, SiHy Daily contact lenses, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an eye redness treatment), Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension) and Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - consists of sales in the U.S. of GI products and includes our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. Our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product accounted for revenues of $1,071 million, $1,452 million and $1,195 million for the nine months ended September 30, 2020 and the years 2019 and 2018, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our acquisition of Salix Pharmaceuticals, Ltd. in April 2015, we acquired the intellectual property to a number of products that have provided us with year-over-year revenue growth, particularly the intellectual property behind Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for, amongst other indications, irritable bowel syndrome with diarrhea (&#8220;IBS-D&#8221;), and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for opioid induced constipation.  Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product increased approximately 22% and 22% in the years 2019 and 2018, respectively. Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product were $1,071 million and $1,056 million for the nine months ended September 30, 2020 and 2019, respectively, representing an increase of 1%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attribute the growth in our Salix revenues to the investments we have been making since 2017, including: (i) hiring 200 trained and experienced sales force representatives to expand the commercial field force for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) increasing the focus on the development of next generation formulations of our Salix intellectual property to address new indications, (iii) completing the strategic acquisition of certain assets of Synergy Pharmaceuticals Inc. (&#8220;Synergy&#8221;), which included the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product and (iv) increasing the number of sales force representatives for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we have entered into licensing agreements for investigational products, which, once developed and if approved by the U.S. Food and Drug Administration ("FDA"), will be new treatments for certain GI and liver diseases and we anticipate will contribute to the future growth. Each of these opportunities potentially provides us with the ability to expand our GI portfolio and allows us to leverage our existing GI sales force, supply channel and distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Ortho Dermatologics segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological products) and (ii) global sales of Solta dermatological devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ortho Dermatologics business is our medical dermatology business dedicated to the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis, onychomycosis and other dermatoses and includes our Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (launched June 2020), Altreno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines. As part of our business strategy for the Ortho Dermatologics segment, we have made significant investments to build out our psoriasis, atopic dermatitis and acne product portfolios, which are the markets within dermatology where we see the greatest opportunities, with a focus on topical gel and lotion products over injectable biologics. We continue to support the use of injectable biologics; however, we believe some patients prefer topical products as an alternative to injectable biologics. Further, as topical products can, in many cases, defer the use of injectable biologics that often come with associated risk/benefit profiles, a topical product is usually readily adopted by payors, is less expensive and can be more cost-effective than injectable biologics. Therefore, we believe topical products represent alternative treatments for physicians, payors and patients, and as the preferred choice of treatment, have the potential to drive greater volumes, generate better margins and potentially be a key contributing factor of our Ortho Dermatologics business.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Solta business is dedicated to the development of innovative treatment technologies that provide proven and effective medical aesthetic and therapeutic benefits to consumers. Global Solta revenues were $166 million and $130 million for the nine months ended September 30, 2020 and 2019, respectively, and $194 million and $135 million for the years 2019 and 2018, respectively. The increase in revenue is primarily attributable to Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. During 2018 and 2019, Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in Hong Kong, Japan, Korea, Taiwan, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, and Australia as part of our Solta medical aesthetic devices portfolio. These launches have been successful as Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues for nine months ended September 30, 2020 and 2019 were $94&#160;million and $47&#160;million, respectively, and in full-year 2019 were $77 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2017 through the date of this filing, we have made significant investments to build out our aesthetics, psoriasis and acne product portfolios, which we believe, coupled with our experienced dermatology sales leadership team and the reorganization of our Ortho Dermatologics sales force, will position our Ortho Dermatologics business for future growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Diversified Products segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, such as Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) generic products, such as Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> authorized generic (&#8220;AG&#8221;), Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Diastat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, and (iii) dentistry products, such as Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NeutraSal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company utilizes the Diversified Products segment to extend the long-term cash flows from a number of assets that are expected to decline over time due to the loss of exclusivity, by launching and selling authorized generic versions of certain branded assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a comprehensive discussion of our business, business strategy, products and other business matters, see Item 1. &#8220;Business&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC and the Canadian Securities Administrators ("CSA") on February&#160;19, 2020.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_1826"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Focus on Value</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we retained a new executive team which implemented a multi-year plan designed to transform and bring out value in our Company. The multi-year plan increased our focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management.  Since that time, we have been executing and continue to execute on our commitments to transform the Company and generate value. Under the multi-year plan we have taken the following actions, among others:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divested non-core assets in order to narrow the Company's activities to our core businesses where we believe we have an existing and sustainable competitive edge and the ability to generate operational efficiencies. To date we received approximately $3,500 million in net proceeds from these divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made strategic investments in our core businesses in order to support recent revenue growth and prepare for additional growth opportunities we plan to capitalize on for our core businesses;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made measurable progress in improving our capital structure as we have repaid over $8,100&#160;million in debt obligations (net of additional borrowings, amounts refinanced and excluding the $1,210 million financing of the U.S. Securities Litigation settlement discussed below) using the proceeds from the divestiture of non-core assets, cash generated from our operations and improved working capital management; and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">resolved many of the Company's legacy litigation matters originating back to 2015 and prior, including the most significant legacy legal matter, the U.S. Securities Litigation settlement discussed below, significantly reducing related possible disruptions and other uncertainties to our operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these and other positive actions we have taken to transform our Company, have properly focused our operations and improved our capital structure, and we also believe that, as a result of such actions, we are now presented with an opportunity to unlock additional value across our portfolio of assets by creating two highly attractive but dissimilar businesses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity (&#8220;Bausch + Lomb&#8221;) from the remainder of Bausch Health Companies Inc. (the &#8220;Separation&#8221;). The Separation will establish two separate companies that include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a fully integrated, pure play eye-health company built on the iconic Bausch + Lomb brand and long history of innovation; and</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversified pharmaceutical company with leading positions in gastroenterology, aesthetics/dermatology, neurology and international pharmaceuticals.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb entity will consist of the Company's Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Rx businesses. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International Rx, Solta, neurology and medical dermatology businesses. We believe the Separation will unlock value across the two post-separation entities and create two highly attractive but dissimilar businesses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As separate entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and best manage its respective capital needs.  Further, the Separation allows us and the market to compare the operating results of each entity with other &#8220;pure play&#8221; peer companies. Although management believes the Separation will bring out additional value, there can be no assurance that it will be successful in doing so. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are in the process of addressing the organization, structure and pro forma capitalizations of the two entities post-separation. Based on our initial assessment, we believe that we will be able to address the organizational matters and regulatory requirements needed to operate the businesses separately and put the Bausch + Lomb business in position to become an independent publicly traded company prior to the end of 2021. Management is also considering the form of the Separation and exploring a number of alternative capitalization structures in order to properly capitalize the entities post-separation and although a public offering of a portion of the Bausch + Lomb business is among the alternate capital structures being considered, this Form 10-Q does not constitute an offer of any securities of Bausch + Lomb for sale. There are considerations, approvals and conditions that will determine the ultimate timing and structure of this transaction, including regulatory approvals, final approval by our board of directors, any shareholder vote requirements that may be applicable, compliance with U.S. and Canadian securities laws and stock exchange rules, receipt of any applicable opinions and/or rulings with respect to the Canadian and U.S. federal income tax treatment of such transaction and determination of the pro forma capitalizations of the two entities. The failure to satisfy all of the required conditions could delay the completion of this transaction for a significant period of time or prevent it from occurring at all. As a result, the information in this Form 10-Q relating to the Separation is preliminary and may change as the transaction progresses and any such change may be material.  </span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_115"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, a novel strain of the coronavirus disease, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread to other parts of the world, including the United States, Canada and Europe, and was declared a global pandemic by the World Health Organization (the "WHO") on March 11, 2020. As a global health care company, now more than ever, we remain focused on our mission of helping to improve people&#8217;s lives with our health care products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. The COVID-19 pandemic has also significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, elective medical procedures and travel. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the global economic landscape changes, there is a wide range of possible outcomes regarding the nature and timing of events related to the COVID-19 pandemic, each of which are highly dependent on variables that are difficult to predict. Developments, including the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence, if any, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it, could have a significant adverse effect on our business, development programs, financial condition, cash flows and results of operations. The extent of these developments and the related impacts are highly uncertain and many are outside the Company's control.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing.   Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand. As a result of our assessment, we immediately initiated profit protection measures to manage and reduce operating expenses and preserve cash during the COVID-19 pandemic. We have also taken actions to manage the level of our investment in support of certain existing products, anticipated launches and the expansion of our sales footprint in Europe.&#160;Postponing these investments may impact the extent and timing in achieving our longer-term forecasts for certain business units, however, we believe these actions will not have a material impact on the underlying value of the related businesses or their associated assets.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and will continue to closely monitor the impacts of the COVID-19 pandemic and related responses from governments and private sector participants on the Company, our customers, supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition and our planned actions and responses to this pandemic. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have responded quickly to the human and commercial challenges brought on by the COVID-19 pandemic and that our early actions have, so far, enabled us to keep our employees safe and our supply lines largely intact and we believe these actions have laid the foundation for us to work our way through the uncertainties to come. Importantly, we believe that the steps we took over the last several years to manage our capital structure place us in a strong position to maintain sufficient liquidity to continue operations through an extended pandemic and we believe that our businesses will not see their long-term value diminished by this unprecedented situation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Employees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health and safety of our employees is paramount. Our senior management team meets regularly to assess this ongoing situation and has implemented multiple actions to protect our employees. For essential personnel in our manufacturing and distribution centers, as well as our office-based and sales force employees who have started to re-enter the workplace, we are taking every precaution to ensure that they are working in an environment that is as safe as possible, including following procedures as prescribed by global public health organizations, such as the WHO and U.S. Centers for Disease Control and Prevention.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Supply Chain and Manufacturing Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective is to maintain the uninterrupted availability of our products to meet the needs of patients, consumers and our customers. Business continuity plans and site-level biosecurity procedures are in place to ensure the well-being of our employees while we work to maintain the integrity of our supply chain. We have been successful in keeping our manufacturing facilities operational, although, due to shelter-in-place orders, our facilities in Milan and China were forced to temporarily close in March and April. These facilities were closed for only a short period of time and were immediately and continually operational once the shelter-in-place orders in the respective geographies were lifted.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, we have not experienced any disruption in our supply chain that would have a material impact on our results or operations.  Our global supply chain team worked diligently to stay ahead of the challenges presented by the COVID-19 pandemic once it appeared in Asia. Although we have put in place procedures to mitigate the risks associated with closures and disruptions at our manufacturing facilities, the COVID-19 pandemic has had an impact on our inventory levels and the manner in which we manage our inventories. During the nine months ended September 30, 2020, our inventories increased 11% primarily due to: (i) lower demand across multiple business units due to COVID-19 pandemic related matters, (ii) additional active pharmaceutical ingredients ("API") acquired for our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products from our suppliers in Italy in contemplation of potential supply disruptions in that region, (iii) additional API for our Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products which have longer procurement times and higher costs and (iv) the acquisition of additional quantities of certain products that were at the lower end of their optimal levels at December 31, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have dual sources of API and intermediates for many of our products, the availability of which has not had, and at this time we do not expect will have, a material impact on our supply chain. With respect to our largest product, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as of October 30, 2020, we have over five months&#8217; supply of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finished goods on hand and enough API to manufacture another eight months&#8217; supply of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finished goods. We also have open orders for API for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we currently expect will arrive on schedule. However, if we were to experience a lack of availability of API for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, such disruption to our supply chain could have a significant adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the impacts of the COVID-19 pandemic and take the actions appropriate to regulate our inventories at levels in line with the current supply and demand for our products. Although these actions have been effective at meeting our objectives, we believe our inventory levels will likely remain above our pre-pandemic levels into next year in order to address the range of potential impacts and outcomes of the COVID-19 pandemic. We will continue to monitor our inventories and continue to take the appropriate actions and make the necessary adjustments to maintain the uninterrupted availability of our products to meet the needs of patients, consumers and our customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Product Pipeline </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leadership team actively manages the Company's product pipeline to identify what we believe are innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth. During the COVID-19 pandemic, our R&amp;D team remains focused on meeting these objectives in a timely manner; however, there are significant events and circumstances regarding the COVID-19 pandemic that may materially affect our R&amp;D team&#8217;s ability to do so, many of which are beyond the Company's control. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the challenges of the COVID-19 pandemic, most notably those attributable to "stay at home" and travel restrictions, certain of our R&amp;D activities were forced to pause. Clinical trials that started prior to governmental shutdowns remain enrolled and existing patients are progressing, while new patient enrollments were paused as most trial sites were not able to accept new patients. However, during our third quarter we saw the pace of new patient enrollments in increase, getting close to their pre-COVID-19 pandemic levels in the U.S., and as a result have not had to make material changes to our development timelines.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the timing and completion of our ongoing and anticipated clinical trial programs. As of the date of this filing, the delays in our clinical trials have not had a material impact on our operating results; however, a resurgence of the virus significant enough to necessitate reenacting certain social restrictions could result in unanticipated delays in our ability to conduct new patient enrollments. Other possible COVID-19 pandemic and resurgence related challenges include, but are not limited to, facility closures, delays by third-party service providers, deferrals of doctor visits, postponement of elective medical procedures and surgeries and changes in prioritization by the FDA and other regulatory authorities. Delays, if any, caused by the COVID-19 pandemic and a possible resurgence of the virus such as these and others will likely adversely affect the timely approval, launch and commercialization and the commercial success of our products, particularly those in early stage clinical trials, which could have a significant adverse effect on our future operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Liquidity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility of $1,225 million due in June 2023 (the &#8220;2023 Revolving Credit Facility&#8221;), issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for at least twelve months from the date of issuance of this Form 10-Q. Further, for the nine months ended September 30, 2020 and the years 2019 and 2018, we generated positive cash from operations of $717&#160;million, $1,501&#160;million and $1,501 million, respectively. Should our operating results during the COVID-19 pandemic materially suffer in comparison to our 2019 and 2018 operating results, we believe we would continue to generate sufficient cash flows from operations to meet our obligations in the ordinary course of business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt maturities or mandatory amortization payments until 2023. Ad</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ditionally, we have no outstanding borrowings, $107 million of issued and outstanding letters of credit and remaining availability of $1,118 million under our 2023 Revolving Credit Facility. In the event of a future, unexpected, need for near-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">term liquidity, our 2023 Revolving Credit Facility would be a source of funding for us. After reviewing the terms of our Restated Credit Agreement and considering a broad range of possible outcomes of the COVID-19 pandemic, we expect that we will have access to capital under our 2023 Revolving Credit Facility across a broad range of scenarios in the event it is required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements and &#8220;Management's Discussion and Analysis - Liquidity and Capital Resources: Long-term Debt&#8221; for additional discussion of these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Operating Results</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are taking actions to mitigate the impact of the COVID-19 pandemic on daily operations, the global response to the pandemic has and is expected to impact our operating results until the impacts of the pandemic subside, the timing of which is uncertain and may be dependent upon, among other matters, the development and distribution of an effective vaccine and/or treatment for the COVID-19 virus. The changing dynamics of the pandemic, related responses from governments and private sector participants and the precautionary measures taken by our customers and the health care patients and consumers we serve, are expected to impact the timing and amount of our revenues. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the pandemic, the public has been advised to engage in certain "social restrictions" such as: (i) remaining at home or shelter-in-place, (ii) limiting social interaction, (iii) closing non-essential businesses and (iv) postponing certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, these factors negatively impacted, most notably, the revenues of the Company's Global Vision Care and Global Surgical businesses in Asia where the COVID-19 pandemic originated. Beginning in March 2020, and throughout most of the second quarter of 2020, the Company experienced steeper declines in these revenues and the revenues of other businesses as social restrictions expanded worldwide, particularly in the U.S. and Europe. Social restrictions negatively impacted the Company's revenues for contact lenses, intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of its Global Ophtho Rx business, medical aesthetics and therapeutic products of its Global Solta business, and certain branded pharmaceutical products of its Salix, Ortho Dermatologics and Dentistry businesses, as the offices of many health care providers were closed and certain surgeries and elective medical procedures were deferred.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues for the nine months ended September 30, 2020 were negatively impacted by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic earlier in the year. However, as </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize.  Presuming there is no material resurgence of the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020. The Company therefore believes that its revenues for the year 2020 will be most impacted by the COVID-19 pandemic in its second quarter, although the Company experienced additional COVID-19 pandemic related declines in the year-over-year revenues in its third quarter, and expects additional COVID-19 pandemic related declines in the fourth quarter of 2020, in many of its businesses and geographies. Presuming any reenactment of social restrictions is not significant, the Company anticipates that its affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the recovery is progressing more quickly in our surgical, vision care and ophthalmology businesses, while our consumer business has been less impacted by the COVID-19 pandemic than any of our other business units. Although certain social restrictions were lifted in Europe and Asia during the summer, recovery in these regions has been more gradual, as consumers have been slower to return to their pre-pandemic habits. Further, various geographies are reinstituting lockdowns or partial lockdowns due to a resurgence of the COVID-19 virus.  For instance, parts of Europe such as Germany, France, Ireland and England have already announced returns to lockdowns of various lengths and have enacted or are considering enacting other social restrictions. In the U.S., the rise in the number of daily average COVID-19 cases in the second half of October 2020 suggests a possible resurgence in the U.S. which could also lead to lockdowns or other social restrictions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we monitor the direction and pace of the recovery in each business and geography, we are also continually monitoring the effectiveness of the profit protection measures we initiated to manage and reduce our operating expenses and preserve cash during the COVID-19 pandemic. These profit protection measures have been successful in expanding the profit margins in many of our businesses during our third quarter as referenced in the discussion of our operating results to follow. As the pace of recovery in each geography accelerates, we will need to allocate more resources to selling and other promotional activities to drive our return to sustainable revenue and profit growth.  Therefore, as the recovery continues, we expect our operating expenses to increase in support of our existing products, product launches and products in development and expect to see our operating expenses in the fourth quarter of 2020 exceed our operating expenses in the third quarter of 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our diverse portfolio of durable products and strong brands has served us well through the COVID-19 pandemic and we continue to be well positioned to grow market share and return to growth as the world recovers. However, this remains a very fluid situation and we continue to monitor the effects of the COVID-19 pandemic and the impacts of any resurgence of the COVID-19 virus on our business and primary goals.  Given these circumstances, we continue to focus on: (i) revising our go-to-market and sales force strategies to address the changing business dynamics created by the COVID-19 pandemic, (ii) building out our e-commerce presence to enable us to reach customers in new ways, (iii) investing in our key promoted brands and product launches to increase market share, (iv) optimizing our cost structure and (v) looking for key trends in the market to meet changing consumer/patient needs and identify areas for investment and growth. We believe focusing on these priorities will best enable us to effectively manage the changing business dynamics created by the COVID-19 pandemic, best prepare us for a possible resurgence of the virus and return us to growth once the impacts of the COVID-19 pandemic substantially subside.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits, including the impacts of COVID-19 pandemic related matters for the three and nine months ended September 30, 2020, are discussed in further detail in the respective subsequent sections &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. However, if market conditions further deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#8217;s expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges can be material.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_118"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Focus on Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to focus on our core businesses where we believe there is potential for strong operating margins and evidence of growth opportunities, we have: (i) directed capital allocation to drive growth within our core businesses, (ii) made measurable progress in effectively managing our capital structure, (iii) increased our efforts to improve patient access and (iv) continued to invest in sustainable growth drivers to position us for long-term growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Capital Allocation to Drive Growth Within Our Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital allocation is driven by our long-term growth strategies.  We have been aggressively allocating resources to promote our core businesses globally through: (i) strategic acquisitions, (ii) R&amp;D investment, (iii) strategic licensing agreements and (iv) strategic investments in our infrastructure. The outcome of this process allows us to better drive value in our product portfolio and generate operational efficiencies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Acquisitions - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain very selective when considering any acquisition and pursue only those opportunities that we believe align well with our current organization and strategic plan. We sometimes refer to these opportunities as "bolt on" acquisitions.  In being selective, we seek to enter into only those acquisitions that provide us with significant synergies with our existing business, thereby minimizing risks to our core businesses and providing long-term growth opportunities. Recently, we have entered into transactions that, although not immediately impactful to our operating results, are expected to be accretive to our bottom line in future years and contribute to our long-term growth strategies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into an agreement which provides the Company an option to acquire all ophthalmology assets of Allegro Ophthalmics, LLC ("Allegro") (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases.  Among the assets to be acquired, if the Option is exercised, is the worldwide rights to risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration ("AMD"). A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. We believe the addition of the ophthalmic assets of Allegro would significantly enhance our comprehensive portfolio of products for AMD and if approved, risuteganib may be the first treatment indicated to help reverse vision loss due to dry AMD and address a significant unmet medical need affecting millions of people globally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we completed the acquisition of certain assets of Synergy whereby we acquired the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product complements our existing Salix products and allows us to effectively leverage our existing GI sales force.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we acquired the U.S. rights to EM-100 (an investigational preservative-free formulation eye drop) from Eton Pharmaceuticals, Inc. On September 25, 2020, the Company announced that the FDA had approved Alaway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100) as the first over-the-counter (OTC) preservative-free formulation eye drop approved to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. Alaway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative Free is expected to complement our broad range of Bausch + Lomb integrated eye-health products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are considering further acquisition opportunities within our core therapeutic areas, some of which could be material in size.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_121"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">R&amp;D Investment -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continuously search for new product opportunities through internal development and strategic licensing agreements, that if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal R&amp;D Projects - Our R&amp;D organization focuses on the development of products through clinical trials. As of December 31, 2019, approximately 1,400 dedicated R&amp;D and quality assurance employees in 23 R&amp;D facilities were involved in our R&amp;D efforts internally. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have approximately 175 projects in our global pipeline. Certain core R&amp;D projects that have received a significant portion of our R&amp;D investment in current and prior periods are listed below. However, due to the challenges of the COVID-19 pandemic, most notably those attributable to "stay at home" and travel restrictions, certain of our R&amp;D activities were forced to pause. Clinical trials that started prior to governmental shutdowns remain enrolled and existing patients are progressing, while new patient enrollments were paused as most trial sites were not able to accept new patients. However, during our third quarter we saw the pace of new patient enrollments in increase, getting close to their pre-COVID-19 pandemic levels in the U.S., and as a result have not had to make material changes to our development timelines.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the timing and completion of our ongoing and anticipated clinical trial programs. As of the date of this filing, the delays in our clinical trials have not had a material impact on our operating results; however, a resurgence of the virus significant enough to necessitate reenacting certain social restrictions could result in unanticipated delays in our ability to conduct new patient enrollments. Other possible COVID-19 pandemic and resurgence related challenges include, but are not limited to, facility closures, delays by third-party service providers, deferrals of doctor visits, postponement of elective medical procedures and surgeries and changes in prioritization by the FDA and other regulatory authorities. Delays, if any, caused by the COVID-19 pandemic and a possible resurgence of the virus such as these and others will likely adversely affect the timely approval, launch and commercialization and the commercial success of our products, particularly those in early stage clinical trials. As a result, our estimates regarding the timing and success of our R&amp;D efforts (some of which are set out below), including as it relates to study initiation, enrollment and completion, availability of study results, regulatory submissions, regulatory approvals and commercial launches, may change. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dermatology - In June 2019, we launched Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene for the treatment of plaque psoriasis in adults.&#160; Halobetasol propionate and tazarotene are each approved to treat plaque psoriasis when used separately, but the duration of halobetasol propionate is limited by FDA labeling constraints and the use of tazarotene can be limited due to tolerability concerns.&#160; However, the combination of these ingredients in Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with a dual mechanism of action, allows for expanded duration of use, with reduced adverse events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - SiHy Daily is a silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. In September 2018, we launched this product in Japan under the branded name SiHy Daily AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160; In August 2020, we launched this product in the U.S. under the branded name Bausch + Lomb Infuse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens. This product has also received regulatory approval for Canada, Australia, New Zealand and Hong Kong where it will be branded as Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY SiHy Daily Disposable contact lens.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dermatology - Internal Development Project ("IDP") 126 is an acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. Phase 3 clinical studies initiated in December 2019 were paused due to COVID-19 pandemic related factors, but resumed in June 2020 and are currently ongoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) is an OTC eye drop developed as an ocular redness reliever. We have several line extensions under development and expect Phase 3 clinical studies to commence in 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gastrointestinal - Top line results from a Phase 2 study for the treatment of overt hepatic encephalopathy with a new formulation of rifaximin showed a treatment benefit.  Patients receiving 40 mg twice daily showed a statistically significant separation from placebo. The top line results from this Phase 2 study will help inform further research on potential new indications for rifaximin using this formulation, including the treatment of sickle cell anemia where we expect our clinical trials to commence 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gastrointestinal - We are preparing to initiate a Phase 2 study to evaluate rifaximin for the treatment of small intestinal bacterial overgrowth or SIBO. New patient enrollments were paused due to COVID-19 pandemic related factors and are expected to commence once clinical sites are activated.  We anticipate clinical trials to commence in the second half of 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gastrointestinal - We have entered into a collaboration with Cedars Sinai Medical Center to evaluate a new formulation of rifaximin for the treatment of IBS.  Studies to support this research program were paused due to COVID-19 pandemic related factors and are expected to resume before the end of 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dermatology - IDP-120 is an acne product with a fixed combination of mutually incompatible ingredients: benzoyl peroxide and tretinoin.  Phase 3 clinical studies have been completed and met the primary endpoints.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dermatology - Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(tazarotene) Lotion, 0.045% (formerly IDP-123) is an acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy and was launched in June 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gastrointestinal - Our partner Alfasigma S.p.A. ("Alfasigma") is initiating a Phase 2/3 study for the treatment of postoperative Crohns disease using a novel rifaximin extended release formulation.  The Phase 2/3 study was paused due to COVID-19 pandemic related factors and is expected to resume once the relevant clinical sites reopen.  We anticipate clinical trials to commence in the third quarter of 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gastrointestinal - We are developing a probiotic supplement to address gastrointestinal disturbances. Clinical trial is completed and a full data set is available. We launched this product in October 2020.&#160;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dermatology - IDP-124 is a topical lotion product designed to treat moderate to severe atopic dermatitis, with pimecrolimus.  Phase 3 clinical studies have been completed with one of the two studies meeting the primary endpoint. We are currently evaluating the next steps for this program.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism is a daily disposable contact lens for astigmatic patients. The Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday contact lens incorporates Surface Active Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to provide a dehydration barrier.&#160; The Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism also includes evolved peri-ballast geometry to deliver stability and comfort for the astigmatic patient.&#160;We launched this product in December 2016 and launched an extended power range and further extended power ranges in 2017, 2018, 2019 and July 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - We are developing a new Ophthalmic Viscosurgical Device ("OVD") product, with a formulation to protect corneal endothelium during phacoemulsification process during a cataract surgery and to help chamber maintenance and lubrication during interocular lens delivery.  In January 2020, we commenced an FDA clinical study for cohesive OVD which was paused due to COVID-19 pandemic related factors and is expected to resume once the relevant clinical sites reopen. In April 2020, we filed a Premarket Approval application for the dispersive OVD with the FDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - In April 2019, we launched Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SM (loteprednol etabonate ophthalmic gel) 0.38%, a new formulation for the treatment of post-operative inflammation and pain following ocular surgery. Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SM is the lowest concentrated loteprednol ophthalmic corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - enVista</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Trifocal intraocular lens is an innovative lens design.  We initiated an investigative device exemption study for this product in May 2018 and initiated a Phase 2 study in October 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - We are developing a preloaded intraocular lens injector platform for enVista interocular lens. We have received approvals from the European Union and Canada and received FDA clearance for the injector. We launched this platform in October 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - We are developing an extended depth of focus intraocular lens, the timing and completion of which has been delayed due to COVID-19 pandemic related matters.  Once developed and if approved, we anticipate that this product could be launched in the second half of 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> monthly silicone hydrogel lens was specifically designed to address the lifestyle and vision needs of patients with MoistureSeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology which maintains 95% of contact lens moisture for a full 16 hours. In the second quarter of 2020, Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received a seven day extended wear indication approval from the European Union and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received regulatory approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the National</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Products Administration in the China.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism contact lens is the first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the Company's unique 3-Zone Progressive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;multifocal design with the stability of its OpticAlign</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;toric with MoistureSeal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.&#160;Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism was launched in June 2019 and received European Union regulatory approval in the second quarter of 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced Multi-Purpose Solution (&#8220;MPS&#8221;) contains a triple disinfectant system that kills 99.9% of germs and has a dual surfactant system that provides up to 20 hours of moisture.  Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS is FDA cleared with indications for use to condition, clean, remove protein, disinfectant, rinse and store soft contact lenses including those composed of silicone hydrogels.  Renu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS has gained regulatory approvals in Korea, India, Mexico, Indonesia, Malaysia, Singapore and, during the second quarter of 2020, the European Union.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - Custom soft contact lens (Ultra Buttons) is a latheable silicone hydrogel button for custom soft specialty lenses including: Sphere, Toric, Multifocal, Toric Multifocal and irregular corneas. If approved by the FDA, we expect to launch in the fourth quarter of 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - In January 2019, we launched Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens for presbyopia exclusively available with Zenlens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RC scleral lenses and will allow eye care professionals to fit presbyopic patients with irregular and regular corneas and those with ocular surface disease, such as dry eye.  The Zen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens incorporates decentered optics, enabling the near power to be positioned over the visual axis.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb - In March 2019, we launched Tangible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a high-water polymer coating that is bonded to the surface of a contact lens and designed to address contact lens discomfort and dry eye.  Tangible</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> coating technology in combination with our Boston</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> materials and Zenlens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> family of scleral lenses will help eye care professionals provide a better lens wearing experience for their patients with challenging vision needs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Licensing Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal R&amp;D initiatives and to build-out and refresh our product portfolio, we also search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company will enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA, (iii) covered by third-party payors or (iv) profitable for distribution is highly uncertain. Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we announced that we entered into two exclusive license agreements which present us with unique developmental opportunities to address the unmet need of treatment for myopia in children. The first of these two licensing agreements is with Eyenovia, Inc. for the development and commercialization in the United States and Canada of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. If approved by the FDA, we believe this investigational product could potentially change the treatment paradigm for the reduction of myopia progression in children. The second is an exclusive global licensing agreement with BHVI for a myopia control contact lens design developed by BHVI. The Company plans to pair BHVI's novel contact lens design with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we announced that we had acquired an exclusive license from Novaliq GmbH for the commercialization and development in the U.S. and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat Dry Eye Disease ("DED") associated with Meibomian gland dysfunction ("MGD"). Enrollment for the initial Phase 3 study has commenced and we expect to initiate a second Phase 3 study for this product in the fourth quarter of 2020. If approved by the FDA, we believe the addition of this investigational treatment for DED will help build upon our strong portfolio of integrated eye-health products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we acquired an exclusive license from Clearside Biomedical, Inc. ("Clearside") for the commercialization and development of Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide suprachoroidal injectable suspension) in the U.S. and Canada. Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside's proprietary SCS Microinjector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that is being investigated as a targeted treatment of macular edema associated with uveitis. We are working closely with Clearside on the resubmission of the New Drug Application for Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the FDA.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we entered into two licensing agreements which present us with unique developmental opportunities to address unmet needs of individuals suffering with certain GI and liver diseases. The first of these two licensing agreements is with the University of California for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in non-alcoholic fatty liver disease (&#8220;NAFLD&#8221;), nonalcoholic steatohepatitis (&#8220;NASH&#8221;) and other GI and liver diseases. The second is an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. We have completed a thorough QTC study, which evaluated the cardiac safety profile of the compound.&#160; Topline results were positive and we expect to initiate a Phase 2 study in the first half of 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Investments in our Infrastructure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In support of our core businesses, we have and continue to make strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland, our Rochester facility in New York and our Lynchburg facility in Virginia. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet the forecasted demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday lenses, in July 2017, we placed into service a $175 million multi-year strategic expansion project of the Waterford facility.  The emphasis of the expansion project was to: (i) develop new technology to manufacture, automatically inspect and package contact lenses, (ii) bring that technology to full validation and (iii) increase the size of the Waterford facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the expected global demand for our Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lens, in December 2017, we completed a multi-year, $200 million strategic upgrade to our Rochester facility.  The upgrade increased production capacity in support of our Bausch + Lomb Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and SiHy Daily AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines and better supports the production of </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other well-established contact lenses, such as our PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PureVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 (SVS, Toric, and Multifocal), SofLens</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 38 and SilSoft</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the expected global demand for our SiHy Daily disposable contact lenses, in November 2018, we initiated $300 million of additional expansion projects to add multiple production lines to our Rochester and Waterford facilities. SiHy Daily disposable contact lenses launched in the U.S. in September 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further help us meet the anticipated demand of our contact lenses, in 2020, we initiated an expansion of the Company's Lynchburg distribution center. The new facility is expected to create new jobs over the next five years and expand the overall site to 190,000 square feet, which will provide distribution capabilities for medical devices, primarily contact lens products, and be the main point of distribution in the U.S.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the investments in our Waterford, Rochester and Lynchburg facilities and related expansion of labor forces further demonstrates the growth potential we see in our Bausch + Lomb products and our eye-health business.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_124"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effectively Managing Our Capital Structure  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to effectively manage our capital structure by: (i) reducing our debt through repayments, (ii) extending the maturities of debt through refinancing and (iii) improving our credit ratings.  </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Debt Repayments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - Excluding the impact of the $1,210 million financing of the U.S. Securities Litigation settlement discussed below, we have been able to repay (net of additional borrowings) over $8,100&#160;million of long-term debt during the period January 1, 2016 through the date of this filing using the net cash proceeds from divestitures of non-core assets, cash generated from operations and cash generated from tighter working capital management. In addition, on October 29, 2020, the Company issued an unconditional notice of redemption to redeem: (i) $99&#160;million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes") and (ii) $51&#160;million of March 2023 Unsecured Notes, on November 30, 2020. This payment will fully repay the May 2023 Unsecured Notes and reduce our remaining amount of 2023 unsecured bonds.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Refinancing Transactions - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March, October, November and December 2017, we accessed the credit markets and completed a series of transactions, whereby we extended approximately $9,500 million in aggregate maturities of certain debt obligations due to mature in April 2018 through April 2022, out to March 2022 through December 2025. As part of these transactions, we also extended commitments under our revolving credit facility, originally set to expire in April 2018, out to April 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Refinancing Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In March, June and November 2018, we accessed the credit markets and completed a series of transactions, whereby we extended approximately $8,300 million in aggregate maturities of certain debt obligations due to mature in March 2020 through July 2022, out to June 2025 through January 2027.&#160; As part of these transactions, we obtained less stringent loan financial maintenance covenants under our Senior Secured Credit Facilities and extended commitments under our revolving credit facility by more than three years by replacing our then-existing revolving credit facility, set to expire in April 2020 with our 2023 Revolving Credit Facility of $1,225 million due in June 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Refinancing Transactions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In March, May and December 2019, we accessed the credit markets and completed a series of transactions, whereby, we extended approximately $4,200 million in aggregate maturities of certain debt obligations due to mature in December 2021 through May 2023, out to January 2027 through January 2030. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing of Litigation Settlement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2019, we announced that we had agreed to resolve the putative securities class action litigation in the U.S. (the "U.S. Securities Litigation") for $1,210 million, subject to final court approval. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. This settlement, once approved by the court, will resolve and discharge all claims against the Company in the class action, and as a result will resolve the most significant of the Company's remaining legacy legal matters and eliminate a material uncertainty regarding our Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To finance the settlement of the U.S. Securities Litigation and extend certain debt maturities, on December 30, 2019, we accessed the credit markets and issued: (i) $1,250 million aggregate principal amount of 5.00% Senior Unsecured Notes due January 2028 (the "5.00% January 2028 Unsecured Notes") and (ii) $1,250 million aggregate principal amount of 5.25% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance amounts owed under the Company's $1,210 million settlement agreement relating to the U.S. Securities Litigation (which is subject to final court approval), $1,010 million of which was paid into an escrow fund in accordance with the related settlement agreement and included in our Restricted cash balance as of September 30, 2020, and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions"). In October 2020, we paid an additional $100 million into the escrow fund relating to the U.S. Securities Litigation settlement. Through this financing, we have in effect extended the payments of the pending litigation settlement of $1,210 million out to 2028 and 2030, without negatively impacting our working capital available for operations. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Refinancing Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In May 2020, we accessed the credit markets and completed a series of transactions, whereby, we extended $1,250 million in aggregate maturities of certain debt obligations due to mature in March 2022 and $250 million in aggregate amortization payments due in March 2022 through December 2022, out to February 2029. In addition to extending $1,500 million in payments due 2022 to February 2029, the refinancing replaced secured debt of   $1,500 million with unsecured debt. This provides us with more secured capacity if the market for unsecured debt in the future is less favorable. Further, by replacing the secured debt with unsecured debt we now have additional room under the debt maintenance covenant of our 2023 Revolving Credit Facility that requires us to maintain a first lien net leverage ratio of not greater than 4.00 to 1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for the details of our debt portfolio as of September&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt repayments and refinancing transactions outlined above have allowed us to: (i) improve our credit ratings, (ii) finance amounts owed under the Company's recently announced $1,210 million settlement agreement relating to the U.S. Securities Litigation (which is subject to final court approval) without negatively impacting our working capital available for operations, (iii) extend maturities of certain debt obligations due out to the year 2025 and beyond and (iv) satisfy all debt maturities and mandatory amortization payments until 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prepayment of debt and refinancing transactions over the last four years translate into lower repayments of principal over the next four years, which, in turn, we believe will permit more cash flows to be directed toward developing our core assets, identifying new product opportunities and repaying additional debt amounts. The mandatory scheduled principal repayments of our debt obligations as of September&#160;30, 2020, were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of the changes in our debt portfolio, approximately 80% of our debt is fixed rate debt as of September&#160;30, 2020, as compared to approximately 60% as of January 1, 2016. The weighted average stated interest rate of the Company's outstanding debt as of September&#160;30, 2020 was 5.94% as compared to 6.21% as of December&#160;31, 2019, resulting in lower cash interest payments in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, giving us the ability to better focus on our core businesses. While we anticipate focusing any future divestiture activities on non-core assets, consistent with our duties to our shareholders and other stakeholders, we will consider dispositions in core areas that we believe represent attractive opportunities for the Company.  Also, the Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements and &#8220;Management's Discussion and Analysis - Liquidity and Capital Resources: Long-term Debt&#8221; for additional discussion of these matters. Cash requirements for future debt repayments including interest can be found in &#8220;Management's Discussion and Analysis - Off-Balance Sheet Arrangements and Contractual Obligations.&#8221;</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_127"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improve Patient Access</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Access and Pricing Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2016, we formed the Patient Access and Pricing Committee which is responsible for setting, changing and monitoring the pricing of our products and evaluating contract arrangements that determine the placement of our products on drug formularies.  The Patient Access and Pricing Committee considers new to market product pricing, price changes and their impact across channels on patient accessibility and affordability. The Patient Access and Pricing Committee remains committed to limiting the average annual price increase for our branded prescription pharmaceutical products to no greater than single digits and has reaffirmed this commitment for 2020. These pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our company revenue and profit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash-pay Prescription Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. The cash-pay program is designed to </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walgreens Fulfillment Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. ("Walgreens"). Under the terms of the brand fulfillment arrangement, as amended in July 2019, we made certain dermatology and ophthalmology products available to eligible patients through patient access and co-pay assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies. Our products available under this fulfillment agreement include certain Ortho Dermatologics products, including our Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Luzu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Retin-A Micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel and Onexton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and select branded prescription pharmaceutical products included in our cash-pay prescription program, and certain ophthalmology products, including our Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Besivance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Alrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Prolensa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bepreve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zylet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_130"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions previously outlined, the events described below have affected and may affect our business trends. The matters discussed in this section contain Forward-Looking Statements.  Please see &#8220;Forward-Looking Statements&#8221; for additional information.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_133"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Invest in Sustainable Growth Drivers to Position us for Long-Term Growth</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market.  We have divested certain businesses where we saw limited growth opportunities, so that we can be more aggressive in redirecting our R&amp;D spend and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. However, our future success is also dependent upon our ability to continually refresh our pipeline, to provide a rotation of product launches that meet new and changing demands and replace other products that have lost momentum.  We believe we have a robust pipeline that not only provides for the next generation of our existing products, but is also poised to bring new products to market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in our Eye-Health Business - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our Global Bausch + Lomb business strategy, we continually look for key trends in the eye-health market to meet changing consumer/patient needs and identify areas for investment to extend our market share through new launches and effective pricing. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, there is an increasing rate of myopia, and importantly, myopia as a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye-health products that address conditions brought on by factors such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population (for example, as more and more baby-boomers in the U.S. are reaching the age of 65).  To extend our market share in eye-health, we continually seek to identify new products tailored to address these key trends for development internally with our own R&amp;D team to generate organic growth. Recent product launches include Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lenses, SiHy Daily contact lenses, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an eye redness treatment), Vyzulta</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension) and Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices).  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also license selective molecules or technology in leveraging our own R&amp;D expertise through development, as well as seek out external product development opportunities. As previously discussed, we acquired exclusive licenses for a myopia control contact lens design developed by BHVI which we plan to pair with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children and for the commercialization and development in the U.S. and Canada for: a microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12; Xipere</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which, if approved by the FDA, will be the first treatment for patients suffering from macular edema associated with uveitis; and NOV03, an investigational drug with a novel mechanism of action to treat DED associated with MGD. We also acquired the U.S. rights to EM-100, which was recently approved by the FDA as Alaway</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative-Free and is the first OTC preservative-free formulation eye drop for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children 3 years of age and older. Recently, we entered into an agreement which provides the Company an option to acquire all ophthalmology assets of Allegro, including risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry AMD. A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. We believe investments in these investigational treatments, if approved by the FDA, will complement, and help build upon, our strong portfolio of integrated eye-health products.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, we have also made strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland to meet the forecasted demand for our Biotrue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday lenses, our Rochester facility in New York to address the expected global demand for our Bausch + Lomb ULTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lens and our Lynchburg facility in Virginia to be main point of distribution in the U.S. During late 2018, we began investing in additional expansion projects at the Waterford and Rochester facilities in order to address the expected global demand for our SiHy Daily disposable contact lenses, which we launched in the U.S. on August 2020, under the branded name Bausch + Lomb Infuse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our recent product launches, licensing arrangements and the investments in our Waterford, Rochester and Lynchburg facilities demonstrate the growth potential we see in our Bausch + Lomb products and our eye-health business and that these investments will position us to further extend our market share in the eye-health market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraging our Salix Infrastructure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We strongly believe in our GI product portfolio and we have implemented initiatives, including increasing our marketing presence and identifying additional opportunities outside our existing GI portfolio, to further capitalize on the value of the infrastructure we built around these products to extend our market share. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2017, we hired approximately 250 trained and experienced sales force representatives and managers to create, bolster and sustain deep relationships with primary care physicians (&#8220;PCP&#8221;). With approximately 70% of IBS-D patients initially presenting symptoms to a PCP, we continue to believe that the dedicated PCP sales force is better positioned to reach more patients in need of IBS-D treatment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This initiative provided us with positive results, as we experienced consistent growth in demand for our GI products throughout 2017 and 2018, which was evident by our growth in Salix revenues of 12% in 2018 when compared to 2017. These results encouraged us to seek out ways to bring out further value through leveraging our existing sales force and, in the later portion of 2018 and in 2019, we identified and executed on certain opportunities which we describe below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Acquisition - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in March 2019, we completed the acquisition of certain assets of Synergy, whereby we acquired the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product complements our existing Salix products and allows us to effectively leverage our existing GI sales force.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing Arrangements - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in April 2019, we entered into two licensing agreements.  The first is for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in NAFLD, NASH and other GI and liver diseases. The second is to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis.  These licenses present unique developmental opportunities to address unmet needs of individuals suffering with certain GI and liver diseases and if developed and approved by the FDA, will allow us to further utilize our existing sales force and infrastructure to extend our market share in the future and create value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Next Generation Formulations - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product increased approximately 22%, 22% and 11% in 2019, 2018 and 2017, respectively. In order to extend growth in Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we continue to directly invest in next generation formulations of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and rifaximin, the principal semi-synthetic antibiotic used in our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product.  In addition to one R&amp;D program in progress, we have three other R&amp;D programs planned for next generation formulations of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) which address new indications.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the acquisition and licensing opportunities discussed above will be accretive to our business by providing us access to products and investigational compounds that are a natural pairing to our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business, allowing us to effectively leverage our existing infrastructure and sales force. We believe these opportunities, coupled with our investment in next generation formulations, will allow our GI franchise to continue to further extend market share.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Position the Ortho Dermatologics Business for Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2018, we realigned our Solta aesthetics business and combined it with our medical dermatology business creating a complete dermatology portfolio.  In support of the complete dermatology portfolio, we have taken and are taking a number of actions that we believe will help our efforts to stabilize our dermatology business. These actions include: (i) rebranding our dermatology business including our aesthetics business, (ii) recruiting a new experienced leadership team, (iii) making significant investment in our core medical device and dermatological products portfolios, (iv) right sizing and reorganizing our dermatology sales force across roughly 195 sales territories, as we work to rebuild relationships with prescribers of our products and (v) improving patient access to our Ortho Dermatologics products through our cash-pay prescription program previously discussed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Our Core Dermatology Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We have made significant investments to build out our aesthetics, psoriasis and acne product portfolios, which are the markets within dermatology where we see the greatest opportunities to extend our market share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aesthetics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2017, we launched our Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product in the U.S., a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. During 2018 and 2019, Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in Hong Kong, Japan, Korea, Taiwan, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, and Australia as part of our Solta medical aesthetic devices portfolio. These launches have been successful as Next Generation Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues for nine months ended September 30, 2020 and 2019 were $94&#160;million and $47&#160;million, respectively, and in full-year 2019 were $77 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Psoriasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - As the number of reported cases of psoriasis in the U.S. has increased, we believe there is a need to make further investments in this market in order to maximize our opportunity and supplement our current psoriasis product portfolio. We have filed NDAs for several new topical psoriasis products, launched Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in June 2019 and launched Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in November 2018. We expect that Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will align well with our existing topical portfolio of psoriasis treatments and, supplemented by our injectable biologic products, such as Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, will provide a diverse choice of psoriasis treatments to doctors and patients. In July 2017, we launched Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an IL-17 receptor blocker monoclonal antibody biologic for treatment of moderate-to-severe plaque psoriasis, which we estimate to be an over $5,000 million market in the U.S. (Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a Black Box Warning for the risks in patients with a history of suicidal thoughts or behavior and was approved with a Risk Evaluation and Mitigation Strategy involving a one-time enrollment for physicians and one-time informed consent for patients).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In support of our established acne product portfolio, we have developed and launched several products, which includes Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tazarotene) Lotion (launched in June 2020), Altreno</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(launched in the U.S. in October 2018), the first lotion (rather than a gel or cream) product containing tretinoin for the treatment of acne, and Retin-A Micro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.06% (launched in January 2018). We also have two other unique acne projects in development that, if approved by the FDA, we believe will further innovate and advance the treatment of acne.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bolstered by new product launches in our aesthetics, psoriasis and acne product lines and the potential of other products under development, our experienced dermatology sales leadership team, our sales force and our cash-pay prescription program, we believe we have set the groundwork to position the Ortho Dermatologics business for future growth.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_136"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Health Care Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the health care industry. In March&#160;2010, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) was enacted in the U.S.&#160;The ACA contains several provisions that impact our business, including: (i) an increase in the minimum Medicaid rebate to states participating in the Medicaid program, (ii) the extension of the Medicaid rebates to Managed Care Organizations that dispense drugs to Medicaid beneficiaries, (iii) the expansion of the 340(B) Public Health Services drug pricing program, which provides outpatient drugs at reduced rates, to include additional hospitals, clinics and health care centers and (iv) a fee payable to the federal government based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2013 federal subsidies began to be phased in for brand-name prescription drugs filled in the Medicare Part D coverage gap. The ACA also included provisions designed to increase the number of Americans covered by health insurance. In 2014, the ACA's private health insurance exchanges began to operate. The ACA also allows states to expand Medicaid coverage with most of the expansion&#8217;s cost paid for by the federal government.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2019 and 2018, we incurred costs of $20 million and $36 million, respectively, related to the annual fee assessed on prescription drug manufacturers and importers that sell branded prescription drugs to specified U.S.&#160;government programs (e.g.,&#160;Medicare and Medicaid). For 2019 and 2018, we also incurred costs of $137 million and $90 million, respectively, on Medicare Part&#160;D utilization incurred by beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part&#160;D coverage gap (i.e.,&#160;the &#8220;donut&#160;hole&#8221;).</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2014, the U.S. Internal Revenue Service issued final regulations related to the branded pharmaceutical drug annual fee pursuant to the ACA.  Under the final regulations, an entity&#8217;s obligation to pay the annual fee is triggered by qualifying sales in the current year, rather than the liability being triggered upon the first qualifying sale of the following year.  We adopted this guidance in the third quarter of 2014, and it did not have a material impact on our financial position or results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impact of the ACA will be affected by certain additional developments over the next few years, including pending implementation guidance and certain health care reform proposals. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Also, it is possible, as discussed further below, that under the current administration, legislation will be passed by Congress repealing the ACA in whole or in part.  Adoption of legislation at the federal or state level could materially affect demand for, or pricing of, our products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we faced uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. However, we believe there is low likelihood of repeal of the ACA, given the recent failure of the Senate&#8217;s multiple attempts to repeal various combinations of ACA provisions. There is no assurance that any replacement or administrative modifications of the ACA will not adversely affect our business and financial results, particularly if the replacing legislation reduces incentives for employer-sponsored insurance coverage, and we cannot predict how future federal or state legislative or administrative changes relating to the reform will affect our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the U.S. Health and Human Services Administration announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the current administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. While we do not believe this will have a significant impact on our future cash flows, we cannot provide assurance as to the ultimate context, timing, effect or impact of such a plan.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Government of Canada (Health Canada) published in the Canadian Gazette the new pricing regulation for patented drugs. These regulations will become effective on January 1, 2021. The draft application guidelines are available with the final guidelines to be published in 2020. The new regulations will change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019; they will also require full transparency of discounts agreed with provincial bodies; and finally, will change the number and composition of reference countries used to determine if a drug&#8217;s price is excessive. While we do not believe this will have a significant impact on our future cash flows, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, U.S. President Donald Trump signed four Executive Orders related to drug pricing, including orders addressing: (i) Part D rebate reform, (ii) the provision of deeply discounted insulin and/or an EpiPen to patients of Federally Qualified Health Centers, (iii) drug importation from Canada and (iv) most favored nation pricing for Medicare. We are currently reviewing those Executive Orders, the impact of which is uncertain at this time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative efforts relating to drug pricing have been enacted and others have been proposed at the U.S. federal and state levels. For instance, certain states have enacted legislation related to prescription drug pricing transparency. Several states have passed importation legislation and Florida is working with the U.S. government to implement an importation program from Canada. We also anticipate that Congress, state legislatures and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations affecting additional fundamental changes in the health care delivery system. We continually review newly enacted and proposed U.S. federal and state legislation, as well as proposed rulemaking and guidance published by the Department of Health and Human Services and the FDA; however, at this time, it is unclear the effect these matters may have on our businesses.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_139"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Generic Competition and Loss of Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products face the expiration of their patent or regulatory exclusivity in 2020 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in 2020 or in later years. Following a loss of exclusivity ("LOE") of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the loss of exclusivity or entry of a generic competitor. Where we have the rights, we may elect to launch </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an authorized generic of such product (either ourselves or through a third-party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products already face generic competition.  Prior to and during 2020, in the U.S., these products include, among others, Ammonul</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Benzaclin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bupap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Edecrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Istalol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Locoid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Suspension, Mephyton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MoviPrep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nitropress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet, Virazole</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin&#160;XL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zegerid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cream.  In Canada, these products include, among others, Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;XL and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ointment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Branded products that began facing generic competition in the U.S. during 2019 include, Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Suspension, Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cream.  In aggregate, these products accounted for 3% of our total revenues in 2019. While certain of these products have already begun experiencing an adverse impact on volume and/or pricing as a result of the entry into the market of generic competition, we are unable to predict the complete magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 through 2024 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Based on current patent expiration dates, settlement agreements and/or competitive information, we have identified branded products that we believe could begin facing potential loss of exclusivity and/or generic competition in the U.S. during the years 2020 through 2024.  These products and year of expected loss of exclusivity include, but are not limited to, Clindagel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2020), Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel (2021), Noritate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2020), Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel (2022), Xerese</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2022)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other products that are subject to settlement agreements which could impact their exclusivity during the years 2020 through 2024.&#160;In aggregate, these products accounted for 3% of our total revenues in 2019. These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 OTC Product Patent Expiry - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and&#160;PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are OTC eye vitamin formulas for those with moderate-to-advanced age-related macular degeneration. PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products accounted for 2% of our total revenues in 2019. The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation patent expires in 2021, but patents covering methods of using the formulation remain in force until 2026. While the Company cannot predict the magnitude or timing of the impact from its patent expiry, this is an OTC product and thus, the impact is not expected to be as significant as the loss of exclusivity of a branded pharmaceutical product. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for a number of our products (including Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Plenvu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the U.S. and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Glenmark) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In December 2019, the Company announced that it had reached an agreement to resolve&#160;the&#160;outstanding&#160;intellectual&#160;property&#160;litigation&#160;with&#160;Glenmark&#160;Pharmaceuticals,&#160;Ltd. ("Glenmark"). Under the terms of the agreement, the Company will grant Glenmark a non-exclusive license to its intellectual property relating to Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and, beginning in 2026 (or earlier under certain circumstances), Glenmark will have the option to market a royalty-free generic version of Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, should it receive approval from the FDA. The parties have agreed to dismiss all litigation related to Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, and all intellectual property protecting Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion remains intact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Perrigo) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-  On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (&#8220;Perrigo&#8221;), in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo&#8217;s generic halobetasol propionate lotion, for which an Abbreviated New Drug Application ("ANDA") has been filed by Perrigo.&#160; On May 1, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA for halobetasol propionate lotion.&#160;On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described below, regarding Perrigo&#8217;s ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion (Perrigo) - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo, in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial manufacture, use or sale of Perrigo&#8217;s generic lotion, for which an ANDA has been filed by Perrigo.  On August 28, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described above, regarding Perrigo&#8217;s ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. We remain confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend our intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 550mg Patent Litigation (Actavis) - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2016, the Company initiated litigation against Actavis Laboratories FL, Inc.&#8217;s ("Actavis"), which alleged infringement by Actavis of one or more claims of each of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents. On September 12, 2018, we announced that we had reached an agreement with Actavis that resolved the existing litigation and eliminated the pending challenges to our intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. As part of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin), Actavis acknowledged the validity of the licensed patents for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in 2029. The agreement also grants Actavis a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). The Company will not make any financial payments or other transfers of value as part of the agreement. In addition, under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Actavis will have the option to: (1) market a royalty-free generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, should it receive approval from the FDA on its ANDA, or (2) market an authorized generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, in which case, we will receive a share of the economics from Actavis on its sales of such an authorized generic. Actavis will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed before January 1, 2028.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">550mg Patent Litigation (Sandoz) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-  In October 2019, the Company announced that it and its licensor, Alfasigma had commenced litigation against Sandoz Inc. ("Sandoz"), a Novartis division, alleging patent infringement of 14 patents by Sandoz's filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550 mg tablets, should it receive approval from the FDA on its ANDA. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not make any financial payments or other transfers of value as part of this agreement with Sandoz.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">550mg Patent Litigation (Norwich) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- On March 26, 2020, the Company and its licensor Alfasigma filed suit against Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), alleging infringement by Norwich of one or more claims of the 23 Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents by Norwich&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets.  Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 23 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">200mg and 550mg Patent Litigation (Sun) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In April 2019, the Company and its licensor, Alfasigma, commenced litigation against Sun Pharmaceutical Industries Ltd. (&#8220;Sun&#8221;), alleging patent infringement by Sun&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will have the right to market royalty-free generic versions of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Tablets Patent Litigation (Actavis)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On December 6, 2016, the Company initiated litigation against Actavis, which alleged infringement by Actavis of one or more claims of U.S.&#160;Patent No. 8,524,276 (the &#8220;&#8216;276 Patent&#8221;), which protects the formulation of RELISTOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets. Actavis had challenged the validity of such patent and alleged non-infringement by its generic version of such product. In July 2019, we announced that the U.S. District Court of New Jersey had upheld the validity of and determined that Actavis infringed the &#8216;276 Patent, expiring in March 2031.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, a generic competitor launched a product which will directly compete with our Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet product. As disclosed in our prior filings, the Company initiated various infringement proceedings against this generic competitor. The Court construed the claims of the asserted patents on August 2, 2019 and, on October 24, 2019, the Company agreed to a judgment that the asserted patents did not cover the generic tablets under the Court&#8217;s claim construction, while reserving its right to appeal the claim construction. On November 22, 2019, the Company filed a Notice of Appeal with respect to the claim construction in the Court of Appeals for the Federal Circuit. The appeal is pending. The Company continues to believe that its Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet-related patents are enforceable and is proceeding with an appeal; however, the ultimate outcome of the matter is not predictable. The ultimate impact of this generic competitor on our future revenues cannot be predicted; however, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet revenues for the nine months ended September 30, 2020 and 2019 were approximately $8 million and $17 million, respectively, and for the years 2019, 2018 and 2017 were approximately $20&#160;million, $84&#160;million and $134&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;) completed its inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and issued a written determination invalidating such patent.&#160; On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues for the nine months ended September 30, 2020 and 2019 were approximately $88 million and $81 million, respectively, and for the full years 2019, 2018 and 2017 were approximately $110 million, $89 million and $96 million, respectively. &#160;The Company continues to believe that the Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related patent is valid and enforceable, but the ultimate outcome of this matter is not predictable. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> continues to be covered by eleven remaining Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, we received notices of the filing of a number of ANDAs with paragraph IV certification, and have timely filed patent infringement suits against these ANDA filers, and, in addition, we have also commenced certain patent infringement proceedings in Canada against two separate defendants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18, "LEGAL PROCEEDINGS" to our unaudited interim Consolidated Financial Statements elsewhere in this Form 10-Q, as well as Note 21, "LEGAL PROCEEDINGS" of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC and the CSA on February&#160;19, 2020 for further details regarding certain infringement proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio.  These risks are not avoidable, but we believe they are manageable.  To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations.  In addition to aggressively defending the Company's patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline.  Our leadership team actively manages the Company's pipeline in order to identify what we believe are the proper projects to pursue. Innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future.  We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A &#8220;Risk Factors&#8221; of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC and the CSA on February&#160;19, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on our competition risks.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_142"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. Through the date of this filing, all of our global operations and facilities have </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the relevant operational good manufacturing practices certificates and all Company products and operating sites are in good compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (&#8220;VAI&#8221;) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities. A Form 483 is issued at the end of each inspection when FDA investigators have observed any condition that in their judgment may constitute violations of current good manufacturing practices.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_145"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELECTED FINANCIAL INFORMATION </span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected unaudited financial information for the three and nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.179%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(563)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Performance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of the Three Months Ended September 30, 2020 Compared to the Three Months Ended September 30, 2019 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the three months ended September 30, 2020 and 2019 was $2,138 million and $2,209 million, respectively, a decrease of $71 million, or 3%. The decrease was due to: (i) a decrease in net average realized pricing, (ii) lower volumes driven by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and the impact of the loss of exclusivity of certain products, (iii) the unfavorable effect of foreign currencies, primarily in Latin America, and (iv) the impact of divestitures and discontinuations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the three months ended September 30, 2020 and 2019 was $460 million and $329&#160;million, respectively, an increase in our operating results of $131 million and reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution (Product sales revenue less Cost of goods sold, excluding amortization and impairments of intangible assets) of $76 million primarily due to: (i) the decrease in revenues, as discussed above, and (ii) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic. The decrease was partially offset by third-party royalty costs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Selling, general and administrative expenses (&#8220;SG&amp;A&#8221;) of $76 million primarily attributable to: (i) the impacts of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and (ii) profit protection measures taken to manage and reduce operating expenses during the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in R&amp;D of $20 million primarily attributable to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $84 million primarily attributable to fully amortized intangible assets no longer being amortized in 2020;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Asset impairments of $31 million, primarily related to impairments during the three months ended September 30, 2019 related to: (i) a certain product line as a result of changes to its forecasted sales due to generic competition and (ii) impairments related to assets being classified as held for sale; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Other expense, net of $6 million, primarily attributable to a $10 million upfront payment for acquired in-process research and development ("IPR&amp;D") costs.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the three months ended September 30, 2020 and 2019 was $460 million and $329 million and  included non-cash charges for Depreciation and amortization of intangible assets of $436 million and $520 million, Asset impairments of $2 million and $33 million and Share-based compensation of $27 million and $26 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes for the three months ended September 30, 2020 was $75 million as compared to a Loss before income taxes for the three months ended September 30, 2019 of $66 million, a favorable change of $141 million. The favorable change in our Income before income taxes is primarily attributable to: (i) the increase in our operating results of $131 million, as previously discussed, and (ii) the decrease in Interest expense of $32 million and was partially offset by an unfavorable net change in Foreign exchange and other of $22 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to Bausch Health Companies Inc. for the three months ended September 30, 2020 was $71&#160;million as compared to a Net loss attributable to Bausch Health Companies Inc. of $49 million for the three months ended September 30, 2019, an increase in our results of $120 million.  The increase in our results was due to the favorable change in our Income before income taxes of $141 million, as previously discussed, offset by the unfavorable change in our Provision for income taxes of $23 million.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_148"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of the Nine Months Ended September 30, 2020 Compared to the Nine Months Ended September 30, 2019 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue for the nine months ended September 30, 2020 and 2019 was $5,814 million and $6,377 million, respectively, a decrease of $563 million, or 9%. The decrease was due to: (i) lower volumes driven by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and the impact of the loss of exclusivity of certain products, (ii) higher sales deductions, (iii) the unfavorable effect of foreign currencies, primarily in Latin America and Europe, and (iv) the impact of divestitures and discontinuations. These decreases in our revenues were partially offset by: (i) higher gross selling prices and (ii) the incremental sales of our Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the nine months ended September 30, 2020 and 2019 was $681 million and $873 million, respectively, a decrease in our operating results of $192 million and reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution of $447 million primarily due to: (i)  the decrease in revenues, as previously discussed, and (ii) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic. The decrease was partially offset by third-party royalty costs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in SG&amp;A of $155 million primarily attributable to: (i) the impacts of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and (ii) profit protection measures taken to manage and reduce operating expenses during the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in R&amp;D of $24 million primarily attributable to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $189 million primarily attributable to fully amortized intangible assets no longer being amortized in 2020;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Asset impairments of $32 million, primarily related to impairments during the nine months ended September 30, 2019 related to: (i) certain product lines as a result of changes to forecasted sales due to generic competition and other factors and (ii) impairments related to assets being classified as held for sale; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Other expense, net of $131 million primarily attributable to: (i) adjustments related to the settlements of certain litigation matters during the nine months ended September 30, 2020 and (ii) a $10 million upfront payment for IPR&amp;D costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the nine months ended September 30, 2020 and 2019 was $681 million and $873&#160;million, respectively, and included non-cash charges for Depreciation and amortization of intangible assets of $1,397 million and $1,583 million, Asset impairments of $17 million and $49 million and Share-based compensation of $81 million and $77&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Loss before income taxes for the nine months ended September 30, 2020 and 2019 was $540 million and $367&#160;million, respectively, an increase of $173 million. The increase in our Loss before income taxes is primarily attributable to: (i) the decrease in our operating results of $192 million, as previously discussed, (ii) the unfavorable change in Foreign exchange and other of $38 million and (iii) an increase in Loss on extinguishment of debt of $11 million. The increase in our Loss before income taxes was partially offset by a decrease in Interest expense of $66 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health Companies Inc. for the nine months ended September 30, 2020 and 2019 was $407 million and $272 million, respectively, a decrease in our results of $135 million.  The decrease in our results was </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to the increase in our Loss before income taxes of $173 million, as previously discussed, partially offset by the increase in Benefit from income taxes of $32 million.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_151"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited operating results for the three and nine months ended September 30, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:5.8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.329%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(563)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring, integration and separation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,504&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(371)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (loss) before (provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="ie8b2716e216c4586bfedb14835ff92cc_154"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended September 30, 2020 Compared to the Three Months Ended September 30, 2019 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $2,138 million and $2,209 million for the three months ended September 30, 2020 and 2019, respectively, a decrease of $71 million, or 3%. The decrease was primarily driven by: (i) a decrease in net average realized pricing of $33 million primarily in our Salix and Ortho Dermatologics segments, (ii) lower volumes of $28 million primarily in our Diversified Products segment primarily due to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, (iii) the unfavorable effect of foreign currencies of $6 million primarily in Latin America and (iv) the impact of divestitures and discontinuations of $4&#160;million. The decrease in net average realizable pricing reflects, among other things, the impact of the 2019 favorable returns provision adjustment related to past sales on branded and generic products.</span></div><div style="margin-bottom:0.8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously discussed, our revenues have been negatively impacted by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, the negative trend in the revenues of certain of our businesses began to level off and stabilize prior to our third quarter. Presuming there is no material resurgence of the spread of the COVID-19 virus, we anticipate an ongoing, gradual global recovery from the macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020. We therefore believe that our revenues for the year 2020 will be most impacted by the COVID-19 pandemic in our second </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:0.8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">quarter, although we experienced some COVID-19 pandemic related declines in the year-over-year revenues in our third quarter, and we expect additional COVID-19 pandemic related declines in the fourth quarter of 2020, in certain of our businesses and geographies. Presuming any reenactment of social restrictions is not significant, we anticipate that our affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits, including the impacts of COVID-19 pandemic related matters for the three and nine months ended September 30, 2020, are discussed in further detail in the respective subsequent sections &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales.&#160;Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks, and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. As more fully discussed in Note 3, "REVENUE RECOGNITION" to our unaudited interim Consolidated Financial Statements, the Company continually monitors the provisions for these deductions and evaluates the estimates used as additional information becomes available.  Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts, such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities.&#160; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate.  Provisions recorded to reduce gross product sales to net product sales and revenues for the three months ended September 30, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 38.5% and 36.4% for the three months ended September 30, 2020 and 2019, respectively, an increase of 2.1 percentage points and includes:  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales was lower primarily due to lower discount rates for certain generic products, such as Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, and was partially offset by: (i) a higher discount rate for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and other products and (ii) the impact of the release the generic Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG (December 2019);</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns as a percentage of gross product sales was higher and reflects a lower adjustment in 2020 as compared to 2019 for improving sales return experience. Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products.  Included in the product returns provision for the three months ended September 30, 2020 and 2019, are reductions in variable consideration for sales returns related to past sales of approximately $38&#160;million and $80 million, respectively. See Note 3, "REVENUE RECOGNITION" to our unaudited interim Consolidated Financial Statements regarding further details related to product sales provisions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due to an increase in gross product sales of certain branded products with higher rebate rates such as Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by: (i) the impact of decreases in gross product sales for products that carry higher contractual rebates and co-pay assistance programs, including the impact of incremental rebates from contractual price increase limitations for promoted products, such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a result of its generic release and (ii) lower rebate rates for branded products such as Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Siliq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were higher primarily due to the impact of: (i) higher product sales and higher chargeback rates for certain branded products such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX and Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) the impact of the release the generic Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG (December 2019). The higher chargebacks as a percentage of gross product sales were partially offset by the impact of lower gross product sales of: (i) certain generic products, such as Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Ofloxacin and Cardizem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and (ii) certain branded products, such as Nifedical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a result of its generic release; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were higher primarily due to the impact of higher gross product sales for products which carry higher distribution service fee rates such as our Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products and was partially offset by the impact of lower gross product sales of our branded product Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a result of its generic release.  Price appreciation credits are offset against the distribution service fees we pay wholesalers. No price appreciation credits were provided during the three months ended September 30, 2020 and 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily includes: manufacturing and packaging; the cost of products we purchase from third parties; royalty payments we make to third parties; depreciation of manufacturing facilities and equipment; and lower of cost or market adjustments to inventories. Cost of goods sold excludes the amortization and impairments of intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $578 million and $571 million for the three months ended September 30, 2020 and 2019, respectively, an increase of $7 million, or 1%. The increase was primarily driven by: (i) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic and (ii) changes in product mix. The increase was partially offset by: (i) lower third-party royalty costs and (ii) lower volumes, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of product sales revenue was 27.4% and 26.2% for the three months ended September 30, 2020 and 2019, respectively, an increase of 1.2 percentage points. Costs of goods sold as a percentage of Product sales revenue was unfavorably impacted as a result of: (i) changes in product mix, (ii) lower average net selling prices and (iii) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic. These factors were partially offset by lower third-party royalty costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses primarily include: employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions; certain outside legal fees and consultancy costs; product promotion expenses; overhead and occupancy costs; depreciation of corporate facilities and equipment; and other general and administrative costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $572 million and $648 million for the three months ended September 30, 2020 and 2019, respectively, a decrease of $76 million, or 12%. The decrease was primarily attributable to: (i) the impacts of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and (ii) profit protection measures taken to manage and reduce operating expenses during the COVID-19 pandemic and resulted in decreases in: (a) selling expenses, (b) advertising and promotion expenses and (c) compensation expense. Also, SG&amp;A </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses for the three months ended September 30, 2019 included a charge associated with the termination of a certain co-promotional agreement.  These decreases in SG&amp;A expenses were offset partially by higher professional fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include: employee compensation costs; overhead and occupancy costs; depreciation of research and development facilities and equipment; clinical trial costs; clinical manufacturing and scale-up costs; and other third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include: employee compensation costs; overhead and occupancy costs; amortization of software; and other third-party costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $103 million and $123 million for the three months ended September 30, 2020 and 2019, respectively, a decrease of $20 million, or 16%.  R&amp;D expenses as a percentage of Product sales were approximately 5% and 6% for the three months ended September 30, 2020 and 2019, respectively, a decrease of 1 percentage point. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As previously discussed, during our second quarter of 2020, certain of our R&amp;D activities were limited and others, including new patient enrollments in clinical trials, were temporarily paused as most trial sites due to government mandated shutdowns were not able to accept new patients. However, during our third quarter of 2020, many of these trial sites began to reopen and we saw the pace of new patient enrollments increasing, getting close to their pre-COVID-19 levels in the U.S. As of the date of this filing, we have not had to make material changes to our development timelines and the pause in our clinical trials have not had a material impact on our operating results; however, a resurgence of the virus could result in unanticipated delays in our ability to conduct new patient enrollments and create other delays which could have a significant adverse effect on our future operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 2 to 20 years. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $391 million and $475 million for the three months ended September 30, 2020 and 2019, respectively, a decrease of $84 million.  The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2020.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements regarding further details related to the Amortization of intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments were $2 million and $33 million for the three months ended September 30, 2020 and 2019, respectively, a decrease of $31 million. Asset impairments for the three months ended September 30, 2020 include impairments of $2 million reflecting a decrease in forecasted sales of a certain product line. Asset impairments for the three months ended September 30, 2019 include impairments of: (i) $25 million, in aggregate, reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors and (ii) $8 million related to assets being classified as held for sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements regarding further details related to our intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration and Separation Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration and separation costs were $2 million and $4 million for the three months ended September 30, 2020 and 2019, respectively, a decrease of $2 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $1 million and $4 million and included: (i) $1 million and $3 million of facility closure costs and (ii) $0 and $1 million of severance costs for the three months ended September 30, 2020 and 2019, respectively. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. Separation costs were $1&#160;million for the three months ended September 30, 2020. The Company is in the planning phase of the Separation and the extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, "RESTRUCTURING, INTEGRATION AND SEPARATION COSTS" to our unaudited interim Consolidated Financial Statements for further details regarding these actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration primarily consists of potential milestone payments and royalty obligations associated with businesses and assets we acquired in the past. These obligations are recorded in the Consolidated Balance Sheets at their estimated fair values at the acquisition date, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration was a loss of $2 million for the three months ended September 30, 2020, and included accretion for the time value of money of $6 million, partially offset by net fair value adjustments of $4 million. Acquisition-related contingent consideration was a loss of $3 million for the three months ended September 30, 2019, and included accretion for the time value of money of $5 million, partially offset by net fair value adjustments of $2 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the three months ended September 30, 2020 and 2019 consists of the following:</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2020, Acquired in process research and development costs includes the $10&#160;million upfront payment for the Option to acquire all ophthalmology assets of Allegro as previously discussed. See Note 4, "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily consists of interest payments due, amortization of debt premiums, discounts and deferred issuance costs on indebtedness under our credit facilities and notes and the amortization of amounts excluded from the assessment of hedge effectiveness over the term of the Company's cross-currency swaps. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $374 million and $406 million, and included non-cash amortization and write-offs of debt premiums, discounts and deferred issuance costs of $13 million and $17 million, for the three months ended September 30, 2020 and 2019, respectively. Interest expense for the three months ended September 30, 2020 decreased $32 million, or 8%, as compared to the three months ended September 30, 2019, primarily due to: (i) a lower weighted average stated rate of interest, partially offset by higher outstanding principal balances, and (ii) a benefit related to the Company's cross-currency swaps. The weighted average stated rate of interest as of September&#160;30, 2020 and 2019 was 5.94% and 6.39%, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, on December 30, 2019, we accessed the credit markets to finance amounts owed under the Company's $1,210 million settlement agreement relating to the U.S. Securities Litigation (which is subject to final court approval). Although that financing increased our outstanding principal balances, it had the effect of extending the payment terms of the pending settlement of $1,210 million out to 2028 and 2030 without negatively impacting our working capital available for operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other primarily includes: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts. Foreign exchange and other was a loss of $13&#160;million and a gain of $9 million for the three months ended September 30, 2020 and 2019, respectively, an unfavorable net change of $22&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $5 million for the three months ended September 30, 2020 as compared to a Benefit from income taxes of $18 million for the three months ended September 30, 2019 an unfavorable change of $23&#160;million. Our effective income tax rate for the three months ended September 30, 2020 and 2019 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) tax law changes, (b) adjustments for book to income tax return provisions and (c) changes in uncertain tax positions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, "INCOME TAXES" to our unaudited interim Consolidated Financial Statements for further details.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_157"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into four operating and reportable segments: (i) Bausch + Lomb/International, (ii) Salix, (iii) Ortho Dermatologics and (iv) Diversified Products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of our segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb/International segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Ortho Dermatologics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Acquired in-process research and development costs, Restructuring, integration and separation costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 19, "SEGMENT INFORMATION" to our unaudited interim Consolidated Financial Statements for a reconciliation of segment profit to Income (loss) before income taxes.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues, and the period-over-period changes in segment revenues for the three months ended September 30, 2020 and 2019.  The following table also presents segment profits, segment profits as a percentage of segment revenues and the period-over-period changes in segment profits for the three months ended September 30, 2020 and 2019.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Revenues and Organic Growth Rates (non-GAAP)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic growth, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations. Organic revenue growth (non-GAAP) is growth in GAAP Revenue (its most directly comparable GAAP financial measure), adjusted for certain items, of businesses that have been owned for one or more years. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and organic revenue growth (non-GAAP) to assess performance of its reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue growth (non-GAAP) reflects adjustments for: (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and/or discontinued.  These adjustments are determined as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency exchange rates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although changes in foreign currency exchange rates are part of our business, they are not within management&#8217;s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, divestitures and discontinuations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue growth (non-GAAP) excludes from the current period, all revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue growth (non-GAAP) excludes from the prior period (but not the current period), all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and the period-over-period changes in organic revenue (Non-GAAP) for the three months ended September 30, 2020 and 2019 by segment.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.006%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Divestitures and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,144&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb/International Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb/International Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb/International segment has a diversified product line with no single product group representing 10% or more of its product sales. The Bausch + Lomb/International segment revenue was $1,169 million and $1,175 million for the three months ended September 30, 2020 and 2019, respectively, a decrease of $6 million, or 1%. The decrease was primarily attributable to: (i) the unfavorable effect of foreign currencies of $7 million, primarily in Latin America, and (ii) the impact of divestitures and discontinuations of $3 million, related to the divestiture and discontinuance of several products. These decreases were partially offset by an increase in average net realized pricing of $4 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The volumes of our Bausch + Lomb/International segment were relatively unchanged for the three months ended September 30, 2020 compared to the three months ended September 30, 2019, as increases in U.S. volumes were offset by decreases in international volumes. In the U.S. the increase was driven by our U.S. Vision Care and U.S. Consumer businesses and were only partially offset by decreases in our U.S. Ophtho business.  Internationally the decrease was driven across all of our international eye-health businesses and was partially offset by increases in the volumes of our International pharmaceuticals business. During the first and second quarter, volumes for our Bausch + Lomb/International segment were negatively impacted by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed. However, as governments began lifting social restrictions, the negative trend in the revenues of these businesses began to level off and stabilize prior to our third quarter. Presuming there is no material resurgence of the spread of the COVID-19 virus, we anticipate an ongoing, gradual global recovery from the macroeconomic and healthcare impacts of the pandemic that occurred during the first-half of 2020. We therefore believe that our revenues for the year 2020 will be most impacted by the COVID-19 pandemic in our second quarter. Although we experienced additional COVID-19 pandemic related declines in year-over-year revenues in certain geographies during our third quarter, presuming any reenactment of social restrictions is not significant, we anticipate that our affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb/International Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb/International segment profit for three months ended September 30, 2020 and 2019 was $336&#160;million and $333 million, respectively, an increase of $3 million, or 1%. The increase was primarily driven by decreases in SG&amp;A expenses partially offset by the decrease in contribution as a result of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line, which accounted for 77% and 72% of the Salix segment product sales and 18% of the Company's product sales for both the three months ended September 30, 2020 and 2019. No other single product group represents 10% or more of the Salix segment product sales. Salix segment revenue for the three months ended September 30, 2020 and 2019 was $496 million and $551 million, respectively, a decrease of $55 million, or 10%. The decrease is a result of decreases in: (i) average realized pricing of $43 million and (ii) volume of $12 million.  The decrease in average realized pricing was primarily attributable to higher sales deductions, primarily for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX. The decrease in volumes was primarily due to: (i) the impact of generic competition as certain products, such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity and (ii) social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit for the three months ended September 30, 2020 and 2019 was $360 million and $375 million, respectively, a decrease of $15 million, or 4%. The decrease was primarily driven by the decrease in contribution as a result of the decrease in revenue, as previously discussed, partially offset by decreases in SG&amp;A expenses due to: (i) COVID-19 pandemic related matters, as previously discussed, and (ii) a charge associated with the termination of a certain co-promotional agreement during the three months ended September 30, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ortho Dermatologics Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ortho Dermatologics segment revenue for the three months ended September 30, 2020 and 2019 was $144 million and $147 million, respectively, a decrease of $3 million, or 2%. The decrease is a result of a decrease in average realized pricing of $23 million, as a result of higher sales deductions in our medical dermatology products, partially offset by: (i) an increase in volume of $19&#160;million and (ii) the favorable effect of foreign currencies of $1 million. The increase in volume is primarily due to increased demand of Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partially offset by: (i) the impact of generic competition as certain products, such as Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lost exclusivity and (ii) the impacts of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ortho Dermatologics segment profit for the three months ended September 30, 2020 and 2019 was $70 million and $58 million, respectively, an increase of $12 million, or 21%. The increase was primarily driven by decreases in: (i) selling expenses and (ii) R&amp;D expenses due to COVID-19 pandemic related matters, as previously discussed.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the Diversified Products segment revenue by product and product revenues as a percentage of segment revenue for the three months ended September 30, 2020 and 2019.</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neo/Poly/HC Otic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pepcid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobramycin/Dexamethasone</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diastat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mysoline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Franchise </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product revenues </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diversified Products revenues </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue for the three months ended September 30, 2020 and 2019 was $329 million and $336 million, respectively, a decrease of $7 million, or 2%. The decrease was primarily driven by: (i) a decrease in volume of $35 million and (ii) the impact of divestitures and discontinuations of $1 million, partially offset by an increase in average realized pricing of $29 million, primarily attributable to lower sales deductions. The decrease in volume was primarily attributable to: (i) the impact of generic competition as certain products in our Neurology and Other business, such as Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity and (ii) the postponement of certain surgeries and elective medical procedures in response to the COVID-19 pandemic primarily impacting our Dentistry business.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit for three months ended September 30, 2020 and 2019 was $248 million and $246 million, respectively, an increase of $2 million, or 1%.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_160"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine Months Ended September 30, 2020 Compared to the Nine Months Ended September 30, 2019 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue was $5,814 million and $6,377 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $563 million, or 9%. The decrease was primarily driven by: (i) lower volumes of $495 million primarily in our Bausch + Lomb/International and Diversified Products segments primarily due to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, (ii) higher sales deductions of $183 million primarily in our Salix segment and includes the unfavorable impact of the 2019 favorable returns provision adjustment related to past sales on branded and generic products, (iii) the unfavorable effect of foreign currencies of $51 million primarily in Latin America and Europe and (iv) the impact of divestitures and discontinuations of $15 million. The decreases in our revenues were partially offset by: (i) higher gross selling prices of $168 million primarily in our Salix and Bausch + Lomb/International segments and (ii) the incremental product sales of our Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy of $13 million. </span></div><div style="margin-bottom:0.8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously discussed, our revenues have been negatively impacted by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, the negative trend in the revenues of certain of our businesses began to level off and stabilize prior to our third quarter. Presuming there is no material resurgence of the spread of the COVID-19 virus, we anticipate an ongoing, gradual global recovery from the macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020. We therefore believe that our revenues for the year 2020 will be most impacted by the COVID-19 pandemic in our second quarter, although we experienced some COVID-19 pandemic related declines in the year-over-year revenues in our third quarter, and we expect additional COVID-19 pandemic related declines in the fourth quarter of 2020, in certain of our businesses and geographies. Presuming any reenactment of social restrictions is not significant, we anticipate that our affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits, including the impacts of COVID-19 pandemic related matters for the three and nine months ended September 30, 2020, are discussed in further detail in the respective subsequent sections &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions recorded to reduce gross product sales to net product sales and revenues for the nine months ended September 30, 2020 and 2019 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 39.2% and 38.0% for the nine months ended September 30, 2020 and 2019, respectively, an increase of 1.2 percentage points and includes:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales was lower primarily due to lower discount rates for certain generic products, such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, partially offset by the impact of the release of the generic Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG (December 2019); </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns as a percentage of gross product sales was higher and reflects a lower adjustment in 2020 as compared to 2019 for improving sales return experience. Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products.  Included in the product sales return provisions for the nine months ended September 30, 2020 and 2019 are reductions in variable consideration for sales returns related to past sales of approximately $38&#160;million and $80 million, during the three months ended September 30, 2020 and 2019, respectively. See Note 3, "REVENUE RECOGNITION" to our unaudited interim Consolidated Financial Statements regarding further details related to product sales provisions;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due the impact of: (i) increases in gross product sales for products that carry higher contractual rebates and co-pay assistance programs, including the impact of incremental rebates from contractual price increase limitations for promoted products, such as Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) sales of our Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, and (iii) rebates associated with our Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product launched in June 2019, partially offset by decreases in gross product sales for products which carry higher rebate rates, such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a result of its generic release, Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suspension and Lotemax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gel;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were higher primarily due to the impact of: (i) higher chargeback rates and gross product sales for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Nifediac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) the release of the generic Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG (December 2019).  The higher chargebacks as a percentage of gross product sales were partially offset by the impact of lower gross product sales of: (i) certain generic products, such as Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Ofloxacin and (ii) the branded product Nifedical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were higher due to the impact of: (i) higher sales of a limited number of branded products, such as Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) higher gross product sales and higher distribution service fee rates associated with our Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX and Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  products and (iii) sales of our Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy.  The higher distribution service fees as a percentage of gross product sales were partially offset by the impact of lower gross product sales of certain branded products, such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a result of its generic release.  Price appreciation credits are offset against the distribution service fees we pay wholesalers and were $4 million and $0 for the nine months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $1,565 million and $1,675 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $110 million, or 7%. The decrease was primarily driven by: (i) lower volumes, as previously discussed, (ii) lower third-party royalty costs and (iii) the favorable impact of foreign currencies. The decrease was partially offset by: (i) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic and (ii) changes in product mix.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of product sales revenue was 27.3% and 26.6% for the nine months ended September 30, 2020 and 2019, respectively, an increase of 0.7 percentage points. Costs of goods sold as a percentage of Product sales revenue was unfavorably impacted as a result of: (i) changes in product mix and (ii) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic. These factors were partially offset by lower third-party royalty costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $1,731 million and $1,886 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $155 million, or 8%. The decrease was primarily attributable to: (i) the impacts of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and (ii) </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">profit protection measures taken to manage and reduce operating expenses during the COVID-19 pandemic and resulted in decreases in: (a) advertising and promotion expenses and (b) selling expenses. Also, SG&amp;A expenses for the nine months ended September 30, 2019 included a charge associated with the termination of a certain  co-promotional agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $333 million and $357 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $24 million, or 7%.  R&amp;D expenses as a percentage of Product sales were approximately 6% and 6% for the nine months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, during our second quarter of 2020, certain of our R&amp;D activities were limited and others, including new patient enrollments in clinical trials, were temporarily paused as most trial sites due to government mandated shutdowns were not able to accept new patients. However, during our third quarter of 2020, many of these trial sites began to reopen and we saw the pace of new patient enrollments increasing, getting close to their pre-COVID-19 levels in the U.S.  As of the date of this filing, we have not had to make material changes to our development timelines and the pause in our clinical trials have not had a material impact on our operating results; however, a resurgence of the virus could result in unanticipated delays in our ability to conduct new patient enrollments and create other delays which could have a significant adverse effect on our future operating results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $1,263 million and $1,452 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $189 million, or 13%. The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2020. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Impairments </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments were $17 million and $49 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $32 million. Asset impairments for the nine months ended September 30, 2020 include impairments of: (i) $16&#160;million, in aggregate, due to decreases in forecasted sales of a certain product lines and (ii) $1&#160;million, in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses. Asset impairments for the nine months ended September 30, 2019 include impairments of: (i) $38&#160;million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale and (iii) $3 million, in aggregate, related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements regarding further details related to our intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration and Separation Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration and separation costs were $13 million and $28 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $15 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $12 million and $28 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $16 million. During the nine months ended September 30, 2020 these costs included: (i) $7 million of facility closure costs and (ii) $5 million of severance costs. During the nine months ended September 30, 2019, these costs included: (i) $11 million of severance and other costs associated with the acquisition of certain assets of Synergy, (ii) $9&#160;million of facility closure costs and (iii) $8 million of other severance costs. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Separation, we incurred separation costs of $1&#160;million for the nine months ended September 30, 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, "RESTRUCTURING, INTEGRATION AND SEPARATION COSTS" to our unaudited interim Consolidated Financial Statements for further details regarding these actions. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration was a loss of $26 million for the nine months ended September 30, 2020 and included: (i) accretion for the time value of money of $17 million and (ii) net fair value adjustments of $9 million. Acquisition-related contingent consideration was a loss of $2 million for the nine months ended September 30, 2019, and included accretion for the time value of money of $16 million, partially offset by net fair value adjustments of $14 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6, "FAIR VALUE MEASUREMENTS" to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the nine months ended September 30, 2020 and 2019 consists of the following:</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, Litigation and other matters includes adjustments related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. Litigation and other matters also includes an insurance recovery related to a certain litigation matter. See Note 18, "LEGAL PROCEEDINGS" to our unaudited interim Consolidated Financial Statements for further details regarding this and other litigation matters. For the nine months ended September 30, 2020, Acquired in process research and development costs includes the $10&#160;million upfront payment for the Option to acquire all ophthalmology assets of Allegro, as previously discussed. See Note 4, "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE" to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $1,155 million and $1,221 million and included non-cash amortization and write-offs of debt premiums, discounts and deferred issuance costs of $45 million and $49 million for the nine months ended September 30, 2020 and 2019, respectively. Interest expense decreased $66 million, or 5%, primarily due to: (i) a lower weighted average interest rate, partially offset by higher outstanding principal balances, and (ii) a benefit related to the Company's cross-currency swaps. The weighted average stated rate of interest as of September&#160;30, 2020 and 2019 was 5.94% and 6.39%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, on December 30, 2019, we accessed the credit markets to finance amounts owed under the Company's $1,210 million settlement agreement relating to the U.S. Securities Litigation (which is subject to final court approval). Although that financing increased our outstanding principal balances, it had the effect of extending the payment terms of the pending settlement of $1,210 million out to 2028 and 2030 without negatively impacting our working capital available for operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt represents the differences between the amounts paid to settle extinguished debts and the carrying value of the related extinguished debt. Loss on extinguishment of debt was $51 million and $40 million for the nine months ended September 30, 2020 and 2019, respectively, primarily associated with a series of transactions which allowed us to refinance portions of our debt arrangements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for further details.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other was a loss of $26 million and a gain of $12 million for the nine months ended September 30, 2020 and 2019, respectively, an unfavorable net change of $38 million primarily due to: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes was $133 million and $101 million for the nine months ended September 30, 2020 and 2019, respectively, an increase of $32 million. Our effective income tax rate for the nine months ended September 30, 2020 and 2019 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) the release of a valuation allowance, (b) tax law changes, (c) adjustments for book to income tax return provisions and (d) changes in uncertain tax positions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 16, "INCOME TAXES" to our unaudited interim Consolidated Financial Statements for further details.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_163"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues, and the year-over-year changes in segment revenues for the nine months ended September 30, 2020 and 2019.  The following table also presents segment profits, segment profits as a percentage of segment revenues and the year-over-year changes in segment profits for the nine months ended September 30, 2020 and 2019. </span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.989%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(563)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents organic revenue (non-GAAP) and the year-over-year changes in organic revenue (non-GAAP) for the nine months ended September 30, 2020 and 2019 by segment. Organic revenues (non-GAAP) and organic growth (non-GAAP) rates are defined in the previous section titled &#8220;Reportable Segment Revenues and Profits&#8221;.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.411%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Acquisition</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Divestitures and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb/International Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb/International Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb/International segment revenue was $3,166 million and $3,501 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $335 million, or 10%. The decrease was primarily attributable to: (i) a decrease in volume of $312 million, as discussed below, (ii) the unfavorable effect of foreign currencies of $51 million, primarily in Latin America and Europe and (iii) the impact of divestitures and discontinuations of $14 million. These decreases were partially offset by an increase in average realized pricing of $42 million, primarily driven by our Global Consumer and International Rx businesses.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The volumes of our Bausch + Lomb/International segment were negatively impacted, primarily in Europe, Asia and the U.S., by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed. The postponement of certain surgical and elective medical procedures related to the COVID-19 pandemic, and associated declines in pre- and post-operative prescriptions, negatively impacted the volumes of our Global Ophthalmology and Global Surgical businesses. The reduction in the consumption of contact lenses worldwide due to limited social interactions and in some regions government recommended use of frames, negatively impacted the volumes of our Global Vision Care business. During our first quarter, certain customers engaged in "pantry-loading" which along with stay-at-home orders, negatively impacted the volumes of our Global Consumer business for our second quarter. However, as governments began lifting social restrictions, the negative trend in the revenues of these businesses began to level off and stabilize prior to our third quarter. Presuming there is no material resurgence of the spread of the COVID-19 virus, we anticipate an ongoing, gradual global recovery from the macroeconomic and healthcare impacts of the pandemic that occurred during the first-half of 2020. We therefore believe that our revenues for the year 2020 will be most impacted by the COVID-19 pandemic in our second quarter. Although we experienced additional COVID-19 pandemic related declines in year-over-year revenues in certain geographies during our third quarter, presuming any reenactment of social restrictions is not significant, we anticipate that our affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb/International Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb/International segment profit for the nine months ended September 30, 2020 and 2019 was $830&#160;million and $989 million, respectively, a decrease of $159 million, or 16%. The decrease was primarily driven by the decrease in contribution as a result of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, partially offset by lower SG&amp;A expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line, which accounted for 78% and 70% of the Salix segment product sales and 19% and 17% of the Company's product sales for the nine months ended September 30, 2020 and 2019, respectively. No other single product group represents 10% or more of the Salix segment product sales. The Salix segment revenue for the nine months ended September 30, 2020 and 2019 was $1,377 million and $1,505 million, respectively, a decrease of $128 million, or 9%. The decrease includes: (i) a decrease in average realized pricing of $91 million, primarily attributable to higher sales deductions for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX partially offset by higher gross selling prices for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and (ii) a decrease in volume of $50 million primarily attributable to the decrease in demand for Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to loss of exclusivity. The decrease in revenue was partially offset by sales of our Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy of $13 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit for the nine months ended September 30, 2020 and 2019 was $968 million and $995 million, respectively, a decrease of $27 million, or 3%. The decrease was primarily driven by the decrease in contribution as a result of the decrease in revenue, as previously discussed, partially offset by: (i) decreases in SG&amp;A expenses due to: (a) COVID-19 pandemic related matters, as previously discussed, and (b) a charge associated with the termination of a certain co-promotional agreement during the three months ended September 30, 2019 and (ii) the contribution from the sales of our Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Ortho Dermatologics Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ortho Dermatologics segment revenue for the nine months ended September 30, 2020 and 2019 was $393 million and $407 million, respectively, a decrease of $14 million, or 3%. The decrease was primarily attributable to a decrease in average realized pricing of $20 million partially offset by an increase in volume of $6&#160;million.  The decrease in average realized pricing was the result of higher sales deductions in our medical dermatology products. The increase in volume was primarily due to increased demand of Thermage FLX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was partially offset by the impact of generic competition as certain products, such as Elidel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Zovirax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Solodyn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ortho Dermatologics segment profit for the nine months ended September 30, 2020 and 2019 was $156 million and $156&#160;million, respectively. Segment profit was flat due to the decrease in contribution as a result of the decrease in revenue, as previously discussed, being offset by a decreases in: (i) selling expenses and (ii) R&amp;D expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the Diversified Products segment revenue by product and product revenues as a percentage of segment revenue for the nine months ended September 30, 2020 and 2019.</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellbutrin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ativan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neo/Poly/HC Otic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tobramycin/Dexamethasone</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Franchise </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diastat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pepcid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product revenues </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diversified Products revenues </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue for the nine months ended September 30, 2020 and 2019 was $878 million and $964 million, respectively, a decrease of $86 million, or 9%. The decrease was primarily driven by: (i) a decrease in volume of $139 million and (ii) the impact of divestitures and discontinuations of $1 million. The decrease was partially offset by an increase in average realized pricing of $54 million due to lower sales deductions and higher gross selling prices. The decrease in volume was primarily attributable to: (i) the impact of generic competition as certain products in our Neurology and Other business, such as Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Migranal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Xenazine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity and (ii) the postponement of certain surgeries and elective medical procedures in response to the COVID-19 pandemic primarily impacting our Dentistry business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit for the nine months ended September 30, 2020 and 2019 was $634 million and $714 million, respectively, a decrease of $80 million, or 11% and was primarily driven by the decrease in revenue, as previously discussed.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_166"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.435%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities before changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,791)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(812)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,360)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $717 million and $1,267 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease of $550 million. The decrease was attributable to net decreases in Cash provided by operating activities before changes in operating assets and liabilities and Changes in operating assets and liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities before changes in operating assets and liabilities for the nine months ended September 30, 2020 and 2019 was $1,103 million and $1,379 million, respectively, a decrease in cash of $276 million.  The decrease is primarily attributable to: (i) the negative impacts to our operating results associated with the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, (ii) higher payments of legal settlements in 2020 as compared to 2019 of $78 million and (iii) the upfront payment in September 2020 for the option to acquire all ophthalmology assets of Allegro of $10&#160;million, previously discussed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities resulted in a net decrease in cash of $386 million and $112 million for the nine months ended September 30, 2020 and 2019, respectively, a decrease in cash of $274 million. During the nine months ended September 30, 2020, Changes in operating assets and liabilities was negatively impacted by: (i) the timing of other payments in the ordinary course of business of $345 million and (ii) an increase in inventories of $178 million and was partially offset by: (i) an increase in accrued interest due to timing of payments of $70 million and (ii) the collection of trade receivables of $67 million. During the nine months ended September 30, 2019, Changes in operating assets and liabilities was negatively impacted by: (i) an increase in inventories of $205 million and (ii) the timing of other payments in the ordinary course of business of $132 million and was partially offset by: (i) an increase in accrued interest due to timing of payments of $115 million and (ii) the collection of trade receivables of $110 million. Pursuant to our credit agreements, a greater portion of our cash interest is scheduled for payment in our second and fourth quarters as opposed to our first and third quarters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $177 million for the nine months ended September 30, 2020 and was driven by Purchases of property, plant and equipment of $222 million offset by: (i) Interest settlements from cross-currency swaps of $23 million and (ii) Proceeds from sale of assets and businesses, net of costs to sell of $21 million primarily related to the receipt of a milestone payment associated with a prior year divestiture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $334 million for the nine months ended September 30, 2019 and was driven by: (i) Purchases of property, plant and equipment of $192 million and (ii) Acquisition of businesses, net of cash acquired of $180 million related to the acquisition of certain assets of Synergy. Net cash used in investing activities was partially offset by Proceeds from sale of assets and businesses, net of costs to sell of $44 million, primarily related to the receipt of a milestone payment associated with a prior year divestiture.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $1,791 million for the nine months ended September 30, 2020 and was primarily driven by repayments of long-term debt, net of issuances and related discounts, of $1,686 million. These repayments include $1,240 million of May 2023 Unsecured Notes, which was previously financed as part of the December 2019 Financing and Refinancing Transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $812 million for the nine months ended September 30, 2019 and was primarily driven by repayments of long-term debt, net of issuances and related discounts, of $718 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for additional information regarding the financing activities described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources of Liquidity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for at least the twelve months following the issuance of this Form 10-Q.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance or repurchase existing debt or issue equity or equity-linked securities. We believe our existing cash and cash generated from operations will be sufficient to service our debt obligations through 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of unamortized premiums, discounts and issuance costs was $24,343 million and $25,895 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively.  Aggregate contractual principal amounts due under our debt obligations were $24,601 million and $26,188 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, a decrease of $1,587 million during the nine months ended September 30, 2020. The decrease was primarily driven by net debt repayments previously discussed under "Cash Flows - Financing Activities".</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prepayment and refinancings of debt over the last four years translate into lower repayments of principal over the next four years, which, in turn, we believe will permit more cash flows to be directed toward developing our core assets, identifying new product opportunities and repaying additional debt amounts. The mandatory scheduled principal repayments of our debt obligations as of September&#160;30, 2020, were as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.092%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our unaudited Consolidated Financial Statements and &#8220;Management's Discussion and Analysis - Liquidity and Capital Resources: Long-term Debt&#8221; for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018, and as further amended (the &#8220;Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $1,225 million, which matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. ("BHA") in an aggregate principal amount in excess of $1,000 million (the "2023 Revolving Credit Facility") and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the "November 2025 Term Loan B Facility"), respectively. Both the Company and BHA are borrowers under the 2023 Revolving Credit Facility, borrowings under which may be made in U.S. dollars, Canadian dollars or euros.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Description of Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.15% and 2.90% per annum, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of September 30, 2020, the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities were $680 million through November 1, 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.&#160; As of September 30, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was 3.15% per annum. As of September&#160;30, 2020, the Company had no outstanding borrowings, $107 million of issued and outstanding letters of credit and remaining availability of $1,118 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. On a non-consolidated basis, the non-guarantor subsidiaries had total assets of $2,552 million and total liabilities of $1,036 million as of September&#160;30, 2020, and revenues of $981 million and operating income of $51 million for the nine months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.25% Senior Secured Notes Due February 2029 - May 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $1,500 million aggregate principal amount of 6.25% Senior Unsecured Notes due February 2029 (the "February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250 million of 6.50% Senior Secured Notes due March 2022, (ii) prepay $303&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions").</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the February 2029 Unsecured Notes is payable semi-annually in arrears on each February 15 and August 15. We may redeem some or all of the February 2029 Unsecured Notes at any time on or after February 15, 2024, at the redemption prices set forth in the indenture. In addition, we may redeem some or all of the February 2029 Unsecured Notes prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium. Prior to August 15, 2023, we may redeem up to 40% of the aggregate principal amount of the February 2029 Unsecured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to comply with the covenants under the terms of our Restated Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our Restated Credit Agreement, holders of our Senior Secured </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2017 through the date of this filing, the Company completed several actions which included using cash flows from operations to repay debt and refinancing debt with near-term maturities. These actions have reduced the Company&#8217;s debt balance and positively affected the Company&#8217;s ability to comply with the financial maintenance covenant. As of September&#160;30, 2020, the Company was in compliance with its financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast as adjusted for the potential impacts of the COVID-19 pandemic, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of this Form 10-Q. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity (&#8220;Bausch + Lomb&#8221;) from the remainder of Bausch Health. Management is in the initial phase of planning the Separation and is still assessing the overall capitalization structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weighted Average Interest Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest of the Company's outstanding debt as of September&#160;30, 2020 and December&#160;31, 2019 was 5.94% and 6.21%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, "FINANCING ARRANGEMENTS" to our unaudited interim Consolidated Financial Statements for further details.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Ratings </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November&#160;3, 2020, the credit ratings and outlook from Moody's, Standard &amp; Poor's and Fitch for certain outstanding obligations of the Company were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.316%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rating Agency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Senior Unsecured Rating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Moody&#8217;s&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ba2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stable</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BB</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stable</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Cash Requirements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our cash requirements for the remainder of 2020 are for debt service. Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), restructuring and integration, benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and/or to make strategic acquisitions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our working capital requirements, as of September&#160;30, 2020, we expect our primary cash requirements during the remainder of 2020 to be as follows:</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Debt service</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;We expect to make interest payments of approximately $393 million during the remainder of 2020. In addition, on October 29, 2020, the Company issued an unconditional notice of redemption to redeem: (i) $99&#160;million of May 2023 Unsecured Notes and (ii) $51&#160;million of March 2023 Unsecured Notes, on November 30, 2020. As a result of prepayments and a series of refinancing transactions we have reduced and extended the maturities of a substantial portion of our long-term debt.  We have no debt maturities or mandatory amortization payments due until 2023. We may elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay amounts under our 2023 Revolving Credit Facility to meet business needs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">IT Infrastructure Investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $8&#160;million for licensing, maintenance and other costs associated with our IT infrastructure improvement projects during the remainder of 2020;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $50 million for property, plant and equipment during the remainder of 2020;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make contingent consideration and other approval/sales-based milestone payments of approximately $13&#160;million during the remainder of 2020; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Restructuring, integration and other transaction payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $5&#160;million during the remainder of 2020 for employee separation costs and lease termination obligations associated with restructuring and integration actions and other transactions we have taken through September&#160;30, 2020;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments under our pension and postretirement obligations of approximately $4&#160;million during the remainder of 2020; and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. Securities Litigation Settlement&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully discussed in Note 18, "LEGAL PROCEEDINGS" to our unaudited interim Consolidated Financial Statements, in December 2019, we announced that we had agreed to resolve the U.S. Securities Litigation for $1,210 million, subject to final court approval. Once approved by the court, the settlement will resolve and discharge all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. This settlement, once approved by the court, will resolve the most significant of the Company's remaining legacy legal matters and eliminate a material uncertainty regarding our Company. As of September&#160;30, 2020, Restricted cash includes $1,010 million of payments into an escrow fund under the terms of a settlement agreement regarding the U.S. Securities Litigation. An additional $100 million was paid into this escrow fund during October 2020. On January 27, 2020, the court preliminarily approved the settlement. A final settlement approval hearing was held on May 27, 2020, and the settlement remains subject to final court approval. The balance of the settlement will be paid in accordance with the payment schedule outlined in the settlement agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs of Separation </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, with the goal of unlocking additional Company value, on August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity. The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. The Company has also incurred, and will incur, separation-related costs which are incremental costs indirectly related to the Separation. Separation-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification.  As of the date of this filing, we are in the planning phase of the Separation and future payments for separation costs and separation-related costs cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Cost Savings Programs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate&#160;redundant processes and expenses. These cost savings programs may include, but are not limited to: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of All Ophthalmology Assets of Allegro </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, on September 21, 2020, we announced that we entered into an agreement which provides us an option to acquire all ophthalmology assets of Allegro. Among the assets to be acquired, if the Option is exercised, is the worldwide rights to risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration ("AMD"). A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. Aggregate payments under the Option are up to $50 million and include an upfront payment of $10 million and a second payment of $40&#160;million should Allegro raise additional funding. During the three months ended September 30, 2020, we made and expensed the upfront payment of $10 million as acquired IPR&amp;D. If the Option is exercised, additional payments to acquire all of the ophthalmology assets of Allegro will be due over time. </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Litigation Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings. See Note 18, "LEGAL PROCEEDINGS"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our unaudited interim Consolidated Financial Statements. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Licensing Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. In connection with these agreements, the Company may pay an upfront fee to secure the agreement. See Note 4, "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our unaudited interim Consolidated Financial Statements. Payments associated with the upfront fee for these agreements cannot be reasonably estimated at this time and could be material.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_169"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material effect on our results of operations, financial condition, capital expenditures, liquidity, or capital resources. The following table summarizes our contractual obligations related to our long-term debt, including interest, as of September&#160;30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 and 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 and 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt obligations, including interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the contractual obligations disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Off-Balance Sheet Arrangements and Contractual Obligations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC and the CSA on February&#160;19, 2020.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_172"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUTSTANDING SHARE DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares trade on the New&#160;York Stock Exchange and the Toronto Stock Exchange under the symbol &#8220;BHC&#8221;. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At October 29,&#160;2020, we had 355,151,002 issued and outstanding common shares. In addition, as of October 29,&#160;2020, we had outstanding 9,038,478 stock options and 5,620,525 time-based restricted share units that each represent the right of a holder to receive one of the Company&#8217;s common shares, and 2,266,024 performance-based restricted share units that represent the right of a holder to receive a number of the Company's common shares up to a specified maximum. A maximum of 4,261,273 common shares could be issued upon vesting of the performance-based restricted share units outstanding.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_175"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our Consolidated Financial Statements, and which require management&#8217;s most subjective and complex judgment due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. Management has reassessed the critical accounting policies and estimates as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Critical Accounting Policies and Estimates&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC and the CSA on February&#160;19, 2020, and determined that there were no significant changes in our critical accounting policies and estimates during the nine months ended September 30, 2020, except for: (i) estimates and assumptions regarding the nature, timing and extent that the COVID-19 pandemic will possibly have on the Company's operations and cash flows as discussed in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our unaudited interim Consolidated Financial Statements, (ii) the impact that the COVID-19 pandemic has on the Company&#8217;s assessment of goodwill as discussed in Note 8, "INTANGIBLE ASSETS AND GOODWILL" to our unaudited interim Consolidated Financial Statements and (iii) recently adopted accounting guidance as discussed in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" to our unaudited interim Consolidated Financial Statements.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_178"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Guidance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recently issued accounting guidance is contained in Note 2, "SIGNIFICANT ACCOUNTING POLICIES" of notes to&#160;the unaudited interim Consolidated Financial Statements.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_181"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-Q contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, product development and future performance and results of current and anticipated products; anticipated revenues for our products; anticipated growth in our Ortho Dermatologics business; expected R&amp;D and marketing spend; our expected primary cash and working capital requirements for 2020 and beyond; the Company's plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to meet the financial and other covenants contained in our Fourth Amended and Restated Credit and Guaranty Agreement (the "Restated Credit Agreement"), and senior notes indentures; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income&#160;taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; and the Company&#8217;s plan to separate its eye-health business, including the structure and timing of completing such separation transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the statements in this Form&#160;10-Q that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the rapidly evolving reaction of governments, private sector participants and the public to that pandemic and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed separation of the Company&#8217;s eye-health business, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the separation transaction, the expected timing of completion of the separation transaction and its terms, the Company&#8217;s ability to complete the separation transaction </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considering the various conditions to the completion of the separation transaction (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other conditions are no longer favorable to completing the transaction, that any shareholder, stock exchange, regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the separation transaction, diversion of management time on the separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from either or both of the Canada Revenue Agency and the Internal Revenue Service will be sought or obtained), potential dissynergy costs resulting from the separation transaction, the impact of the separation transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC ("Philidor")), including pending investigations by the U.S. Attorney's Office for the District of Massachusetts and the&#160;U.S. Attorney's Office for the Southern District of New York, the investigation order issued by the Company from the Autorit&#233; des march&#233;s financiers (the &#8220;AMF&#8221;) (the Company&#8217;s principal securities regulator in Canada), a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the recently settled securities class action, (which is subject to final court approval, and remains subject to the risk and uncertainty that the U.S. District Court for the District of New Jersey may not approve the $1,210 million settlement agreement)) and certain opt-out actions in Canada relating to the recently settled class action in Canada (which is subject to court approval) and purported class actions under the federal RICO statute and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing (including the investigations by the&#160;U.S. Attorney's Offices for the District of Massachusetts&#160;and the Southern District of New York), and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s commitment that the average annual price increase for our branded prescription pharmaceutical products will be set at no greater than single digits, or any future pricing actions we may take following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the "FDA") and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to meet the financial and other covenants contained in our Restated Credit Agreement, senior notes indentures, 2023 Revolving Credit Facility and other current or future debt agreements and the limitations, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2023 Revolving Credit Facility and restrictions on our ability to make certain investments and other restricted payments;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or Restated Credit Agreement and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in the filing of any future financial statements or other filings and any default under the terms of our senior notes indentures or Restated Credit Agreement as a result of such delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2020 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in our Restated Credit Agreement and/or senior notes indentures and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, including, but not limited to, our ability to provide the time, resources, expertise and costs required for the commercial launch of new products, the acceptance and demand for new pharmaceutical products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit executives and other key&#160;employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated growth in our Ortho Dermatologics business, including the success of recently launched products (such as Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the ability to successfully implement and operate our new cash-pay prescription program for certain of our Ortho Dermatologics branded products, and the ability of such program to achieve the anticipated goals respecting patient access and fulfillment, the approval of pending and pipeline products (and the timing of such approvals), expected geographic expansion, changes in estimates on market potential for dermatology products and continued investment in and success of our sales force;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our Restated Credit Agreement, senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers ("PBMs") and other third-party payors; the impact our distribution, pricing and other practices (including as it relates to our current relationship with Walgreen Co. ("Walgreens")) may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; and the impact of obtaining or maintaining such reimbursement on the price and sales of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company, including the impact to the Company of our former relationship with Philidor and any alleged legal or contractual non-compliance by Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) and any potential changes to other trade agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the final outcome and impact of Brexit negotiations; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the United States and China;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any additional divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements, including the impact of our arrangements with Walgreens;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreens, including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptance and success of our new cash-pay prescription program for certain of our Ortho Dermatologics branded products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;Health Care Reform Act&#8221;) and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its business and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken following the election of the next administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed on February 19, 2020, risks in Item 1A. &#8220;Risk Factors&#8221; of Part II of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, filed on May 7, 2020, risks in Item 1A. &#8220;Risk Factors&#8221; of Part II of this </span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 10-Q and risks detailed from time to time in our other filings with the SEC and the Canadian Securities Administrators (the&#160;&#8220;CSA&#8221;), as well as our ability to anticipate and manage the risks associated with the&#160;foregoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed on February 19, 2020, under Item&#160;1A. &#8220;Risk Factors&#8221;, in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, filed on May 7, 2020, under Item&#160;1A. &#8220;Risk Factors&#8221; of Part II, under Item&#160;1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q and in the Company&#8217;s other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_184"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;Quantitative and&#160;Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as indicated below under &#8220;&#8212; Interest Rate Risk&#8221;, and under 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q, there have been no material changes to our exposures to market risks as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Quantitative and Qualitative Disclosures About Market Risks&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC and the CSA on February&#160;19, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we had $18,145&#160;million and $4,698&#160;million principal amount of issued fixed rate debt and variable rate debt, respectively, that requires U.S. dollar repayment, as well as &#8364;1,500 million principal amount of issued fixed rate debt that requires repayment in euros. The estimated fair value of our issued fixed rate debt as of September&#160;30, 2020, including the foreign currency-denominated debt, was $20,667&#160;million. If interest rates were to increase by 100 basis-points, the fair value of our issued fixed rate debt would decrease by approximately $569&#160;million. If interest rates were to decrease by 100 basis-points, the fair value of our issued fixed rate debt would increase by approximately $396&#160;million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-points increase in interest rates, based on 3-month LIBOR, would have an annualized pre-tax effect of approximately $47&#160;million in our Consolidated Statements of Operations and Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value. </span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_187"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Controls and&#160;Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), has evaluated the effectiveness of our disclosure controls and procedures as of September&#160;30, 2020. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of September&#160;30, 2020. </span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_190"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in the Company's internal controls over financial reporting that occurred during the three months ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_193"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_196"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information concerning legal proceedings, reference is made to Note 18, "LEGAL PROCEEDINGS" of notes to&#160;the unaudited interim Consolidated Financial Statements included elsewhere in this Form&#160;10-Q.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_199"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as set forth below, there have been no material changes to the risk factors as disclosed in Item 1A. &#8220;Risk Factors&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC and the CSA on February&#160;19, 2020, as supplemented by risk factors disclosed in Item 1A. &#8220;Risk Factors&#8221; of Part II of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC and CSA on May 7, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risk Relating to the Separation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our plan to separate our eye-health business into an independent publicly traded entity from the remainder of the Company is subject to various risks and uncertainties and may not be completed in accordance with the expected plans or anticipated timeline, or at all, and will involve significant time, expense, and distraction, which could disrupt or have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced that we intend to separate our eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;Separation&#8221;). The Separation will establish two separate companies that include: (i) a fully integrated eye-health company which will consist of our Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Rx businesses and (ii) a diversified pharmaceutical company which will include our Salix, International Rx, Solta, neurology and medical dermatology pharmaceutical businesses. The anticipated Separation is subject to regulatory approvals and certain conditions, including final approval by the Company&#8217;s Board of Directors, any shareholder vote requirements that may be applicable, compliance with (including completion of all necessary filings required by) U.S. and Canadian securities laws and stock exchange rules, receipt of any applicable opinions and/or rulings with respect to the Canadian and U.S. federal income tax treatment of the Separation and determination of the pro forma capitalizations of the two separate companies.  The failure to satisfy all of the required conditions could delay the completion of the Separation for a significant period of time or prevent it from occurring at all.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unanticipated developments, including changes in market conditions, possible delays in obtaining any necessary shareholder, stock exchange, regulatory or other approval or the failure to obtain any such approvals, possible delays in obtaining any required tax opinions or rulings or the failure to obtain any such tax opinions or rulings, negotiating challenges, the uncertainty of the financial markets, changes in the law, and other challenges in executing the Separation, could delay or prevent the completion of the Separation, or cause the Separation to occur on terms or conditions that are different or less favorable than expected. Any changes to the Separation or delay in completing the Separation could cause us not to realize some or all of the expected benefits, or realize them on a different timeline than expected. Further, our Board of Directors could decide, either because of a failure of conditions or because of market or other factors, to abandon the Separation. No assurance can be given as to whether and when the Separation will occur or whether the Separation will achieve the benefits we expect. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executing the Separation will require significant resources, time and attention from our senior management and employees, which could cause distractions and divert attention and resources away from other projects and the day-to-day operation of our business. We may also experience increased difficulties in attracting, retaining, and motivating management and employees during the pendency of the Separation and following its completion. The Separation, whether or not completed, may also have an adverse impact on our relationships with our customers, suppliers and other business counterparties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have already incurred expenses in connection with the Separation, and expect that the process of completing the Separation will be time-consuming and involve significant additional costs and expenses, which may not yield a discernible benefit if the Separation is not completed. In addition, if the Separation is not completed, we will still be required to pay certain costs and expenses incurred in connection therewith, such as legal, accounting, and other professional and advisory fees. Furthermore, the Separation, if completed, may result in potential dissynergy costs, which may be greater than we anticipate and/or may be significant. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above factors could cause the Separation (or the failure to consummate the Separation) to have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares and/or debt securities to decline.</span></div><div><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_202"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of equity securities by the Company during the three months ended September 30, 2020.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_205"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_208"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_211"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Officer Severance Arrangement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Talent and Compensation Committee of the Board of Directors approved an update effective January 1, 2021 to the cash severance payment for which our Executive Officers are eligible, excluding our Chairman and CEO whose employment agreement remains unchanged. In connection with a qualifying termination of employment, the cash severance payment for which they are eligible will be equal to one and a half times the sum of annual base salary and annual target incentive.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other terms and conditions under each Executive Officer&#8217;s employment agreement remain unchanged. This provision was approved effective through December 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Separation Bonus Opportunity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Talent and Compensation Committee of the Board of Directors approved a performance-based Separation bonus program for a limited number of key senior leaders.  For any payment to be made, this program requires the achievement of pre-determined milestones related to the recently announced Separation transaction.  The aggregate target opportunity for eligible executive officers is $3,000,000.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment will be made in cash, with 50% conditioned upon the successful operational separation of the two companies and the remaining 50% conditioned upon the successful close of the Separation transaction. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any payment not made prior to a participant&#8217;s termination of employment, except in limited circumstances, will be forfeited. </span></div><div id="ie8b2716e216c4586bfedb14835ff92cc_214"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;Exhibits </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q32020.htm">31.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q32020.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q32020.htm">31.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q32020.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q32020.htm">32.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q32020.htm">Certificate of the Chief Executive Officer of Bausch Health Companies&#160;Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q32020.htm">32.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q32020.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*     Filed herewith.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_217"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Health Companies&#160;Inc.</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JOSEPH C. PAPA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa<br/>Chief Executive Officer<br/>(Principal Executive Officer and Chairman of the Board)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ PAUL S. HERENDEEN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul S. Herendeen<br/>Executive Vice President and <br/>Chief Financial Officer <br/>(Principal Financial Officer)</span></td></tr></table></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="ie8b2716e216c4586bfedb14835ff92cc_220"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:36.00pt 54.00pt 36.00pt 54.00pt"><div style="-sec-extract:summary;margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q32020.htm">31.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q32020.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q32020.htm">31.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q32020.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q32020.htm">32.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q32020.htm">Certificate of the Chief Executive Officer of Bausch Health Companies&#160;Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q32020.htm">32.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q32020.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">*     Filed herewith.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311q32020.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i29941eff247a4f9f8a493d2237a6ab4e_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph C. Papa, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br><br>&#47;s&#47; JOSEPH C. PAPA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312q32020.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ibb1895016d7748c3b3ad53791d5ffa2c_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul S. Herendeen, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br><br>&#47;s&#47; PAUL S. HERENDEEN</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul S. Herendeen</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321q32020.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie2dafb29d6324033b7c54bef2b5c366e_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph C. Papa, Chairman of the Board and Chief Executive Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended September&#160;30, 2020 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br><br>&#47;s&#47; JOSEPH C. PAPA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322q32020.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i453719df1f1e4bfca2ed713b372c833f_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul S. Herendeen, Executive Vice-President and Chief Financial Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended September&#160;30, 2020 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br><br>&#47;s&#47; PAUL S. HERENDEEN</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paul S. Herendeen</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>bhc-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:52525664-5cd4-4495-a34d-b14e0c25a97b,g:cfe4b6e8-8eeb-4675-b5cb-546679211f6a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhc="http://www.bauschhealth.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bauschhealth.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails">
        <link:definition>2402401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>2405402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION">
        <link:definition>2106103 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONTables" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables">
        <link:definition>2307301 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails">
        <link:definition>2408403 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONVariableConsiderationProvisionsDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
        <link:definition>2409404 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails">
        <link:definition>2410405 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE" roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE">
        <link:definition>2111104 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables" roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables">
        <link:definition>2312302 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails">
        <link:definition>2413406 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2414407 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS">
        <link:definition>2115105 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails">
        <link:definition>2416408 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS">
        <link:definition>2117106 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables">
        <link:definition>2318303 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2419409 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
        <link:definition>2420410 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
        <link:definition>2421411 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
        <link:definition>2422412 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
        <link:definition>2423413 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
        <link:definition>2424414 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails">
        <link:definition>2425415 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
        <link:definition>2426416 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.bauschhealth.com/role/INVENTORIES">
        <link:definition>2127107 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.bauschhealth.com/role/INVENTORIESTables">
        <link:definition>2328304 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESComponentsofInventoriesDetails" roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails">
        <link:definition>2429417 - Disclosure - INVENTORIES - Components of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILL" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL">
        <link:definition>2130108 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLTables" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables">
        <link:definition>2331305 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
        <link:definition>2432418 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
        <link:definition>2433419 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails">
        <link:definition>2434420 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
        <link:definition>2435421 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIES" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES">
        <link:definition>2136109 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables">
        <link:definition>2337306 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>2438422 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTS" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS">
        <link:definition>2139110 - Disclosure - FINANCING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSTables" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables">
        <link:definition>2340307 - Disclosure - FINANCING ARRANGEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
        <link:definition>2441423 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCovenantComplianceDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails">
        <link:definition>2442424 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
        <link:definition>2443425 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
        <link:definition>2444426 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
        <link:definition>2445427 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
        <link:definition>2446428 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails">
        <link:definition>2447429 - Disclosure - FINANCING ARRANGEMENTS - Maturities and Mandatory Payments, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails">
        <link:definition>2448430 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS">
        <link:definition>2149111 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables">
        <link:definition>2350308 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>2451431 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>2152112 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>2353309 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2454432 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>2455433 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
        <link:definition>2456434 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>2157113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>2358310 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails">
        <link:definition>2459435 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails">
        <link:definition>2460436 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENT" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT">
        <link:definition>2161114 - Disclosure - RESEARCH AND DEVELOPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTTables" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables">
        <link:definition>2362311 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails">
        <link:definition>2463437 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENET" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET">
        <link:definition>2164115 - Disclosure - OTHER EXPENSE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETTables" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables">
        <link:definition>2365312 - Disclosure - OTHER EXPENSE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETSummaryofOtherExpenseNetDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails">
        <link:definition>2466438 - Disclosure - OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bauschhealth.com/role/INCOMETAXES">
        <link:definition>2167116 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2468439 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>2169117 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>2370313 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails">
        <link:definition>2471440 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARENarrativeDetails" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails">
        <link:definition>2472441 - Disclosure - EARNINGS (LOSS) PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGS" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS">
        <link:definition>2173118 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails">
        <link:definition>2474442 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
        <link:definition>2475443 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSAntitrustDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails">
        <link:definition>2476444 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSProductLiabilityDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails">
        <link:definition>2477445 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSGeneralCivilActionsDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails">
        <link:definition>2478446 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSCompletedorDormantMattersDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails">
        <link:definition>2479447 - Disclosure - LEGAL PROCEEDINGS - Completed or Dormant Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION">
        <link:definition>2180119 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables">
        <link:definition>2381314 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
        <link:definition>2482448 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONDisaggregationofRevenueDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails">
        <link:definition>2483449 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2484450 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
        <link:definition>2485451 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONMajorCustomersDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails">
        <link:definition>2486452 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bhc_OrthoDermatologicsSegmentMember" abstract="true" name="OrthoDermatologicsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_LitigationwithFormerSalixCEOMember" abstract="true" name="LitigationwithFormerSalixCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_GenericPricingAntitrustLitigationMember" abstract="true" name="GenericPricingAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_GoodwillReclassifiedDuringPeriod" abstract="false" name="GoodwillReclassifiedDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AssetAcquisitionDomain" abstract="true" name="AssetAcquisitionDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes5875DueMay2023Member" abstract="true" name="SeniorNotes5875DueMay2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseQualityAssurance" abstract="false" name="ResearchAndDevelopmentExpenseQualityAssurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bhc_RICOClassActionsMember" abstract="true" name="RICOClassActionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_DiscontinuedProductLinesMember" abstract="true" name="DiscontinuedProductLinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" abstract="false" name="AccountsReceivableAllowanceForForeignExchangeAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PlaintiffsDirectPurchasersMember" abstract="true" name="PlaintiffsDirectPurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_PharmaceuticalProductsMember" abstract="true" name="PharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" abstract="false" name="DebtInstrumentCovenantAmountAvailableForRestrictedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes550DueMarch2023Member" abstract="true" name="SeniorNotes550DueMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes925DueApril2026Member" abstract="true" name="SeniorNotes925DueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" abstract="false" name="AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DeviceProductsMember" abstract="true" name="DeviceProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_AssetAcquisitionAxis" abstract="true" name="AssetAcquisitionAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_DebtInstrumentAnnualAmortizationRatePercentage" abstract="false" name="DebtInstrumentAnnualAmortizationRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bhc_TSRPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="TSRPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" abstract="false" name="SummaryOfValuationAndQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccretionForTimeValueOfMoneyMember" abstract="true" name="AccretionForTimeValueOfMoneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" abstract="false" name="DebtInstrumentRedemptionPricePercentageChangeinControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfInsurancePolicyPeriods" abstract="false" name="LossContingencyNumberOfInsurancePolicyPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PotentialAssetAcquisitionAggregatePurchasePrice" abstract="false" name="PotentialAssetAcquisitionAggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes525DueJanuary2030Member" abstract="true" name="SeniorNotes525DueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ReserveForDiscountsAndAllowancesMember" abstract="true" name="ReserveForDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes700DueJanuary2028Member" abstract="true" name="SeniorNotes700DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" abstract="false" name="SummaryOfResearchAndDevelopmentExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice" abstract="false" name="PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DerivativeGainExcludedComponent" abstract="false" name="DerivativeGainExcludedComponent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" abstract="false" name="DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilityMember" abstract="true" name="SeniorSecuredCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes900DueDecember2025Member" abstract="true" name="SeniorNotes900DueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" abstract="false" name="BusinessAcquisitionContingentConsiderationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice" abstract="false" name="PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SalixSegmentMember" abstract="true" name="SalixSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" abstract="true" name="TermLoanBFacilityDueJune2025AndNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseProductRelated" abstract="false" name="ResearchAndDevelopmentExpenseProductRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" abstract="true" name="SeniorSecuredNotes7.00PercentDueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_OtherMiscellaneousNonoperatingIncomeExpense" abstract="false" name="OtherMiscellaneousNonoperatingIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember" abstract="true" name="InvestigationbytheStateofTexasStatesMedicaidProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_NonemployeeDirectorMember" abstract="true" name="NonemployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" abstract="false" name="BusinessAcquisitionProFormaOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TimeBasedRSUMember" abstract="true" name="TimeBasedRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueJune2023Member" abstract="true" name="RevolvingCreditFacilityDueJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueJanuary2028Member" abstract="true" name="SeniorNotes500DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DoctorsAllergyFormulaLLCLitigationMember" abstract="true" name="DoctorsAllergyFormulaLLCLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ReserveForChargebacksMember" abstract="true" name="ReserveForChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ValeantUSSecuritiesLitigationMember" abstract="true" name="ValeantUSSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeparationCostsMember" abstract="true" name="SeparationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_DisposalGroupNumberOfProductsForDisposal" abstract="false" name="DisposalGroupNumberOfProductsForDisposal" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_OrthoDermatologicsReportUnitMember" abstract="true" name="OrthoDermatologicsReportUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_UnitedStatesandPuertoRicoMember" abstract="true" name="UnitedStatesandPuertoRicoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_AccruedProductRebateCurrent" abstract="false" name="AccruedProductRebateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" abstract="true" name="SeniorSecuredNotes6.50PercentDueMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" abstract="false" name="LossContingencyNewClaimsFiledButNotYetServedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025Member" abstract="true" name="TermLoanBFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes850DueJanuary2027Member" abstract="true" name="SeniorNotes850DueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" abstract="false" name="AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecured5.50NotesDueNovember2025Member" abstract="true" name="SeniorSecured5.50NotesDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_AllegroOphthalmicsLLCMember" abstract="true" name="AllegroOphthalmicsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_DerivativeLawsuitsMember" abstract="true" name="DerivativeLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_AccruedProductReturnCurrent" abstract="false" name="AccruedProductReturnCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BaseRateOrPrimeRateMember" abstract="true" name="BaseRateOrPrimeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" abstract="false" name="BusinessCombinationContingentConsiderationNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes725DueMay2029Member" abstract="true" name="SeniorNotes725DueMay2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" abstract="false" name="AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="bhc_BrandedandOtherGenericProductsMember" abstract="true" name="BrandedandOtherGenericProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014Member" abstract="true" name="OmnibusIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantComplianceSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_ProductBrandsMember" abstract="true" name="ProductBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesAdvertisingCreditsPortionMember" abstract="true" name="ReserveForRebatesAdvertisingCreditsPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ReserveForCustomerReturnsMember" abstract="true" name="ReserveForCustomerReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.75NotesDueAugust2027Member" abstract="true" name="SeniorSecured5.75NotesDueAugust2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_MeasurementInputWeightedAverageDiscountRateMember" abstract="true" name="MeasurementInputWeightedAverageDiscountRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_InsuranceCoverageLawsuitMember" abstract="true" name="InsuranceCoverageLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfHealthPlansFiledLawsuits" abstract="false" name="LossContingencyNumberOfHealthPlansFiledLawsuits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_PaymentOfAccretedInterestOnContingentConsideration" abstract="false" name="PaymentOfAccretedInterestOnContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DiversifiedProductsSegmentMember" abstract="true" name="DiversifiedProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_DeferredIncomeTaxNoncashExpenseBenefit" abstract="false" name="DeferredIncomeTaxNoncashExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bhc_SeniorNotes450DueMay2023Member" abstract="true" name="SeniorNotes450DueMay2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SECInvestigationLitigationMember" abstract="true" name="SECInvestigationLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes5.625PercentDueDecember2021Member" abstract="true" name="SeniorNotes5.625PercentDueDecember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_RestructuringAndIntegrationCostsMember" abstract="true" name="RestructuringAndIntegrationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" abstract="true" name="SeniorSecuredNotesAndSeniorUnsecuredNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ShowertoShowerProductLiabilityLitigationMember" abstract="true" name="ShowertoShowerProductLiabilityLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" abstract="true" name="ViolationofCanadianProvincialSecuritiesLegislationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_GainLossRelatedToLitigationSettlementGross" abstract="false" name="GainLossRelatedToLitigationSettlementGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_InterestSettlementOnCrossCurrencySwaps" abstract="false" name="InterestSettlementOnCrossCurrencySwaps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_HighlyLiquidInvestmentsMaturityPeriod" abstract="false" name="HighlyLiquidInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" abstract="false" name="UnrecognizedTaxBenefitsIncludingInterestAndPenalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SynergyPharmaceuticalsInc.Member" abstract="true" name="SynergyPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ReserveForDistributionFeesMember" abstract="true" name="ReserveForDistributionFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes625DueFebruary2029Member" abstract="true" name="SeniorNotes625DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_BaushandLombInternationalSegmentMember" abstract="true" name="BaushandLombInternationalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_OutLicensedTechnologyMember" abstract="true" name="OutLicensedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="ROTCPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" abstract="false" name="DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" abstract="false" name="LossContingencyNumberOfAllegedStockholdersFiledLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ReserveForRebatesMember" abstract="true" name="ReserveForRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationMember" abstract="true" name="GlumetzaAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" abstract="true" name="CertainProductsForDisposalSeptemberTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_AllowancesForLossesOnAccountsReceivableAndInventories" abstract="false" name="AllowancesForLossesOnAccountsReceivableAndInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" abstract="true" name="FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_PartnerRelationshipsMember" abstract="true" name="PartnerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" abstract="true" name="GlumetzaAntitrustLitigationNonClassComplaintsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" abstract="false" name="BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OvertheCounterProductsMember" abstract="true" name="OvertheCounterProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" abstract="false" name="LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_PaymentForDebtAmortizationPrepaymentCost" abstract="false" name="PaymentForDebtAmortizationPrepaymentCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueNovember2025Member" abstract="true" name="TermLoanBFacilityDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_RevenuesNetMember" abstract="true" name="RevenuesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_SeniorNotes6125DueApril2025Member" abstract="true" name="SeniorNotes6125DueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_AcquiredInProcessResearchAndDevelopmentMember" abstract="true" name="AcquiredInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_CanadaBankersAcceptanceRateMember" abstract="true" name="CanadaBankersAcceptanceRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_BauschLombInternationalMember" abstract="true" name="BauschLombInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_Legalsettlementsandrelatedfees" abstract="false" name="Legalsettlementsandrelatedfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PriceAppreciationCreditMember" abstract="true" name="PriceAppreciationCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestLongTermGrowthRate" abstract="false" name="ReportingUnitImpairmentTestLongTermGrowthRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>bhc-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:52525664-5cd4-4495-a34d-b14e0c25a97b,g:cfe4b6e8-8eeb-4675-b5cb-546679211f6a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="bhc-20200930.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25485daf-5bb8-4491-94aa-9c0827bf3cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a65af950-29ee-426e-9406-41bdbc423cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25485daf-5bb8-4491-94aa-9c0827bf3cde" xlink:to="loc_us-gaap_CommonStockValue_a65af950-29ee-426e-9406-41bdbc423cb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ded35a9a-7385-4643-9622-3522c46ff96a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25485daf-5bb8-4491-94aa-9c0827bf3cde" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ded35a9a-7385-4643-9622-3522c46ff96a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5a765bd4-2ae4-469e-bedc-9dfff6917059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25485daf-5bb8-4491-94aa-9c0827bf3cde" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5a765bd4-2ae4-469e-bedc-9dfff6917059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2a1c9aa2-22b6-49a7-818b-df4777e0a658" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_25485daf-5bb8-4491-94aa-9c0827bf3cde" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2a1c9aa2-22b6-49a7-818b-df4777e0a658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b536342e-d340-48cc-9361-657780f74747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5de51b60-0839-4c80-8ef7-39ec60a6671c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b536342e-d340-48cc-9361-657780f74747" xlink:to="loc_us-gaap_StockholdersEquity_5de51b60-0839-4c80-8ef7-39ec60a6671c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_33044cf8-2453-4d81-a910-ae905712c309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b536342e-d340-48cc-9361-657780f74747" xlink:to="loc_us-gaap_MinorityInterest_33044cf8-2453-4d81-a910-ae905712c309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2d8f990a-61cc-44dd-9127-76d2808268a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65b4806d-96f7-44a9-86b2-fe1f395f36da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2d8f990a-61cc-44dd-9127-76d2808268a4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65b4806d-96f7-44a9-86b2-fe1f395f36da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_654e6453-9170-4538-9ba1-2f17e0b6de92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2d8f990a-61cc-44dd-9127-76d2808268a4" xlink:to="loc_us-gaap_RestrictedCashCurrent_654e6453-9170-4538-9ba1-2f17e0b6de92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_91a06233-deca-46ef-b98b-1a8388fd27b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2d8f990a-61cc-44dd-9127-76d2808268a4" xlink:to="loc_us-gaap_ReceivablesNetCurrent_91a06233-deca-46ef-b98b-1a8388fd27b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8df2c2e9-28b9-48fd-a59e-04ac5f16d65b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2d8f990a-61cc-44dd-9127-76d2808268a4" xlink:to="loc_us-gaap_InventoryNet_8df2c2e9-28b9-48fd-a59e-04ac5f16d65b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ac7ff2e-2903-4de0-a553-35c7ea3510f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2d8f990a-61cc-44dd-9127-76d2808268a4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ac7ff2e-2903-4de0-a553-35c7ea3510f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9236fbe1-1f7f-4eff-a881-3b0cd5b9a5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c7ab3c84-897b-452e-9946-2e2ce782b2fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9236fbe1-1f7f-4eff-a881-3b0cd5b9a5c4" xlink:to="loc_us-gaap_AssetsCurrent_c7ab3c84-897b-452e-9946-2e2ce782b2fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e92d5bd9-0de7-4020-b738-927c5fbced95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9236fbe1-1f7f-4eff-a881-3b0cd5b9a5c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e92d5bd9-0de7-4020-b738-927c5fbced95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2673367a-6e31-48df-ae9c-8cebd2ca6de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9236fbe1-1f7f-4eff-a881-3b0cd5b9a5c4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2673367a-6e31-48df-ae9c-8cebd2ca6de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eda0aba3-7a6d-49a3-90ee-00bfa9511f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9236fbe1-1f7f-4eff-a881-3b0cd5b9a5c4" xlink:to="loc_us-gaap_Goodwill_eda0aba3-7a6d-49a3-90ee-00bfa9511f4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_88d18f0b-c639-4636-9da4-e40014199b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9236fbe1-1f7f-4eff-a881-3b0cd5b9a5c4" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_88d18f0b-c639-4636-9da4-e40014199b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_55257264-27db-4457-b3b9-592a0b252100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9236fbe1-1f7f-4eff-a881-3b0cd5b9a5c4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_55257264-27db-4457-b3b9-592a0b252100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9a3ecbe7-e7a9-4943-869f-939d7151238a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3b51a495-7290-41a4-b3ec-8a929562f643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a3ecbe7-e7a9-4943-869f-939d7151238a" xlink:to="loc_us-gaap_AccountsPayableCurrent_3b51a495-7290-41a4-b3ec-8a929562f643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0e480443-0a27-4939-8618-cbe5cdb03fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a3ecbe7-e7a9-4943-869f-939d7151238a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0e480443-0a27-4939-8618-cbe5cdb03fba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f131aec1-5a37-4f87-a9b2-ffb03443e47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9a3ecbe7-e7a9-4943-869f-939d7151238a" xlink:to="loc_us-gaap_LongTermDebtCurrent_f131aec1-5a37-4f87-a9b2-ffb03443e47b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a08ce61e-f641-44bd-bedf-49b8a62f83c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e911706a-945c-4347-8ecd-fb7d96f835d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a08ce61e-f641-44bd-bedf-49b8a62f83c4" xlink:to="loc_us-gaap_Liabilities_e911706a-945c-4347-8ecd-fb7d96f835d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_839c4431-dbc5-40da-a5e0-bf94fa474027" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a08ce61e-f641-44bd-bedf-49b8a62f83c4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_839c4431-dbc5-40da-a5e0-bf94fa474027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_78715ce9-9f2f-49fd-820c-d9a6168309c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a08ce61e-f641-44bd-bedf-49b8a62f83c4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_78715ce9-9f2f-49fd-820c-d9a6168309c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8bb25424-76a1-41d9-b6b8-3ead62661b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a94d5e48-0f9c-4537-979e-42de31912371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8bb25424-76a1-41d9-b6b8-3ead62661b78" xlink:to="loc_us-gaap_LiabilitiesCurrent_a94d5e48-0f9c-4537-979e-42de31912371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_34b986e0-3191-4c7b-bb76-7a1af97f121e" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8bb25424-76a1-41d9-b6b8-3ead62661b78" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_34b986e0-3191-4c7b-bb76-7a1af97f121e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_deb8f498-466e-4337-a2e8-8b68b6a197bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8bb25424-76a1-41d9-b6b8-3ead62661b78" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_deb8f498-466e-4337-a2e8-8b68b6a197bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_294d1a99-1406-49bf-b28e-18486c124982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8bb25424-76a1-41d9-b6b8-3ead62661b78" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_294d1a99-1406-49bf-b28e-18486c124982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e07230e2-18fb-4b8f-a5fa-976b7e80b4e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8bb25424-76a1-41d9-b6b8-3ead62661b78" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e07230e2-18fb-4b8f-a5fa-976b7e80b4e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5d1ea137-b665-436b-99ff-884ee18ec333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2a11e78e-a8d0-4f45-8b07-dfbf33dd07f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d1ea137-b665-436b-99ff-884ee18ec333" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2a11e78e-a8d0-4f45-8b07-dfbf33dd07f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8de8dee9-a0ca-46b3-8111-427799c64dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d1ea137-b665-436b-99ff-884ee18ec333" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8de8dee9-a0ca-46b3-8111-427799c64dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_3899b554-817c-4697-a53d-26ba380b18cf" xlink:href="bhc-20200930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d1ea137-b665-436b-99ff-884ee18ec333" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_3899b554-817c-4697-a53d-26ba380b18cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_bff9e2c6-d9cb-4a40-a2b8-3ca09b43186b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d1ea137-b665-436b-99ff-884ee18ec333" xlink:to="loc_us-gaap_AssetImpairmentCharges_bff9e2c6-d9cb-4a40-a2b8-3ca09b43186b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_2e204b50-44d2-4d2f-9ad9-668cddf33eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d1ea137-b665-436b-99ff-884ee18ec333" xlink:to="loc_us-gaap_RestructuringCharges_2e204b50-44d2-4d2f-9ad9-668cddf33eb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_76e1710f-cebb-441c-a696-ddc754ec8f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d1ea137-b665-436b-99ff-884ee18ec333" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_76e1710f-cebb-441c-a696-ddc754ec8f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_12fb1cd8-2d28-4034-962f-b4421d2b0e9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d1ea137-b665-436b-99ff-884ee18ec333" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_12fb1cd8-2d28-4034-962f-b4421d2b0e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6be647aa-5d66-4ebf-b7d0-890b65ebc546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5d1ea137-b665-436b-99ff-884ee18ec333" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6be647aa-5d66-4ebf-b7d0-890b65ebc546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aca2ef40-9bcc-49b4-83b2-9e44c8f033c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d994981d-59ad-46bc-b188-7b21bb4b153b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aca2ef40-9bcc-49b4-83b2-9e44c8f033c9" xlink:to="loc_us-gaap_OperatingIncomeLoss_d994981d-59ad-46bc-b188-7b21bb4b153b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cd434407-6b5d-420c-a76f-6d727828cd30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aca2ef40-9bcc-49b4-83b2-9e44c8f033c9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cd434407-6b5d-420c-a76f-6d727828cd30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_4077a89d-2711-480b-9e7a-7b348a16b3b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aca2ef40-9bcc-49b4-83b2-9e44c8f033c9" xlink:to="loc_us-gaap_InterestExpenseDebt_4077a89d-2711-480b-9e7a-7b348a16b3b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1a9cf4b4-2225-4832-9e05-c943230213bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aca2ef40-9bcc-49b4-83b2-9e44c8f033c9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1a9cf4b4-2225-4832-9e05-c943230213bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f09de32d-6907-4c6d-9ac8-24982f81862a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_aca2ef40-9bcc-49b4-83b2-9e44c8f033c9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f09de32d-6907-4c6d-9ac8-24982f81862a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5c0d58e0-9fef-4744-a64b-3f2ef4795f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a7df7597-427b-4f29-a692-2b4b32cffc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5c0d58e0-9fef-4744-a64b-3f2ef4795f18" xlink:to="loc_us-gaap_ProfitLoss_a7df7597-427b-4f29-a692-2b4b32cffc1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d50fb5bf-f5ac-4bbe-ac75-afdb98a1fced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5c0d58e0-9fef-4744-a64b-3f2ef4795f18" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d50fb5bf-f5ac-4bbe-ac75-afdb98a1fced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_44876a93-c76c-46d7-b1a1-cdb6f7f41be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d16bb94d-0d54-4504-ae9e-27021dce54c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_44876a93-c76c-46d7-b1a1-cdb6f7f41be2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d16bb94d-0d54-4504-ae9e-27021dce54c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0cba60af-c6f9-4922-a219-90ad4bbc2b9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_44876a93-c76c-46d7-b1a1-cdb6f7f41be2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0cba60af-c6f9-4922-a219-90ad4bbc2b9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a0312db7-824e-4fcf-9de7-ee3c61d5458a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3447adf2-30db-40cc-a098-e6fa30028e01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a0312db7-824e-4fcf-9de7-ee3c61d5458a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3447adf2-30db-40cc-a098-e6fa30028e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_79f10044-71c2-4bd3-860e-ffbf8c59e3a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a0312db7-824e-4fcf-9de7-ee3c61d5458a" xlink:to="loc_us-gaap_CostsAndExpenses_79f10044-71c2-4bd3-860e-ffbf8c59e3a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6a9ad5c0-0bb7-4176-a053-a2e1f5e29e1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0c8a5cd7-a3bd-48ca-9995-9af44ae8c3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6a9ad5c0-0bb7-4176-a053-a2e1f5e29e1a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0c8a5cd7-a3bd-48ca-9995-9af44ae8c3cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_f0068477-966c-4af5-b8d4-84a3c2939af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6a9ad5c0-0bb7-4176-a053-a2e1f5e29e1a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_f0068477-966c-4af5-b8d4-84a3c2939af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e2621f0-3448-4e7b-8550-5f9092a0dbe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9e2f8001-ef5b-4628-90f2-abe98810991d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e2621f0-3448-4e7b-8550-5f9092a0dbe4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9e2f8001-ef5b-4628-90f2-abe98810991d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_963f7990-0beb-4eb4-8132-75ed4be1b69c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9e2621f0-3448-4e7b-8550-5f9092a0dbe4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_963f7990-0beb-4eb4-8132-75ed4be1b69c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9da1754e-9b55-497f-b519-5b9ffdf3faa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_51a2b88c-6e4d-403a-8092-f068cecb963b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9da1754e-9b55-497f-b519-5b9ffdf3faa0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_51a2b88c-6e4d-403a-8092-f068cecb963b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ad0f130e-f3ee-4c29-b5ad-bbd167089300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9da1754e-9b55-497f-b519-5b9ffdf3faa0" xlink:to="loc_us-gaap_ProfitLoss_ad0f130e-f3ee-4c29-b5ad-bbd167089300" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecadc33a-e8be-4025-8847-14c19c969067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cf97ee28-4a90-4f73-80c4-b997ea821f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecadc33a-e8be-4025-8847-14c19c969067" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cf97ee28-4a90-4f73-80c4-b997ea821f83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_cb7f77a2-6cc6-4d08-bd98-f699441c658d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecadc33a-e8be-4025-8847-14c19c969067" xlink:to="loc_us-gaap_RestrictedCashCurrent_cb7f77a2-6cc6-4d08-bd98-f699441c658d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d121d24b-f471-47e5-b6cc-297911ff3468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_689fb541-bd3a-4d9f-8792-58425c4834e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d121d24b-f471-47e5-b6cc-297911ff3468" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_689fb541-bd3a-4d9f-8792-58425c4834e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e617551-84be-4970-8c94-c0607818d16c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d121d24b-f471-47e5-b6cc-297911ff3468" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e617551-84be-4970-8c94-c0607818d16c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0be9e701-3bba-42b3-b439-076de67c80e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d121d24b-f471-47e5-b6cc-297911ff3468" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0be9e701-3bba-42b3-b439-076de67c80e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4e2e5e77-4403-40d5-9cc7-03f29532b777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d121d24b-f471-47e5-b6cc-297911ff3468" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4e2e5e77-4403-40d5-9cc7-03f29532b777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_387a33d5-7796-45db-a289-216f3d5d145b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d121d24b-f471-47e5-b6cc-297911ff3468" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_387a33d5-7796-45db-a289-216f3d5d145b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_d482ef3c-1418-4896-a014-884bbae6c00c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d121d24b-f471-47e5-b6cc-297911ff3468" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_d482ef3c-1418-4896-a014-884bbae6c00c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_27945fdd-6b4f-4529-b1bf-181ab7265d3e" xlink:href="bhc-20200930.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d121d24b-f471-47e5-b6cc-297911ff3468" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_27945fdd-6b4f-4529-b1bf-181ab7265d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_413cf00c-eb0f-4ab5-bd2d-37e707ed8d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5a817141-9f42-442d-8637-7619dbece625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_413cf00c-eb0f-4ab5-bd2d-37e707ed8d54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5a817141-9f42-442d-8637-7619dbece625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a29225a6-7873-4ff9-9787-bd029d68bacb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_413cf00c-eb0f-4ab5-bd2d-37e707ed8d54" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a29225a6-7873-4ff9-9787-bd029d68bacb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_a899079a-09fb-4619-9a03-ab115e20959a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_413cf00c-eb0f-4ab5-bd2d-37e707ed8d54" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_a899079a-09fb-4619-9a03-ab115e20959a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_b8a4b8e6-679b-40cb-98e8-bf1d2745869d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_413cf00c-eb0f-4ab5-bd2d-37e707ed8d54" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_b8a4b8e6-679b-40cb-98e8-bf1d2745869d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_65ea2444-5cca-465d-b1b1-928ef82db23e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_413cf00c-eb0f-4ab5-bd2d-37e707ed8d54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_65ea2444-5cca-465d-b1b1-928ef82db23e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_579bbd4c-f48f-4418-80b1-0b60ab93cb67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_413cf00c-eb0f-4ab5-bd2d-37e707ed8d54" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_579bbd4c-f48f-4418-80b1-0b60ab93cb67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8fc4f359-828c-4fee-a6ba-ea1f9489e73e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_413cf00c-eb0f-4ab5-bd2d-37e707ed8d54" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8fc4f359-828c-4fee-a6ba-ea1f9489e73e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_01d4560d-a2ce-4dd3-9e9f-3d3ca97b8b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_413cf00c-eb0f-4ab5-bd2d-37e707ed8d54" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_01d4560d-a2ce-4dd3-9e9f-3d3ca97b8b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1403bcc-9984-4ea6-86f0-02b4665ff715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_76973089-af81-4271-a37f-59f1fa8e7ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1403bcc-9984-4ea6-86f0-02b4665ff715" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_76973089-af81-4271-a37f-59f1fa8e7ade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d84b8df-01af-4e4b-9fb3-eb717a0893f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1403bcc-9984-4ea6-86f0-02b4665ff715" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d84b8df-01af-4e4b-9fb3-eb717a0893f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ed1d1e80-4065-4c62-807e-bb1a9624bb10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1403bcc-9984-4ea6-86f0-02b4665ff715" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ed1d1e80-4065-4c62-807e-bb1a9624bb10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f506fa40-b48c-4d96-8203-73a2bca10cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1403bcc-9984-4ea6-86f0-02b4665ff715" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f506fa40-b48c-4d96-8203-73a2bca10cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_baaa0130-5f37-40bb-b50a-338326388ab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_ProfitLoss_baaa0130-5f37-40bb-b50a-338326388ab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d8f30032-fd57-46e1-93a9-fda3b3bcc2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_DepreciationAndAmortization_d8f30032-fd57-46e1-93a9-fda3b3bcc2a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0a52dd8b-5c2d-4ad1-8145-d636f3f09606" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0a52dd8b-5c2d-4ad1-8145-d636f3f09606" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_5e39afeb-62b4-4399-b7c2-23125465d422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_AssetImpairmentCharges_5e39afeb-62b4-4399-b7c2-23125465d422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_2468570f-8688-486b-8903-91f0a441a937" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_2468570f-8688-486b-8903-91f0a441a937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_896df225-b30b-4135-8487-8d76127a8c51" xlink:href="bhc-20200930.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_896df225-b30b-4135-8487-8d76127a8c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_e9750da0-3bad-43b1-bfb9-0c482f883342" xlink:href="bhc-20200930.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_e9750da0-3bad-43b1-bfb9-0c482f883342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_2311249e-08fc-402b-a403-3924780aae63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_2311249e-08fc-402b-a403-3924780aae63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_60776f24-39d9-45fb-b562-c2132ff81db9" xlink:href="bhc-20200930.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_60776f24-39d9-45fb-b562-c2132ff81db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_a7c51c71-92dc-442b-b90b-8dbfb25d6f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_a7c51c71-92dc-442b-b90b-8dbfb25d6f8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_360e8e64-130b-46f4-a330-b6d363cdf395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_ShareBasedCompensation_360e8e64-130b-46f4-a330-b6d363cdf395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f98da8ab-1217-4f68-a1ef-830551452677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f98da8ab-1217-4f68-a1ef-830551452677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_236f9c95-4c48-443c-994f-aced4eb89902" xlink:href="bhc-20200930.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_bhc_DerivativeGainExcludedComponent_236f9c95-4c48-443c-994f-aced4eb89902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6e4b88a3-5977-4f9b-a5de-3d926040d707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6e4b88a3-5977-4f9b-a5de-3d926040d707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentOfAccretedInterestOnContingentConsideration_55ad8896-47d3-4169-a379-a34d6eecb330" xlink:href="bhc-20200930.xsd#bhc_PaymentOfAccretedInterestOnContingentConsideration"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_bhc_PaymentOfAccretedInterestOnContingentConsideration_55ad8896-47d3-4169-a379-a34d6eecb330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8decfb83-d91f-4f6f-8e69-3fe960a9ea4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8decfb83-d91f-4f6f-8e69-3fe960a9ea4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbb41d4c-4d37-4253-a86b-cc3a9ab34294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbb41d4c-4d37-4253-a86b-cc3a9ab34294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9524b67f-37f0-4b28-a7b9-bf96426cf347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9524b67f-37f0-4b28-a7b9-bf96426cf347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b3df0a79-9e94-4983-9071-2fddefe87a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b3df0a79-9e94-4983-9071-2fddefe87a78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0065d615-835c-4fd8-aadb-e5540d545827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1c68760e-2f90-475e-a963-5580219c8925" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0065d615-835c-4fd8-aadb-e5540d545827" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20200930.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20200930.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20200930.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITION"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0fc5357d-921e-409e-8577-27c68102db54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_da134277-025a-4bae-abb0-81aa512e39d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0fc5357d-921e-409e-8577-27c68102db54" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_da134277-025a-4bae-abb0-81aa512e39d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_fc924514-dbc5-44e0-bf28-e486bf1da225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0fc5357d-921e-409e-8577-27c68102db54" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_fc924514-dbc5-44e0-bf28-e486bf1da225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0fbee014-7cea-46f5-8c41-d6dce8882282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0fc5357d-921e-409e-8577-27c68102db54" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_0fbee014-7cea-46f5-8c41-d6dce8882282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_256bef0c-cf58-43ec-a3cf-68c43cf1cff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0fc5357d-921e-409e-8577-27c68102db54" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_256bef0c-cf58-43ec-a3cf-68c43cf1cff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_d0738295-98fa-4d6f-ba87-6c0d73575b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0fc5357d-921e-409e-8577-27c68102db54" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_d0738295-98fa-4d6f-ba87-6c0d73575b57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_8bb8d96d-cb24-4101-8c33-8e7031be042e" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0fc5357d-921e-409e-8577-27c68102db54" xlink:to="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_8bb8d96d-cb24-4101-8c33-8e7031be042e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ba94c259-cb94-452e-8719-246c99c97ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2b1305c4-b009-4859-8e1e-730394ff712f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ba94c259-cb94-452e-8719-246c99c97ca0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2b1305c4-b009-4859-8e1e-730394ff712f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0cca5bd9-049f-40f6-97b4-942e8c663be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ba94c259-cb94-452e-8719-246c99c97ca0" xlink:to="loc_us-gaap_Goodwill_0cca5bd9-049f-40f6-97b4-942e8c663be1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4f13a311-74d6-45f2-a329-80426268331f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ca3dc4b1-8e4b-4c79-be72-a796f498981f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4f13a311-74d6-45f2-a329-80426268331f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_ca3dc4b1-8e4b-4c79-be72-a796f498981f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_842de787-3c1a-4f2d-a72a-a98309ef83bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4f13a311-74d6-45f2-a329-80426268331f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_842de787-3c1a-4f2d-a72a-a98309ef83bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20200930.xsd#INVENTORIES"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#INVENTORIESTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_a42a97e4-c5eb-4557-b0ef-27a8686206fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_47bde3f5-f105-4a0f-b4e6-7eda81024a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a42a97e4-c5eb-4557-b0ef-27a8686206fd" xlink:to="loc_us-gaap_InventoryRawMaterials_47bde3f5-f105-4a0f-b4e6-7eda81024a87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_af8ac694-d8c3-4b68-b6ae-76ac08444817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a42a97e4-c5eb-4557-b0ef-27a8686206fd" xlink:to="loc_us-gaap_InventoryWorkInProcess_af8ac694-d8c3-4b68-b6ae-76ac08444817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_809155ca-7d1d-4655-972f-d1c9e853bb5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_a42a97e4-c5eb-4557-b0ef-27a8686206fd" xlink:to="loc_us-gaap_InventoryFinishedGoods_809155ca-7d1d-4655-972f-d1c9e853bb5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bd6baf88-b194-4bec-9c24-c1335f6c7b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cbaefd11-a9df-4d80-bf13-b6530b795765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bd6baf88-b194-4bec-9c24-c1335f6c7b0b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_cbaefd11-a9df-4d80-bf13-b6530b795765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d0d8a804-d0b5-4673-8e0d-39ba4c503bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_bd6baf88-b194-4bec-9c24-c1335f6c7b0b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d0d8a804-d0b5-4673-8e0d-39ba4c503bb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1b2cac1b-4f09-4e72-8b29-b9d837393a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e9cb9999-321c-4376-ac2d-1e3f90f3d509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1b2cac1b-4f09-4e72-8b29-b9d837393a87" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e9cb9999-321c-4376-ac2d-1e3f90f3d509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_21940e89-f202-47c4-9b36-0b1b1fb9213c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1b2cac1b-4f09-4e72-8b29-b9d837393a87" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_21940e89-f202-47c4-9b36-0b1b1fb9213c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5d48a078-d587-4c92-ae85-711814859bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7277a0ee-a0f0-4869-9649-886d31e244eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5d48a078-d587-4c92-ae85-711814859bc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7277a0ee-a0f0-4869-9649-886d31e244eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2188c2d0-a2d3-4fde-9cd0-5e08db6a1af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5d48a078-d587-4c92-ae85-711814859bc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2188c2d0-a2d3-4fde-9cd0-5e08db6a1af8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_435a0007-14d5-4b42-be13-b524a65b7c86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2261fa2d-d4e5-4f82-beac-d21d779bd342" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_435a0007-14d5-4b42-be13-b524a65b7c86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2261fa2d-d4e5-4f82-beac-d21d779bd342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc35798f-8e3c-41da-891e-9c322edb7c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_435a0007-14d5-4b42-be13-b524a65b7c86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc35798f-8e3c-41da-891e-9c322edb7c2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bf34dabf-35b4-4874-9ecf-5e838086e889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_435a0007-14d5-4b42-be13-b524a65b7c86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bf34dabf-35b4-4874-9ecf-5e838086e889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_abb5a7f4-8154-4276-bba8-0141629e2fe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_435a0007-14d5-4b42-be13-b524a65b7c86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_abb5a7f4-8154-4276-bba8-0141629e2fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2765f0df-f6c1-4ac3-b764-a60ce885b817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_435a0007-14d5-4b42-be13-b524a65b7c86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2765f0df-f6c1-4ac3-b764-a60ce885b817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_59e18a27-1cf9-4ff8-b868-a77048d5b7b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_435a0007-14d5-4b42-be13-b524a65b7c86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_59e18a27-1cf9-4ff8-b868-a77048d5b7b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_06b2816e-1a6c-4cc1-aa59-e1ec84fa25ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_435a0007-14d5-4b42-be13-b524a65b7c86" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_06b2816e-1a6c-4cc1-aa59-e1ec84fa25ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f3256044-7ece-47e3-9eea-39077feac12f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_4d4c02e6-241a-4fdc-8de8-f3d64e783f6d" xlink:href="bhc-20200930.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f3256044-7ece-47e3-9eea-39077feac12f" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_4d4c02e6-241a-4fdc-8de8-f3d64e783f6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_8ee34e46-7e05-4ca9-97ee-01d36d1ce540" xlink:href="bhc-20200930.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f3256044-7ece-47e3-9eea-39077feac12f" xlink:to="loc_bhc_AccruedProductRebateCurrent_8ee34e46-7e05-4ca9-97ee-01d36d1ce540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_5bb5abf6-b322-4f91-a632-23406d2bc634" xlink:href="bhc-20200930.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f3256044-7ece-47e3-9eea-39077feac12f" xlink:to="loc_bhc_AccruedProductReturnCurrent_5bb5abf6-b322-4f91-a632-23406d2bc634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_ac80e872-f15d-48dd-9e86-163d1c64e2c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f3256044-7ece-47e3-9eea-39077feac12f" xlink:to="loc_us-gaap_InterestPayableCurrent_ac80e872-f15d-48dd-9e86-163d1c64e2c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_67751e4d-0fa4-4c62-acce-5bc0f83f6941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f3256044-7ece-47e3-9eea-39077feac12f" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_67751e4d-0fa4-4c62-acce-5bc0f83f6941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_ed1ac0ae-38e2-4831-ad61-a5a118591a7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f3256044-7ece-47e3-9eea-39077feac12f" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_ed1ac0ae-38e2-4831-ad61-a5a118591a7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64ebdbfc-5962-4550-916f-a813a758bc7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f3256044-7ece-47e3-9eea-39077feac12f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_64ebdbfc-5962-4550-916f-a813a758bc7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c6e66d4d-eb41-4450-a9be-e94616317b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_6691b0c7-8e20-446c-aa56-18c9311768de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c6e66d4d-eb41-4450-a9be-e94616317b24" xlink:to="loc_us-gaap_LongTermDebtCurrent_6691b0c7-8e20-446c-aa56-18c9311768de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_32428f61-f9e9-4a3d-8c61-b9dbdb5ff42d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c6e66d4d-eb41-4450-a9be-e94616317b24" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_32428f61-f9e9-4a3d-8c61-b9dbdb5ff42d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_917dc72e-864d-4470-b0d7-e16eff31a382" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_fa554172-dd80-4ef5-aad4-5a7417783b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_917dc72e-864d-4470-b0d7-e16eff31a382" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_fa554172-dd80-4ef5-aad4-5a7417783b7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_75f0e8bd-969e-4687-9234-7643d838daf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_917dc72e-864d-4470-b0d7-e16eff31a382" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_75f0e8bd-969e-4687-9234-7643d838daf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_99f742fe-1efa-4ac3-9132-ee3fd6c739d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_917dc72e-864d-4470-b0d7-e16eff31a382" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_99f742fe-1efa-4ac3-9132-ee3fd6c739d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a83511c7-8edc-436f-b703-1eb359e9fe77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_917dc72e-864d-4470-b0d7-e16eff31a382" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a83511c7-8edc-436f-b703-1eb359e9fe77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_452d97a8-bc1e-4c22-9a18-944c7ab82e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_917dc72e-864d-4470-b0d7-e16eff31a382" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_452d97a8-bc1e-4c22-9a18-944c7ab82e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5aae7d81-6cfc-4c1a-8a9a-ef710fd283d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_917dc72e-864d-4470-b0d7-e16eff31a382" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5aae7d81-6cfc-4c1a-8a9a-ef710fd283d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_9ce7bb55-1ea6-4412-adec-fed831ccbae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_917dc72e-864d-4470-b0d7-e16eff31a382" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_9ce7bb55-1ea6-4412-adec-fed831ccbae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_028b8532-9267-4bdb-a781-630132b679b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1330975e-183f-4a74-9ac2-0beed39ef442" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_028b8532-9267-4bdb-a781-630132b679b3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1330975e-183f-4a74-9ac2-0beed39ef442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7b56e4bf-dd54-4b0e-b38f-6eedd1fb64a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_028b8532-9267-4bdb-a781-630132b679b3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_7b56e4bf-dd54-4b0e-b38f-6eedd1fb64a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bhc-20200930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_041e50aa-1275-4165-8614-f625d143b2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_2271b26a-50bf-47f4-9f45-c6c8f4d53703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_041e50aa-1275-4165-8614-f625d143b2be" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_2271b26a-50bf-47f4-9f45-c6c8f4d53703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_34e9b60c-a64f-49a7-b480-932ea0a3ac4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_041e50aa-1275-4165-8614-f625d143b2be" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_34e9b60c-a64f-49a7-b480-932ea0a3ac4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f5c8b760-5084-49a1-b148-f6d037bd51f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_041e50aa-1275-4165-8614-f625d143b2be" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f5c8b760-5084-49a1-b148-f6d037bd51f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f8cdd91b-c402-463c-8b18-ea0e9526b491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_041e50aa-1275-4165-8614-f625d143b2be" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f8cdd91b-c402-463c-8b18-ea0e9526b491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_44702fd1-c804-4d67-a8f6-c4af60ef1fa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_041e50aa-1275-4165-8614-f625d143b2be" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_44702fd1-c804-4d67-a8f6-c4af60ef1fa6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATION"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9aa8de66-16d7-4581-b488-e995339c563a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_7d6eaf56-78f8-458d-a5f0-827eb6b974bb" xlink:href="bhc-20200930.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9aa8de66-16d7-4581-b488-e995339c563a" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_7d6eaf56-78f8-458d-a5f0-827eb6b974bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_5ec49b2b-cccf-4389-97cd-2c04be33713c" xlink:href="bhc-20200930.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9aa8de66-16d7-4581-b488-e995339c563a" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_5ec49b2b-cccf-4389-97cd-2c04be33713c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="simple" xlink:href="bhc-20200930.xsd#OTHEREXPENSENET"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#OTHEREXPENSENETTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#OTHEREXPENSENETSummaryofOtherExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e518a17c-66b0-4932-a7ef-e509729053dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_0eec8500-8ffe-4779-92e3-9c8c4e60f801" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e518a17c-66b0-4932-a7ef-e509729053dd" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_0eec8500-8ffe-4779-92e3-9c8c4e60f801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_d8ee841d-d8d8-444d-92a9-bdf5ffd141d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e518a17c-66b0-4932-a7ef-e509729053dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_d8ee841d-d8d8-444d-92a9-bdf5ffd141d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c2c672e6-0fd6-4b00-9796-c14eac546181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e518a17c-66b0-4932-a7ef-e509729053dd" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c2c672e6-0fd6-4b00-9796-c14eac546181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_66f10990-b0d7-4df1-ba3b-f2bcd501e62c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e518a17c-66b0-4932-a7ef-e509729053dd" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_66f10990-b0d7-4df1-ba3b-f2bcd501e62c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherMiscellaneousNonoperatingIncomeExpense_a5b7977d-1a33-4e8d-bcdf-dbf277a0f7dc" xlink:href="bhc-20200930.xsd#bhc_OtherMiscellaneousNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_e518a17c-66b0-4932-a7ef-e509729053dd" xlink:to="loc_bhc_OtherMiscellaneousNonoperatingIncomeExpense_a5b7977d-1a33-4e8d-bcdf-dbf277a0f7dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20200930.xsd#INCOMETAXES"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INCOMETAXESNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e435baa4-404a-4754-bdcd-c89b62da6163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6bdc1ef-54ba-4377-b0f8-d15b9faa2ac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e435baa4-404a-4754-bdcd-c89b62da6163" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6bdc1ef-54ba-4377-b0f8-d15b9faa2ac9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5e6bf1bf-0e01-46e2-a0ad-9f7758a73a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e435baa4-404a-4754-bdcd-c89b62da6163" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5e6bf1bf-0e01-46e2-a0ad-9f7758a73a1b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHARENarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSCompletedorDormantMattersDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATION"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONTables"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>bhc-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:52525664-5cd4-4495-a34d-b14e0c25a97b,g:cfe4b6e8-8eeb-4675-b5cb-546679211f6a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="bhc-20200930.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="extended" id="i831a2555638847b0aeaff4d10095ec94_DocumentandEntityInformation"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i6fa63cb3bcea40dda57cfb3d1278cad2_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i279e643a28ee44f19f474737ffda661e_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i543863c059f3495387476a558f2fed5f_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_afbe5bfb-0a1a-449d-ab5a-e7045a4ada3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_RevenuesAbstract_afbe5bfb-0a1a-449d-ab5a-e7045a4ada3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dba74754-1eaf-4859-95fd-133cc7a7eb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_afbe5bfb-0a1a-449d-ab5a-e7045a4ada3b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dba74754-1eaf-4859-95fd-133cc7a7eb4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_006f261f-f770-4a2f-879c-27c67de5e839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_006f261f-f770-4a2f-879c-27c67de5e839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e360eae7-7070-415a-ba19-a0c442d0d956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e360eae7-7070-415a-ba19-a0c442d0d956" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_dc59bcde-e736-4322-8c0a-2e72d9a011f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_dc59bcde-e736-4322-8c0a-2e72d9a011f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_11203f94-9048-4b1f-b419-73ca93cc5edb" xlink:href="bhc-20200930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_11203f94-9048-4b1f-b419-73ca93cc5edb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7828b641-62a8-4e2d-a521-3dd4a54186b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_AssetImpairmentCharges_7828b641-62a8-4e2d-a521-3dd4a54186b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3d9aa59d-1024-4f45-80f0-0bec87a84c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_RestructuringCharges_3d9aa59d-1024-4f45-80f0-0bec87a84c31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_5f43758e-6582-4676-9af8-1f75c12d0d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_5f43758e-6582-4676-9af8-1f75c12d0d6c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_142f3f49-2549-4d1f-9ba7-c858de262001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_142f3f49-2549-4d1f-9ba7-c858de262001" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0ad5dc3c-b289-4c76-a557-5d9b92d45f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_CostsAndExpenses_0ad5dc3c-b289-4c76-a557-5d9b92d45f91" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_23271844-3816-4c37-8518-d34c8cba480d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_OperatingIncomeLoss_23271844-3816-4c37-8518-d34c8cba480d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e92404c2-d649-4832-8569-e874732d5b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e92404c2-d649-4832-8569-e874732d5b3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1699d7a1-1e98-4445-8dba-b8f748a768ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_InterestExpenseDebt_1699d7a1-1e98-4445-8dba-b8f748a768ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96c05ae0-fa73-412b-8b45-561eb94d72e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96c05ae0-fa73-412b-8b45-561eb94d72e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5a96786a-dd8a-4872-94a1-e308f122239f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5a96786a-dd8a-4872-94a1-e308f122239f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a4d95089-451f-42aa-8673-ddc9481b7582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a4d95089-451f-42aa-8673-ddc9481b7582" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fb5aea6b-1818-4ecc-abea-51f9a907c150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fb5aea6b-1818-4ecc-abea-51f9a907c150" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a9ca8b12-93ad-42d5-a5b2-ddfa9d734827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_ProfitLoss_a9ca8b12-93ad-42d5-a5b2-ddfa9d734827" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f4a8dd26-48e2-4753-8888-b2c9e4dd5bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f4a8dd26-48e2-4753-8888-b2c9e4dd5bcf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_89e6254b-0561-48f0-9f17-717dadb62579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_89e6254b-0561-48f0-9f17-717dadb62579" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a5f09da8-4719-45e7-9700-155c3e8e2088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a5f09da8-4719-45e7-9700-155c3e8e2088" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8df00e6a-3dd1-4735-96d1-9c713199e8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a5f09da8-4719-45e7-9700-155c3e8e2088" xlink:to="loc_us-gaap_EarningsPerShareBasic_8df00e6a-3dd1-4735-96d1-9c713199e8ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_330c0962-2097-4a45-874b-1f3098655307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a5f09da8-4719-45e7-9700-155c3e8e2088" xlink:to="loc_us-gaap_EarningsPerShareDiluted_330c0962-2097-4a45-874b-1f3098655307" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_888e6969-5326-4d0b-9612-8a3b7ae8a4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_888e6969-5326-4d0b-9612-8a3b7ae8a4da" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a4ed5a7-3cab-4323-ac05-d5d09577a344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_888e6969-5326-4d0b-9612-8a3b7ae8a4da" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a4ed5a7-3cab-4323-ac05-d5d09577a344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cc1f025a-c1df-473f-ac6d-7f8a4c6fdbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_888e6969-5326-4d0b-9612-8a3b7ae8a4da" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cc1f025a-c1df-473f-ac6d-7f8a4c6fdbee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c3a087c7-05be-43b5-b085-aeedb744ed8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_StatementTable_c3a087c7-05be-43b5-b085-aeedb744ed8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eb9654be-c60f-454e-a841-03e7e70bc421" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c3a087c7-05be-43b5-b085-aeedb744ed8b" xlink:to="loc_srt_ProductOrServiceAxis_eb9654be-c60f-454e-a841-03e7e70bc421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb9654be-c60f-454e-a841-03e7e70bc421_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_eb9654be-c60f-454e-a841-03e7e70bc421" xlink:to="loc_srt_ProductsAndServicesDomain_eb9654be-c60f-454e-a841-03e7e70bc421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3727376-6004-42e1-96f0-e6df1aa55d1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_eb9654be-c60f-454e-a841-03e7e70bc421" xlink:to="loc_srt_ProductsAndServicesDomain_f3727376-6004-42e1-96f0-e6df1aa55d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dc8ec238-5bc4-4f7b-8479-b899c3306514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f3727376-6004-42e1-96f0-e6df1aa55d1d" xlink:to="loc_us-gaap_ProductMember_dc8ec238-5bc4-4f7b-8479-b899c3306514" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_75ca1bc0-f548-4b0b-a7ab-738ac96dd5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f3727376-6004-42e1-96f0-e6df1aa55d1d" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_75ca1bc0-f548-4b0b-a7ab-738ac96dd5d9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended" id="i4b9a60621ddf400590acf3c4baa25a2e_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended" id="ib13c37660fa8490a8b8de8e8a98a43e8_CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c9820d0f-8ea4-4b61-bd16-96389f44a5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c9820d0f-8ea4-4b61-bd16-96389f44a5bb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_915f6d4c-14b9-42fa-b502-31e7d33f4973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_915f6d4c-14b9-42fa-b502-31e7d33f4973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_947ae3d8-5659-49cc-b083-059cb604834a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_947ae3d8-5659-49cc-b083-059cb604834a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0418e10a-0451-4763-8147-6fee3dbd8335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0418e10a-0451-4763-8147-6fee3dbd8335" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bde25cf8-6532-4e08-9973-fe753fb0913c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bde25cf8-6532-4e08-9973-fe753fb0913c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ce342086-f7e2-4cfd-8a79-a99103ce2e70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ce342086-f7e2-4cfd-8a79-a99103ce2e70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3fdd54ee-8f00-478f-83cd-9ededac22fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3fdd54ee-8f00-478f-83cd-9ededac22fd7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_8a7cf898-0f57-4bda-b200-ff5ffa82a3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_8a7cf898-0f57-4bda-b200-ff5ffa82a3e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b938e794-2a4d-4255-94dc-0046173dd9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_ProfitLoss_b938e794-2a4d-4255-94dc-0046173dd9b2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6970ec43-c5ca-4efd-afb4-565083974bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6970ec43-c5ca-4efd-afb4-565083974bb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7ce067c6-7503-4290-bd73-43e6d78cdf68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5af08d79-e2b8-4489-ae1a-ebb0e9adb797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f7745f75-cba5-4656-a26f-cd3d61e0395b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c9820d0f-8ea4-4b61-bd16-96389f44a5bb" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f7745f75-cba5-4656-a26f-cd3d61e0395b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50e06be6-cf35-4644-aca1-c047e51205f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c9820d0f-8ea4-4b61-bd16-96389f44a5bb" xlink:to="loc_us-gaap_StatementTable_50e06be6-cf35-4644-aca1-c047e51205f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_df6c9808-3c60-4c43-b72b-1797571b418f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50e06be6-cf35-4644-aca1-c047e51205f5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_df6c9808-3c60-4c43-b72b-1797571b418f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_df6c9808-3c60-4c43-b72b-1797571b418f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_df6c9808-3c60-4c43-b72b-1797571b418f" xlink:to="loc_us-gaap_EquityComponentDomain_df6c9808-3c60-4c43-b72b-1797571b418f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_df6c9808-3c60-4c43-b72b-1797571b418f" xlink:to="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_28c6ad01-e186-4e50-8689-12cc943e7db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_CommonStockMember_28c6ad01-e186-4e50-8689-12cc943e7db8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b87cc867-4ca3-4a75-bee9-8535af3f1006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b87cc867-4ca3-4a75-bee9-8535af3f1006" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d8db11e5-d7d4-47ca-a496-208dc0e84285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_RetainedEarningsMember_d8db11e5-d7d4-47ca-a496-208dc0e84285" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fad8657a-b3ef-4631-9a56-b05743212b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fad8657a-b3ef-4631-9a56-b05743212b44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_fc835b45-f9bc-48bd-9efd-b0a95165291b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_ParentMember_fc835b45-f9bc-48bd-9efd-b0a95165291b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b4d9f2eb-7601-49db-bec6-53a166c63297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b4d9f2eb-7601-49db-bec6-53a166c63297" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bf5ffdb5-1028-4db8-a01e-b8b8ea7fd0db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_50e06be6-cf35-4644-aca1-c047e51205f5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bf5ffdb5-1028-4db8-a01e-b8b8ea7fd0db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_bf5ffdb5-1028-4db8-a01e-b8b8ea7fd0db_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bf5ffdb5-1028-4db8-a01e-b8b8ea7fd0db" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_bf5ffdb5-1028-4db8-a01e-b8b8ea7fd0db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_87f83386-146b-4050-af9c-c1a23d86d598" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bf5ffdb5-1028-4db8-a01e-b8b8ea7fd0db" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_87f83386-146b-4050-af9c-c1a23d86d598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7be71bb0-fb0e-4e54-959c-1a97733050ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_87f83386-146b-4050-af9c-c1a23d86d598" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7be71bb0-fb0e-4e54-959c-1a97733050ef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i48f8790f6f884ad4b0e64ad11f59b0a7_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20200930.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended" id="id1170577c38e4e79af84259d6b44b05f_DESCRIPTIONOFBUSINESS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended" id="ib6b6a69587694611a0cbbf285cde6ff4_DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20200930.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="i4dd8644298e845e9bf3c118e0914dc8c_SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20200930.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="ida76da37a089419fbbcbbeb9845fd469_SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="i77d339970cbe42a894ba3f4c6d28ff40_SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a273a68e-8dc9-434f-9c18-4be82ca7e343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_b464e76d-1d57-4723-b79a-36762b47e440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a273a68e-8dc9-434f-9c18-4be82ca7e343" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_b464e76d-1d57-4723-b79a-36762b47e440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf9a1f77-c585-4a5f-805b-919d691d948b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a273a68e-8dc9-434f-9c18-4be82ca7e343" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf9a1f77-c585-4a5f-805b-919d691d948b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b14f1fce-8858-4920-913c-4977435f5728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a273a68e-8dc9-434f-9c18-4be82ca7e343" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b14f1fce-8858-4920-913c-4977435f5728" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40b0a795-05fd-428d-972a-512b8e7ba097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b14f1fce-8858-4920-913c-4977435f5728" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40b0a795-05fd-428d-972a-512b8e7ba097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_40b0a795-05fd-428d-972a-512b8e7ba097_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40b0a795-05fd-428d-972a-512b8e7ba097" xlink:to="loc_us-gaap_EquityComponentDomain_40b0a795-05fd-428d-972a-512b8e7ba097_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_767c2541-9857-464e-9bb3-2bb68ece16d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40b0a795-05fd-428d-972a-512b8e7ba097" xlink:to="loc_us-gaap_EquityComponentDomain_767c2541-9857-464e-9bb3-2bb68ece16d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c0749f5c-f4cb-4ce3-b43f-2bfabdb32abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_767c2541-9857-464e-9bb3-2bb68ece16d6" xlink:to="loc_us-gaap_RetainedEarningsMember_c0749f5c-f4cb-4ce3-b43f-2bfabdb32abe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e2b8809b-b5ea-4ae1-9303-59d763e57d3b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b14f1fce-8858-4920-913c-4977435f5728" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e2b8809b-b5ea-4ae1-9303-59d763e57d3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e2b8809b-b5ea-4ae1-9303-59d763e57d3b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e2b8809b-b5ea-4ae1-9303-59d763e57d3b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e2b8809b-b5ea-4ae1-9303-59d763e57d3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d9a5e70c-9c51-4c5d-8ce9-7b7ea4729970" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e2b8809b-b5ea-4ae1-9303-59d763e57d3b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d9a5e70c-9c51-4c5d-8ce9-7b7ea4729970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_28e8b943-2268-4c16-aa8c-9b6cf80c8277" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d9a5e70c-9c51-4c5d-8ce9-7b7ea4729970" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_28e8b943-2268-4c16-aa8c-9b6cf80c8277" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITION"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="extended" id="i3046a2edc968401aa644eadcc33284fd_REVENUERECOGNITION"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="extended" id="i2634fce6a7ac47e98b3fffc1e618e754_REVENUERECOGNITIONTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended" id="ibe66f1aa9b4746179c3f54e495bc08e3_REVENUERECOGNITIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_cd1d9176-8a72-424c-b993-77d362793700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_cd1d9176-8a72-424c-b993-77d362793700" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_87487d53-db02-48ac-bf2d-9b540f068e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_87487d53-db02-48ac-bf2d-9b540f068e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d339109f-f6aa-452a-aa2f-9d09e89e6f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d339109f-f6aa-452a-aa2f-9d09e89e6f6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73a6f83b-34cb-4d3e-b34c-864d600ceb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73a6f83b-34cb-4d3e-b34c-864d600ceb21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6b9c118b-ff81-4252-885a-44fdcd071883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6b9c118b-ff81-4252-885a-44fdcd071883" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_fc83b89c-dea2-4e4e-a9dd-a16e197ac1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6b9c118b-ff81-4252-885a-44fdcd071883" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_fc83b89c-dea2-4e4e-a9dd-a16e197ac1d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_fc83b89c-dea2-4e4e-a9dd-a16e197ac1d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_fc83b89c-dea2-4e4e-a9dd-a16e197ac1d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_fc83b89c-dea2-4e4e-a9dd-a16e197ac1d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8a0f9c86-75f7-4a6f-a3a7-86d0816f51be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_fc83b89c-dea2-4e4e-a9dd-a16e197ac1d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8a0f9c86-75f7-4a6f-a3a7-86d0816f51be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_8b28a210-ede0-4bed-b1c2-cd4e3ad38e68" xlink:href="bhc-20200930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8a0f9c86-75f7-4a6f-a3a7-86d0816f51be" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_8b28a210-ede0-4bed-b1c2-cd4e3ad38e68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_f9cc61b0-0fc8-4490-b01b-a83a103cc612" xlink:href="bhc-20200930.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8a0f9c86-75f7-4a6f-a3a7-86d0816f51be" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_f9cc61b0-0fc8-4490-b01b-a83a103cc612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00924278-4a43-4694-a1e5-afc7bc74d634" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6b9c118b-ff81-4252-885a-44fdcd071883" xlink:to="loc_srt_ProductOrServiceAxis_00924278-4a43-4694-a1e5-afc7bc74d634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00924278-4a43-4694-a1e5-afc7bc74d634_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_00924278-4a43-4694-a1e5-afc7bc74d634" xlink:to="loc_srt_ProductsAndServicesDomain_00924278-4a43-4694-a1e5-afc7bc74d634_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5dd409c-81c8-4145-8d24-fe7806bc316f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_00924278-4a43-4694-a1e5-afc7bc74d634" xlink:to="loc_srt_ProductsAndServicesDomain_a5dd409c-81c8-4145-8d24-fe7806bc316f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_3f8eb03e-3d19-480f-8ed9-da5d02f0defc" xlink:href="bhc-20200930.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a5dd409c-81c8-4145-8d24-fe7806bc316f" xlink:to="loc_bhc_PriceAppreciationCreditMember_3f8eb03e-3d19-480f-8ed9-da5d02f0defc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended" id="i2543669c22ac47e593d9db41fdbab592_REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_33438d3d-7899-421b-bce2-1b087595674e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_33438d3d-7899-421b-bce2-1b087595674e" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d4b954b-ca0f-43c0-b3a8-43061ab2cdf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d4b954b-ca0f-43c0-b3a8-43061ab2cdf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_f297bb1a-296b-4302-b3b6-caf2e5f76b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_f297bb1a-296b-4302-b3b6-caf2e5f76b82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_83ee139f-0c6e-4039-b1ac-30b23f09ead1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_83ee139f-0c6e-4039-b1ac-30b23f09ead1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_c6e0a073-394a-4e59-a60e-5b8a9fb53d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_c6e0a073-394a-4e59-a60e-5b8a9fb53d45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4b1d1a4a-2918-44fc-95bb-3dd8b2aca857" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_06242150-c9be-41eb-a58f-cc6cfe979cc1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_33438d3d-7899-421b-bce2-1b087595674e" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_06242150-c9be-41eb-a58f-cc6cfe979cc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_555c001a-bfc1-41cb-881f-d605d6cf7407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_06242150-c9be-41eb-a58f-cc6cfe979cc1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_555c001a-bfc1-41cb-881f-d605d6cf7407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_555c001a-bfc1-41cb-881f-d605d6cf7407_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_555c001a-bfc1-41cb-881f-d605d6cf7407" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_555c001a-bfc1-41cb-881f-d605d6cf7407_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_555c001a-bfc1-41cb-881f-d605d6cf7407" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_484e6c51-8cb8-4a69-9d79-b10136d31510" xlink:href="bhc-20200930.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_484e6c51-8cb8-4a69-9d79-b10136d31510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_be61e34c-0840-40ce-b462-b1e8aeb6c64c" xlink:href="bhc-20200930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_be61e34c-0840-40ce-b462-b1e8aeb6c64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_515d1a02-65fe-4c8f-8416-7f9d4905af92" xlink:href="bhc-20200930.xsd#bhc_ReserveForRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForRebatesMember_515d1a02-65fe-4c8f-8416-7f9d4905af92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_212d3471-75c4-45c3-8a6b-088c29ab7a48" xlink:href="bhc-20200930.xsd#bhc_ReserveForChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForChargebacksMember_212d3471-75c4-45c3-8a6b-088c29ab7a48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_a8d00763-d5bf-4d7a-a976-4508a69fb174" xlink:href="bhc-20200930.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForDistributionFeesMember_a8d00763-d5bf-4d7a-a976-4508a69fb174" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="extended" id="i3516be4df2b844a99924ebed170615a3_REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE" xlink:type="extended" id="i75a8136ad237446bbd20e4203d65010f_ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables" xlink:type="extended" id="i19752f24e57544d1b475d5f01b23013d_ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" xlink:type="extended" id="id860028768134342a7133218f4e11013_ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_43a78513-638f-49a0-8120-97fff501fd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_43a78513-638f-49a0-8120-97fff501fd55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ec5ff740-cbf8-4990-a9cb-778e7267aab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ec5ff740-cbf8-4990-a9cb-778e7267aab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_2052d8cb-b128-4646-a5b7-2c493fc26076" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_2052d8cb-b128-4646-a5b7-2c493fc26076" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_172cab87-698d-4f5b-843f-2e8c5d2d02b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_172cab87-698d-4f5b-843f-2e8c5d2d02b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_1efd1bbe-1d91-44b8-905d-6d1689c92738" xlink:href="bhc-20200930.xsd#bhc_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_1efd1bbe-1d91-44b8-905d-6d1689c92738" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_382fb240-208d-4348-b0e4-d32bac54df51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_382fb240-208d-4348-b0e4-d32bac54df51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PotentialAssetAcquisitionAggregatePurchasePrice_070ffb7c-6acf-4f09-ba9c-483cab2aed75" xlink:href="bhc-20200930.xsd#bhc_PotentialAssetAcquisitionAggregatePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_PotentialAssetAcquisitionAggregatePurchasePrice_070ffb7c-6acf-4f09-ba9c-483cab2aed75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice_6a09f5bc-515d-4d10-9a99-cceac6e2412c" xlink:href="bhc-20200930.xsd#bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice_6a09f5bc-515d-4d10-9a99-cceac6e2412c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice_4a7c0f45-265e-4479-b579-6674d2918648" xlink:href="bhc-20200930.xsd#bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice_4a7c0f45-265e-4479-b579-6674d2918648" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupNumberOfProductsForDisposal_09fa7387-6b37-4a2b-8d5d-763764d510b7" xlink:href="bhc-20200930.xsd#bhc_DisposalGroupNumberOfProductsForDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_DisposalGroupNumberOfProductsForDisposal_09fa7387-6b37-4a2b-8d5d-763764d510b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9e473ade-9fd5-49b5-bdeb-a3a24231a59b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9e473ade-9fd5-49b5-bdeb-a3a24231a59b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3452e20a-ec3c-4230-85ad-cf95942eb529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3452e20a-ec3c-4230-85ad-cf95942eb529" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_cd84702e-7c57-4eab-ba85-5ce2bb03c95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_cd84702e-7c57-4eab-ba85-5ce2bb03c95b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e9638a2c-fcb2-4db0-92a6-f7b560be9908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_Assets_e9638a2c-fcb2-4db0-92a6-f7b560be9908" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_abd9c64b-90a6-40e4-a330-fcfc4d995a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_abd9c64b-90a6-40e4-a330-fcfc4d995a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_abd9c64b-90a6-40e4-a330-fcfc4d995a37_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_abd9c64b-90a6-40e4-a330-fcfc4d995a37" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_abd9c64b-90a6-40e4-a330-fcfc4d995a37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5791bf7a-9b1e-4b6d-81c2-1bd75480f638" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_abd9c64b-90a6-40e4-a330-fcfc4d995a37" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5791bf7a-9b1e-4b6d-81c2-1bd75480f638" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_4ff13e12-6f1b-4cf0-a321-a6088b24cf48" xlink:href="bhc-20200930.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5791bf7a-9b1e-4b6d-81c2-1bd75480f638" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_4ff13e12-6f1b-4cf0-a321-a6088b24cf48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAxis_4f38c5d7-8ec8-4b19-bd49-af604c65833d" xlink:href="bhc-20200930.xsd#bhc_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_bhc_AssetAcquisitionAxis_4f38c5d7-8ec8-4b19-bd49-af604c65833d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionDomain_4f38c5d7-8ec8-4b19-bd49-af604c65833d_default" xlink:href="bhc-20200930.xsd#bhc_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bhc_AssetAcquisitionAxis_4f38c5d7-8ec8-4b19-bd49-af604c65833d" xlink:to="loc_bhc_AssetAcquisitionDomain_4f38c5d7-8ec8-4b19-bd49-af604c65833d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionDomain_95aaeb06-abaf-485e-893a-5a50d6e061b5" xlink:href="bhc-20200930.xsd#bhc_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bhc_AssetAcquisitionAxis_4f38c5d7-8ec8-4b19-bd49-af604c65833d" xlink:to="loc_bhc_AssetAcquisitionDomain_95aaeb06-abaf-485e-893a-5a50d6e061b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllegroOphthalmicsLLCMember_18eb5abe-22ef-4530-a33f-50c56b535e16" xlink:href="bhc-20200930.xsd#bhc_AllegroOphthalmicsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_AssetAcquisitionDomain_95aaeb06-abaf-485e-893a-5a50d6e061b5" xlink:to="loc_bhc_AllegroOphthalmicsLLCMember_18eb5abe-22ef-4530-a33f-50c56b535e16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e25cf4bf-500c-48a8-9b72-d2ef3875d1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e25cf4bf-500c-48a8-9b72-d2ef3875d1b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e25cf4bf-500c-48a8-9b72-d2ef3875d1b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e25cf4bf-500c-48a8-9b72-d2ef3875d1b1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e25cf4bf-500c-48a8-9b72-d2ef3875d1b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9513e9f7-081d-4731-b204-363126d61423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e25cf4bf-500c-48a8-9b72-d2ef3875d1b1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9513e9f7-081d-4731-b204-363126d61423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_4aa24603-d52d-448a-ba86-d306e96a7d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9513e9f7-081d-4731-b204-363126d61423" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_4aa24603-d52d-448a-ba86-d306e96a7d11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f4c5a8b6-30af-488c-a264-470af3252c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f4c5a8b6-30af-488c-a264-470af3252c3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f4c5a8b6-30af-488c-a264-470af3252c3d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f4c5a8b6-30af-488c-a264-470af3252c3d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f4c5a8b6-30af-488c-a264-470af3252c3d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_35abf6f4-af42-448e-ac42-b747c2dcb60d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f4c5a8b6-30af-488c-a264-470af3252c3d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_35abf6f4-af42-448e-ac42-b747c2dcb60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_0774f288-d7d9-4a33-9a1c-246d9521baf8" xlink:href="bhc-20200930.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_35abf6f4-af42-448e-ac42-b747c2dcb60d" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_0774f288-d7d9-4a33-9a1c-246d9521baf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e16624c-fced-425a-a0db-097c3c6e315b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_srt_ProductOrServiceAxis_7e16624c-fced-425a-a0db-097c3c6e315b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7e16624c-fced-425a-a0db-097c3c6e315b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7e16624c-fced-425a-a0db-097c3c6e315b" xlink:to="loc_srt_ProductsAndServicesDomain_7e16624c-fced-425a-a0db-097c3c6e315b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_69de9ffa-effb-4a5a-b3c4-7a96c0be0c09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7e16624c-fced-425a-a0db-097c3c6e315b" xlink:to="loc_srt_ProductsAndServicesDomain_69de9ffa-effb-4a5a-b3c4-7a96c0be0c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_224939c2-611d-4ab6-bc53-9ee652cbd8e1" xlink:href="bhc-20200930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_69de9ffa-effb-4a5a-b3c4-7a96c0be0c09" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_224939c2-611d-4ab6-bc53-9ee652cbd8e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6c10636d-68ee-4e1b-a6e5-34e1422ff9e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_srt_RestatementAxis_6c10636d-68ee-4e1b-a6e5-34e1422ff9e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_6c10636d-68ee-4e1b-a6e5-34e1422ff9e9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_6c10636d-68ee-4e1b-a6e5-34e1422ff9e9" xlink:to="loc_srt_RestatementDomain_6c10636d-68ee-4e1b-a6e5-34e1422ff9e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_295ee46d-3a10-4fa5-8ebd-a60fe0f2967d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_6c10636d-68ee-4e1b-a6e5-34e1422ff9e9" xlink:to="loc_srt_RestatementDomain_295ee46d-3a10-4fa5-8ebd-a60fe0f2967d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_71fb0c88-5c72-4a12-8515-c0a4a7072e4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_295ee46d-3a10-4fa5-8ebd-a60fe0f2967d" xlink:to="loc_srt_RestatementAdjustmentMember_71fb0c88-5c72-4a12-8515-c0a4a7072e4a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="ie9b502e16a8b4a4487d58f72d3292ad1_ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_354dfd21-7155-4707-843b-77afd036d947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_354dfd21-7155-4707-843b-77afd036d947" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0a7eb4aa-7437-4e9c-9e16-758611fec44d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0a7eb4aa-7437-4e9c-9e16-758611fec44d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_a0b95dd6-1513-438d-adbb-8c6ab17d4dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_a0b95dd6-1513-438d-adbb-8c6ab17d4dc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31f0bedf-9e5e-4884-b683-7fff63a83d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31f0bedf-9e5e-4884-b683-7fff63a83d8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_245ba1de-56ee-4aff-878b-465f41f2b8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_245ba1de-56ee-4aff-878b-465f41f2b8bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_42ebf326-74d1-428e-a04c-a0c8dd937ab9" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_42ebf326-74d1-428e-a04c-a0c8dd937ab9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4a3386ef-719a-46e8-9ab3-7f119d24b28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4a3386ef-719a-46e8-9ab3-7f119d24b28d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fb294e42-469f-43a2-a0b5-dc5daa51cb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_Goodwill_fb294e42-469f-43a2-a0b5-dc5daa51cb4a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3f0a5d2f-b7c8-4e2f-985e-632e63df65f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3f0a5d2f-b7c8-4e2f-985e-632e63df65f7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10f0066b-51e7-4354-9257-fb1efae8d727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10f0066b-51e7-4354-9257-fb1efae8d727" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3e05b8f-4e0a-4256-b119-050160092b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3e05b8f-4e0a-4256-b119-050160092b59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_635a8850-29ed-431b-9d48-106b431fff2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3e05b8f-4e0a-4256-b119-050160092b59" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_635a8850-29ed-431b-9d48-106b431fff2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_635a8850-29ed-431b-9d48-106b431fff2c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_635a8850-29ed-431b-9d48-106b431fff2c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_635a8850-29ed-431b-9d48-106b431fff2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ede6b286-7388-48c2-ad85-22296e3ef9e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_635a8850-29ed-431b-9d48-106b431fff2c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ede6b286-7388-48c2-ad85-22296e3ef9e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_0e7d364d-9589-41dc-b02f-b4b88fa613e2" xlink:href="bhc-20200930.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ede6b286-7388-48c2-ad85-22296e3ef9e4" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_0e7d364d-9589-41dc-b02f-b4b88fa613e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS" xlink:type="extended" id="i6ed47fce020f43c482bdc39416bd335c_RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" xlink:type="extended" id="i5dc5692e19244384a9b0ad27086eb6ec_RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fba2b4c7-28ad-41ff-bb5f-efe9ae6c6b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_RestructuringReserve_fba2b4c7-28ad-41ff-bb5f-efe9ae6c6b9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_08521324-dfa8-41c8-bb5b-d7318facf870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_08521324-dfa8-41c8-bb5b-d7318facf870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_13736520-0003-45c1-949e-fedae45a32b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_BusinessExitCosts1_13736520-0003-45c1-949e-fedae45a32b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_5403da52-9664-42c2-9e7d-2b0f63ef83a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_SeveranceCosts1_5403da52-9664-42c2-9e7d-2b0f63ef83a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_1da5fce6-ea6f-419d-9ec6-79a4a2345f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_PaymentsForRestructuring_1da5fce6-ea6f-419d-9ec6-79a4a2345f48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_28e1d789-ab3c-4591-bfd7-98fcb4ef78c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_OtherRestructuringCosts_28e1d789-ab3c-4591-bfd7-98fcb4ef78c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6f02c477-1fdf-4f54-b130-a03d21a5e5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_RestructuringCharges_6f02c477-1fdf-4f54-b130-a03d21a5e5ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4fbf35e-b0d2-489b-b099-94c644c021ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4fbf35e-b0d2-489b-b099-94c644c021ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a7e37da1-a874-47f0-b96c-11c1cb56211a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a7e37da1-a874-47f0-b96c-11c1cb56211a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_974a46fb-b6a0-493e-b66b-c28423408495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a7e37da1-a874-47f0-b96c-11c1cb56211a" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_974a46fb-b6a0-493e-b66b-c28423408495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_974a46fb-b6a0-493e-b66b-c28423408495_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_974a46fb-b6a0-493e-b66b-c28423408495" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_974a46fb-b6a0-493e-b66b-c28423408495_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3abafd63-1d00-48c4-a06a-557413eb1b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_974a46fb-b6a0-493e-b66b-c28423408495" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3abafd63-1d00-48c4-a06a-557413eb1b7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_a39f314f-0d49-41ce-b60f-66722a1c2200" xlink:href="bhc-20200930.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3abafd63-1d00-48c4-a06a-557413eb1b7a" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_a39f314f-0d49-41ce-b60f-66722a1c2200" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationCostsMember_e57bf198-df89-4d65-a191-3ffe879f9485" xlink:href="bhc-20200930.xsd#bhc_SeparationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3abafd63-1d00-48c4-a06a-557413eb1b7a" xlink:to="loc_bhc_SeparationCostsMember_e57bf198-df89-4d65-a191-3ffe879f9485" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="extended" id="if196982a2f98455c802ede86417e76ca_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="extended" id="if15a0c4214d244bca3a8db570b28c442_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="ic919b5c55d1344da916c57007811fbe2_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_100c0fdd-8ed5-4e01-ae58-b5ea7e75b4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_100c0fdd-8ed5-4e01-ae58-b5ea7e75b4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure_6618cf94-8833-404f-800b-2d909afe8b3e" xlink:href="bhc-20200930.xsd#bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure_6618cf94-8833-404f-800b-2d909afe8b3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_616f19ef-9614-4881-b31c-61afc0072dba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:to="loc_us-gaap_DerivativeAssets_616f19ef-9614-4881-b31c-61afc0072dba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e576abe6-4104-40b8-8a54-a70e7990635f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e576abe6-4104-40b8-8a54-a70e7990635f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_e543e8fa-a95d-4f15-b2b4-351c1974cec2" xlink:href="bhc-20200930.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e576abe6-4104-40b8-8a54-a70e7990635f" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_e543e8fa-a95d-4f15-b2b4-351c1974cec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8991d9e1-5112-4c41-a15e-14b2a0dbdec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e576abe6-4104-40b8-8a54-a70e7990635f" xlink:to="loc_us-gaap_DerivativeLiabilities_8991d9e1-5112-4c41-a15e-14b2a0dbdec9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_3377d76e-063f-4e0a-8958-0d91af63912f" xlink:href="bhc-20200930.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_3377d76e-063f-4e0a-8958-0d91af63912f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_10207bd0-8b14-4ba9-8789-de9c013add15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_10207bd0-8b14-4ba9-8789-de9c013add15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5cdafd24-c94c-4414-bc5a-2b1169bd2c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5cdafd24-c94c-4414-bc5a-2b1169bd2c6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5cdafd24-c94c-4414-bc5a-2b1169bd2c6e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5cdafd24-c94c-4414-bc5a-2b1169bd2c6e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5cdafd24-c94c-4414-bc5a-2b1169bd2c6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7df03bf8-a813-4faf-9692-8e353c57f86c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5cdafd24-c94c-4414-bc5a-2b1169bd2c6e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7df03bf8-a813-4faf-9692-8e353c57f86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c41780df-6a53-4636-b25a-9cc5a767010a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7df03bf8-a813-4faf-9692-8e353c57f86c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c41780df-6a53-4636-b25a-9cc5a767010a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6cfaa121-d30f-4920-8c04-641e6c2b04d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6cfaa121-d30f-4920-8c04-641e6c2b04d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6cfaa121-d30f-4920-8c04-641e6c2b04d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6cfaa121-d30f-4920-8c04-641e6c2b04d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6cfaa121-d30f-4920-8c04-641e6c2b04d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6cfaa121-d30f-4920-8c04-641e6c2b04d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c5ead521-d9be-4b58-a5fd-0d7d16097a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c5ead521-d9be-4b58-a5fd-0d7d16097a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_90a21843-c5e3-43b5-908d-966d97cbb54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_90a21843-c5e3-43b5-908d-966d97cbb54d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_905613e0-3b79-4d5a-a288-f6bdd81e0cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_905613e0-3b79-4d5a-a288-f6bdd81e0cce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3dcb7efc-6712-4ac5-950a-4e322e9a6204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3dcb7efc-6712-4ac5-950a-4e322e9a6204" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3dcb7efc-6712-4ac5-950a-4e322e9a6204_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3dcb7efc-6712-4ac5-950a-4e322e9a6204" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3dcb7efc-6712-4ac5-950a-4e322e9a6204_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_faf3f81a-06a9-41a6-b14e-ddbe021c1bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3dcb7efc-6712-4ac5-950a-4e322e9a6204" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_faf3f81a-06a9-41a6-b14e-ddbe021c1bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_1b447502-99a2-4e0a-a8fc-e60736642245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_faf3f81a-06a9-41a6-b14e-ddbe021c1bee" xlink:to="loc_us-gaap_CurrencySwapMember_1b447502-99a2-4e0a-a8fc-e60736642245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6c8a7aae-ac5b-4da8-98ea-53bafb4529ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_faf3f81a-06a9-41a6-b14e-ddbe021c1bee" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6c8a7aae-ac5b-4da8-98ea-53bafb4529ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ca58a1d3-a823-4f93-93ce-825bad26fdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ca58a1d3-a823-4f93-93ce-825bad26fdbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ca58a1d3-a823-4f93-93ce-825bad26fdbc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ca58a1d3-a823-4f93-93ce-825bad26fdbc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ca58a1d3-a823-4f93-93ce-825bad26fdbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cd36a1d5-91bc-415e-83be-540f7c25827a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ca58a1d3-a823-4f93-93ce-825bad26fdbc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cd36a1d5-91bc-415e-83be-540f7c25827a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_21d0d594-91fb-4687-b659-14ea8c7bf18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_cd36a1d5-91bc-415e-83be-540f7c25827a" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_21d0d594-91fb-4687-b659-14ea8c7bf18b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_45e4f20d-cad4-4bc3-991c-d54d2f53e0c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_HedgingDesignationAxis_45e4f20d-cad4-4bc3-991c-d54d2f53e0c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_45e4f20d-cad4-4bc3-991c-d54d2f53e0c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_45e4f20d-cad4-4bc3-991c-d54d2f53e0c5" xlink:to="loc_us-gaap_HedgingDesignationDomain_45e4f20d-cad4-4bc3-991c-d54d2f53e0c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_83cd343f-20e5-44bb-83ba-e4abc1ab2a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_45e4f20d-cad4-4bc3-991c-d54d2f53e0c5" xlink:to="loc_us-gaap_HedgingDesignationDomain_83cd343f-20e5-44bb-83ba-e4abc1ab2a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5ce53ecf-20e2-41a0-94ee-4c5e9c741bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_83cd343f-20e5-44bb-83ba-e4abc1ab2a33" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5ce53ecf-20e2-41a0-94ee-4c5e9c741bca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_d5b8f085-67c1-4358-ab09-13bf4a56a1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_83cd343f-20e5-44bb-83ba-e4abc1ab2a33" xlink:to="loc_us-gaap_NondesignatedMember_d5b8f085-67c1-4358-ab09-13bf4a56a1e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a619c099-93b3-40f1-a691-d3c80c6fd0b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_srt_LitigationCaseAxis_a619c099-93b3-40f1-a691-d3c80c6fd0b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a619c099-93b3-40f1-a691-d3c80c6fd0b5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a619c099-93b3-40f1-a691-d3c80c6fd0b5" xlink:to="loc_srt_LitigationCaseTypeDomain_a619c099-93b3-40f1-a691-d3c80c6fd0b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_da992a17-aae3-4289-af9d-b871c83aebcc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a619c099-93b3-40f1-a691-d3c80c6fd0b5" xlink:to="loc_srt_LitigationCaseTypeDomain_da992a17-aae3-4289-af9d-b871c83aebcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_7c803310-7cb7-48aa-beb8-841d054d352a" xlink:href="bhc-20200930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_da992a17-aae3-4289-af9d-b871c83aebcc" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_7c803310-7cb7-48aa-beb8-841d054d352a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_ebfb4030-0b25-4cba-9cc0-d39826b58def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_LitigationStatusAxis_ebfb4030-0b25-4cba-9cc0-d39826b58def" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ebfb4030-0b25-4cba-9cc0-d39826b58def_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_ebfb4030-0b25-4cba-9cc0-d39826b58def" xlink:to="loc_us-gaap_LitigationStatusDomain_ebfb4030-0b25-4cba-9cc0-d39826b58def_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ff0e7707-d899-48e2-88db-05c90feb7114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_ebfb4030-0b25-4cba-9cc0-d39826b58def" xlink:to="loc_us-gaap_LitigationStatusDomain_ff0e7707-d899-48e2-88db-05c90feb7114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_171cffef-768c-4793-8c48-eed965754660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_ff0e7707-d899-48e2-88db-05c90feb7114" xlink:to="loc_us-gaap_SettledLitigationMember_171cffef-768c-4793-8c48-eed965754660" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ded20dbb-347d-4a10-aeb8-2c96c99546ff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_srt_StatementGeographicalAxis_ded20dbb-347d-4a10-aeb8-2c96c99546ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ded20dbb-347d-4a10-aeb8-2c96c99546ff_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ded20dbb-347d-4a10-aeb8-2c96c99546ff" xlink:to="loc_srt_SegmentGeographicalDomain_ded20dbb-347d-4a10-aeb8-2c96c99546ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fff229ff-e51e-4282-9306-ed8751962611" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ded20dbb-347d-4a10-aeb8-2c96c99546ff" xlink:to="loc_srt_SegmentGeographicalDomain_fff229ff-e51e-4282-9306-ed8751962611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_e222d0d7-b2b9-43eb-927d-9051eaf61562" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fff229ff-e51e-4282-9306-ed8751962611" xlink:to="loc_stpr_NJ_e222d0d7-b2b9-43eb-927d-9051eaf61562" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended" id="i42d25d0a002d404b88c8ca35acaab2a3_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e9228edb-5e6a-4bab-9884-9481a918585f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e9228edb-5e6a-4bab-9884-9481a918585f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_987dba5d-b002-451b-95d7-bf7c8d48d572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_987dba5d-b002-451b-95d7-bf7c8d48d572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_bb94a222-6ae6-4b31-9d28-1497c67550cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_bb94a222-6ae6-4b31-9d28-1497c67550cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f45c544c-651f-47df-a1f6-e5f75f02c935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f45c544c-651f-47df-a1f6-e5f75f02c935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f45c544c-651f-47df-a1f6-e5f75f02c935_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f45c544c-651f-47df-a1f6-e5f75f02c935" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f45c544c-651f-47df-a1f6-e5f75f02c935_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_80c21cce-5f87-4459-8bf8-0f76e96182b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f45c544c-651f-47df-a1f6-e5f75f02c935" xlink:to="loc_us-gaap_HedgingRelationshipDomain_80c21cce-5f87-4459-8bf8-0f76e96182b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_e8a3a66d-5a6b-4266-91fd-42dc87a5d8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_80c21cce-5f87-4459-8bf8-0f76e96182b2" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_e8a3a66d-5a6b-4266-91fd-42dc87a5d8e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_67330f16-099d-4795-ba1f-9e8a0ff462f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_67330f16-099d-4795-ba1f-9e8a0ff462f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_67330f16-099d-4795-ba1f-9e8a0ff462f0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_67330f16-099d-4795-ba1f-9e8a0ff462f0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_67330f16-099d-4795-ba1f-9e8a0ff462f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5696d976-06ad-4171-a868-3c2d5c7ba6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_67330f16-099d-4795-ba1f-9e8a0ff462f0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5696d976-06ad-4171-a868-3c2d5c7ba6e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_36e3d29b-ad3a-4df0-966f-9a60c3733858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5696d976-06ad-4171-a868-3c2d5c7ba6e3" xlink:to="loc_us-gaap_CurrencySwapMember_36e3d29b-ad3a-4df0-966f-9a60c3733858" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_213d4fe0-564a-4d38-9dc5-86df91df54f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:to="loc_us-gaap_HedgingDesignationAxis_213d4fe0-564a-4d38-9dc5-86df91df54f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_213d4fe0-564a-4d38-9dc5-86df91df54f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_213d4fe0-564a-4d38-9dc5-86df91df54f1" xlink:to="loc_us-gaap_HedgingDesignationDomain_213d4fe0-564a-4d38-9dc5-86df91df54f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f8ab8de1-112c-4612-a72c-9ec471a00f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_213d4fe0-564a-4d38-9dc5-86df91df54f1" xlink:to="loc_us-gaap_HedgingDesignationDomain_f8ab8de1-112c-4612-a72c-9ec471a00f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d72d8a4c-b310-441b-9d57-4da004f7848a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_f8ab8de1-112c-4612-a72c-9ec471a00f9a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d72d8a4c-b310-441b-9d57-4da004f7848a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9c47ab12-8aa4-43fe-8aa1-543240404f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9c47ab12-8aa4-43fe-8aa1-543240404f49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9c47ab12-8aa4-43fe-8aa1-543240404f49_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9c47ab12-8aa4-43fe-8aa1-543240404f49" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9c47ab12-8aa4-43fe-8aa1-543240404f49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_186e571c-5ccf-4759-aa94-008dda75be28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9c47ab12-8aa4-43fe-8aa1-543240404f49" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_186e571c-5ccf-4759-aa94-008dda75be28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_50b2081d-8f02-4aa7-83cf-96d7a0c7d066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_186e571c-5ccf-4759-aa94-008dda75be28" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_50b2081d-8f02-4aa7-83cf-96d7a0c7d066" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e92aaa08-76bd-412d-afde-b42de57a2ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_186e571c-5ccf-4759-aa94-008dda75be28" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e92aaa08-76bd-412d-afde-b42de57a2ab7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended" id="i6152d91ddf794fcebe365f575de1d272_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ca6fa39-649c-45f6-865c-d208ef64d0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_56aa75db-525a-4ecf-b589-d11f1d02d182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ca6fa39-649c-45f6-865c-d208ef64d0e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_56aa75db-525a-4ecf-b589-d11f1d02d182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_04ac2a49-7e9d-470c-8dc2-f4a25735cb10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ca6fa39-649c-45f6-865c-d208ef64d0e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_04ac2a49-7e9d-470c-8dc2-f4a25735cb10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ca6fa39-649c-45f6-865c-d208ef64d0e5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6f9465a0-d4a5-40a1-8dda-71399a430793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6f9465a0-d4a5-40a1-8dda-71399a430793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_6f9465a0-d4a5-40a1-8dda-71399a430793_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6f9465a0-d4a5-40a1-8dda-71399a430793" xlink:to="loc_us-gaap_HedgingRelationshipDomain_6f9465a0-d4a5-40a1-8dda-71399a430793_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4940a09a-adda-4798-b8f1-3bcbccaba931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6f9465a0-d4a5-40a1-8dda-71399a430793" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4940a09a-adda-4798-b8f1-3bcbccaba931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_dac56478-ae58-481b-947f-83b71ac775e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4940a09a-adda-4798-b8f1-3bcbccaba931" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_dac56478-ae58-481b-947f-83b71ac775e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a9f3ab15-bc7b-4787-bddf-3591635bbb77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a9f3ab15-bc7b-4787-bddf-3591635bbb77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a9f3ab15-bc7b-4787-bddf-3591635bbb77_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a9f3ab15-bc7b-4787-bddf-3591635bbb77" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a9f3ab15-bc7b-4787-bddf-3591635bbb77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b1a5957a-f04b-4878-b322-29015a251e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a9f3ab15-bc7b-4787-bddf-3591635bbb77" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b1a5957a-f04b-4878-b322-29015a251e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_101c70c0-09c9-47af-a53f-91630ba3fe4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b1a5957a-f04b-4878-b322-29015a251e38" xlink:to="loc_us-gaap_CurrencySwapMember_101c70c0-09c9-47af-a53f-91630ba3fe4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7c3936cc-4db6-44fb-a8ad-4161adf68b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:to="loc_us-gaap_HedgingDesignationAxis_7c3936cc-4db6-44fb-a8ad-4161adf68b28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7c3936cc-4db6-44fb-a8ad-4161adf68b28_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7c3936cc-4db6-44fb-a8ad-4161adf68b28" xlink:to="loc_us-gaap_HedgingDesignationDomain_7c3936cc-4db6-44fb-a8ad-4161adf68b28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7666f6d6-8478-4e9a-9387-8c8f88e63ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7c3936cc-4db6-44fb-a8ad-4161adf68b28" xlink:to="loc_us-gaap_HedgingDesignationDomain_7666f6d6-8478-4e9a-9387-8c8f88e63ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9bb433d2-0225-4993-a6a4-dae7de9ea356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7666f6d6-8478-4e9a-9387-8c8f88e63ac8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9bb433d2-0225-4993-a6a4-dae7de9ea356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_62e4291f-6384-4a35-b245-c46bd21234dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_62e4291f-6384-4a35-b245-c46bd21234dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_62e4291f-6384-4a35-b245-c46bd21234dc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_62e4291f-6384-4a35-b245-c46bd21234dc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_62e4291f-6384-4a35-b245-c46bd21234dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eb353ae9-dc3b-4bf5-b024-31385d523c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_62e4291f-6384-4a35-b245-c46bd21234dc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eb353ae9-dc3b-4bf5-b024-31385d523c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_54c1222b-3358-4228-96ea-2f0cfe45e3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb353ae9-dc3b-4bf5-b024-31385d523c79" xlink:to="loc_us-gaap_InterestExpenseMember_54c1222b-3358-4228-96ea-2f0cfe45e3f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended" id="i93d4a996611f41c49ee29e12736340b4_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_40a3ba0a-7ac8-453d-b456-943ee55d4380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_40a3ba0a-7ac8-453d-b456-943ee55d4380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_81f3a7d2-d001-4114-a8f9-59ed267c15c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeLiabilities_81f3a7d2-d001-4114-a8f9-59ed267c15c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_eb35d4b7-4631-4942-b634-70a24c0cabe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_eb35d4b7-4631-4942-b634-70a24c0cabe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7c695ffc-ced9-4f18-930b-46dba96c028c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7c695ffc-ced9-4f18-930b-46dba96c028c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_db4c7496-ceca-4205-9e1a-99e62e97cecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_db4c7496-ceca-4205-9e1a-99e62e97cecb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_f935989c-2fa0-48ca-b43a-cc4125e6f60f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_f935989c-2fa0-48ca-b43a-cc4125e6f60f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30e904d2-d58b-4def-978f-2119d3fcfe7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30e904d2-d58b-4def-978f-2119d3fcfe7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_92694260-507b-408e-9990-b0a9b2ca8b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30e904d2-d58b-4def-978f-2119d3fcfe7b" xlink:to="loc_us-gaap_HedgingDesignationAxis_92694260-507b-408e-9990-b0a9b2ca8b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_92694260-507b-408e-9990-b0a9b2ca8b4c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_92694260-507b-408e-9990-b0a9b2ca8b4c" xlink:to="loc_us-gaap_HedgingDesignationDomain_92694260-507b-408e-9990-b0a9b2ca8b4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_45d4c55a-49c2-4501-a27f-f41e4a88822b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_92694260-507b-408e-9990-b0a9b2ca8b4c" xlink:to="loc_us-gaap_HedgingDesignationDomain_45d4c55a-49c2-4501-a27f-f41e4a88822b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_f8eb7387-db4d-4e59-a356-bb26954cd495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_45d4c55a-49c2-4501-a27f-f41e4a88822b" xlink:to="loc_us-gaap_NondesignatedMember_f8eb7387-db4d-4e59-a356-bb26954cd495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0b4e5965-4b7d-4049-bc60-5ba051350316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30e904d2-d58b-4def-978f-2119d3fcfe7b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0b4e5965-4b7d-4049-bc60-5ba051350316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0b4e5965-4b7d-4049-bc60-5ba051350316_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0b4e5965-4b7d-4049-bc60-5ba051350316" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0b4e5965-4b7d-4049-bc60-5ba051350316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_381f9625-46f2-4a77-9383-86a79f9f3a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0b4e5965-4b7d-4049-bc60-5ba051350316" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_381f9625-46f2-4a77-9383-86a79f9f3a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_049163ab-bad0-4bab-8210-3f88198f778b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_381f9625-46f2-4a77-9383-86a79f9f3a3c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_049163ab-bad0-4bab-8210-3f88198f778b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended" id="i7d1d446a430b4866b87418a3168e0e0e_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c91ba5f6-ec13-4140-8f20-32cebce17957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_711a1045-c97c-4925-af9f-5f0380d30a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c91ba5f6-ec13-4140-8f20-32cebce17957" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_711a1045-c97c-4925-af9f-5f0380d30a3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c91ba5f6-ec13-4140-8f20-32cebce17957" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48152d49-3689-43c0-9e95-94caf60a68ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48152d49-3689-43c0-9e95-94caf60a68ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_48152d49-3689-43c0-9e95-94caf60a68ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48152d49-3689-43c0-9e95-94caf60a68ab" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_48152d49-3689-43c0-9e95-94caf60a68ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b1869682-ed70-42e7-a621-94815b5e39ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48152d49-3689-43c0-9e95-94caf60a68ab" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b1869682-ed70-42e7-a621-94815b5e39ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6eaef6ec-530c-4be3-a261-6d48f02947a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b1869682-ed70-42e7-a621-94815b5e39ac" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6eaef6ec-530c-4be3-a261-6d48f02947a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9f1218ae-49de-4417-943b-4892c5def519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9f1218ae-49de-4417-943b-4892c5def519" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9f1218ae-49de-4417-943b-4892c5def519_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9f1218ae-49de-4417-943b-4892c5def519" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9f1218ae-49de-4417-943b-4892c5def519_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_07dae508-d9f2-475b-85cc-de86b2a9a3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9f1218ae-49de-4417-943b-4892c5def519" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_07dae508-d9f2-475b-85cc-de86b2a9a3e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_53f3e300-c863-410b-ac4d-1ac04d05dab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07dae508-d9f2-475b-85cc-de86b2a9a3e7" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_53f3e300-c863-410b-ac4d-1ac04d05dab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_5b4254ca-fd4e-4608-b376-36ea3b76887b" xlink:href="bhc-20200930.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07dae508-d9f2-475b-85cc-de86b2a9a3e7" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_5b4254ca-fd4e-4608-b376-36ea3b76887b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fd94332-c41c-4c51-904b-bca9fc3bfc26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fd94332-c41c-4c51-904b-bca9fc3bfc26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fd94332-c41c-4c51-904b-bca9fc3bfc26_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fd94332-c41c-4c51-904b-bca9fc3bfc26" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7fd94332-c41c-4c51-904b-bca9fc3bfc26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4496a168-4f3e-446f-b261-52a8a24b9737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fd94332-c41c-4c51-904b-bca9fc3bfc26" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4496a168-4f3e-446f-b261-52a8a24b9737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9f66618c-8d59-42ea-baeb-77196bd79ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4496a168-4f3e-446f-b261-52a8a24b9737" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9f66618c-8d59-42ea-baeb-77196bd79ed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16170d49-6515-41fa-a4ac-a72d7bca20dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:to="loc_srt_RangeAxis_16170d49-6515-41fa-a4ac-a72d7bca20dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_16170d49-6515-41fa-a4ac-a72d7bca20dc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16170d49-6515-41fa-a4ac-a72d7bca20dc" xlink:to="loc_srt_RangeMember_16170d49-6515-41fa-a4ac-a72d7bca20dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db1fdd82-8318-4a2e-9f4e-46f1027da35b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16170d49-6515-41fa-a4ac-a72d7bca20dc" xlink:to="loc_srt_RangeMember_db1fdd82-8318-4a2e-9f4e-46f1027da35b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72ebb012-909c-4631-a94a-1a41d5617996" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_db1fdd82-8318-4a2e-9f4e-46f1027da35b" xlink:to="loc_srt_MinimumMember_72ebb012-909c-4631-a94a-1a41d5617996" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_317322bf-84ec-48f6-b3c4-000b3c3dcbe0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_db1fdd82-8318-4a2e-9f4e-46f1027da35b" xlink:to="loc_srt_MaximumMember_317322bf-84ec-48f6-b3c4-000b3c3dcbe0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended" id="i3a5a66e4b28943ebaf40c7b207e33eee_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_87da4160-c4eb-45b2-844f-2edb9c5fe013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_87da4160-c4eb-45b2-844f-2edb9c5fe013" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f5b114f1-bf85-4c4b-ac26-7f1caba736dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f5b114f1-bf85-4c4b-ac26-7f1caba736dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a9c4c801-aec4-48bc-a045-b3942450cd64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a9c4c801-aec4-48bc-a045-b3942450cd64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c25a6e39-ed67-4858-962a-f9fad1d42a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c25a6e39-ed67-4858-962a-f9fad1d42a06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0a82a3b8-86e6-4b43-842f-736c3d480d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fb12d7dc-269d-4b2b-b185-4955c4403d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fb12d7dc-269d-4b2b-b185-4955c4403d24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3f4be04e-ab7c-4ccf-94b2-f292ca9657da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3f4be04e-ab7c-4ccf-94b2-f292ca9657da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2da34501-44a7-438b-a6b0-9176a70d187a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_87da4160-c4eb-45b2-844f-2edb9c5fe013" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2da34501-44a7-438b-a6b0-9176a70d187a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_43326199-68dc-4c1b-9e7d-a926bc39b8de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2da34501-44a7-438b-a6b0-9176a70d187a" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_43326199-68dc-4c1b-9e7d-a926bc39b8de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_43326199-68dc-4c1b-9e7d-a926bc39b8de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_43326199-68dc-4c1b-9e7d-a926bc39b8de" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_43326199-68dc-4c1b-9e7d-a926bc39b8de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c36cfc74-7013-4564-9f18-9b3ada6344a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_43326199-68dc-4c1b-9e7d-a926bc39b8de" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c36cfc74-7013-4564-9f18-9b3ada6344a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_4ec2db58-3451-484a-9835-bc98f8a5549a" xlink:href="bhc-20200930.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c36cfc74-7013-4564-9f18-9b3ada6344a0" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_4ec2db58-3451-484a-9835-bc98f8a5549a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_9b645577-418f-4769-bfb0-f409d23c040a" xlink:href="bhc-20200930.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c36cfc74-7013-4564-9f18-9b3ada6344a0" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_9b645577-418f-4769-bfb0-f409d23c040a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="extended" id="i09e0cdfa00904e83ba42315b4883a52a_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ff7e6d1-9633-4ca7-88a4-a0d2b14473db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_c14f4594-885a-438d-8e60-8eaa0056b4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ff7e6d1-9633-4ca7-88a4-a0d2b14473db" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_c14f4594-885a-438d-8e60-8eaa0056b4c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_a43842cb-378c-471c-bd2b-3e7ca15eb53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_c14f4594-885a-438d-8e60-8eaa0056b4c3" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_a43842cb-378c-471c-bd2b-3e7ca15eb53c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d009d3c0-bf4f-4dbb-acdb-8c76759f726e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ff7e6d1-9633-4ca7-88a4-a0d2b14473db" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d009d3c0-bf4f-4dbb-acdb-8c76759f726e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6517e7a-ce7f-460f-be17-bb67d6596e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d009d3c0-bf4f-4dbb-acdb-8c76759f726e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6517e7a-ce7f-460f-be17-bb67d6596e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6517e7a-ce7f-460f-be17-bb67d6596e02_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6517e7a-ce7f-460f-be17-bb67d6596e02" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6517e7a-ce7f-460f-be17-bb67d6596e02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_436bc20d-fa98-411d-b50b-439052f5594c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6517e7a-ce7f-460f-be17-bb67d6596e02" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_436bc20d-fa98-411d-b50b-439052f5594c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_5b6965fc-fa4a-499d-83ef-ef98913f09db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_436bc20d-fa98-411d-b50b-439052f5594c" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_5b6965fc-fa4a-499d-83ef-ef98913f09db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3c9e367f-7350-4638-8a38-a131f01e62cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d009d3c0-bf4f-4dbb-acdb-8c76759f726e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3c9e367f-7350-4638-8a38-a131f01e62cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9e367f-7350-4638-8a38-a131f01e62cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3c9e367f-7350-4638-8a38-a131f01e62cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9e367f-7350-4638-8a38-a131f01e62cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3c9e367f-7350-4638-8a38-a131f01e62cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e9b8e2eb-37ff-420a-8e6a-c75db0ebb4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e9b8e2eb-37ff-420a-8e6a-c75db0ebb4fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_132d5dd0-4be2-4a4b-9dca-687d59cddbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_132d5dd0-4be2-4a4b-9dca-687d59cddbf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_72c246ad-6b59-422b-811d-c9fdea267bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_72c246ad-6b59-422b-811d-c9fdea267bfa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended" id="iee219cb8e64d4f8e8cdbd6e8f0bcd3d6_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86198869-624e-45f0-b2a3-bcf40b80d9df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_2bb80dff-9bfc-49e5-b4fe-28aa039203ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86198869-624e-45f0-b2a3-bcf40b80d9df" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_2bb80dff-9bfc-49e5-b4fe-28aa039203ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_634cf896-5b8b-472c-bc34-ded7ea8a3f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86198869-624e-45f0-b2a3-bcf40b80d9df" xlink:to="loc_us-gaap_DebtInstrumentFairValue_634cf896-5b8b-472c-bc34-ded7ea8a3f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c03a39e8-fca9-4924-87fd-73cbb986435b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86198869-624e-45f0-b2a3-bcf40b80d9df" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c03a39e8-fca9-4924-87fd-73cbb986435b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888f8eae-4fd9-4141-a319-c3845ea959a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c03a39e8-fca9-4924-87fd-73cbb986435b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888f8eae-4fd9-4141-a319-c3845ea959a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_888f8eae-4fd9-4141-a319-c3845ea959a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888f8eae-4fd9-4141-a319-c3845ea959a7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_888f8eae-4fd9-4141-a319-c3845ea959a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e638fa3-81ab-404a-a348-0aae98da0c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888f8eae-4fd9-4141-a319-c3845ea959a7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e638fa3-81ab-404a-a348-0aae98da0c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_d8fd57f5-1822-4170-ab7c-a522a520a9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e638fa3-81ab-404a-a348-0aae98da0c92" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_d8fd57f5-1822-4170-ab7c-a522a520a9fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23401dca-8c12-4575-a159-a60fdd913011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c03a39e8-fca9-4924-87fd-73cbb986435b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23401dca-8c12-4575-a159-a60fdd913011" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23401dca-8c12-4575-a159-a60fdd913011_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23401dca-8c12-4575-a159-a60fdd913011" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23401dca-8c12-4575-a159-a60fdd913011_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2416e0b1-bad2-409a-935e-a6d8d6568b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23401dca-8c12-4575-a159-a60fdd913011" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2416e0b1-bad2-409a-935e-a6d8d6568b8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_be20f9a2-0b0f-4c1f-b51b-86ed011f70cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2416e0b1-bad2-409a-935e-a6d8d6568b8f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_be20f9a2-0b0f-4c1f-b51b-86ed011f70cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20200930.xsd#INVENTORIES"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended" id="ie50b6d326fe844dd814dc8185ab62862_INVENTORIES"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#INVENTORIESTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended" id="i5694ccea4c644afcb9df862ef08c9ca7_INVENTORIESTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended" id="i72c37d4d5b6742b1ad3ee55c1e928e04_INVENTORIESComponentsofInventoriesDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended" id="iac819426f1754111a2f15c70675c7dda_INTANGIBLEASSETSANDGOODWILL"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended" id="i436ef32250fb467780aa4cec4027cbe1_INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended" id="ia62c8ce7ce2b4af59ec8843e06f48104_INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:href="bhc-20200930.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9af2c563-30bd-4ee5-a0c5-619d02439306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9af2c563-30bd-4ee5-a0c5-619d02439306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a43eb22e-4f22-42c9-89f7-38b3eb5126c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a43eb22e-4f22-42c9-89f7-38b3eb5126c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21eb3c80-a422-49d1-9bb8-85877d9f6fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21eb3c80-a422-49d1-9bb8-85877d9f6fbd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_80d66d64-934e-4130-983f-07c0b84e5ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_80d66d64-934e-4130-983f-07c0b84e5ca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b555089b-7cab-4e24-9e9b-59cd419609f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_80d66d64-934e-4130-983f-07c0b84e5ca0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b555089b-7cab-4e24-9e9b-59cd419609f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9750c91e-338e-4db9-9baa-383a408f7066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9750c91e-338e-4db9-9baa-383a408f7066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9c818e07-d6ed-409f-9288-e639486d231f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9750c91e-338e-4db9-9baa-383a408f7066" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9c818e07-d6ed-409f-9288-e639486d231f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90d9b561-6c6c-4324-bc9d-901ae45dcbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9750c91e-338e-4db9-9baa-383a408f7066" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90d9b561-6c6c-4324-bc9d-901ae45dcbd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c1b17dec-6799-4b4b-9af2-0ffec70840d0" xlink:href="bhc-20200930.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c1b17dec-6799-4b4b-9af2-0ffec70840d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8d400-5c2e-4e71-9bd4-47cd1fc9e00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c1b17dec-6799-4b4b-9af2-0ffec70840d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8d400-5c2e-4e71-9bd4-47cd1fc9e00b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70c8d400-5c2e-4e71-9bd4-47cd1fc9e00b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8d400-5c2e-4e71-9bd4-47cd1fc9e00b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70c8d400-5c2e-4e71-9bd4-47cd1fc9e00b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8d400-5c2e-4e71-9bd4-47cd1fc9e00b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_e09ef553-e49e-43ef-8e2f-0d511be1ed26" xlink:href="bhc-20200930.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_bhc_ProductBrandsMember_e09ef553-e49e-43ef-8e2f-0d511be1ed26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_27b7fc61-9857-45f9-9a79-480d62203e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_us-gaap_TradeNamesMember_27b7fc61-9857-45f9-9a79-480d62203e63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_9abb0daa-1547-4c7a-b86e-0e6d2b95d15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_us-gaap_ContractualRightsMember_9abb0daa-1547-4c7a-b86e-0e6d2b95d15f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_350c7dfb-acb1-4ff8-82bc-0876ba24e884" xlink:href="bhc-20200930.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_bhc_PartnerRelationshipsMember_350c7dfb-acb1-4ff8-82bc-0876ba24e884" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_26e8d378-aa52-4db0-acb0-149de369a8b7" xlink:href="bhc-20200930.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_bhc_OutLicensedTechnologyMember_26e8d378-aa52-4db0-acb0-149de369a8b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c9f08048-d071-4154-99bd-56ad3ab622cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c1b17dec-6799-4b4b-9af2-0ffec70840d0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c9f08048-d071-4154-99bd-56ad3ab622cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c9f08048-d071-4154-99bd-56ad3ab622cb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c9f08048-d071-4154-99bd-56ad3ab622cb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c9f08048-d071-4154-99bd-56ad3ab622cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ea8b50be-49b8-42cc-b1ec-90effd83e4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c9f08048-d071-4154-99bd-56ad3ab622cb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ea8b50be-49b8-42cc-b1ec-90effd83e4f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_ce63d278-69db-4658-a589-3c5d76b75459" xlink:href="bhc-20200930.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ea8b50be-49b8-42cc-b1ec-90effd83e4f3" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_ce63d278-69db-4658-a589-3c5d76b75459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_d96c7c7c-8f88-4775-acd3-1472b47ef81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ea8b50be-49b8-42cc-b1ec-90effd83e4f3" xlink:to="loc_us-gaap_TradeNamesMember_d96c7c7c-8f88-4775-acd3-1472b47ef81a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended" id="icb671d87e354480f82fe66f6a3cb2790_INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_6ea2b2af-4baf-4261-9528-f192b178abdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_6ea2b2af-4baf-4261-9528-f192b178abdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_d3318dce-3ebc-4a4f-87b1-8446eafc3114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_d3318dce-3ebc-4a4f-87b1-8446eafc3114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_bcfc4c95-5ea5-451d-ab55-e424f9d611c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_bcfc4c95-5ea5-451d-ab55-e424f9d611c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_786e6400-5c2b-450f-8ba0-b4d744ef7ff1" xlink:href="bhc-20200930.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_786e6400-5c2b-450f-8ba0-b4d744ef7ff1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_374522d4-7b35-4533-882d-cee0782ffefa" xlink:href="bhc-20200930.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_374522d4-7b35-4533-882d-cee0782ffefa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9ecc3846-53bf-490e-b12d-c572c62ae0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9ecc3846-53bf-490e-b12d-c572c62ae0d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6cd7b9b5-1c64-4388-9f88-43fd1767524e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6cd7b9b5-1c64-4388-9f88-43fd1767524e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_756ea664-bac7-4d38-8a31-627ee24c8e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_756ea664-bac7-4d38-8a31-627ee24c8e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_756ea664-bac7-4d38-8a31-627ee24c8e71_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_756ea664-bac7-4d38-8a31-627ee24c8e71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_756ea664-bac7-4d38-8a31-627ee24c8e71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51af483c-b68f-4d58-95cf-42b7e18fbc83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_756ea664-bac7-4d38-8a31-627ee24c8e71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51af483c-b68f-4d58-95cf-42b7e18fbc83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_df971909-3dc3-4c82-8512-2223260d1cb7" xlink:href="bhc-20200930.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51af483c-b68f-4d58-95cf-42b7e18fbc83" xlink:to="loc_bhc_ProductBrandsMember_df971909-3dc3-4c82-8512-2223260d1cb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_e063c07a-0bef-43d9-b5b9-8b8ea805de8d" xlink:href="bhc-20200930.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51af483c-b68f-4d58-95cf-42b7e18fbc83" xlink:to="loc_bhc_DiscontinuedProductLinesMember_e063c07a-0bef-43d9-b5b9-8b8ea805de8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_749de55e-e15e-42e5-8db3-06908e3f764f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_srt_RangeAxis_749de55e-e15e-42e5-8db3-06908e3f764f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_749de55e-e15e-42e5-8db3-06908e3f764f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_749de55e-e15e-42e5-8db3-06908e3f764f" xlink:to="loc_srt_RangeMember_749de55e-e15e-42e5-8db3-06908e3f764f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cba96f4-d3d8-402e-9569-467b319b5c78" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_749de55e-e15e-42e5-8db3-06908e3f764f" xlink:to="loc_srt_RangeMember_1cba96f4-d3d8-402e-9569-467b319b5c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_639f0f88-e8bd-4358-b5fc-26b7f45b706d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cba96f4-d3d8-402e-9569-467b319b5c78" xlink:to="loc_srt_MaximumMember_639f0f88-e8bd-4358-b5fc-26b7f45b706d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d29d8ef9-0063-43d9-b71c-bada000547e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1cba96f4-d3d8-402e-9569-467b319b5c78" xlink:to="loc_srt_MinimumMember_d29d8ef9-0063-43d9-b71c-bada000547e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_dfb6435e-46bf-48ae-ae64-492777635ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_dfb6435e-46bf-48ae-ae64-492777635ede" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dfb6435e-46bf-48ae-ae64-492777635ede_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dfb6435e-46bf-48ae-ae64-492777635ede" xlink:to="loc_us-gaap_SegmentDomain_dfb6435e-46bf-48ae-ae64-492777635ede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1acf021e-5aa1-4059-b1c7-226cea045da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dfb6435e-46bf-48ae-ae64-492777635ede" xlink:to="loc_us-gaap_SegmentDomain_1acf021e-5aa1-4059-b1c7-226cea045da0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_726f8bda-11cd-4063-a3f2-199f36677fb8" xlink:href="bhc-20200930.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1acf021e-5aa1-4059-b1c7-226cea045da0" xlink:to="loc_bhc_SalixSegmentMember_726f8bda-11cd-4063-a3f2-199f36677fb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_8c810610-76ac-482f-b8e5-8d55e9569dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_ReportingUnitAxis_8c810610-76ac-482f-b8e5-8d55e9569dbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_8c810610-76ac-482f-b8e5-8d55e9569dbe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_8c810610-76ac-482f-b8e5-8d55e9569dbe" xlink:to="loc_us-gaap_ReportingUnitDomain_8c810610-76ac-482f-b8e5-8d55e9569dbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_7fbc21d2-e748-42fc-9963-d388e6dee387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_8c810610-76ac-482f-b8e5-8d55e9569dbe" xlink:to="loc_us-gaap_ReportingUnitDomain_7fbc21d2-e748-42fc-9963-d388e6dee387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportUnitMember_179c90ed-82c8-4a88-a462-bb588a05024a" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsReportUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_7fbc21d2-e748-42fc-9963-d388e6dee387" xlink:to="loc_bhc_OrthoDermatologicsReportUnitMember_179c90ed-82c8-4a88-a462-bb588a05024a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_67392d4c-d21f-4007-a054-93891db23c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_67392d4c-d21f-4007-a054-93891db23c4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_67392d4c-d21f-4007-a054-93891db23c4f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_67392d4c-d21f-4007-a054-93891db23c4f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_67392d4c-d21f-4007-a054-93891db23c4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_783c09b6-72cf-4932-858b-b05006c9e856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_67392d4c-d21f-4007-a054-93891db23c4f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_783c09b6-72cf-4932-858b-b05006c9e856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_ac629a55-29f9-4796-951e-416cd717bf46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_783c09b6-72cf-4932-858b-b05006c9e856" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_ac629a55-29f9-4796-951e-416cd717bf46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4e1a7557-972d-431f-80ed-278d945be186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4e1a7557-972d-431f-80ed-278d945be186" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e1a7557-972d-431f-80ed-278d945be186_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4e1a7557-972d-431f-80ed-278d945be186" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4e1a7557-972d-431f-80ed-278d945be186_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b62b8dc7-7b31-4ea8-8fef-c4eb07e6caf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4e1a7557-972d-431f-80ed-278d945be186" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b62b8dc7-7b31-4ea8-8fef-c4eb07e6caf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_20133bd2-4a5a-4890-abba-86acfb0364bf" xlink:href="bhc-20200930.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b62b8dc7-7b31-4ea8-8fef-c4eb07e6caf7" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_20133bd2-4a5a-4890-abba-86acfb0364bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended" id="i8356ef7044524f888c08f3585d29686f_INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended" id="i8e0e85ca525442c8b4ba62d4f7538bce_INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_0dcf7321-1022-42de-8b7d-b44e1b10fd3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcf7321-1022-42de-8b7d-b44e1b10fd3a" xlink:to="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eaa046ad-328e-4fcf-8883-9d7c9920105f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_us-gaap_Goodwill_eaa046ad-328e-4fcf-8883-9d7c9920105f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_77a99352-142f-4ab3-b4f5-cf9c99e87545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_77a99352-142f-4ab3-b4f5-cf9c99e87545" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_8b704bac-3c02-4d52-90d8-01208eac1f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_8b704bac-3c02-4d52-90d8-01208eac1f65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4c646985-b398-44f8-bb95-54ba4e6bb733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4c646985-b398-44f8-bb95-54ba4e6bb733" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillReclassifiedDuringPeriod_7e4fc29c-1c6a-4dae-b2b8-9c530c89e07f" xlink:href="bhc-20200930.xsd#bhc_GoodwillReclassifiedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_bhc_GoodwillReclassifiedDuringPeriod_7e4fc29c-1c6a-4dae-b2b8-9c530c89e07f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f04e2394-440a-4879-8f48-34b2f4785b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_94a4fed7-13c7-47ce-9395-77f9c668f4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_0dcf7321-1022-42de-8b7d-b44e1b10fd3a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_94a4fed7-13c7-47ce-9395-77f9c668f4b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e933ebff-e0f3-4dc2-913b-3da77df6ff8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_94a4fed7-13c7-47ce-9395-77f9c668f4b1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e933ebff-e0f3-4dc2-913b-3da77df6ff8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e933ebff-e0f3-4dc2-913b-3da77df6ff8c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e933ebff-e0f3-4dc2-913b-3da77df6ff8c" xlink:to="loc_us-gaap_SegmentDomain_e933ebff-e0f3-4dc2-913b-3da77df6ff8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e933ebff-e0f3-4dc2-913b-3da77df6ff8c" xlink:to="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_35d6fdff-2c2b-4221-a0e7-30bf546478f9" xlink:href="bhc-20200930.xsd#bhc_BauschLombInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:to="loc_bhc_BauschLombInternationalMember_35d6fdff-2c2b-4221-a0e7-30bf546478f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_8f3b2ece-0af4-4138-8334-7b711e5446d9" xlink:href="bhc-20200930.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:to="loc_bhc_SalixSegmentMember_8f3b2ece-0af4-4138-8334-7b711e5446d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_31c0487d-492d-4df5-bed0-f906ab018ece" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_31c0487d-492d-4df5-bed0-f906ab018ece" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_33ee28d2-1d80-443b-8d95-4acbdd7e7708" xlink:href="bhc-20200930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_33ee28d2-1d80-443b-8d95-4acbdd7e7708" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended" id="ieedc5217aa014b8cae267dc3be8f6793_ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended" id="ife1f4d2dd0a74f27a4060da1583177bf_ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended" id="ib083e9a0917744d3895417279ab3bcaa_ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended" id="i0934092d97614afc93b93bd2b7c2bf5f_FINANCINGARRANGEMENTS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended" id="ib0eeba41bdc74495863d67d0a0c81639_FINANCINGARRANGEMENTSTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended" id="ic58b25daf5244db38b7020f988f0e4bb_FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cef5d64a-7ee7-4c7a-835c-369f2640eaaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cef5d64a-7ee7-4c7a-835c-369f2640eaaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f1ee83ae-6023-42b4-a54b-700bd38c07f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f1ee83ae-6023-42b4-a54b-700bd38c07f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_013cf1f2-710d-4eb2-a1e2-c4f55555e1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_LongTermDebt_013cf1f2-710d-4eb2-a1e2-c4f55555e1c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5675a3e3-ad64-4f2a-a320-2baef422dc82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_LongTermDebtCurrent_5675a3e3-ad64-4f2a-a320-2baef422dc82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_be3f3966-2442-4c4a-b770-ef575516d4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_be3f3966-2442-4c4a-b770-ef575516d4bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_756306c3-84bc-4aba-a714-f38158b49fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:to="loc_us-gaap_CreditFacilityAxis_756306c3-84bc-4aba-a714-f38158b49fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_756306c3-84bc-4aba-a714-f38158b49fc2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_756306c3-84bc-4aba-a714-f38158b49fc2" xlink:to="loc_us-gaap_CreditFacilityDomain_756306c3-84bc-4aba-a714-f38158b49fc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_da02eee5-76bc-4821-b54c-1c7cf2205385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_756306c3-84bc-4aba-a714-f38158b49fc2" xlink:to="loc_us-gaap_CreditFacilityDomain_da02eee5-76bc-4821-b54c-1c7cf2205385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a28e4419-3ca4-42ac-b79e-468bad4b75dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_da02eee5-76bc-4821-b54c-1c7cf2205385" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a28e4419-3ca4-42ac-b79e-468bad4b75dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e6d6563c-3e95-4ebf-a89b-1dda484f094d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e6d6563c-3e95-4ebf-a89b-1dda484f094d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e6d6563c-3e95-4ebf-a89b-1dda484f094d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e6d6563c-3e95-4ebf-a89b-1dda484f094d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e6d6563c-3e95-4ebf-a89b-1dda484f094d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_41d66e37-0817-445c-9414-12b7637cab48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e6d6563c-3e95-4ebf-a89b-1dda484f094d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_41d66e37-0817-445c-9414-12b7637cab48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d4aea9fc-c369-4a69-b575-a2c91f66471e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_41d66e37-0817-445c-9414-12b7637cab48" xlink:to="loc_us-gaap_SecuredDebtMember_d4aea9fc-c369-4a69-b575-a2c91f66471e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_4fbacee1-3796-4c7b-8f3f-3c06d9060c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_41d66e37-0817-445c-9414-12b7637cab48" xlink:to="loc_us-gaap_UnsecuredDebtMember_4fbacee1-3796-4c7b-8f3f-3c06d9060c3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_14f44f64-1818-42ee-95d1-e3b330798642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:to="loc_us-gaap_DebtInstrumentAxis_14f44f64-1818-42ee-95d1-e3b330798642" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14f44f64-1818-42ee-95d1-e3b330798642_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_14f44f64-1818-42ee-95d1-e3b330798642" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14f44f64-1818-42ee-95d1-e3b330798642_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_14f44f64-1818-42ee-95d1-e3b330798642" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_bb2da989-2ac8-448c-ace2-8fe4ac7e0695" xlink:href="bhc-20200930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_bb2da989-2ac8-448c-ace2-8fe4ac7e0695" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_02df8a27-ab34-4bca-85bd-bacad8729460" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_02df8a27-ab34-4bca-85bd-bacad8729460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_97518453-1b22-4ec0-ab78-4b12c155e9d4" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_97518453-1b22-4ec0-ab78-4b12c155e9d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_a4596cc3-e0d1-44a7-9619-527fc4d108c0" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_a4596cc3-e0d1-44a7-9619-527fc4d108c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_f0428e97-dd38-4ab0-a825-fdeee87aa543" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_f0428e97-dd38-4ab0-a825-fdeee87aa543" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_2ba46414-d15a-44b7-bbaf-3ad0f598feaa" xlink:href="bhc-20200930.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_2ba46414-d15a-44b7-bbaf-3ad0f598feaa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_bd7ea5e3-240e-42f0-a20a-455ed76e29ee" xlink:href="bhc-20200930.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_bd7ea5e3-240e-42f0-a20a-455ed76e29ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_16b7f753-b1fa-4a67-b89e-c01e22f395b1" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_16b7f753-b1fa-4a67-b89e-c01e22f395b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5875DueMay2023Member_3fd6c17b-abae-49e8-822a-44318e2c71d6" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5875DueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes5875DueMay2023Member_3fd6c17b-abae-49e8-822a-44318e2c71d6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes450DueMay2023Member_0b7d5983-0de1-46d7-942c-dc3b072f44b5" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes450DueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes450DueMay2023Member_0b7d5983-0de1-46d7-942c-dc3b072f44b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_47ad5689-857c-4d7a-a34f-bda230abf2c0" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_47ad5689-857c-4d7a-a34f-bda230abf2c0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_34ca6438-4b75-4e0c-8ebd-eb71a85e0890" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_34ca6438-4b75-4e0c-8ebd-eb71a85e0890" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_4fcc618d-7d2e-4e4e-ac40-103fd22186d5" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_4fcc618d-7d2e-4e4e-ac40-103fd22186d5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_5ededdae-e56e-4365-88a9-5cf900811cc4" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_5ededdae-e56e-4365-88a9-5cf900811cc4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_ffc643c0-556e-4763-831a-7ffc74353195" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_ffc643c0-556e-4763-831a-7ffc74353195" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_5014402c-0df6-4d90-8172-ec27927dc543" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_5014402c-0df6-4d90-8172-ec27927dc543" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_ae0ad5d7-1f04-4307-9ee4-91bda4de5878" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_ae0ad5d7-1f04-4307-9ee4-91bda4de5878" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_35022a6b-2f71-4fc2-8221-fef2903abc5b" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_35022a6b-2f71-4fc2-8221-fef2903abc5b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_64fbffad-bbcd-4e1e-b825-7020363bea63" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_64fbffad-bbcd-4e1e-b825-7020363bea63" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_8725da31-82f8-4b93-bff0-dc63383cf722" xlink:href="bhc-20200930.xsd#bhc_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_OtherLongTermDebtMember_8725da31-82f8-4b93-bff0-dc63383cf722" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended" id="ic56d216ca6514352825f51ef69fac79c_FINANCINGARRANGEMENTSCovenantComplianceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d0e9a79f-5064-4580-8c68-1a75a95ff063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_3f3f8449-57ac-4088-9b2c-a2639096d85b" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0e9a79f-5064-4580-8c68-1a75a95ff063" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_3f3f8449-57ac-4088-9b2c-a2639096d85b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_ff34cfb3-f2e7-4b95-9957-66fd9d59ca6f" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0e9a79f-5064-4580-8c68-1a75a95ff063" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_ff34cfb3-f2e7-4b95-9957-66fd9d59ca6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1f9e5910-9bf4-4b94-bb5f-79b237011e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0e9a79f-5064-4580-8c68-1a75a95ff063" xlink:to="loc_us-gaap_DebtInstrumentTable_1f9e5910-9bf4-4b94-bb5f-79b237011e4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_27d7d6ca-9a39-4230-9054-63a095655c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1f9e5910-9bf4-4b94-bb5f-79b237011e4c" xlink:to="loc_us-gaap_CreditFacilityAxis_27d7d6ca-9a39-4230-9054-63a095655c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_27d7d6ca-9a39-4230-9054-63a095655c28_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_27d7d6ca-9a39-4230-9054-63a095655c28" xlink:to="loc_us-gaap_CreditFacilityDomain_27d7d6ca-9a39-4230-9054-63a095655c28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bec0b115-a70d-4b7a-9a15-c2825b676b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_27d7d6ca-9a39-4230-9054-63a095655c28" xlink:to="loc_us-gaap_CreditFacilityDomain_bec0b115-a70d-4b7a-9a15-c2825b676b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_2fd068b3-82e5-4590-b261-9d1420ecb976" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_bec0b115-a70d-4b7a-9a15-c2825b676b32" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_2fd068b3-82e5-4590-b261-9d1420ecb976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_68c3c5f4-e078-4fd3-b713-15ad62b5fa37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_bec0b115-a70d-4b7a-9a15-c2825b676b32" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_68c3c5f4-e078-4fd3-b713-15ad62b5fa37" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="ia75778e61f8e4703bb9074ed7227aa7e_FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_660ce00f-43d3-449c-b74d-05774e4708bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_660ce00f-43d3-449c-b74d-05774e4708bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_ed2cb750-39eb-4074-a6d6-f3eeb972fbbb" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_ed2cb750-39eb-4074-a6d6-f3eeb972fbbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_dfb77c9c-cc9a-4409-a475-946fab04e36c" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_dfb77c9c-cc9a-4409-a475-946fab04e36c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8abccabb-fc9a-4a8f-84ad-376b3ad50c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8abccabb-fc9a-4a8f-84ad-376b3ad50c90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c57b93c8-3b85-4788-9928-f8fc117f6b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c57b93c8-3b85-4788-9928-f8fc117f6b06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_ae857b93-e923-4f79-a878-e527fe73f0d2" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_ae857b93-e923-4f79-a878-e527fe73f0d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_1f4a4b91-5c5b-4f9a-8cad-3f4b91ad27f1" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_1f4a4b91-5c5b-4f9a-8cad-3f4b91ad27f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_34d97977-62bd-4307-a774-6e86d249d5bd" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_34d97977-62bd-4307-a774-6e86d249d5bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_2ba4237e-5103-4c67-bdad-4aace3748681" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_2ba4237e-5103-4c67-bdad-4aace3748681" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ded5e76d-f383-4447-8785-051aaff29104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ded5e76d-f383-4447-8785-051aaff29104" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_c136c31a-832d-45d9-8a46-b20d240c0613" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_c136c31a-832d-45d9-8a46-b20d240c0613" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_ecc0f426-d710-47fb-a3c3-48e0b8ba4e54" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_ecc0f426-d710-47fb-a3c3-48e0b8ba4e54" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_dff1f456-cead-4de9-b87b-af84f268bad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_LongTermDebt_dff1f456-cead-4de9-b87b-af84f268bad4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f7b2e6d0-6149-441c-9f71-dfbeee2426b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f7b2e6d0-6149-441c-9f71-dfbeee2426b9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_46f7eded-2f13-42a0-ac08-baa7422a4b19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_46f7eded-2f13-42a0-ac08-baa7422a4b19" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_cce180bf-fbfb-40e3-8484-ae1ed101d4bb" xlink:href="bhc-20200930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_cce180bf-fbfb-40e3-8484-ae1ed101d4bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_c24c0162-159f-444c-96b2-bd515750a4f7" xlink:href="bhc-20200930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_c24c0162-159f-444c-96b2-bd515750a4f7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_c056eee3-2dff-423a-9f2a-233e1d6d0b7d" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_c056eee3-2dff-423a-9f2a-233e1d6d0b7d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_1fe7153f-11ee-4622-917a-dc1242cddd67" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_1fe7153f-11ee-4622-917a-dc1242cddd67" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_490e1924-fcc3-4bd9-87fd-3435749270ac" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_490e1924-fcc3-4bd9-87fd-3435749270ac" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d75288c0-9f98-4376-b070-b5167760576c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_us-gaap_CreditFacilityAxis_d75288c0-9f98-4376-b070-b5167760576c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d75288c0-9f98-4376-b070-b5167760576c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_d75288c0-9f98-4376-b070-b5167760576c" xlink:to="loc_us-gaap_CreditFacilityDomain_d75288c0-9f98-4376-b070-b5167760576c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a26561d5-1f3c-485b-9b3f-a8f25466f816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_d75288c0-9f98-4376-b070-b5167760576c" xlink:to="loc_us-gaap_CreditFacilityDomain_a26561d5-1f3c-485b-9b3f-a8f25466f816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2fa5c800-b792-4bd4-9ed8-55ffcfd4c790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a26561d5-1f3c-485b-9b3f-a8f25466f816" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2fa5c800-b792-4bd4-9ed8-55ffcfd4c790" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_23a6ca58-5976-4bf4-9efe-00eb4ddaecaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_a26561d5-1f3c-485b-9b3f-a8f25466f816" xlink:to="loc_us-gaap_LetterOfCreditMember_23a6ca58-5976-4bf4-9efe-00eb4ddaecaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af4c7957-6c88-4f40-9dc4-85990890eff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_us-gaap_DebtInstrumentAxis_af4c7957-6c88-4f40-9dc4-85990890eff9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_af4c7957-6c88-4f40-9dc4-85990890eff9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_af4c7957-6c88-4f40-9dc4-85990890eff9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_af4c7957-6c88-4f40-9dc4-85990890eff9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_af4c7957-6c88-4f40-9dc4-85990890eff9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_7e743d06-28ff-4069-b9c5-033b4f5e0d4b" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_7e743d06-28ff-4069-b9c5-033b4f5e0d4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_d14f477b-66cf-4dc0-b5da-6fc248163e8a" xlink:href="bhc-20200930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_d14f477b-66cf-4dc0-b5da-6fc248163e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_1be0bfbd-7aff-4287-a378-e70cdac6cf45" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_1be0bfbd-7aff-4287-a378-e70cdac6cf45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_316311db-c9c4-4a56-85c1-8c844f3bd959" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_316311db-c9c4-4a56-85c1-8c844f3bd959" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f793e17a-cc90-478f-8c6c-b99fd5ab2452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_us-gaap_VariableRateAxis_f793e17a-cc90-478f-8c6c-b99fd5ab2452" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f793e17a-cc90-478f-8c6c-b99fd5ab2452_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_f793e17a-cc90-478f-8c6c-b99fd5ab2452" xlink:to="loc_us-gaap_VariableRateDomain_f793e17a-cc90-478f-8c6c-b99fd5ab2452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_f793e17a-cc90-478f-8c6c-b99fd5ab2452" xlink:to="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_56ce3ca2-afa2-4c38-96a3-1a1fa5acd2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_56ce3ca2-afa2-4c38-96a3-1a1fa5acd2f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_adb79af5-addf-419d-9016-b64021553465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_us-gaap_EurodollarMember_adb79af5-addf-419d-9016-b64021553465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember_fc1fe481-0e7c-4947-8ace-dce825579b9f" xlink:href="bhc-20200930.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_bhc_CanadaBankersAcceptanceRateMember_fc1fe481-0e7c-4947-8ace-dce825579b9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_48b98c23-b4b4-4c86-9617-7747f73894b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_us-gaap_BaseRateMember_48b98c23-b4b4-4c86-9617-7747f73894b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember_7a5092b8-6b7e-44c9-808a-ad9bdd996042" xlink:href="bhc-20200930.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_bhc_BaseRateOrPrimeRateMember_7a5092b8-6b7e-44c9-808a-ad9bdd996042" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5dd1baa-400e-4365-b3a0-9548a9e0bacd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_srt_RangeAxis_c5dd1baa-400e-4365-b3a0-9548a9e0bacd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5dd1baa-400e-4365-b3a0-9548a9e0bacd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c5dd1baa-400e-4365-b3a0-9548a9e0bacd" xlink:to="loc_srt_RangeMember_c5dd1baa-400e-4365-b3a0-9548a9e0bacd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27097549-a1ab-4377-903e-c0d0e465d66e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c5dd1baa-400e-4365-b3a0-9548a9e0bacd" xlink:to="loc_srt_RangeMember_27097549-a1ab-4377-903e-c0d0e465d66e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7df0d951-6b26-444c-a639-c4d6ba606482" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27097549-a1ab-4377-903e-c0d0e465d66e" xlink:to="loc_srt_MinimumMember_7df0d951-6b26-444c-a639-c4d6ba606482" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b87b6a2e-e3aa-4b52-b47f-f6667c962107" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_27097549-a1ab-4377-903e-c0d0e465d66e" xlink:to="loc_srt_MaximumMember_b87b6a2e-e3aa-4b52-b47f-f6667c962107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4384dc22-35bc-4e97-9752-94075b4b6c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4384dc22-35bc-4e97-9752-94075b4b6c08" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4384dc22-35bc-4e97-9752-94075b4b6c08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4384dc22-35bc-4e97-9752-94075b4b6c08" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4384dc22-35bc-4e97-9752-94075b4b6c08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d77d9d17-d48c-495b-9604-0b9286ef14d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4384dc22-35bc-4e97-9752-94075b4b6c08" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d77d9d17-d48c-495b-9604-0b9286ef14d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_11f7f0ef-5145-4f22-bc41-cdabd27d538f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d77d9d17-d48c-495b-9604-0b9286ef14d7" xlink:to="loc_us-gaap_SecuredDebtMember_11f7f0ef-5145-4f22-bc41-cdabd27d538f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_a223f9f8-1d50-4ae3-89ee-c20b4084acb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d77d9d17-d48c-495b-9604-0b9286ef14d7" xlink:to="loc_us-gaap_UnsecuredDebtMember_a223f9f8-1d50-4ae3-89ee-c20b4084acb7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended" id="i34076cc5fa8d44588006195c52e18dd7_FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_98c32d10-1824-42d9-9b01-4f5155f40930" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_98c32d10-1824-42d9-9b01-4f5155f40930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_84b06420-48f7-41b5-a3e4-cabab1a5bbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_84b06420-48f7-41b5-a3e4-cabab1a5bbf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_19628d44-b4f3-4b8b-a0b3-fa7874dd7177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_19628d44-b4f3-4b8b-a0b3-fa7874dd7177" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_84d682ba-bb7e-404d-abae-2f0714c736f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_84d682ba-bb7e-404d-abae-2f0714c736f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_aac94320-1220-49cf-99d4-a0bacc3b16aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:to="loc_us-gaap_DebtInstrumentTable_aac94320-1220-49cf-99d4-a0bacc3b16aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e6b48dda-2171-4198-97cd-a8917e69f496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aac94320-1220-49cf-99d4-a0bacc3b16aa" xlink:to="loc_us-gaap_DebtInstrumentAxis_e6b48dda-2171-4198-97cd-a8917e69f496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e6b48dda-2171-4198-97cd-a8917e69f496_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e6b48dda-2171-4198-97cd-a8917e69f496" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e6b48dda-2171-4198-97cd-a8917e69f496_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e6b48dda-2171-4198-97cd-a8917e69f496" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_7c4168b0-150f-433c-835b-fc5954b26b6d" xlink:href="bhc-20200930.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_7c4168b0-150f-433c-835b-fc5954b26b6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_ddce5228-bcb2-4ae6-91f0-beea62246ad5" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_ddce5228-bcb2-4ae6-91f0-beea62246ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5875DueMay2023Member_57c2835d-925a-42cc-9ab9-2924599ebff3" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5875DueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorNotes5875DueMay2023Member_57c2835d-925a-42cc-9ab9-2924599ebff3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_e218ba79-c294-42c5-8e10-7fb9b3145b5c" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5.625PercentDueDecember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_e218ba79-c294-42c5-8e10-7fb9b3145b5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_7ac63515-ff9e-4b0c-8cc1-02f57ee23d94" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_7ac63515-ff9e-4b0c-8cc1-02f57ee23d94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_d67d1a23-c781-453b-b018-81907859c9ef" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_d67d1a23-c781-453b-b018-81907859c9ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e63aec2c-c198-4566-b6b4-695f6dfa3eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aac94320-1220-49cf-99d4-a0bacc3b16aa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e63aec2c-c198-4566-b6b4-695f6dfa3eea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e63aec2c-c198-4566-b6b4-695f6dfa3eea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e63aec2c-c198-4566-b6b4-695f6dfa3eea" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e63aec2c-c198-4566-b6b4-695f6dfa3eea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_896837c2-5ec0-4897-8769-4276a1fe0499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e63aec2c-c198-4566-b6b4-695f6dfa3eea" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_896837c2-5ec0-4897-8769-4276a1fe0499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5b5e390f-27ad-41e3-86a1-ffc5657dd12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_896837c2-5ec0-4897-8769-4276a1fe0499" xlink:to="loc_us-gaap_SeniorNotesMember_5b5e390f-27ad-41e3-86a1-ffc5657dd12e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_70b7ab4d-957c-45f9-a488-8dfb2b3275e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_896837c2-5ec0-4897-8769-4276a1fe0499" xlink:to="loc_us-gaap_UnsecuredDebtMember_70b7ab4d-957c-45f9-a488-8dfb2b3275e3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended" id="i08f7a532b5944df5962cbe3ee35379db_FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_4ea7b8c5-e809-4aa7-81e7-5d8a942023dd" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_4ea7b8c5-e809-4aa7-81e7-5d8a942023dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1b938380-b656-4002-9b4a-294f05b7883c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1b938380-b656-4002-9b4a-294f05b7883c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3001cf31-c46b-4c4f-a1ca-2e4f04c272b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3001cf31-c46b-4c4f-a1ca-2e4f04c272b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_7f1e873b-c2ea-4f2d-9c43-5ea3362f7aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_7f1e873b-c2ea-4f2d-9c43-5ea3362f7aa7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8467c1d8-17a3-4641-9e5b-baae2508b10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8467c1d8-17a3-4641-9e5b-baae2508b10b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e096aca6-994c-4245-988d-49d57e3c75a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e096aca6-994c-4245-988d-49d57e3c75a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_7514641c-a73e-4994-8d5c-542816485966" xlink:href="bhc-20200930.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_7514641c-a73e-4994-8d5c-542816485966" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_81a50fcb-12c6-443c-96f6-e55f924c68f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_81a50fcb-12c6-443c-96f6-e55f924c68f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a3200daf-8354-4404-a881-2246fc60ca07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a3200daf-8354-4404-a881-2246fc60ca07" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_368aa0ef-2b4e-4beb-bc24-90cb06dcbba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_368aa0ef-2b4e-4beb-bc24-90cb06dcbba5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3883e554-55f8-4178-90f1-964e2630030a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3883e554-55f8-4178-90f1-964e2630030a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3883e554-55f8-4178-90f1-964e2630030a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3883e554-55f8-4178-90f1-964e2630030a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3883e554-55f8-4178-90f1-964e2630030a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_076e3d6f-4cb4-4158-9c14-491e9efb33ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3883e554-55f8-4178-90f1-964e2630030a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_076e3d6f-4cb4-4158-9c14-491e9efb33ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2aadace3-133a-4e46-9144-13e9ae0913c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_076e3d6f-4cb4-4158-9c14-491e9efb33ed" xlink:to="loc_us-gaap_UnsecuredDebtMember_2aadace3-133a-4e46-9144-13e9ae0913c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_75779b8a-5aab-41aa-8704-4453ac65cd9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_076e3d6f-4cb4-4158-9c14-491e9efb33ed" xlink:to="loc_us-gaap_SecuredDebtMember_75779b8a-5aab-41aa-8704-4453ac65cd9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6005f907-1985-45cf-802f-eda04cc56e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_us-gaap_DebtInstrumentAxis_6005f907-1985-45cf-802f-eda04cc56e92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6005f907-1985-45cf-802f-eda04cc56e92_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6005f907-1985-45cf-802f-eda04cc56e92" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6005f907-1985-45cf-802f-eda04cc56e92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6005f907-1985-45cf-802f-eda04cc56e92" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_03141143-00c5-4bd0-b783-cc47d2d1c3ca" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_03141143-00c5-4bd0-b783-cc47d2d1c3ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_ee7bca17-60db-4c81-9879-4ae114caa1a2" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_ee7bca17-60db-4c81-9879-4ae114caa1a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_f63c970b-4663-4ef7-a237-35da67456beb" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_f63c970b-4663-4ef7-a237-35da67456beb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5875DueMay2023Member_a87be135-20d2-48b6-8f8d-539bed12474d" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5875DueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes5875DueMay2023Member_a87be135-20d2-48b6-8f8d-539bed12474d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_cadd5f6e-7bd8-459c-97d8-0526969edd59" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_cadd5f6e-7bd8-459c-97d8-0526969edd59" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_2ec53454-e4a6-4089-bc19-1e837380ac5d" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_2ec53454-e4a6-4089-bc19-1e837380ac5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_2ce60fe9-047c-46d7-a133-ffe93d278349" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_2ce60fe9-047c-46d7-a133-ffe93d278349" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_8e27d390-cf4f-4ce3-9df9-3a34986f30be" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_8e27d390-cf4f-4ce3-9df9-3a34986f30be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_48285e1e-d1a7-4623-a494-4869bf29fe02" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_48285e1e-d1a7-4623-a494-4869bf29fe02" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_d37c2462-6867-4d16-9700-2ed3f01e13ac" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_d37c2462-6867-4d16-9700-2ed3f01e13ac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_30a884bd-2d87-435b-b187-98cae0554d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_us-gaap_LitigationStatusAxis_30a884bd-2d87-435b-b187-98cae0554d0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_30a884bd-2d87-435b-b187-98cae0554d0d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_30a884bd-2d87-435b-b187-98cae0554d0d" xlink:to="loc_us-gaap_LitigationStatusDomain_30a884bd-2d87-435b-b187-98cae0554d0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_1adca61f-aabb-4287-baed-3207f51a7a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_30a884bd-2d87-435b-b187-98cae0554d0d" xlink:to="loc_us-gaap_LitigationStatusDomain_1adca61f-aabb-4287-baed-3207f51a7a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_25b5c548-305d-40e3-8ba2-aedda1871684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_1adca61f-aabb-4287-baed-3207f51a7a47" xlink:to="loc_us-gaap_SettledLitigationMember_25b5c548-305d-40e3-8ba2-aedda1871684" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_17e7cf13-2518-4038-a85e-341b477c2c4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_srt_LitigationCaseAxis_17e7cf13-2518-4038-a85e-341b477c2c4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_17e7cf13-2518-4038-a85e-341b477c2c4e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_17e7cf13-2518-4038-a85e-341b477c2c4e" xlink:to="loc_srt_LitigationCaseTypeDomain_17e7cf13-2518-4038-a85e-341b477c2c4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d1c0df08-4e2f-4d6e-b314-3eceb6c83d22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_17e7cf13-2518-4038-a85e-341b477c2c4e" xlink:to="loc_srt_LitigationCaseTypeDomain_d1c0df08-4e2f-4d6e-b314-3eceb6c83d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_8ecf02c6-af86-46a5-bf8a-394b5f7f719b" xlink:href="bhc-20200930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d1c0df08-4e2f-4d6e-b314-3eceb6c83d22" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_8ecf02c6-af86-46a5-bf8a-394b5f7f719b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b3d8ffc6-c7bd-443c-b8ea-770c7feea9c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_srt_StatementGeographicalAxis_b3d8ffc6-c7bd-443c-b8ea-770c7feea9c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b3d8ffc6-c7bd-443c-b8ea-770c7feea9c2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b3d8ffc6-c7bd-443c-b8ea-770c7feea9c2" xlink:to="loc_srt_SegmentGeographicalDomain_b3d8ffc6-c7bd-443c-b8ea-770c7feea9c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a3fa2a46-5c8f-44da-8047-4ac829e3b5a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b3d8ffc6-c7bd-443c-b8ea-770c7feea9c2" xlink:to="loc_srt_SegmentGeographicalDomain_a3fa2a46-5c8f-44da-8047-4ac829e3b5a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_bee607c6-e6be-4ea6-9f9c-d58ed7601b6e" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a3fa2a46-5c8f-44da-8047-4ac829e3b5a9" xlink:to="loc_stpr_NJ_bee607c6-e6be-4ea6-9f9c-d58ed7601b6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_86adb035-bb05-49d4-8440-b06799afc77e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_86adb035-bb05-49d4-8440-b06799afc77e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_86adb035-bb05-49d4-8440-b06799afc77e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_86adb035-bb05-49d4-8440-b06799afc77e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_86adb035-bb05-49d4-8440-b06799afc77e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ace62224-0a8e-4f49-928d-a31f1fe83ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_86adb035-bb05-49d4-8440-b06799afc77e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ace62224-0a8e-4f49-928d-a31f1fe83ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1d0aef21-b97f-46f5-8c6b-8b45506d3691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ace62224-0a8e-4f49-928d-a31f1fe83ab6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1d0aef21-b97f-46f5-8c6b-8b45506d3691" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_77804e5d-ea1d-4d86-b376-dfa4c336e709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ace62224-0a8e-4f49-928d-a31f1fe83ab6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_77804e5d-ea1d-4d86-b376-dfa4c336e709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_212a9cac-b24f-45c7-872f-3617b0538615" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_srt_RangeAxis_212a9cac-b24f-45c7-872f-3617b0538615" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_212a9cac-b24f-45c7-872f-3617b0538615_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_212a9cac-b24f-45c7-872f-3617b0538615" xlink:to="loc_srt_RangeMember_212a9cac-b24f-45c7-872f-3617b0538615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_31986216-3700-4a66-b358-12e79d6102f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_212a9cac-b24f-45c7-872f-3617b0538615" xlink:to="loc_srt_RangeMember_31986216-3700-4a66-b358-12e79d6102f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3030dc99-d048-4dd6-b83f-c077d5c7b686" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_31986216-3700-4a66-b358-12e79d6102f7" xlink:to="loc_srt_MaximumMember_3030dc99-d048-4dd6-b83f-c077d5c7b686" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended" id="i801fa29a4301449992fa21a04c22198c_FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails" xlink:type="extended" id="i35ff3f82c06c4e5b862798bf3509a1e3_FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_c6a57b6a-c09f-4e41-b566-18474e2f1d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_c6a57b6a-c09f-4e41-b566-18474e2f1d4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_77a145ef-8148-4406-88dd-b00eee34b8ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_77a145ef-8148-4406-88dd-b00eee34b8ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fa45c67c-d12f-467d-a5d7-9acbd6c7ede0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fa45c67c-d12f-467d-a5d7-9acbd6c7ede0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:to="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cc3603c9-99fe-4a44-964c-25dd51841a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cc3603c9-99fe-4a44-964c-25dd51841a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cc3603c9-99fe-4a44-964c-25dd51841a61_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc3603c9-99fe-4a44-964c-25dd51841a61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cc3603c9-99fe-4a44-964c-25dd51841a61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3e8d936d-5fca-44a3-959b-b7329470e15d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc3603c9-99fe-4a44-964c-25dd51841a61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3e8d936d-5fca-44a3-959b-b7329470e15d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_eb231539-d0e9-4d49-b514-6ce018d7f7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3e8d936d-5fca-44a3-959b-b7329470e15d" xlink:to="loc_us-gaap_UnsecuredDebtMember_eb231539-d0e9-4d49-b514-6ce018d7f7a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f14def85-e966-4573-b15f-bc6ce9635826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:to="loc_us-gaap_DebtInstrumentAxis_f14def85-e966-4573-b15f-bc6ce9635826" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f14def85-e966-4573-b15f-bc6ce9635826_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f14def85-e966-4573-b15f-bc6ce9635826" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f14def85-e966-4573-b15f-bc6ce9635826_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0cc0296f-09b2-4380-a59f-b970c57dbf97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f14def85-e966-4573-b15f-bc6ce9635826" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0cc0296f-09b2-4380-a59f-b970c57dbf97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5875DueMay2023Member_3bae71ff-ea44-4684-966c-2e0b076985ce" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5875DueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cc0296f-09b2-4380-a59f-b970c57dbf97" xlink:to="loc_bhc_SeniorNotes5875DueMay2023Member_3bae71ff-ea44-4684-966c-2e0b076985ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_ecfb7d58-c3d6-4d06-a594-7cf9c3d05e0a" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cc0296f-09b2-4380-a59f-b970c57dbf97" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_ecfb7d58-c3d6-4d06-a594-7cf9c3d05e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e6b6a2b4-0d1f-40b2-bbe5-6c0f0c4d0e73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e6b6a2b4-0d1f-40b2-bbe5-6c0f0c4d0e73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e6b6a2b4-0d1f-40b2-bbe5-6c0f0c4d0e73_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e6b6a2b4-0d1f-40b2-bbe5-6c0f0c4d0e73" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e6b6a2b4-0d1f-40b2-bbe5-6c0f0c4d0e73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c17ed53b-0d4a-44d9-967b-655ec49eea57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e6b6a2b4-0d1f-40b2-bbe5-6c0f0c4d0e73" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c17ed53b-0d4a-44d9-967b-655ec49eea57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_fc7c6139-03e5-41b5-b52b-1c961c1c52f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c17ed53b-0d4a-44d9-967b-655ec49eea57" xlink:to="loc_us-gaap_SubsequentEventMember_fc7c6139-03e5-41b5-b52b-1c961c1c52f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended" id="i46cf871b61b3444abd4bb0fbd1e7a2ca_FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bhc-20200930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="extended" id="i300614ac9793487caa18c622b7fd0a5f_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="extended" id="i8e18e8ca062c4cdfa636f741320c183d_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i1ade2d63b0e54a608231bd0e988a8173_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_094dd824-c468-44c2-a3f8-f49a85086138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_094dd824-c468-44c2-a3f8-f49a85086138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_61f0088f-bca4-4167-ba8e-a72bcf824583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_61f0088f-bca4-4167-ba8e-a72bcf824583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7ad2ea32-2f18-45f3-902f-433d8dd67b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7ad2ea32-2f18-45f3-902f-433d8dd67b59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1ce78242-2d70-432b-8e8d-492abfa366b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1ce78242-2d70-432b-8e8d-492abfa366b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_67ddc2f5-2421-4696-8341-c90f4f0ed274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_67ddc2f5-2421-4696-8341-c90f4f0ed274" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_aa11ca40-e86d-48d7-9ff9-9eed0e6faae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_aa11ca40-e86d-48d7-9ff9-9eed0e6faae2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b584f1b6-a876-4802-8f1c-67356000ce71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b584f1b6-a876-4802-8f1c-67356000ce71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_18f2b388-d26e-4c57-a5b9-628d47f2a293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b584f1b6-a876-4802-8f1c-67356000ce71" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_18f2b388-d26e-4c57-a5b9-628d47f2a293" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_18f2b388-d26e-4c57-a5b9-628d47f2a293_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_18f2b388-d26e-4c57-a5b9-628d47f2a293" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_18f2b388-d26e-4c57-a5b9-628d47f2a293_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6b917c7f-02cd-41a3-ac6d-deddd92716c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_18f2b388-d26e-4c57-a5b9-628d47f2a293" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6b917c7f-02cd-41a3-ac6d-deddd92716c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_09b2a07f-c292-43f4-ab67-ffe766b4394d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6b917c7f-02cd-41a3-ac6d-deddd92716c6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_09b2a07f-c292-43f4-ab67-ffe766b4394d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5aa9e9be-19a1-4a0e-a3ff-94f49cb71fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6b917c7f-02cd-41a3-ac6d-deddd92716c6" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5aa9e9be-19a1-4a0e-a3ff-94f49cb71fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb347fa8-8517-4ece-b3e9-bf76cc245db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b584f1b6-a876-4802-8f1c-67356000ce71" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb347fa8-8517-4ece-b3e9-bf76cc245db3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_fb347fa8-8517-4ece-b3e9-bf76cc245db3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb347fa8-8517-4ece-b3e9-bf76cc245db3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_fb347fa8-8517-4ece-b3e9-bf76cc245db3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_429f5fcd-6494-4407-8d36-6f9fdcb0a97f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb347fa8-8517-4ece-b3e9-bf76cc245db3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_429f5fcd-6494-4407-8d36-6f9fdcb0a97f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_07b23712-cf23-4234-8972-c85cd6fc75b3" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_429f5fcd-6494-4407-8d36-6f9fdcb0a97f" xlink:to="loc_country_US_07b23712-cf23-4234-8972-c85cd6fc75b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_385cd01f-7146-49a6-a2a6-a82f4c1d6e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_429f5fcd-6494-4407-8d36-6f9fdcb0a97f" xlink:to="loc_us-gaap_ForeignPlanMember_385cd01f-7146-49a6-a2a6-a82f4c1d6e64" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATION"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended" id="id81c4a22177440eb8d82a5baa77fe0ba_SHAREBASEDCOMPENSATION"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended" id="i0f996f1a972f43eeba85d9abdf57621e_SHAREBASEDCOMPENSATIONTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i89135153c2f145e0a62098f29a156fa6_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_68f2a7e3-00f3-4cf8-9b55-852abd1cbbd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_68f2a7e3-00f3-4cf8-9b55-852abd1cbbd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9c4aec36-edb5-434d-91b0-3eb659339977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9c4aec36-edb5-434d-91b0-3eb659339977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b501b671-a8e8-4b5b-84eb-d0fdd138e895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b501b671-a8e8-4b5b-84eb-d0fdd138e895" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_4f299517-8060-4215-98ed-42d4cf9b3aae" xlink:href="bhc-20200930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_4f299517-8060-4215-98ed-42d4cf9b3aae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1a6bb4cd-36c5-4d9c-b0d1-3fac985acab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1a6bb4cd-36c5-4d9c-b0d1-3fac985acab5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_45377550-3714-4196-bd2f-e53c921c5848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_45377550-3714-4196-bd2f-e53c921c5848" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bd1b7bcb-de30-4c36-9be0-9b44fe3a5292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bd1b7bcb-de30-4c36-9be0-9b44fe3a5292" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f16ab856-de62-42dc-b69a-7b1891f673f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f16ab856-de62-42dc-b69a-7b1891f673f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_28ddcafb-3500-49f0-a6df-0156bdf63fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f16ab856-de62-42dc-b69a-7b1891f673f7" xlink:to="loc_us-gaap_PlanNameAxis_28ddcafb-3500-49f0-a6df-0156bdf63fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_28ddcafb-3500-49f0-a6df-0156bdf63fc8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_28ddcafb-3500-49f0-a6df-0156bdf63fc8" xlink:to="loc_us-gaap_PlanNameDomain_28ddcafb-3500-49f0-a6df-0156bdf63fc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cd3037a6-a38b-45bf-a88d-6881cb21ee43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_28ddcafb-3500-49f0-a6df-0156bdf63fc8" xlink:to="loc_us-gaap_PlanNameDomain_cd3037a6-a38b-45bf-a88d-6881cb21ee43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_c68230e3-148e-4e5b-843d-3a3f1a094796" xlink:href="bhc-20200930.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cd3037a6-a38b-45bf-a88d-6881cb21ee43" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_c68230e3-148e-4e5b-843d-3a3f1a094796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_078f1232-87cc-45f7-b0ea-4d66fb0f8c0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f16ab856-de62-42dc-b69a-7b1891f673f7" xlink:to="loc_srt_TitleOfIndividualAxis_078f1232-87cc-45f7-b0ea-4d66fb0f8c0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_078f1232-87cc-45f7-b0ea-4d66fb0f8c0f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_078f1232-87cc-45f7-b0ea-4d66fb0f8c0f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_078f1232-87cc-45f7-b0ea-4d66fb0f8c0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c502f908-09dc-4960-b905-e59eb0b6bb3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_078f1232-87cc-45f7-b0ea-4d66fb0f8c0f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c502f908-09dc-4960-b905-e59eb0b6bb3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember_6575c4aa-857c-435b-b524-6400a6c34e54" xlink:href="bhc-20200930.xsd#bhc_NonemployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c502f908-09dc-4960-b905-e59eb0b6bb3e" xlink:to="loc_bhc_NonemployeeDirectorMember_6575c4aa-857c-435b-b524-6400a6c34e54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i6d4afb458e0f4827a3503492ade54f04_SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c012fbb5-a907-454e-9305-d79c74e3f4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6d45309-90f1-49a9-a498-8628b2a92ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c012fbb5-a907-454e-9305-d79c74e3f4b3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6d45309-90f1-49a9-a498-8628b2a92ed2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3888be0-caa2-4661-a5d8-b2465b6b6727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c012fbb5-a907-454e-9305-d79c74e3f4b3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3888be0-caa2-4661-a5d8-b2465b6b6727" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd008387-a95b-4bb9-b77c-a2c9ec90f17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3888be0-caa2-4661-a5d8-b2465b6b6727" xlink:to="loc_us-gaap_AwardTypeAxis_bd008387-a95b-4bb9-b77c-a2c9ec90f17a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd008387-a95b-4bb9-b77c-a2c9ec90f17a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bd008387-a95b-4bb9-b77c-a2c9ec90f17a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd008387-a95b-4bb9-b77c-a2c9ec90f17a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e303567-e7f8-463c-b6e9-8ed7de8153d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bd008387-a95b-4bb9-b77c-a2c9ec90f17a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e303567-e7f8-463c-b6e9-8ed7de8153d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e899aa81-3981-410d-95cf-6f581da63dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e303567-e7f8-463c-b6e9-8ed7de8153d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e899aa81-3981-410d-95cf-6f581da63dce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f12b8058-4472-4e50-937f-fd7d615ed0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e303567-e7f8-463c-b6e9-8ed7de8153d9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f12b8058-4472-4e50-937f-fd7d615ed0cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_97af7879-38bd-4f3a-aa48-e1c246bd515b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3888be0-caa2-4661-a5d8-b2465b6b6727" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_97af7879-38bd-4f3a-aa48-e1c246bd515b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97af7879-38bd-4f3a-aa48-e1c246bd515b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97af7879-38bd-4f3a-aa48-e1c246bd515b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97af7879-38bd-4f3a-aa48-e1c246bd515b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dcf18c37-67ba-4d0b-a380-8ae60e174f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97af7879-38bd-4f3a-aa48-e1c246bd515b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dcf18c37-67ba-4d0b-a380-8ae60e174f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f03c0e2-b9b4-456c-8e0d-1606970a9a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dcf18c37-67ba-4d0b-a380-8ae60e174f33" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f03c0e2-b9b4-456c-8e0d-1606970a9a71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea18d5a2-3833-46d3-be93-62878bb42ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dcf18c37-67ba-4d0b-a380-8ae60e174f33" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea18d5a2-3833-46d3-be93-62878bb42ee3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended" id="ic403558c8fcf4caeae6775948b3e261d_SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e13f48ba-163a-4272-a8e7-842260323621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e13f48ba-163a-4272-a8e7-842260323621" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8e1a763e-185a-4ddc-8e28-d4a5b1b6950c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8e1a763e-185a-4ddc-8e28-d4a5b1b6950c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_69f09852-fe7c-4c17-8fe5-3c397f5cfa9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_69f09852-fe7c-4c17-8fe5-3c397f5cfa9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c4b71497-c49e-48b2-997b-89f8e07343a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c4b71497-c49e-48b2-997b-89f8e07343a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_a1a529c0-6e2a-4db7-bb7b-10fc9bc89b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e13f48ba-163a-4272-a8e7-842260323621" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_a1a529c0-6e2a-4db7-bb7b-10fc9bc89b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cdcc1808-68fa-4171-8673-2f378b682aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_a1a529c0-6e2a-4db7-bb7b-10fc9bc89b30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cdcc1808-68fa-4171-8673-2f378b682aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_de878281-d7e5-40c0-a350-beef24d08d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_a1a529c0-6e2a-4db7-bb7b-10fc9bc89b30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_de878281-d7e5-40c0-a350-beef24d08d4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c6b06b1-5edf-406e-b139-69d23336eb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e13f48ba-163a-4272-a8e7-842260323621" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c6b06b1-5edf-406e-b139-69d23336eb3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_36cada02-3f7f-4a63-850a-1e2304805822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c6b06b1-5edf-406e-b139-69d23336eb3b" xlink:to="loc_us-gaap_AwardTypeAxis_36cada02-3f7f-4a63-850a-1e2304805822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36cada02-3f7f-4a63-850a-1e2304805822_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_36cada02-3f7f-4a63-850a-1e2304805822" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_36cada02-3f7f-4a63-850a-1e2304805822_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_36cada02-3f7f-4a63-850a-1e2304805822" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_02db71d9-f1fc-49ba-8398-47c5a55a0900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_02db71d9-f1fc-49ba-8398-47c5a55a0900" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_73bd8985-6085-48c1-bc47-9ba095484e5d" xlink:href="bhc-20200930.xsd#bhc_TimeBasedRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:to="loc_bhc_TimeBasedRSUMember_73bd8985-6085-48c1-bc47-9ba095484e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_bd6ef3c5-e22d-4f70-bdf4-1b8663b8b3f4" xlink:href="bhc-20200930.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_bd6ef3c5-e22d-4f70-bdf4-1b8663b8b3f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_2bf17a71-2bd2-45fd-8bf6-ee0f45659ca8" xlink:href="bhc-20200930.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_2bf17a71-2bd2-45fd-8bf6-ee0f45659ca8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended" id="i14474aef19d24590b959d8094997a9f2_ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended" id="i5f976a007e8849039eec78f8cded8915_ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails" xlink:type="extended" id="i7b4acf32a5ea4b57abed883c9293939f_ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ec4db645-f144-4f8c-a65e-a8205ae3ac88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43dce50f-e01e-4645-9fa0-23be04aa9ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ec4db645-f144-4f8c-a65e-a8205ae3ac88" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43dce50f-e01e-4645-9fa0-23be04aa9ab7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac73c6d9-e512-4b47-a605-48ad3403239a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ec4db645-f144-4f8c-a65e-a8205ae3ac88" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac73c6d9-e512-4b47-a605-48ad3403239a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2847b5fd-93b8-4693-8231-1e21a85cf882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac73c6d9-e512-4b47-a605-48ad3403239a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2847b5fd-93b8-4693-8231-1e21a85cf882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2847b5fd-93b8-4693-8231-1e21a85cf882_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2847b5fd-93b8-4693-8231-1e21a85cf882" xlink:to="loc_us-gaap_EquityComponentDomain_2847b5fd-93b8-4693-8231-1e21a85cf882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2847b5fd-93b8-4693-8231-1e21a85cf882" xlink:to="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_c133456b-cdd9-4844-8f27-a39aa71e9b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_c133456b-cdd9-4844-8f27-a39aa71e9b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4843a890-b4ee-4280-8814-55fbdfa20578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4843a890-b4ee-4280-8814-55fbdfa20578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_731555eb-ac32-435a-b899-bfecb8499a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_731555eb-ac32-435a-b899-bfecb8499a1e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended" id="i01cbff59ed634ceb97fc9e3079503775_ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended" id="i0d6474312dcd43abb0ddaa95a768c16f_RESEARCHANDDEVELOPMENT"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended" id="i9a69faca68cb4a748a2ee65ef83daca4_RESEARCHANDDEVELOPMENTTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended" id="i531c69a538fc494e8c800edc17d4facb_RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="simple" xlink:href="bhc-20200930.xsd#OTHEREXPENSENET"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="extended" id="ic8c6918ef6dc4e62b5ca505645ebac4e_OTHEREXPENSENET"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#OTHEREXPENSENETTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="extended" id="iec67616634c24799b019f3f77e737682_OTHEREXPENSENETTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#OTHEREXPENSENETSummaryofOtherExpenseNetDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="extended" id="ifdf89e2ea9204072b92b39f3489f3afb_OTHEREXPENSENETSummaryofOtherExpenseNetDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20200930.xsd#INCOMETAXES"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended" id="i5ea16cffd2b240239a6e88a21dd4380a_INCOMETAXES"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="icec22d0f521749389729607f888a8afb_INCOMETAXESNarrativeDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended" id="i1ac0d2bd948a4802836e043c2d220d3b_EARNINGSLOSSPERSHARE"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended" id="i5dac7d65cb29401c9b4e967a812b35fb_EARNINGSLOSSPERSHARETables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails" xlink:type="extended" id="i1e9e98381ddd42b5b069b55c1355ebe2_EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="extended" id="i31cafe7cce9a40fb8c9773ea97aa3cc9_EARNINGSLOSSPERSHARENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43e74e94-ef8e-4480-83a1-5d373b8da3be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bb3bc663-4e4d-4145-b365-e31d67627aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43e74e94-ef8e-4480-83a1-5d373b8da3be" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bb3bc663-4e4d-4145-b365-e31d67627aeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_add40c49-0309-4d5c-b023-9c1348d206fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43e74e94-ef8e-4480-83a1-5d373b8da3be" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_add40c49-0309-4d5c-b023-9c1348d206fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92771124-25d4-4c49-8013-ccce45d1ec33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_add40c49-0309-4d5c-b023-9c1348d206fb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92771124-25d4-4c49-8013-ccce45d1ec33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92771124-25d4-4c49-8013-ccce45d1ec33_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92771124-25d4-4c49-8013-ccce45d1ec33" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_92771124-25d4-4c49-8013-ccce45d1ec33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67a02b5-ff23-4f84-a177-2e6c86f79fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92771124-25d4-4c49-8013-ccce45d1ec33" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67a02b5-ff23-4f84-a177-2e6c86f79fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_8abd3f74-4991-4bb8-8cb8-b3097c4a1158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67a02b5-ff23-4f84-a177-2e6c86f79fcf" xlink:to="loc_us-gaap_StockCompensationPlanMember_8abd3f74-4991-4bb8-8cb8-b3097c4a1158" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_8b789c1b-5ab1-49fa-93b3-3338b7dc8632" xlink:href="bhc-20200930.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67a02b5-ff23-4f84-a177-2e6c86f79fcf" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_8b789c1b-5ab1-49fa-93b3-3338b7dc8632" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended" id="i19de626d799d47cab90f4f2788d05c37_LEGALPROCEEDINGS"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="extended" id="i1489299ce2434eeeabf3cca4a4ee5394_LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended" id="i300effdaa4c74c0cbe888ac460ac21b7_LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e1011ebd-223e-4856-a59a-af5d5c1c83b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e1011ebd-223e-4856-a59a-af5d5c1c83b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_17f2c8be-24ae-4976-a5e3-161affef66fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_17f2c8be-24ae-4976-a5e3-161affef66fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_e898ea2e-db41-454f-881e-381dc6b1eaca" xlink:href="bhc-20200930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_e898ea2e-db41-454f-881e-381dc6b1eaca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_d6bafdfc-ac34-4a08-873c-ee67f2f21e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_d6bafdfc-ac34-4a08-873c-ee67f2f21e57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_b3a343ce-9727-4739-ae6f-02aea96931e7" xlink:href="bhc-20200930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_b3a343ce-9727-4739-ae6f-02aea96931e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_656eb6fd-a457-44b8-afbf-d233ab7e8890" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_656eb6fd-a457-44b8-afbf-d233ab7e8890" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_49f7b381-cdbc-481b-bb67-0a8cc27d0ced" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_49f7b381-cdbc-481b-bb67-0a8cc27d0ced" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_564ddbb7-068e-4fa6-a6de-b0d51b157f30" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_564ddbb7-068e-4fa6-a6de-b0d51b157f30" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_191628c0-1cf8-4503-9dcb-1b23c77c05a5" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_191628c0-1cf8-4503-9dcb-1b23c77c05a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_8b3a839f-8a61-498e-8cff-e660c72f634e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:to="loc_srt_LitigationCaseAxis_8b3a839f-8a61-498e-8cff-e660c72f634e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8b3a839f-8a61-498e-8cff-e660c72f634e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_8b3a839f-8a61-498e-8cff-e660c72f634e" xlink:to="loc_srt_LitigationCaseTypeDomain_8b3a839f-8a61-498e-8cff-e660c72f634e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_8b3a839f-8a61-498e-8cff-e660c72f634e" xlink:to="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_a6b3ee36-d8ed-45eb-8406-11ca7c7d701b" xlink:href="bhc-20200930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_a6b3ee36-d8ed-45eb-8406-11ca7c7d701b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember_d46a2212-ab76-42e0-86f9-0bf3b6036d72" xlink:href="bhc-20200930.xsd#bhc_RICOClassActionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:to="loc_bhc_RICOClassActionsMember_d46a2212-ab76-42e0-86f9-0bf3b6036d72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeLawsuitsMember_4816492c-8173-4fc7-a91e-5a308f6dde80" xlink:href="bhc-20200930.xsd#bhc_DerivativeLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:to="loc_bhc_DerivativeLawsuitsMember_4816492c-8173-4fc7-a91e-5a308f6dde80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_82031462-1e79-4c40-b748-1dcfaa86a680" xlink:href="bhc-20200930.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_82031462-1e79-4c40-b748-1dcfaa86a680" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b5f4c61a-5bd9-4a96-ac08-969669a7197b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:to="loc_us-gaap_LitigationStatusAxis_b5f4c61a-5bd9-4a96-ac08-969669a7197b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b5f4c61a-5bd9-4a96-ac08-969669a7197b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_b5f4c61a-5bd9-4a96-ac08-969669a7197b" xlink:to="loc_us-gaap_LitigationStatusDomain_b5f4c61a-5bd9-4a96-ac08-969669a7197b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7d5975dc-df3f-4f80-b94a-8a331014f9c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_b5f4c61a-5bd9-4a96-ac08-969669a7197b" xlink:to="loc_us-gaap_LitigationStatusDomain_7d5975dc-df3f-4f80-b94a-8a331014f9c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_cd094ebd-7056-4386-b2eb-0e75532a0d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_7d5975dc-df3f-4f80-b94a-8a331014f9c2" xlink:to="loc_us-gaap_SettledLitigationMember_cd094ebd-7056-4386-b2eb-0e75532a0d7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b22eaa87-9ab8-494c-a922-2a6c93f4f7aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:to="loc_srt_StatementGeographicalAxis_b22eaa87-9ab8-494c-a922-2a6c93f4f7aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b22eaa87-9ab8-494c-a922-2a6c93f4f7aa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b22eaa87-9ab8-494c-a922-2a6c93f4f7aa" xlink:to="loc_srt_SegmentGeographicalDomain_b22eaa87-9ab8-494c-a922-2a6c93f4f7aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c56b565a-404a-47e6-ba8c-0c909c27bc69" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b22eaa87-9ab8-494c-a922-2a6c93f4f7aa" xlink:to="loc_srt_SegmentGeographicalDomain_c56b565a-404a-47e6-ba8c-0c909c27bc69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_aa5d8579-8d3d-45f3-a372-203a38e68ddb" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c56b565a-404a-47e6-ba8c-0c909c27bc69" xlink:to="loc_stpr_NJ_aa5d8579-8d3d-45f3-a372-203a38e68ddb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_3c426199-1df3-4549-92c0-c5d050905f5e" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c56b565a-404a-47e6-ba8c-0c909c27bc69" xlink:to="loc_country_CA_3c426199-1df3-4549-92c0-c5d050905f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_0efea7b0-a0cc-49e0-9558-85331d72cfa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_0efea7b0-a0cc-49e0-9558-85331d72cfa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_0efea7b0-a0cc-49e0-9558-85331d72cfa6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_0efea7b0-a0cc-49e0-9558-85331d72cfa6" xlink:to="loc_us-gaap_LossContingencyNatureDomain_0efea7b0-a0cc-49e0-9558-85331d72cfa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_bd919887-4bb4-4de2-9082-6f03d852a825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_0efea7b0-a0cc-49e0-9558-85331d72cfa6" xlink:to="loc_us-gaap_LossContingencyNatureDomain_bd919887-4bb4-4de2-9082-6f03d852a825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_50d1ad68-62f5-4df8-b8d9-a1bdb8d68aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_bd919887-4bb4-4de2-9082-6f03d852a825" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_50d1ad68-62f5-4df8-b8d9-a1bdb8d68aa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_5b0463d4-5104-4af6-bcc8-48eb8440a1dc" xlink:href="bhc-20200930.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_bd919887-4bb4-4de2-9082-6f03d852a825" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_5b0463d4-5104-4af6-bcc8-48eb8440a1dc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended" id="ieb8c040085d44a82b293e264edf90bbb_LEGALPROCEEDINGSAntitrustDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_cbb35c9d-3269-4530-9318-4be37ce76a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_cbb35c9d-3269-4530-9318-4be37ce76a56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits_6f96bb01-a642-4a81-9639-0bd43de8d2c4" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfHealthPlansFiledLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:to="loc_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits_6f96bb01-a642-4a81-9639-0bd43de8d2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_8930abb7-0143-4a43-8fea-7db470968fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_8930abb7-0143-4a43-8fea-7db470968fe1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:to="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_68d1a91f-66c0-4005-915f-93b846791d3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:to="loc_srt_LitigationCaseAxis_68d1a91f-66c0-4005-915f-93b846791d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_68d1a91f-66c0-4005-915f-93b846791d3c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_68d1a91f-66c0-4005-915f-93b846791d3c" xlink:to="loc_srt_LitigationCaseTypeDomain_68d1a91f-66c0-4005-915f-93b846791d3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_68d1a91f-66c0-4005-915f-93b846791d3c" xlink:to="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_0acae793-de71-461e-8db9-dec5b9bead99" xlink:href="bhc-20200930.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_0acae793-de71-461e-8db9-dec5b9bead99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_6b7f7ad4-159f-46ed-8631-c8efc0a3525f" xlink:href="bhc-20200930.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_6b7f7ad4-159f-46ed-8631-c8efc0a3525f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GenericPricingAntitrustLitigationMember_eceec3b2-3732-4538-8cb5-b1407519c46f" xlink:href="bhc-20200930.xsd#bhc_GenericPricingAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:to="loc_bhc_GenericPricingAntitrustLitigationMember_eceec3b2-3732-4538-8cb5-b1407519c46f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6b9aeb69-82f4-4c22-b417-bb6bc07b3c1a" xlink:href="bhc-20200930.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:to="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6b9aeb69-82f4-4c22-b417-bb6bc07b3c1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ed05ceee-3d7e-4e9e-b466-da8458d6925f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:to="loc_srt_CounterpartyNameAxis_ed05ceee-3d7e-4e9e-b466-da8458d6925f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed05ceee-3d7e-4e9e-b466-da8458d6925f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ed05ceee-3d7e-4e9e-b466-da8458d6925f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed05ceee-3d7e-4e9e-b466-da8458d6925f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a06b74-697f-4402-925f-7c7cece826c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ed05ceee-3d7e-4e9e-b466-da8458d6925f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a06b74-697f-4402-925f-7c7cece826c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_4055fb8f-8ce3-462e-bf9e-1b6e33f87782" xlink:href="bhc-20200930.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a06b74-697f-4402-925f-7c7cece826c4" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_4055fb8f-8ce3-462e-bf9e-1b6e33f87782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8db21c13-e325-45ae-8801-96aa8f2a2d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:to="loc_us-gaap_LitigationStatusAxis_8db21c13-e325-45ae-8801-96aa8f2a2d92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_8db21c13-e325-45ae-8801-96aa8f2a2d92_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_8db21c13-e325-45ae-8801-96aa8f2a2d92" xlink:to="loc_us-gaap_LitigationStatusDomain_8db21c13-e325-45ae-8801-96aa8f2a2d92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_d9cd91f3-323b-408a-8e6e-48efce44e452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_8db21c13-e325-45ae-8801-96aa8f2a2d92" xlink:to="loc_us-gaap_LitigationStatusDomain_d9cd91f3-323b-408a-8e6e-48efce44e452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_44cfc5e3-9023-43a7-b016-20dfbd1ac7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_d9cd91f3-323b-408a-8e6e-48efce44e452" xlink:to="loc_us-gaap_PendingLitigationMember_44cfc5e3-9023-43a7-b016-20dfbd1ac7c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended" id="i6ce951aef60f48838b7c8409e101679f_LEGALPROCEEDINGSProductLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7802ba37-f918-4777-9bb0-0a74d08a93c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_877c7c04-80ed-4a04-8a55-ffbe72a94d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7802ba37-f918-4777-9bb0-0a74d08a93c7" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_877c7c04-80ed-4a04-8a55-ffbe72a94d2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8ea2cdbe-0de5-465b-8735-6abc56c5db6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7802ba37-f918-4777-9bb0-0a74d08a93c7" xlink:to="loc_us-gaap_LossContingenciesTable_8ea2cdbe-0de5-465b-8735-6abc56c5db6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b88317d6-1236-4c70-8fdf-8255c80ef59b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8ea2cdbe-0de5-465b-8735-6abc56c5db6c" xlink:to="loc_srt_LitigationCaseAxis_b88317d6-1236-4c70-8fdf-8255c80ef59b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b88317d6-1236-4c70-8fdf-8255c80ef59b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b88317d6-1236-4c70-8fdf-8255c80ef59b" xlink:to="loc_srt_LitigationCaseTypeDomain_b88317d6-1236-4c70-8fdf-8255c80ef59b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bfa72dd6-824d-427b-9da1-6b93875f7a27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b88317d6-1236-4c70-8fdf-8255c80ef59b" xlink:to="loc_srt_LitigationCaseTypeDomain_bfa72dd6-824d-427b-9da1-6b93875f7a27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_83708732-60d8-4a5b-9bc7-31d2f0d843a1" xlink:href="bhc-20200930.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_bfa72dd6-824d-427b-9da1-6b93875f7a27" xlink:to="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_83708732-60d8-4a5b-9bc7-31d2f0d843a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d087461d-eb80-4f7e-bec3-59dee90135ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8ea2cdbe-0de5-465b-8735-6abc56c5db6c" xlink:to="loc_us-gaap_LitigationStatusAxis_d087461d-eb80-4f7e-bec3-59dee90135ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_d087461d-eb80-4f7e-bec3-59dee90135ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_d087461d-eb80-4f7e-bec3-59dee90135ec" xlink:to="loc_us-gaap_LitigationStatusDomain_d087461d-eb80-4f7e-bec3-59dee90135ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ce82c06d-d40b-462e-9ac4-77db53c19e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_d087461d-eb80-4f7e-bec3-59dee90135ec" xlink:to="loc_us-gaap_LitigationStatusDomain_ce82c06d-d40b-462e-9ac4-77db53c19e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_e8605ad3-ebb9-4e40-8538-4dc42159b53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_ce82c06d-d40b-462e-9ac4-77db53c19e9d" xlink:to="loc_us-gaap_PendingLitigationMember_e8605ad3-ebb9-4e40-8538-4dc42159b53f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended" id="ibe6b5580b190477aab0e14afe9c938dd_LEGALPROCEEDINGSGeneralCivilActionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_3907de4b-ae01-4ae2-91e0-1b076d8e97a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_0a76b336-0d4a-42a2-80e5-3219aa02abac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3907de4b-ae01-4ae2-91e0-1b076d8e97a9" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_0a76b336-0d4a-42a2-80e5-3219aa02abac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1edfe7e7-f75d-4c21-8d44-8fff7f9b9b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_3907de4b-ae01-4ae2-91e0-1b076d8e97a9" xlink:to="loc_us-gaap_LossContingenciesTable_1edfe7e7-f75d-4c21-8d44-8fff7f9b9b67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9e190757-7728-45db-abdd-8401e2c7fd77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1edfe7e7-f75d-4c21-8d44-8fff7f9b9b67" xlink:to="loc_srt_LitigationCaseAxis_9e190757-7728-45db-abdd-8401e2c7fd77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9e190757-7728-45db-abdd-8401e2c7fd77_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_9e190757-7728-45db-abdd-8401e2c7fd77" xlink:to="loc_srt_LitigationCaseTypeDomain_9e190757-7728-45db-abdd-8401e2c7fd77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8c0da42c-e280-4835-963e-8b16c458fd63" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_9e190757-7728-45db-abdd-8401e2c7fd77" xlink:to="loc_srt_LitigationCaseTypeDomain_8c0da42c-e280-4835-963e-8b16c458fd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_1a26ee63-7ec1-4b42-8fcc-489c355e6499" xlink:href="bhc-20200930.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8c0da42c-e280-4835-963e-8b16c458fd63" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_1a26ee63-7ec1-4b42-8fcc-489c355e6499" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_609834ed-0a7c-477b-b090-ac6dd74956c0" xlink:href="bhc-20200930.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8c0da42c-e280-4835-963e-8b16c458fd63" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_609834ed-0a7c-477b-b090-ac6dd74956c0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSCompletedorDormantMattersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails" xlink:type="extended" id="i603c6fa64ae44359a05896d8e417383a_LEGALPROCEEDINGSCompletedorDormantMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7b6ef430-37d8-4b6a-a113-2792a653dbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e62d1c6b-b766-48c8-837c-91dcf83295af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b6ef430-37d8-4b6a-a113-2792a653dbcc" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e62d1c6b-b766-48c8-837c-91dcf83295af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_42e4831c-5790-479b-8958-fdc6165a1a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b6ef430-37d8-4b6a-a113-2792a653dbcc" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_42e4831c-5790-479b-8958-fdc6165a1a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_89328537-b5fd-4ad6-9277-4846bddbcb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b6ef430-37d8-4b6a-a113-2792a653dbcc" xlink:to="loc_us-gaap_LossContingenciesTable_89328537-b5fd-4ad6-9277-4846bddbcb49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b560490e-297d-4b65-8d05-8f453a2bcba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_89328537-b5fd-4ad6-9277-4846bddbcb49" xlink:to="loc_us-gaap_LitigationStatusAxis_b560490e-297d-4b65-8d05-8f453a2bcba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_b560490e-297d-4b65-8d05-8f453a2bcba9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_b560490e-297d-4b65-8d05-8f453a2bcba9" xlink:to="loc_us-gaap_LitigationStatusDomain_b560490e-297d-4b65-8d05-8f453a2bcba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_2782057a-8b3e-45ac-9bc1-0cdc4d95c4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_b560490e-297d-4b65-8d05-8f453a2bcba9" xlink:to="loc_us-gaap_LitigationStatusDomain_2782057a-8b3e-45ac-9bc1-0cdc4d95c4a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_21f70b1f-94e6-4905-8280-9ca395336d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_2782057a-8b3e-45ac-9bc1-0cdc4d95c4a4" xlink:to="loc_us-gaap_SettledLitigationMember_21f70b1f-94e6-4905-8280-9ca395336d20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_584a0d4e-eb23-4d45-b06d-7db4bd352c4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_89328537-b5fd-4ad6-9277-4846bddbcb49" xlink:to="loc_srt_LitigationCaseAxis_584a0d4e-eb23-4d45-b06d-7db4bd352c4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_584a0d4e-eb23-4d45-b06d-7db4bd352c4e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_584a0d4e-eb23-4d45-b06d-7db4bd352c4e" xlink:to="loc_srt_LitigationCaseTypeDomain_584a0d4e-eb23-4d45-b06d-7db4bd352c4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bfeac65d-2be1-4eb0-a1ee-937b14af753e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_584a0d4e-eb23-4d45-b06d-7db4bd352c4e" xlink:to="loc_srt_LitigationCaseTypeDomain_bfeac65d-2be1-4eb0-a1ee-937b14af753e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECInvestigationLitigationMember_152b48b4-8f81-41f4-9dc7-d84f8b167522" xlink:href="bhc-20200930.xsd#bhc_SECInvestigationLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_bfeac65d-2be1-4eb0-a1ee-937b14af753e" xlink:to="loc_bhc_SECInvestigationLitigationMember_152b48b4-8f81-41f4-9dc7-d84f8b167522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember_d50b1a47-e8aa-4329-91e7-1ce9748e5985" xlink:href="bhc-20200930.xsd#bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_bfeac65d-2be1-4eb0-a1ee-937b14af753e" xlink:to="loc_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember_d50b1a47-e8aa-4329-91e7-1ce9748e5985" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATION"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended" id="i0cbb42d8cb2540ee8fca00e5d3d0b12f_SEGMENTINFORMATION"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONTables"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended" id="ifcbe6b96e6884d58a1c2729986b168c2_SEGMENTINFORMATIONTables"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended" id="i898fc5d3cc754001a6bbf7658d80a351_SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48fe5e59-0cb3-455e-a0e8-554a770b33e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48fe5e59-0cb3-455e-a0e8-554a770b33e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_283ea7a6-a443-4a59-84e3-935571b249ec" xlink:href="bhc-20200930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_283ea7a6-a443-4a59-84e3-935571b249ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_22d73b87-a999-4199-a158-33d17f20fa35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_AssetImpairmentCharges_22d73b87-a999-4199-a158-33d17f20fa35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_239ba838-6f08-4b0d-a624-cf60a6fd7499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_RestructuringCharges_239ba838-6f08-4b0d-a624-cf60a6fd7499" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_af5cddb1-578d-463c-8d61-356f15d1c7f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_af5cddb1-578d-463c-8d61-356f15d1c7f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a263d89f-e9f5-4bb0-97fa-2ad6976fa007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a263d89f-e9f5-4bb0-97fa-2ad6976fa007" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9a201f25-59d3-4360-b305-7df41b58a5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9a201f25-59d3-4360-b305-7df41b58a5bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_262711ba-cd2f-406b-8d57-d2702c05dbec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_262711ba-cd2f-406b-8d57-d2702c05dbec" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_0da2915d-37ba-42fc-9a48-04742989d93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_InterestAndDebtExpense_0da2915d-37ba-42fc-9a48-04742989d93f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_38566241-d02e-41c1-8702-547d343a0b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_38566241-d02e-41c1-8702-547d343a0b96" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_04173b7e-a43d-44b8-9f51-22b2c62492d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_04173b7e-a43d-44b8-9f51-22b2c62492d3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51d67eb3-cbf1-4835-9567-f8c57d9e2f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51d67eb3-cbf1-4835-9567-f8c57d9e2f84" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_517bbd5c-3e30-4207-8453-2ef40a47b133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_517bbd5c-3e30-4207-8453-2ef40a47b133" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a6fb8559-3390-449b-86d9-0808d01d881d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_517bbd5c-3e30-4207-8453-2ef40a47b133" xlink:to="loc_srt_ConsolidationItemsAxis_a6fb8559-3390-449b-86d9-0808d01d881d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a6fb8559-3390-449b-86d9-0808d01d881d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_a6fb8559-3390-449b-86d9-0808d01d881d" xlink:to="loc_srt_ConsolidationItemsDomain_a6fb8559-3390-449b-86d9-0808d01d881d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cfb9be57-7a9d-49fc-87cb-1069dbcca6dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_a6fb8559-3390-449b-86d9-0808d01d881d" xlink:to="loc_srt_ConsolidationItemsDomain_cfb9be57-7a9d-49fc-87cb-1069dbcca6dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d71346e0-f348-494a-b86f-d18fe5544dcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_cfb9be57-7a9d-49fc-87cb-1069dbcca6dd" xlink:to="loc_us-gaap_OperatingSegmentsMember_d71346e0-f348-494a-b86f-d18fe5544dcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_bc80e876-b726-471a-a406-74265e24c47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_cfb9be57-7a9d-49fc-87cb-1069dbcca6dd" xlink:to="loc_us-gaap_CorporateNonSegmentMember_bc80e876-b726-471a-a406-74265e24c47b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6394c299-6754-45da-9d57-d46fc4d96628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_517bbd5c-3e30-4207-8453-2ef40a47b133" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6394c299-6754-45da-9d57-d46fc4d96628" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6394c299-6754-45da-9d57-d46fc4d96628_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6394c299-6754-45da-9d57-d46fc4d96628" xlink:to="loc_us-gaap_SegmentDomain_6394c299-6754-45da-9d57-d46fc4d96628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6394c299-6754-45da-9d57-d46fc4d96628" xlink:to="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaushandLombInternationalSegmentMember_4a26c13a-8f15-41c5-ab1e-6f4e93c9d33e" xlink:href="bhc-20200930.xsd#bhc_BaushandLombInternationalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:to="loc_bhc_BaushandLombInternationalSegmentMember_4a26c13a-8f15-41c5-ab1e-6f4e93c9d33e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_9dfc9c11-a5f5-4a8f-817b-836342a9e37e" xlink:href="bhc-20200930.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:to="loc_bhc_SalixSegmentMember_9dfc9c11-a5f5-4a8f-817b-836342a9e37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_77b01e0c-6c37-468e-9da3-16aa2c4315e0" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_77b01e0c-6c37-468e-9da3-16aa2c4315e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_7d4970b2-7dbd-4cac-9113-fdadf97e983e" xlink:href="bhc-20200930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_7d4970b2-7dbd-4cac-9113-fdadf97e983e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended" id="i9d8c4bdddcca4966bc95813a2622ebeb_SEGMENTINFORMATIONDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_dbc341d0-ae6d-4f53-81fa-7d5e6568ecbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a3134b96-06f8-4162-ab28-103c54ced3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dbc341d0-ae6d-4f53-81fa-7d5e6568ecbb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a3134b96-06f8-4162-ab28-103c54ced3db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e1a28509-6013-45b1-8272-b25b49f0dff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dbc341d0-ae6d-4f53-81fa-7d5e6568ecbb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e1a28509-6013-45b1-8272-b25b49f0dff5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_32dee295-897a-4954-8d0d-ab6e3d2c82aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e1a28509-6013-45b1-8272-b25b49f0dff5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_32dee295-897a-4954-8d0d-ab6e3d2c82aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_32dee295-897a-4954-8d0d-ab6e3d2c82aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_32dee295-897a-4954-8d0d-ab6e3d2c82aa" xlink:to="loc_us-gaap_SegmentDomain_32dee295-897a-4954-8d0d-ab6e3d2c82aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_32dee295-897a-4954-8d0d-ab6e3d2c82aa" xlink:to="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaushandLombInternationalSegmentMember_9504e7dd-9ef3-4ab5-b4e6-bea4ea41f7f4" xlink:href="bhc-20200930.xsd#bhc_BaushandLombInternationalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:to="loc_bhc_BaushandLombInternationalSegmentMember_9504e7dd-9ef3-4ab5-b4e6-bea4ea41f7f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_6a83a0cd-9fae-4bc6-bd8a-2e6a43eb6cdd" xlink:href="bhc-20200930.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:to="loc_bhc_SalixSegmentMember_6a83a0cd-9fae-4bc6-bd8a-2e6a43eb6cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_9f920a2c-3730-40ac-b0e0-511f57ad68a2" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_9f920a2c-3730-40ac-b0e0-511f57ad68a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_a0f142a1-9f08-4f2f-b4f4-9dcfadf713e3" xlink:href="bhc-20200930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_a0f142a1-9f08-4f2f-b4f4-9dcfadf713e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_473de52b-be52-45c0-bc8a-e8d2a4691eb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e1a28509-6013-45b1-8272-b25b49f0dff5" xlink:to="loc_srt_ProductOrServiceAxis_473de52b-be52-45c0-bc8a-e8d2a4691eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_473de52b-be52-45c0-bc8a-e8d2a4691eb2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_473de52b-be52-45c0-bc8a-e8d2a4691eb2" xlink:to="loc_srt_ProductsAndServicesDomain_473de52b-be52-45c0-bc8a-e8d2a4691eb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_473de52b-be52-45c0-bc8a-e8d2a4691eb2" xlink:to="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_fd59ee82-4d35-4482-a437-c5e627b1c033" xlink:href="bhc-20200930.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_PharmaceuticalProductsMember_fd59ee82-4d35-4482-a437-c5e627b1c033" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_183ef124-274b-49dc-bec3-96c8f6649282" xlink:href="bhc-20200930.xsd#bhc_DeviceProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_DeviceProductsMember_183ef124-274b-49dc-bec3-96c8f6649282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_affaa26b-3325-44df-8af8-e8aaec4bf6a9" xlink:href="bhc-20200930.xsd#bhc_OvertheCounterProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_OvertheCounterProductsMember_affaa26b-3325-44df-8af8-e8aaec4bf6a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_846549a5-536c-43cf-9e9e-476824770cf3" xlink:href="bhc-20200930.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_846549a5-536c-43cf-9e9e-476824770cf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_6ea0c698-f716-4d90-9419-0a799e5c0fd5" xlink:href="bhc-20200930.xsd#bhc_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_OtherRevenuesMember_6ea0c698-f716-4d90-9419-0a799e5c0fd5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="i2e7d770950114495bd795734a951e147_SEGMENTINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_580a3088-3b4a-43e8-89fd-a8fc7434169d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_d25946b3-2598-4503-8ddb-03026b280a71" xlink:href="bhc-20200930.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_580a3088-3b4a-43e8-89fd-a8fc7434169d" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_d25946b3-2598-4503-8ddb-03026b280a71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c7a37159-a57d-4437-9fb4-b221a4a0af47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_580a3088-3b4a-43e8-89fd-a8fc7434169d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c7a37159-a57d-4437-9fb4-b221a4a0af47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_92468803-51f5-4f3f-b328-6f21367463fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_580a3088-3b4a-43e8-89fd-a8fc7434169d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_92468803-51f5-4f3f-b328-6f21367463fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fd794598-86e4-42cf-9e0e-006abfd053af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_92468803-51f5-4f3f-b328-6f21367463fd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fd794598-86e4-42cf-9e0e-006abfd053af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fd794598-86e4-42cf-9e0e-006abfd053af_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fd794598-86e4-42cf-9e0e-006abfd053af" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fd794598-86e4-42cf-9e0e-006abfd053af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_27498886-c076-418b-bcb3-77ef2fe80fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fd794598-86e4-42cf-9e0e-006abfd053af" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_27498886-c076-418b-bcb3-77ef2fe80fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_64165c46-6c8c-46ef-9d90-8ff704f671a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_27498886-c076-418b-bcb3-77ef2fe80fa3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_64165c46-6c8c-46ef-9d90-8ff704f671a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3ef9d37f-bb29-4d9e-95c8-428b1a37b1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_92468803-51f5-4f3f-b328-6f21367463fd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3ef9d37f-bb29-4d9e-95c8-428b1a37b1ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3ef9d37f-bb29-4d9e-95c8-428b1a37b1ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3ef9d37f-bb29-4d9e-95c8-428b1a37b1ee" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3ef9d37f-bb29-4d9e-95c8-428b1a37b1ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aedde349-1c5b-4e63-b29c-69d9820e5c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3ef9d37f-bb29-4d9e-95c8-428b1a37b1ee" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aedde349-1c5b-4e63-b29c-69d9820e5c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_b580da00-3099-4a03-9a30-43ad1ed617d5" xlink:href="bhc-20200930.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aedde349-1c5b-4e63-b29c-69d9820e5c75" xlink:to="loc_bhc_RevenuesNetMember_b580da00-3099-4a03-9a30-43ad1ed617d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended" id="ic3dabbfc79b04182a01763d138806dfd_SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3609284c-4c05-4cf8-b4a9-1e9601cfabe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb619b9a-6242-479d-b87f-4d739730342c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3609284c-4c05-4cf8-b4a9-1e9601cfabe2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb619b9a-6242-479d-b87f-4d739730342c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_159eada2-86ec-43eb-9e49-f8f249fde351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3609284c-4c05-4cf8-b4a9-1e9601cfabe2" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_159eada2-86ec-43eb-9e49-f8f249fde351" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_81bbcd8b-08a1-4b92-b6b5-4e2bc2fccd17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_159eada2-86ec-43eb-9e49-f8f249fde351" xlink:to="loc_srt_StatementGeographicalAxis_81bbcd8b-08a1-4b92-b6b5-4e2bc2fccd17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_81bbcd8b-08a1-4b92-b6b5-4e2bc2fccd17_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_81bbcd8b-08a1-4b92-b6b5-4e2bc2fccd17" xlink:to="loc_srt_SegmentGeographicalDomain_81bbcd8b-08a1-4b92-b6b5-4e2bc2fccd17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_81bbcd8b-08a1-4b92-b6b5-4e2bc2fccd17" xlink:to="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_b3ea1b9b-2f45-4f7c-94c4-fee82b3b67a6" xlink:href="bhc-20200930.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_b3ea1b9b-2f45-4f7c-94c4-fee82b3b67a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_a16b7115-388f-40d2-8fa9-195e60636da4" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_CN_a16b7115-388f-40d2-8fa9-195e60636da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_39b0a23f-ecba-4c7e-a134-0d3d8e960477" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_CA_39b0a23f-ecba-4c7e-a134-0d3d8e960477" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_b9d0b968-93c1-4a9e-b849-a19124ab32af" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_MX_b9d0b968-93c1-4a9e-b849-a19124ab32af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_EG_d224f54e-199c-4690-9e89-fb2d160adf9a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_EG"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_EG_d224f54e-199c-4690-9e89-fb2d160adf9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_5c952a47-eaed-42a9-a9b7-8b964d91e4a9" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_PL_5c952a47-eaed-42a9-a9b7-8b964d91e4a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_8ac6a977-0815-45c0-b3e1-234a887ccafe" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_JP_8ac6a977-0815-45c0-b3e1-234a887ccafe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_8085e048-9459-4e8d-be6e-e79f5304f476" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_FR_8085e048-9459-4e8d-be6e-e79f5304f476" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_4c31dac2-64cd-438f-851d-2bb29ffcaf4a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_DE_4c31dac2-64cd-438f-851d-2bb29ffcaf4a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_6de75227-ef63-4083-b713-584aab880695" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_RU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_RU_6de75227-ef63-4083-b713-584aab880695" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_1347fa9b-e4f5-4914-902f-2f7c21d778ce" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_ES_1347fa9b-e4f5-4914-902f-2f7c21d778ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_92e52a97-463b-4d4b-8bdf-287b34ba7a6b" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_GB_92e52a97-463b-4d4b-8bdf-287b34ba7a6b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_d3b18b7c-c481-4ed1-b7cd-93ed938ba8b6" xlink:href="bhc-20200930.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_bhc_OtherCountriesMember_d3b18b7c-c481-4ed1-b7cd-93ed938ba8b6" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended" id="ie72925d4f5644c15b26f6616394e18b1_SEGMENTINFORMATIONMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_560449d5-5cf7-4208-88ad-fe03f9a3842e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5f602d24-5b35-40d8-81fe-ad3aa2996529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_560449d5-5cf7-4208-88ad-fe03f9a3842e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5f602d24-5b35-40d8-81fe-ad3aa2996529" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_560449d5-5cf7-4208-88ad-fe03f9a3842e" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65cbab6d-6d2e-4414-a671-2baaa99ab4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65cbab6d-6d2e-4414-a671-2baaa99ab4a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65cbab6d-6d2e-4414-a671-2baaa99ab4a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65cbab6d-6d2e-4414-a671-2baaa99ab4a1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_65cbab6d-6d2e-4414-a671-2baaa99ab4a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f801d62-c0a9-49ad-a390-dc5a7406e8d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65cbab6d-6d2e-4414-a671-2baaa99ab4a1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f801d62-c0a9-49ad-a390-dc5a7406e8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_1c75cdb0-63fd-4988-af9a-8ffda8dbc9a1" xlink:href="bhc-20200930.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f801d62-c0a9-49ad-a390-dc5a7406e8d0" xlink:to="loc_bhc_RevenuesNetMember_1c75cdb0-63fd-4988-af9a-8ffda8dbc9a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_71e5789a-35ac-4cda-b3e5-1a66187e7979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_71e5789a-35ac-4cda-b3e5-1a66187e7979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_71e5789a-35ac-4cda-b3e5-1a66187e7979_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_71e5789a-35ac-4cda-b3e5-1a66187e7979" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_71e5789a-35ac-4cda-b3e5-1a66187e7979_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b2e3f141-48d3-4d09-8dc2-3a8e0983f6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_71e5789a-35ac-4cda-b3e5-1a66187e7979" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b2e3f141-48d3-4d09-8dc2-3a8e0983f6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_bd059a6c-76ca-4bf7-a873-a81ce4e16756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b2e3f141-48d3-4d09-8dc2-3a8e0983f6de" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_bd059a6c-76ca-4bf7-a873-a81ce4e16756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3879fd70-7a5b-40df-ac45-3fa3cd1c45d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:to="loc_srt_MajorCustomersAxis_3879fd70-7a5b-40df-ac45-3fa3cd1c45d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3879fd70-7a5b-40df-ac45-3fa3cd1c45d1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3879fd70-7a5b-40df-ac45-3fa3cd1c45d1" xlink:to="loc_srt_NameOfMajorCustomerDomain_3879fd70-7a5b-40df-ac45-3fa3cd1c45d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3879fd70-7a5b-40df-ac45-3fa3cd1c45d1" xlink:to="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_a8ba746a-36c8-44e6-b2bc-3b778bbcda23" xlink:href="bhc-20200930.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_a8ba746a-36c8-44e6-b2bc-3b778bbcda23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_759d67aa-4bc6-4948-abce-7d764a1ef782" xlink:href="bhc-20200930.xsd#bhc_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:to="loc_bhc_McKessonCorporationMember_759d67aa-4bc6-4948-abce-7d764a1ef782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_4b55f4b3-b90b-4116-8d2c-a2b60755b1c2" xlink:href="bhc-20200930.xsd#bhc_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:to="loc_bhc_CardinalHealthIncMember_4b55f4b3-b90b-4116-8d2c-a2b60755b1c2" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>bhc-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:52525664-5cd4-4495-a34d-b14e0c25a97b,g:cfe4b6e8-8eeb-4675-b5cb-546679211f6a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueNetAssetLiabilityAbstract_0e434881-20e9-40bb-b36d-30f8fe5b26bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets:</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_292c6280-0747-4bbc-ad97-70fb66ed1f15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_1a60db36-0c3b-451b-8833-df70a0436d15_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ca2a70f1-aa44-45b2-a6b1-83db33ec96c5_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d44067e7-56b9-4f20-9597-2251cf456c27_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ab448afb-1b46-479b-93fa-21817a460f41_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2fb81e1b-016f-491b-9842-9dca0f758f95_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice_fc42be6d-fd57-4226-8738-06ef47206650_terseLabel_en-US" xlink:label="lab_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential asset acquisition, upfront payment included in aggregate purchase price</link:label>
    <link:label id="lab_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice_label_en-US" xlink:label="lab_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Asset Acquisition, Upfront Payment Included In Aggregate Purchase Price</link:label>
    <link:label id="lab_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice_documentation_en-US" xlink:label="lab_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Asset Acquisition, Upfront Payment Included In Aggregate Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice" xlink:href="bhc-20200930.xsd#bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice" xlink:to="lab_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes450DueMay2023Member_d0c0d0e5-2ac1-476c-b5a8-f6af21f3ac1e_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes450DueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Notes euro-denoted debt Due May 2023</link:label>
    <link:label id="lab_bhc_SeniorNotes450DueMay2023Member_label_en-US" xlink:label="lab_bhc_SeniorNotes450DueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, Due May 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes450DueMay2023Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes450DueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes450DueMay2023Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes450DueMay2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes450DueMay2023Member" xlink:to="lab_bhc_SeniorNotes450DueMay2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_197f31fe-5449-4b7e-8d66-4fc63b858f81_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_04c9f887-ad35-4c68-bc31-e9b83af757d6_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_label_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense" xlink:to="lab_us-gaap_InterestAndDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_17cb99f2-cf70-4e8c-84c5-c6f7fb6208ac_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_a401839f-dc7b-4e7b-8173-99364b32c07d_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_959b6c52-49cd-41b1-9970-3ccf45d53ccb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_fcad621a-e9f4-4e9e-ad5b-0fa131a65f58_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_5b5b5a88-e420-4e01-b1c6-b872a40711f2_negatedTerseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit for discrete items</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_25804254-8aaf-4059-96c1-93df6ff14f00_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_05135452-0266-4860-b55b-445cbb0cedf6_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_99343509-3b27-403f-b930-15cf63bc72d3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_453432eb-cfc3-4180-aded-25821c57c289_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_96a4a1e0-a5b9-433c-a2b1-28897148590b_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a0e1c469-c23e-4ca7-8afd-1c6277716d92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member_b6966f65-00ca-4fdb-b402-c474e07338b6_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.625% Senior Notes Due December 2021</link:label>
    <link:label id="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member_label_en-US" xlink:label="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 5.625 Percent Due December 2021 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 5.625 Percent Due December 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5.625PercentDueDecember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:to="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8b140474-1b03-432f-b095-3feb6619a725_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2757ae09-58b9-4070-86c4-685e09b101b2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_2056a964-3107-443f-a114-5e38cad893c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d91d68d8-3daf-49e4-a877-f60397815574_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_c50567a7-5acf-4a5e-af46-a1af36cc1419_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to change in United States law</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_bcfacf9c-d16d-45ea-af10-7b02f3af256d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_29769e93-118d-49cd-8b3a-51a48268f219_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2d94391e-f620-42ba-b2fe-3a31fb6205fc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_e0da991c-d551-499b-9b95-93eb540fe093_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax charges (benefits) related to changes in uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_da02b9df-2ef9-4547-8a8c-3a81b5a6d933_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments or receipts in settlement of cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e6364e59-55e9-47c7-ac9f-3f86f7f4a570_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_0fdfe097-7d70-4fdb-8636-b09b78dca1b1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost-rationalization and integration initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c9f9932d-587e-4942-b1c6-0d685ea3682b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_dfa7f7bd-f163-4f4d-9cd1-876971bef3fc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_a56bf9d6-c73e-44ff-9a11-8f6b1e5249a2_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of reporting value, greater than its carrying value</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SynergyPharmaceuticalsInc.Member_aa7429ef-f2ea-4854-b1e0-6ebedaf8631f_terseLabel_en-US" xlink:label="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synergy Pharmaceuticals Inc.</link:label>
    <link:label id="lab_bhc_SynergyPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synergy Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_bhc_SynergyPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synergy Pharmaceuticals Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member" xlink:href="bhc-20200930.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SynergyPharmaceuticalsInc.Member" xlink:to="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_bf84379a-e5bb-4018-9e25-e7f064903ed4_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_90776f72-30e1-4cc7-bc45-cc19e328c0d9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1a3e305b-df42-48bd-81b2-5a756ed062da_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_834d1494-5d94-4f22-b964-e62860246213_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_country_EG_8128ab0c-c9be-4138-86da-c6e6258bce5a_terseLabel_en-US" xlink:label="lab_country_EG" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Egypt</link:label>
    <link:label id="lab_country_EG_label_en-US" xlink:label="lab_country_EG" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EGYPT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_EG" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_EG"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_EG" xlink:to="lab_country_EG" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes5875DueMay2023Member_8cb50328-94a2-4989-8bea-36ec3e2e7149_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes5875DueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes Due May 2023</link:label>
    <link:label id="lab_bhc_SeniorNotes5875DueMay2023Member_label_en-US" xlink:label="lab_bhc_SeniorNotes5875DueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.875%, Due May 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes5875DueMay2023Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes5875DueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5875DueMay2023Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5875DueMay2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes5875DueMay2023Member" xlink:to="lab_bhc_SeniorNotes5875DueMay2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_81dbe94a-a8d2-4c74-9606-c7b83f000786_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ce211cd9-6195-4dc1-bb1b-c6c4d033f6c3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4c3cf94b-9838-4c36-a4d7-e0e69e6a4853_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_472d37dd-71cf-4145-a192-2d5500a54d23_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ed6a88d5-fb03-4d26-9d0e-ae3cdf39aad3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_aeb09198-3d48-4e25-a8e4-40aa4c9d09c3_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33322776-b0e6-43b6-a282-7c14878ba0a0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_68f367d8-575c-4ad3-a0ef-9105356b0966_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_f6e723b4-ffe5-4992-a8ca-b072c276d1ab_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_2aeca1d3-6fe5-465b-b175-c10db3a49899_terseLabel_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_label_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_documentation_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:href="bhc-20200930.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:to="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8a23971-8086-487c-9c92-7f956457fcbd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ab827dfb-e4f3-4e64-9767-63acf447bc3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5b7bc161-5e99-4f65-b7de-9ba08bf9b01e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_e19e92d8-3786-445f-813e-66f3ff5fd6ca_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, mandatory prepayments, percentage net cash proceeds, property and asset losses</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_eb9029bf-b4ec-4de8-bf85-40f11e5e0c57_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_7eb9def1-8e04-4221-8da4-978596452ccf_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_c8f52917-f5e7-4c70-b1dc-08a1d102d6e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_f52b0c14-9a55-461b-b55a-f2acffb4e9ea_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_55a115a9-7333-4ecd-a9d5-ed78605420b8_terseLabel_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, AmerisourceBergen Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember" xlink:href="bhc-20200930.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmerisourceBergenCorporationMember" xlink:to="lab_bhc_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_012986a7-926e-4e17-be3d-bcd35e5db05b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ae411f04-b884-455d-8d63-57944b9df551_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_38569e8b-f120-47ec-8a29-74ee4d5f4967_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit on ordinary loss</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4f5e6d13-8c60-45a4-bfcf-4c4a357ed455_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_a3a8bec0-85f5-449e-90c1-3ad4aa7f4bbf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_6ae96566-2f92-4747-ba5a-06bbda45d831_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating results of acquiree</link:label>
    <link:label id="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_label_en-US" xlink:label="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual</link:label>
    <link:label id="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:to="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_54670d67-b1a1-447f-b925-d7d81dbd6519_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c925aa71-2e39-48bc-896a-e84b435dfe94_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1dc14eb5-dc5f-4662-b8ce-eeb0c0818f43_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_923c8d1e-81c9-4a90-b0aa-6ca37ad5b1ad_terseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_fe9fa992-4a94-45f7-87a6-8001805bcf91_negatedLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_label_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_documentation_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:href="bhc-20200930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:to="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_61a9e014-842b-4f07-92ab-0cd73cb1a026_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice_c21ca930-8fba-4e64-8d02-2e75ce5496a3_terseLabel_en-US" xlink:label="lab_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential asset acquisition, additional funding payment included in aggregate purchase price</link:label>
    <link:label id="lab_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice_label_en-US" xlink:label="lab_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Asset Acquisition, Additional Funding Payment Included In Aggregate Purchase Price</link:label>
    <link:label id="lab_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice_documentation_en-US" xlink:label="lab_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Asset Acquisition, Additional Funding Payment Included In Aggregate Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice" xlink:href="bhc-20200930.xsd#bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice" xlink:to="lab_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4f665051-5740-4729-950a-9930de18bc7f_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0ae66780-3370-4a62-9869-66810f3ee5a5_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_e8d374c4-5bb0-4036-8c40-29e5d03c8671_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_d72376bc-369d-4678-b86b-7e0215015bd9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_b5e80614-dd02-43a3-9902-b286ed08f032_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of accrued legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_185a55dc-2af1-41a4-8baa-db50f1cade5c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for legal settlement</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3d2c98a9-78fe-41e6-9c33-1c504a013432_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components and classification of financial assets and liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6f6f470f-eedd-46a3-b7ec-b49b3bde7821_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unrecognized compensation expense related to non-vested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_8828e0c7-9ee8-468b-8590-c55715719327_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEGAL PROCEEDINGS</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_10365eeb-611a-42d3-9bbb-1356323a7f59_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:href="bhc-20200930.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e89332b3-8f21-4071-be0f-959b7404838b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_dca9a799-0ed3-4960-9584-08b31312384a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_faafdaf7-33af-4542-ba23-15ec573376d9_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_b9939b00-788b-480e-80c0-866642f56e7f_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Notes Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 7.00 Percent Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 7.00 Percent Due March 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:to="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_7f82ab54-2cf5-4460-9237-87af7361258b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in fair value, loss</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_692ca1e5-bc6d-46f4-81e9-654a8b16116a_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_04a493cb-44c2-48d8-873f-191a79e37f82_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25 % Senior Notes Due May 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.25%, Due May 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.25 Percent Due May 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes725DueMay2029Member" xlink:to="lab_bhc_SeniorNotes725DueMay2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_7cbe69b1-0391-45cf-bec2-eb707379f61d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0e3a5ab9-c2c1-4fd4-9df0-0c2403e670b8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_e39ec616-6dfb-45bc-9143-410f42d92e19_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_349f8db4-1117-4199-b346-e512089022c3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6be6d56-4f67-46fa-acc9-cdd271644736_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2064a5b5-2367-4410-ad45-bc6c0b745943_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_c5e4e530-54d1-49dc-b982-6b6972e79217_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70429648-053d-426e-98b1-854ce9af0c75_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afc183dc-9f82-4326-bfa4-b40d792d2880_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price appreciation credits</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_5afdcba4-74be-41e1-b6b7-e70e21663444_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_fde6a590-663a-424e-985b-6bd459b6693d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_f30da95a-ab14-4277-9ba9-b769bff1ac5a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ef0d8dab-ed43-4ec1-8396-2cfa3ef7fa42_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8b071fa-343f-42d4-92b3-934efcd892b5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a3799460-61df-4e6f-9d03-e94fcb2fd9ae_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7ab77e61-244d-4752-830f-837ca567b332_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e0a721be-4d77-4cf7-99d8-7f66e3be6b88_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_beb56272-d2c9-493f-98ee-c837d5f14da7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_f8c6cbf0-e899-4e8d-bb66-24e02bd479c9_terseLabel_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_label_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Noncash Expense (Benefit)</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_documentation_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:href="bhc-20200930.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:to="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_1bfad564-10bb-478f-9850-9d7fdf72db37_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3df7af2c-ed06-47cf-be97-953aadac848b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_b3829e2e-8bc3-475b-9494-9d88c97f02b8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8a07d013-e052-40f3-bfd3-a2821d03ee30_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_dc6e2f70-2c43-4c8c-95d0-8b29c4b705ff_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_3d228da1-61be-4b6b-8e77-272353a635d7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_3a3a9d24-7b3d-4068-9808-0319e8956b39_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c362e607-f6d1-49e4-9479-c0bc28eb4f14_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_d2e1b944-e2c9-4628-91ee-0f64c98e6ad8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_74cdd20f-23af-412e-9ecd-9177404d1133_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_0790094b-ce6d-433d-834a-8b055d1e0712_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForChargebacksMember_cd4fab8b-024d-4a9a-908f-26f7c8b0502e_terseLabel_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_label_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_documentation_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember" xlink:href="bhc-20200930.xsd#bhc_ReserveForChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForChargebacksMember" xlink:to="lab_bhc_ReserveForChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonemployeeDirectorMember_fc227ab2-0f70-4111-b26f-84029a0c4054_terseLabel_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Director</link:label>
    <link:label id="lab_bhc_NonemployeeDirectorMember_label_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director [Member]</link:label>
    <link:label id="lab_bhc_NonemployeeDirectorMember_documentation_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember" xlink:href="bhc-20200930.xsd#bhc_NonemployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonemployeeDirectorMember" xlink:to="lab_bhc_NonemployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_c09c1482-584b-42ae-91f9-bf70a162420b_terseLabel_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments due to changes in estimates of other future payments</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_label_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_documentation_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:href="bhc-20200930.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:to="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_3a4147a6-3efd-404e-81f3-600245facf6a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_dddd93ec-122a-416c-9ce0-67904e7b4185_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring adjustment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetAcquisitionAxis_8c78285f-09e4-4142-a2f3-e8bfde33e5d3_terseLabel_en-US" xlink:label="lab_bhc_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAxis_label_en-US" xlink:label="lab_bhc_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionAxis_documentation_en-US" xlink:label="lab_bhc_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAxis" xlink:href="bhc-20200930.xsd#bhc_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetAcquisitionAxis" xlink:to="lab_bhc_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_67c114da-189c-40fb-a34b-9cde5f33fa57_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_f5d09d3c-af29-4560-89e3-50d878e7ac70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherLongTermDebtMember_28722f1b-653a-4262-84f2-1501704f3072_terseLabel_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_label_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents long-term debt obligations not elsewhere enumerated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember" xlink:href="bhc-20200930.xsd#bhc_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherLongTermDebtMember" xlink:to="lab_bhc_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ca31a9a1-b2cd-4dfc-9f18-963c959e481a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_810c371b-0c24-4147-8475-a4123aa267ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_a3ee01f7-249f-44a4-b425-1e85a4e0b5c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_1cf67012-241a-4c36-b5e6-b2d406be6bed_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_367d0c79-49eb-4260-a77c-49c21a29d6ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d5ed878a-7641-4b7c-9592-c750b497ca7d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22a778bb-1fe0-414f-b1b4-5a30c47251f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_c3e0007d-8c08-45cb-9f26-9076f25d825d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue associated with products for disposal</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember_1c28e6da-7ffa-4d3f-b3a8-5065726989b7_terseLabel_en-US" xlink:label="lab_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation by the State of Texas, State's Medicaid Program</link:label>
    <link:label id="lab_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember_label_en-US" xlink:label="lab_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation by the State of Texas, State's Medicaid Program [Member]</link:label>
    <link:label id="lab_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember_documentation_en-US" xlink:label="lab_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investigation by the State of Texas, State's Medicaid Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember" xlink:href="bhc-20200930.xsd#bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember" xlink:to="lab_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_b3c9c8b6-8d51-443e-b31e-556e63322f9c_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product related research and development</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:href="bhc-20200930.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3cc95f48-a17f-46ff-b1b2-c076b910186c_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_56605000-c124-4eec-b988-e1e02319f936_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_e81f57ce-be0e-4e5f-a65f-fc431af10b3a_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_98edf8d3-a0aa-42c4-8a87-9a07f252c38c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bc0235e4-848d-4f9b-8896-b64afcb45661_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_61175142-7018-4c92-9072-5c0032c16ca1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_7670efc7-a837-448f-8de3-f5921811ef80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a57bbcf6-ffd5-4683-a4aa-b916802db2f2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c8d3d73c-4f22-4b91-998a-ac93996ef9e0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits related to interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bdaa68c2-6bbb-4e60-b58c-57b58cfd8585_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f31ec450-f760-4dbd-af40-384e1d126ac2_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_7325bafd-ef26-433d-8a1c-238a1f9c60fe_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_eb41f6bf-96dc-48ee-8927-f936762d261b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c3918ed3-892a-408d-93d5-082a3507f365_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_77dac218-90a5-4d82-a613-c7268ddd5d80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values of assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_d5a1126e-b2f0-4f58-862d-964466705ff3_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8bdc8ccb-0391-4bc4-83db-6df644577821_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_abb58a36-0589-4690-bceb-b299c559429e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6215f407-6957-4059-9410-39ae5e8d4fd1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_1f5befe1-57ab-4fbb-a67d-0e106d182a2e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount reclassified from accumulated other comprehensive loss into operating results</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_1d03ce87-f18d-48e5-b8d8-f56915db71fc_terseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4638b681-eda2-4277-9d56-0887258bb162_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b9fae0ac-c8bf-4904-8ca6-1358a3b69bcb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b3208d90-4bf1-4092-affc-e87269b0bd3f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING, INTEGRATION AND SEPARATION COSTS</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_cd4f4eeb-d8a0-4376-9097-165fd33adf01_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_8e3eda26-f3b1-4da7-a815-9002bb49ef7a_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action, remain pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:href="bhc-20200930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_fd28d038-9153-4caa-af30-baab20542ebd_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_04cbc60c-d180-4880-8928-bb067e0c5762_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_069e746a-d101-4172-8ad9-8f3076b582c5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_4f416f7a-3b3d-484b-a3f1-f37523f569b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount_0afb7327-67bc-4dea-b3cd-5a771f565eaf_negatedTerseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to Global Intangible Low Taxed Income (GILTI)</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income, Expense (Benefit), Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income, Expense (Benefit), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ccd381d0-54ba-48dc-bda1-30fc5cfb6ab8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_7fc1b316-722a-40a6-aa65-e7ba111e7984_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the issuances of short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits_0ab05082-068c-4fd6-98bc-5573d5e2e2c3_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of health plans commenced action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Health Plans, Filed Lawsuits</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Health Plans, Filed Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfHealthPlansFiledLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits" xlink:to="lab_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_bf7eb47b-4354-4f9d-8696-e34dec8a1a6f_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e6c4b10d-6a3c-41f2-9f71-c64c3359ad59_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_46be233d-b96d-47f1-81b9-d052ef6e33f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to release of valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_654aa49d-45dc-4557-81c4-88f0a3973a91_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_bdef5ccc-282f-4450-bfc1-dcf18e93d6c3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_b9e2eb61-b523-4066-97dd-3019a3315578_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_2dd9eb76-b715-4356-995d-89fc82206552_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_699c1fb7-dcbe-447a-8a43-1aff7b22e281_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4e30e120-dc54-41a1-9c3e-8a216ae90f2f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2d170611-239b-4407-a202-4eec4b807d5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by segment and product category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4fb134c5-c9b3-42d4-9fbf-bb1564205920_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cooperative advertising credits included in rebates</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_74c2b6e8-a5eb-4c1c-a15b-42791a24acb0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_56982b6c-64ff-455d-9440-d1403e8bfdf5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_c0700847-00a2-4913-bab2-4b310203a451_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f0135753-fb52-4b56-8460-d166e8e15ef1_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherMiscellaneousNonoperatingIncomeExpense_4467b763-225a-415e-9de4-7e2e89674f7e_negatedTerseLabel_en-US" xlink:label="lab_bhc_OtherMiscellaneousNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_bhc_OtherMiscellaneousNonoperatingIncomeExpense_label_en-US" xlink:label="lab_bhc_OtherMiscellaneousNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Nonoperating Income (Expense)</link:label>
    <link:label id="lab_bhc_OtherMiscellaneousNonoperatingIncomeExpense_documentation_en-US" xlink:label="lab_bhc_OtherMiscellaneousNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Miscellaneous Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherMiscellaneousNonoperatingIncomeExpense" xlink:href="bhc-20200930.xsd#bhc_OtherMiscellaneousNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherMiscellaneousNonoperatingIncomeExpense" xlink:to="lab_bhc_OtherMiscellaneousNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_098ad4fb-6434-415a-8da9-4f8c3e1268a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e75597fb-7db4-4590-b1ad-3a7afdd6c298_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c7945afe-6814-4abf-8abc-eab2ed45fbf2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_8d965d1d-a407-430b-98d1-da8a36418594_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_6ef6c67f-97ec-45be-baa7-9bc3869f3aab_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_82bd8c03-57b0-47dd-9dcc-0ebbfd8866b9_terseLabel_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived and Indefinite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="bhc-20200930.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_d60884b9-79ac-4d48-b169-93df95cf1d1e_negatedTerseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_label_en-US" xlink:label="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses</link:label>
    <link:label id="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:to="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_bbd12c66-1d34-4b29-ab53-fa1f18d58449_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_f5ccd35b-158e-43c4-b8b0-142e6607385e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_e7daf15e-634c-4037-b21b-14c98d3fef30_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.25% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_380a4d68-c8a9-4553-8e8d-da66efeebb32_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_56a160e0-b381-4b8f-a639-5f800b0cc056_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_9b9353fa-0c88-4336-88ae-560a809afab3_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e9ce2edd-7728-4b65-ae06-a64c416846d4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_d5f8aee9-0c15-4842-adfc-24c1ba243e55_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets reclassified, held and used</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_0b1bdbe0-a02a-49c4-92d5-6d763e2a0969_negatedTerseLabel_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from hedge effectiveness</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_label_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_documentation_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent" xlink:href="bhc-20200930.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeGainExcludedComponent" xlink:to="lab_bhc_DerivativeGainExcludedComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_960a964c-4353-43d5-8988-6d2ec00acfef_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Return Current</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent" xlink:href="bhc-20200930.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductReturnCurrent" xlink:to="lab_bhc_AccruedProductReturnCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_3010e725-6668-441b-9ab5-d0bd989757ee_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_27e4bda9-d87b-41c4-8f03-cfa370fda2af_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_5253929f-b011-407c-bcd0-84871985f577_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_135a1b24-82fc-4cfe-bd16-fda03c91178f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4a774ac8-0cfb-4e6f-8d7a-9ae6bb4dfa60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_515d01c9-6da2-407a-92f8-a19014af4eee_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_44cd594e-7729-4b15-b305-8995ed848bd6_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed but not yet served</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_label_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_documentation_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:to="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_06708b28-e2a4-44ca-b8e9-ba8a27919a01_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0989e764-84ee-443c-b687-cc41466dca70_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c891317-3022-48b0-b3d6-fe13474a6c9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_fc764cc0-832c-4bc1-ae53-1a75d829b541_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility closure costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_98dff8ef-2998-45b6-9ed0-1f957e499525_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_4f9d8361-03ce-46b5-bdd7-e496f63d85f7_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, long-term growth rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:href="bhc-20200930.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_526259e5-b5ae-4a4b-accb-8fde8be0d7d7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_de4ec62b-4a12-4c41-acd7-8b1499e55d3f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_abbfa03e-77f8-4f31-8d84-74e5bbd6758f_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Fees</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_label_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember" xlink:href="bhc-20200930.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDistributionFeesMember" xlink:to="lab_bhc_ReserveForDistributionFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_3b385e87-bfc4-4d46-ab96-cf62216ce6b0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_1a75c6a2-d7a6-4564-a38a-c3ea02699843_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2bf6a063-cf1c-4ed1-9578-a1daff9fe9be_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_dc8f44ff-8aa5-4d3a-92a1-c39bd7c0f7a2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OvertheCounterProductsMember_662ccf79-a87e-45d2-a894-efc39d22e664_terseLabel_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_label_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_documentation_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember" xlink:href="bhc-20200930.xsd#bhc_OvertheCounterProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OvertheCounterProductsMember" xlink:to="lab_bhc_OvertheCounterProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_34d6fae3-0c6b-4a9c-94e4-5b6e2677f212_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits including interest and penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest and Penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:href="bhc-20200930.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:to="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_9451b809-aedf-4621-8e30-70fc44e0d3b3_terseLabel_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR performance-based RSUs</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20200930.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_516284ab-792b-43b7-9120-7bc9744ff1a9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7bca0528-404a-43c9-97b2-5f7f32554f7b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average service period over which compensation cost is expected to be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_84cb9e93-5fc7-40e7-ab95-e637dd362461_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_04817f0b-6740-46fa-bf8a-908f9b9e5afc_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_346a8b72-c8bc-4227-8188-00f6e2465f45_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Long Lived, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:to="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9c47fcca-d2a8-4ecc-a6a4-637644492282_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5e374ada-28e8-43ce-a3a4-478ca4b61576_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_567970f4-c1d6-4445-95f7-b93e7bb21b10_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7a49b464-82de-4bc3-a29e-873ea5938075_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a82aecf6-2589-4819-b4c5-1cac07f6c490_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_9fdebd53-b89e-4f8d-b221-14d438e3d5f0_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_3aa26beb-9054-4b50-a28c-e331790a2b7d_terseLabel_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal matters and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_label_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_documentation_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees" xlink:href="bhc-20200930.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_Legalsettlementsandrelatedfees" xlink:to="lab_bhc_Legalsettlementsandrelatedfees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_e03c4783-74ef-42cf-8d57-38d831c8a5f2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_0e2e9a8b-f95b-4b4b-964c-29750219b389_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d2dcd24c-6a31-4540-9ddb-bfa8abaef697_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_06daf9e4-63e5-45d1-9578-bd3500fcf3bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_e20d1ea2-17ca-4aef-ba43-0db2014b079c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESEARCH AND DEVELOPMENT</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_62383059-3a1f-42bc-982b-abac02d675be_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e771d6c1-8df3-41bc-8075-bcdcab56799f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_c3beeeaf-2e46-4ab2-9ef7-32e24ca6436a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_72795798-be8b-42bb-83f4-fa8fce62693b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_08be8d6f-e16c-4e6a-8f8c-dac0470cc49f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other expense, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_0283d6de-1b4a-4e44-8d31-3875bf7917e5_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_2fcf9654-953d-467e-b4c3-b3d231550ae3_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma operating results</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Operating Income (Loss)</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:href="bhc-20200930.xsd#bhc_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:to="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ad199aec-42a4-48b7-aedd-9843e9bb17aa_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_fd7def3d-c543-49ab-92ec-c79351745d6b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_8d70a1d9-917f-4ffa-a36c-2f426fc57eac_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:href="bhc-20200930.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_c1654499-9a5a-4078-bf16-a7b00cc80049_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_4f5bdc6a-5707-4994-8f6d-fb3894f28f27_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_856add2a-a1e9-4843-832e-cbba1042b8d2_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_710b407d-458e-4f47-91ae-8172c51ee7e7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_a167cced-2f38-4359-b7df-c15173517aa3_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_52e39f11-ed19-4a52-9139-5bd356f72ee8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_711ad479-ab22-4618-b0d4-9fc199784512_terseLabel_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly liquid investments, maturity period (or less)</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:href="bhc-20200930.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:to="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_2f9764ee-2c09-424e-8d50-5d66c5d2e602_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_42095663-61b5-4c0b-9b65-dff26b6d31c2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Synergy</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_89c896c2-3262-4b84-b6bb-bb446df5e135_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PotentialAssetAcquisitionAggregatePurchasePrice_b7067fdb-56bc-4917-bc15-94c2341f6ae0_terseLabel_en-US" xlink:label="lab_bhc_PotentialAssetAcquisitionAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential asset acquisition, aggregate purchase price</link:label>
    <link:label id="lab_bhc_PotentialAssetAcquisitionAggregatePurchasePrice_label_en-US" xlink:label="lab_bhc_PotentialAssetAcquisitionAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Asset Acquisition, Aggregate Purchase Price</link:label>
    <link:label id="lab_bhc_PotentialAssetAcquisitionAggregatePurchasePrice_documentation_en-US" xlink:label="lab_bhc_PotentialAssetAcquisitionAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Asset Acquisition, Aggregate Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PotentialAssetAcquisitionAggregatePurchasePrice" xlink:href="bhc-20200930.xsd#bhc_PotentialAssetAcquisitionAggregatePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PotentialAssetAcquisitionAggregatePurchasePrice" xlink:to="lab_bhc_PotentialAssetAcquisitionAggregatePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fed7fe14-99c5-4f65-a029-fc8e277fa276_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_bd0325f2-e31b-495f-8364-dd94fa4541fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RICOClassActionsMember_0a1a0506-eb31-4682-bd16-44fde35de77e_terseLabel_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions</link:label>
    <link:label id="lab_bhc_RICOClassActionsMember_label_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions [Member]</link:label>
    <link:label id="lab_bhc_RICOClassActionsMember_documentation_en-US" xlink:label="lab_bhc_RICOClassActionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember" xlink:href="bhc-20200930.xsd#bhc_RICOClassActionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RICOClassActionsMember" xlink:to="lab_bhc_RICOClassActionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_4f095fee-def8-44de-9b0e-77b4ff4d474f_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_d82b597a-551d-419b-8f6d-5999dfb3135d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_c044a625-8e2b-4745-940b-846f55c86d8f_negatedTerseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_label_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:href="bhc-20200930.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:to="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_3ecc44ac-bda4-4c7f-ad6b-1b58c74dffac_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_0032cc66-03bc-4136-b897-5037b44c9134_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, mandatory prepayments, percentage net cash proceeds, incurrence of debt</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PL_1cb09403-2823-4b79-b2e6-6240e8fcbe08_terseLabel_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Poland</link:label>
    <link:label id="lab_country_PL_label_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">POLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_PL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PL" xlink:to="lab_country_PL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fe147448-64dc-4ad6-8638-a94ff3a77d2c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7815a4ca-5297-4d11-9f21-5138b407392a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_314bed64-1006-4750-bcf0-cf05e2e9f791_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a93b350b-7130-4ab6-867b-5f41fe775f3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted effect of stock options and RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_ecf26bb2-7794-4400-8c29-a7cde506dd21_terseLabel_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_label_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_documentation_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember" xlink:href="bhc-20200930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForCustomerReturnsMember" xlink:to="lab_bhc_ReserveForCustomerReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_231828cd-3f9f-4d9e-9579-a395d907b03b_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense related to filing certain tax returns</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ddc44b94-d0e2-48e7-adbf-815f410f3e54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment revenues and profit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_9024c220-5f5f-4582-89f6-ce0eeb6c5d79_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:href="bhc-20200930.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_04646857-12c0-48d7-b39c-a3962fffc580_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_5c012f71-b10d-44a4-9b62-240b0a4a1af3_terseLabel_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generics</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_label_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_documentation_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember" xlink:href="bhc-20200930.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BrandedandOtherGenericProductsMember" xlink:to="lab_bhc_BrandedandOtherGenericProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4d410fb1-477f-4f14-8f7b-93bd1e614559_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effect of hedging instruments on financial statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_08044d1f-4866-466d-9b54-f968fb3471fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e7be4aee-91c1-4476-9d61-bfcf17e9873b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_d47a64a6-26c4-459f-836f-9677b6759c79_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_716599df-582a-4313-9312-721416fe8691_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_13bc8f40-917e-4965-94b3-48d2481789b2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9660a773-87fb-46f8-89de-6bac3d8a4ed1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_93d8f64d-ac70-4e0f-97d1-5acf9f10d126_terseLabel_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC performance-based RSUs</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20200930.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_b422f09b-6d1b-4978-91cd-572629c573dd_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:to="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b12b8392-00ee-473a-b07c-af61b4829233_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_065c8f3f-e737-4230-8d44-792fbde4311f_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Integration Costs</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_label_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs [Member]</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_documentation_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:href="bhc-20200930.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:to="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_6ca1813c-39f9-45a0-97ff-ec7a19e8498b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f2e0a4a6-d63d-44b3-b401-0d9d1aa3d837_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_edffc939-6f3e-4b83-893b-3048e77f01ee_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of alleged stockholders, filed lawsuits</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:to="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_2524e6ec-afdf-4540-badb-a4507655f5b6_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:label id="lab_stpr_NJ_5a14a194-520e-4a13-93a5-e1da300913b8_verboseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_501747ab-20c2-46d4-96b8-2b8748f4bef3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_2be5b6b1-cc9b-40c5-b59d-f6ede784e8cb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_eacf3616-6dd1-46db-97b7-72f305aee863_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_18728464-4788-4b24-b4e9-d23e641bd571_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for restricted payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:to="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_f2121524-dc8a-42be-8e93-c7fb97c8233d_terseLabel_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest settlements from cross-currency swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_label_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_documentation_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:href="bhc-20200930.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:to="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_779b06cc-da6d-4492-b80c-3d6c4308a756_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_3d55bfdb-e666-4e07-bd52-c5bb9d2814d0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_31148cd6-4297-422e-9833-5bffc7029b6e_terseLabel_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_label_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember" xlink:href="bhc-20200930.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PharmaceuticalProductsMember" xlink:to="lab_bhc_PharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DisposalGroupNumberOfProductsForDisposal_45f047a6-8235-41e6-9e6d-6d27f9705ef5_terseLabel_en-US" xlink:label="lab_bhc_DisposalGroupNumberOfProductsForDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products for disposal</link:label>
    <link:label id="lab_bhc_DisposalGroupNumberOfProductsForDisposal_label_en-US" xlink:label="lab_bhc_DisposalGroupNumberOfProductsForDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Number Of Products For Disposal</link:label>
    <link:label id="lab_bhc_DisposalGroupNumberOfProductsForDisposal_documentation_en-US" xlink:label="lab_bhc_DisposalGroupNumberOfProductsForDisposal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Number Of Products For Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupNumberOfProductsForDisposal" xlink:href="bhc-20200930.xsd#bhc_DisposalGroupNumberOfProductsForDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DisposalGroupNumberOfProductsForDisposal" xlink:to="lab_bhc_DisposalGroupNumberOfProductsForDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_fbe54451-b33b-4043-b8a8-f7428cc9cd02_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:href="bhc-20200930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GenericPricingAntitrustLitigationMember_74b42ca0-3152-4bb3-bc64-fe2b6c37efc5_terseLabel_en-US" xlink:label="lab_bhc_GenericPricingAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generic Pricing Antitrust Litigation</link:label>
    <link:label id="lab_bhc_GenericPricingAntitrustLitigationMember_label_en-US" xlink:label="lab_bhc_GenericPricingAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generic Pricing Antitrust Litigation [Member]</link:label>
    <link:label id="lab_bhc_GenericPricingAntitrustLitigationMember_documentation_en-US" xlink:label="lab_bhc_GenericPricingAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generic Pricing Antitrust Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GenericPricingAntitrustLitigationMember" xlink:href="bhc-20200930.xsd#bhc_GenericPricingAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GenericPricingAntitrustLitigationMember" xlink:to="lab_bhc_GenericPricingAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e7583362-d5b1-4ceb-abc3-0ccaa90a2e88_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PartnerRelationshipsMember_f337a1eb-6b1f-4405-a15e-7499c7710a15_terseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_label_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Relationships [Member]</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_documentation_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember" xlink:href="bhc-20200930.xsd#bhc_PartnerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PartnerRelationshipsMember" xlink:to="lab_bhc_PartnerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetAcquisitionDomain_d8bca01d-fb5a-4b95-8311-9eddb4991f5e_terseLabel_en-US" xlink:label="lab_bhc_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionDomain_label_en-US" xlink:label="lab_bhc_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_bhc_AssetAcquisitionDomain_documentation_en-US" xlink:label="lab_bhc_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionDomain" xlink:href="bhc-20200930.xsd#bhc_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetAcquisitionDomain" xlink:to="lab_bhc_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_06a1b91b-03d2-4cf7-b5bb-aac0c37d92eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a9bc7d33-c4c0-41f2-9a14-89681d9db2bf_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_7d5fae8f-7dfe-4be8-b243-f040aece7241_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_933696d8-1939-4437-9c25-923f91f4763a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_49e6803a-e5f5-447e-ab0d-8ad7c9fe440a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_231f5074-b432-4a67-a113-3495c4f641af_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_0cd71ba7-009d-4054-958c-f8f9df66200f_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Adjustment</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f5caf0c9-ba3b-4406-809b-c8905532e0c8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_4b02eaa9-f37b-4d9b-85e8-7e0b9d45d587_verboseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes Due August 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:href="bhc-20200930.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:to="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_b769f287-34bb-4ba4-8a54-78ad66bfc0a0_terseLabel_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_label_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_documentation_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:href="bhc-20200930.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:to="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_31ceb55a-4754-4232-bd1f-949c494512e6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_be3f87d5-08c0-4167-9588-e67891b540e4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to settlements during period</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount_3e15516e-b464-4309-91bd-20784cc19c8d_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to filing certain tax returns</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Benefit Filing Tax Returns, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Benefit Filing Tax Returns, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_83ca153c-9049-4279-a1ba-f4b7c8e252ab_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_8a578471-8d74-4fb5-977b-052829802675_terseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_84a9818d-6417-411d-b052-025b18fea568_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherRevenuesMember_70e2afa8-ac52-4968-8ef9-85e6addb0d4d_terseLabel_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_label_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_documentation_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember" xlink:href="bhc-20200930.xsd#bhc_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherRevenuesMember" xlink:to="lab_bhc_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_cad290ea-cc76-4732-9969-96abf96f8437_terseLabel_en-US" xlink:label="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Products For Disposal, September 2019</link:label>
    <link:label id="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_label_en-US" xlink:label="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Products For Disposal, September Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Products For Disposal, September Two Thousand Nineteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:href="bhc-20200930.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:to="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_de710f63-82c7-40f1-9cce-703adc56d69e_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7dd0ace3-6211-42bf-8a95-ab29226dcbed_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e7cf9a4d-b6b3-4360-9dee-bd12077ba890_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_b0f7dffb-d63d-44be-98b4-a5ccda550965_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_label_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 8.50%, Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:to="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_a293a6da-6889-412b-ba51-37736228d8f0_terseLabel_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_label_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_documentation_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:href="bhc-20200930.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:to="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_66a05d8f-97af-460b-ac79-95f117a121cf_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before (provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_83cf0c86-f254-4d7c-b627-8bc3a8311758_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_644cebf2-1e93-416a-a56f-11bfe4cdeaf9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_8bb514b0-a7a1-4d9a-bfb3-a8093bcb80d2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3cf10752-0802-4842-8e28-832e1626a47c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities measured at fair value on a non-recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_283974d9-1b8a-4e68-86cd-7b4a8f8202e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0ebc0817-1914-46f4-9579-b28d29d383e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_bb38f2bd-9468-42ee-bd95-991ba74381b5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a4610933-9c15-4ac4-8257-fe7fd14991da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_6791cd1b-675e-46a4-b143-c3fbd24da4d2_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amortization rate (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_label_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:to="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_3fbdc4a1-b079-44ff-b60d-746173fa7315_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_28dc1a86-47c1-490d-9ce5-97f55558a37d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_57ed4627-4229-4224-a61e-d6b88e59ac08_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e531c8e1-6e13-47e0-ba9b-a09fddc8528b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_e05420e4-8f54-40d3-883e-51b66889fa4a_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_c1312b99-d01d-4c00-be23-60c17cd68fed_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_389936d5-3c9b-4f6d-860a-cb46b5fa6d0b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_359dbc20-84cc-42e2-8d91-ce1998cf0008_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_4518dbd6-8dec-431f-9b63-5981769f5c8c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of certain assets of Synergy</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_36074f6a-745c-42ac-a10a-4a121af5c7d9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_d1657f2b-693c-4665-9e49-b37f6ce74f30_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_0e39e18f-a50b-44fc-8ee2-4411b5967096_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_dc6860c0-e7cc-4cca-a2ec-c03c5e29d40b_terseLabel_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D not in service</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in Process Research and Development [Member]</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:href="bhc-20200930.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:to="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b05286a7-7df2-4899-94a5-4fea373e6ea2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_644eba78-f641-4c6c-b9be-b89bdd114a12_terseLabel_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_label_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_documentation_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember" xlink:href="bhc-20200930.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PriceAppreciationCreditMember" xlink:to="lab_bhc_PriceAppreciationCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_cf099b0c-8a83-46cf-860a-9391eb914c4f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_25eb9f76-499b-465b-906d-c08f0cd3a334_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_b59c3e23-788d-4972-a7a9-3e6bffe1e34d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e91bf24c-692c-4100-a7e4-1660cffd95df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_72ae83a0-5044-426f-9c15-f977eda88d8f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_8ef70109-b34d-4cf1-8a2b-0219a4583b2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER EXPENSE, NET</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_1de2932b-9e34-4eec-9cbc-c1ad215ec3b7_terseLabel_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_label_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_documentation_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:href="bhc-20200930.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:to="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0d99ab54-35c0-47fb-8f79-f5e42c54ab34_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9b2662de-0670-45d5-be89-dc7cda3fa047_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeLawsuitsMember_07512fb2-9654-4ac2-bf4a-705fe26f5df5_terseLabel_en-US" xlink:label="lab_bhc_DerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Lawsuits</link:label>
    <link:label id="lab_bhc_DerivativeLawsuitsMember_label_en-US" xlink:label="lab_bhc_DerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Lawsuits [Member]</link:label>
    <link:label id="lab_bhc_DerivativeLawsuitsMember_documentation_en-US" xlink:label="lab_bhc_DerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeLawsuitsMember" xlink:href="bhc-20200930.xsd#bhc_DerivativeLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeLawsuitsMember" xlink:to="lab_bhc_DerivativeLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3fefc968-7307-43e2-9165-b41ac769ca0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_614502cd-e865-47c1-913f-110d5e2ffab7_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_8e936ecd-a893-47c7-a332-344768a82eeb_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_80cb6424-0ed8-4a88-9396-7632527547ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_43691637-2347-4daa-9924-18a2637f9ddf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_8c0c52ad-ec71-46e8-a982-712a9774ef92_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_9199eec6-a4c9-463d-bb0d-0dff2d618320_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products represented of total revenue</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:href="bhc-20200930.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:to="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c297b1ac-0055-434b-846c-862ddfddb484_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_5657198b-4344-43c3-ad3d-fa7406d9edd4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_c0021f96-e8d0-4bb3-9b7d-ab48a2d91926_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased debt, aggregate par value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_fb046a47-5fd9-4860-abda-d869147a410f_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of research and development</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:href="bhc-20200930.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:to="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69564335-4c4d-4399-a124-e6e67a07cf29_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_6ade6982-a66f-4fb8-8e2d-8ccc2fee3438_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes and Senior Unsecured Notes</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes And Senior Unsecured Notes [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes And Senior Unsecured Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:to="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_88c23cf8-f532-4418-a46c-05c7cf3abde2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_1f90d935-3dce-4979-8e1f-47cafa2ad448_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from assessment of hedge effectiveness</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_9a9a9971-a7e3-4236-8c6b-47daf3518dd2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_96b75a6e-22d4-43ec-9744-c5c8ac27f735_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_db5521eb-2c88-4b5d-8b5f-624b8059f2a1_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes Due March 2023</link:label>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_label_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.50%, Due March 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes550DueMarch2023Member" xlink:to="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_121c28e4-2f8e-4bd9-92f6-51631b088e82_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_99bd6cb2-4c63-49a6-94af-9e4a73231943_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (income) attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_35a04476-6ab5-459c-9858-deb4b48caee3_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:href="bhc-20200930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b345881e-0cc2-4c80-8efc-c039ff76e5cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_af939406-2e32-4e8b-a445-700c40c15ce4_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_label_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.25%, Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes925DueApril2026Member" xlink:to="lab_bhc_SeniorNotes925DueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_675bfff8-5830-4020-9224-2bcb543bacb9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c329dd58-d38c-4125-b2b3-7add063054f6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_13f021fa-bd4e-4ba3-8759-8b8adf88b22e_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a4099d28-ad10-4dd9-a252-7bc0b7963b4d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Plan</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ea5cdef5-a69c-4b97-85f0-8f0eb7bda071_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_e8ba0047-fc67-46ba-8a90-afac0fafc469_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:href="bhc-20200930.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:to="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1771198b-8a3c-48e8-b14f-39f08c41a6c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e4c76e6c-cd80-4d0f-ae4f-218ea501c299_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_2723fc5c-c4a4-47b4-9020-69a6018d2f69_terseLabel_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs, Performance-based RSUs and Stock Options</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20200930.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_96a74fc5-ccf1-4ade-8c2f-42bf3de833a6_terseLabel_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_label_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_documentation_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember" xlink:href="bhc-20200930.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InsuranceCoverageLawsuitMember" xlink:to="lab_bhc_InsuranceCoverageLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_74c17bda-b82d-4465-a054-67cb22bb57fe_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_375b9ae3-ca2f-4163-8fff-4261d6face64_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_1683c966-8f30-443b-88c6-bb37be2010dd_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7af16544-6e4f-4bbd-a841-51ceb52aa693_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_459b50f2-f71f-4d38-b408-3d630e99f36c_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage to change in control (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_label_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:to="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_48b00497-e040-447e-8773-79f4aa5f852e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, mandatory prepayments, percentage net cash proceeds, asset sales</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_113d191a-fb65-4cc7-b977-cce69bfca288_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a8ec0175-4e38-4aaf-92d9-a3c366ebfd2e_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_30cb4ff6-cb8b-4475-b827-ea44b484c6f3_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, agreed to pay</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9d4a1206-918b-43a1-ba92-3a630080835e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_21d4439f-147f-4f73-ac31-c1b341ee39e1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_9fecdd83-154e-4329-aad3-f78c26e62a98_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ba19ceb0-d79a-4aec-b304-576af594072c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_b7ed0d1c-b8d6-4091-88ec-e03ccfc94f65_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_f72ba339-6f85-4077-b602-021fd23eb8a1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_6e274a16-4d05-428d-968c-9202ff9e2d6a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_d5be56aa-ef35-4ea1-a0ac-95a4f2fb83c0_negatedLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_72b61236-89b5-4e15-9dbe-e9df0ca4559d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixSegmentMember_66e4f67b-86af-4032-98f0-f1229f94afc4_terseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_label_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_documentation_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember" xlink:href="bhc-20200930.xsd#bhc_SalixSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixSegmentMember" xlink:to="lab_bhc_SalixSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount_017bf221-fb5f-455b-90c1-ce33c41ccd45_negatedTerseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to royalty payments by affiliate</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deductible Royalty Expense (Benefit), Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deductible Royalty Expense (Benefit), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_d87b2c19-2c96-4f2c-9ddb-c464c9f9ae79_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c2463c16-8e04-4bf7-bee5-2ea7dc2f3268_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_b71312ac-131f-411f-a3db-33c1dd0697d2_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_936cd02a-06c8-496f-acf5-6f321ec15eeb_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit, amount possible to decrease in next twelve months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RU_4e56793b-4cd8-40de-b2cd-b21322015f33_terseLabel_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Russia</link:label>
    <link:label id="lab_country_RU_label_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RUSSIAN FEDERATION</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_RU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_e9016ffd-e55f-4b6a-90b4-a770853c367e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest coverage ratio (not less than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_b0cde48f-0620-404c-a256-923962974791_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_841a1b58-668a-4eca-894b-4fd345f1b8f8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_66ab357e-0c6f-4c19-8be2-375c21bb2ba9_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fba28e1f-384c-430a-b43c-e9727b23ad95_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_1006e715-8375-4f91-a13d-106b67d658f9_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_39789bcc-e655-402b-aa68-0193de5c595b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_7bfdb182-465b-48a8-9221-5af655fbb2a2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_65e2374b-76dd-4e63-9f5c-2ae64bc953ad_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowertoShowerProductLiabilityLitigationMember_15ba1c14-9e23-4ef2-b857-caeb7b96081a_terseLabel_en-US" xlink:label="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation</link:label>
    <link:label id="lab_bhc_ShowertoShowerProductLiabilityLitigationMember_label_en-US" xlink:label="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:label id="lab_bhc_ShowertoShowerProductLiabilityLitigationMember_documentation_en-US" xlink:label="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:href="bhc-20200930.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:to="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_c040251a-5dba-43a0-bff0-cd1b35794806_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_5a7d74c7-1b96-468b-90d5-eae03bdc68b2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_aef34b8d-f281-4eef-86fd-f1de746651d1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities associated with restructuring, integration and separation costs</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_87392fee-c015-4587-a2d8-1e7181b8b836_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_d91a3979-5e48-44de-8dfc-9add3fdbac4d_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_1d2c7b8d-2c79-4fff-a7ff-49cea8f2b404_verboseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_7d938676-6ec0-418a-9001-3be969c53309_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:href="bhc-20200930.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_586f0311-6645-4ff2-ae96-ea833539730f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_ba79c8d6-d67b-43a3-b756-90d1059fcea2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_eb6104dc-9802-4eba-a8c8-d1447b0f88ea_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_15e2595e-d317-4d43-8eaa-0a5ee46d15b9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_7be33153-7434-4454-8c20-dfaf073a79f8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TimeBasedRSUMember_c2a8f6bd-04bf-410b-b6c5-f3e2fd2d32e3_terseLabel_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_label_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based RSU [Member]</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_documentation_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember" xlink:href="bhc-20200930.xsd#bhc_TimeBasedRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TimeBasedRSUMember" xlink:to="lab_bhc_TimeBasedRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c10385c1-a1c8-43e8-a087-4e55b8eee7ff_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_f48e4729-65af-406e-9577-0e83ad31d1d3_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_e6f4d1ef-ead2-437b-9181-8426c4ac8cae_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_7bad6af2-c1f3-44ae-8144-a91f74b62bef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of customers that accounted for 10% or more of total revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_1e651ea0-5686-4447-840c-348d9ed45253_negatedLabel_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to accrued legal settlements</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_label_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_documentation_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:href="bhc-20200930.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:to="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8bc460a8-0369-4429-8c91-f099ec2bcf01_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_fb402594-47a3-4b77-ad05-abc4347d7291_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_a6705b43-e58d-4277-bff8-0789d0edcb9c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_e52f9ba5-b79b-4c10-af4f-d43e55847061_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dd0d4e60-ee9b-4f81-b3d8-bba40c6a124a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_f963fb16-4cf4-4b15-8111-87fb7423eff4_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_9ab35d1b-6895-47ec-bd88-92fe4c2d6028_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, derivative, included in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_8ba343c1-7cef-468a-887b-77835bee34ce_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:href="bhc-20200930.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:to="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_1c8abc71-d8db-4469-bb72-93f110166ff8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_33beb230-2d69-411c-addb-f49d609c5178_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_417ca4d8-d2de-41f2-9965-3270d5f67fea_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6e812317-4cb8-4ca8-996f-28a6701d79a2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_f6474bda-6caa-4e9f-9d4c-a05d92fcb7d0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, contingent consideration obligations, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_382861e9-a346-4c25-9305-12c551b08202_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_c6c67ddc-5242-4572-a715-16159c1d95e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_becef2f2-6956-4367-abf7-eac5e97a355e_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct insurance policy periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:to="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c76435d4-50a3-4368-b5af-bb98c6577c14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_e57682a1-d5e6-48c8-bb98-f6b3c380980b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current accrued loss contingencies</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_4d06c0e8-d026-4ea9-9179-8a61321bedf5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4ae3e471-38b2-471c-8887-6ef775cfeee9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_7be74b62-eed8-498f-9c27-7e32030f268e_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_cc7e6405-f9aa-4d29-bab5-fff253656046_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_b774559e-443a-4451-8b7c-682e6cba30c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_aa997028-f7e5-428e-b995-e244abb4d4fe_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ec2996f5-9aba-43e5-93bc-dd5b52eb7e7e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated aggregate amortization expense for each of the five succeeding years</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_73bf7dc3-575a-489a-bee0-3344e4fc54fb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6a6bb423-3053-44ac-9e98-f1c5f7df0a7c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a38f9844-f65d-4fef-823a-7f2ad5361e51_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_abf41ff2-24d6-4ad5-ae77-0f16ae3c8388_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_58bc7cbc-ad67-48be-919c-72160988d56a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c79e810d-c2a4-40d2-816a-2bf46c22c1b7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_59ce70b3-2500-42e6-aff0-a5b39b84da9f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_4db0d7c9-2516-4c0c-b08f-55ef9137eab7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_0d6152f4-8eac-49e5-be03-e99fa3f4a9ea_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00 % Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.00 Percent Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1123e0f1-7b32-4cae-8fb7-c3d69cb87a3c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_436f7050-998a-4b85-93ad-8c0246e7a486_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_092de0ea-0a75-49ca-849e-71d2c13f8837_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) Gain recognized in Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_2ada760c-0870-4d9f-b204-1bb52081b157_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_a61fa686-a30e-4193-a8ac-e4d4cf23ceb4_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Senior Notes Due March 2022</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 6.50 Percent Due March 2022 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 6.50 Percent Due March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:to="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2f34cb83-b4a8-413a-a005-718fbe6f7b1e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and write-off of debt premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_04182f3d-9377-4cf9-bdd3-4ed4daecf66c_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_86c5d5ce-3603-4cbf-b471-5e96de1d044f_verboseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7b1512ee-e077-43e5-9d04-61670fdb9f9b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_3abec169-705a-46ce-a155-09a3f110384b_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_45022968-5544-4f1e-a51d-2661798f1775_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_60130077-620c-4a52-88c6-09b1980d890a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1d4df2a1-3bc2-4f7d-93f9-20406e61e11f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeviceProductsMember_bdc4fa5f-71aa-4e74-b847-db2c14a0baea_terseLabel_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_label_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_documentation_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember" xlink:href="bhc-20200930.xsd#bhc_DeviceProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeviceProductsMember" xlink:to="lab_bhc_DeviceProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_1712cc40-830e-420f-9022-027423611c1d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_56d082cd-38cd-4545-853d-b92cd747f117_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5f797d75-3bbf-4991-b5c8-cfb642709f45_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_784d7c65-b708-491c-848c-375b46f817fe_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, no par value, unlimited shares authorized, 355,026,950 and 352,562,636 issued and outstanding at September 30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c21b1460-dd65-490f-a5cf-c6f7fa6d60d1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_fb251744-f079-49ff-8b7f-704a27b568a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_6f22cfdb-fe09-48d3-b633-e5621eda8371_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_293b1bf6-e266-44d8-ad49-dc87aa786566_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9c62321a-9790-4779-803e-f8715916ec3a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_6b32b956-f7c1-434a-986d-1e8f124ceb3b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_1559bd3a-1c87-4196-a84c-87a56000ae8f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash, current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_3d985cea-49ec-4845-90e4-0fd410c0266f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_339665a5-c4b9-4de6-a5db-ae8d7eb2b3a7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f03f76ba-34bd-46a5-81f5-90f0a7e1eec6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity in allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e3474ccf-aa53-4a79-ac7c-2bf0a342469b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f5dfbaf8-2aa5-456c-a6ca-4bac71959a57_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_f11f13d6-8280-4305-809a-7db8ea85543e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, mandatory prepayments, percentage of consolidated excess cash flow</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_8b24993e-e05e-4996-9cd1-a74ff20f1943_terseLabel_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_label_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_documentation_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:href="bhc-20200930.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:to="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SECInvestigationLitigationMember_72da6222-a483-4942-bd25-3fae929494b9_terseLabel_en-US" xlink:label="lab_bhc_SECInvestigationLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Investigation Litigation</link:label>
    <link:label id="lab_bhc_SECInvestigationLitigationMember_label_en-US" xlink:label="lab_bhc_SECInvestigationLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Investigation Litigation [Member]</link:label>
    <link:label id="lab_bhc_SECInvestigationLitigationMember_documentation_en-US" xlink:label="lab_bhc_SECInvestigationLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Investigation Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECInvestigationLitigationMember" xlink:href="bhc-20200930.xsd#bhc_SECInvestigationLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SECInvestigationLitigationMember" xlink:to="lab_bhc_SECInvestigationLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_36244348-4899-4ec5-8263-be9380530041_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_d0349219-3755-4bbe-b470-71d2b582fd90_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_df743245-634f-45f8-acd1-16a45eb59f63_terseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_label_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_documentation_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember" xlink:href="bhc-20200930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiversifiedProductsSegmentMember" xlink:to="lab_bhc_DiversifiedProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_97078b78-b1fa-46c4-9295-f0050b79813e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, principal amount maturity threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_88bb8ec4-96e4-4f81-993b-2d10b4345a4b_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rebates</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Rebate Current</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current portion of accrued product rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent" xlink:href="bhc-20200930.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductRebateCurrent" xlink:to="lab_bhc_AccruedProductRebateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a5462f2b-bb79-4a51-ad3a-4f104b2eb75f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_690453ae-57d6-4f06-b94e-ad9262c4efd0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a83172b0-67cb-4cca-81c1-1cf6fc800518_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_8d355a9f-7cd3-4d53-b871-30764c740e22_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_8cedb8e7-ce4e-4b1c-8b1d-d3046f41aa67_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_92c0ccac-b309-44d7-9bdd-b1a3927d6f83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_2ec888a9-528e-412d-b868-313f4e348f86_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_209ad41d-0584-4a12-a030-15668d92354d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_78ac747a-114d-4bc0-ab81-b886034d7b64_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2130ca5f-930c-41d0-ac7d-7c1b4d00edac_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_819c3398-d885-49d1-be46-7a4c02899cb0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_482ceca9-1d9b-4f51-ba4e-338466b52c9c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_3631acc9-8cd8-4962-bd13-82bff4fdef76_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurocurrency rate</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_4edb0333-355d-41fb-a598-a9c5eaf2ba7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8fa3038d-d3a9-467a-9a66-325ea48cbdb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_ebabd510-6a46-4731-bb20-33e8136f4f4b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentOfAccretedInterestOnContingentConsideration_720fcc47-0a44-4cf9-a977-ed8776bc6f42_negatedTerseLabel_en-US" xlink:label="lab_bhc_PaymentOfAccretedInterestOnContingentConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration adjustments, including accretion</link:label>
    <link:label id="lab_bhc_PaymentOfAccretedInterestOnContingentConsideration_label_en-US" xlink:label="lab_bhc_PaymentOfAccretedInterestOnContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Accreted Interest On Contingent Consideration</link:label>
    <link:label id="lab_bhc_PaymentOfAccretedInterestOnContingentConsideration_documentation_en-US" xlink:label="lab_bhc_PaymentOfAccretedInterestOnContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Accreted Interest On Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentOfAccretedInterestOnContingentConsideration" xlink:href="bhc-20200930.xsd#bhc_PaymentOfAccretedInterestOnContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentOfAccretedInterestOnContingentConsideration" xlink:to="lab_bhc_PaymentOfAccretedInterestOnContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_66b2ac29-23f9-4694-9714-7083c48bce76_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1cd47796-8aa9-4e8a-a6cf-ad973db48d69_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_202b9e98-8ca7-4a85-a142-b31a5fe2dac4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_cf907612-d318-4be9-8b9b-74c8103ef7f5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, derivative, included in other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_e1b3c2fd-7a36-4dd8-aa3c-dc58a65b3303_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_74fba748-8ba5-40e5-a0cc-a3912f11c199_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of principal amount that can be redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7a1f3ce1-9272-4d4d-a29c-764a55d23b92_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c08b39cc-a9a8-444a-940a-d97b859f50b6_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d334cc51-b908-4325-9e01-b5c7a3219f6a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_36fa0260-5244-4c08-aa39-92e45eaded7f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b5eb849f-1701-458d-8439-91ebd08915ce_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Bausch Health Companies Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_9c60ae55-08f7-49f3-9eec-119c4cd22ebd_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_886fc9a3-fc71-4253-91c8-b20e782a1443_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_McKessonCorporationMember_7d25379b-0494-4166-bb16-d38b68c9ba28_terseLabel_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation (including McKesson Specialty)</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_label_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mc Kesson Corporation [Member]</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_documentation_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, McKesson Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember" xlink:href="bhc-20200930.xsd#bhc_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_McKessonCorporationMember" xlink:to="lab_bhc_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_47ffc76a-2f64-4e35-8b16-49663f3813b9_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of variable consideration provisions</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:href="bhc-20200930.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:to="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_3c909db2-0cce-439f-b739-d8e40bc06014_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_fdd5e9a1-c471-4bbc-9140-4d6974b118ed_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5abf203f-7d0e-4e71-9631-54ff89160c00_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8a50ac78-247e-4e7f-9fd2-e4ab68c8805c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_5ba1f79e-0df5-4865-9747-15e1136687a9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fb32ed17-36e8-4b13-be6e-643d319216ed_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1bac482d-ca39-49b1-9c59-0b7b743b0961_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_067ade97-2cc5-4d5b-9115-b48a355aabf4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for intangible and other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_788a4d6f-4781-49e8-b216-38f26ad46562_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsReportUnitMember_9ec2917a-006c-42a5-9ee2-c31bf6ed3a72_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Report Unit</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportUnitMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Report Unit [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportUnitMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Report Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportUnitMember" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsReportUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsReportUnitMember" xlink:to="lab_bhc_OrthoDermatologicsReportUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_908ce74f-6c76-4be9-8d0f-4b346d16317d_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Health Companies&#160;Inc. Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_819daf22-dcfc-4d2e-9f86-c8a6f9a12c78_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0c99e310-6a1e-480c-aaa1-95d45d47ef72_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_8eb4da0f-0343-43e3-80fc-f014b8843bbf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other severance costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts" xlink:to="lab_us-gaap_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fb355ca7-b966-43ef-8891-683960f89d96_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_1f766236-102c-4e67-abe3-764ff7301a2d_terseLabel_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion for the time value of money</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_label_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_documentation_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:href="bhc-20200930.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:to="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_567ea154-2ac2-42b3-83f6-97a75c289fd6_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_6ef1b1f7-a82c-4314-8e0b-0ab9e41d1ca5_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_61f9a2d9-6847-4d84-beae-aa3c7936e7a0_terseLabel_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt amortization prepayment</link:label>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_label_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Amortization Prepayment Cost</link:label>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_documentation_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Amortization Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:href="bhc-20200930.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:to="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_393464cd-ebba-42ea-bd75-c8fc3aa8aa6c_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due April 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:to="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b48b5871-22f3-4dbc-ad36-91aab7c939dc_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7829e5d1-11e7-4b52-a430-3bb27ebeba49_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brand intangible assets, estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_04bcd536-dcb9-4839-80e7-4e622e3a8bef_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_9a8ffc13-8571-4d06-a507-28e10cbd7828_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_6efa9475-1420-4c36-a010-3786e29af60d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_176adfbc-64c9-4604-b4ff-ed26ffa0b377_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d79f51d7-c00e-4a90-ab49-d0955f5e8c88_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dbec0338-0c55-416c-8167-4b43491eeb91_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_0bf73bff-9d28-4354-acdd-458a8ab20674_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets reclassified, held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bcd323e9-8761-44cf-b9c7-a1ccbe090211_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_300f0d23-f5fb-43f0-8f0e-740dc7231d7b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_3ffba6de-c83a-4806-8c88-0aa96426e220_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair market value on awards granted during any calendar year</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:href="bhc-20200930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_f918414e-6909-44d6-8df2-e5600d76ca79_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Advertising Credits Portion</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:href="bhc-20200930.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:to="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aa12dfad-df04-4fb0-9b86-21eb4ae9f1e5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a94b0081-8f8d-4f5a-9273-8de29e4b51c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_51195a6d-37aa-46b7-91d3-14faedf96a12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_be6783ec-d5aa-451e-9bb6-23dd613a3b86_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9aa57985-4cf9-46b4-ac23-38081e058565_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fd7d3637-4f66-477c-a895-7369cabf29b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_f7a7a1d9-3cc0-4c4b-a1e6-937404e919e5_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate brands</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_612b61da-551f-4f55-89a2-5884c2c9fd8f_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb Trademark</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_a6602989-f24c-444d-a44f-5cda20442330_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombInternationalMember_09e42c9e-e25c-4f39-9f3b-1bbf501fc3ee_terseLabel_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/ International</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_label_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_documentation_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember" xlink:href="bhc-20200930.xsd#bhc_BauschLombInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombInternationalMember" xlink:to="lab_bhc_BauschLombInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_cf2ba71e-1736-4ea8-a0e2-0db6433a3f40_terseLabel_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_label_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_documentation_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:href="bhc-20200930.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:to="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_404e18ca-125b-4dea-97a3-7cb584027595_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProductBrandsMember_f998db6b-a60f-46ed-9de1-9ed4fff4d819_terseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_label_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Brands [Member]</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_documentation_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to non-patented product brands.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember" xlink:href="bhc-20200930.xsd#bhc_ProductBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProductBrandsMember" xlink:to="lab_bhc_ProductBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7a4dc4e2-e02b-4d77-afe2-57f0b2bbfc9c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7d01fdc3-0430-4548-8408-c8cd20d2ea0e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_70e939f7-4b36-4001-808e-7b7c540f527b_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_d4698bb0-43c6-44f8-958d-4cb4ecc20302_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (income) loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6682bc36-b78d-4b1b-a57d-847627b54f51_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_35e45e4f-c929-4700-9f57-6a3b76c39ee5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration and separation costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_9903731a-54c1-4d50-9582-0e17ce58a564_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration and separation costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_06291c43-1e73-4c1d-a356-1209806c0854_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities, exercised opt-out right, pursuing action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:to="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2ada9f8b-9a90-40b4-990d-49ceb04b78cc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares not included in the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_86340d19-415f-4567-abf6-ab6965cad49e_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_68b755ea-50b2-46dc-946f-6ddeea2c6242_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for incremental borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:href="bhc-20200930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_bcad562c-55a6-493a-9d34-dae695d3334d_terseLabel_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate</link:label>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_label_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate [Member]</link:label>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_documentation_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember" xlink:href="bhc-20200930.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadaBankersAcceptanceRateMember" xlink:to="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_b7c5c38a-b87a-4a31-a88d-43e21a71ca5f_terseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_label_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Technology [Member]</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_documentation_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember" xlink:href="bhc-20200930.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OutLicensedTechnologyMember" xlink:to="lab_bhc_OutLicensedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_c95c93fa-ee1c-451a-b601-c1eede502a29_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in variable consideration provision, adjustment</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_922039f8-260c-4a8e-a833-5b91dd3d77fd_terseLabel_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for losses on trade receivable and inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_label_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for Losses on Accounts Receivable and Inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_documentation_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:href="bhc-20200930.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:to="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f633c5ef-598c-46f5-a535-c79f07e6fd2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments, net of income taxes</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2405f7f7-1109-49e1-a743-cb6775096968_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_cc109a35-7e8f-488d-a0b0-d7bd4580768f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_fdaea07c-55f6-4d77-afdb-5707b00c1ed3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brand intangible assets (estimated useful life - 7 years)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_eeea88bf-3100-4b1a-a8a3-f520b1e4ab38_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e87bd263-c0a2-4794-98a9-1d6f50860765_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5ffdef3f-0a5d-44ab-aa7f-c5de6a31e356_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_b771e866-ab23-41e3-b1b4-2942988c21df_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_9c02b1da-6b65-474d-9daa-16713e646d5a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments, net of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_3d146bf8-e3c3-4ac7-8213-acfa199d16e5_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and other matters</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_5e384986-604e-48f5-bf18-53079bc928ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_07b019de-7eff-4ad9-9a71-61d5ca6de875_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_efdcadf9-cf53-42b3-8b8d-773a2006cb2e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_54309603-1828-476e-95d2-44040102f2ad_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_22ddb434-1d38-4c6e-abfd-c183c252e510_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_c345df7f-6711-44fb-9c15-cd8a97b748f5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_66dbbd9e-29b5-48ac-8e2b-f97d2c90df84_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_aceac7c1-d5b7-4835-9b3b-5d1c0b7f8436_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio, Maximum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_aa96888b-6eab-4583-b931-8f1aa68e1454_terseLabel_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate or Prime Rate</link:label>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_label_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Or Prime Rate [Member]</link:label>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_documentation_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Or Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember" xlink:href="bhc-20200930.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BaseRateOrPrimeRateMember" xlink:to="lab_bhc_BaseRateOrPrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_e08bd0ab-b240-4353-bdf0-e053e46a7142_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes Due December 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.00%, Due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:to="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_e7c5a02b-9915-4702-9f20-f356d8e761f8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_dcc4319c-9222-49de-a348-1a4a61674b29_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e09e3cd3-f7e1-440a-9744-cd38d7761b44_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_883b01b3-0528-48d0-be02-77903f5d1f18_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_83f37720-4224-48a8-a7ea-d936f3ee34cf_terseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retrospective effect of application of new accounting standard</link:label>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_label_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</link:label>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:href="bhc-20200930.xsd#bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:to="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_4fa79994-3eae-42d7-a940-18c94fbaf613_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f85112a8-eaf7-42e2-a314-159c200353f0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate on debt (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cdd9e5a6-c197-43cd-b2e6-dd4eab090a75_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_45c06c10-b4c1-461c-8037-953c90e45817_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_5b07e626-7430-4399-9e36-2d964e6a4bb9_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_aa87ce8e-e537-49cd-94ce-78cea65be954_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and RSUs</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CardinalHealthIncMember_6533049a-f211-4f5a-bcde-cf02c68f18a3_terseLabel_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health,&#160;Inc.</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_label_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember" xlink:href="bhc-20200930.xsd#bhc_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CardinalHealthIncMember" xlink:to="lab_bhc_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_9c9646e4-066d-407c-9f10-98ca3e733a13_terseLabel_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_label_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines [Member]</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_documentation_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember" xlink:href="bhc-20200930.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiscontinuedProductLinesMember" xlink:to="lab_bhc_DiscontinuedProductLinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_2861a46f-04a8-4aa4-b0b8-e1ebf0cc0513_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58f6e136-f85d-4520-a739-6be23999abdf_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_1bd35f48-db25-4608-88b4-2b40c6eb05df_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_dfbf5a9d-c71b-4cd7-b818-e2b7dbcece67_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_f68165cd-3148-466b-9534-405f603f97a9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b7c9124d-5064-4449-a25d-9220aaf36bc7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_3907b664-c7e2-4d7c-8e24-d7130ab9f5c6_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsSegmentMember" xlink:to="lab_bhc_OrthoDermatologicsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b9e7ace4-1c36-4f57-ac89-7368edd7e201_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ac536d31-5216-456d-8a0f-9c824e09aeac_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_875a0d23-8105-403c-a693-283884e12efc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate (as a percentage)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_fb0437e5-ed97-43c0-b326-5900c206d850_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a2a7badd-c9cc-4385-819c-f985fea85cef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_57899a38-252b-44ed-b7c3-5f27d72832a0_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Class Actions Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:href="bhc-20200930.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_47f8fc46-b8a4-48af-a14d-04b8d19cd0bb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_e2d7c145-5c2e-400d-bef8-e0582d7e56bc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_40f0ac67-f5ad-49a3-a7d5-87e10ebf468f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_ec7eb440-f173-48cf-9aa2-b18012fc4089_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillReclassifiedDuringPeriod_e392ff39-e4a7-4ee3-948b-23d6e82762e5_terseLabel_en-US" xlink:label="lab_bhc_GoodwillReclassifiedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale reclassified to goodwill (Note 4)</link:label>
    <link:label id="lab_bhc_GoodwillReclassifiedDuringPeriod_label_en-US" xlink:label="lab_bhc_GoodwillReclassifiedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Reclassified During Period</link:label>
    <link:label id="lab_bhc_GoodwillReclassifiedDuringPeriod_documentation_en-US" xlink:label="lab_bhc_GoodwillReclassifiedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Reclassified During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillReclassifiedDuringPeriod" xlink:href="bhc-20200930.xsd#bhc_GoodwillReclassifiedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillReclassifiedDuringPeriod" xlink:to="lab_bhc_GoodwillReclassifiedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_310bd7ab-b0fb-4a5f-872c-027385f2bada_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8a010ed7-d6cf-4af8-84f1-426fb32d501d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59fac842-a0bb-485d-b628-7e1e679e98fa_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d12c097c-3f1c-4d18-8730-b215292236a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative-effect adjustment to accumulated deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5baab3ac-55bd-405f-af4a-2838fc2f9a0c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1c3ca70a-d760-47b7-be4c-5c3df9545e7a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b83cfbd6-3093-4a67-8100-198f9f644a03_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8f0a4ba0-75c1-4a1f-a949-617c333c6ecb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f3520dd7-5f45-4ef5-a60c-44cfeebd9d5c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_a63c275b-6b43-423d-81e4-8f9473d3b156_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member" xlink:href="bhc-20200930.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member" xlink:to="lab_bhc_OmnibusIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherCountriesMember_0043009c-fc08-44ca-879a-ec7d2ef10f10_terseLabel_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_label_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_documentation_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember" xlink:href="bhc-20200930.xsd#bhc_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherCountriesMember" xlink:to="lab_bhc_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94231aff-9348-4d0b-8f90-f02ef085e62e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e30e754-6731-439e-9a71-2ca5006de6e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71b4459f-1b1a-4b1f-88d4-9fe06cd40df7_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fffe147d-b86c-4d31-87df-43d16796c964_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_be0b9cc4-8c0c-4d10-b4c0-21796a633e8f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7f3718c1-b096-4d1c-aff5-cea723c13b33_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_7db36501-fa56-4d29-8784-aa74813766cd_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bdd61aa8-1495-4f9a-a183-b794aeaca445_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_81df055a-bd7f-435c-b0d5-605577637129_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0f0ea665-cbcf-47b8-9514-ff9921f37637_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllegroOphthalmicsLLCMember_c7a1fa7b-79a6-457d-ae12-d955c2857569_terseLabel_en-US" xlink:label="lab_bhc_AllegroOphthalmicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegro</link:label>
    <link:label id="lab_bhc_AllegroOphthalmicsLLCMember_label_en-US" xlink:label="lab_bhc_AllegroOphthalmicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegro Ophthalmics, LLC [Member]</link:label>
    <link:label id="lab_bhc_AllegroOphthalmicsLLCMember_documentation_en-US" xlink:label="lab_bhc_AllegroOphthalmicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegro Ophthalmics, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllegroOphthalmicsLLCMember" xlink:href="bhc-20200930.xsd#bhc_AllegroOphthalmicsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllegroOphthalmicsLLCMember" xlink:to="lab_bhc_AllegroOphthalmicsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_fd279b12-eb66-4ab3-831d-a868e9301f20_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_704f7ae9-1d7c-4593-b751-96521b43d16a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue attributed to a geographic region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3ed3e711-4007-4e62-b206-9e1d07d9a028_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_a1006567-a381-4ecd-a2e3-d960d624de79_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_94ccc871-94f4-4889-a96d-f5442857766d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments to acquire certain assets and assumed liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_9d1ad7b6-263c-4129-8feb-f7491aae5a3a_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_9aad6dc8-aa7d-44ed-8a47-6af3f162d072_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_d16811a8-60e9-4224-b7c2-191372f2f9fb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue of acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d74dae53-3727-482a-b59e-863c2c1796ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_c7c4cff1-afb3-4bb9-9b7c-7ab01ba8f36e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e01268e5-50b2-4222-a2f2-da40fb5d9312_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_43b905a5-c05d-4849-9dd7-81993ee52cdb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_ac59c016-9555-463e-98f6-fae0119f1a24_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_9c66a032-14d5-489b-a674-8ebeee079299_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes Due November 2025</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:href="bhc-20200930.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:to="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_11bcacd4-857f-4580-9b41-b264c3430b02_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_9caf85ad-36b3-49dc-bf57-e954b280314a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets and businesses, net of costs to sell</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_cb7a6ebe-23db-45ae-bcfe-2d8c29d56fe9_terseLabel_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_label_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_documentation_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:href="bhc-20200930.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:to="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6fe23fe0-9819-44f9-8a00-8b9a622feab1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_70149bd7-b451-412d-ac58-7a759458743c_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BaushandLombInternationalSegmentMember_176c6924-05c6-4d61-9dd2-28d173d58c49_terseLabel_en-US" xlink:label="lab_bhc_BaushandLombInternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/International</link:label>
    <link:label id="lab_bhc_BaushandLombInternationalSegmentMember_d3f38179-6d0f-43a0-9703-7c1bbaeee03b_verboseLabel_en-US" xlink:label="lab_bhc_BaushandLombInternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/ International</link:label>
    <link:label id="lab_bhc_BaushandLombInternationalSegmentMember_label_en-US" xlink:label="lab_bhc_BaushandLombInternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baush and Lomb/International Segment [Member]</link:label>
    <link:label id="lab_bhc_BaushandLombInternationalSegmentMember_documentation_en-US" xlink:label="lab_bhc_BaushandLombInternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baush and Lomb/International Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaushandLombInternationalSegmentMember" xlink:href="bhc-20200930.xsd#bhc_BaushandLombInternationalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BaushandLombInternationalSegmentMember" xlink:to="lab_bhc_BaushandLombInternationalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_7ddcaac8-96bf-47ec-9940-65b00a792cf6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_574b468d-d4b8-4023-b15d-c16caaa5803a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets classified as held for sale</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesMember_d7121d2f-6384-40bf-9da4-1741975cd5ff_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember" xlink:href="bhc-20200930.xsd#bhc_ReserveForRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesMember" xlink:to="lab_bhc_ReserveForRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3a198ff9-9f18-44a9-8abf-b37149bbfbf3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8b97dbea-f987-435c-9b1e-d4ac55571d04_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ad8aa3d2-e4dd-4df2-a120-5d433e74c4e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e916acee-c263-4b3d-a85b-980a59d76419_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of contingent payment obligations measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_f277e4d9-2d13-4ec6-a7f9-71bd0fa131fe_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cb87923c-9fd7-4a78-8b16-931d3050de39_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization and Impairments</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9c5036c0-a063-46c5-808d-06eddf86271a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_b2fd93e9-560d-4e81-946e-f34c5e8db121_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_82be59af-aaf5-4545-9e75-ee37e6d3944f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure_daac789e-768d-4f23-a6ee-a92947853370_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:href="bhc-20200930.xsd#bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ba1717cb-2986-4df7-8c59-46f3ee9a0af0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_6f3790c8-6c4f-4f8e-ba11-cd8a08e1b69f_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill reclassified to assets held for sale (Note 4)</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_81f7c3d3-b837-426e-9892-575c8ad9869b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_fa896962-0e48-43d5-84e3-9b080ef5b4ae_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_b4fe36f1-9d22-4fc6-976d-5ce6cfecaee0_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of putative antitrust class actions filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_4978699c-71c0-4619-bf4c-a5bcefbca8af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7fe87699-70f4-48a5-9bad-e5d15ec21f21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_92000baf-797f-403e-b117-ded011b3b7de_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0d78c160-920e-4ca9-9434-4e74cff1abee_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ba588162-156b-4664-9a9a-02787a99dcab_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_05a275bc-5b04-4d14-8b41-9ee796d2200a_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82a09f56-d928-44f8-9147-df5b8f9eeed9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_3ef8201f-a3e0-403e-8803-0ee21372aca0_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_c9130014-0768-4e6a-a0c7-4ef8d65fa888_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8a5f0ce-4f93-4a16-b8f3-a95586ddc288_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_72902229-f07d-4f1d-88e0-96a32db0e13f_terseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:href="bhc-20200930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:to="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_6b1062e7-1f6b-474d-8fc7-d02ca70bcaaf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_fe57d2e6-77ca-470a-86f8-9c3b6b514013_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_678c182c-d280-460d-b93c-e4b6b63baad5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income Loss [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_00a78e63-a455-430e-a5eb-af5aac606d9f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_5db8824d-e36d-4049-8227-a7d0e3015524_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_d208a4ff-db7a-496f-9aba-bd039330a0fb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_7f69d6a9-b9bc-45bf-97f1-8d9426000bd2_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_97d59289-7a41-400a-acad-754c308e4ab2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ab9ecbae-f802-4f0c-8e20-9060193474e0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_32aea5b7-9ea1-499f-a900-abcbffe85d79_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62371204-933c-444f-a8b6-14851e61f24c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_b341d17c-9486-453a-bf9c-358a01b62ec7_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for incremental borrowings, percentage of adjusted EBITDA</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:href="bhc-20200930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1a5d5632-4166-4057-bc3d-57d39efc471f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b1c050a4-93bf-4e4b-a2cc-77fd1fa66079_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e26cc312-7030-401d-8024-b1d24355f606_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8bedf2fa-3014-4333-9acc-95fa0a50f0aa_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_52aacf3c-0c46-49d1-894f-c3012a68e861_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_6c9bee96-6f00-486a-9d42-118e0abbad9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuesNetMember_74aa3029-5be9-48d8-bc4f-f6d218ee7112_terseLabel_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_label_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Net [Member]</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_documentation_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net revenues during the period in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember" xlink:href="bhc-20200930.xsd#bhc_RevenuesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuesNetMember" xlink:to="lab_bhc_RevenuesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationCostsMember_00f7ba77-aa82-49a8-9bfb-def712f5be7c_terseLabel_en-US" xlink:label="lab_bhc_SeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs</link:label>
    <link:label id="lab_bhc_SeparationCostsMember_label_en-US" xlink:label="lab_bhc_SeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs [Member]</link:label>
    <link:label id="lab_bhc_SeparationCostsMember_documentation_en-US" xlink:label="lab_bhc_SeparationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationCostsMember" xlink:href="bhc-20200930.xsd#bhc_SeparationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationCostsMember" xlink:to="lab_bhc_SeparationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_18884f19-42ad-4d5d-834a-4ea7ae1656bb_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 And November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 And November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 And November 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ee5cec0f-c194-4bca-b22d-e527ce136de4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Guidance and Recently Issued Accounting Standards, Not Adopted as of September 30, 2020</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_76d665a0-b20c-495c-8984-00c80ceae474_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3f27bdb0-0fd2-4128-bd86-aed5cf0ba8fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_6a9743f8-e8ac-43fb-aa9a-8ec2f477e570_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>bhc-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:52525664-5cd4-4495-a34d-b14e0c25a97b,g:cfe4b6e8-8eeb-4675-b5cb-546679211f6a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="bhc-20200930.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_06dfe339-f4e7-4c9d-9a97-3687a8c70e15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_DocumentType_06dfe339-f4e7-4c9d-9a97-3687a8c70e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e8d283d9-83b8-4076-bfe7-c1f34ef8a6ea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_DocumentQuarterlyReport_e8d283d9-83b8-4076-bfe7-c1f34ef8a6ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b7ecef2d-0adb-4999-a6e5-4d58d20e2671" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_DocumentPeriodEndDate_b7ecef2d-0adb-4999-a6e5-4d58d20e2671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c49ba9be-eee3-49b6-863a-eaa532cf63af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_DocumentTransitionReport_c49ba9be-eee3-49b6-863a-eaa532cf63af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a274ada5-b822-4a4e-8c97-1034d91f7c6c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityFileNumber_a274ada5-b822-4a4e-8c97-1034d91f7c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9b0c046e-be05-4582-8cf4-7fb67afd6fbd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityRegistrantName_9b0c046e-be05-4582-8cf4-7fb67afd6fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_77eef6bb-61cb-4a7f-8e13-28e6d0a26854" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityIncorporationStateCountryCode_77eef6bb-61cb-4a7f-8e13-28e6d0a26854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_340df447-d03f-4c00-9af9-94177f284b8d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityAddressCountry_340df447-d03f-4c00-9af9-94177f284b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8f071125-555d-4bc8-8b04-26569c721aee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityTaxIdentificationNumber_8f071125-555d-4bc8-8b04-26569c721aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1e7ae0e8-50c8-479e-a03f-e1b1e356bbf9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityAddressAddressLine1_1e7ae0e8-50c8-479e-a03f-e1b1e356bbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d87ded9e-45ee-4845-b197-02eb7a8c3cc5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityAddressCityOrTown_d87ded9e-45ee-4845-b197-02eb7a8c3cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d2fbce13-e58e-487b-9d55-d0d47eecbe74" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityAddressStateOrProvince_d2fbce13-e58e-487b-9d55-d0d47eecbe74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_01419d0a-2ac4-46a7-81b2-5fe667b64270" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityAddressPostalZipCode_01419d0a-2ac4-46a7-81b2-5fe667b64270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_200d6b8c-26d1-463f-9b4a-fc43ecf8c756" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_CityAreaCode_200d6b8c-26d1-463f-9b4a-fc43ecf8c756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_51764559-4bd5-4a0b-b7db-374e5f26b50d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_LocalPhoneNumber_51764559-4bd5-4a0b-b7db-374e5f26b50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f814d96b-f2b7-4fa2-8e06-e4dc29dcf96a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_Security12bTitle_f814d96b-f2b7-4fa2-8e06-e4dc29dcf96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9f607b70-a01c-4658-9d54-f6b6cc6caf98" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_TradingSymbol_9f607b70-a01c-4658-9d54-f6b6cc6caf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_12885bf0-3359-43fd-a0b2-ef1dafe87bde" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_SecurityExchangeName_12885bf0-3359-43fd-a0b2-ef1dafe87bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_228e5db7-e061-4d14-a1ca-96f7ffad03e1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityCurrentReportingStatus_228e5db7-e061-4d14-a1ca-96f7ffad03e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d41146a8-ca28-469e-bfd1-7795267757b8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityInteractiveDataCurrent_d41146a8-ca28-469e-bfd1-7795267757b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2695b44e-f50a-466c-9f06-5049b7b40881" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityFilerCategory_2695b44e-f50a-466c-9f06-5049b7b40881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7e2320cf-10b7-401e-88c5-877ee804df8b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntitySmallBusiness_7e2320cf-10b7-401e-88c5-877ee804df8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_18cf0da0-45cb-46a4-ba94-3636862919af" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityEmergingGrowthCompany_18cf0da0-45cb-46a4-ba94-3636862919af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_390b615a-56cf-4bdd-8a1f-595979a101aa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityShellCompany_390b615a-56cf-4bdd-8a1f-595979a101aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a64ea356-314a-4ee9-9ced-e84974cc012e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a64ea356-314a-4ee9-9ced-e84974cc012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e2a6f415-9d9d-4304-b5d6-fd1b0cd38a36" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_EntityCentralIndexKey_e2a6f415-9d9d-4304-b5d6-fd1b0cd38a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1b37c011-d13d-45e5-8d19-782aeb416a2d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_CurrentFiscalYearEndDate_1b37c011-d13d-45e5-8d19-782aeb416a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ad2e1830-aa8d-4017-9c35-4ff273148f5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_DocumentFiscalYearFocus_ad2e1830-aa8d-4017-9c35-4ff273148f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a5eabc6d-bcee-4f17-831b-12556ebc2db7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a5eabc6d-bcee-4f17-831b-12556ebc2db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c3eba105-8c66-4bb0-a8fe-d3bae25afd03" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5b42a102-bf99-4c32-8ca4-10be2556e347" xlink:to="loc_dei_AmendmentFlag_c3eba105-8c66-4bb0-a8fe-d3bae25afd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c62443e5-1c33-4fac-8bb0-58e126e7d69e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7503e917-0b79-4445-9f9a-725ef86cdb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c62443e5-1c33-4fac-8bb0-58e126e7d69e" xlink:to="loc_us-gaap_AssetsAbstract_7503e917-0b79-4445-9f9a-725ef86cdb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1d0667b3-3cc0-424c-9d81-cbf75495124e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7503e917-0b79-4445-9f9a-725ef86cdb0a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1d0667b3-3cc0-424c-9d81-cbf75495124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6aeb390-2edd-4500-805b-3056f67268d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d0667b3-3cc0-424c-9d81-cbf75495124e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b6aeb390-2edd-4500-805b-3056f67268d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_fff2350f-9a59-4606-be2e-624083af548a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d0667b3-3cc0-424c-9d81-cbf75495124e" xlink:to="loc_us-gaap_RestrictedCashCurrent_fff2350f-9a59-4606-be2e-624083af548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_1a6cb255-b959-405c-9b23-7b31b3c5212c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d0667b3-3cc0-424c-9d81-cbf75495124e" xlink:to="loc_us-gaap_ReceivablesNetCurrent_1a6cb255-b959-405c-9b23-7b31b3c5212c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_fe8644c6-a846-4b2c-87c1-bb2b60efceaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d0667b3-3cc0-424c-9d81-cbf75495124e" xlink:to="loc_us-gaap_InventoryNet_fe8644c6-a846-4b2c-87c1-bb2b60efceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d3f3989d-d47f-485f-95cb-087f538ef453" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d0667b3-3cc0-424c-9d81-cbf75495124e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d3f3989d-d47f-485f-95cb-087f538ef453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_11246218-c4c8-485c-ac52-2a66d4c42c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d0667b3-3cc0-424c-9d81-cbf75495124e" xlink:to="loc_us-gaap_AssetsCurrent_11246218-c4c8-485c-ac52-2a66d4c42c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c3d5be17-f7dd-474e-8a9b-6bb108e81a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7503e917-0b79-4445-9f9a-725ef86cdb0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c3d5be17-f7dd-474e-8a9b-6bb108e81a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_756c2b1c-700e-4697-b30e-d256a434377a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7503e917-0b79-4445-9f9a-725ef86cdb0a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_756c2b1c-700e-4697-b30e-d256a434377a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d9e37da5-de38-4ba0-9bf5-2ad587f8bb7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7503e917-0b79-4445-9f9a-725ef86cdb0a" xlink:to="loc_us-gaap_Goodwill_d9e37da5-de38-4ba0-9bf5-2ad587f8bb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_dadc9785-b0f7-4049-ab89-961279d24ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7503e917-0b79-4445-9f9a-725ef86cdb0a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_dadc9785-b0f7-4049-ab89-961279d24ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_71f728cd-7306-4877-b647-8845f8fa22e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7503e917-0b79-4445-9f9a-725ef86cdb0a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_71f728cd-7306-4877-b647-8845f8fa22e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1c0df313-65f4-4c77-9521-f22ac7078930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7503e917-0b79-4445-9f9a-725ef86cdb0a" xlink:to="loc_us-gaap_Assets_1c0df313-65f4-4c77-9521-f22ac7078930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_dbb7c74f-f233-4a65-a77f-14c58552c962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c62443e5-1c33-4fac-8bb0-58e126e7d69e" xlink:to="loc_us-gaap_LiabilitiesAbstract_dbb7c74f-f233-4a65-a77f-14c58552c962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cb5408f3-a994-485a-a907-3905d422adb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_dbb7c74f-f233-4a65-a77f-14c58552c962" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cb5408f3-a994-485a-a907-3905d422adb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d5906cd9-adcb-4f69-ae85-428e5bcc9479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cb5408f3-a994-485a-a907-3905d422adb9" xlink:to="loc_us-gaap_AccountsPayableCurrent_d5906cd9-adcb-4f69-ae85-428e5bcc9479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d555ce49-c250-4d8d-9693-88c8c23a4214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cb5408f3-a994-485a-a907-3905d422adb9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d555ce49-c250-4d8d-9693-88c8c23a4214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_edd54fa6-1c39-4ef5-aa0d-f94be12e7018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cb5408f3-a994-485a-a907-3905d422adb9" xlink:to="loc_us-gaap_LongTermDebtCurrent_edd54fa6-1c39-4ef5-aa0d-f94be12e7018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ed085c80-9b08-4bf7-895e-b1112c5b47de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cb5408f3-a994-485a-a907-3905d422adb9" xlink:to="loc_us-gaap_LiabilitiesCurrent_ed085c80-9b08-4bf7-895e-b1112c5b47de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_7e003c23-26be-47ad-84cb-f90aa60b7abb" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_dbb7c74f-f233-4a65-a77f-14c58552c962" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_7e003c23-26be-47ad-84cb-f90aa60b7abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d22576ac-d912-4e7e-880b-4be4eadca018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_dbb7c74f-f233-4a65-a77f-14c58552c962" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d22576ac-d912-4e7e-880b-4be4eadca018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_358dcfc4-1a21-4cfe-9663-4df41413b81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_dbb7c74f-f233-4a65-a77f-14c58552c962" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_358dcfc4-1a21-4cfe-9663-4df41413b81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6576f3c6-d5bb-4984-bb05-b222fd93505e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_dbb7c74f-f233-4a65-a77f-14c58552c962" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6576f3c6-d5bb-4984-bb05-b222fd93505e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_95e12eeb-b7c0-407c-8253-723c07461d77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_dbb7c74f-f233-4a65-a77f-14c58552c962" xlink:to="loc_us-gaap_Liabilities_95e12eeb-b7c0-407c-8253-723c07461d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e0c2d045-92a3-404a-aa6c-f8feb52209a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c62443e5-1c33-4fac-8bb0-58e126e7d69e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e0c2d045-92a3-404a-aa6c-f8feb52209a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2ef3e864-6b74-4d00-9677-539beca23fd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c62443e5-1c33-4fac-8bb0-58e126e7d69e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2ef3e864-6b74-4d00-9677-539beca23fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ca16e9fc-2e28-42a9-9115-b6ccec15a268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ef3e864-6b74-4d00-9677-539beca23fd0" xlink:to="loc_us-gaap_CommonStockValue_ca16e9fc-2e28-42a9-9115-b6ccec15a268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c637d7d9-bf9a-475a-9743-0f99f5d9e89d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ef3e864-6b74-4d00-9677-539beca23fd0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c637d7d9-bf9a-475a-9743-0f99f5d9e89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d18df4e-f2bb-4b8e-a324-437907fa3bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ef3e864-6b74-4d00-9677-539beca23fd0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d18df4e-f2bb-4b8e-a324-437907fa3bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d0f6bb16-74f3-4a12-a051-0615a3124fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ef3e864-6b74-4d00-9677-539beca23fd0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d0f6bb16-74f3-4a12-a051-0615a3124fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4d3c007-6f28-43c9-ba25-722661b56bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ef3e864-6b74-4d00-9677-539beca23fd0" xlink:to="loc_us-gaap_StockholdersEquity_b4d3c007-6f28-43c9-ba25-722661b56bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b4daeca0-d43b-472b-9ac6-b4f9cc661c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ef3e864-6b74-4d00-9677-539beca23fd0" xlink:to="loc_us-gaap_MinorityInterest_b4daeca0-d43b-472b-9ac6-b4f9cc661c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1359afc5-2dc4-464b-bd2c-3bd33283909f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ef3e864-6b74-4d00-9677-539beca23fd0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1359afc5-2dc4-464b-bd2c-3bd33283909f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b76974c7-9ab8-4af8-9092-b9f48327f7eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c62443e5-1c33-4fac-8bb0-58e126e7d69e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b76974c7-9ab8-4af8-9092-b9f48327f7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ef0cab5a-6fe3-4bb9-8ae6-40faeae65257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c59e995c-2dda-4fb3-a998-77c8ac986e09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef0cab5a-6fe3-4bb9-8ae6-40faeae65257" xlink:to="loc_us-gaap_CommonStockSharesIssued_c59e995c-2dda-4fb3-a998-77c8ac986e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ca1d8ae4-3040-43bc-8143-d705f8e2d329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ef0cab5a-6fe3-4bb9-8ae6-40faeae65257" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ca1d8ae4-3040-43bc-8143-d705f8e2d329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_54e29494-6a5f-4c3b-b8be-37fb2e9ca345" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c3a087c7-05be-43b5-b085-aeedb744ed8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_54e29494-6a5f-4c3b-b8be-37fb2e9ca345" xlink:to="loc_us-gaap_StatementTable_c3a087c7-05be-43b5-b085-aeedb744ed8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eb9654be-c60f-454e-a841-03e7e70bc421" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c3a087c7-05be-43b5-b085-aeedb744ed8b" xlink:to="loc_srt_ProductOrServiceAxis_eb9654be-c60f-454e-a841-03e7e70bc421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f3727376-6004-42e1-96f0-e6df1aa55d1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_eb9654be-c60f-454e-a841-03e7e70bc421" xlink:to="loc_srt_ProductsAndServicesDomain_f3727376-6004-42e1-96f0-e6df1aa55d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_dc8ec238-5bc4-4f7b-8479-b899c3306514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f3727376-6004-42e1-96f0-e6df1aa55d1d" xlink:to="loc_us-gaap_ProductMember_dc8ec238-5bc4-4f7b-8479-b899c3306514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_75ca1bc0-f548-4b0b-a7ab-738ac96dd5d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f3727376-6004-42e1-96f0-e6df1aa55d1d" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_75ca1bc0-f548-4b0b-a7ab-738ac96dd5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c3a087c7-05be-43b5-b085-aeedb744ed8b" xlink:to="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_afbe5bfb-0a1a-449d-ab5a-e7045a4ada3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_RevenuesAbstract_afbe5bfb-0a1a-449d-ab5a-e7045a4ada3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dba74754-1eaf-4859-95fd-133cc7a7eb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_afbe5bfb-0a1a-449d-ab5a-e7045a4ada3b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dba74754-1eaf-4859-95fd-133cc7a7eb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_006f261f-f770-4a2f-879c-27c67de5e839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_006f261f-f770-4a2f-879c-27c67de5e839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e360eae7-7070-415a-ba19-a0c442d0d956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e360eae7-7070-415a-ba19-a0c442d0d956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_dc59bcde-e736-4322-8c0a-2e72d9a011f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_dc59bcde-e736-4322-8c0a-2e72d9a011f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_11203f94-9048-4b1f-b419-73ca93cc5edb" xlink:href="bhc-20200930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_11203f94-9048-4b1f-b419-73ca93cc5edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7828b641-62a8-4e2d-a521-3dd4a54186b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_AssetImpairmentCharges_7828b641-62a8-4e2d-a521-3dd4a54186b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3d9aa59d-1024-4f45-80f0-0bec87a84c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_RestructuringCharges_3d9aa59d-1024-4f45-80f0-0bec87a84c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_5f43758e-6582-4676-9af8-1f75c12d0d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_5f43758e-6582-4676-9af8-1f75c12d0d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_142f3f49-2549-4d1f-9ba7-c858de262001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_142f3f49-2549-4d1f-9ba7-c858de262001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0ad5dc3c-b289-4c76-a557-5d9b92d45f91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_5744c5a1-40f7-4d54-9a47-ee1cd86df100" xlink:to="loc_us-gaap_CostsAndExpenses_0ad5dc3c-b289-4c76-a557-5d9b92d45f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_23271844-3816-4c37-8518-d34c8cba480d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_OperatingIncomeLoss_23271844-3816-4c37-8518-d34c8cba480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e92404c2-d649-4832-8569-e874732d5b3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e92404c2-d649-4832-8569-e874732d5b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_1699d7a1-1e98-4445-8dba-b8f748a768ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_InterestExpenseDebt_1699d7a1-1e98-4445-8dba-b8f748a768ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96c05ae0-fa73-412b-8b45-561eb94d72e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_96c05ae0-fa73-412b-8b45-561eb94d72e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5a96786a-dd8a-4872-94a1-e308f122239f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_5a96786a-dd8a-4872-94a1-e308f122239f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a4d95089-451f-42aa-8673-ddc9481b7582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a4d95089-451f-42aa-8673-ddc9481b7582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fb5aea6b-1818-4ecc-abea-51f9a907c150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fb5aea6b-1818-4ecc-abea-51f9a907c150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a9ca8b12-93ad-42d5-a5b2-ddfa9d734827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_ProfitLoss_a9ca8b12-93ad-42d5-a5b2-ddfa9d734827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f4a8dd26-48e2-4753-8888-b2c9e4dd5bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f4a8dd26-48e2-4753-8888-b2c9e4dd5bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_89e6254b-0561-48f0-9f17-717dadb62579" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_89e6254b-0561-48f0-9f17-717dadb62579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a5f09da8-4719-45e7-9700-155c3e8e2088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_EarningsPerShareAbstract_a5f09da8-4719-45e7-9700-155c3e8e2088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8df00e6a-3dd1-4735-96d1-9c713199e8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a5f09da8-4719-45e7-9700-155c3e8e2088" xlink:to="loc_us-gaap_EarningsPerShareBasic_8df00e6a-3dd1-4735-96d1-9c713199e8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_330c0962-2097-4a45-874b-1f3098655307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a5f09da8-4719-45e7-9700-155c3e8e2088" xlink:to="loc_us-gaap_EarningsPerShareDiluted_330c0962-2097-4a45-874b-1f3098655307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_888e6969-5326-4d0b-9612-8a3b7ae8a4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_90cf814f-079b-4fad-8652-46057a5fa794" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_888e6969-5326-4d0b-9612-8a3b7ae8a4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a4ed5a7-3cab-4323-ac05-d5d09577a344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_888e6969-5326-4d0b-9612-8a3b7ae8a4da" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0a4ed5a7-3cab-4323-ac05-d5d09577a344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cc1f025a-c1df-473f-ac6d-7f8a4c6fdbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_888e6969-5326-4d0b-9612-8a3b7ae8a4da" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cc1f025a-c1df-473f-ac6d-7f8a4c6fdbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_aff5b4a2-06b7-49ee-ba50-4320206c67cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1a2f4f6a-bbea-4d17-99bc-b33067ad6d96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_aff5b4a2-06b7-49ee-ba50-4320206c67cb" xlink:to="loc_us-gaap_ProfitLoss_1a2f4f6a-bbea-4d17-99bc-b33067ad6d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d7a332b9-b59e-440d-a089-b328aea2361f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_aff5b4a2-06b7-49ee-ba50-4320206c67cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d7a332b9-b59e-440d-a089-b328aea2361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_64a7a28a-65dd-4aa3-819d-56e120558cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d7a332b9-b59e-440d-a089-b328aea2361f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_64a7a28a-65dd-4aa3-819d-56e120558cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_7913add3-1730-45a3-b4ad-8d2a4cf69012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d7a332b9-b59e-440d-a089-b328aea2361f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_7913add3-1730-45a3-b4ad-8d2a4cf69012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d95e4b43-9b4a-42d8-b3dc-c45aad824828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d7a332b9-b59e-440d-a089-b328aea2361f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d95e4b43-9b4a-42d8-b3dc-c45aad824828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320b353d-fc11-47e1-9547-440235f39cf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_aff5b4a2-06b7-49ee-ba50-4320206c67cb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320b353d-fc11-47e1-9547-440235f39cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_93fae438-d868-49d7-9459-69b4bb859dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_aff5b4a2-06b7-49ee-ba50-4320206c67cb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_93fae438-d868-49d7-9459-69b4bb859dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_dbfc2247-79df-4667-96c9-874e2ba7211c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_aff5b4a2-06b7-49ee-ba50-4320206c67cb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_dbfc2247-79df-4667-96c9-874e2ba7211c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ad68c014-4ff7-42c2-a60b-3f241b44cbb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_50e06be6-cf35-4644-aca1-c047e51205f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ad68c014-4ff7-42c2-a60b-3f241b44cbb2" xlink:to="loc_us-gaap_StatementTable_50e06be6-cf35-4644-aca1-c047e51205f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_df6c9808-3c60-4c43-b72b-1797571b418f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50e06be6-cf35-4644-aca1-c047e51205f5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_df6c9808-3c60-4c43-b72b-1797571b418f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_df6c9808-3c60-4c43-b72b-1797571b418f" xlink:to="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_28c6ad01-e186-4e50-8689-12cc943e7db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_CommonStockMember_28c6ad01-e186-4e50-8689-12cc943e7db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b87cc867-4ca3-4a75-bee9-8535af3f1006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b87cc867-4ca3-4a75-bee9-8535af3f1006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d8db11e5-d7d4-47ca-a496-208dc0e84285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_RetainedEarningsMember_d8db11e5-d7d4-47ca-a496-208dc0e84285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fad8657a-b3ef-4631-9a56-b05743212b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fad8657a-b3ef-4631-9a56-b05743212b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_fc835b45-f9bc-48bd-9efd-b0a95165291b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_ParentMember_fc835b45-f9bc-48bd-9efd-b0a95165291b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_b4d9f2eb-7601-49db-bec6-53a166c63297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45ed0a48-9f63-4fd9-b627-bcf88971fda3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_b4d9f2eb-7601-49db-bec6-53a166c63297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bf5ffdb5-1028-4db8-a01e-b8b8ea7fd0db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50e06be6-cf35-4644-aca1-c047e51205f5" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bf5ffdb5-1028-4db8-a01e-b8b8ea7fd0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_87f83386-146b-4050-af9c-c1a23d86d598" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_bf5ffdb5-1028-4db8-a01e-b8b8ea7fd0db" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_87f83386-146b-4050-af9c-c1a23d86d598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7be71bb0-fb0e-4e54-959c-1a97733050ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_87f83386-146b-4050-af9c-c1a23d86d598" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7be71bb0-fb0e-4e54-959c-1a97733050ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c9820d0f-8ea4-4b61-bd16-96389f44a5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_50e06be6-cf35-4644-aca1-c047e51205f5" xlink:to="loc_us-gaap_StatementLineItems_c9820d0f-8ea4-4b61-bd16-96389f44a5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c9820d0f-8ea4-4b61-bd16-96389f44a5bb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_915f6d4c-14b9-42fa-b502-31e7d33f4973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_915f6d4c-14b9-42fa-b502-31e7d33f4973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_947ae3d8-5659-49cc-b083-059cb604834a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_947ae3d8-5659-49cc-b083-059cb604834a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0418e10a-0451-4763-8147-6fee3dbd8335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0418e10a-0451-4763-8147-6fee3dbd8335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bde25cf8-6532-4e08-9973-fe753fb0913c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_bde25cf8-6532-4e08-9973-fe753fb0913c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ce342086-f7e2-4cfd-8a79-a99103ce2e70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ce342086-f7e2-4cfd-8a79-a99103ce2e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3fdd54ee-8f00-478f-83cd-9ededac22fd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3fdd54ee-8f00-478f-83cd-9ededac22fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_8a7cf898-0f57-4bda-b200-ff5ffa82a3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_8a7cf898-0f57-4bda-b200-ff5ffa82a3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b938e794-2a4d-4255-94dc-0046173dd9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_ProfitLoss_b938e794-2a4d-4255-94dc-0046173dd9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6970ec43-c5ca-4efd-afb4-565083974bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6970ec43-c5ca-4efd-afb4-565083974bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7ce067c6-7503-4290-bd73-43e6d78cdf68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_CommonStockSharesIssued_7ce067c6-7503-4290-bd73-43e6d78cdf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5af08d79-e2b8-4489-ae1a-ebb0e9adb797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_717e368a-6368-4fed-95d8-cb640d2972e2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5af08d79-e2b8-4489-ae1a-ebb0e9adb797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f7745f75-cba5-4656-a26f-cd3d61e0395b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c9820d0f-8ea4-4b61-bd16-96389f44a5bb" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f7745f75-cba5-4656-a26f-cd3d61e0395b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8825bfd5-e2c7-4966-b761-e25bfb19347a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8825bfd5-e2c7-4966-b761-e25bfb19347a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_537098fc-0a1a-4f66-843d-5dbb150df29f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8825bfd5-e2c7-4966-b761-e25bfb19347a" xlink:to="loc_us-gaap_ProfitLoss_537098fc-0a1a-4f66-843d-5dbb150df29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8825bfd5-e2c7-4966-b761-e25bfb19347a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_45694c6a-b5dc-4bd5-a9d3-be4efe0af99b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_DepreciationAndAmortization_45694c6a-b5dc-4bd5-a9d3-be4efe0af99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f9b95b0c-f62d-47c8-9d22-9ab35b882618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f9b95b0c-f62d-47c8-9d22-9ab35b882618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d682f5d4-3ded-4917-918f-7153e9aa2718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_AssetImpairmentCharges_d682f5d4-3ded-4917-918f-7153e9aa2718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_874b827e-0ed0-4220-9d7d-450dcbd75f66" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_874b827e-0ed0-4220-9d7d-450dcbd75f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_ce235cca-663b-4452-ac51-7ad50c1e4a53" xlink:href="bhc-20200930.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_ce235cca-663b-4452-ac51-7ad50c1e4a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_75fe3e94-e0c0-4c96-8684-af2181e03934" xlink:href="bhc-20200930.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_75fe3e94-e0c0-4c96-8684-af2181e03934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_6e540fd0-9de7-41c2-b28c-3fe5ff0fb74f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_6e540fd0-9de7-41c2-b28c-3fe5ff0fb74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_e716c9a6-64ca-45fb-8e44-25202067e49d" xlink:href="bhc-20200930.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_e716c9a6-64ca-45fb-8e44-25202067e49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_e202d7be-b1c4-456f-8ead-00a1d2ffea1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_e202d7be-b1c4-456f-8ead-00a1d2ffea1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_762ccd54-4531-4e99-a68e-f1a2ece1c8bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_ShareBasedCompensation_762ccd54-4531-4e99-a68e-f1a2ece1c8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5654017e-0b0f-4246-81fa-2e1eb9db880f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_5654017e-0b0f-4246-81fa-2e1eb9db880f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_6713406f-2ffd-4269-9b48-9cccb1968b47" xlink:href="bhc-20200930.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_bhc_DerivativeGainExcludedComponent_6713406f-2ffd-4269-9b48-9cccb1968b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dee85145-cc76-4eea-ac37-8eb1dbd7b279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dee85145-cc76-4eea-ac37-8eb1dbd7b279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentOfAccretedInterestOnContingentConsideration_6a99b2a4-7117-4b7d-b607-190207a11b40" xlink:href="bhc-20200930.xsd#bhc_PaymentOfAccretedInterestOnContingentConsideration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_bhc_PaymentOfAccretedInterestOnContingentConsideration_6a99b2a4-7117-4b7d-b607-190207a11b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c489dcfe-0feb-44d2-b3e6-6fdc0e77ca37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c489dcfe-0feb-44d2-b3e6-6fdc0e77ca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_791434da-494b-483d-a44c-88e5bac43ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3bf3e54c-7014-430b-acc2-6b312b1c25e0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_791434da-494b-483d-a44c-88e5bac43ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8e2ce126-8c27-450a-a5be-276f4bacf7d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_791434da-494b-483d-a44c-88e5bac43ada" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8e2ce126-8c27-450a-a5be-276f4bacf7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c5ff347f-693d-45e1-a884-5a98f47eb256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_791434da-494b-483d-a44c-88e5bac43ada" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c5ff347f-693d-45e1-a884-5a98f47eb256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bae68f24-d570-43f7-8986-ac0b57c253d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_791434da-494b-483d-a44c-88e5bac43ada" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bae68f24-d570-43f7-8986-ac0b57c253d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_700f7619-2144-49e5-8662-b8a90948a99f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_791434da-494b-483d-a44c-88e5bac43ada" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_700f7619-2144-49e5-8662-b8a90948a99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_241bba4a-2175-4dce-bae4-b445135698ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8825bfd5-e2c7-4966-b761-e25bfb19347a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_241bba4a-2175-4dce-bae4-b445135698ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7cb80f46-8026-4af0-85c8-8eec635d7119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7cb80f46-8026-4af0-85c8-8eec635d7119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe10dd8c-ca86-4689-94d8-2b55d724389b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe10dd8c-ca86-4689-94d8-2b55d724389b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2524fe7e-b3bd-4792-8036-3afb24070ff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2524fe7e-b3bd-4792-8036-3afb24070ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6d45345e-0b58-424c-8ffd-1aa352dfc975" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_6d45345e-0b58-424c-8ffd-1aa352dfc975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_be436930-a447-4b31-94e3-322cacdd8170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_be436930-a447-4b31-94e3-322cacdd8170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_ff51ccf8-cbfe-4097-9c63-8841d1354839" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_ff51ccf8-cbfe-4097-9c63-8841d1354839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_a971008c-46c1-4f03-8fc4-e980a93f53f5" xlink:href="bhc-20200930.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_a971008c-46c1-4f03-8fc4-e980a93f53f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2fd2e0f-5c36-49f9-842f-b0c3428cb4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0f3051e-42e6-4b5f-a378-49868bc7a805" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e2fd2e0f-5c36-49f9-842f-b0c3428cb4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3d86f3ee-2717-4f6f-8cb9-66439ab44690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3d86f3ee-2717-4f6f-8cb9-66439ab44690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3c3952aa-75f5-47d4-ab95-2f726e70a1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3c3952aa-75f5-47d4-ab95-2f726e70a1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_24df354a-f180-413c-a0dd-06c28368ea8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_24df354a-f180-413c-a0dd-06c28368ea8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_b7e2c87e-e797-4db3-bea9-b19bb4e0e1e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_b7e2c87e-e797-4db3-bea9-b19bb4e0e1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_95996a8e-381b-41e0-a0d9-7286edbd06dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_95996a8e-381b-41e0-a0d9-7286edbd06dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c1ece148-a2a3-438c-976c-8258aab89d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_c1ece148-a2a3-438c-976c-8258aab89d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_cfff5bda-79c3-4e56-b741-d184ff879be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_cfff5bda-79c3-4e56-b741-d184ff879be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_826aebc9-b6da-448c-9ddb-8b362b6ec276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_826aebc9-b6da-448c-9ddb-8b362b6ec276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_787c0410-d5c0-45f4-8062-3dc0d73d930a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d5a89a72-1880-4599-b9ae-afbb6ea5387b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_787c0410-d5c0-45f4-8062-3dc0d73d930a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed3892a1-5993-4beb-a75b-f8951ce726a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed3892a1-5993-4beb-a75b-f8951ce726a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c962a6ae-2172-4036-a974-3dc014c444c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c962a6ae-2172-4036-a974-3dc014c444c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ff773a6-85e6-4993-997b-8da324a97535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ff773a6-85e6-4993-997b-8da324a97535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5e10c19-4d74-40d4-aa73-814de702acab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5e10c19-4d74-40d4-aa73-814de702acab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_db36b5d6-f98c-433d-83dc-1ace843be5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_db36b5d6-f98c-433d-83dc-1ace843be5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_e1bc066f-88ea-4369-9954-f45bcccf7d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_RestrictedCashCurrent_e1bc066f-88ea-4369-9954-f45bcccf7d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54ada6d8-8507-4b29-bb46-01e1be0dcf2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82628dd2-6718-4970-83ce-717e08eb8266" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54ada6d8-8507-4b29-bb46-01e1be0dcf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20200930.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7cfa1f67-0756-4ee9-af38-b5c11f682e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_3ca7981b-a747-49e4-9357-020903e8cbef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7cfa1f67-0756-4ee9-af38-b5c11f682e00" xlink:to="loc_us-gaap_NatureOfOperations_3ca7981b-a747-49e4-9357-020903e8cbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ee1e412-3502-4975-bd11-f4a589a45461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_34f2a166-a065-4bb4-985d-9481cfeb34e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ee1e412-3502-4975-bd11-f4a589a45461" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_34f2a166-a065-4bb4-985d-9481cfeb34e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20200930.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_df6ef312-1b35-4bf8-a086-b2a16617b4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_df7633ac-7b8e-4098-a27b-976dc608ea45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_df6ef312-1b35-4bf8-a086-b2a16617b4c4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_df7633ac-7b8e-4098-a27b-976dc608ea45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20200930.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_989e9410-8827-4f44-bdf0-d383ebd2e494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_634d5928-8d96-42e6-a0b2-ec74c7052a00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_989e9410-8827-4f44-bdf0-d383ebd2e494" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_634d5928-8d96-42e6-a0b2-ec74c7052a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_248fe1b9-b062-448d-916d-8ad4af01bf77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_989e9410-8827-4f44-bdf0-d383ebd2e494" xlink:to="loc_us-gaap_UseOfEstimates_248fe1b9-b062-448d-916d-8ad4af01bf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_123ab50b-bd87-405d-bb3e-b9ed996a31d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_989e9410-8827-4f44-bdf0-d383ebd2e494" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_123ab50b-bd87-405d-bb3e-b9ed996a31d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39e9e6e1-5695-4be8-a949-09e41809d195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_989e9410-8827-4f44-bdf0-d383ebd2e494" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_39e9e6e1-5695-4be8-a949-09e41809d195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_08c06b02-8413-455f-8246-013124701b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_989e9410-8827-4f44-bdf0-d383ebd2e494" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_08c06b02-8413-455f-8246-013124701b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9cb90430-a959-4529-b35f-a9a02d9bab16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b14f1fce-8858-4920-913c-4977435f5728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9cb90430-a959-4529-b35f-a9a02d9bab16" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b14f1fce-8858-4920-913c-4977435f5728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40b0a795-05fd-428d-972a-512b8e7ba097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b14f1fce-8858-4920-913c-4977435f5728" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40b0a795-05fd-428d-972a-512b8e7ba097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_767c2541-9857-464e-9bb3-2bb68ece16d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40b0a795-05fd-428d-972a-512b8e7ba097" xlink:to="loc_us-gaap_EquityComponentDomain_767c2541-9857-464e-9bb3-2bb68ece16d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c0749f5c-f4cb-4ce3-b43f-2bfabdb32abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_767c2541-9857-464e-9bb3-2bb68ece16d6" xlink:to="loc_us-gaap_RetainedEarningsMember_c0749f5c-f4cb-4ce3-b43f-2bfabdb32abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e2b8809b-b5ea-4ae1-9303-59d763e57d3b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b14f1fce-8858-4920-913c-4977435f5728" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e2b8809b-b5ea-4ae1-9303-59d763e57d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d9a5e70c-9c51-4c5d-8ce9-7b7ea4729970" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e2b8809b-b5ea-4ae1-9303-59d763e57d3b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d9a5e70c-9c51-4c5d-8ce9-7b7ea4729970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_28e8b943-2268-4c16-aa8c-9b6cf80c8277" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_d9a5e70c-9c51-4c5d-8ce9-7b7ea4729970" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_28e8b943-2268-4c16-aa8c-9b6cf80c8277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a273a68e-8dc9-434f-9c18-4be82ca7e343" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_b14f1fce-8858-4920-913c-4977435f5728" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a273a68e-8dc9-434f-9c18-4be82ca7e343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_b464e76d-1d57-4723-b79a-36762b47e440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a273a68e-8dc9-434f-9c18-4be82ca7e343" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_b464e76d-1d57-4723-b79a-36762b47e440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf9a1f77-c585-4a5f-805b-919d691d948b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_a273a68e-8dc9-434f-9c18-4be82ca7e343" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cf9a1f77-c585-4a5f-805b-919d691d948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_230211eb-e692-44dd-80ee-865e8ae55db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3ddbd0f3-bb33-469d-aee2-41341ee8c36e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_230211eb-e692-44dd-80ee-865e8ae55db6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3ddbd0f3-bb33-469d-aee2-41341ee8c36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ab9633eb-f8e1-4c52-92ad-6daf16e4e72e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_aeda4720-8120-418c-aaf8-cbde0560a860" xlink:href="bhc-20200930.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ab9633eb-f8e1-4c52-92ad-6daf16e4e72e" xlink:to="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_aeda4720-8120-418c-aaf8-cbde0560a860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_5c4c5209-4010-4e10-8c99-383911d501ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ab9633eb-f8e1-4c52-92ad-6daf16e4e72e" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_5c4c5209-4010-4e10-8c99-383911d501ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e9719d63-463a-42b0-98bf-5e9b88ea92b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6b9c118b-ff81-4252-885a-44fdcd071883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e9719d63-463a-42b0-98bf-5e9b88ea92b8" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6b9c118b-ff81-4252-885a-44fdcd071883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_fc83b89c-dea2-4e4e-a9dd-a16e197ac1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6b9c118b-ff81-4252-885a-44fdcd071883" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_fc83b89c-dea2-4e4e-a9dd-a16e197ac1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8a0f9c86-75f7-4a6f-a3a7-86d0816f51be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_fc83b89c-dea2-4e4e-a9dd-a16e197ac1d7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8a0f9c86-75f7-4a6f-a3a7-86d0816f51be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_8b28a210-ede0-4bed-b1c2-cd4e3ad38e68" xlink:href="bhc-20200930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8a0f9c86-75f7-4a6f-a3a7-86d0816f51be" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_8b28a210-ede0-4bed-b1c2-cd4e3ad38e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_f9cc61b0-0fc8-4490-b01b-a83a103cc612" xlink:href="bhc-20200930.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_8a0f9c86-75f7-4a6f-a3a7-86d0816f51be" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_f9cc61b0-0fc8-4490-b01b-a83a103cc612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00924278-4a43-4694-a1e5-afc7bc74d634" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6b9c118b-ff81-4252-885a-44fdcd071883" xlink:to="loc_srt_ProductOrServiceAxis_00924278-4a43-4694-a1e5-afc7bc74d634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a5dd409c-81c8-4145-8d24-fe7806bc316f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_00924278-4a43-4694-a1e5-afc7bc74d634" xlink:to="loc_srt_ProductsAndServicesDomain_a5dd409c-81c8-4145-8d24-fe7806bc316f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_3f8eb03e-3d19-480f-8ed9-da5d02f0defc" xlink:href="bhc-20200930.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a5dd409c-81c8-4145-8d24-fe7806bc316f" xlink:to="loc_bhc_PriceAppreciationCreditMember_3f8eb03e-3d19-480f-8ed9-da5d02f0defc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_6b9c118b-ff81-4252-885a-44fdcd071883" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_cd1d9176-8a72-424c-b993-77d362793700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_cd1d9176-8a72-424c-b993-77d362793700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_87487d53-db02-48ac-bf2d-9b540f068e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_87487d53-db02-48ac-bf2d-9b540f068e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_d339109f-f6aa-452a-aa2f-9d09e89e6f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_d339109f-f6aa-452a-aa2f-9d09e89e6f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73a6f83b-34cb-4d3e-b34c-864d600ceb21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_0fce4a74-9378-4566-95c0-154d44de722b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73a6f83b-34cb-4d3e-b34c-864d600ceb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9d800ee6-d74e-48bb-854c-9b069e808eb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_06242150-c9be-41eb-a58f-cc6cfe979cc1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9d800ee6-d74e-48bb-854c-9b069e808eb4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_06242150-c9be-41eb-a58f-cc6cfe979cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_555c001a-bfc1-41cb-881f-d605d6cf7407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_06242150-c9be-41eb-a58f-cc6cfe979cc1" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_555c001a-bfc1-41cb-881f-d605d6cf7407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_555c001a-bfc1-41cb-881f-d605d6cf7407" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_484e6c51-8cb8-4a69-9d79-b10136d31510" xlink:href="bhc-20200930.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_484e6c51-8cb8-4a69-9d79-b10136d31510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_be61e34c-0840-40ce-b462-b1e8aeb6c64c" xlink:href="bhc-20200930.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_be61e34c-0840-40ce-b462-b1e8aeb6c64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_515d1a02-65fe-4c8f-8416-7f9d4905af92" xlink:href="bhc-20200930.xsd#bhc_ReserveForRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForRebatesMember_515d1a02-65fe-4c8f-8416-7f9d4905af92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_212d3471-75c4-45c3-8a6b-088c29ab7a48" xlink:href="bhc-20200930.xsd#bhc_ReserveForChargebacksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForChargebacksMember_212d3471-75c4-45c3-8a6b-088c29ab7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_a8d00763-d5bf-4d7a-a976-4508a69fb174" xlink:href="bhc-20200930.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e481a1c8-11ab-48a8-8297-0798d30a880d" xlink:to="loc_bhc_ReserveForDistributionFeesMember_a8d00763-d5bf-4d7a-a976-4508a69fb174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_33438d3d-7899-421b-bce2-1b087595674e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_06242150-c9be-41eb-a58f-cc6cfe979cc1" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_33438d3d-7899-421b-bce2-1b087595674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_33438d3d-7899-421b-bce2-1b087595674e" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d4b954b-ca0f-43c0-b3a8-43061ab2cdf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2d4b954b-ca0f-43c0-b3a8-43061ab2cdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_f297bb1a-296b-4302-b3b6-caf2e5f76b82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired_f297bb1a-296b-4302-b3b6-caf2e5f76b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_83ee139f-0c6e-4039-b1ac-30b23f09ead1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_83ee139f-0c6e-4039-b1ac-30b23f09ead1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_c6e0a073-394a-4e59-a60e-5b8a9fb53d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_c6e0a073-394a-4e59-a60e-5b8a9fb53d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4b1d1a4a-2918-44fc-95bb-3dd8b2aca857" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_415aeb30-d2cb-41e7-b36a-4dca5477412b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4b1d1a4a-2918-44fc-95bb-3dd8b2aca857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8075adb1-54b2-41ff-b3e5-700bc92bed39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7c791675-d935-4252-bf8f-d2ebf8a2e000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8075adb1-54b2-41ff-b3e5-700bc92bed39" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7c791675-d935-4252-bf8f-d2ebf8a2e000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_a55cdd57-17ca-4bb5-a363-798203d6cf4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7c791675-d935-4252-bf8f-d2ebf8a2e000" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_a55cdd57-17ca-4bb5-a363-798203d6cf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_07d2f455-6431-4222-b665-48a9e3c50091" xlink:href="bhc-20200930.xsd#bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7c791675-d935-4252-bf8f-d2ebf8a2e000" xlink:to="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_07d2f455-6431-4222-b665-48a9e3c50091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_32280c9c-91b3-48f0-9a91-0ebbd2387e16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7c791675-d935-4252-bf8f-d2ebf8a2e000" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_32280c9c-91b3-48f0-9a91-0ebbd2387e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a65323fc-9da6-454d-8339-2b3e5b45f37d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7c791675-d935-4252-bf8f-d2ebf8a2e000" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_a65323fc-9da6-454d-8339-2b3e5b45f37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_f593da30-1162-4d69-8cfe-618be95c09b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7c791675-d935-4252-bf8f-d2ebf8a2e000" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_f593da30-1162-4d69-8cfe-618be95c09b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_67721569-2d3c-4aca-8d71-e69e900414e7" xlink:href="bhc-20200930.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7c791675-d935-4252-bf8f-d2ebf8a2e000" xlink:to="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_67721569-2d3c-4aca-8d71-e69e900414e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_dd9af4eb-23fc-455e-b96d-b4ca749f7928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_7c791675-d935-4252-bf8f-d2ebf8a2e000" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_dd9af4eb-23fc-455e-b96d-b4ca749f7928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5cce1ff0-3a4c-4571-bcd4-37bb8c574535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_445929fb-10f2-49ce-9690-6eeb81f67f2e" xlink:href="bhc-20200930.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5cce1ff0-3a4c-4571-bcd4-37bb8c574535" xlink:to="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_445929fb-10f2-49ce-9690-6eeb81f67f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2634e2f3-9b2b-4be1-8204-7bdff2302bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3d01484a-46e3-4ac2-90c0-73fcf252835e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2634e2f3-9b2b-4be1-8204-7bdff2302bac" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_3d01484a-46e3-4ac2-90c0-73fcf252835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_633a12c8-2ae7-43d1-baf9-ba93e34d0d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_633a12c8-2ae7-43d1-baf9-ba93e34d0d03" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_abd9c64b-90a6-40e4-a330-fcfc4d995a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_abd9c64b-90a6-40e4-a330-fcfc4d995a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5791bf7a-9b1e-4b6d-81c2-1bd75480f638" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_abd9c64b-90a6-40e4-a330-fcfc4d995a37" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5791bf7a-9b1e-4b6d-81c2-1bd75480f638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_4ff13e12-6f1b-4cf0-a321-a6088b24cf48" xlink:href="bhc-20200930.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5791bf7a-9b1e-4b6d-81c2-1bd75480f638" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_4ff13e12-6f1b-4cf0-a321-a6088b24cf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionAxis_4f38c5d7-8ec8-4b19-bd49-af604c65833d" xlink:href="bhc-20200930.xsd#bhc_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_bhc_AssetAcquisitionAxis_4f38c5d7-8ec8-4b19-bd49-af604c65833d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetAcquisitionDomain_95aaeb06-abaf-485e-893a-5a50d6e061b5" xlink:href="bhc-20200930.xsd#bhc_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionAxis_4f38c5d7-8ec8-4b19-bd49-af604c65833d" xlink:to="loc_bhc_AssetAcquisitionDomain_95aaeb06-abaf-485e-893a-5a50d6e061b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllegroOphthalmicsLLCMember_18eb5abe-22ef-4530-a33f-50c56b535e16" xlink:href="bhc-20200930.xsd#bhc_AllegroOphthalmicsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetAcquisitionDomain_95aaeb06-abaf-485e-893a-5a50d6e061b5" xlink:to="loc_bhc_AllegroOphthalmicsLLCMember_18eb5abe-22ef-4530-a33f-50c56b535e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e25cf4bf-500c-48a8-9b72-d2ef3875d1b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e25cf4bf-500c-48a8-9b72-d2ef3875d1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9513e9f7-081d-4731-b204-363126d61423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e25cf4bf-500c-48a8-9b72-d2ef3875d1b1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9513e9f7-081d-4731-b204-363126d61423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_4aa24603-d52d-448a-ba86-d306e96a7d11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9513e9f7-081d-4731-b204-363126d61423" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_4aa24603-d52d-448a-ba86-d306e96a7d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f4c5a8b6-30af-488c-a264-470af3252c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f4c5a8b6-30af-488c-a264-470af3252c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_35abf6f4-af42-448e-ac42-b747c2dcb60d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f4c5a8b6-30af-488c-a264-470af3252c3d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_35abf6f4-af42-448e-ac42-b747c2dcb60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_0774f288-d7d9-4a33-9a1c-246d9521baf8" xlink:href="bhc-20200930.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_35abf6f4-af42-448e-ac42-b747c2dcb60d" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_0774f288-d7d9-4a33-9a1c-246d9521baf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7e16624c-fced-425a-a0db-097c3c6e315b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_srt_ProductOrServiceAxis_7e16624c-fced-425a-a0db-097c3c6e315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_69de9ffa-effb-4a5a-b3c4-7a96c0be0c09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7e16624c-fced-425a-a0db-097c3c6e315b" xlink:to="loc_srt_ProductsAndServicesDomain_69de9ffa-effb-4a5a-b3c4-7a96c0be0c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_224939c2-611d-4ab6-bc53-9ee652cbd8e1" xlink:href="bhc-20200930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_69de9ffa-effb-4a5a-b3c4-7a96c0be0c09" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_224939c2-611d-4ab6-bc53-9ee652cbd8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6c10636d-68ee-4e1b-a6e5-34e1422ff9e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_srt_RestatementAxis_6c10636d-68ee-4e1b-a6e5-34e1422ff9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_295ee46d-3a10-4fa5-8ebd-a60fe0f2967d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_6c10636d-68ee-4e1b-a6e5-34e1422ff9e9" xlink:to="loc_srt_RestatementDomain_295ee46d-3a10-4fa5-8ebd-a60fe0f2967d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_71fb0c88-5c72-4a12-8515-c0a4a7072e4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_295ee46d-3a10-4fa5-8ebd-a60fe0f2967d" xlink:to="loc_srt_RestatementAdjustmentMember_71fb0c88-5c72-4a12-8515-c0a4a7072e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9d2cf466-e7d9-433e-abe5-00c0e5552dd8" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_43a78513-638f-49a0-8120-97fff501fd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_43a78513-638f-49a0-8120-97fff501fd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ec5ff740-cbf8-4990-a9cb-778e7267aab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_ec5ff740-cbf8-4990-a9cb-778e7267aab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_2052d8cb-b128-4646-a5b7-2c493fc26076" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_2052d8cb-b128-4646-a5b7-2c493fc26076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_172cab87-698d-4f5b-843f-2e8c5d2d02b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_172cab87-698d-4f5b-843f-2e8c5d2d02b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_1efd1bbe-1d91-44b8-905d-6d1689c92738" xlink:href="bhc-20200930.xsd#bhc_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_1efd1bbe-1d91-44b8-905d-6d1689c92738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_382fb240-208d-4348-b0e4-d32bac54df51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_382fb240-208d-4348-b0e4-d32bac54df51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PotentialAssetAcquisitionAggregatePurchasePrice_070ffb7c-6acf-4f09-ba9c-483cab2aed75" xlink:href="bhc-20200930.xsd#bhc_PotentialAssetAcquisitionAggregatePurchasePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_PotentialAssetAcquisitionAggregatePurchasePrice_070ffb7c-6acf-4f09-ba9c-483cab2aed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice_6a09f5bc-515d-4d10-9a99-cceac6e2412c" xlink:href="bhc-20200930.xsd#bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice_6a09f5bc-515d-4d10-9a99-cceac6e2412c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice_4a7c0f45-265e-4479-b579-6674d2918648" xlink:href="bhc-20200930.xsd#bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice_4a7c0f45-265e-4479-b579-6674d2918648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupNumberOfProductsForDisposal_09fa7387-6b37-4a2b-8d5d-763764d510b7" xlink:href="bhc-20200930.xsd#bhc_DisposalGroupNumberOfProductsForDisposal"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_bhc_DisposalGroupNumberOfProductsForDisposal_09fa7387-6b37-4a2b-8d5d-763764d510b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9e473ade-9fd5-49b5-bdeb-a3a24231a59b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_9e473ade-9fd5-49b5-bdeb-a3a24231a59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3452e20a-ec3c-4230-85ad-cf95942eb529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_3452e20a-ec3c-4230-85ad-cf95942eb529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_cd84702e-7c57-4eab-ba85-5ce2bb03c95b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_cd84702e-7c57-4eab-ba85-5ce2bb03c95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e9638a2c-fcb2-4db0-92a6-f7b560be9908" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b39f2872-c4fe-42de-9003-0142f508bc14" xlink:to="loc_us-gaap_Assets_e9638a2c-fcb2-4db0-92a6-f7b560be9908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3c2b64af-2575-4fa7-9ef8-12f2e1127e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3e05b8f-4e0a-4256-b119-050160092b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3c2b64af-2575-4fa7-9ef8-12f2e1127e00" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3e05b8f-4e0a-4256-b119-050160092b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_635a8850-29ed-431b-9d48-106b431fff2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3e05b8f-4e0a-4256-b119-050160092b59" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_635a8850-29ed-431b-9d48-106b431fff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ede6b286-7388-48c2-ad85-22296e3ef9e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_635a8850-29ed-431b-9d48-106b431fff2c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ede6b286-7388-48c2-ad85-22296e3ef9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_0e7d364d-9589-41dc-b02f-b4b88fa613e2" xlink:href="bhc-20200930.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ede6b286-7388-48c2-ad85-22296e3ef9e4" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_0e7d364d-9589-41dc-b02f-b4b88fa613e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f3e05b8f-4e0a-4256-b119-050160092b59" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_354dfd21-7155-4707-843b-77afd036d947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_354dfd21-7155-4707-843b-77afd036d947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0a7eb4aa-7437-4e9c-9e16-758611fec44d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_0a7eb4aa-7437-4e9c-9e16-758611fec44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_a0b95dd6-1513-438d-adbb-8c6ab17d4dc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_a0b95dd6-1513-438d-adbb-8c6ab17d4dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31f0bedf-9e5e-4884-b683-7fff63a83d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31f0bedf-9e5e-4884-b683-7fff63a83d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_245ba1de-56ee-4aff-878b-465f41f2b8bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_245ba1de-56ee-4aff-878b-465f41f2b8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_42ebf326-74d1-428e-a04c-a0c8dd937ab9" xlink:href="bhc-20200930.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_42ebf326-74d1-428e-a04c-a0c8dd937ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4a3386ef-719a-46e8-9ab3-7f119d24b28d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_4a3386ef-719a-46e8-9ab3-7f119d24b28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fb294e42-469f-43a2-a0b5-dc5daa51cb4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_Goodwill_fb294e42-469f-43a2-a0b5-dc5daa51cb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3f0a5d2f-b7c8-4e2f-985e-632e63df65f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3f0a5d2f-b7c8-4e2f-985e-632e63df65f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10f0066b-51e7-4354-9257-fb1efae8d727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_242aee2e-02c1-4d12-9dd3-6576a9233b01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_10f0066b-51e7-4354-9257-fb1efae8d727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_11906dbd-66b3-4a40-abaf-d55baefabaf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a902b4e8-7509-4b88-a69e-11294c652c32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_11906dbd-66b3-4a40-abaf-d55baefabaf5" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a902b4e8-7509-4b88-a69e-11294c652c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b19bd010-3ccf-468b-a743-1da3860c3174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a7e37da1-a874-47f0-b96c-11c1cb56211a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b19bd010-3ccf-468b-a743-1da3860c3174" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a7e37da1-a874-47f0-b96c-11c1cb56211a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_974a46fb-b6a0-493e-b66b-c28423408495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a7e37da1-a874-47f0-b96c-11c1cb56211a" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_974a46fb-b6a0-493e-b66b-c28423408495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3abafd63-1d00-48c4-a06a-557413eb1b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_974a46fb-b6a0-493e-b66b-c28423408495" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3abafd63-1d00-48c4-a06a-557413eb1b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_a39f314f-0d49-41ce-b60f-66722a1c2200" xlink:href="bhc-20200930.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3abafd63-1d00-48c4-a06a-557413eb1b7a" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_a39f314f-0d49-41ce-b60f-66722a1c2200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationCostsMember_e57bf198-df89-4d65-a191-3ffe879f9485" xlink:href="bhc-20200930.xsd#bhc_SeparationCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3abafd63-1d00-48c4-a06a-557413eb1b7a" xlink:to="loc_bhc_SeparationCostsMember_e57bf198-df89-4d65-a191-3ffe879f9485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_a7e37da1-a874-47f0-b96c-11c1cb56211a" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fba2b4c7-28ad-41ff-bb5f-efe9ae6c6b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_RestructuringReserve_fba2b4c7-28ad-41ff-bb5f-efe9ae6c6b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_08521324-dfa8-41c8-bb5b-d7318facf870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_08521324-dfa8-41c8-bb5b-d7318facf870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_13736520-0003-45c1-949e-fedae45a32b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_BusinessExitCosts1_13736520-0003-45c1-949e-fedae45a32b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_5403da52-9664-42c2-9e7d-2b0f63ef83a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_SeveranceCosts1_5403da52-9664-42c2-9e7d-2b0f63ef83a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_1da5fce6-ea6f-419d-9ec6-79a4a2345f48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_PaymentsForRestructuring_1da5fce6-ea6f-419d-9ec6-79a4a2345f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_28e1d789-ab3c-4591-bfd7-98fcb4ef78c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_OtherRestructuringCosts_28e1d789-ab3c-4591-bfd7-98fcb4ef78c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6f02c477-1fdf-4f54-b130-a03d21a5e5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_RestructuringCharges_6f02c477-1fdf-4f54-b130-a03d21a5e5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4fbf35e-b0d2-489b-b099-94c644c021ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_fb9198c9-af75-4fc5-b318-b267e3d9d7d0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4fbf35e-b0d2-489b-b099-94c644c021ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_69646ae4-7a8c-4c50-bf0d-b5eec79477d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ed8fef82-f2e2-4f53-b9ab-ec58fae5b92a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_69646ae4-7a8c-4c50-bf0d-b5eec79477d9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ed8fef82-f2e2-4f53-b9ab-ec58fae5b92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1d173b07-4884-4d9b-becc-00fa39988472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b3a9d858-eaed-4e24-b63f-bf67d722c808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1d173b07-4884-4d9b-becc-00fa39988472" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b3a9d858-eaed-4e24-b63f-bf67d722c808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_7b0de63e-585d-4ae0-9d6b-9ea6bcfaccdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1d173b07-4884-4d9b-becc-00fa39988472" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_7b0de63e-585d-4ae0-9d6b-9ea6bcfaccdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c1ad8fe5-0396-4535-afff-342c4be621d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1d173b07-4884-4d9b-becc-00fa39988472" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c1ad8fe5-0396-4535-afff-342c4be621d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ed5e745e-a900-4ce2-ac66-dd9dc34d38a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1d173b07-4884-4d9b-becc-00fa39988472" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ed5e745e-a900-4ce2-ac66-dd9dc34d38a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_64a7d405-71ff-457d-a746-08c68a7c6413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_64a7d405-71ff-457d-a746-08c68a7c6413" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5cdafd24-c94c-4414-bc5a-2b1169bd2c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5cdafd24-c94c-4414-bc5a-2b1169bd2c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7df03bf8-a813-4faf-9692-8e353c57f86c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5cdafd24-c94c-4414-bc5a-2b1169bd2c6e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7df03bf8-a813-4faf-9692-8e353c57f86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c41780df-6a53-4636-b25a-9cc5a767010a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7df03bf8-a813-4faf-9692-8e353c57f86c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c41780df-6a53-4636-b25a-9cc5a767010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6cfaa121-d30f-4920-8c04-641e6c2b04d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6cfaa121-d30f-4920-8c04-641e6c2b04d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6cfaa121-d30f-4920-8c04-641e6c2b04d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c5ead521-d9be-4b58-a5fd-0d7d16097a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c5ead521-d9be-4b58-a5fd-0d7d16097a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_90a21843-c5e3-43b5-908d-966d97cbb54d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_90a21843-c5e3-43b5-908d-966d97cbb54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_905613e0-3b79-4d5a-a288-f6bdd81e0cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_406fdd73-f4b1-44ae-a16c-75e576f2a308" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_905613e0-3b79-4d5a-a288-f6bdd81e0cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3dcb7efc-6712-4ac5-950a-4e322e9a6204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3dcb7efc-6712-4ac5-950a-4e322e9a6204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_faf3f81a-06a9-41a6-b14e-ddbe021c1bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3dcb7efc-6712-4ac5-950a-4e322e9a6204" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_faf3f81a-06a9-41a6-b14e-ddbe021c1bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_1b447502-99a2-4e0a-a8fc-e60736642245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_faf3f81a-06a9-41a6-b14e-ddbe021c1bee" xlink:to="loc_us-gaap_CurrencySwapMember_1b447502-99a2-4e0a-a8fc-e60736642245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_6c8a7aae-ac5b-4da8-98ea-53bafb4529ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_faf3f81a-06a9-41a6-b14e-ddbe021c1bee" xlink:to="loc_us-gaap_ForeignExchangeContractMember_6c8a7aae-ac5b-4da8-98ea-53bafb4529ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ca58a1d3-a823-4f93-93ce-825bad26fdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ca58a1d3-a823-4f93-93ce-825bad26fdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cd36a1d5-91bc-415e-83be-540f7c25827a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ca58a1d3-a823-4f93-93ce-825bad26fdbc" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cd36a1d5-91bc-415e-83be-540f7c25827a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_21d0d594-91fb-4687-b659-14ea8c7bf18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_cd36a1d5-91bc-415e-83be-540f7c25827a" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_21d0d594-91fb-4687-b659-14ea8c7bf18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_45e4f20d-cad4-4bc3-991c-d54d2f53e0c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_HedgingDesignationAxis_45e4f20d-cad4-4bc3-991c-d54d2f53e0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_83cd343f-20e5-44bb-83ba-e4abc1ab2a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_45e4f20d-cad4-4bc3-991c-d54d2f53e0c5" xlink:to="loc_us-gaap_HedgingDesignationDomain_83cd343f-20e5-44bb-83ba-e4abc1ab2a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5ce53ecf-20e2-41a0-94ee-4c5e9c741bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_83cd343f-20e5-44bb-83ba-e4abc1ab2a33" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_5ce53ecf-20e2-41a0-94ee-4c5e9c741bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_d5b8f085-67c1-4358-ab09-13bf4a56a1e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_83cd343f-20e5-44bb-83ba-e4abc1ab2a33" xlink:to="loc_us-gaap_NondesignatedMember_d5b8f085-67c1-4358-ab09-13bf4a56a1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a619c099-93b3-40f1-a691-d3c80c6fd0b5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_srt_LitigationCaseAxis_a619c099-93b3-40f1-a691-d3c80c6fd0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_da992a17-aae3-4289-af9d-b871c83aebcc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a619c099-93b3-40f1-a691-d3c80c6fd0b5" xlink:to="loc_srt_LitigationCaseTypeDomain_da992a17-aae3-4289-af9d-b871c83aebcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_7c803310-7cb7-48aa-beb8-841d054d352a" xlink:href="bhc-20200930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_da992a17-aae3-4289-af9d-b871c83aebcc" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_7c803310-7cb7-48aa-beb8-841d054d352a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_ebfb4030-0b25-4cba-9cc0-d39826b58def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_LitigationStatusAxis_ebfb4030-0b25-4cba-9cc0-d39826b58def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ff0e7707-d899-48e2-88db-05c90feb7114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_ebfb4030-0b25-4cba-9cc0-d39826b58def" xlink:to="loc_us-gaap_LitigationStatusDomain_ff0e7707-d899-48e2-88db-05c90feb7114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_171cffef-768c-4793-8c48-eed965754660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_ff0e7707-d899-48e2-88db-05c90feb7114" xlink:to="loc_us-gaap_SettledLitigationMember_171cffef-768c-4793-8c48-eed965754660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ded20dbb-347d-4a10-aeb8-2c96c99546ff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_srt_StatementGeographicalAxis_ded20dbb-347d-4a10-aeb8-2c96c99546ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fff229ff-e51e-4282-9306-ed8751962611" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ded20dbb-347d-4a10-aeb8-2c96c99546ff" xlink:to="loc_srt_SegmentGeographicalDomain_fff229ff-e51e-4282-9306-ed8751962611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_e222d0d7-b2b9-43eb-927d-9051eaf61562" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fff229ff-e51e-4282-9306-ed8751962611" xlink:to="loc_stpr_NJ_e222d0d7-b2b9-43eb-927d-9051eaf61562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_300bfaac-cecf-4fd4-a099-56772d97a209" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_100c0fdd-8ed5-4e01-ae58-b5ea7e75b4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_100c0fdd-8ed5-4e01-ae58-b5ea7e75b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure_6618cf94-8833-404f-800b-2d909afe8b3e" xlink:href="bhc-20200930.xsd#bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure_6618cf94-8833-404f-800b-2d909afe8b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_616f19ef-9614-4881-b31c-61afc0072dba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_afc7901b-ca50-4e24-87e4-c0666b644a32" xlink:to="loc_us-gaap_DerivativeAssets_616f19ef-9614-4881-b31c-61afc0072dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e576abe6-4104-40b8-8a54-a70e7990635f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e576abe6-4104-40b8-8a54-a70e7990635f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_e543e8fa-a95d-4f15-b2b4-351c1974cec2" xlink:href="bhc-20200930.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e576abe6-4104-40b8-8a54-a70e7990635f" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_e543e8fa-a95d-4f15-b2b4-351c1974cec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8991d9e1-5112-4c41-a15e-14b2a0dbdec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e576abe6-4104-40b8-8a54-a70e7990635f" xlink:to="loc_us-gaap_DerivativeLiabilities_8991d9e1-5112-4c41-a15e-14b2a0dbdec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_3377d76e-063f-4e0a-8958-0d91af63912f" xlink:href="bhc-20200930.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_3377d76e-063f-4e0a-8958-0d91af63912f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_10207bd0-8b14-4ba9-8789-de9c013add15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3c3922d1-f733-4d84-8239-a820e279d61d" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_10207bd0-8b14-4ba9-8789-de9c013add15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dc10d113-0942-4e8f-afb1-3957f44280f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dc10d113-0942-4e8f-afb1-3957f44280f8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f45c544c-651f-47df-a1f6-e5f75f02c935" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f45c544c-651f-47df-a1f6-e5f75f02c935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_80c21cce-5f87-4459-8bf8-0f76e96182b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_f45c544c-651f-47df-a1f6-e5f75f02c935" xlink:to="loc_us-gaap_HedgingRelationshipDomain_80c21cce-5f87-4459-8bf8-0f76e96182b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_e8a3a66d-5a6b-4266-91fd-42dc87a5d8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_80c21cce-5f87-4459-8bf8-0f76e96182b2" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_e8a3a66d-5a6b-4266-91fd-42dc87a5d8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_67330f16-099d-4795-ba1f-9e8a0ff462f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_67330f16-099d-4795-ba1f-9e8a0ff462f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5696d976-06ad-4171-a868-3c2d5c7ba6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_67330f16-099d-4795-ba1f-9e8a0ff462f0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5696d976-06ad-4171-a868-3c2d5c7ba6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_36e3d29b-ad3a-4df0-966f-9a60c3733858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_5696d976-06ad-4171-a868-3c2d5c7ba6e3" xlink:to="loc_us-gaap_CurrencySwapMember_36e3d29b-ad3a-4df0-966f-9a60c3733858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_213d4fe0-564a-4d38-9dc5-86df91df54f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:to="loc_us-gaap_HedgingDesignationAxis_213d4fe0-564a-4d38-9dc5-86df91df54f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f8ab8de1-112c-4612-a72c-9ec471a00f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_213d4fe0-564a-4d38-9dc5-86df91df54f1" xlink:to="loc_us-gaap_HedgingDesignationDomain_f8ab8de1-112c-4612-a72c-9ec471a00f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d72d8a4c-b310-441b-9d57-4da004f7848a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_f8ab8de1-112c-4612-a72c-9ec471a00f9a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d72d8a4c-b310-441b-9d57-4da004f7848a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9c47ab12-8aa4-43fe-8aa1-543240404f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9c47ab12-8aa4-43fe-8aa1-543240404f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_186e571c-5ccf-4759-aa94-008dda75be28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9c47ab12-8aa4-43fe-8aa1-543240404f49" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_186e571c-5ccf-4759-aa94-008dda75be28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_50b2081d-8f02-4aa7-83cf-96d7a0c7d066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_186e571c-5ccf-4759-aa94-008dda75be28" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_50b2081d-8f02-4aa7-83cf-96d7a0c7d066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e92aaa08-76bd-412d-afde-b42de57a2ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_186e571c-5ccf-4759-aa94-008dda75be28" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_e92aaa08-76bd-412d-afde-b42de57a2ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93651f76-ea5f-429f-b03d-9f9771fcb434" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e9228edb-5e6a-4bab-9884-9481a918585f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e9228edb-5e6a-4bab-9884-9481a918585f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_987dba5d-b002-451b-95d7-bf7c8d48d572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_987dba5d-b002-451b-95d7-bf7c8d48d572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_bb94a222-6ae6-4b31-9d28-1497c67550cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_22a41e63-b3f1-464a-825a-e61fa59375cc" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_bb94a222-6ae6-4b31-9d28-1497c67550cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_701ccbae-482b-4ef2-8c30-4ec4c387e8ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_701ccbae-482b-4ef2-8c30-4ec4c387e8ea" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6f9465a0-d4a5-40a1-8dda-71399a430793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6f9465a0-d4a5-40a1-8dda-71399a430793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4940a09a-adda-4798-b8f1-3bcbccaba931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_6f9465a0-d4a5-40a1-8dda-71399a430793" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4940a09a-adda-4798-b8f1-3bcbccaba931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_dac56478-ae58-481b-947f-83b71ac775e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_4940a09a-adda-4798-b8f1-3bcbccaba931" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_dac56478-ae58-481b-947f-83b71ac775e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a9f3ab15-bc7b-4787-bddf-3591635bbb77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a9f3ab15-bc7b-4787-bddf-3591635bbb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b1a5957a-f04b-4878-b322-29015a251e38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a9f3ab15-bc7b-4787-bddf-3591635bbb77" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b1a5957a-f04b-4878-b322-29015a251e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_101c70c0-09c9-47af-a53f-91630ba3fe4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b1a5957a-f04b-4878-b322-29015a251e38" xlink:to="loc_us-gaap_CurrencySwapMember_101c70c0-09c9-47af-a53f-91630ba3fe4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7c3936cc-4db6-44fb-a8ad-4161adf68b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:to="loc_us-gaap_HedgingDesignationAxis_7c3936cc-4db6-44fb-a8ad-4161adf68b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7666f6d6-8478-4e9a-9387-8c8f88e63ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7c3936cc-4db6-44fb-a8ad-4161adf68b28" xlink:to="loc_us-gaap_HedgingDesignationDomain_7666f6d6-8478-4e9a-9387-8c8f88e63ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9bb433d2-0225-4993-a6a4-dae7de9ea356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7666f6d6-8478-4e9a-9387-8c8f88e63ac8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9bb433d2-0225-4993-a6a4-dae7de9ea356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_62e4291f-6384-4a35-b245-c46bd21234dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_62e4291f-6384-4a35-b245-c46bd21234dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eb353ae9-dc3b-4bf5-b024-31385d523c79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_62e4291f-6384-4a35-b245-c46bd21234dc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eb353ae9-dc3b-4bf5-b024-31385d523c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_54c1222b-3358-4228-96ea-2f0cfe45e3f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb353ae9-dc3b-4bf5-b024-31385d523c79" xlink:to="loc_us-gaap_InterestExpenseMember_54c1222b-3358-4228-96ea-2f0cfe45e3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ca6fa39-649c-45f6-865c-d208ef64d0e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_44a055cd-3288-4375-ab02-d43e76f8fa37" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ca6fa39-649c-45f6-865c-d208ef64d0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_56aa75db-525a-4ecf-b589-d11f1d02d182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ca6fa39-649c-45f6-865c-d208ef64d0e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_56aa75db-525a-4ecf-b589-d11f1d02d182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_04ac2a49-7e9d-470c-8dc2-f4a25735cb10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ca6fa39-649c-45f6-865c-d208ef64d0e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_04ac2a49-7e9d-470c-8dc2-f4a25735cb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_365f6e4a-ce63-4c64-881c-9408a3e31832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30e904d2-d58b-4def-978f-2119d3fcfe7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_365f6e4a-ce63-4c64-881c-9408a3e31832" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30e904d2-d58b-4def-978f-2119d3fcfe7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_92694260-507b-408e-9990-b0a9b2ca8b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30e904d2-d58b-4def-978f-2119d3fcfe7b" xlink:to="loc_us-gaap_HedgingDesignationAxis_92694260-507b-408e-9990-b0a9b2ca8b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_45d4c55a-49c2-4501-a27f-f41e4a88822b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_92694260-507b-408e-9990-b0a9b2ca8b4c" xlink:to="loc_us-gaap_HedgingDesignationDomain_45d4c55a-49c2-4501-a27f-f41e4a88822b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_f8eb7387-db4d-4e59-a356-bb26954cd495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_45d4c55a-49c2-4501-a27f-f41e4a88822b" xlink:to="loc_us-gaap_NondesignatedMember_f8eb7387-db4d-4e59-a356-bb26954cd495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0b4e5965-4b7d-4049-bc60-5ba051350316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30e904d2-d58b-4def-978f-2119d3fcfe7b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0b4e5965-4b7d-4049-bc60-5ba051350316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_381f9625-46f2-4a77-9383-86a79f9f3a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0b4e5965-4b7d-4049-bc60-5ba051350316" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_381f9625-46f2-4a77-9383-86a79f9f3a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_049163ab-bad0-4bab-8210-3f88198f778b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_381f9625-46f2-4a77-9383-86a79f9f3a3c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_049163ab-bad0-4bab-8210-3f88198f778b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_30e904d2-d58b-4def-978f-2119d3fcfe7b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_40a3ba0a-7ac8-453d-b456-943ee55d4380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_40a3ba0a-7ac8-453d-b456-943ee55d4380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_81f3a7d2-d001-4114-a8f9-59ed267c15c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeLiabilities_81f3a7d2-d001-4114-a8f9-59ed267c15c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_eb35d4b7-4631-4942-b634-70a24c0cabe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_eb35d4b7-4631-4942-b634-70a24c0cabe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7c695ffc-ced9-4f18-930b-46dba96c028c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7c695ffc-ced9-4f18-930b-46dba96c028c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_db4c7496-ceca-4205-9e1a-99e62e97cecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_db4c7496-ceca-4205-9e1a-99e62e97cecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_f935989c-2fa0-48ca-b43a-cc4125e6f60f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3afd1464-20ab-4612-98fd-5d5c39eebed0" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_f935989c-2fa0-48ca-b43a-cc4125e6f60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1297698b-2ca5-4c84-90c9-504bc1e56555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1297698b-2ca5-4c84-90c9-504bc1e56555" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48152d49-3689-43c0-9e95-94caf60a68ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48152d49-3689-43c0-9e95-94caf60a68ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b1869682-ed70-42e7-a621-94815b5e39ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48152d49-3689-43c0-9e95-94caf60a68ab" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b1869682-ed70-42e7-a621-94815b5e39ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6eaef6ec-530c-4be3-a261-6d48f02947a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b1869682-ed70-42e7-a621-94815b5e39ac" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6eaef6ec-530c-4be3-a261-6d48f02947a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_9f1218ae-49de-4417-943b-4892c5def519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_9f1218ae-49de-4417-943b-4892c5def519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_07dae508-d9f2-475b-85cc-de86b2a9a3e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_9f1218ae-49de-4417-943b-4892c5def519" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_07dae508-d9f2-475b-85cc-de86b2a9a3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_53f3e300-c863-410b-ac4d-1ac04d05dab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07dae508-d9f2-475b-85cc-de86b2a9a3e7" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_53f3e300-c863-410b-ac4d-1ac04d05dab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_5b4254ca-fd4e-4608-b376-36ea3b76887b" xlink:href="bhc-20200930.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07dae508-d9f2-475b-85cc-de86b2a9a3e7" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_5b4254ca-fd4e-4608-b376-36ea3b76887b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fd94332-c41c-4c51-904b-bca9fc3bfc26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fd94332-c41c-4c51-904b-bca9fc3bfc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4496a168-4f3e-446f-b261-52a8a24b9737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7fd94332-c41c-4c51-904b-bca9fc3bfc26" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4496a168-4f3e-446f-b261-52a8a24b9737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9f66618c-8d59-42ea-baeb-77196bd79ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4496a168-4f3e-446f-b261-52a8a24b9737" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9f66618c-8d59-42ea-baeb-77196bd79ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_16170d49-6515-41fa-a4ac-a72d7bca20dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:to="loc_srt_RangeAxis_16170d49-6515-41fa-a4ac-a72d7bca20dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db1fdd82-8318-4a2e-9f4e-46f1027da35b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_16170d49-6515-41fa-a4ac-a72d7bca20dc" xlink:to="loc_srt_RangeMember_db1fdd82-8318-4a2e-9f4e-46f1027da35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_72ebb012-909c-4631-a94a-1a41d5617996" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_db1fdd82-8318-4a2e-9f4e-46f1027da35b" xlink:to="loc_srt_MinimumMember_72ebb012-909c-4631-a94a-1a41d5617996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_317322bf-84ec-48f6-b3c4-000b3c3dcbe0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_db1fdd82-8318-4a2e-9f4e-46f1027da35b" xlink:to="loc_srt_MaximumMember_317322bf-84ec-48f6-b3c4-000b3c3dcbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c91ba5f6-ec13-4140-8f20-32cebce17957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_242de7bb-bd3e-4444-8b58-0e246356229b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c91ba5f6-ec13-4140-8f20-32cebce17957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_711a1045-c97c-4925-af9f-5f0380d30a3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c91ba5f6-ec13-4140-8f20-32cebce17957" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_711a1045-c97c-4925-af9f-5f0380d30a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_59589bc7-b847-4275-812a-aec5bb5d6dcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2da34501-44a7-438b-a6b0-9176a70d187a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_59589bc7-b847-4275-812a-aec5bb5d6dcb" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2da34501-44a7-438b-a6b0-9176a70d187a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_43326199-68dc-4c1b-9e7d-a926bc39b8de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2da34501-44a7-438b-a6b0-9176a70d187a" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_43326199-68dc-4c1b-9e7d-a926bc39b8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c36cfc74-7013-4564-9f18-9b3ada6344a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_43326199-68dc-4c1b-9e7d-a926bc39b8de" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c36cfc74-7013-4564-9f18-9b3ada6344a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_4ec2db58-3451-484a-9835-bc98f8a5549a" xlink:href="bhc-20200930.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c36cfc74-7013-4564-9f18-9b3ada6344a0" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_4ec2db58-3451-484a-9835-bc98f8a5549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_9b645577-418f-4769-bfb0-f409d23c040a" xlink:href="bhc-20200930.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c36cfc74-7013-4564-9f18-9b3ada6344a0" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_9b645577-418f-4769-bfb0-f409d23c040a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_87da4160-c4eb-45b2-844f-2edb9c5fe013" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2da34501-44a7-438b-a6b0-9176a70d187a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_87da4160-c4eb-45b2-844f-2edb9c5fe013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_87da4160-c4eb-45b2-844f-2edb9c5fe013" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f5b114f1-bf85-4c4b-ac26-7f1caba736dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f5b114f1-bf85-4c4b-ac26-7f1caba736dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a9c4c801-aec4-48bc-a045-b3942450cd64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a9c4c801-aec4-48bc-a045-b3942450cd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c25a6e39-ed67-4858-962a-f9fad1d42a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c25a6e39-ed67-4858-962a-f9fad1d42a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0a82a3b8-86e6-4b43-842f-736c3d480d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0a82a3b8-86e6-4b43-842f-736c3d480d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fb12d7dc-269d-4b2b-b185-4955c4403d24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_fb12d7dc-269d-4b2b-b185-4955c4403d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3f4be04e-ab7c-4ccf-94b2-f292ca9657da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_355f17fe-6569-4aef-800b-c8f3a5ce4805" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3f4be04e-ab7c-4ccf-94b2-f292ca9657da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_390fbdbb-8db6-48ff-91e5-621d89b8eed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d009d3c0-bf4f-4dbb-acdb-8c76759f726e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_390fbdbb-8db6-48ff-91e5-621d89b8eed2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d009d3c0-bf4f-4dbb-acdb-8c76759f726e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6517e7a-ce7f-460f-be17-bb67d6596e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d009d3c0-bf4f-4dbb-acdb-8c76759f726e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6517e7a-ce7f-460f-be17-bb67d6596e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_436bc20d-fa98-411d-b50b-439052f5594c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6517e7a-ce7f-460f-be17-bb67d6596e02" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_436bc20d-fa98-411d-b50b-439052f5594c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_5b6965fc-fa4a-499d-83ef-ef98913f09db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_436bc20d-fa98-411d-b50b-439052f5594c" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_5b6965fc-fa4a-499d-83ef-ef98913f09db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3c9e367f-7350-4638-8a38-a131f01e62cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d009d3c0-bf4f-4dbb-acdb-8c76759f726e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3c9e367f-7350-4638-8a38-a131f01e62cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_3c9e367f-7350-4638-8a38-a131f01e62cb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e9b8e2eb-37ff-420a-8e6a-c75db0ebb4fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e9b8e2eb-37ff-420a-8e6a-c75db0ebb4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_132d5dd0-4be2-4a4b-9dca-687d59cddbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_132d5dd0-4be2-4a4b-9dca-687d59cddbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_72c246ad-6b59-422b-811d-c9fdea267bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_96d8a8a1-3751-4fa5-9bf1-3bd591ba1083" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_72c246ad-6b59-422b-811d-c9fdea267bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ff7e6d1-9633-4ca7-88a4-a0d2b14473db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d009d3c0-bf4f-4dbb-acdb-8c76759f726e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ff7e6d1-9633-4ca7-88a4-a0d2b14473db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_c14f4594-885a-438d-8e60-8eaa0056b4c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9ff7e6d1-9633-4ca7-88a4-a0d2b14473db" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_c14f4594-885a-438d-8e60-8eaa0056b4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_a43842cb-378c-471c-bd2b-3e7ca15eb53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_c14f4594-885a-438d-8e60-8eaa0056b4c3" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_a43842cb-378c-471c-bd2b-3e7ca15eb53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c2d54280-f455-40a8-9306-f6afc37e2761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c03a39e8-fca9-4924-87fd-73cbb986435b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c2d54280-f455-40a8-9306-f6afc37e2761" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c03a39e8-fca9-4924-87fd-73cbb986435b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888f8eae-4fd9-4141-a319-c3845ea959a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c03a39e8-fca9-4924-87fd-73cbb986435b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888f8eae-4fd9-4141-a319-c3845ea959a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e638fa3-81ab-404a-a348-0aae98da0c92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_888f8eae-4fd9-4141-a319-c3845ea959a7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e638fa3-81ab-404a-a348-0aae98da0c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_d8fd57f5-1822-4170-ab7c-a522a520a9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8e638fa3-81ab-404a-a348-0aae98da0c92" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_d8fd57f5-1822-4170-ab7c-a522a520a9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23401dca-8c12-4575-a159-a60fdd913011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c03a39e8-fca9-4924-87fd-73cbb986435b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23401dca-8c12-4575-a159-a60fdd913011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2416e0b1-bad2-409a-935e-a6d8d6568b8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_23401dca-8c12-4575-a159-a60fdd913011" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2416e0b1-bad2-409a-935e-a6d8d6568b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_be20f9a2-0b0f-4c1f-b51b-86ed011f70cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2416e0b1-bad2-409a-935e-a6d8d6568b8f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_be20f9a2-0b0f-4c1f-b51b-86ed011f70cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86198869-624e-45f0-b2a3-bcf40b80d9df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c03a39e8-fca9-4924-87fd-73cbb986435b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86198869-624e-45f0-b2a3-bcf40b80d9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_2bb80dff-9bfc-49e5-b4fe-28aa039203ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86198869-624e-45f0-b2a3-bcf40b80d9df" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_2bb80dff-9bfc-49e5-b4fe-28aa039203ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_634cf896-5b8b-472c-bc34-ded7ea8a3f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_86198869-624e-45f0-b2a3-bcf40b80d9df" xlink:to="loc_us-gaap_DebtInstrumentFairValue_634cf896-5b8b-472c-bc34-ded7ea8a3f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20200930.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6cc99669-2a6e-482f-aff6-2f9a59f1ab16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_295ac604-0cb7-4c8f-8009-e790de74482e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6cc99669-2a6e-482f-aff6-2f9a59f1ab16" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_295ac604-0cb7-4c8f-8009-e790de74482e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5d875781-80d2-4a4d-a69b-d2f4e1a7ee13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_771b2f68-4e22-4817-a237-3f3deef604b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5d875781-80d2-4a4d-a69b-d2f4e1a7ee13" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_771b2f68-4e22-4817-a237-3f3deef604b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_30fe6059-a9c4-4568-adea-c0455a5001b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_31a1059e-54ac-4cf7-800b-06a141d49068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_30fe6059-a9c4-4568-adea-c0455a5001b0" xlink:to="loc_us-gaap_InventoryRawMaterials_31a1059e-54ac-4cf7-800b-06a141d49068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_bbdb0da1-587c-4e55-940f-be418135e101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_30fe6059-a9c4-4568-adea-c0455a5001b0" xlink:to="loc_us-gaap_InventoryWorkInProcess_bbdb0da1-587c-4e55-940f-be418135e101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_0b2f6802-af5f-4db3-b52e-4adfe536ded3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_30fe6059-a9c4-4568-adea-c0455a5001b0" xlink:to="loc_us-gaap_InventoryFinishedGoods_0b2f6802-af5f-4db3-b52e-4adfe536ded3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_753659c7-33e2-48b2-ad34-e2e094948251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_30fe6059-a9c4-4568-adea-c0455a5001b0" xlink:to="loc_us-gaap_InventoryGross_753659c7-33e2-48b2-ad34-e2e094948251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a2fcaac-0b1a-4e61-ad11-c3a75e629480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_78ff14ce-13e3-4b2d-a876-88bb7c0a3f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4a2fcaac-0b1a-4e61-ad11-c3a75e629480" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_78ff14ce-13e3-4b2d-a876-88bb7c0a3f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a4ce58a6-b979-4289-baf1-9bb280d02d95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_86eea7bb-e8a0-44d4-bd09-3c9e1a2d4cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a4ce58a6-b979-4289-baf1-9bb280d02d95" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_86eea7bb-e8a0-44d4-bd09-3c9e1a2d4cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5bdbf442-4041-4f3c-bae5-cd3bf0def19e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a4ce58a6-b979-4289-baf1-9bb280d02d95" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5bdbf442-4041-4f3c-bae5-cd3bf0def19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_714f5bea-067f-47ea-8c39-51a30819ad3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a4ce58a6-b979-4289-baf1-9bb280d02d95" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_714f5bea-067f-47ea-8c39-51a30819ad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1a43033a-800e-4e6a-ae90-7a05028080d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a4ce58a6-b979-4289-baf1-9bb280d02d95" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1a43033a-800e-4e6a-ae90-7a05028080d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6376f9cb-b73e-469a-8da2-9082d982704a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c1b17dec-6799-4b4b-9af2-0ffec70840d0" xlink:href="bhc-20200930.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6376f9cb-b73e-469a-8da2-9082d982704a" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c1b17dec-6799-4b4b-9af2-0ffec70840d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8d400-5c2e-4e71-9bd4-47cd1fc9e00b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c1b17dec-6799-4b4b-9af2-0ffec70840d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8d400-5c2e-4e71-9bd4-47cd1fc9e00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70c8d400-5c2e-4e71-9bd4-47cd1fc9e00b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_e09ef553-e49e-43ef-8e2f-0d511be1ed26" xlink:href="bhc-20200930.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_bhc_ProductBrandsMember_e09ef553-e49e-43ef-8e2f-0d511be1ed26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_27b7fc61-9857-45f9-9a79-480d62203e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_us-gaap_TradeNamesMember_27b7fc61-9857-45f9-9a79-480d62203e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_9abb0daa-1547-4c7a-b86e-0e6d2b95d15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_us-gaap_ContractualRightsMember_9abb0daa-1547-4c7a-b86e-0e6d2b95d15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_350c7dfb-acb1-4ff8-82bc-0876ba24e884" xlink:href="bhc-20200930.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_bhc_PartnerRelationshipsMember_350c7dfb-acb1-4ff8-82bc-0876ba24e884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_26e8d378-aa52-4db0-acb0-149de369a8b7" xlink:href="bhc-20200930.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ba72f02a-cc8b-4c92-b840-d4e5bdd09340" xlink:to="loc_bhc_OutLicensedTechnologyMember_26e8d378-aa52-4db0-acb0-149de369a8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c9f08048-d071-4154-99bd-56ad3ab622cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c1b17dec-6799-4b4b-9af2-0ffec70840d0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c9f08048-d071-4154-99bd-56ad3ab622cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ea8b50be-49b8-42cc-b1ec-90effd83e4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c9f08048-d071-4154-99bd-56ad3ab622cb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ea8b50be-49b8-42cc-b1ec-90effd83e4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_ce63d278-69db-4658-a589-3c5d76b75459" xlink:href="bhc-20200930.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ea8b50be-49b8-42cc-b1ec-90effd83e4f3" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_ce63d278-69db-4658-a589-3c5d76b75459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_d96c7c7c-8f88-4775-acd3-1472b47ef81a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ea8b50be-49b8-42cc-b1ec-90effd83e4f3" xlink:to="loc_us-gaap_TradeNamesMember_d96c7c7c-8f88-4775-acd3-1472b47ef81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:href="bhc-20200930.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_c1b17dec-6799-4b4b-9af2-0ffec70840d0" xlink:to="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9af2c563-30bd-4ee5-a0c5-619d02439306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9af2c563-30bd-4ee5-a0c5-619d02439306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a43eb22e-4f22-42c9-89f7-38b3eb5126c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a43eb22e-4f22-42c9-89f7-38b3eb5126c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21eb3c80-a422-49d1-9bb8-85877d9f6fbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_94b017f8-ef7a-4803-9c55-89509ea648ab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_21eb3c80-a422-49d1-9bb8-85877d9f6fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_80d66d64-934e-4130-983f-07c0b84e5ca0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_80d66d64-934e-4130-983f-07c0b84e5ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b555089b-7cab-4e24-9e9b-59cd419609f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_80d66d64-934e-4130-983f-07c0b84e5ca0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b555089b-7cab-4e24-9e9b-59cd419609f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9750c91e-338e-4db9-9baa-383a408f7066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_e8f91ee9-484a-48b9-960b-de0d2d1b8306" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9750c91e-338e-4db9-9baa-383a408f7066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9c818e07-d6ed-409f-9288-e639486d231f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9750c91e-338e-4db9-9baa-383a408f7066" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_9c818e07-d6ed-409f-9288-e639486d231f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90d9b561-6c6c-4324-bc9d-901ae45dcbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_9750c91e-338e-4db9-9baa-383a408f7066" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90d9b561-6c6c-4324-bc9d-901ae45dcbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_40cf037e-1c41-4196-b01f-abba7c9504e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_40cf037e-1c41-4196-b01f-abba7c9504e3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_756ea664-bac7-4d38-8a31-627ee24c8e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_756ea664-bac7-4d38-8a31-627ee24c8e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51af483c-b68f-4d58-95cf-42b7e18fbc83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_756ea664-bac7-4d38-8a31-627ee24c8e71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51af483c-b68f-4d58-95cf-42b7e18fbc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_df971909-3dc3-4c82-8512-2223260d1cb7" xlink:href="bhc-20200930.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51af483c-b68f-4d58-95cf-42b7e18fbc83" xlink:to="loc_bhc_ProductBrandsMember_df971909-3dc3-4c82-8512-2223260d1cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_e063c07a-0bef-43d9-b5b9-8b8ea805de8d" xlink:href="bhc-20200930.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51af483c-b68f-4d58-95cf-42b7e18fbc83" xlink:to="loc_bhc_DiscontinuedProductLinesMember_e063c07a-0bef-43d9-b5b9-8b8ea805de8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_749de55e-e15e-42e5-8db3-06908e3f764f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_srt_RangeAxis_749de55e-e15e-42e5-8db3-06908e3f764f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cba96f4-d3d8-402e-9569-467b319b5c78" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_749de55e-e15e-42e5-8db3-06908e3f764f" xlink:to="loc_srt_RangeMember_1cba96f4-d3d8-402e-9569-467b319b5c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_639f0f88-e8bd-4358-b5fc-26b7f45b706d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cba96f4-d3d8-402e-9569-467b319b5c78" xlink:to="loc_srt_MaximumMember_639f0f88-e8bd-4358-b5fc-26b7f45b706d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d29d8ef9-0063-43d9-b71c-bada000547e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1cba96f4-d3d8-402e-9569-467b319b5c78" xlink:to="loc_srt_MinimumMember_d29d8ef9-0063-43d9-b71c-bada000547e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_dfb6435e-46bf-48ae-ae64-492777635ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_dfb6435e-46bf-48ae-ae64-492777635ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1acf021e-5aa1-4059-b1c7-226cea045da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dfb6435e-46bf-48ae-ae64-492777635ede" xlink:to="loc_us-gaap_SegmentDomain_1acf021e-5aa1-4059-b1c7-226cea045da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_726f8bda-11cd-4063-a3f2-199f36677fb8" xlink:href="bhc-20200930.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1acf021e-5aa1-4059-b1c7-226cea045da0" xlink:to="loc_bhc_SalixSegmentMember_726f8bda-11cd-4063-a3f2-199f36677fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_8c810610-76ac-482f-b8e5-8d55e9569dbe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_ReportingUnitAxis_8c810610-76ac-482f-b8e5-8d55e9569dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_7fbc21d2-e748-42fc-9963-d388e6dee387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_8c810610-76ac-482f-b8e5-8d55e9569dbe" xlink:to="loc_us-gaap_ReportingUnitDomain_7fbc21d2-e748-42fc-9963-d388e6dee387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportUnitMember_179c90ed-82c8-4a88-a462-bb588a05024a" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsReportUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_7fbc21d2-e748-42fc-9963-d388e6dee387" xlink:to="loc_bhc_OrthoDermatologicsReportUnitMember_179c90ed-82c8-4a88-a462-bb588a05024a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_67392d4c-d21f-4007-a054-93891db23c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_67392d4c-d21f-4007-a054-93891db23c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_783c09b6-72cf-4932-858b-b05006c9e856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_67392d4c-d21f-4007-a054-93891db23c4f" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_783c09b6-72cf-4932-858b-b05006c9e856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_ac629a55-29f9-4796-951e-416cd717bf46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_783c09b6-72cf-4932-858b-b05006c9e856" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_ac629a55-29f9-4796-951e-416cd717bf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4e1a7557-972d-431f-80ed-278d945be186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4e1a7557-972d-431f-80ed-278d945be186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b62b8dc7-7b31-4ea8-8fef-c4eb07e6caf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4e1a7557-972d-431f-80ed-278d945be186" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b62b8dc7-7b31-4ea8-8fef-c4eb07e6caf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_20133bd2-4a5a-4890-abba-86acfb0364bf" xlink:href="bhc-20200930.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b62b8dc7-7b31-4ea8-8fef-c4eb07e6caf7" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_20133bd2-4a5a-4890-abba-86acfb0364bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d00ff1f7-00e6-429b-b8a6-a7334bb74fb1" xlink:to="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_6ea2b2af-4baf-4261-9528-f192b178abdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_6ea2b2af-4baf-4261-9528-f192b178abdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_d3318dce-3ebc-4a4f-87b1-8446eafc3114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_d3318dce-3ebc-4a4f-87b1-8446eafc3114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_bcfc4c95-5ea5-451d-ab55-e424f9d611c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_bcfc4c95-5ea5-451d-ab55-e424f9d611c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_786e6400-5c2b-450f-8ba0-b4d744ef7ff1" xlink:href="bhc-20200930.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_786e6400-5c2b-450f-8ba0-b4d744ef7ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_374522d4-7b35-4533-882d-cee0782ffefa" xlink:href="bhc-20200930.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_374522d4-7b35-4533-882d-cee0782ffefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9ecc3846-53bf-490e-b12d-c572c62ae0d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9ecc3846-53bf-490e-b12d-c572c62ae0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6cd7b9b5-1c64-4388-9f88-43fd1767524e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1a9e6b8b-385a-47bb-a432-225ef30c1e3d" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_6cd7b9b5-1c64-4388-9f88-43fd1767524e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81b8c72b-6ca6-4f1c-9e98-080a1b2deafb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_bdc43740-6c9b-4ec3-babc-3b44a34244f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81b8c72b-6ca6-4f1c-9e98-080a1b2deafb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_bdc43740-6c9b-4ec3-babc-3b44a34244f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_305f8d2f-7afa-48f8-af04-0e8fb93b4726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81b8c72b-6ca6-4f1c-9e98-080a1b2deafb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_305f8d2f-7afa-48f8-af04-0e8fb93b4726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1f2133d3-d5c0-480b-ab0b-120fa410b95e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81b8c72b-6ca6-4f1c-9e98-080a1b2deafb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1f2133d3-d5c0-480b-ab0b-120fa410b95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f3dc5890-28ad-441a-920f-59846a89de94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81b8c72b-6ca6-4f1c-9e98-080a1b2deafb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f3dc5890-28ad-441a-920f-59846a89de94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6711c57d-d7be-4e11-8ae3-19934bce4509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81b8c72b-6ca6-4f1c-9e98-080a1b2deafb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_6711c57d-d7be-4e11-8ae3-19934bce4509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b9d4782e-6864-4045-984b-54609956f078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81b8c72b-6ca6-4f1c-9e98-080a1b2deafb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b9d4782e-6864-4045-984b-54609956f078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9d920deb-3d0c-46e8-82b0-5a7cdb014e6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81b8c72b-6ca6-4f1c-9e98-080a1b2deafb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9d920deb-3d0c-46e8-82b0-5a7cdb014e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1513a226-c574-4645-8da6-b79815fd5bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_81b8c72b-6ca6-4f1c-9e98-080a1b2deafb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1513a226-c574-4645-8da6-b79815fd5bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daaed253-14ae-40ec-829d-92548472de21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_94a4fed7-13c7-47ce-9395-77f9c668f4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_daaed253-14ae-40ec-829d-92548472de21" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_94a4fed7-13c7-47ce-9395-77f9c668f4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e933ebff-e0f3-4dc2-913b-3da77df6ff8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_94a4fed7-13c7-47ce-9395-77f9c668f4b1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e933ebff-e0f3-4dc2-913b-3da77df6ff8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e933ebff-e0f3-4dc2-913b-3da77df6ff8c" xlink:to="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_35d6fdff-2c2b-4221-a0e7-30bf546478f9" xlink:href="bhc-20200930.xsd#bhc_BauschLombInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:to="loc_bhc_BauschLombInternationalMember_35d6fdff-2c2b-4221-a0e7-30bf546478f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_8f3b2ece-0af4-4138-8334-7b711e5446d9" xlink:href="bhc-20200930.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:to="loc_bhc_SalixSegmentMember_8f3b2ece-0af4-4138-8334-7b711e5446d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_31c0487d-492d-4df5-bed0-f906ab018ece" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_31c0487d-492d-4df5-bed0-f906ab018ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_33ee28d2-1d80-443b-8d95-4acbdd7e7708" xlink:href="bhc-20200930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_49367a3e-d3fd-436c-8aa2-4571232c63a8" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_33ee28d2-1d80-443b-8d95-4acbdd7e7708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_0dcf7321-1022-42de-8b7d-b44e1b10fd3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_94a4fed7-13c7-47ce-9395-77f9c668f4b1" xlink:to="loc_us-gaap_GoodwillLineItems_0dcf7321-1022-42de-8b7d-b44e1b10fd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcf7321-1022-42de-8b7d-b44e1b10fd3a" xlink:to="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_eaa046ad-328e-4fcf-8883-9d7c9920105f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_us-gaap_Goodwill_eaa046ad-328e-4fcf-8883-9d7c9920105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_77a99352-142f-4ab3-b4f5-cf9c99e87545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_77a99352-142f-4ab3-b4f5-cf9c99e87545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_8b704bac-3c02-4d52-90d8-01208eac1f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_8b704bac-3c02-4d52-90d8-01208eac1f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4c646985-b398-44f8-bb95-54ba4e6bb733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_4c646985-b398-44f8-bb95-54ba4e6bb733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillReclassifiedDuringPeriod_7e4fc29c-1c6a-4dae-b2b8-9c530c89e07f" xlink:href="bhc-20200930.xsd#bhc_GoodwillReclassifiedDuringPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_bhc_GoodwillReclassifiedDuringPeriod_7e4fc29c-1c6a-4dae-b2b8-9c530c89e07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f04e2394-440a-4879-8f48-34b2f4785b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_52bfb7d1-f1bb-4159-b0a3-3df336c3345a" xlink:to="loc_us-gaap_Goodwill_f04e2394-440a-4879-8f48-34b2f4785b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_01f9cd5f-1ea7-47ba-bd81-e9dadb6be077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0780d0f9-650e-4f77-a787-3074763673b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_01f9cd5f-1ea7-47ba-bd81-e9dadb6be077" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0780d0f9-650e-4f77-a787-3074763673b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_49979cab-3d40-4c44-b8c5-24de6a5f95a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_827390df-0c0d-4e26-8397-b8594c7fbd1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_49979cab-3d40-4c44-b8c5-24de6a5f95a1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_827390df-0c0d-4e26-8397-b8594c7fbd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e0dfd56a-23db-4204-962b-a3cde31b89d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_0a13ccf9-36e0-4926-bbbf-f01b7b2764f6" xlink:href="bhc-20200930.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e0dfd56a-23db-4204-962b-a3cde31b89d3" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_0a13ccf9-36e0-4926-bbbf-f01b7b2764f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_97cbb2f2-572b-44ae-98f0-19ef446c12b1" xlink:href="bhc-20200930.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e0dfd56a-23db-4204-962b-a3cde31b89d3" xlink:to="loc_bhc_AccruedProductRebateCurrent_97cbb2f2-572b-44ae-98f0-19ef446c12b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_fc1cdb32-2486-40f1-8276-0e9fb6cff6ba" xlink:href="bhc-20200930.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e0dfd56a-23db-4204-962b-a3cde31b89d3" xlink:to="loc_bhc_AccruedProductReturnCurrent_fc1cdb32-2486-40f1-8276-0e9fb6cff6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_9aaba455-c666-45c2-a38e-508a3cf42fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e0dfd56a-23db-4204-962b-a3cde31b89d3" xlink:to="loc_us-gaap_InterestPayableCurrent_9aaba455-c666-45c2-a38e-508a3cf42fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6752fc38-0c7a-456b-a617-9add1e29be42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e0dfd56a-23db-4204-962b-a3cde31b89d3" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6752fc38-0c7a-456b-a617-9add1e29be42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_684ce103-8f7f-4420-9ba4-b0a1fa9cbea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e0dfd56a-23db-4204-962b-a3cde31b89d3" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_684ce103-8f7f-4420-9ba4-b0a1fa9cbea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3ca746f4-0cb5-4513-ab30-84f0d6a283aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e0dfd56a-23db-4204-962b-a3cde31b89d3" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3ca746f4-0cb5-4513-ab30-84f0d6a283aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ff32ee10-7d62-4ffa-ac32-b88e43bf14ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e0dfd56a-23db-4204-962b-a3cde31b89d3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ff32ee10-7d62-4ffa-ac32-b88e43bf14ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d187e095-69d7-4503-9809-35a342a9c3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_99a24bd1-5189-4f4f-ba8a-ec2fe593dc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d187e095-69d7-4503-9809-35a342a9c3a1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_99a24bd1-5189-4f4f-ba8a-ec2fe593dc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c702fbc9-c44b-476b-84dc-52553e598554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_e3a2124d-b223-4aae-9277-0a704b3e2df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c702fbc9-c44b-476b-84dc-52553e598554" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_e3a2124d-b223-4aae-9277-0a704b3e2df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_07de1b6c-7835-4f4f-9d36-0b747bc59bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c702fbc9-c44b-476b-84dc-52553e598554" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_07de1b6c-7835-4f4f-9d36-0b747bc59bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3ed50fb0-670f-4c80-9fe7-b023b0caf228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3ed50fb0-670f-4c80-9fe7-b023b0caf228" xlink:to="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_756306c3-84bc-4aba-a714-f38158b49fc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:to="loc_us-gaap_CreditFacilityAxis_756306c3-84bc-4aba-a714-f38158b49fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_da02eee5-76bc-4821-b54c-1c7cf2205385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_756306c3-84bc-4aba-a714-f38158b49fc2" xlink:to="loc_us-gaap_CreditFacilityDomain_da02eee5-76bc-4821-b54c-1c7cf2205385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a28e4419-3ca4-42ac-b79e-468bad4b75dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_da02eee5-76bc-4821-b54c-1c7cf2205385" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a28e4419-3ca4-42ac-b79e-468bad4b75dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e6d6563c-3e95-4ebf-a89b-1dda484f094d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e6d6563c-3e95-4ebf-a89b-1dda484f094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_41d66e37-0817-445c-9414-12b7637cab48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e6d6563c-3e95-4ebf-a89b-1dda484f094d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_41d66e37-0817-445c-9414-12b7637cab48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d4aea9fc-c369-4a69-b575-a2c91f66471e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_41d66e37-0817-445c-9414-12b7637cab48" xlink:to="loc_us-gaap_SecuredDebtMember_d4aea9fc-c369-4a69-b575-a2c91f66471e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_4fbacee1-3796-4c7b-8f3f-3c06d9060c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_41d66e37-0817-445c-9414-12b7637cab48" xlink:to="loc_us-gaap_UnsecuredDebtMember_4fbacee1-3796-4c7b-8f3f-3c06d9060c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_14f44f64-1818-42ee-95d1-e3b330798642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:to="loc_us-gaap_DebtInstrumentAxis_14f44f64-1818-42ee-95d1-e3b330798642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_14f44f64-1818-42ee-95d1-e3b330798642" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_bb2da989-2ac8-448c-ace2-8fe4ac7e0695" xlink:href="bhc-20200930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_bb2da989-2ac8-448c-ace2-8fe4ac7e0695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_02df8a27-ab34-4bca-85bd-bacad8729460" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_02df8a27-ab34-4bca-85bd-bacad8729460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_97518453-1b22-4ec0-ab78-4b12c155e9d4" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_97518453-1b22-4ec0-ab78-4b12c155e9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_a4596cc3-e0d1-44a7-9619-527fc4d108c0" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_a4596cc3-e0d1-44a7-9619-527fc4d108c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_f0428e97-dd38-4ab0-a825-fdeee87aa543" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_f0428e97-dd38-4ab0-a825-fdeee87aa543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_2ba46414-d15a-44b7-bbaf-3ad0f598feaa" xlink:href="bhc-20200930.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_2ba46414-d15a-44b7-bbaf-3ad0f598feaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_bd7ea5e3-240e-42f0-a20a-455ed76e29ee" xlink:href="bhc-20200930.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_bd7ea5e3-240e-42f0-a20a-455ed76e29ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_16b7f753-b1fa-4a67-b89e-c01e22f395b1" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_16b7f753-b1fa-4a67-b89e-c01e22f395b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5875DueMay2023Member_3fd6c17b-abae-49e8-822a-44318e2c71d6" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5875DueMay2023Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes5875DueMay2023Member_3fd6c17b-abae-49e8-822a-44318e2c71d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes450DueMay2023Member_0b7d5983-0de1-46d7-942c-dc3b072f44b5" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes450DueMay2023Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes450DueMay2023Member_0b7d5983-0de1-46d7-942c-dc3b072f44b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_47ad5689-857c-4d7a-a34f-bda230abf2c0" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_47ad5689-857c-4d7a-a34f-bda230abf2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_34ca6438-4b75-4e0c-8ebd-eb71a85e0890" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_34ca6438-4b75-4e0c-8ebd-eb71a85e0890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_4fcc618d-7d2e-4e4e-ac40-103fd22186d5" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_4fcc618d-7d2e-4e4e-ac40-103fd22186d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_5ededdae-e56e-4365-88a9-5cf900811cc4" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_5ededdae-e56e-4365-88a9-5cf900811cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_ffc643c0-556e-4763-831a-7ffc74353195" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_ffc643c0-556e-4763-831a-7ffc74353195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_5014402c-0df6-4d90-8172-ec27927dc543" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_5014402c-0df6-4d90-8172-ec27927dc543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_ae0ad5d7-1f04-4307-9ee4-91bda4de5878" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_ae0ad5d7-1f04-4307-9ee4-91bda4de5878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_35022a6b-2f71-4fc2-8221-fef2903abc5b" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_35022a6b-2f71-4fc2-8221-fef2903abc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_64fbffad-bbcd-4e1e-b825-7020363bea63" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_64fbffad-bbcd-4e1e-b825-7020363bea63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_8725da31-82f8-4b93-bff0-dc63383cf722" xlink:href="bhc-20200930.xsd#bhc_OtherLongTermDebtMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_064eb33a-c7df-4c62-a5be-cfc725c593f1" xlink:to="loc_bhc_OtherLongTermDebtMember_8725da31-82f8-4b93-bff0-dc63383cf722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9d4aa5ec-fb51-4b78-b67b-10948ae78b1b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cef5d64a-7ee7-4c7a-835c-369f2640eaaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_cef5d64a-7ee7-4c7a-835c-369f2640eaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f1ee83ae-6023-42b4-a54b-700bd38c07f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_f1ee83ae-6023-42b4-a54b-700bd38c07f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_013cf1f2-710d-4eb2-a1e2-c4f55555e1c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_LongTermDebt_013cf1f2-710d-4eb2-a1e2-c4f55555e1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5675a3e3-ad64-4f2a-a320-2baef422dc82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_LongTermDebtCurrent_5675a3e3-ad64-4f2a-a320-2baef422dc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_be3f3966-2442-4c4a-b770-ef575516d4bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85acfc60-4587-48da-8794-4aadfb6f53cf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_be3f3966-2442-4c4a-b770-ef575516d4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e67e428a-b0dd-404c-bb1b-36b2442dab22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_1f9e5910-9bf4-4b94-bb5f-79b237011e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e67e428a-b0dd-404c-bb1b-36b2442dab22" xlink:to="loc_us-gaap_DebtInstrumentTable_1f9e5910-9bf4-4b94-bb5f-79b237011e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_27d7d6ca-9a39-4230-9054-63a095655c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f9e5910-9bf4-4b94-bb5f-79b237011e4c" xlink:to="loc_us-gaap_CreditFacilityAxis_27d7d6ca-9a39-4230-9054-63a095655c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bec0b115-a70d-4b7a-9a15-c2825b676b32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_27d7d6ca-9a39-4230-9054-63a095655c28" xlink:to="loc_us-gaap_CreditFacilityDomain_bec0b115-a70d-4b7a-9a15-c2825b676b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_2fd068b3-82e5-4590-b261-9d1420ecb976" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_bec0b115-a70d-4b7a-9a15-c2825b676b32" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_2fd068b3-82e5-4590-b261-9d1420ecb976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_68c3c5f4-e078-4fd3-b713-15ad62b5fa37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_bec0b115-a70d-4b7a-9a15-c2825b676b32" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_68c3c5f4-e078-4fd3-b713-15ad62b5fa37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d0e9a79f-5064-4580-8c68-1a75a95ff063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1f9e5910-9bf4-4b94-bb5f-79b237011e4c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d0e9a79f-5064-4580-8c68-1a75a95ff063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_3f3f8449-57ac-4088-9b2c-a2639096d85b" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0e9a79f-5064-4580-8c68-1a75a95ff063" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_3f3f8449-57ac-4088-9b2c-a2639096d85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_ff34cfb3-f2e7-4b95-9957-66fd9d59ca6f" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d0e9a79f-5064-4580-8c68-1a75a95ff063" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_ff34cfb3-f2e7-4b95-9957-66fd9d59ca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f7e9378d-cc42-4677-930a-728f5203d726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f7e9378d-cc42-4677-930a-728f5203d726" xlink:to="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_d75288c0-9f98-4376-b070-b5167760576c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_us-gaap_CreditFacilityAxis_d75288c0-9f98-4376-b070-b5167760576c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a26561d5-1f3c-485b-9b3f-a8f25466f816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_d75288c0-9f98-4376-b070-b5167760576c" xlink:to="loc_us-gaap_CreditFacilityDomain_a26561d5-1f3c-485b-9b3f-a8f25466f816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2fa5c800-b792-4bd4-9ed8-55ffcfd4c790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a26561d5-1f3c-485b-9b3f-a8f25466f816" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2fa5c800-b792-4bd4-9ed8-55ffcfd4c790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_23a6ca58-5976-4bf4-9efe-00eb4ddaecaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_a26561d5-1f3c-485b-9b3f-a8f25466f816" xlink:to="loc_us-gaap_LetterOfCreditMember_23a6ca58-5976-4bf4-9efe-00eb4ddaecaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af4c7957-6c88-4f40-9dc4-85990890eff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_us-gaap_DebtInstrumentAxis_af4c7957-6c88-4f40-9dc4-85990890eff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_af4c7957-6c88-4f40-9dc4-85990890eff9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_7e743d06-28ff-4069-b9c5-033b4f5e0d4b" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_7e743d06-28ff-4069-b9c5-033b4f5e0d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_d14f477b-66cf-4dc0-b5da-6fc248163e8a" xlink:href="bhc-20200930.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_d14f477b-66cf-4dc0-b5da-6fc248163e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_1be0bfbd-7aff-4287-a378-e70cdac6cf45" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_1be0bfbd-7aff-4287-a378-e70cdac6cf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_316311db-c9c4-4a56-85c1-8c844f3bd959" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_23cb956c-e65d-4b04-8be0-e4d838501297" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_316311db-c9c4-4a56-85c1-8c844f3bd959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f793e17a-cc90-478f-8c6c-b99fd5ab2452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_us-gaap_VariableRateAxis_f793e17a-cc90-478f-8c6c-b99fd5ab2452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_f793e17a-cc90-478f-8c6c-b99fd5ab2452" xlink:to="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_56ce3ca2-afa2-4c38-96a3-1a1fa5acd2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_56ce3ca2-afa2-4c38-96a3-1a1fa5acd2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_adb79af5-addf-419d-9016-b64021553465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_us-gaap_EurodollarMember_adb79af5-addf-419d-9016-b64021553465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember_fc1fe481-0e7c-4947-8ace-dce825579b9f" xlink:href="bhc-20200930.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_bhc_CanadaBankersAcceptanceRateMember_fc1fe481-0e7c-4947-8ace-dce825579b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_48b98c23-b4b4-4c86-9617-7747f73894b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_us-gaap_BaseRateMember_48b98c23-b4b4-4c86-9617-7747f73894b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember_7a5092b8-6b7e-44c9-808a-ad9bdd996042" xlink:href="bhc-20200930.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_c9874d8c-5ed6-484d-bb41-9c571905c3b8" xlink:to="loc_bhc_BaseRateOrPrimeRateMember_7a5092b8-6b7e-44c9-808a-ad9bdd996042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5dd1baa-400e-4365-b3a0-9548a9e0bacd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_srt_RangeAxis_c5dd1baa-400e-4365-b3a0-9548a9e0bacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27097549-a1ab-4377-903e-c0d0e465d66e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c5dd1baa-400e-4365-b3a0-9548a9e0bacd" xlink:to="loc_srt_RangeMember_27097549-a1ab-4377-903e-c0d0e465d66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7df0d951-6b26-444c-a639-c4d6ba606482" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27097549-a1ab-4377-903e-c0d0e465d66e" xlink:to="loc_srt_MinimumMember_7df0d951-6b26-444c-a639-c4d6ba606482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b87b6a2e-e3aa-4b52-b47f-f6667c962107" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_27097549-a1ab-4377-903e-c0d0e465d66e" xlink:to="loc_srt_MaximumMember_b87b6a2e-e3aa-4b52-b47f-f6667c962107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4384dc22-35bc-4e97-9752-94075b4b6c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4384dc22-35bc-4e97-9752-94075b4b6c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d77d9d17-d48c-495b-9604-0b9286ef14d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4384dc22-35bc-4e97-9752-94075b4b6c08" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d77d9d17-d48c-495b-9604-0b9286ef14d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_11f7f0ef-5145-4f22-bc41-cdabd27d538f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d77d9d17-d48c-495b-9604-0b9286ef14d7" xlink:to="loc_us-gaap_SecuredDebtMember_11f7f0ef-5145-4f22-bc41-cdabd27d538f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_a223f9f8-1d50-4ae3-89ee-c20b4084acb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d77d9d17-d48c-495b-9604-0b9286ef14d7" xlink:to="loc_us-gaap_UnsecuredDebtMember_a223f9f8-1d50-4ae3-89ee-c20b4084acb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_cf598173-7975-4a57-883c-58866c427cf7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_660ce00f-43d3-449c-b74d-05774e4708bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_660ce00f-43d3-449c-b74d-05774e4708bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_ed2cb750-39eb-4074-a6d6-f3eeb972fbbb" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_ed2cb750-39eb-4074-a6d6-f3eeb972fbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_dfb77c9c-cc9a-4409-a475-946fab04e36c" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_dfb77c9c-cc9a-4409-a475-946fab04e36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8abccabb-fc9a-4a8f-84ad-376b3ad50c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8abccabb-fc9a-4a8f-84ad-376b3ad50c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c57b93c8-3b85-4788-9928-f8fc117f6b06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c57b93c8-3b85-4788-9928-f8fc117f6b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_ae857b93-e923-4f79-a878-e527fe73f0d2" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet_ae857b93-e923-4f79-a878-e527fe73f0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_1f4a4b91-5c5b-4f9a-8cad-3f4b91ad27f1" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet_1f4a4b91-5c5b-4f9a-8cad-3f4b91ad27f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_34d97977-62bd-4307-a774-6e86d249d5bd" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet_34d97977-62bd-4307-a774-6e86d249d5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_2ba4237e-5103-4c67-bdad-4aace3748681" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet_2ba4237e-5103-4c67-bdad-4aace3748681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ded5e76d-f383-4447-8785-051aaff29104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ded5e76d-f383-4447-8785-051aaff29104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_c136c31a-832d-45d9-8a46-b20d240c0613" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_c136c31a-832d-45d9-8a46-b20d240c0613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_ecc0f426-d710-47fb-a3c3-48e0b8ba4e54" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_ecc0f426-d710-47fb-a3c3-48e0b8ba4e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_dff1f456-cead-4de9-b87b-af84f268bad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_LongTermDebt_dff1f456-cead-4de9-b87b-af84f268bad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f7b2e6d0-6149-441c-9f71-dfbeee2426b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f7b2e6d0-6149-441c-9f71-dfbeee2426b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_46f7eded-2f13-42a0-ac08-baa7422a4b19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_46f7eded-2f13-42a0-ac08-baa7422a4b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_cce180bf-fbfb-40e3-8484-ae1ed101d4bb" xlink:href="bhc-20200930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_cce180bf-fbfb-40e3-8484-ae1ed101d4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_c24c0162-159f-444c-96b2-bd515750a4f7" xlink:href="bhc-20200930.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA_c24c0162-159f-444c-96b2-bd515750a4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_c056eee3-2dff-423a-9f2a-233e1d6d0b7d" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_c056eee3-2dff-423a-9f2a-233e1d6d0b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_1fe7153f-11ee-4622-917a-dc1242cddd67" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_1fe7153f-11ee-4622-917a-dc1242cddd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_490e1924-fcc3-4bd9-87fd-3435749270ac" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3d42828f-8d27-41d1-a7df-36aa5edcb0d9" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_490e1924-fcc3-4bd9-87fd-3435749270ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ee9e67e5-0ee5-4b91-a2d3-01e77d17c8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_aac94320-1220-49cf-99d4-a0bacc3b16aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ee9e67e5-0ee5-4b91-a2d3-01e77d17c8c9" xlink:to="loc_us-gaap_DebtInstrumentTable_aac94320-1220-49cf-99d4-a0bacc3b16aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e6b48dda-2171-4198-97cd-a8917e69f496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aac94320-1220-49cf-99d4-a0bacc3b16aa" xlink:to="loc_us-gaap_DebtInstrumentAxis_e6b48dda-2171-4198-97cd-a8917e69f496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e6b48dda-2171-4198-97cd-a8917e69f496" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_7c4168b0-150f-433c-835b-fc5954b26b6d" xlink:href="bhc-20200930.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_7c4168b0-150f-433c-835b-fc5954b26b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_ddce5228-bcb2-4ae6-91f0-beea62246ad5" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_ddce5228-bcb2-4ae6-91f0-beea62246ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5875DueMay2023Member_57c2835d-925a-42cc-9ab9-2924599ebff3" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5875DueMay2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorNotes5875DueMay2023Member_57c2835d-925a-42cc-9ab9-2924599ebff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_e218ba79-c294-42c5-8e10-7fb9b3145b5c" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5.625PercentDueDecember2021Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_e218ba79-c294-42c5-8e10-7fb9b3145b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_7ac63515-ff9e-4b0c-8cc1-02f57ee23d94" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_7ac63515-ff9e-4b0c-8cc1-02f57ee23d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_d67d1a23-c781-453b-b018-81907859c9ef" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4a658876-61f8-48ef-88e9-c8093e66456d" xlink:to="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_d67d1a23-c781-453b-b018-81907859c9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e63aec2c-c198-4566-b6b4-695f6dfa3eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aac94320-1220-49cf-99d4-a0bacc3b16aa" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e63aec2c-c198-4566-b6b4-695f6dfa3eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_896837c2-5ec0-4897-8769-4276a1fe0499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e63aec2c-c198-4566-b6b4-695f6dfa3eea" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_896837c2-5ec0-4897-8769-4276a1fe0499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_5b5e390f-27ad-41e3-86a1-ffc5657dd12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_896837c2-5ec0-4897-8769-4276a1fe0499" xlink:to="loc_us-gaap_SeniorNotesMember_5b5e390f-27ad-41e3-86a1-ffc5657dd12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_70b7ab4d-957c-45f9-a488-8dfb2b3275e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_896837c2-5ec0-4897-8769-4276a1fe0499" xlink:to="loc_us-gaap_UnsecuredDebtMember_70b7ab4d-957c-45f9-a488-8dfb2b3275e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aac94320-1220-49cf-99d4-a0bacc3b16aa" xlink:to="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_98c32d10-1824-42d9-9b01-4f5155f40930" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_98c32d10-1824-42d9-9b01-4f5155f40930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_84b06420-48f7-41b5-a3e4-cabab1a5bbf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_84b06420-48f7-41b5-a3e4-cabab1a5bbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_19628d44-b4f3-4b8b-a0b3-fa7874dd7177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_19628d44-b4f3-4b8b-a0b3-fa7874dd7177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_84d682ba-bb7e-404d-abae-2f0714c736f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_94c769be-ec67-4bd9-90b6-f35c693f1415" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_84d682ba-bb7e-404d-abae-2f0714c736f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_04c9013a-ab34-454d-8577-7b593ac218dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_04c9013a-ab34-454d-8577-7b593ac218dd" xlink:to="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3883e554-55f8-4178-90f1-964e2630030a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3883e554-55f8-4178-90f1-964e2630030a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_076e3d6f-4cb4-4158-9c14-491e9efb33ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3883e554-55f8-4178-90f1-964e2630030a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_076e3d6f-4cb4-4158-9c14-491e9efb33ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2aadace3-133a-4e46-9144-13e9ae0913c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_076e3d6f-4cb4-4158-9c14-491e9efb33ed" xlink:to="loc_us-gaap_UnsecuredDebtMember_2aadace3-133a-4e46-9144-13e9ae0913c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_75779b8a-5aab-41aa-8704-4453ac65cd9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_076e3d6f-4cb4-4158-9c14-491e9efb33ed" xlink:to="loc_us-gaap_SecuredDebtMember_75779b8a-5aab-41aa-8704-4453ac65cd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6005f907-1985-45cf-802f-eda04cc56e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_us-gaap_DebtInstrumentAxis_6005f907-1985-45cf-802f-eda04cc56e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6005f907-1985-45cf-802f-eda04cc56e92" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_03141143-00c5-4bd0-b783-cc47d2d1c3ca" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_03141143-00c5-4bd0-b783-cc47d2d1c3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_ee7bca17-60db-4c81-9879-4ae114caa1a2" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_ee7bca17-60db-4c81-9879-4ae114caa1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_f63c970b-4663-4ef7-a237-35da67456beb" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_f63c970b-4663-4ef7-a237-35da67456beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5875DueMay2023Member_a87be135-20d2-48b6-8f8d-539bed12474d" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5875DueMay2023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes5875DueMay2023Member_a87be135-20d2-48b6-8f8d-539bed12474d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_cadd5f6e-7bd8-459c-97d8-0526969edd59" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_cadd5f6e-7bd8-459c-97d8-0526969edd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_2ec53454-e4a6-4089-bc19-1e837380ac5d" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_2ec53454-e4a6-4089-bc19-1e837380ac5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_2ce60fe9-047c-46d7-a133-ffe93d278349" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_2ce60fe9-047c-46d7-a133-ffe93d278349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_8e27d390-cf4f-4ce3-9df9-3a34986f30be" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_8e27d390-cf4f-4ce3-9df9-3a34986f30be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_48285e1e-d1a7-4623-a494-4869bf29fe02" xlink:href="bhc-20200930.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_48285e1e-d1a7-4623-a494-4869bf29fe02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_d37c2462-6867-4d16-9700-2ed3f01e13ac" xlink:href="bhc-20200930.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cd62a6b-85e2-47a8-ae0b-32143c0f78bc" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_d37c2462-6867-4d16-9700-2ed3f01e13ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_30a884bd-2d87-435b-b187-98cae0554d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_us-gaap_LitigationStatusAxis_30a884bd-2d87-435b-b187-98cae0554d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_1adca61f-aabb-4287-baed-3207f51a7a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_30a884bd-2d87-435b-b187-98cae0554d0d" xlink:to="loc_us-gaap_LitigationStatusDomain_1adca61f-aabb-4287-baed-3207f51a7a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_25b5c548-305d-40e3-8ba2-aedda1871684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_1adca61f-aabb-4287-baed-3207f51a7a47" xlink:to="loc_us-gaap_SettledLitigationMember_25b5c548-305d-40e3-8ba2-aedda1871684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_17e7cf13-2518-4038-a85e-341b477c2c4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_srt_LitigationCaseAxis_17e7cf13-2518-4038-a85e-341b477c2c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d1c0df08-4e2f-4d6e-b314-3eceb6c83d22" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_17e7cf13-2518-4038-a85e-341b477c2c4e" xlink:to="loc_srt_LitigationCaseTypeDomain_d1c0df08-4e2f-4d6e-b314-3eceb6c83d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_8ecf02c6-af86-46a5-bf8a-394b5f7f719b" xlink:href="bhc-20200930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d1c0df08-4e2f-4d6e-b314-3eceb6c83d22" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_8ecf02c6-af86-46a5-bf8a-394b5f7f719b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b3d8ffc6-c7bd-443c-b8ea-770c7feea9c2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_srt_StatementGeographicalAxis_b3d8ffc6-c7bd-443c-b8ea-770c7feea9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a3fa2a46-5c8f-44da-8047-4ac829e3b5a9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b3d8ffc6-c7bd-443c-b8ea-770c7feea9c2" xlink:to="loc_srt_SegmentGeographicalDomain_a3fa2a46-5c8f-44da-8047-4ac829e3b5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_bee607c6-e6be-4ea6-9f9c-d58ed7601b6e" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a3fa2a46-5c8f-44da-8047-4ac829e3b5a9" xlink:to="loc_stpr_NJ_bee607c6-e6be-4ea6-9f9c-d58ed7601b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_86adb035-bb05-49d4-8440-b06799afc77e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_86adb035-bb05-49d4-8440-b06799afc77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ace62224-0a8e-4f49-928d-a31f1fe83ab6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_86adb035-bb05-49d4-8440-b06799afc77e" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ace62224-0a8e-4f49-928d-a31f1fe83ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1d0aef21-b97f-46f5-8c6b-8b45506d3691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ace62224-0a8e-4f49-928d-a31f1fe83ab6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1d0aef21-b97f-46f5-8c6b-8b45506d3691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_77804e5d-ea1d-4d86-b376-dfa4c336e709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_ace62224-0a8e-4f49-928d-a31f1fe83ab6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_77804e5d-ea1d-4d86-b376-dfa4c336e709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_212a9cac-b24f-45c7-872f-3617b0538615" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_srt_RangeAxis_212a9cac-b24f-45c7-872f-3617b0538615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_31986216-3700-4a66-b358-12e79d6102f7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_212a9cac-b24f-45c7-872f-3617b0538615" xlink:to="loc_srt_RangeMember_31986216-3700-4a66-b358-12e79d6102f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3030dc99-d048-4dd6-b83f-c077d5c7b686" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_31986216-3700-4a66-b358-12e79d6102f7" xlink:to="loc_srt_MaximumMember_3030dc99-d048-4dd6-b83f-c077d5c7b686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b0144d30-a1ff-40a3-97e9-283ba6466a2c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_4ea7b8c5-e809-4aa7-81e7-5d8a942023dd" xlink:href="bhc-20200930.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_4ea7b8c5-e809-4aa7-81e7-5d8a942023dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1b938380-b656-4002-9b4a-294f05b7883c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1b938380-b656-4002-9b4a-294f05b7883c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_3001cf31-c46b-4c4f-a1ca-2e4f04c272b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_3001cf31-c46b-4c4f-a1ca-2e4f04c272b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_7f1e873b-c2ea-4f2d-9c43-5ea3362f7aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_7f1e873b-c2ea-4f2d-9c43-5ea3362f7aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8467c1d8-17a3-4641-9e5b-baae2508b10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8467c1d8-17a3-4641-9e5b-baae2508b10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e096aca6-994c-4245-988d-49d57e3c75a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e096aca6-994c-4245-988d-49d57e3c75a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_7514641c-a73e-4994-8d5c-542816485966" xlink:href="bhc-20200930.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_7514641c-a73e-4994-8d5c-542816485966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_81a50fcb-12c6-443c-96f6-e55f924c68f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_81a50fcb-12c6-443c-96f6-e55f924c68f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a3200daf-8354-4404-a881-2246fc60ca07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a3200daf-8354-4404-a881-2246fc60ca07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_368aa0ef-2b4e-4beb-bc24-90cb06dcbba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_347bc5fc-6b0f-4b50-b9df-b6ab7b707a5d" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_368aa0ef-2b4e-4beb-bc24-90cb06dcbba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0c654645-b61b-49f4-9a83-eb1fb5a2a73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_1498fa58-84a9-4b7c-8c85-c144e3d0aa71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0c654645-b61b-49f4-9a83-eb1fb5a2a73d" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_1498fa58-84a9-4b7c-8c85-c144e3d0aa71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_38e2e7d0-6961-4906-8278-ae3ef6e2dad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_38e2e7d0-6961-4906-8278-ae3ef6e2dad9" xlink:to="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cc3603c9-99fe-4a44-964c-25dd51841a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cc3603c9-99fe-4a44-964c-25dd51841a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3e8d936d-5fca-44a3-959b-b7329470e15d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cc3603c9-99fe-4a44-964c-25dd51841a61" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3e8d936d-5fca-44a3-959b-b7329470e15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_eb231539-d0e9-4d49-b514-6ce018d7f7a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3e8d936d-5fca-44a3-959b-b7329470e15d" xlink:to="loc_us-gaap_UnsecuredDebtMember_eb231539-d0e9-4d49-b514-6ce018d7f7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f14def85-e966-4573-b15f-bc6ce9635826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:to="loc_us-gaap_DebtInstrumentAxis_f14def85-e966-4573-b15f-bc6ce9635826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0cc0296f-09b2-4380-a59f-b970c57dbf97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f14def85-e966-4573-b15f-bc6ce9635826" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0cc0296f-09b2-4380-a59f-b970c57dbf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5875DueMay2023Member_3bae71ff-ea44-4684-966c-2e0b076985ce" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes5875DueMay2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cc0296f-09b2-4380-a59f-b970c57dbf97" xlink:to="loc_bhc_SeniorNotes5875DueMay2023Member_3bae71ff-ea44-4684-966c-2e0b076985ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_ecfb7d58-c3d6-4d06-a594-7cf9c3d05e0a" xlink:href="bhc-20200930.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cc0296f-09b2-4380-a59f-b970c57dbf97" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_ecfb7d58-c3d6-4d06-a594-7cf9c3d05e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e6b6a2b4-0d1f-40b2-bbe5-6c0f0c4d0e73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e6b6a2b4-0d1f-40b2-bbe5-6c0f0c4d0e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c17ed53b-0d4a-44d9-967b-655ec49eea57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e6b6a2b4-0d1f-40b2-bbe5-6c0f0c4d0e73" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c17ed53b-0d4a-44d9-967b-655ec49eea57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_fc7c6139-03e5-41b5-b52b-1c961c1c52f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c17ed53b-0d4a-44d9-967b-655ec49eea57" xlink:to="loc_us-gaap_SubsequentEventMember_fc7c6139-03e5-41b5-b52b-1c961c1c52f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3386d254-9c3b-4266-9088-5d7dc95f6f46" xlink:to="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_c6a57b6a-c09f-4e41-b566-18474e2f1d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_c6a57b6a-c09f-4e41-b566-18474e2f1d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_77a145ef-8148-4406-88dd-b00eee34b8ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_77a145ef-8148-4406-88dd-b00eee34b8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fa45c67c-d12f-467d-a5d7-9acbd6c7ede0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85efd5f0-a0d9-4353-9e21-761cd47c22fa" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fa45c67c-d12f-467d-a5d7-9acbd6c7ede0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_fc682aef-55c4-4490-85f9-8d9dfb432c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_fc682aef-55c4-4490-85f9-8d9dfb432c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9cc0be56-3d8c-413d-9be7-04fae27ee2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9cc0be56-3d8c-413d-9be7-04fae27ee2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e861773a-2d6f-479d-80ad-13a984c3a3ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e861773a-2d6f-479d-80ad-13a984c3a3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a31acd05-a4e8-4e4f-a4d4-cbcea1b2ccfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a31acd05-a4e8-4e4f-a4d4-cbcea1b2ccfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_047cd1c2-fb32-4e08-af85-cf0f56b2af87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_047cd1c2-fb32-4e08-af85-cf0f56b2af87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f4b1cfbb-a5fd-42ae-91b5-e0dda48752a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f4b1cfbb-a5fd-42ae-91b5-e0dda48752a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_82fe7842-08f7-483d-b39d-e7ed50bb81c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_82fe7842-08f7-483d-b39d-e7ed50bb81c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_56516bb4-043a-4ee2-b8e5-96af285e3f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_56516bb4-043a-4ee2-b8e5-96af285e3f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e1e11db7-0f80-4285-8082-84043f8115d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e1e11db7-0f80-4285-8082-84043f8115d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0eaff6f6-868b-4c94-a576-d18878dab96c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7634a54e-376d-4e18-9866-670cb505d564" xlink:to="loc_us-gaap_LongTermDebt_0eaff6f6-868b-4c94-a576-d18878dab96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bhc-20200930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03cd2c13-04af-4969-9231-80e0efb161b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_dd5b8be5-8a1b-4dc7-84fe-ba67fd2337f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03cd2c13-04af-4969-9231-80e0efb161b6" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_dd5b8be5-8a1b-4dc7-84fe-ba67fd2337f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b601afb1-6984-43c2-96f5-7cefdeb859df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8857d765-1468-4297-9765-8a205dba6a6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b601afb1-6984-43c2-96f5-7cefdeb859df" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_8857d765-1468-4297-9765-8a205dba6a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_804233b2-1d3c-4905-b3a6-a180cca19321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b584f1b6-a876-4802-8f1c-67356000ce71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_804233b2-1d3c-4905-b3a6-a180cca19321" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b584f1b6-a876-4802-8f1c-67356000ce71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_18f2b388-d26e-4c57-a5b9-628d47f2a293" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b584f1b6-a876-4802-8f1c-67356000ce71" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_18f2b388-d26e-4c57-a5b9-628d47f2a293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6b917c7f-02cd-41a3-ac6d-deddd92716c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_18f2b388-d26e-4c57-a5b9-628d47f2a293" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6b917c7f-02cd-41a3-ac6d-deddd92716c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_09b2a07f-c292-43f4-ab67-ffe766b4394d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6b917c7f-02cd-41a3-ac6d-deddd92716c6" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_09b2a07f-c292-43f4-ab67-ffe766b4394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5aa9e9be-19a1-4a0e-a3ff-94f49cb71fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6b917c7f-02cd-41a3-ac6d-deddd92716c6" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5aa9e9be-19a1-4a0e-a3ff-94f49cb71fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb347fa8-8517-4ece-b3e9-bf76cc245db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b584f1b6-a876-4802-8f1c-67356000ce71" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb347fa8-8517-4ece-b3e9-bf76cc245db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_429f5fcd-6494-4407-8d36-6f9fdcb0a97f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb347fa8-8517-4ece-b3e9-bf76cc245db3" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_429f5fcd-6494-4407-8d36-6f9fdcb0a97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_07b23712-cf23-4234-8972-c85cd6fc75b3" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_429f5fcd-6494-4407-8d36-6f9fdcb0a97f" xlink:to="loc_country_US_07b23712-cf23-4234-8972-c85cd6fc75b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_385cd01f-7146-49a6-a2a6-a82f4c1d6e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_429f5fcd-6494-4407-8d36-6f9fdcb0a97f" xlink:to="loc_us-gaap_ForeignPlanMember_385cd01f-7146-49a6-a2a6-a82f4c1d6e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b584f1b6-a876-4802-8f1c-67356000ce71" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_094dd824-c468-44c2-a3f8-f49a85086138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_094dd824-c468-44c2-a3f8-f49a85086138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_61f0088f-bca4-4167-ba8e-a72bcf824583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_61f0088f-bca4-4167-ba8e-a72bcf824583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7ad2ea32-2f18-45f3-902f-433d8dd67b59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7ad2ea32-2f18-45f3-902f-433d8dd67b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1ce78242-2d70-432b-8e8d-492abfa366b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_1ce78242-2d70-432b-8e8d-492abfa366b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_67ddc2f5-2421-4696-8341-c90f4f0ed274" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_67ddc2f5-2421-4696-8341-c90f4f0ed274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_aa11ca40-e86d-48d7-9ff9-9eed0e6faae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6f554c50-e68c-4fa7-97f3-4ecaa7318a99" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_aa11ca40-e86d-48d7-9ff9-9eed0e6faae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a738e82d-1989-4cbc-a12b-b73dae7e4237" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bb70932d-1beb-464d-beb9-b379e71a6e34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a738e82d-1989-4cbc-a12b-b73dae7e4237" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bb70932d-1beb-464d-beb9-b379e71a6e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_884e47db-04b4-4793-8572-02d615afa2bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_a3ec32c0-e3a7-4226-b3e2-9cfa32818587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_884e47db-04b4-4793-8572-02d615afa2bc" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_a3ec32c0-e3a7-4226-b3e2-9cfa32818587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_68c44bc0-198f-4bd9-82fb-80e0a478ee98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_884e47db-04b4-4793-8572-02d615afa2bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_68c44bc0-198f-4bd9-82fb-80e0a478ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a1b7d25-03d6-429a-9792-05f47c0a23d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f16ab856-de62-42dc-b69a-7b1891f673f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7a1b7d25-03d6-429a-9792-05f47c0a23d7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f16ab856-de62-42dc-b69a-7b1891f673f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_28ddcafb-3500-49f0-a6df-0156bdf63fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f16ab856-de62-42dc-b69a-7b1891f673f7" xlink:to="loc_us-gaap_PlanNameAxis_28ddcafb-3500-49f0-a6df-0156bdf63fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cd3037a6-a38b-45bf-a88d-6881cb21ee43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_28ddcafb-3500-49f0-a6df-0156bdf63fc8" xlink:to="loc_us-gaap_PlanNameDomain_cd3037a6-a38b-45bf-a88d-6881cb21ee43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_c68230e3-148e-4e5b-843d-3a3f1a094796" xlink:href="bhc-20200930.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cd3037a6-a38b-45bf-a88d-6881cb21ee43" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_c68230e3-148e-4e5b-843d-3a3f1a094796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_078f1232-87cc-45f7-b0ea-4d66fb0f8c0f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f16ab856-de62-42dc-b69a-7b1891f673f7" xlink:to="loc_srt_TitleOfIndividualAxis_078f1232-87cc-45f7-b0ea-4d66fb0f8c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c502f908-09dc-4960-b905-e59eb0b6bb3e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_078f1232-87cc-45f7-b0ea-4d66fb0f8c0f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c502f908-09dc-4960-b905-e59eb0b6bb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember_6575c4aa-857c-435b-b524-6400a6c34e54" xlink:href="bhc-20200930.xsd#bhc_NonemployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c502f908-09dc-4960-b905-e59eb0b6bb3e" xlink:to="loc_bhc_NonemployeeDirectorMember_6575c4aa-857c-435b-b524-6400a6c34e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f16ab856-de62-42dc-b69a-7b1891f673f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_68f2a7e3-00f3-4cf8-9b55-852abd1cbbd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_68f2a7e3-00f3-4cf8-9b55-852abd1cbbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9c4aec36-edb5-434d-91b0-3eb659339977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9c4aec36-edb5-434d-91b0-3eb659339977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b501b671-a8e8-4b5b-84eb-d0fdd138e895" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b501b671-a8e8-4b5b-84eb-d0fdd138e895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_4f299517-8060-4215-98ed-42d4cf9b3aae" xlink:href="bhc-20200930.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_4f299517-8060-4215-98ed-42d4cf9b3aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1a6bb4cd-36c5-4d9c-b0d1-3fac985acab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1a6bb4cd-36c5-4d9c-b0d1-3fac985acab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_45377550-3714-4196-bd2f-e53c921c5848" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_45377550-3714-4196-bd2f-e53c921c5848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bd1b7bcb-de30-4c36-9be0-9b44fe3a5292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6d53b46d-f258-4592-8d68-aaf0153eb332" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bd1b7bcb-de30-4c36-9be0-9b44fe3a5292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7684527d-f36f-4e90-bcd8-8463e200f6bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3888be0-caa2-4661-a5d8-b2465b6b6727" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7684527d-f36f-4e90-bcd8-8463e200f6bc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3888be0-caa2-4661-a5d8-b2465b6b6727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd008387-a95b-4bb9-b77c-a2c9ec90f17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3888be0-caa2-4661-a5d8-b2465b6b6727" xlink:to="loc_us-gaap_AwardTypeAxis_bd008387-a95b-4bb9-b77c-a2c9ec90f17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e303567-e7f8-463c-b6e9-8ed7de8153d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bd008387-a95b-4bb9-b77c-a2c9ec90f17a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e303567-e7f8-463c-b6e9-8ed7de8153d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e899aa81-3981-410d-95cf-6f581da63dce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e303567-e7f8-463c-b6e9-8ed7de8153d9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e899aa81-3981-410d-95cf-6f581da63dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f12b8058-4472-4e50-937f-fd7d615ed0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e303567-e7f8-463c-b6e9-8ed7de8153d9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f12b8058-4472-4e50-937f-fd7d615ed0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_97af7879-38bd-4f3a-aa48-e1c246bd515b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3888be0-caa2-4661-a5d8-b2465b6b6727" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_97af7879-38bd-4f3a-aa48-e1c246bd515b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dcf18c37-67ba-4d0b-a380-8ae60e174f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_97af7879-38bd-4f3a-aa48-e1c246bd515b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dcf18c37-67ba-4d0b-a380-8ae60e174f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f03c0e2-b9b4-456c-8e0d-1606970a9a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dcf18c37-67ba-4d0b-a380-8ae60e174f33" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9f03c0e2-b9b4-456c-8e0d-1606970a9a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea18d5a2-3833-46d3-be93-62878bb42ee3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_dcf18c37-67ba-4d0b-a380-8ae60e174f33" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ea18d5a2-3833-46d3-be93-62878bb42ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c012fbb5-a907-454e-9305-d79c74e3f4b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a3888be0-caa2-4661-a5d8-b2465b6b6727" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c012fbb5-a907-454e-9305-d79c74e3f4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6d45309-90f1-49a9-a498-8628b2a92ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c012fbb5-a907-454e-9305-d79c74e3f4b3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6d45309-90f1-49a9-a498-8628b2a92ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8528ddd5-eb10-401e-a750-e636850ffa3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c6b06b1-5edf-406e-b139-69d23336eb3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8528ddd5-eb10-401e-a750-e636850ffa3f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c6b06b1-5edf-406e-b139-69d23336eb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_36cada02-3f7f-4a63-850a-1e2304805822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c6b06b1-5edf-406e-b139-69d23336eb3b" xlink:to="loc_us-gaap_AwardTypeAxis_36cada02-3f7f-4a63-850a-1e2304805822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_36cada02-3f7f-4a63-850a-1e2304805822" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_02db71d9-f1fc-49ba-8398-47c5a55a0900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_02db71d9-f1fc-49ba-8398-47c5a55a0900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_73bd8985-6085-48c1-bc47-9ba095484e5d" xlink:href="bhc-20200930.xsd#bhc_TimeBasedRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:to="loc_bhc_TimeBasedRSUMember_73bd8985-6085-48c1-bc47-9ba095484e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_bd6ef3c5-e22d-4f70-bdf4-1b8663b8b3f4" xlink:href="bhc-20200930.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_bd6ef3c5-e22d-4f70-bdf4-1b8663b8b3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_2bf17a71-2bd2-45fd-8bf6-ee0f45659ca8" xlink:href="bhc-20200930.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c6fa126-05aa-4c4e-9768-f8fbb335aca8" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_2bf17a71-2bd2-45fd-8bf6-ee0f45659ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e13f48ba-163a-4272-a8e7-842260323621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c6b06b1-5edf-406e-b139-69d23336eb3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e13f48ba-163a-4272-a8e7-842260323621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e13f48ba-163a-4272-a8e7-842260323621" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8e1a763e-185a-4ddc-8e28-d4a5b1b6950c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_8e1a763e-185a-4ddc-8e28-d4a5b1b6950c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_69f09852-fe7c-4c17-8fe5-3c397f5cfa9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_69f09852-fe7c-4c17-8fe5-3c397f5cfa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c4b71497-c49e-48b2-997b-89f8e07343a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_5dd8e520-5452-4ada-8731-73f2f9f220e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c4b71497-c49e-48b2-997b-89f8e07343a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_a1a529c0-6e2a-4db7-bb7b-10fc9bc89b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e13f48ba-163a-4272-a8e7-842260323621" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_a1a529c0-6e2a-4db7-bb7b-10fc9bc89b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cdcc1808-68fa-4171-8673-2f378b682aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_a1a529c0-6e2a-4db7-bb7b-10fc9bc89b30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cdcc1808-68fa-4171-8673-2f378b682aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_de878281-d7e5-40c0-a350-beef24d08d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_a1a529c0-6e2a-4db7-bb7b-10fc9bc89b30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_de878281-d7e5-40c0-a350-beef24d08d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7a762ae0-5bc6-4263-b4cd-5746d0295daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_2b99450b-9031-41df-82fa-a5b30c328c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_7a762ae0-5bc6-4263-b4cd-5746d0295daa" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_2b99450b-9031-41df-82fa-a5b30c328c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2adddf14-c0ff-43d0-b06f-07c3309d2a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_68170f1b-962d-4231-be08-fbe5200dd3b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2adddf14-c0ff-43d0-b06f-07c3309d2a3a" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_68170f1b-962d-4231-be08-fbe5200dd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_49359a69-b5d6-4dde-bd49-50616047f434" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac73c6d9-e512-4b47-a605-48ad3403239a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_49359a69-b5d6-4dde-bd49-50616047f434" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac73c6d9-e512-4b47-a605-48ad3403239a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2847b5fd-93b8-4693-8231-1e21a85cf882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac73c6d9-e512-4b47-a605-48ad3403239a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2847b5fd-93b8-4693-8231-1e21a85cf882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2847b5fd-93b8-4693-8231-1e21a85cf882" xlink:to="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_c133456b-cdd9-4844-8f27-a39aa71e9b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_c133456b-cdd9-4844-8f27-a39aa71e9b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4843a890-b4ee-4280-8814-55fbdfa20578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4843a890-b4ee-4280-8814-55fbdfa20578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_731555eb-ac32-435a-b899-bfecb8499a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d0b36112-1fdc-49ef-8b58-b6cd2b2132df" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_731555eb-ac32-435a-b899-bfecb8499a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ec4db645-f144-4f8c-a65e-a8205ae3ac88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ac73c6d9-e512-4b47-a605-48ad3403239a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ec4db645-f144-4f8c-a65e-a8205ae3ac88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43dce50f-e01e-4645-9fa0-23be04aa9ab7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ec4db645-f144-4f8c-a65e-a8205ae3ac88" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_43dce50f-e01e-4645-9fa0-23be04aa9ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_8f1bd469-7531-4a08-ac6f-b25e5150c245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_4c4376c0-a4bf-4907-be7a-5e64f3d5ab3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_8f1bd469-7531-4a08-ac6f-b25e5150c245" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_4c4376c0-a4bf-4907-be7a-5e64f3d5ab3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_830d3c5f-3b42-470a-9710-8b3dfbba2635" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_7abe3187-11f0-4676-9202-8fa54527eb01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_830d3c5f-3b42-470a-9710-8b3dfbba2635" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_7abe3187-11f0-4676-9202-8fa54527eb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_6e6e83c7-af60-4744-8f7a-ebe363628b6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_1aafa31c-13ad-4d66-b2f2-bebaf95f843d" xlink:href="bhc-20200930.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_6e6e83c7-af60-4744-8f7a-ebe363628b6e" xlink:to="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_1aafa31c-13ad-4d66-b2f2-bebaf95f843d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_99240e0f-0374-47c6-9aa6-a41c9fedf60b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_11da3da0-d8e4-401a-b2c6-efa8a264aae9" xlink:href="bhc-20200930.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_99240e0f-0374-47c6-9aa6-a41c9fedf60b" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_11da3da0-d8e4-401a-b2c6-efa8a264aae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_92b6b352-2718-4225-bdbb-27ed954f01de" xlink:href="bhc-20200930.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_99240e0f-0374-47c6-9aa6-a41c9fedf60b" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_92b6b352-2718-4225-bdbb-27ed954f01de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5dc3ed62-92c7-4d09-9896-b3798f10a3dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_99240e0f-0374-47c6-9aa6-a41c9fedf60b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5dc3ed62-92c7-4d09-9896-b3798f10a3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="simple" xlink:href="bhc-20200930.xsd#OTHEREXPENSENET"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_931bc97a-8c77-41da-85ec-97aa83c3584e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_a9f54e3f-5b90-487b-8e50-795cd88f9503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_931bc97a-8c77-41da-85ec-97aa83c3584e" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_a9f54e3f-5b90-487b-8e50-795cd88f9503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#OTHEREXPENSENETTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d64297d-5f12-4665-a757-7518bfa10ea9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_e280813c-aea3-41de-8173-589eff7a0611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_5d64297d-5f12-4665-a757-7518bfa10ea9" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_e280813c-aea3-41de-8173-589eff7a0611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#OTHEREXPENSENETSummaryofOtherExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_dac53f36-f031-494b-9d24-2861d6b6f160" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_97da2491-0531-4bfb-b38b-a5dbce258dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dac53f36-f031-494b-9d24-2861d6b6f160" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_97da2491-0531-4bfb-b38b-a5dbce258dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3210950d-1a38-4b4c-baaa-03e7a5c99119" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dac53f36-f031-494b-9d24-2861d6b6f160" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3210950d-1a38-4b4c-baaa-03e7a5c99119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5ea2796f-6437-4087-b452-7576787b37ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dac53f36-f031-494b-9d24-2861d6b6f160" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_5ea2796f-6437-4087-b452-7576787b37ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_92767760-16c8-40dc-95a1-271a3279273e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dac53f36-f031-494b-9d24-2861d6b6f160" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_92767760-16c8-40dc-95a1-271a3279273e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherMiscellaneousNonoperatingIncomeExpense_d4ac418a-9d8d-40e4-93d4-919850bc6ff6" xlink:href="bhc-20200930.xsd#bhc_OtherMiscellaneousNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dac53f36-f031-494b-9d24-2861d6b6f160" xlink:to="loc_bhc_OtherMiscellaneousNonoperatingIncomeExpense_d4ac418a-9d8d-40e4-93d4-919850bc6ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e7899af4-3b8c-43a4-b432-1a2872bd8a59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_dac53f36-f031-494b-9d24-2861d6b6f160" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e7899af4-3b8c-43a4-b432-1a2872bd8a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20200930.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_aa962f8b-ceba-41be-883d-82513d7cb7f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8c45110f-ead5-4d13-a8b5-4f31575c8a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_aa962f8b-ceba-41be-883d-82513d7cb7f1" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_8c45110f-ead5-4d13-a8b5-4f31575c8a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b2e55459-2b32-4027-8f05-32af3542677c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b2e55459-2b32-4027-8f05-32af3542677c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_62ddb173-698c-4e6d-bfa1-89fa42f21480" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_62ddb173-698c-4e6d-bfa1-89fa42f21480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a6e4cdde-dba1-4d0b-a3cd-ec8c60227731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a6e4cdde-dba1-4d0b-a3cd-ec8c60227731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_f48c88ee-ec88-49e7-ba42-d45b52a057af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_f48c88ee-ec88-49e7-ba42-d45b52a057af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_a59e96aa-8b09-458b-b115-cdbaf2231e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_a59e96aa-8b09-458b-b115-cdbaf2231e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_a28a082f-6c4b-4046-ac44-8536162b7c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_a28a082f-6c4b-4046-ac44-8536162b7c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_7801dd75-4476-4a8c-a8d6-c45586df1c51" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_7801dd75-4476-4a8c-a8d6-c45586df1c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_86c1a210-4a62-49b1-8a60-0703bc272c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_86c1a210-4a62-49b1-8a60-0703bc272c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount_c22f11c1-2879-4275-a73c-42ff804ee859" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount_c22f11c1-2879-4275-a73c-42ff804ee859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount_fa5e55c3-32c6-4079-b72f-ae826520b7ec" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount_fa5e55c3-32c6-4079-b72f-ae826520b7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c77614cc-4fef-4926-a6be-8cb95a98a467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c77614cc-4fef-4926-a6be-8cb95a98a467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount_8f30b732-7782-4851-af97-e513515c4949" xlink:href="bhc-20200930.xsd#bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount_8f30b732-7782-4851-af97-e513515c4949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_b90bd6fd-ad1f-4f67-9b94-5e901bb515bb" xlink:href="bhc-20200930.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_b90bd6fd-ad1f-4f67-9b94-5e901bb515bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d206cc46-d068-4352-8ca5-f2e97a10c866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_d206cc46-d068-4352-8ca5-f2e97a10c866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cda644cc-fdd2-439f-841e-92d498770a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_cda644cc-fdd2-439f-841e-92d498770a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_8cf6d5d8-622a-43aa-a864-30c74b8a949d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3130fb95-1179-4806-ab82-b3bace32cd6f" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_8cf6d5d8-622a-43aa-a864-30c74b8a949d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8c19d48e-472d-4097-8a5c-0318491cc07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d6510d2e-2bff-4066-98ae-d5a0b3219f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8c19d48e-472d-4097-8a5c-0318491cc07b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d6510d2e-2bff-4066-98ae-d5a0b3219f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0411b360-4f76-4e37-9177-020a4f74a481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8cd70146-4814-494b-9e44-cd9018b01741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0411b360-4f76-4e37-9177-020a4f74a481" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8cd70146-4814-494b-9e44-cd9018b01741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d08a1ffb-0b6a-47b4-8340-b08fcc937625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_38e6a7e3-c5de-470d-b318-cc2fca2c7b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d08a1ffb-0b6a-47b4-8340-b08fcc937625" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_38e6a7e3-c5de-470d-b318-cc2fca2c7b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1f83240e-0a13-46c7-9966-b52cfcc3ff74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d08a1ffb-0b6a-47b4-8340-b08fcc937625" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1f83240e-0a13-46c7-9966-b52cfcc3ff74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7dad2246-1065-4ce4-a817-2bb3baeb9842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d08a1ffb-0b6a-47b4-8340-b08fcc937625" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7dad2246-1065-4ce4-a817-2bb3baeb9842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cbdd71d1-e644-4eb3-b24b-05ac2cf146e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d08a1ffb-0b6a-47b4-8340-b08fcc937625" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cbdd71d1-e644-4eb3-b24b-05ac2cf146e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_d65b8c8b-6d3f-4f19-b11d-a3d28ef595cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d08a1ffb-0b6a-47b4-8340-b08fcc937625" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_d65b8c8b-6d3f-4f19-b11d-a3d28ef595cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a3875c1c-ec49-49a3-b2cd-04a6f3e3c77b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_d65b8c8b-6d3f-4f19-b11d-a3d28ef595cc" xlink:to="loc_us-gaap_EarningsPerShareBasic_a3875c1c-ec49-49a3-b2cd-04a6f3e3c77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_542d095e-5e72-44ab-8a05-3255f8c23615" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_d65b8c8b-6d3f-4f19-b11d-a3d28ef595cc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_542d095e-5e72-44ab-8a05-3255f8c23615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#EARNINGSLOSSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3b76cbf8-910a-48e6-a69a-46fb5f09365c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_add40c49-0309-4d5c-b023-9c1348d206fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3b76cbf8-910a-48e6-a69a-46fb5f09365c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_add40c49-0309-4d5c-b023-9c1348d206fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92771124-25d4-4c49-8013-ccce45d1ec33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_add40c49-0309-4d5c-b023-9c1348d206fb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92771124-25d4-4c49-8013-ccce45d1ec33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67a02b5-ff23-4f84-a177-2e6c86f79fcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_92771124-25d4-4c49-8013-ccce45d1ec33" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67a02b5-ff23-4f84-a177-2e6c86f79fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_8abd3f74-4991-4bb8-8cb8-b3097c4a1158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67a02b5-ff23-4f84-a177-2e6c86f79fcf" xlink:to="loc_us-gaap_StockCompensationPlanMember_8abd3f74-4991-4bb8-8cb8-b3097c4a1158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_8b789c1b-5ab1-49fa-93b3-3338b7dc8632" xlink:href="bhc-20200930.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a67a02b5-ff23-4f84-a177-2e6c86f79fcf" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_8b789c1b-5ab1-49fa-93b3-3338b7dc8632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43e74e94-ef8e-4480-83a1-5d373b8da3be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_add40c49-0309-4d5c-b023-9c1348d206fb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43e74e94-ef8e-4480-83a1-5d373b8da3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bb3bc663-4e4d-4145-b365-e31d67627aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_43e74e94-ef8e-4480-83a1-5d373b8da3be" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bb3bc663-4e4d-4145-b365-e31d67627aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50f8b22e-cbed-4f9f-9a97-a385bf8e1a14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_acc8a8ef-83c5-40b3-ac93-ee4a60f4c54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_50f8b22e-cbed-4f9f-9a97-a385bf8e1a14" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_acc8a8ef-83c5-40b3-ac93-ee4a60f4c54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3277042e-a8e8-4a75-8786-248551fb980c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_dfc0c356-6dda-4037-a0a3-0205b6658796" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3277042e-a8e8-4a75-8786-248551fb980c" xlink:to="loc_us-gaap_LitigationReserveCurrent_dfc0c356-6dda-4037-a0a3-0205b6658796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d86f09f5-7bb6-4246-a0fa-fd771e11cea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d86f09f5-7bb6-4246-a0fa-fd771e11cea8" xlink:to="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_8b3a839f-8a61-498e-8cff-e660c72f634e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:to="loc_srt_LitigationCaseAxis_8b3a839f-8a61-498e-8cff-e660c72f634e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_8b3a839f-8a61-498e-8cff-e660c72f634e" xlink:to="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_a6b3ee36-d8ed-45eb-8406-11ca7c7d701b" xlink:href="bhc-20200930.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_a6b3ee36-d8ed-45eb-8406-11ca7c7d701b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsMember_d46a2212-ab76-42e0-86f9-0bf3b6036d72" xlink:href="bhc-20200930.xsd#bhc_RICOClassActionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:to="loc_bhc_RICOClassActionsMember_d46a2212-ab76-42e0-86f9-0bf3b6036d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeLawsuitsMember_4816492c-8173-4fc7-a91e-5a308f6dde80" xlink:href="bhc-20200930.xsd#bhc_DerivativeLawsuitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:to="loc_bhc_DerivativeLawsuitsMember_4816492c-8173-4fc7-a91e-5a308f6dde80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_82031462-1e79-4c40-b748-1dcfaa86a680" xlink:href="bhc-20200930.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c574c32a-a204-4883-81f7-c6708c37d1e9" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_82031462-1e79-4c40-b748-1dcfaa86a680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b5f4c61a-5bd9-4a96-ac08-969669a7197b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:to="loc_us-gaap_LitigationStatusAxis_b5f4c61a-5bd9-4a96-ac08-969669a7197b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7d5975dc-df3f-4f80-b94a-8a331014f9c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_b5f4c61a-5bd9-4a96-ac08-969669a7197b" xlink:to="loc_us-gaap_LitigationStatusDomain_7d5975dc-df3f-4f80-b94a-8a331014f9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_cd094ebd-7056-4386-b2eb-0e75532a0d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_7d5975dc-df3f-4f80-b94a-8a331014f9c2" xlink:to="loc_us-gaap_SettledLitigationMember_cd094ebd-7056-4386-b2eb-0e75532a0d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b22eaa87-9ab8-494c-a922-2a6c93f4f7aa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:to="loc_srt_StatementGeographicalAxis_b22eaa87-9ab8-494c-a922-2a6c93f4f7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c56b565a-404a-47e6-ba8c-0c909c27bc69" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b22eaa87-9ab8-494c-a922-2a6c93f4f7aa" xlink:to="loc_srt_SegmentGeographicalDomain_c56b565a-404a-47e6-ba8c-0c909c27bc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_aa5d8579-8d3d-45f3-a372-203a38e68ddb" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c56b565a-404a-47e6-ba8c-0c909c27bc69" xlink:to="loc_stpr_NJ_aa5d8579-8d3d-45f3-a372-203a38e68ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_3c426199-1df3-4549-92c0-c5d050905f5e" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c56b565a-404a-47e6-ba8c-0c909c27bc69" xlink:to="loc_country_CA_3c426199-1df3-4549-92c0-c5d050905f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_0efea7b0-a0cc-49e0-9558-85331d72cfa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_0efea7b0-a0cc-49e0-9558-85331d72cfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_bd919887-4bb4-4de2-9082-6f03d852a825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_0efea7b0-a0cc-49e0-9558-85331d72cfa6" xlink:to="loc_us-gaap_LossContingencyNatureDomain_bd919887-4bb4-4de2-9082-6f03d852a825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_50d1ad68-62f5-4df8-b8d9-a1bdb8d68aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_bd919887-4bb4-4de2-9082-6f03d852a825" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_50d1ad68-62f5-4df8-b8d9-a1bdb8d68aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_5b0463d4-5104-4af6-bcc8-48eb8440a1dc" xlink:href="bhc-20200930.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_bd919887-4bb4-4de2-9082-6f03d852a825" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_5b0463d4-5104-4af6-bcc8-48eb8440a1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_eeda50fd-26d0-49d4-bf34-1470e92bc8e5" xlink:to="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e1011ebd-223e-4856-a59a-af5d5c1c83b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_e1011ebd-223e-4856-a59a-af5d5c1c83b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_17f2c8be-24ae-4976-a5e3-161affef66fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_17f2c8be-24ae-4976-a5e3-161affef66fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_e898ea2e-db41-454f-881e-381dc6b1eaca" xlink:href="bhc-20200930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_e898ea2e-db41-454f-881e-381dc6b1eaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_d6bafdfc-ac34-4a08-873c-ee67f2f21e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_d6bafdfc-ac34-4a08-873c-ee67f2f21e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_b3a343ce-9727-4739-ae6f-02aea96931e7" xlink:href="bhc-20200930.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_b3a343ce-9727-4739-ae6f-02aea96931e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_656eb6fd-a457-44b8-afbf-d233ab7e8890" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_656eb6fd-a457-44b8-afbf-d233ab7e8890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_49f7b381-cdbc-481b-bb67-0a8cc27d0ced" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_49f7b381-cdbc-481b-bb67-0a8cc27d0ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_564ddbb7-068e-4fa6-a6de-b0d51b157f30" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_564ddbb7-068e-4fa6-a6de-b0d51b157f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_191628c0-1cf8-4503-9dcb-1b23c77c05a5" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4a5d49ef-4d28-4870-b4e2-60c4e4c15c07" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_191628c0-1cf8-4503-9dcb-1b23c77c05a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_524d46e9-29a0-47a0-b777-5e1036b68723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_524d46e9-29a0-47a0-b777-5e1036b68723" xlink:to="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_68d1a91f-66c0-4005-915f-93b846791d3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:to="loc_srt_LitigationCaseAxis_68d1a91f-66c0-4005-915f-93b846791d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_68d1a91f-66c0-4005-915f-93b846791d3c" xlink:to="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_0acae793-de71-461e-8db9-dec5b9bead99" xlink:href="bhc-20200930.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_0acae793-de71-461e-8db9-dec5b9bead99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_6b7f7ad4-159f-46ed-8631-c8efc0a3525f" xlink:href="bhc-20200930.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_6b7f7ad4-159f-46ed-8631-c8efc0a3525f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GenericPricingAntitrustLitigationMember_eceec3b2-3732-4538-8cb5-b1407519c46f" xlink:href="bhc-20200930.xsd#bhc_GenericPricingAntitrustLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:to="loc_bhc_GenericPricingAntitrustLitigationMember_eceec3b2-3732-4538-8cb5-b1407519c46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6b9aeb69-82f4-4c22-b417-bb6bc07b3c1a" xlink:href="bhc-20200930.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f888788b-4241-4248-9998-6c63f9871d92" xlink:to="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_6b9aeb69-82f4-4c22-b417-bb6bc07b3c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ed05ceee-3d7e-4e9e-b466-da8458d6925f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:to="loc_srt_CounterpartyNameAxis_ed05ceee-3d7e-4e9e-b466-da8458d6925f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a06b74-697f-4402-925f-7c7cece826c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ed05ceee-3d7e-4e9e-b466-da8458d6925f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a06b74-697f-4402-925f-7c7cece826c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_4055fb8f-8ce3-462e-bf9e-1b6e33f87782" xlink:href="bhc-20200930.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d5a06b74-697f-4402-925f-7c7cece826c4" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_4055fb8f-8ce3-462e-bf9e-1b6e33f87782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8db21c13-e325-45ae-8801-96aa8f2a2d92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:to="loc_us-gaap_LitigationStatusAxis_8db21c13-e325-45ae-8801-96aa8f2a2d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_d9cd91f3-323b-408a-8e6e-48efce44e452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_8db21c13-e325-45ae-8801-96aa8f2a2d92" xlink:to="loc_us-gaap_LitigationStatusDomain_d9cd91f3-323b-408a-8e6e-48efce44e452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_44cfc5e3-9023-43a7-b016-20dfbd1ac7c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_d9cd91f3-323b-408a-8e6e-48efce44e452" xlink:to="loc_us-gaap_PendingLitigationMember_44cfc5e3-9023-43a7-b016-20dfbd1ac7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0b4dee99-65fe-46e7-bac6-9b2eb94e91e9" xlink:to="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_cbb35c9d-3269-4530-9318-4be37ce76a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_cbb35c9d-3269-4530-9318-4be37ce76a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits_6f96bb01-a642-4a81-9639-0bd43de8d2c4" xlink:href="bhc-20200930.xsd#bhc_LossContingencyNumberOfHealthPlansFiledLawsuits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:to="loc_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits_6f96bb01-a642-4a81-9639-0bd43de8d2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_8930abb7-0143-4a43-8fea-7db470968fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e18fe7ba-8a0f-47f3-b35d-fa6a1d210251" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_8930abb7-0143-4a43-8fea-7db470968fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63b2da7a-dc77-49d2-a59b-506172ff638c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8ea2cdbe-0de5-465b-8735-6abc56c5db6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_63b2da7a-dc77-49d2-a59b-506172ff638c" xlink:to="loc_us-gaap_LossContingenciesTable_8ea2cdbe-0de5-465b-8735-6abc56c5db6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b88317d6-1236-4c70-8fdf-8255c80ef59b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8ea2cdbe-0de5-465b-8735-6abc56c5db6c" xlink:to="loc_srt_LitigationCaseAxis_b88317d6-1236-4c70-8fdf-8255c80ef59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bfa72dd6-824d-427b-9da1-6b93875f7a27" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b88317d6-1236-4c70-8fdf-8255c80ef59b" xlink:to="loc_srt_LitigationCaseTypeDomain_bfa72dd6-824d-427b-9da1-6b93875f7a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_83708732-60d8-4a5b-9bc7-31d2f0d843a1" xlink:href="bhc-20200930.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_bfa72dd6-824d-427b-9da1-6b93875f7a27" xlink:to="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_83708732-60d8-4a5b-9bc7-31d2f0d843a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_d087461d-eb80-4f7e-bec3-59dee90135ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8ea2cdbe-0de5-465b-8735-6abc56c5db6c" xlink:to="loc_us-gaap_LitigationStatusAxis_d087461d-eb80-4f7e-bec3-59dee90135ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ce82c06d-d40b-462e-9ac4-77db53c19e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_d087461d-eb80-4f7e-bec3-59dee90135ec" xlink:to="loc_us-gaap_LitigationStatusDomain_ce82c06d-d40b-462e-9ac4-77db53c19e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_e8605ad3-ebb9-4e40-8538-4dc42159b53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_ce82c06d-d40b-462e-9ac4-77db53c19e9d" xlink:to="loc_us-gaap_PendingLitigationMember_e8605ad3-ebb9-4e40-8538-4dc42159b53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7802ba37-f918-4777-9bb0-0a74d08a93c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8ea2cdbe-0de5-465b-8735-6abc56c5db6c" xlink:to="loc_us-gaap_LossContingenciesLineItems_7802ba37-f918-4777-9bb0-0a74d08a93c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_877c7c04-80ed-4a04-8a55-ffbe72a94d2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7802ba37-f918-4777-9bb0-0a74d08a93c7" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_877c7c04-80ed-4a04-8a55-ffbe72a94d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14df44ce-777c-44fd-be8e-fa9695b54ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_1edfe7e7-f75d-4c21-8d44-8fff7f9b9b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_14df44ce-777c-44fd-be8e-fa9695b54ee7" xlink:to="loc_us-gaap_LossContingenciesTable_1edfe7e7-f75d-4c21-8d44-8fff7f9b9b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9e190757-7728-45db-abdd-8401e2c7fd77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1edfe7e7-f75d-4c21-8d44-8fff7f9b9b67" xlink:to="loc_srt_LitigationCaseAxis_9e190757-7728-45db-abdd-8401e2c7fd77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8c0da42c-e280-4835-963e-8b16c458fd63" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_9e190757-7728-45db-abdd-8401e2c7fd77" xlink:to="loc_srt_LitigationCaseTypeDomain_8c0da42c-e280-4835-963e-8b16c458fd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_1a26ee63-7ec1-4b42-8fcc-489c355e6499" xlink:href="bhc-20200930.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8c0da42c-e280-4835-963e-8b16c458fd63" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_1a26ee63-7ec1-4b42-8fcc-489c355e6499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_609834ed-0a7c-477b-b090-ac6dd74956c0" xlink:href="bhc-20200930.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8c0da42c-e280-4835-963e-8b16c458fd63" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_609834ed-0a7c-477b-b090-ac6dd74956c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_3907de4b-ae01-4ae2-91e0-1b076d8e97a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1edfe7e7-f75d-4c21-8d44-8fff7f9b9b67" xlink:to="loc_us-gaap_LossContingenciesLineItems_3907de4b-ae01-4ae2-91e0-1b076d8e97a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_0a76b336-0d4a-42a2-80e5-3219aa02abac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3907de4b-ae01-4ae2-91e0-1b076d8e97a9" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_0a76b336-0d4a-42a2-80e5-3219aa02abac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#LEGALPROCEEDINGSCompletedorDormantMattersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6576e6d1-8872-4da2-9b98-99640eeeb441" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_89328537-b5fd-4ad6-9277-4846bddbcb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6576e6d1-8872-4da2-9b98-99640eeeb441" xlink:to="loc_us-gaap_LossContingenciesTable_89328537-b5fd-4ad6-9277-4846bddbcb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_b560490e-297d-4b65-8d05-8f453a2bcba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_89328537-b5fd-4ad6-9277-4846bddbcb49" xlink:to="loc_us-gaap_LitigationStatusAxis_b560490e-297d-4b65-8d05-8f453a2bcba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_2782057a-8b3e-45ac-9bc1-0cdc4d95c4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_b560490e-297d-4b65-8d05-8f453a2bcba9" xlink:to="loc_us-gaap_LitigationStatusDomain_2782057a-8b3e-45ac-9bc1-0cdc4d95c4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_21f70b1f-94e6-4905-8280-9ca395336d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_2782057a-8b3e-45ac-9bc1-0cdc4d95c4a4" xlink:to="loc_us-gaap_SettledLitigationMember_21f70b1f-94e6-4905-8280-9ca395336d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_584a0d4e-eb23-4d45-b06d-7db4bd352c4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_89328537-b5fd-4ad6-9277-4846bddbcb49" xlink:to="loc_srt_LitigationCaseAxis_584a0d4e-eb23-4d45-b06d-7db4bd352c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_bfeac65d-2be1-4eb0-a1ee-937b14af753e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_584a0d4e-eb23-4d45-b06d-7db4bd352c4e" xlink:to="loc_srt_LitigationCaseTypeDomain_bfeac65d-2be1-4eb0-a1ee-937b14af753e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECInvestigationLitigationMember_152b48b4-8f81-41f4-9dc7-d84f8b167522" xlink:href="bhc-20200930.xsd#bhc_SECInvestigationLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_bfeac65d-2be1-4eb0-a1ee-937b14af753e" xlink:to="loc_bhc_SECInvestigationLitigationMember_152b48b4-8f81-41f4-9dc7-d84f8b167522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember_d50b1a47-e8aa-4329-91e7-1ce9748e5985" xlink:href="bhc-20200930.xsd#bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_bfeac65d-2be1-4eb0-a1ee-937b14af753e" xlink:to="loc_bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember_d50b1a47-e8aa-4329-91e7-1ce9748e5985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7b6ef430-37d8-4b6a-a113-2792a653dbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_89328537-b5fd-4ad6-9277-4846bddbcb49" xlink:to="loc_us-gaap_LossContingenciesLineItems_7b6ef430-37d8-4b6a-a113-2792a653dbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e62d1c6b-b766-48c8-837c-91dcf83295af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b6ef430-37d8-4b6a-a113-2792a653dbcc" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_e62d1c6b-b766-48c8-837c-91dcf83295af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_42e4831c-5790-479b-8958-fdc6165a1a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b6ef430-37d8-4b6a-a113-2792a653dbcc" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_42e4831c-5790-479b-8958-fdc6165a1a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fc7f2f01-36db-4c66-adb1-99cfc1d69243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_a4735235-0ab6-4623-99c0-378a33bd866c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fc7f2f01-36db-4c66-adb1-99cfc1d69243" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_a4735235-0ab6-4623-99c0-378a33bd866c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_da479f2a-71b9-4b48-98ef-8bb161589828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d7985037-9ffa-4996-b85d-31cb0a8f6054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_da479f2a-71b9-4b48-98ef-8bb161589828" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d7985037-9ffa-4996-b85d-31cb0a8f6054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_56fa977d-93d2-4d26-8f39-fe46a8df5b9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_da479f2a-71b9-4b48-98ef-8bb161589828" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_56fa977d-93d2-4d26-8f39-fe46a8df5b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_36a2662d-85a6-4fba-8cfc-465f8e4a33d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_da479f2a-71b9-4b48-98ef-8bb161589828" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_36a2662d-85a6-4fba-8cfc-465f8e4a33d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_18947bd2-c58a-4608-a2b7-9e9fb6993896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_da479f2a-71b9-4b48-98ef-8bb161589828" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_18947bd2-c58a-4608-a2b7-9e9fb6993896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a1c83ef2-4a63-4976-8e83-269e45c0860c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_517bbd5c-3e30-4207-8453-2ef40a47b133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a1c83ef2-4a63-4976-8e83-269e45c0860c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_517bbd5c-3e30-4207-8453-2ef40a47b133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_a6fb8559-3390-449b-86d9-0808d01d881d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_517bbd5c-3e30-4207-8453-2ef40a47b133" xlink:to="loc_srt_ConsolidationItemsAxis_a6fb8559-3390-449b-86d9-0808d01d881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cfb9be57-7a9d-49fc-87cb-1069dbcca6dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_a6fb8559-3390-449b-86d9-0808d01d881d" xlink:to="loc_srt_ConsolidationItemsDomain_cfb9be57-7a9d-49fc-87cb-1069dbcca6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d71346e0-f348-494a-b86f-d18fe5544dcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_cfb9be57-7a9d-49fc-87cb-1069dbcca6dd" xlink:to="loc_us-gaap_OperatingSegmentsMember_d71346e0-f348-494a-b86f-d18fe5544dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_bc80e876-b726-471a-a406-74265e24c47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_cfb9be57-7a9d-49fc-87cb-1069dbcca6dd" xlink:to="loc_us-gaap_CorporateNonSegmentMember_bc80e876-b726-471a-a406-74265e24c47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6394c299-6754-45da-9d57-d46fc4d96628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_517bbd5c-3e30-4207-8453-2ef40a47b133" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6394c299-6754-45da-9d57-d46fc4d96628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6394c299-6754-45da-9d57-d46fc4d96628" xlink:to="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaushandLombInternationalSegmentMember_4a26c13a-8f15-41c5-ab1e-6f4e93c9d33e" xlink:href="bhc-20200930.xsd#bhc_BaushandLombInternationalSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:to="loc_bhc_BaushandLombInternationalSegmentMember_4a26c13a-8f15-41c5-ab1e-6f4e93c9d33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_9dfc9c11-a5f5-4a8f-817b-836342a9e37e" xlink:href="bhc-20200930.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:to="loc_bhc_SalixSegmentMember_9dfc9c11-a5f5-4a8f-817b-836342a9e37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_77b01e0c-6c37-468e-9da3-16aa2c4315e0" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_77b01e0c-6c37-468e-9da3-16aa2c4315e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_7d4970b2-7dbd-4cac-9113-fdadf97e983e" xlink:href="bhc-20200930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e54a4743-ff08-4f2f-8884-f2e6510a186c" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_7d4970b2-7dbd-4cac-9113-fdadf97e983e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_517bbd5c-3e30-4207-8453-2ef40a47b133" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48fe5e59-0cb3-455e-a0e8-554a770b33e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48fe5e59-0cb3-455e-a0e8-554a770b33e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_283ea7a6-a443-4a59-84e3-935571b249ec" xlink:href="bhc-20200930.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_283ea7a6-a443-4a59-84e3-935571b249ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_22d73b87-a999-4199-a158-33d17f20fa35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_AssetImpairmentCharges_22d73b87-a999-4199-a158-33d17f20fa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_239ba838-6f08-4b0d-a624-cf60a6fd7499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_RestructuringCharges_239ba838-6f08-4b0d-a624-cf60a6fd7499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_af5cddb1-578d-463c-8d61-356f15d1c7f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_af5cddb1-578d-463c-8d61-356f15d1c7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a263d89f-e9f5-4bb0-97fa-2ad6976fa007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a263d89f-e9f5-4bb0-97fa-2ad6976fa007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9a201f25-59d3-4360-b305-7df41b58a5bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9a201f25-59d3-4360-b305-7df41b58a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_262711ba-cd2f-406b-8d57-d2702c05dbec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_262711ba-cd2f-406b-8d57-d2702c05dbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_0da2915d-37ba-42fc-9a48-04742989d93f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_InterestAndDebtExpense_0da2915d-37ba-42fc-9a48-04742989d93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_38566241-d02e-41c1-8702-547d343a0b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_38566241-d02e-41c1-8702-547d343a0b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_04173b7e-a43d-44b8-9f51-22b2c62492d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_04173b7e-a43d-44b8-9f51-22b2c62492d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51d67eb3-cbf1-4835-9567-f8c57d9e2f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5d565fb6-205a-4635-af57-9c827cc741c0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_51d67eb3-cbf1-4835-9567-f8c57d9e2f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_285e56a5-4032-4c7b-9dc0-53640083353b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e1a28509-6013-45b1-8272-b25b49f0dff5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_285e56a5-4032-4c7b-9dc0-53640083353b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e1a28509-6013-45b1-8272-b25b49f0dff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_32dee295-897a-4954-8d0d-ab6e3d2c82aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e1a28509-6013-45b1-8272-b25b49f0dff5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_32dee295-897a-4954-8d0d-ab6e3d2c82aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_32dee295-897a-4954-8d0d-ab6e3d2c82aa" xlink:to="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaushandLombInternationalSegmentMember_9504e7dd-9ef3-4ab5-b4e6-bea4ea41f7f4" xlink:href="bhc-20200930.xsd#bhc_BaushandLombInternationalSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:to="loc_bhc_BaushandLombInternationalSegmentMember_9504e7dd-9ef3-4ab5-b4e6-bea4ea41f7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_6a83a0cd-9fae-4bc6-bd8a-2e6a43eb6cdd" xlink:href="bhc-20200930.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:to="loc_bhc_SalixSegmentMember_6a83a0cd-9fae-4bc6-bd8a-2e6a43eb6cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_9f920a2c-3730-40ac-b0e0-511f57ad68a2" xlink:href="bhc-20200930.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_9f920a2c-3730-40ac-b0e0-511f57ad68a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_a0f142a1-9f08-4f2f-b4f4-9dcfadf713e3" xlink:href="bhc-20200930.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_581eb4cb-d5e4-4c4f-8d25-a78fa2a0802c" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_a0f142a1-9f08-4f2f-b4f4-9dcfadf713e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_473de52b-be52-45c0-bc8a-e8d2a4691eb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e1a28509-6013-45b1-8272-b25b49f0dff5" xlink:to="loc_srt_ProductOrServiceAxis_473de52b-be52-45c0-bc8a-e8d2a4691eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_473de52b-be52-45c0-bc8a-e8d2a4691eb2" xlink:to="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_fd59ee82-4d35-4482-a437-c5e627b1c033" xlink:href="bhc-20200930.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_PharmaceuticalProductsMember_fd59ee82-4d35-4482-a437-c5e627b1c033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_183ef124-274b-49dc-bec3-96c8f6649282" xlink:href="bhc-20200930.xsd#bhc_DeviceProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_DeviceProductsMember_183ef124-274b-49dc-bec3-96c8f6649282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_affaa26b-3325-44df-8af8-e8aaec4bf6a9" xlink:href="bhc-20200930.xsd#bhc_OvertheCounterProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_OvertheCounterProductsMember_affaa26b-3325-44df-8af8-e8aaec4bf6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_846549a5-536c-43cf-9e9e-476824770cf3" xlink:href="bhc-20200930.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_846549a5-536c-43cf-9e9e-476824770cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_6ea0c698-f716-4d90-9419-0a799e5c0fd5" xlink:href="bhc-20200930.xsd#bhc_OtherRevenuesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_479a4a86-46c4-416d-8933-4fdf593c6a05" xlink:to="loc_bhc_OtherRevenuesMember_6ea0c698-f716-4d90-9419-0a799e5c0fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_dbc341d0-ae6d-4f53-81fa-7d5e6568ecbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e1a28509-6013-45b1-8272-b25b49f0dff5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_dbc341d0-ae6d-4f53-81fa-7d5e6568ecbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a3134b96-06f8-4162-ab28-103c54ced3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_dbc341d0-ae6d-4f53-81fa-7d5e6568ecbb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a3134b96-06f8-4162-ab28-103c54ced3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7f1eb386-cd0c-4c02-b0fd-ed754ed67c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_92468803-51f5-4f3f-b328-6f21367463fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7f1eb386-cd0c-4c02-b0fd-ed754ed67c19" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_92468803-51f5-4f3f-b328-6f21367463fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fd794598-86e4-42cf-9e0e-006abfd053af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_92468803-51f5-4f3f-b328-6f21367463fd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fd794598-86e4-42cf-9e0e-006abfd053af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_27498886-c076-418b-bcb3-77ef2fe80fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fd794598-86e4-42cf-9e0e-006abfd053af" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_27498886-c076-418b-bcb3-77ef2fe80fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_64165c46-6c8c-46ef-9d90-8ff704f671a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_27498886-c076-418b-bcb3-77ef2fe80fa3" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_64165c46-6c8c-46ef-9d90-8ff704f671a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3ef9d37f-bb29-4d9e-95c8-428b1a37b1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_92468803-51f5-4f3f-b328-6f21367463fd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3ef9d37f-bb29-4d9e-95c8-428b1a37b1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aedde349-1c5b-4e63-b29c-69d9820e5c75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_3ef9d37f-bb29-4d9e-95c8-428b1a37b1ee" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aedde349-1c5b-4e63-b29c-69d9820e5c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_b580da00-3099-4a03-9a30-43ad1ed617d5" xlink:href="bhc-20200930.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aedde349-1c5b-4e63-b29c-69d9820e5c75" xlink:to="loc_bhc_RevenuesNetMember_b580da00-3099-4a03-9a30-43ad1ed617d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_580a3088-3b4a-43e8-89fd-a8fc7434169d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_92468803-51f5-4f3f-b328-6f21367463fd" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_580a3088-3b4a-43e8-89fd-a8fc7434169d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_d25946b3-2598-4503-8ddb-03026b280a71" xlink:href="bhc-20200930.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_580a3088-3b4a-43e8-89fd-a8fc7434169d" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_d25946b3-2598-4503-8ddb-03026b280a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c7a37159-a57d-4437-9fb4-b221a4a0af47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_580a3088-3b4a-43e8-89fd-a8fc7434169d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c7a37159-a57d-4437-9fb4-b221a4a0af47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_36af7057-d4e2-416b-b61d-b7f5d7123c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_159eada2-86ec-43eb-9e49-f8f249fde351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_36af7057-d4e2-416b-b61d-b7f5d7123c45" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_159eada2-86ec-43eb-9e49-f8f249fde351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_81bbcd8b-08a1-4b92-b6b5-4e2bc2fccd17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_159eada2-86ec-43eb-9e49-f8f249fde351" xlink:to="loc_srt_StatementGeographicalAxis_81bbcd8b-08a1-4b92-b6b5-4e2bc2fccd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_81bbcd8b-08a1-4b92-b6b5-4e2bc2fccd17" xlink:to="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_b3ea1b9b-2f45-4f7c-94c4-fee82b3b67a6" xlink:href="bhc-20200930.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_b3ea1b9b-2f45-4f7c-94c4-fee82b3b67a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_a16b7115-388f-40d2-8fa9-195e60636da4" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_CN_a16b7115-388f-40d2-8fa9-195e60636da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_39b0a23f-ecba-4c7e-a134-0d3d8e960477" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_CA_39b0a23f-ecba-4c7e-a134-0d3d8e960477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_b9d0b968-93c1-4a9e-b849-a19124ab32af" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_MX"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_MX_b9d0b968-93c1-4a9e-b849-a19124ab32af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_EG_d224f54e-199c-4690-9e89-fb2d160adf9a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_EG"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_EG_d224f54e-199c-4690-9e89-fb2d160adf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_5c952a47-eaed-42a9-a9b7-8b964d91e4a9" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_PL"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_PL_5c952a47-eaed-42a9-a9b7-8b964d91e4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_8ac6a977-0815-45c0-b3e1-234a887ccafe" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_JP"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_JP_8ac6a977-0815-45c0-b3e1-234a887ccafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_8085e048-9459-4e8d-be6e-e79f5304f476" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_FR"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_FR_8085e048-9459-4e8d-be6e-e79f5304f476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_4c31dac2-64cd-438f-851d-2bb29ffcaf4a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_DE"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_DE_4c31dac2-64cd-438f-851d-2bb29ffcaf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_6de75227-ef63-4083-b713-584aab880695" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_RU"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_RU_6de75227-ef63-4083-b713-584aab880695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_1347fa9b-e4f5-4914-902f-2f7c21d778ce" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_ES"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_ES_1347fa9b-e4f5-4914-902f-2f7c21d778ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_92e52a97-463b-4d4b-8bdf-287b34ba7a6b" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_GB"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_country_GB_92e52a97-463b-4d4b-8bdf-287b34ba7a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_d3b18b7c-c481-4ed1-b7cd-93ed938ba8b6" xlink:href="bhc-20200930.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_88da7fa1-d22d-4925-82b6-aa08c039e146" xlink:to="loc_bhc_OtherCountriesMember_d3b18b7c-c481-4ed1-b7cd-93ed938ba8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3609284c-4c05-4cf8-b4a9-1e9601cfabe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_159eada2-86ec-43eb-9e49-f8f249fde351" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3609284c-4c05-4cf8-b4a9-1e9601cfabe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb619b9a-6242-479d-b87f-4d739730342c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3609284c-4c05-4cf8-b4a9-1e9601cfabe2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb619b9a-6242-479d-b87f-4d739730342c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20200930.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f1484695-089e-440a-99ab-fad6e2a08a90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f1484695-089e-440a-99ab-fad6e2a08a90" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65cbab6d-6d2e-4414-a671-2baaa99ab4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65cbab6d-6d2e-4414-a671-2baaa99ab4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f801d62-c0a9-49ad-a390-dc5a7406e8d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_65cbab6d-6d2e-4414-a671-2baaa99ab4a1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f801d62-c0a9-49ad-a390-dc5a7406e8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_1c75cdb0-63fd-4988-af9a-8ffda8dbc9a1" xlink:href="bhc-20200930.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4f801d62-c0a9-49ad-a390-dc5a7406e8d0" xlink:to="loc_bhc_RevenuesNetMember_1c75cdb0-63fd-4988-af9a-8ffda8dbc9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_71e5789a-35ac-4cda-b3e5-1a66187e7979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_71e5789a-35ac-4cda-b3e5-1a66187e7979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b2e3f141-48d3-4d09-8dc2-3a8e0983f6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_71e5789a-35ac-4cda-b3e5-1a66187e7979" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b2e3f141-48d3-4d09-8dc2-3a8e0983f6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_bd059a6c-76ca-4bf7-a873-a81ce4e16756" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_b2e3f141-48d3-4d09-8dc2-3a8e0983f6de" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_bd059a6c-76ca-4bf7-a873-a81ce4e16756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3879fd70-7a5b-40df-ac45-3fa3cd1c45d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:to="loc_srt_MajorCustomersAxis_3879fd70-7a5b-40df-ac45-3fa3cd1c45d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3879fd70-7a5b-40df-ac45-3fa3cd1c45d1" xlink:to="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_a8ba746a-36c8-44e6-b2bc-3b778bbcda23" xlink:href="bhc-20200930.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_a8ba746a-36c8-44e6-b2bc-3b778bbcda23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_759d67aa-4bc6-4948-abce-7d764a1ef782" xlink:href="bhc-20200930.xsd#bhc_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:to="loc_bhc_McKessonCorporationMember_759d67aa-4bc6-4948-abce-7d764a1ef782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_4b55f4b3-b90b-4116-8d2c-a2b60755b1c2" xlink:href="bhc-20200930.xsd#bhc_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_083bd716-c785-4c8f-af09-7186c977dc36" xlink:to="loc_bhc_CardinalHealthIncMember_4b55f4b3-b90b-4116-8d2c-a2b60755b1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_560449d5-5cf7-4208-88ad-fe03f9a3842e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_753e1a58-64ab-44ec-b736-31303566500c" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_560449d5-5cf7-4208-88ad-fe03f9a3842e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5f602d24-5b35-40d8-81fe-ad3aa2996529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_560449d5-5cf7-4208-88ad-fe03f9a3842e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5f602d24-5b35-40d8-81fe-ad3aa2996529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>bhc-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bhc="http://www.bauschhealth.com/20200930"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bhc-20200930.xsd" xlink:type="simple"/>
    <context id="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58165bdb49574b6aa695effb47a3b6fd_I20201029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2020-10-29</instant>
        </period>
    </context>
    <context id="i9da4fed668814346810326af9b4d6598_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i644a5c6073d342b280ceb7503b40fffc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9bf79c1fea774ba78e8ae4e67f3aae19_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie19134db53624c3dbe16d17f7a2c887b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i397ad4497f454ed4b5c8ed511d657a01_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i02c3faa5394c4efa803b0d07a332d877_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i77a193aab3454c7c8df01544d3d5234a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1e26a204cce2408c8c2b0e4eeba1bd23_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7f203fd5d2ce4c9287eab1215ce4afc0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id4b4cd54f5e342ecaa9c703653b2eca2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2b183b5868ef437cbfabaff430ddb177_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icb91d49706df4bceb73a8b27d4b2cadf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5b51462eae944b27b08ebf45591f45d4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i54958c2a43bd4549bdafae413e7d07d5_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id9d717e4e6074467bd481358cfd95ccf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3eba536ebee74aa3ac183442a212ee35_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5c66878a6b314d1c8fa41e056f0e38a6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb63cfcaabb846eb9475e1a816a4cfd5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i496cdf76600d4d3b8075d83c64d87524_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6ec221254f7246e5ac168ac3177d8dc2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i992ce3be69be4136b963377397c88687_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i34d1a74a2f6d479e80e6da708c4c0ea9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i614bd8e75e8b483b836943e11a8cff8c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i86b09d66e5904f00bdfc6d7dcac58e24_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iee6469a3085b415b81023abb0f50fd08_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i129921e9b4d049ed8ee7f90c0ac8ebcb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7eeabd830b4744f9a609670edfae6e15_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i412d37633553439b9d65c47d77b03846_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id0aee1138db3436cad68141f33b4b0eb_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i95cdd8bdc8a642d58cfe7370d8001f2a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ifdda6c0d36a84d3592d9e9418514b1fc_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iec8fffeeb09e4491b53ff8013f59e0f8_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8f1cd9b31f0a4d949e1701489137acd5_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8e4bd8ca4ffe403ea5a27d2506365172_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6042397c7cfb490393cbd31597df38f8_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8935c278faab48a1946ca3d3bf7e95a3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i898150194c8a49858946a480cb32bcd1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic7ff222b1e2f4984a09b68fa09674122_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ib2e79eda62004863b250270a4ac6e2e2_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i76b9993210a745b9b43f1f5d49bc5f63_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0679fbabd2d543829b45838f2d32c8b1_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9d9736297cfb443ab15742dc0bb31bba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if1e4834a7c874cc1827742f22e88673d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i45390232e74c44a99af3ec366a6470bf_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i550ff3adb4da4b33b8c7b447a74a6ef0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0724670b830242fcb80b31e2447ea7a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee8d639acfc34aeab0f9340f2ef71914_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib7807cd27ff842ef98aaf27968fece25_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ida4e60de3b154f7395827c52cfbe8a3c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5629ad6776d5426ba54b6e7f66992f37_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2d07813deb7b4c7a8b32656f580c213d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibba3122b39dd4ec2976cc26a4121ca76_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9388a44254d042458ac025d5a3287ff3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf713c297ba443efac779956ff34bb58_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i19280811252b4ca18390037dfc0e63f5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9a25f11c2bfe443ea2f446aca2bb3794_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i292d75e4b4024bed95e33679bcebcbe2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia713159518cb42a0b248bc95796377b4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0cfbeac78f9548d18d3b871368be2ee1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i911bb2eff7e84f7cbb8079fd03ee877f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i326aa3bfc5ee4f3daab3236db5b49940_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i85916a34835d4e4fae8f2fdf0dcf8c27_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifa4a0c3396e645879bc46329d323ac1b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i45afbb8c565241ff8ad164f429208ab3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if95828f039eb46b1833d2a857454ec2c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9cc32bfd1c3d470cbe8ccec2d8c006a7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if28e8de9d52f4b1fb26013832875c24a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1e72b076a70a45c584feaa8d3245efbd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic90695475f3742f7bc22d422180c86a9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i626ac4778b4748438a325abd1b9e0d84_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib9975f10d37a4b9f8ab190b71f48d126_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i926e8404d24b4f67a639801625df9821_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i60746b3a7f484dad99381c010e94f132_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie229cebfd8564ef69cc3b87b8cca2163_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d2ec754640b47e3bc475ba39e2f15b3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4865f0c8877843d2a74d4a34949d8990_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64e6b19fad9e422cbb35846a705746dc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4544171997534f44b301068e2ca91ee1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id2a7fc687b364d7b91dd305f5f2c2a47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0d9b898b4dd4de4afef0d16544c30e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9396aa2e3a194b7d88a01028c2d8726f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcb4b2fb825447fba3ebaf7786b43dc7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6b21a7ff737c4ce9bcf3101d1496b9e8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i05ef307c522049b29a69292368af3288_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id29dfca8902e4b9ca9b215022329120a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i563d7e65dd4f4fd3a57a525126385f71_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic06448dd5b9c4a5a8833d7aeb0462adc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia84a1548bc2b4290bf923185b9809a3c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0d5fc05eca2d45039ef1c66ddd5fd5bb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if87d338bc71847cbaa721c2e753719df_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4b081d921d2542fab60f3ee0f92c0b0c_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="ibbb36916236a49af8aabec568346f93f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1ef27070c30b49c1a8b37fca2d781143_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iba58938db3e44a8ab10e6ad34541726a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib7d0d96c365941de8f6f60a38bcb3768_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5216708cf09e4690887e64359dfa0177_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9935a6414aaa4e8e9a55fa03b280060c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i08d75e8d917347f5beaf038cb1a07543_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4767169b3e8b4b7f9c14e03ce1450592_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i00d9912296e4423eb2f0c58b058f3d53_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i10ab9e834c5043c3b3c019c844bf6906_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i251db7175d9c4d7498e6bbc45a12b1a7_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i43ca4779d36d4db0a4416740976e51df_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i90e68a168c934bf0b76363ae269a8dd4_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if477ae61fd124d7aac6ae9ddab03f3cf_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3f26ca1233014e19a4813bfb570654cc_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i22581c99ab8945728931a540b016ef35_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i53b5ad55c3114bbb9e240bd272663878_I20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="iea55888e199a4f30aa6537db612f8d50_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id525861ca12645cbbfa8004f60ba9429_D20190306-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-06</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="if407461ef48547d3adc0e65ccd56a10c_I20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-06</instant>
        </period>
    </context>
    <context id="ic76a9522ae624b31ba4b70987bd03b75_D20190306-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-06</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib738e1928e864b82b2984cc187349f0d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5183e10738b0469fafeab79f0c1a49bd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i85e9f322f6594cb29a915174676fb28d_D20200921-20200921">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bhc:AssetAcquisitionAxis">bhc:AllegroOphthalmicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-21</startDate>
            <endDate>2020-09-21</endDate>
        </period>
    </context>
    <context id="i596976330b084b2083ea00b7d8939d1e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="bhc:AssetAcquisitionAxis">bhc:AllegroOphthalmicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ied8b6d4a32f24bef886f050abd26218d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5bc655cb9eb649d7ab9cd303e9abe56d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2a7193c3b1a346ab8b76b004d6fab3b0_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9a254f3c123b4ca1bd8ea40230250dde_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id9aec834c676489bb24751c37138f0ae_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic4358fb6f74742fdb0a980244f01c440_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i630d2760251f4bf096f3e18b26d2c348_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i46838e1d7a4a42c3a16733f85f00c538_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5238086c98844119970f8779efb8724d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie79caecdf5264091b27165fac0949180_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5703e3dc34b5445690b680201a721c40_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia7ba393fb386441abbb663abd8248a98_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i17077f1b6f0d4339a06e1372d84405db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7213b15a279a460cb57c398f93e64324_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id041afe2abf047cc82ee51281520ae03_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia07ebc37151443b8a5b057c7a3cfc60a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i188c7aa31f4846398b02780a637146ca_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i44b34ec25e124642a594402f4d39fd61_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2392471a1d8d4ca9aff058dfa66f23a9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i53ca7375bec54df1831d5ec1bb7ce35f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i55a91dd3637642f194adf2e407393f51_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i639cfded29ff480cac614d7849308b01_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib9b592bb3c924615aeffe086aa4dcc11_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85c2fa48fde14cd796cde7eac723cdc9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf5b3db7d10d49d98b2d4ef9c94455ad_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id74922aa0e2c416dab84eaa66f9f5e9b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4fbc708e24684f8c9c6e746a68d8705c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ided937c13e414b9f9a600c9abd30c643_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie382e8171db64a9b8b111fb4def54606_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07084c19d2c84f91a4a467900df34873_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4442b581e9fb476e88434975a33029ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i676ba929c33c424d9ab4a59672a49177_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2d18c502e914148abcdf8a1c2043e91_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icfb95a9cbc524e899e63d817b3d8db10_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecc04b34723745959d6941b061c3195b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if2d60cf3b5dd4469bb5e47f010bbf50d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2d3c9eab53e34f758a889ff1b9eef4af_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia73ddeb398ad40a697491174c66a253e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic1d2c2593af94b8e894e62f71bab9723_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc55d9233fce40c7825223f6de02ff68_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if8497a03630a4de5833e5a80958dbce4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if3d471827df64e0fbd5711fd783ab1e9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1512c924cb094c078074e4aa0ffe4a40_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7093ac6fc1334022aa3265c9294c3e7a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i13118f68b4df41a393ca9750e6026f86_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia8202bf5ca3346e7b18cf85e6d73a250_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3e77a2db2998441c921cc42c8c4a50c8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i99c0052b44d34257a40d70925ddf626c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0b552f30645f4c44b3ed3df8ec2d60cf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i38cb6a98dc8e41d69bdbcc7404a2eb8e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i85b5b7c7ce56466d86e248603302e40d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2cf0cf8e00c24e43afee18043d34a006_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i134b8d5216ea4c389549e0da9a4a0aae_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8a85fa3c7eea46178ce2c429ccf9dc45_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id5402810168f441a989e311c9910ffff_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa9d2b6c03b4436ab40680ad98a02f2a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if76287d4ad9248b093a21f0f369b5af6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5d02c0d1ca7046cc873ad6dc780a7de5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibb0bbb2a96944d2281f1f89a0ad18937_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i90eeaa1d0b8e49aa8bf06da2ebbe726c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i78c91ac833ae4d6a85617b9307192c5d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ice8e52c2f7344bd9aaac24f3c709799e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9d4e7897d68043b2ac3bba1cb881d410_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i57206313b8ad44a69c438d9a2d26e856_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60b628768eab4646b40e4bdaf0246e63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id5c8146e6c714086b4e9c25c3c92eed0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60de702a35f848f989e520b9af116415_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7a7d5353c4a04e4bab13e493b248f929_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic1b9f564f7684ff0b786ed6ee60bbc93_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0a9c4ec0dda0434ead7d7e333f7c0370_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9e98dbf115d34eb7a1ad3c065774fa63_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1219c91340a14f5bad320111435c4733_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i32f288455ff543adb3dba8d444c258df_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i62565a11ef494521b8f3aa6a1473a264_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d948a6f072e4f7b8c8b385b727ebcd0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7532691dd59d4bdeb91fcdaa78acc1ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i90067b409ecb46e7a0730f1885ddd46a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic5eb558f1acd4fa3890d17ea839f934f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id1524d6d70de47e4bf378c17d3a6fb88_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i98aa749670ef4cb2bcbe79c1b3f35d01_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f3c80353f4a458e9cf3e5ea8ee4bb86_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i88876a23cdf3417d8234422eedf815f1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic084d62da2994e0b8eac7d247b4df526_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icf690e4cf1844b909f7af94cd53ff788_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4df44c5814334fcb9850108f2c45d7d7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i37e1d6d0d86b4260a9dafbceb3ca67b3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i92ce595b55e84cc1b6036ed5e3783ef7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2a82463a67ee4a98aebdb33bda1870ee_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iff834d7d5db945ffb10479e4d06e77d1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i60250601219a4629a0ff2f0c1dc4062f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idbf24fa76f6a402bb9e6156b05d6b5f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1c4612f6b4d649079848c866b406b98b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45b5cf1e2a7748d998e39be96bdcffe8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23ddb02b4b9240f4a9c623f147564d77_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id1ac25e181e840fcba249ad8ca572ded_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i02972067b44c4ebbb40b0dce231c9b74_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5788f2e64d25455ab4cc8ee55962643c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2c98652fcf224ee890fa8c7644b8f148_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3901dd0ca3ae42fba60b944fd1072d67_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7242e85fe1ed4cbc935e2d4c982c7f86_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7796cbaae34c4708bf7e612f118984d4_D20191001-20191001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-01</endDate>
        </period>
    </context>
    <context id="i49d1b68c815f41ad8f89064d1e9fc9da_I20191001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-01</instant>
        </period>
    </context>
    <context id="i46d706dfc2e941c7aceac6173927bd08_I20191001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-01</instant>
        </period>
    </context>
    <context id="i3ab0c68ed13d4af2b182ef303b0fe3ad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9bfb00e0e8444c42bf506fb600021040_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4a13f2e9033b495d9444dd5e982f843f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i497e92548eac4239bd07de80e571194e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie43ad075e98f4dd89ef32cfaff2d61e7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5c5435fc465e4452bd424177d30f58bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica7020a01b884f0db71be5081d3f6c00_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2717ecbbb85c46189233254a15f62cb8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i98399a1cca534743bbf269f1fb3a7bd3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaf8b907b90fb44f7aaa306fa87dcc261_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i316ad5c435e840ef90de3b77001a0859_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idf3f33246acf4dbca28fc09e8480089e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7d696c5338494267913e8de2e88aa076_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib4174779ec8e4c1ca5559035fd373586_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i497f5686edd647cda52dac088120c9ef_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7f354431d8b04f3bb3386e747317da6f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i87368b9b19074dd5bcef3473b1da76c9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaa57f23b3f05469cb9fb7459da7dafe2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icae95739a04e4d7e98f843bed573f29d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8d6a7be2d30645a2aa38edcdea6ea2d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16f95753426e401589837076426992c3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2400aa7f3799471ba8c54285606aa32b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6324b2addc314c438452dc1212149f94_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes450DueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i460140edb8e84ba8a14c588b51b5c03b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes450DueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ec30846b9da42938cce5010c3a35bcd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iad32b98d9b574350bd3358b9c05d9ce6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i53587a104f1b4a54a2d8ff9c9b6bd142_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id810e7631eea4dff84546da8b682136d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50e1cfc4864b4b47939f26aad6d97167_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9962ff5f6e1a4381b06b75c4fe70b3cf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb407c4dee97479aaed7d0a54af5a221_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia4435aa298394060ac34998db6d5518a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a207b5e7c8f4f558db12a478c0a5d91_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if2b37d1f5b4f444890c50f2aabcafde2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id04297c5b7e24c3baf8e9267fbf3225d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8d7ec9f615434b68bcfe0abda5733b00_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i01dddd98cd27486db73e8eb05dad1238_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i708265c3841641feae11212bbe24bd13_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i50ef442c17d9418f8c9a539cb1195ec0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iac1907fe5d474e3b8211ac9e30f9be82_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie72ff37863f94b4283e88af507ae245a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib31dccdddcfb4000b0c308332ce9f610_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc75983ef66546d6bddf3613cff7f8a4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i05453b6c881c458a820a5ac7d0ef7dfe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic43b82b77a204cbfb726e9c81f307b6e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2fb8e2769d544690be3abd9e969d7f6f_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i31ba7f21ed03439b841008aab77cae59_D20180601-20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-01</endDate>
        </period>
    </context>
    <context id="i53bbc40a99854970b78201ecfae1f0b0_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i7d6f3842a7cc43d0b05b379a3197003c_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i776fc34ad45242c7b664a96b5697cafc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i395e8b6493b243d785d218551ad6bc95_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i84316338b21741c5b5edb758134470bd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib4c920ee5bc74d47b13bdda58721672a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7cfbb77dee664f9f9fafde904ea66301_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i680f1d5e868b46d9b7570e6c1901ea09_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1c27340fb9c6435297c9931c627217e6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia89d453429494c1db0f7a576c7b8b619_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ica05a2309e6e49efa816d3d0e6070d96_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b43c4704f924701a890d5f962a8caa7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c8b8449c734458ebb0e65b656a6f94b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7eaf4c3ede854933aa1ae74e0977f05f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0c735278fc854ebcad677441f39d21a3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id59f859e9860470f84bad3c7b6b2ddad_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i00c24c309eb54c4f804c01312f186da1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idde9534012fd4b75b3ce796e32bc14a2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaafc5c0d6e0c425db5de7640999583ad_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iebbc28b6be8d43069e00894b8781bf0e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i084e681a0032449983710ed54eb3ad01_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2af09f0132c5448bab7483f939d8c584_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="ib9d8578871b7406b986dbb995cb8af67_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="ifaf7cc4e25d7482581fa9522ffd8054c_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i756c2741402c442dbf8d5d9b6d2b0761_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i0cf372dafcdc4256a52a45555ce48252_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i6f2e689cc9bc45aea09d11c8f10fbdc2_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i62a835f93c3841ec9faa2b983380dc84_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i26953919345a48ac8c4fc7b3d9f771e5_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i24b0bf33724f4f958b89a4381b10a2a7_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i7225129913c342a3996cf248b001bd71_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotesAndSeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i1b169ebb131842c7b5dab7380388dbb9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i556544584b844001980693b54a079641_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="i422f3d2912d24190bc5966214fdc77d5_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="i156e9d3804a244b6a29b74a3e3e52c7b_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="i0b8d1168c7204d658dfb66babf4ccc26_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="i38b42858a98247d79b9bcf64d8e4cae8_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="iaa041cac555c42fba824f78513336e7f_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ic9330108a6824e37b8217d2a11ded672_D20200116-20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-16</startDate>
            <endDate>2020-01-16</endDate>
        </period>
    </context>
    <context id="i7907ded04dab4554a0ef907fa261b6f7_D20191216-20191216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="iba7b866fe620404c9be6000f21284d31_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="ifc5ee50d3e974a62ba9571a1f2f84fc0_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="i35061b0459224831a5dd5ee11d9692a9_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025AndNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i4927b0e336fe4ef1b1ffb40e143d6d6f_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="ib1fd33b8ea2042dfb42c2639a2b086ab_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="id782e23cbd724954b6368623a4d54175_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i1f1c7ed275704247962d8203458ab574_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3e190fe005974b5ea0fe1ade4aa15972_D20201029-20201029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5875DueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-29</startDate>
            <endDate>2020-10-29</endDate>
        </period>
    </context>
    <context id="i9b698175e9eb43f389d1012167ab199d_D20201029-20201029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-29</startDate>
            <endDate>2020-10-29</endDate>
        </period>
    </context>
    <context id="i6d1265def2fe4e2daba508971d3b269a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2f844286327848db87c6c0846469186e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie31f5ab3c2924d3b8c230faa96e03243_I20140531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-05-31</instant>
        </period>
    </context>
    <context id="if1234c5878b345c3be0c7887e84c8c4b_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="id1f9e1c5bb0d428cb4b9c7514e892230_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonemployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i37ebdf9ce1ce47ce953dd272b4116d9f_D20200428-20200428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-28</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="i5bcdb72d89d2453a81215c5d89199ddb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7e5e06f512ef41418fe077ef11562faa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if47991fff46a44fa8907b87f6e475934_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9c1f53d1c1fd4dd699f102722ad4ab30_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb6705ae1cc944e9b0c9948e2cc52937_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5d204a1b39c34ebf957a3002d5e89825_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i106b3eee455e4af59474ab03ba414fb7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0e61c443cd46403f897e0842ba3f568e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie657a420eece4d10b6860b72c457aaab_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ife7d401df9e9436187d1434bcf9382ca_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8a7f83031f2049529b19147c57eb7ff0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id9987cef2d1d4602aa101e2592aabc48_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0418ceeffa1443e9802453c68467828b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifdf089cab8914facba6578b77bebb264_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide4414ac166c4b98b170244eb491149f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6f757f31530c45ddaa86c86406b50a0c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7333dc2ff308421588477f444d77526f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iffd6ad7504a94a299b44307bf31e726b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5b3127099e704d8e902e5069aa1e0b13_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i472ae620787344d6baf50d96060d90ab_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i898bb6c7930c478587dd044061b9d2a2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i741bd4dd7c0149f6b7ffc048b13bc0ee_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic862f703a2734648bf7d042a71301d5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i57608adce9004fa8829f1bf5a0f4c66c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i21d1c6b9142d4a759b71dc4abddbb243_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie07c162ca742405c98233c58abdd8aac_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1dd54993dd634b0e82dc598e88544ff5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i762b42904b7d4c47b7d9c94632f27fd6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i70173b7267ae47adacd4ad3ca61345b6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcfc0abb71864f4a8d26e6f9694c6f5f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i563b2181888e4e4ebcc9b80b5cc2f344_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6b05369642d5468d80a1713347b981b1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5aaed5342aab4e6ab0cdebeb807e227b_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9761d415100240bda346f87cf5e43c87_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="if22f2ae279114a87892281886f95c6b6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id21158059b994e63a17e72acde64ae62_D20200804-20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="i15509ff699a54e30814d181db390b519_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="ibf179bff49a0406f8a4e9ebf6c739aa8_D20160527-20160916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-27</startDate>
            <endDate>2016-09-16</endDate>
        </period>
    </context>
    <context id="if4b754682f144667ad815ed4518db769_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="iee5b12e58e9e44f8ac5eb07d4df04f45_I20190913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-13</instant>
        </period>
    </context>
    <context id="ideecfb512d4a4ea28fd5ec735471c964_D20171207-20171207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-07</startDate>
            <endDate>2017-12-07</endDate>
        </period>
    </context>
    <context id="ic882bdf321904c1a8e0bb5f1007fe242_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i45d3c5867e5e41f8914f1ce2d2dbfc1e_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i69e5ff05a4c0418eb2417e345fc2103d_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="iab043430936d464bb3fafd27f4d9e799_D20191125-20191125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-25</startDate>
            <endDate>2019-11-25</endDate>
        </period>
    </context>
    <context id="ib845c8cc5de943d88c90123be7710ee5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5e0b356ae3324301ab3aeacbefbdc8b4_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GenericPricingAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i2988c46f79404f97bf0bb7d6d8a49295_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GenericPricingAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ia09727ee9461493e9f4e2df94a1f1591_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4e734b47f6ad4ad984cd62d97f81a208_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="id819c010b7eb43699a500c0115cc5647_D20190128-20190128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="i7ce77ea687ee470cace2bc7c9451c86d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SECInvestigationLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8cf776ee426f4162b6f648f87bccf843_D20200401-20200401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InvestigationbytheStateofTexasStatesMedicaidProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="i897313242ab641dc9046ace39af16263_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id12cb1b6cda347f9967513c7742fcb23_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i80d7bbb8cfa04946a18339b2648304fd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d197803d96f4ffcbd4159fa39ebc261_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic7932c3cbe2342548eee1258aa49347e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idafc86557cbe4d14b4c893a64ca76cf9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie7fe2b7d367f4dae834989f4487131d7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74f4f9fe18664f5683fa137fff600592_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9630fad3411d4ecdbb4e6cecfef710ee_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2fff547485ae43d2968ff0cc7028a326_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i353913d5fc9242c18667b11e98757190_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i34a7b69b1fdb4a07b595627842521754_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie96a2f7723254ec5a9f11c4c934d4889_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib9c0c48d8f5d49e0a298cb9e6244ac8a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i945442a1ab3a4f6fb3811c26a1bab0bc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i961d00fe6e394e0097042fdf55f1f75b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if8298bc44b8d4fa9a438061d2df01a40_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i992e52a4d5fb436e95fb7cfa4b72df3d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9c51a36d127d44c9946fde415735fe2c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id5c46aa3b1cd4b5789f0ca5a453ed7b5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i73f73a15d2634d3a8c0cca7a35b9ff85_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9fcb52bae97844d694512c2bb87bdf17_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i85eae108232242838086f4642eb70b08_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i84c3fed40d05492ba7b7087a16d03b78_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ief0221b682984fa68ee492bfa59a5d75_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i12293851b1144e018c4c9985157b6af8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie45707f6b6bd4627847a810f8a92f826_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i51df325c7f5b40f7a71d8a18b3dcdb9d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i29ce34cdc90749658459a53d39ce83a0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib99f5f97c68d4eafb2e79dfd4f048b96_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i094e6cb87ab042c69be51aa8c8116f04_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic5be2becb71a48feaf9761c4c7541a2f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib990d0233da244b0972eca21ff43328a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5062980ba6b7479fb407d0f9cd02aa37_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iead2ba6fee0a4fb5b5d850fb95ea9e74_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i314220a4165d4110a6c992a829224748_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id732816e0fe14e848ad4ed7bcec29df9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7720a5e8447f4e1381a984683f37f801_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i31809eee74c441e785284208908b1f6e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79ac2fb975044cb48922c5f545218179_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i64afb07c58eb4178b97dc69e29d5361b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7daf0166ae784d4dacd516d2bd1ccfb3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icef91f1f0ee3457e970eccecfdf34433_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8cd9b71a39574ae1b4eb9b5b3a159df7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i94726a2e6540441193932a85a2d2cc8e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib0e74417efd54c5fb043305c8ecdd0b5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7132aba1acc24050873b3abeb89f87fd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b45b1049375405a9881452df1db8885_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia1eba4cc97be4881bf868d652d2c87f5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1195d51db05e405381373f1b2ed59c87_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia7d8c27663374e2881ba2608476c974d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i579b7b5f0e22488caa4243c078316934_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7396b7657687421eb28bc8e668bf24f1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idd8079e095cb462d8a0027725dbbbf9d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i28e935d66b524719955d26d4a15f28b7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idda25f4386fa403f9d99a5596c2399a8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i83fe7793dda5457b86b9bdaa7e2b4a3b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f08c50efaef40919b09f698d45f387f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic915105196dc4a20b1ba1cd55527b01f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b4872d17e0e4ba9800e4027b125c7d6_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i25793ee653304f0aa6306ddf6ef5b8de_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie59b022ef9b644f1996fe90ee1d0db81_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8648caf684ff4103860761d13f0a4022_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ide34d3ab6c14458cbfef1276056d1463_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if93bc6d99c624444a2dd857bc569b178_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9a664e5247e946dc82a303af2757e881_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87c11c3e047f45a8adce344026ef9adf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i868cfdaa81514efeb8f0a0de1e553842_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id1ed423758174f5d8bebe48cf827f4ad_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i83c702359f3d476aae3c6070536997d3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2e4dc2eddb6b41afba1498f1b41eb3af_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4a6bfdb0ca114a3a8781da2f91c440dd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7f1c56b5e7db49989979d7e8ab238911_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7a10616d5c494d258d21007f1d4ffe1d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ica0936b4182347c0ba81f792a94fb471_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2c8c78d6fd8848b4959e510c9f80474c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i663dfd024395400792b600237c407f71_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7bfe83d14ce24791a3d5132de0b09aac_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia6f9e05033db4fbeadb4c0989ca169b4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i57f934afe4f64ccf8f499b8522d5d316_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i72cef8d89cc3414c9c3e300be0a5e506_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i77e2e17f2af240a08bb7068b4295f5c2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i831dca10038f44b7aba289500a72d53e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic04ff547f0df4e0896495412b8e3aad8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic6c2d87d9fe043c1ace3fe783ed9d84e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0bc10941479946efa1ee8c411876db52_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia0a85a453134467498de7319fa2fd19d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i370c9e50384c49a68b916ab0f055e398_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i38ed869b702741d29a4ebbc97df0ebaf_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i49df4ed56dce435c94526ec4c09c1c2f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id17680b424174ddb8afb72789e7a072c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia00b7a96dc7c4c748b6fc009269bf96b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9e1bdf848e27419782e283160a6e7641_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8106cbd6b8fd4566bf0bb4e848d2fee0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4cdf8fc7e882466b8e513669a8181321_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib806f0a34d7f41cc8b031f6eebdb460e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i56662828b4c14cdaa652dc064c47d1a8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i57c5373b0b2e49bd9e26811bcb5264d6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib8358f514f3b4ffda10dd8a1dde466f9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia4b46b63623c4a798936bae68871eb7f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0816679b5f144948af03427be4bb31d5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i786b9c0d86944563927834ab30da4a64_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i72b229547ad046528b0cd05c36cf6248_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie62332dea55b46b8954d57e7ba3dc9f2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2c0e7f99a52e43e48893dceaa0497adb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i62f195e557e04786bec86a970774242c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0b960aeb700f41daa129bb69d64f7f80_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie6b601a52f89407f99c32a3569b6cd90_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i68bed0a8366846bca633f75f6ce317bf_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2bc889ba7d354ed0a200fac110801a10_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idcc89498ee0a490bbbf373ea6031e5d4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idfb0d8e06b70439093e5b2e57f467fbd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ice49f702f91540afa6e04bac724e0f16_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6a7ad86ee09244ffa6a3158acbdb9e91_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ide576ffb75654cfeb9e83e3cf858df8f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6869bdf9417e4259950f8ca43e04a5bb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i169f654e818c4d728fa7590a5cc9e306_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i67120e7176db4b1883ff589a8f3f08e7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i10d41709f1fc4926a6fb326d3fe3ba3d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5602fb5d32ec4b2382470ba9e6490b80_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i468251afcacf4241a879487d7f54a848_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7de78745671b495ab8a2e476e94c3894_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i79496248f2784fc4aaefcbc556fa23ba_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i100bb87dcfcf4840a8fecbd84eb6c20b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79f857d233d64f27abaa8c813fb2a7d9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b2eb21ef8614e1da439f89a40feb4a7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i21a3c7c318944c1bb5d18c5f1f1e809c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i54ed07bae93244349ef6061cab4695fb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ied4647195db84913b150f83d6b75649e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icecc5176f338476fadf188689a0d0f68_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2afc3f9dccba4cd1820e8c7514dcd21e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie0b6efa686104cbb8083a6040e07a9e2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icb4e98e35c504f19af4f7f6f7f90aa99_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd721943ada444938c0d07fde3a6cc26_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifee8da0bfabc4a0c9e458c09a7305cc3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7174942dd2a84a72be602fdbd7377d7b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd7f0a0d16e745bfae02ba539c5e89d8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BaushandLombInternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id56b60056c744cfdb5d527a6fe378f4f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1062e5544f2849cd93a2b26f2aa99d36_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i67fafda9e64f435ab86b3c470ccd987e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia3b658a083e346888a69fe6190860bd5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i73b54d06035d4aad967bc1fe46878888_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8e0f0ac6ffaa46f4a17dc33321f25e38_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0fa6a46c3ea345c5a6bd0ff77c6ab9da_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i27f07775356c46c28fa094499e05be60_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d30a915ca464a4ebf4fbbb5194076e0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i02c96794f6994ca0923eb04b451e6f05_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2ef026f34c88467cacd0c7e88c3b10c4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i796193ce9afc4d12b6379f979c427b32_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2f7be92a538f410c806913c3950dc54f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic14c7ebc09514fa29a41b6fe5a2836f8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ebbbb3cbe22449e808dbfaf4d1e174a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaf506968c6f545d189921bdd9e912182_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id7e8c38f3f154fb49bb310a1dcb6fd83_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9a1618b6d63a4ef9bccc4d597fd44d7d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i95891e4c7e3e457580e75965a1382082_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i16d66aef5c9743df9092cc861ecc3cf6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie36ad9ac246b4dd0bf391aa521396851_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i577cd70d30de44d98818fb4178e165de_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i342f9146a8194fbf8362fe186beb1150_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iac25f9c6e9594c37a2bc71cd2f9ac2f7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id57036c953dd4ecd9a2259ce4d2a664d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i59b54efdf337413095503da19334d74f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i81d0676dcb034bed9b3ac2d108318bfd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2342292213084417ab197a7ec39e2b32_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8c453b5fedc64ccb8be26bdd2dbce3f8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic899b1ac11d94d5f912e083ac00a9925_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i02bb5c4f94dc483eac3113fa75769620_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i208fbc90ac92433891048e7b267b2c4e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i263314b31684477a858ce1870a2e2935_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i518266816f6142088c1cd572e0b2e809_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3810d5f192614d9e904b2333976b6d3e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib90335586b5244348e2bb80b34efb485_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7ed3660f61d54acaa7f0f86779347965_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4bc7e5aff7cc4ff89c60f1e3e20b5914_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i92707ddce02f4496b1a61598b20a9fa3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib1ec6e666dbd4225ba98fddbddb193e8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib838e1722e0e4d97a13e8bf28d909626_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifbcd2550da3f4409b5137f5be1419151_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id92405cf9f6e4d37a4052058cf207929_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i711aaaa53fba4ac29293979ceec66046_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida52154f667f4dc8a7f3ff3a48088ca3_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iefc5f79887314486bdc0ac6a2c93b5f8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac5dd515351d49189d4ea130cb854c26_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i36ede38bb8cc4a18b46ced535622b166_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c7c731a4d7b4bf69d3798a82bd76fdd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie59f176c51ad42579aa28217a7a898fd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9be82f95757f4dcbbd90b7b2c038ad94_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i03b5d0d8f5834a3db8a3fcc9475f9cbb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2a61a4c91bff4480a041bd2adb0a40b0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i55062b8f73664b389c95dbdb8d84eaf8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2dde1c7051314b9aa3cda5a9a878059e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i173c07ccf3334f6d87290a617f2f61e2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id597c4b3289e490a8b7183707736dfff_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id87f54aacbd14ddb9195134667720744_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iea718c704e394d629a0bb52b758793a4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia6a8f2aed6a0439783600917b76ae723_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i74b9314e78a044d0b3e782173dfe569e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4caac1fc03db442481ef398991140fe8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b8c67a640b5458da2fe72d26d0b549d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="country">
        <measure>bhc:country</measure>
    </unit>
    <unit id="product">
        <measure>bhc:product</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="case">
        <measure>bhc:case</measure>
    </unit>
    <unit id="group">
        <measure>bhc:group</measure>
    </unit>
    <unit id="action">
        <measure>bhc:action</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="entity">
        <measure>bhc:entity</measure>
    </unit>
    <unit id="insurance_policy_period">
        <measure>bhc:insurance_policy_period</measure>
    </unit>
    <unit id="healthplan">
        <measure>bhc:healthPlan</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y18zLTEtMS0xLTA_71e2265b-e0e3-43ad-8ac2-db84ee316a98">0000885590</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y180LTEtMS0xLTA_39d28950-a424-41f0-9d15-6c3512834380">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y181LTEtMS0xLTA_bb81f688-5059-4577-b2ae-f0be5031ef2d">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y182LTEtMS0xLTA_6eb15814-f4c7-49d2-ab29-147025273cd7">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180L2ZyYWc6Y2FhMWNmY2NjZDc0NDY2OGI4ODI5ZjhhMTY4MGE0MzYvdGFibGU6Njk4MWZiYmYxYWVkNGUxY2E4OTE0NzI0NjliZjAxOGMvdGFibGVyYW5nZTo2OTgxZmJiZjFhZWQ0ZTFjYTg5MTQ3MjQ2OWJmMDE4Y183LTEtMS0xLTA_25041103-031f-4868-8e22-05b0cdd15fc3">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjQtMC0xLTEtMA_f74c8ce8-3b2b-4446-b674-801bf69a03f8">us-gaap:AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ0Nw_fc60b351-a915-4b1e-a9cf-8bbc63693281">us-gaap:AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6d1265def2fe4e2daba508971d3b269a_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183MC9mcmFnOmU4OTA5NGU3Yjg4ZjRkMzQ4MGRmYmVlZmU3ZmJmMjllL3RhYmxlOjcwOGZlZGJkMmI2OTQ0NWNhNjliNjc1NDliMGU3YzNiL3RhYmxlcmFuZ2U6NzA4ZmVkYmQyYjY5NDQ1Y2E2OWI2NzU0OWIwZTdjM2JfMy0xLTEtMS0w_4267d429-dfe6-4215-bc35-e5db56b625b7"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <dei:DocumentType
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc3_a55c6123-632c-4d50-836c-ecc0d8ae04f1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YWE5M2RjNzRjZDBjNDI3ZTllZmQwODBkNTkwMGYwODUvdGFibGVyYW5nZTphYTkzZGM3NGNkMGM0MjdlOWVmZDA4MGQ1OTAwZjA4NV8wLTAtMS0xLTA_63f43dd6-98a2-405e-b734-62757acd1b42">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YWE5M2RjNzRjZDBjNDI3ZTllZmQwODBkNTkwMGYwODUvdGFibGVyYW5nZTphYTkzZGM3NGNkMGM0MjdlOWVmZDA4MGQ1OTAwZjA4NV8xLTItMS0xLTA_f0e45347-c373-4c61-bb0b-40e6636da09a">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YWE5M2RjNzRjZDBjNDI3ZTllZmQwODBkNTkwMGYwODUvdGFibGVyYW5nZTphYTkzZGM3NGNkMGM0MjdlOWVmZDA4MGQ1OTAwZjA4NV8zLTAtMS0xLTA_5edd564e-f6f4-434f-b842-7b2702c21ab4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTgw_18e360ba-600d-4d72-9e2e-8208504a9724">001-14956</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTgx_16af0fb4-f0be-4e9c-a5fb-b6a91db2af1c">Bausch Health Companies Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6ZDNhNDk2OTZkYzZiNDZhYmJmYTE4YmNjYWQ3MTY4M2YvdGFibGVyYW5nZTpkM2E0OTY5NmRjNmI0NmFiYmZhMThiY2NhZDcxNjgzZl8wLTAtMS0xLTA_bcd81431-5115-4202-9c55-46654872c7bb">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6ZDNhNDk2OTZkYzZiNDZhYmJmYTE4YmNjYWQ3MTY4M2YvdGFibGVyYW5nZTpkM2E0OTY5NmRjNmI0NmFiYmZhMThiY2NhZDcxNjgzZl8wLTQtMS0xLTA_ad880aac-be60-4d9d-b561-a4bb931ddaa4">CA</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6ZDNhNDk2OTZkYzZiNDZhYmJmYTE4YmNjYWQ3MTY4M2YvdGFibGVyYW5nZTpkM2E0OTY5NmRjNmI0NmFiYmZhMThiY2NhZDcxNjgzZl8wLTctMS0xLTA_8673f230-0f77-48eb-a743-edf0ad92d376">98-0448205</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTgy_9dc8e9cb-feb4-4ee8-833d-d1d254334833">2150 St. Elz&#xe9;ar Blvd. West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTgz_8fa9e64a-89b5-4c06-bd62-4ac79e2d4867">Laval</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc0_ee65cb7d-f8e0-4f99-bcb0-f0c7410c5551">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTg2_9272e2c3-f814-47f2-aec7-5ff26cae642e">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTg3_5d41e7a3-d628-47a1-ba8e-477677d03175">H7L 4A8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc4_cc9cd1e5-3247-472a-af1d-ad1e293b0312">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc1_7289f567-0872-4194-818a-46a3c8073bb8">744-6792</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6NDM2MTJiYTk2NzFiNDAwNmIxMTU1NTNlYTdlOGNiMTEvdGFibGVyYW5nZTo0MzYxMmJhOTY3MWI0MDA2YjExNTU1M2VhN2U4Y2IxMV8xLTAtMS0xLTA_183b2cf9-cc86-4594-86c7-7f8e380786ac">Common Shares, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6NDM2MTJiYTk2NzFiNDAwNmIxMTU1NTNlYTdlOGNiMTEvdGFibGVyYW5nZTo0MzYxMmJhOTY3MWI0MDA2YjExNTU1M2VhN2U4Y2IxMV8xLTEtMS0xLTA_879242a5-8bc6-422c-8159-0c7bd2593417">BHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6NDM2MTJiYTk2NzFiNDAwNmIxMTU1NTNlYTdlOGNiMTEvdGFibGVyYW5nZTo0MzYxMmJhOTY3MWI0MDA2YjExNTU1M2VhN2U4Y2IxMV8xLTItMS0xLTA_c13769bb-3e04-45b0-b381-3b1a38a26b5f">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc2_1285478a-5ceb-4211-917a-1d8d0c78dcfd">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTg0_ee82dd3d-8c4d-4aa1-9d6a-49cc692f5510">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YjFjNGZmZDk5ODcwNDBjMDhhZDc3MDU4YTI4MGQzZTMvdGFibGVyYW5nZTpiMWM0ZmZkOTk4NzA0MGMwOGFkNzcwNThhMjgwZDNlM18wLTAtMS0xLTA_009efea8-0a0d-4f09-bb33-6a5aaa5ee664">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YjFjNGZmZDk5ODcwNDBjMDhhZDc3MDU4YTI4MGQzZTMvdGFibGVyYW5nZTpiMWM0ZmZkOTk4NzA0MGMwOGFkNzcwNThhMjgwZDNlM18wLTctMS0xLTA_5cc012d7-7c16-41e6-8427-9b7b82e62c21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGFibGU6YjFjNGZmZDk5ODcwNDBjMDhhZDc3MDU4YTI4MGQzZTMvdGFibGVyYW5nZTpiMWM0ZmZkOTk4NzA0MGMwOGFkNzcwNThhMjgwZDNlM18wLTktMS0xLTA_87666884-cc0a-4729-b794-711dc085d0fd">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTc5_ba380940-2f62-4ebf-bbe6-5533f8b407dc">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i58165bdb49574b6aa695effb47a3b6fd_I20201029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xL2ZyYWc6NWEyNTMzMzM1ZDJkNDYzMmEzZWM5YzhhZDNhYTJmMzYvdGV4dHJlZ2lvbjo1YTI1MzMzMzVkMmQ0NjMyYTNlYzljOGFkM2FhMmYzNl8xOTMw_5182cd31-eec8-4c8b-a094-2ffed00a5f80"
      unitRef="shares">355151002</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMy0xLTEtMS0w_6b74a35f-70e1-40b5-82a4-cb9b359cc3f5"
      unitRef="usd">977000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMy0zLTEtMS0w_b2d5ea94-7b58-445a-b300-8a34afa2b4e8"
      unitRef="usd">3243000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNC0xLTEtMS0w_3d3c8053-3a48-4c18-82e1-64a7d1c02ab0"
      unitRef="usd">1011000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNC0zLTEtMS0w_a7c14ec5-53b0-4727-ac38-d140be0c7473"
      unitRef="usd">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNS0xLTEtMS0w_d2aa71e2-687e-447a-97a3-f4ad746db3e1"
      unitRef="usd">1733000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNS0zLTEtMS0w_9c38822c-efe3-459a-a041-6fc46f87acff"
      unitRef="usd">1839000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNi0xLTEtMS0w_b2cd88d2-3f81-4bc3-863b-963f705d2d85"
      unitRef="usd">1224000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNi0zLTEtMS0w_0565fd26-db62-4822-ba87-454bd8ab764e"
      unitRef="usd">1107000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNy0xLTEtMS0w_245ecd22-d845-4b99-be3f-a3adec4c6309"
      unitRef="usd">726000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfNy0zLTEtMS0w_aee5ff7e-8b0d-4216-ab70-1198627701be"
      unitRef="usd">779000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfOC0xLTEtMS0w_4db5c4fe-d67e-4f86-b6c3-0238bbfbcae2"
      unitRef="usd">5671000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfOC0zLTEtMS0w_a0506b18-4f60-454d-b804-ef62e01ae46c"
      unitRef="usd">6969000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfOS0xLTEtMS0w_5c7928b7-1e6c-435a-b905-c91e509cc08f"
      unitRef="usd">1550000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfOS0zLTEtMS0w_2a78c76c-e467-4662-a507-41482de21893"
      unitRef="usd">1466000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTAtMS0xLTEtMA_a1ffdbe4-37ec-4854-99ff-274a8a07431a"
      unitRef="usd">8923000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTAtMy0xLTEtMA_1e6a4635-f2a1-471b-9f1f-d2cc9ef2de80"
      unitRef="usd">10201000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTEtMS0xLTEtMA_bcbadd75-8103-44ab-a8d8-f3ce9a1d29ef"
      unitRef="usd">13160000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTEtMy0xLTEtMA_57443242-dce2-4db7-8971-cba309efdb8e"
      unitRef="usd">13126000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTItMS0xLTEtMA_535af6e3-d7ff-468b-84ca-bd5e131561b0"
      unitRef="usd">1913000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTItMy0xLTEtMA_b0280887-8632-49b3-8b52-d64d5c14261a"
      unitRef="usd">1690000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTMtMS0xLTEtMA_a4a73d0c-a5fc-4747-b219-8a44fdc8db57"
      unitRef="usd">345000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTMtMy0xLTEtMA_a85c16e9-7d06-44c6-b2c8-8a29ccd8db40"
      unitRef="usd">411000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTQtMS0xLTEtMA_8254b89d-c986-42e2-8f4c-645ae2ed3c6f"
      unitRef="usd">31562000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTQtMy0xLTEtMA_759b6745-671d-449e-91d1-9f2a054e2424"
      unitRef="usd">33863000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTctMS0xLTEtMA_dc866677-7c0b-471c-bf02-04890a742236"
      unitRef="usd">379000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTctMy0xLTEtMA_d7b95dd7-110e-42a4-89e4-a070b3a1c184"
      unitRef="usd">503000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTgtMS0xLTEtMA_81abf809-c5c9-4cc7-b74f-edb1580c61e7"
      unitRef="usd">4353000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTgtMy0xLTEtMA_de6eea64-9a3b-41c8-952d-cc99c33df0f0"
      unitRef="usd">4511000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTktMS0xLTEtMA_1a7bb015-c7b7-45e2-b5bd-58ea6b8f062f"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMTktMy0xLTEtMA_3f5a7c67-4bf9-4145-8018-6e6b77b2a2ff"
      unitRef="usd">1234000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjAtMS0xLTEtMA_2ba996d1-18f6-438d-b228-e420da41b46d"
      unitRef="usd">4732000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjAtMy0xLTEtMA_27e9e6d1-e904-406d-9ccf-06e816813aa7"
      unitRef="usd">6248000000</us-gaap:LiabilitiesCurrent>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjEtMS0xLTEtMA_32dc226b-a6fd-40d2-b7c3-f188690c740f"
      unitRef="usd">275000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjEtMy0xLTEtMA_eb7a87ab-f27e-4836-b42c-b695c0b67e2c"
      unitRef="usd">262000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjItMS0xLTEtMA_e7e46d8b-b7f3-4daa-aaf6-b5cdad2ebd99"
      unitRef="usd">24343000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjItMy0xLTEtMA_11755010-adcf-436b-8f74-f0872c1db4fc"
      unitRef="usd">24661000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjMtMS0xLTEtMA_2ab31a26-58d7-414c-8b04-bee683eb0fc0"
      unitRef="usd">650000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjMtMy0xLTEtMA_1f5bbd55-2be8-4c29-86e6-7d7366cb5cb9"
      unitRef="usd">705000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjQtMS0xLTEtMA_50c2ac96-5a94-40e7-9435-9aa34b125e2d"
      unitRef="usd">907000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjQtMy0xLTEtMA_56dcfff2-e28a-4a56-9b16-e87b389b4a87"
      unitRef="usd">851000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjUtMS0xLTEtMA_6c8bc39c-5b99-4e9b-84a0-d1e2c55996d0"
      unitRef="usd">30907000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjUtMy0xLTEtMA_9756d990-13d9-4350-9791-979cd123ca7b"
      unitRef="usd">32727000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjYtMS0xLTEtMA_d836edd4-55dc-4262-8e67-84eb845b948f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjYtMy0xLTEtMA_55156f16-4381-443b-8f24-f6276d04995d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNmYzUxZTJiOGM5MTQ5OTg4NDUxZjI1ZDRlYjE1ZWY2XzYz_2a32524f-0510-4a7e-918d-fc205a9a971e"
      unitRef="shares">355026950</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNmYzUxZTJiOGM5MTQ5OTg4NDUxZjI1ZDRlYjE1ZWY2XzYz_796a1f39-79db-454d-94bf-f3ee72d75cf4"
      unitRef="shares">355026950</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNmYzUxZTJiOGM5MTQ5OTg4NDUxZjI1ZDRlYjE1ZWY2Xzcw_859899c9-9e4d-48bd-83fc-51b55be0c542"
      unitRef="shares">352562636</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNmYzUxZTJiOGM5MTQ5OTg4NDUxZjI1ZDRlYjE1ZWY2Xzcw_b28f5530-b63d-4498-8e54-383d66c2b7d5"
      unitRef="shares">352562636</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMS0xLTEtMA_2ef356b9-0940-4b50-b14c-e9179c3de267"
      unitRef="usd">10219000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjgtMy0xLTEtMA_82bccfba-b7b2-4411-b930-b019c695ea10"
      unitRef="usd">10172000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjktMS0xLTEtMA_b037c78b-3139-4f9e-9828-4eac267a20bf"
      unitRef="usd">435000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMjktMy0xLTEtMA_b6b83749-4475-47b7-9fac-13bf3197ca31"
      unitRef="usd">429000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzAtMS0xLTEtMA_bae629bf-7467-4166-a0f2-7034eddb09d1"
      unitRef="usd">-7860000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzAtMy0xLTEtMA_dccc5e74-2461-4d5f-8bba-9afe8e3dfe76"
      unitRef="usd">-7452000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzEtMS0xLTEtMA_d0bd8c8a-dcdb-4e4b-937a-024481bb0f26"
      unitRef="usd">-2207000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzEtMy0xLTEtMA_9ed8a57a-6797-466f-a357-efe9063820f2"
      unitRef="usd">-2086000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzItMS0xLTEtMA_b63dd2ec-df3b-4c52-802a-06da229835f2"
      unitRef="usd">587000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzItMy0xLTEtMA_22b8d954-97c6-4ff0-a151-678f2291eacf"
      unitRef="usd">1063000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzMtMS0xLTEtMA_30a10165-ce4a-4ff9-aba4-08901c992ce9"
      unitRef="usd">68000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzMtMy0xLTEtMA_fce3ef31-de30-4585-aafb-f6c3f1b085fb"
      unitRef="usd">73000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzQtMS0xLTEtMA_a835e8d5-e446-4947-95f0-a12a548170d6"
      unitRef="usd">655000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzQtMy0xLTEtMA_68ba0fb0-fe75-4394-9c9f-4b80be3bc6c5"
      unitRef="usd">1136000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzUtMS0xLTEtMA_778e6ac6-20ca-478e-a17f-464a36036690"
      unitRef="usd">31562000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yMi9mcmFnOmYxZDcwNmZjYzI3YjQ2MjY5YTkzY2Y2ZDg3MmNhMjI4L3RhYmxlOjRlYTdjNGI4NGVjYTQxMzc4ZmNiM2NkNTM1NzJkNTlkL3RhYmxlcmFuZ2U6NGVhN2M0Yjg0ZWNhNDEzNzhmY2IzY2Q1MzU3MmQ1OWRfMzUtMy0xLTEtMA_cebc088e-546e-41b2-b8de-fbd156898672"
      unitRef="usd">33863000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i644a5c6073d342b280ceb7503b40fffc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMy0xLTEtMS0w_d4448441-72ea-4c5c-8f98-12608b29f47b"
      unitRef="usd">2111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9bf79c1fea774ba78e8ae4e67f3aae19_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMy0zLTEtMS0w_44cdf530-cc3c-4fb5-bbfc-4559922d85d7"
      unitRef="usd">2180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie19134db53624c3dbe16d17f7a2c887b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMy01LTEtMS0w_5aa9c379-3962-424b-8516-2221c72a6e31"
      unitRef="usd">5734000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i397ad4497f454ed4b5c8ed511d657a01_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMy03LTEtMS0w_9e819772-aa89-40a8-bd64-3b574ea0d89b"
      unitRef="usd">6291000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02c3faa5394c4efa803b0d07a332d877_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNC0xLTEtMS0w_d8a793d5-2b67-4e70-8991-e6fc14bf388a"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77a193aab3454c7c8df01544d3d5234a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNC0zLTEtMS0w_27596646-f89e-4b2e-bba8-c8c9c3df8930"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e26a204cce2408c8c2b0e4eeba1bd23_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNC01LTEtMS0w_9b09e782-aeaf-416f-994e-e55c32c09cc8"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f203fd5d2ce4c9287eab1215ce4afc0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNC03LTEtMS0w_37c1d5ac-acd0-4bcc-9c85-6df6204ebcbf"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNS0xLTEtMS0w_344bd34d-520e-4d37-bb34-a82428efd1ca"
      unitRef="usd">2138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNS0zLTEtMS0w_df42d1a3-717e-4f46-9ecb-f884ec3702b9"
      unitRef="usd">2209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNS01LTEtMS0w_de66e8e9-737e-4aab-921a-30289ad0732c"
      unitRef="usd">5814000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNS03LTEtMS0w_bb58abc5-e454-4e1a-9e7f-39e37f7f488f"
      unitRef="usd">6377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i644a5c6073d342b280ceb7503b40fffc_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNy0xLTEtMS0w_b215eac7-a6e0-47a7-ad42-5b9bb851bf3a"
      unitRef="usd">578000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9bf79c1fea774ba78e8ae4e67f3aae19_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNy0zLTEtMS0w_cb0e5b36-2810-4c3c-9a2e-dacdca10d7b0"
      unitRef="usd">571000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie19134db53624c3dbe16d17f7a2c887b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNy01LTEtMS0w_1ab520e0-5791-4f45-a497-fa7f9cc3f308"
      unitRef="usd">1565000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i397ad4497f454ed4b5c8ed511d657a01_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfNy03LTEtMS0w_7d03ea7b-c249-4072-9d90-412aa2659cba"
      unitRef="usd">1675000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i02c3faa5394c4efa803b0d07a332d877_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOC0xLTEtMS0w_254d7015-e279-4d78-bc4e-8ba8cb304b69"
      unitRef="usd">12000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i77a193aab3454c7c8df01544d3d5234a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOC0zLTEtMS0w_342b07c3-9848-414a-adb0-13866ce80f38"
      unitRef="usd">13000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1e26a204cce2408c8c2b0e4eeba1bd23_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOC01LTEtMS0w_aaebbe57-d711-4931-8a83-4394d64d2d01"
      unitRef="usd">39000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7f203fd5d2ce4c9287eab1215ce4afc0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOC03LTEtMS0w_4f6860ee-d14c-4e5b-9a36-67d76349a546"
      unitRef="usd">40000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOS0xLTEtMS0w_31796805-6164-4c07-9b37-f5fe9f8bd6ac"
      unitRef="usd">572000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOS0zLTEtMS0w_0bbe461f-4f9b-469c-bbcb-f0a46f01bbb6"
      unitRef="usd">648000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOS01LTEtMS0w_512e7998-a12c-427a-be2c-b16f86920a88"
      unitRef="usd">1731000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfOS03LTEtMS0w_7e670db8-757e-4b2a-80fd-3f1a83157fc4"
      unitRef="usd">1886000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTAtMS0xLTEtMA_42090460-b958-4962-99de-3427e6ffd1cd"
      unitRef="usd">103000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTAtMy0xLTEtMA_4dbc3fe1-09a1-4877-ad35-966dbb27b35d"
      unitRef="usd">123000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTAtNS0xLTEtMA_05211246-3e96-4d44-bb44-1cc4a7bc3023"
      unitRef="usd">333000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTAtNy0xLTEtMA_3493a12e-f547-4b03-a4f3-91631c7c426c"
      unitRef="usd">357000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTEtMS0xLTEtMA_99f3d960-205c-49a0-9dcc-c7d9b50064c1"
      unitRef="usd">391000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTEtMy0xLTEtMA_55488ef5-d86f-47c9-a495-d19e3f6c5015"
      unitRef="usd">475000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTEtNS0xLTEtMA_14588fad-bdba-4094-8052-cd6cdac6041e"
      unitRef="usd">1263000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTEtNy0xLTEtMA_71f2c5f7-c139-41a8-8229-c726a5c393c1"
      unitRef="usd">1452000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTItMS0xLTEtMA_33ef9d94-1755-452b-b42a-542ef78b1526"
      unitRef="usd">2000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTItMy0xLTEtMA_b4ab8a8b-8fad-4915-851a-46ff51e9cf76"
      unitRef="usd">33000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTItNS0xLTEtMA_b3d6b38e-1e86-4f41-90cc-bececbf8df90"
      unitRef="usd">17000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTItNy0xLTEtMA_f28a9d0f-fee0-450e-9f6a-4da1a6285d19"
      unitRef="usd">49000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTMtMS0xLTEtMA_9ed79b1f-28ea-4343-80e9-7d6c50510618"
      unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTMtMy0xLTEtMA_8ea96e68-ec6e-4c49-8b13-e202925afea0"
      unitRef="usd">4000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTMtNS0xLTEtMA_eb23e368-e03b-4236-a921-54e04c66df57"
      unitRef="usd">13000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTMtNy0xLTEtMA_22c02771-d2c4-455a-a887-0a23087ce6c8"
      unitRef="usd">28000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTQtMS0xLTEtMA_c866e507-d155-42f1-9516-2507a0350d4d"
      unitRef="usd">-2000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTQtMy0xLTEtMA_87f52c44-301a-43af-981e-c55f6f6d7805"
      unitRef="usd">-3000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTQtNS0xLTEtMA_bde9f472-967a-4a5c-9d77-3b0653316f3c"
      unitRef="usd">-26000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTQtNy0xLTEtMA_fee3d4c7-7a2a-4552-9791-a0f9dc037bb0"
      unitRef="usd">-2000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTUtMS0xLTEtMA_3015180b-a5dc-496f-8bf0-c8d5ad7c7582"
      unitRef="usd">-16000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTUtMy0xLTEtMA_73c69c66-d782-4dc0-a692-3a93941c89c2"
      unitRef="usd">-10000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTUtNS0xLTEtMA_68d0d713-aef8-41de-b27a-4a07e0d3aea7"
      unitRef="usd">-146000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTUtNy0xLTEtMA_7f616b56-b9e5-4a92-af6a-877c476c8430"
      unitRef="usd">-15000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTYtMS0xLTEtMA_2af577ad-d4df-43c1-b97f-af64670336a6"
      unitRef="usd">1678000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTYtMy0xLTEtMA_91972cc9-34fc-450b-8d56-d6638e7e7c4c"
      unitRef="usd">1880000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTYtNS0xLTEtMA_89d3ac6c-5d5d-46e8-a700-0cc591f63a72"
      unitRef="usd">5133000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTYtNy0xLTEtMA_0a2f1ca6-0490-4f6b-9ba4-d3089d20a722"
      unitRef="usd">5504000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTctMS0xLTEtMA_505e68de-33c9-401d-825d-751633514f20"
      unitRef="usd">460000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTctMy0xLTEtMA_44b10611-036d-4b20-bdf0-70c43db67e61"
      unitRef="usd">329000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTctNS0xLTEtMA_72b3b1c5-a796-4ef9-9863-347bff137658"
      unitRef="usd">681000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTctNy0xLTEtMA_e0127e7d-213e-43e4-b002-659792540b4f"
      unitRef="usd">873000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTgtMS0xLTEtMA_ac5388ec-05c6-404d-ad52-ff62656a054e"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTgtMy0xLTEtMA_8a8422ec-f5e2-494e-bf75-98803329dd5c"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTgtNS0xLTEtMA_874d4b9c-cac1-4008-a70b-736449b9f6c0"
      unitRef="usd">11000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTgtNy0xLTEtMA_4140b070-17d7-4599-ab5c-a6f57a732375"
      unitRef="usd">9000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTktMS0xLTEtMA_a124cf1a-aa99-42c7-ab98-f98bff52b509"
      unitRef="usd">374000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTktMy0xLTEtMA_ae76d258-ebda-4e3d-a9cd-0216c7c91461"
      unitRef="usd">406000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTktNS0xLTEtMA_32188f8b-3020-468e-ab6c-5e859f3eaa06"
      unitRef="usd">1155000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMTktNy0xLTEtMA_cde5b3ae-e578-47ac-a10e-771963ff6588"
      unitRef="usd">1221000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjAtMS0xLTEtMA_e4a1e289-d4df-4ee7-8e9b-82d8361fb2a7"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjAtMy0xLTEtMA_73578cc2-8a88-4cbc-a05d-9d1cb396586c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjAtNS0xLTEtMA_d718b0b3-bc02-49c6-8997-cd263b0d041f"
      unitRef="usd">-51000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjAtNy0xLTEtMA_ef69c169-e734-4ebe-817a-2484a19cc0dd"
      unitRef="usd">-40000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjEtMS0xLTEtMA_11891486-f4a0-42d7-a6a6-1c82aba39c09"
      unitRef="usd">-13000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjEtMy0xLTEtMA_f5dd09b4-fa3a-4670-97ce-16f9cd58003a"
      unitRef="usd">9000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjEtNS0xLTEtMA_c09d0919-3ecc-485b-8b0c-62b8bf2c787c"
      unitRef="usd">-26000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjEtNy0xLTEtMA_6e71dcad-f1c7-4084-a04e-3c2dfd1d45fb"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjItMS0xLTEtMA_660b6144-0ff0-4eb1-906f-4ec2ebc758f6"
      unitRef="usd">75000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjItMy0xLTEtMA_623eee78-466b-4ef3-9dc0-1c48dbf8b538"
      unitRef="usd">-66000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjItNS0xLTEtMA_d99a3cbd-7869-4bd1-86f1-7f6f92d91b90"
      unitRef="usd">-540000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjItNy0xLTEtMA_fe8a374a-f7a9-4467-a9e2-dce0ff92412d"
      unitRef="usd">-367000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjMtMS0xLTEtMA_35a1e77f-8c2d-4be2-8490-c0c6cd1deaf6"
      unitRef="usd">5000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjMtMy0xLTEtMA_d77f4f36-de0e-4fc4-996e-cb150f11a5df"
      unitRef="usd">-18000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjMtNS0xLTEtMA_87b0b14c-1ab7-47e5-8de3-511a3344bbb0"
      unitRef="usd">-133000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjMtNy0xLTEtMA_df99febe-8bab-45a9-a639-a2424b6db713"
      unitRef="usd">-101000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjQtMS0xLTEtMA_f2699f8c-a55c-4f50-9d55-93d81f771f14"
      unitRef="usd">70000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjQtMy0xLTEtMA_abbd3006-c542-4498-9279-8d0fc9c7f289"
      unitRef="usd">-48000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjQtNS0xLTEtMA_f6cc09f4-5dc9-48e6-a649-c3c1655132b4"
      unitRef="usd">-407000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjQtNy0xLTEtMA_0ccd7228-f338-4adb-8e1e-4b14f3cf8de8"
      unitRef="usd">-266000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjUtMS0xLTEtMA_bfeb0b48-2040-4701-8664-f2e1963ec55d"
      unitRef="usd">-1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjUtMy0xLTEtMA_e5843f9e-3fbd-45e8-84ef-8e07bd55ec72"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjUtNS0xLTEtMA_0f529a32-48d0-4eec-af43-2a3936d448c4"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjUtNy0xLTEtMA_f97dcdae-4e5a-4003-87ee-b25cf355b0eb"
      unitRef="usd">6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjYtMS0xLTEtMA_b6086910-f9fa-4855-9a23-c1adcdb28912"
      unitRef="usd">71000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjYtMy0xLTEtMA_92c9e6cd-ed94-4acc-bab9-8921814b7024"
      unitRef="usd">-49000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjYtNS0xLTEtMA_bed0149c-cc18-4932-be57-21feda5a0f79"
      unitRef="usd">-407000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjYtNy0xLTEtMA_0f6154c1-7584-4e46-aaaa-ff12ae1e32e6"
      unitRef="usd">-272000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjktMS0xLTEtNDA4NQ_f2c4b984-4702-478e-bb77-f2b4767b2de2"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjktMy0xLTEtNDA4NQ_c8b027cc-696c-434d-9373-2511a36c8436"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjktNS0xLTEtNDA4NQ_f35c9ab4-c4bd-4b8a-9313-c7cba7a65944"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMjktNy0xLTEtNDA4NQ_7c6f0f80-69a4-4d07-9f86-4c57f7f8f475"
      unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzAtMS0xLTEtNDEwNA_d49b7381-dfed-463e-a45c-50952168b0f5"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzAtMy0xLTEtNDEwNA_e4c59e56-5fce-4c80-8bf3-c734919ad25e"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzAtNS0xLTEtNDEwNw_eba0cb46-7d86-4ce3-9397-9624fb78dd8a"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzAtNy0xLTEtNDEwNw_f3bbbb2b-739b-4551-9bfc-724dea74734d"
      unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzEtMS0xLTEtNDAxOA_5db1c38a-5b69-4381-99a3-655b918ba269"
      unitRef="shares">355600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzEtMy0xLTEtNDAxOA_10fe2e1b-ea77-409a-9289-0885eee2dc43"
      unitRef="shares">352400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzEtNS0xLTEtNDAxOA_56dbbc9c-beb0-4411-a7f8-2b0805614bfe"
      unitRef="shares">354700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzEtNy0xLTEtNDAxOA_d4b3ace7-b112-4c57-934c-f395649beebf"
      unitRef="shares">351900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzItMS0xLTEtNDAyMQ_f5e1a83d-8317-4826-9301-fa0d9d171666"
      unitRef="shares">357800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzItMy0xLTEtNDAyMQ_ff73c632-5e4f-4c41-b9ac-f6de18a04c87"
      unitRef="shares">352400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzItNS0xLTEtNDAyMQ_46f268a8-ce17-4e73-93aa-a75b5120b0b2"
      unitRef="shares">354700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yNS9mcmFnOjVhNjA3ZmJhNGRmYzRlZGJhNmJjNDJlODBiZTUzNDQyL3RhYmxlOmM0YzdkNjIyYjhiMDQwM2JhMDI4OTExMTIyYzY5Mjk1L3RhYmxlcmFuZ2U6YzRjN2Q2MjJiOGIwNDAzYmEwMjg5MTExMjJjNjkyOTVfMzItNy0xLTEtNDAyMQ_b2ec8888-54eb-4c9a-a14d-4065fdbff4d7"
      unitRef="shares">351900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfMi0xLTEtMS0w_7e2a2b22-048f-43be-9e98-63472710f137"
      unitRef="usd">70000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfMi0zLTEtMS0w_f945f142-b03c-4a7a-a3ae-a18378393b21"
      unitRef="usd">-48000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfMi01LTEtMS0w_52e96380-7e72-41b1-918c-425679815aae"
      unitRef="usd">-407000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfMi03LTEtMS0w_fd7e627c-7830-4ad8-85e3-467e6cabcbc1"
      unitRef="usd">-266000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNC0xLTEtMS0w_649cdcb9-a78f-450b-abd7-787cd677b6d6"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNC0zLTEtMS0w_86ee870d-bfe3-4800-b01a-139c79738fd3"
      unitRef="usd">-97000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNC01LTEtMS0w_98dfd2d4-67e2-43f9-8d16-d4a863d4de18"
      unitRef="usd">-118000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNC03LTEtMS0w_abab72e5-c971-4302-9365-ba44be77c2dc"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNS0xLTEtMS0w_f5460575-4454-454c-acea-2f0378ac1009"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNS0zLTEtMS0w_fede19f0-eead-4287-9653-55b558b7feeb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNS01LTEtMS0w_2adafff4-e477-41d2-b2a0-370e400ad2b5"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNS03LTEtMS0w_bf8fc491-afb2-4ba0-91ef-da076dd28104"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNi0xLTEtMS0w_b058bf96-8c38-4354-abec-d714bed3d70a"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNi0zLTEtMS0w_64ddc255-4177-4d28-800b-3f9df7037eb8"
      unitRef="usd">-97000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNi01LTEtMS0w_944ed985-f289-455e-b25f-ffd79d072940"
      unitRef="usd">-120000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNi03LTEtMS0w_fa5484b5-4abc-4dfd-bc40-354f673915f9"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNy0xLTEtMS0w_81ef848f-7779-4d96-b60f-3ec9ed16913e"
      unitRef="usd">89000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNy0zLTEtMS0w_4ace5ba1-0fae-4a86-8e26-5a1369d6e07c"
      unitRef="usd">-145000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNy01LTEtMS0w_31b58289-4ab4-425a-a8ce-ebe0b4a1e6c9"
      unitRef="usd">-527000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfNy03LTEtMS0w_b366967f-823a-430e-b3a6-a1b6cd580494"
      unitRef="usd">-287000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOC0xLTEtMS0w_ae0e140b-44a9-4071-acc3-396f73bdad6e"
      unitRef="usd">2000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOC0zLTEtMS0w_41618b4e-609b-4408-ad12-0deee8cf64bf"
      unitRef="usd">-1000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOC01LTEtMS0w_de547e5f-d29a-4c34-b0af-62864efd089a"
      unitRef="usd">1000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOC03LTEtMS0w_631ae174-92da-47e1-947e-83c68deb9b53"
      unitRef="usd">4000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOS0xLTEtMS0w_e050a761-263c-4860-91de-65949ad4922f"
      unitRef="usd">87000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOS0zLTEtMS0w_849bbc11-0cde-47c8-91a2-0bb897987b4e"
      unitRef="usd">-144000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOS01LTEtMS0w_d8d590ec-4464-4e64-85d1-27b67cadb1cc"
      unitRef="usd">-528000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18yOC9mcmFnOmVjMzM2YmIwNTgxNTRhMDJhOGE1ODM4ZWZkNTU1NmRjL3RhYmxlOjA2MjY5YjkwNTg1NzQ1ZTJiM2NiYmU3OGI1ZTNkMTQ1L3RhYmxlcmFuZ2U6MDYyNjliOTA1ODU3NDVlMmIzY2JiZTc4YjVlM2QxNDVfOS03LTEtMS0w_bef1b4a5-8e10-4856-a915-0c0eedd4bdd1"
      unitRef="usd">-291000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="id4b4cd54f5e342ecaa9c703653b2eca2_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0yLTEtMS0w_e9cf9fb9-dd73-421e-8cd6-e135d6ffb985"
      unitRef="shares">354900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4b4cd54f5e342ecaa9c703653b2eca2_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC00LTEtMS0w_65294f79-cb06-4758-8b7d-999364904c07"
      unitRef="usd">10217000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b183b5868ef437cbfabaff430ddb177_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC02LTEtMS0w_e841349d-8d1c-4fb9-9766-f7ef9edf26d5"
      unitRef="usd">411000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb91d49706df4bceb73a8b27d4b2cadf_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC04LTEtMS0w_581db994-3094-4848-8ba7-b40ac8282f5f"
      unitRef="usd">-7931000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b51462eae944b27b08ebf45591f45d4_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0xMC0xLTEtMA_581f291b-1247-4ac4-b1f7-693cd3e4e3d6"
      unitRef="usd">-2223000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54958c2a43bd4549bdafae413e7d07d5_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0xMi0xLTEtMA_ce27b87e-4a07-4b15-a27b-4190d4ce7665"
      unitRef="usd">474000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9d717e4e6074467bd481358cfd95ccf_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0xNC0xLTEtMA_c5596f06-e212-4b3c-8540-4ed741edc2c3"
      unitRef="usd">72000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3eba536ebee74aa3ac183442a212ee35_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNC0xNi0xLTEtMA_38edbdaa-9b40-4df6-94e8-ee40c26433c9"
      unitRef="usd">546000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5c66878a6b314d1c8fa41e056f0e38a6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS0yLTEtMS0w_66ec4ab4-0a29-47ed-83ce-ef255ad09ae5"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5c66878a6b314d1c8fa41e056f0e38a6_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS00LTEtMS0w_ecd6a05d-9c11-449d-9c7a-31343770732f"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibb63cfcaabb846eb9475e1a816a4cfd5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS02LTEtMS0w_a700bf65-63ab-46c8-8fde-264357081926"
      unitRef="usd">-2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS0xMi0xLTEtMA_64c71f76-80df-4e00-b82a-422246c099ad"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNS0xNi0xLTEtMA_cb31ab09-08e6-48c5-878e-8dc011a0ddd8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibb63cfcaabb846eb9475e1a816a4cfd5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNi02LTEtMS0w_95a33f19-3689-4e3c-b60e-6911587e1cdb"
      unitRef="usd">27000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNi0xMi0xLTEtMA_c47bab62-bb0e-49bb-8fc4-c892b82795c5"
      unitRef="usd">27000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNi0xNi0xLTEtMA_ce898cd6-61a1-4cc3-a358-98c70c99d5f1"
      unitRef="usd">27000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibb63cfcaabb846eb9475e1a816a4cfd5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNy02LTEtMS0w_14340d96-303e-4883-b993-c6016310f0a0"
      unitRef="usd">1000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNy0xMi0xLTEtMA_a45d6735-2ccb-41a1-9eb5-dcc3bf3869da"
      unitRef="usd">1000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNy0xNi0xLTEtMA_c1736d97-7045-4f8d-979d-90b8875aab02"
      unitRef="usd">1000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i496cdf76600d4d3b8075d83c64d87524_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOC0xNC0xLTEtNzU5Mg_c43ff654-65c4-4c9f-8af3-4392a4d0d85e"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOC0xNi0xLTEtNzU5NA_6f1bb8eb-df35-44b3-84c0-9822aeec8e59"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i6ec221254f7246e5ac168ac3177d8dc2_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOS04LTEtMS0w_2784979f-097a-412c-aa98-e5472d8426d9"
      unitRef="usd">71000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOS0xMi0xLTEtMA_75e7b866-680e-474f-9163-3f20f114a062"
      unitRef="usd">71000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i496cdf76600d4d3b8075d83c64d87524_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOS0xNC0xLTEtMA_a278ad4f-4be4-4835-967f-41293fe83f5b"
      unitRef="usd">-1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfOS0xNi0xLTEtMA_6fb0c385-b959-4cd9-952c-da9fd0dc8581"
      unitRef="usd">70000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i992ce3be69be4136b963377397c88687_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTAtMTAtMS0xLTA_6a9cac0e-be63-42c9-9b05-d5e22564beb8"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7977ad7769b24537a3a6e2f5a20e0d9c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTAtMTItMS0xLTA_1e57ebbf-184e-440b-b68f-d6c9f86f4481"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i496cdf76600d4d3b8075d83c64d87524_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTAtMTQtMS0xLTc1OTY_205f29b4-9c7b-4f0b-95b2-a6e016cbaecc"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTAtMTYtMS0xLTA_a8da3f70-54f2-4240-a4c0-01ec8e8e8b35"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMi0xLTEtMA_898ac5f5-98f2-432e-9a98-7d3519a592f1"
      unitRef="shares">355000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtNC0xLTEtMA_0806fb92-3916-4d3e-8c21-9e6c41c2730c"
      unitRef="usd">10219000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34d1a74a2f6d479e80e6da708c4c0ea9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtNi0xLTEtMA_f5c9c7a1-acca-4d7d-b0f1-a9a1129f7ff4"
      unitRef="usd">435000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i614bd8e75e8b483b836943e11a8cff8c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtOC0xLTEtMA_9434e083-9240-4793-a12b-3adecfac2a93"
      unitRef="usd">-7860000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86b09d66e5904f00bdfc6d7dcac58e24_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMTAtMS0xLTA_2febc636-56ad-4867-8b7c-3e6890497ce1"
      unitRef="usd">-2207000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee6469a3085b415b81023abb0f50fd08_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMTItMS0xLTA_889b5615-09a2-4eab-bda2-3286aba825b7"
      unitRef="usd">587000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i129921e9b4d049ed8ee7f90c0ac8ebcb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMTQtMS0xLTA_01e56249-e697-4307-9ffe-14d52b6a56b0"
      unitRef="usd">68000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTEtMTYtMS0xLTA_476ceb97-2299-4006-989a-04e12070a763"
      unitRef="usd">655000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7eeabd830b4744f9a609670edfae6e15_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMi0xLTEtMA_b520c7e9-0573-4999-84ea-17ce99421003"
      unitRef="shares">352200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7eeabd830b4744f9a609670edfae6e15_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtNC0xLTEtMA_75dc06da-90d4-4fab-a639-81edf3f0f047"
      unitRef="usd">10165000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i412d37633553439b9d65c47d77b03846_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtNi0xLTEtMA_3ec422d0-135e-47c2-b272-e08784369c76"
      unitRef="usd">384000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0aee1138db3436cad68141f33b4b0eb_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtOC0xLTEtMA_874320e1-c004-45b0-b21d-adbaf8aab737"
      unitRef="usd">-5887000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95cdd8bdc8a642d58cfe7370d8001f2a_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMTAtMS0xLTA_9ae1e310-43c5-4514-a385-e491d7a97400"
      unitRef="usd">-2061000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifdda6c0d36a84d3592d9e9418514b1fc_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMTItMS0xLTA_824868b7-e69e-4e7d-afca-94db5a746d61"
      unitRef="usd">2601000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec8fffeeb09e4491b53ff8013f59e0f8_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMTQtMS0xLTA_52ecb345-4bc9-4f78-8fda-a38790731282"
      unitRef="usd">87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f1cd9b31f0a4d949e1701489137acd5_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTQtMTYtMS0xLTA_6cd4e5ea-413d-4049-9a1e-5439efe24abd"
      unitRef="usd">2688000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8e4bd8ca4ffe403ea5a27d2506365172_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtMi0xLTEtMA_624e9c8a-abe7-49cc-97ac-8096af186810"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8e4bd8ca4ffe403ea5a27d2506365172_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtNC0xLTEtMA_bc317494-7740-4f3c-8836-698a4909d91d"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6042397c7cfb490393cbd31597df38f8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtNi0xLTEtMA_0124ab85-8bdf-4117-9151-2349391d1d4b"
      unitRef="usd">-3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtMTItMS0xLTA_950580b5-c1da-41df-a446-eb296f2508ca"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTUtMTYtMS0xLTA_6ed1fe0e-136a-4a6d-9998-6fd2cfd4adc8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6042397c7cfb490393cbd31597df38f8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTYtNi0xLTEtMA_eb57e7ad-e361-46e5-b7a0-e18f860d4005"
      unitRef="usd">26000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTYtMTItMS0xLTA_833c8b51-0106-422f-89ab-d576dcddd7c8"
      unitRef="usd">26000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTYtMTYtMS0xLTA_2ec48db3-8cae-45b6-b5aa-99f7e7752c98"
      unitRef="usd">26000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i6042397c7cfb490393cbd31597df38f8_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTctNi0xLTEtMA_73377b93-4cf1-4d68-989e-5fb3b4223e2f"
      unitRef="usd">1000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTctMTItMS0xLTA_7e19c186-241e-4299-a95f-68b165757428"
      unitRef="usd">1000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTctMTYtMS0xLTA_137a1b88-abac-45ec-8ef9-5f99f49c8423"
      unitRef="usd">1000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8935c278faab48a1946ca3d3bf7e95a3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTQtMS0xLTMxMDc_62891a35-7149-4cb3-af5d-fa181960bf59"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTYtMS0xLTMxMDc_5377104e-5ae4-4652-a92e-ace69cd0e271"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i898150194c8a49858946a480cb32bcd1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtOC0xLTEtMA_778d8f2a-e110-494a-9e32-7a41ac8ec574"
      unitRef="usd">-49000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTItMS0xLTA_244d82a4-926a-46b2-9028-863fcb258678"
      unitRef="usd">-49000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8935c278faab48a1946ca3d3bf7e95a3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTQtMS0xLTA_00a639de-45cc-4b36-8a5b-6db60fc37a63"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTgtMTYtMS0xLTA_b1e70608-1e8f-4469-89b3-409f6f43ca62"
      unitRef="usd">-48000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic7ff222b1e2f4984a09b68fa09674122_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTktMTAtMS0xLTA_b5208f67-aa3d-44a6-90f9-7fa8dd18bb7b"
      unitRef="usd">-95000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaabced904ae248a2971e8f78c6d5a036_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTktMTItMS0xLTA_3394b741-5a04-424d-9115-4ebf521782eb"
      unitRef="usd">-95000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8935c278faab48a1946ca3d3bf7e95a3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTQtMS0xLTMxMTM_f8dcd0d0-4f43-4fa2-af7a-8c2b76695af4"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMTktMTYtMS0xLTA_78ffd9d5-8a68-4f36-900d-6d79c1b8a33b"
      unitRef="usd">-97000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMi0xLTEtMA_be931eb1-e7c6-4f3f-b06b-c8a160ed9f54"
      unitRef="shares">352400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtNC0xLTEtMA_1987399f-a2cd-4f70-b558-3b7b5e96e1a5"
      unitRef="usd">10168000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2e79eda62004863b250270a4ac6e2e2_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtNi0xLTEtMA_216e086b-695a-44d3-b258-ecdd121c7ed1"
      unitRef="usd">406000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76b9993210a745b9b43f1f5d49bc5f63_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtOC0xLTEtMA_63b359fb-f589-4c46-8aba-24b78a898645"
      unitRef="usd">-5936000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0679fbabd2d543829b45838f2d32c8b1_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTAtMS0xLTA_812652a0-24f7-4f03-a151-afecf2133842"
      unitRef="usd">-2156000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d9736297cfb443ab15742dc0bb31bba_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTItMS0xLTA_dd125d45-ee27-44ef-9b42-982191ef5eec"
      unitRef="usd">2482000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1e4834a7c874cc1827742f22e88673d_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTQtMS0xLTA_ec6c50cb-b7c2-41c7-a617-09141ab1246e"
      unitRef="usd">78000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjAtMTYtMS0xLTA_9b6842f5-2a78-4385-b7d8-768240486edf"
      unitRef="usd">2560000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i550ff3adb4da4b33b8c7b447a74a6ef0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMi0xLTEtMA_7a0a89b0-c9df-4124-93f2-847212990125"
      unitRef="shares">352600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i550ff3adb4da4b33b8c7b447a74a6ef0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtNC0xLTEtMA_a677f2ec-db9e-4d92-b712-9d583eb73bb8"
      unitRef="usd">10172000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0724670b830242fcb80b31e2447ea7a9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtNi0xLTEtMA_b1716fb1-d96b-4fcb-8697-d65a6948961e"
      unitRef="usd">429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee8d639acfc34aeab0f9340f2ef71914_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtOC0xLTEtMA_5726a07d-ab06-4ad8-9dbe-2c31e118b76b"
      unitRef="usd">-7452000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7807cd27ff842ef98aaf27968fece25_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMTAtMS0xLTA_5bc93ee4-491c-4821-9f7a-e07e2073e200"
      unitRef="usd">-2086000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida4e60de3b154f7395827c52cfbe8a3c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMTItMS0xLTA_2f9ca242-4858-4127-8b41-a99766d4069c"
      unitRef="usd">1063000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5629ad6776d5426ba54b6e7f66992f37_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMTQtMS0xLTA_21470e20-7216-4026-948c-535dbf1828e0"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjMtMTYtMS0xLTA_ac2c38be-4521-4590-b95f-2128060506cb"
      unitRef="usd">1136000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d07813deb7b4c7a8b32656f580c213d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjQtOC0xLTEtMA_89861307-7054-4a2b-a051-d0fc298fc367"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibba3122b39dd4ec2976cc26a4121ca76_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjQtMTItMS0xLTA_79b4a4de-6fb6-4885-9c56-d38d3e94a514"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9388a44254d042458ac025d5a3287ff3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjQtMTYtMS0xLTA_6d8d9530-5efe-42fb-9aa7-366ed248f53b"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="icf713c297ba443efac779956ff34bb58_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtMi0xLTEtMA_5d36b08c-4a8d-472c-a0ce-eeed4e1cb4aa"
      unitRef="shares">2400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icf713c297ba443efac779956ff34bb58_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtNC0xLTEtMA_411b8829-8954-4a35-8303-4e9d1cb49751"
      unitRef="usd">47000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i19280811252b4ca18390037dfc0e63f5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtNi0xLTEtMA_8ba1b95f-46b8-4c09-9e42-c5ae4c938948"
      unitRef="usd">-45000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtMTItMS0xLTA_4fd11ab8-ae4f-4962-b140-668f5e16d79c"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjUtMTYtMS0xLTA_6366655b-003d-4b85-b964-8ac55c1e973f"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i19280811252b4ca18390037dfc0e63f5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjYtNi0xLTEtMA_2190f3dc-4203-4eef-999e-dfe5daaf4e2b"
      unitRef="usd">81000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjYtMTItMS0xLTA_10b463ff-c02d-4593-bdc5-8a7512ce9480"
      unitRef="usd">81000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjYtMTYtMS0xLTA_4d327492-752b-4250-af7d-93c448dfcfe2"
      unitRef="usd">81000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i19280811252b4ca18390037dfc0e63f5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjctNi0xLTEtMA_02b0d842-3950-4568-85d9-0ef236552998"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjctMTItMS0xLTA_271be536-6fd1-43d5-8898-e42604766676"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjctMTYtMS0xLTA_ede11bc3-8d60-4f68-a1d5-1d1e41bd3bbb"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i9a25f11c2bfe443ea2f446aca2bb3794_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTQtMS0xLTU4Nzg_a2e98968-3edb-400f-b5eb-14318f987018"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTYtMS0xLTU4Nzg_fc4d2e76-8d62-4880-a8cc-be8d107c84e9"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i292d75e4b4024bed95e33679bcebcbe2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjgtOC0xLTEtMA_0f5de52c-eff6-46b1-869f-b77c465322ff"
      unitRef="usd">-407000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjgtMTItMS0xLTA_9b2d9643-8563-4a78-a3d8-0efcc05c70dc"
      unitRef="usd">-407000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjgtMTYtMS0xLTA_52e7f2f3-7d8d-41d8-8e30-cb0943705792"
      unitRef="usd">-407000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia713159518cb42a0b248bc95796377b4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTAtMS0xLTA_9ddd2885-8b4e-4813-b2c2-6156a3bdac4f"
      unitRef="usd">-121000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7a7d3e361f8646a78bc91b4b7ee3b0a5_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTItMS0xLTA_e030a94b-6d98-43eb-946e-a22dbe139133"
      unitRef="usd">-121000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9a25f11c2bfe443ea2f446aca2bb3794_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTQtMS0xLTA_7f27ca57-2482-4901-9b97-384d2a0475ac"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMjktMTYtMS0xLTA_9e7639eb-fa2f-45ae-837b-07357d9040c0"
      unitRef="usd">-120000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMi0xLTEtMA_6e354808-0c4c-4b2a-afc6-e6c4599ca3af"
      unitRef="shares">355000000.0</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic800c9b1cbfd46a0b7bde7ee565e62ff_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtNC0xLTEtMA_0a8ff72e-0572-4ce8-8a15-a0a639437dd0"
      unitRef="usd">10219000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34d1a74a2f6d479e80e6da708c4c0ea9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtNi0xLTEtMA_4332f835-8145-418c-8b59-d55dd04a1128"
      unitRef="usd">435000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i614bd8e75e8b483b836943e11a8cff8c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtOC0xLTEtMA_92d083dc-bad1-4ee7-bdf8-3bb3da2fae45"
      unitRef="usd">-7860000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86b09d66e5904f00bdfc6d7dcac58e24_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMTAtMS0xLTA_7fe439c6-9de7-4a14-b5e1-86211f1888cf"
      unitRef="usd">-2207000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee6469a3085b415b81023abb0f50fd08_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMTItMS0xLTA_e3dbc869-f631-4779-820d-50eceadf2c40"
      unitRef="usd">587000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i129921e9b4d049ed8ee7f90c0ac8ebcb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMTQtMS0xLTA_ca53c320-7a09-4a69-b707-1855d923a485"
      unitRef="usd">68000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzAtMTYtMS0xLTA_3dde98f8-e03a-4fad-833c-a6c28eb3fc77"
      unitRef="usd">655000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0cfbeac78f9548d18d3b871368be2ee1_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMi0xLTEtMA_e0748139-bb3e-4134-919a-60be233936e1"
      unitRef="shares">349900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0cfbeac78f9548d18d3b871368be2ee1_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtNC0xLTEtMA_7b5c9645-cdf2-4409-90f3-00746e61b364"
      unitRef="usd">10121000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i911bb2eff7e84f7cbb8079fd03ee877f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtNi0xLTEtMA_3d30b3c6-7bc3-40d1-b7de-a90e79a30857"
      unitRef="usd">413000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i326aa3bfc5ee4f3daab3236db5b49940_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtOC0xLTEtMA_387d13a5-2174-4f06-9a0e-94fe334e49c8"
      unitRef="usd">-5664000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85916a34835d4e4fae8f2fdf0dcf8c27_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMTAtMS0xLTA_d05a1bd5-6a4b-4370-b20b-c317a2e9b39b"
      unitRef="usd">-2137000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa4a0c3396e645879bc46329d323ac1b_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMTItMS0xLTA_a30f68d9-9c7b-48c5-b4bd-b8e778fcd818"
      unitRef="usd">2733000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45afbb8c565241ff8ad164f429208ab3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMTQtMS0xLTA_183bf575-5151-4c21-914e-6a42650e9db6"
      unitRef="usd">82000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzMtMTYtMS0xLTA_2ac79043-7f92-4c0a-860d-e17e91649a2d"
      unitRef="usd">2815000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i9cc32bfd1c3d470cbe8ccec2d8c006a7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtMi0xLTEtMA_35598b3c-f4ea-49bd-8942-6c0a46832eee"
      unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9cc32bfd1c3d470cbe8ccec2d8c006a7_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtNC0xLTEtMA_9c4576e4-ef2c-4651-8669-6dc4b35ea42c"
      unitRef="usd">47000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if28e8de9d52f4b1fb26013832875c24a_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtNi0xLTEtMA_4ef57697-1e20-46e5-8dde-996659a8397c"
      unitRef="usd">-44000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtMTItMS0xLTA_e7cbb693-9a2f-4c39-acbb-c593b16fc6fb"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzQtMTYtMS0xLTA_05416ad6-a928-4c0b-8802-b5312a62fb02"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if28e8de9d52f4b1fb26013832875c24a_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzUtNi0xLTEtMA_4e477b96-1239-4f52-90bf-92241ec177af"
      unitRef="usd">77000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzUtMTItMS0xLTA_7d174c42-68e6-43f3-a6d4-4c8416cbf63c"
      unitRef="usd">77000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzUtMTYtMS0xLTA_6ab1f8af-a80c-45f3-96e0-a30072d0993a"
      unitRef="usd">77000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if28e8de9d52f4b1fb26013832875c24a_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzYtNi0xLTEtMA_ee909d40-30d9-4ca5-bb09-a9312933cd91"
      unitRef="usd">40000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzYtMTItMS0xLTA_f84c71e5-4003-4c0d-aa6c-db962905a5c7"
      unitRef="usd">40000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzYtMTYtMS0xLTA_a3bfde90-e01e-4c5d-8eac-bf9f4127f8da"
      unitRef="usd">40000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i1e72b076a70a45c584feaa8d3245efbd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTQtMS0xLTMxMDk_f54d07c6-52fc-437d-8a30-bdf8de1b0018"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTYtMS0xLTMxMDk_d78dabeb-8bc3-4eb2-8f2b-c444152eabc4"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="ic90695475f3742f7bc22d422180c86a9_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzctOC0xLTEtMA_2fab2eb2-26d2-46e7-8192-a10078c05226"
      unitRef="usd">-272000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzctMTItMS0xLTA_b6bb75cf-1be3-4a90-ab63-72ae5525aa63"
      unitRef="usd">-272000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1e72b076a70a45c584feaa8d3245efbd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzctMTQtMS0xLTA_e4fa7b40-a2ba-41e4-8847-90ca36342d19"
      unitRef="usd">6000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzctMTYtMS0xLTA_341eeaec-3077-4add-b630-d6dd0daa89e2"
      unitRef="usd">-266000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i626ac4778b4748438a325abd1b9e0d84_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTAtMS0xLTA_522670ce-53e3-455d-8286-6ab5138abcb7"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5720cdf0186f4732a6477852cc20a1e4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTItMS0xLTA_23c0a0d3-4357-45dd-9873-5a29598daccb"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1e72b076a70a45c584feaa8d3245efbd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfNDAtMTQtMS0xLTMxMTE_3d6ae2fc-d992-4708-a0a4-3ab6a8fb0453"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzgtMTYtMS0xLTA_84c255cc-d445-438f-8f58-48118db3a1a4"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMi0xLTEtMA_18a87327-3e82-4005-b621-49028d94d09d"
      unitRef="shares">352400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c81eaf5163a476b9d83f369ac2bf9cb_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktNC0xLTEtMA_61ca538b-6a12-46af-9690-b04a0a9353f2"
      unitRef="usd">10168000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2e79eda62004863b250270a4ac6e2e2_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktNi0xLTEtMA_b17b6bd5-2a44-4f83-afb3-6e7d576ce058"
      unitRef="usd">406000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76b9993210a745b9b43f1f5d49bc5f63_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktOC0xLTEtMA_6c6cc80e-00c3-4dd3-bb49-f4659881a53c"
      unitRef="usd">-5936000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0679fbabd2d543829b45838f2d32c8b1_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMTAtMS0xLTA_443521a3-890c-4a19-9df1-47e3fe8050fa"
      unitRef="usd">-2156000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d9736297cfb443ab15742dc0bb31bba_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMTItMS0xLTA_aaeefbe1-252e-4df2-9b96-9e5f17d217f5"
      unitRef="usd">2482000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1e4834a7c874cc1827742f22e88673d_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMTQtMS0xLTA_c3097550-884e-40c1-8fa9-54e41b67834a"
      unitRef="usd">78000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zMS9mcmFnOjBhMjcwMmEzZTI1YzQxNjBhM2ZkYWU3NjE4ZDI3NGE1L3RhYmxlOmYyZmUwNjRlZmY5NTQ1NGQ5ZTk5OThlN2NmYWRiNzhiL3RhYmxlcmFuZ2U6ZjJmZTA2NGVmZjk1NDU0ZDllOTk5OGU3Y2ZhZGI3OGJfMzktMTYtMS0xLTA_ec6eba8b-ab99-404b-a09b-0bf799b705f1"
      unitRef="usd">2560000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMy0xLTEtMS0w_52e96380-7e72-41b1-918c-425679815aae"
      unitRef="usd">-407000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMy0zLTEtMS0w_fd7e627c-7830-4ad8-85e3-467e6cabcbc1"
      unitRef="usd">-266000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNS0xLTEtMS0w_ad46fb66-225c-47b2-842a-efe8d3bccf29"
      unitRef="usd">1397000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNS0zLTEtMS0w_15210dec-2832-4a9f-9cca-3378b877bdda"
      unitRef="usd">1583000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNi0xLTEtMS0w_25615016-beb4-4c27-87a5-2943b60478a6"
      unitRef="usd">45000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNi0zLTEtMS0w_2893bb90-124a-4b82-91a9-33aa181564a7"
      unitRef="usd">49000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AssetImpairmentCharges
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNy0xLTEtMS0w_b3d6b38e-1e86-4f41-90cc-bececbf8df90"
      unitRef="usd">17000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNy0zLTEtMS0w_f28a9d0f-fee0-450e-9f6a-4da1a6285d19"
      unitRef="usd">49000000</us-gaap:AssetImpairmentCharges>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfOC0xLTEtMS0w_cd5eaa53-087d-49bc-af7a-45cec68f1c45"
      unitRef="usd">26000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfOC0zLTEtMS0w_3e66351b-04da-4430-bc54-1eaa2e7437f0"
      unitRef="usd">2000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfOS0xLTEtMS0w_48115e8a-8bf3-4473-883f-06cfccaf8dc1"
      unitRef="usd">52000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfOS0zLTEtMS0w_ae19ef5f-3f89-4281-b948-e2e41b1c6419"
      unitRef="usd">46000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTAtMS0xLTEtMA_9cc15706-8bb1-41fa-ae72-8ae325e3b9a5"
      unitRef="usd">-213000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTAtMy0xLTEtMA_919b799d-90ec-4e0c-9d7a-3dbe2ca580da"
      unitRef="usd">-233000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTEtMS0xLTEtMA_9eccb6e1-6e28-4333-8b9a-a85617d9fd57"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTEtMy0xLTEtMA_864d4084-1c2d-448c-b3ea-30cf6542984f"
      unitRef="usd">10000000</us-gaap:GainLossOnDispositionOfAssets1>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTItMS0xLTEtMA_e6bd0861-686b-4bf6-9632-b5a445bb270a"
      unitRef="usd">-147000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTItMy0xLTEtMA_0d1b63d1-29fa-4f7a-a519-eb9ae4ea6a06"
      unitRef="usd">-12000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTMtMS0xLTEtMA_5d0ffedc-9e67-4520-8229-701d8141fbdf"
      unitRef="usd">82000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTMtMy0xLTEtMA_c8d76899-4090-413d-90c2-4d59d25ec00d"
      unitRef="usd">4000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ShareBasedCompensation
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTQtMS0xLTEtMA_58e253de-25f1-4f07-aeb0-e6a38d227360"
      unitRef="usd">81000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTQtMy0xLTEtMA_b0e45881-0f6c-4ed1-99bd-03280850476b"
      unitRef="usd">77000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTUtMS0xLTEtMA_2e6f3c61-b1ab-4efc-8266-e7858e05c52b"
      unitRef="usd">-14000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTUtMy0xLTEtMA_72d77a11-0043-4840-a9ea-411e07eb57a9"
      unitRef="usd">-8000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <bhc:DerivativeGainExcludedComponent
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTYtMS0xLTEtMA_5d376686-3727-4baa-93d8-3c86627fb44d"
      unitRef="usd">17000000</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTYtMy0xLTEtMA_9a6778d9-984c-4efa-8af6-110aac76ff01"
      unitRef="usd">3000000</bhc:DerivativeGainExcludedComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTctMS0xLTEtMA_4a459ddc-7a48-46b6-a4a7-fe3a54735660"
      unitRef="usd">-51000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTctMy0xLTEtMA_b2857638-8ece-489e-a405-2dc8d38a1683"
      unitRef="usd">-40000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bhc:PaymentOfAccretedInterestOnContingentConsideration
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTgtMS0xLTEtMA_3b85b7e9-3610-4fc8-9bb5-df17f5904a80"
      unitRef="usd">0</bhc:PaymentOfAccretedInterestOnContingentConsideration>
    <bhc:PaymentOfAccretedInterestOnContingentConsideration
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTgtMy0xLTEtMA_7bb77de5-4e00-4726-a6a3-fc773f75611d"
      unitRef="usd">1000000</bhc:PaymentOfAccretedInterestOnContingentConsideration>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTktMS0xLTEtMA_2e770609-5c6e-4220-af3f-c57957d89374"
      unitRef="usd">7000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMTktMy0xLTEtMA_d7c6576f-d0b3-4c6e-ab18-2083334775b2"
      unitRef="usd">-30000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjEtMS0xLTEtMA_b41870c4-6d40-43b4-ad96-54512b4efcd0"
      unitRef="usd">-67000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjEtMy0xLTEtMA_003a3009-711d-47f4-aeac-01924348c440"
      unitRef="usd">-110000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjItMS0xLTEtMA_70114cdf-e02b-410b-a2a6-1881cd3d88ae"
      unitRef="usd">178000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjItMy0xLTEtMA_b6d2bf71-cd84-430e-9f55-8abd2b78333f"
      unitRef="usd">205000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjMtMS0xLTEtMA_f8f913c4-1cd4-4e9b-bb4c-720684078deb"
      unitRef="usd">-11000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjMtMy0xLTEtMA_eb4a5c07-ea0e-44ad-b357-4151cb9b6dfa"
      unitRef="usd">-16000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjQtMS0xLTEtMA_6b3a54d4-b50e-425b-880d-547aecf19fc6"
      unitRef="usd">-286000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjQtMy0xLTEtMA_b1c45be8-581c-456d-9927-e878053bcf5a"
      unitRef="usd">-33000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjUtMS0xLTEtMA_810d616c-1908-4a19-9a92-4308604f607c"
      unitRef="usd">717000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjUtMy0xLTEtMA_943a5c62-75b4-427e-9eae-f98b02f570bb"
      unitRef="usd">1267000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjctMS0xLTEtMA_dbb0222c-df61-42d0-a1d8-561c453ca35b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjctMy0xLTEtMA_97ca7d8b-2b71-4470-829a-eb081c432175"
      unitRef="usd">180000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjgtMS0xLTEtMA_b46e4778-504c-4fe7-9b74-3d1fe205aa25"
      unitRef="usd">222000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjgtMy0xLTEtMA_c83c507e-007f-46c1-b837-a38a8e5eadbe"
      unitRef="usd">192000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjktMS0xLTEtMA_ccb885b5-80ba-4a9c-a6e0-b5039535ef35"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMjktMy0xLTEtMA_3e7c2248-bd65-49f6-a65f-4e4cd96314b9"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzAtMS0xLTEtMA_eebb8e78-5c77-4a58-8dc3-172c628019c8"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzAtMy0xLTEtMA_2c462f28-88eb-4913-9c8a-00e0d30a2e40"
      unitRef="usd">8000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzEtMS0xLTEtMA_26a707d4-81f9-4f6b-a838-6913f7e6d2ed"
      unitRef="usd">7000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzEtMy0xLTEtMA_fc4b464a-70ec-4882-8744-c553076a5cf7"
      unitRef="usd">3000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzItMS0xLTEtMA_be261086-fe99-43ca-b486-0b5556a495b4"
      unitRef="usd">21000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzItMy0xLTEtMA_2054b76b-9ffa-437a-bd33-ec19276c7f0b"
      unitRef="usd">44000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzMtMS0xLTEtMA_1f649321-385d-4362-a267-da880d7167a8"
      unitRef="usd">23000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzMtMy0xLTEtMA_b9ef6442-2b36-44f0-b1a7-a8832fac4582"
      unitRef="usd">0</bhc:InterestSettlementOnCrossCurrencySwaps>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzQtMS0xLTEtMA_63aba4a3-f1d3-47af-8836-4428b8d1f77a"
      unitRef="usd">-177000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzQtMy0xLTEtMA_b9256a47-52b7-40b9-84a8-037e1193b973"
      unitRef="usd">-334000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzYtMS0xLTEtMA_910e04a2-250c-4757-a1f0-5b1e12759f3a"
      unitRef="usd">1476000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzYtMy0xLTEtMA_59d2c1fb-9a9e-46ee-b18c-bf047fa486f0"
      unitRef="usd">3238000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzctMS0xLTEtMA_42a0530b-0b49-4f8c-8e29-213cb2d7b517"
      unitRef="usd">3162000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzctMy0xLTEtMA_e88d437d-44ba-421c-8b21-15afd59b3b38"
      unitRef="usd">3956000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzgtMS0xLTEtMA_d10b47cd-d5f5-4524-b5fe-dbd7e061e0b2"
      unitRef="usd">1000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzgtMy0xLTEtMA_14a098e8-0124-4ff9-adf7-bf9bb8c95ee9"
      unitRef="usd">12000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzktMS0xLTEtMA_9c4fa155-5de1-487f-b9dd-ec289785dfff"
      unitRef="usd">1000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfMzktMy0xLTEtMA_37ebfa34-000b-4e56-b158-32af76a176d2"
      unitRef="usd">12000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDAtMS0xLTEtMA_f5211f20-db7f-4517-989c-1c4c4bfb66fd"
      unitRef="usd">30000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDAtMy0xLTEtMA_06e26e3b-8579-489f-bbcd-6579ee70269d"
      unitRef="usd">40000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDEtMS0xLTEtMA_212f3eb6-ae0e-40cb-923b-f91872650301"
      unitRef="usd">30000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDEtMy0xLTEtMA_b4de7a77-2f7c-42a3-b915-91b6e78a8adf"
      unitRef="usd">27000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDItMS0xLTEtMA_6e690148-f0d5-44de-b61e-72053e6853ad"
      unitRef="usd">39000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDItMy0xLTEtMA_3f1c8478-68a4-4079-a696-9f35df5b5353"
      unitRef="usd">26000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDMtMS0xLTEtMA_b72e24b2-2da6-435b-afee-0d680ee21640"
      unitRef="usd">-6000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDMtMy0xLTEtMA_2b02da7b-c523-4585-b7b3-a743c7821ccc"
      unitRef="usd">-1000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDQtMS0xLTEtMA_47052671-aaa1-4f10-8573-9da26252dc93"
      unitRef="usd">-1791000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDQtMy0xLTEtMA_58b732c1-a430-4846-a23d-eb9c1c78ff24"
      unitRef="usd">-812000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDUtMS0xLTEtMA_bdbb4ebb-b488-41dc-be76-b548952ae180"
      unitRef="usd">-5000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDUtMy0xLTEtMA_6ac9f254-f03c-4d9d-80f0-f16e2bd51de2"
      unitRef="usd">-17000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDYtMS0xLTEtMA_5379881a-3f90-436e-9ff4-19eeb339ee7e"
      unitRef="usd">-1256000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDYtMy0xLTEtMA_d7537893-483c-437a-8caa-80f5c525d359"
      unitRef="usd">104000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDctMS0xLTEtMA_03241e46-1530-4f23-a983-6f1596d9f7e3"
      unitRef="usd">3244000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDctMy0xLTEtMA_74739041-6bb3-4fa4-9a4d-15a0dd4d98d5"
      unitRef="usd">723000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDgtMS0xLTEtMA_17b75c73-0584-49f7-b4cc-f25940c79b0a"
      unitRef="usd">1988000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDgtMy0xLTEtMA_8ac5a72a-f7e2-41bd-a9a2-f21ff712f131"
      unitRef="usd">827000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDktMS0xLTEtMA_7866c4e4-4734-4e64-8ab7-ac33c3d7920d"
      unitRef="usd">977000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNDktMy0xLTEtMA_d46db9ec-ddbf-4a1e-a3ff-bece870d7da4"
      unitRef="usd">825000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNTAtMS0xLTEtMA_9db44b13-2c69-4174-a5a1-d9acaf4a5b1e"
      unitRef="usd">1011000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNTAtMy0xLTEtMA_59b729b0-77ea-470e-9ba6-0c2487727033"
      unitRef="usd">2000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNTEtMS0xLTEtMA_60dfbe10-db9c-4aec-b39e-1aa70058689b"
      unitRef="usd">1988000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18zNC9mcmFnOjQyZmQzYjExYzlkODQ2Nzg4ZWM4N2U5NDJjYjNkY2FiL3RhYmxlOjljYWY1M2Q0MDgyMjQ2Mzc5ZTQ0MjEwZGE2YTAwOGQ4L3RhYmxlcmFuZ2U6OWNhZjUzZDQwODIyNDYzNzllNDQyMTBkYTZhMDA4ZDhfNTEtMy0xLTEtMA_4eafb6e9-c1b2-4a44-a8f5-5c7be15f8c93"
      unitRef="usd">827000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180MC9mcmFnOmEwOTkyMTkyZWI0MTRhNmZhNzg4MTJhNzc0ZDQ5ZTA4L3RleHRyZWdpb246YTA5OTIxOTJlYjQxNGE2ZmE3ODgxMmE3NzRkNDllMDhfNTkx_5425cfda-c574-4fce-9c16-dd2b997dd22b">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#x201c;Company&#x201d; or "Bausch Health") is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#x201c;OTC&#x201d;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries.</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180MC9mcmFnOmEwOTkyMTkyZWI0MTRhNmZhNzg4MTJhNzc0ZDQ5ZTA4L3RleHRyZWdpb246YTA5OTIxOTJlYjQxNGE2ZmE3ODgxMmE3NzRkNDllMDhfNTc0_a25c53ad-a43c-4e65-b9ea-a567865dfbb9"
      unitRef="country">100</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQzMg_3af0b913-9134-45e2-9f1e-3aba6eb75bb8">SIGNIFICANT ACCOUNTING POLICIES &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (the&#160;&#x201c;SEC&#x201d;) and the Canadian Securities Administrators on February&#160;19, 2020. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2019, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Separation of the Bausch + Lomb Eye-Health Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#x201c;Separation&#x201d;). The Separation will establish two separate companies that include: (i) a fully integrated eye-health company which will consist of the Company&#x2019;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Rx businesses and (ii) a diversified pharmaceutical company which will include the Company&#x2019;s Salix, International Rx, Solta, neurology and medical dermatology pharmaceutical businesses. The anticipated separation is subject to regulatory approvals and certain conditions, including final approval by the Company&#x2019;s Board of Directors and any shareholder vote requirements that may be applicable. These unaudited Consolidated Financial Statements do not include any adjustments to give effect to the Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has begun addressing the internal organizational design and structure of the new entity which it anticipates having substantially completed in late 2021. Management is also exploring various capitalization structures and the form of the Separation transaction in order to properly capitalize both entities post-separation. As of the date of the issuance of these financial statements, the Company is in the planning phase of the Separation. As such, there are considerations, approvals and conditions that will determine the ultimate timing and structure of the Separation and there can be no assurance that a transaction will occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impacts of COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. The COVID-19 pandemic has also significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, elective medical procedures and travel. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence, if any, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing.   Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New&#160;Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued guidance on the impairment of financial instruments requiring an &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ0Nw_fc60b351-a915-4b1e-a9cf-8bbc63693281"&gt;impairment model based on expected losses&lt;/span&gt; rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.&#160; The guidance was effective for the Company beginning January 1, 2020.&#160; The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During the nine months ended September 30, 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards, Not Adopted as of September&#160;30, 2020 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on its disclosures.&lt;/span&gt;&lt;/div&gt;In December 2019, the FASB issued guidance simplifying the accounting for income taxes.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on the Company's financial position, results of operations and cash flows.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfOTg5NTYwNDY2MDg4NA_cb545697-8b90-46ee-b583-c8b9213c0a82">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (the&#160;&#x201c;SEC&#x201d;) and the Canadian Securities Administrators on February&#160;19, 2020. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2019, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfOTg5NTYwNDY2MDg4NQ_539ac518-4c12-4bdf-a7fe-249c75afab4a">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ1NQ_135ff645-a548-4531-8e84-4be971a75950">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ0Mw_4c509346-e058-467a-931e-0386a19f9a6b">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New&#160;Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued guidance on the impairment of financial instruments requiring an &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ0Nw_fc60b351-a915-4b1e-a9cf-8bbc63693281"&gt;impairment model based on expected losses&lt;/span&gt; rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.&#160; The guidance was effective for the Company beginning January 1, 2020.&#160; The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During the nine months ended September 30, 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards, Not Adopted as of September&#160;30, 2020 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on its disclosures.&lt;/span&gt;&lt;/div&gt;In December 2019, the FASB issued guidance simplifying the accounting for income taxes.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on the Company's financial position, results of operations and cash flows.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9975f10d37a4b9f8ab190b71f48d126_I20200101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNDkyNQ_eb883b8e-faf8-4b27-96a6-317930d93e58"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTU2NQ_e58a2f6b-66f5-4826-aa9a-90ea6d02de25">REVENUE RECOGNITION &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities.  All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for the nine months ended September 30, 2020 and 2019 were $71 million and $50&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $38&#160;million and $80&#160;million for the three months ended September 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the nine months ended September 30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $33 million and $29&#160;million as of September 30, 2020 and January 1, 2020, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. Included as a reduction of Distribution Fees in the table above are price appreciation credits of approximately $4 million during the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of Synergy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $26 million and $26&#160;million as of September 30, 2019 and January 1, 2019, respectively. There were no price appreciation credits during the nine months ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2020 is as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retrospective effect of application of new accounting standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTU5MA_c925f730-e740-4dfb-b159-388e16127893">REVENUE RECOGNITION &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities.  All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i926e8404d24b4f67a639801625df9821_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNjA0NzMxMzk2MjI4OQ_4248a727-413f-492b-a219-f73cb6c314d5"
      unitRef="usd">71000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i60746b3a7f484dad99381c010e94f132_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTQ5NzU1ODE0ODI4OQ_198c2304-e9d6-4b80-a59c-76356abf9ac3"
      unitRef="usd">50000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="ie229cebfd8564ef69cc3b87b8cca2163_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDM5ODA0NjUyMDY1OA_1ec2b961-de10-40dc-a5ed-16cd9f16681a"
      unitRef="usd">-38000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i7d2ec754640b47e3bc475ba39e2f15b3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTQ5NzU1ODE0ODI3Ng_b140316e-8912-4c17-a61e-b2e0a0bbb5f3"
      unitRef="usd">-80000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTU2NA_50578ff4-41a1-453b-97ab-326d7dd5c262">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the nine months ended September 30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,845)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $33 million and $29&#160;million as of September 30, 2020 and January 1, 2020, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. Included as a reduction of Distribution Fees in the table above are price appreciation credits of approximately $4 million during the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of Synergy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4865f0c8877843d2a74d4a34949d8990_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi0yLTEtMS0w_a7c56802-71e6-443a-972d-61f1410f6bac"
      unitRef="usd">182000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i64e6b19fad9e422cbb35846a705746dc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi00LTEtMS0w_90770b8a-20a3-42de-99b4-c524aec974cd"
      unitRef="usd">691000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4544171997534f44b301068e2ca91ee1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi02LTEtMS0w_7c99e0fc-ee50-411a-9246-9ca2d6b545e0"
      unitRef="usd">927000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id2a7fc687b364d7b91dd305f5f2c2a47_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi04LTEtMS0w_90678e4a-b320-41aa-bff7-3eeb2a7d934c"
      unitRef="usd">168000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic0d9b898b4dd4de4afef0d16544c30e4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi0xMC0xLTEtMA_6c054241-e6de-4aca-9407-fe22e866c46b"
      unitRef="usd">82000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMi0xMi0xLTEtMA_f910167b-383a-4943-a534-b8aa842c94e0"
      unitRef="usd">2050000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i9396aa2e3a194b7d88a01028c2d8726f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy0yLTEtMS0w_b0a59229-2011-4c07-8282-09e27e1d9973"
      unitRef="usd">457000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i926e8404d24b4f67a639801625df9821_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy00LTEtMS0w_4248a727-413f-492b-a219-f73cb6c314d5"
      unitRef="usd">71000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ibcb4b2fb825447fba3ebaf7786b43dc7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy02LTEtMS0w_c7ec3a05-e55b-4f2d-afee-d4efcf9eb9de"
      unitRef="usd">1587000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i6b21a7ff737c4ce9bcf3101d1496b9e8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy04LTEtMS0w_76874f2b-108a-4051-82a9-0a97e8017a12"
      unitRef="usd">1433000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i05ef307c522049b29a69292368af3288_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy0xMC0xLTEtMA_76e7ab63-1ccd-4f06-b673-ea1d4f6b7d6c"
      unitRef="usd">149000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfMy0xMi0xLTEtMA_d0e84e1e-98f2-4261-afeb-c1de8200f95d"
      unitRef="usd">3697000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9396aa2e3a194b7d88a01028c2d8726f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC0yLTEtMS0w_f6210a16-8455-42a3-aad1-bdd3be269ae7"
      unitRef="usd">454000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i926e8404d24b4f67a639801625df9821_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC00LTEtMS0w_1d489f44-0013-4826-8f85-f883a5f99ac2"
      unitRef="usd">185000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ibcb4b2fb825447fba3ebaf7786b43dc7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC02LTEtMS0w_76541a0e-dfd8-456e-b2ab-8eeb4209712f"
      unitRef="usd">1605000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i6b21a7ff737c4ce9bcf3101d1496b9e8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC04LTEtMS0w_9ac0ea02-a8d2-4afd-8368-f1a2ccf9e8a2"
      unitRef="usd">1451000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i05ef307c522049b29a69292368af3288_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC0xMC0xLTEtMA_c2ab1eea-a5d5-4e2e-aeca-f5fd8fe9dae5"
      unitRef="usd">150000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNC0xMi0xLTEtMA_5543ebe9-f8c7-458c-a353-0ef2fc698273"
      unitRef="usd">3845000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id29dfca8902e4b9ca9b215022329120a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS0yLTEtMS0w_3440b139-9d74-457e-bac3-ac227378cf75"
      unitRef="usd">185000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i563d7e65dd4f4fd3a57a525126385f71_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS00LTEtMS0w_80c3d3b5-0d06-40b1-b588-509df56f4325"
      unitRef="usd">577000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic06448dd5b9c4a5a8833d7aeb0462adc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS02LTEtMS0w_a631cd4d-e929-4f7f-91fa-bb010965f3cd"
      unitRef="usd">909000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia84a1548bc2b4290bf923185b9809a3c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS04LTEtMS0w_2347b503-e974-4d79-9c26-d6333e323da4"
      unitRef="usd">150000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0d5fc05eca2d45039ef1c66ddd5fd5bb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS0xMC0xLTEtMA_5bcd5766-ef6e-49e3-9d83-153d1fd8e41e"
      unitRef="usd">81000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOmY3Y2VkODQxNTU1ZjQwYzJhZGNhMDA1ZGYzNjAxMDUyL3RhYmxlcmFuZ2U6ZjdjZWQ4NDE1NTVmNDBjMmFkY2EwMDVkZjM2MDEwNTJfNS0xMi0xLTEtMA_f503be33-a37a-4238-8bc6-204aa57e1375"
      unitRef="usd">1902000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if87d338bc71847cbaa721c2e753719df_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfMzg2OA_d96bfbab-a574-46ce-96eb-54b2ac726dc1"
      unitRef="usd">33000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4b081d921d2542fab60f3ee0f92c0b0c_I20200101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfMzg3NQ_336b70e8-dfd3-4445-9718-ef4192a0f0fd"
      unitRef="usd">29000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbb36916236a49af8aabec568346f93f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDEyNQ_0c063207-e805-46da-b441-38db5979c905"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1ef27070c30b49c1a8b37fca2d781143_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi0yLTEtMS0w_662db892-e4d9-4c67-9781-81cee123b790"
      unitRef="usd">175000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iba58938db3e44a8ab10e6ad34541726a_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi00LTEtMS0w_33992278-4eae-43a6-98c3-cfcd4db458d2"
      unitRef="usd">813000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib7d0d96c365941de8f6f60a38bcb3768_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi02LTEtMS0w_b96cd33a-e3ec-4f47-b1b6-246b30061c53"
      unitRef="usd">1024000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5216708cf09e4690887e64359dfa0177_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi04LTEtMS0w_507e8c03-d91b-4a9c-a907-e7b8c611de35"
      unitRef="usd">209000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9935a6414aaa4e8e9a55fa03b280060c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi0xMC0xLTEtMA_fa622b29-0494-48f2-90a0-af97037218f2"
      unitRef="usd">163000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMi0xMi0xLTEtMA_80613c4e-2c5f-477c-b85f-6acc43f2da02"
      unitRef="usd">2384000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i08d75e8d917347f5beaf038cb1a07543_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy0yLTEtMS0w_953c9e60-1d97-4635-a6c9-240366f2af13"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i60746b3a7f484dad99381c010e94f132_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy00LTEtMS0w_67d0177e-b3be-45c9-b960-9762af7ae3b8"
      unitRef="usd">3000000</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i4767169b3e8b4b7f9c14e03ce1450592_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy02LTEtMS0w_0baa0902-7b7e-4727-814a-0daae041b4e8"
      unitRef="usd">12000000</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i00d9912296e4423eb2f0c58b058f3d53_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy04LTEtMS0w_677de5f7-eddd-4a76-b1fb-df3680a4fbbd"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="i10ab9e834c5043c3b3c019c844bf6906_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy0xMC0xLTEtMA_1c19a9c3-38af-46ab-9397-04b9ad7326c5"
      unitRef="usd">1000000</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfMy0xMi0xLTEtMA_91d8a8e7-e8ea-4b8d-aced-a1f322b21c17"
      unitRef="usd">16000000</us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i08d75e8d917347f5beaf038cb1a07543_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC0yLTEtMS0w_6413770a-e8d3-4d68-ba4d-326b25daf7a2"
      unitRef="usd">585000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i60746b3a7f484dad99381c010e94f132_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC00LTEtMS0w_b178f36b-43a8-4abf-b95a-c61e75967ea4"
      unitRef="usd">50000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i4767169b3e8b4b7f9c14e03ce1450592_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC02LTEtMS0w_b11df698-9478-4ba4-b1d1-7f7ae940f1a1"
      unitRef="usd">1650000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i00d9912296e4423eb2f0c58b058f3d53_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC04LTEtMS0w_1375a2b7-cd4d-45fd-a12f-94af50734592"
      unitRef="usd">1425000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i10ab9e834c5043c3b3c019c844bf6906_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC0xMC0xLTEtMA_579a4bb8-e96b-456c-8b7b-9a6e9c030488"
      unitRef="usd">150000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNC0xMi0xLTEtMA_1b0c2f3b-e2cb-4be8-9439-ea3a09488783"
      unitRef="usd">3860000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i08d75e8d917347f5beaf038cb1a07543_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS0yLTEtMS0w_ab7dda91-6423-489d-b153-03bc404a8a41"
      unitRef="usd">583000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i60746b3a7f484dad99381c010e94f132_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS00LTEtMS0w_b2314cfb-5a70-4da8-bb6f-2c9c73e508c4"
      unitRef="usd">187000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i4767169b3e8b4b7f9c14e03ce1450592_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS02LTEtMS0w_7a76b653-866f-4cab-b432-9e972d741862"
      unitRef="usd">1673000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i00d9912296e4423eb2f0c58b058f3d53_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS04LTEtMS0w_c78e7e3e-9b6d-45d9-95fd-518d247b8ea0"
      unitRef="usd">1480000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i10ab9e834c5043c3b3c019c844bf6906_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS0xMC0xLTEtMA_be94c93d-20c6-4c1f-903c-a12a5170495e"
      unitRef="usd">181000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNS0xMi0xLTEtMA_53e7a20d-697f-423e-819c-ecd3812d9685"
      unitRef="usd">4104000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i251db7175d9c4d7498e6bbc45a12b1a7_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi0yLTEtMS0w_75c7c041-f7b6-4c65-8006-2ad11bfb7902"
      unitRef="usd">177000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i43ca4779d36d4db0a4416740976e51df_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi00LTEtMS0w_914ea82c-9cd0-484a-9be9-42af1b8ca491"
      unitRef="usd">679000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i90e68a168c934bf0b76363ae269a8dd4_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi02LTEtMS0w_f53d3f1c-141f-4f84-908a-22a223806eeb"
      unitRef="usd">1013000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if477ae61fd124d7aac6ae9ddab03f3cf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi04LTEtMS0w_3359708b-eb1c-4eef-9708-45997c5faf34"
      unitRef="usd">154000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3f26ca1233014e19a4813bfb570654cc_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi0xMC0xLTEtMA_3418b98e-5763-49e6-af82-2e6fa1ec2b1b"
      unitRef="usd">133000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjM3MDcxNjljNjQyODRmYzg5MmI4OGQ2YTY3ZjY5MGE4L3RhYmxlcmFuZ2U6MzcwNzE2OWM2NDI4NGZjODkyYjg4ZDZhNjdmNjkwYThfNi0xMi0xLTEtMA_2ed68237-64a3-4add-9e8a-e7af33aa9134"
      unitRef="usd">2156000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i22581c99ab8945728931a540b016ef35_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDI1NA_29fd2d94-5afd-4377-8c3d-12157c7d4250"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i53b5ad55c3114bbb9e240bd272663878_I20190101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDI2MQ_0b7df582-57f3-42d2-966b-76575d09a7d2"
      unitRef="usd">26000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea55888e199a4f30aa6537db612f8d50_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNDMxMw_bd37f609-69cc-4438-b037-7baf2f4c8df2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RleHRyZWdpb246YjM3Mjk0M2FmZWRlNDI2NWI1YzM3MWFhMzJjM2RiYmFfNTU3Mw_5598f9e1-6b15-42d0-8285-166105d76ca7">The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2020 is as follows.&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retrospective effect of application of new accounting standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfMS0xLTEtMS0w_762ada39-807c-4ec1-99b8-32f22da608c7"
      unitRef="usd">48000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfMi0xLTEtMS0w_22608d95-b134-4376-a337-3a982418c83c"
      unitRef="usd">1000000</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfMy0xLTEtMS0w_daf5f938-7388-44c0-820f-f5980a10f974"
      unitRef="usd">7000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfNC0xLTEtMS0w_821f53b8-804d-4f15-9c84-099faaef9394"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfNS0xLTEtMS0w_5bc5d4ed-5286-4816-bb96-986bee71ff99"
      unitRef="usd">1000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfNi0xLTEtMS0w_9b6f43c4-63cd-4fc7-8d58-a27db5e924d8"
      unitRef="usd">1000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180Ni9mcmFnOmIzNzI5NDNhZmVkZTQyNjViNWMzNzFhYTMyYzNkYmJhL3RhYmxlOjVhZjI1NGUyNDIzMDQ2M2RhZTQ1Mjg5OGY3M2YwYTI0L3RhYmxlcmFuZ2U6NWFmMjU0ZTI0MjMwNDYzZGFlNDUyODk4ZjczZjBhMjRfNy0xLTEtMS0w_a3a6e6e8-2c3f-49c4-9c28-0619be14f11a"
      unitRef="usd">53000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfNDE2Mw_f06af6e6-0ac0-49ef-b18d-1a3a7101f608">ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition of Certain Assets of Synergy Pharmaceuticals Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of&#160;approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired were the worldwide rights to the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and has, to date, resulted in additional revenues and certain business synergies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting as: (i) substantially all the fair value of the assets acquired is not&#160;concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brand intangible assets (estimated useful life - 7 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue and Operating Results &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55&#160;million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the nine months ended September 30, 2019 and the year 2019 were not material. Included in Other expense, net during the nine months ended September 30, 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC ("Allegro")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 21, 2020, the Company announced that it entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option is exercised, is the worldwide rights to risuteganib (Luminate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration ("AMD"). A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. The aggregate payments to acquire the Option are $50&#160;million and include an upfront payment of $10&#160;million and a second payment of $40&#160;million should Allegro raise additional funding. During the three months ended September 30, 2020, the Company made and expensed the upfront payment of $10&#160;million as acquired in-process research and development ("IPR&amp;amp;D") included in Other expense, net. If the Option is exercised, additional payments to acquire all ophthalmology assets of Allegro will be due.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred.  Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company identified certain products in the Bausch + Lomb/International segment and one product in the Diversified Products segment for disposal. The products and the related assets and liabilities of this disposal group qualified as a business. Revenues associated with this business were $14 million and $19 million for the years 2019 and 2018, respectively. The carrying value of the business, including inventories, intangible assets, goodwill and deferred income taxes, was adjusted to its estimated fair value less costs to sell and reclassified as held for sale as of September 30, 2019 and an impairment of $8 million associated with this business was recognized during the three months ended September 30, 2019. As a result of changing business dynamics, during the three months ended March 31, 2020, the Company decided not to sell these assets and reclassified $39 million of held for sale assets as assets held and used at their respective fair values at the date of the decision not to sell. This reclassification did not impact the Consolidated Statement of Operations for the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;</bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id525861ca12645cbbfa8004f60ba9429_D20190306-20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMjY4_bcc00371-607e-4fc1-9d50-8a485df4bf73"
      unitRef="usd">180000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfNDE2Nw_4f528711-c3bd-41ed-841f-de35ef6b7bb3">The following table summarizes the fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brand intangible assets (estimated useful life - 7 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfMS0xLTEtMS0w_028891a2-b8f1-4f5a-bedc-0e598dbddc67"
      unitRef="usd">7000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfMi0xLTEtMS0w_98b8f601-245b-44b7-9e9e-a0c432ec24c4"
      unitRef="usd">24000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfMy0xLTEtMS0w_8a886233-1ea9-4930-bd17-00219f1418c2"
      unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id525861ca12645cbbfa8004f60ba9429_D20190306-20190306"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNC0wLTEtMS0wL3RleHRyZWdpb246YzA4NDRmOWJhOWQ0NDJmMzg3ZmJiYjJlODZiYzU0MDRfNjE_71618cfc-41e0-4b49-9bc9-386b18c9cb7e">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNC0xLTEtMS0w_a558a7ea-482d-42ee-96c5-330620c985d7"
      unitRef="usd">159000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNS0xLTEtMS0w_13b59df0-1fbf-4821-ac02-00cc9080f705"
      unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <bhc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses
      contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNi0xLTEtMS0w_614a5599-2d65-47d2-95ae-64e503ba3d8a"
      unitRef="usd">17000000</bhc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfNy0xLTEtMS0w_abf4ccd2-d132-4036-b2c0-3433e3b94295"
      unitRef="usd">177000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfOC0xLTEtMS0w_882ef03c-67af-4a22-a8bb-20a83576e14b"
      unitRef="usd">3000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="if407461ef48547d3adc0e65ccd56a10c_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RhYmxlOmE4NzE3NzhkMGRiZTQ2OTRiNDUwN2UzMTg5YWZlMWQ2L3RhYmxlcmFuZ2U6YTg3MTc3OGQwZGJlNDY5NGI0NTA3ZTMxODlhZmUxZDZfOS0xLTEtMS0w_90e6fbec-9f8a-421e-8f17-c39ebebbe125"
      unitRef="usd">180000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="ic76a9522ae624b31ba4b70987bd03b75_D20190306-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTY1OQ_b663d7f0-3e82-4cc3-b5ae-ba45beff6526"
      unitRef="usd">55000000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <bhc:BusinessAcquisitionProFormaOperatingIncomeLoss
      contextRef="ib738e1928e864b82b2984cc187349f0d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_51c80e5f-ad42-4e8f-8394-72ffa5c8be41"
      unitRef="usd">0</bhc:BusinessAcquisitionProFormaOperatingIncomeLoss>
    <bhc:BusinessAcquisitionProFormaOperatingIncomeLoss
      contextRef="i5183e10738b0469fafeab79f0c1a49bd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_6f4d4898-4196-4c49-8844-3573ff00b375"
      unitRef="usd">0</bhc:BusinessAcquisitionProFormaOperatingIncomeLoss>
    <bhc:BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual
      contextRef="ic76a9522ae624b31ba4b70987bd03b75_D20190306-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_9a82669f-598a-4f0b-af1e-9f6257e087a7"
      unitRef="usd">0</bhc:BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ib738e1928e864b82b2984cc187349f0d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_ba1e81e0-9bdf-428f-b558-1f5d1c590952"
      unitRef="usd">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i5183e10738b0469fafeab79f0c1a49bd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTg5Mw_f217488e-15a4-4e17-8bb7-97f485326d9a"
      unitRef="usd">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5183e10738b0469fafeab79f0c1a49bd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTk2OQ_67d97e0b-e42e-46a3-8b88-08957beda054"
      unitRef="usd">-8000000</us-gaap:OtherNonoperatingIncomeExpense>
    <bhc:PotentialAssetAcquisitionAggregatePurchasePrice
      contextRef="i85e9f322f6594cb29a915174676fb28d_D20200921-20200921"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTA5OTUxMTYzMDE5MDc_03d323bb-f3d4-487f-abd3-3c81153af961"
      unitRef="usd">50000000</bhc:PotentialAssetAcquisitionAggregatePurchasePrice>
    <bhc:PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice
      contextRef="i85e9f322f6594cb29a915174676fb28d_D20200921-20200921"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTA5OTUxMTYzMDE5MjA_d9c962a9-35a0-4bbd-b65b-5c9206f42bdd"
      unitRef="usd">10000000</bhc:PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice>
    <bhc:PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice
      contextRef="i85e9f322f6594cb29a915174676fb28d_D20200921-20200921"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMjc0ODc3OTA3NTE0OA_01763962-40cd-4abe-8460-e4e2455cc1a1"
      unitRef="usd">40000000</bhc:PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i596976330b084b2083ea00b7d8939d1e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMTA5OTUxMTYzMDE5MzM_760ca55e-26b5-4bb4-91c3-79682c83e0b0"
      unitRef="usd">-10000000</us-gaap:OtherNonoperatingIncomeExpense>
    <bhc:DisposalGroupNumberOfProductsForDisposal
      contextRef="ied8b6d4a32f24bef886f050abd26218d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzE5MA_bf29eaa7-fdd4-4377-a817-8e4c7a9825e0"
      unitRef="product">1</bhc:DisposalGroupNumberOfProductsForDisposal>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i5bc655cb9eb649d7ab9cd303e9abe56d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzM5NQ_987bede9-772e-4de9-951b-b373e37e1506"
      unitRef="usd">14000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i2a7193c3b1a346ab8b76b004d6fab3b0_D20180101-20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzQwMg_c7366162-22bb-4c9b-9df8-f3f65cc441a2"
      unitRef="usd">19000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i9a254f3c123b4ca1bd8ea40230250dde_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzcwMg_7a7730e6-6cc0-40af-833f-9ce575532046"
      unitRef="usd">8000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:Assets
      contextRef="id9aec834c676489bb24751c37138f0ae_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzk1MQ_72720392-31c5-4f46-aa63-c860ad7779a6"
      unitRef="usd">39000000</us-gaap:Assets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="id9aec834c676489bb24751c37138f0ae_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180OS9mcmFnOmFmYjU3MWIyY2E3NDQ4ZTc4MjBjYmVlZGU3M2U4ODgzL3RleHRyZWdpb246YWZiNTcxYjJjYTc0NDhlNzgyMGNiZWVkZTczZTg4ODNfMzk1MQ_791143cb-b772-4a91-af6d-c86e3005f8a6"
      unitRef="usd">-39000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMTE3MA_3fdcb211-fa90-4280-9ac2-7346595df92c">RESTRUCTURING, INTEGRATION AND SEPARATION COSTS &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring and integration costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of September 30, 2020 was $25 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2020, the Company incurred $12 million of restructuring and integration costs. These costs included: (i) $7 million of facility closure costs and (ii) $5 million of severance costs. The Company made payments of $14&#160;million for the nine months ended September 30, 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2019, the Company incurred $28 million of restructuring and integration costs. These costs included: (i) $11 million of severance and other costs associated with the acquisition of certain assets of Synergy, (ii) $9&#160;million of facility closure costs and (iii) $8 million of other severance costs. The Company made payments of $27 million for the nine months ended September 30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation costs and separation-related costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. Included in Restructuring, integration and separation costs for the three and nine months ended September 30, 2020 is $1&#160;million of separation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also incurred, and will incur, separation-related costs which are incremental costs indirectly related to the Separation. Separation-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative expenses for the three and nine months ended September 30, 2020 is $4&#160;million of separation-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is in the planning phase of the Separation and the extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ic4358fb6f74742fdb0a980244f01c440_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNjE2_b08033ca-5c16-4b3a-a609-c0c276ba4073"
      unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNjU2_4f615802-866a-45a5-bdb8-dc8b919dd907"
      unitRef="usd">12000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:BusinessExitCosts1
      contextRef="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNzI1_cd0d2f23-a667-46ce-805b-71da289ab00b"
      unitRef="usd">7000000</us-gaap:BusinessExitCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNzYz_631c2376-1e1a-4cc8-8ae2-84e55574b37d"
      unitRef="usd">5000000</us-gaap:SeveranceCosts1>
    <us-gaap:PaymentsForRestructuring
      contextRef="i131e0328fd084b5da77d42beb644efd7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfODE1_65b76fd6-f3e4-4cb0-8b04-7b6984323c76"
      unitRef="usd">14000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfODY4_9d0c837e-6430-410b-b59c-ba834933ff19"
      unitRef="usd">28000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:SeveranceCosts1
      contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfOTM3_1186d165-aca3-4c8b-9e6f-e3a26c49cec4"
      unitRef="usd">11000000</us-gaap:SeveranceCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMTAzNg_8cdf8a00-0d6b-4902-adba-8a06e89648b5"
      unitRef="usd">9000000</us-gaap:BusinessExitCosts1>
    <us-gaap:OtherRestructuringCosts
      contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMTA3MQ_dceddedf-d8cb-4281-8ac6-7efb31d7ae36"
      unitRef="usd">8000000</us-gaap:OtherRestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="ic09223d3d1a94146bb1751fc8830d2e1_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMTE1Nw_c8a677e9-f922-4a88-8cd2-a0fa67ca21bf"
      unitRef="usd">27000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringCharges
      contextRef="i630d2760251f4bf096f3e18b26d2c348_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMzI5ODUzNDg5MjkxOA_10d53c6b-a176-4eda-909a-5603942aa4fc"
      unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i46838e1d7a4a42c3a16733f85f00c538_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfMzI5ODUzNDg5MjkxOA_b3e8aaeb-b63a-4cf3-b8b9-f1b6002ef9c6"
      unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i46838e1d7a4a42c3a16733f85f00c538_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNDM5ODA0NjUyMDQ3MQ_b6eb7bc8-b4ff-4f25-ad67-bb94c0f3e6a2"
      unitRef="usd">4000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i630d2760251f4bf096f3e18b26d2c348_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181Mi9mcmFnOjQ0ODc1NDM0YjY4YjQ3MjlhOGQzMWRiZWY0OGRkNjM2L3RleHRyZWdpb246NDQ4NzU0MzRiNjhiNDcyOWE4ZDMxZGJlZjQ4ZGQ2MzZfNDM5ODA0NjUyMDQ3MQ_bfc47b65-ca98-42df-8d73-adf1bbc8462b"
      unitRef="usd">4000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNDM5ODA0NjUyMjI1OA_0313fb2d-b3f8-43f5-9ceb-31d814cd185b">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014;&#160;Quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, Restricted cash includes $1,010&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation, subject to final court approval, and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature.  These payments will remain in escrow until final approval of the settlement as discussed in Note 18, "LEGAL PROCEEDINGS".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 during the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cross-currency Swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is the Company&#x2019;s investment in certain euro-denominated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values.  The fair value is determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs may include: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective and remain in Accumulative other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the nine months ended September 30, 2020 and 2019. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s cross-currency swaps liability as of September 30, 2020 and December 31, 2019 was $18 million and $13&#160;million, respectively. Included in Other non-current liabilities is $21 million and $22&#160;million of cross-currency swaps and included in Prepaid expenses and other current assets is $3 million and $9&#160;million of earned interest within the Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) Gain recognized in Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlement of the Company's cross-currency swaps occur in February and August each year. During the nine months ended September 30, 2020, the Company received $23 million in settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2020, the Company entered into foreign currency exchange contracts, with an aggregate notional amount of $187&#160;million. The Company had no foreign currency exchange contracts during 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company's foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#x2019;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company's foreign currency exchange contracts liability as of September 30, 2020 was $1&#160;million. Included in Accrued and other current liabilities are $2&#160;million and included in Prepaid expenses and other current assets are $1&#160;million of foreign currency exchange contracts within the Consolidated Balance Sheets. During the three and nine months ended September 30, 2020, the net change in fair value was $0 and a loss of $1&#160;million, respectively. Settlements of the Company's foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. During the nine months ended September 30, 2020, the Company reported a realized loss of $1&#160;million related to settlements of the Company's foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At September&#160;30, 2020, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 5% to 25%, and a weighted average risk-adjusted discount rate of 8%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a non-recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current assets held for sale of $39 million included in the Consolidated Balance Sheets as of December 31, 2019 were remeasured to their estimated fair values less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. As discussed in Note 4, "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE", due to changing business dynamics, the Company decided not to sell these assets during the three months ended March 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of long-term debt as of September&#160;30, 2020 and December&#160;31, 2019 was $25,258 million and $27,520 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODIyMQ_71013458-42fe-4255-ba2e-6ac4f7052c03">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5238086c98844119970f8779efb8724d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0yLTEtMS0w_0b2446f2-d04f-4f35-b348-a7ea7d6bf9bc"
      unitRef="usd">423000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie79caecdf5264091b27165fac0949180_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy00LTEtMS0w_50858658-9223-4361-9122-7b8019959588"
      unitRef="usd">393000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5703e3dc34b5445690b680201a721c40_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy02LTEtMS0w_f5758650-eff1-495c-ba12-cbd5a5e0a0cd"
      unitRef="usd">30000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia7ba393fb386441abbb663abd8248a98_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy04LTEtMS0w_cc374fea-f5e5-4092-9ae4-1c7ffe4c8cb1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i17077f1b6f0d4339a06e1372d84405db_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0xMC0xLTEtMA_4749384e-0ea3-4bc6-a53f-5f067a45f971"
      unitRef="usd">2696000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7213b15a279a460cb57c398f93e64324_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0xMi0xLTEtMA_4cbe8603-81dd-4e01-ac91-5069294d55c2"
      unitRef="usd">2646000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id041afe2abf047cc82ee51281520ae03_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0xNC0xLTEtMA_5c485a0b-1981-45a4-9d50-08d5ca114531"
      unitRef="usd">50000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia07ebc37151443b8a5b057c7a3cfc60a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMy0xNi0xLTEtMA_2dc46820-ffed-4ad5-8718-dd4e5f0da8c2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i5238086c98844119970f8779efb8724d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0yLTEtMS0w_0357a7d5-e801-4997-a64b-a88ccd334884"
      unitRef="usd">1011000000</bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="ie79caecdf5264091b27165fac0949180_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC00LTEtMS0w_bc346a91-551f-43e9-9490-6e51d0185ce3"
      unitRef="usd">1011000000</bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i5703e3dc34b5445690b680201a721c40_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC02LTEtMS0w_f3f8ce19-8066-4b7f-a78a-ab6c16c84cbc"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="ia7ba393fb386441abbb663abd8248a98_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC04LTEtMS0w_3b785ffa-8e94-497f-9437-6c2d83019ebe"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i17077f1b6f0d4339a06e1372d84405db_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0xMC0xLTEtMA_c01e95f0-dd39-424c-85bd-de00f950f455"
      unitRef="usd">1000000</bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i7213b15a279a460cb57c398f93e64324_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0xMi0xLTEtMA_cddebd84-cefc-4274-a469-1733ee000f4c"
      unitRef="usd">1000000</bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="id041afe2abf047cc82ee51281520ae03_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0xNC0xLTEtMA_3dc240a8-0047-4c56-82ba-6d82c784d136"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="ia07ebc37151443b8a5b057c7a3cfc60a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNC0xNi0xLTEtMA_55037714-e066-4bdf-b008-888c1ad8119e"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="i188c7aa31f4846398b02780a637146ca_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0yLTEtMS0w_fe0fe334-5843-4503-8a25-486c4290e55e"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i44b34ec25e124642a594402f4d39fd61_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi00LTEtMS0w_631334d6-c3a8-4b64-b378-7662c9786bb1"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2392471a1d8d4ca9aff058dfa66f23a9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi02LTEtMS0w_4884d117-b830-4226-9f9f-2e21c01174c9"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i53ca7375bec54df1831d5ec1bb7ce35f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi04LTEtMS0w_14db03ce-b3ed-456e-995b-2d04a65f280f"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i55a91dd3637642f194adf2e407393f51_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0xMC0xLTEtMA_d148ae1b-adb1-4506-9d85-62dab4a96a16"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i639cfded29ff480cac614d7849308b01_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0xMi0xLTEtMA_8dc747ec-98ca-408f-97c5-46a08f7e0f71"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ib9b592bb3c924615aeffe086aa4dcc11_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0xNC0xLTEtMA_e576fc88-20e8-4292-ad07-7147479d2fc2"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i85c2fa48fde14cd796cde7eac723cdc9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfNi0xNi0xLTEtMA_ccdbb2db-5df2-4406-9723-feb2fcf21ce3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i5238086c98844119970f8779efb8724d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0yLTEtMS0w_f1dbf323-b896-43bc-93c7-b2d8914d552c"
      unitRef="usd">312000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ie79caecdf5264091b27165fac0949180_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC00LTEtMS0w_4b38397b-5638-4357-b1b0-6c88ece70ae3"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i5703e3dc34b5445690b680201a721c40_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC02LTEtMS0w_cfc63258-da7c-4d16-aa14-97bf83ba0e6a"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ia7ba393fb386441abbb663abd8248a98_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC04LTEtMS0w_8a423910-b796-4340-9e89-da781f904941"
      unitRef="usd">312000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i17077f1b6f0d4339a06e1372d84405db_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0xMC0xLTEtMA_bcc54f0d-899a-47a1-9ee7-a6492c4bc0d0"
      unitRef="usd">316000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i7213b15a279a460cb57c398f93e64324_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0xMi0xLTEtMA_2be3c651-389b-459c-a2f6-b9eb142591cc"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="id041afe2abf047cc82ee51281520ae03_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0xNC0xLTEtMA_5a32209b-9c14-4c11-ab2c-a2a9ce198216"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ia07ebc37151443b8a5b057c7a3cfc60a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOC0xNi0xLTEtMA_71203c41-08d4-4be6-9601-4e8927406a3d"
      unitRef="usd">316000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="icf5b3db7d10d49d98b2d4ef9c94455ad_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0yLTEtMS0w_1d0e6013-f6b3-4437-8f3e-222d1c85ed40"
      unitRef="usd">18000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id74922aa0e2c416dab84eaa66f9f5e9b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS00LTEtMS0w_610c1c1b-8824-476e-96b1-13cdb3fcb748"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4fbc708e24684f8c9c6e746a68d8705c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS02LTEtMS0w_2128ca06-2cca-4c74-ac58-3fd18050c008"
      unitRef="usd">18000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ided937c13e414b9f9a600c9abd30c643_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS04LTEtMS0w_06e92589-279d-4834-9b5a-5088e3eeb05e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie382e8171db64a9b8b111fb4def54606_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0xMC0xLTEtMA_244802d5-a5bf-457e-893d-5fc2cbb69e2e"
      unitRef="usd">13000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i07084c19d2c84f91a4a467900df34873_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0xMi0xLTEtMA_a85e5c30-b6ef-4be1-aa45-dfefea9697ad"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4442b581e9fb476e88434975a33029ed_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0xNC0xLTEtMA_0bed43d6-7c46-442f-a3ba-a87632e7df4b"
      unitRef="usd">13000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i676ba929c33c424d9ab4a59672a49177_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfOS0xNi0xLTEtMA_9e305cd5-e983-43b1-98b7-d82e7dafc6ad"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i188c7aa31f4846398b02780a637146ca_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMi0xLTEtMA_57715f66-643d-4a93-8f10-be9fb01112ac"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i44b34ec25e124642a594402f4d39fd61_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtNC0xLTEtMA_1a325c78-ce86-4ecc-b2f2-524dbd800f6c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2392471a1d8d4ca9aff058dfa66f23a9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtNi0xLTEtMA_e3b8df2b-c079-4ab7-97d9-fa6d52f9f038"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i53ca7375bec54df1831d5ec1bb7ce35f_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtOC0xLTEtMA_e13a07cc-0ebc-4a59-bce8-6d62fe832a09"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i55a91dd3637642f194adf2e407393f51_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMTAtMS0xLTA_408d7022-9820-4c05-b343-6b96e06d998a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i639cfded29ff480cac614d7849308b01_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMTItMS0xLTA_abcdff8f-8eb9-4f10-9184-17aea8aee2c2"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib9b592bb3c924615aeffe086aa4dcc11_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMTQtMS0xLTA_a315ecd7-5747-4dfb-bb24-881ce56af9f8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i85c2fa48fde14cd796cde7eac723cdc9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjk3ZGUyNjRlYmExNjQ3Y2I4YTFiZWExZWU2NWFiZWZjL3RhYmxlcmFuZ2U6OTdkZTI2NGViYTE2NDdjYjhhMWJlYTFlZTY1YWJlZmNfMTAtMTYtMS0xLTA_fa9be649-70bb-4cc1-a4e3-6d68cedc7e4d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <bhc:HighlyLiquidInvestmentsMaturityPeriod
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTQyOA_8fd2bf45-529a-4282-827f-11f0e53b8936">P3M</bhc:HighlyLiquidInvestmentsMaturityPeriod>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ib2d18c502e914148abcdf8a1c2043e91_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTA5OTUxMTYzNzg1MQ_e023ec10-5ea7-4005-b6a0-5d7b35266090"
      unitRef="usd">1010000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icfb95a9cbc524e899e63d817b3d8db10_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMjIyNA_0229cc62-2f44-489d-b4ae-d9b7b2e4f7c8"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iecc04b34723745959d6941b061c3195b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMzkzNQ_25a99b8e-f35c-4385-9751-7c30407ed823"
      unitRef="usd">18000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="icfb95a9cbc524e899e63d817b3d8db10_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTA5OTUxMTYzODE1Nw_09dbd726-90c1-4c36-b76d-298fc257ea0c"
      unitRef="usd">13000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="if2d60cf3b5dd4469bb5e47f010bbf50d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMzk4MA_5422a834-c081-48e0-b250-8b940fadaefa"
      unitRef="usd">21000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2d3c9eab53e34f758a889ff1b9eef4af_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTA5OTUxMTYzODE0NA_e67ae605-b6b1-412e-9ad3-279167c4377b"
      unitRef="usd">22000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia73ddeb398ad40a697491174c66a253e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNDA2OA_ef62d63c-1436-4445-9228-8a82b20b3ea0"
      unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic1d2c2593af94b8e894e62f71bab9723_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfMTA5OTUxMTYzODE3MA_056c338e-d3b8-4758-a394-b1648869a3ee"
      unitRef="usd">9000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODIxNA_3c4f6039-6153-4b82-9577-cb117e19af91">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.792%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) Gain recognized in Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="icc55d9233fce40c7825223f6de02ff68_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMS0xLTEtMS0w_42bbc31f-6324-46bd-b85a-b4857788407f"
      unitRef="usd">-54000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="if8497a03630a4de5833e5a80958dbce4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMS0zLTEtMS0w_d8916664-ef1f-4a27-af8a-9266aae66d38"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="if3d471827df64e0fbd5711fd783ab1e9_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMi01LTEtMS0zMDg1_19dcb074-a053-4e55-bedd-7abedc92ffb5"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i1512c924cb094c078074e4aa0ffe4a40_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMi03LTEtMS0zMDg3_5e97b51b-3c0b-4709-9a4d-c04421f361ec"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i7093ac6fc1334022aa3265c9294c3e7a_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMi0xLTEtMS0w_e7fc4fe7-22cc-42af-8a02-4dc3e6224892"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i13118f68b4df41a393ca9750e6026f86_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMi0zLTEtMS0w_f89a0c4c-b455-4ee3-a399-a12703825982"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ia8202bf5ca3346e7b18cf85e6d73a250_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMy01LTEtMS0zMDg1_52760cbe-65ea-4075-be05-2e2c5f64259f"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i3e77a2db2998441c921cc42c8c4a50c8_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjc3OTAxZDA1OTI3YzQzOTVhNmFlNzA3Zjg2ZjlhYmUyL3RhYmxlcmFuZ2U6Nzc5MDFkMDU5MjdjNDM5NWE2YWU3MDdmODZmOWFiZTJfMy03LTEtMS0zMDg3_73aeaed4-df17-4de9-84b4-a9f1dbae7c4f"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNDQ3MA_b69416c3-973c-4844-93c6-7031d62e27e3"
      unitRef="usd">23000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i99c0052b44d34257a40d70925ddf626c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNDcyNw_010edae7-dabd-4937-b5b5-79a2264bbf25"
      unitRef="usd">187000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i99c0052b44d34257a40d70925ddf626c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTQ3Ng_afff2d30-fb1a-4993-9fa3-5f24890bbb23"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i99c0052b44d34257a40d70925ddf626c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTUzNA_5c375bc7-e9d7-42d3-8e50-9afcfbddf818"
      unitRef="usd">2000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i99c0052b44d34257a40d70925ddf626c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTU5OQ_7bad7fed-a95a-4b1c-9733-4e386d001f3d"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0b552f30645f4c44b3ed3df8ec2d60cf_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTc0OQ_9f34c3e1-5528-4655-8ca5-72ce1437846f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i38cb6a98dc8e41d69bdbcc7404a2eb8e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNTc2Ng_aca45e61-94ef-4765-b1ec-7695a7de9aad"
      unitRef="usd">-1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="i85b5b7c7ce56466d86e248603302e40d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNjA3Nw_8924ad2f-1cca-4503-9901-5b312173199b"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i2cf0cf8e00c24e43afee18043d34a006_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNjk5NA_7d3465d4-05a6-4dda-8cfa-ff4a47fbdf4a"
      unitRef="number">0.05</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i134b8d5216ea4c389549e0da9a4a0aae_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNzAwMA_22eed1dd-93aa-446d-9313-c1e9445e6a6e"
      unitRef="number">0.25</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i8a85fa3c7eea46178ce2c429ccf9dc45_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNzA1OA_df81f532-81dc-4554-8f40-649f2da5ebf1"
      unitRef="number">0.08</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODIzMw_e1c575dd-0d62-4396-b61c-69cbfb9178a3">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfMi00LTEtMS0w_8068900a-8aa8-44b7-ac2d-a0fc736331d7"
      unitRef="usd">316000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfMi04LTEtMS0w_2be82f4d-cf3f-48c3-b6fe-562de38f8521"
      unitRef="usd">339000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="id5402810168f441a989e311c9910ffff_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNC0yLTEtMS0w_4273bb9a-ed91-45a6-81b2-b8ec6d93396b"
      unitRef="usd">17000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iaa9d2b6c03b4436ab40680ad98a02f2a_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNC02LTEtMS0w_b2e526ca-f340-4adc-bcec-af75b91c5539"
      unitRef="usd">16000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if76287d4ad9248b093a21f0f369b5af6_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNS0yLTEtMS0w_eab3decf-29f5-415e-985a-b7e89989b3ad"
      unitRef="usd">9000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5d02c0d1ca7046cc873ad6dc780a7de5_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNS02LTEtMS0w_b8cf70c7-a89a-4269-9ab1-0f92aba473a0"
      unitRef="usd">-14000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNi00LTEtMS0w_5696a808-f3ff-4578-a03e-b4aa27c50bb4"
      unitRef="usd">26000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNi04LTEtMS0w_98c708e6-084b-44e9-8776-7e582c1c7cba"
      unitRef="usd">2000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNy00LTEtMS0w_eca9f807-4b7e-4c36-a6c9-eff0e51960dd"
      unitRef="usd">30000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfNy04LTEtMS0w_29c241cd-5e1f-4a63-a48c-170cb0d871af"
      unitRef="usd">28000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfOC00LTEtMS0w_47d17850-67be-460a-a46c-fc074ee2a2cf"
      unitRef="usd">312000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfOC04LTEtMS0w_1c52744e-cf80-48c7-9bb1-9ae94bb2efc9"
      unitRef="usd">313000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfOS00LTEtMS0w_2e9411c7-4cb1-4aa0-a03d-1be04160d83b"
      unitRef="usd">37000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfOS04LTEtMS0w_1e5f6ba7-1a4f-4e75-af90-c66a0c848284"
      unitRef="usd">46000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfMTAtNC0xLTEtMA_18872e4c-c5d8-415b-90fd-ae9f86d81869"
      unitRef="usd">275000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i45390232e74c44a99af3ec366a6470bf_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOjViNTNmNjE0MWU5NzQ4NGM4MjA0ODQ2ZGQ0NTBhYWI1L3RhYmxlcmFuZ2U6NWI1M2Y2MTQxZTk3NDg0YzgyMDQ4NDZkZDQ1MGFhYjVfMTAtOC0xLTEtMA_d80917d4-a92b-4581-988b-6a325efdcda5"
      unitRef="usd">267000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODIyNA_216305de-d535-4a64-88bf-aebe3d462783">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a non-recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="ibb0bbb2a96944d2281f1f89a0ad18937_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0yLTEtMS0w_5f31231e-d24c-4e64-b355-df939c17caec"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i90eeaa1d0b8e49aa8bf06da2ebbe726c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy00LTEtMS0w_118f7381-95e6-47e4-9c19-9bc1698e87eb"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i78c91ac833ae4d6a85617b9307192c5d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy02LTEtMS0w_6d9590f1-22ce-4669-99c3-7b975452d42d"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="ice8e52c2f7344bd9aaac24f3c709799e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy04LTEtMS0w_0332262f-4820-437d-9bb2-39dc03a2d3b2"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i9d4e7897d68043b2ac3bba1cb881d410_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0xMC0xLTEtMA_b96afbe2-73d9-45e4-b4cc-928d5c39c8d2"
      unitRef="usd">39000000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i57206313b8ad44a69c438d9a2d26e856_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0xMi0xLTEtMA_ef96e143-dd85-4bb7-8edf-c6ae017e1aae"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i60b628768eab4646b40e4bdaf0246e63_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0xNC0xLTEtMA_bfcd1c71-2534-413b-a5a5-a1df533a9408"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="id5c8146e6c714086b4e9c25c3c92eed0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RhYmxlOmE4NzZlZWI4ZjE0ZjRhNDg4NjQ1ZmNkNWYwZTBlZTgwL3RhYmxlcmFuZ2U6YTg3NmVlYjhmMTRmNGE0ODg2NDVmY2Q1ZjBlMGVlODBfMy0xNi0xLTEtMA_875ab9e2-6b20-4770-8526-ef7017508761"
      unitRef="usd">39000000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i9d4e7897d68043b2ac3bba1cb881d410_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfNzYzMg_ac960ee3-fe0a-4792-b59f-8d3a9248ffed"
      unitRef="usd">39000000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i78c91ac833ae4d6a85617b9307192c5d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODA5MQ_9fff14a2-552f-4405-ac01-8baeadc72c17"
      unitRef="usd">25258000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i60b628768eab4646b40e4bdaf0246e63_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181NS9mcmFnOjhhMjUwYmVmOTlkNzRhMmFiMTljMWE1NWVhNTJkN2UxL3RleHRyZWdpb246OGEyNTBiZWY5OWQ3NGEyYWIxOWMxYTU1ZWE1MmQ3ZTFfODA5OA_a5a8ecb5-db59-4417-8834-0c44b9a46f44"
      unitRef="usd">27520000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RleHRyZWdpb246OWU4MTU1OTc1MTVhNGJmMzkwMTU2OGYyZWEyODFjMzRfODI_62b6ead5-b410-4485-8887-a221aff6435d">INVENTORIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net of allowances for obsolescence consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RleHRyZWdpb246OWU4MTU1OTc1MTVhNGJmMzkwMTU2OGYyZWEyODFjMzRfODU_b5c58bb7-58e7-45b3-af5c-53c0a116e1fa">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net of allowances for obsolescence consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMS0yLTEtMS0w_ca522a84-77ab-4b31-8ecd-fe579a3211d0"
      unitRef="usd">339000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMS00LTEtMS0w_6c5a59cd-268a-47af-87d5-ec9a4030f253"
      unitRef="usd">319000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMi0yLTEtMS0w_dfdd638c-9e0e-4e27-8b0a-3fc95bdae4fc"
      unitRef="usd">159000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMi00LTEtMS0w_0f867e4c-6263-4e60-907a-742635914676"
      unitRef="usd">149000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMy0yLTEtMS0w_9c8913d1-b866-4ddf-b9cd-687d6cde5161"
      unitRef="usd">726000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfMy00LTEtMS0w_17564992-2ab0-4341-a48a-165e568a732c"
      unitRef="usd">639000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfNC0yLTEtMS0w_c0260dce-3263-4366-b3a5-2e2aec8987e4"
      unitRef="usd">1224000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY181OC9mcmFnOjllODE1NTk3NTE1YTRiZjM5MDE1NjhmMmVhMjgxYzM0L3RhYmxlOmUwZDFkMjhjZWRkYzQ2M2ViODZkMzQ2NmEwNjliMjRkL3RhYmxlcmFuZ2U6ZTBkMWQyOGNlZGRjNDYzZWI4NmQzNDY2YTA2OWIyNGRfNC00LTEtMS0w_4d706e59-dfb2-4934-a4b6-609c19b4993e"
      unitRef="usd">1107000000</us-gaap:InventoryGross>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMTk_d763e032-56e7-457c-9ac7-1741dc9d84a5">INTANGIBLE ASSETS AND GOODWILL &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D not in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments for the nine months ended September 30, 2020 were $17&#160;million and include impairments of: (i) $16&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) $1&#160;million, in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments for the nine months ended September 30, 2019 were $49&#160;million and include impairments of: (i) $38&#160;million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8&#160;million related to assets being classified as held for sale and (iii) $3 million due to the discontinuance of specific product lines not aligned with the focus of the Company's core businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2020 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the nine months ended September 30, 2020 and the year ended December&#160;31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of certain assets of Synergy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale (Note 4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets held for sale reclassified to goodwill (Note 4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of all reporting units using a discounted cash flow model which utilizes Level 3 unobservable inputs.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The Company performed its annual impairment test as of October 1, 2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount (Step 0). Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit (Step 1). The quantitative fair value test was performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company forecasts cash flows for each reporting unit and takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts were based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#x2019;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such charges could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2019, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value and therefore, no impairments were recorded. The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was no impairment to the goodwill of any reporting unit. The Company performed quantitative fair value tests for the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of October 1, 2019, utilizing long-term growth rates of 2.0% and 1.5%, and discount rates of 9.8% and 9.0%, respectively, in estimation of the fair value of these reporting units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Interim Goodwill Impairment Assessments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In response to the COVID-19 pandemic, the Company has taken actions to protect its employees, customers and other stakeholders and mitigate the negative impact of the COVID-19 pandemic on its operations and operating results. These and additional actions can increase the costs of doing business during the pandemic and, in the periods that follow, may include the costs of idling and reopening certain facilities in affected areas.  Further, social restrictions and other precautionary measures taken by customers, health care patients and consumers in response to the pandemic are expected to impact the timing and amount of revenues during the COVID-19 pandemic. Although the Company's revenues for the nine months ended September 30, 2020 were less than those forecasted on the date goodwill was last tested for impairment (October 1, 2019) and additional pandemic-related declines in revenues may occur for the remainder of 2020, there are no indications that these trends are materially related to developments other than the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative impacts of the COVID-19 pandemic on the global economy were not existing conditions on the date goodwill was last tested for impairment (October 1, 2019) and have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows.  In performing its assessment, the Company considered the possible affects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts as of October 1, 2019 (the date goodwill was last tested for impairment) for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the pandemic, the public has been advised to engage in certain "social restrictions" such as: (i) remaining at home or shelter-in-place, (ii) limiting social interaction, (iii) closing non-essential businesses and (iv) postponing certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, these factors negatively impacted, most notably, the revenues of the Company's Global Vision Care and Global Surgical businesses in Asia where the COVID-19 pandemic originated. Beginning in March 2020, and throughout most of the second quarter of 2020, the Company experienced steeper declines in these revenues and the revenues of other businesses as social restrictions expanded worldwide, particularly in the U.S. and Europe. Social restrictions negatively impacted the Company's revenues for contact lenses, intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of its Global Ophtho Rx business, medical aesthetics and therapeutic products of its Global Solta business, and certain branded pharmaceutical products of its Salix, Ortho Dermatologics and Dentistry businesses, as the offices of many health care providers were closed and certain surgeries and elective medical procedures were deferred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues for the nine months ended September 30, 2020 were negatively impacted by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic earlier in the year. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize.  Presuming there is no material resurgence of the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020. The Company therefore believes that its revenues for the year 2020 will be most impacted by the COVID-19 pandemic in its second quarter, although the Company experienced additional COVID-19 pandemic related declines in the year-over-year revenues in its third quarter, and expects additional COVID-19 pandemic related declines in the fourth quarter of 2020, in many of its businesses and geographies. Presuming any reenactment of social restrictions is not significant, the Company anticipates that its affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's latest forecasts of cash flows gives consideration to the nature and timing of the expected revenue losses disclosed above.  The changes in the amounts and timing of these revenues as presented in the latest forecasts include a range of potential outcomes and, with the exception of the Ortho Dermatologics reporting unit as discussed below, are not substantial enough to materially adversely affect the recoverability of any of the associated reporting units&#x2019; assets and are not material enough to indicate that the fair values of those reporting units might be below their respective carrying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the results of the October 1, 2019 annual goodwill impairment test, the Company continues to assess the performance of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit and performs quarterly qualitative assessments of their respective carrying values and fair values to determine if quantitative fair value testing is warranted. As part of these qualitative assessments, management considers the totality of all relevant events or circumstances that effect the carrying amount and fair value of each reporting unit, including comparing actual operating results to the forecast used to test the goodwill of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of October 1, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neuro and Other Reporting Unit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believed that based on its qualitative assessments as of March 31, 2020, June 30, 2020 and September 30, 2020, it was more likely than not that the carrying amount of the Neuro and Other reporting unit was less than its fair value and, therefore, concluded a quantitative assessment was not required at March 31, 2020, June 30, 2020 and September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ortho Dermatologics Reporting Unit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2020, the operating results for the Ortho Dermatologics reporting unit were less than those forecasted at October 1, 2019 for that period. As part of its qualitative assessment as of March 31, 2020, the Company revised its forecasts for the year 2020, for among other matters, the lower than originally forecasted operating results for the three months ended March 31, 2020 and the range of potential impacts of the COVID-19 pandemic, including longer than expected launch cycles for certain new products. Management believed that the revisions to its forecasts for the year 2020 were indicators that there was less headroom as of March 31, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2019).  Therefore, a quantitative test for the Ortho Dermatologics reporting unit was performed at March 31, 2020. Based on the quantitative test, the fair value of the Ortho Dermatologics &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2020, the Company identified certain Ortho Dermatologics&#x2019; products that were experiencing longer launch cycles than originally anticipated due to the COVID-19 pandemic and, as a direct result, took actions to mitigate the impact of these matters, including right-sizing its Ortho Dermatologics&#x2019; sales force. As part of its qualitative assessment as of June 30, 2020, the Company revised its long-term forecasts for, among other matters, the decrease in forecasted revenues of the identified products, the reduction in sales force and related costs and a range of potential impacts of COVID-19 pandemic related matters.  Management believes that these events are indicators that there is less headroom as of June 30, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (March 31, 2020). Therefore, a quantitative test for the Ortho Dermatologics reporting unit was performed. The quantitative test utilized the Company's most recent cash flow projections, including a range of potential outcomes, along with a long-term growth rate of 2.0% and a range of discount rates between 9.5% and 10.0%. Based on the quantitative test, the fair value of the Ortho Dermatologics reporting unit was 10% to 15% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believed that based on its qualitative assessments as of September 30, 2020, it was more likely than not that the carrying amount of the Ortho Dermatologics reporting unit was less than its fair value and, therefore, concluded a quantitative assessment was not required at September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit and Neuro and Other reporting unit including: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for new products and (iv) ongoing pricing pressures, which could negatively impact the reporting units' results over the long term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If market conditions further deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#x2019;s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges can be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No other events occurred or circumstances changed during the period October 1, 2019 (the date goodwill was last tested for impairment) through September&#160;30, 2020 that indicate it is more likely than not the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit may be below its carrying value. The Company will perform its annual impairment test as of October 1, 2020. In addition, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021, and as a result the Company may need to perform an impairment test upon realignment of its operating segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated goodwill impairment charges through September&#160;30, 2020 were $3,711 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMDM_bad93be6-ae39-4c2a-9d86-417a467a739f">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D not in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMTM_95759182-35fc-4696-b9fb-37990b2f1dfe">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D not in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i60de702a35f848f989e520b9af116415_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy0yLTEtMS0w_0b81b270-5eef-4705-841c-90b5ad5456fe"
      unitRef="usd">21057000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i60de702a35f848f989e520b9af116415_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy00LTEtMS0w_b177aa89-8f43-44c2-9b0d-8ee6a9d2bbde"
      unitRef="usd">14673000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i60de702a35f848f989e520b9af116415_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy02LTEtMS0w_b47a56b8-9d9e-4ce8-8000-b21d75ad903f"
      unitRef="usd">6384000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7a7d5353c4a04e4bab13e493b248f929_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy04LTEtMS0w_930a6bf0-4ae1-4703-b316-89d00a0582db"
      unitRef="usd">21011000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7a7d5353c4a04e4bab13e493b248f929_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy0xMC0xLTEtMA_70ed3a09-d514-412b-9267-c40598977543"
      unitRef="usd">13544000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7a7d5353c4a04e4bab13e493b248f929_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMy0xMi0xLTEtMA_627b438e-c59b-49c7-ade4-f590f34f6f0d"
      unitRef="usd">7467000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic1b9f564f7684ff0b786ed6ee60bbc93_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC0yLTEtMS0w_aec730fa-2cdb-4865-81bb-1650fd1fac46"
      unitRef="usd">921000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic1b9f564f7684ff0b786ed6ee60bbc93_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC00LTEtMS0w_f9689712-a27a-4d43-91d1-3f824d0c6288"
      unitRef="usd">388000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic1b9f564f7684ff0b786ed6ee60bbc93_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC02LTEtMS0w_10fb7e29-6d6c-4eae-85e2-8b67d34a1119"
      unitRef="usd">533000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0a9c4ec0dda0434ead7d7e333f7c0370_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC04LTEtMS0w_6afc0c28-ab1e-410d-80cb-9bde40372030"
      unitRef="usd">930000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0a9c4ec0dda0434ead7d7e333f7c0370_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC0xMC0xLTEtMA_42ccf664-72db-4b2a-98db-ac3d1ca9f6c7"
      unitRef="usd">338000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0a9c4ec0dda0434ead7d7e333f7c0370_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNC0xMi0xLTEtMA_203c1fc8-0f5d-4ae9-b4e2-340533a582cd"
      unitRef="usd">592000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9e98dbf115d34eb7a1ad3c065774fa63_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS0yLTEtMS0w_f72670d6-0f86-4c7a-90d2-9980e1d64752"
      unitRef="usd">3295000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9e98dbf115d34eb7a1ad3c065774fa63_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS00LTEtMS0w_6848dcbf-8a21-4791-a940-8c0f8c7b95fa"
      unitRef="usd">3013000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9e98dbf115d34eb7a1ad3c065774fa63_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS02LTEtMS0w_d18017f1-e59a-462d-a6e9-97b0732a53ab"
      unitRef="usd">282000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1219c91340a14f5bad320111435c4733_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS04LTEtMS0w_0fafaa14-b24e-4a0b-8f81-81e35a579be6"
      unitRef="usd">3297000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1219c91340a14f5bad320111435c4733_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS0xMC0xLTEtMA_39c1c1ac-6659-4b4e-9165-e47ae8ce6d27"
      unitRef="usd">2887000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1219c91340a14f5bad320111435c4733_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNS0xMi0xLTEtMA_cb143701-411c-41dc-aa4b-6d3d2661a4f2"
      unitRef="usd">410000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i32f288455ff543adb3dba8d444c258df_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi0yLTEtMS0w_8779c5bb-0068-457b-87a7-b96f65b1d890"
      unitRef="usd">164000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i32f288455ff543adb3dba8d444c258df_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi00LTEtMS0w_7533843d-7e68-47b0-93c2-55f7dce032fd"
      unitRef="usd">163000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i32f288455ff543adb3dba8d444c258df_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi02LTEtMS0w_a0d8198c-aa53-4c44-8550-93952a301f49"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i62565a11ef494521b8f3aa6a1473a264_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi04LTEtMS0w_c85a9390-0c47-45b0-a0bd-fd95a5d62bfb"
      unitRef="usd">166000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i62565a11ef494521b8f3aa6a1473a264_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi0xMC0xLTEtMA_80c21a67-01ef-4c96-826b-4f438c47c202"
      unitRef="usd">165000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i62565a11ef494521b8f3aa6a1473a264_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNi0xMi0xLTEtMA_0d7ca736-9b8f-4c58-a649-d923b89b9106"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3d948a6f072e4f7b8c8b385b727ebcd0_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy0yLTEtMS0w_d3ac4d22-59e8-4bde-9dc3-6680e38d96d8"
      unitRef="usd">207000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3d948a6f072e4f7b8c8b385b727ebcd0_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy00LTEtMS0w_84971e0b-a571-487e-bb5d-ed68c9134175"
      unitRef="usd">195000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3d948a6f072e4f7b8c8b385b727ebcd0_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy02LTEtMS0w_b07c0e9d-c89d-4728-bc21-0918b2a245df"
      unitRef="usd">12000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7532691dd59d4bdeb91fcdaa78acc1ea_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy04LTEtMS0w_f09604d3-5790-42b3-b000-b1eb8347cd33"
      unitRef="usd">209000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7532691dd59d4bdeb91fcdaa78acc1ea_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy0xMC0xLTEtMA_7b8ebf4a-fd73-4469-a744-7f68883f7b16"
      unitRef="usd">189000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7532691dd59d4bdeb91fcdaa78acc1ea_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfNy0xMi0xLTEtMA_ac77878f-9a4f-4893-b141-c1d973ec79ea"
      unitRef="usd">20000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC0yLTEtMS0w_5713e6b8-18b2-4e76-ab6d-7e8df2d22db1"
      unitRef="usd">25644000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC00LTEtMS0w_2f08778b-47af-40e1-8b56-26c6cbb474c3"
      unitRef="usd">18432000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC02LTEtMS0w_ccdf0361-8378-4ed5-b08d-f2c0c6e2a23e"
      unitRef="usd">7212000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC04LTEtMS0w_1cbbd834-5dcb-4306-90b5-e664fb549bf1"
      unitRef="usd">25613000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC0xMC0xLTEtMA_683a9342-cd76-47cf-a415-b47b47c5bfc2"
      unitRef="usd">17123000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOC0xMi0xLTEtMA_bd937fd6-25b5-47da-8e4c-b49a18526a5a"
      unitRef="usd">8490000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i90067b409ecb46e7a0730f1885ddd46a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOS0yLTEtMS0w_8303e0fe-a106-4495-92a8-04a3d29c3409"
      unitRef="usd">13000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i90067b409ecb46e7a0730f1885ddd46a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOS02LTEtMS0w_913e256c-a928-4675-b531-308a72a8c9af"
      unitRef="usd">13000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic5eb558f1acd4fa3890d17ea839f934f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOS04LTEtMS0w_c32f5772-a67c-47bc-857a-3e6a690aab1e"
      unitRef="usd">13000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic5eb558f1acd4fa3890d17ea839f934f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfOS0xMi0xLTEtMA_8ae8a382-9396-469b-9cc9-823e945aa795"
      unitRef="usd">13000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id1524d6d70de47e4bf378c17d3a6fb88_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTAtMi0xLTEtMA_8b3aa41d-0caf-47f8-bdb2-1fc09dcd2e8d"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id1524d6d70de47e4bf378c17d3a6fb88_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTAtNi0xLTEtMA_4017e783-d953-46ab-b757-dd16b4313d26"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i98aa749670ef4cb2bcbe79c1b3f35d01_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTAtOC0xLTEtMA_fa76fe5d-51ee-422c-af4d-82124b03306b"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i98aa749670ef4cb2bcbe79c1b3f35d01_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTAtMTItMS0xLTA_d71cbdaf-9709-4aa8-aca6-7756f07f2cbb"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtMi0xLTEtMA_908d1dff-8dad-4f18-aa18-15cc8dbf7d6e"
      unitRef="usd">27355000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtNC0xLTEtMA_239f4b9c-0cb1-403e-a2bc-fd2b92e5d06f"
      unitRef="usd">18432000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtNi0xLTEtMA_a221a219-bbf5-436d-995c-ab6fffd91a83"
      unitRef="usd">8923000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtOC0xLTEtMA_9d7d692c-4b23-41e1-89ef-4022cbbf928a"
      unitRef="usd">27324000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtMTAtMS0xLTA_d3cdf615-4ddf-42f5-ad87-e0020abac648"
      unitRef="usd">17123000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOmM3ZjM5YzMzNjlhMDRmOWQ4OWUxZmJlMTI0YWJlYzg3L3RhYmxlcmFuZ2U6YzdmMzljMzM2OWEwNGY5ZDg5ZTFmYmUxMjRhYmVjODdfMTEtMTItMS0xLTA_2828f27b-8e5c-49ac-9f2e-3542897d4ea7"
      unitRef="usd">10201000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNjI3_cca0c65f-7107-4f81-8e89-ad279eed20a9"
      unitRef="usd">17000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i2f3c80353f4a458e9cf3e5ea8ee4bb86_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNjYy_473c2e25-4ba3-4089-b4f8-0d04cceeb0b9"
      unitRef="usd">16000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i88876a23cdf3417d8234422eedf815f1_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNzM3_acbe30e4-fab6-4c88-a78a-791b0bd0369c"
      unitRef="usd">1000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfOTA1_c92db02d-a61e-4384-892e-d4ba752f4d99"
      unitRef="usd">49000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ic084d62da2994e0b8eac7d247b4df526_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfOTQw_6ef752e4-1060-48c3-aba4-75a476c442eb"
      unitRef="usd">38000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="icf690e4cf1844b909f7af94cd53ff788_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfOTg5NTYwNDY3NTg4Mg_acb17949-3fd9-49cb-b48e-17305f2d8c1f"
      unitRef="usd">8000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i4df44c5814334fcb9850108f2c45d7d7_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTA0Ng_b5239c1d-5682-41f5-baac-3cda86e9c0e0"
      unitRef="usd">3000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMzI_03290997-c1b5-4eee-a459-b0c8b15ae0a5">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2020 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0yLTEtMS0w_caade619-2f3d-466a-aa8f-a8c940445870"
      unitRef="usd">380000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS00LTEtMS0w_1fd86f3b-18ea-471e-8707-6fc8c351278c"
      unitRef="usd">1410000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS02LTEtMS0w_8d2ba600-543f-48d7-ab5f-7bf92185fc77"
      unitRef="usd">1227000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS04LTEtMS0w_e68f4c30-b8dd-47c0-8c62-4065771aeeee"
      unitRef="usd">1055000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0xMC0xLTEtMA_9afd49fb-4ed8-46d0-9ad7-398cf00df8f1"
      unitRef="usd">925000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0xMi0xLTEtMA_98712df5-cdbd-4901-99af-bd02714b889f"
      unitRef="usd">821000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0xNC0xLTEtMA_9164bbea-3c1d-4f8e-9f04-e3fead3dcdd2"
      unitRef="usd">1394000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjk5YzE2MGNjNTFlZTQ5ZWFiN2ZmNmU5YzBmM2QxYjk1L3RhYmxlcmFuZ2U6OTljMTYwY2M1MWVlNDllYWI3ZmY2ZTljMGYzZDFiOTVfMS0xNi0xLTEtMA_566cb719-9448-4fc7-b883-711e87571514"
      unitRef="usd">7212000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYyMDA_16b4250e-04d1-42f5-9747-955f2caa1b3c">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the nine months ended September 30, 2020 and the year ended December&#160;31, 2019 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisition of certain assets of Synergy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale (Note 4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets held for sale reclassified to goodwill (Note 4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i37e1d6d0d86b4260a9dafbceb3ca67b3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS0yLTEtMS0w_ec4713f2-a06a-444b-bc5c-82b3168b1aa2"
      unitRef="usd">5805000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i92ce595b55e84cc1b6036ed5e3783ef7_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS00LTEtMS0w_f03a2c57-714f-4f3f-99da-9ec5bef3f7a7"
      unitRef="usd">3156000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2a82463a67ee4a98aebdb33bda1870ee_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS02LTEtMS0w_b2c65c03-222a-4c4e-8386-3697fa6ec726"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iff834d7d5db945ffb10479e4d06e77d1_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS04LTEtMS0w_0e808717-8e61-45e7-9972-55fa36e11167"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if95828f039eb46b1833d2a857454ec2c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMS0xMC0xLTEtMA_e7a8c0d1-198d-4e01-b89e-d03003a7ade4"
      unitRef="usd">13142000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i60250601219a4629a0ff2f0c1dc4062f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMi00LTEtMS0w_e52aed55-d1b3-4e4b-b3ed-3cf0c992e916"
      unitRef="usd">3000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMi0xMC0xLTEtMA_c7812dd1-f291-4fd8-aec2-baea553c53c3"
      unitRef="usd">3000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="idbf24fa76f6a402bb9e6156b05d6b5f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMy0yLTEtMS0w_76be00cf-8e18-4c78-b3c8-cc544decbb22"
      unitRef="usd">18000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfMy0xMC0xLTEtMA_d815b406-63fd-451f-82f5-78e59e00a2cf"
      unitRef="usd">18000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="idbf24fa76f6a402bb9e6156b05d6b5f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNC0yLTEtMS0w_f9450315-2432-433b-873b-d753ceeb08f7"
      unitRef="usd">1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNC0xMC0xLTEtMA_d810d522-9840-4989-aa9f-092ef550d701"
      unitRef="usd">1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i1c4612f6b4d649079848c866b406b98b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS0yLTEtMS0w_777bf8b6-7074-42fd-ba53-106e518a49c4"
      unitRef="usd">5786000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i45b5cf1e2a7748d998e39be96bdcffe8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS00LTEtMS0w_07013301-144f-4952-8061-1200739684f3"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i23ddb02b4b9240f4a9c623f147564d77_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS02LTEtMS0w_acb8cbb1-f71c-4aad-aba3-f8e447702765"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id1ac25e181e840fcba249ad8ca572ded_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS04LTEtMS0w_6fc9eaef-d308-4b8c-ae13-3785189507c1"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNS0xMC0xLTEtMA_c360cbfe-8964-4cd6-b721-db9ffb97de2c"
      unitRef="usd">13126000000</us-gaap:Goodwill>
    <bhc:GoodwillReclassifiedDuringPeriod
      contextRef="i02972067b44c4ebbb40b0dce231c9b74_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNi0yLTEtMS0w_01f2b004-f3cd-4aed-b929-5dd85742f18c"
      unitRef="usd">18000000</bhc:GoodwillReclassifiedDuringPeriod>
    <bhc:GoodwillReclassifiedDuringPeriod
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNi0xMC0xLTEtMA_0fd82929-5c51-45c4-9052-136700fbd74e"
      unitRef="usd">18000000</bhc:GoodwillReclassifiedDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i02972067b44c4ebbb40b0dce231c9b74_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNy0yLTEtMS0w_17853935-07f9-4204-a8a8-15a0abfcc479"
      unitRef="usd">-16000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfNy0xMC0xLTEtMA_ad5dfefe-ecc8-499d-9106-65d63c376937"
      unitRef="usd">-16000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i5788f2e64d25455ab4cc8ee55962643c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC0yLTEtMS0w_b8129203-3526-4ca8-b07e-abea85d3c3d0"
      unitRef="usd">5820000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2c98652fcf224ee890fa8c7644b8f148_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC00LTEtMS0w_15b18880-c0d1-4162-9842-c90a92e1f547"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3901dd0ca3ae42fba60b944fd1072d67_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC02LTEtMS0w_a5e5f127-81fc-4de2-b3e4-1f3fcc8ae3ce"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7242e85fe1ed4cbc935e2d4c982c7f86_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC04LTEtMS0w_e58d8922-4cf1-40c4-809a-8f238c3564ff"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RhYmxlOjc4ZDQ5Y2IwZmIwODQzMTJhYWFjMTU5ZGJhN2NmYmYzL3RhYmxlcmFuZ2U6NzhkNDljYjBmYjA4NDMxMmFhYWMxNTlkYmE3Y2ZiZjNfOC0xMC0xLTEtMA_44f80a28-0f1a-4feb-aec7-db89ac8c12e1"
      unitRef="usd">13160000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i7796cbaae34c4708bf7e612f118984d4_D20191001-20191001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTM1NQ_ebce36b2-15be-4f11-a57d-105ec2236629"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i49d1b68c815f41ad8f89064d1e9fc9da_I20191001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTYwMQ_c0be2b3d-52e1-42e9-9b8e-1b712eca37c4"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i46d706dfc2e941c7aceac6173927bd08_I20191001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTYwOA_c0a257b3-eefa-40c5-872e-57375350ddfd"
      unitRef="number">0.015</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i49d1b68c815f41ad8f89064d1e9fc9da_I20191001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTYzNA_0b107570-a0bc-40ab-b19d-7de57aceceef"
      unitRef="number">0.098</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i46d706dfc2e941c7aceac6173927bd08_I20191001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNTY0MQ_0efa800a-31f2-4e21-b233-7f7497994128"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3ab0c68ed13d4af2b182ef303b0fe3ad_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfNDM5ODA0NjU0NDM1Mw_522644c4-49c8-4d16-96d8-aa604a43a1f9"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i9bfb00e0e8444c42bf506fb600021040_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ3OTA_d5613b5a-65fc-460f-af79-c22f96d39af6"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i4a13f2e9033b495d9444dd5e982f843f_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ4MzE_2d503e8c-a172-4eab-8dae-e003d746e75e"
      unitRef="number">0.095</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i497e92548eac4239bd07de80e571194e_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ4Mzg_a7a9623f-feba-4cee-9580-60e08dbd49f2"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i4a13f2e9033b495d9444dd5e982f843f_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ5MzU_ccaa2b19-b857-41a9-be9f-9dc5595726d6"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i497e92548eac4239bd07de80e571194e_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTQ5NDE_03c3b84e-fee2-453a-94e6-d10c990e58e6"
      unitRef="number">0.15</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie43ad075e98f4dd89ef32cfaff2d61e7_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTUwMDI_17ba7059-5301-4b11-9149-552c9c041769"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182MS9mcmFnOjcyODNjM2U5NTE5YzRkNDZhNmI5ZmE1ZjExNDQxNzEyL3RleHRyZWdpb246NzI4M2MzZTk1MTljNGQ0NmE2YjlmYTVmMTE0NDE3MTJfMTYxOTI_be0934a4-32a0-4c5b-9e38-fc613d25ff61"
      unitRef="usd">3711000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RleHRyZWdpb246MTU1NGMzMWMxYWQ0NGMzMmJhNzA4NjVlMDBiYmI0OTRfOTU_9cba617b-7f81-4b9b-99c4-aa6b1441eda7">ACCRUED AND OTHER CURRENT LIABILITIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RleHRyZWdpb246MTU1NGMzMWMxYWQ0NGMzMmJhNzA4NjVlMDBiYmI0OTRfMTAx_f745ca6a-3ef1-42d8-85a4-bccaf8c9aeab">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMS0yLTEtMS0w_79cfedcf-70a9-4a78-ab4b-2f0b4c5458d9"
      unitRef="usd">1462000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMS00LTEtMS0w_1333fd15-fce1-4573-b927-42a7677ca65e"
      unitRef="usd">1397000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:AccruedProductRebateCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMi0yLTEtMS0w_9a38944c-6319-4a54-bb8d-21c56c37b337"
      unitRef="usd">876000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductRebateCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMi00LTEtMS0w_fb1aaf78-5471-4290-8d2b-bfe5054378df"
      unitRef="usd">898000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMy0yLTEtMS0w_50c74908-312c-45ed-9a99-2d2def8b5d14"
      unitRef="usd">577000000</bhc:AccruedProductReturnCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfMy00LTEtMS0w_354b7283-0e7f-41b4-aa08-832cc40ab24e"
      unitRef="usd">691000000</bhc:AccruedProductReturnCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNC0yLTEtMS0w_cd0065d3-a103-444e-8f60-b28ab693b390"
      unitRef="usd">375000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNC00LTEtMS0w_e9ed9578-313c-4bd9-8302-aec9acdd7478"
      unitRef="usd">305000000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNS0yLTEtMS0w_c611d9b9-0974-4bf7-9d46-fe2ef6a2d707"
      unitRef="usd">300000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNS00LTEtMS0w_9a22b603-9ca8-4cf2-b9b9-98f532556405"
      unitRef="usd">304000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNi0yLTEtMS0w_035021ae-a92a-4777-9559-b266bb4fc402"
      unitRef="usd">149000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNi00LTEtMS0w_ad803188-cf41-4a86-b9be-4d965fa410d9"
      unitRef="usd">196000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNy0yLTEtMS0w_fd68610c-b207-49dc-bd10-8435f3d4c027"
      unitRef="usd">614000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfNy00LTEtMS0w_4527fbe7-aa7c-4df8-84a0-6f0d68821699"
      unitRef="usd">720000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfOC0yLTEtMS0w_b3bdcd4e-70f4-4ac7-aa51-e643d941c1d0"
      unitRef="usd">4353000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182NC9mcmFnOjE1NTRjMzFjMWFkNDRjMzJiYTcwODY1ZTAwYmJiNDk0L3RhYmxlOjgwNzAyOGRlYzVhMjQxYTc5M2I0ODQ2NTAwOTM4NjEzL3RhYmxlcmFuZ2U6ODA3MDI4ZGVjNWEyNDFhNzkzYjQ4NDY1MDA5Mzg2MTNfOC00LTEtMS0w_77a90edf-32d0-4827-80e3-b5be54817d94"
      unitRef="usd">4511000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNDM5ODA0NjUyOTY0OQ_11790faa-aca6-4a99-8183-9d141d626bad">FINANCING ARRANGEMENTS&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.875%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.50% euro-denominated debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenant Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#x2019;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of September&#160;30, 2020, the amount available for restricted payments under the Company&#x2019;s most restrictive indentures (as defined by those indentures) was approximately $12,600&#160;million. The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. As the global economic landscape changes, there is a wide range of possible outcomes regarding the nature and timing of events and reactions to the COVID-19 pandemic, each of which are highly dependent on variables that are difficult to predict at this time.  While there are a number of standard borrowing conditions that must be met to make borrowings under the 2023 Revolving Credit Facility, the Company has considered the economy's impact on its non-financial and financial maintenance covenants and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;believes the current state of the economy does not limit its access to capital under the 2023 Revolving Credit Facility at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2020, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast as adjusted for the potential impacts of the COVID-19 pandemic, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#x2019;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#x201c;Senior Secured Credit Facilities&#x201d; under the Company&#x2019;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018, and as further amended (the &#x201c;Restated Credit Agreement&#x201d;) with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $1,225 million, which matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. ("BHA") in an aggregate principal amount in excess of $1,000 million (the "2023 Revolving Credit Facility") and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#x201c;June 2025 Term Loan B Facility&#x201d;) and November 2025 (the "November 2025 Term Loan B Facility"), respectively. Both the Company and BHA are borrowers under the 2023 Revolving Credit Facility, borrowings under which may be made in U.S. dollars, Canadian dollars or euros.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Current Description of Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#x201c;Canadian Prime Rate&#x201d; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#x2019; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#x201c;BA rate&#x201d;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of September 30, 2020, the stated rates of interest on the Company&#x2019;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.15% and 2.90% per annum, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of September 30, 2020, the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities were $680 million through November 1, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.&#160; As of September 30, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was 3.15% per annum. As of September&#160;30, 2020, the Company had no outstanding borrowings, $107 million of issued and outstanding letters of credit and remaining availability of $1,118 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes are guaranteed by each of the Company&#x2019;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#x201c;Note Guarantors&#x201d;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#x2019;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#x2019;s and Note Guarantors&#x2019; respective existing and future unsubordinated indebtedness and senior to the Company&#x2019;s and Note Guarantors&#x2019; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;pari passu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#x2019;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#x2019;s debt that is secured by assets that are not collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#x2019;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.75% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of 8.50% Senior Unsecured Notes due January 2027 (the "January 2027 Unsecured Notes") and (ii) $500 million aggregate principal amount of 5.75% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds, and cash on hand, were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the &#x201c;December 2021 Unsecured Notes&#x201d;), (iii) repurchase $216 million of 5.50% Senior Unsecured Notes due 2023 (the &#x201c;March 2023 Unsecured Notes&#x201d;) and (iv) pay all fees and expenses associated with these transactions (collectively, the &#x201c;March 2019 Refinancing Transactions&#x201d;). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Unsecured Notes issued by the Company are the Company&#x2019;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;8.50% Senior Unsecured Notes due 2027 - March 2019 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of January 2027 Unsecured Notes. These are additional notes and form part of the same series as BHA&#x2019;s existing January 2027 Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;7.00% Senior Unsecured Notes due 2028 and 7.25% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.00% Senior Unsecured Notes due January 2028 (the "7.00% January 2028 Unsecured Notes") and (ii) $750 million aggregate principal amount of 7.25% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement. The proceeds and cash on hand, were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;May 2019 Refinancing Transactions&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.00% Senior Unsecured Notes due 2028 and 5.25% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.00% Senior Unsecured Notes due January 2028 (the "5.00% January 2028 Unsecured Notes") and (ii) $1,250 million aggregate principal amount of 5.25% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the $1,210 million settlement of certain U.S. securities litigation, subject to final court approval, as discussed in Note 18, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.25% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 26, 2020, the Company issued $1,500 million aggregate principal amount of 6.25% Senior Unsecured Notes due February 2029 (the "February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250&#160;million aggregate principal amount of outstanding 6.50% Senior Secured Notes due March 2022, (ii) prepay $303&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions"). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The February 2029 Unsecured Notes accrue interest at the rate of 6.25% per year, payable semi-annually in arrears on each of February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the February 2029 Unsecured Notes at the applicable redemption prices set forth in the February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Stated Rate of Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average stated rate of interest for the Company's outstanding debt obligations as of September&#160;30, 2020 and December&#160;31, 2019 was 5.94% and 6.21%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities and Mandatory Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to reduce future cash interest payments, as well as future maturities and mandatory payments, the Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. During the nine months ended September 30, 2020, the Company repurchased and retired, outstanding senior unsecured notes with an aggregate par value of $27 million in the open market, for an aggregate cost of $26 million.  In connection with these repurchases, the Company recognized a gain of $1 million included in Loss on extinguishment of debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities and mandatory payments of debt obligations for the remainder of 2020, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 29, 2020, the Company issued an unconditional notice of redemption to redeem: (i) $99&#160;million of May 2023 Unsecured Notes, representing the remaining outstanding principal balance of the May 2023 Unsecured Notes and (ii) $51&#160;million of March 2023 Unsecured Notes, on November 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTg0Njk_b444bdda-63f4-4e07-983d-c6f7f8aded0d">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.875%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.50% euro-denominated debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMy00LTEtMS0w_29c3b1f0-ef10-440c-b270-bfc8c844b089"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMy02LTEtMS0w_9bde65c0-75fd-4305-92a7-7d304a00625b"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5c5435fc465e4452bd424177d30f58bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMy04LTEtMS0w_6f73f234-ff75-43b9-9532-e958b11339e3"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5c5435fc465e4452bd424177d30f58bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMy0xMC0xLTEtMA_a5a50ca3-ad15-437f-b9a3-e853f9309ca9"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ica7020a01b884f0db71be5081d3f6c00_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNC00LTEtMS0w_78cd4c84-dae0-43b5-bf8a-7c883ed816f8"
      unitRef="usd">3498000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ica7020a01b884f0db71be5081d3f6c00_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNC02LTEtMS0w_98b569d6-4a04-497a-b898-95316cc6c0f9"
      unitRef="usd">3414000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2717ecbbb85c46189233254a15f62cb8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNC04LTEtMS0w_dddc085d-fb51-4176-b6cb-c9c13eaece6d"
      unitRef="usd">3869000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2717ecbbb85c46189233254a15f62cb8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNC0xMC0xLTEtMA_d14e8dec-fb3f-46fe-9f16-6f1d8ce30afb"
      unitRef="usd">3768000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i98399a1cca534743bbf269f1fb3a7bd3_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNS00LTEtMS0w_6f68bdf7-087b-44ce-a188-66eff3cbadd4"
      unitRef="usd">1200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i98399a1cca534743bbf269f1fb3a7bd3_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNS02LTEtMS0w_8ea2add5-0149-4dc0-bdbc-54aab1dbaa0f"
      unitRef="usd">1185000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaf8b907b90fb44f7aaa306fa87dcc261_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNS04LTEtMS0w_13eb6b20-3a2c-465b-95ee-d06a6dc7768f"
      unitRef="usd">1275000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iaf8b907b90fb44f7aaa306fa87dcc261_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNS0xMC0xLTEtMA_6b3c07a3-985d-4c7a-9042-137bba9fd196"
      unitRef="usd">1257000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i316ad5c435e840ef90de3b77001a0859_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy0wLTEtMS0wL3RleHRyZWdpb246ODgwMGNiOTExMjc0NDQwOWE5ZDg2OWY0ZGE3ZTY5MDFfNA_bc6c98f0-c600-47f0-be20-20cd0f0c6bbf"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i316ad5c435e840ef90de3b77001a0859_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy00LTEtMS0w_80e24bb6-ee20-4347-8ab1-b0de9695a1f5"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i316ad5c435e840ef90de3b77001a0859_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy02LTEtMS0w_2b64433d-fb42-4e9a-b443-5febb9737ab6"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="idf3f33246acf4dbca28fc09e8480089e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy04LTEtMS0w_9912a63e-6bfe-414f-97fe-ba8b9371c412"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="idf3f33246acf4dbca28fc09e8480089e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfNy0xMC0xLTEtMA_ab269bae-81b3-4e14-a1a5-e48a9456ca56"
      unitRef="usd">1242000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7d696c5338494267913e8de2e88aa076_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC0wLTEtMS0wL3RleHRyZWdpb246NjBkY2RkOTIxNmRjNGUzNTk4MTljOGVjNDUwMjBmYWZfNA_9b175bd0-5930-473c-8e1e-97d6fcd79e77"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7d696c5338494267913e8de2e88aa076_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC00LTEtMS0w_ed7add89-1b74-4fc7-aa62-71677e20f2ed"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i7d696c5338494267913e8de2e88aa076_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC02LTEtMS0w_0b413df9-b7fd-42d5-81c4-69f127776009"
      unitRef="usd">1986000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib4174779ec8e4c1ca5559035fd373586_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC04LTEtMS0w_9ad719f1-7cd9-4253-8936-7f6382ebe86d"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib4174779ec8e4c1ca5559035fd373586_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOC0xMC0xLTEtMA_a21a36f9-8a75-4e60-a01d-daed3e8236e9"
      unitRef="usd">1983000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i497f5686edd647cda52dac088120c9ef_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS0wLTEtMS0wL3RleHRyZWdpb246MGNiODhlNmU1YmI3NDc4YTkxNjgwMGYyM2JlZWQzNWNfNA_e376a7cb-b155-4a3c-99f8-eac1e5f34037"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i497f5686edd647cda52dac088120c9ef_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS00LTEtMS0w_8a233c12-ca66-468b-830a-0cbd5b154af3"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i497f5686edd647cda52dac088120c9ef_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS02LTEtMS0w_44cd15ac-902f-4121-b583-510757f61bc2"
      unitRef="usd">1735000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7f354431d8b04f3bb3386e747317da6f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS04LTEtMS0w_70005462-1823-4353-b9ae-9de36149517f"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i7f354431d8b04f3bb3386e747317da6f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfOS0xMC0xLTEtMA_d3e404ef-8cb6-471e-acd7-dea38233aece"
      unitRef="usd">1733000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i87368b9b19074dd5bcef3473b1da76c9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOmRkZTM3N2JmODZlZjRmOTVhMGMwZjJhYTk5YTUxMjkzXzQ_953084bf-3c47-4849-ada8-5eb264c299f3"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i87368b9b19074dd5bcef3473b1da76c9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtNC0xLTEtMA_4e04f346-37f0-4757-897d-af6f49c43b06"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i87368b9b19074dd5bcef3473b1da76c9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtNi0xLTEtMA_a99f0097-2d3c-46d6-a728-903c91020375"
      unitRef="usd">494000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaa57f23b3f05469cb9fb7459da7dafe2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtOC0xLTEtMA_735dfa22-94d9-47a2-b8ef-58e1b030d3e7"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iaa57f23b3f05469cb9fb7459da7dafe2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTAtMTAtMS0xLTA_12a3eebb-0d62-46ae-ab15-8508914e234f"
      unitRef="usd">493000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icae95739a04e4d7e98f843bed573f29d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjYzOTU4MzY4ZjM2ZTRjMDk4OWM5ZjFiZmMxNjliMTVhXzQ_6b60bc35-37c8-4a6e-852e-c3e90a531238"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icae95739a04e4d7e98f843bed573f29d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItNC0xLTEtMA_3a60a678-7b95-4b6e-8f0d-aa586d72c27d"
      unitRef="usd">284000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="icae95739a04e4d7e98f843bed573f29d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItNi0xLTEtMA_9f376ecf-9793-49ce-abec-db9ea3162462"
      unitRef="usd">283000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8d6a7be2d30645a2aa38edcdea6ea2d8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItOC0xLTEtMA_85b0c9ca-74ff-4824-8d63-8747134bd19e"
      unitRef="usd">402000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i8d6a7be2d30645a2aa38edcdea6ea2d8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTItMTAtMS0xLTA_d91cd166-231e-4428-99c6-64bcc631d2f4"
      unitRef="usd">400000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i16f95753426e401589837076426992c3_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtMC0xLTEtMC90ZXh0cmVnaW9uOjFkNTIwMjBjZDdiZjQzN2Q5ZWFhYTE2NGY1YWE1ZmIwXzQ_7e927b73-f29a-4fd2-967b-b20a06f216f4"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i16f95753426e401589837076426992c3_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtNC0xLTEtMA_4584eba4-f178-4580-9266-a142d68a60d5"
      unitRef="usd">99000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i16f95753426e401589837076426992c3_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtNi0xLTEtMA_5921b1c1-804d-4d41-bf80-9d905b2189e9"
      unitRef="usd">99000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2400aa7f3799471ba8c54285606aa32b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtOC0xLTEtMA_a22667eb-4d99-46f5-a88d-3b9cca7c2d55"
      unitRef="usd">1448000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2400aa7f3799471ba8c54285606aa32b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTMtMTAtMS0xLTA_0139faba-8bff-49b6-b16f-648a68626a78"
      unitRef="usd">1441000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6324b2addc314c438452dc1212149f94_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtMC0xLTEtMC90ZXh0cmVnaW9uOjVlMjllNmU2NGVhNTQ0OGQ4YjYzOGRkYjdkMzJlZTVhXzQ_8ef96e44-b4a3-4607-9567-1fe3d61add2e"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6324b2addc314c438452dc1212149f94_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtNC0xLTEtMA_f8130cc5-e628-4971-9e6c-5781e546bf2b"
      unitRef="usd">1758000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6324b2addc314c438452dc1212149f94_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtNi0xLTEtMA_9ce79e0a-1e33-49d6-81d5-ef798d89a1f9"
      unitRef="usd">1752000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i460140edb8e84ba8a14c588b51b5c03b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtOC0xLTEtMA_963d7b68-3a7f-4af1-ab9e-e9847a096334"
      unitRef="usd">1682000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i460140edb8e84ba8a14c588b51b5c03b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTQtMTAtMS0xLTA_ddc0141b-7389-4f13-bc88-a48102b47a3b"
      unitRef="usd">1674000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6ec30846b9da42938cce5010c3a35bcd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtMC0xLTEtMC90ZXh0cmVnaW9uOmYzMTA5ZTMzYzZmMzRkOTU4MjRkOTJkMTIxMDc1ODYyXzQ_ef868129-4f2c-4826-8b96-1833355d88ae"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6ec30846b9da42938cce5010c3a35bcd_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtNC0xLTEtMA_629d97d7-0e7f-4aa1-9e67-e8fac7393aba"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6ec30846b9da42938cce5010c3a35bcd_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtNi0xLTEtMA_e8d21f0c-62d1-429e-a51b-b928371cb149"
      unitRef="usd">3233000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iad32b98d9b574350bd3358b9c05d9ce6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtOC0xLTEtMA_35f12811-2136-4650-913e-bb5f0614ef70"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iad32b98d9b574350bd3358b9c05d9ce6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTUtMTAtMS0xLTA_c09446c4-1f38-4174-a1a2-fd533e074f3a"
      unitRef="usd">3230000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i53587a104f1b4a54a2d8ff9c9b6bd142_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtMC0xLTEtMC90ZXh0cmVnaW9uOjM1YmM1MGQwYWEzNDRlNTliMjgwNGZhZTk5MzFiOGZjXzQ_5b2d53c5-d895-491c-9905-c7f12672aa19"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i53587a104f1b4a54a2d8ff9c9b6bd142_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtNC0xLTEtMA_3f568345-8e8a-4e77-820d-f0804dbf0c1b"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i53587a104f1b4a54a2d8ff9c9b6bd142_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtNi0xLTEtMA_2dab3d32-5562-442d-a172-24604c4b01be"
      unitRef="usd">1477000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id810e7631eea4dff84546da8b682136d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtOC0xLTEtMA_44d96c4e-e056-45a2-b948-a58c7ac43be5"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id810e7631eea4dff84546da8b682136d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTYtMTAtMS0xLTA_4a0b75f9-bd28-4901-b288-52cde47ecb6a"
      unitRef="usd">1473000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50e1cfc4864b4b47939f26aad6d97167_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctMC0xLTEtMC90ZXh0cmVnaW9uOmNjZGVmMDRjY2MxNjRhYjBhN2Q2MzZjZDU3Y2I3OTFlXzQ_dea8d4a9-2779-4082-8715-3789e2381171"
      unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i50e1cfc4864b4b47939f26aad6d97167_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctNC0xLTEtMA_c477dca8-9e52-4d44-bc1e-52e8f8d06626"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i50e1cfc4864b4b47939f26aad6d97167_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctNi0xLTEtMA_a04a93d0-8120-4d78-9fbf-b4060abca2dc"
      unitRef="usd">1486000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9962ff5f6e1a4381b06b75c4fe70b3cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctOC0xLTEtMA_9aba713b-9952-40e1-9d1e-54f8ea6fba49"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i9962ff5f6e1a4381b06b75c4fe70b3cf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTctMTAtMS0xLTA_884d1b62-78f2-4e30-b42e-2804c6e2de73"
      unitRef="usd">1484000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifb407c4dee97479aaed7d0a54af5a221_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtMC0xLTEtMC90ZXh0cmVnaW9uOmQ2NDAzOWE3NjAxNDQ1NTRhZjA1MmU4OTc2ZTg3NDRjXzQ_0941c101-dbc3-4ca4-8001-196bfa3da2f7"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifb407c4dee97479aaed7d0a54af5a221_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtNC0xLTEtMA_61e70667-4f68-473a-83c8-787405eaf023"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ifb407c4dee97479aaed7d0a54af5a221_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtNi0xLTEtMA_26326908-f36d-4eac-899e-e14c5cf2fcbf"
      unitRef="usd">1755000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia4435aa298394060ac34998db6d5518a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtOC0xLTEtMA_a4fc098e-b39d-45cf-a68e-2cee10780a7d"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia4435aa298394060ac34998db6d5518a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTgtMTAtMS0xLTA_f37f835f-cd91-4a77-a981-5b661fd2eb58"
      unitRef="usd">1756000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0a207b5e7c8f4f558db12a478c0a5d91_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktMC0xLTEtMC90ZXh0cmVnaW9uOmEwNTFlNWM3NzhjOTRhNDQ4YTBkYjJhNDA2OTQ0N2MwXzQ_8a9cd470-e676-4736-a0e9-86acad2b6114"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0a207b5e7c8f4f558db12a478c0a5d91_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktNC0xLTEtMA_9e341abb-298f-4adc-8ea8-0a7f063c0738"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0a207b5e7c8f4f558db12a478c0a5d91_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktNi0xLTEtMA_169b11df-9a49-445a-bdf3-a7105c2ff4a8"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if2b37d1f5b4f444890c50f2aabcafde2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktOC0xLTEtMA_d5893ece-d5dc-4382-9311-54b68dad1b01"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="if2b37d1f5b4f444890c50f2aabcafde2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMTktMTAtMS0xLTA_4ff82337-7cff-4261-84ba-f73309cafaad"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id04297c5b7e24c3baf8e9267fbf3225d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtMC0xLTEtMC90ZXh0cmVnaW9uOmY1MGU1MzBmZjM1MDRjODM4Yzc1MzZmNjM3OWQyYWQ0XzQ_6b11aa6f-ab41-49fc-ad80-8b5442e1a356"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id04297c5b7e24c3baf8e9267fbf3225d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtNC0xLTEtMA_c5aebfe4-7dd7-454a-b4c4-30afcc0a41b4"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id04297c5b7e24c3baf8e9267fbf3225d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtNi0xLTEtMA_8f616bb6-9b22-48b6-8757-9ed850aafe1b"
      unitRef="usd">1235000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8d7ec9f615434b68bcfe0abda5733b00_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtOC0xLTEtMA_ad275036-e7a8-4e90-b74f-3c524314bb38"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i8d7ec9f615434b68bcfe0abda5733b00_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjAtMTAtMS0xLTA_e1b742ef-15df-4d77-b30b-c7ed2f6f7ecb"
      unitRef="usd">1234000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i01dddd98cd27486db73e8eb05dad1238_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtMC0xLTEtMC90ZXh0cmVnaW9uOjA0M2MyMjQwYzgxYjQ2YmZiYzBjY2E2MzVkMWNiOWU0XzQ_9e6b25b9-e092-486a-9a44-d31e4aea9750"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i01dddd98cd27486db73e8eb05dad1238_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtNC0xLTEtMA_e0608dab-b2c7-4af5-9c3f-d43a6e3370b1"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i01dddd98cd27486db73e8eb05dad1238_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtNi0xLTEtMA_1cd108d4-2f01-4613-8b04-1f8c4dd5b254"
      unitRef="usd">1480000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i708265c3841641feae11212bbe24bd13_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtOC0xLTEtMA_6e2d3891-b44e-4bee-ac61-7cd3c51177c1"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i708265c3841641feae11212bbe24bd13_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjEtMTAtMS0xLTA_a360b086-22bb-465a-a702-9189eedd7383"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50ef442c17d9418f8c9a539cb1195ec0_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItMC0xLTEtMC90ZXh0cmVnaW9uOjY0MDI3MzhmZGI0OTQ2YWI4YjIyNGVhYmRiZDk1YWNhXzQ_daabd3e0-255a-47d2-952d-9020ccb99dad"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i50ef442c17d9418f8c9a539cb1195ec0_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItNC0xLTEtMA_39a65776-5d89-4873-8ba6-78111fee4fde"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i50ef442c17d9418f8c9a539cb1195ec0_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItNi0xLTEtMA_e25bb200-cd9a-4cef-a3a3-9d9e4a1e5d83"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iac1907fe5d474e3b8211ac9e30f9be82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItOC0xLTEtMA_bcb5b5f8-b344-401f-b5da-2e90cd2ad731"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iac1907fe5d474e3b8211ac9e30f9be82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjItMTAtMS0xLTA_5dd18f23-6108-4ef7-ab23-6e63beb7df1d"
      unitRef="usd">740000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie72ff37863f94b4283e88af507ae245a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtMC0xLTEtMC90ZXh0cmVnaW9uOjA0NDViZTBmYmIwNTRjNTBiYTQ2ZjNmY2FhMGVkMzRkXzQ_80fb1c38-669a-4335-97d7-c442487289c7"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie72ff37863f94b4283e88af507ae245a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtNC0xLTEtMA_17b6c9a4-382d-4cee-a40e-e1c2ca77ad68"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ie72ff37863f94b4283e88af507ae245a_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtNi0xLTEtMA_a7e02388-0c39-43e9-8b6d-a354c37f7539"
      unitRef="usd">1235000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib31dccdddcfb4000b0c308332ce9f610_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtOC0xLTEtMA_fbfee038-a5d3-476a-9bbc-05f89130164f"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib31dccdddcfb4000b0c308332ce9f610_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjMtMTAtMS0xLTA_c63d0242-70bb-401b-8983-3e4fe2a36832"
      unitRef="usd">1234000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icc75983ef66546d6bddf3613cff7f8a4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjQtNC0xLTEtMA_dda268f0-f968-442b-9b73-9c5d275efc1d"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="icc75983ef66546d6bddf3613cff7f8a4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjQtNi0xLTEtMA_fa5fe651-4834-4ebb-b990-8f8bc155acb3"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i05453b6c881c458a820a5ac7d0ef7dfe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjQtOC0xLTEtMA_1be6449b-2c9e-4efb-80e8-56558e1fb508"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i05453b6c881c458a820a5ac7d0ef7dfe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjQtMTAtMS0xLTA_d55dc8be-7886-4c26-847b-c6f87e5857b2"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjUtNC0xLTEtMA_841863dc-b531-4806-b6cc-dcbe1fdf82b1"
      unitRef="usd">24601000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjUtNi0xLTEtMA_94f01093-a71d-4b11-944b-9db994608987"
      unitRef="usd">24343000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjUtOC0xLTEtMA_c9043a37-4c8c-4227-8c92-8571c38973aa"
      unitRef="usd">26188000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjUtMTAtMS0xLTA_6c353933-73a4-4834-bdb0-d5e498b0e753"
      unitRef="usd">25895000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjYtNi0xLTEtMA_1a7bb015-c7b7-45e2-b5bd-58ea6b8f062f"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjYtMTAtMS0xLTA_3f5a7c67-4bf9-4145-8018-6e6b77b2a2ff"
      unitRef="usd">1234000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjctNi0xLTEtMA_f54a3a50-9632-4dfe-972e-262bd43c4407"
      unitRef="usd">24343000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjE2OTg5ZjVmMTMwOTQwMmM5NmFmMjBlOTQ4Y2QyYjA2L3RhYmxlcmFuZ2U6MTY5ODlmNWYxMzA5NDAyYzk2YWYyMGU5NDhjZDJiMDZfMjctMTAtMS0xLTA_110d1997-87ca-4fa5-9274-6f41152eb4dd"
      unitRef="usd">24661000000</us-gaap:LongTermDebtNoncurrent>
    <bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments
      contextRef="ic43b82b77a204cbfb726e9c81f307b6e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTA5OTUxMTY0NjM1Mw_1991d110-e568-4fa9-8336-096c4d3503c2"
      unitRef="usd">12600000000</bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments>
    <bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio
      contextRef="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM4Mw_e5be68de-d311-4fc4-9a95-3bacf44a0b2c"
      unitRef="number">4.00</bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2fb8e2769d544690be3abd9e969d7f6f_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzYyOA_4c7aebe8-6d8a-4367-a9d0-7497437a09c3"
      unitRef="usd">1225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="i31ba7f21ed03439b841008aab77cae59_D20180601-20180601"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzY5OA_90e03f99-9851-4d0e-ab3c-f5dfeaf9f624">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="i2fb8e2769d544690be3abd9e969d7f6f_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzg4NA_678699d0-9dc1-48ba-8511-2d562aad65cf"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i53bbc40a99854970b78201ecfae1f0b0_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzk4NA_3c86027a-494c-4c11-80e3-5bd351dcb452"
      unitRef="usd">4565000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7d6f3842a7cc43d0b05b379a3197003c_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMzk5MQ_b1d40d7e-716a-4d6e-9174-e64f3a17c32c"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i776fc34ad45242c7b664a96b5697cafc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNDc3OA_4dcd0fc2-8c7f-47a3-a4df-148f1551d9d5"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i776fc34ad45242c7b664a96b5697cafc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNDgzOQ_c295ce53-ff43-4307-b12e-5b480c23164e"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i395e8b6493b243d785d218551ad6bc95_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNTEwNw_c05363e2-d2fe-474d-a914-a51a7c023e78"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i84316338b21741c5b5edb758134470bd_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNTQ1Mg_7a746a9b-deba-4fc4-a048-4396f556af57"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib4c920ee5bc74d47b13bdda58721672a_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjAwOQ_2505242b-1b6a-4a3b-bacd-6f2eaf0376f0"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7cfbb77dee664f9f9fafde904ea66301_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjA4MQ_0cb8ced3-9b06-4937-8f16-495365c98c6b"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7cfbb77dee664f9f9fafde904ea66301_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjMxNg_4a336abd-8b9a-40f7-9e4d-65818a22fa84"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet
      contextRef="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjYyNg_bf5c87c8-cee4-452c-aff8-721ceb1ba429"
      unitRef="number">1</bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet>
    <bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet
      contextRef="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjc4OA_1068ff05-8ab6-4708-abbf-cae1f763f252"
      unitRef="number">1</bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet>
    <bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet
      contextRef="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNjkyNQ_3e8c558c-0c51-424a-a49e-18555e4ad844"
      unitRef="number">0.50</bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet>
    <bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet
      contextRef="i3f162016e969457b84bcd686dd3e501d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzA4Mg_54f7ded8-48bb-48ab-96e9-f9338a6a0231"
      unitRef="number">1</bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i680f1d5e868b46d9b7570e6c1901ea09_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzI5Mg_7c55299a-0603-46c2-b139-5315ec96e420"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1c27340fb9c6435297c9931c627217e6_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzI5OQ_2b85caa1-161c-490d-9cdf-bfeff1893ad8"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia89d453429494c1db0f7a576c7b8b619_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzM3Mw_6886d111-b73b-4484-9364-b5bf1a70250a"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ica05a2309e6e49efa816d3d0e6070d96_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzM4MA_16b7c3d9-67f0-4728-88e0-abab1f75dbc2"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ica7020a01b884f0db71be5081d3f6c00_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzU0Ng_05ee7dbd-4204-4746-bc57-4dc79fd5e9bb"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i98399a1cca534743bbf269f1fb3a7bd3_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzU1Mw_d3d934a3-da86-4136-b2be-6792720881aa"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="ica7020a01b884f0db71be5081d3f6c00_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzYzMw_4b563c28-7890-48bd-860e-f7a49736bb8d"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="i98399a1cca534743bbf269f1fb3a7bd3_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzYzMw_4cbed7be-1353-486e-a588-302ebb987bb0"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="i4b43c4704f924701a890d5f962a8caa7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzg2Ng_792ebf86-9b40-4122-b6c0-747c827ec747"
      unitRef="usd">680000000</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9c8b8449c734458ebb0e65b656a6f94b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzk5Mg_fc8cf1be-2d1e-4fb3-a169-d3f219c941ff"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7eaf4c3ede854933aa1ae74e0977f05f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfNzk5NQ_cee45379-7955-4bf7-b2e9-42dd1410aec2"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0c735278fc854ebcad677441f39d21a3_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODA1Mw_a145d4b8-b831-4cd0-8657-cccb8e8b7eeb"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id59f859e9860470f84bad3c7b6b2ddad_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODA1Ng_6b98b65b-5240-4f85-8153-1db39d8df7a3"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODE5MQ_ba3ec2c3-8aa2-41b4-897c-59bb71ddf71b"
      unitRef="number">0.0315</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODIzMQ_9d0b4ca9-a8a4-4d2f-8db2-25f75e93cb3c"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i00c24c309eb54c4f804c01312f186da1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODI1OA_7ff1e6d5-e903-4cf0-91ea-17e7e9a5f5aa"
      unitRef="usd">107000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i13df17a79a214b60a3a91a5a7ff03ef9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODMzNQ_f93a8953-28c1-4c86-849c-d0aaf6083dfc"
      unitRef="usd">1118000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="idde9534012fd4b75b3ce796e32bc14a2_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODQ0Mw_10cc3b78-4d25-46e8-9465-a96846467b52"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="iaafc5c0d6e0c425db5de7640999583ad_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfODQ0Ng_170ffd0e-2080-4d5c-8747-ae5ea57c557f"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings
      contextRef="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTA5Ng_0dca49af-bf1c-4b8e-8e48-cd70e968d407"
      unitRef="usd">1000000000</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA
      contextRef="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTEwMw_aa61e2f4-3f4f-4940-ae13-056bbc06fbb9"
      unitRef="number">0.285</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA>
    <bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio
      contextRef="iebbc28b6be8d43069e00894b8781bf0e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTM2Mw_79f914b6-3900-4e38-8ed2-b9902dd20912"
      unitRef="number">3.50</bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio>
    <bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum
      contextRef="i084e681a0032449983710ed54eb3ad01_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTQ0OQ_cab894ae-9c3f-4a0d-8455-19593f607e0a"
      unitRef="number">6.50</bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum>
    <bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="idbb81f8f3f8247d2ba1dcdea3491affd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfOTUwMg_61de89f6-cfe6-4e83-b649-dcbdbf4e438f"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE0Nzk_c6226dfc-5805-43cd-beb2-a3b4fe214014"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2af09f0132c5448bab7483f939d8c584_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE1NDg_c979d9f9-039b-46a2-a734-d4690ffe5446"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib9d8578871b7406b986dbb995cb8af67_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE2Njk_d6ef278c-0cd3-4997-8d42-d6a1e2adc0ab"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib9d8578871b7406b986dbb995cb8af67_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE3MDI_35eee638-471f-41da-af71-ebe7398e67ff"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2af09f0132c5448bab7483f939d8c584_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE3OTE_1992c040-9012-452a-a5fd-d23fd7ac6d35"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2af09f0132c5448bab7483f939d8c584_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTE4MjQ_d4f237c6-f87c-4d09-a27c-73f4f9762e1b"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ifaf7cc4e25d7482581fa9522ffd8054c_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIwMTE_3dde00b6-2137-4323-a3a6-c3c428fcbf5b"
      unitRef="usd">584000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i756c2741402c442dbf8d5d9b6d2b0761_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIwMTc_8f24abc1-6dce-4ed4-b051-5bea8147baa6"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0cf372dafcdc4256a52a45555ce48252_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIxMDI_757e2eb5-3937-4b9e-9bf3-21e433597821"
      unitRef="usd">518000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6f2e689cc9bc45aea09d11c8f10fbdc2_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIxMDg_6c11d647-c079-4c67-b10d-f2937cd2a870"
      unitRef="number">0.05625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i62a835f93c3841ec9faa2b983380dc84_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIxOTk_f45b2934-07cf-44cd-a5cb-a5eb8d1fd28e"
      unitRef="usd">216000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i26953919345a48ac8c4fc7b3d9f771e5_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTIyMDU_7259abb2-72ae-4c3a-97b5-6d2424dde76c"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i24b0bf33724f4f958b89a4381b10a2a7_D20190401-20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTI0NDQ_e1fe33af-d579-4c74-b813-036d39672a68"
      unitRef="usd">182000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7225129913c342a3996cf248b001bd71_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTI2MTM_b82a2a26-d0de-4a6a-9a5c-5003c5817cf9"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="i1b169ebb131842c7b5dab7380388dbb9_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM1NDQ_13d85847-cdc6-4542-84aa-cd0db6c7281c"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifb407c4dee97479aaed7d0a54af5a221_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM2NTg_1bf70b51-8b55-4ada-879c-aa3fc50d75a1"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib9d8578871b7406b986dbb995cb8af67_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM4MTA_d6ef278c-0cd3-4997-8d42-d6a1e2adc0ab"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i556544584b844001980693b54a079641_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTM5ODE_5d018957-422f-440e-93ef-b7873ebab9b5"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i422f3d2912d24190bc5966214fdc77d5_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQwMjA_b2212213-a800-41f9-b568-9eec0de0cf1f"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i556544584b844001980693b54a079641_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQxMzI_f506e8d0-6467-476f-856b-a1d963253a3d"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i556544584b844001980693b54a079641_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQxNjU_5d018957-422f-440e-93ef-b7873ebab9b5"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i556544584b844001980693b54a079641_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQyMTQ_5d018957-422f-440e-93ef-b7873ebab9b5"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i422f3d2912d24190bc5966214fdc77d5_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQyNTc_09a324ab-a307-4a81-bd79-0171690d6a7e"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i422f3d2912d24190bc5966214fdc77d5_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQyOTA_b2212213-a800-41f9-b568-9eec0de0cf1f"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i156e9d3804a244b6a29b74a3e3e52c7b_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ0NjE_0679cab7-c237-40d5-87ff-2473b2cd50e9"
      unitRef="usd">1118000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i0b8d1168c7204d658dfb66babf4ccc26_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ1MDk_0efdb761-fea2-4037-a562-3b5a1558a2dd"
      unitRef="usd">382000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i38b42858a98247d79b9bcf64d8e4cae8_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ2NzA_d8a85269-bae9-4454-93d8-0af91d37983f"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaa041cac555c42fba824f78513336e7f_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ3MDk_e59427cc-5508-46aa-936a-e09b8ead4687"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i38b42858a98247d79b9bcf64d8e4cae8_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ4NDU_169d8ad1-e900-4375-a6c1-22ee09168fa8"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i38b42858a98247d79b9bcf64d8e4cae8_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ4Nzg_d8a85269-bae9-4454-93d8-0af91d37983f"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i38b42858a98247d79b9bcf64d8e4cae8_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ5Mjc_d8a85269-bae9-4454-93d8-0af91d37983f"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaa041cac555c42fba824f78513336e7f_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTQ5NzA_d8548a87-ab18-4aa9-86c1-2733669e1a7d"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaa041cac555c42fba824f78513336e7f_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTUwMDM_e59427cc-5508-46aa-936a-e09b8ead4687"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic9330108a6824e37b8217d2a11ded672_D20200116-20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTUxNjI_c985841e-d531-421c-87f0-8187dd54ec9f"
      unitRef="usd">1240000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i7907ded04dab4554a0ef907fa261b6f7_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTUyMzE_536b031b-bf41-4527-ad30-980a36ecae44"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iba7b866fe620404c9be6000f21284d31_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU0ODM_a0237ac6-9f41-4bc0-8682-8aa7cd23a028"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iba7b866fe620404c9be6000f21284d31_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU1OTA_9bf5aa64-eaab-4869-b758-c1dd0d46d70c"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iba7b866fe620404c9be6000f21284d31_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU2MjM_f58bfaa7-d834-4d4a-8c42-75f642cb50cf"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ifc5ee50d3e974a62ba9571a1f2f84fc0_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU3ODg_ed6e94d8-9c70-414b-bf79-e75e7f272da3"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifc5ee50d3e974a62ba9571a1f2f84fc0_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU4MzM_761c4ffa-9170-40a8-a82c-d2b58c50cbf7"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:PaymentForDebtAmortizationPrepaymentCost
      contextRef="i35061b0459224831a5dd5ee11d9692a9_D20200526-20200526"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTU4ODU_fa7e712b-57c4-4017-8062-22ea4cc0a939"
      unitRef="usd">303000000</bhc:PaymentForDebtAmortizationPrepaymentCost>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4927b0e336fe4ef1b1ffb40e143d6d6f_D20200526-20200526"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTYyOTA_11748946-bc9d-4d47-8d8e-061256b26700"
      unitRef="usd">-27000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iba7b866fe620404c9be6000f21284d31_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTY0ODY_92ac7b87-2e42-41d5-9cae-eb74a70c74c2"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ib1fd33b8ea2042dfb42c2639a2b086ab_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTY3MDc_1a18c83e-25b6-42eb-8da4-29687bd0d76f"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="id782e23cbd724954b6368623a4d54175_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTY5MjE_34d6781f-c120-434c-b1c5-86e39e17c97d"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTc1NzQ_566c1cba-15af-4561-90e6-63da545bc4e8"
      unitRef="number">0.0594</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTc1ODE_4f52bc45-47a6-4e2a-b38b-2ded881c7289"
      unitRef="number">0.0621</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i1f1c7ed275704247962d8203458ab574_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTgxNDc_416248d1-8dc7-4c05-b052-798436e0b9e3"
      unitRef="usd">27000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i1b169ebb131842c7b5dab7380388dbb9_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTgxOTU_c2b67f3f-2b5b-4072-b2f9-8a78181432bc"
      unitRef="usd">26000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i1b169ebb131842c7b5dab7380388dbb9_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTgyNzE_84c054ee-89b8-44a6-8125-3b944927a370"
      unitRef="usd">1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTg0NjY_7bb87fa7-ad06-4c22-8bed-0863ddd3cd39">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities and mandatory payments of debt obligations for the remainder of 2020, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfMS0xLTEtMS0w_2a25206d-dbbd-4454-a171-16a71c8aeec9"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfMi0xLTEtMS0w_5e654750-2bc5-4d10-b517-020f1dce2385"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfMy0xLTEtMS0w_19312461-9130-48d5-8665-ecdfdac9f3dc"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfNC0xLTEtMS0w_56eb29fa-9de6-4087-b3ea-d6bf3cfd51bb"
      unitRef="usd">2404000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfNS0xLTEtMS0w_c6366527-5e01-4846-9b79-9333112cff3f"
      unitRef="usd">2303000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfNi0xLTEtMS0w_076f2a94-6584-4bfb-a9b5-57ba669af331"
      unitRef="usd">10632000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfNy0xLTEtMS0w_7a005991-f899-438b-a1c9-82eb07df5a81"
      unitRef="usd">9262000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfOC0xLTEtMS0w_8b56cbeb-e652-4e62-be56-8c8697aad18e"
      unitRef="usd">24601000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfOS0xLTEtMS0w_6ec5ef86-eba2-4b90-a3d1-96aa1edc9537"
      unitRef="usd">258000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RhYmxlOjYxYTdlOWQ3YjRmYTQyOGE4NTMxZTk2MGNkZGY5MTMzL3RhYmxlcmFuZ2U6NjFhN2U5ZDdiNGZhNDI4YTg1MzFlOTYwY2RkZjkxMzNfMTAtMS0xLTEtMA_94f01093-a71d-4b11-944b-9db994608987"
      unitRef="usd">24343000000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3e190fe005974b5ea0fe1ade4aa15972_D20201029-20201029"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTA5OTUxMTY0NzE3OQ_a1111ac6-84e5-4b92-9101-e97cadeb9aad"
      unitRef="usd">99000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9b698175e9eb43f389d1012167ab199d_D20201029-20201029"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY182Ny9mcmFnOjZiYmE1NWUyYjcxNDQ3YjU5MzJmYWVmYTExOTc3MTMwL3RleHRyZWdpb246NmJiYTU1ZTJiNzE0NDdiNTkzMmZhZWZhMTE5NzcxMzBfMTA5OTUxMTY0NzE5Mg_d5b59b13-98d1-486f-aeda-1ee2ceac2d90"
      unitRef="usd">51000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RleHRyZWdpb246ODRlYjQ3OTVlYWNkNDAzYmJhYzY0OWQ2YmVjNmYxNTZfMzk1_d402203a-5c05-49e5-bc30-4f72f5d091f1">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2020 and 2019 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;br/&gt;Benefit&lt;br/&gt;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 3.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RleHRyZWdpb246ODRlYjQ3OTVlYWNkNDAzYmJhYzY0OWQ2YmVjNmYxNTZfNDA0_c9451297-d408-4b5e-b923-123b097f6cd5">Net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2020 and 2019 consists of: &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Postretirement&lt;br/&gt;Benefit&lt;br/&gt;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 3.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy0yLTEtMS0w_87136ba7-0bb5-433b-a230-a30279b70132"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy00LTEtMS0w_71b9741b-e1af-47ae-85dc-488980447780"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy02LTEtMS0w_8cbe6e45-3cea-4d6e-b469-d2840b918fb5"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy04LTEtMS0w_f828d7ff-9eb9-4621-9c2e-6073a0a84331"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy0xMC0xLTEtMA_9e0c2254-ca0f-4e54-a174-0c6eb2cf1bed"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfMy0xMi0xLTEtMA_54e3f6da-6499-4b81-a155-1ce6259cf536"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC0yLTEtMS0w_8007d542-fb8c-4a65-b846-0d8def2bae3c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC00LTEtMS0w_f39b50a8-3ee8-4ee9-a26f-5b11f54e84df"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC02LTEtMS0w_bdb7fc3a-e4fb-48db-89a8-c05c796491c0"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC04LTEtMS0w_0bf4449b-073b-4dd8-9270-9183744df48c"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC0xMC0xLTEtMA_e5540bb2-ac49-4948-bea0-6a91edb80b71"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNC0xMi0xLTEtMA_c7de34ec-b58d-474c-9075-27a416770bff"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS0yLTEtMS0w_ae038fbb-9c71-4266-beb5-fd8672609792"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS00LTEtMS0w_b167181f-ed81-4eee-9d10-3b52a68abd0d"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS02LTEtMS0w_7559ef04-5b84-440e-a6d5-d5916881187e"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS04LTEtMS0w_17f27906-04cd-45b1-88cd-e53209ac581a"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS0xMC0xLTEtMA_4b631084-ef80-43d8-9607-f684b08c671d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNS0xMi0xLTEtMA_511bf920-baea-4fca-8049-c0c5ebcda84f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi0yLTEtMS0w_7a5b4232-f1c6-4db4-ac96-53c67ee57430"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi00LTEtMS0w_25e8242f-9693-44d7-be1d-de77f34f401a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi02LTEtMS0w_8fedcd53-ccdd-438d-a7ad-9d71ffb70613"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi04LTEtMS0w_3456fdc7-acfa-4c3a-adc5-5c0e773a4491"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi0xMC0xLTEtMA_15829af4-082e-4fbb-8e8e-b1a66a472956"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNi0xMi0xLTEtMA_3d22e801-4d96-45a0-8c74-ba87e6ed34fc"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0yLTEtMS03MjU_0d216bc7-d272-493c-8d65-d76a427b6474"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy00LTEtMS0zMTcy_b2b0f36d-6d57-4d8e-b9cf-e4396f183a7e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy02LTEtMS03Mjk_ec03c79a-a075-419b-accb-f2a21af7d9c8"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy04LTEtMS0zMTcy_cdaf4de6-ae56-4b40-8558-764598284cdd"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0xMC0xLTEtNzMz_2f513b0a-2e4d-440a-98d9-303c7bb41c50"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0xMi0xLTEtMzE3Mg_2ee1e9d8-4a8d-47c6-b5b3-88db61715e24"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ie5495c8c275a4cfa86648504274cec51_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0yLTEtMS0w_f842ea77-34c4-4695-b50a-8479075cb3cb"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ibfffc733a82a4161b90b323f1e02690c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy00LTEtMS0w_54c39a90-d6e3-4a78-b04e-c0c8de8c2ecf"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i2f844286327848db87c6c0846469186e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy02LTEtMS0w_ff53dcae-9d81-4529-8a2a-6a5b9f3b4c18"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7ffeab75116047e7a3c8622e7e4b0d68_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy04LTEtMS0w_1e505db8-0147-4d8a-ba5c-56897e8fa8a3"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i886ab6d168894537a5b1025209fcf54d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0xMC0xLTEtMA_9ca68843-02cd-4cec-a452-d8df03de5c08"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i247a4f593120439e83e53ac68d167d4c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183My9mcmFnOjg0ZWI0Nzk1ZWFjZDQwM2JiYWM2NDlkNmJlYzZmMTU2L3RhYmxlOjU2YjIwOTQzOTQ5MDQ1Y2Y5M2EzOTNlNGE3NzgxMWIwL3RhYmxlcmFuZ2U6NTZiMjA5NDM5NDkwNDVjZjkzYTM5M2U0YTc3ODExYjBfNy0xMi0xLTEtMA_1c1230bb-beef-44f5-9e87-cd0f5b79bece"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQ1NQ_b56e3751-9af4-4a6c-995d-8aebacde2495">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014, shareholders approved the Company&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;) which replaced the Company&#x2019;s 2011 Omnibus Incentive Plan (the &#x201c;2011 Plan&#x201d;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#x2019;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#x201c;Amended and Restated 2014 Plan&#x201d;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company&#x2019;s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#x2019;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#x201c;Further Amended and Restated 2014 Plan&#x201d;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#x2019;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#x201c;SARs&#x201d;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#x201c;underwater&#x201d; stock option or SAR and (iv) other housekeeping and/or clerical changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 17,067,000 common shares were available for future grants as of September&#160;30, 2020. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#x2019;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term.  The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#x201c;RSUs&#x201d;) and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#x201c;TSR&#x201d;) and (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#x2019;s return on tangible capital (&#x201c;ROTC&#x201d;).   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of share-based compensation expense related to stock options and RSUs for the three and nine months ended September 30, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,895,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROTC performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the remaining unrecognized compensation expense related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $116 million, which will be amortized over a weighted-average period of 1.59 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ie31f5ab3c2924d3b8c230faa96e03243_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQ0_1d3a830f-c6f4-4e22-b22d-4cca58315da2"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie31f5ab3c2924d3b8c230faa96e03243_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfODA0_ee69f985-bc64-43d7-a822-07997aebbe25"
      unitRef="shares">20000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if1234c5878b345c3be0c7887e84c8c4b_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfMTE4OA_0abc975f-d837-4f46-9cb4-355f30e126c2"
      unitRef="shares">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant
      contextRef="id1f9e1c5bb0d428cb4b9c7514e892230_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfMTM0NQ_79c0d203-7cfb-46a7-b41e-fd6690c415b1"
      unitRef="usd">750000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i37ebdf9ce1ce47ce953dd272b4116d9f_D20200428-20200428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfMjIzNA_5220048a-4915-4cfe-9c1c-7b1481c4a8af"
      unitRef="shares">13500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5bcdb72d89d2453a81215c5d89199ddb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfMzA0MQ_6271b1b0-70a3-4039-86fc-1624c4b1d7ec"
      unitRef="shares">17067000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQ1OA_79f77136-631c-4d94-abf2-677afca94288">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of share-based compensation expense related to stock options and RSUs for the three and nine months ended September 30, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e5e06f512ef41418fe077ef11562faa_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMi0xLTEtMS0w_5b287845-e824-40a7-9f82-ae423dc83c63"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if47991fff46a44fa8907b87f6e475934_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMi0zLTEtMS0w_f864c36d-d7d5-4793-94aa-cdc108bee137"
      unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMi01LTEtMS0w_0abd357b-87bb-4b75-b76b-d964d6dac261"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMi03LTEtMS0w_c03511af-e4bd-46ad-972c-53a4d3276e4b"
      unitRef="usd">17000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c1f53d1c1fd4dd699f102722ad4ab30_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMy0xLTEtMS0w_21e913e4-327f-4a5e-8bb7-a46d1b1b6e43"
      unitRef="usd">23000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb6705ae1cc944e9b0c9948e2cc52937_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMy0zLTEtMS0w_07fc2651-0fa9-4c54-aa56-05d19e41eded"
      unitRef="usd">21000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d204a1b39c34ebf957a3002d5e89825_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMy01LTEtMS0w_7dd31e87-2d15-433b-8426-45f6a86d43b8"
      unitRef="usd">69000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i106b3eee455e4af59474ab03ba414fb7_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfMy03LTEtMS0w_ae7b22cd-1344-433f-8074-9c06c6ccc862"
      unitRef="usd">60000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNC0xLTEtMS0w_ea9cc6b9-df1b-49cd-b132-ffbe4888efbc"
      unitRef="usd">27000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNC0zLTEtMS0w_6c790cf2-03ed-4051-bc38-9997f2d71a1c"
      unitRef="usd">26000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNC01LTEtMS0w_424475d8-15cf-4e33-9bb8-a36286421ed4"
      unitRef="usd">81000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNC03LTEtMS0w_2e045b18-4674-4773-b858-8291e770b96a"
      unitRef="usd">77000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e61c443cd46403f897e0842ba3f568e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNi0xLTEtMS0w_cdd94197-c532-4a27-b28f-e219152a2f78"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie657a420eece4d10b6860b72c457aaab_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNi0zLTEtMS0w_fbed6538-d4fc-4315-a1e9-d98223e080a6"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife7d401df9e9436187d1434bcf9382ca_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNi01LTEtMS0w_fadbeb7e-d823-4bcd-b22e-f3fa530d4f20"
      unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a7f83031f2049529b19147c57eb7ff0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNi03LTEtMS0w_1e76774a-fa67-49b3-8466-04e4b2bbb2e7"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9987cef2d1d4602aa101e2592aabc48_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNy0xLTEtMS0w_3bf62ed9-9635-4c78-a1db-3ef496f454b4"
      unitRef="usd">24000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0418ceeffa1443e9802453c68467828b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNy0zLTEtMS0w_7160bf29-5d79-45ac-863f-f03ee42864fd"
      unitRef="usd">24000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifdf089cab8914facba6578b77bebb264_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNy01LTEtMS0w_21d724ef-a854-46a4-af75-6811e5930785"
      unitRef="usd">72000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide4414ac166c4b98b170244eb491149f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfNy03LTEtMS0w_c8eb226b-554b-4b8b-8bd5-d232fa15b99b"
      unitRef="usd">70000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfOC0xLTEtMS0w_ebfe71be-1953-41a0-a24b-82363f60d6c3"
      unitRef="usd">27000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfOC0zLTEtMS0w_2d9f037d-89ba-454e-90ab-17c017ceb2ef"
      unitRef="usd">26000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfOC01LTEtMS0w_7f8d0458-223d-494d-9b16-59233687c619"
      unitRef="usd">81000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmY3M2QyYmI2NTRhODRkZjhiMWM2N2QyZDJlNmNmOGRhL3RhYmxlcmFuZ2U6ZjczZDJiYjY1NGE4NGRmOGIxYzY3ZDJkMmU2Y2Y4ZGFfOC03LTEtMS0w_61258ecb-fcc2-4a09-8e35-ffc4c0038000"
      unitRef="usd">77000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQ1MA_f9acff0d-183e-4d62-9afb-b5efec2a83da">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended &lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,084,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,895,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROTC performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMy0xLTEtMS0w_be8c9765-3302-4a9d-831e-7a7f622b9c55"
      unitRef="shares">2269000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMy0zLTEtMS0w_c43da226-2479-41d6-8581-a278f6e95d8d"
      unitRef="shares">1725000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfNC0xLTEtMS0w_ff9792e7-b746-468d-92fe-10184caf9b59"
      unitRef="usdPerShare">24.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfNC0zLTEtMS0w_24cbba63-8992-4119-9a26-f640ecfa794c"
      unitRef="usdPerShare">23.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfNS0xLTEtMS0w_38650105-6f2d-421e-81c2-16a6cd11b559"
      unitRef="usdPerShare">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i93d004c6f73444efa8ec9d8544c2afb3_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfNS0zLTEtMS0w_872c241b-3882-418f-96f1-8e74f0b20c13"
      unitRef="usdPerShare">8.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6f757f31530c45ddaa86c86406b50a0c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfOC0xLTEtMS0w_f1226e01-2007-4f04-891a-de5f6839ba97"
      unitRef="shares">3084000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7333dc2ff308421588477f444d77526f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfOC0zLTEtMS0w_3ece06a4-8889-4658-86a8-57335baecf57"
      unitRef="shares">2895000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6f757f31530c45ddaa86c86406b50a0c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfOS0xLTEtMS0w_4c2f9547-04f5-4dfc-91c2-228fbe972157"
      unitRef="usdPerShare">22.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7333dc2ff308421588477f444d77526f_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfOS0zLTEtMS0w_c95b61cf-bf25-418d-806e-d596b0e898bf"
      unitRef="usdPerShare">23.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iffd6ad7504a94a299b44307bf31e726b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTItMS0xLTEtMA_966910e7-0958-4501-bfff-4fc529b4b501"
      unitRef="shares">425000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5b3127099e704d8e902e5069aa1e0b13_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTItMy0xLTEtMA_d30147e2-209f-4fee-b1dd-171678bbc6de"
      unitRef="shares">454000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iffd6ad7504a94a299b44307bf31e726b_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTMtMS0xLTEtMA_def8a59d-11ac-4292-9313-46fc0ae92179"
      unitRef="usdPerShare">26.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5b3127099e704d8e902e5069aa1e0b13_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTMtMy0xLTEtMA_075996e3-07ca-4158-b8c8-0f8bbfa459dd"
      unitRef="usdPerShare">34.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i472ae620787344d6baf50d96060d90ab_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTYtMS0xLTEtMA_5f8b677e-9739-4beb-9834-3671ef8d0437"
      unitRef="shares">472000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i898bb6c7930c478587dd044061b9d2a2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTYtMy0xLTEtMA_ae08f0ca-da55-455e-ab9e-4205d84f879b"
      unitRef="shares">505000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i472ae620787344d6baf50d96060d90ab_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTctMS0xLTEtMA_20c92d4e-36a0-49e5-af68-8001b2106745"
      unitRef="usdPerShare">27.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i898bb6c7930c478587dd044061b9d2a2_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RhYmxlOmQwZDliMzZiZmQ0ZjQ3YTRiNWJiZGYyMGRkNjZlNGE3L3RhYmxlcmFuZ2U6ZDBkOWIzNmJmZDRmNDdhNGI1YmJkZjIwZGQ2NmU0YTdfMTctMy0xLTEtMA_476cb488-05e4-4459-a490-da6f8003650d"
      unitRef="usdPerShare">25.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDM3NA_f03181f5-785a-4258-b7bc-16712f61a304"
      unitRef="usd">116000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183Ni9mcmFnOjIyMGM3YTkwMzRjZDQ0ZmRhOGU2YmE0MmYzNThiNWUzL3RleHRyZWdpb246MjIwYzdhOTAzNGNkNDRmZGE4ZTZiYTQyZjM1OGI1ZTNfNDQzNg_93c3c005-7fe8-4dd9-8ef6-3cb695690c35">P1Y7M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RleHRyZWdpb246NjUyYjFlOGUwMzg2NGI4NzhhYTc3YWE0ZWMxZjAyNWJfNjE5_1890b1c3-a72d-4718-84e5-39458ad82b34">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and postretirement benefit plan adjustments, net of income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#x2019;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#x2019;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020, amounts reclassified from Accumulated other comprehensive loss into the Company's operating results were not material.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RleHRyZWdpb246NjUyYjFlOGUwMzg2NGI4NzhhYTc3YWE0ZWMxZjAyNWJfNjEy_076df75d-fb85-41ef-b723-800f8493b28c">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension and postretirement benefit plan adjustments, net of income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i741bd4dd7c0149f6b7ffc048b13bc0ee_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMS0yLTEtMS0w_71e9ec1d-e96d-4aab-9849-4d01968d88d4"
      unitRef="usd">-2165000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic862f703a2734648bf7d042a71301d5d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMS00LTEtMS0w_5946a62e-f206-42f7-a165-d5b02ecc4b5f"
      unitRef="usd">-2046000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57608adce9004fa8829f1bf5a0f4c66c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMi0yLTEtMS0w_9debba7b-244e-4f24-b36f-67d850de300d"
      unitRef="usd">-42000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21d1c6b9142d4a759b71dc4abddbb243_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMi00LTEtMS0w_1a26fad5-2b81-4759-9544-124c3aa20de8"
      unitRef="usd">-40000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86b09d66e5904f00bdfc6d7dcac58e24_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMy0yLTEtMS0w_e48ef5d0-16fa-4a75-876a-d317fd3290b9"
      unitRef="usd">-2207000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7807cd27ff842ef98aaf27968fece25_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RhYmxlOjY1MzM5ZmJjMDg4ZTQ0MGQ4NGI2YWFjODY2ZmJhODMwL3RhYmxlcmFuZ2U6NjUzMzlmYmMwODhlNDQwZDg0YjZhYWM4NjZmYmE4MzBfMy00LTEtMS0w_c6a89831-45ff-457e-99ae-b0bab89637b4"
      unitRef="usd">-2086000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RleHRyZWdpb246NjUyYjFlOGUwMzg2NGI4NzhhYTc3YWE0ZWMxZjAyNWJfNTk4_15f989b9-8f31-4863-b5c4-d643e6be07ba"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY183OS9mcmFnOjY1MmIxZThlMDM4NjRiODc4YWE3N2FhNGVjMWYwMjViL3RleHRyZWdpb246NjUyYjFlOGUwMzg2NGI4NzhhYTc3YWE0ZWMxZjAyNWJfNTk4_a5292e37-aaa7-4229-bf44-cc67212fb6fe"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RleHRyZWdpb246N2JjNjJkNjQ0YzFkNDcxMThmNjUxNjdhNjNmMzZiZjNfMjM0_dee05da5-073d-4617-9f4e-0fba5bc83c75">RESEARCH AND DEVELOPMENT&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RleHRyZWdpb246N2JjNjJkNjQ0YzFkNDcxMThmNjUxNjdhNjNmMzZiZjNfMjM3_fd7fb91e-d03f-4c57-9205-28dc6cdb6c95">Research and development costs consist of:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMi0yLTEtMS0w_4674b5cf-a64c-4592-b102-ea7018ca74f9"
      unitRef="usd">95000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMi00LTEtMS0w_acbeaf82-4aa0-4e81-8b22-43e1287bed13"
      unitRef="usd">114000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMi02LTEtMS0w_1b9df7a9-1d3c-4970-9e85-ffee3436943f"
      unitRef="usd">309000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMi04LTEtMS0w_e9fcab0c-27ad-467c-8f63-6c69bb5f89d4"
      unitRef="usd">329000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMy0yLTEtMS0w_1f142541-37dd-4162-8b4f-1d44e1577699"
      unitRef="usd">8000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMy00LTEtMS0w_e179e273-0d4d-4c47-9ec1-f4e38a515b69"
      unitRef="usd">9000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMy02LTEtMS0w_7e210f7f-84dc-414d-9b50-86a63aa3e1dc"
      unitRef="usd">24000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfMy04LTEtMS0w_18a8f9d9-233e-4a69-9886-5a0c92ef9e9b"
      unitRef="usd">28000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfNC0yLTEtMS0w_697af62a-b242-4749-a34a-0829f85d4926"
      unitRef="usd">103000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfNC00LTEtMS0w_36900f7c-d618-47c6-b5d8-67e5aba43b94"
      unitRef="usd">123000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfNC02LTEtMS0w_4b802918-0468-4230-b859-4975f928178a"
      unitRef="usd">333000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184Mi9mcmFnOjdiYzYyZDY0NGMxZDQ3MTE4ZjY1MTY3YTYzZjM2YmYzL3RhYmxlOmUyMGMxMTJlYmQ4NTRjM2E5OTYyY2IyODc5NjUzYWY5L3RhYmxlcmFuZ2U6ZTIwYzExMmViZDg1NGMzYTk5NjJjYjI4Nzk2NTNhZjlfNC04LTEtMS0w_5b7fb719-336b-4248-8aba-d71129db6b5c"
      unitRef="usd">357000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RleHRyZWdpb246NWNiOWY5YWU0Yjg0NDEwOWEyZWUxODY0ZjI2MzgzODNfNDUz_2ab35b8a-f5c3-4467-94e2-1051508c09ac">OTHER EXPENSE, NET&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain on sale of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2020, Litigation and other matters includes adjustments related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. Litigation and other matters also includes an insurance recovery related to a certain litigation matter.  See Note 18, "LEGAL PROCEEDINGS" for further details regarding these and other litigation matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RleHRyZWdpb246NWNiOWY5YWU0Yjg0NDEwOWEyZWUxODY0ZjI2MzgzODNfNDU1_acca34af-e329-48c9-b4f5-2d903af75dc8">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain on sale of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMi0yLTEtMS0w_a9760a66-3d60-482f-b82f-d85d812d87a3"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMi00LTEtMS0w_4ee0fe35-6958-4d9b-af39-2be37f1e76f7"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMi02LTEtMS0w_ce421253-c05b-4165-9e50-448ae91e593b"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMi04LTEtMS0w_1e887c5b-6158-4826-b942-aab16c94aa4a"
      unitRef="usd">10000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMy0yLTEtMS0w_c4a441bb-91e0-4242-97c0-8e1f9fe72957"
      unitRef="usd">12000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMy00LTEtMS0w_7f35e1d2-5ca8-4e9e-bd35-c7501a3371e8"
      unitRef="usd">1000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMy02LTEtMS0w_83227e31-30f1-424b-87f9-0f6f97eadf73"
      unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfMy04LTEtMS0w_4f33b40d-12d9-457a-bebb-32e7b26ef732"
      unitRef="usd">9000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNC0yLTEtMS0w_3f4ace4a-7ab7-481f-80a9-931e27b1f95d"
      unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNC00LTEtMS0w_707154f2-f308-4993-a146-ee7d55aeeeda"
      unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNC02LTEtMS0w_3a140ffd-1c65-4c35-b330-999dddb18cff"
      unitRef="usd">0</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNC04LTEtMS0w_8fafb168-d98c-4ae4-9a2a-c61da4e63e43"
      unitRef="usd">8000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNS0yLTEtMS0w_6036faac-e7bc-4c02-8289-ec97a23a3d66"
      unitRef="usd">-4000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNS00LTEtMS0w_1d5774e7-e809-4a7d-8524-c21bb32c044c"
      unitRef="usd">-9000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNS02LTEtMS0w_6f4754c5-81b2-4a79-8ab7-158c39478a1b"
      unitRef="usd">-127000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNS04LTEtMS0w_52beb311-ae20-4d8a-8bba-dbc81b834bc8"
      unitRef="usd">-12000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <bhc:OtherMiscellaneousNonoperatingIncomeExpense
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNi0yLTEtMS0w_dfad94e6-ee5e-47a5-8110-065ce31d3d27"
      unitRef="usd">0</bhc:OtherMiscellaneousNonoperatingIncomeExpense>
    <bhc:OtherMiscellaneousNonoperatingIncomeExpense
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNi00LTEtMS0w_a2127add-c650-46a7-86a1-c953945b7ae8"
      unitRef="usd">-1000000</bhc:OtherMiscellaneousNonoperatingIncomeExpense>
    <bhc:OtherMiscellaneousNonoperatingIncomeExpense
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNi02LTEtMS0w_519c0ed6-3f0b-4e0d-ba6b-ff06e8cf6fcd"
      unitRef="usd">0</bhc:OtherMiscellaneousNonoperatingIncomeExpense>
    <bhc:OtherMiscellaneousNonoperatingIncomeExpense
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNi04LTEtMS0w_3c64420c-b3bb-4b7b-bf4c-a43068d4740b"
      unitRef="usd">4000000</bhc:OtherMiscellaneousNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNy0yLTEtMS0w_e7a2c7cc-2a57-439d-a876-e3bbd43da8b5"
      unitRef="usd">-16000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNy00LTEtMS0w_194bd1f6-950e-4ce3-b1af-dea5a7369d3a"
      unitRef="usd">-10000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNy02LTEtMS0w_83fbd9c6-e1e6-4c8f-a6c4-dcfb68706b29"
      unitRef="usd">-146000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184NS9mcmFnOjVjYjlmOWFlNGI4NDQxMDlhMmVlMTg2NGYyNjM4MzgzL3RhYmxlOjAxNDA4YTgxYWM1ZjRkODQ4MmE4ZmUxOTZkY2NhNTlmL3RhYmxlcmFuZ2U6MDE0MDhhODFhYzVmNGQ4NDgyYThmZTE5NmRjY2E1OWZfNy04LTEtMS0w_8d14333b-5043-49fe-b32b-072ada5743ef"
      unitRef="usd">-15000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfNDM5ODA0NjUxODEwMg_ff3832aa-483f-4260-b598-db2b910dfc19">INCOME TAXES &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company's ordinary income, subject to certain limitations on the benefit of losses. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company's income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company's estimated annual effective income tax rate may be revised, if necessary, in each interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Benefit from income taxes for the nine months ended September 30, 2020 was $133 million and included: (i) $105 million of net income tax benefit for discrete items, which includes: (a) $63&#160;million in net tax benefits related to the release of a valuation allowance, (b) $36&#160;million in tax benefits associated with law changes in the United States, (c) $10 million in tax benefits recognized for changes in uncertain tax positions, (d) a $7 million tax benefit related to a deduction for stock compensation and (e) $11 million of net tax expense associated with filing certain tax returns and (ii) $28 million of income tax benefit for the Company's ordinary loss for the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefit from income taxes for the nine months ended September 30, 2019 was $101 million and included: (i) $46 million of net income tax benefit for discrete items, which includes: (a) $32 million of tax benefit recognized upon a ruling from the Polish tax authorities confirming the deductibility of royalty payments by an affiliate, (b) $13 million of net tax benefits associated with filing certain tax returns and (c) $1 million of net tax charges related to other changes in uncertain tax positions and (ii) $55&#160;million of income tax benefit for the Company's ordinary loss for the nine months ended September 30, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made except that, as a result of the 2018 adoption of guidance regarding intra-entity transfers, any change in valuation allowance surrounding the adoption of the intra-entity transfer resulting from this adoption was recorded within equity. The valuation allowance against deferred tax assets was $2,756 million and $2,831 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively.  The decrease was primarily due to: (i) the change in the expected realizability of previously established losses in Germany, recorded discretely and (ii) income in Canada. The Company will continue to assess the need for a valuation allowance on a go-forward basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2020, the U.S. Treasury Department and the Internal Revenue Service (the "IRS") released final regulations under the Global Intangible Low Taxed Income ("GILTI") and Subpart F income provisions of the Internal Revenue Code regarding the treatment of income that is subject to a high rate of foreign tax. The final regulations allow taxpayers to exclude certain high-taxed income of a controlled foreign corporation from their GILTI computation on an elective basis. The Company has evaluated the effects of these final regulations and has discretely recorded a $19&#160;million tax benefit during the three months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2020 and December&#160;31, 2019, the Company had $1,009 million and $1,002 million of unrecognized tax benefits, which included $51 million and $45 million of interest and penalties, respectively. Of the total unrecognized tax &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;benefits as of September&#160;30, 2020, $363 million would reduce the Company&#x2019;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at September&#160;30, 2020 could decrease by approximately $141 million in the next 12 months as a result of the resolution of certain tax audits and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to be under examination by the Canada Revenue Agency. The Company&#x2019;s position as of September&#160;30, 2020 with regard to proposed audit adjustments has not changed and the proposed adjustments continue to result primarily in a loss of tax attributes that are subject to a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IRS completed its examinations of the Company&#x2019;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations.  The 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the IRS has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. At this time, the Company does not expect that proposed adjustments, if any, for these periods would be material to the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2010 through 2011 and 2015 through 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Germany are under audit for tax years 2014 through 2016.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2011 through 2015. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfNzY0_87b0b14c-1ab7-47e5-8de3-511a3344bbb0"
      unitRef="usd">-133000000</us-gaap:IncomeTaxExpenseBenefit>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfNzg1_c1293aac-9365-4e64-a0a3-f1de3b4e98bf"
      unitRef="usd">-105000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfODU0_2e1cdf57-a248-4c73-990c-42a4ea349fd6"
      unitRef="usd">-63000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTY0OTI2NzQ0ODU1OA_ad898e0f-19c4-44f1-809b-80fac2be12ed"
      unitRef="usd">-36000000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfOTMw_b6374249-8aee-439c-b59c-c9d8ecbb141c"
      unitRef="usd">-10000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTA3MQ_0bdce8de-d85f-467f-86e9-48f38ed8ae49"
      unitRef="usd">-7000000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTE0MA_1632dfa8-ad74-4309-beb8-fc962dcbddc9"
      unitRef="usd">11000000</bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTIxNA_66dedf89-eee9-4ee8-a6bf-32c2bcb94e48"
      unitRef="usd">-28000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTMxNA_df99febe-8bab-45a9-a639-a2424b6db713"
      unitRef="usd">-101000000</us-gaap:IncomeTaxExpenseBenefit>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTMzNQ_9e13e0b7-174f-4280-96e4-43b8335c2ee5"
      unitRef="usd">-46000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTQwNA_d4b8fe4c-0970-49cf-855b-b5aa02da04de"
      unitRef="usd">-32000000</bhc:EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTU0OQ_add6c00c-996c-4725-9617-ee30e2c9522a"
      unitRef="usd">13000000</bhc:EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTYyMw_3a59639c-ef80-4be5-96be-19d7b44b9e57"
      unitRef="usd">1000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTcwNg_f1f6925f-bb08-4e88-b2d0-0b1c2e064f35"
      unitRef="usd">-55000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMjQ1Ng_02843538-931e-4361-ba63-885aa9afc61a"
      unitRef="usd">2756000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMjQ2Mw_797e9d08-3ba3-4410-aebe-4d75a954bb71"
      unitRef="usd">2831000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bhc:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMTA5OTUxMTYzNDc2Mg_26a322cf-0018-4ed1-996a-85c320c75e96"
      unitRef="usd">-19000000</bhc:EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzUwNg_e8c29c84-e71f-4602-b0a7-c33c750cf20b"
      unitRef="usd">1009000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzUxMw_18cea1cf-e444-4670-83c9-c231b2034ae2"
      unitRef="usd">1002000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzU2MQ_23589fa6-00f5-4a85-b03a-ea93c468fa14"
      unitRef="usd">51000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i6f36fa5d62a24709bc859aad4a3e7e82_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzU2OA_b39c4cc1-d023-438e-aa52-93c7383f0fc0"
      unitRef="usd">45000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzY2MQ_0a093e51-772f-40ab-b6a0-18930d726871"
      unitRef="usd">363000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY184OC9mcmFnOmZkZTg3OWNlMmFkYTQ5ZTc4ZGE0ZmFlZmUwNjgyZjZiL3RleHRyZWdpb246ZmRlODc5Y2UyYWRhNDllNzhkYTRmYWVmZTA2ODJmNmJfMzg2Nw_0a7622f9-2be2-4534-9a3b-ff0c74167aed"
      unitRef="usd">141000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTIwMQ_52168956-0db5-45f8-a70b-27cf5d50d3db">EARNINGS (LOSS) PER SHARE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted effect of stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Earnings (loss) per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September 30, 2020 and the three and nine months ended September 30, 2019, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive.  The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,144,000 common shares for the nine months ended September 30, 2020, and approximately 4,453,000 and 4,589,000 common shares for the three and nine months September 30, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September 30, 2020, time-based RSUs, performance-based RSUs and stock options to purchase approximately 10,489,000 and 10,604,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2019, time-based RSUs, performance-based RSUs and stock options to purchase approximately 5,363,000 and 5,363,000 common shares, respectively were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTIxNA_2fbb5d75-16f8-4fea-993c-e8043619daf5">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted effect of stock options and RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Earnings (loss) per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMi0xLTEtMS0w_1110133a-ffd4-4eca-b168-868b79b0053c"
      unitRef="usd">71000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMi0zLTEtMS0w_3d2da526-41cd-43ee-aa97-166d8ecf79e9"
      unitRef="usd">-49000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMi01LTEtMS0w_4fc29f87-e041-4050-82e2-764189962967"
      unitRef="usd">-407000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMi03LTEtMS0w_b879c12c-1fa7-4320-8293-ad7c366811a7"
      unitRef="usd">-272000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNC0xLTEtMS00NDQ4_5db1c38a-5b69-4381-99a3-655b918ba269"
      unitRef="shares">355600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNC0zLTEtMS00NDQ4_10fe2e1b-ea77-409a-9289-0885eee2dc43"
      unitRef="shares">352400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNC01LTEtMS00NDQ4_56dbbc9c-beb0-4411-a7f8-2b0805614bfe"
      unitRef="shares">354700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNC03LTEtMS00NDQ4_d4b3ace7-b112-4c57-934c-f395649beebf"
      unitRef="shares">351900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMy0xLTEtMS0w_3faaf2bb-c228-4e14-a8c3-8255359ac6e6"
      unitRef="shares">2200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMy0zLTEtMS0w_2f1d2d50-6d50-4413-b6de-89043eff9b18"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMy01LTEtMS0w_bdd2923e-41c7-448d-b6a5-9971dece40ce"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMy03LTEtMS0w_f68b79a3-a85f-4180-a17e-a464630e8351"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNi0xLTEtMS00NDUx_f5e1a83d-8317-4826-9301-fa0d9d171666"
      unitRef="shares">357800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNi0zLTEtMS00NDUx_ff73c632-5e4f-4c41-b9ac-f6de18a04c87"
      unitRef="shares">352400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNi01LTEtMS00NDUx_46f268a8-ce17-4e73-93aa-a75b5120b0b2"
      unitRef="shares">354700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfNi03LTEtMS00NDUx_b2ec8888-54eb-4c9a-a14d-4065fdbff4d7"
      unitRef="shares">351900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfOS0xLTEtMS00NDY3_f2c4b984-4702-478e-bb77-f2b4767b2de2"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfOS0zLTEtMS00NDY3_c8b027cc-696c-434d-9373-2511a36c8436"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfOS01LTEtMS00NDY3_f35c9ab4-c4bd-4b8a-9313-c7cba7a65944"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfOS03LTEtMS00NDY3_7c6f0f80-69a4-4d07-9f86-4c57f7f8f475"
      unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMTAtMS0xLTEtNDQ2Nw_d49b7381-dfed-463e-a45c-50952168b0f5"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMTAtMy0xLTEtNDQ2Nw_e4c59e56-5fce-4c80-8bf3-c734919ad25e"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMTAtNS0xLTEtNDQ2Nw_eba0cb46-7d86-4ce3-9397-9624fb78dd8a"
      unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RhYmxlOjJiZDJlNmE4MjU4MjRiMTc5OTY1NWZkNTY1YWQ0YzM1L3RhYmxlcmFuZ2U6MmJkMmU2YTgyNTgyNGIxNzk5NjU1ZmQ1NjVhZDRjMzVfMTAtNy0xLTEtNDQ2Nw_f3bbbb2b-739b-4551-9bfc-724dea74734d"
      unitRef="usdPerShare">-0.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie07c162ca742405c98233c58abdd8aac_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTA5OTUxMTYyOTM1Mg_c4551944-3003-4c2a-9fbf-43c54e2486c5"
      unitRef="shares">3144000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1dd54993dd634b0e82dc598e88544ff5_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTA5OTUxMTYyOTM0MQ_06e375a5-02cf-466c-b676-0a303bbc472d"
      unitRef="shares">4453000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i762b42904b7d4c47b7d9c94632f27fd6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfNTY0_47283e01-fe76-443c-a3a9-21fa051d41e0"
      unitRef="shares">4589000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i70173b7267ae47adacd4ad3ca61345b6_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfNzE2_c827c1aa-1d65-454c-b038-fddcb0eda6ce"
      unitRef="shares">10489000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibcfc0abb71864f4a8d26e6f9694c6f5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfNzIz_ea967be3-e585-4e20-a962-e4370dbecb7a"
      unitRef="shares">10604000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i563b2181888e4e4ebcc9b80b5cc2f344_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTAxMw_c66d45aa-7fe2-4335-aa77-2043dcc84132"
      unitRef="shares">5363000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6b05369642d5468d80a1713347b981b1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185MS9mcmFnOjNiNzhlNzIxNjZmYTRlYmY5YmQyNjg3ZjNlYjg4MTYwL3RleHRyZWdpb246M2I3OGU3MjE2NmZhNGViZjliZDI2ODdmM2ViODgxNjBfMTAyMA_80a7c0d0-b917-407c-84e5-d12e29204473"
      unitRef="shares">5363000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNDM5ODA0NjU3NTg1OA_e41dcccd-81ee-470f-9626-41573c69fb3e">LEGAL PROCEEDINGS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued.  As of September 30, 2020, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,462 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome -of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#x2019;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental and Regulatory Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#x201c;Governmental and Regulatory Inquiries&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. These matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney's Office for the District of Massachusetts - re Arestin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including related support services, and other matters.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is cooperating with this investigation.  The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - Opt-Out Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval.  Once approved by the court, the settlement will resolve and discharge all claims against the Company in the class action.  As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. On January 27, 2020 the court preliminarily approved the settlement. A final settlement approval hearing was held on May 27, 2020 and the settlement remains subject to final court approval. In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payment is being paid in accordance with the payment schedule outlined in the settlement agreement. The opt-out litigations discussed below remain ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#x201c;Timber Hill&#x201d;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#x2019;s common stock during the period January 4, 2013 through August 11, 2016.  On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658).  On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#x2019;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. In addition to the matters captioned Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (&#x201c;Maverick&#x201d;), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (&#x201c;Templeton&#x201d;), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (&#x201c;USAA&#x201d;), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (&#x201c;GIC&#x201d;), these actions were captioned previously in the Company&#x2019;s Annual Report on Form 10K for the year ended December 31, 2019, filed on February 19, 2020. Seven of the thirty-seven opt out actions have been dismissed; and the total number of remaining opt out actions pending in the District of New Jersey is thirty actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case.  On September 10, 2019, the Court granted defendants&#x2019; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#x201c;Aly&#x201d;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions.  On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, has been discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding.  On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#x2019;s auditors and the action was dismissed as against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements.  As part of the settlement, the Company and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement agreement is subject to court approval. If court approval is granted, the Catucci action will be dismissed against the Company, its current and former directors and officers, its underwriters and its insurers. The hearing to approve the settlement is scheduled for November 16, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action.  On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights (&#x201c;CalSTRS&#x201d;) served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#x2019; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#x201c;price appreciation credits&#x201d; in respect of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt; during the period covered by the claims. The Company has notified CalSTRS of its intention to oppose the amendments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RICO Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#x201c;RICO&#x201d;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#x2019;s consent to renew the prescription.&#160; The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;A special master appointed by the Court has recommended that the Company&#x2019;s motion to dismiss be denied, but a final decision is still pending with the Court. The Company believes these claims are without merit and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#x201c;Securities and RICO Class Actions and Related Matters&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. Such matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;complaint was filed, captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Case No. 19-cv-17833). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plaintiffs assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor. The consolidated complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases are based on the same purported conduct that is at issue in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Valeant Pharmaceuticals International, Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint.  Briefing on this motion concluded on August 3, 2020. The Company disputes these claims and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Coverage Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16.&#160; The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).&#160; In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in&#160;In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and certain of the investigations described above (under the 2015-2016 coverage period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hound Partners Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act.  This matter is currently stayed pending the completion of discovery in one of the above-noted federal opt-out cases. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#x201c;Company&#x201d;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020.  The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020.  The Company&#x2019;s motion to dismiss the insurer plaintiff&#x2019;s amended complaint is pending. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These actions, five (5) of which remain pending, have been consolidated and coordinated in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA. The lawsuits allege that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so. The complaints allege that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs seek damages under federal antitrust laws for claims based on direct purchases. The insurer plaintiff also seeks damages and equitable relief under various state laws for claims based on indirect purchases. The Company disputes the claims against it and intends to vigorously defend these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pricing Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#x201c;Oceanside&#x201d;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#x201c;Bausch Health US&#x201d;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#x201c;Bausch Health Americas&#x201d;) (for the purposes of this subsection, collectively, the &#x201c;Company&#x201d;), are defendants in multidistrict antitrust litigation (&#x201c;MDL&#x201d;) entitled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Generic Pharmaceuticals Pricing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16-MD-2724).  The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#x2019;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals.  The initial lawsuit to which the Company was added as a defendant in June 2018 was filed by a putative class of direct purchaser plaintiffs.  In December 2018, certain direct purchaser plaintiffs that had opted out of this putative class filed an amended complaint in the MDL that added the Company, alleging similar claims as the direct purchaser plaintiffs&#x2019; putative class action complaint.  In February 2019, the Company filed a motion to dismiss the individual claims brought against it and that motion remains pending.  In October 2019, an end payer plaintiff that had opted out of the putative end payer class filed a complaint against the Company in the Eastern District of Pennsylvania alleging similar claims.  In December 2019, end payer opt-out complaints also were filed against the Company in the Eastern District of Pennsylvania and in the Northern District of California.  In December 2019, separate putative class action complaints were filed against the Company in the Eastern District of Pennsylvania by end payer and indirect reseller plaintiffs.  In February 2020, a putative class action complaint was filed against the Company in the Eastern District of Pennsylvania by direct purchaser plaintiffs.  In June 2020, an opt-out complaint raising both direct purchaser and end payer claims was filed against the Company in the Eastern District of Pennsylvania.  Also in June 2020, State Attorneys General filed a Complaint against the Company in the District of Connecticut. In July 2020, a direct purchaser opt-out complaint was filed against the Company in the Eastern District of Pennsylvania. In August 2020, a complaint was filed against the Company by Suffolk County, New York in the Eastern District of New York.  In September 2020, a direct purchaser opt-out complaint was filed against the Company in the Eastern District of Pennsylvania.  The cases have been or will be consolidated into the MDL.  There are also additional, separate complaints by other plaintiffs which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant.  In July 2019, 87 health plans commenced an action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed and the case has been put in deferred status.  In May 2020, seven health plans commenced an additional action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed.  The Company disputes the claims against it and continues to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation/Paragraph IV Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Relistor&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Uceris&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 550mg, Plenvu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States and Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in Canada, or other similar suits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (&#x201c;Perrigo&#x201d;), in which Perrigo asserted that certain U.S. patents, each of which is listed in the U.S.&#160;Food and Drug Administration's (the "FDA") Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo&#x2019;s generic lotion, for which an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) has been filed by Perrigo.  On August 28, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described below, regarding Perrigo&#x2019;s ANDA for generic Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related patents and will vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo, in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo&#x2019;s generic halobetasol propionate lotion, for which an ANDA has been filed by Perrigo.  On May 1, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described above, regarding Perrigo&#x2019;s ANDA for generic Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2020, the Company and Alfasigma S.p.A. ("Alfasigma") received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#x201c;Norwich&#x201d;), in which Norwich asserted that the U.S. patents listed in the FDA's Orange &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#x2019;s generic rifaximin tablets, 550 mg, for which an ANDA has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#x2019;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of Norwich&#x2019;s ANDA for rifaximin tablets, 550 mg. Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is protected by 23 patents covering the composition of matter and the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. The Company remains confident in the strength of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and will continue to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, the Company and Alfasigma commenced litigation against Sun Pharmaceutical Industries Ltd. (&#x201c;Sun&#x201d;), alleging patent infringement by Sun&#x2019;s filing of its ANDA for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#x2019;s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#x2019;s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) and all intellectual property protecting Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) 200 mg and 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent &amp;amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution.&#160; IPR challenges have been brought against patents covering the Company's branded pharmaceutical products.&#160; For example, following Acrux DDS&#x2019;s IPR petition, the U.S. Patent and Trial Appeal Board ("PTAB"), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;continues to be covered by eleven other Orange Book-listed patents owned by the Company and its licensor, which expire in the years 2028 through 2035.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain proceedings or actions as described under &#x201c;Product Liability&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. These matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Products Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; body powder product acquired in September 2012 from Johnson &amp;amp; Johnson; due to dismissals, only twelve (12) of such product liability suits currently remain pending. Potential liability (including its attorneys&#x2019; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp;amp; Johnson owed to the Company, and legal fees and costs will be paid by Johnson &amp;amp; Johnson. Ten of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the plaintiffs to develop ovarian cancer or mesothelioma. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages.  The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#x2019; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp;amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp;amp; Johnson&#x2019;s Baby Powder or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.  The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. In accordance with the indemnification agreement, Johnson &amp;amp; Johnson will continue to vigorously defend the Company in each of the remaining actions that are not voluntarily dismissed or subject to a grant of summary judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Proposition 65 Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Graham v. Bausch Health Companies, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp;amp; Johnson (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gutierrez, et al. v. Johnson &amp;amp; Johnson, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#x2019; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted.  In August 2020, Plaintiffs filed the Fifth Amended Complaint and the Company&#x2019;s motion to dismiss that complaint is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Consumer Protection Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp;amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower&#xae; and its alleged causal link to mesothelioma and other cancers.  In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US expects to file its Answer in November 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As referenced above, during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain proceedings or actions as described under &#x201c;General Civil Actions&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019), filed with the SEC on February 19, 2020. These matters include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Doctors Allergy Formula Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Doctors Allergy Formula, LLC (&#x201c;Doctors Allergy&#x201d;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23 million. The Company has asserted counterclaims against Doctors Allergy.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Former Salix CEO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief.  The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd.  Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Completed or Dormant Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since July 1, 2020 or the Company anticipates that no further material activity will take place with respect thereto, or the matters have been dormant for several quarters. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;SEC Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in November 2015, the Company received from the staff of the Los Angeles Regional Office of the SEC ("the Staff") subpoenas for documents, as well as various document, testimony and interview requests, related to its investigation of the Company, including requests concerning the Company's former relationship with Philidor Rx Services, LLC ("Philidor"), its accounting practices and policies, its public disclosures and other matters. On March 27, 2020, the Staff  issued a Wells Notice informing the Company that they had reached a preliminary determination to recommend that the SEC bring charges against the Company for violating the federal securities laws as a result of SEC filings and other statements made by Valeant and its former executives in 2014-2015 concerning Philidor, as well as other accounting and disclosure matters, including the Company&#x2019;s disclosure of certain price appreciation credits in 2015 - 2016. The Company has entered into a settlement with the SEC that has resolved all allegations by the SEC against the Company. Under the terms of the settlement, the Company neither admitted nor denied the SEC&#x2019;s allegations and agreed to pay a $45&#160;million civil monetary penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AMF Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 12, 2016, the Company received a letter from the Autorit&#xe9; des march&#xe9;s financiers (the &#x201c;AMF&#x201d;) requesting documents concerning the work of the Company&#x2019;s ad hoc committee of independent directors, the Company&#x2019;s former relationship with Philidor, the Company's accounting practices and policies and other matters. In July 2018, the Company was advised by the AMF that it had issued a formal investigation order against it. On September 30, 2020, the AMF confirmed that it had closed its investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the State of Texas&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 27, 2014, the State of Texas served Bausch &amp;amp; Lomb Incorporated (&#x201c;B&amp;amp;L Inc.&#x201d;) with a Civil Investigative Demand (&#x201c;CID&#x201d;) concerning various price reporting matters relating to the State's Medicaid program and the amounts the State paid in reimbursement for B&amp;amp;L products for the period from 1995 to the date of the CID.&#160; B&amp;amp;L Inc. and the State agreed to settle the matter for $10 million. The Company made the payment on April 1, 2020. On July 1, 2020, the State moved to dismiss the case by filing a notice that it was taking a nonsuit, with prejudice to refiling, effective immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney's Office for the District of Massachusetts regarding patient assistance and pricing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015 and June 2016, the Company received two subpoenas from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents and witness interviews with respect to the Company&#x2019;s patient assistance programs and contributions to patient assistance organizations that provide financial assistance to Medicare patients taking products sold by the Company, and the Company&#x2019;s pricing of its products.  The Company is cooperating with this investigation. There has been no material activity for several quarters on the part of the Company with respect to this matter nor has the Company had recent contact from the U.S. Attorney's Office for the District of Massachusetts with respect to this matter. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney's Office for the Southern District of New York&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the Southern District of New York, requesting materials including documents and witness interviews with respect to the Company&#x2019;s patient assistance programs; its former relationship with Philidor and other pharmacies; the Company&#x2019;s accounting treatment for sales by specialty pharmacies; information provided to the Centers for Medicare and Medicaid Services; the Company&#x2019;s pricing (including discounts and rebates), marketing and distribution of its products; the Company&#x2019;s compliance program; and employee compensation. The Company is cooperating with this investigation. There has been no material activity for several quarters on the part of the Company with respect to this matter. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="i9da4fed668814346810326af9b4d6598_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTM2Nw_1e5b6ddd-f6f5-4e27-a335-194f12ac3b99"
      unitRef="usd">1462000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i5aaed5342aab4e6ab0cdebeb807e227b_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzQ5Mg_c3d805c5-6d22-4aa0-933f-c31dbe66ec0d"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i5aaed5342aab4e6ab0cdebeb807e227b_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNDAzMw_0fc3c455-b967-4962-9c29-d635662756b2"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i7907ded04dab4554a0ef907fa261b6f7_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNDMzMw_e8dc9a06-f9d4-40dd-854f-86ea8b9534db"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNjM2MQ_6130fb1d-8a33-43be-b5b7-a82cde008a88"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNzI4MQ_db6538f2-cf08-4f6f-b5df-0283a0c0a3e1"
      unitRef="case">7</us-gaap:LossContingencyClaimsDismissedNumber>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNzI5MQ_6130fb1d-8a33-43be-b5b7-a82cde008a88"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending
      contextRef="i5ea193d6dfe242cdb3e2ef0e30e0630f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNzQyMg_c76cca73-72e5-4f1e-bfba-95f65b2cf4fc"
      unitRef="group">30</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i9761d415100240bda346f87cf5e43c87_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfOTMyNQ_b6b35997-b999-468b-819e-b0690f8b52d4"
      unitRef="case">6</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNewClaimsFiledButNotYetServedNumber
      contextRef="if22f2ae279114a87892281886f95c6b6_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfOTU0Mw_9012afea-0f0a-44cc-be02-2e0e6a7a61bb"
      unitRef="action">2</bhc:LossContingencyNewClaimsFiledButNotYetServedNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="id21158059b994e63a17e72acde64ae62_D20200804-20200804"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTA5NjE_d6dca385-4f86-4aa6-ab5c-7257eac07a22"
      unitRef="cad">94000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i15509ff699a54e30814d181db390b519_I20190215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTIzODQ_a0a8caab-17e5-476d-b431-0a3294a9607f"
      unitRef="entity">1</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ibf179bff49a0406f8a4e9ebf6c739aa8_D20160527-20160916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTA5OTUxMTY3NTgwMw_018e5056-3401-403a-8693-860b3ba62168"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits
      contextRef="if4b754682f144667ad815ed4518db769_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTM3MTI_94bff517-f26b-476e-a5ae-2460be50e9bb"
      unitRef="action">2</bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits>
    <bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits
      contextRef="iee5b12e58e9e44f8ac5eb07d4df04f45_I20190913"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTM3MTI_b5942670-bed8-45fc-867b-49e71dc98bb8"
      unitRef="action">2</bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits>
    <bhc:LossContingencyNumberOfInsurancePolicyPeriods
      contextRef="ideecfb512d4a4ea28fd5ec735471c964_D20171207-20171207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTU4NDk_33831d09-c440-4628-a0bf-e475219ab88c"
      unitRef="insurance_policy_period">2</bhc:LossContingencyNumberOfInsurancePolicyPeriods>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ic882bdf321904c1a8e0bb5f1007fe242_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTg4Mzk_78108d12-1162-4ba7-a784-4b2070909b60"
      unitRef="case">8</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i45d3c5867e5e41f8914f1ce2d2dbfc1e_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTg4ODM_607fe60c-215f-4619-8ae6-3ebb0958b2ea"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i69e5ff05a4c0418eb2417e345fc2103d_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTkyNzc_3abeec3c-ecb0-44c0-9816-c9d34b4f96c2"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="iab043430936d464bb3fafd27f4d9e799_D20191125-20191125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTk2NzA_e1af007f-6358-41a3-99c8-41aba6b2e8fb"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib845c8cc5de943d88c90123be7710ee5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMTA5OTUxMTY3OTg4OA_696f7a1f-5f64-4a07-9a89-f1004b96657a"
      unitRef="case">5</us-gaap:LossContingencyPendingClaimsNumber>
    <bhc:LossContingencyNumberOfHealthPlansFiledLawsuits
      contextRef="i5e0b356ae3324301ab3aeacbefbdc8b4_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMjM3ODY_af719e76-ef04-417a-bd08-19ae9470e53d"
      unitRef="healthplan">87</bhc:LossContingencyNumberOfHealthPlansFiledLawsuits>
    <bhc:LossContingencyNumberOfHealthPlansFiledLawsuits
      contextRef="i2988c46f79404f97bf0bb7d6d8a49295_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMjQwNDg_3371796d-58ce-431a-b422-3b17d347ec9e"
      unitRef="healthplan">7</bhc:LossContingencyNumberOfHealthPlansFiledLawsuits>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ia09727ee9461493e9f4e2df94a1f1591_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzEwMTI_9098c11e-2995-40f6-9704-98338166d2e7"
      unitRef="case">12</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i4e734b47f6ad4ad984cd62d97f81a208_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzcxNTA_2fee9498-91b8-491a-a953-e29dcb758bc7"
      unitRef="usd">23000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="id819c010b7eb43699a500c0115cc5647_D20190128-20190128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzc1MDk_132a575e-310d-4613-bcc1-02d96ebf29fa"
      unitRef="usd">30000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i7ce77ea687ee470cace2bc7c9451c86d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfMzk5NDk_eb90aea5-b9d9-4f19-a5ff-7f4a795fc283"
      unitRef="usd">45000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i8cf776ee426f4162b6f648f87bccf843_D20200401-20200401"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY185NC9mcmFnOjBlZWUyZDQwMmQyYjQyNjI4MjE3NzFmODlkNzhjYmQ2L3RleHRyZWdpb246MGVlZTJkNDAyZDJiNDI2MjgyMTc3MWY4OWQ3OGNiZDZfNDA4Mzc_c5ae58c0-750e-4618-b450-96fac91ace7f"
      unitRef="usd">10000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyOTE_9748f319-ed92-4c8f-95ff-1e4702512400">SEGMENT INFORMATION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Chief Executive Officer ("CEO"), who is the Company&#x2019;s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company&#x2019;s CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports.&#160;The Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a brief description of the Company&#x2019;s segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Bausch + Lomb/International segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Salix segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales in the U.S. of GI products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Ortho Dermatologics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Diversified Products segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Acquired in-process research and development costs, Restructuring, integration and separation costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the planned separation of its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun addressing the internal organizational design and structure of the new entity, which it anticipates having substantially complete in late 2021. As of the date of the issuance of these financial statements, these matters are in the planning phase. In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021.  Accordingly, the Company expects to begin reporting its segment results to reflect the proposed realignment of its operating segments on a retrospective basis beginning with its first quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Revenues and Profits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb/International&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb/International&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration and separation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before (provision for) benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues by Segment and Product Category &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The top ten products for the nine months ended September 30, 2020 and 2019 represented 41% and 38% of total revenues for the nine months ended September 30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyNjU_aba9a717-2891-4ea9-9fb5-95b55c14dbb8">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb/International&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb/International&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration and separation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,221)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before (provision for) benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i897313242ab641dc9046ace39af16263_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzMtMS0xLTEtMA_5530b3d3-fb29-4e18-b9ba-07b07ed23efd"
      unitRef="usd">1169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id12cb1b6cda347f9967513c7742fcb23_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzMtMy0xLTEtMA_a5a39e46-572e-4fcc-9ea6-173c7184eda0"
      unitRef="usd">1175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80d7bbb8cfa04946a18339b2648304fd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzMtNS0xLTEtMA_b759965b-50b2-46b4-80c0-ba4381bad822"
      unitRef="usd">3166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d197803d96f4ffcbd4159fa39ebc261_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzMtNy0xLTEtMA_95617793-0138-416a-836d-f3786114de6a"
      unitRef="usd">3501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7932c3cbe2342548eee1258aa49347e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzQtMS0xLTEtMA_7d54586f-2451-45fb-a7d9-7a3386a44ad9"
      unitRef="usd">496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idafc86557cbe4d14b4c893a64ca76cf9_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzQtMy0xLTEtMA_3113684e-18b9-45a6-b710-7068db71cf3b"
      unitRef="usd">551000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7fe2b7d367f4dae834989f4487131d7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzQtNS0xLTEtMA_7b493132-8065-47bf-9e1b-36c9f2f7d10b"
      unitRef="usd">1377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74f4f9fe18664f5683fa137fff600592_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzQtNy0xLTEtMA_305e2ad7-4d46-4e65-9b68-1558f83273dc"
      unitRef="usd">1505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9630fad3411d4ecdbb4e6cecfef710ee_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzUtMS0xLTEtMA_3ecc13ee-b994-4186-87e9-ba3a103c42c6"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2fff547485ae43d2968ff0cc7028a326_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzUtMy0xLTEtMA_7bca7fdd-63fa-4f6e-915d-11aa39b87807"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i353913d5fc9242c18667b11e98757190_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzUtNS0xLTEtMA_6cd1edad-654e-489c-807b-2d93b02cb1b3"
      unitRef="usd">393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34a7b69b1fdb4a07b595627842521754_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzUtNy0xLTEtMA_bc411ab2-4bbf-4725-a9b7-fa677b6d8af7"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie96a2f7723254ec5a9f11c4c934d4889_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzYtMS0xLTEtMA_66aad1f8-f505-44df-a125-7d0161380d28"
      unitRef="usd">329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9c0c48d8f5d49e0a298cb9e6244ac8a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzYtMy0xLTEtMA_aa666936-0883-4f0e-9e0e-183487650480"
      unitRef="usd">336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i945442a1ab3a4f6fb3811c26a1bab0bc_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzYtNS0xLTEtMA_f3948e85-1452-4ce6-afc1-ad1c866a38cb"
      unitRef="usd">878000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i961d00fe6e394e0097042fdf55f1f75b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzYtNy0xLTEtMA_58c7c77d-30d7-4100-b4bc-57e65985ea3c"
      unitRef="usd">964000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8298bc44b8d4fa9a438061d2df01a40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzctMS0xLTEtMA_46dd45f1-e414-4cb1-859c-d5e222c0b1f5"
      unitRef="usd">2138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i992e52a4d5fb436e95fb7cfa4b72df3d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzctMy0xLTEtMA_06b59886-0eb0-4303-9114-5540cfae742a"
      unitRef="usd">2209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c51a36d127d44c9946fde415735fe2c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzctNS0xLTEtMA_d8d310fa-4b22-432e-98b2-de3e56f4b894"
      unitRef="usd">5814000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5c46aa3b1cd4b5789f0ca5a453ed7b5_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzctNy0xLTEtMA_b5983dbe-96c1-4f29-945c-99b72847b067"
      unitRef="usd">6377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i897313242ab641dc9046ace39af16263_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEwLTEtMS0xLTA_ae90b1d7-d30e-4679-9417-a97304946424"
      unitRef="usd">336000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id12cb1b6cda347f9967513c7742fcb23_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEwLTMtMS0xLTA_c8f66e6d-ad70-49ba-80fa-b5083e1c597d"
      unitRef="usd">333000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i80d7bbb8cfa04946a18339b2648304fd_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEwLTUtMS0xLTA_d137f316-5249-4077-ba58-be39b2995231"
      unitRef="usd">830000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3d197803d96f4ffcbd4159fa39ebc261_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEwLTctMS0xLTA_9f043741-7e26-4ebf-a70b-7c7ebd1041b4"
      unitRef="usd">989000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic7932c3cbe2342548eee1258aa49347e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzExLTEtMS0xLTA_8bc56fe7-cce8-4838-86fb-6ccf41c26b77"
      unitRef="usd">360000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idafc86557cbe4d14b4c893a64ca76cf9_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzExLTMtMS0xLTA_2f932a3b-a18b-4b3b-9746-3b89e9a12cd2"
      unitRef="usd">375000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie7fe2b7d367f4dae834989f4487131d7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzExLTUtMS0xLTA_77eae22e-0927-4f1d-b6af-0f4c207c1f2e"
      unitRef="usd">968000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i74f4f9fe18664f5683fa137fff600592_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzExLTctMS0xLTA_8119a27a-34e4-45c5-aee5-1a815564646c"
      unitRef="usd">995000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9630fad3411d4ecdbb4e6cecfef710ee_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEyLTEtMS0xLTA_21727fa8-d9ff-4ef4-b5ad-ce859c01d8ac"
      unitRef="usd">70000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2fff547485ae43d2968ff0cc7028a326_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEyLTMtMS0xLTA_4e5b69ca-48b1-4ae8-b79b-8d8a3ee30f82"
      unitRef="usd">58000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i353913d5fc9242c18667b11e98757190_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEyLTUtMS0xLTA_e30cd823-cb3d-4d40-8d13-c57e0743111a"
      unitRef="usd">156000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i34a7b69b1fdb4a07b595627842521754_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEyLTctMS0xLTA_7571c6bf-7d26-4eaa-8199-ae672e5f45db"
      unitRef="usd">156000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie96a2f7723254ec5a9f11c4c934d4889_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEzLTEtMS0xLTA_07cf0fa9-0d41-4c77-837a-9a5e1b243880"
      unitRef="usd">248000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib9c0c48d8f5d49e0a298cb9e6244ac8a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEzLTMtMS0xLTA_7ef62a57-2a3a-4511-8993-2e27b18d01c2"
      unitRef="usd">246000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i945442a1ab3a4f6fb3811c26a1bab0bc_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEzLTUtMS0xLTA_01d60a51-3d82-409f-a0c6-c078a8e597c3"
      unitRef="usd">634000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i961d00fe6e394e0097042fdf55f1f75b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzEzLTctMS0xLTA_c5c6b65d-f081-46dd-a79c-ec3658fb6364"
      unitRef="usd">714000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if8298bc44b8d4fa9a438061d2df01a40_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE0LTEtMS0xLTA_13f94505-f8ba-485f-a2d4-6787e0b83aa4"
      unitRef="usd">1014000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i992e52a4d5fb436e95fb7cfa4b72df3d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE0LTMtMS0xLTA_a28b96b0-e140-450d-b2e5-1aef28ae6b38"
      unitRef="usd">1012000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9c51a36d127d44c9946fde415735fe2c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE0LTUtMS0xLTA_8e603057-a419-4887-81e9-09537fba84d2"
      unitRef="usd">2588000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id5c46aa3b1cd4b5789f0ca5a453ed7b5_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE0LTctMS0xLTA_86235591-8f9a-4c64-bd23-e5a13911f5b0"
      unitRef="usd">2854000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i73f73a15d2634d3a8c0cca7a35b9ff85_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE1LTEtMS0xLTA_b2c4bcba-a7dc-4975-b7f0-ff8f28f186eb"
      unitRef="usd">-141000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9fcb52bae97844d694512c2bb87bdf17_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE1LTMtMS0xLTA_4e95077f-8586-4f60-ad0e-145bcd9fc993"
      unitRef="usd">-158000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i85eae108232242838086f4642eb70b08_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE1LTUtMS0xLTA_4241e9d4-9bc8-47e8-a0b2-11c1c727f03f"
      unitRef="usd">-442000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i84c3fed40d05492ba7b7087a16d03b78_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE1LTctMS0xLTA_3a405689-e805-4578-8d6e-38852b0b6d2c"
      unitRef="usd">-435000000</us-gaap:OperatingIncomeLoss>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE2LTEtMS0xLTA_d0466226-82f4-405b-8b39-46125f007f27"
      unitRef="usd">391000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE2LTMtMS0xLTA_cb3cfc1b-1693-4d51-b362-10a241aa5b0b"
      unitRef="usd">475000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE2LTUtMS0xLTA_874e6aa0-eeac-403d-82ce-e315838bbe45"
      unitRef="usd">1263000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE2LTctMS0xLTA_083bcdc5-8b0c-45f6-a6b7-edd2ad9bceb3"
      unitRef="usd">1452000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE3LTEtMS0xLTA_00b223a0-1d15-46f0-b648-546a659c64bc"
      unitRef="usd">2000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE3LTMtMS0xLTA_11d5c681-475c-493d-be96-d54dbde83076"
      unitRef="usd">33000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE3LTUtMS0xLTA_521afbbd-34e6-4ff5-a186-4235ca9383dc"
      unitRef="usd">17000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE3LTctMS0xLTA_117afb85-fff4-4e5f-977e-75906726fae5"
      unitRef="usd">49000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE4LTEtMS0xLTA_cf1f41b7-c5f7-4055-85cf-2bb448abcbf0"
      unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE4LTMtMS0xLTA_f97a6227-79d5-4e76-bb5b-e8006a13d174"
      unitRef="usd">4000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE4LTUtMS0xLTA_8c330888-6eed-4306-ae75-4860900f0c2b"
      unitRef="usd">13000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE4LTctMS0xLTA_9767b429-e434-44cc-b539-353e029c20b3"
      unitRef="usd">28000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE5LTEtMS0xLTA_87dfd17c-1468-4bfb-ab95-8da9256c4766"
      unitRef="usd">-2000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE5LTMtMS0xLTA_b14c19c3-8daf-4904-8d7a-4e01b5b13b5b"
      unitRef="usd">-3000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE5LTUtMS0xLTA_f6275f9a-fadd-4f14-9c7b-8311ca223c11"
      unitRef="usd">-26000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzE5LTctMS0xLTA_ca34344c-9f7b-4696-9768-990bc6dcdf88"
      unitRef="usd">-2000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIwLTEtMS0xLTA_0455468a-45de-4688-ad04-0c8d622d47e5"
      unitRef="usd">-16000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIwLTMtMS0xLTA_c1f9f638-ff27-4346-9814-9eabe54e67ab"
      unitRef="usd">-10000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIwLTUtMS0xLTA_cf13a1ee-0dcb-4808-8f53-e31d44cc38d1"
      unitRef="usd">-146000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIwLTctMS0xLTA_b4791451-c7fd-43a7-817f-a7ca7923c4e3"
      unitRef="usd">-15000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIxLTEtMS0xLTA_2f1c14d5-cd73-445b-8f48-32a147530219"
      unitRef="usd">460000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIxLTMtMS0xLTA_b4c871ea-6e69-4d3e-9b52-7ef070a927c8"
      unitRef="usd">329000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIxLTUtMS0xLTA_438a301e-182c-49c8-9a26-9cfc2978fa78"
      unitRef="usd">681000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIxLTctMS0xLTA_bc456c67-56d8-4a03-9142-c5f763ac8bd7"
      unitRef="usd">873000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIyLTEtMS0xLTA_edaa993c-2a90-4440-9d40-cfe7c5cce932"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIyLTMtMS0xLTA_d202a0ec-9cfb-4353-9955-4c935d1d3668"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIyLTUtMS0xLTA_01db22eb-674f-4520-9e2e-220ceeddf569"
      unitRef="usd">11000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIyLTctMS0xLTA_358d65b7-dc0d-463b-91cc-e91e327bd6f7"
      unitRef="usd">9000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestAndDebtExpense
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIzLTEtMS0xLTA_c678cfe1-c810-4bd9-886c-e5ad21679a2b"
      unitRef="usd">374000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIzLTMtMS0xLTA_c3e2018a-8f34-4c03-98f9-c4090a74afd2"
      unitRef="usd">406000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIzLTUtMS0xLTA_49d6dac3-cacb-4082-8975-ee5399c7bf38"
      unitRef="usd">1155000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzIzLTctMS0xLTA_d791219d-6780-4f96-8047-23c4e38a4f92"
      unitRef="usd">1221000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI0LTEtMS0xLTA_4423089e-56f4-45d3-b63d-6661bf2950aa"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI0LTMtMS0xLTA_dbc8e14d-8d4d-496f-a8f8-b7bb0d0e3d5f"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI0LTUtMS0xLTA_f252a8f4-b4e0-4576-b83a-159d454291df"
      unitRef="usd">-51000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI0LTctMS0xLTA_d0ef2cb3-4bab-4eaa-bc6c-57a1daac5926"
      unitRef="usd">-40000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI1LTEtMS0xLTA_d29b6c9e-14ea-4089-8db9-75fd30ff1c32"
      unitRef="usd">-13000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI1LTMtMS0xLTA_020e5fac-9f52-4744-a954-62c5a2b5c7b8"
      unitRef="usd">9000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI1LTUtMS0xLTA_2c06cffb-cbfa-4a53-ab21-b3b7e3df572e"
      unitRef="usd">-26000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI1LTctMS0xLTA_3b5bb004-6892-4490-8ee7-b6e9e8ec0409"
      unitRef="usd">12000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI2LTEtMS0xLTA_15464da8-6223-4291-882a-109cc45f96a7"
      unitRef="usd">75000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI2LTMtMS0xLTA_a14affee-98b0-4d23-b470-563f50170b83"
      unitRef="usd">-66000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI2LTUtMS0xLTA_67f0645f-9ad9-490b-bbbd-9516ecd2d400"
      unitRef="usd">-540000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo0MjMwZjkyNTU5MGM0YTQ5ODI4NDg2MWYwMTBkYTk5NC90YWJsZXJhbmdlOjQyMzBmOTI1NTkwYzRhNDk4Mjg0ODYxZjAxMGRhOTk0XzI2LTctMS0xLTA_8ccdc5b4-86e5-49c2-8b57-b3c533a4ba5c"
      unitRef="usd">-367000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyNzY_dec5e302-084f-461f-be5f-554b0f904f46">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb/ International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief0221b682984fa68ee492bfa59a5d75_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMS0xLTEtMA_8163ec69-e851-478b-86b4-9b93d38ee140"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12293851b1144e018c4c9985157b6af8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMy0xLTEtMA_5ccf53ce-79a6-4b2a-82e3-50036c99138f"
      unitRef="usd">494000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie45707f6b6bd4627847a810f8a92f826_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItNS0xLTEtMA_f5f1dd56-d68e-416c-9226-7f686baeec1c"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51df325c7f5b40f7a71d8a18b3dcdb9d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItNy0xLTEtMA_26a0cc8a-b7ec-4b9d-89ba-d5b949cdf8d2"
      unitRef="usd">217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29ce34cdc90749658459a53d39ce83a0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItOS0xLTEtMA_fcabf783-c010-4a0f-8bae-57ba1d1ccea9"
      unitRef="usd">976000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib99f5f97c68d4eafb2e79dfd4f048b96_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTEtMS0xLTA_9cc88017-4f18-4659-88e6-c2f4e04f869d"
      unitRef="usd">217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i094e6cb87ab042c69be51aa8c8116f04_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTMtMS0xLTA_ee9cba5a-fd26-45d0-90c7-effc6677cd42"
      unitRef="usd">551000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5be2becb71a48feaf9761c4c7541a2f_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTUtMS0xLTA_194743f1-fbf2-4ca6-9088-a14c69451ed3"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib990d0233da244b0972eca21ff43328a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTctMS0xLTA_9233ac27-6bd1-48c8-a4e2-3fe32f58f6f6"
      unitRef="usd">207000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5062980ba6b7479fb407d0f9cd02aa37_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzItMTktMS0xLTA_86ff3409-45d5-44ca-b6df-033f56572d16"
      unitRef="usd">1072000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iead2ba6fee0a4fb5b5d850fb95ea9e74_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMS0xLTEtMA_4bd23bd6-3562-442d-8b5d-df42533f158b"
      unitRef="usd">360000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i314220a4165d4110a6c992a829224748_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMy0xLTEtMA_50cf2d7c-08eb-4cf5-a66b-44a60117034d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id732816e0fe14e848ad4ed7bcec29df9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtNS0xLTEtMA_04c5544b-36e2-4081-9d79-6b496545b628"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7720a5e8447f4e1381a984683f37f801_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtNy0xLTEtMA_bcbc737e-fda1-4a01-91bf-7c0a726f1b26"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31809eee74c441e785284208908b1f6e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtOS0xLTEtMA_dd94f9de-8bca-434f-b0c2-2227aa2c0dbe"
      unitRef="usd">432000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79ac2fb975044cb48922c5f545218179_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTEtMS0xLTA_c2bc9a33-d123-4a1e-a7d1-8447d87c3085"
      unitRef="usd">375000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64afb07c58eb4178b97dc69e29d5361b_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTMtMS0xLTA_2ab2cb18-528a-4a7a-9ebb-1614f7883f27"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7daf0166ae784d4dacd516d2bd1ccfb3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTUtMS0xLTA_c2e00ca0-a16d-4f0b-b552-003bad5d4a56"
      unitRef="usd">46000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icef91f1f0ee3457e970eccecfdf34433_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTctMS0xLTA_95332be5-b18a-48e1-9c50-28ba27bab411"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cd9b71a39574ae1b4eb9b5b3a159df7_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzMtMTktMS0xLTA_8c97adb1-7aab-4364-857b-edb173cc4560"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94726a2e6540441193932a85a2d2cc8e_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMS0xLTEtMA_0b103782-739d-447f-be64-8652d1be4a65"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0e74417efd54c5fb043305c8ecdd0b5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMy0xLTEtMA_4fcaf462-899d-41ac-985a-2effb82f29aa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7132aba1acc24050873b3abeb89f87fd_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtNS0xLTEtMA_aef31675-1bc4-4d91-908e-4499a358e08d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b45b1049375405a9881452df1db8885_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtNy0xLTEtMA_77c6e585-9e12-4529-b375-618766f94385"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1eba4cc97be4881bf868d652d2c87f5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtOS0xLTEtMA_32c31e35-d4f1-4649-b561-82cd46fa7e46"
      unitRef="usd">374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1195d51db05e405381373f1b2ed59c87_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTEtMS0xLTA_9b24366e-a5ef-4c90-a9ba-8e7966eabcbe"
      unitRef="usd">371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7d8c27663374e2881ba2608476c974d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTMtMS0xLTA_fee4190d-5f80-447e-b42e-997306c69907"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i579b7b5f0e22488caa4243c078316934_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTUtMS0xLTA_039c480a-12a0-4784-a98d-2b3594bbe51d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7396b7657687421eb28bc8e668bf24f1_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTctMS0xLTA_0d96abf9-9d9a-41ba-be3c-3ab39c62231d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd8079e095cb462d8a0027725dbbbf9d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzQtMTktMS0xLTA_706ed4c1-3940-47bd-b930-f32b0ce7a121"
      unitRef="usd">371000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28e935d66b524719955d26d4a15f28b7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMS0xLTEtMA_2b8d88b5-1070-4434-9887-301423080e1c"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idda25f4386fa403f9d99a5596c2399a8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMy0xLTEtMA_f4132b34-c409-4bc8-b670-399ee466bd2c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83fe7793dda5457b86b9bdaa7e2b4a3b_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtNS0xLTEtMA_3b7d7b74-2f68-4b70-9a38-980664475d34"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f08c50efaef40919b09f698d45f387f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtNy0xLTEtMA_73c7b07e-d355-41b6-9815-8e240bf06b0f"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic915105196dc4a20b1ba1cd55527b01f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtOS0xLTEtMA_b06e44c9-2145-4e96-b929-8c3c58a16bdc"
      unitRef="usd">329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b4872d17e0e4ba9800e4027b125c7d6_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTEtMS0xLTA_7bbafeb3-7b1e-484e-b2d9-d58ba87bf7dc"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25793ee653304f0aa6306ddf6ef5b8de_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTMtMS0xLTA_12ac7587-c7dd-493f-abb0-7f8c5757d28a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie59b022ef9b644f1996fe90ee1d0db81_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTUtMS0xLTA_26f78bd3-0026-4cab-ab3d-97b90c1cd58b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8648caf684ff4103860761d13f0a4022_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTctMS0xLTA_1c055c60-bf2d-4734-8496-5d4a8c881bf1"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide34d3ab6c14458cbfef1276056d1463_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzUtMTktMS0xLTA_f9f80864-61fa-49be-9ece-10c3a9eca4b6"
      unitRef="usd">316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if93bc6d99c624444a2dd857bc569b178_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMS0xLTEtMA_ed74e05a-1702-4403-8fa6-72630eaba351"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a664e5247e946dc82a303af2757e881_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMy0xLTEtMA_7cc2a994-f7e2-44fd-bf7b-1ffebd2d20d1"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87c11c3e047f45a8adce344026ef9adf_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtNS0xLTEtMA_2e5f467a-9bfb-4ae1-8812-8ce442cbc6d1"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i868cfdaa81514efeb8f0a0de1e553842_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtNy0xLTEtMA_42606f71-0a00-4897-a9a4-d3ade58168e3"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1ed423758174f5d8bebe48cf827f4ad_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtOS0xLTEtMA_8a560660-6081-4b14-a292-3b5366aec1e9"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83c702359f3d476aae3c6070536997d3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTEtMS0xLTA_c238b0ae-3775-4e59-908f-515ba64a321d"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e4dc2eddb6b41afba1498f1b41eb3af_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTMtMS0xLTA_d8c0080d-c8ef-46de-80a5-72c9ab49c180"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a6bfdb0ca114a3a8781da2f91c440dd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTUtMS0xLTA_bb157371-4362-4e14-ab97-043ca5cdcefb"
      unitRef="usd">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f1c56b5e7db49989979d7e8ab238911_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTctMS0xLTA_4024b5fe-2adc-45dd-a156-812016b5b1c4"
      unitRef="usd">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a10616d5c494d258d21007f1d4ffe1d_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzYtMTktMS0xLTA_ec49680c-a0d9-44c3-a36f-9a17c9d67c64"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica0936b4182347c0ba81f792a94fb471_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMS0xLTEtMA_70a211ea-4a05-47f4-a6c9-3f9004a463dd"
      unitRef="usd">1169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c8c78d6fd8848b4959e510c9f80474c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMy0xLTEtMA_4889bd66-a416-44a5-aecf-d535e81fe2f1"
      unitRef="usd">496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i663dfd024395400792b600237c407f71_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctNS0xLTEtMA_39b67a60-2eeb-463e-a33d-085a4b70f955"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bfe83d14ce24791a3d5132de0b09aac_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctNy0xLTEtMA_2b88220e-8d56-4fb0-8f60-35fde374fb0f"
      unitRef="usd">329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctOS0xLTEtMA_6caf8dc5-f1f6-4cca-bc92-33d93bf14d61"
      unitRef="usd">2138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6f9e05033db4fbeadb4c0989ca169b4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTEtMS0xLTA_cafa2d81-e981-4c5c-9503-f2911c615bfd"
      unitRef="usd">1175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57f934afe4f64ccf8f499b8522d5d316_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTMtMS0xLTA_cd77b560-e3d4-40a8-9161-692ac0e7c536"
      unitRef="usd">551000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72cef8d89cc3414c9c3e300be0a5e506_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTUtMS0xLTA_6ff398d6-c589-409e-93b3-6fdb75f0faff"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77e2e17f2af240a08bb7068b4295f5c2_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTctMS0xLTA_ec963003-cd17-428a-8e84-32711c75e8f4"
      unitRef="usd">336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTplMTczNTcxM2Q4Yjc0YTJiYjcyMjA4ZjIyNzI4N2E0Mi90YWJsZXJhbmdlOmUxNzM1NzEzZDhiNzRhMmJiNzIyMDhmMjI3Mjg3YTQyXzctMTktMS0xLTA_1c752666-e2d5-4ec7-aec1-d2afdcde2d7f"
      unitRef="usd">2209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i831dca10038f44b7aba289500a72d53e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMS0xLTEtMA_2aafdc56-8b69-4a8c-a0da-d36369cfb5d5"
      unitRef="usd">552000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic04ff547f0df4e0896495412b8e3aad8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMy0xLTEtMA_8fbbaa34-759c-466c-8649-185140201f3b"
      unitRef="usd">1374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6c2d87d9fe043c1ace3fe783ed9d84e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItNS0xLTEtMA_fe422b9b-62e6-4269-8e98-38b053928244"
      unitRef="usd">213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bc10941479946efa1ee8c411876db52_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItNy0xLTEtMA_2567d284-b338-4444-9da5-b3ba8be6f9c4"
      unitRef="usd">557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0a85a453134467498de7319fa2fd19d_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItOS0xLTEtMA_3a1f666b-098a-494a-bb04-3fca54c44e0d"
      unitRef="usd">2696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i370c9e50384c49a68b916ab0f055e398_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTEtMS0xLTA_733af1e4-0b85-4e3b-a477-a7078e764a47"
      unitRef="usd">670000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38ed869b702741d29a4ebbc97df0ebaf_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTMtMS0xLTA_51ca6bd2-7c0a-4956-848c-f8659ac8c3af"
      unitRef="usd">1505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49df4ed56dce435c94526ec4c09c1c2f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTUtMS0xLTA_897e3fde-a2a8-4644-89cb-e22e57a16d86"
      unitRef="usd">265000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id17680b424174ddb8afb72789e7a072c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTctMS0xLTA_8e390a60-4559-4709-83c9-387110b01c48"
      unitRef="usd">617000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia00b7a96dc7c4c748b6fc009269bf96b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzItMTktMS0xLTA_9caebee6-3bf0-4f97-bc0c-1fbcb92052a9"
      unitRef="usd">3057000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e1bdf848e27419782e283160a6e7641_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMS0xLTEtMA_e413d4af-67a9-4219-960d-401ae0be941c"
      unitRef="usd">921000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8106cbd6b8fd4566bf0bb4e848d2fee0_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMy0xLTEtMA_dcc7f393-5bb1-448f-8699-6ebd4b6a9630"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cdf8fc7e882466b8e513669a8181321_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtNS0xLTEtMA_0c484642-2540-4d22-bab0-c73ee05ea076"
      unitRef="usd">165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib806f0a34d7f41cc8b031f6eebdb460e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtNy0xLTEtMA_30dbc0e2-7893-400a-8cbf-725e2f26ee71"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56662828b4c14cdaa652dc064c47d1a8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtOS0xLTEtMA_a790071f-14ce-4abb-856b-11e3c9e667f5"
      unitRef="usd">1086000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57c5373b0b2e49bd9e26811bcb5264d6_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTEtMS0xLTA_e6a720a8-be07-4db6-8dbe-52ada427b029"
      unitRef="usd">1127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8358f514f3b4ffda10dd8a1dde466f9_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTMtMS0xLTA_008aa0ad-5644-4a3a-af9c-fb8f0edc1f8a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4b46b63623c4a798936bae68871eb7f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTUtMS0xLTA_27de551e-f1a5-4965-bc07-cf01bf983bf4"
      unitRef="usd">130000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0816679b5f144948af03427be4bb31d5_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTctMS0xLTA_1957f6d7-0d59-46f7-b157-5201c7ec894a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i786b9c0d86944563927834ab30da4a64_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzMtMTktMS0xLTA_4cf64040-903b-4e78-9ec5-ec4c990f6f8b"
      unitRef="usd">1257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72b229547ad046528b0cd05c36cf6248_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMS0xLTEtMA_ea5e7e20-bd34-48ae-8682-1dccf138bbbe"
      unitRef="usd">1043000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie62332dea55b46b8954d57e7ba3dc9f2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMy0xLTEtMA_62a8689b-0a38-4f1a-b2f8-82a7a8b95d0b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c0e7f99a52e43e48893dceaa0497adb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtNS0xLTEtMA_ccc90897-abb4-4d39-af29-105af3bccec0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62f195e557e04786bec86a970774242c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtNy0xLTEtMA_625c83bb-8349-4ed7-b393-60c11dc77973"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b960aeb700f41daa129bb69d64f7f80_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtOS0xLTEtMA_305f0926-d05b-4cb9-a22e-fcf94c1701ff"
      unitRef="usd">1043000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6b601a52f89407f99c32a3569b6cd90_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTEtMS0xLTA_62a69072-eb3e-4e87-82b9-20fbbb62800c"
      unitRef="usd">1063000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68bed0a8366846bca633f75f6ce317bf_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTMtMS0xLTA_5118cd70-33d3-4512-9b84-87beef36db2b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bc889ba7d354ed0a200fac110801a10_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTUtMS0xLTA_06c672f0-a115-4e25-a798-928c77307e8c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcc89498ee0a490bbbf373ea6031e5d4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTctMS0xLTA_c5179c73-1807-46b8-8c76-3ef0b9ec1e9c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfb0d8e06b70439093e5b2e57f467fbd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzQtMTktMS0xLTA_4024d004-6d7a-4982-9064-fbf71d79965b"
      unitRef="usd">1063000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice49f702f91540afa6e04bac724e0f16_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMS0xLTEtMA_fb7328bd-e8ce-4591-b3ef-7008374f0a2d"
      unitRef="usd">597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a7ad86ee09244ffa6a3158acbdb9e91_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMy0xLTEtMA_dbc982bd-88af-480a-9fb8-0959a23785e4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide576ffb75654cfeb9e83e3cf858df8f_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtNS0xLTEtMA_aa499027-4a50-4ded-8212-a033810cbf92"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6869bdf9417e4259950f8ca43e04a5bb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtNy0xLTEtMA_ffcda8ff-5f37-4f2a-870c-35029f026a48"
      unitRef="usd">312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i169f654e818c4d728fa7590a5cc9e306_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtOS0xLTEtMA_864a0c3a-0c81-418a-a3f5-ed030348f1a8"
      unitRef="usd">909000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67120e7176db4b1883ff589a8f3f08e7_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTEtMS0xLTA_97870a85-e851-4d9a-97a2-65ca96c6d192"
      unitRef="usd">582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10d41709f1fc4926a6fb326d3fe3ba3d_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTMtMS0xLTA_4da19e24-d599-414a-8060-ef3dc8dcedaa"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5602fb5d32ec4b2382470ba9e6490b80_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTUtMS0xLTA_e8d1de64-8f14-4f36-841b-9cd7d04e246b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i468251afcacf4241a879487d7f54a848_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTctMS0xLTA_e24156b3-08ab-4286-aa32-dcf5cda4611d"
      unitRef="usd">332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7de78745671b495ab8a2e476e94c3894_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzUtMTktMS0xLTA_c5bc1922-2bd4-4af8-b515-256052bfc37c"
      unitRef="usd">914000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79496248f2784fc4aaefcbc556fa23ba_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMS0xLTEtMA_284cc4e1-fe6e-4655-90fe-52d2f317d116"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i100bb87dcfcf4840a8fecbd84eb6c20b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMy0xLTEtMA_445ff007-0dbf-48f8-9b60-63e772e4b0f2"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79f857d233d64f27abaa8c813fb2a7d9_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtNS0xLTEtMA_650e785b-22ab-4e2a-a9c0-0c8faca1a9ec"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b2eb21ef8614e1da439f89a40feb4a7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtNy0xLTEtMA_5b94a3bd-9245-48bb-9a72-63c82ee98f9b"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21a3c7c318944c1bb5d18c5f1f1e809c_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtOS0xLTEtMA_8cc32766-e8aa-429f-9075-bfc892a3cf9c"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54ed07bae93244349ef6061cab4695fb_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTEtMS0xLTA_ade0aba5-605c-4ea3-826a-d4bf4f23de4b"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied4647195db84913b150f83d6b75649e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTMtMS0xLTA_4f7ad249-08cc-4779-bb4f-c02d6826690a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icecc5176f338476fadf188689a0d0f68_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTUtMS0xLTA_160fe15e-cb47-4815-a5d8-b4207cd23e69"
      unitRef="usd">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2afc3f9dccba4cd1820e8c7514dcd21e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTctMS0xLTA_b9af2c51-346c-4543-89db-bbd2caeffca9"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0b6efa686104cbb8083a6040e07a9e2_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzYtMTktMS0xLTA_7695b502-64bf-4ff6-85bf-9a339edef156"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb4e98e35c504f19af4f7f6f7f90aa99_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMS0xLTEtMA_5a1a0a59-cf9e-4a3e-b52a-9331e829c10d"
      unitRef="usd">3166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd721943ada444938c0d07fde3a6cc26_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMy0xLTEtMA_62231e3a-95b6-4198-a427-b686d4633d93"
      unitRef="usd">1377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifee8da0bfabc4a0c9e458c09a7305cc3_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctNS0xLTEtMA_7f9381af-089c-4d3f-93c7-fb3953187dec"
      unitRef="usd">393000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7174942dd2a84a72be602fdbd7377d7b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctNy0xLTEtMA_a4b4b014-79b5-4e9e-bcdb-a71c66b2c155"
      unitRef="usd">878000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctOS0xLTEtMA_b30806ab-dd2e-48ca-987c-cbb40a612a29"
      unitRef="usd">5814000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd7f0a0d16e745bfae02ba539c5e89d8_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTEtMS0xLTA_dbb9a13a-9ec9-420a-bf15-a9c910e2ddcb"
      unitRef="usd">3501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id56b60056c744cfdb5d527a6fe378f4f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTMtMS0xLTA_b4d22c77-e877-4976-bf6c-f85be3e2ef7d"
      unitRef="usd">1505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1062e5544f2849cd93a2b26f2aa99d36_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTUtMS0xLTA_e996069e-aa41-429c-a9b4-6de8630f9cef"
      unitRef="usd">407000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67fafda9e64f435ab86b3c470ccd987e_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTctMS0xLTA_6f9291d4-673f-4f3b-b489-c295f2d83c7b"
      unitRef="usd">964000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo4ZGJjMWQzZmM2ODQ0ZmEzODliMDk5MGYwN2ZlMGE0My90YWJsZXJhbmdlOjhkYmMxZDNmYzY4NDRmYTM4OWIwOTkwZjA3ZmUwYTQzXzctMTktMS0xLTA_1c4cbfb3-5499-424b-8709-853e4d3a8972"
      unitRef="usd">6377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzI5NDA_148ac1f9-0255-47ca-b424-52bdc56ca51a"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzI5NDA_bc5ec9a1-cc4c-411a-b4fc-eb8142c59755"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia3b658a083e346888a69fe6190860bd5_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzI5NzU_7db1b860-fa0e-42bc-98ba-edbc6192f6b3"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i73b54d06035d4aad967bc1fe46878888_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzI5ODI_fc397c80-183e-457f-a7a0-8740f9d5eb95"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyOTI_965e2bf2-a47f-4a9e-9bd0-8337d54ec629">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e0f0ac6ffaa46f4a17dc33321f25e38_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzItMS0xLTEtMA_aeb2f64b-eb10-4221-83a0-4f9082ce8673"
      unitRef="usd">1301000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fa6a46c3ea345c5a6bd0ff77c6ab9da_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzItMy0xLTEtMA_55b25d97-d92a-4483-acc2-e7cfac8d10a9"
      unitRef="usd">1369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27f07775356c46c28fa094499e05be60_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzItNS0xLTEtMA_cf1d800e-afb1-4ceb-a894-fc0cdc9e30e4"
      unitRef="usd">3522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d30a915ca464a4ebf4fbbb5194076e0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzItNy0xLTEtMA_248fb07c-3aea-430c-8f86-3ba62cb09778"
      unitRef="usd">3851000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02c96794f6994ca0923eb04b451e6f05_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzMtMS0xLTEtMA_668a772d-832b-4961-a65e-dd8cf3f8707f"
      unitRef="usd">94000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ef026f34c88467cacd0c7e88c3b10c4_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzMtMy0xLTEtMA_31a30e48-3b98-4a2e-a002-2c5c6f4bd0d7"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i796193ce9afc4d12b6379f979c427b32_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzMtNS0xLTEtMA_1e58ba67-ab3f-4a16-952c-15edba7e21bd"
      unitRef="usd">231000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f7be92a538f410c806913c3950dc54f_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzMtNy0xLTEtMA_035aa4fe-7e15-4eb6-a52e-8b8d4b666734"
      unitRef="usd">275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic14c7ebc09514fa29a41b6fe5a2836f8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzQtMS0xLTEtMA_22ac8646-9504-4591-913e-42799c8adca0"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ebbbb3cbe22449e808dbfaf4d1e174a_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzQtMy0xLTEtMA_8a70d072-3f5b-4276-b473-6fbd6405d3dc"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf506968c6f545d189921bdd9e912182_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzQtNS0xLTEtMA_d2d8f218-b727-4d3d-b259-f3fc51794bc2"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7e8c38f3f154fb49bb310a1dcb6fd83_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzQtNy0xLTEtMA_2758a2fe-616c-4cb1-a861-777fc932d330"
      unitRef="usd">252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a1618b6d63a4ef9bccc4d597fd44d7d_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzUtMS0xLTEtMA_ed9190d8-3269-4f2f-b655-44653535072d"
      unitRef="usd">68000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95891e4c7e3e457580e75965a1382082_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzUtMy0xLTEtMA_460f19ae-170e-44da-b3e9-cf96981a4bb7"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16d66aef5c9743df9092cc861ecc3cf6_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzUtNS0xLTEtMA_d74a16b6-fee2-4811-b526-df3046d692e2"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie36ad9ac246b4dd0bf391aa521396851_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzUtNy0xLTEtMA_bae6e769-606f-4a71-ac37-861759b20dea"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i577cd70d30de44d98818fb4178e165de_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzYtMS0xLTEtMA_b471a3e0-115b-479e-b8c8-096cdbd2f44a"
      unitRef="usd">59000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i342f9146a8194fbf8362fe186beb1150_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzYtMy0xLTEtMA_42176b5b-8ea7-4d4a-aa2c-4489698cb3d6"
      unitRef="usd">55000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac25f9c6e9594c37a2bc71cd2f9ac2f7_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzYtNS0xLTEtMA_a2653657-c09a-4efc-95bf-dcbc58487620"
      unitRef="usd">175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id57036c953dd4ecd9a2259ce4d2a664d_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzYtNy0xLTEtMA_0837dd4f-1f41-425a-ad28-bab4e078f27f"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59b54efdf337413095503da19334d74f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzctMS0xLTEtMA_e0c7d577-3f2e-43cb-ad30-acbd3ca7d51f"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81d0676dcb034bed9b3ac2d108318bfd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzctMy0xLTEtMA_f35d70a8-0f5f-4445-9103-5c4f9bfc9e07"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2342292213084417ab197a7ec39e2b32_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzctNS0xLTEtMA_b2edac0c-d1f6-49a8-bb40-12810d4302ad"
      unitRef="usd">168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c453b5fedc64ccb8be26bdd2dbce3f8_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzctNy0xLTEtMA_96447271-6d0a-4958-8aad-224b4c01c0c4"
      unitRef="usd">168000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic899b1ac11d94d5f912e083ac00a9925_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzgtMS0xLTEtMA_d5c910d5-ecd1-461a-b846-36537d13f383"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02bb5c4f94dc483eac3113fa75769620_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzgtMy0xLTEtMA_411ae2aa-d573-4df8-bd6e-e2e69f590338"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i208fbc90ac92433891048e7b267b2c4e_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzgtNS0xLTEtMA_61d4656a-d673-47af-a00c-fd22a258b893"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i263314b31684477a858ce1870a2e2935_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzgtNy0xLTEtMA_4bd3cdb3-a4e4-4f5f-ad41-fac5f3de49ae"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i518266816f6142088c1cd572e0b2e809_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzktMS0xLTEtMA_33fac381-ae8d-4c08-b7d4-c8030bcf9944"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3810d5f192614d9e904b2333976b6d3e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzktMy0xLTEtMA_b816e7dd-1836-4225-9236-418c923b3810"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib90335586b5244348e2bb80b34efb485_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzktNS0xLTEtMA_3cadb654-eda4-4b7e-bace-ed52b1a083f0"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ed3660f61d54acaa7f0f86779347965_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzktNy0xLTEtMA_5c7e2446-380e-4960-b3ca-9ad4d80ae4e5"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bc7e5aff7cc4ff89c60f1e3e20b5914_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEwLTEtMS0xLTA_64721c73-81fc-41f2-aef8-76506aa32c50"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92707ddce02f4496b1a61598b20a9fa3_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEwLTMtMS0xLTA_b9d7a155-66ae-40dc-aaf4-3d28dd9a603d"
      unitRef="usd">33000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1ec6e666dbd4225ba98fddbddb193e8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEwLTUtMS0xLTA_9751973d-cf9b-4c0e-88f0-ca6e67febf09"
      unitRef="usd">108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib838e1722e0e4d97a13e8bf28d909626_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEwLTctMS0xLTA_dcd1cee7-5130-4d4c-938a-67c36a3147c8"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbcd2550da3f4409b5137f5be1419151_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzExLTEtMS0xLTA_14ca24cb-c35c-4e32-8d35-10e670adc31a"
      unitRef="usd">32000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id92405cf9f6e4d37a4052058cf207929_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzExLTMtMS0xLTA_b5b61a6d-d98b-4895-940e-97f739d45e71"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i711aaaa53fba4ac29293979ceec66046_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzExLTUtMS0xLTA_8b32fa13-1136-4fbe-8a58-72045bde1336"
      unitRef="usd">89000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida52154f667f4dc8a7f3ff3a48088ca3_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzExLTctMS0xLTA_8fe83a41-3e77-4cbc-b83c-6b6e41b8fefa"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefc5f79887314486bdc0ac6a2c93b5f8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEyLTEtMS0xLTA_6986462c-ab33-4ff1-abb3-e37192b5a958"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac5dd515351d49189d4ea130cb854c26_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEyLTMtMS0xLTA_1a311e13-540c-44a3-92a5-6f5ecdc7dca5"
      unitRef="usd">18000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36ede38bb8cc4a18b46ced535622b166_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEyLTUtMS0xLTA_6cd337b6-0af6-4531-bede-f364df6f3b21"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c7c731a4d7b4bf69d3798a82bd76fdd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEyLTctMS0xLTA_dcde7fb1-cac2-473a-84e9-8ad4ec0a9687"
      unitRef="usd">62000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie59f176c51ad42579aa28217a7a898fd_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTEtMS0xLTU4MzQ_8d84af11-a1ae-4014-acf6-1697d5d6de49"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9be82f95757f4dcbbd90b7b2c038ad94_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTMtMS0xLTU4MzQ_ed51b0da-6ef9-45b8-b9a5-3816607eefbd"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03b5d0d8f5834a3db8a3fcc9475f9cbb_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTUtMS0xLTU4MzQ_6a8e8331-3c36-4302-a1d5-d34b3b46c9c1"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a61a4c91bff4480a041bd2adb0a40b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTctMS0xLTU4MzQ_12fdb791-7b49-47a4-97ef-1692ae988d4c"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55062b8f73664b389c95dbdb8d84eaf8_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTEtMS0xLTA_741e0588-5fb6-480f-aa46-3f49e2e8dd45"
      unitRef="usd">267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dde1c7051314b9aa3cda5a9a878059e_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTMtMS0xLTA_321d2d53-b7b6-4a8d-8d50-b279e790d5bb"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i173c07ccf3334f6d87290a617f2f61e2_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTUtMS0xLTA_f0fc29eb-887f-4080-9be4-e4a2cf5146a5"
      unitRef="usd">719000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id597c4b3289e490a8b7183707736dfff_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzEzLTctMS0xLTA_e9bc6b00-d45b-4a95-b1f9-e27f264a684f"
      unitRef="usd">782000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzE0LTEtMS0xLTA_c87d4c4f-6d77-4957-a111-4869c4a01698"
      unitRef="usd">2138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6f212b0cf09413da561d46fd6fa18aa_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzE0LTMtMS0xLTA_4d01856d-a99f-4630-8816-c20f1a18ade2"
      unitRef="usd">2209000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzE0LTUtMS0xLTA_bab8ef72-2be5-4044-b34a-e2db0e2a8a7b"
      unitRef="usd">5814000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTo5NGQ4OWRlNzlkMjE0MjUxOGY0YWI4N2Q3NDVhNWExNC90YWJsZXJhbmdlOjk0ZDg5ZGU3OWQyMTQyNTE4ZjRhYjg3ZDc0NWE1YTE0XzE0LTctMS0xLTA_3fbb7583-5fb2-45cc-ae9f-4d9f417d25a9"
      unitRef="usd">6377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90ZXh0cmVnaW9uOjE3YjAzMmJiY2EwNzQ5N2ViNjcxZmYxOTZlNmI1NWQ5XzMyOTk_d5c53669-5697-4746-a3bd-b86b3efae596">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id87f54aacbd14ddb9195134667720744_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzItMS0xLTEtMA_b17fe241-669f-4050-8ed4-4162ee442e9f"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iea718c704e394d629a0bb52b758793a4_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzItMy0xLTEtMA_fdc67091-aa59-40af-b1a9-a71c2fcf5e52"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6a8f2aed6a0439783600917b76ae723_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzMtMS0xLTEtMA_6689c7c9-a254-4887-8909-03438a80096e"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i74b9314e78a044d0b3e782173dfe569e_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzMtMy0xLTEtMA_cecd94b6-c2eb-4bbe-a21c-a41289b7340d"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4caac1fc03db442481ef398991140fe8_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzQtMS0xLTEtMA_b7533050-cf78-4ff7-bef5-e2d5f6961eeb"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1b8c67a640b5458da2fe72d26d0b549d_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY18xMDAvZnJhZzoxN2IwMzJiYmNhMDc0OTdlYjY3MWZmMTk2ZTZiNTVkOS90YWJsZTpjZTdlZDUxZTY4NjA0YjM5ODNjOWEyZWU1YmEyZWM0Yi90YWJsZXJhbmdlOmNlN2VkNTFlNjg2MDRiMzk4M2M5YTJlZTViYTJlYzRiXzQtMy0xLTEtMA_cb156b37-a7b6-47b7-9dd0-4ec57f363d27"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288835511336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bausch Health Companies Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0448205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2150 St. Elz&#233;ar Blvd. West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Laval<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H7L 4A8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-6792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, No Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,151,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839586408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 977<span></span>
</td>
<td class="nump">$ 3,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,671<span></span>
</td>
<td class="nump">6,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="nump">1,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">8,923<span></span>
</td>
<td class="nump">10,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,160<span></span>
</td>
<td class="nump">13,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">1,913<span></span>
</td>
<td class="nump">1,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">411<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">31,562<span></span>
</td>
<td class="nump">33,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">4,353<span></span>
</td>
<td class="nump">4,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,732<span></span>
</td>
<td class="nump">6,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">24,343<span></span>
</td>
<td class="nump">24,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,907<span></span>
</td>
<td class="nump">32,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited shares authorized, 355,026,950 and 352,562,636 issued and outstanding at September 30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">10,219<span></span>
</td>
<td class="nump">10,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">435<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(7,860)<span></span>
</td>
<td class="num">(7,452)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,207)<span></span>
</td>
<td class="num">(2,086)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Bausch Health Companies Inc. shareholders&#8217; equity</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 31,562<span></span>
</td>
<td class="nump">$ 33,863<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839511256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in shares)</a></td>
<td class="nump">355,026,950<span></span>
</td>
<td class="nump">352,562,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">355,026,950<span></span>
</td>
<td class="nump">352,562,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288840356456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,138<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 5,814<span></span>
</td>
<td class="nump">$ 6,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration and separation costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">1,678<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
<td class="nump">5,504<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(374)<span></span>
</td>
<td class="num">(406)<span></span>
</td>
<td class="num">(1,155)<span></span>
</td>
<td class="num">(1,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before (provision for) benefit from income taxes</a></td>
<td class="nump">75<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(540)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">70<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interest</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to Bausch Health Companies Inc.</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="num">$ (49)<span></span>
</td>
<td class="num">$ (407)<span></span>
</td>
<td class="num">$ (272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to Bausch Health Companies Inc.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Weighted-average common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">355.6<span></span>
</td>
<td class="nump">352.4<span></span>
</td>
<td class="nump">354.7<span></span>
</td>
<td class="nump">351.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">357.8<span></span>
</td>
<td class="nump">352.4<span></span>
</td>
<td class="nump">354.7<span></span>
</td>
<td class="nump">351.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,111<span></span>
</td>
<td class="nump">$ 2,180<span></span>
</td>
<td class="nump">$ 5,734<span></span>
</td>
<td class="nump">$ 6,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">578<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">1,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288826973224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="num">$ (407)<span></span>
</td>
<td class="num">$ (266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">20<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Pension and postretirement benefit plan adjustments, net of income taxes</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">19<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">89<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive (income) loss attributable to noncontrolling interest</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Bausch Health Companies Inc.</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="num">$ (144)<span></span>
</td>
<td class="num">$ (528)<span></span>
</td>
<td class="num">$ (291)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288834202760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Bausch Health Companies&#160;Inc. Shareholders' Equity</div></th>
<th class="th">
<div>Bausch Health Companies&#160;Inc. Shareholders' Equity </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 2,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,121<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="num">$ (5,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,137)<span></span>
</td>
<td class="nump">$ 2,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(266)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">2,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,168<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="num">(5,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,156)<span></span>
</td>
<td class="nump">2,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 2,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,121<span></span>
</td>
<td class="nump">413<span></span>
</td>
<td class="num">(5,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,137)<span></span>
</td>
<td class="nump">2,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">352,562,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 10,172<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="num">(7,452)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,086)<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 2,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,165<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="num">(5,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,061)<span></span>
</td>
<td class="nump">2,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(97)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 2,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,168<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="num">(5,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,156)<span></span>
</td>
<td class="nump">2,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">352,562,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 10,172<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="num">(7,452)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,086)<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">$ (120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">355,026,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,219<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="num">(7,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,207)<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,217<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="num">(7,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,223)<span></span>
</td>
<td class="nump">474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">355,026,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,219<span></span>
</td>
<td class="nump">$ 435<span></span>
</td>
<td class="num">$ (7,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,207)<span></span>
</td>
<td class="nump">$ 587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288838688888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (407)<span></span>
</td>
<td class="num">$ (266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and write-off of debt premiums, discounts and issuance costs</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories', window );">Allowances for losses on trade receivable and inventories</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainLossRelatedToLitigationSettlementGross', window );">Additions to accrued legal settlements</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments of accrued legal settlements</a></td>
<td class="num">(82)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign exchange loss</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DerivativeGainExcludedComponent', window );">Gain excluded from hedge effectiveness</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PaymentOfAccretedInterestOnContingentConsideration', window );">Payments of contingent consideration adjustments, including accretion</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(178)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of businesses, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(222)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments for intangible and other assets</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of assets and businesses, net of costs to sell</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_InterestSettlementOnCrossCurrencySwaps', window );">Interest settlements from cross-currency swaps</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(177)<span></span>
</td>
<td class="num">(334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt, net of discounts</a></td>
<td class="nump">1,476<span></span>
</td>
<td class="nump">3,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(3,162)<span></span>
</td>
<td class="num">(3,956)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from the issuances of short-term debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of short-term debt</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of employee withholding taxes related to share-based awards</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of acquisition-related contingent consideration</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of financing costs</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,791)<span></span>
</td>
<td class="num">(812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents and restricted cash</a></td>
<td class="num">(1,256)<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">3,244<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, end of period</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash, end of period</a></td>
<td class="nump">$ 1,988<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AllowancesForLossesOnAccountsReceivableAndInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredIncomeTaxNoncashExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DerivativeGainExcludedComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Gain, Excluded Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DerivativeGainExcludedComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainLossRelatedToLitigationSettlementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainLossRelatedToLitigationSettlementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_InterestSettlementOnCrossCurrencySwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Settlement On Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_InterestSettlementOnCrossCurrencySwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentOfAccretedInterestOnContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Accreted Interest On Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentOfAccretedInterestOnContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839090232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or "Bausch Health") is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of eye-health, gastroenterology ("GI") and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829781336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators on February&#160;19, 2020. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2019, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced that it intends to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;Separation&#8221;). The Separation will establish two separate companies that include: (i) a fully integrated eye-health company which will consist of the Company&#8217;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Rx businesses and (ii) a diversified pharmaceutical company which will include the Company&#8217;s Salix, International Rx, Solta, neurology and medical dermatology pharmaceutical businesses. The anticipated separation is subject to regulatory approvals and certain conditions, including final approval by the Company&#8217;s Board of Directors and any shareholder vote requirements that may be applicable. These unaudited Consolidated Financial Statements do not include any adjustments to give effect to the Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has begun addressing the internal organizational design and structure of the new entity which it anticipates having substantially completed in late 2021. Management is also exploring various capitalization structures and the form of the Separation transaction in order to properly capitalize both entities post-separation. As of the date of the issuance of these financial statements, the Company is in the planning phase of the Separation. As such, there are considerations, approvals and conditions that will determine the ultimate timing and structure of the Separation and there can be no assurance that a transaction will occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. The COVID-19 pandemic and the rapidly evolving reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have intensified and have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facilities closures and production suspensions. The COVID-19 pandemic has also significantly increased demand for certain goods and services, such as pandemic-related medical services and supplies, alongside decreased demand for others, such as retail, hospitality, elective medical procedures and travel. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence, if any, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing.   Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Guidance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued guidance on the impairment of financial instruments requiring an <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ0Nw_fc60b351-a915-4b1e-a9cf-8bbc63693281">impairment model based on expected losses</span> rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.&#160; The guidance was effective for the Company beginning January 1, 2020.&#160; The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During the nine months ended September 30, 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Adopted as of September&#160;30, 2020 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on its disclosures.</span></div>In December 2019, the FASB issued guidance simplifying the accounting for income taxes.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on the Company's financial position, results of operations and cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288833616504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities.  All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for the nine months ended September 30, 2020 and 2019 were $71 million and $50&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $38&#160;million and $80&#160;million for the three months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the nine months ended September 30, 2020 and 2019.</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $33 million and $29&#160;million as of September 30, 2020 and January 1, 2020, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. Included as a reduction of Distribution Fees in the table above are price appreciation credits of approximately $4 million during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Synergy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $26 million and $26&#160;million as of September 30, 2019 and January 1, 2019, respectively. There were no price appreciation credits during the nine months ended September 30, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2020 is as follows.</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.829%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839646040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock', window );">ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE</a></td>
<td class="text">ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of Certain Assets of Synergy Pharmaceuticals Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc. ("Synergy") for a cash purchase price of&#160;approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired were the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and has, to date, resulted in additional revenues and certain business synergies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting as: (i) substantially all the fair value of the assets acquired is not&#160;concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.829%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life - 7 years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Results </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55&#160;million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the nine months ended September 30, 2019 and the year 2019 were not material. Included in Other expense, net during the nine months ended September 30, 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC ("Allegro")</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2020, the Company announced that it entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the "Option"), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option is exercised, is the worldwide rights to risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration ("AMD"). A U.S. Phase 2a study with risuteganib in intermediate dry AMD met its primary endpoint of vision recovery and Phase 3 testing is in the planning stages. The aggregate payments to acquire the Option are $50&#160;million and include an upfront payment of $10&#160;million and a second payment of $40&#160;million should Allegro raise additional funding. During the three months ended September 30, 2020, the Company made and expensed the upfront payment of $10&#160;million as acquired in-process research and development ("IPR&amp;D") included in Other expense, net. If the Option is exercised, additional payments to acquire all ophthalmology assets of Allegro will be due.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred.  Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held for Sale</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company identified certain products in the Bausch + Lomb/International segment and one product in the Diversified Products segment for disposal. The products and the related assets and liabilities of this disposal group qualified as a business. Revenues associated with this business were $14 million and $19 million for the years 2019 and 2018, respectively. The carrying value of the business, including inventories, intangible assets, goodwill and deferred income taxes, was adjusted to its estimated fair value less costs to sell and reclassified as held for sale as of September 30, 2019 and an impairment of $8 million associated with this business was recognized during the three months ended September 30, 2019. As a result of changing business dynamics, during the three months ended March 31, 2020, the Company decided not to sell these assets and reclassified $39 million of held for sale assets as assets held and used at their respective fair values at the date of the decision not to sell. This reclassification did not impact the Consolidated Statement of Operations for the nine months ended September 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839014888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION AND SEPARATION COSTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING, INTEGRATION AND SEPARATION COSTS</a></td>
<td class="text">RESTRUCTURING, INTEGRATION AND SEPARATION COSTS <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of September 30, 2020 was $25 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company incurred $12 million of restructuring and integration costs. These costs included: (i) $7 million of facility closure costs and (ii) $5 million of severance costs. The Company made payments of $14&#160;million for the nine months ended September 30, 2020.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2019, the Company incurred $28 million of restructuring and integration costs. These costs included: (i) $11 million of severance and other costs associated with the acquisition of certain assets of Synergy, (ii) $9&#160;million of facility closure costs and (iii) $8 million of other severance costs. The Company made payments of $27 million for the nine months ended September 30, 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation costs and separation-related costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the Separation. These activities include: (i) separating the eye-health business from the remainder of the Company and (ii) registering the eye-health business as an independent publicly traded entity. Separation costs are incremental costs directly related to the Separation and include, but are not limited to: (i) legal, audit and advisory fees, (ii) employee hiring, relocation and travel costs and (iii) costs associated with establishing a new board of directors and audit committee. Included in Restructuring, integration and separation costs for the three and nine months ended September 30, 2020 is $1&#160;million of separation costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and will incur, separation-related costs which are incremental costs indirectly related to the Separation. Separation-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative expenses for the three and nine months ended September 30, 2020 is $4&#160;million of separation-related costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the planning phase of the Separation and the extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288833077816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, Restricted cash includes $1,010&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding certain U.S. securities litigation, subject to final court approval, and is reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to its short-term nature.  These payments will remain in escrow until final approval of the settlement as discussed in Note 18, "LEGAL PROCEEDINGS".</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is the Company&#8217;s investment in certain euro-denominated subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cross-currency swaps qualify for and have been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values.  The fair value is determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs may include: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective and remain in Accumulative other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the nine months ended September 30, 2020 and 2019. The Company uses the spot method of assessing hedge effectiveness. The Company has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s cross-currency swaps liability as of September 30, 2020 and December 31, 2019 was $18 million and $13&#160;million, respectively. Included in Other non-current liabilities is $21 million and $22&#160;million of cross-currency swaps and included in Prepaid expenses and other current assets is $3 million and $9&#160;million of earned interest within the Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Gain recognized in Other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of the Company's cross-currency swaps occur in February and August each year. During the nine months ended September 30, 2020, the Company received $23 million in settlements which are reported as investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, the Company entered into foreign currency exchange contracts, with an aggregate notional amount of $187&#160;million. The Company had no foreign currency exchange contracts during 2019.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company's foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company's foreign currency exchange contracts liability as of September 30, 2020 was $1&#160;million. Included in Accrued and other current liabilities are $2&#160;million and included in Prepaid expenses and other current assets are $1&#160;million of foreign currency exchange contracts within the Consolidated Balance Sheets. During the three and nine months ended September 30, 2020, the net change in fair value was $0 and a loss of $1&#160;million, respectively. Settlements of the Company's foreign currency exchange contracts are reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Consolidated Statements of Cash Flows. During the nine months ended September 30, 2020, the Company reported a realized loss of $1&#160;million related to settlements of the Company's foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At September&#160;30, 2020, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 5% to 25%, and a weighted average risk-adjusted discount rate of 8%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at September&#160;30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.194%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current assets held for sale of $39 million included in the Consolidated Balance Sheets as of December 31, 2019 were remeasured to their estimated fair values less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. As discussed in Note 4, "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE", due to changing business dynamics, the Company decided not to sell these assets during the three months ended March 31, 2020. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of September&#160;30, 2020 and December&#160;31, 2019 was $25,258 million and $27,520 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839518808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net of allowances for obsolescence consist of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829781336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,432)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,355&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,432)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments for the nine months ended September 30, 2020 were $17&#160;million and include impairments of: (i) $16&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines and (ii) $1&#160;million, in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments for the nine months ended September 30, 2019 were $49&#160;million and include impairments of: (i) $38&#160;million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8&#160;million related to assets being classified as held for sale and (iii) $3 million due to the discontinuance of specific product lines not aligned with the focus of the Company's core businesses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2020 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the nine months ended September 30, 2020 and the year ended December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.626%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.491%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill (Note 4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,160&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of all reporting units using a discounted cash flow model which utilizes Level 3 unobservable inputs.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The Company performed its annual impairment test as of October 1, 2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount (Step 0). Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit (Step 1). The quantitative fair value test was performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. </span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company forecasts cash flows for each reporting unit and takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts were based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such charges could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Goodwill Impairment Testing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2019, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value and therefore, no impairments were recorded. The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was no impairment to the goodwill of any reporting unit. The Company performed quantitative fair value tests for the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of October 1, 2019, utilizing long-term growth rates of 2.0% and 1.5%, and discount rates of 9.8% and 9.0%, respectively, in estimation of the fair value of these reporting units.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessments </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, the Company has taken actions to protect its employees, customers and other stakeholders and mitigate the negative impact of the COVID-19 pandemic on its operations and operating results. These and additional actions can increase the costs of doing business during the pandemic and, in the periods that follow, may include the costs of idling and reopening certain facilities in affected areas.  Further, social restrictions and other precautionary measures taken by customers, health care patients and consumers in response to the pandemic are expected to impact the timing and amount of revenues during the COVID-19 pandemic. Although the Company's revenues for the nine months ended September 30, 2020 were less than those forecasted on the date goodwill was last tested for impairment (October 1, 2019) and additional pandemic-related declines in revenues may occur for the remainder of 2020, there are no indications that these trends are materially related to developments other than the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative impacts of the COVID-19 pandemic on the global economy were not existing conditions on the date goodwill was last tested for impairment (October 1, 2019) and have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows.  In performing its assessment, the Company considered the possible affects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts as of October 1, 2019 (the date goodwill was last tested for impairment) for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the pandemic, the public has been advised to engage in certain "social restrictions" such as: (i) remaining at home or shelter-in-place, (ii) limiting social interaction, (iii) closing non-essential businesses and (iv) postponing certain surgical and elective medical procedures in order to prioritize/conserve available health care resources. During the three months ended March 31, 2020, these factors negatively impacted, most notably, the revenues of the Company's Global Vision Care and Global Surgical businesses in Asia where the COVID-19 pandemic originated. Beginning in March 2020, and throughout most of the second quarter of 2020, the Company experienced steeper declines in these revenues and the revenues of other businesses as social restrictions expanded worldwide, particularly in the U.S. and Europe. Social restrictions negatively impacted the Company's revenues for contact lenses, intraocular lenses, medical devices, surgical systems and certain pre- and post-operative eye-medications of its Global Ophtho Rx business, medical aesthetics and therapeutic products of its Global Solta business, and certain branded pharmaceutical products of its Salix, Ortho Dermatologics and Dentistry businesses, as the offices of many health care providers were closed and certain surgeries and elective medical procedures were deferred.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues for the nine months ended September 30, 2020 were negatively impacted by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic earlier in the year. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize.  Presuming there is no material resurgence of the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020. The Company therefore believes that its revenues for the year 2020 will be most impacted by the COVID-19 pandemic in its second quarter, although the Company experienced additional COVID-19 pandemic related declines in the year-over-year revenues in its third quarter, and expects additional COVID-19 pandemic related declines in the fourth quarter of 2020, in many of its businesses and geographies. Presuming any reenactment of social restrictions is not significant, the Company anticipates that its affected businesses could possibly return to pre-pandemic levels as early as late 2020 or in 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's latest forecasts of cash flows gives consideration to the nature and timing of the expected revenue losses disclosed above.  The changes in the amounts and timing of these revenues as presented in the latest forecasts include a range of potential outcomes and, with the exception of the Ortho Dermatologics reporting unit as discussed below, are not substantial enough to materially adversely affect the recoverability of any of the associated reporting units&#8217; assets and are not material enough to indicate that the fair values of those reporting units might be below their respective carrying values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results of the October 1, 2019 annual goodwill impairment test, the Company continues to assess the performance of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit and performs quarterly qualitative assessments of their respective carrying values and fair values to determine if quantitative fair value testing is warranted. As part of these qualitative assessments, management considers the totality of all relevant events or circumstances that effect the carrying amount and fair value of each reporting unit, including comparing actual operating results to the forecast used to test the goodwill of the Ortho Dermatologics reporting unit and the Neuro and Other reporting unit as of October 1, 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neuro and Other Reporting Unit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believed that based on its qualitative assessments as of March 31, 2020, June 30, 2020 and September 30, 2020, it was more likely than not that the carrying amount of the Neuro and Other reporting unit was less than its fair value and, therefore, concluded a quantitative assessment was not required at March 31, 2020, June 30, 2020 and September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ortho Dermatologics Reporting Unit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020, the operating results for the Ortho Dermatologics reporting unit were less than those forecasted at October 1, 2019 for that period. As part of its qualitative assessment as of March 31, 2020, the Company revised its forecasts for the year 2020, for among other matters, the lower than originally forecasted operating results for the three months ended March 31, 2020 and the range of potential impacts of the COVID-19 pandemic, including longer than expected launch cycles for certain new products. Management believed that the revisions to its forecasts for the year 2020 were indicators that there was less headroom as of March 31, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2019).  Therefore, a quantitative test for the Ortho Dermatologics reporting unit was performed at March 31, 2020. Based on the quantitative test, the fair value of the Ortho Dermatologics </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2020, the Company identified certain Ortho Dermatologics&#8217; products that were experiencing longer launch cycles than originally anticipated due to the COVID-19 pandemic and, as a direct result, took actions to mitigate the impact of these matters, including right-sizing its Ortho Dermatologics&#8217; sales force. As part of its qualitative assessment as of June 30, 2020, the Company revised its long-term forecasts for, among other matters, the decrease in forecasted revenues of the identified products, the reduction in sales force and related costs and a range of potential impacts of COVID-19 pandemic related matters.  Management believes that these events are indicators that there is less headroom as of June 30, 2020 as compared to the headroom calculated on the date goodwill was last tested for impairment (March 31, 2020). Therefore, a quantitative test for the Ortho Dermatologics reporting unit was performed. The quantitative test utilized the Company's most recent cash flow projections, including a range of potential outcomes, along with a long-term growth rate of 2.0% and a range of discount rates between 9.5% and 10.0%. Based on the quantitative test, the fair value of the Ortho Dermatologics reporting unit was 10% to 15% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at June 30, 2020.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believed that based on its qualitative assessments as of September 30, 2020, it was more likely than not that the carrying amount of the Ortho Dermatologics reporting unit was less than its fair value and, therefore, concluded a quantitative assessment was not required at September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit and Neuro and Other reporting unit including: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for new products and (iv) ongoing pricing pressures, which could negatively impact the reporting units' results over the long term. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If market conditions further deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#8217;s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges can be material.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No other events occurred or circumstances changed during the period October 1, 2019 (the date goodwill was last tested for impairment) through September&#160;30, 2020 that indicate it is more likely than not the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit may be below its carrying value. The Company will perform its annual impairment test as of October 1, 2020. In addition, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021, and as a result the Company may need to perform an impairment test upon realignment of its operating segments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through September&#160;30, 2020 were $3,711 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288832263656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED AND OTHER CURRENT LIABILITIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,353&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828400312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">FINANCING ARRANGEMENTS</a></td>
<td class="text">FINANCING ARRANGEMENTS<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.875%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50% euro-denominated debt</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,343&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,661&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of September&#160;30, 2020, the amount available for restricted payments under the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $12,600&#160;million. The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has adversely impacted the global economy. As the global economic landscape changes, there is a wide range of possible outcomes regarding the nature and timing of events and reactions to the COVID-19 pandemic, each of which are highly dependent on variables that are difficult to predict at this time.  While there are a number of standard borrowing conditions that must be met to make borrowings under the 2023 Revolving Credit Facility, the Company has considered the economy's impact on its non-financial and financial maintenance covenants and </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believes the current state of the economy does not limit its access to capital under the 2023 Revolving Credit Facility at this time.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast as adjusted for the potential impacts of the COVID-19 pandemic, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of these financial statements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018, and as further amended (the &#8220;Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $1,225 million, which matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. ("BHA") in an aggregate principal amount in excess of $1,000 million (the "2023 Revolving Credit Facility") and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the "November 2025 Term Loan B Facility"), respectively. Both the Company and BHA are borrowers under the 2023 Revolving Credit Facility, borrowings under which may be made in U.S. dollars, Canadian dollars or euros.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Description of Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros bear interest at a eurocurrency rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of September 30, 2020, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.15% and 2.90% per annum, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of September 30, 2020, the aggregate remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities were $680 million through November 1, 2025.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.&#160; As of September 30, 2020, the stated rate of interest on the 2023 Revolving Credit Facility was 3.15% per annum. As of September&#160;30, 2020, the Company had no outstanding borrowings, $107 million of issued and outstanding letters of credit and remaining availability of $1,118 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.75% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of 8.50% Senior Unsecured Notes due January 2027 (the "January 2027 Unsecured Notes") and (ii) $500 million aggregate principal amount of 5.75% Senior Secured Notes due August 2027 (the "August 2027 Secured Notes"), respectively, in a private placement. A portion of the proceeds, and cash on hand, were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the "May 2023 Unsecured Notes"), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the &#8220;December 2021 Unsecured Notes&#8221;), (iii) repurchase $216 million of 5.50% Senior Unsecured Notes due 2023 (the &#8220;March 2023 Unsecured Notes&#8221;) and (iv) pay all fees and expenses associated with these transactions (collectively, the &#8220;March 2019 Refinancing Transactions&#8221;). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">8.50% Senior Unsecured Notes due 2027 - March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of January 2027 Unsecured Notes. These are additional notes and form part of the same series as BHA&#8217;s existing January 2027 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">7.00% Senior Unsecured Notes due 2028 and 7.25% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.00% Senior Unsecured Notes due January 2028 (the "7.00% January 2028 Unsecured Notes") and (ii) $750 million aggregate principal amount of 7.25% Senior Unsecured Notes due May 2029 (the "May 2029 Unsecured Notes"), respectively, in a private placement. The proceeds and cash on hand, were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2019 Refinancing Transactions&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.00% Senior Unsecured Notes due 2028 and 5.25% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.00% Senior Unsecured Notes due January 2028 (the "5.00% January 2028 Unsecured Notes") and (ii) $1,250 million aggregate principal amount of 5.25% Senior Unsecured Notes due January 2030 (the "January 2030 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the $1,210 million settlement of certain U.S. securities litigation, subject to final court approval, as discussed in Note 18, "LEGAL PROCEEDINGS" and (iii) pay all fees and expenses associated with these transactions (collectively, the "December 2019 Financing and Refinancing Transactions").</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.25% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $1,500 million aggregate principal amount of 6.25% Senior Unsecured Notes due February 2029 (the "February 2029 Unsecured Notes") in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250&#160;million aggregate principal amount of outstanding 6.50% Senior Secured Notes due March 2022, (ii) prepay $303&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the "May 2020 Refinancing Transactions"). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The February 2029 Unsecured Notes accrue interest at the rate of 6.25% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the February 2029 Unsecured Notes at the applicable redemption prices set forth in the February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company's outstanding debt obligations as of September&#160;30, 2020 and December&#160;31, 2019 was 5.94% and 6.21%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to reduce future cash interest payments, as well as future maturities and mandatory payments, the Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. During the nine months ended September 30, 2020, the Company repurchased and retired, outstanding senior unsecured notes with an aggregate par value of $27 million in the open market, for an aggregate cost of $26 million.  In connection with these repurchases, the Company recognized a gain of $1 million included in Loss on extinguishment of debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the remainder of 2020, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,343&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 29, 2020, the Company issued an unconditional notice of redemption to redeem: (i) $99&#160;million of May 2023 Unsecured Notes, representing the remaining outstanding principal balance of the May 2023 Unsecured Notes and (ii) $51&#160;million of March 2023 Unsecured Notes, on November 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828421384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers certain U.S. employees and employees in certain other countries. Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2020 and 2019 consists of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 3.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828458616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#8220;Amended and Restated 2014 Plan&#8221;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#8217;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 17,067,000 common shares were available for future grants as of September&#160;30, 2020. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation while maintaining focus on improving total shareholder return over the long-term.  The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;) and (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;).   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of share-based compensation expense related to stock options and RSUs for the three and nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:11pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the remaining unrecognized compensation expense related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $116 million, which will be amortized over a weighted-average period of 1.59 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828361832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,046)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,207)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,086)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, amounts reclassified from Accumulated other comprehensive loss into the Company's operating results were not material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828358968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text">RESEARCH AND DEVELOPMENT<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829691272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">OTHER EXPENSE, NET</a></td>
<td class="text">OTHER EXPENSE, NET<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of:</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, Litigation and other matters includes adjustments related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. Litigation and other matters also includes an insurance recovery related to a certain litigation matter.  See Note 18, "LEGAL PROCEEDINGS" for further details regarding these and other litigation matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828419720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company's ordinary income, subject to certain limitations on the benefit of losses. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company's income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates, and an evaluation of valuation allowances. The Company's estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Benefit from income taxes for the nine months ended September 30, 2020 was $133 million and included: (i) $105 million of net income tax benefit for discrete items, which includes: (a) $63&#160;million in net tax benefits related to the release of a valuation allowance, (b) $36&#160;million in tax benefits associated with law changes in the United States, (c) $10 million in tax benefits recognized for changes in uncertain tax positions, (d) a $7 million tax benefit related to a deduction for stock compensation and (e) $11 million of net tax expense associated with filing certain tax returns and (ii) $28 million of income tax benefit for the Company's ordinary loss for the nine months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes for the nine months ended September 30, 2019 was $101 million and included: (i) $46 million of net income tax benefit for discrete items, which includes: (a) $32 million of tax benefit recognized upon a ruling from the Polish tax authorities confirming the deductibility of royalty payments by an affiliate, (b) $13 million of net tax benefits associated with filing certain tax returns and (c) $1 million of net tax charges related to other changes in uncertain tax positions and (ii) $55&#160;million of income tax benefit for the Company's ordinary loss for the nine months ended September 30, 2019. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made except that, as a result of the 2018 adoption of guidance regarding intra-entity transfers, any change in valuation allowance surrounding the adoption of the intra-entity transfer resulting from this adoption was recorded within equity. The valuation allowance against deferred tax assets was $2,756 million and $2,831 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively.  The decrease was primarily due to: (i) the change in the expected realizability of previously established losses in Germany, recorded discretely and (ii) income in Canada. The Company will continue to assess the need for a valuation allowance on a go-forward basis.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2020, the U.S. Treasury Department and the Internal Revenue Service (the "IRS") released final regulations under the Global Intangible Low Taxed Income ("GILTI") and Subpart F income provisions of the Internal Revenue Code regarding the treatment of income that is subject to a high rate of foreign tax. The final regulations allow taxpayers to exclude certain high-taxed income of a controlled foreign corporation from their GILTI computation on an elective basis. The Company has evaluated the effects of these final regulations and has discretely recorded a $19&#160;million tax benefit during the three months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December&#160;31, 2019, the Company had $1,009 million and $1,002 million of unrecognized tax benefits, which included $51 million and $45 million of interest and penalties, respectively. Of the total unrecognized tax </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits as of September&#160;30, 2020, $363 million would reduce the Company&#8217;s effective tax rate, if recognized. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at September&#160;30, 2020 could decrease by approximately $141 million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. The Company&#8217;s position as of September&#160;30, 2020 with regard to proposed audit adjustments has not changed and the proposed adjustments continue to result primarily in a loss of tax attributes that are subject to a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRS completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations.  The 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the IRS has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. At this time, the Company does not expect that proposed adjustments, if any, for these periods would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2010 through 2011 and 2015 through 2017.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2011 through 2015. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829691272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted effect of stock options and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (loss) per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020 and the three and nine months ended September 30, 2019, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive.  The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,144,000 common shares for the nine months ended September 30, 2020, and approximately 4,453,000 and 4,589,000 common shares for the three and nine months September 30, 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, time-based RSUs, performance-based RSUs and stock options to purchase approximately 10,489,000 and 10,604,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three and nine months ended September 30, 2019, time-based RSUs, performance-based RSUs and stock options to purchase approximately 5,363,000 and 5,363,000 common shares, respectively were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828378664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text">LEGAL PROCEEDINGS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020. Except as described below, there have been no material updates or developments with respect to any such proceedings or actions during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued.  As of September 30, 2020, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,462 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome -of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Governmental and Regulatory Inquiries&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the District of Massachusetts - re Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation.  The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval.  Once approved by the court, the settlement will resolve and discharge all claims against the Company in the class action.  As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. On January 27, 2020 the court preliminarily approved the settlement. A final settlement approval hearing was held on May 27, 2020 and the settlement remains subject to final court approval. In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payment is being paid in accordance with the payment schedule outlined in the settlement agreement. The opt-out litigations discussed below remain ongoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#8220;Timber Hill&#8221;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016.  On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658).  On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. In addition to the matters captioned Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (&#8220;Maverick&#8221;), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (&#8220;Templeton&#8221;), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (&#8220;USAA&#8221;), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (&#8220;GIC&#8221;), these actions were captioned previously in the Company&#8217;s Annual Report on Form 10K for the year ended December 31, 2019, filed on February 19, 2020. Seven of the thirty-seven opt out actions have been dismissed; and the total number of remaining opt out actions pending in the District of New Jersey is thirty actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case.  On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions.  On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the factual allegations made in these actions are substantially similar to those outlined above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, has been discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding.  On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements.  As part of the settlement, the Company and </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement agreement is subject to court approval. If court approval is granted, the Catucci action will be dismissed against the Company, its current and former directors and officers, its underwriters and its insurers. The hearing to approve the settlement is scheduled for November 16, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action.  On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights (&#8220;CalSTRS&#8221;) served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:103%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"> during the period covered by the claims. The Company has notified CalSTRS of its intention to oppose the amendments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%">   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160; The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;A special master appointed by the Court has recommended that the Company&#8217;s motion to dismiss be denied, but a final decision is still pending with the Court. The Company believes these claims are without merit and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain other proceedings or actions as described under &#8220;Securities and RICO Class Actions and Related Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. Such matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Lawsuits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complaint was filed, captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Case No. 19-cv-17833). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs assert claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. The consolidated complaint also asserts a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases are based on the same purported conduct that is at issue in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Valeant Pharmaceuticals International, Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint.  Briefing on this motion concluded on August 3, 2020. The Company disputes these claims and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16.&#160; The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).&#160; In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in&#160;In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and certain of the investigations described above (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act.  This matter is currently stayed pending the completion of discovery in one of the above-noted federal opt-out cases. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020.  The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020.  The Company&#8217;s motion to dismiss the insurer plaintiff&#8217;s amended complaint is pending. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions, five (5) of which remain pending, have been consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA. The lawsuits allege that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints allege that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs seek damages under federal antitrust laws for claims based on direct purchases. The insurer plaintiff also seeks damages and equitable relief under various state laws for claims based on indirect purchases. The Company disputes the claims against it and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this subsection, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16-MD-2724).  The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals.  The initial lawsuit to which the Company was added as a defendant in June 2018 was filed by a putative class of direct purchaser plaintiffs.  In December 2018, certain direct purchaser plaintiffs that had opted out of this putative class filed an amended complaint in the MDL that added the Company, alleging similar claims as the direct purchaser plaintiffs&#8217; putative class action complaint.  In February 2019, the Company filed a motion to dismiss the individual claims brought against it and that motion remains pending.  In October 2019, an end payer plaintiff that had opted out of the putative end payer class filed a complaint against the Company in the Eastern District of Pennsylvania alleging similar claims.  In December 2019, end payer opt-out complaints also were filed against the Company in the Eastern District of Pennsylvania and in the Northern District of California.  In December 2019, separate putative class action complaints were filed against the Company in the Eastern District of Pennsylvania by end payer and indirect reseller plaintiffs.  In February 2020, a putative class action complaint was filed against the Company in the Eastern District of Pennsylvania by direct purchaser plaintiffs.  In June 2020, an opt-out complaint raising both direct purchaser and end payer claims was filed against the Company in the Eastern District of Pennsylvania.  Also in June 2020, State Attorneys General filed a Complaint against the Company in the District of Connecticut. In July 2020, a direct purchaser opt-out complaint was filed against the Company in the Eastern District of Pennsylvania. In August 2020, a complaint was filed against the Company by Suffolk County, New York in the Eastern District of New York.  In September 2020, a direct purchaser opt-out complaint was filed against the Company in the Eastern District of Pennsylvania.  The cases have been or will be consolidated into the MDL.  There are also additional, separate complaints by other plaintiffs which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant.  In July 2019, 87 health plans commenced an action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed and the case has been put in deferred status.  In May 2020, seven health plans commenced an additional action in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed.  The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Plenvu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada, or other similar suits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (&#8220;Perrigo&#8221;), in which Perrigo asserted that certain U.S. patents, each of which is listed in the U.S.&#160;Food and Drug Administration's (the "FDA") Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo&#8217;s generic lotion, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Perrigo.  On August 28, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described below, regarding Perrigo&#8217;s ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo, in which Perrigo asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Perrigo&#8217;s generic halobetasol propionate lotion, for which an ANDA has been filed by Perrigo.  On May 1, 2020, the Company filed suit against Perrigo pursuant to the Hatch-Waxman Act, alleging infringement by Perrigo of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Perrigo ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Perrigo described above, regarding Perrigo&#8217;s ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. ("Alfasigma") received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA's Orange </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an ANDA has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 23 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company and Alfasigma commenced litigation against Sun Pharmaceutical Industries Ltd. (&#8220;Sun&#8221;), alleging patent infringement by Sun&#8217;s filing of its ANDA for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 200 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) and all intellectual property protecting Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the United States before January 1, 2028. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review ("IPR") at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution.&#160; IPR challenges have been brought against patents covering the Company's branded pharmaceutical products.&#160; For example, following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board ("PTAB"), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continues to be covered by eleven other Orange Book-listed patents owned by the Company and its licensor, which expire in the years 2028 through 2035.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;Product Liability&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on February 19, 2020. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, only twelve (12) of such product liability suits currently remain pending. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company, and legal fees and costs will be paid by Johnson &amp; Johnson. Ten of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer or mesothelioma. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages.  The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. In accordance with the indemnification agreement, Johnson &amp; Johnson will continue to vigorously defend the Company in each of the remaining actions that are not voluntarily dismissed or subject to a grant of summary judgment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Graham v. Bausch Health Companies, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gutierrez, et al. v. Johnson &amp; Johnson, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted.  In August 2020, Plaintiffs filed the Fifth Amended Complaint and the Company&#8217;s motion to dismiss that complaint is pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower&#174; and its alleged causal link to mesothelioma and other cancers.  In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US expects to file its Answer in November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend each of these lawsuits vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As referenced above, during the three months ended September 30, 2020, there have been no material updates or developments with respect to certain proceedings or actions as described under &#8220;General Civil Actions&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019), filed with the SEC on February 19, 2020. These matters include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23 million. The Company has asserted counterclaims against Doctors Allergy.&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief.  The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd.  Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in each of these matters and intends to vigorously defend the matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Completed or Dormant Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since July 1, 2020 or the Company anticipates that no further material activity will take place with respect thereto, or the matters have been dormant for several quarters. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in November 2015, the Company received from the staff of the Los Angeles Regional Office of the SEC ("the Staff") subpoenas for documents, as well as various document, testimony and interview requests, related to its investigation of the Company, including requests concerning the Company's former relationship with Philidor Rx Services, LLC ("Philidor"), its accounting practices and policies, its public disclosures and other matters. On March 27, 2020, the Staff  issued a Wells Notice informing the Company that they had reached a preliminary determination to recommend that the SEC bring charges against the Company for violating the federal securities laws as a result of SEC filings and other statements made by Valeant and its former executives in 2014-2015 concerning Philidor, as well as other accounting and disclosure matters, including the Company&#8217;s disclosure of certain price appreciation credits in 2015 - 2016. The Company has entered into a settlement with the SEC that has resolved all allegations by the SEC against the Company. Under the terms of the settlement, the Company neither admitted nor denied the SEC&#8217;s allegations and agreed to pay a $45&#160;million civil monetary penalty.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMF Investigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2016, the Company received a letter from the Autorit&#233; des march&#233;s financiers (the &#8220;AMF&#8221;) requesting documents concerning the work of the Company&#8217;s ad hoc committee of independent directors, the Company&#8217;s former relationship with Philidor, the Company's accounting practices and policies and other matters. In July 2018, the Company was advised by the AMF that it had issued a formal investigation order against it. On September 30, 2020, the AMF confirmed that it had closed its investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the State of Texas</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 27, 2014, the State of Texas served Bausch &amp; Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) with a Civil Investigative Demand (&#8220;CID&#8221;) concerning various price reporting matters relating to the State's Medicaid program and the amounts the State paid in reimbursement for B&amp;L products for the period from 1995 to the date of the CID.&#160; B&amp;L Inc. and the State agreed to settle the matter for $10 million. The Company made the payment on April 1, 2020. On July 1, 2020, the State moved to dismiss the case by filing a notice that it was taking a nonsuit, with prejudice to refiling, effective immediately.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the District of Massachusetts regarding patient assistance and pricing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015 and June 2016, the Company received two subpoenas from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents and witness interviews with respect to the Company&#8217;s patient assistance programs and contributions to patient assistance organizations that provide financial assistance to Medicare patients taking products sold by the Company, and the Company&#8217;s pricing of its products.  The Company is cooperating with this investigation. There has been no material activity for several quarters on the part of the Company with respect to this matter nor has the Company had recent contact from the U.S. Attorney's Office for the District of Massachusetts with respect to this matter. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the Southern District of New York</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, the Company received a subpoena from the U.S. Attorney's Office for the Southern District of New York, requesting materials including documents and witness interviews with respect to the Company&#8217;s patient assistance programs; its former relationship with Philidor and other pharmacies; the Company&#8217;s accounting treatment for sales by specialty pharmacies; information provided to the Centers for Medicare and Medicaid Services; the Company&#8217;s pricing (including discounts and rebates), marketing and distribution of its products; the Company&#8217;s compliance program; and employee compensation. The Company is cooperating with this investigation. There has been no material activity for several quarters on the part of the Company with respect to this matter. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829975288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Chief Executive Officer ("CEO"), who is the Company&#8217;s Chief Operating Decision Maker, manages the business through operating and reportable segments consistent with how the Company&#8217;s CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports.&#160;The Company operates in the following reportable segments: (i) Bausch + Lomb/International segment, (ii) Salix segment, (iii) Ortho Dermatologics segment and (iv) Diversified Products segment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb/International segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of pharmaceutical products, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the Vision Care, Surgical, Consumer and Ophthalmology Rx products and (ii) with the exception of sales of Solta products, sales in Canada, Europe, Asia, Australia, Latin America, Africa and the Middle East of branded pharmaceutical products, branded generic pharmaceutical products, OTC products, medical device products and Bausch + Lomb products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Ortho Dermatologics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of: (i) sales in the U.S. of Ortho Dermatologics (dermatological) products and (ii) global sales of Solta medical aesthetic devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products and (iii) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, Asset impairments, Acquired in-process research and development costs, Restructuring, integration and separation costs, Acquisition-related contingent consideration costs and Other expense (income), net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun addressing the internal organizational design and structure of the new entity, which it anticipates having substantially complete in late 2021. As of the date of the issuance of these financial statements, these matters are in the planning phase. In connection with the Separation, the Company expects to realign and begin managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Separation during the first quarter of 2021.  Accordingly, the Company expects to begin reporting its segment results to reflect the proposed realignment of its operating segments on a retrospective basis beginning with its first quarter of 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration and separation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before (provision for) benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows: </span></div><div style="margin-bottom:5pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.748%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top ten products for the nine months ended September 30, 2020 and 2019 represented 41% and 38% of total revenues for the nine months ended September 30, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows: </span></div><div style="margin-bottom:13pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288840071512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the U.S. Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) and the Canadian Securities Administrators on February&#160;19, 2020. The unaudited Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2019, except for the new accounting guidance adopted during the period. The unaudited Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Consolidated Financial Statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Guidance and Recently Issued Accounting Standards, Not Adopted as of September 30, 2020</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Guidance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued guidance on the impairment of financial instruments requiring an <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU4YjI3MTZlMjE2YzQ1ODZiZmVkYjE0ODM1ZmY5MmNjL3NlYzplOGIyNzE2ZTIxNmM0NTg2YmZlZGIxNDgzNWZmOTJjY180My9mcmFnOjNhYjczNjBmMGNkNzQ4OWI5ZWQ5ODU4YWY5YmUzZTI3L3RleHRyZWdpb246M2FiNzM2MGYwY2Q3NDg5YjllZDk4NThhZjliZTNlMjdfNzQ0Nw_fc60b351-a915-4b1e-a9cf-8bbc63693281">impairment model based on expected losses</span> rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to accumulated deficit of less than $1 million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.&#160; The guidance was effective for the Company beginning January 1, 2020.&#160; The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During the nine months ended September 30, 2020, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022 the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Adopted as of September&#160;30, 2020 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on its disclosures.</span></div>In December 2019, the FASB issued guidance simplifying the accounting for income taxes.&#160; The guidance is effective for annual periods ending after December 15, 2020, with early adoption permitted.&#160; The Company is evaluating the impact of adoption of this guidance on the Company's financial position, results of operations and cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">REVENUE RECOGNITION <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 19, "SEGMENT INFORMATION" for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities.  All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839994376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock', window );">Summary of variable consideration provisions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the nine months ended September 30, 2020 and 2019.</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(454)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,902&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $33 million and $29&#160;million as of September 30, 2020 and January 1, 2020, respectively, which are reflected as a reduction of Trade receivables, net in the Consolidated Balance Sheets. Included as a reduction of Distribution Fees in the table above are price appreciation credits of approximately $4 million during the nine months ended September 30, 2020.</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,384&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Synergy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, September 30, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of activity in allowance for credit losses</a></td>
<td class="text">The activity in the allowance for credit losses for trade receivables for the nine months ended September 30, 2020 is as follows.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.829%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Valuation And Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828339704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Fair values of assets acquired and liabilities assumed</a></td>
<td class="text">The following table summarizes the fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.829%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life - 7 years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828184360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of components and classification of financial assets and liabilities measured at fair value</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effect of hedging instruments on financial statements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Comprehensive Income (Loss) and the Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.792%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.585%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) Gain recognized in Other comprehensive income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.194%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on a non-recurring basis</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.493%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288833849368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of the components of inventories</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net of allowances for obsolescence consist of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829594120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of indefinite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,432)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,355&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,432)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,887)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,432)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,355&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,432)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,201&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate amortization expense for each of the five succeeding years</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2020 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in the carrying amount of goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the nine months ended September 30, 2020 and the year ended December&#160;31, 2019 were as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.626%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.491%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill (Note 4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, September 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,820&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,160&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829665352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,353&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,511&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829855592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of long-term debt</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.875%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.50% euro-denominated debt</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,343&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,661&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of long-term debt maturities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the remainder of 2020, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,343&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829631016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of net periodic benefit cost</a></td>
<td class="text">Net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan for the nine months ended September 30, 2020 and 2019 consists of: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.980%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Postretirement<br/>Benefit<br/>Plan</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 3.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288835128728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of the components and classification of share-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of share-based compensation expense related to stock options and RSUs for the three and nine months ended September 30, 2020 and 2019: </span></div><div style="margin-bottom:11pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of share-based awards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted consist of:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended <br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTC performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829707672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of the components of Accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,046)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,207)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,086)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828452120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock', window );">Summary of research and development</a></td>
<td class="text">Research and development costs consist of:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Research And Development Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829889688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other expense, net</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of:</span></div><div style="margin-bottom:13pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829698744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of earnings (loss) per share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:13pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.507%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted effect of stock options and RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (loss) per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288835484008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment revenues and profit</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb/International</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ortho Dermatologics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(435)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration and separation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,155)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before (provision for) benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of revenues by segment and product category</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows: </span></div><div style="margin-bottom:5pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.748%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.638%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + Lomb/ International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,086&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,377&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,501&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of revenue attributed to a geographic region</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of customers that accounted for 10% or more of total revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows: </span></div><div style="margin-bottom:13pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829694152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates</a></td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288840254280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate201613Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative-effect adjustment to accumulated deficit</a></td>
<td class="nump">$ 655<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,560<span></span>
</td>
<td class="nump">$ 2,688<span></span>
</td>
<td class="nump">$ 2,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative-effect adjustment to accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative-effect adjustment to accumulated deficit</a></td>
<td class="num">$ (7,860)<span></span>
</td>
<td class="num">(7,452)<span></span>
</td>
<td class="num">$ (7,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,936)<span></span>
</td>
<td class="num">$ (5,887)<span></span>
</td>
<td class="num">$ (5,664)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Cumulative-effect adjustment to accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839393288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,697,000,000<span></span>
</td>
<td class="nump">$ 3,860,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 1,902,000,000<span></span>
</td>
<td class="nump">$ 2,156,000,000<span></span>
</td>
<td class="nump">1,902,000,000<span></span>
</td>
<td class="nump">2,156,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,050,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,384,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">2,138,000,000<span></span>
</td>
<td class="nump">2,209,000,000<span></span>
</td>
<td class="nump">5,814,000,000<span></span>
</td>
<td class="nump">6,377,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember', window );">Price Appreciation Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Reduction in variable consideration provision, adjustment</a></td>
<td class="nump">38,000,000<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">577,000,000<span></span>
</td>
<td class="nump">679,000,000<span></span>
</td>
<td class="nump">577,000,000<span></span>
</td>
<td class="nump">679,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 691,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 813,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember', window );">Rebates, Advertising Credits Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="nump">$ 29,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288838599832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Variable Consideration Provisions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">$ 2,050<span></span>
</td>
<td class="nump">$ 2,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired', window );">Acquisition of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">3,697<span></span>
</td>
<td class="nump">3,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(3,845)<span></span>
</td>
<td class="num">(4,104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">1,902<span></span>
</td>
<td class="nump">2,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember', window );">Discounts and Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired', window );">Acquisition of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(454)<span></span>
</td>
<td class="num">(583)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired', window );">Acquisition of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired', window );">Acquisition of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(1,605)<span></span>
</td>
<td class="num">(1,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">909<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired', window );">Acquisition of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">1,433<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(1,451)<span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember', window );">Distribution Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired', window );">Acquisition of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828090888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate', window );">Retrospective effect of application of new accounting standard</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Foreign Exchange And Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableAllowanceForForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288831480888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 21, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 06, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 146,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets reclassified, held and used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,562,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,562,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,863,000,000<span></span>
</td>
<td class="nump">$ 33,863,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations | Certain Products For Disposal, September 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue associated with products for disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets classified as held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations | Certain Products For Disposal, September 2019 | Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets reclassified, held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets reclassified, held and used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations | Certain Products For Disposal, September 2019 | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DisposalGroupNumberOfProductsForDisposal', window );">Number of products for disposal | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember', window );">Allegro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PotentialAssetAcquisitionAggregatePurchasePrice', window );">Potential asset acquisition, aggregate purchase price</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice', window );">Potential asset acquisition, upfront payment included in aggregate purchase price</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice', window );">Potential asset acquisition, additional funding payment included in aggregate purchase price</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member', window );">Synergy Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments to acquire certain assets and assumed liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue of acquiree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual', window );">Operating results of acquiree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Pro forma revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss', window );">Pro forma operating results</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Pro Forma Operating Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionProFormaOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DisposalGroupNumberOfProductsForDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Number Of Products For Disposal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DisposalGroupNumberOfProductsForDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Asset Acquisition, Additional Funding Payment Included In Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PotentialAssetAcquisitionAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Asset Acquisition, Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PotentialAssetAcquisitionAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Asset Acquisition, Upfront Payment Included In Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288835308376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,160<span></span>
</td>
<td class="nump">$ 13,126<span></span>
</td>
<td class="nump">$ 13,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member', window );">Synergy Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Product brand intangible assets (estimated useful life - 7 years)</a></td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses', window );">Accrued expenses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total fair value of consideration transferred</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Product brand intangible assets, estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288838892600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration and separation costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">$ 648<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember', window );">Restructuring and Integration Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Liabilities associated with restructuring, integration and separation costs</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Facility closure costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationCostsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration and separation costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288832826824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 16, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_HighlyLiquidInvestmentsMaturityPeriod', window );">Highly liquid investments, maturity period (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | NEW JERSEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, escrow fund included in restricted cash</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="nump">$ 1,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_HighlyLiquidInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Highly Liquid Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_HighlyLiquidInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839229112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Payments or receipts in settlement of cross-currency swaps</a></td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument | Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">21,000,000<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument | Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288835334808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - Net Investment Hedging - Cross-currency swaps - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">(Loss) Gain recognized in Other comprehensive income (loss)</a></td>
<td class="num">$ (54)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain excluded from assessment of hedge effectiveness</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839005816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details) - Foreign currency exchange contracts<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss', window );">Loss related to settlements during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 187,000,000<span></span>
</td>
<td class="nump">187,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value, derivative liability</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Fair value, derivative, included in other current liabilities</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value, derivative, included in prepaid expenses and other current assets</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Net change in fair value, loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288826865224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details) - Recurring basis - Level&#160;3<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Weighted-Average Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.08<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288840072920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 316<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion included in Accrued and other current liabilities</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember', window );">Accretion for the time value of money</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember', window );">Fair value adjustments due to changes in estimates of other future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839177320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details) - Fair Value, Nonrecurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828215528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details) - Nonrecurring adjustment - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">$ 25,258<span></span>
</td>
<td class="nump">$ 27,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828200728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Components of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">726<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total Inventories</a></td>
<td class="nump">$ 1,224<span></span>
</td>
<td class="nump">$ 1,107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288838815816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,644<span></span>
</td>
<td class="nump">$ 25,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(18,432)<span></span>
</td>
<td class="num">(17,123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">7,212<span></span>
</td>
<td class="nump">8,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">27,355<span></span>
</td>
<td class="nump">27,324<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">8,923<span></span>
</td>
<td class="nump">10,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D not in service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Bausch Lomb Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">21,057<span></span>
</td>
<td class="nump">21,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(14,673)<span></span>
</td>
<td class="num">(13,544)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">6,384<span></span>
</td>
<td class="nump">7,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Bausch Lomb Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">921<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(388)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">3,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(3,013)<span></span>
</td>
<td class="num">(2,887)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288835465800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="nump">$ 49,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,711,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations | Certain Products For Disposal, September 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets classified as held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportUnitMember', window );">Ortho Dermatologics Report Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Ortho Dermatologics Report Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Ortho Dermatologics Report Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">38,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember', window );">Discontinued Product Lines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Long-Term Growth Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestLongTermGrowthRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288826918408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">1,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2025</a></td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 7,212<span></span>
</td>
<td class="nump">$ 8,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288840179400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 13,126<span></span>
</td>
<td class="nump">$ 13,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of certain assets of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillReclassifiedDuringPeriod', window );">Assets held for sale reclassified to goodwill (Note 4)</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">13,160<span></span>
</td>
<td class="nump">13,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember', window );">Bausch + Lomb/ International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">5,786<span></span>
</td>
<td class="nump">5,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillReclassifiedDuringPeriod', window );">Assets held for sale reclassified to goodwill (Note 4)</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">5,820<span></span>
</td>
<td class="nump">5,786<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">3,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of certain assets of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">3,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">2,914<span></span>
</td>
<td class="nump">2,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">$ 2,914<span></span>
</td>
<td class="nump">$ 2,914<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillReclassifiedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Reclassified During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillReclassifiedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288835334936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_Legalsettlementsandrelatedfees', window );">Legal matters and related fees</a></td>
<td class="nump">$ 1,462<span></span>
</td>
<td class="nump">$ 1,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductRebateCurrent', window );">Product rebates</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductReturnCurrent', window );">Product returns</a></td>
<td class="nump">577<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefit costs</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 4,353<span></span>
</td>
<td class="nump">$ 4,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the current portion of accrued product rebates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductReturnCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductReturnCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_Legalsettlementsandrelatedfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal settlements and related fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_Legalsettlementsandrelatedfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288831851656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
<th class="th"><div>May 23, 2019</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 24,601,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,188,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">24,343,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,895,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,234,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 24,343,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,661,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 3,498,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,869,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 3,414,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,768,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 6.50% Senior Notes Due March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,242,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 7.00% Senior Notes Due March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,986,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,983,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.50% Senior Notes Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,735,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,733,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.75% Senior Notes Due August 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 494,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.50% Senior Notes Due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 284,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 283,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Notes Due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 99,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,448,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 99,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,441,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 4.50% Senior Notes euro-denoted debt Due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,758,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,682,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,752,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,674,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 3,233,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Notes Due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,477,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,473,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.25% Senior Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,486,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,484,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,755,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,756,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00 % Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 741,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,235,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,234,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.25% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,480,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25 % Senior Notes Due May 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 741,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">1,235,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,234,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5875DueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5875DueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes450DueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes450DueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839484728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Covenant Compliance (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember', window );">Senior Secured Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments', window );">Amount available for restricted payments</a></td>
<td class="nump">$ 12,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Amount Available For Restricted Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288917939320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,343,000,000<span></span>
</td>
<td class="nump">$ 25,895,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet', window );">Debt covenant, mandatory prepayments, percentage net cash proceeds, property and asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet', window );">Debt covenant, mandatory prepayments, percentage net cash proceeds, incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet', window );">Debt covenant, mandatory prepayments, percentage of consolidated excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet', window );">Debt covenant, mandatory prepayments, percentage net cash proceeds, asset sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities | Federal Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities | Eurocurrency rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities | Eurocurrency rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">Revolving Credit Facility Due June 2023 | Eurocurrency rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">Revolving Credit Facility Due June 2023 | Canada Bankers Acceptance Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">Revolving Credit Facility Due June 2023 | Canada Bankers Acceptance Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 4,565,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,414,000,000<span></span>
</td>
<td class="nump">3,768,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025 | Eurocurrency rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,185,000,000<span></span>
</td>
<td class="nump">1,257,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025 | Eurocurrency rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025 | Base Rate or Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Threshold for incremental borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA', window );">Threshold for incremental borrowings, percentage of adjusted EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Eurocurrency rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Eurocurrency rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023 | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Amortization Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAnnualAmortizationRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288840216344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 16, 2020</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,162,000,000<span></span>
</td>
<td class="nump">$ 3,956,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member', window );">5.75% Senior Notes Due August 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member', window );">8.50% Senior Notes Due January 2027 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5875DueMay2023Member', window );">5.875% Senior Notes Due May 2023 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="nump">$ 584,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5.625PercentDueDecember2021Member', window );">5.625% Senior Notes Due December 2021 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 518,000,000<span></span>
</td>
<td class="nump">$ 182,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member', window );">5.50% Senior Notes Due March 2023 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember', window );">Senior Secured Notes and Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5875DueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5875DueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5.625PercentDueDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5.625PercentDueDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288830590488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Jan. 16, 2020</div></th>
<th class="th"><div>Dec. 16, 2019</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
<th class="th"><div>May 23, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,162,000,000<span></span>
</td>
<td class="nump">$ 3,956,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">51,000,000<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | US Securities Litigation | NEW JERSEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, escrow fund included in restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,010,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member', window );">Term Loan B Facility Due June 2025 And November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PaymentForDebtAmortizationPrepaymentCost', window );">Debt amortization prepayment</a></td>
<td class="nump">$ 303,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 8.50% Senior Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 7.00 % Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 7.25 % Senior Notes Due May 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 5.875% Senior Notes Due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 584,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 5.50% Senior Notes Due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 5.00% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 5.25% Senior Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 6.25% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 6.25% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 6.25% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 6.50% Senior Notes Due March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased principal amount</a></td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForDebtAmortizationPrepaymentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Debt Amortization Prepayment Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForDebtAmortizationPrepaymentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5875DueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5875DueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828427992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">5.94%<span></span>
</td>
<td class="nump">6.21%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288840116728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Maturities and Mandatory Payments, Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 29, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Jan. 16, 2020</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>May 23, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,162,000,000<span></span>
</td>
<td class="nump">$ 3,956,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(51,000,000)<span></span>
</td>
<td class="num">$ (40,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased debt, aggregate par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Notes Due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased debt, aggregate par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="nump">$ 584,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Notes Due May 2023 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 99,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.50% Senior Notes Due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased debt, aggregate par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.50% Senior Notes Due March 2023 | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5875DueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5875DueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839117816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">2,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">2,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2025</a></td>
<td class="nump">10,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt obligations</a></td>
<td class="nump">24,601<span></span>
</td>
<td class="nump">$ 26,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized premiums, discounts and issuance costs</a></td>
<td class="num">(258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 24,343<span></span>
</td>
<td class="nump">$ 25,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288838911064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | U.S. Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit and other</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839084168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 28, 2020</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average service period over which compensation cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">2014 Plan | Non-employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant', window );">Aggregate fair market value on awards granted during any calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_NonemployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_NonemployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288826233016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288838702264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price (in usd per share)</a></td>
<td class="nump">$ 24.74<span></span>
</td>
<td class="nump">$ 23.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 8.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,084<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 22.05<span></span>
</td>
<td class="nump">$ 23.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember', window );">TSR performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 26.13<span></span>
</td>
<td class="nump">$ 34.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember', window );">ROTC performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 27.05<span></span>
</td>
<td class="nump">$ 25.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288840046488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of AOCI (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">$ 655<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="nump">$ 2,560<span></span>
</td>
<td class="nump">$ 2,688<span></span>
</td>
<td class="nump">$ 2,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2,165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension and postretirement benefit plan adjustments, net of income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (2,207)<span></span>
</td>
<td class="num">$ (2,223)<span></span>
</td>
<td class="num">$ (2,086)<span></span>
</td>
<td class="num">$ (2,156)<span></span>
</td>
<td class="num">$ (2,061)<span></span>
</td>
<td class="num">$ (2,137)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828320200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amount reclassified from accumulated other comprehensive loss into operating results</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288834987704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseProductRelated', window );">Product related research and development</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance', window );">Quality assurance</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseProductRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Product Related</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseProductRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Quality Assurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseQualityAssurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288835250568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Summary of Other Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net gain on sale of assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development costs</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_OtherMiscellaneousNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherMiscellaneousNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Miscellaneous Nonoperating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherMiscellaneousNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288832694216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount', window );">Benefit for discrete items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Tax benefit related to release of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax benefit related to change in United States law</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Tax charges (benefits) related to changes in uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax benefit related to stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount', window );">Tax expense related to filing certain tax returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit on ordinary loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount', window );">Tax benefit related to royalty payments by affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount', window );">Tax benefit related to filing certain tax returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="nump">2,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount', window );">Tax benefit related to Global Intangible Low Taxed Income (GILTI)</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties', window );">Unrecognized tax benefits including interest and penalties</a></td>
<td class="nump">1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits related to interest and penalties</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</a></td>
<td class="nump">363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Unrecognized tax benefit, amount possible to decrease in next twelve months</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Benefit Filing Tax Returns, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deductible Royalty Expense (Benefit), Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Discrete Items, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income, Expense (Benefit), Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839502264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE - Schedule of Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to Bausch Health Companies Inc.</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="num">$ (49)<span></span>
</td>
<td class="num">$ (407)<span></span>
</td>
<td class="num">$ (272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">355.6<span></span>
</td>
<td class="nump">352.4<span></span>
</td>
<td class="nump">354.7<span></span>
</td>
<td class="nump">351.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Diluted effect of stock options and RSUs (in shares)</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">357.8<span></span>
</td>
<td class="nump">352.4<span></span>
</td>
<td class="nump">354.7<span></span>
</td>
<td class="nump">351.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings (loss) per share attributable to Bausch Health Companies Inc.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in usd per share)</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in usd per share)</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (1.15)<span></span>
</td>
<td class="num">$ (0.77)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140289027022488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock Options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,453<span></span>
</td>
<td class="nump">3,144<span></span>
</td>
<td class="nump">4,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember', window );">Time-based RSUs, Performance-based RSUs and Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="nump">10,489<span></span>
</td>
<td class="nump">5,363<span></span>
</td>
<td class="nump">10,604<span></span>
</td>
<td class="nump">5,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288828413128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Current accrued loss contingencies</a></td>
<td class="nump">$ 1,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288917926424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 04, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2017 </div>
<div>insurance_policy_period</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Sep. 16, 2016 </div>
<div>action</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>group </div>
<div>case </div>
<div>action</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Sep. 13, 2019 </div>
<div>action</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>action</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>entity</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber', window );">Number of suits filed but not yet served | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction', window );">Number of entities, exercised opt-out right, pursuing action | entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors', window );">Number of groups of investors filing action | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of claims dismissed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending', window );">Number of groups of investors filing action, remain pending | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_RICOClassActionsMember', window );">RICO Class Actions | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DerivativeLawsuitsMember', window );">Derivative Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits', window );">Number of alleged stockholders, filed lawsuits | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods', window );">Number of distinct insurance policy periods | insurance_policy_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency New Claims Filed But Not Yet Served Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNewClaimsFiledButNotYetServedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Insurance Policy Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfInsurancePolicyPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_RICOClassActionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_RICOClassActionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DerivativeLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DerivativeLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288838636952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Antitrust (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 25, 2019 </div>
<div>case</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>healthPlan</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>healthPlan</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>case</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>case</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GenericPricingAntitrustLitigationMember', window );">Generic Pricing Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits', window );">Number of health plans commenced action | healthPlan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfHealthPlansFiledLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Health Plans, Filed Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfHealthPlansFiledLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GenericPricingAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GenericPricingAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288829675416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Product Liability (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>case</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="nump">12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839344680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - General Civil Actions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember', window );">Doctors Allergy Formula, LLC Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember', window );">Litigation with Former Salix CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839962056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Completed or Dormant Matters (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payment for legal settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | SEC Investigation Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | Investigation by the State of Texas, State's Medicaid Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payment for legal settlement</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_SECInvestigationLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_SECInvestigationLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288941479272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Segment Revenues and Profit (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,138<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 5,814<span></span>
</td>
<td class="nump">$ 6,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="num">(1,263)<span></span>
</td>
<td class="num">(1,452)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration and separation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Acquisition-related contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(374)<span></span>
</td>
<td class="num">(406)<span></span>
</td>
<td class="num">(1,155)<span></span>
</td>
<td class="num">(1,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">$ (27)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before (provision for) benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="num">(540)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember', window );">Bausch + Lomb/International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">3,166<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,138<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
<td class="nump">5,814<span></span>
</td>
<td class="nump">6,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">2,588<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Bausch + Lomb/International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">3,166<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">333<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (158)<span></span>
</td>
<td class="num">$ (442)<span></span>
</td>
<td class="num">$ (435)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288826416344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,138<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 5,814<span></span>
</td>
<td class="nump">$ 6,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">976<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember', window );">Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember', window );">OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember', window );">Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember', window );">Bausch + Lomb/ International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">3,166<span></span>
</td>
<td class="nump">3,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember', window );">Bausch + Lomb/ International | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="nump">552<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember', window );">Bausch + Lomb/ International | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember', window );">Bausch + Lomb/ International | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember', window );">Bausch + Lomb/ International | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember', window );">Bausch + Lomb/ International | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">494<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">1,374<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">557<span></span>
</td>
<td class="nump">617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_DeviceProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BaushandLombInternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288831616488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details) - product<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ConcentrationRiskNumberOfProducts', window );">Number of products represented of total revenue</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288839613240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenue by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,138<span></span>
</td>
<td class="nump">$ 2,209<span></span>
</td>
<td class="nump">$ 5,814<span></span>
</td>
<td class="nump">$ 6,377<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,301<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
<td class="nump">3,522<span></span>
</td>
<td class="nump">3,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_EG', window );">Egypt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RU', window );">Russia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 719<span></span>
</td>
<td class="nump">$ 782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_EG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_EG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140288840019208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Major Customers (Details) - Revenues - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">McKesson Corporation (including McKesson Specialty)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">Cardinal Health,&#160;Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M8 6L^$;BH][>0.LG=7RYEM;_LFU3FR8!RS<6==6"24$E5//EK^T<]@"]_A%
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M;T+F &28>.L+@.*HAW(GJG!857T5DA=K2WFY,7**UT57V)P,TO4ESM MDC,
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M2>AM]6,,/SB$*P"\WS(FWP8J0/G+-/H%4$L#!!0    (  ^)8U'+8)F3B D
M  LZ   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULQ9MO<]HZ%H>_BH:]
MLWL[4XKUSYANDIDDD(M+VV1+NCL[._O" 1&\U]A<VS3MM[\RN A+Q[*3D&Q?
M-)#\))TCGR,].H*3AR3]/5L*D:/OJRC.3CO+/%^_[_6RV5*L@NQ=LA:Q_,LB
M25=!+M^F][ULG8I@OFVTBGK$<=S>*@CCSMG)]G<WZ=E)LLFC,!8W*<HVJU60
M_K@04?)PVL&=G[_X$MXO\^(7O;.3=7 OIB+_NKY)Y;O>OI=YN!)Q%B8Q2L7B
MM'..WT]XOVBP5?PS% _9P6M4N'*7)+\7;_SY:<<I+!*1F.5%%X'\\4U<BB@J
M>I)V_%%VVMF/630\?/VS]ZNM\]*9NR 3ETGTKW">+T\[7@?-Q2+81/F7Y&$L
M2H=XT=\LB;+M_^AAI^V3#IIMLCQ9E8VE!:LPWOT,OI<3<=" N34-2-F : VX
M4]. E@VHU@"SF@:L;,"T!J1?TX"7#;C>H,XDMVS@:@W<04V#?MF@KS6@=29Y
M90.O[2P-R@8#K8%7UP [/Y^<H[M=-[%X_[!W0;>+DFV(#8,\.#M)DP>4%GK9
M7_%B&Z?;]C*RPKA(J6F>RK^&LEU^=GG]>7K]T1^>WXZ&:'HK?WP:?;Z=HNLK
M-!V??QF-KS\.1U^F?T.C?WSU;_^-NNCK=(A^_>4-^@6%,?H41I',C.RDETMC
MBBY[LW+@B]W I&;@VR0/(J#9I;W9Y6:UB8(B#=%HL9!Y^1;=B#1,YBA9H/-Y
MLBX2]:U\]3\Y>S+U<V"(8<,0R6HEDWVZ#%(!.3:R-S^?S\/"B"!"-T$X[_HQ
MN@S6(>SM54-?L]G.7S%'0[$(9R'DSV^/[N08LSAN/^IUOA0IDO,J5_UEL1S+
M<3\F&32YOKW7BV C=Q4T%D&4+[<]!G$HLK_^!;O.W_UX]F[WV)9)-!=I)J/V
MCTV8_P#&^? 2XQQC6B=VPSXG\2R)\S21>1??(S_.A8Q2K:.>7 3V*P'9KP1D
MVS.K<UG<AW%<='H11$$\$^A7F>#9-@O>H""7L2/=IO@M(@[VH+3:]<^W_1=;
M^;<SR@8#I_AWTOL&F$;WIM%'FM;"G(M=G^Z!.<3#?&_)SF93A!U,<%4U,E4,
MTZKFRM1TN>NRJFH,J BF_:K*!TSO4VW B2GR"#S/;#_/;-N&ULRS#&R)99E\
M\G)RMZ_>%(M\<TI51N/[T;CUJ9;K["["4)AE&[E4;&(YRNYWW0*5YF@FDT^N
M&<&6P-;R\6>'@0G%(3?BD'!+%+I[>]V7L1<*3M?,%2TR73/FM# 9F9UTF19P
MOFV@RC3T]]/0MT[#M,97R,N^,7A?]Z%9XELE%1^\O0^>U8?1:ATE/X20N)4O
MB\@NUI8\^"Z?:RIV>U:>5)YJ\!"D<_!)>L!#<#0G6VA\NZ;BYF#OYL#JIK99
MA.5F@>9AEJ?AW2:O0[>!:8NGK3Y62<5:["@6=>SVRB-D*$U>R14HDGP 9?=%
MV4=E9.*ZVFH,JOI$F_-6J@F@<FM</<!N;'5UAT2S"A+M?"YG '0= ^9J>]48
M$N&![G@+T00<KL9Q11G8CAFC>&YAC*E8RTW=V6[J Q#= <C@A%F6=ZPH ]LQ
M0S.MA3D798_5O<;54GN(0<IPM90: 9TQQPAL4]3E ^KJ40#(".:N'@> _<PS
M$L!4]>N27;$&9B_,F^4 CP!.K-@$V^'D:<A9=MK G( *@DYL<HQ)G8 (PDY(
M!G G( / $U#5D2=6<(7M=&5?%PYG'DY$@'.X3$7BZJDQA*6N+6P4&V$[')E+
M2+/E?3,:L&[T):#J8MTQH"<'Z]O9")L\Q<A CRM3U.TSKO7U6PNSQE!7Q/&,
MI<B48<?58N]#BP$G0$_]&NC%BABQ]PIG(ZS0#=O9[7PV2S9Q7D33- _B>8&?
MZ.MZ+N$4_6?T/2^8X2X2Z*-DN?^"<67O?Y-U[X-@_5Z-LQ]F-XJ,5Q?33V)U
M)U);>4'1';'37>."_V$3VS=_8H*8S%QBR5RB@(S8@0Q<\)LLNB@[K2SXKJ=M
M[$- 5>S_VKXP(B9O44];R:\ 49=[GK:2CR$9<5PM57Q )E="/:$ E5=S B,'
MY2;R"@E%%-T1.]V]6+F!  QE"TE%2,1.2$<M.! 3EG1,+26'84KU$#5[Z5(]
MIFPC5:="X1BQX]ACB@X$@!A7]Z-9X]LU54<4YI &S#EBY8$ ]1\=(EMH?+NF
MZJ@B(6(GH2?7'@B "WKQP:ZI6JQV>&(O"K6J/A"H3./I:S0DTH_@;4030%3W
M9!19$/O._Z32 P'J/0-CTX%$7/>[A6@"B6J.&%0!"+4#R#-+#Q2D#UOI@2KZ
MH';Z>$+I@0+H898> !54>J#F#F^6'@ 15'J 9$#I 9 !I0= 55=ZH H]Z!&O
MNN#)!\M0X'$3EMJ.F_3@7NR9%V.P\4 YRCQQ BKCQ GU!)PX*5#8,DZ<@ @Z
M<;8P:PQU!9PX 1EPXFPQX 3HJ>[$217^T=>XC:.*L>C_Z3Z. B!E73853=%7
MO)*C)@81/=Y;7,H!W729O@E:QZI.AB(N>KR+.6H"E&=<>C=K?+NFZH@",?IZ
MMW,4H"RJ7\^U$?D-HJJO"L;H"UW148"07'U9LFJJ'Q%0%,6.<$G'@(LUYFBI
M<M5*Y3>IJGXHY&(O< /'3)SJ8J*%RIA!MVMZ?=]OI9H JIH$8XI_V)'NX K/
M@$F B(8[Q!UP'3]KI);%GRGX8<^XKJNQW-S+7:Y?SP B[!#]=G3$ *BA7(]P
M"&H\G=+'D(P0,Q-,&=<K?Q- Y-80,SOX8-!KL A3+,+L+/+LZG=#_\>J?C.%
M*LR.*H^I?H/!.V30O16S77<RQ0[,S@Y-U>^:=#(O8SC3SS^ J$@G'9L8<"N%
ML9Y.T*W4@.K\#\D((7JA$AJRS_1T BZ3ZCYFIPB'O<9E$E.4P>R4\6)HSTS"
MP): Y(HRN)TRCDKVW"0(?:,J)95JBA:A0"]=_0-%UI&J4Z% A=M!Y3%<SX&B
MBIYI+32^75-U1&$';\".(W(]-\'"J'VWT/AV3=5112;<3B9/AGH.<( .]79-
MU6*UOW/[55,KJ.?FQ4Y?RZ,K2&/,>;-F FAJG\O!!X[MN_Z3D)\#G];16'#,
MS0H'UJM-+3030%-31N(*//AS/EC3B,P<H@X8]FNDMOU  0I_[ =KFBTWP<.$
M?4 $P3X@,V$?$$&P#\D V =D)NQ#/NJPWSOX=ECQ-<E/02IA+T.16,A&SKN^
M?&#I[IN'NS=YLMY^8>PNR?-DM7VY%('<>@N!_/LB2?*?;XKOH.V__WGV)U!+
M P04    "  /B6-1/>B;_7((  #B)   &    'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;*V:76_;N!*&_PIA[,4N$-<6)7\528 T;<X&:)N@[IZ]9B0ZUJDD
M>DDZ;O;7GR'MB+(XI!/LWK2R,Y)>CF;FF:%UOA/RAUISKLG/NFK4Q6"M]>;]
M:*3R-:^9>B<VO(&_K(2LF8:/\G&D-I*SPIY45R,Z'D]'-2N;P>6Y_>Y>7IZ+
MK:[*AM]+HK9US>3S!UZ)W<4@&;Q\\:U\7&OSQ>CR?,,>^9+K/S;W$CZ-VJL4
M9<T;58J&2+ZZ&%PE[Z\G8W."M?AOR7>J<TS,4AZ$^&$^W!87@[%1Q"N>:W,)
M!O\]\6M>5>9*H..OPT4'[3W-B=WCEZO?V,7#8AZ8XM>B^K,L]/IB,!^0@J_8
MMM+?Q.YW?EC0Q%PO%Y6R_Y+=P78\(/E6:5$?3@8%==GL_V<_#X[HG #7P4^@
MAQ-H_X0L<$)Z."&U"]TKL\OZR#2[/)=B1Z2QAJN9 ^L;>S:LIFS,8UQJ"7\M
MX3Q]>7WW=7GW^?;CU?=/'\GR._SWY=/7[TMR=T.NKY:_DYO/=W\NR9#\L?Q(
M?OWE-_(+*1ORI:PJ> ;J?*1!@KG0*#_<[L/^=C1PNP7Y(AJ]5N134_#B^/P1
M2&_UTQ?]'VCT@DN^>4?2\1FA8SI&]%R_^O1D$9&3MNY,[?72D#N96I,;R U%
M;J2HR=V&2Z;+YI%<F7@M=<E5Y#99>YO,WB8+W.8KY'<E%/H ]F=.[9DFB9\N
MA]EX=CYZZGH%,:+3:6MT)&K2BII$UWY5_ _B%5)<*Z(%Y'@NFKRL.&D.:LVW
MYC@W3MI(\51"#)"'9R):+['62^\C;IJVBJ91-WWD4-KRDNT+1E,05@NIR[_W
M7X@5Q+)FS6/Y "*94ERC#MW?8]+Q59(N^@Y%C";S%'?HK)4_B\J_ZJHU\G>R
MU'PH5BNCO> /&KS(ZW);JS-2E"H76^-[8UDJM65-SDDN%+ZJF2<XF_36A)@L
M\!7-VQ7-XRLR3B9EO6&EM(&"*9O[KNQ[VS<)*5NTRA9Q9?E?VU*5QM5#R2NF
M(3(A?DU0@DYSJ"!:I7T6F.B%IXA.>Z(1$UQS,G;%>QQ774&I,<]9$2"Z33(X
MA&C1DA7<I" OGY@-;Q,4S1.L14BO!ATJ]]@3.*&]-2 V6:!L)!T$)2?2=,6E
MY$9@+FI.-/L94)AX=Q_2).UKQ*S20"XFU*FD497_@9[(N%8Q<"?D7[A@'"YT
M)"#IB\1LQ@&-CCY)&H^'HK A;$LMRW.Y!:]6_)%5!,3JB@>3[G#AHZS+^FF'
M&85BV*$LB;/LGCWOF6%\^B;)F>_"N1>PB%$6D.Q ETRBDI=K)OG0=(^F2-30
M4JM@83A<JBM@[@6#;S.;!40Z]B5Q^$&7"SUL0_C/? V0X\&&(4'8E?45^C;S
M@$!'MR2.-YM0H*[:FC9@9=JE-2] *%^MN.WN&QY0[)-IZ#$",PH5 <>O) ZP
MSZ:-$4:V(0,08VW"\P7'J%:?51/O^2,\"]4"![0D3K1N7H5(1ICKV<Y,^85G
ML6_#<LF#$>V#;-Q?D&_2J8#'C;Z#'8W#[DZON<0$41]*PWXT(#9IP,74@8LF
M\6[?)I8R(U&GA;5<L,"M2O905B?;6>H81.,,^M[#.IH=U$?+U'.';Y.$\$,=
M?F@</[?Q!H/Z^("TG?>E(59T/ EH<YBA)S C.72=!62N*==\_X"$"2D8LZ'[
M@-0($YWZ%$GZ28S9!%HCZDA#XZ2YR@]-_88]FP=^UB+2R>]$&:K=A\N0SOO-
M*685ZIFH8Q"-,^CK:Z<]5+C/G)E7Y1&CA$X#\*2.373VICG>1+9Z_1Q/'5#H
MB8G(S1VF4#]L56FHQZ$<FU'9U&XCA1DSV=\Q.?C)IT>_'B,FPV0>RG>'&'H"
M,5L)O84=.5;F$<.#U<]G9%,QDTT0H!Q4;PQ=4-T()"CM-W"85;((=)VI@TD:
MATE+1S,W=;<!VK0*5X,4X4U_",%L @1,'6_2^*!TY.^:R1]<V^%.<2AAP3Q*
MD7G(DXO8!!J\U-$JC=/J7HJ<\T+M>[N7N>GUNGU&];,?,0G4K+2S@Q>'&*ZZ
M0W4L1\TNBYFY%*\J="T^U&@?((A-%AA54H>]-(Z]VT9S":6K.TSM5Y9+Z&6'
M>_;EST3MV 9_##[7J!<^ODV@N*0.?6D<?2T[MLIN#=CM"_4*;J0(RI*9%SHH
M\$+^=L1+IV\"QTW9L"9_-3A21Z@T/CW=ONSP0?A5HGD<PG.N[1321F6[)8AZ
MR1^/8.#OMP6(54K34&5PU$OCU/L&O9B;3H[EHV(1?J7)M,\*U&PQ"71AJ>-<
M>H)S1R4!Z-#NKUK]:BVD/K$ GV)>^B,F <QE#G-9''/'CGZ%T"S*K<./!YA-
M2*J#6W8";AVAO-Y4XIESLBOU>BTJ.Y3:;4'RLCEKBFUG&X;MF"SPWT,P_/4;
M),PH-()G#H#9"0 >;6W]LPWF#-DP])>!&-% ,YPY(F8GB-A9QJJM9\%?%C)D
M@$L7?:78E!=(U*SSLUB<=L$M@@S9!NS7.LPFT+)ECF+9&RGF'!BG6(92;.'E
M(F(V#R:CPU@6']P^V2TXFXHOVX<0FISDAQT/F%;V<PGT0_; =/I/T"L%:)/Y
M8]JP_W,39I.$@M=Q,HMSTCR 7PN>2PYUXC>SQV6/S*,(KL!^:;HF6>8V3^'O
MZ*JP?4@Z\0(+0>TXT&EDCJ%9G*'7;U%_1A[X8]DT)N[,K,9E*=!A,O,1FM*L
MOQV,6,UHH//.'&:S.&;?N")N1K7H6A"B+N;]_2;$:AZJF1,'WDD<O/_V6@ZW
MF\;7@ECY:QEUWA:IN7RT+]$H8EO%_8L7[;?MBSI7]O64WO<?DO?7^]=MW&7V
M;_]\81*B39&*K^"2XW<S\*[<OU"S_Z#%QKZ3\B"T%K4]7',&_#,&\/>5$/KE
M@[E!^UK3Y?\!4$L#!!0    (  ^)8U'\MTH&10,  . &   8    >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&ULI551;]LV$/XK!Q4H$L"Q9"7MNL8V$+M)ZX<V
M1MQN#\,>:.DL$9%(E:3B>+]^'RE92X V&+8'V^3Q[N-WWQW/T[TV][9D=O18
M5\K.HM*YYGT<VZSD6MBQ;ECA9*=-+1RVIHAM8UCD(:BNXC1)WL:UD"J:3X-M
M;>93W;I**EX;LFU="W-8<*7WLV@2'0UWLBB=-\3S:2,*WK#[UJP-=O& DLN:
ME95:D>'=++J:O%]<>/_@\)ODO7VR)I_)5NM[OUGELRCQA+CBS'D$@9\'7G)5
M>2#0^-YC1L.5/O#I^HA^$W)'+EMA>:FKWV7NREGT+J*<=Z*MW)W>?^(^GS<>
M+].5#=^T[WV3B++6.EWWP6!02]7]BL=>AW\3D/8!:>#=7118?A!.S*=&[\EX
M;Z#Y14@U1(.<5+XH&V=P*A'GYA^N-\N[U?KKZO8+W=[0XMMF]>5ZLYG&#N#>
M)<YZH$4'E/X$Z%?ZK)4K+5VKG//G\3%(#<S2([-%^B+@AILQG2<C2I,T>0'O
M?,CT/."=_P3OUA1"R;^$;X81+;6RNI*YZ'I#Y;0V;%FYSJ!W=".54)D4%6U@
M9#2BL_3'U=8Z@U;Z\P5&%P.CB\#HXO]K_Y^ :"%:O&+ZQ*)R)5*N&RC EE8J
M&].)*_GUJ\G;Y/+UJW=IFEQVYX>PFUR2-A0] XA.25H25*/AH8W7250CL@U[
ME=R!FE+@G63<.IE!-B]JS7E8Y_P@,Z:LNX)<*9RW828T=H1^5NT.HK8H01<F
MS#T[G#1&8BVK TF%*/8?(YIP!0E,(>M+Q0<^*P/'$14"!=(H%AM=Z>) )]''
M%:A[V)S].P[F$1+9&BUR,D(5[%&V6*%U <&*C<='2&\<;,]S!$/]P.8,K,XR
MW?I+Z:27\_;KLI?R%&GHO,V<_8$FEDXR/!QD3Q5F'0-2*K28SMI*F,&FFQ*B
M534HV-84 8"_M[+Q?1E@!5O0 "U[1#ZE?2E1/NC4*XI$<FDP$"$HZBO5L(.\
MH@'-1^CM&(9)DE!(R:!CQC_J]OC)U*G9%&&VVBZH&T"#=1C?5]W4^L>]F_V?
M!5)2%MGN$)J,?WD3D>GF:;=QN@DS;*L=)F)8HN"HIW? ^4YK=]SX"X8_M?G?
M4$L#!!0    (  ^)8U&83BA61@X  /$F   8    >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&ULM5IM<QNW$?XK&'6F=::TWNPD3F)[AI+?E":VQK+3#YU^ .]
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MY]L5I2$.VG.DIWR9B \&&J"&KWT4OB%/R(0)<<QGP05(A)'7 H+LQ /FAF\
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M I<<H\G+(6JN4Y'01,%R8&7LACB'+QN+?J8<W:CY$\]>["815/)2?L^2APL
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M%'2!X/OTL5VK EQ!;0@*4<,"ZS?>@@41R5$W'')'*.C8KKH';$V=I:&&AMZ
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M?(Y7?CSJ#P"GJTX&:OM@,IT)X&_8G\YG>)V,QV(XN1#C_OG%3'R4.Y\%.9L
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M.O;8GI$?37V(XY&4]M#I 0*7(B8@P "@9/;7=Q<@:<F6'*5-+Q()[G[[[1/
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MQ8;=EN*;\A5NM$*9$+2.-8):P?PAH3;]HP20B1XO&3R2=TTE*I*10EQ#7$
M9]J2< 7P, /84N+"H,>KH7[.-:7?@U4=RW**F1<)K J==<2B)/S4*MY&PM"T
MX]C]X/_"*]R%C8<#5UX<=%!S:ZBW!LKOM80<%/9W,K-3('X8WA+9HQ,P>ZUZ
M>!9@R_, A(M $&#Q3"Z+:'H&A/1\G6*"B;BYR=A.H.IL0=K.@K6P(CA&HBP
M\.^ 6B"GV9E<F+C4*HF)]'VI@%8"_!LT I$(FM4@H=T7HL, E0"_] $Q =ZD
MY?I2Q<ZES99>D[2-07IPJT/)<;ME<9P.%189D)B0W5+JQ.#6P#VL' Q$R7RM
MFE)##"9YE0(?TS9@\G.B1Z+1L!6@P8$Q"585?\Z#W85"0'W+^-<429_K_O%8
M^3*<]%0%\D$4Y;.<R."5KWFCAD"\"A_GE0ZE-C96A@H88Q-8FZ_A&L5M]<H#
MDP:^+[T86K\Q]?CE-Z]%SYP08-/E0F@_-XWZO&J*VXV0056>#T9LJ+Y*96]&
MIG*NB@ ETQ2/FR0 B80*69H0Q(R6\J<JXSI\@;PE]K&T*/"=*^JR!FF!JK "
M'$4X;U4'V%X5CH) A-U2&QC;;1&(5N/&FLJKE7E1>2U)C%80Q@I?+:H6DD#8
M28G :-0V '69\[">N==' M.X2H/RL+);-KX458(7)FO4?_#"[5ZW2;?7JR.]
M=BURFZMB\@&N+ &B@T;]@. 6@6LH0(EAO\GOM,Y.29MZ1.#W*+0%OHOBGJ3/
MA_IJ5N0MQ;>W-BX:8-@TJ-Y9,3\7K+A]M*'YE=[KT1;-?9(?GV&M-+'>@Q8W
M1*'QI%G$,P6VP^I;$/X=Q4.K(C-)N=%9&EPS&NJPXH0G;8MGAP?T<1@*X4-/
MI^GS37]O"2B82#4KE97=8_YR;:IVB$\GXXIHV4"I L!E"  K#X85"&_Z]Z]K
M/-L@'U#;4[Q5(YLC/K/&!_DD=P&F+&'9NW6\O,F^->$R]*RP=G+1RH7 LRH9
M7%&[,%2JLJL'6,0Y="VUVBC'4A7XEMK6NV4B/2\6?EF@E?.R8O^IU36*@?78
MJ.P/%+5!NKX\\-7!R7&AK(<I**9*:0-61;&TD@E_=1M-_TN1ZVKO&"(L4$;[
MRJ)3,X'5CKK'HQT![))IP#G?WN8-:ZKN1Y>)4$!%1\18I@B6=;1;SJO*@*IL
M69-,.1M$8=M&/O*7$+OBS\4)UK%A@=(I0B^T;D*ON@EC'^K^IT%K+9"W8-12
M-67V_ [:V'!?-H ='F!4?E)'$,"Z-J<%K^3T.I*@S=_N-3+[CR$$)M2M8X)-
MUK@93MA=;5ALFD([+?91VQA6H,^STEL#QYYU"&U8"]D_M*</(_S?;HJA *HX
MAN+\9W+*3V;#0A9\E0G#CU7%BZ(WCNCJ?E+INZU-]_.JZ7[>:+K?CI+0NG0/
MW?C!(=/:OKVID9 HRCG:$S@:4>0G#(2H. JG>*ZUAS&W9A3<?V?!MS+PJO6T
M\6%[(T]7&QS]IS0XJD/SD(XYWNH9]T[&)-EG%35D<+5^1DWP\HPWFFJ(4<=E
M8VR,L<^ *J&NZGBSU"@VLCP:;+8ZJ,>QXSL -8WX[DEQC!F*@+!K#Z2JU%G)
M#\^NG2Y"(S!-BG;PRU@5/ZC'E89%F4J'U%F U_B=AS )^9M#HO9-L=JQ):56
ML(9KL+^CQ%]C7+#8;*TCM4_Q[?JG'"YQAV$%E#RB7B11.%9IRX>_D*I[A[^$
M$Q)1ZA7YW,K)XUL%:4]^\7GR2?,H8 .E1'E2W#_PTTDL1F>%V__J? SAWDFE
M,MFFV.^4DGRF:M((YE/6*1OY?@D=VPYF@\+KQ]IYR\V&RH-_J -TUE(F-H>O
M*QI#"NX EF'3T\+[E=4F+D\>^_U3,2C;<8XLXBDGG&>,4A0KKBR1]:S6[?<'
M>:%4!,O:;1]9XQM.=VH O(AB[!@^%8YS.NRI3GE0#G=1T#[I2+9W)'KB0T'A
M67__N7C6.WE>:4NE<4U/=$K;[_9#^965K3_]9*#6/Q8'1^*FUA J:&V+WC&5
MY+VCXQ^YYT D'[_K\']QK2'EW?E_N-JPVIJ3X;+#S<HSE"S(!WP7BGK(FY^$
MPZ_6OO@N&X)2_=-:KZ$RMLTZ<BVM3-4LALNCZ@HMU(O=Q(,<YT."HWM-*ZE&
M/HYG BS(,^U!8J'^EB#)I^.K9ZX'';$U./_]T]7PZN/5[4U'7%^=7]X,KV[>
MB<&[N\O:S<+!<'B)K[]=7E^(M[=W8CBXOMSJ-*(*6UT!W^)E*E$MNR:T!530
MI&:J98M59PRWPB[%CQZ[OJ=+1$'CE)/JCCH6UR:=^#/K"S7*6@K,I!P0TX ?
M:57W#CN]PP?MZMYQY["WWUX0^<Q/4RLK\'M+2PSW$$,+HW8=T1^IS%3])AS+
MK)W+N4E0.YC;;;NWNE>[*SQ3=L(WHIT_W_+7ALNGY:7K@;]K7 WW-[:A=>PM
M6>P84_=WCP^W $#X%K3_D9DYWSP>F2PS,_XZ51()@0;@_=A@F>$',2BOHK_^
M+U!+ P04    "  /B6-1769).FH"   5!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6R=5$MOVS ,_BN$L<,&!/4K?21( C1]8#VL*Y*M/0P[*#83
M"Y4E3U3J]M^/DA,O ]8<=K%$BM]'4N:G26OL,U6(#EYKI6D:5<XUXSBFHL):
MT(EI4//)VMA:.#;M)J;&HB@#J%9QEB1G<2VDCF:3X'NPLXG9.B4U/EB@;5T+
M^S9'9=IIE$9[QT)N*N<=\6S2B TNT7UO'BQ;<<]2RAHU2:/!XGH:7:;C^=#'
MAX!'B2T=[,%WLC+FV1MWY31*?$&HL'">0?#R@E>HE"?B,G[M.*,^I0<>[O?L
MMZ%W[F4E"*^,>I*EJZ;1100EKL56N85I/^.NGU//5QA%X0MM%YMG$11;<J;>
M@;F"6NIN%:^[>S@ 7"3O +(=( MU=XE"E=?"B=G$FA:LCV8VOPFM!C07)[7_
M*4MG^50RSLWN[A]O[K]]7=S=+">Q8T+OCHL=>-Z!LW? (_ABM*L(;G2)Y=_X
MF OIJ\GVU<RSHX1+;$X@3P:0)5ERA"_ON\L#7_Y>=_H%M3/V#:XE%<K0UB+\
MN%R1LSP./X]D&/89AB'#\/_N[RC8"VY,C2AP&K&B".T+1H>,L*]?(@U LT3-
M&H1B(0E=( %K$LR*C$(JD#U0&%8+^; Q?)2:!T8IGGWZ!'RS#NL5VG"]UUCL
MC'0 "]'R1#FT4BB"#Y#G(_]-1_#$@@*F::SA= 3IZ0C2X0ANI98\<B5LC"D)
MSK,S. N@=)!EP["FR3G\ZWKC@U&MT6Z"((D+WVK736WO[35_V8WZG_#NP?@B
M[$9J H5KAB8GYZ<1V$Z$G>%,$P9_91S+*&PK?K?0^@ ^7QOC]H9/T+^$L]]0
M2P,$%     @ #XEC47.C*C#2%P  C$\  !D   !X;"]W;W)K<VAE971S+W-H
M965T,34N>&ULW5Q;<]O&DOXK**W/B50+42*I:^*X2K:3')U*;)?E) ];^P "
M0W*.00R# 20QOWZ_[IX!!B!(V8ES=FM?)!+ S/3T].7K"_C\P90?[5*I*GI<
MY87]]F!95>NO3TYLNE2KQ([,6A6X,S?E*JGPM5R<V'6IDHP'K?*3R>GIQ<DJ
MT<7!B^=\[5WYXKFIJUP7ZET9V7JU2LK-2Y6;AV\/Q@?^PGN]6%9TX>3%\W6R
M4'>J^GG]KL2WDV:63*]48;4IHE+-OSVX&7_]\HR>YP=^T>K!!I\CVLG,F(_T
MY3;[]N"4"%*Y2BN:(<&_>_5*Y3E-!#)^<W,>-$O2P/"SG_U[WCOV,DNL>F7R
M7W56+;\]N#J(,C5/ZKQZ;Q[^H=Q^SFF^U.26_T8/\NSY]"!*:UN9E1L,"E:Z
MD/_)H^-#,.#J=,> B1LP8;IE(:;R=5(E+YZ7YB$JZ6G,1A]XJSP:Q.F"#N6N
M*G%78USUXO;-AYLW/]R^_/&[Z.;N[KL/=]'-F]?1#V_?OO[U]L<?GY]46(.>
M/$G=?"]EOLF.^:ZCGTQ1+6WT79&IK#O^!+0U!$X\@2\G>R>\4^M1-#V-H\GI
MY'3/?--FPU.>;[ICOA^,R1YTGD=)D46W1944"SW+571CK:IL]%K;-#>V+E7T
M7S<S6Y40F__>L^Q9L^P9+WOVQ?C\9^8;V-B'I8+<_,N446I6:U.H A?-/-+M
MDXD\F1JHG*UP\^L(W*_4:J;*Y@BBURIU5\9T97P='>H"HIGGT#)[%/U0&FNC
MFS2M5W6>5"J+WL"V#%_]7A>Z4L<Y%#/;IN3KZ%UILCJMHEF)T[+1LV@RCD_/
M+_'A<'P67UQ.C_#Q(IY>G;E[XS'?F\;G9V=T[S(^N[B,7IER;4JLZB>ZGHRC
MP^G5U5%T/IU&U]-3?)O2M^M)LV9)^FQ/UAA&K)K&D^MS/(8UL.KD:L)7+J/#
M27QU=7D4G8U/HW=)617@3*FP1>+&4J]M-+XX TD7&#7&YPOZ?$Z?/ZAT69C<
M+#8LBZ9:8NCD%%..K^F!";Z N>.K:ZQW&GTP59)'\[T<BR;G\<49+7<5GTTG
M1]C_A.;!U?$45R_C\01TX.;U*0[CMUJ7F.;VW?N_)ZOU-Z^CPE28-+*JO->I
MBC#F[_]QA1F^H8_=;R^3&AXB^L_H1[.:11_*)(.W*#]&X_CB^JI]D+\-7<-Y
M7<;3\W,^+T?M,U!V/9FZ>Y,SON=H?A:-3V.(&]8K%F[_;M,/NEHZQD1TPT8)
MU+=2EL0,?BO2JW6B2[B2*GI8JD+=@]'XPQH ?5B"B1B$C:>ZA(!:<#7E"YE.
M26JJ95+ACXK2I"PWNEA$]TE>*U*?I! JH%L;9M],X?A3@R42G,LHNFW7QD(E
M+80!)M6L!$PZ9K;-"1+INDCS.N,#%O4-=L!T$BVO(%\FUQG/<U?A'R\"FMZN
ML3C+WXC5_A44/BDVI-B5+FI04)EH9< O[)ZF:@C6N:XV;!6PSA.B1C)+/+8\
MQ?;]'N/UW//3E&)XVGNT9T *B\^C@0W/'9D%;"#13>Y%D7L9,D\/"I,]&U]Z
MB\1T.H9V9B7S=J@A6.,+_VQ,O$T6BU(MP,XXRG#&8%6F4N =*R("8E2:L&C9
M)%>\E525%? /]B"F@XRU,.A0\PJ[%F!#@9FP"&TP@_.1,R(!W#TSR5F2ZT41
M2! ( UR@,55[Y%^1-0<_9K6E@=C"G^,OC+WP]^SZT_D[O6J>!>)B. 8-^H-,
M=4>R@!:7.F5?IBI=>4+$B,[AM"%EL6-_N'[#;R>E,T7$I#F^ZKEFFQ(M52YV
M@VCQQ\@[:29R9 P?FEVK%).E7_+4OK.57C'MR<J4E?Z=%3Q2CT#GEE=]0EWG
MC:X35,_ )8QAC:$-J@2VW%$QQPP Z6FJ5$;,V:BD9(&@+X'W%PL ?JMD7N&*
M)LN&=7( ??MU#Q6\WUH6?\;TA]P<;#[^G-&?<S)9?DKQ>3?ACI]%TZM3\@8Q
M>5SZ/YE<\O]3=B;7$_H+3\/7IM=GC +("S;(CVQB8/0[AAW<K1TR6OCGL[JD
M6Y]L@AQ?F''NJ6W0Q'JTFU\=]WI">$Z5!7, #+F#&#U&;\MJ:3 SQ28$(W1*
M\!5VW$FR S+6<?%EDI. QM$_$XAJN8D\)<^B\_CJE+@VC<?G%\+3"^+I)+X>
M$_^ I\9G$P$,5I0M4% G8+ARMX%6 LYX3]\"AO9*<PK0^%;K6H7L*M_A&P/_
M"R@'C'"T-9O_SS<1I"$$(Y60LPWLP>%XW]BCEC7;QW0>7UY=,&.N'5N$*<22
MR84'UUVB^SMK!*G9S?AJ)SVXM6<G\%4[!UZT^Q@02CYE_B^;&3[EB]/V@+0S
M6:)]V,JLKNCB,+ "0LIAS_&A@'CE^29RF*E4:YH "E3#0.&A>Y7#"_6O:\$1
M-EF16L0$S!"DR..PTM"1F,"6$6R#458M5@P82)WG(", 9?W)X7>@%MYBKTL"
MMPSJ'DR-DQ/,IMARXAFKL'MZD,="1Q/ 1I,K=MX@H809P_X0&Q8VD>3"3%4/
M2D&! 8'A7=<(!'2J8<RK'@93SH[+;ENR67\25HN0<AN1#X!9$C<#TP02X2F!
M=\$16*(,W'E8:IB*N@)Z^QT3_<@LFV*\F1&2)QP*TM>UIV7/5'"0FFAAK:Y7
M:T:1$<&5DLU_2; 93%X@_(4'HY@*9[7@X [>;JZKF/[_"TZ>O)PI/[)[3=::
M3% !CX+'B;^X'(L73R043[(5'!@%W)2F\8[-$D:RL*/8(#V5T=[,FB6N?<3/
MSU<R72%ZMP2U@ YPSLFCI]-O7+X[!%MB78P-=P0VF>:D@D.*0R_=S.:.LH4P
M#5/Y4-FU=D^U>PR\9F?FFF 1A@@DEOE5 P >.--$2( P.\Q#:CA:]VR(G4 X
ML"7#&=]#O$2?..XG-TNK:_L1W^Y-+L"!L7]/?TP3433.C8G&/*4"NR$N Z+O
MM(M.!2 (BH5S++KJ@'DIL4@+<TA!IB.T*F1K2 ,IJ@&F(XOF+?-L Z12\FVP
MB[7D-XP&!UB ' 84_"ZGK"CZ8S,J]F9%("O7'Q4I,RPMF[LFUNN:E(%3I"F
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M8O.XO(79EUOX^O!IN8'%XV:S_/( =ZO9?'6W>E@M[\<Q,94/B*L3[+R#S=Z
M'<%GHVGO8*EKK'^-CUGB66?VJG.>O0MXC^TUY,D59$F6O(.7G_/. U[^!MY:
MO(A2H0.A:YA5E3T(Y>"?6>G(\DOY]QV*XDQ1!(KB_S[:=V%]E=ZX5E0XB;@,
M'=HGC/X;5Y<GUB%G0WNT_,*L14V@I"BEDB3Y1"K#)><(S/8&/DK-KTXI+B#W
M!_ E$#8EQ_F;N,7J9*17<(<[H?AA$J'M#M6B$L1D6V3,#Y!>%?TLC/EH &MK
MZD-%[%2RDX/AH _#T?!BG0Y6.^@-!M ?I;#2C(LL*A_TF+P'RZ95Y@61U3;<
MH)SH:IQY2]2XE<0;CAS[)OP5#,".""2>F:WM+A_28@3IJ ]?PUGTTP(&6<(:
MBZN\EX>QEZ;PNZ<07U1<@W87^HH_NH.FKOC.J^?6->LJ]J=[U_<^"[N3G*K"
M+8<FUX->!+;K)9U!I@WU6QKB;A"F>VZ_:+T#[V^-H5?#$YP;^O0'4$L#!!0
M   (  ^)8U'GE*35N!@  (A8   9    >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;+5<:7,;M[+]*U-ZNN]*531%4J1$V4ZJ)"^)4O%2MI-\>/4^#&= $O$L
MS"R2=7_]/=T-8##D<)&7JH2FAE@:C5Y.-QKS_#XO/I=+I:K@2YIDY4]'RZI:
M/3T[*Z.E2L.RGZ]4AE_F>9&&%?XL%F?EJE!AS)W2Y&PT&%R<I:'.CGY^SL_>
M%S\_S^LJT9EZ7P1EG:9A\7"CDOS^IZ/AD7WP02^6%3TX^_GY*ERHCZKZ8_6^
MP%]G;I18IRHK=9X%A9K_='0]?'HSIO;<X$^M[DOO>T KF>7Y9_KC-O[I:$ $
MJ41%%8T0XI\[]4(E"0T$,OXQ8QZY*:FC_]V._IK7CK7,PE*]R)._=%PM?SJ:
M'@6QFH=U4GW([W]59CT3&B_*DY(_@WMI.[H\"J*ZK/+4= 8%J<[DW_"+X8/7
M83K8TF%D.HR8;IF(J7P95N'/SXO\/BBH-4:C+[Q4[@WB=$:;\K$J\*M&O^KG
MU[=OK]^^N'W[2W#]X</UVU]>O7GU]M/'YV<5QJ869Y$9YT;&&6T9YRIXDV?5
ML@Q>9;&*V_W/0),C;&0)NQGM'/"C6O6#\T$O& U&@QWCG;N%GO-XYUO&>ZEF
M5?!2EU&2EW6A@O^[GI55 :'X_QV#C]W@8QY\_,U<_)IQ@O>%SB*]"I,@3/,Z
MJ\H@GT/TL*!\ENA%2/)=!F$6!ZN#6F90=CR'%J>Z3LM>$(,OTIP&T659AUFD
M@B@O\2A"%UURCVJI@GF>0)-UMG@:8(\JE<Y4X38J>*DB\V1(3X97P8G.(+A)
M0C.?!F_"JBYT]>"MZ9HI#=X*4>\=42];1-U:HEXP4=_8_:/*=%[@GPBR$ <O
M\*&KX'48Z4176I5/:37GP0=UER=W6.M:BX?@MSI3TN8X^-__F8Z&HV=[OMD>
MD^"3*M+@]SS,@IO- 2?!>6]\-:7/X1B?TXLK?%Y>3(.W^9VP=OL@[2;#'DPS
M/H=3_G[)GY/+]<6_S2M:\$5_,OA7^R%VJXB6--C(+</^2T/1X*/Q*+CL#[9W
M'0>CWH#IN)I>>-_/@TG'C.LKN.1)+L_][]3S<K+>\[I>P%Q2O\M@@CG&5V/S
M[[E=\1]9V5ZS4.!(/0]&4Y +TL:#$?X?H,&49GH3/LCO5U?TW[ W'D_Y<QB,
M>0A5%_F36&4Y3'1880+6.=>-:)_RYPB?%U/^O!R#Y\,1AK^&VB9V\XFM^,0J
MF^^#X(I9[+3+<&?"O!Q?7GK?062_->A%\^/4_SX.IDS[;V%6PQ\+YQR7)Q['
M)Q=FB[VFTX!^O 0'[+^3S29.2,XGWG=:-U'X6LT*V_;*(VRP(6R7W-ZP\VIM
M9MHE^KF9^7RP=>9W,&%%\&=8Z+PN@^&H^>]37L&:)'FV>%*1;O$.DNG(N<MQ
M,!KW+@9#^N=\3&H_NH!F38/1I#>]F@2_JQ("]:(N"@5KM,H+!AVP2%M']#0)
MA+W-LR?1WM['WO0@YV((>W:GLA"=7N3I*M%LXS[!3.^S<,%)6!)\@0>*@QF!
MLU.FC4R\A@_/8*?1:H'ABXPL8+4YJ"@>]>I6,'(=%8"A 3*T.>%\K@E, 8IQ
MQTPMY(_(K$/&*U<JTG.-@10>6S?&6*M/RRO5(2/!121UK'KD#+$"87NUQ&K@
M'WB:>O8WX&%0Y4&D"B;UGSI,,'/D.57U)8*CHS][WN#5,JP 2P$B-(VP5+P#
M8?; ^WKY#'UG8I4M6^W?6(O& )B\U+&&*()35?Z4R*V+ &Q<0(XQAT*7&+N&
MF2&9M"DSF)8,@O8LB(# *T6-5Q .[&RB@90#PKEEJ2JT6$%;8GVGL94Q_Q"%
M*TTBCJV(/E-/[)-2:0__KFI80&!;>5IIX*.-UB W+V)CWMK$I.%GY1BHLSLP
M)55V*X7KEE'H"\+XUV>!RA8 _@$!!%4L5$&[$OU3ZU([;F=EGNC8VXPP#9-%
MF,J39P$@7%;.,0%O)\"]H\/R@7?03<3MPTC&N]?5DN4(>@-Q[0?7+&B;L*8G
M^R=(([P+=1+.$H)"G0L+:G"GZ!2)%.C#=2%A]52MI9 /Z)Z7_N^GP3T:A*M5
MD7_16+]*'H+CX0@V:6#Q%:O&/N32I?=)F5M=Q10!?H0=T=A]"NLJ$OBHT2LK
M^=@H(MM;)ND1]V#^8YBB%,%DQ)E E0O:AH(VCQB=Y56P8$$F;@'*C.%"G@[Q
M(2O90T<*"9\IL 6,C$E$0[ ?T0?O*P)0)HU$B&RJ0:]L2A."37/+D(0Z%2)=
M'A,:F]71IZS0NJS =J&TS@"F(T5[A?DS KG*3OGBW9^W+Y\ "8-%,=!I%"QI
M(V-PHZ1-U. =RP\U7B3Y#.M5("1/'U@B-QYCA(2FAXIB?>#;0I4LH9A3$^D(
M(8G+>,XP/R]+3>(*ED1YBBTK8"I)E<6H&VK92NF4GJ*3,;OT$!MD] 7;V[F@
M7H F2^IVO]3X$F*X)<)A+"Y6*\4B3!;H#K:.%,<83VH6:ZA?!+-.@Z](5&%,
M0]HZK 3DJ'[PUU*#>%D>=0F#K&;MQ'R\#UA+ -M4<%1"6R@VT\R2$BJ$F*2J
M$OF$K7*M?5W=K3>]EJ#3#G)<A,YFY\R6_;LT&TH+)C.?P;$W@DP,W2W6PG1H
MIL8>R.Y;7(#55DZLS'Q!G*N2-2G1Y =HRC"*8)?9JQDK?N@JUUB_VQY:9I!=
M(B?? ! VK$3)'@TN5,+N!)12Z_5 573+3-/C[$MLV6IY ANLHA!;S#KU-S8;
M;<@P$X4KH)"LHNEE3\JM.@D1_@+,43'7$$.*)_N:-='NI91.<RLJ57&GT<0/
MP8G"D&PBD<Z&Z5XE\ >I9%%<D,V_Q6;;76 NJRA]"\FRP>ZGQ36V:#JKE6@O
M"3\XM.*_P),B)Q]$? &, &F8$#8=ZL@-@"C(,I@A,,G7L@.&FJ<6+."9$TA?
M':F&5>0C$OX%*&R1R2Q=CK3!Q93%J=0"\B%PC]8 W ,?JQWFF]6E)JA"=K)0
MAF)J9Q$Y<98>D%,CA%:8;T\2G7U6A"PB2EL04F/W"4['XHL196'Z_GZ\_2Z3
M&%_R(M.V"K'O,<"E"QYB4@,*<W@J\C(%HS!CD8DMH\&S?31PL^&S'?CD=5X7
MX/BU<:1$U@?%HN6&HV>_""T/P37<-TM=C_7/=&/THH+7[/]O,V!5:L*Y&C2@
M[]:5K _NC1?S\Y!5MLD*7%KN,1:$]!&]JG'])QX[M@YN^'!J &!0/L!E1$;)
M&GD&#JAT53?84Z M[0!F-K!!M&WK5 &I&+R$T7A(G[6\D;1TD )3'R,41%QO
MT%S/>-,T%'P(P\=V/RS@&MC[-?($FVZC##86[/E@QJ^&< %$:5C@AX>2$H1D
M&X7[E.*/ZT3%,H>-33QLSU2+MZ16>:8>G GU1/<FK#%6\*L*$Y$>P-L0NH:]
M[P<G1S>_7A^=DCD%A H7"X(?H'$]5TD-*-0J2\.+08-L95^/=CNO(Q/!KL,U
M4B",F!=ZH2F2ZDR2'H][DPO'>Q[H6%(2;CN$29A79UZZSI>XW3D^)W8T>#O1
M)<O;G^$[.B4#1M$Q10\) .)-WK:0LA^_7C-4,CM7/ ;F;& C*X4,MM,PYCCJ
MC_['/J!'DH04M;T(LQ"F*K-/V(#610[ML!F1EZJ,"KVR>8V]YO*F"Z+M[;5&
M&2B&X&LVER7CRI"B#T5!,Q@%'$EV'H)0Y3V!/HZ/_R:?6/&^*TTFYFEPHK%U
MC$)DD%B1J-EX#7X%LY#O,]I%"%AQWAQ=PU,!) 5PE?3VXS"=[;:&V/63F8PP
M1Y!1@.)Y36&]FL]%%,RR$DIJG8V(PT-.QX%;)Y'TI T1U!0]? 4)QH"!<SJ/
M69\R U?,M#S?"1IIX/(:(K,Y8;D,$:$36(4HA:7Q>!02]*3_*1.LF=&;W?<P
M7(XKR(0S;XA>3Q@H%,E+1BP&'3JY,&L"&E5WH3@G7D 35+20I<LP-,D9F?K$
M&/LX6$+K$-_UQ!!W<U^8@9^SG.$V\21AW$ZA\(#9Z>3TM,?FD<*LB 2064[F
M= 5 %G$V K$J[%N_6W/VP'X:F_2U2V&^QS[0&-^T 3^6M=^?FQL6\0=8(L^8
M'&**BI8E*FQ,84E**!+YI\XK&8-0S5_$Q8]50=',;T"&).EAZ2-.M\SW3,L'
M#&I!9HXM@B78-DZ$R$>"$IY3]IN(ZK6,9\,>1ZBPK48P52X;L'D39I]I/4Q1
M2&22I'DL(K]HC>C0&*Z;ZTU#:')B@$U1+=%I'.KDH67D=@BC-^,!4MC8.^H[
MPQK@K T:YS!^57$XQ>.1VJS)5:-3QGY_RHN<H@+F%HU'@OP9?/=ABEFVPR/?
M61\M5W^4@?NXF;5O4O022KG<';PU5H]H2G&J@&+6/8ZN'9CITF8Z8Y<]2BGG
MA##@@1)6+NEK8#$!ST=!%FEJ%Q+I(JK3DG>]]$/:>9&GHOA#]NLR&^55P:XE
MA1F14G$I*HVPG<7&I#1CE6:<=VB:T993](II.=SE;#F(IQ@Y./'.10K5)/2#
M@FI<2G/<4C6C54N(S3)/8@(J>B^-M!8C<,9N*U>G<&)/:;#W<K3ACE-920E%
MS@Z$3)I(F0@EKR2R>$&$O(:&/Q+\>!R)%1V^E*K)1[4SV^7ZT5+8\,>=(9 Q
MTG<-H[8P2;:E#)/]NW)J#\:ZQ=/@][H402Y!:3E_@(N6Y&]*1X[_82&1B-;3
MN[;E%2ULG/B>N@8;EAY0O4 1RXBM G4:TAE_.]KI2<!N'M$R&C!NJE^L[?6B
M&/KEW T[.F38343!4=7U^MC[,J1&G*A7V7*V)I9?3[]TYJ6_'X/O*85^WA].
M+"NN? N\'EE^6K;EHG%",QMS?C_28&<G;8?03F.F?)I9\/Z0G_%%>V:DU4@V
M.:H6W:XA)=>*6'(G-N.Q]]#/Y2LD*TRVN-$P0+8"6PIXT#VC59*]7H"WYOAB
MVF0\8#/R>K%LF">)GLDCU/,KCCE8"8=4%_)$5'&[QK$'V:9P(Q[BO'.(3>W"
M4-^D7%VZM6>==&@AJN!)W&'G'<LP)DB3UQ4?/]'H#=6]X'@XN'2[:++V)I?J
M=TD4/%O!$T9-9K41,G/,["<'A\.I&U@VE)#?[H7V@]LF4MV);:A@(,I3>%SV
M*G,E-FM Q35/!EPJU*#Q]3VM^!"TKC#G?U3LC?.8U!,H8(ENM(JB; A*6*R=
M:O")]2;] I"$LQYC92DB%FGX1:=8P,9A/LDV JDBO+?,)?2Z>\=,2E.&LO&;
MF(UUV$KS;PK^UV@H92>]G8!"ZG(W[PPH:U#QO. CG85PQL%_[WBI6SH%40'I
MT *H[][L-R.XL@/L:>]88#T5[G-E93EJ"P4V<\-L;Z;]"0.I%ZYD!/1<V[3-
MJYO;3R^O'YMS\\N#6M4 KE@@MI4J(9GPQ(7'[;6VJG@.6G8+/=J:J@,**,ZA
MIEQ P0<D/;M(CJC0OG;U602H>X1,I>IM_\@7=F2.%K+&W-))WV;?)LX;-34=
MG>5CG[;6E<$3N4HHCO-ME4$7=&I74YGCC[ Y-?/T:[NX2K67EJ/#+35M)U6^
M4!2C]/Q$"/UFC\7RPIZT"2;?7C;'<FV76#;'X53K0%L/#I32=[W06W[B\5IR
MVH1,4A#6.ECDR,JO9C.YDS),E:G6X?,AKHKA[LQ(F:>3ZSY9AS"X:2-J9#;S
M406'C^0IY4#8-(M)Y&")YG4 TIP"DK'O%BTYKMG87TK1-(BYD1LN\9"P"OJV
MK6K.%*QEWG'<U\UKIMHZT;>+H#MDH"P8% P?\!3;S^8;V/\U/&LQR:H>!#7L
MDE#KU2/*AE5\,")']?L*5OTU[=^%[[0::Y:<&?83/)S)WFU[>@%[:AG$8\W?
M-;=FE5U+HYE%J2^55P1W%R:UJR-J6-<!%;<:YK(JZ@@K9+5JR1Y5LG)^&@J5
M: &PY@26D-O!YCO.Q0FY6MB=^REG1MO'YP12!^ND2C1P]6@TI<^1/U9&PO*H
MY=%-W9W4"&55D2==X.)1=@V H\Z,WVQ7FJDOJH@T96X(2XD%D^(9F%7?<F6Y
M2300:"!6]@+*.AD@MY6!%%P;)-V:F^=PM<$<6,MPCJV9B"66>X]?.)#3%/X6
M54_..%QOJ"U8YS#R<#!T"<*-0@ V/E2YR#G@*"IL_%1GJU#'#GOTW460CD7%
MM9(K#4_<!8_A%5Q34_WSR:\%?I>99E.YM]230W2C_$W(1+&<"/@Z"MU>V("E
M3,U=ETY(0:2V;F%(.4#KT5H?4^O 8G\\.9B,/?SR[] (#?Z3CVT"UI-H7/.+
M2>_D)#J,V.4CJ/;O,\A^2XI3BG@XZXD?EPQ8.0]BDI3"9D\"CR?3L1]9F]LY
M.[C*H92LQ%W&V>"D"8]:$WF1-D]T,=H[T;!UQN)?U1FN=['PT.:H_:E'PXOV
MU'L$IUFBF=F[SK1EVB;]3#$_V0^. P7]KN!$N.*LS"/-%MTZ>G(GOLJ<D*%L
M]K^#A!T*UR#DE^*N[7TE4CU?Y<3**2K'F8Y\SE"CG5SFFPV0426Q+I]ZNO2*
M']@WFC(+$Z_ <O?P)@9,5XB5F_&;U4J@ZNNF/>,0IY&9B\D.1QW M?XV2? P
MWOI/)O]DL+[+H&Q!] 8,-9%B5^3Q=PX3G#P8#$OQ'\$ +UCC',7&4)RJ\ .Y
MS6LP.P.W?5G4_F%LL-51.Y<*ZJP#^!XK;K&>]&P;!_SS+Q!P^LTL>>WB@V:2
MKA*^7Z_YO)XKK<UAD9]=Z\1A:SP&@&P/3-8$$])99A=D:BMZQZ1\W!J2XM 5
MGS8<80X*RO$*RC9,P+=!D]W>=#LG/$+CW@$X9B\\> 22N2YYE9; 0[HTQZKA
M##A5L(]1F$?!G%V0Q5W<*UKWVC)G2^D5$RW2.2]AMA@P&$0Y,^4BI=TSVIO)
MN_@ZY<GEBNGNEE>\ P^'($DT.N]U>+,6@*3[JX?Q=>\Z6M=N!?!T7-G=!2(?
M0\P>5KF+NBWD==6%O Z#D)\\U/AHT-@^-P']VY!@!PX\;T..[=#*2X__,$RU
M1_ :1#4Y6.HG^Z7^? "I]X 0*'CMYI<+ ML5H7D=Q&"O-L@U[4/CF,?K0\?]
M]%WZ\#AR]K"Q=3=]/;K#HTU"ODH5.C6!DP2TG/'@$"V@L2QMPPM[_LD\D7T6
M!$ ##IL!2U55B>1XZ<C(9)RY_-:[.T.81 !6*VD]UU)#6\/T\Z6:NS#A(Q5Z
M+TE=EI)0X00<7?TX^OW5+]>_!^\_O'OQZM7+V[>_?#SZ@>IW]#6R?P0MO'B4
M1QD-]GN4BZ[3Z,9-'YX&V$M:^]4,(K#M9S]28GW;?;@2^A'=A8^G-O,<S7M-
MC&1+.0GL_>#<UY&FT*-5WM'<F^$R.G.,@/7SFU(V;E?]N_0*93;O?G34P^@?
MZE".]DK<D3FXVB^:O'V MK0)AA\AUVVJ+P3/:ETNK5%PE^U:TBL'I0">7'S(
MI^3=/2F<'C6%%1NA/=TD-E7/,U7=*R4I6",?C+>I.HCME,V)FWE<@:$A;N,7
M[& 4%L4#S<7)<V'/3HTP@+]5\\TI E.O(CI(Y_@/*BR: _Q2I?H)'>W;$RMS
MB,^L,5&CFW@H F6R=,/)9M&4GR3F^QOM7-R>)52<4^?B77=SS)N<[='8QE/K
M8=1@;X9W?VC4Q*3F),/>A:5UI:8L7@:Q0(F"QB<<\]E2=/.BJ[7SC<[%.4[*
MK;K-"-7P4^H2QH-'1(J^?=K-=I<1:A79>G[57E,EB9>2*R-;CBEF-S;*GG=/
M[,XK^N1S2%[F5 #0L>-;V/+58K96,[.^D(X"[@-7LE_$^,K%K*[X[,>=Q_6V
M2%L_^(O?]$?5):;PX:,<=G\P;6_MN*2*][9Q:!IOJUJS13C>I0]/7C9?]K:E
M4HT7N/D2-JIVF_2OQE+X"=,S_-=ZN:=Y,YMU/6^<ZWMOBQEO;?ED<W';G'*R
M1V]N#Y@.K:H8TS)MS^+5*KM.:Z+5,^7BI*:57"3H-;F;#2;Q!2TAARZU9_;^
M@^U1FKK%.WF#2J86>24>M&KG6?D^BFIU4U_<VS:L5;J'.S(ON0A86!45E$F1
M*,_K%PD9'B0:ZAN3 IM<EUDX9\5  !E0]XX8FW:5M. </^=4#/>R.>/.=.;>
M&R"7H/<5,'K)*5-T2*_\02#M<W,CEYDUMJE]CS<LFA-EWT4;1?5VH2< P>]-
ME\6DXT7S&IO;S@0Y%9XV&[*^I"A?9%Q[& 8+<XW^>.C1PJ^"XD#B]YU 8T,3
M-F6TP21K;W1HCAA,E7'#^SE5")1U1+:<V/O /ET)KSV%M2 $/I]M+V?+[ LA
MRJ=KKU/\L#Z9]\)!/K/P_ACY?YP'H]YX,+8OZ"/<*^^4&_0NSD=DNBP!5[W1
MA7T[VL:BS3O1_L@,/E;QH6^5/!E-IJ<'O72-7G<&;_0.DL^8^6I'%!12[:93
M.<DNZFC-A#=GYR;S<'5U6'KH6X^3MH;<WE'N\+!\4X\$V,415LW[7>\R/?/>
M#LOOV:)WX-+K:[ U\J)8]]2]9O=:WB[;-)=W]+XQQ>6)FJ/KH'\Y.9)R!/M'
ME:_X7;.SO*KRE+\N50CYI ;X?9Z#>/,'3>!>/OSS?P%02P,$%     @ #XEC
M43NJO]5C P  ]@<  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULM55M
M;]I($/XK([<Z@=3#QI V30$)4E>'U! +Z%75J1\6>XQ7M7=]NTM([M??[/H%
MFB;Y="?D?9UYGIG9869RE.J'SA$-W)>%T%,O-Z:Z\GV=Y%@R/9 5"KK)I"J9
MH:W:^[I2R%*G5!9^& 1O_9)QX<TF[BQ6LXD\F((+C!7H0UDR];# 0AZGWM!K
M#]9\GQM[X,\F%=OC!LV7*E:T\SN4E)<H-)<"%&93;SZ\6HRMO!/XD^-1GZW!
M>K*3\H?=+-.I%UB#L,#$6 1&TQU>8U%8(#+C[P;3ZRBMXOFZ1?_D?"=?=DSC
MM2R^\M3D4^_2@Q0S=BC,6A[_P,:?"XN7R$*[$8ZU[$7@07+01I:-,EE0<E'/
M[+Z)PYG"Y7,*8:,0.KMK(F?E1V;8;*+D$925)C2[<*XZ;3*."_LH&Z/HEI.>
MF<71:K.\7<%\]1'BV\UV'6V7Z^@F6FTANHD_WWZ+(EA$J^C3<@OQY_EJ,_$-
MT5IE/VDH%C5%^ S%>[B1PN0:(I%B^K.^3^9V-H>MS8OP1< -5@,8!6\@#,+@
M!;Q1%X.1PQL]@[=&PQ52IAE8H,",&PU_S7?:*,J9[R\0C#N"L2,8_Y]!_H\I
M8)LC7,NR8N(!="6%EDK;?";@%'9U'* JF-# 1 H,*J8,3WC%C%0/OTI*BM<I
MD"6F/&&%4RUXAL"%/B@F$G28;^"8\R2'1-XAT2:H#!40^#+8# #+JI /B#7O
M:4?WK9PT.2I2/@BC..H!K*A\5:BX)%;H-3;U24(;H,H%YN3L;Z\NP^&[#T_X
MVI2:D\^/?#H/2H<J" /*.L'1)CA0>AHL=V1@FZ,.+ R&[\D@XM"47S*[@K@A
M;)(.8D<<_TSJ0F)O8"7%[]U.0X_B4/*B( 3=KVD<Q5.K#:H[3J%W\7@-P^8+
MF\^%)/QPMEH*@PI)V&F,X2V,:!S2+[JOJ*"2FV3C0=%3U $#IC627[UAT&^&
M<?VUD.T\+R7ET3_,%669046O1EVBM5!1XA@7L/J1'ZNW<V](\&']/884E V%
MU/H7)>O X[.74N<U]"[Z=ASUS\)EJ=WX5&GPSVIQB6KO.HZN<[4NR]UIU]3F
M=2T_B=<=\8:I/?UMH,",5(/!NPL/5-UEZHV1E:OL.VFH3[AE3HT9E16@^TQ*
MTVXL0=?J9_\"4$L#!!0    (  ^)8U%WB$375 D  +\9   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;,U96V_;.!;^*X2W6"2 ZXM\2]HT@)-F=OK0
M-H@S.P^+?: EVN*&$C4D9=?SZ_<[I"3+B9VVB\5B@=B6J,-S/]\Y5*ZVVCS9
M5 C'OF4JMQ\ZJ7/%NW[?QJG(N.WI0N1XLM(FXPZW9MVWA1$\\9LRU8\&@VD_
MXS+O7%_YM7MS?:5+IV0N[@VS999QL[L12F\_=(:=>N%!KE-'"_WKJX*OQ4*X
MWXI[@[M^PR61F<BMU#DS8O6A,Q^^NQD3O2?XNQ1;V[IF9,E2ZR>Z^91\Z Q(
M(:%$[(@#Q\]&W JEB!'4^*/BV6E$TL;V=<W]%V\[;%ER*VZU^ETF+OW0N>BP
M1*QXJ=R#WOXJ*GLFQ"_6ROIOM@VTXU&'Q:5U.JLV0X-,YN&7?ZO\T-IP,3BQ
M(:HV1%[O(,AK^9$[?GUE])89H@8WNO"F^MU03N84E(4S>"JQSUTO?IT_W+V]
MF2_N/K+;KY_O[[XLYH^?OGZYZCMP)YI^7'&Z"9RB$YPNV6>=N]2RNSP1R>'^
M/K1J5(MJU6ZB5QDN1-%CHT&718-H\ J_46/JR/,;G>*7<B/>4@@3=L]WR"S'
MYL;P?"W\]3_F2^L,TN2?KP@;-\+&7MCXO^#7_XP3^Y2SSWP'[PS'76;)N%2K
M1!C+>%$8O8&9+A7L5F<%SW=__<M%-)R]MYZ>?<URN2PM>,0P'77![A7/V1EM
M(,IH\-[3T:J_'[X_9]M4QBDJL5 \/LU\^(/,AX?,@2]L5;K2"";^**7;,;[E
M)K%LC0@YB%ONVA)[['%_PQ"VW*Z$,95:L<XRE+QW"MRQX5+QI1*L1&H:3]$H
MP)RN%X*Y@3-*3&9EQO(R6V*+7CWCZ5+N0+1C2\&DM24)UJS@QLE80B=G#X4%
MWFS++9G'%5$/+[J#P8 ^A\R[K%"E]3M/B3]F"-:%H:@O2P>"2BN>)RS7+NQ0
M.YFO&;#9.JS3=>5DHGI-WE+@WM,WOJ2 &5%:P?C*84_-"0'$+8@YHM8ELI60
M_C+F2 BEZ%)\BU,JO(1IZA ('*F'VV.&U<J]3+;!C-V%9*%G:!7<0_T^C'6"
M&+&6UGD)T>"XU]M&.QT_>0/)B:3UL6#VV-UJ)7Q78?/"2%6!%<+:5I?QC(P+
MD8 <1WYYEA;MTIBWR!]J\A?%&,Q[G9;)/%9E(D(JK;1"!_8QI%T$>?8=.Y/G
MKP:>ER[51OX)OB?\\1T=4D[9([PRF!ILJ&2*:I)(BA9J83CL7AXO!-X"LPH
M#,&#14:U=#Y$/W<T6WB>4]VM12X,?C-T3')&*A22,'\1P3,)S\C<&9V488"
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MO6'3GO?N16\\98][4/$!J!4:=0<78Z]&U+VX/*'0*0%1U!M,@EZ7(X::/0%
MC;1Q9?)X,OY)2=/>D.(]&O<F(T;U]UU1L\B+F Q^UJA99=2D-QBQ^8FFW:V&
MY:SJ+V4.Z-/H@W_^0 5S.C"UWC#1490 [=5>$!#[),CC^*'+NL^^&2)/JC+M
M5B\EZZD8=#@-DYJ^SW$,+L\\ P%2^Y%NV)M<^G.T[1U[X=MOO53/!$"6_G6
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M(2$LI$&(1ST(;M/WLUM8WGV:I^F[F\7[50#TGL"F58Y C@3#;6X*IO)*%#9
MC0<4_^5!]W_5L.'!(*Q1%6[<:ZJH5A@_$[O3[D69^4'ZI.Z?HX],%10_<-R0
M:=2_. ] ^1'O-T8V;JRNI:$A[<227D545N'<!DCA[S;60??.3O\!4$L#!!0
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M-S+(5V?.KH6CT9!&%VPJSX9RVE!0KH+#6XUYX=7E/RX^?G@KKL__]?;J["!
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M_LG10+CX?3#>!%OS-[F9#<&N^'*I) )% _!^;FUH;VB![B/MJ_\!4$L#!!0
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M'D*5*IH*9H?AX:V&5 8  !,D,U/ !9@ 5EIGA3)+&.UC\"K<*G+ -:BWZ3\
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M:)TTR\TYC:BG=8?\B(^C#CM(7GW.]*H%K 4XF*)%)/X#U"P4$&&J=9F4%3
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M8&303J%SL5"-%SY._!#U;0G<\=XW476(L?"%+<SE(? 6$E<<N7"GZ]Z22]G
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M,:JP#&IG).TO(*7(IVW%HJ-I0";!@UKS^]9@/%:HY\<EHEX6$"I^P$SM.;9
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M!OZ;#N"5M<9=06T-ER-(SP:0]@=P)[7D:2Q@94Q!<)&=PWE(2D^RK!_6-+F
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MZIMU/3%R96^S,VGP;FR'2XZ?0$4;<'TN,8C-A!2TOS=._@502P,$%     @
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M!P&GF#>@%7R!, B# WBM*A@MA]?Z &^"ABND*V=@B *7W&CX/9AKH^CR_#E
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M;X)9<Q5^-V\^*!ZY3'/21X%;<O7=B,0JFTNZ&6A1VXMQ(S1=L[:;T7<-2F-
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MW32E7Q"5=:#SK93FN+ !ZG]U_ Y02P,$%     @ #XEC4;,!9.._ @  X04
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MH#S":#()W]&8AF,:Q^&4QB2\AO=<M"XQ6);42EP1Z57FCZ :5U0#!(=M]L5
M&J;PXP]7:9+^_*^Y)_DN/=/PZ@4]_U/=N_R\@3BD8E#2XC 9^^PE83(9=B=3
MRF>O_#\M7WHXT5EGJE'O??\U%#1=B:Y)G4Y/+7[9=;9_S+O_PT>F]YS2+; D
M*'F<!*"[GMMMK&I\G]LI2UW3+ROZ3:%V!O2]5,KV&^?@].-;_ U02P,$%
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MBW%LX(?U?.C4&+!D+*J .+N W#JU%N<XOP8M^PHXMF.;'*JG#W$DZ5#18<=
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M/N Z(*O4%](XE__!L9)UA'!8Y)PF-5AXD)"T^D4_:B): *%'#3!J@#$48-8
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MG%4'(=4-IYG\2MY0+KZYY>4>(]$@2P'Q?$LI?[DI#33'4;/_ 5!+ P04
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M!7FEOP7-BNHO.#2VS@ L=@6GFV:P4+!)\_HS_MT$XFB \*,?@)H!J#O -0S
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MH>\HY:\U"TPHE2!'=I"_H_Y5D$=.U)6I&D'']+C!$OCX#>"O8[82$%@\V2"
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M;,^2:KP025);ZYT/=!?->KYNQ=?]Y  BL4%)L9:O^[_)[%5TO:-TIF)-.^.
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M9QZ)I&,>_,9\M;FH]6K(IRN2!.J!;V?4.-36]CP>R/0WVAI9IX:\1"H>&F5
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M B,I=/$+VW*NVX$HUT:F)9@4I#S;_;/GLA ' *_7 /!+@/]10+<$=#\*Z)6
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M>V>V1.:=,Y]HL<F:ST)HT\JR86*^-E!:@%E?":$_)K:?E=\OG7]02P,$%
M  @ #XEC4220SJO2 @  B <  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N
M>&ULS55=;]HP%/TK5UDUM1)M0OAJ.T!*^="0 %50NH=I#R:Y@%<G9K:![M_/
M=D(&+41]V,->$G_<<WSNN<Y-<\?%BUPA*GB-62);SDJI];WKRG"%,9$W?(V)
MWEEP$1.EIV+IRK5 $EE0S%S?\^IN3&CBM)MV[5&TFWRC&$WP48#<Q#$1OQ^0
M\5W+*3O[A0E=KI19<-O--5GB%-5L_2CTS,U9(AIC(BE/0."BY03E^T[#Q-N
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M4PSO8JCA90,OWQW#75V/O"A^7A3?\E7.%27WJ/01L__:;**.S$I]_S[4!\!
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M?%]G:RBH/I<E"'RSE*J@!J=JY>M2 <V=J>!^% 2)7U FO'3HUNY5.I0;PYF
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M% :#/3I_YX#;R_66JA43FG!8HBTX'V!QJKZPZHF1I3OS"VGP!G'#-=[QH*P
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M52##;2#!@4"FL+Q$H?<)!5[@-<A'Q^4I9%KN&[G?_5ONZI+4=0GJN@367WC
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MIEC&"Z,S!&GFJ$&'4J"5?3)]X2#G+W6MS".WU@0%]6+:I9BV4TRY5"2$B9'
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M:0W,^YDP.Y'BQB8HS^X&_P-02P,$%     @ #XEC412O*O@I P  % D  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULC99M;]HP$,>_BA7M12MMS7-"
M*D"BP#2D/B!HMQ?37IAP@%4GSFQ3VF\_VTE3"B[K&XCC^]_][FR?T]TQ_B@V
M !(]%[04/6<C977INB+?0('%!:N@5#,KQ@LLU9"O75%QP$LC*J@;>%[B%IB4
M3K]KWDUYO\NVDI(2IAR);5%@_G(%E.UZCN^\OIB1]4;J%VZ_6^$US$$^5%.N
M1F[K94D** 5A)>*PZCD#_W+H>UI@+'X2V(F]9Z1363#VJ >39<_Q-!%0R*5V
M@=7?$PR!4NU)<?QMG#IM3"W<?W[U_MTDKY)98 %#1G^1I=STG(Z#EK#"6RIG
M;/<#FH1B[2]G5)A?M&ML/0?E6R%9T8@504'*^A\_-X78$_C1!X*@$02?%82-
M(#2)UF0FK1&6N-_E;(>XME;>](.IC5&K;$BIEW$NN9HE2B?[@^%P]C >H<'M
M"-W=_QC/T/!A-AO?WJ/KR>!J<CVYGXSGZ!N:U\N,V H-\IQO88EPN41W<@,<
M#;><0RG1-<$+0HDD(-#9""0F5)PK\<-\A,Z^G*,OB)3HAE"J%E!T7:GX-86;
M-ZQ7-6OP >L<J@L4>E]1X 6>13X\+1]!KN2^EOO9>[FKJM:6+FA+%QA_X0?^
MIO@%+ZA*51?"% 53@7X/%D)RM3O_G @1MB%"$R+Z(,0UK#%5RRTE\#H.!XJE
M*OX*P%K!VE]B_.DC_-3WHR3HND_[=;(8A5G:&KU#C5K4Z"3JE+/E-I<*<*$
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MGU4X4VG10'__F.@:6KTI?OUB\Y,M%_\'4$L#!!0    (  ^)8U'\JN%W8P(
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M*PTLV8@^ MD]SX04^':&H-T0M#U!^P3!&!;()LJB*>EA(OO^F1S8!"&W/\[
M=QKXSEG]PUR7A,HK*C)?2&#4=/3RB4YD2 D5_,W1'BUXC=SSR*X3J[05]Z(H
M":LC@KJ-H.Y903.HM*R$6O]#+7L-=N]_U++?P/?_\A;J1R"A D/CA1E.8^!8
MY6J<[D'E.G]4+3SH+S>J'KE9"V4)>T4QT76?@DW=_K6!NO MM]!(#>RW&YJ8
M8)P#W:^TQKWANKB9P>DO4$L#!!0    (  ^)8U&"4Q75+P@  )PT   9
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M;/T;*2?D*;Z0Q5GQ'ZPW?7W? F&>"9:48!E!$M'-%7\O$[$#D#SU %0"T*D
MMP2XIP+:):!]*L K =ZI +\$^$7N-\DJ,CW$ O<ZG*T!5[TEF[HIEJM RP1'
M5"EK*KA\&TF<Z-V/QOWQ8#3^ OJ327_\Y>[A;OQU"CZ!*:$1X_(2YIS,P9@)
MDH&K(1$XBK./LL/3= BN?OG8L84,0Y'983GD[69(=&3(WS%M >C_"I"#G!KX
MP Q_P+P%G$#!X4T-?&B&]U,)=YVC\#LS?$K2+;PV^/N3X8>CVW+EJN5#U?*A
M@L\]PC<D,P%&-!,\EY^[ '__(3N D2!)]H^!WJWHW8*^?81^0N8D20L+2'D4
M$I 2'LIQI.< P4"XPE3>112$C HNQ7N%,X"WO>JT<6<>$#JPY3@?#*&WJ]#;
M#:&G^(?*20;8 L2,+C\)PA/I.C-1%]>&S2_8E!T_]USH2W]6?QW[>7>):[K>
M>/Y!U[V@O2IHSQAT^=$]T6SWLS-DPZ^(_4OHY+JBO_Z_=6(>L%DG015Z\*XZ
M"5XL/C(N_4T5QXTQ#J]U[7W8NN[&;8<Y ?U\*3<!Y3;7X+]:4S;D #IZ%W N
MH0^XL\U L[(%%C+BB,KD$CDA+IM RD6EN5D-@P;V(GFF.+6?0F1D>N01#:,4
MQP G+*=U$AB4%+L:\!S') *H#1>:#3!H>4Z-#.2>F<O"[T 'I_L$U+8)VQ=1
M@K8XV.!Q9RK!S%[DKW9;?S5N?W[:::%_OH+\%PJ"3H.$M!=#LS=ZK:#62AYP
MH1_W3?K1=@J#B^A'^R0T&^6Y^FFRX>"%E90">CUPOZ339HR<]]R2;DNZ/36A
M]J&:-M.OZ>L%;9/PD/9XU.3"/JH3WI"$))D1KM0'WZ(^M%,.7Z0>1MJ?D=F?
MSU1? _LF@Z9 M8^C=ZU_!^AE5>O!H$Y#PYJN,#@LE??#UKL#,ONP5[__R1]]
MX>K-[H6T>:.+U,E(FS,RF_.Y^FFR_B.[W^MQ^_/3]H_>M9P>H)IZ&AH+:J1W
M"M2P4]0=86 Z?[V 7.W=[D4*:5>;K&LVV1/*BV%)L?>!'JM0[9VS(W66*+^T
M940S$).%!#NRL+8 WQS/;1J"I<5QTHP)P9+B=D7PG'#50;Y?,)G,LJ%.J*I#
MTMY/4$L#!!0    (  ^)8U&305$J, <   8K   9    >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;+5::V^C.!3]*U:T(\U(G00;3))16ZF/I.ESJV9F1ZO5
M?G")VZ#AD06GC]7^^+T0$D,  TF9#U,@/M?7U]?G7!L.7_W@5SCG7* WU_'"
MH\Y<B,6W7B^TYMQE8==?< ]^>?(#EPFX#9Y[X2+@;!:#7*='-,WLN<SV.L>'
M\;/[X/C07PK']OA]@,*EZ[+@_90[_NM1!W?6#Q[LY[F('O2.#Q?LF4^Y^+&X
M#^"NM[$RLUWNA;;OH8 _'75.\+=K,P;$+?ZP^6N8ND;14!Y]_U=T<SD[ZFB1
M1]SAEHA,,/CSPL^XXT26P(]_$J.=39\1,'V]MCZ.!P^#>60A/_.=G_9,S(\Z
M@PZ:\2>V=,2#_SKAR8!H9,_RG3#^'[TF;;4.LI:A\-T$#!ZXMK?ZR]Z20*0
M8*<80!( J0O0$X!>%V D *,N@"8 N@TP2@!F C#K OH)H%_7I4$"&-0%#!/
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MO0V;73AM'-I4PVM[BQM4YI0;'":/BV6ZG"V63R1=K]/ET\/SP_+;AGPF+TX
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M/&S[1\>V(>@J?:6=4"%?D=/+)<$SPE2 ?#ZGLO"ZH=Z2L[^;VO\#4$L#!!0
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M L),T.]7G*NW@3GFZL^:X7]02P,$%     @ #XEC4=#YK2Y-!   5A(  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S(N>&ULO9A9;^HX%,>_BA7=AU::DL0L
M+14@L>1JD J-2GNO1J-Y2,D!K)O8&=N4SF@^_#@+"5EPAZET7R#+6?['R^^
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MR<&(*J:KDJEU@6D ;DC.]PQ<YS&.G^<;0G4MW3I+7UFC@"$N=&";'X%E6N8
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M"V&)\R]2^/I7J69G!X4-X#9MAD9O ?=389Z6.G;K>@.R37>B[>WI6[W<$;9
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M4$2V.(_EBAV>2)E05_%M6"ST+SJ46-="FUQ(EI3&$$%"T^(?_RB%J!D C]G
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MV*!G\&(>+A:297K@6S,)XZ.^W,,W!.$* />WC,GC0CFHODK&_P)02P,$%
M  @ #XEC4>UE;GP! P  2PD  !D   !X;"]W;W)K<VAE971S+W-H965T.#(N
M>&ULS59;3]LP%/XK5IY  I+F4@IJ*_6V@32@:F![-HG36"1V9CN4_?L=.VG6
MEC1#FS3MI;&/S_>=:WT\W'#Q(E-"%'K+,R9'5JI4<6W;,DI)CN4%+PB#DX2+
M'"O8BK4M"T%P;$!Y9KN.T[=S3)DU'AK94HR'O%09960ID"SS'(L?4Y+QS<CJ
M65O!BJY3I07V>%C@-0F)>BJ6 G9VPQ+3G#!).4.")"-KTKM>#+2^4?A*R4;N
MK)&.Y)GS%[VYC4>6HQTB&8F49L#P>24SDF6:"-SX7G-:C4D-W%UOV3^9V"&6
M9RS)C&??:*S2D36P4$P27&9JQ3<WI(XGT'P1SZ3Y19M:U[%05$K%\QH,'N24
M55_\5N=A!P \[0"W!KB' /\(P*L!WD<M^#7 _ZB%H :8T.TJ=I.X.59X/!1\
M@X36!C:],-DW:,@79;I/0B7@E ).C1>3U?WM_><0G7QY",-3M%RL4'@S62W0
M.;K'0F!=1W0R)PK33)Z"5*98$+G]4(8>4UY*S&(YM!5XI'GMJ+8^K:R[1ZQ[
MZ(XSE4JT8#&)6_#S;OQ5!]Z&3#3I<+?IF+J=A"$I+I#GG"'7<9T6?V8?AO>N
MVL+Y.^N+/[:^EPROZ0W/\/G'^!2/7M!#H?_1$D&%T2I\DAW$?D/L&V+O"/&$
M*7H>TZPTS55W$N,*NBG*2JBD;BN5$A3QO"@5-E<*3Y"!P"G!@E&VEJ@@HH)W
M.!4T3@6=T<ZW_I D@5M,VRNX(N JSK0C.?A0NWI"M\O3MAZI[ 3&CKZG7\>^
M'WA#^W6W$]XK>3W?WU=:M# %@ZM&:2_.?A-GOS/.1[CFS_7=6I7S#"V),/.&
M1;MR4^^]#NC(\65C^_+_*?R@<6KP;PH_';PK5\_Q=^I5M<=[K<#K'[9'&U7?
M.>R/WU!5Z;!WID-.Q-J,90F1E4Q5ET$C;2;_Q R\ _FT=SWKM<CG\%*H!OLO
M^NJ9<8?%FL+=D9$$3#D7E^"JJ$9WM5&\,+/IF2N8=&:9PFN'"*T YPF'2M0;
M;:!Y/XU_ E!+ P04    "  /B6-1OOC)9B8"   H!   &0   'AL+W=O<FMS
M:&5E=',O<VAE970X,RYX;6Q]5-UOVR 0_U=.5A]::0N.TV93Y5C*U[)(Z18E
MZO8P[8'8%P<5@PLX;O_[ 78L3UKV8CBX^WW X;B6ZD6?$ V\%5SH27 RIGPD
M1*<G+*@>R!*%W3E*55!C0Y4372JDF2\J.(G"<$P*RD20Q'YMJY)85H8S@5L%
MNBH*JMYGR&4]"8;!96''\I-Q"R2)2YKC'LUSN54V(AU*Q@H4FDD!"H^38#I\
MG(U<OD_XP;#6O3DX)P<I7URPSB9!Z 0AQ]0X!&J',\Z1<P=D9;RVF$%'Z0K[
M\POZ%^_=>CE0C7/)?[+,G";!YP R/-**FYVLOV+KY\'AI9)K_X6ZS0T#2"MM
M9-$66P4%$\U(W]ISZ!5$PRL%45L0>=T-D5>YH(8FL9(U*)=MT=S$6_755AP3
M[E+V1ME=9NM,LEFNIAO8[K[/E\O%^MMJ#Q]A@SGEL%4R1<PT4)'!2IY1"7L9
MQNZXA1WF%:=&JG=8B]>**88:;A=H*./Z#FZ "7ABG-N3US$Q5JGC(VFK:M:H
MBJZHVF,Y@%'X :(P"I_W"[B]N?L;A5B?G=FH,QMYV-$5V+DL"F:<B\;57 K#
M1(XB=>H73*=<ZDHA_)H>M%&V8W[_AW74L8X\Z_TUUDHI2VD;,%459F Y-*1]
MZG\=4(,Y]ICN99V3X?TXBLFYKX3T+MZ]H2>J<B8T<#S:LG#PZ2$ U?1E$QA9
M^EXX2&,[RT]/]BFC<@EV_RBEN02NO;J?0_('4$L#!!0    (  ^)8U&H,%OY
M- 4  $X6   9    >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;+58VV[;.!#]
M%<+H0PNDL4CYEL(QD-JY.'7;($:Z#XM%0<NT3(02M21M-\!^_ XE1;(3B56+
M^B419<[AF>',X8C#G52/>LV803\B$>OSUMJ8Y$.[K8,UBZ@^E0F+X9>55!$U
M,%1A6R>*T65J%(DV\;Q>.Z(\;HV&Z;L[-1K*C1$\9G<*Z4T44?7TD0FY.V_A
MUO.+>QZNC7W1'@T3&K(Y,P_)G8)1NT!9\HC%FLL8*;8Z;UW@#Y_\U""=\8VS
MG=Y[1M:5A92/=C!=GK<\RX@)%A@+0>'?EHV9$!8)>/R;@[:*-:WA_O,S^E7J
M/#BSH)J-I?B++\WZO#5HH25;T8TP]W)WPW*'NA8OD$*G?]$NG^NU4+#11D:Y
M,3"(>)S]IS_R0.P9$%QC0'(#TM3 SPW\%P9^O\:@DQMT7AC@08U!-S?HOJ14
MYW0O-^B]I-2K,>CG!OVFE :YP: II;/<X*RI ?:>=\YK;%)L=I9T69:D*3:A
MAHZ&2NZ0LO,!SSZD>9K:0V;QV);4W"CXE8.=&<TNKR]FZ.[^Z_CR<C+]<CU'
M[]&<!1O%#6<:T7B)[J?CKV@LJ-;H(JV#_#43U+ E^DR-84JCMQ-F*!?Z'7J#
M>(P^<R'LW)/#X;!M@+5=NQWD##]F#$D-PXM->(J\S@DB'O'&%Q/T]LV["I2Q
M&V7"@E.$>Q8%GSW,ZU F#5"\?HK2Y['>*!H'['LB!0^>OB=,<;FL0+UTHWX-
MS"GR<8K:#4 ?*B"NW!!SEA3N]6BZ2Q4@UPU ?"^+=!ZC4,E-8CG5@MXT"-E/
MG)LV<<[/]JZ6QVT3$.\G()_<(%=L 2#=#(3%AING0Y VE%]1@Z2H09*B=FI0
MQS2F2^H \@L@/P7RZXI90HV.)?"*0Q8'MH#_GL$<-#4LTO\X5N@4*W2<5+]L
MH@532*[@#.9&HQ47( '_H9J-O<G0NBF:/=VWH]ZPO:T@T"T(=!O$"E;\QB7H
MCSV5@4SZEM,8W2FYY> Y%?LJ-F,AU]EL1PQZ!87>D:+<+U;H_T:4%QN#8FG0
M$S1:FJEM&OCZ6N^_"CVI#OV@8#5HR"K-?/#[!+$?3 5< Q69F/?0LB%E>Y@3
ME&P4<(_#G" PK2J7K.8&KYCB:J9G!=,S)U-H!(V-V Q8AC1?_XB9@[WRM/6.
ME#MX[T3'#;R'MA>V@8:*02",1 E] M_?5)Z_&5YO;P/..M4[@$M-PVY1>Y@?
MQ'%_)[Y HWT++0-SB2<N10\?2_5P*7NXJ>ZE!Z*V3SS>,NC05%J?!ZF>SJD\
M?U_KH=^OB72IB-@MB26W0% >:;3D.N):NX3Y.L?<9U)'I-1%W/M303J!SS'[
MP8?@TW!I7[N"UGL=-*^&:ZFPV"VQC=(3!@_QBFZEH@O!H.,--Z %4CWEC; K
MM4I5Q8-CI6^IA]@MB+]X;%_F</LAKQ$$4DH?\7XWXI5ZW4@E2*F*!!\IS&2O
MCW-KWJ\J[SC'VU=>3'"9W%D!5,WR<$T)D%(WB>]D6_%=]X>2GY2Z2CK'VI52
M'TE3?3Q,_MK6Z8J\%D>_)MJE.!*W.$[@XW!+[?T1FM%=RL3E72EDI'^L")82
M19IV?E0(%D+T0-*#Q[442TB5DSRB(G?+%=HI>=WLD<-TOW5..?2@%$#B%L#I
M\[<ZA&K+% V+77!]=I7:YA^KK?-+ ?/=;5VY"7"^PT*!0<4-!,IN(%!V V%W
MH/GEQ"1?UQ7O]MX%D[UI_4Q5""L@P59@XYWVP5AEEY?9P,@DO7-:2&-DE#ZN
M&85LL1/@]Y64YGE@K[&**^31_U!+ P04    "  /B6-1"Y<CIY0#  #N#@
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M-0BSDTM5432I*GQ=*Z"9 U7<#X/@VJ\H$UX<N;5$Q9%LD#,!B2*ZJ2JJWI;
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M;OZBQQ8;]=!X52NQ:(/U#!9%M?Z?/[4+L16 :4< :0.(&\ Z F@;0/<-8&T
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MFQL?E"6L(S=6JDE8JNT.HEW,T+)9;23I81)C-9.$=S[!Q/C;$.!@"D+Y)U,
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MZY\ K2^46#8_6;D72HE%\W+.\PF7!J _GPJAGB_,KV V/\0Z_1]02P,$%
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M2OJA7?LG]-4NAU#)+/2[9$SI,@R.9RQH%3'0WV8&C!_JC+4QT._KC!E @7>
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M%Y+$ZG!)24SS$B#OSSD7[R?E ,TVYN@_4$L#!!0    (  ^)8U$.]RK S0(
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M8($SJF9\?0&%H&/#%W(J[1.MB[V>@\),*IX48%U!0EC^QO?%06P!-,]^0%
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MDC5B6I6'Y[S8J-O(7S$$/Z.-P^OK,8@?JO\3QG*]SI=B4BX/>U$TQSA68J<
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MO95 ;T6]E4!O1;V50.^(>D<"O2/J'0GTCJAW)- [HMZ10.\XV>PFT#NBWI%
M[XAZ1P*](^H="?2.J'<DT#NBWI% ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-
M0&^;_%E)H+>AWD:@MZ'>1J"WH=Y&H+>AWD:@MZ/>3J"WH]Y.H+>CWDZ@MZ/>
M3J"WH]Y.H+>CWDZ@MT\.FQ#H[:BW$^CMJ+<3Z.VHMQ/HG5#O1*!W0KT3@=X)
M]4X$>B?4.Q'HG5#O1*!W0KT3@=X)]4X$>J?)84$"O1/JG0CT3JAW(M [H]Z9
M0.^,>F<"O3/JG0GTSJAW)M [H]Z90.^,>F<"O3/JG0GTSJAW)M [3PY[$^B=
M4>],H'>#>C<$>C>H=T.@=X-Z-P1Z-ZAW\Y-Z#^/7H0RWGN\U/O\GJ1XOWRVW
MQU^7WQ<GK\H5Y_J^8GCZ"U!+ P04    "  /B6-1??/N/T,"   #-0  $P
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M\S/MJW9XS<_F_S[=_ 102P$"% ,4    "  /B6-1!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  ^)
M8U$QC7XH[0   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    (  ^)8U&97)PC$ 8  )PG   3              "
M <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ #XEC43A\I]%9
M!0  %Q8  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    (  ^)8U'/_4]R6 8  # 9   8              "
M@9L-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  /B6-1
M LB]TST"  !#!0  &               @($I%   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ #XEC41[5*HUU!P   R,  !@
M     ("!G!8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M  ^)8U%$O:C^X@,  #X-   8              " @4<>  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    "  /B6-1RV"9DX@)   +.@  &
M            @(%?(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ #XEC43WHF_UR"   XB0  !@              ("!'2P  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (  ^)8U'\MTH&10,  . &
M   8              " @<4T  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    "  /B6-1F$XH5D8.  #Q)@  &               @(% .
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ #XEC40;/X3JZ
M#   /"(  !D              ("!O$8  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    "  /B6-15"&W)1H+   X'   &0
M@(&M4P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (  ^)
M8U'^EP((E@4  /L/   9              " @?Y>  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ #XEC48!A9'HB#@  EBX  !D
M         ("!RV0  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    "  /B6-1769).FH"   5!0  &0              @($D<P  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (  ^)8U%SHRHPTA<  (Q/
M   9              " @<5U  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ #XEC427W#VC- @  W 4  !D              ("!SHT
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  /B6-1YY2D
MU;@8  "(6   &0              @('2D   >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    (  ^)8U$[JK_58P,  /8'   9
M  " @<&I  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M#XEC47>(1-=4"0  OQD  !D              ("!6ZT  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    "  /B6-1P"G<G8X#  #H!P  &0
M            @('FM@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    (  ^)8U$&$G/?N0(  #,&   9              " @:NZ  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ #XEC40:/:257 P
M<P<  !D              ("!F[T  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    "  /B6-1SCJS?2@*  "P'0  &0              @($I
MP0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (  ^)8U&(
MWT$P/P0  #T,   9              " @8C+  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ #XEC4<H#Z#=G)0  'X<  !D
M     ("!_L\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ^)8U$PWZ0EG04  &,1   9              "
M@2$7 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ #XEC
M47)R;P.& @  , 4  !D              ("!]1P! 'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    "  /B6-1T W/A9L%  #J$   &0
M        @(&R'P$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   (  ^)8U'03Y(>VP(  ,L%   9              " @80E 0!X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ #XEC40E^GUP#!0  QPP
M !D              ("!EB@! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    "  /B6-12+V]=AP#  #V!@  &0              @('0+0$
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (  ^)8U&%=/KG
MN0,  #4)   9              " @2,Q 0!X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ #XEC48'.W^B_ @  MP4  !D
M ("!$S4! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  /
MB6-1.L8^VWH"  !C!0  &0              @($). $ >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (  ^)8U&S 63COP(  .$%   9
M          " @;HZ 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#
M%     @ #XEC44@NU3 , P  ! <  !D              ("!L#T! 'AL+W=O
M<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  /B6-1!(D9)$L'  "(
M$P  &0              @('S0 $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM
M;%!+ 0(4 Q0    (  ^)8U$V+N  &P(  !8$   9              " @75(
M 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ #XEC40-=
M K#C P  2 \  !D              ("!QTH! 'AL+W=O<FMS:&5E=',O<VAE
M970T,RYX;6Q02P$"% ,4    "  /B6-1\PR3?D\$  ":$@  &0
M    @('A3@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M  ^)8U&FU!+X; 4  -,;   9              " @6=3 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ #XEC41>+I7?A @  A <  !D
M             ("!"ED! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    "  /B6-1\^->L(8%   Y&   &0              @($B7 $ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (  ^)8U%W4@\YR0,
M .(+   9              " @=]A 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ #XEC40N@TFG; P  H X  !D              ("!
MWV4! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  /B6-1
M0N7-HW,&  !S)   &0              @('Q:0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    (  ^)8U$<Y:\K@P,  .D+   9
M      " @9MP 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ #XEC4?%A;!!- P  /PD  !D              ("!570! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  /B6-1R< VS7L#  ":"@
M&0              @('9=P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    (  ^)8U%#4SY+W@(  )@(   9              " @8M[ 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ #XEC464("FKH
M P  \0P  !D              ("!H'X! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    "  /B6-1*SON0;@"  #+"   &0
M@(&_@@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (  ^)
M8U$DD,ZKT@(  (@'   9              " @:Z% 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ #XEC4;))(Z!T @  008  !D
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M=#8R+GAM;%!+ 0(4 Q0    (  ^)8U$4KRKX*0,  !0)   9
M  " @2>= 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @
M#XEC440WLT%%"0  OD4  !D              ("!AZ ! 'AL+W=O<FMS:&5E
M=',O<VAE970V-"YX;6Q02P$"% ,4    "  /B6-1_*KA=V,"  "/!0  &0
M            @($#J@$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4
M Q0    (  ^)8U&"4Q75+P@  )PT   9              " @9VL 0!X;"]W
M;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ #XEC4>?=H3A9!
M,!4  !D              ("! [4! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX
M;6Q02P$"% ,4    "  /B6-1DT%1*C '   &*P  &0              @(&3
MN0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (  ^)8U%X
ML"KH$P(  *0$   9              " @?K  0!X;"]W;W)K<VAE971S+W-H
M965T-CDN>&UL4$L! A0#%     @ #XEC417P'=4?!   >A(  !D
M     ("!1,,! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ^)8U$V[^. F ,  %,-   9              "
M@0#7 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ #XEC
M41FV$H1< P  4 P  !D              ("!S]H! 'AL+W=O<FMS:&5E=',O
M<VAE970W-BYX;6Q02P$"% ,4    "  /B6-1?"+[?(P"  "S!0  &0
M        @(%BW@$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0
M   (  ^)8U%K2=0HWP(  )@(   9              " @27A 0!X;"]W;W)K
M<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ #XEC41,6WW17 P  ,@L
M !D              ("!.^0! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q0
M2P$"% ,4    "  /B6-1N+;,H_8$  #L$0  &0              @(')YP$
M>&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    (  ^)8U&S#UUS
MNP,  *$,   9              " @?;L 0!X;"]W;W)K<VAE971S+W-H965T
M.#$N>&UL4$L! A0#%     @ #XEC4>UE;GP! P  2PD  !D
M ("!Z/ ! 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    "  /
MB6-1OOC)9B8"   H!   &0              @($@] $ >&PO=V]R:W-H965T
M<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    (  ^)8U&H,%OY- 4  $X6   9
M          " @7WV 0!X;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#
M%     @ #XEC40N7(Z>4 P  [@X  !D              ("!Z/L! 'AL+W=O
M<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    "  /B6-1P MM8A4"  !7
M!   &0              @(&S_P$ >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM
M;%!+ 0(4 Q0    (  ^)8U%BF*M!9@(  /$%   9              " @?\!
M @!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @ #XEC43VT
MJT"X @  PP<  !D              ("!G 0" 'AL+W=O<FMS:&5E=',O<VAE
M970X."YX;6Q02P$"% ,4    "  /B6-1HUY^< @'  "4)0  &0
M    @(&+!P( >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    (
M  ^)8U&P8ZD,YP<  .TV   9              " @<H. @!X;"]W;W)K<VAE
M971S+W-H965T.3 N>&UL4$L! A0#%     @ #XEC49G"*,63 @  Q@8  !D
M             ("!Z!8" 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"
M% ,4    "  /B6-1+KX_PRP%  #2'   &0              @(&R&0( >&PO
M=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    (  ^)8U$.]RK S0(
M  @)   9              " @14? @!X;"]W;W)K<VAE971S+W-H965T.3,N
M>&UL4$L! A0#%     @ #XEC40,;#?8Y @  7 H   T              ( !
M&2(" 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  /B6-1EXJ[',     3 @
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8;6Q02P4&     &4 90"Z&P  VC$"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>600</ContextCount>
  <ElementCount>441</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>156</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE</Role>
      <ShortName>ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS</Role>
      <ShortName>RESTRUCTURING, INTEGRATION AND SEPARATION COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127107 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136109 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - FINANCING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</Role>
      <ShortName>FINANCING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149111 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2157113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2161114 - Disclosure - RESEARCH AND DEVELOPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</Role>
      <ShortName>RESEARCH AND DEVELOPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2164115 - Disclosure - OTHER EXPENSE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENET</Role>
      <ShortName>OTHER EXPENSE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2167116 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2169117 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2173118 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGS</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2180119 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/REVENUERECOGNITION</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables</Role>
      <ShortName>ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2328304 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INVENTORIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2340307 - Disclosure - FINANCING ARRANGEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables</Role>
      <ShortName>FINANCING ARRANGEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2350308 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2353309 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2358310 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2362311 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2365312 - Disclosure - OTHER EXPENSE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETTables</Role>
      <ShortName>OTHER EXPENSE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSENET</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2370313 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2381314 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails</Role>
      <ShortName>REVENUE RECOGNITION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails</Role>
      <ShortName>REVENUE RECOGNITION - Variable Consideration Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails</Role>
      <ShortName>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails</Role>
      <ShortName>ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails</Role>
      <ShortName>RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - INVENTORIES - Components of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails</Role>
      <ShortName>INVENTORIES - Components of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Covenant Compliance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2444426 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2447429 - Disclosure - FINANCING ARRANGEMENTS - Maturities and Mandatory Payments, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Maturities and Mandatory Payments, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2448430 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2451431 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2455433 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2456434 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2459435 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2460436 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2463437 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2466438 - Disclosure - OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2468439 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2471440 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE - Schedule of Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2472441 - Disclosure - EARNINGS (LOSS) PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2474442 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2475443 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2476444 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Antitrust (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2477445 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Product Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2478446 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - General Civil Actions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2479447 - Disclosure - LEGAL PROCEEDINGS - Completed or Dormant Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Completed or Dormant Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2482448 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails</Role>
      <ShortName>SEGMENT INFORMATION - Segment Revenues and Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2483449 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails</Role>
      <ShortName>SEGMENT INFORMATION - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2484450 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2485451 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails</Role>
      <ShortName>SEGMENT INFORMATION - Revenue by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bhc-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2486452 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails</Role>
      <ShortName>SEGMENT INFORMATION - Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="bhc-20200930.htm">bhc-20200930.htm</File>
    <File>bhc-20200930.xsd</File>
    <File>bhc-20200930_cal.xml</File>
    <File>bhc-20200930_def.xml</File>
    <File>bhc-20200930_lab.xml</File>
    <File>bhc-20200930_pre.xml</File>
    <File>exhibit311q32020.htm</File>
    <File>exhibit312q32020.htm</File>
    <File>exhibit321q32020.htm</File>
    <File>exhibit322q32020.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhc-20200930.htm": {
   "axisCustom": 1,
   "axisStandard": 44,
   "contextCount": 600,
   "dts": {
    "calculationLink": {
     "local": [
      "bhc-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bhc-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "bhc-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhc-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhc-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "bhc-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 717,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 3,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 8
   },
   "keyCustom": 64,
   "keyStandard": 377,
   "memberCustom": 84,
   "memberStandard": 70,
   "nsprefix": "bhc",
   "nsuri": "http://www.bauschhealth.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.bauschhealth.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - REVENUE RECOGNITION",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE",
     "shortName": "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS",
     "shortName": "RESTRUCTURING, INTEGRATION AND SEPARATION COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127107 - Disclosure - INVENTORIES",
     "role": "http://www.bauschhealth.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136109 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - FINANCING ARRANGEMENTS",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS",
     "shortName": "FINANCING ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149111 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157113 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161114 - Disclosure - RESEARCH AND DEVELOPMENT",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT",
     "shortName": "RESEARCH AND DEVELOPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164115 - Disclosure - OTHER EXPENSE, NET",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENET",
     "shortName": "OTHER EXPENSE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167116 - Disclosure - INCOME TAXES",
     "role": "http://www.bauschhealth.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169117 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2173118 - Disclosure - LEGAL PROCEEDINGS",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGS",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2180119 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - REVENUE RECOGNITION (Tables)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables",
     "shortName": "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328304 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340307 - Disclosure - FINANCING ARRANGEMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables",
     "shortName": "FINANCING ARRANGEMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350308 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353309 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358310 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2362311 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables",
     "shortName": "RESEARCH AND DEVELOPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365312 - Disclosure - OTHER EXPENSE, NET (Tables)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETTables",
     "shortName": "OTHER EXPENSE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2370313 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2381314 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
     "shortName": "DESCRIPTION OF BUSINESS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ib9975f10d37a4b9f8ab190b71f48d126_I20200101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - REVENUE RECOGNITION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
     "shortName": "REVENUE RECOGNITION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ibbb36916236a49af8aabec568346f93f_D20200101-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i6f36fa5d62a24709bc859aad4a3e7e82_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails",
     "shortName": "REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "id9e3c92fe3464f88a360c3f4a50c31b0_D20190101-20190930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesReservesOfBusinessesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i6f36fa5d62a24709bc859aad4a3e7e82_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails",
     "shortName": "REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i6f36fa5d62a24709bc859aad4a3e7e82_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
     "shortName": "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i5bc655cb9eb649d7ab9cd303e9abe56d_D20190101-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "if407461ef48547d3adc0e65ccd56a10c_I20190306",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails",
     "shortName": "RESTRUCTURING, INTEGRATION AND SEPARATION COSTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i131e0328fd084b5da77d42beb644efd7_D20200101-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "icc55d9233fce40c7825223f6de02ff68_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "icc55d9233fce40c7825223f6de02ff68_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i85b5b7c7ce56466d86e248603302e40d_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i85b5b7c7ce56466d86e248603302e40d_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i2cf0cf8e00c24e43afee18043d34a006_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i2cf0cf8e00c24e43afee18043d34a006_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i6f36fa5d62a24709bc859aad4a3e7e82_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i6f36fa5d62a24709bc859aad4a3e7e82_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ibb0bbb2a96944d2281f1f89a0ad18937_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i90eeaa1d0b8e49aa8bf06da2ebbe726c_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ibb0bbb2a96944d2281f1f89a0ad18937_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i78c91ac833ae4d6a85617b9307192c5d_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - INVENTORIES - Components of Inventories (Details)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails",
     "shortName": "INVENTORIES - Components of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i0cfbeac78f9548d18d3b871368be2ee1_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9cc32bfd1c3d470cbe8ccec2d8c006a7_D20190101-20190930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i6f36fa5d62a24709bc859aad4a3e7e82_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i579542b4ba7747ffb47059ab2dca33a0_D20190101-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ica7020a01b884f0db71be5081d3f6c00_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ic43b82b77a204cbfb726e9c81f307b6e_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
     "shortName": "FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ic43b82b77a204cbfb726e9c81f307b6e_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i3f162016e969457b84bcd686dd3e501d_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444426 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i2af09f0132c5448bab7483f939d8c584_I20190308",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i35061b0459224831a5dd5ee11d9692a9_D20200526-20200526",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:PaymentForDebtAmortizationPrepaymentCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
     "shortName": "FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447429 - Disclosure - FINANCING ARRANGEMENTS - Maturities and Mandatory Payments, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
     "shortName": "FINANCING ARRANGEMENTS - Maturities and Mandatory Payments, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i3e190fe005974b5ea0fe1ade4aa15972_D20201029-20201029",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448430 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie5495c8c275a4cfa86648504274cec51_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451431 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie5495c8c275a4cfa86648504274cec51_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455433 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456434 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "if529f0515f5a4f35a1b4dfeb5cffd713_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459435 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of AOCI (Details)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i741bd4dd7c0149f6b7ffc048b13bc0ee_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460436 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463437 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails",
     "shortName": "RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466438 - Disclosure - OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails",
     "shortName": "OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468439 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471440 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Loss Per Share (Details)",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE - Schedule of Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i1dd54993dd634b0e82dc598e88544ff5_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472441 - Disclosure - EARNINGS (LOSS) PER SHARE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i1dd54993dd634b0e82dc598e88544ff5_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474442 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails",
     "shortName": "LEGAL PROCEEDINGS - Legal Proceeds and Governmental and Regulatory Inquiries (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9da4fed668814346810326af9b4d6598_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9761d415100240bda346f87cf5e43c87_D20150101-20151231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475443 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
     "shortName": "LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i9761d415100240bda346f87cf5e43c87_D20150101-20151231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ic882bdf321904c1a8e0bb5f1007fe242_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2476444 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
     "shortName": "LEGAL PROCEEDINGS - Antitrust (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ic882bdf321904c1a8e0bb5f1007fe242_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ia09727ee9461493e9f4e2df94a1f1591_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unitRef": "case",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477445 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
     "shortName": "LEGAL PROCEEDINGS - Product Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i4e734b47f6ad4ad984cd62d97f81a208_D20180401-20180430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478446 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
     "shortName": "LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i4e734b47f6ad4ad984cd62d97f81a208_D20180401-20180430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479447 - Disclosure - LEGAL PROCEEDINGS - Completed or Dormant Matters (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails",
     "shortName": "LEGAL PROCEEDINGS - Completed or Dormant Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i7ce77ea687ee470cace2bc7c9451c86d_D20200101-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementAmountAwardedToOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482448 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
     "shortName": "SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InterestAndDebtExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2483449 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
     "shortName": "SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i29ce34cdc90749658459a53d39ce83a0_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2484450 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i15e3e5ed4f394256b42ed9228ef66175_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "ie3651577659a4783932cc209e5cf2cb5_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2485451 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
     "shortName": "SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "i8e0f0ac6ffaa46f4a17dc33321f25e38_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "id87f54aacbd14ddb9195134667720744_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2486452 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
     "shortName": "SEGMENT INFORMATION - Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20200930.htm",
      "contextRef": "id87f54aacbd14ddb9195134667720744_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 156,
   "tag": {
    "bhc_AccountsReceivableAllowanceForForeignExchangeAndOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "label": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForForeignExchangeAndOther",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update",
        "label": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update",
        "terseLabel": "Retrospective effect of application of new accounting standard"
       }
      }
     },
     "localname": "AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccretionForTimeValueOfMoneyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accretion For Time Value Of Money [Member]",
        "label": "Accretion For Time Value Of Money [Member]",
        "terseLabel": "Accretion for the time value of money"
       }
      }
     },
     "localname": "AccretionForTimeValueOfMoneyMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedProductRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the current portion of accrued product rebates.",
        "label": "Accrued Product Rebate Current",
        "terseLabel": "Product rebates"
       }
      }
     },
     "localname": "AccruedProductRebateCurrent",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccruedProductReturnCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Product Return Current",
        "terseLabel": "Product returns"
       }
      }
     },
     "localname": "AccruedProductReturnCurrent",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AcquiredInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.",
        "label": "Acquired in Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D not in service"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "label": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "terseLabel": "ACQUISITION, LICENSING AGREEMENTS AND ASSETS HELD FOR SALE"
       }
      }
     },
     "localname": "AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AllegroOphthalmicsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allegro Ophthalmics, LLC",
        "label": "Allegro Ophthalmics, LLC [Member]",
        "terseLabel": "Allegro"
       }
      }
     },
     "localname": "AllegroOphthalmicsLLCMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AllowancesForLossesOnAccountsReceivableAndInventories": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.",
        "label": "Allowances for Losses on Accounts Receivable and Inventories",
        "terseLabel": "Allowances for losses on trade receivable and inventories"
       }
      }
     },
     "localname": "AllowancesForLossesOnAccountsReceivableAndInventories",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the major customer of the entity, AmerisourceBergen Corporation.",
        "label": "Amerisource Bergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.",
        "label": "Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold",
        "negatedLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BaseRateOrPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Base Rate Or Prime Rate [Member]",
        "label": "Base Rate Or Prime Rate [Member]",
        "terseLabel": "Base Rate or Prime Rate"
       }
      }
     },
     "localname": "BaseRateOrPrimeRateMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bausch Lomb/International [Member]",
        "label": "Bausch Lomb/International [Member]",
        "terseLabel": "Bausch + Lomb/ International"
       }
      }
     },
     "localname": "BauschLombInternationalMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BaushandLombInternationalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Baush and Lomb/International Segment [Member]",
        "label": "Baush and Lomb/International Segment [Member]",
        "terseLabel": "Bausch + Lomb/International",
        "verboseLabel": "Bausch + Lomb/ International"
       }
      }
     },
     "localname": "BaushandLombInternationalSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BrandedandOtherGenericProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Branded and Other Generic Products [Member]",
        "label": "Branded and Other Generic Products [Member]",
        "terseLabel": "Branded and Other Generics"
       }
      }
     },
     "localname": "BrandedandOtherGenericProductsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.",
        "label": "Business Acquisition, Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessAcquisitionProFormaOperatingIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Acquisition, Pro Forma Operating Income (Loss)",
        "label": "Business Acquisition, Pro Forma Operating Income (Loss)",
        "terseLabel": "Pro forma operating results"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaOperatingIncomeLoss",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationNoncurrentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "label": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationNoncurrentLiability",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual",
        "label": "Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual",
        "terseLabel": "Operating results of acquiree"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses",
        "negatedTerseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_CanadaBankersAcceptanceRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Canada Bankers Acceptance Rate [Member]",
        "label": "Canada Bankers Acceptance Rate [Member]",
        "terseLabel": "Canada Bankers Acceptance Rate"
       }
      }
     },
     "localname": "CanadaBankersAcceptanceRateMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the major customer of the entity, Cardinal Health, Inc.",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health,\u00a0Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Certain Products For Disposal, September Two Thousand Nineteen [Member]",
        "label": "Certain Products For Disposal, September Two Thousand Nineteen [Member]",
        "terseLabel": "Certain Products For Disposal, September 2019"
       }
      }
     },
     "localname": "CertainProductsForDisposalSeptemberTwoThousandNineteenMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ConcentrationRiskNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Concentration Risk, Number Of Products",
        "label": "Concentration Risk, Number Of Products",
        "terseLabel": "Number of products represented of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfProducts",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "label": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "terseLabel": "Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "label": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "terseLabel": "Alternate term, principal amount maturity threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAnnualAmortizationRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Annual Amortization Rate, Percentage",
        "label": "Debt Instrument, Annual Amortization Rate, Percentage",
        "terseLabel": "Annual amortization rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentAnnualAmortizationRatePercentage",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "label": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "terseLabel": "Amount available for restricted payments"
       }
      }
     },
     "localname": "DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Asset Sales, If Circumstances Met",
        "terseLabel": "Debt covenant, mandatory prepayments, percentage net cash proceeds, asset sales"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsAssetSalesIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Incurrence Of Debt, If Circumstances Met",
        "terseLabel": "Debt covenant, mandatory prepayments, percentage net cash proceeds, incurrence of debt"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsIncurrenceOfDebtIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Net Cash Proceeds, Property And Asset Losses, If Circumstances Met",
        "terseLabel": "Debt covenant, mandatory prepayments, percentage net cash proceeds, property and asset losses"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMandatoryPrepaymentsPercentageNetCashProceedsPropertyAndAssetLossesIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Mandatory Prepayments, Percentage Of Consolidated Excess Cash Flow, If Circumstances Met",
        "terseLabel": "Debt covenant, mandatory prepayments, percentage of consolidated excess cash flow"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMandatoryPrepaymentsPercentageOfConsolidatedExcessCashFlowIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio, Maximum",
        "terseLabel": "Total leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatioMaximum",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "terseLabel": "Quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentRedemptionPricePercentageChangeinControl": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "label": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "terseLabel": "Redemption price percentage to change in control (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageChangeinControl",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DeferredIncomeTaxNoncashExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.",
        "label": "Deferred Income Tax Noncash Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxNoncashExpenseBenefit",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DerivativeGainExcludedComponent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative, Gain, Excluded Component",
        "label": "Derivative, Gain, Excluded Component",
        "negatedTerseLabel": "Gain excluded from hedge effectiveness"
       }
      }
     },
     "localname": "DerivativeGainExcludedComponent",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DerivativeLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative Lawsuits [Member]",
        "label": "Derivative Lawsuits [Member]",
        "terseLabel": "Derivative Lawsuits"
       }
      }
     },
     "localname": "DerivativeLawsuitsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DeviceProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Device Products [Member]",
        "label": "Device Products [Member]",
        "terseLabel": "Devices"
       }
      }
     },
     "localname": "DeviceProductsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiscontinuedProductLinesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discontinued Product Lines",
        "label": "Discontinued Product Lines [Member]",
        "terseLabel": "Discontinued Product Lines"
       }
      }
     },
     "localname": "DiscontinuedProductLinesMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DisposalGroupNumberOfProductsForDisposal": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Number Of Products For Disposal",
        "label": "Disposal Group, Number Of Products For Disposal",
        "terseLabel": "Number of products for disposal"
       }
      }
     },
     "localname": "DisposalGroupNumberOfProductsForDisposal",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_DiversifiedProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Diversified Products Segment [Member]",
        "label": "Diversified Products Segment [Member]",
        "terseLabel": "Diversified Products"
       }
      }
     },
     "localname": "DiversifiedProductsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DoctorsAllergyFormulaLLCLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Doctors Allergy Formula, LLC Litigation [Member]",
        "label": "Doctors Allergy Formula, LLC Litigation [Member]",
        "terseLabel": "Doctors Allergy Formula, LLC Litigation"
       }
      }
     },
     "localname": "DoctorsAllergyFormulaLLCLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Benefit Filing Tax Returns, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Benefit Filing Tax Returns, Amount",
        "terseLabel": "Tax benefit related to filing certain tax returns"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationBenefitFilingTaxReturnsAmount",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deductible Royalty Expense (Benefit), Amount",
        "label": "Effective Income Tax Rate Reconciliation, Deductible Royalty Expense (Benefit), Amount",
        "negatedTerseLabel": "Tax benefit related to royalty payments by affiliate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductibleRoyaltyExpenseBenefitAmount",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "negatedTerseLabel": "Benefit for discrete items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "terseLabel": "Tax expense related to filing certain tax returns"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income, Expense (Benefit), Amount",
        "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income, Expense (Benefit), Amount",
        "negatedTerseLabel": "Tax benefit related to Global Intangible Low Taxed Income (GILTI)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeExpenseBenefitAmount",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "label": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Time-based RSUs, Performance-based RSUs and Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "label": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "terseLabel": "Fair value adjustments due to changes in estimates of other future payments"
       }
      }
     },
     "localname": "FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Finite Lived and Indefinite Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_GainLossRelatedToLitigationSettlementGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.",
        "label": "Gain (Loss) Related To Litigation Settlement, Gross",
        "negatedLabel": "Additions to accrued legal settlements"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementGross",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GenericPricingAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generic Pricing Antitrust Litigation",
        "label": "Generic Pricing Antitrust Litigation [Member]",
        "terseLabel": "Generic Pricing Antitrust Litigation"
       }
      }
     },
     "localname": "GenericPricingAntitrustLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Glumetza Antitrust Class Actions Litigation [Member]",
        "label": "Glumetza Antitrust Litigation [Member]",
        "terseLabel": "Glumetza Antitrust Litigation"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "label": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "terseLabel": "Glumetza Antitrust Litigation, Non-Class Complaints"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationNonClassComplaintsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GoodwillReclassifiedDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Goodwill, Reclassified During Period",
        "label": "Goodwill, Reclassified During Period",
        "terseLabel": "Assets held for sale reclassified to goodwill (Note 4)"
       }
      }
     },
     "localname": "GoodwillReclassifiedDuringPeriod",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_HighlyLiquidInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Highly Liquid Investments, Maturity Period",
        "label": "Highly Liquid Investments, Maturity Period",
        "terseLabel": "Highly liquid investments, maturity period (or less)"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentsMaturityPeriod",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_InsuranceCoverageLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Insurance Coverage Lawsuit [Member]",
        "label": "Insurance Coverage Lawsuit [Member]",
        "terseLabel": "Insurance Coverage Lawsuit"
       }
      }
     },
     "localname": "InsuranceCoverageLawsuitMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InterestSettlementOnCrossCurrencySwaps": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Settlement On Cross-Currency Swaps",
        "label": "Interest Settlement On Cross-Currency Swaps",
        "terseLabel": "Interest settlements from cross-currency swaps"
       }
      }
     },
     "localname": "InterestSettlementOnCrossCurrencySwaps",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InvestigationbytheStateofTexasStatesMedicaidProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investigation by the State of Texas, State's Medicaid Program [Member]",
        "label": "Investigation by the State of Texas, State's Medicaid Program [Member]",
        "terseLabel": "Investigation by the State of Texas, State's Medicaid Program"
       }
      }
     },
     "localname": "InvestigationbytheStateofTexasStatesMedicaidProgramMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_Legalsettlementsandrelatedfees": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Legal settlements and related fees",
        "label": "Legal settlements and related fees",
        "terseLabel": "Legal matters and related fees"
       }
      }
     },
     "localname": "Legalsettlementsandrelatedfees",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "terseLabel": "Threshold for incremental borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowings",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings, Percentage Of Adjusted EBITDA",
        "terseLabel": "Threshold for incremental borrowings, percentage of adjusted EBITDA"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentageOfAdjustedEBITDA",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LitigationwithFormerSalixCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Litigation with Former Salix CEO [Member]",
        "label": "Litigation with Former Salix CEO [Member]",
        "terseLabel": "Litigation with Former Salix CEO"
       }
      }
     },
     "localname": "LitigationwithFormerSalixCEOMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LossContingencyNewClaimsFiledButNotYetServedNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "label": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "terseLabel": "Number of suits filed but not yet served"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledButNotYetServedNumber",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits",
        "label": "Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits",
        "terseLabel": "Number of alleged stockholders, filed lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfAllegedStockholdersFiledLawsuits",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "label": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "terseLabel": "Number of entities, exercised opt-out right, pursuing action"
       }
      }
     },
     "localname": "LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfHealthPlansFiledLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Number Of Health Plans, Filed Lawsuits",
        "label": "Loss Contingency, Number Of Health Plans, Filed Lawsuits",
        "terseLabel": "Number of health plans commenced action"
       }
      }
     },
     "localname": "LossContingencyNumberOfHealthPlansFiledLawsuits",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfInsurancePolicyPeriods": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Number Of Insurance Policy Periods",
        "label": "Loss Contingency, Number Of Insurance Policy Periods",
        "terseLabel": "Number of distinct insurance policy periods"
       }
      }
     },
     "localname": "LossContingencyNumberOfInsurancePolicyPeriods",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "terseLabel": "Number of groups of investors filing action"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestors",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "terseLabel": "Number of groups of investors filing action, remain pending"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestorsPending",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the major customer of the entity, McKesson Corporation.",
        "label": "Mc Kesson Corporation [Member]",
        "terseLabel": "McKesson Corporation (including McKesson Specialty)"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MeasurementInputWeightedAverageDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "label": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "terseLabel": "Measurement Input, Weighted-Average Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageDiscountRateMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonemployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonemployee Director [Member]",
        "label": "Nonemployee Director [Member]",
        "terseLabel": "Non-employee Director"
       }
      }
     },
     "localname": "NonemployeeDirectorMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OmnibusIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014 [Member]",
        "label": "Omnibus Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsReportUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ortho Dermatologics Report Unit",
        "label": "Ortho Dermatologics Report Unit [Member]",
        "terseLabel": "Ortho Dermatologics Report Unit"
       }
      }
     },
     "localname": "OrthoDermatologicsReportUnitMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ortho Dermatologics Segment [Member]",
        "label": "Ortho Dermatologics Segment [Member]",
        "terseLabel": "Ortho Dermatologics"
       }
      }
     },
     "localname": "OrthoDermatologicsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents long-term debt obligations not elsewhere enumerated.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherMiscellaneousNonoperatingIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Miscellaneous Nonoperating Income (Expense)",
        "label": "Other Miscellaneous Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherMiscellaneousNonoperatingIncomeExpense",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OutLicensedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).",
        "label": "Out Licensed Technology [Member]",
        "terseLabel": "Technology and other"
       }
      }
     },
     "localname": "OutLicensedTechnologyMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OvertheCounterProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Over the Counter Products [Member]",
        "label": "Over the Counter Products [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OvertheCounterProductsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PartnerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.",
        "label": "Partner Relationships [Member]",
        "terseLabel": "Partner relationships"
       }
      }
     },
     "localname": "PartnerRelationshipsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PaymentForDebtAmortizationPrepaymentCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment For Debt Amortization Prepayment Cost",
        "label": "Payment For Debt Amortization Prepayment Cost",
        "terseLabel": "Debt amortization prepayment"
       }
      }
     },
     "localname": "PaymentForDebtAmortizationPrepaymentCost",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PaymentOfAccretedInterestOnContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Of Accreted Interest On Contingent Consideration",
        "label": "Payment Of Accreted Interest On Contingent Consideration",
        "negatedTerseLabel": "Payments of contingent consideration adjustments, including accretion"
       }
      }
     },
     "localname": "PaymentOfAccretedInterestOnContingentConsideration",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PharmaceuticalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmaceutical Products [Member]",
        "label": "Pharmaceutical Products [Member]",
        "terseLabel": "Pharmaceuticals"
       }
      }
     },
     "localname": "PharmaceuticalProductsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PlaintiffsDirectPurchasersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plaintiffs, Direct Purchasers [Member]",
        "label": "Plaintiffs, Direct Purchasers [Member]",
        "terseLabel": "Plaintiffs, Direct Purchasers"
       }
      }
     },
     "localname": "PlaintiffsDirectPurchasersMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Asset Acquisition, Additional Funding Payment Included In Aggregate Purchase Price",
        "label": "Potential Asset Acquisition, Additional Funding Payment Included In Aggregate Purchase Price",
        "terseLabel": "Potential asset acquisition, additional funding payment included in aggregate purchase price"
       }
      }
     },
     "localname": "PotentialAssetAcquisitionAdditionalFundingPaymentIncludedInAggregatePurchasePrice",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PotentialAssetAcquisitionAggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Asset Acquisition, Aggregate Purchase Price",
        "label": "Potential Asset Acquisition, Aggregate Purchase Price",
        "terseLabel": "Potential asset acquisition, aggregate purchase price"
       }
      }
     },
     "localname": "PotentialAssetAcquisitionAggregatePurchasePrice",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential Asset Acquisition, Upfront Payment Included In Aggregate Purchase Price",
        "label": "Potential Asset Acquisition, Upfront Payment Included In Aggregate Purchase Price",
        "terseLabel": "Potential asset acquisition, upfront payment included in aggregate purchase price"
       }
      }
     },
     "localname": "PotentialAssetAcquisitionUpfrontPaymentIncludedInAggregatePurchasePrice",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PriceAppreciationCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price Appreciation Credit [Member]",
        "label": "Price Appreciation Credit [Member]",
        "terseLabel": "Price Appreciation Credit"
       }
      }
     },
     "localname": "PriceAppreciationCreditMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ProductBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the rights to non-patented product brands.",
        "label": "Product Brands [Member]",
        "terseLabel": "Product brands"
       }
      }
     },
     "localname": "ProductBrandsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RICOClassActionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "RICO Class Actions",
        "label": "RICO Class Actions [Member]",
        "terseLabel": "RICO Class Actions"
       }
      }
     },
     "localname": "RICOClassActionsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ROTCPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ROTC Performance-Based Restricted Stock Units [Member]",
        "label": "ROTC Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "ROTC performance-based RSUs"
       }
      }
     },
     "localname": "ROTCPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestLongTermGrowthRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "label": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "terseLabel": "Reporting unit, impairment test, long-term growth rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestLongTermGrowthRate",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseProductRelated": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Expense, Product Related",
        "label": "Research And Development Expense, Product Related",
        "terseLabel": "Product related research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseProductRelated",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseQualityAssurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research And Development Expense, Quality Assurance",
        "label": "Research And Development Expense, Quality Assurance",
        "terseLabel": "Quality assurance"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseQualityAssurance",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ReserveForChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve For Chargebacks [Member]",
        "label": "Reserve For Chargebacks [Member]",
        "terseLabel": "Chargebacks"
       }
      }
     },
     "localname": "ReserveForChargebacksMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForCustomerReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve For Customer Returns [Member]",
        "label": "Reserve For Customer Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ReserveForCustomerReturnsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve For Discounts And Allowances [Member]",
        "label": "Reserve For Discounts And Allowances [Member]",
        "terseLabel": "Discounts and Allowances"
       }
      }
     },
     "localname": "ReserveForDiscountsAndAllowancesMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDistributionFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve For Distribution Fees [Member]",
        "label": "Reserve For Distribution Fees [Member]",
        "terseLabel": "Distribution Fees"
       }
      }
     },
     "localname": "ReserveForDistributionFeesMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesAdvertisingCreditsPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "label": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "terseLabel": "Rebates, Advertising Credits Portion"
       }
      }
     },
     "localname": "ReserveForRebatesAdvertisingCreditsPortionMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reserve For Rebates [Member]",
        "label": "Reserve For Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ReserveForRebatesMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestrictedCashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted Cash And Cash Equivalents, Fair Value Disclosure",
        "label": "Restricted Cash And Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestructuringAndIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring And Integration Costs",
        "label": "Restructuring And Integration Costs [Member]",
        "terseLabel": "Restructuring and Integration Costs"
       }
      }
     },
     "localname": "RestructuringAndIntegrationCostsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevenuesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate net revenues during the period in the normal course of business.",
        "label": "Revenues Net [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesNetMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueJune2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revolving Credit Facility Due June 2023 [Member]",
        "label": "Revolving Credit Facility Due June 2023 [Member]",
        "terseLabel": "Revolving Credit Facility Due June 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueJune2023Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SECInvestigationLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SEC Investigation Litigation",
        "label": "SEC Investigation Litigation [Member]",
        "terseLabel": "SEC Investigation Litigation"
       }
      }
     },
     "localname": "SECInvestigationLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SalixSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Salix Segment [Member]",
        "label": "Salix Segment [Member]",
        "terseLabel": "Salix"
       }
      }
     },
     "localname": "SalixSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_SeniorNotes450DueMay2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes, 4.50%, 2023 [Member]",
        "label": "Senior Notes, 4.50%, Due May 2023 [Member]",
        "verboseLabel": "4.50% Senior Notes euro-denoted debt Due May 2023"
       }
      }
     },
     "localname": "SeniorNotes450DueMay2023Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes5.625PercentDueDecember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes 5.625 Percent Due December 2021 [Member]",
        "label": "Senior Notes 5.625 Percent Due December 2021 [Member]",
        "verboseLabel": "5.625% Senior Notes Due December 2021"
       }
      }
     },
     "localname": "SeniorNotes5.625PercentDueDecember2021Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "Senior Notes, 5.00%, Due January 2028 [Member]",
        "terseLabel": "5.00% Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes500DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "Senior Notes, 5.25%, Due January 2030 [Member]",
        "terseLabel": "5.25% Senior Notes Due January 2030"
       }
      }
     },
     "localname": "SeniorNotes525DueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes550DueMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "5.50% Senior Notes due March 2023 [Member]",
        "label": "Senior Notes, 5.50%, Due March 2023 [Member]",
        "verboseLabel": "5.50% Senior Notes Due March 2023"
       }
      }
     },
     "localname": "SeniorNotes550DueMarch2023Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes5875DueMay2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "5.875% Senior Notes due May 2023 [Member]",
        "label": "Senior Notes, 5.875%, Due May 2023 [Member]",
        "verboseLabel": "5.875% Senior Notes Due May 2023"
       }
      }
     },
     "localname": "SeniorNotes5875DueMay2023Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes6125DueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "Senior Notes, 6.125%, Due April 2025 [Member]",
        "terseLabel": "6.125% Senior Notes Due April 2025"
       }
      }
     },
     "localname": "SeniorNotes6125DueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes625DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes, 6.25%, Due February 2029",
        "label": "Senior Notes, 6.25%, Due February 2029 [Member]",
        "terseLabel": "6.25% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes625DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes 7.00 Percent Due January 2028 [Member]",
        "label": "Senior Notes, 7.00%, Due January 2028 [Member]",
        "terseLabel": "7.00 % Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes700DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes725DueMay2029Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes 7.25 Percent Due May 2029 [Member]",
        "label": "Senior Notes, 7.25%, Due May 2029 [Member]",
        "terseLabel": "7.25 % Senior Notes Due May 2029"
       }
      }
     },
     "localname": "SeniorNotes725DueMay2029Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes850DueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "Senior Notes, 8.50%, Due January 2027 [Member]",
        "terseLabel": "8.50% Senior Notes Due January 2027"
       }
      }
     },
     "localname": "SeniorNotes850DueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes900DueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "Senior Notes, 9.00%, Due December 2025 [Member]",
        "terseLabel": "9.00% Senior Notes Due December 2025"
       }
      }
     },
     "localname": "SeniorNotes900DueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes925DueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "Senior Notes, 9.25%, Due April 2026 [Member]",
        "verboseLabel": "9.25% Senior Notes Due April 2026"
       }
      }
     },
     "localname": "SeniorNotes925DueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.50NotesDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "label": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "terseLabel": "5.50% Senior Notes Due November 2025"
       }
      }
     },
     "localname": "SeniorSecured5.50NotesDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.75NotesDueAugust2027Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "label": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "verboseLabel": "5.75% Senior Notes Due August 2027"
       }
      }
     },
     "localname": "SeniorSecured5.75NotesDueAugust2027Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Secured Credit Facilities [Member]",
        "label": "Senior Secured Credit Facilities [Member]",
        "terseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Secured Credit Facility",
        "label": "Senior Secured Credit Facility [Member]",
        "terseLabel": "Senior Secured Credit Facility"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilityMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]",
        "label": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]",
        "terseLabel": "6.50% Senior Notes Due March 2022"
       }
      }
     },
     "localname": "SeniorSecuredNotes6.50PercentDueMarch2022Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]",
        "label": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]",
        "terseLabel": "7.00% Senior Notes Due March 2024"
       }
      }
     },
     "localname": "SeniorSecuredNotes7.00PercentDueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Secured Notes And Senior Unsecured Notes [Member]",
        "label": "Senior Secured Notes And Senior Unsecured Notes [Member]",
        "terseLabel": "Senior Secured Notes and Senior Unsecured Notes"
       }
      }
     },
     "localname": "SeniorSecuredNotesAndSeniorUnsecuredNotesMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeparationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Separation Costs",
        "label": "Separation Costs [Member]",
        "terseLabel": "Separation Costs"
       }
      }
     },
     "localname": "SeparationCostsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant",
        "terseLabel": "Aggregate fair market value on awards granted during any calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ShowertoShowerProductLiabilityLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shower to Shower Product Liability Litigation [Member]",
        "label": "Shower to Shower Product Liability Litigation [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation"
       }
      }
     },
     "localname": "ShowertoShowerProductLiabilityLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Research And Development Expense [Table Text Block]",
        "label": "Summary Of Research And Development Expense [Table Text Block]",
        "terseLabel": "Summary of research and development"
       }
      }
     },
     "localname": "SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "label": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of variable consideration provisions"
       }
      }
     },
     "localname": "SummaryOfValuationAndQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SynergyPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Synergy Pharmaceuticals Inc. [Member]",
        "label": "Synergy Pharmaceuticals Inc. [Member]",
        "terseLabel": "Synergy Pharmaceuticals Inc."
       }
      }
     },
     "localname": "SynergyPharmaceuticalsInc.Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TSRPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TSR Performance-Based Restricted Stock Units [Member]",
        "label": "TSR Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR performance-based RSUs"
       }
      }
     },
     "localname": "TSRPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025AndNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 And November 2025",
        "label": "Term Loan B Facility Due June 2025 And November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due June 2025 And November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025AndNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 [Member]",
        "label": "Term Loan B Facility Due June 2025 [Member]",
        "verboseLabel": "Term Loan B Facility Due June 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan B Facility Due November 2025 [Member]",
        "label": "Term Loan B Facility Due November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TimeBasedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Time Based RSU [Member]",
        "terseLabel": "Time-based RSUs"
       }
      }
     },
     "localname": "TimeBasedRSUMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnitedStatesandPuertoRicoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "United States and Puerto Rico [Member]",
        "label": "United States and Puerto Rico [Member]",
        "terseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UnitedStatesandPuertoRicoMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.",
        "label": "Unrecognized Tax Benefits, Including Interest and Penalties",
        "terseLabel": "Unrecognized tax benefits including interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ValeantUSSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valeant US Securities Litigation [Member]",
        "label": "Valeant US Securities Litigation [Member]",
        "terseLabel": "US Securities Litigation"
       }
      }
     },
     "localname": "ValeantUSSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ViolationofCanadianProvincialSecuritiesLegislationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Violation of Canadian Provincial Securities Legislation [Member]",
        "label": "Violation of Canadian Provincial Securities Legislation [Member]",
        "terseLabel": "Violation of Canadian Provincial Securities Legislation"
       }
      }
     },
     "localname": "ViolationofCanadianProvincialSecuritiesLegislationMember",
     "nsuri": "http://www.bauschhealth.com/20200930",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_EG": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "EGYPT",
        "terseLabel": "Egypt"
       }
      }
     },
     "localname": "EG",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PL": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "POLAND",
        "terseLabel": "Poland"
       }
      }
     },
     "localname": "PL",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russia"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. Plan"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r187",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r207",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r187",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r207",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r61",
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r137",
      "r145",
      "r228",
      "r456",
      "r457",
      "r458",
      "r481",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r137",
      "r145",
      "r228",
      "r456",
      "r457",
      "r458",
      "r481",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r137",
      "r145",
      "r228",
      "r456",
      "r457",
      "r458",
      "r481",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r218",
      "r331",
      "r335",
      "r638"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r427",
      "r432",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r635",
      "r639"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r427",
      "r432",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r635",
      "r639"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r218",
      "r331",
      "r335",
      "r638"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r214",
      "r331",
      "r333",
      "r595",
      "r634",
      "r636"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r214",
      "r331",
      "r333",
      "r595",
      "r634",
      "r636"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r368",
      "r427",
      "r432",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r635",
      "r639"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r368",
      "r427",
      "r432",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r594",
      "r635",
      "r639"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r150",
      "r151",
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Restatement Adjustment"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r166",
      "r229",
      "r230",
      "r459",
      "r482",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Restatement [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r143",
      "r144",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r166",
      "r229",
      "r230",
      "r459",
      "r482",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Restatement [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r331",
      "r334",
      "r637",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r331",
      "r334",
      "r637",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r220",
      "r582"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "NEW JERSEY",
        "verboseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r481",
      "r482",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r42"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefit costs"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r19",
      "r604",
      "r619"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r67",
      "r72",
      "r73",
      "r517"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Pension and postretirement benefit plan adjustments, net of income taxes"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r70",
      "r71",
      "r72",
      "r621",
      "r647",
      "r651"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income Loss [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r69",
      "r72",
      "r73",
      "r133",
      "r134",
      "r136",
      "r517",
      "r642",
      "r643"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r65",
      "r72",
      "r73",
      "r517",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r136",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r434",
      "r436",
      "r461",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r436",
      "r449",
      "r460"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r221",
      "r231",
      "r232",
      "r236"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r112",
      "r580"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and write-off of debt premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive effect of potential common shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive shares not included in the computation of diluted earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r112",
      "r266"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Asset impairments",
        "terseLabel": "Asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r118",
      "r195",
      "r202",
      "r209",
      "r224",
      "r510",
      "r518",
      "r563",
      "r602",
      "r618"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets reclassified, held and used",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r56",
      "r118",
      "r224",
      "r510",
      "r518",
      "r563"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of assets classified as held for sale.",
        "label": "Assets Held-for-sale, Long Lived, Fair Value Disclosure",
        "terseLabel": "Non-current assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleLongLivedFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r4",
      "r5",
      "r6",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "negatedTerseLabel": "Assets reclassified, held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r438",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r527",
      "r531"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r423",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r423",
      "r428",
      "r494",
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r492",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Pro forma revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "auth_ref": [
      "r111",
      "r504"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
        "negatedTerseLabel": "Acquisition-related contingent consideration",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r501",
      "r502"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion included in Accrued and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value, contingent consideration obligations, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r501",
      "r502"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue of acquiree"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Product brand intangible assets (estimated useful life - 7 years)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r112",
      "r273",
      "r279",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Facility closure costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r36",
      "r114"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r108",
      "r114",
      "r115"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of period",
        "terseLabel": "Cash and cash equivalents and restricted cash, end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r108",
      "r568"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r47",
      "r286",
      "r608",
      "r627"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, no par value, unlimited shares authorized, 355,026,950 and 352,562,636 issued and outstanding at September 30, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r76",
      "r78",
      "r79",
      "r85",
      "r612",
      "r631"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r78",
      "r84",
      "r508",
      "r509",
      "r522",
      "r611",
      "r630"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive (income) loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r78",
      "r83",
      "r507",
      "r522",
      "r610",
      "r629"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r82",
      "r95",
      "r609",
      "r628"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r218",
      "r561",
      "r562"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r218",
      "r561",
      "r562",
      "r652"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r218",
      "r561",
      "r562",
      "r652"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r177",
      "r178",
      "r218",
      "r561",
      "r562"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r218",
      "r561",
      "r562"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r512"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Product rights/patents"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r211",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r90",
      "r595"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "verboseLabel": "Cross-currency swaps"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r175",
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "FINANCING ARRANGEMENTS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r603",
      "r605",
      "r617"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percentage)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r301",
      "r605",
      "r617"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal Amount",
        "totalLabel": "Total debt obligations"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r579",
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate on debt (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Long-term debt, net of unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Maximum percentage of principal amount that can be redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Repurchased principal amount",
        "verboseLabel": "Repurchased debt, aggregate par value"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r45",
      "r121",
      "r309",
      "r310",
      "r311",
      "r312",
      "r578",
      "r579",
      "r581",
      "r616"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r302",
      "r580"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Unrecognized tax benefit, amount possible to decrease in next twelve months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r346",
      "r384",
      "r411",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Amortization of net loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r346",
      "r385",
      "r412",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credit and other"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r346",
      "r383",
      "r410",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r346",
      "r350",
      "r382",
      "r409",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r380",
      "r407",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r348",
      "r381",
      "r408",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r112",
      "r267"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r58",
      "r63",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "terseLabel": "Fair value, derivative, included in other current liabilities"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r59",
      "r60",
      "r560"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative Assets"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r57",
      "r62",
      "r529",
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Fair value, derivative, included in prepaid expenses and other current assets",
        "verboseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r528",
      "r530",
      "r535",
      "r541"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r526",
      "r528",
      "r535"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r526",
      "r528",
      "r535",
      "r541",
      "r542",
      "r543",
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "negatedTerseLabel": "Net change in fair value, loss"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss",
        "terseLabel": "Loss related to settlements during period"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r59",
      "r60",
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative Liabilities",
        "verboseLabel": "Fair value, derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r523",
      "r524"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r5",
      "r264",
      "r272"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r3",
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenue associated with products for disposal"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r423",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings (loss) per share attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r86",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r155",
      "r160",
      "r161",
      "r162",
      "r166",
      "r167",
      "r613",
      "r632"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings (loss) per share attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average common shares"
       }
      }
     },
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r86",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r155",
      "r160",
      "r161",
      "r162",
      "r166",
      "r167",
      "r613",
      "r632"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r568"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r463",
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "negatedTerseLabel": "Tax benefit related to stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Remaining unrecognized compensation expense related to non-vested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average service period over which compensation cost is expected to be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r133",
      "r134",
      "r136",
      "r139",
      "r148",
      "r151",
      "r169",
      "r228",
      "r308",
      "r313",
      "r456",
      "r457",
      "r458",
      "r481",
      "r482",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurocurrency rate"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r547",
      "r548",
      "r549",
      "r558"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r547",
      "r548"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value on a non-recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r417",
      "r548",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r547",
      "r548",
      "r551",
      "r552",
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r369",
      "r371",
      "r376",
      "r417",
      "r548",
      "r584"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "verboseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r369",
      "r371",
      "r376",
      "r417",
      "r548",
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02",
        "verboseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r417",
      "r548",
      "r586"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03",
        "verboseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "verboseLabel": "Reconciliation of contingent payment obligations measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r553",
      "r558"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r553",
      "r558"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r417",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r547",
      "r548",
      "r551",
      "r552",
      "r556",
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring adjustment",
        "verboseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r557",
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Net Asset (Liability) [Abstract]",
        "terseLabel": "Other non-current assets:"
       }
      }
     },
     "localname": "FairValueNetAssetLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Product brand intangible assets, estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization and Impairments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r252",
      "r254",
      "r257",
      "r260",
      "r596",
      "r600"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r257",
      "r600"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r252",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r257",
      "r596"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r113",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r369",
      "r539"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r422",
      "r426",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Non-U.S. Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Gain on sale of assets",
        "negatedTerseLabel": "Net gain on sale of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Litigation and other matters"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r112",
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Gain on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r238",
      "r240",
      "r601"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisition of certain assets of Synergy"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r241",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r112",
      "r239",
      "r244",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Change in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedLabel": "Goodwill reclassified to assets held for sale (Note 4)"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r526",
      "r542"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r112",
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r112",
      "r265"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment of long-lived assets classified as held for sale"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r122",
      "r195",
      "r201",
      "r205",
      "r208",
      "r211"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before (provision for) benefit from income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r423",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r472",
      "r476",
      "r478",
      "r483",
      "r485",
      "r487",
      "r488",
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r119",
      "r150",
      "r151",
      "r193",
      "r470",
      "r484",
      "r486",
      "r633"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from income taxes",
        "negatedTerseLabel": "(Provision for) benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedTerseLabel": "Tax benefit related to release of valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r467",
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "negatedTerseLabel": "Tax benefit related to change in United States law"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "negatedTerseLabel": "Income tax benefit on ordinary loss"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Tax charges (benefits) related to changes in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r162"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Diluted effect of stock options and RSUs (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r253",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r253",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r251",
      "r255"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r93",
      "r304"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r42"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total Inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r55"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r92",
      "r188"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r118",
      "r203",
      "r224",
      "r511",
      "r518",
      "r519",
      "r563"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r118",
      "r224",
      "r563",
      "r607",
      "r624"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r118",
      "r224",
      "r511",
      "r518",
      "r519",
      "r563"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r47",
      "r286",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Current accrued loss contingencies"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsandGovernmentalandRegulatoryInquiriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement, agreed to pay",
        "verboseLabel": "Settlement, escrow fund included in restricted cash"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r20",
      "r303",
      "r605",
      "r620"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt and other"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt and other",
        "verboseLabel": "Less: Current portion of long-term debt and other"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r124",
      "r299"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r124",
      "r299"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r124",
      "r299"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r124",
      "r299"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r124",
      "r299"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r124",
      "r299"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2020"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of long-term debt",
        "verboseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r45",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r286",
      "r289",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r297",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of suits filed",
        "verboseLabel": "Number of putative antitrust class actions filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of lawsuits pending"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r51",
      "r118",
      "r224",
      "r563",
      "r606",
      "r623"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r170",
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r108",
      "r110",
      "r113"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r77",
      "r150",
      "r151",
      "r514",
      "r521"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss (income) attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r152",
      "r153",
      "r159",
      "r162",
      "r195",
      "r201",
      "r205",
      "r208",
      "r211"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income (loss) attributable to Bausch Health Companies Inc.",
        "verboseLabel": "Net income (loss) attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r145",
      "r166",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r479",
      "r480",
      "r481",
      "r482",
      "r597",
      "r598",
      "r599",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Guidance and Recently Issued Accounting Standards, Not Adopted as of September 30, 2020"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r136",
      "r313",
      "r505"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r195",
      "r201",
      "r205",
      "r208",
      "r211"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segment"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r42"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r68",
      "r70",
      "r507",
      "r516"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Pension and postretirement benefit plan adjustments, net of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r66",
      "r70",
      "r533",
      "r538",
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain excluded from assessment of hedge effectiveness"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r537"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "(Loss) Gain recognized in Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r75",
      "r78",
      "r80",
      "r82",
      "r308",
      "r569",
      "r574",
      "r575",
      "r609",
      "r628"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive (loss) income",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r342",
      "r465"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "OTHER EXPENSE, NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense, net",
        "negatedTotalLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other expense, net",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r398",
      "r402",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Benefit Plan"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringCosts": {
     "auth_ref": [
      "r112",
      "r273",
      "r279",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.",
        "label": "Other Restructuring Costs",
        "terseLabel": "Other severance costs"
       }
      }
     },
     "localname": "OtherRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Bausch Health Companies\u00a0Inc. Shareholders' Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "negatedTerseLabel": "Payments of accrued legal settlements",
        "terseLabel": "Payment for legal settlement"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Payments for (Proceeds from) Hedge, Investing Activities",
        "terseLabel": "Payments or receipts in settlement of cross-currency swaps"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r106",
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Restructuring payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments of employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r97",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash payments to acquire certain assets and assumed liabilities"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Payments for intangible and other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r368",
      "r370",
      "r376",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r417",
      "r419",
      "r420",
      "r421",
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r343",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r398",
      "r402",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefit Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r438",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from sale of assets and businesses, net of costs to sell"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Issuance of long-term debt, net of discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r100",
      "r105",
      "r123"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from the issuances of short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r74",
      "r77",
      "r107",
      "r118",
      "r138",
      "r150",
      "r151",
      "r195",
      "r201",
      "r205",
      "r208",
      "r211",
      "r224",
      "r507",
      "r513",
      "r515",
      "r521",
      "r522",
      "r563",
      "r614"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r268",
      "r626"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r87",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r23",
      "r30",
      "r625",
      "r653"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r72",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedTerseLabel": "Amount reclassified from accumulated other comprehensive loss into operating results"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedTerseLabel": "Repayments of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Fair value of reporting value, greater than its carrying value"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "totalLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r15",
      "r115"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash, current"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING, INTEGRATION AND SEPARATION COSTS"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r274",
      "r276",
      "r282",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Costs incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r112",
      "r273",
      "r279",
      "r283"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedTerseLabel": "Restructuring, integration and separation costs",
        "terseLabel": "Restructuring, integration and separation costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Cost-rationalization and integration initiatives"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r275",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Liabilities associated with restructuring, integration and separation costs"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r313",
      "r459",
      "r622",
      "r646",
      "r651"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r133",
      "r134",
      "r136",
      "r139",
      "r148",
      "r151",
      "r228",
      "r456",
      "r457",
      "r458",
      "r481",
      "r482",
      "r642",
      "r644"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r398",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r422",
      "r426",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r398",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r422",
      "r426",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r398",
      "r402",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r398",
      "r402",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r429",
      "r430",
      "r431"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r186",
      "r187",
      "r200",
      "r206",
      "r207",
      "r214",
      "r215",
      "r218",
      "r330",
      "r331",
      "r595"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Price appreciation credits"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r332",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of activity in allowance for credit losses"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r72",
      "r574",
      "r575"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of the components of Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r494",
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALEEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of the components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r401",
      "r402",
      "r405",
      "r406",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of earnings (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r436",
      "r448",
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of revenues by segment and product category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r547",
      "r548"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of components and classification of financial assets and liabilities measured at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r252",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r247",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r247",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r259",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r14",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of the components of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effect of hedging instruments on financial statements"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other expense, net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Fair values of assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONLICENSINGAGREEMENTSANDASSETSHELDFORSALETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r277",
      "r278",
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of customers that accounted for 10% or more of total revenue"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r89",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of revenue attributed to a geographic region"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r81",
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r195",
      "r198",
      "r204",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r195",
      "r198",
      "r204",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment revenues and profit"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r442",
      "r444",
      "r446"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of share-based awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r438",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated aggregate amortization expense for each of the five succeeding years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Senior Secured Notes"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r183",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r218",
      "r634"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r183",
      "r184",
      "r185",
      "r195",
      "r199",
      "r205",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Secured Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSCompletedorDormantMattersDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r112",
      "r273",
      "r279",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r435",
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r2",
      "r183",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r218",
      "r247",
      "r271",
      "r276",
      "r284",
      "r634"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r49",
      "r133",
      "r134",
      "r136",
      "r139",
      "r148",
      "r151",
      "r169",
      "r228",
      "r308",
      "r313",
      "r456",
      "r457",
      "r458",
      "r481",
      "r482",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r136",
      "r169",
      "r595"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Stock Options and RSUs"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r21",
      "r22",
      "r308",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r21",
      "r22",
      "r313",
      "r437",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r27",
      "r28",
      "r118",
      "r222",
      "r224",
      "r563"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Bausch Health Companies Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r118",
      "r133",
      "r134",
      "r136",
      "r139",
      "r148",
      "r224",
      "r228",
      "r313",
      "r456",
      "r457",
      "r458",
      "r481",
      "r482",
      "r505",
      "r506",
      "r520",
      "r563",
      "r569",
      "r570",
      "r575",
      "r643",
      "r644"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Cumulative-effect adjustment to accumulated deficit",
        "totalLabel": "Total equity",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAOCIDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r576",
      "r583"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r576",
      "r583"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r576",
      "r583"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate brands",
        "verboseLabel": "Bausch Lomb Trademark"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONANDSEPARATIONCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits related to interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Senior Unsecured Notes",
        "verboseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesandMandatoryPaymentsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r179",
      "r180",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "negatedTerseLabel": "Reduction in variable consideration provision, adjustment"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r125",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Reserve ending balance",
        "periodStartLabel": "Reserve beginning balance",
        "terseLabel": "Cooperative advertising credits included in rebates"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Current period provisions",
        "verboseLabel": "Sales return provisions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and credits"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesReservesOfBusinessesAcquired": {
     "auth_ref": [
      "r128"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from business combination.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Business Acquired",
        "terseLabel": "Acquisition of Synergy"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesReservesOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r154",
      "r162"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted weighted-average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r152",
      "r162"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic weighted-average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121607252&loc=SL5864739-113975"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r665": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r666": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r667": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r668": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r669": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r670": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0000885590-20-000060-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885590-20-000060-xbrl.zip
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M@YM*2L@IQ4(.@D]JL:*X%M 9,5R&4%JQ(4Y__5A"B95;BM$8!O:430J<?8W
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M C4H;$_'HS-@QZ?]PM]!=7RV'_+[\W/HPXL37+QS\;R?X:.2XFI3CY7%F.I
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MC=01N%IR#*[5YAR(Y&(:YIHB &5U9@.H^=@@>K%$7+R&4\RF8F]KXAIA-%0
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MX\>^$$I5F@;YGBQCBG4 D<EF.I+P30H7<GCK].7I;*[W,0W$5B"&U)PGWTR
M6"J51@E"49%@;.(VWU;LA.(&\N=20O)E,4."4U]4S>!)?U7RS94!S#W\<Z'X
M:3Q;M5@L9"$$<XEE#F6,?>:(B<2Q-Q$".D2?A2L+1D'' TC8?_'2L$3;8&-3
MVQ \N"A@;,@E^V12U.>EN#K@%8++T.04%MB\7>:"Z_+$<%-,@P-C$#7>2*5
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MP$A)B83/N:?'!K#HMW$ZMYX%L1!BZ.7MT&O=%;&232R> J!))<*%S@7GMQ_
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M(^98<^PC!X/!LXT4 ]'J#Y(?BZXP>M0/.!/>TM15\MYS=:WYGN.P(6=(J0$
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M,4L23J3@#!L!)+GC,=FBT;IIN,L29#P6UH("I!DC-N<IY8S&7,1<$9>M0QN
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MXS*A-JR<\R$Z=-+<B81)9YG+F-:..["K%$\I-:E)R#HDAZZDF%V284.U==P
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M? *_/#P<^O0GR:2+G6(]%RO;8U;HGDR=ZJE,"F(4E8[HG6<_RDFE+Z(0Z8^
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M4E>1OK"P86QC"+:)]7DM6 ;9*7IX1&HOZ86L(E?TK8EDOP]78*%S!7__.RG
MDHG@])2M+X ' V_$')"V6'54UO_T%:M@&^%K:@:*U2/-F4?[>HP_8[%J9.!7
M,$'QTLO2:NL-4D+#DWQ7ABIZU#P9>'943<"\JBY&6)+1%'".+^1X?E,?Y>S*
M<=GAYGI?CW<C.331(]K9O +V#Q>I=[ UO,E?#W?BHNJ'83%XA=(CK%E6XTC$
MX0E&7E5[]Q]K>SXI2UA$J$-'G6TLQY-J+:72WW([TS\)Y2G+N>REVBI0O CI
M"9++'C'<@/+%C79FY]F9K>;%R%^J8/T#SAK1L_I[M/GI^Q3.+GYY!+;8,C<_
M^FL-_=::O2)C 9XR*,9C8$6V#[P%1!'*Q?Y59$%&7D5'*"ZE]C'4 SF6H:YV
MCO%.GW$Y*:L)/AI^>#WIVP!1%J?(5E_;\TE?3CGSF][I]^.R88TMW[35X^_
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M[ SD@9?,(TKG9QP=[E]KHX$%KAWFW=9#P.M<P7R_F63;P8  [XB()/&S;N7
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M:&%$%^0]Z@;];E9<RVF0 08Y@GDET7""PA:WTQSS$ 2W[DO,ZNHDU173@^^
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M=JLDK1#M?4,EZ<8A%3--=Z:(U[UW;K9$VT-U!MVF3J+:DQ,2;L(@C,U!JLU
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M-?[:KO&_[55@=Q4C4Z_WV(=1PCIQ+>TZCT&*Y=]@A>.+HNHLQUN-_FG&C^F
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M L73ZI K\[PNQLE>T^Z5:6J8=4:NFLZCD$%;9KP&BBJ X"71VQ()P5*4Q(9
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M:FRHRD>S\-&G:W57O4/%K$^@1:D1394"1Q(#3;C &#VQ,?.1WC3JY@K%OVJ
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MO.!Y%&+_(D/OLX'FX\/6C=W_/.$ K<U$L=P*OCN]6&/=<TX!U\KZ:FU0N:"
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M7N0;B#LH53+!ZH! 5;(A2D,(=PM(R*O0;?'<^W@.>P7QXX%XRG7/4VL&,;7
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M!*8L2(CV44H,FMV&X)JDTUKP/EW_@[N*G59$/S:BIP(')$EF'6<@3"R[&#&
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M*T"X$, [;\%81@T57A-6UJYO5O)LW_I6I;I*=2N7@5.I[G&I;BK:YC$2*FR
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MEK=&4@_ZO7)F@_YIOJ"W>Z4J&0YK9'4F:OLX%;8P%),I)8BTUEG-1*O *Y*
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M.AS3(4?O)%?H$;5PCKM #1>"N8PI1%[E8<OI<"(/N<&8Q;T#ZPL)QJ3 "C2
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MQ%Q)*96L>^*CTN.*MH]!2BL9('?H'ZUH>^=H.W=]QA )<9XA'218( DL$$L
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M7.+S^&5_<AH&X_;]*QMTGC1'V%[_=U(.POG>),_EV\$P#W![W)R!LR"+Z\[
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M.Z$[\O#DP%OS)[NCT227)899&GTG&WFTO3?OEXTL8]6BR [2FR8#IW^\DZ4
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MTMSGY7)8S(6\KM9EQ\X[Q&WF8@] L9NF;WX8:S[$_77^^A*'@U *V,WMGU:
M!VF[2",?*!_'81R-#ZXKG5?Q;"4\.UYD(LQIX50TB$F"$4]>(^.<0"$1E83!
MW&I@(O_W_VA*Z+_6*#A;?1CK[,.H.GSW.KP0!7%.J1!%+@D!.JPH6!/2,I2\
M4BPI(0D)-SN?7=T:WZF!!^.3.'Q>WHL'/7E1YKLM/-,4HFG+SU1\60E?/BRG
M2BB%)39(> DV#Z48V<02\D(9H8(V3/&-K9L$-ZJ?8FT9_]WY*:JNWIJNSKE
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M8_TV_<WU>K^V7V@83/M*WL#T=/OH]@,\_4M$=%FQ#S$#9+;F[O_N4V5&V02
MK^2=8T8S]R>G<$U_"_4%+E28L^/),!ZD@[.VZ<[H8=DAWINRP]/7GPZ./@ S
M^W#^Q^^[>._HW<G^Z1\GF2'N'?T;?GH,3 Z8WW9F>KWX\SOX7#ASE$M@@.(
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M.CN+KM(W,U?IX<Q5VCFQ'V/'Q=@'7AG/@-T!33TO[+BE\)G-_?;B\$4G#'I
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M!3>!19Z3(LICC5;;G5H6.15$T<.%_0AFX#B#>&SZF[2D;[[2KP^'/AY8.EK
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MT_A#/R;J'!Q][>T='; #^I]/>]NOOK;WWY+WAZ^^''S[N_/^1;NSN[U%WK^
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MDE%N'F2/CX>#K\"EX]@[:?W/*L?(5&CB 1^<-EPHJ@TC5G#L,)$Q,5& XGI
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M?@ODWACHL8JXRUQU,!A^ROE#-5\TH<R/6EM'@R8IM&&"&7-46<7YPI?!L!=
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M4!%K9=5*A' GP'Y:ZUFL*3>EAD;7^=4WV%D2=0Z(!;!-B%- =">$1B2)0+P
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M*5OV_PS&L2KO5\F.14M].K6IO/DG%^G]A?6G+;&W__;K[O[!M]WM9V)WVW_
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M=IBK*E8ET*8:Y/F464\-<*K4/KRR]B$IM0_OL?;AE7K&*;V$,JHQ98(Q07D
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MVMBGQU];9%FZ9)/P3"O.2C#=O2*+:VLY:^(SV=G,_)))X3REC7.^FMNC7;T
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M&8$3S^T=BPE70.BA@-#-0[D*"-TI",T/)WT($718CGQ,'D!(<01;9Q!1C$4
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MO%3, E)W"%+S^'KNF&9&.20DTP!2 O").(RDUSKZJ+!=3Y]C :H"5/=3'+4
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M2R7]V:(_V:W"'@,HE'_UXC'L6>96#PJA!0[_:^?]#ESKQ]C?FFSW=M$?NE.
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MAX(JB;V+2(IH$<<J.P^Q0#12+Y+D@%]I:Y>H&K]J_-H0_ ++4%D:'#5&<T[
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ME.8R;>TNZ(M4-IZI-- EC7*FO9/6Z.!UY"1(XX+S7G',+8U.QQOX%"=I[K>
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M.2P=H6$X[+R+V?:%^?UNP03Y:\;T*&'R70X\\'!7U0/E^;8_^7YP_CD2+Y0
M^8J#I(@S(Y&3Q"-IO$O.@$"S[!FT/[%E:> I5=S8DIY$ZN1CP_R0BO*R60C&
M866@S!A5\X;PR":[9 _?JGOUBYN&?Q VOT?EYTWH>B+ECA)J0YIHR!UB;CN>
M>JQ/9ZPW>^I=^Z@L<2DEEPO;CW%AKJ32VF:LW+#A2%$W&[E)LY%E<INNJ[ZU
M8:1RU^X12^6#/9DU>X9](T;A.-N%BZ K=<;'"_"P;KC7?,(;/&-EO4U6^H*Z
M!&A= O22>U0F)I,58%M:FNM#.J]%#CKAED45-;V^N?0U!O^,S_-#<W!RQ;CO
MSUOW_7E?P,1U6CYKT^,21I4 _FXVCAKPYI?XX,-?HO']+6^\/N 'IWLPKK?T
MT^NW\.[?3SY^>$.N5 * [P[H1WIP]/;;IZ,O#,:%/WX_OCC8AV?L?_KR:?\M
M.7C]ZN3CZ=^Y"!.>%&'26&J#L47:6HTX=PI93P.R.'G%)&,DJ*U=1NY<06[#
MBB#7&%YC^)/#\&2$ICIA9J+CTA'-6*!6"\4%CYZ6,>H 8C6&;P*&\PF&4P?R
M-^5JS8DEQ+5GR,D4D9 T1*:3%I0 AC.S*1C^',HWSU0SRH$-BZ+@KG-;O[B5
MT?*3HE[U,Y[H,U9DX9>,G!WWZ\Y7WO=B*0@GK>?A\=,TU':W$R_NP^I?9CV?
MJ$KU-+6F(#BFFF B=>*<6*--9(1X8PC.;+=T5<_;JD_7:$_C+)EQ<NR;SDO;
MRUZNC0_7?U"5JO$'OICI$JF8<\:B& Q!/$<J:N(H<CIZ&0SH4M*MHKCG#[!V
M PS?^WQ&#:=/%$ZM-8$ZZ3%SG#-I'<=28QM,[EN0J%VZR&@-IVL*IW0"IXY&
M0:6W*#&.$;?!(^>C1S8IX0SQ0C #<+HJ)^-3@M,5V<*;HKZ_FHFKG;&0P[ L
ME313(FF</%3FGE2YH6DXR*6%SD:%#._52J;+[<!"";71,)Z4I%H%X&5#N7:Y
MWQ E"2<FC1,VR5HK?AHP_GY&*X[6,=C"A*A) G$B(C)E[W05M0&SR+&<A'YG
M-^/Z5;Q?NV<\3?CY90G\$0%3CP/Q5F$NO=<*B$\&KT"75"&*&ZB1DS(6-1!M
M!!#-Z)/:)X6]0E:#C<ZIS.TJ'4$X&6J=Y4 +&/1)?@6)KH32/2<06J4GF.@U
M5R27.5!Y\D%@=Y(G-W6XK)\\>=A*Z[44V0 I,AO[)*215F.-$DL)<:$TLIA%
MY+BU5'F!G>-;N_29>R5J<'IT< HF,F]HBHQ+GK2V3&+/4MF4B1&W?/OU&IS6
M%)RF03U&>X5UE AK[A#GN3V34A*I*#3UQ"OO[/7U3Q\#FYY#U,Z_'\*WN"[/
MJ)T,ZZX5SA1PK)%V&:2]F%$#H[<F::P0=RHB[IE$5GJ# !=Q%,1(',+6+KM:
MA/59.Q-JL%DUV*R[EE>#S:W!9B96VWC*B0](1 (VIY4,6:X](@I[AX-6Q"90
MZZY6-GH4L'E6V:$Q%QE>E[S0=3&L[Y8EM'Z O$Q'AV!YBD%*K0D'3-8$,RIM
M,HX'*8R^OJ-#G2VS7@A\^,>,NL=5($H+C*1RH.Y); &!I4?)8\5CI);ZW/>8
MK,JT?HH9CS4Z/3HZ<<$,IHQ&E3MY6&-L8A%L%VDE5]BE*A^[1J>-0*>I?DB\
MH(KSB#R8I#F73R'C'$'&1L.=HS%YD]'ISGW9ZUR^U;'M'Z/6465GQ[*S[Y)M
MRFIWXL9:^(^@4-ZBP/"(0FM<7@:7W\]HC13@EQ! 8^X!C;FU.)\5!T1<Q!R
M-VCF )?OG!!4>PIK''DHU:_&D8?"D1G]+HHDG56(@"Q /"J!0 !@Y&'WL-=<
M4\VW=OF=8TYJ)^!2W-?H=I"?U^*>L@?PAE;!J* H \()W6&N(7RI.OES+QZT
MB@5Z,F+I$=5;8%]?2Z;EJP@=[0T:?^!OI73:^TRT5C1RC[P(.J?W.&1P"LA&
MD[0,FFAIMG:INMJBY4Z^AQ4P4>TZK6&]AO4G9VW4L'YK6#^<PGK0V! 5.+*&
M.L2%)LAH[9"TC(J8@@]6Y##W514S>7Q8+RV6?Y0-+'9G>B]-V]BL2:?4'_=%
M[?=C[F?2"<5,;YQBW!PGMYTJD^7_KBI;Y:8EV8J9',L4Y;G,?"^1!^KE4PU]
M01N?O4Z ,?;F3HZ.\C8]X]X]%XV]SY1(AD6(* @F<E001\"A"30O%UG@DBK]
M''KW5$U9VV?=3M7*!TC?MVR_7[;<&3?SF>F1_#__1U.B?NL7"01*QS=MJ[!3
MKIDY7YDV]P&NF6G=5G)-I\P0G&OW\V*>;9Y>"QYJ=H2X7:.4AV^_HG8TU1LR
M5KG#M:G'^JS'6M-K/588JV&K;!FU7O;VXNXRB^V%'TSJ)LVM-JO!SM7&?L]Z
M.?:C'ZT&V2Z6;3ZT%J2_-@V\;M#1:H']O.;T\8?M]2Y@N/_/]?ZQ6]J.=^GH
M-3O_Y[6.9=_1@M2+=_O%H_7BW7[Q6(UP-<+5"+?>BU<CW,H0[CG$1!V6T>J=
MF<BHRKEZN_8S3ZHB43W(>I#U(.M!+C'(9U;'O7%%;!0GL17*IDQ]V[J1$KQL
MAL R2_G4 I@63?')A" YAYUSU!II. ^4:I)(TL9B&X@V3%T?60KDUK8#>,2W
MP8OOL=<-MG]R.6RABE;X)U#GJV[O/=#FG]W.\9_-KS%, AKVFWW?ZN83Y*<1
MB-1^R1O?X;D?WO!/,)9/I^].X/F\<?H6QM3XTOCP\?S3T>^M3T?'YY<#D3X>
M';-&^^_6Q].3]L'1NW;C=9[+,6WL_]W^2.'^T]];!Z__;AWN_YX.+F:*QXO$
M<F?1B +E'O$H.7),"!228<83Y6WT^0A!4T)_6Z/TAQJ<:G#Z8=@[CM%:$K#3
MD1MKM4M8!DNC<U%1Z6MP6EMPFJ9W$J*38CDR4D2)N(H< 2899)PGTNBH570U
M.-7@M!9S6P*<E/:&6*\9LY$':;601#G (D4,]2+4X+2VX#3M=B&#$08G@BCU
MN6)1[G9A/$.PD4IP00.GH0:G&IS68FY+@)./.@KJ*4A>SET W<EZRA/S"AME
M3*S!:6W!:9K0CAFC5-*$N*88<:9"+EA$$3/!8V9I8([6X%2#TUK,;:EL9AZ5
M-BI(C3G0L/7,.4N\TYH$3G"5]I8]&C].>ZMAZ!YAZ-O!-,W-&6F3BQ0I%@SB
M DPXQ[U'ANH@/#->!P B]@2[$]88]$0Q2"B*)2/,:1LXM])XSC3H2310&<&4
MNQZ#:@7IT9&I.4&FF(R,A#,4@A:(.Z>0CB$A+VW$1$5B;:Q5I!J>UF)N2\"3
MQ"[W@)8Z6L<EEX[C"':<39AR&26KX6E]X6FF[(M+/A"O"**"<<1!W" KK$"6
MA"08LX9C7<-3#4]K,;=E^JD(KTD&(J!M(&& IV@\!5/ &QICJ"VX]0"BJ9ZD
ME;#.@ 4G778E*861%E2BF!2H20*#J"%K9L&MMM+(^I1I^%GX5B[$\%\/XDV9
M514ZPW;H#D:_/VLVO77!D<;WC]\/CC];;R2.D:$4L056,Q0Y81+2 >0]Y3JE
M&!:RVCBG<:[&>562HU-&09:-MD<]=8KW)[&LQM'/]'(E%[0XC[U8Y)8#H^(<
M@VY^5+-71*#]=OFD:;&.?M&*_3Z053]7"ND6_=AJ :T,8J\-Y!N*7%[JN+!%
M@$T&;B_[?8-:6:16][RP'=NZZ#?[Q?E)TY\4PT&S!=P0BE%L/Y#NM-L!S"BW
M.]@I]OKEPX9 6.4T&]U!+/AVL;7WQ]N_WKQ_<_3FL+%=_/GFCY>-]V\:KXN]
MU^]>OCQXV3AZ7^PU]HN]]^]?PI__?/GG?O'J\%WQ?N_/EUO;11C&/'Q_8CO'
M9<&145VL(EP 03=]?WNVQ$G)#7F9.]W!9-;P>S^.^3(,R[HE^9[!22_&H@V,
M=]+/[8S@M@/;@_E6*T[Q3G'#PB:/C$W7YMHN+I4T6P<I%9GO428+H#@WV(P)
M_[QFSDS1FE2T)E,,,,41?TU2SRMQ.,X_+VOAC'EO]-.$ >'.96!\->$$/X3Q
MO&=O.OU!;Y@[D4R@^]D"]N'^GCAX^]F QD*XI4B(?-;&,=AG'A.DG8TV>$4]
M45N[5&Q3<;5WW 2T,RDLL]^KL?#K_5YROP_W/H,%KJ-W @60R[#?1"&MP3S'
MGG-G+)>)Y][T:EO0JXU)Q_N]#<*U?Q;A2Y!R%]OE]F>6GXK72FAFV?&?83=_
M 1CX)0Z*,U!= <"RNI=_[,.6%5GU:\*3;:]"G6:_/\Q2OE_\,LHOG-0Y>(QZ
M>3OS2)_7Q)?U)8=EZ; *^TM2BMI1162D1'HNP# $9<<1KIE("6#,?Q9ZZ]8"
MHPEBMS-X@<CC50Y4.X^W#V.K"F6O"-RR(\IEN-_"@V\Z7V'-N[V+J8*_+@4%
M#_\8PT<+3%Z B5R[\^@E^7CTKOGI]$ <Y.^RJ=S^&^#E^!MHY_@*?'SXBQ\
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MR9MH8T*!88TX<#RRD3#$E 9MW0BL/'F>2=\UD]\H_RPQF:P(D@)W*VR<U\*
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M=1DR,:E6;7LSM:HOW?Y5V%TB<C1:OT*#Y\HN7UYUN5[,J @!649%ARH5<RK
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M#SV&<9]N?WTGOFWNT^VON_C;AW?L&SRKO?D^;6WL.2^]T0DC+S%&7,$K%\&
MIM@'G+"7SH'%+%^)B_#4?\]JA[FJN@U^?CU;MNW 'V3PG#;@^0/Z W>39TWB
MR\^7:E/<7.-(N7,2Q2R-..,*:>L(<K!W1AIA21*K&'S>\.Y3XMW&C;\[KTY!
M<^HDYXSE4"5PW7DT%CGX (D4G3.**>MDPZO/GU=#8HDQL$&M3SPX;ZE.'AM@
M7(VQ-K&!S5>*@:>PN8%-L9)%E/M_($YX0D;!*V>U,TP1SPDM4;CFD+IAWP8V
M?Q1VG4G-=%0:9R/2Q#'0N(0C2ZQ D6MKN)#>BA(VYW2%&/9GP^9/'XE301KI
M!6.:&TZE,H3E&%,:M;86*]D@<8_,E]MO+T?BM@[??-^EG[]O%W/]?+CUX<OY
MULYWWM[I'F[GQF^;7TYA+#"';QF),XXHX0)& K83<<4\TI%$T,1!)A^4B4JM
MO5:O%@2*+0^)>ZFIOQ,DCC>YOP]H8MQ-GC4>PB.)MBD<%X,"NM0&$:<XXJGH
MWBLI4D0J%2E.-(:UUW0=WS^,M<E&>LGLVW@(=V?7*2*''<]U!@UR*A>PHT&
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MT4QA)>&],=1?TN^S0<5^(ENVKT#%WG_?VOF8:S/"]:'S[?#3^1;])+Y]?7\
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MF"!'M4:"^A"YBMY)6ZK<5:J=VL3%W1J,PY'XY+F6W,$?99A)5%H;9#"*2-6
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M\^NQ]S-_\]K]0O&Y+23_%G!TH<>H&J]>@;>"!,CCC5-_^Y?:<EQZ\VH=?JU
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M>6,8\9*"%Z&B;';Z878Z ]U."V\M0402C[C! 1D?$G(IID2T86!89*!;70S
M_N_9"-CU,M^N^B@+TFG 7R:)&O)=BVR]/;%8;0(7#-S*'#1.@L-)6:&D!S/
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M24+4)DGD4Y0@1S1#N8XS"MX%EWCD3*=+CNL+HGA:'L>-&F-N]4?/H@7%SL5
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M?N&OLHO[W'MGJFBF<_ \+U6,P3Z>&@D;Y/&%?ZB.(*S (PEC^/3OZJU(,DF
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M+CB8$T$C;),A@2FC6<J)"$_D>;46<^*MSSF+G"9G@122TH(PQF14J:*!^=(
MRP@<A>%4>8^$P#I7.;)  ]*BB(W3T08NM<HT<'?/*\,%F@VH!XS\,$'(3!VO
MVQD[F?FP=^B\/+(/ ,K*XGX L_#Z^M<],*L!,P/)/2;!VF)*("L]091&X!?0
M)Y/->2S+]*EL[DIL/C45G.T_FMA\L$^VHH:GI091._0/HX;'\,D^0(VJ),1#
MJ&&H4@L.! %FK".@3EEKD"XEA(+%ER82J\*32HA*J7Y2*OAZ4ENO/9I2/84+
M4*XOEL6#CRXCR+W<L5=Z8\M:U'?!(6\8PP1K*X'D(E,NQZD%:@D),4@U:35,
M)!K_4F5>SY$2?]8//^UYDP/K241!,((X);G9;,)($ZU"[KOE32KQB/\ZS_4Z
M-VPFF3$)$ID-'8I'KMFA<3=,F;E37K3!"B@$\V =%_E .2;X*%DJB9-IE+%/
M:$DWPU\>T!A],,I.W(Z#0:MDCJ$D6SNQ/1A%H[N94Y(^V]X;[HL.Q'1:.]O8
M$TPZS(A#+G&2*S:"F L,(Z.Q!6$"*B;G)3&17Q!3?[+096O;42N=KRO;*Z/F
M%&4_A-9D8\YUX\DTU0)R.>X-<H/?7O>';94M%$.S[X_[_6%I_K(9!='+Q=(_
M&Q_7_BD^;VV^W]A8_U3_N+WTB![AI?LX.Y8JQ_"OR_I:$!Q2IB@IYIA[XZ*$
MN21*J.:!C7-*0 .O])=Y,'H>\YX%I,\56)$I&=UY$!@@Q9&V-A>W8O"]SBT#
M'Q2.2?$K]P"6TYS(Q,O.O[NEB=R?#RJK[@'\0'*4A7%)6"LYBM8ZQ'6V]I70
MR),0,&CS06%_8[60N18[KU#Q2:F U@YK>TEHEP !4=",(QZX11IL:J1$DIQZ
M)[!/]T'%#]'UQEZ@<<#-^<\>TZZ[7UEB+V(4.+"<Z6DE==8(12Q)-&F>/)X_
M&E7Q$Q=(DFVN[^^!(1T-#QH9KW+X%\^ZN3(H*A%5HKD>++O.W?1__A>1^,_;
MH=-L\:P[Y@3?GU(JI+H'6?#:66U/2>)Y2A89DLD"6XVLIAX%ZH3V@%- )->T
M?/Y%6?5)F T=6?A'9;_,NQU?"@Q6/.:Y% K7C%@1 A (R2D-AMIQO04@!W05
M7=S*N,^5&#X/W4$?NKU,-X 6O4'SS YK,8Q]1>^[_3>-('QS_>M>LBHJ0AT2
MRH-0PT0AC27-1YJ6>X^M869IE6%V WX 2(#.'.R@"T++SJPW+/!!#,>M6&:S
M%N,&JR# ,B7-5',9*<?_MU_\?=PI;04Q:G?Z8U*33Q39LU?\T\T%8F8JO3RF
M57^CM;(TZDI\XX5#^6N]S[ Z6@^;!YD[4,+%Q\W^P=@Q4A:6N]0IJ5,V*0P@
M^UO=?NE\N^;..]8BY(8JAR-CH%+RF(@C*1=SB(2S((-,MV#+/MA<\-L=!/Q'
MV^ST_X%YQ/YF9^/</#;3&_?>[I31W80HK@V7R'D3LL:9T]-U1("AN4LBE0KC
MI56J;N#-2U4Q0S-7Y"F;7;HX.(EQV,YR)._+BB>#[LA3-^Z0.MH=(+YSI'GI
M&^!?;WN]T_RNLI7JD#E^J=".2JY,RJSD"C]E=<VLCU3&T8*3*HQY9P^$MX=E
M5XA&,(DX"0)T4AM1S-'W8!XK[NFUQM$1H/MIM+WEC-[6M7*)@W83V4YGTJ,;
M2 HN&$+>J'S8A*3(4%",FKP0\4(\JC<6GYPMK37;#+:7;;_SS6AN8*]!V?UW
M  ,<=HC.[#VS?*6/BH\+:SVDGA8(CL!8/N0$WJ,!A CU5#)CJ<-:6G>#(+F1
M":^MJ?6F.9#5UOT>&%7::Q81%4XB3J,#86$YHD9JY0(.2N:COBOC4&YHWWIS
M8:QI^;Q13^TP@N[>9,/&#QE'SN?J<*@L[C8*D<_V1+MYW+[0:?M*XIWP>DFZ
M['(INA&_'!_=G8:#TC12YEU0E!O!G6122\HL#X)/NQ'/GX8WT^?Q!@S]&UNC
MBN=OFK@%S&./\2"5)@EY@$?$&??($2^0EI&92)0W.:[FBD/L.Q2(FW5R_!I/
M)R6>.W$P=;?-'&?F(HB#TV'A0WA<?Z+03+9^!+.@8V6%&1XW:BG^ZQ=/&HZO
M%)N=4A#D(J]70?DU_'!O^5$NX=%1J^E+^7QQ(OU[S^1F; $.7B[<\:!L/P];
MUSK.6[1\#<R\+.%_=4GM;^4?L!IKN=CJ?BR&^F:Q-9KM6!5]45.]7L\Y&4_7
MCJ;;'TYWK/Y/""$;S.==!;,\.S1\9TMKCTJ+'@U*!\+0*!J&XX.5GBEM?&(_
M^HH,(_6+$[CS;C+#@*1-,4BI-=C,7&J"&94V&9?3"XV^NO0AOTI0C#=_M/>S
M9L=;E@.>U,^^[ DI/?'.(B)L0EQ(@@R.$DD6K.#">1YUCJPSEWOQ_>][I"3)
MQ&2R(DAJ*5?8.*^%L3;DA&(5-9U$3Y)J6^^[K;D&&$^"YNYEB"L+NFND%CFF
M':(A!N"H7 '6E-;C%15@SV>@KU25Y&^L)$^K2O+/6$G^Y5>&OUIIJ=G!.'HO
M VUM<AHP.HMY#5$]G[+2'<;%S,,Q:/!I6&*^/&>?*"KC:.0R-O$D@M(-/T=7
MML^OT_349'K3!>5]N4B];GMH 6?S&GXN3^N?7U*!LI8T&D[1/8H=>$3O>S94
M1G?TLP4PBAUHG8(-L]\=#(]%9L]"5HKM8W\P$R!0WA9_#LO ]Z<&_TD3IA<B
MO*AL! !&_ _;;.71C-X++#"TY>&FT1JTFF @A6PBC>K%CR9>5I:' 63?4UY(
M,"VF75*&S0$2?-WM]2?=PDHS##:J:,.]!_T"A@$SF2A]Q5C?N]A+;!).4#Z[
M%P>Y:OWRN=6\U-&@,[7^[+DC<]L;^KKO>NY"$LBV&*@2"G/0,(RD05/,N-#6
M"<5_43&[BJ.8B_ZQ#\_V>YQ(RG4@2 >O$/=8Y,:_%"FC.9,1.Q/9E0<MD^BN
MD=$[PV_+P_.]63KQW?Z=C^8>V*&@2J-X*'UL-K[N>>JD2BPAZH1#'"N*'$T&
M::LTR18?:*] ']>WYEPILE/SBBYA_3@+L1=!RG?W.R">\H'O?O8K+3#M5*>Y
MOR"B/+8]G7&%QXBT<1IQ#I:.)E0@Y@S/!_"6Y9[!ERV<&8S)OJ]ACL,_OSS_
M7[F@_PZ?6 <) !+U8L&L7!HK!IZ8R7W#':<Q@#JJ8Y)RZNT^3R/GMWY[%.&Q
MF:8ZX'D :62G80/>^5>KZ[^_O?W']<.=/>6<5LGFI!D,1JZG%&D7 \):LA "
M\X&9I2("EQQE:[%W'!??%+A:3:[=I.).XU1FW'5C[]ZP9V?6LN&JJ>J6P!PO
M^L<^.]NS=G9:G@?'H:IVT9$WCD\ ^[7TD)<5]OO#;U.WU>J>]-_=TAXA[/Q*
MEW]?N=2#X='U10NS98_Z\=WXES]#LW_4LJ?OFIURX<J;_OP1>X,FP./HF?">
MJ2D-UF1I3@]Z\"^,GS_Z>J7\ZH]!N/R=P2N<J&N_QBODVN]^]5BUPC2[U5/_
M*$<\'#5,/Z_V_[?$EJ8>AJ$=38]^%N3\FK9B&EQ<D^%VS)NB]=WSF\K=^ TP
M>(3+_=\GE#1:D5],%N>IWG*!G/7?]WN@H(>QHR(3?TI_+L3*W8P%Y4)M7>3F
MBXMUE\GBXB5,^;\>-,79J?7R4Q=J;G?0/N]W)G)1Z3R+O6ZP_8-+J;LSZL54
MWLQ:,)/#] D);J8/S:R$[H#H>.GJZ,%.^V=K\W#GYTXCM#:_Y6NWX)HOIYL?
M-WB]4?NYV_A.:Q_KWW<_PM@:M;/Q/?"NXUWZ5=8//QS4Z5>QFU67C[L']?5/
M?*>Q3VIG'UJ;C9V3';KU???P.Z@P]53;QC__:6P,X.?)'K544"P# A,B#"N>
M6*(((M(JXK6-T9NEU;(O#?WSFM#$AW (L']Q1TZY']JF\G\O"FUSW_)KI1&]
MVURO!-L*D>:!2)\Z=1A4XR2V?L1:Z;>LX.@N<-2<@2,1I>!*8$2=%X@'@I$3
M1"'8R42"CY1I,3<XNAH2G@:.7J#REU,\[@5'M]7]*CB:#QQEC:AQTJU0Z"XH
M=#J#0L0P0GD.1R$,(ZYSO7,I!8H^I&"]22SX2BEZ-A1BE5+TN"CTZS)+=X:B
M@UZ,%1C= 8SJ[V=5(AD=-3G_-T2).-8*.18M"M(EYE,0Q#E@BV6.+X?)50K1
M(T,1KQ2BEP1%'[K'E:_H3D@TZRORDH$61!42$1-0B[A$QBF##&.,$.I3RM5Q
MZ?+U">:54O1H2"0JI>A%(5'S1Z43W0F)9MU$6,E$K>%("LT1=\DA:YQ 0CDK
MI;$) "FG1RY+=KG;4*44/29?-B;G])5J]#( :2UO5H5)]\&D6:>1LA@+8PA*
MVAC$<\:+)=X@3:/#*B1A-6"26:;RP9!4:4=W@Z3NP+8NA2@]1%\:Q0.5$42P
M\&5Z23&>2(5=#\2N\T'N[T<%:%Y'=/N3XM/FK!]).R&]BPY%L.$0CY(B%X5$
MVFMIE+6!Z B6!%^6^'+8ZOUTIENS2:507<^;7SNC"FPQC(MJ])?+&NF9'X9!
MF;D&<5F?/R<EW _97J[B]=N3H->O(&IFB]9'^_)YN%-KG5!>.MJ?7*6P7X\5
MBMT)Q69]4#)Z$9.6*+K<9-89C"P+!!EI+8G!&\$4H)BXW(CX4F!GI5[-4[UJ
M@<&!!KF@XZ2D7)GC=]VJ#T7#*"R;P?*&[G&.N+Z0OWM/%6OA%NG:,-+YK<-B
MH_1BJ9BO*2'N:>,D&FN#20#IVI[A"1/8"605"0#'!)"8<X=,<,9PB;7)S;%
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M^^AD5IGL]>]#SPF8?-ES,O;M-+,Q=UKD'>L$VRM.(_QGT 4RGO&H%"<'75#
MX4,8*HKMHU;W-,8B-'N@L79[)2< *QQTP?;\'N-19IJA-=DOGQ4"<&H?V#(K
M4[/?;,<AAQ!)?VO_GMDGL^6GK'%E";$5?T00KL"G(>:7_/A]UJ:-/X_R8UNG
M8*ZZ0WC2V*%TD:U]RY[DHY3B"!0%?UK*K-^FS\JVN 4)UQ[;O@YD[>!XM#K
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MV]\ W@]*3@=6'=W?LH#_>=2Q=/\.>K;\F1_[^TBR#@-69U@[;P=L0'X-"#>
MYG)X6;X#!MG1]9?7J!Q/.?,L\V#V$61$<^PZSH,Y&O):GCL(G&:(G5(F3G[/
M&_\CZPJ#X1-_<Z.7Y9L;Y1?EY^><O]F;VAP,XF1)_^H"*^<_UD<:1'_\S5@D
M@)8"0UPN16[W>#!+72-JM*WEHA_C]RST8REFBJ%;.6]>Z5-/Y0>PLC^:H)B
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MW5TE+>//_'LV"5MV+ @NV1TE'HU-C,%!+PY!'< ;@!S&?] OAMZ.B1Y0C%6
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MM.)_MDYWOX4C1[FL'7XZV3D+!YN-M;/ZQ_KW^OI6>Q=T@MW&;G.G 7K$88W
MF,ANHY[JZU](;6TOP?:DA ."(43$@Z3(V.20$S%%3ZUFP2X5$92LH\SAO>-X
MGN?;MK</+#)"B]R3??1)EN/ZO.)_>-P?--/I,Z%"20O(96(H[(GMA7ZQW[-
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M_$+K[:]XIQ'.=U)S47NCI$",X>RV- %I1B)25B5)J3->") @RU2:9:#5!0K
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MH%ZX=;@]8%\UQ5<'V$^N@SX$K\LOUX%B/P#!_IOIM0+MNX#V]FQ!(RT%;*M
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MF8"L5A)%@-7 P3+5N0L/D7/RK#Y_Y[H*/BOX7%3X?+S(D H^YPF?,R$AAKM
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MM]:=.^>LZ:2(P,30[JM4_);V[K2K0X1%]>O6$U<W@LZ^PQGWXH/AJK>J1;/
M9(JI5J#]HBKG\&RX2\Z7C&1Y"B9?8.O^S5DY.T]Q-P]8 X\1EMZ;MU]O@@G/
MK>4X4?"\C6&U/N.R:MI('=PAW(-=HIMMK4[OK(9!\$QS%TJ+9, WIP6(Y41?
MLG/&C!VP:FX[(VE!P:W*@EKU3X=N["[/DK9+(0YC?3XXBDYFMT[/"4PC)? 3
MFTYA0Y1]_@&4#DP#G%%6GU@,S&B@B[H:O2<@M8 0BSJ=%[/MS@D<]W/3=4K1
MZ*2YAE!V&2A7"S2-#^!S_-]T6HPP4VN"W#:=2WC)'@="1SIJCYX82:F\KL,C
MN0W-'OZ]^^K]L5KEIR&,6V8.LP4FR9LU2 *Y!)UJJS$[17XZ>R:N.>/HV:!\
M83PZF&+,2UCBXJRJR=)_)(MX2VC[+INPK&"3X4C%XYCR=1[TVR.9XQ"[%A(,
MT?&L)&.N%^11F.8^]]PT$A L7Q6;]&UG U+\1C;)T<G!XO#=:1(DKA_'H9G$
M<6QZ0928D1V#86(%L95'B>]DWM:+IOA\!9!Y+7J9"MMB?8[LWGS(R(/H:+%6
MJZNK"U"7A%;Z$D]:<PZO*&%["S8"_C]#%92>\F[.$Y[VJR9A:!(+.PFY 8]8
M2\[B[^6VG(Z3.XP[86S;'HO""(O.V5$4Y+&?!FV1\_LWN_O$_'(^.ZQF?_/9
M,2WW3T_;'ZR#R]/8LAV6<V9:N<5,STM3,^&68SK<X@$+66 G"=C;E]6 L=V9
M@VO(G *L&JVW8"M0GT!"4'T4@5%+0"J*"BID5F ^'ID6\F0L9\!)?U+.1,$T
MW0(BTT:0O5[(JR9D&;8*PAI$H.NLV$0MWHM*/CP2@7NMUJ(6 ,X#KVGBPE(%
MW:+2],I6$DM.(>HTM4(9[B@:I?KIF(O^QO,K,!?#,$'M'=+J5WN,2K/ 50C<
M!19: FT*3$+.L!X5_-*"%30+6?H-X5M,P,!_#V$W=:BVKUG-, )M'432AE+J
M&^ J;>2M5WBM#1$.9^6):Z<J*^-IT-(K!F>SJ],S>-Y';9(+:TV2>9H6*O0J
METY(&.-X3MM;"SMC1-:^<ARWV#(*AZX^:H14J!+AA>46"J/EXSP#XE:6*,F^
MSHX#F_*"BZI]E)[;,J2B7G45J6'VO%"B(M\<.$8-BY?I0-8VXU<85&TF6Z /
M3W>X8$7%3+[]CWE6T*';$9R1UNNH+H 61*:+R'U]J]54>@)$M8.03; L%>BY
MFFBGU=8-<AW)+(S1#HU;#!*;<J-U.S2F!S=K4Y08[ &I3^H"#8[5N:%8#]$^
M?A*)EQW&RALHD]>Z (!RJ_[2MT!H#4?=<RG*31GUI4:[)R,4$,U<UM*455)G
M:Y);EC98>56Z8F6[.WM7&5K+J2Z98]M^9/DQJ/4>#UQFASQT6)KQP&,\<*1:
M&EF>J7[YSJDN/YM.B@W5#C^^.LV"+&4NMD_)L1TS8X')$A^[H/HA9ZD5,L?9
M>A%3_Y3A\OW3<MZTD'[TUTUT=562#!68O0!>(_UZPA3KB%LKZ(L^WZJ9*4.K
M:2N7-+?+6]G@_J_%_<<;W/\/Q/U?B^-?QOVGK@MG-7;]*/%\YL=PI\7B((>+
MD]"-'RONOTLP^RYY94N92YU<+9JE>MC]A*Y\Z2.\7BJ_HR&A22E["=?UF56G
MDZA9K;Q-!)@4[J;.PT2UA*3S25R^E+$JBES#D^<U5PGR2LU#+4)H<LN)53A;
MF7]%+UTVWIY&9>4A7/62#:%;G+($)5H\T[HH#=OID@8ZZ8):JO26D"[&)LK+
MTFI+POSI):D,VF)(G'_@"J5<=MD"2X4>J'2J:VRD^TUCZ5:%ZCNU.,B7)4L_
MO4>@\ [64C<.V 2D M&1]'Z^*<84F%O!BK;PT6=BPN@?I&BA;UFF;2,NU?9]
M$U2@YVMC[-JP;AEC5V=R*?VUC0=&^OZ2&Z*;:IN%J;S'L(J=E:CO^.#40M.V
MW-"+86KN\]Y&T7MT7D>8CQ5DA[;KN\4%4.-N)?QMJFRI4H+P<<K'LA) ?Q+6
MZ[*'G)SCHGQYKVZKLCN5@ZNW^_PS]G=H6D> "A'6^"*D?3R5DDEHT6([@KUB
M&=461L+I@+IMDLQ:2XA(:+'<==KWK3C/@SAFOL==*[*]S([L+'%C*_'M&"N2
MV['EV/X]N>;)^WZ4OY+T_$JMP]%T=C2?O<?IOT7& ]?OR*#"3VL5[7\YVGMW
MRBP6I8PE<(H1&A<&F9EXKHV]I9W8 YW+"O.M%\ :UR)W6^8A+.V.]E!6+U&>
M0E7LLO+XY/UQBZR0,J8G>@;DS4WE2R>7[DG2C&X?+EOR/+<=.H0_" 4 )KRO
MD4*[F$9?U9.""?R'<0(6*AS[%OORGL^*6HBEXT4SXV.40R_9'!0=B>J1;\9)
M$:#E.MGDAXX##-R^NVQ:==BLDT\*WD5(G58:*9KIU7H_DDE^0J(0IDL2D8@B
MKJ,@7?M9*[P"R_-@[L%&>-W9Y=?*C![J9_C$Z@YU[9C+V)'<W(FNDPT=;"'B
MNEZ*2P#3J_:K?_ U\%0P,/@E!%9O]!J5M,-3:"ZD6A1NS96PI8>PAY8K]E!%
M&2):_19(UN\9W&[06&3\%+.^J;&N2)GJ5\6,"0QX[7E8+OR+U37F$U&?J^9L
MIGQP4J!@;3%180;KAXD'8.G5F2I%OW0@?R_G8S[[PKY)@=UP.[K!4J\K#.QM
M.P^V,#!1R$"2.GD\M<H^ YVX,!*'+M&\$/*-B$<VOB"LFK)<JRD6J)5>>* M
MX1#]-A-V;C;A)U?2N-^QK!"HZ(N"L!/$RQKJ3&?P7H"VQ7;NRV\09]9W&/RT
MJ,/56L*/8YI73NJE#'=VM:+L@&2"!MD.5'W%V\&WDMP.XR3/O9A9GA7D$?-X
MS),\2$,W9BPB/&)@^0ZVX(9?XGY)N T>\5[C8T<G'SX?G/R-K48OL8"B'7'?
M\@/3]2S;]"R7F5$0N_##2MR$!8X=4 Y?S0?,PN]23+7-;D'TNXF!,E3BGLU6
M4YP1H(7-!B:S<M%+Y7\N"Z8.*H@YSQ#9-)SYL3;KH[5OD1NTQNVU]624;=E-
M9H%AQDHUKJ,*8W*(724SD+6JVBFMHGJ*7"8S ?T4%3.LO;J: .1H\*;6'QY+
M+!/H&('U&XGO7O&#KJ*)T-N:816O;8.IJ<6(MA+C%B7Q"4>5BEY98U:(5D*7
M!9(,E>])%FJJA.&HJ766]/,G>D$W5!I;9%2__X-L,J'JWQ<-9?L(U)B\.Z<Q
MU&#JUA3@,I[9SVGH128\6C0N$ $@$E4-W7EKW"-J7WXAR]4N?C.>.<\E6)\&
MV30RM4'+L)<%9L26PAWN<]ACH. )HOB! -#Q7F!+,OC.$T]C%[!(*C@$3R/H
M79'"1LC<%9#F(B?VF2]G0&&23*LS-$'M6@ @4/<6-GVW>OUM5SN=PRG%S94[
MWFYN(_</'PL+-<?]Q%G@<"@-5YT<N7^L_PG>-BW@(ZHWT.+EU,J2.*7%GHD0
M.G5.RW2_@@+4+)VG^81J").:F;$Q(RH5KBG9 0'LAZ1LVUHMOTVNPHXJ10QW
M4684V!95,9EU2FZ73E9S@27,M&*J*T"@U6PEC)@1(8P(J<ID?45E*U+<:E90
MP42!/VSA,/3JM3UHE[()\2YTIV #Y]G/G1I":!C=ZG]J72!NVX/N<;:@^ZH-
MU/P 3[Y%V?&<N-U/T*%LCU/U'&3_;]@EM?!^'/.\SH^ZFA2[;'BYU\;DAO-F
M/ 3A!)&3VYX7!"'+(MOGF>?;49:$@8K)Q?9]I<O(F-R.\/0=8]:Z*#@@K"^U
M;3^Q_74 <]D_C3TPAWT[-',G2# 2QTWF,V["XZP$S#$>8]+,[3:;<S^Q'>Y'
M8%M['AC9J<\3*\R\++>\W//;S78WF_U=-SOQ8\\)0LL$X1:9GI^G8%R'L.TQ
M#^TLC:,DB88SI 8,;NE#;[35EK(BZ]AC*9<>PR8H@*A/R J NK6QI=TM8YRM
MEEF!G=3#O///((S)^I M-VH0/:%2%EC??E2Q FU8&^SJ=<+ M3;8U1^)7;T.
MB[J$78TR[CAY&/'4X<#$K=BQ+2]*TIAE%GK.'BMVM5_-EMB+7@3Z&P>D;MVX
M%LL:7XF'>/W+?_^R\\OM2A]W#-;0%<^5X@(_Y!!IU4EB49TD<MVGT<--JYK2
M+TZ%=A,R/1&ERHML#N88%@^9SQ8C)-0999:G%8H\D;K9\)GL*#6?X*S W*J+
M]%PZ##<-MF[<8.M*[S#F]<O*[$PVVB ?-6PU&/1S#?R3\?&DR!7"2_K6]K3:
MX++3:0>-U_64>3DKT/U 6X*E" ;*:L-+@2YFK9ZT7,Y*3D5ZS'H7-5Q6G>J5
MY6K1/*TJU;Y#Q%,;@WXB.@6>\Q!9XYTKOO_8SL14:C^7;MTJ)5!>UN%:,356
M%'DG;+MCZW">O9O6G1]4736J6:I 7[0^7H2N"!]0EU#LZNUDAJK^:$[;G]E%
MNX]1"VJBLZL:>TNC\7%,]\8]:$,]@[NM3R )4AIK6M*/3'NAE4E;34:R&\KY
M[KZ? M6FU-T2EU"+;Q)"<VUN#D9*BPSD9RL2\-/A]!SE.%[KCFA'<TJC69P*
MI-!RMBSG:9[XMI-YS./,B?+,YVGH^EYHIW'@$0H@A,4C% #]<K^.BI;<WM(H
MWXK:$#^Q>^*#=[CWZ=1U(]?.+- C/<\RO<")3&8EN0D6C>_8,4NB*%U3P 5X
M&BPRB$*Q[ZK<QLAX5CRGD+-I>R).68@/?-,.]-"CHOVBS18K%\NE>_NU\6[9
M-/DK2KLCNGIG_W=#YT[BQ*HR)TQ=^IOA_FI'YNZ?IF5Y,2C@<FJRY(2<7?_8
M-YQ_DJ<5&1Y,X%=:+B&%&A$E%W* T-?4L@QSV+6SG5!;F!EJ4-)IH]5V;=JV
M!^IOQ+&"JH,(!BGFBXD8J5 0EKY\6U>?%\:?;9AVN$@)OF2E&U!7JJX4T?0^
M'@(E.2K9C0*44QF=V9RD+BP[',D&U6_C^#]SU,)VV12%B9:8-3+>;+_MMNI9
M%]<E<H,?7K>V@AQE65@B0;' 0+)"B2!5F# &[4<%B?0)5]F.,OZRMHTP35)5
MY9-%2WN57@KJ5]0N6=JKEBL;671-W_HY>TOS\PD>M3*_IZD<_+O"\J18SF""
M!/-T%(-^D_)H9"S-] A,W_,*J!_KLP*]OUVYX@U:JZ*(J_@>"6OIFEV$5$^P
M] "%1;MKUZD=?62G"#JN)-UHK!4V!+CN!<$7?CG@=4JNX_F$C#;05)1)J%GO
M7U%_N5]D"@=UQP+,(B-4Q$O[8@<L^@4:%I+QMF8C5U@5*BL$1X_6IYIP-2(Z
MJN:D(HR1Q)+U6,)Z0V"-&= I_LHBF'6C?B3'79Z!<!B>@'@K;,/R..9R2]:E
M$@Z,=II/JRBI@@JK^EDJ8$TE@(7Q?9MRI6D4.4F6N]@TR$MM%G$K2?S<MJR0
MVBR(CM%6I*H[AO?9Y&4##^Z9!&?>P9=/IV%D6U%F.Z9M!X[I)2PT61AY\!L8
M959LQ4E@;;T@DE@U"IY%SSN<'FM/P*K:=!L:\?S,3?TH"+G//3N/8MO+[90[
MF9,E>6KS#8U\3QJ!,9]BLC /K-1T;#\'L]&.S8CQP'1YDEBQ'R4.9ULO<M <
M!DC$>V[ !Z:@":V8-6R#DKVMN^(86-[G90-N1"VTUGXI[#D"T3 L33MO5*EW
MJ@J)KMQ&58P4!5*DCHZU_,$::C/?<"0JC[GSE\NF7EK4H$,_CW0P/%JG8$,V
M.2?C0D+,#BN"V4YZ5FN7!GR[%EE!S/T\MWSFI99G1QSVTPZYBS #Q[;<;',R
MOM_)^ 1C2T]=EG">NJG)T\3"BKB6&4=V8*9QYGJ)E\=!ZF"*UF!&!>+#]0)W
M0RD6_9H@Z%"0D:%6@Q:!&)%Q()QZ;2%554M'BV=TE5=7KFW-A9Z#/"]JX.@K
M;G)1VU)YQDGC%P<<\QMS+;%?NNI;'[DH020OH]<M#T0^J="4#KQ9SF2H3:/&
M5=I50TUZ"EI^K<^0X*V,JAJ!3J.:$A3EHJMQ=+L3R1++<SW7BMT@\P(O2=R<
MY9D3YEX6\S".Q8FT;8?L>?IE<R*_U8ET#K_LG'*;Y:A-FH'K1Z9G,]>,XY1^
M2U@ DBK*DYN<R$&9U3^8:TX;RL'9^= #1JNYZVWP$6R!<_5$&4'M/[X9:6W#
M$W2YJ8I9'8? 0]-JYJ)$H9XFU>9TZSA4[71=G]O0):!H;^V*HJYPB:+MSO8D
M  LG>A[:[2R?)/+\-$I3/^.QYV91E&(U=3?A86A;G!-D\[Z[6LHV<8))_/3\
MH4N'/$*]=N<T(+27G9M^'H#!PZS0C%D4FVB.>DD<!'Z(:BV(FP%.X3_O(M6B
M?XNB])&61=&/-:-/N*HP(XW^?J 8@ANY-'X,/J"%0KF_"C"4Y8.&;O[U[YUM
M/<:DX![2.XE>"T>O'"CR-1D6)S#*+LS1I@M^VS(2P;9_@^FN*R/ATMT/LXR$
M *QE,%[TKJI41G1-DQ^5J[9^ ONC%:[$%@X@94HVGZ2B.E17-5T]YEM7]WCJ
MVP)K3J5M"'4E+-E4H<)E)BS5M\DJHZFV^]FB_0,U6U=_5."S!&<[AW=3$EB!
M\"W<\<WNW6'W%&RC/53_F1<7(,AAU4ES;#%29)=1J?S>^=LV7E8ROBE-)^Q:
MV*JH2S:FRK"5^7DJTM%Y^)#1*JNOI\8N*ZV"D%8555G<"^/CZEV4=@#3FE&Y
MDAH37W,Y %46H&WK./SR59WY!N&8?OW=:R(SO&G;?#R2V,QMXQF2:-X*S.E3
M#6L,63M]G-11RN'Y1<:'/8YM28CVNLY9V,>G?S@>(6""W)%CCC"(=4 5\A4:
M.YC0G3*\YWG[EN5':IY)+*36^U8^0'>#7OW>'D!FW3O54[NNF0J/<U\NUKI7
M6 +[P"(*.%-^4XWY="J;&NO!WIMV8%3@H7R8N0N_&NT!6]H$=> VB5/7)D[9
MF\2I'Y@X=6TBU%+BE,U8GON>%UJ![Z49BZS$#[R0YS9S+"=ZR(E3MSSA#\]>
M_AIXY2L"$/4#5F_Y9-(LR@N&E6N? ;,UG-#Q1H8=F =[)O[^7+H06PO\2C52
M->CN*Y0C^2DZ3>9C44%BIN'I5A-[2!,DC7?)/+E*MB^W*-)*UL#?>?&9QH%)
M*5^XD*\UPSYTPI098<UC(RDRJ;!.SA">1UW+ZT]<*)$I#+,:B^(ZE5937VGD
MTS[OETM7P.Y@T0F%UFJ;'/6*WV(B3);)WE*=P!2>WPD7Y;[[CN*!TE0K,9?.
M (#1[&MX=H%;4U#&*^X3BW_."".)^OA\UFH$2P-HR]$/.(P%I2*)">=-EO7+
M_VK5O52E8J7)-[)XT]HAJBK+UT21Q JT]3?TSN5]./\Z_WC;PWD)P[MD:XCR
M597T/:$+4?.6&WWL8(R4J >U6DMJW;)KP;+NMM[ZZ]&\]<C :_G!FOU8I2.8
M0S>2H?;6:!/JW6[O,JBN O6U(?B!<39\RBBQ\-J XSV-MQ>Q[,5_,,J+H.V5
M(ZH1J,C)OV:L&E>XXTBOY1Z2$]&P)JM;30P5*48/>G5/DZTY.Y+%,W0O@\?^
M6TAD16^(HA3[#F@<]80O&J&BP^E5QV3W)L>D1UP259[.9]MB.<INEU:FN[H\
M]S37_5X$?=0[\%>_ O;X>)[G5?E)XGQ'I)/\7=6?KGJ]ND8003_$^'VG+MR7
MA-'O@C$@@55+HUY<AO0 *77$K7"DT1P5^:YM*SB-+6@,(%'>5$T4:MV)5\-
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M>XH62C3*GEO-?[BB'NQ 581]W&+X] V,;X8]#K%C1M.6F5\)!^" -Q1Z-UQ
M=3FAUN_\<UK.&ZH!H2H--<8STB5:9>2YK*XBQ;\,^W5>K$!I.$M=-:[,].UK
M0 -&O])%M'CC3=K.[,%F7.*1ZYHS.A;5([,\UWI^%Q^"&M&5/H0-8?XP'\(R
M[VLM\K7,;WNS77?8+LP>%V4 A)!PW-9":-N@2=&EYHC;I!F#^*WLDKG9B*_?
MB/7>^ATZ'EQB,]XJZ#:YP3"9DDU).ANO5,TR,#-?P2]"8VX(I8//%-:=8/RH
M.7ZEQV6SR5^_R2M1,V6G;/PN6ATG5=-\N2Y$7]WHLL^T@E5*\3B>3Y945U!<
MLSFJ&-A[34=:P:5:E2RE-PRELU#:]J0]ES*S1";)M()J<S[NX#)NI3SV.$3I
MKJ3]MN@V1=HE5N/03)N\*LOJ4K1V3GDQE05H;^YP@TW5_&=(.OB&K_>?;<SR
M;VV6"]J0_4%N9I=7\S*[JV&NG_XKC'(QNFVXO"L./]*:&MO70 9ZR;1W(>,-
M"3]<$E:>FX=)PE?YE;(EOQ(\<BF.ZSC#\9))-2>!+4I/Z16JVZ?6"&-105ZD
M8;I6M&V5E:JJ^0RL1U5Y;4 -ZK*XVZ=T(=\-\=ZK>$:=3!!+)ZD_M)U607'M
MO"KM;@NRP"Q7<B+AQYE>Y0L[R/3JQK>I_IO-NY_-DS7]UAP?51=P<UJ^_6D1
M9J#L< ';P61_&IW_S\%&+ W^>5J(0O^4F((7=07LG'C4IH:C'UC8]AU_I9Q]
MJD_?",V BI.WCF.]0+VHL3=$%V(#1'^L#6%\:\(83%U+T#J=X![\ 4*>L DD
M:B,JA,!9719 #Z(>J/+DIT6=SL<H,E/>/+\)>[[[6T9$943;5*:+ZB[@&B#M
MR%*>=;5@Y6QAYO#>P6H%&QK[QC0V,IIS4BJ+F3(_.F>\+$A!A@%5_Y=.CF:[
MV]L$6S:7Q#:4.P9,=- 6Q18C!2EJ*< FGXADP56]4]:C0&\T,2FT@M0X1)LM
M#-E<<S-1;2.[T%-A"R!641,HF>M9;TLG*L< T!*A/XEV6ON=(3D:]NI+U?Q?
M6$.54:G8?NW<KE#(F"VHL-\Y>LC([A KW]9W$;L#VOI$]B#4OM1+B*!HJ4GY
MXUC-Y** N3[;VG_[?@O4$LU(E35Y_@\;3W\S3FJ6<:0I;.D.HDKV7=1?#R(*
MP86"*65%GG-L1FZ0I0"J?R/HN2T1-3!&4HIJM))F?*(:EDM3!"9K1P:%KH@U
MH9.QF,T)N"@\Z@9,H5L>O2[B<GG:N^V$>MUK"OPR'.1(<X'MI/7\L[&W=]Q:
M>3BN*9Q%00;+ZXN3/JG1:MR93CG\\[*"U8(=>7NR\W)+X,I$'3@$P:EIBZJ.
M*_LH&P]I/@13^ABD.[6=\B;]^JM/->P8.9.HPBJ%[;&"--A-<\(97M;%#.DW
MXRC=BXGJ%$J>!:&^$3<5.[)M[$R0U7*%X 8.C%7X&H6\ELUW6]]5*%ZX;;30
M 7LI0UI6>Q/DU+1.I->R.ODNZ@DD;U#4DTFOOY/J@<-1GZBZU#+\D;#TD]).
MD33IN?F\%J5!NV.\O2&MKR>M7FD[*N-Z097<L7IRB04!)9=?>\ ;Q*2L%NE2
MW96$E5'5(^E3(I.&*[F\ %6A$6JF B4YENL_KJ#6<"D]&;0UWA14^!YLJ4<U
MJ37]&)#ODYA-N]R*;-Z*M!DV@54R4Q2BUU(]=!]XS35Q.4$# 8X\RJ3Y-",E
M#14YH+^RFHZ)RLBO)^W=7A$Z72.HVX;/K-&20(2&H,HL+&^,# 4B31Y6H$\X
MH!#*:]^\^GWGC?'V_='NJU=[^X>_'X_4Q9(O=3)\5\]7>0U,>$*.65(YQ0R$
M0M0II=V].Y,)6MWO.?:41LX+DGYLV);YWRTOQ9,B5[0MK.Z2YHHA4\&RVRR9
MXU>[])06S!Z/NG[17;\M-:)?'P=EWK+"X_%Y=<FI@9OX[5N+AUL-[R%;F;=<
MYPZ>TK&Z)]79[+A &Q<.6M /;K1P6RQ,3*>:&1,J18S*D#)1RW91VD8NH)E5
MY87BF=^;3A\I55Y-@TF5+8QI=9D)U9!6GJ6RZ.=2<V[;$8;A']4YL.R)M#?E
M7[^!..-:9(( T-6D!.WFDI<@L)[=JIF]%8=.R'GL!;87NSS./>YD>>PQ.[?]
MV+ZB1?6F#?5-BUQ_>75Y<+)_&EMQE-HV-YTX]DW/R@,S#BW/C"/7C>P@R!P>
M;KVPG94*U]1V6AA(*V=6'-AT7M>BWWN_+S68U!7JP-1CJ+WGF>;Y0."7ZH*A
M>N7D7.*HTZJ98=586?BVZS/3</DB8;H1SR <]D>I_.1SBN1D?#SI$ $5&$%G
MLAHL/&>0O$%9[RIH=_U_8#!8JK9<&EOK\9NR@C3\P6>"5L$GW<A;-M=&B[7V
M/5I'A^4&4Q)0NF&']\ .4S9OI#&MMY.JE$IM5-C_%?UVZ+NO"1//&[3TR@)>
M+T-);?EB%9EH5 <0J3@:.2O*>4W\\I+5DQ'JW+ 8A%I$3'X'2T!*5I].^!DL
M&=H0(^.L!L[6^R2I55D+L!5!X9?)JN-I6:".RVKT%E-#T12HJM2;C<&O:!:0
M*);=,M639P9P\YKC ^$/62C^LJXF9W"68&1L=CXRRDKT\J+<<]C=^5@!,:;(
MY=%7+ONOR1KRJAM;(]Q]:EG0D0A6+X.#OU#7Z Y14!?(P0<3I,P->C-V:CD3
MA@_H^G3T4S9E:8&]8M:/K'V72K&9(H,2'G3TB,)S8!]PSNA7/YL7#0([/A=\
M)HQTD'/P"+@1-F9ZOFAH8+#:K*C'RENHWLXG'ZN%ZO=>%CD'!J@?:-F &/@H
M-^E&.$ S\^,\.QL+9"5VB6O@1?PSQ]K\M1C"\N)*O^PRW]SDJ%YW[EUWDZ/Z
M W-4K\TY7<I1C;B=VCR/XL!QO3"UH@1TQ8S[%E@5:>3QQYJCBDK$MK'3 AJI
M3_%E1:B""N62WDU-#YL(C:$M-KJV-8AJ7CZLXE"W8H09/<-T+^EL.9X#4QIK
MSNJ7-5P$O' 7CO8XD?WM^C=PZ@#?WO%NSA.>/A_UR^;#50W.XO*\$C-1O;@H
M%DEB>'"8;;#F)<,Z-\)T@3LV^L_="5!U*^N16:MOMJKF3 0411AZD@)'1-U&
M.19EWQM0SC\!*2V3RW/<JTYM0:I!94A"901^!HU&$G?:-Z@FX;OUIPMYIUT$
ME%I)!$4;C6UC\Q)*0>X&;&<!;X$%FP#-/),4*D.EG61NM;=V+4!G0TE-&7J7
M%"N%,9V)+GTC YVL!?[24V2&1#6UQ&-I"LP4-<G.!;ELG&A0D^%3>U5NC$R"
MT=D 3$FIB00T:<TE-44!.(5Y(GKV G8--*"Z*!?*L!?G4[.IF, A"&-P/$;E
M1&DN3R$>H5HP[I+2O"-6Z7',ZY8.R:X1*;4P4BF,@8^]3,@]_W2Z^V#-:@EC
M<6(57FEU<OS.^+UFYVS<MMY4O9"?/2POLASEQ?92D0%QWLG<PS($8#H@LG'[
M1TJ7D:&EJ!^?[/YIN7X843>A-Q4&<\YXR1O5WFQ)CQA0:49+4_YP+,PWC)9C
MC)[BK[V60*,.XU35C0R@@] J,:B#')&5*5B(?7]HHZ6Z7115V7F*UA^89+%D
MPDN+4;R;I-7@JXB12X:<GO.QJ&8DX\;S%HQ(G0?!Y$>I@=XOV4ZU8-2V5-C
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MN:8$R3&PG2LZF2-J!:$*!>%4NS! Y__O5H4\7ZT'"Y@DJ*\RBUB$ _-B1E[
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M$V@4 &*=-@H+>\EA65C3OZ/F N;.F@0TIZHQ%=E*,E/$":J;#(T37+EJN#;
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M"6'L\=#U$B_, Y9Y+(LC+\T")XO#/,+*Z-'I'M*#Y8$M(G[I0XW-8 O9"O
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MNAP>QJNC7T$;>4[I#@WE*+3/AE]($R+'SH0 ,F?SDF&S/7CV"&Z#^\8$ 43
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M:#:I!#ZKE,361XBL0]S>">NXK'==.GB^47C1D(M)/RL,_)ES";MGO>+D\UY
M9L(9CT<KK[^5:[J<-NFE]LT:S!^9CWW9&-SQ'M-YC^L/S=SXW.C+'B-/[N&7
MMZ??]X@WQF1>0V[T-^WBAQ?57._/*J[_X^CD9-B]*]F]]_Z<V;RS/8"O_TTU
M:38EJN)T51!B-WQ-5"0#-\NU"A9N:##:$)T;*CIKR&\^1&?]HK/[6G0RMA!J
M*(I*U IZ107LFY#L-;IJLD^Q=-&Y\N6X(3I#=#8G1_D0G?6+SL^O1:?TK$O.
M!.4M) 4Z1L7D47'MPY22M\YL[\A@#=$9HK,AHK.&/.-#=-8O.OFUZ*2FP44P
M*E;;4X1Q4Q0UJYACY6(T&!;W*N&4+NS=L@1A'Y\K_%;D,%A[KO A,5>6F!>+
M.SC(V8=6HQ()0"76)BH,C57(N4&_4L8QBC,5KFS7C$PCTZ5T[<G !Z7KH'2^
MY6&;R"@Y5N(7L@*6CU*$H!QCJHF,S:77.;J)9=D&I6O,]CTH73^E\SV"&"M5
M:ZO2R48%S13%@9K2#;+5,9MF:[\0N*[+,8/2"5*ZAHS=@]+U4SIWJM&81#:2
M<E!!@<]>4:U>&4+C?0#YKU_;35-:2V]96JYU9=V^)6D$UIQU>PC.E07GY:*+
M;4VTL1&JDEI34!LH]B23M/;+L]H4)!&<> -/#@:DGRRK]H!T'9#./6RHGD/*
MI #9*!#O2G%,K%#H=+6*Q*)XV'XDY+G!D*X]:_: =!V0SAULP3 7M$YE=J77
MS='"IY%/?:PZ@C/&T/:.\3<PW'!0^LG28@]*UT'IW,'N8ID#-Q7+[-2:2*%)
M2;SL$&WU#7SAJ5%ZRTZMUY;W^E9LZ:T][_50G"LKSJM%#UO'W'2CI'0!,=YS
MC I=))7(5\,6'/:<N!;&QOL-IG3MB:T'I>N@=.YBQ]J")1^5)2=^MC=&84I.
MV6K%S<*B3;:=TBO;!8/2Z5*Z]LS5@])U4#KWL;4I09,WRHFGK4"GIDCGH+*.
M2%A]BMEM[P0WBD#>9$K7G9IZ4+H.2N<^=O;B80=?5-,H%F\H15%,6=7L@L?&
MP078WHEKR[LUA4/LJVR)72W?UD:S?)WYF ?F5\9<+SJVQC4QF+17#;D?37E9
MC&T!%2+&JAD=$?0:\?KJH*\*R@;MA]]B^*\S"?& ?QWPS_UELL@IL%;5@!9_
M61?%=A:H5IM%JD%\IS/X[8!_P/]Y,^\.^-<!_]P-QQJTTSXJ I-DY<>HT-2D
M=/(N-B:$?N/#?N%Q72$I _X;!?]UIIL=\*\#_H40]6"=]\DH;$G,_AQ <;%.
M54_&)6.:YWZ>]07ZC3'[;T-JSF^/CI\="0CUEAVE_VV5ZS&N14?&%QL<%$>8
M=<X4R7E.K:%?8C?B1!Y8/AHBM'81,HM[#VPS<&92%$M6D*)7')M6,DKB?C2#
MH?8P'C#O2-!_CC. FX!J:IF]9:HI(D )";RQV3)CY-),7&+O8*#Z"5%=#%Y/
M7L?8%'H,"EK0BDJO"0V><Y%Q3,GUB+MW786!ZHU M1<;K4:C==:"18<:0^O9
M5RM'S1J7\/0'JI\0U;E?#Q;$C2^@$F=4$"LJTFR5,=GD?D],N[:] _#NEMY
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MK^?YUOYLHE\E:N 6%^A8>\#^R/]Y9>5YL>B9VV:R@>)5+M$I@)Y2KP$J9\E
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M]-E)P_D)WOG[G[]\9_;26[I[_IJ]$UVZ]&5]QUS^HW_QMO%.BO&CWO6O7_,
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MF>+':KA!/,Y#NDSRL842E2X]I"NTJ-CX*/:I-CG6C G&:CA5)B,&3EGW6S0
M/KAD(SIQ_9T6WX("#,=QT\"<AQE!;@$T:)6T8P4UHDHU>]5O!J2D6V@X2P5F
M5PTSNH: H9N0?O;AHV^7B"):ZDEOGNY8MC9YB%0T!&^1=2[:9Q=DTEH8V\@;
MI3L_O!%Y1+[&:K7BXL0[1JH* UIE2L[-.&3F.MM&AG4EYII0'/< _!SP*OZU
MLT4F@^_^-@KKQ<<:F5S)J2V3<VH8^Q-A>WYT&RP)RXF5IIZ)2CQPQ;:A0DN1
MD),OFC_2UA]T;Q#=-NL:6TKD;057 3$)UI5(0Y(EG0?=&T/W0IQ4SCEI3%$1
MLZS<Q25%S29EM*?F6"9V_M@@Q4'W!M$=;#/)5R_KM8:^0U S!DI1QP@6SFY9
M#KHW@^[%M=MG=#VHPT%24$M4W".2@\Y&;/,84W2#[IM/M^84-%6.6C<PA<C8
MQ!Q2"=!BPU4O& S7^S,COI@D4?O6KXBJHCTKR"P+N+55M=P29!.U:6VXWC<=
M\!HX:".F><,$NIOIV5ER/B0.N20]]O0W"_#%8#!QP$/2T:K*KLHBCE%\;\'<
MZL8BXA:USC/"PR#\YA(>D&O1A"X$A,"9@G,M^A9R=2;RJGGOAH'^.>%>3'EG
M,)>HE7/%*?#&JL0("B/+G':AL!V[:[< ;\L9,3'%XCQTT,4*;R1>FD99U\VJ
M"_C ^W/B/0]<TR&':)M69$Q/ZVN]ZO&'*ED4[]OI6#$/O&\^WB7WF*B$M6J"
MI,5N:RZZ2D$[4WU9->9FX/TY\9['P65O8LK1*8/]GD9@5,)U4*XVS:EF4]/
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M0FJR"E8TF*%$BXVB3YI\SJDZ/?S"*8*W$-*% 4AG1TIG- H,DB+7O*I%.^T
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MNH&V9-<L.7^FL;,^>\.[^V*5[N<E]IK_MG^X);_G0-:LD_]<8D*LLC7XN:;
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M7BK-01>WL.UD_)C?T-[;P&+?P:FTX!J 13%UZ,78%?^<''$TYODC[(OY8=O
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M W<?V2<XZ0H..:MGZ(,:&O]T=[VE]U;*MVV=Q]M6JJ)!JA]5!:!L1QB[#JP
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M8]W)7A\-F]F?:#2\DYI \[+&93TV@V7T(AXCN\.VVX-F)KKWG)OSZ594N3"
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MTW,"I]6I,Q, I$G+I!$1MFD/3,:4U^H@;F7$PP'9P0@&EC9$=/=RQ?@PI-7
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MCS&4BZKB?TRG(%;CO&H)7-_TD%EC(2Z&MP%";[=U3$#8PVX.)+V^50,6UK;
MJH!64,DC"G0]4IWBE=>FB^TY52K=/#8=#)H.%F/3P2A/OJ)G%7(5T* 84C.Q
M7>S#)8;K*F5@4!KM=(D.N:"+X;MX=^"_1I6#;>!]DAKH9$T3_C[*G6((QM*4
MI[=7E?D^3FCI!HSU7:U3TU9N,I(J0*&O*(%&X%9RHP'I]"A*L1[MP*-*6OX
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MTY$\Q+G -._"]1!JXZO5.,31MS@_P@-Z+4#/;>"#X3_0=HP9=EAS6@Z$&AO
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M72#P5%U9V;+NB:'Y".7,3<A#8ZZR/2ZY<Z@3LKZZ]BXCEVR>OL3MX[Q:?(N
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MT6F3EO$*BR3D[90]AR0'=[J&T%-8P24U"TD<!=0YSE[K IJAO"\H%PZO"?_
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M0]PI/XW#*VD'(_,_XCS#J01X&_D7*LIDB,US<Q'R;[ K/"!SRC\5<13^&?V
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M1C$N9_H^]^(H'JM>RMBTYBYC$R,3=.?3G*,.LWBLER\O]B+1G=%,H22_S+2
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M.#H"CC]"29"@),#OOI&HPZK"<2&6TG4Z[9/R9X\+;;JV0"BV*AMMEW[^BD7
M1UV![@R2/5%J]_"\=5KQ:I_,=VG7]]0-JIN+S^DJOB+Q$,V<'A?03 G8)@HC
M@@_H^K[C=X V28@X2!)!X1YG183]IAVK*+%[:>8I[7:] 0 J7<KQL*H?=QG_
M0=4[=XFB 2Q%(U!9%RS3_2*_&1"5&T- 25R X)V.(\@?^G>%"4K7PWYB7R^
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MF)TAX(PACNN EU64)2+NY:%([._BR0CV'([A8VD.B,<%Y-^YFE"+95Q;R!1
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MN>"CXQ<Z[/32GZD0R%S$T\X-ZA,Y".$(@#P!1#O4D,Q&\+>T5MD0_D02O0!
M(F%[$0+-U%*+/EYH0E\B0Q(4 .Z)2+6,P ;TACWCH2R+ULA?EJDTZMO,1YK'
MP$<N%A%3[#*8$6 GZ$J)J!H*Y@0:Z "B[O2AB;X>_ XW%BB$J'\8P[\BNL^P
MJ2$ +50#'!<P;QM,(&;;00:4WS=RQ)X/"*<'JKA0))7PZ-T<A)8$4)A/P-9"
M>#R$!P8L\D S5\BCD$Z1L\;T(I!ET@_^SD62R:0._$*F^1CWAI  2DV#* Z
M,P&Z>*<@B26*44V\*0!+],U/%A)7*LGA+-<H;D$^@_J2X3^!4H<QK%X+AHGH
MY[#B,(R[M' /H30M)#'H%DD,OXWBL=9 6+D)>J@\,3)3\UT#>%9RXAZQ#+C=
M>:*/$@Q4DF9'H$X,\!V4&/7@+]:DN$U95X9*(L1I!9>:C!R:2E!.2-9< V>
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ML,H4+;\1I/@@'RDVT(OS$'3*.$U5-YQJU8"$?R*/[)F)T:<H:@"6\!C\ X'
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M"A;<@6;"?UV\UGSU$(#81S41P&G\O"E3K-$6BP4!9?^DI],<\6X>9T4/]@D
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M[.;+!_;QZ]</_[S_]&GWA5^09%XDOV.YZ%16K^#FV'UZ;^-$">[3G,!=K$?
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M*5O34@5I:8'9=U"*JA+4WOQR/$;!(O/]PLI\Y,[/"]2O+$M<U+>QVN(B@#E
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MOQ#%Z'1;.0:]*A7'D%Z_].EEX*%]E48P,A:*],K_QJ, /.__8I^\R>#=/5H
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MB>< =Y/ &D@#=N-%(Q('XL<4 S$ 6,"4-UDT2JP^0;4@7P0Q5>"R+A%XE[3
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M7I.V.KV=ZM%F>\Z)8W-K>]'(I<7G\^FZTDC?CH5^JL[0S3*+0$D_C.X&PO0
M*']$8&K+4SH$5"T1%"K 'B,-LT"?0,W'6(D/^1)+)I>7Y<(^IB!],)-7N+[G
M.#*J N.:L%P,63*PAC@FK=)P@*\I>#!D5$UY%$@'9H).'3W'P,0@Z4V&T,@#
M*>Q2GC# 2F8M!N,HM+QG5ZT/,VJ5509K-X$BLHL"8?QW<#=@E!Q,R/F8!\D$
MDX2E?X.&6&8] S'BKDSS!5WCJG@C4.^S3%KE)E'U<G 0RY #,!(A:2K3\1)K
MSR;[\#)15#+/-TZ)_:W^"%QUD[A>" ?YMPTZQ99^Q;.0B;L(#TK>13WY.S ,
MQ\Q/V$CL$ZJ@OY6*2!8"32)Q29TF-P2HP?GQT0(F\_/P=(8X7"+?2G6RU+3!
M>S:.42$=5M!IKIE<NGNR_0ASP",GULTX?^1R-[1->TJXM\!6G07QNO@ ]@YN
M(^P(21S%R3($4*8AH  !IY)::225[$&3TK8X('SDVD/8+PQ!5D"09D'+>8<1
M>,QB?H.GZ;G>9*.G@*O[-%IZ0]'24Y6MA7W/18GCV&FSVRIZK^U.<[?>:_\J
MIW:-5BGW%2@80S(J+B[3PPM[<['Z$<@+'T1?)H8NS65<:IU])C.<!(BJC$"!
M'AP _T^;!BD"<X$2>1*Y!/),58;_#&BF2WS&BJ<G24M%(^A1T@\R]AKB(]%D
M2O[UB=JRQ%?L/G-*<:H\1AO-'L>HD% OSU'MJYVR4ROAUCJ;7U*I&9775CAB
MDO&BMT8W5R("#2GPRT98<B$4M=CHR:4KXL&#R0,R?-*;5['MEB1#)LJ;PD!O
MC97S%/B0ZIM)_E7J>/'P9&DA(67]3U5$95C@:!.6S091@"]*E_@58$V=X<5@
M+5;>4)*#ZJ*\!,O%6XW-3W6,C85I1&@GYX?2A%"!;G7&]+;/TOD3^"IQ)F6H
MZ6"5@Z$M;=ZQ )LC+C>2.8)ZVV(OXZVP['=H'DG1B-,M"A3,8QD9 @V=+:+Y
M1,544G"E7V-O[K]\O_GR\?YOG^[8S>/CW?='=O/E _OX]>N'?]Y_^K3[VBLX
M^)R^/E%%^("Q]$@=4-70]!0C/SW'!T'!U4=YMG:B]%< @UT 0Y""09YG*R5:
M,$N;_1V?J"1*]'C1L)0^UT",*@J;XH:0<;RP>.W.8S)L[I<,NZDM]R$] UAK
M"AGWD8N/P^_*QD@-4KP-PDT9>< 8#H8"<M=(X.E.]FE9D Z5KCS?+K<LW/"*
M=1G&XJE2,T6M;8%)L'Y9$[FKJ[R9]2(@\E81QAEI07/P^)XIT9>KL2>>N!-1
MS&:*=U0C5\8EX1<@/L$G2)9TWS IVZ<J,R.# +_@-5=;G7_@7&!J80&[@(T<
M;X#.*A[5A&,O&HTQ\)/80P[PD^4I6TC\L.%-'LIP&X;*\D4%)WR6F1#C9U09
M,)T9!@A5J:L@O(S+"\:1!3_/2&F!.C*[*-(DYS/CVR/9F-4@#?!MUP2HM-@M
MZOWCW?C*;=ZC('5==0Z:L&VZ>XKZ@D# P,@",X#$89YGRTC<8R:H]<SY#M5/
M?/S^\-OM]]\>[K]\!!/SR_>[CP\W6$:1[/K'NV\WZN/MU\?OCZ^R[Q'Z\Y9]
M;/.'V2J<1>#KNQR]IK[+<>S^W$UJ<5P^*)?VEC3^",,7M]E2K+L3/KW#Q3LS
M^X]=>C/=?[X4[3.7!9,#*<F;K[@0ES<:N6EB;GYF(+1J&!I;9$/#B&(FM4<^
M#DMFH"M"L/ML7SV?EG*6R[S*A%)?L]L--HNF<G:W93;:38-NB^ZLOK!IHWT"
MON]Z.K,+.O/7F_L']H^;3[_=L<]W-X^_/=Q]OONR?=UXFN>ILCVNNNM;@WG"
M'=I9AQ-U<ILBWB8QT$:ENTE,!.G%\Z&'+5Y0;:X)-J.U)GW(X]$YO>[P:2"N
MXS_>6W8 #N+LVG9IT_12,3\/IDEM"M#A9%>H/J-J?/5SG7XJ-%63O_5Z]7;/
M6/ISH[[I;YUV>Z,W5RVV7^_WEO]:O;6NMYX7^L.6:!GWXJ-7<X\N:)TH#? #
MM0B<$V=$UE^0F3]+9KY#9B:C.<?093J@5Z*S;K]\7()@<6&[L1V0R2%\!5%D
M6@Z6Z)98<8I!\;Y.,^)U=GQND#.NRC#32?2O1@-I1!=577E4CC<@\A?/]M\;
M]]Q;WQY]9]L+8TY ;VWK!VY8JTGX7$BX43T:+JV1AO2_H])(%-?R*;J!*5:F
M"#",GTD_RMZMSU\"*,/F!<@L-76:Y:"[D*NK1]W-1LF^XXL)::>"^+PQ='4X
M!)V#W;LX>KZI,%FWR?TJ4ET Q",A5:S<:33?ER38Q41S2-/NQ-'4/QR"SL%N
M^03"9,0+M]@G/ R%KRV4\N TFCUMHE0=1=I&V25\Z9"/#O>T4:*-DM-$TT6[
M=)2E"@;).B<C9<=XZ3T575+G[BW8N>5%>*9>N!=W?J''[0.HVDQCM+N;:=[M
M0>C EI7F%<TK:_)*YUA9A734.[H!=7(7'G\M<5FMQE:YUO%]U"!W;;20A$\U
M?AZ%&?DRQRD=4&;_/-[=LGOW202Y>2@/B;O<L@% "]]6I>[D7-XTO/0B3+E:
MN5[N!%YFT5B>,HADQI8O3"S)-,OEN">98TXZJAP+MZ3NC1J8._WI[N/-)_;M
MX>OMW=V'^R\?=YM.86?K;\ZM#:!0#L>98Q^VWK%/"D2<Y:W1R"?C1-.A#Y-B
M,7MZ)[X?^96*F\B"5C0E8,0!Y(W#,7<F0/^C629)[\9Q!,B'I>5!,SAH PIN
M;O_GM_O'>\QH ;*]O[W[\@B(8#<?'^[D+5Y*>U&9[7^_^_2!_?KU@3W>?+H[
MT^N]*R_S?O'<RZ])':A[U_0F,O=2W>\]CBV6O,&,:?B8MKB+359( R3;5)>8
MXWI/F=+!<;VG9C-?P#C)0'"!/DP>C.=[$#R#J!:7F&& 3&R) 18]%1,[F@0U
M6:PCB@N766(H*,//#H(H39RES(-V9Y>5<NIL#@AQLC7,U>WFBE!U?JK-50Y7
M"2>JYK<$-R9F8 ;P2$CY@:/[5.!D4>:%*E6.:BN$12*;86-$K CGL &GID!!
MI@0R9P/A"JPAN[3<E(E-8BY5*?\9"Y[Y5&4ASRTP"&D(7U7<2];+97YT#$<I
MU^?OKB/%=.I7;57+LMZZ^NG,"U,"729M8=.L'>Q(9*)"%=*FD:UA0%'[OZMJ
M8$-2*@+YB/@"Z,D"160)OX!<Y,:TLP0#*@H=6:0LJ8 K*8-LA)>,+W8ALZW!
ME BBP;^I'IE<#&:4@SZ354N?N/-S)I<<]'2H5HRSQ*T!+%D7\05*ME7]QG%:
M=G (W!<*-\X230P&+/Z;Y$5,U0.9'5-J4@X<,#EN *BTKZBTU:#,8OS!Q3I#
M1):JE&-<+O/9\W^G D9\BDH"N /T-R5+H(Q)D^^/1*.75'>?*"?-!6V' (GL
M8!P#]P-*[1/EX'C78F[7I*M\,47;%UE15I<"4D5Q2K52PV<A9 &#F%VGW"9!
M+(DS,R@5]1R$:>51D_O^3+:C4%EZJD$W">*Y%\&56;U04MJ=0G^!=F.[-4@R
ME18+=38XMJZR9:VQ$'RH(*[P(.4*QUPFE&1QR4,EYK#<!3VFJO/25@ R6,*5
M#.I351RIO]C 1,/[+S=?;LD_>7BX^?)Q+WF&.M6^U]*I]L>NM7Y5':ON?LC"
MS[(C-I']B8J.>,<BNV,9_%F>2H_/<)5?,LP5J]I68ZBT:9.@+%BU.*H[FE9'
M6NPXD<9PI"5*K1'?X1X$Z3L2>:8J0N1XW(UU:-I7R;%EB6P[6QP4]X1CT5!Q
MI<M"?[-9"D1,V/>QQ<V1&'<O1"XH0/.=_SC9+DM_4][OT/<FZ'G@?D/<KPI?
M%!M$& UCZR2?[866*Z[[%92V=&JPWU6Z.NE@;Y8?+DW/0&X87T>?/0H]?Y:&
MQHLS+>&VL0QPR_@QK%V6'R-0H9TF"Z>"@'%#R5.X8&G'N1X-'H<>J!\M,2HX
MCA@YP4YMM93_LL]2D5FR5V@'5-C>Q5K:5&T;V[:A_\=]ERJ7#6;LW^"F!I;L
M,%5H78B.MB]"[%T@>!C;P7%X'F=5L>^LR9K&263K&V5OQPCDB\!0H\XW.*##
MG^/6 O"E^7/ND ,!-/"\WU'$9'$@PLBG(/J3'215VRZL7..ZR,VN.S:B=FGX
M-NM5L'N[5&/V]NOG._;]YE]W^ZBJ85O__<86_4&S9W1%T^B:[4Z_.Q@*:V"T
M^ZW.<'C5-,W_-;JM-T<M_1\$NE6DB!_%B+CC0797E 3XC7I/[5 Q')+ OF=+
M9S )A<2%#Q0X5+-)[(M=^&91#Y_0"ZG?7?Q.[,+/0%I=XC'A)?Z5Y>FY43<2
M^:K!>'$W=&PYMR794"RS(_7%H@W-;WKM'<6C;KBAS6BN<R253-JM^E7_ZDBJ
M@_3J_6;_2-;:K??ZW2-9JX:KABO ]:IRE7=:<[5"XL)11UXN9*XT#WMU69[M
M5CHZJ=(L>RAJ<Z*0*Q2UT9!;$W*W9(8>776M3<I^Z_)::U/%#1VYZ@);F\#N
MFQG6-6%IPM*$I0GK.& W1UBGE7:\>-/%Z.U.DX_7&&-K=*D7J1>I%[EJD5NJ
MTT+I;ETZIZ^(I%OL\OR-1X$Y9O_%/GF3P3NZC.^J!E*[J-A2!HHGFG9Z1(FC
MK9K1W3#-ND*)TB=>@J;3/@B&#K'5G[1(TB*ITS"T2*HVDCH;%AS0(DF+I.,3
M21>M5F?]"DY:&.T;/66JF)^*(-I2D.Y8O-A'6,,/72&P--R,6JM7ML:HK@^X
M9R0URSIXV\'0X868)H_U>+C3*&MO:Q[6/*QYN#HPNS":_8,4@=7H60L]5_M&
MSN$9]\S.P;[ZX=AC'X0_X2$6P+--W;%@@^CL54O'9JN-HL.TE#B\/-/4L0[,
MV@W=<J3B*#K,@;QFX..@C@NC1#<)S;M[/RK21Q$G?A3QP8;5!/;0%E3OP8I,
MW5!QDTY]O0/VZM,HVDE;B5,)C6CR6*M[;_<P,6^-(LW!FH.W8JWVN_I0HKK8
MT8<2IWXH\3U7_^P0-TUUC[C3: '7J?6-#?-$CJ4?8IG0T>O(NGKHA?]6#[F'
M5Q=:2&HA6>9D98/;L%I(:B&IA:06DF<C)"\ZW?*'6*<H'H]0 I8)&9S8\6.\
MB/A)62?] !5)MES59$%7;KU*O4J]RI)C;"FR6!&;9755,]6&@KUC^6_89ZK\
MO]N+SWH,/<8ICW%FUYVV73_L!3G_ZG.\R@%P?4=RT1:K;8GW6V4C+OH4><\H
M:I:]3GXJ1\E:()VA0+KJ7VF!5&T4-0]S[U<+)"V0#A&1-3I[O\:EA5$)].S]
M!N3A!=&97;+;O'98^<.D(V2!J^YJA:Q/[_:%B=Z&UQ>.7B!I\EB+4:\.4W57
MHVC]"V8Z=U^3QPIKL]G3N?O5Q8[.W3_UPZQM%0$[;Z?9Z!SF3$&CJ$29)QUD
MU>2A.?AX4=32QR2:/);#["__T6\:S?>:BS6:JK3?LSYHV%IEL//VP[NMPS0\
MU"A:_Z2BJ>.<FCR6D\>FI2@T!^\-1;JIK":/%;'P_MY[ZFGLE+BU9.BCBA,_
MJI"EP0*5OS>5&7V'N$^J<CXE,!:E?9YMX8?M ZC:_-BL=?H;1B6W!R,=K]KI
MN9$N&*N%J1:F>Q&F_<Z&];.U,-7"M&);U<)4"].#7JSLEL_CT6+T.,3HV=9!
M?Q=R($?XU[*??ODK_"=>TX3*^,24VX?QU3=(JOT\/O\=!:$]G,FO;-<2;GC=
M;%/\8_\[;5)D8RS8T',<[QE0Q&B/;.J+ %86,,\?<=<VXYKH[,+UW,N/-S??
M?F;<M5@([\X$]R\]P-TE_L7,,7='L#K;7?7RT//I91>6PR:PQG' !$##8H]B
M&HK)0/BLU:BQ9J/9H)F:#>.*#69Q!*;.ON8'#XI+BR<'@GP.Q]E??1["X]P7
MS!)#F-_"M>)B8-=/MA<%,(F))558:(<._(RW!IJ-]P]BZOD2/G$=IX=X<IQ1
ME7FBIXWW]82 5I-+)T\NG87D J0A)XXY38I"(!&'3P-Q'?_QWK*#J<-GU[9+
MB*:7BGP%T[Q_MJUPC*1>;Q"YQY$\-;[ZN4X_%;A<_=:O]]O+?V[4C0U_Z[3;
M&[VY:K&=>O]JLU'WO]9>O=$_GK4V6ZTC66N_WFX>RUJ/B5Z-1KW?.);%[HH(
M6E>='1!!N]T[$KBVZVUCO?4L*0_;7%$>MA(E'_MK57Q<'&!8L:?EOH.QSOY-
M@07@]@.!7KVS%@R^H$GW69IT=TM,NFU R.B<+H2,JVU Z.H- ^.WZ(L>&;!N
MR9\ $_VO __=+['5KPSOUU:>+E&5<IU'%T"[3-"BZJB(@8Z(X '](WTB8:TB
MUTVA<L:0ODV=Z+L?TJ-F#^BV:CAO%<XWYA^1'=CH[&O(;A6R!4'-+K[$\9>2
M@-:PU')W;Y#&E)$@M,/(5S&]#W9@PENV&U&192U_CTE*'*NOV4VA1T->VR%,
M9ZYS-@,& \SD(*FN!&%Y^_>4R.YFXD5NN,X9^6OY]P2!]\T,ZUNY";PI4 X7
M]#F*DOS'<LOB:J>7+*I[AV*]?;=J1NGJ91OPU2'O26A"/@="[AB:BC45'SL5
MOZIPA"9E3<K5V7>KUC3*=MW6A*P)N8*$W&EHXT(3\M$3\H71WO2VO*;@2F'R
M7"FX56OWM4VA"?GH"?FBV2M1:>7(2+A,8M+KR+EZ>.U7"JL'@,!.2D%6683M
ML\_4450S6@]L1JW5*ZO*=<6I8XA&:BSMVZW;>P<3C9P28JZKJV)6'4>=ANZQ
M5FT<:55T#%C2G%1]'%T8[;V7$=7861L[):J>5+#$ZUYB!(NKO50Y1J ;T&TC
M^'_5TGUO*HTAW9U(8TEC24N[\\!0N['A4;3&D)9T&DN:CXX&0YM<'-/(V1=R
M2IS^5+!.JKY5L+1"@&XJ^5HH]GME&Y?H>.<QF&@:2QI+&DM:VAT;AJ[T79"*
M8^A"GXU6%C=7W;(A48VA?5]_[VCVJ2QR]-6"$[Q:0 UC=1NNRF:J'7$7KC4+
M[]3ZQKEW--2\HGEE#T6J-*-H1CD/1BF5TZ291#/).3()6%Z=IE8HFE<TK[P(
MF.X&Z>::5S2OG".O7!@EHKB:2323G".3@$+I:N-+\XKFE3442L?8N-K9\7/)
MB5\_+E_Q["1.%=]1SWOXU[*?XO_"?^*%J==;71A_ZLG6?]>^<'AH/XGW<4MK
MZG2<>4L1>R-]A0^ KJ-P^2MS77RV#2&C\1*(FKBF7CN!408B\K_CI#?6E(_$
MY< 7_/=+/H3%7G/GF<^"-^]R>YK8[F46@,6]RQW^0AWJ%LV:@R@)B3P4U)?T
MR#7)C?BKN)%T S<=TVFK2Y]9IRW_+7S.XV/"_1$L7V$2._NH;U!.]?/,_.\H
M".WA;'<8DSM<IZT7X%"NS!*FYU-;H6O@7.'C4RM[#[%',9H Y5WG,?$ZD,BO
M;%@ #-QLUF5SW2I :2U8S/4-WCI(VO7>3F&R$@+?QX*M@D*@H."K=GO//&!O
MJ=-0W#6.FAZ^I<KJR5=#SV<AC.QBV^J)1VVKQ9+&WO0^]J^NP23!5)@H5IU9
MC7$&! SR)1#,&\(,K4X\?HW!^$;CISK#Y2=/X=JFO@W@!S@Q'H:^/8A(MK/0
MNV87]L_9,6V7/8$\GJC1C68Z.HQCV8$9!0&L>" <[[D&;\/KN*?('?(GX"L<
M%E0@K!<'@!T#6%UF1KXO7-,&#.&P'2,=-5T:3/T) .RRFPE@S>0$@KO(]Z:"
M_H2YU&3V9,KE!%:QSZ15Z#-)\QGM>#Z"39!")V#/PA=LRD$3<P<6X0V'@0C9
M "#EPHI2J'#0UB#; 1M M'\"!&#A)@A/FJ#=7+0ARX?5N3B6%_GLH^,-@'1N
M85$ 7I]6FZ>JAQ]L$ 5 ' #AH,[8"3.7I#'"#L)F'5XC1+EBQ"4G*"(05H&$
M),'4V$U@2PI"@OFM_EBO(2("SP0\(TL!&YB20O A#Y[R82!A\HCF]6=L J@G
MN@KY[P*)@3@1WD#&H6%OO_[C_L.E<07T X"=V"8Q"8SR9'M1@!00\XOD23!Z
M0AA T'Y@ZR88@!S&A6E&: C24H0CF1WFM^C+J>^9PJ*5D'T%M+=B?AB!![1-
M?!#H'!% #;!A79?T.R[C$H#D$RCQ^\#T[2E!H[8(Q#19 66*G+].Q^&8.Q.@
MG=&,1E<_/,9[RI(T L$7F.N%\A#6A .;Q!$T/0$%" BYVQ$N\:?G.Q98+<"S
M$0'>L2<VKDFATD9BX1E4(CR]"<XSHN]&'G"NJ\2UZ4TF4N1&4H .?0Z;*KOK
M?]@!KO:6 TG&^ZNS#Y%/ @&>&]I^$+(_(I KPJ\EB 9B (X5/LK]$4@36BW8
MC&[HSRX=CZ,U]H8]CVU@!NYX,-BS'8Z!0?GLDH>78]P7V7&E5YR(G7BYI(WP
M@0"  F!3:ZVSOWO/H-5\(N44=@%(_!'("L<>AKC)!8Q4D\I-+8N%(/&M&,=*
M4=*J0I+ *5FHD1&U\)2#(I@0";L>V"AKD<%1=7JTWG!L^YGE?H,E1!-<$K(P
MB.J N1Z; /7[:H% B*![A)J:!4#OW(H_)2ST9/L1;.$9=0UX9?841D = $CP
M8/0:&_G<BF#$D00HTA( 9P84Y$UHJ DW?0^!Z0$GT@[&H"O"L8E4(E$4[S]A
M6/C 0128I""!724%X1-$09? 6D-\!TV".ONGD)M$M8H:V!8(9QH! )/ .+8S
M9H+[TIAX!N4$+X#1 5294 O(PX52!)&VB#)N8#->-!HCD,0/D!\VPA7D#7@1
M2EC/CQ6+K*PDPH5=(O0N:8G)PI%#%*>,A < GX[19+!2OLHAOT:B2R*?NS,8
M1[BPLUBZ+I+U1!TA"T SVD,03VY81'D"3DY6#((II533BQR2GX$]<'!",#R(
M<E&V)ELF,@Z0?V!W:',%#&$@40&X@>W!GT9=^Q.I/_'-]X9V>+00V8HW,248
M;.8F2!>DWVK(B'W."[GJ7Z7FZ4IOPNA<Y;V)[FIO(K5PP^Q#R,>P;G(T:!7
M#"2)G:6,N0\CK+;0S@<_!F9]_/@7/IF^OR'!AH;'5KFS(JRX*@!"5?[/+M21
MV_49!#7D?F.! _ZM$UG(7/#3O^PA_\'=>/-;76%WKB7Z0O*<CR,C8"];]'8Q
M6@Z"1E(N2+Q>^SW;R<+7!.U4%K!@^$LMMM]-L!9<-"!0H/?Z/Y&,ZS5^BFW
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M:BC4CUN",2:VC [A+GEZ?.!= DXGGHH;\9$OY%E2)FX<CN'+U6A&,1(K;'4
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M^EYOV4:JI\+ 9W-*?8/%A\_2]SG17FYKXKV]84?+(PU9'2&&RCJG%6RY=\C
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M6H[O-[S6W?!H3\MQ+<>K2AY:CFLY?F9R_*)?OCCD68KP(Q3"%U=G>CC\+N1
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MYO#[+KUBI_$5T\P=7M7 VUGK6$!T#C-LXH4+9HL@]<RZG,/4FP_[[>KB-\$
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M0).#K@9)0$Q\X 6(_S5@ORV\5F#9YBPN2B)$>^T8@[+22 H=J3'Y" NCP2'
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MZ7Q6M.[^0F>^2-H!J=]&:9F[TLZW9'*=!C&W@XW3D.+NSC'4[)@Z45%@[SF
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M8]34%\),-2T%BN7I]13V4O]9*[)3<U+JZ]1O(*NG-Q:4:NSNI.UOX(=F!W&
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M&YQQ3 FBN&FN*UMTAOATI?\?08Q$G0"3V()AZC]AK!L6GE;.GBW2U2;9K)7
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M9TVVO,\I%2,(7"T,&B3;-<8DT92'YS2D+-D F*1>-*A3LMV9 T [?5,0WD1
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ML=J?"+"!]> Y6T7$\(T56A0UHGAJZ,S9 H).9)_!/#=#LKHT<EJ3Y\-ILRZ
M[HD=J.]T2D6"F40*$^K( 8J1#I1QP@6]:(HV)8?+4-D6V&+F>_X2#Y#13O.!
M+>9965TFQ2XYCA55'[M=]NIJ%QJE7K?MR3E:XY.CJ4P*<TH-NQ@JRD$71"TX
M&5&.>MM0H5(O4G&4HO5;W\5H6#]D%F_2UHK <N:31&77$YZ'7VU0>XU&BJX)
MN'/M3FT'F4ZV9E]?K23JF1(IK$Z\M?6*=>^80U?KTPHN'XR1;BYM;][ JZ_0
MKW>/\/^;2]XXVGZ,Y(WN=K=-WG@A0=ZNQ'A_3S+$JBJHL.]*8\*>@HP!F]4I
M3"<?$MLGDM?P6D/"U30W Y.K>$D<9E-#WKQO^MJ#4PVZVWNO)=5@9\L[4<.
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MDV;8I&99=K[2="TXC$#\VP_)UP*BV-YY]'RMW0[0VL&COW9O>ZN[._OR ]+
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M0$VL^1LJW^8XE$"<NA%8G%^ZY],YYO _&)1],^R :+" ^IYF_AE06%(-Q^J
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MLHA*V<&4,]&TF&+2,"JC>*^9BR\L.<1K3UJ4F<$<58R)M]OZ6T?OP^D>7LA
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MX6II8#VD_E70#6UKM-"!S2NHX0*N\*_>_PHCF/@K!'>4/J"-RYAGPT^PM,(
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MR1&9F2VWQ16#I."=CI3;*EMMW\.U.]U(K"/R*AP'KMV;Q.7YP=WGV\W+,QQ
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MVXAV[]M^G='>) COE+.^-G,V@I;2:<^T)3+/7SR=22A;"(I[Z[D,SM2Y6.\
M!-9\7_ P]-6&JIJZFD_BT[D%Q$TSTZRU9K9</ZE<V>GR)'@(Q!CF=$C&0:J[
M-W@?TV%L"7;$YB;=[$A%AR[W=#(;O"VY?/.7@FEF:-DOUXHI]/NS)U[Z2+SA
MR>";P6FC#K+XH7>T@']:U<$W3_VNG:'M[=]AA?\MB)N;&!K :.'%-)=#]U/
MXW[)#@RL<KB#^3J<^%?AI,!R2I83*QA.6YX#<7D>NF5&.<:-0C7)<S@,%C<L
M_MV3V,9J'9/W.UKJP_6')1##(01:"N%IN=&W]$3R3GK"O&1)X4B=:Q+)-J+O
MFR?WMQ+O9/MQ%X;K>$7]W7^^ T0P(S@/F5@)",1F38*(DE!*\7>18H F#1&;
M,7CWR4^0P:T-M_$=?'(%!=^Z%N/\^+\XW,J#[<?R1$H4.B)KI99!>.6U!AFX
M+0TY@\^21A,X-2 $0/U:ANV'=3#IS*>WV;06YQO)-,50'P,JJ0).2U)FPB$%
M%U4&RJK<P'Z(10\=8GKIK^+UX@*-M^.KJ]?CR9]^D@9"J<Q,!G2^- :R'G#Z
MQOF:1)M1UA&DI54: U0?V3,IF&CS-E3,+>] /37+*>[L!?UC.+N\-YB5&7+Z
M=J6AU;)<9/Y9@ZP"8S(S$K+%>"3*<IS*-3&9E;N=C=!U+N:I,IHG_1ITH;H&
MF\']2J:GPX@F@]HPIILNEB>C>'6-;L[)Z-A/1OACY2+9**,M?5( /7MI X;I
MI9PJ"">Y5#0FW5MZ:I41_GA?GH*T*B1(=CS0"YC-%E52TT'D&!^ < 22-C@R
M52YSX9YDEWTI@^:>ULUNZ'Q(/]Z2@Q1/3PD5NZ^7U%ON1;#$:M!$!BG0J^69
MX$(914)+)WU0;T0+%ZN7RO;%13RS00Z,)Y,BX=HEM",/)+#B@3BEHI14)%YE
M.=X>\H^98R_D5^C>O 7R,[3E$KS(,@"50'PHA?@Q9N)P""1SQZ-W6F'<>R#*
M_8KZAWCW)8'[^M4'M+>V3"A(7LQ[2$KI<:46%H- '2AQS&AO:&+65)'TCUX,
MA[=?UEX1A]*+8<,+_.++;;5+R</3S#FB;2KO+0O$@4G$.ZY#%"[8!#5T_BBR
MYY.:U$8WXYK\5=BLV@#P3G5$$X UT[(?1;B?5.R.F6VFFQUIV8M^(D:1.9IR
M!UGIQZ.T)&Y^;500/GDMRAWPST@WCV18[ULV;=CH4"ZE7.HHQ@D4..CLOD.#
M+6\8^WT\@B_+I!4)D:>2]HD3+LZW5GKB;+G+.SJ;K5=*NA6G;6TYVN-/ZC]V
MZ)B:<36[=ER3^+6[=_KG]70VWT9[.>^ .CT9'4]GPP]^!M/S?#Z[A,GKZQDN
MTV_\E_F/W61W!RV5,KCT,IN)-!@8A8SK;Y;4)2XBE;2)*'8&\IPTTR\K!YI?
M-F\W[]>VFQ^/_-GJAG!/F6);HMI'SE<7!ES)WJ(.:$S9H_&H!"N"EUPP%:2U
MPBONVV5O;0EP_Q>I?0VA7<X&=&+$:8%O>,00Q%HOB:>)!R:E$>E@+U,[[3SS
MZ@QF<SRW.UA'83IOHSV(3&:IG$3KE"M$A$W$@J;XBT<Q*1UDK)NHMA':4[\.
ML8T"-V[B=$-<A:REA8E^@ZN$[M.%OX+3\>C]Z? 3I%OLI9#_:ER,-O"(3_(8
MB# 6G7/#(@EH!2+ 1,\4!%7G H56*/<HN(YH'O?%4<WTGYVOLTFX"*;2=R]D
MB2Y6"B6/*05BH]%&N6RXKK*U]YW?H]G)?-<K^8>R6]VDK632BADPGD0PN;1
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MY(6\SY=)"&93!"(@Q#)2)!-K B-62EQ#CH*Q-HG771&>DL;4HZ*!>W:S[%^
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M?Y$<%+$I"$*UHQ9$-EIV*3' A]XY _"G]?W_WEM/P2[=7XP5H_6W(&[FO'>
MT<.2[,YJ_4]YMV5X  /K'!X@OA9?Y@H.;OS>Z2Q)$LD223G@OJ,=D=H$P5Q0
MT70)BQX'BUMLKOHD]I%:9?+^\'^/OEU_6P'1PF5:HEQ@2_M1@<=&4!G/1QU,
MEBH8JKLDFG2B[]Z;ASM1#Y+]I(;@*AI$"R HJE] $G?)0G9X+FBQ.J$-BV4&
MBJ>4*FF@RP#';@S>??,S9'!OP35PAC_-_7P1&/SM>E8,KMFG97APZ;*E',J
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M>6)-N5+ROC1>RDK$-G7NF_$<7!UQ[[&+8 ?,%C.I%O&Q]&N^T&6$K)*6GA@
M7'DTN'*A(A':9:XE!>^;Y-AUA_@$B><5M.1!Q4(;2EKTA+B'=&W65&8 5G@@
MFG)1^FU+XI4,Q% :T#*)U.0N#3@/5)>G'OW57D$.$'N#VX6;,8@%XR5EN J6
M.3&,)B(A<.(9<!)E5N5_@,4FTVCO@C@-RO<6:X-<O;M85F[!I=)&>0&"^%0Z
M#6;NB1?(#0\>LN0\1=OD8]^ Y?0(WT?(#3+L[D*ZF(SC"E4 D873FJ 1Q_$,
MPM,H&$,)'DU&*::3#$UFLF^&<WKL[RGJ!EW^[J]TE2:1<#T*(LE!,2*#L21H
M$PBCKG0>-3:PT/Z4'S3MJ/V1WE^TQY)X]&H*:31_XV,)$OV\F;(DJ(Z"6+F8
M@QYPUS),DBPL0P=0NAR;' T/H3Q5BM'!Y$ZJ"KF!U7<?T:_I:CLQM4PMV@3J
M:3*,#B7L4?X/D/90FI \Y0"@B-%AT?*2D:!D20<V,7-.E;!-\FZ'TX =N49#
M*$ ?(3=I_OIC<O4#_=#[X&XZ.'$+4C)'1/1X(G(?T7)QI46Y#1[-%J-2DY33
M1U$-;RL>3MR#AK"UI-X@/'0W*/L9_YME8IU.&E4_$@'E*A]")MXZ//A2\M+*
MC.=?,W=A'<RI& 0'"[I1E. NIILDV ZH6AH%FV$]C5EP.&T[].  F3<*#6Y
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M.)W-9C!_-\%?9V_SJ]$T7G^;S<L]VNP/F%]ZL(N%$G!E8%(VN$E:])6AM$@
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MN+2']?L?(<&W[T4+/DQ'\4Z+JE=?BVLV&K^:C.?(^:6S4?#$*&&62R)YD4!
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MQ>2:A-"/MT7?(90?)M_F-ZV+S4Q3JK*CAC!G%9$JHM=,>2:0/)4Q*@VNR03
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MQ6>(5\$1S6V2)G//71.';S.<ITJ!:$C_@V+*@VEHX.X]1'4SSJ #KI:I$=N
M/4UF1 WR=NK# 9(?4C-T<,Q$DPGE$4]3Y@7Q$<_5!"DEQPW3L8EG-JQ&[,B*
M&%(A^@B\@2)\6(IDN2/>VR17=_8E:=!3Q!>Y*]F#61(?M"DS< UZ>U*X]6GP
M=11B%[#A;=XZ%$X:RK]!8/G]_"M,/Z"=/;U=_;U#=!-DY;T#AT<T<Q[=.D^A
MQ,(S<:7180R&Y="DF<<>6$]$BUJSU/P$^O1],IY-IN_*?U;$OR@_" )W56^)
M5<P4<[^,>P%'0C8Z1BY5"@/8L!N0O31S]E!R&L2='P5X4W;4 >)P1NY&C,=@
M[Q[,;A_=.8":H?>@%53)7589=V2]F/HMJ2$V"4UT=CG%0+TS30ZS)].>7K;Q
M4RA/'T8J*DTL/;*F/R___'1)3>#",$YBYH)(+B2QSN"/5L6D<S1JT\GT8&S+
MZHE+G5C]L*X.O][ZU*9*!3(F!TFR@77[9C*%T9>%]7U3NE9>3%DFADD\-9W'
M\Y.77RS/,K*D03>Y-7J Y'3HKB/LK5]R]7SP3_\\^WC^V]FG\]>OWO]1<N+.
M/K]]?[%'_N&6!U5*(.P"<RT#,%D6I>><&8/40;#)<J^"]\9DH,%?[D9<2YQ[
MI^T^^KBFHNV0BDNS<SHS_ I0@05 \%8EYT/*RFC.8(N :R3=;GYRA9ZQ'1_<
M5/2].K]:QX1B2D2>2Q]#ZC6GSF:.;J[2V>LM)%1N[OKIJY_";Z7#9DF51>-J
M:2#A.\9?E@[ZSU__9-5@]NPO/TUW;KY*]8W4B62N2FZ/0P\N:4N\SQ37!T&(
M-I5)!T,_^%)U7P07U^5@>9\7?SL[NYY_G4Q'_POI4J,"> ."4%KN#F.VQ 6E
MT$;E^'FR&$(Z+EEN6\D35(@-J\D/[G"?5!<:&)VXC&^3\:?Y)/[W*_]]-/=7
M2X0?80;3'Y#03GIS/;^>PMO9[-J/(UPZ/+4AHID%*2@BA4S$L4 )"DXK)X1S
MIDFM:F^D+TXYVW+9H@;VT*_I+*4%I3<KO?-=!54&<!J&]CN@((,*Q$H()-&<
M$A/XAZ[+L)_A]]CM:WIQ"GTL^E$Q9KSH9;+OLA;>ZB2-\FCI![_QH^D??OK?
M,/^7O[J&=Z-OH_G[\=EX?.VO?L>GS2\E6IJN1+XLU91(SA1Q%A+^+N%1XX+P
MOE,7H<$0OQ@=/V)%:-$8I9+=] .=H>*?XE&V7!?S.@09$Q$ZX@F67"2!)MR5
MLX_.*A]].,YM?LN"7HS^'Y5F-,CG/O_V_6KR$V!5MK!YF1>3\0^8E0D_946S
MSQ.TV>[^?<DIOIC,_POF'R%.OHP7)Y=4PABET$HSK)1M.4W01\@$E(B.LZBL
M;%)DV6Q%+T[GCT,W&N2?-UO8,M<>O^W5'Y5_QR[1/PXF1#3:0."A5AP9%X#B
M+U)F$%YQUR2.,NPR__UY'(\6/?QF=+V:C9UBGVV3^S+))C/M@U4:%Z)YL>SP
MQ-/.$Q.8=2QK(SK-T3R@GN/ %0Q5Z_'4)L^3,'XL12*+ZBG_;34(U:84?0Y$
MJ#)(TY5!,3IE5#*E0\I:Y-C$EKD+XNDSZ 95@_6<WWWI:)'_O<*RNM_O@J9E
MSMQ].$^3'K<_/5MX/D"V[1F/25!A2M*%L %WU9")MS81;2V+@3, V23+=@BF
M=Z2RM2*ZCT@KMSA__VT\"M>SM^.(V]7H!Q1DG#*Y2KB)VG)!01 F+9 R%I58
M*=!?]R(S3YTT;JVZ9V-L\O&W#&\\'R+_21/A5;PV+$.L/X_FY=!Z.TZC'Z-T
M[:\6*DN-S8P+-(-,C*7WAR&!@B<R:9T#S3;2+JFIG:: ;T3P,H_Q.H14O.#8
M".@_1_.O'^%J(8_9U]'WSY-S5.KYSYNF\!V@]CCH]].AQS$.>_I78O4Q'6E
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M)Q>3<8F8HT[A$[^\'<]ABJ?BI2PM%13-!"@#(HO@7/:4<!& 2N^=#VU2!:K
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MYN>T$5^'O0:B-IKI<F9R:9P+E+DLLC%@!.[G?%V(-3:9M4?>*OS"1%NUP;N
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M%9(V=M\061<)+P6, 5 K^=<["X<DXF(W4-T$H8V8T' D3?=7^65796;EP1P
MY>"AAXCF%F0G%>QNHQE/!+N/Y*"_6#=+,2>3#,E&Q9*,S(B-4J)?G[/)SCNO
M^[G\.958=STE.$C&)QKK=@FW=*,,'N5EBB,Z=P1\C&4*$TL\F!Q-1Q&P$_1\
M6_&Y/];=1JY]13N;8/JM8MVM2&H2]CQ$PGVQ;P.-('D@B1<OS@I5FIDD8CW3
M02J;HVZ2OG."K+>+=5<GO8U@*\>Z7XT#_N&TC-B>W'[_8SSY\G /;]]>;3A;
M#+A.20MB4L##STNT47)I(&E=$$HE+1L5 3=]WXG$MULQ,^Y8K+7;1OW \L_A
M[*Y@3)-/<#_\=G5]LZI'H\X*F6*YS@_E=M\33QTE$'2,1CJE0Z.9]D^^Z873
M75F4S]?&<%Z6G&8ICB>O<!4PFKV#V2Q-*H8LGGQ%1X&+=DM;3]6C(N@,&HU^
M*85R0)5UQ>:7S @K8"-\\>3;NLO9\SIE*2@1IMR5>0T$&!.$&\=!*Q%]Z"=%
MJ5X0XV=(<3Z!J#@Q%U]*E<W%/P&_C_AY?#.[2Y,/I>)FD#2/+&C\O(S6^ T'
M2ZS 3\Z5(856<*>@DPAL*Y0G%=QHHS%[HO.5N>D@T/$!OA=\4]R@WZ;;TG9V
M!7DZD#SA?L\"409W96F<)]8I2W(,FFD%#%R3LL7V@?O=F,Y&26K)O8^I%LL;
M;">X5<(0KW+)/HV:.&X,JJS4:.K[X.7OU?GNJ#WB>!D_=^QK[^VF5YI*1Q/A
MSL0B&T5LI/A+EDH QX5T=&WP C)!VG#<; )M<UGW=^_?!-5OG0G2BK:F$VC;
MR[P_C>#&<JH,H.N(_J-4$$K&&B,TQ""C4T%")^;$J6>"=* (;43=@0+LFHK*
M63;4LTR<3&CKNK+($E5P 8130NC(:1<:<.H3:%O1U7 ";1M95_0K=L2'E95
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M::,@,E)'; R<"+").BNRCOWT>SCA1C%=J4<;V7>A%LM]<U>K$A^I<J #,3H
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M-K%<Z?X[ A(K\J K./%].\*!8Y3MMJ.ON3D+I6S_][_8OO7_:*:AT@'4";P
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M&% 846G&!2+R?.0%@A*C0KBF LR-[1OYU<GF^EYV6X4SE7^^]0'XO=3#M#R
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MR597RZJ4"E929US3@AIC!(\?*7_@N(Q,H^NL0RW5RJMB9>XT#%KJG8$#-;%
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MU'<6KQ)%,YQ=)>>/CUEI!=_*;\T3SOEM%E.^H(Y-L21W& J"JZHT(;,<Z/#
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M=.!NA](2]YCT@;&P(;(Q@B'!&#+B6<*FF'&/&K'XB8!/2>'U5H8JH+J+\'
M:S+X,+"-3=_-=U-!5LH)[C6^E.;,?1R-06F[H[MI.?NXWGN$K?%*SQ2F](FS
MU9+?B"\XSLJT?W5=I81]BS%1%3MB50L-YZN,LYODCM-5ID[T/^$\SA]4PH?-
M)1V7.30*54[J4'#),]R'$75=:%//0MBR723YW22[Z9#2S8V9&N74&J"RFZ8)
M;\K<TR7.\UC$=!VM(^($)W1]^E(]MMQ  )YK#%3B)R'! J\*+<,<J8-^&?0X
M\<.&>&06;8^NTJS)K7J^&;Z6>J#13_GC:PU!J2+XO502C'(=;!3X!TW%.JB
MTV9I'0/;O02NHW32LZK*\\LR?>/\GF>O,3V0/_8Z35YY+NWL\S]PQO*'M,#+
M]M]5T,]U6OR-%RH%V6,2_Q=G"U_X @66@)PSM0TA'0>B<CH2%!&7,!Z$CE;.
MB]$EG=LB<\>?<:S"Z,$JR=92;F?3;B( LZK*O KT2]($5KH#7"IO6-UEM"^"
MWJ(RB^$=>X$YEJ1[K1\H%3RK0G:E1N"-%V"CT_!9($>'?] "-:,).VU)F[$Q
MWRN",WJ'/>]1*P?I.RX4N\HU\"(MZX?Q1%4/VQBG8>B$W*(!C#@/Y8(2$AAZ
MD06IYP6V_+_(=8QJ,6OU.K?%X=OEU_-OX/;NYN+R\O/5]5?#G UZ2.LQ]N#X
MC<R^U;Y(+7!IS6^)/%+R!B.4!KT'K=7QM->>3;#8N^5L]+)YK.H=S[E\X4FV
M_9F_\F7ZHM;D.GGN_[O"J@ZJ---7F;I-L; MU_<X)]"W;0R1PUP8$4*@[7J^
MZ[@X$)[6(9MQSW,CI%H^M<=1":@?0FB&>#<IC8KCR,34R VDX* E.:A%/P,-
MR.=C@ZP?@SD:V)-5 !L.=*.PR5[ =81$FK4W6;AC+S7;H8S]&NAG@%[S/UIU
M:[,TD3_2:K/^)KLH,_%>)>TGRG0:2_YM7?24AY'K.L2%H7!LB*S AH1; D9>
M1 )DH= -C8J$G2S1W-8)J1!HUVK>4DF5@JF44E<.MAZK]3JA;NWI@ZMG#T\Z
M9",O29.,EK$M/1C"0]K9IPLUJ0T^&(:[]OEP#9MQ>)X5BZUBOOGYCSA?,(HC
M'$01M+BTS5'D6Y*+0P2MD+BV:SMNB+3*@+_?_-S8=5.,6DFG29 'D.MFN]/Q
M&)FZ=*'09I]NC3NH1+[8HA'YVRZ%'&AY$C[HUJJ9W$>>,INIM+Y_?'&^$!@+
MAD4 71<+B#SD0((=%]H>IU[@NH&O%Z.Z:7)V,Q(GF&&]B=@"IGOR]5-W[ EW
M?GW^^?ST>;:O7,=UZ_KA:G[5O^Q.KU:#DTRI?06::?3.7\PWJ.YY$J?9O3H+
MYDRE,<V#7RSKEF<J(O2SJF@OO24) :I#E$D4N1&Q+!B$(8$HM#@,+55RQ?=]
MY C/YWHWJWKT/;?)J(3]5U I46;JS8$4&I12 R6V_GZ*Z2@<W[8:$=NQSS,K
M0&O1:V"5\*"6?@?E'J7J3>'6W\ :$?:)MK"&A]]H(ZLG@!U;6:8M3K:9U5/5
M]G96WR;Z;6A]YEG\BHLRZW5>9.6W,9>]?N9Y_)BHD)'S_"^</9:)^=</-)5S
MKGFQ"$3H8.(AZ-"R0I?RGQRWS*HG M>W'2\D/>+^3Q9,:QY.?SM 2@;H>D]D
M$\UYUJ/XZNF#I[=A-<U83+,4;70!+5G+T)F-.@#GH%:H_=19NP+8&9"*#;=E
M-1C&0VY9G2[4I%M6@V&XNV4U7,/]6+INN^E.&@N?4Q7[M_ CAV*;>Y!07\5.
M"@1#FT?0]Q .B>W;MJ^U>76LH[G9Z<WD; D*?J]$-=ST/PBM'C4. =C(C-<+
M*V/^.@;$D+1TL*])V>:8QKLD<O3YOIY^920Z7FD<ODG,HMK'L1!&D4NE3X^H
M(QU[%DJKS!70CFP<1-Q5IIN98W^HJ[GQ0_"+XX%W'?DWY>%$IG[E08AUO?8A
M@)O&22\E/0,*P7\]VP*MMU=^$#U3)WP(%*?UN1M?6WX=MWUM74A[>-K'4#KJ
M6!]L8&(_^I@B^V[ST3?ZV5\WJK#R.S6B:NON1CS@'[<JW6V:G!=%%I-54=Z]
M26^Q*I=]3J1-B*GTE2GA?D1L:+F1#9%'!21<4C,G@16X021\6ZN8P,!RS8V]
M2[7*>RR;(FIQ741MV5E]>=31T[,(/V!,1EX8JN'HJ&E7NL+J,J14[0S4RH&V
M=NK>4:4?^+W1<$#C<V#,A[15AQ)M4M-V8#QW+>&AFS^!U%O7**\E-F61\&)A
M<1=[F$20.E3RM& (1DS(X:4.LESN!Q8)C7GZW:[F2;WJBF M8/LB>@_:?1]?
M R8]&;5)R+$E97DYKY9S8(;KQ&)PTGJ_M^EYJ%/K=ZFE^XV^!R6"RW98Q522
MH*J;V&H3G;L1I[[M0Y\)Z6M[A,+(1BY$MB60PR*'VY%9WL;#G9E\\Z=)V-C(
M"@K\HTY@<0:2CJUQ4WAUSRB&@&STPX<:J]I\DF+622,&/TTXAL:PQP0'>YMX
M__^8UOL;^T??Z$<7Y^P_5WE1'@,\I)N<RK<XEGU=X)>XP,OR6BW9O59[QZM<
MS,WEV]NRL$Y]A58]4.:!6+@H$B$C"-JV'4BJB2)(7.1#[MF.%4:6XU"CFIEC
M"SPW0Z=]Q;Z=,<&,MD8?9CWRF]/@C4RAY[=7%V?@:(($.:$SKO+8JT1G97*$
MED[#\>Q4P _)UJ/+/"GG3S4"NRO'9/WV3-<C!*?2D[[\406;W.&"WTBY\B?U
M_Y=2@E>\5,+?<>E,Q[20,LH_G"=L^X/6DPOB$^XSSY<.L1^HPV8,,:7226;,
M"6P?H<#5*JHUHHQS6V4J%=76&*^5!)DJLU']7.:6IU*#*C&<^H%O=#%,RS/"
M@.LM/A\\C".O-YL1;/0#2D$U<DKHL_*_H"7[&=BH5?U1#>[N9Y<:XVR>FV>\
MD1@T*\\(8DZ;CV<\G/<R\8S85;^5Y2IYE:VDV9ORS1W+1]@C'G1<M20@VX*8
MH3(<B5HD0%Z$C+R0=N-SX_)&MG*/SWB#8PLV/6+M"\;(C+@6:^ ]B_?4'9)V
MMMJ?E"_>TVQWHK_[3,\L66GR^,"S9U5!XCLN5EFY$WK'ZZI]^8VH[]3BY;F0
M,^=O'&=?XE>^H!Y'W',MZ"%F0Q0Q"DD4.M G?A0X/(@<VRQQ5D]!YC;S'YZX
M=":5A(9)M/H.A!X_3 'OR%RB5(!*A[(LS1FHU9#44L(-E,A R3Q@GJT341LT
M]59?6:;-QG4B8GL)NDYMKQ\MUI6GOTC]5$XP=8+\U[AX:BXL;PI7JWH\TF=_
MP#\6@86<R$<AM#R70>3X'$8AL6'H(<HC+"P:>":,V$.&N9%A4\#;C K[@(\%
MM4-7+D*1"%5%$<>'1& $";*87(N8$X:6V;G:R/!/<^!6EEL$^.4EXS2NPKEI
MQEELNF/09TCT%J:181YY3:JE!XH(02,_^$,J !H-SL!:!] HH0[SAENE3H!P
MR 6JCQB3KDTGX+2[+)W25+\5:9W5O<[@KE:_+QG_QXHG]*V^AN)AP2B1K!<@
M4I;=L"'Q20!Y8''']GT7(62R FGT.;<5IR4I6(O:\[J/#N1Z)#<PD".36D\,
MC7G+ )4A>4JGVTEYR0"'71XR>;4?[^P5AZNO)N!';B\$XSY6Z;(EMZB$M4B9
MO!Z!/F'(BXCO1ZY1C'I79W-CFNVJAIFJ:OBREM:,:#HQUF.8H9 ;F5KV2T&>
M@=OCJ!E3BPX<0W)*9W^3DHF.YKLLHO5./_KXM,KC1)I [:KQ*A^<<"V&(P]#
M3&PDF2,(8$1P!$G@1T0(&U//Z#+R@7[F1AJ-F* EIU%ZO6.XZK'% &B-3!1]
M@#)FB2,P#$D0A[J:E!N.Z+M+"\<>-T^I><\?E87RE:>/&7YYBBE>UG8T%Q8+
M&2:0,Q4-S:D-0S?R5:(8['(1"(RTKA]W]C(W-FA+:.BC=*/9S0*#830R!YC!
M8Y1Z\ZCZIV;@/-S!9(DXC^K8SL=Y_.'>5R$DA[!//)$_%+=R?#_'.5VFREGY
MMLZ%S4)B!;; T$6N4(4O$(Q4WO/(15Q0%LI?C+;.M7J=&QO40H-::J#$!ANY
M3TA6KC<(>J;#X-".3"*#H-KG3H4^2@-?K]#H>.J;%OI8O'/IPN!E<XM$;9Z4
M;L]YPLKZ#^)-;=M6&<7S]Z8)=H,H4IGK?)M)KN*^@!&S7,@C)"AQ!(LPU[54
MC'N?&V?=7UZ IO+H&; =:$5G8*U5&<VXT:O)ZI^?QFK]ANVX233J8(S,<A.-
M@Y&-U1O/4VTO\XXGL\EZ8]*VU?HWTK,V?(&+<F=Y,YL"3(* ^S9T$&(0!9XC
MW35+R/\$%'M^0%S# N][7<R.Z1H)3[##W@%2S^@Z#9ZQN<<,&?/2Y >5'[2^
M^'XOTQ8)/ZCE7J7OPT^>MD=[D3Z3.*GO'3556*^8["D6L4JJ41<45]M!&6?;
MA<55U:QGSBZJ"_35D[<9?\$QJ\MKR>?+&_?5WQ;<PH%CJW-J%@0041' *&(A
M#(3O<Y=PGX1&>3,^1(NYL50M:U/*NZI(FE8IDNH<'=6U^WZ[S=-^0\SVLF<[
M[E/ME+< .&N5]09M#.H, J!!H?Q^M'  -1!GH(9BG7*@^6;5<)0O5OE,SKN_
M4+UWY3]D0,?8\Y]6D0\Y4?B0L3IT7O$QPO2](267!9X7M_A-259WNR"<>+X3
M.) Y-((H<@6,0LXAE08V\X2-&#:Z7?%^-W-;O1HI36]+O0NAWNIQ.C CTWLC
M(*@E7#/SD)>INC 8]EK5NSU-?,&J2]O]JU:=3YNG8=[+(J.R3JE+EQ6YU!N=
M"Q%2GQ)A01Y&D@!XR" AOB_];6XYA*$@HMJEP/6ZG!L9K/,?U=D\"_Q#]R*!
M <[=+#$.>N.?>.PECJIE7EMO/]5B:V9'-0!4/TWS\,!.E*[YX8FKK(<EH"H=
M4)HH0SD5K6]JXX"5*66DL:!" ^.4 6E(2$EX5=E6?1XWN6=^8KSZZ6=5ZT7]
M23U5O/WW'+#]K&FE^=W*MJC:+W"<E,VF4BK5PTK]ELJ_E'CDOPR3-]ILV#KR
M1VLV-%D>:3/%VOFD#=\<;)>F%9ASQY>JM(C*7I0O;"(P\WP$;8L0B()068^>
M!2,6""8"AQ'7R'K4[WINBTA+3)A5<LK)D0^P_W$(^]Z;%@,@^B$[#>T O5KP
M,HG6N#L"1] :V8T_U/M'^]Y'4-%PF(^U,!AW791+U*-<Y.1/><SJ5:KQQ-]:
M&8!=R5E8.!1R9OF2SLI,^%$ (\_%F&$:HI"<2&?ZTLR-X:Y;Z9=?JCS8)W.;
MP=CTIKMQ$/\0!MRH K9T.5OOK+Z-D^AY$%A'IDH#@3Z:/<VQTR#4'HWVX]C6
M#;"KY&55/,AFZG!@XH9.Q!T.0T)==5I/8(0BE:<^#&D4",LQ2U%_N*NYL6/[
M*F,I*E"R]KP/VH&P'@T.@]O('-<7,F/V.H[&D-34T=NDO'-<ZUU2T7CCQ+B>
M![6UN0BQ%3#+=B&W/ <B2[B0".9"[(2.S2R7<]?J%=-3-C\W9FA%K93R]0WE
MJ;#3F__]$1EYSNN#T3]Z9TOG42)WJAX^)FIG2[N#$3O;3_5,!!$G<<&_Q:]J
MOZF0HQAO3C2?E0/P7Z6!T1Q6;N4*8]3GC@@LZ%!URXJ&5#I1S))V@1-11 ++
M$\(H041_6>;&!WWSMITR''JL,1'((U-,I04LU0 ;/:KHD;/R8*+,>-M6:<3,
M;@. .FA.BA/$F397Q>FX[>6P&*#)GH4WELOT#RSU_I)FG],5*<1JV811WW'*
MXU?%UW_-I'@W0N0+ESE.R+ -_3)ND?@$ACP(H!,XKN=BW_58L$CXH]HV>S H
MIV$FAM:DCJI)O2?,>!.\E ^F4D##LAB&@Z!'FF-@.E'1BN9RQD;,,[!6IZI1
M4:9P ZH$WADH=9"P#UBHHA]V@]:=,!1AVC(2_?#9JPK1LYFA+N(VH2UJ@W_A
M8A='S$$P("IYI>6', JM$%JN'?$P\GSB:L6;Z'4W-^-O'62ES@9/O5N[A:L>
M6PV'ULCD]-YM6E5 IX;OH@N^ 2[1OH?*N+=GMWK\X&NS[VE__+[LNV^97Y2]
M4Q4%RA0SU/4=[EL!%'Z9^9LC&*$@@M0BU DY0<+6RC*XU>K<&$&Y['%>E*DG
MVCNB)KEZMF'K9H+>8$RP,]0#!Z.+HGMZGWH!=-/@9!<[]W1H7]C<_V._-5SM
M_-Z(LEC'BJI<V,EC??[ '&Z3""'(RWAQWY'+M\TYM(2/:!1R'S.C$YZ#/<UM
MGI9G$ZD 6Z+V/-\Y#*_>*CX(:"//YYYX&:_=1[$8<MD^W-FD*_91G7<7Z^,O
M],S96?J'7S M3YC+U2= JO*:):#C8@&1[7 8<<HD2P0!LA"S;=>H^,Y^%W-C
MAMI);D3LE67O'2#UJ. T>$;F $-DS)-O'E1^T)2;^[U,FVCSH)9[Z34//]G7
MER?%5:)8H\SWV^0 7EA!9%D1(I!R7SKQKO3D0Q=A&!++\YC-K< VRLIPH)^Y
MS70E&'A5DJF5;:G*Q!2J3 R3XILZ\^\#J^O%GPS7Z.X[44$=C8AGH(2NE+*5
M"V9(#[X3D6%=]_>[FMAG[]1WWUGO?MS\=IFT)7CVJG84+YYP]L@)IG_/O_-G
MPK,%94A@$A)H.2IG"XXPC*Q06@2^"*BB",O12EQUI)^YL4-+0/W+3ETX=I/!
M@.B,3 :UE."+.E'8R E^KR35-)6.H:5_'VP@U":Z!-8;/:/+5AJ8=-RPZGI[
MLFM5&BJT[U+I/&[.B]=IPI]?END;YY_CC%.)>/W]%-1Q DP<:*FX&&3;-B22
M$6&(+"?"%D66I[6;V=G+W#A171IH) 6-J/KS_3":Q[EQ$(Q&9L:6C&MT>M#B
M89CT27$0N":BQ'ZP&?'A43@ZV/#PNY-QX5'QVTQX_&%S'ES;F.?L/U=Y4990
MO*CJRU\EEWD1/^."YS>B3'#R955(;^"VKK386)%61&T4.M +I:.)',QA9(L(
M$DF?V/8=Y%A:E[$&D69NO-KR1/%&)<#D[^I6=J6:NM_-&^64QUKEYQ*E?J I
M;*E/,Z>/Z7'6GG2D1F;WEL_;TN8,U/I(_QBL-0(WHLYR52D%&JUZ+ >GCY/^
MLC'I>$VTO$PT;D;KT6 X=ZQ;I_<QV?HV&!SM=7"X1H>KO)C+Q5DNR:M,G=G4
ML]/%R$8!]J'+A0JA0AR&MG"A;UD.\@2FPL=F)6@U>S:9J].4G=U,U?+BZUK>
MT^LOO@<\D_\3N9Q"VW&P=.%\"B/*+>@'D1R$@" [-*H>,0+L$SEU:PE;YL<X
MF.OMB(^ Y&3&P?8W=\!UHR<X8Y? ?*_K#R^#V8&'3BG,KM?-G:?R3L)NP;60
M!J$3>@):*A!.K@ .Q(YD?1X2P;CK<H]I':P?ZF!N+%/*V+M\W4$8C[L@IX(S
M,G&,A(N^R7\J/A-9\7LX#6.(=VG?85N_^]IDYG*7T&T+N/.Y?D;M5M#1><+J
M9#_GM(A?JSRX)"_+FB_\@-HJWRRTPXBJ:^$$8A<1:6(Q[@G7%=@S2B:FW?/<
MF&\[9$XEX&O276UDEY.^EMXPTDA_//0LKU%0'O] <A" C2TQ8["&M,7T.Y_4
M&C/&9-<>,V]@L-QBF\DB/&9%S*40"R>"R/,M&$;<A9[%PB#D ::!44Z+KL[F
MQE?O):OJ3U"=,.MQTE#@C4Q#O7$;(G_7J%33V=]'9]\Z2BA:[YA[=>6VX;<T
M>7S@V;.*R*IW.)PP<!QA$^A[+H;(\1T8(N% V[/LP$+"M0*M8,J./N;&&*68
M^@[+(>2.^W(#X#$R"52'!TI$H&0$9>2D^9G/(8CTW;H!H)HL(JK.;9WOQ.""
ME"SCQYI'D[0 ?)GS/U2^%< 3*5FF[(*!LE,?@:O#%3STYF3>X!'1VP[AL4?-
M6)#Q>'%9)AN_?\;+9<.S"XI=&T=8!411!A$3%$;"#F'DNS3R(HY"&^LPX('V
MY\9^I7!RTLOOL<HZ(F>^7&E></*F-]T/H=C-A@-@,S(35M*!4CS0R'?Z9#VB
M^,;LR1N[)^?TE\?T]5?Y9F7RR!]V+9U#K4XRB8^HU$S@8X_UO/,ER35=QJRD
MV5OY$WU[X#^*3U*POR]"VZ)N(&T9BSKE)G4@;9G @QC9CHNQXP=Z-8MU.IO;
MM+Z5_B>-7Y95K,V6Y(:7P;H0UO. AL)MY"F_)>89J 0%O]?_*HE!*?*0=\8T
MD!GT]EA7?]/>(]/0?.]&F<X[_7BD-"UNJJ(AR6-5T:).O77-BP5V.;=L$4 '
M10(BA!$DR/&@S4,/(VX1CSH]4F!U]ZHU-:;/>%7Y"'6EES.0<,.S]B-0VU3X
M@64[$FI;.J#4]2'QN/R/PY#EJP*IG)F0]@ 83^V+C@>N'E\/!]DD[NI:TJ;T
MTT^UL#^?@>L. (W96@^7(?GZ2(^3,K:>]KN<K?E6WS*25?&HSW41J:ODOI!K
MP5.ZE&WDE_]826OS+ETNOZ39'SAC"]</F$4#55J2JRANWX(X"*C\E3HV=B+F
M4R.#T+#_N9'-U;H*U^=V%:[[)YSQ6H?_#BHM3&M3FHV+'BV-B/;(/'4(Z);X
M#=#@=Z4"J'48T-3LB=ZP=3#-1)BX0&8O?/8K9_9KIG]*A,T-]HU?QCRN3OHP
M#'QD0T0"E?$Z<B -/(N@** X,#*B#O0S-T+[<G5]?GUQ=?T5G-_=G5]_O?Q^
M>?UP;YX,X3U(]3AJ *!&YJ)R2W\C(OA]%,?V" Y#IT!XKZO)4R!TZ/M>"H2N
MQP<,V5]_^)=8&F$9?7JKLWLYCK1]0D*@+;BZ HP$)#9!T,.N15'@>+;0N@+<
MJ_?9,<?FELU:TC(6Y_K\/WKF53,;#3UZ&0WCD4GG-'B'B3$_!M/HD>8'!?CX
M>/-CV&A%G1]MI*>-$^<O:8Z77[-T]2+-J^6*J8QQDCVK<K^<W33%?N_X*Y<?
M+*C++<L*& RI%4+D40(CX?@PL@)?.!X+Y?\;F3_&(LR-WVJQ5!WEE,9E=.$?
M<?$$7K*4K6B1EPG66:VFH<%D/CZ:MM2HJ(]M9M7"@U)ZE2RZEA^T%0!K#<Y
MK<. -EAO_ 8US\REF-9RZXW2GE'7OR7S^*VKY%7=IJ_B2\A;\<3+<DNID,8D
MSLN?\^^<Q13'[#9+'S/\7 ?AV"I=M<^D;R@$AHBYTNYS<0@]R_<"QX_"B&A%
MMI\DQ=SX<4L10-[*4O2E_.KXM-3FK/K]O^>@T0C4*ND'1O4?M6[*G&PL1M\H
M.V$8>@2J]1\/_5"V2<9EHF"WD<?'*.;M9%P[HN+ZMSU9W-S)ZK<CZTYOK%_2
M1N4EG"?LLUP.E^F+^@+79T.WE5U:WYY8$)=&-"0^#)EG0X1<+M<LFT//\[GO
MNHXC(FJ2Q%&SW[FM4K5T(*LO"&6U*J4KS3;*F.4PU!V$XTO02-".O.@T4@,I
M-FC)#2Z;8_@&]UKV<> U2QDY LP3II <!F[CG)*&H!W),:G;VJ0Y)PU5W,U!
M:?IZSQ+,?"G_^OB5)](?6LK^SMESG,3J4DL1OS;Q 4W^)Y?2R!,HA-@.!$2^
M*#>J'4BMP">1;=FA3\TRS!CU;S*%ILDS4XM_!AXK!4KZQULJ-"%$AE4)S09&
M;QMG-+!'7A;6*']MH;PM>T-90^;7.@FV00M,&PDP;?WI/MCLE:?NU<@0I0ON
M..//+V40*\_BE-TDO)Y1GN];GF59D-HJ8IUS"DD4AI#;W')<.Q*1Z_<O97"P
MW[G9N7L)^S>22^N@E!U(X4^I<G!X#/0/^@=&=HJ#_^.@CD!EAEB-5Q_A<-<?
M6"_A*![=]1..OV[NFM_S)$ZS>Y5"BK.M.B[Q>O'GH2V\@$I'G%M<4I4G(/;E
M?P1%KHV%;1%7ZYJ<9G]SHZA*9%#+#+:+"\6Z=I<NV,==[X$A'-VVZD:OQU:N
M#HSZ+O; <$[D6I\.JY%+;0!2ARNMT\ID+K2!2FW7V>2U?A;DUS1E?\3+93ML
M.@HY$R%S(;:PRM5 $0QQ&, (6X%P/(>ZH=:N:$<?<Z/=*@.N"IY6)P\49]E;
MF37I6=4/5V<0C[4.9K;A>^CJV8$G8C8RSS;2C195WJ'^D&;<>]U,:K)UZ+EK
MGG4]:IZAX%PN&ZRLD[7$CPM"I1OH<3G/4<@@$A&!81CYD/@("TJ0]!]MW=P$
M6RW/;9ZOA0-*.OU4!-MP=4_ADT 8>>)JZF^4=^!=74_(.+#=WF2Y!MY5HYUE
MX/T'>NY4TR?.5DM^(RYQELBE)I=>5GE!ZA/.8ZJVRN/E2MV\Q639NBW@VW;@
MJ:RX@66'$-'(4<&'#O2HU-:AMD^QUD0]48ZY3>M&#;524[RDJV4522!_Y;5>
MX*=EFN<_@Q>>@5PI:+B#W7/ -/>RQQ^&L3VOU@@T.JC=G^K6WQDH]2BWNFM-
MP.^E+N/D/S@1ST&WNWN*,NW&]VEX[6V!G]A<3TZM.Y">4OJL-ME+#CC/,F7:
M*][^]+9YI*YI<:[,J)MRFRO_*A\L\JMZO^N:%S="VEF"QZH&QB8[8^ '%A<T
M@#AT XA0*&#(N N%%SEV:-M<A$9),*<1>W:,K6XO@K12P9"*IQEG3>:>W>B-
M3?1*&TB4.J"M,FCIK"+XVL_5>H-2\3-0JWX&*N65UUVI7^954"M("X)14H5.
M.VJ#+B?32#[MZC/I:.PM5M/VWO,*9IS$!?\6OW)VE112LE@NG&4B^_P[_L\T
MNUCB/+^6T[:^]H>]@! J?"@$\R#R0Q=BA#$DD>V'EL.((XQJUQOV/[?5IA(?
MEO*#C0*@TN ,E#J 4@F@M.A[-=-PE/26F!&Q'WFM&!YV\RN;_< ;]-*FH0C3
M7MOLA\_>Q<V>S?1CP]]4&:+T,8G_2[D0/S[QA(M8<;#* B0_N.4)7I9)\1,E
M#I??Z>*<TFS%V8*&S&6!2R$2C@.1)$0HO\888AJY4>1S$7$C\_T$6>;&DFU5
M0(%_ %(KLPX,+U)IK%4ZE+[\2Z.<&4^>,GYZG#G1J(S,GUL#(J4&C1YG34HR
M]>%:EW)(&FU K<YP5#H ID/2ZBGB3$JQ ^"V2[=#-#E<+I"_QL73;TE*<IZ]
MJ@V=J^1E5>1W7.$3+^,J5?E=4SA.;0'EWV),U#'V6]G6@C",_9 ZT">$0,1]
M"Q(OI%!:L?(?P4(O]!8OI8%]7^"LT#1:QY#5A!YV)1Z/*3YA^2OE9Y*R'^-$
M;;DI-[KJ__3T(J</L'!M3I%G01'(L46,,(@%LJ ;(FXSV_$Q=>H!ODS8/]7P
M-O).,+A<\ONLAE73@?GH@1K;S6E5.6VI6&7":"L)*BW!MIHJ8K:IBUHJ>@;6
MJE;-CIO!9K"A&#O3S>F"?GA&G,&PULF<,UQGO9/HJ^2L4A*583MF=9**!]E:
MO0$2N(Y'L&"0JS0ZR'49#+%-H>/*?T1$?4N89M+O[G%N+M=&8+ E,5 B]]R%
M.@Z['FT/"N;(%'PBCGT2[.MA,W"6_2.=3IUJ7P^#=_+M:[XX:#76BS0OI(<D
MV:[Z><$)LH5/!(Q\1B$*.8=AY 10W88*?(<YODT&J,6ZV^_\."@O#^$J"0<I
MM+H'M1[CC #@R+QSN,BJ$K3<IBG%+G\=O<3J(: F*+"ZU_4<RJL>PD.SN.K!
MUR>.3[E>J4#_&U'^-3]?%4]IIG9^%M2-[) S5]$6AL@*&8Q<YD$K=+#K68%P
M?6^24)1#$LZ-ZK[C'_'SZKD* ,P!7@L*?HJ3^M.?)XI&.3BJ(P>>##%6\X\Q
MJ;14NR65GF"CZ S"2(Z-P2PB1@X*^<\1''(,X\'B0(YV=&J(^-UZK_^*R4YC
M$7-6G:V>TW^L8KDZR36K\=S5IG^>KY[W(I&#@&'JJ(*3%O8@8J$#L6^[D :.
M'S+&/&88MSBL?'-;*LI-O5>U"U)6NL.E/@#7"I6FWG*CDOJ[TJEO4/DP0ZRY
M<GS<P(V];K2"T#>Z@8UR=>0).&\/8TM!4&LX47#ZH/B/$[0^C(@?%,P^*+Z'
M@]R'[:;O7FOVDJK2S]=I<L\?U>+47$[WL&T[OK23'&%!)+P0AKXC/04?(=\/
M+$\(UVR/]4!/<V/PM:"FVZ>'D-3=-AT G]&W2VL9I:&<)K 6<X04+4?!&'9_
M]%!G$^^+'M%Y?S_TV L?N^'PBN.EXJHO:58&.R]"PFA(*8&6&ZDR4"I!@,L(
M])F0I.(%0>B8W4(<2="Y,=+&*6TV(!J)RSH)8J5"QL&C$OWC-R3V1GW:?8E3
MQO*?<7MBZYM0:CR_?8I#8S+'[8H]6?\I=RT.(3[6YL7!_DXH?UT''K8,X NU
MI2X9!1/BA=CUH>6%$41^9$%".9&6:A11SXN0$QD=_W=W-[?5H)2V1QGFPWCJ
M,?1P*(W,LU49YEK2MIM^!FIA!Z[!?!24P6LP'^YQ^AK,1[5_MP;S\;?Z4<>G
M51XG/,\EGY$XJ:O;[/K9>'W+I-/35F4($CG^;PO?L3V!K #ZD1= 9'D1C)!M
M03?"W.,A0X(96:ZC2#DWHFH$,[[G,<X8ZK'<AX_,R.38Z =:"IZ]M^N)-S?N
MCNY[JH"%6M7AJ'74D1B2D<<1=%(B'Q7K7?X?M[.^L5]47364'=-2H"\2HO.4
MQO6BU+JD_8!_G!=%%I-546[$IK>X-*)LX1$NN V] !.(!"$0^P&#%K<MG]FA
M@QV^2/BCBA!Y, D..U$P+>Z)*N[9$V\\'CJO4B1F:_4DNZCO)<"4KIY753!4
M6EIR5+HF&7^2WHG*<:_2,:G;A"E(J_)UR:,J/+.2$]4T!NW4(==;4:89P:GB
MUK9UJ8;L_.;B:FU;[^;DD$J=@;9:ZC9HI=B0@6T#83QLR-NI0DT<##<0AOMA
M<D,U;,;M5#&,-/PN[Q<VLUS*PP *6R6J#+D'2<A"*#P_LCU& EMHI:;=-#DW
M8_O^!<>)'@&V<.EFL'[:CKV+>GM^=7TZ<^SKUI%ZLGZXFOKU+[NSOM7@)--V
M7X%FWKWSEWY&D9R3%SA_NLW2UYAQ]NGMMUQ97#?-NGM.B_BUM,86R'=#XH<V
MY P[$#E! "/F^= *P\#Q0D)LWUD4:8&7>F:/?M=&$W$MP(B'-7+9HU)T5<NZ
ME%UMZ6],%;P6W,Q:,1@+/;-D'(1'GOP*7"4UN&V!^Y.27)J$/X.U\.#\.,S&
M1H8Y8D-:$P:]3VHVF*.R:Q_T:,$\<?6E]"J+MPMI361X>94P_N-_\;<%B03F
M%J:0AD1 %%D(AA3[T';5 0/Q(T*UKO(<[&%N9D(E)*BE!*680,JIG]+Z?2"[
M.6<0>$:F%F-DC))==VI_0M+K]]N=+/EUIUKM)-C=#PYZ7V]#%ZK6_3)5UYHW
ML:[$=:R0119$1-@069$#L1 42N? D=/=(LP5 US>ZQ1B;J1P=WG_</?;Q<-O
M=U?77\_ U?7#Y=>[\X>KFVMP?OT9W%_>GM>_7MS</]P/<M6O>Y1T=U;&Q7[T
MS91#EP W&H"-"N#W4<**3P%Q@@N"W7+,X;:@%E*:5P?UVCHQ!=.GMU:RAR\9
M_\>*)_3M_$><+RA# G%.( NQI$@W\&%D10&T?4\PU\5,6$;GG!I]SHT,VYE8
MUH*"WY6HIFD]-0#7([J!81R9UWHAV#\ES7%,1DDPT]'MQZ2+.8[#P>0O&J^:
M5VW\EJHCOCIE WV[7>)8G>R)O(H=2\77+%V]Y*E09WBY'.S\EB=,/KT(N:NV
MD7PH7")M-(95TGS;DU1D.82@B(M NY9C;RGFQDN;T,_'4F+U4]S(#$2\;':7
MU'F^'$FII\JSJ531KUK8?\RZB6RRD1B9VI0.H*7$&=BHT8[._;H>HK4RJJCM
M9*.A7UERDE&9J-[DJ*-C5(KR9%0["E3V;WNRLI4GJ]\N9GEZ8_V.#;]^6@CF
MA,QR0QC9G@L1Q1ABX5J08$P<RT,.)\SDV/#KI[FM*K^I_-L,_"\)%TN?S<X/
M)4!ZYX=F:H],X;]=7SU<?@;_Z^KZZ^>;[\,=)&Z4'.@@438XZ4'B1H'=@\36
M7_JYGI]Y%K]*\G_EK4+A<?[WT@6R$"74MRAD=BA]SE#^)XR<$!)B^0&WJ!?X
M1C4GNCJ;V_3;R HVPO9R-CLAUO,RAP)NY G<"S-C]U('C"']RL[^)G4H=33?
M]22UWAF\A(UT6]=%(BHJ\2,>(!]+*I$((SMP8(A9!$.Y: <^\4*'&B6V,NA[
M;LS274-%'9NWJZCTVMXR&!C-;:YQX!Z9CP9%>LA"-8<PFZA(S5[W<RE0<P@7
M@^(T!YOH:Q^)..&LKL<@/9SD\L<+I](RO^/%*DMN$O59U?4""63[(L#0):Z*
M940$8E?84+B!Y[@JHI&$/0+-3630FGW3QY0W H.LE!BD"7B1#]1)F$SM*8,A
MT;6O!D9X*GNK%!O4<JL]E>0,K+&N9 <_?2O+)$O(U=]K\AO2'#/';ECSS*#_
MB<TU<V3VS;<>;9B?"%P*P6EE)-8%9^XD-6PGEO^Z3(F*$&GX]EOZAWQ.,;!Z
M18F5Y+P6M+I#LK"P(('K!- /"(6(<0R)2QGT<!#8D@\]CH4!(8XGZ4QI\V%3
MLJM=L:O2KVW12 U!J6)31NJGKU??'JXT$XV,^ TX?OCP@0,Z4?A:HV"[Q)?2
M<:]JR/%QK=A=*@M^JM7]^0Q4&G_X4.N?;'S\D$]T[/'10V]T,C+NJ'0<FXS4
M\61G*N,"USYP&;FG4]/:=KAE.WE-*65N:#,+>HA@Z2DQ"@G#TK:S!/6H(#Z6
MGE*OU+7:,LQM6ZB=ZE14&Q?+<N,BWG!"'W>IS_#H>4TC@S[RLMS&^\A&T32Y
M8XU!'"<_K+X8'Y0#UABGPWE>S9OJ1Y&W64HY9[FZ7WO_E&:%=!Z>/W-2+ )!
M;>+:/@R<LN #]B'&O@=Y0+!MVSR(0F1"A =[FAO=-8)6]]2+)P[B/%^IJHAY
ME4Y1R@ZE(,^ 2>G-*.\PW'K$-@B((]/7-G[W&[@^=\%E3$]'H1B2A YW-BG5
M'-5YEU".OW!RC&:3U>\O'"^+)[7GDW^)EYQ]PW_DJ[C(%Q8FEF>%#K3\4)5"
M9SZ,0D*AYP4N\[C#':J5%+I'WW.CEDTXV5,I<;G5G*MD)=+EHRI74AF+V3O:
M[^A8'-_T&!'AD7EG/Y*OAOM&@$K\<ILY/P.E!J!183RT>T=4#HGZA\51GHC^
M*;&3NOCI1TP>;?&CXB1U5>V(CM1NHJ<7SI,XS:[3@N=U<GLB DY00"!R/217
MA(C!T(]\R%W$. VQC7VC^Y1[/<R-]RL!P;VJ?RN_^Z6DAK[R'HB:GO IT(SM
MYU:HE,*-4 _@H.J#>J=[G4SK>Q[2<<^S//B@V:3.LV)Q+]>2\M;/5YX^9OCE
M*:9X68;L<)\B8EL,^MB5IIXM'!B)P(;41]1UO0@S+]*9V)V]S&URM^4S"HKJ
MQK)[?@^&T,ASW 0<[1FNI7S'+)?OMV:X_&UW=G=W,,D,U]*QF>5Z#_=;OC<;
M^EN;^1=/*MW[5?*9"ZZ*EJHT;.7VE+H<6&6$7R[3/]2VR0+YA#NJX#J)? 91
M(&P8VB2"S/(<+GSNNL+O$7UTNF3_7(?K\D>.\W);^+51!>!&%S-[8H!1U3-
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M7SUDQBW]P-<CG=$A'9F-E/SPH0D6/0.U#F]G0 D+E+3#T=%)8 W)4_T$F93
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MO/JDLI(8_*%E!H70MM?1ND W,W[[A'+@)>5,%.VOKAE"T^M%MJX^Q[W69HC
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M$:0QI9!2A&(N(^&'D5V9 Z-^IT:6]54K_4V 6G#P4TD.:M%-]K3.&@HSQAP
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MV)"USUO1W8CT>R&ZI;^1[T)W:WYX#=K@'>=2QLJ8?2!_[4MH[?PSRKTPB&0
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MCB".:0H#FB8HE8@*LV2"K;U,C6LNWUS3_U^6H?5'<31S6\]&9^ 96,HW S5
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MBB-ONEK]6>5')YO-.J/;ZNKXNOEY\,;GL5J"I?BIVECQ+=N4:B@9]!1]%1M
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M=AQ]C%WRI%O9O,]1E#01Y27VXL9'<?FGNONS3WP:XRA&81A!Q'0^MQ!C2/P
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MN^QDYSB&O4YV+L9R)"_U[,LXW,E.)T1V)SO''_$S3G8ZC3EQLM-]3U]GLHG
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MHK;8%#E9RK\V8/-#+KY+\+1:;KXY1OGT&T,[BAI\9 ;FK_<MG%\-D-FG:VP
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M&!&128&2*(GG2_EHGG-^(\5>L-4WGE7?>%O\@&<M0N15J*]>J=+ZF&6A12]
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MYCXG2B3J3B^E638'@%U!TT'XD6X*_@"^9(\,5-J:\,D3<;0CXU.PF9AX*]5
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M2(L_UQDK9%ZM[Z[63YO2M'-=FY.=:DE7]UC!(4<1]Q!DF'L01QZ'"0IB2,*
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MJ(A9!/THX!![)EY72095C(E'J0QI8+7;92]R<5RTU1K4:I\U'=7,[D>K^H#
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MO^N*H7\,)EP^'!$\; (TYRY7ZZ+,J^S9"YKGSUJ=\T=3%.X.!XR@D(:0HU!
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MO7"C"21,,2BDBCU?:::+K6)$#TI8&J_ME*QV2QSX[6T CW/<R;!,ON1ZB<@
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M[HO^Z7__M_8W^C^,%O)__[?_#U!+ P04    "  /B6-1G[]2,VWH  !"<@H
M%    &)H8RTR,#(P,#DS,%]P<F4N>&UL[+U9=UM)DB;XWK\B)OMU/,/WI4Y5
M]6%05"3/*$25R,CLGA<<7\Q)=(( "P 54OWZ,0? ':2P7,=U1<_)2(D+=*\M
MGYN;N=ORK__CZ_7HIR\PG0TGXW_["_LK_<M/,(Z3-!Q?_MM??K]X3^Q?_L>_
M_[?_]J__%R'_\Y?/'WYZ-XFWUS">_W0\!3^']-,?P_G53_](,/OG3WDZN?[I
M'Y/I/X=?/"'_OOA'QY.;;]/AY=7\)TXY??[;Z;\HCO_36A(5DR12.D6\D(D$
M)H%&KKPSX?^^_)>8008-EEB 0*0VB@05 U%2:^,X8UDO'SH:CO_Y+^6/X&?P
M$S(WGBV^_;>_7,WG-__R\\]__/''7[^&Z>BOD^GESYQ2\?/=I_^R^OC7%Y__
M0RP^S9QS/R]^>__1V7#=!_&Q[.?_^=N'\W@%UYX,Q[.Y'\?R@MGP7V:+'WZ8
M1#]?R/R[=/WTZB?*=^3N8Z3\B#!.!/OKUUGZR[__MY]^6HIC.AG!9\@_E;]_
M_WSZY)7!WR)!5^!'\ZN_QLGUS^5#/]]IV8_3R7@^G'\['>?)]'I!,7*Q>.K\
MVPW\VU]FP^N;$=S][&H*^=_^$JXB*=JF3M!"RG]_\W$_/Q!Z,X59^5CY^0?\
MP>JIA:1.B8:O<Q@G6,KH[N6C27SRH5'1T&1Z]R]'/L!H\=-!@N'@>(*+YBC,
MYE,?YP,5)/>,<A*R<T1&P8F-7A)& W"E- AIGLJH<#-#=A8*G4'\Z^7DR\_X
MX)^+X,H7"PD2RE;J_.\O7KH4W&[4WXGJ C\[H#IE$,*1+,$@\2X1A\N."&V-
MM]%08*H#XA^_\RGMC]5^-(T_3:8)IFB,[E[JI_$%!)XNA-4G?K[Q4WP0B5?#
M4;K[U\4J=:&W^:0#^2V5@^3^Y2?D.L-T"NG#4C>O,K?@;(XF&A:?[$+O_W'K
MI_C$T;?/<#.9S@=@$[<B.6)%L$12HU$BR$QD64C(UFOP'4+@V>LW0@-O'PW[
M2+418'R"Z7""YC.]P\U]$ Q$R#P1ZA/NNKC]$:19$9D4LD:!:\,ZA,63EV\$
M"M$^*':7:".0N)CZ\6Q8!+^"=90N>!>  (! 'H(F5@M/P'LE>,SX=>YROWCV
M_HV (=L'QEYR[1D;2__J_7 $'V^O TP'GAOIDT>OW').I)> PL ]D%%TYAW+
M)NK8 2:>OW<C+*AVL;"7')O P&>X'!8AC.<?_34,7*"12@TD $6KIFP11);$
MY*"-STGGD#K#P=-W;X0%W3H6]I!G$W@X'<?)%,W90O#G*'\XGMR.Y]-OQY,$
M V, L@Z!:(;!N_0F8T#/!.$6=**>:ZMD9_!XDY2-T&):1TMWTFX"/$<IH2)F
M*QX&0M*4I30D49%1-I1B8)4=<9(9D[F5P79G3)Z^>R-XV-;AL8<\F\##A?]Z
MFE!>PSQ<GI:M=DF;J6&,*Z*42D2&:(D-5!*NE7;1<.8!.@/&*T1LA!#7.D*Z
MD' 34%E!??77A^$8V("!\4#!$D61?FD<$%^0#RPP$ HM8W9=VX_'!&QVRD5;
MQ\B^HFT)'\?XY=GT8O+'>)"L29"0<*D _[ 2G6Z&KC;E$,JYG8BQBV//5UZ_
M&38:/@+M0JPM(6/A/9U-/TTG7X;C"(/$<XC%6P)E"Q\F$)>4PKTS2?2K8@#3
MG:NZGH;-,-+PP6AG FX)*)\FL[D?_;_#FX6/39ED#IUIPGV41&IOB&6!$Y5!
M:Q.TY(9V#9,G%&P&DH8/2CL2;L\0*1;P: I^03<^/.E@([I+B2'=N#&Z(#W)
M40J(V4:C= >@>/S.S6#0\+'HS@+L6?'E(G_TZ6HROCO"4\QHJ13R'I+"J)L&
M$DP*1!@)*G,=%.TB:GW^WLT T/!9Z%Z"[!D$YQ!OIPA@QL/%<#Z"0;9,)J<#
MR3P8(K-'(0#5!&2*W*68G>[B0O7Y>S<#0<.'H'L)LF<07$Q]29LZ_W8=)J.!
MRYJ:8"C&12RB"5.VN#>29!UTC#KZ[&P'"'CRTLW4W_"IYNXB;,0 G'R-5WY\
M"8O#>\:M52%3(D2Q8B(GY 3=%\@L^0SH\:8NCJG6O7LS)#1\@+FW0)L(&8YO
MIT5<RPO> FS4P>ULP+D%E=">H25#]R8Q23R+GCB=3<X^40%=Y%6\1<-F &G^
M_+(# 3<!E-,Q/@W%,?P"[_S<K]@:),D8ACV61,\M6D '*";TB(UQBFMCE E=
M;")OT;!9<E;SAY@="+@)H)1<@>FQG\/E9/IMP+5#L4@@66&4++6.Q&7TCA25
M+I@@J;7=&9(GK]X,%LV?7^XNSB;0<'[M1Z-?;F?#,<QF P-<<!ISX1U]9<J
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M875H7!M91$V2"F7TG94D!*I(X)SGY(2BJHKW]#I)_5YY=8VDCD3? (@>,3%
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M(:B1;:X;$]:)U!M!SUDN;5 ?>X_GDU$:4*HSURR3; PETO-,K'&1<!.U2:#
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M7$0@J,V,<R[J=&38@L:^VRYT"K9:NFD =@^.WUV"TW!\BXMIY1E.QBO6[CN
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M\4DG5Z7N>=M[@NJ^7P6$O'&'L(W8&]A=-YF5M'9(Q++W^\,87W0;! ^.!.6
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M&'G+%$I_5H\R8BX$"1085&D7^2I%39X_'\*$[:Z7]NX_MAX6ZE!LVEL@PK*
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M*,9LV= *IE]@=H%/65RMYFA%L"Z2!![C*=Q;B'<8PWG<9Y@S/E:J/-J,O"9
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M+AI>FXW0F;B; =#Z;)T FD&)A:B5E$B,A4B0FB,KI98OZ*CE)A>"7:1#]9O
MLC]D]A=P,UA9Y>*L6%!,)>8I)UIE= 0B^@!6,DU,=DDZJGQV.V4];8&-:L=O
M!\+&[@)M!A/+FY7@XS_OV.",)R$-(T9%2:2*@EBO R+=1NY\,%YNF4KY_!7]
MGG0=RF[L)=AF\($[YK(%!0KL/=QCW=M$J=&")!4RD<EXXIW1R!5%GEP.S,AM
M79,U[^FW;__AG))]1=QS(MNF$>C#6;$04J!X$C'6.8(!:2 A0IFB1ZU13FDC
M-RD.Z/08Z<-6226=^S6'">7KJZN!B/ZWR9=%$Y_3\=M+^/-D-,(%^(>?IH%D
M"ATW04GBY3:!@2%!:(\++WHEC9&L3@[4#K2V?]2T(W(FAU5C TC=[**6)QF<
MDH%$3W$K$)$B4[C12$$U[CH\IERETT]W%^W5#@ZJ8V2GF_5M%+8S"F\6-[/G
M<S^='P"+=W^?Y5]N9[B\RT7L4?S/VR&2.\CH\83 /.$.'5KD$B-A$32RGSFH
M;'2P_/  ?8OD?L\NVD)M9ZIMWJ"^DD=H!0 3+A,:=9FP+,JAGX]$T,!%I@Y\
MJI(E4BU+M-K!2EO [4"=S4/V'93BAY(',4!NJ*=&$.$DB@^4(UY3("I8C_&@
M$JG.B/9-">SW7*<M:.ZHMA\M!50&EIB797<H34]ECL2I$(A(R0;NH[>JASOY
M;3S3:J=';>%Q%X7MZ9F>C-.AT^:.<,E]&<XQ*+T70IY,E]5='R;%K^DR<V[S
MMU5,GMN1Y0/GSUEJE$^!$0R*2KO/G!'8H(BA-$3' R11I9SA0)VF[D5?CG,G
MMV&>;T=W[LA#@[:RTO-JI9MH'--&D>2$6M9^A6PS+GS OST'6J<P:6M*?XR\
MNFWP]:*]?%7E->!@;L;@P"L54^F<STS$+2<$1;S0@AAG.14E1T=6*>?8C+R>
MIY?6Q<A.B-Q*8;V?,I4[KY<\+*L)SO)GF$\GLQLHFQD\JCZX[W[Y<OC#@)K$
MLU2*:"E*^2Q'"6NMRAV< Q$5;MWL.WMZYT3U>ZQT&)3VJ\D&[.E]:<(:,0\$
MYY9&AVXU"P(YR)0X[QBA$$+BPAJH,RK[+:+Z/3,ZK.WL3#D- &TSR?UC.IS#
M6<ZS@==*<%%"NN1+HH!,Q KA""^^4) J"U,E27E+.OL])VIQ*]]-A>T<%FTH
M4XB3+^A.P&R0E1/)"TH8T^BO)^V(C1F(9C9 J1ITH<J%T;:$]GN$U")4=U1B
MSPEM+_EXS"W^!\/+\<G7N!CY=#1.BPN%@3:&,X5L\53&ZWGTLFTRK(Q( 4>I
M9!+,3A[F!B_?"'GZQT;>833SHYG)04K.9PF!+#8"](N!!*<3"3+Z,KS;.%ZE
M+7N'@;CYL8%946&M'ZH?'?_'[Z?GBZ/E#Z?')Q_/3S_^>O3KYY.3WTX^7IP?
M?7QW='Y^<G'^MY,/[]Z??3X_^G"RPUGZ#B_I[ A]7P8[.CF_2[4XGER'X7C!
MR^S^.%/%""QC="*\+(!"RQ9BDD28$&Q41BI1Y:;W+:+VVW[_\W:X[!<Q^S",
M96CG^/+H<@K+68NE&FLV@_GL;S!*N-3._0@>D@EG#X--I%2.NQP(HQD]#A>!
M..THT0#!LJQ-?CXUZI4-N1-R^CV2[ Q 3W?CPRNJY0DTVQN+G0?![?RJ'BUC
MQ4%R;\*;:R&!9T$PP@BE&SDCEE-)3$@YETF&P<<?Q3[>/?MAX%,)L2['P_^"
M=)I0F\,\A-6RN\O*PW7X8>C#<(0K%6;XN]OKTA/GR1 HD2B3MF2<:!#%1>;$
MT4B)01\EHQ=DA:HR?Z%C/AHVLMN@\/7Q7H?7]I_+X'8P$JR#E_9HA \R4NS-
MA:"%\(Q'2[@'0Z1(Z&WX[/ /)T#(1!.M,BGK,.;X[BV/?:-?OCWZ;EF-Y1*/
M66I-P*0R"5P P:<J0G$9@E**IU0E:M^6T(8-ZC8X>MV@5M!7 W=!:[A:]%7Q
M(;FH94!S7RX,*$CBA: $S7Z4R3GE194,S%?HZ1===4$PZ5XCC0)KZ7C JL19
M&<="-A[]' ;HY^A4&NZ7&KYD5.F/KT45R_9=RMHP97OI?P-,[:Z,GB]=SK^-
M87KY[=.5GU[["+?S8?2CV>DX_O6NXT[.3 #C1&>&#G3,%"7%64F/MS9P_,%&
MK2:^]Y[V8+*'2B>5Y-OW!5V)>)ZO))F%C2H98J',]P@,78$D'?%94QFULD*D
M#?"Q[MG])FH=9)_J1*R-P6*U8M"&>@A4HQ!\)M(J(-8)3Y17-&F@F@6U S#Z
MW%6ZT=8;JM]!='TK?S2"R^GD[.9J?N5'U\,X^_#A>&7:F(6@\..$<T VE"BF
M362B:%0Z**%>I-FM1\#KKV@'!KMH;M*]&!OP5=\-9S>3F1_].IW<WAR/_&PV
MS*O\TL5: :[03)8YTF@8E\UX7#"\W/7B*C(JL5"ED/<[=/6;?WG0H*A+#;4-
MN/M5B2Z6RX90RQ*11C 2RB&PT()QG323O,K9UW<IZ]?K[10'FV-L!Z6TAK)R
MM9HG4_P6/D[FBXZE)6G^%M+9S:HW_GW'4N^YU+2T"./()DJ1!&\U28)J<-J;
MQ.J;N\WI;1:1NZ#F+4Q64F$#2,7@<G(-YZBU14+ JJKX_ K081FGHY06VX@?
M/4H*^.7;$]F4^'0YRV.]7):CSV54W@9-!%VX.C82S[5$G>#W@BL>GP=^W0#[
M,.SUF_]^4'>@0;PTL(JV8O"CO[X[*!+HJF>=)<9^DA=C@9J(^%4PTD2>8M!U
MFM#O2&^_]KY%Z+VU:53"0<\Q_#%,YTCRW0S?9;O3!=/G<#-?[($7?TPNKB:W
M,S].']$>S0'NIL)38V3FUI*TL#P8F1+G&8;Q4B>G.,,X>)/SX7UH:,AGJ060
M20_::F/R^M,!XZ7X3Y<9HCE"*HGBGGB: J'.1!$U"*8VZ0"ZS=#U)P3T6VMT
M$+>@$]FW@9TUX\BU2Q@^9$\@YX + )D((DIBO-.1!D#!;-+D9!L O:2B]SGM
M>RCV)4KVE'+/F]^[X1=\SB*C[XZ?<[@LWLA=2W@NG7"1$\U*Q.G1C0A1H=T$
MT.@YA&1ADQ8&WWM/[YC85XV32C+MV91\AMF=>[I8+#HRJH5.1%L (H$%XC6:
M5(%?2LYS=M"9 7GV[G[+#0^V^>PC\7; LEI"W"D =*Z(\(P2F;TB%D(JU_L9
M:.9.;U3NORU<^MYG]M+A>BSL(-!VT/ P;GQE 0W+@49TQ%4TZ/U[QHE53)%(
MO?2&&@[2US CS^AH B&[:/85>[&/F!LX=%IC63_<M^D/PF'HAFQ$6687\03$
M(0VH;,FSHC9$5F6^[5M$]5MHW'<JZ6ZZ:0!GG_RW1:W@Q625YO;05/S7Z60V
M&TCA#2X40;2PF4CG*;$,T>%,SL@/RTE5*6[]'F'-I0GN"('G#9&ZU$<#^%I3
M08"!P/O)]-J?CG/YJ_QHU3BR=!U;YEJ>#\<8DCY*JD&S?A3GMWXT@*ARF3]*
M8L@6!> H\2X&8HP%P[7Q_GDV6;7RE?TXZ3>IL1J"^]5XSV<(FS&_.@4>7RYO
M/4KCW^?LKUCG%'<BB[P&QI%U+37Q*AC"(X;-.7)-S2:)<QV3U6^&5.?([5MQ
M#9GIQU[3'?^KI3I@AD<?K"':V81>N0K$2I$)AY+QRA/EH4JOQ UHZ_>.OKHI
M[4HKC1C'1^S<<;-F80T8Y,1" ,*28T3*8%%R*A&=F+8N.FZ>%S*]:?LV>VN_
MUSI535L%L3=@N18=QCY.QI.GK)Q\O8'Q# ;"\APX^@Z<EN4AI"6AU'@E4>K]
ME4Q954FZ>YNL?L]OJ]FK#G6Q;QNXO8W5I\F\]'?PHQ=E'I>7T\4[/MU.XY6?
MP:?I,):NR#3G8"+1/F)<ENFB$+HDRPJTS]Q#,IL4N6SYVGY/7:J8JYJ"[WD#
M?)6UWV]0N./Y*OA?9HY .GV-9>VIPXT^DC+$G,C$%HV1'8D1?-3 )>-Q'ZQM
M1\Y&&+1_#@Q65%2KV'S(O7M_.R[Y3)LR+[V)-$M%N%8H?&EP82K\0VLC4QEH
MI#>J%^Z<L(WPZOX<>#V(\GK/VWB4=O?QMMSVG.4U27$#7(L>G5<,E8(P1'J.
MH5+"=6FT,%HFQ6C8I$'PIN_;[(2:_E! JR+K!J*()WR]G;EY%W@[D$;X(KB<
M%)$N*!)2&>HN/)=<,*]<E1'DVY.Z&1!_O+N2RDIK ):GUS=^."T&^RQ_F(PO
M/PR_W+6;NYC\ DL!()MY(*3BP*DG$$N+;2XHL<HG$K-33G((BE<9V;8QA9N!
M\,>[[JBCH@:PM^3A+&^QR@8Q66DH!V*B0JL//I3Z.$54!!X"%=%ME)2]?2_T
M[6G=#(\_SB7&H=364'_^!:<#<%I8STO.<ADFF +&6-QKDDU0F@9PCM;IO[]X
M_68P^O&N'G80[I^K4>G);#Z\+H!]C^:]3.N%IVU>_;HVKX=L:KH7@3TV0.U.
ML(=HEBHB#UKZ3+@RJJ0B&N(@6\)XYL 8-U!G\FM3S5*S *I"23<"=%\D5YH$
MQARABC*-&.9!57$N_T3-4K?!T=[-4K?15P.>YFNM&;50WEI%"7>E&DFP0%R2
M*#.J WZ7<WY^S/W_-TO=$00;-DO=1B.- NMI,T=(H .WFAAA+9$V<N(3>KZ<
M<Z=!0'9PJ$SJ'Z%9ZE;ZW[I9ZC;*:+U9*@63A):).&4=D2Q%$BC/),A@;?::
M">#?<0G_#,U2MU+I-LU2MY%OFY;H(4[CDGL #+\ICZS<$G)<54D0K8SVC@L1
M:)4<E;W+.=KIN-KQ9K>;;AK"V2,?].7$DL78QN_/+#F^G19=+3_Y,#]O-A E
M52=Q1@Q3JK1.,27EL.1C^YRHT,G)JDWL:S+7G$'=$8K?3\KO%Q=_LK5R.OZ"
MGY],OPVH-Q"D]\3(<O$)97PY,-P E=6,98A25NGZ5(6;ADM46ED-NVG^3P;_
M)R;ATQ1N_#"MLC[OA@"O#I0]#4ZEI DK-6Q2V(0.80C$1NT#,TFF6-77.2BW
M#=?)M+)\ZB#G3[:\3A$UX\OA_8<78KFX\N-?)Y/TQW T&F#L30.DC!:GI&M9
M*TG05I!2%*J%MR+9*N,##\IEPU4^K2RG;I'R)UM&*UOS^!>KZ>"?_+=%&,FE
M"IXE($J7YB0^9V*-#41JE27+/-B06U]&W^6RX1*G5I91MTCI/V7BE0K73>2S
M]CH6I3&]A;N->C8HV4M9</1U46=$\M+!DLJ(?T2;DA/&AV<7A)N6*7=%8L,5
M5[N OB6%]@_O&B;@(\P'I2NJU9")86XQJ]<2YT/9*QESB<O ;?.Q//+1<)%8
M*P9_6VWO[AE-YG[4"=CO/;H<N)-0.@=KES$P\AR7:5 D196\5RR&C1J(;8W2
MK=SR?NJ_]H'73O+]<3WF.W9?71XB4Z]2N6(S9;(9X%>N3+72@H,6*:/CT]*I
M__?X:;@*K >CV*GV&S".[X?CX1P6N?C/0N+?9Y!O1Q^&&0:,9DJU#D2QQ0!K
M)8GCRI <&&0/-AE>!=&;$-=R\=@^^.Q<,2UG'7\^.;_X_/OQ!7[ZXZ^G'R].
M?OU\5#)ECSZ^.S_Y=+3\YOCL_.)\AXSA+1[>6;;OK@QUE*E;^GM.;^/\=CH<
M7Z*I^@RC$D <Q?GPR])@W:5;HL=&=0J)((H$AN>2+N<P)H5A.V((OZ[2)&YC
M"O<U<-]]T<.@E N4_B_X;_\Y\([R(-&O-8HZ4C)EB-<."&/HX<32;UOP7J2R
MAMA^+^+K(.VY,:RNQ#^'<?SHIZ50Z0OL7EZQQ\MZ,)YO,WQP8QJ8"XDR2D0L
M'5:T#<0;*0A+'@-F&@4S59)D#V9,']+-7GGE\60VGRTSS;P!89)GQ%M3YD9E
M2H+3$9=?Q$A0:<Y8E6A["QI_%-.Y#:Y>KXGH5F4-!/!/&"IL+)B:P?3+<DB+
M,[C+Z!Q(T)X2Z03@5^@L1VXE%Y):Z>K[-B_I:J4\HF,\O+5E[ZF<!K!V@9][
M)K*[H63%<TFZK$9*2^:V))YJ3Y0RD@D(+)@J=NY5BAJR:OOJ?5)#"3U71#Q?
M=AC=P^6ROGRQ]%9Y^UZX+)C,A"99\O9CD1/-I:\0YYY%SI_74ZZ]*=SL;?U"
MIB.U3JK*N.\Z&D!9OF  E F9.4M2+L4=22OBF4-3D3-8X[*3=I->BFL?WF]*
M:_>8V%^"#6Q#;UC7AV/''!QR%!WQ>5%"&Q4)@ED2N,8-/;ED4I52[$V(:Z5<
MIC?G9S<UM0:]%3/(@^=!1D.X]0DM:,XD!)4)DN@\Z*B#JY).N8Z89OV>'57^
M%J9VD7]K&'JZZD['L>22+;X>4*LX$URB5?:V;,RVL!5(,BBM[&.VIKX%>YV^
M?HW889'6D98: -_=5=W)U^%\8>?9@ DCM"I0*.U^I(J,..F 9$@>I/*"/V]T
MV>U5_0,I_59 5(?4GK)O #WG\ 6F?AQA1;Z25"2O.'%:HWO (WX%)A$>:-8"
MLA6^RA71,SKZ3?6OCIM]I-X :.Z&E+V?3)^(:L"0B1Q!$_ ZH^ET"?F(FACG
MI>="JOR\Y7.WP^*>$]1OJGMU&'6BAP;PM*A2>2&MV8!;8,E@ .M#Z9BI,( -
M.1GB;(Y!0C8V5H'3*_3TFT->'4U=:*$!,#WEX,I/+V$VT)GR*(TA+*<R)$))
M$IB@Q*/=Y<PK4%"EL&<=,?VF8Q_6S=Y%_@U@Z!Q&^*O+7V&,VW1)BCQ*U\/Q
ML-Q;EFOYNX$V('/(0@$)-'$BK0OXE7.DY&%(&2EG=5"U&7G]YF4?P(?J7$<M
MI\N\/SK]_/>C#[^?_'9R=/[[Y_O^FN]//QY]/#X]^G#ZL:27+'Z\0X+,5H_O
M+"5F=Z8Z2H*Y[T'ZD&GUD)^@G98:@S9BO,6-+RJ*&Q]-)"B :!R:LU2E[>5;
M1.V=&+WFV0^Y99!LQFB#D\R!%S,M2' ^$(C*9@\J.%[ETO=-JOH] .T,(2\R
MH3O3Q)_%;%TL.S#5-5X7C]H\'=J$K6/P$(:,)69$H&99[B]3V0,A1D)I]L(Y
M_*&I<JA3TY ]W'D][R/]I(3E-_#EM>FLE,'<3HLS\HN?#9>780_++0CODE46
M ^;2V!)XZ8H@,JYF;9+A/-HZ3>0[Y:)A0[D- E]/]3NTIEN(1.Z9_PCSTFMJ
M-B]'/G^#A&'5.6H7%B= *)OAV(_CT(\^P70QK[J,I1ZGAQ]/5F4\Y95W?1,?
MQ&+0/08M@"A;)M5YH,0E'8@#KT/,/L94I=?R@?CK]VKK $NC'70TL&CNY;V!
M>?A]/ DE*BT,GXYO;N>E7!)E,AHN!7$O@\A\\<D4H<)I(I50&+7F3(3D40;0
M'!59=1/MD)E^K^6J+8?>]=X2]I=[Y!KV<=U_G(RG;VV2D!08J8!X5Y+1(H8@
M/FI-4G(I"IF$];HJUO<@OM^KP_K8/I1>_RQ1Y5)>?JVOZ.?W8IV,_5,#L7NQ
MV2&IZR6.[52D!SG)D]XD214Q)95,*I-*I9$FU$9MO8E:/DQZ^U$"X&V#H5?-
MPT!0&K+WD4183%!/)?78.:*T,3PYXSFM>\ZY+P<-![[;(.\[)O] &F[)A_GE
MVXK-$L:\G\)_WL(X?EL4W*B8?$X8O4<G(Y&281P?E2<\,*9=2#SJ*BFZ&]#6
M"!P/BYK7L-N1"EM"Y3J&5E4<)F4J0K;$V]*D./M,G':<6!!*1&6RU56.43:@
MK1%4=H6'U_#6D7(:Q=OL?MFN"GVB9,;2E(GV"GG20I/ 468NHN2,-I31NC=V
M;Q#7".*Z0L0&B-M+/2U![I=O]U_^;0A3).KJVP?X J/E&+"(VP+CC"1!<6-P
MB! ;J23HS("./%"9JMR6;$9>(V>]K6R_72FR)7@^7G(O^5LM;DEU3LD(DF5@
MN)UX()[I2(P"973F7M2YT]N*RD9L9(<PV<1,=J*SE@"Y.$&>+23&[DR_ I]4
M$9H+0&10N,NHG A-)C%-<?W:NO<%+VEJ!&S=(^$US.VIED81QE>L..HYLU(0
MY*E,1 F*.&I3*2+![2&&H.J,FGJ#ID;VWEX0MHM:&D68N&=%E4F:E(A@2AL!
M]%P]MY9D'5*R#&B,=0]97M+4R-5E+PC;12T-(.P=3(=?%DG9I^.2%%Z$]GDX
M^^?"MQ I!@,Y$FT8)])'7"VJS/ $P3DXKSFMTESN+:(:P5BO$41G2FL*@,>3
M\>)<OO1A62U2#/I%MLP3JGWIEN/+Z%@))*4 E+/( E2Q<6\1U:^CUIWJ7\74
MGGIH %/+$4'QV_D?_F9EEEF0TBC*B7.>+R<1>XN2 DV-T%IR+JLTYGM)2BOX
MV5?-DTYEOC-JOL T3+IRMR93&%Z.3[[&*S^^O)?0BAT=K3>^^ E1!=S9O27.
M@B=*!)^#5-Q!G>/<MZCJUZFOAJ;N--& .5IGLV>_HH@^3&:S7[Z5C-!%?YW1
M0F^SJ^'-PII'KZQG2>"BX>4 W GB1 1BN0H^<71?0Y7[JMW(;22UJSF_K&-%
M-P#G-6RL5GQ,0B,CZ'6P$''%*^1!!"!*TFPB5Y;7Z4OZ*D6M[+7UX#"IH9L&
M0/8B9_[AWHZS1)-R$CG)9:BC-21HY0CN+=[&TEO1AAHH>YVD?F'6D<XG5130
M )16Q+^#&7H42ZV49285R,QI(M'_?^R]:7=3R9(V^HOBW)R'CT!!-;THJ N<
M[G4_>>40"7K;2+1D5Q7OK[^1\H QLKVWM%,[5>><7NVRP2AC>#(R(C,&LO$J
M)MIFGB?(6F51M$26FD0$N\F9MQM.'\?G!(KJ$F[7N]%)VH]*%@(&:E"JSD<G
MAQ50A9AXB"+()HFN#Q'4A=4Z2-E/XF</R7> H!L&,#_;7//TW8&XML$Z(0DC
M;5D2-;ABX%6==IPT^F05&?PFKM8 VGK#U3X@^,FQGU8C'8",['>^Y>J:A:RC
M*\QI,+8.CY/U_34R.MAE+"IH\B6P20_4';3,>Z_1!$2'2GQ&T&S6%V=OR!GX
M=-7,/&RN!BL$PWW:-NR1=;X6*[R.NZJI*,FQ1($*BT-<*/KT.UBAG^[C9/?R
M\[9\F]=EFD A7<'ISK5A#MZ+P"V$4)_H16UN5WR&Z"Q/3@:,:<BUUQZ@FON-
M9PJE/HB//24\\PP*VF$8EA?__/"A;ISMWOK.UK4-M20&*3D#FV(MWPP!(D8'
M3E&<2FZCU/<;(^V<2#%@J5Y@L:\N5^T$VX%'\YW^VEWA<K/=/!A+5$S2QH^"
M#NP4M_G=C#:/=\)$[7*;-H"[B)FWN60?,?[!2NH0:#?O786AM<Q"=B0,Y2@*
M<"Y'8#IY5C!:SIMDR^PF9]XH[' U/X&;/63> 7(^X,7%.:UZW])R,M:E8 %K
M:J\ZZR6XI!P@9F^TU<J8)H'7 _3TA9U]5/U3/]+#Y3ZSOWS;,>A77'U:AZ^?
M%RE<50!DS()EBD2ELK4!$!W8H1[3(GF3O"<FRI C;I##_" 5\S:TG3\8FT8]
M<V,,/]UGX7;S%2%\*8":8W4S!44CS !F9S7W1A@^I&!B&,8>HF(^]WLB[:ZF
M%O6<>+GXNCY[^Y]G*(3(+%N((I)9EAC!"Q*%9T1^*(9KLZ-_Y>8&&AM,__BT
M^N/_J1]']'&W_0[J=W=A<;78C "81EVK_677@?<RA95]<]M?7";IB7T.Q4J*
M7+-3X(3T->N!H; ^&]ZV0F8*+@8ATO\]C[WY8='!GKCB>4>;F=LN,Z$DZQF/
MD()F5TU-G44%B1ECHE$JR"8-?I^DK).*P^.C9M52A1U@\D78?"9QU?^\_-_+
MQ1_A_(=*J.\,GG'&$BLY@\.L:X8V)^]%N]HC/5BT.JK<I+YB,(7S8G1B9-S/
MF&^BIAY&C2]2G=TXF#UCN$O%D^A<W;Q,%7!T'@$=/,R'@B[*I]KZ[;GTO*_,
M;>!U#"UT8.2^)]=>B?',<%.XQ]HEAJO:Q9/7>34)#"<I,D9N3&R4$?,C(?,6
M*+8U60<)O0/0W'$Q'A-1K0"F?VQ <49<L?KF%32YQ):A]9X9J1L]&@TAKY,Z
M_MG]M@;*G/GPO!E9^RR1J;YJ^EXKGTALI!CZ;K,@W6XUO<N HU8270D0?&T$
M7[BN]PH*I.:)>ZLHM!,#CM&#B)C[Y6!Z1*SF4$\'IO*[J;\CU3/G/<\>.6A>
M*XR3(D^TEA5P%45@.69,3=K1[J1F7D/8$&S3Z6!F@_8?BT^?S[^]6=!^R=^K
M23:_A3IZ\.+;[\3?*I]):6VV!H'582_;.F'G*;QAV9,;8:3GH@PP7(,6._WV
M$8<=GFVTTH&]NO-JO'WLK2P]^[*ZI*]_!E)K_KC:#M']/:POOE%$+9B-F8&+
MU6^-P9,3[#QD](EQ&7+F38I_1E%Y^B6U4SEZK50[8=>!F2<IO%BO-IMTIP?#
MYFU87TU;/<ZPA $$S#(/8:Q@CC'R("?.,N<2F%>U,88K$$HD8^&U+4H)QTK;
M[I==CSSPTFA>K $,F@X>X0M$)C/XXJWE=:ZY;))']Z\P\F ,\MJ-/!BCX0Y<
MBSWK^(O222N5H#(+RF:2-2_$M"Y6UYGK7C;Q,1KV[^CZ-7 /;$W3OV.,HCN
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M2>1^,.6GWX9X:E@? P+C,>^O,+_$3Y66CS-#O_)\5KS4WOD$H@0&RA'74<D
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MJNW FM=GD=?+S<7Z<AN0WC!T9J1*Q7D#.CH*1:U()"NI(&.V&%R013=)XGJ
MGM./H*;!XA3JZOF!]O7;_WKY]N.[]Z]??MCCE?3NOY[LJ?)!DB9Z+WR]_(.(
M6ZV_?3<BMX\V)B7O#4%%!$-0<:) *,6 (']1^\)#Y$UZ-#U"TZ$&9\='?R1)
M/J??^9\SX75(ABD@E]>2*^RVO2T\H/4LHU4D@28WB(\1->\Q.!4Z[AN2R=1P
M(M9DZ^#NDWGQ\V>TL"R[R#N"?='966T=)_7F;=YYIFC61\BB*.3!(K;I6M_0
MOGQ(GS%?GN.[<KO(=>^FK8R_@]Q:'D4Q#A36BW#'+00A+<@B,V(A^$??@O>A
M!/9K=\:@YK[=::*>$[%!+U9?OJZ6]8YI=<L].9#[9X4-_^P6-FL,.T>P99(5
M-*S> ?O:+E<3=$+& (DIK8-FC,<FTZV.X2N]#W_^%@BLBW"^.9-UB*OV"%J%
MVH:KV*L&8,P$KGA6GAG7E-&[U/1KI<;@X4'O:&_!=Q#:WS+QWZOU_[Q>_KY>
M)=QLSF+,D>7 0;O:Q0VU!J^V3304=UQJY*S)4^EN<N8-[)OC9W_1]P2@5XOE
M8D/G]J^K5=Z<L>VYS 0%&WI;O",A:D$!2,@%M31DYMLZC3^0,^_=>W, [2_Z
MG@#TZWI%\+=$H?:)?#A9JUQ=)#ZR5( "F5>>HDK=UO)LR9BW571SP(P7]?Y
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M>>$RI2NTOS![0, U<,F8!6^*@BRS \4$TGXP'I2Q47(?=;)#+J6&8V#.T^4
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M;,Q[JS 5 N_;N!E5W7,KA"?-S/9V>)^<Q:&??#R+N8N5(]A-Y;WU*=3T#,5
M):4@NJ1!J(PFZ.)U:))LU]!N?G]$^'D?;:7\?:,X826%NP588AG(O3#@I+<D
M NU5LB5FWB0K>SB)_=J[,<AY.-=P4A6=M"W[</GE2UA_6]V()%R;_&OK?M?R
M[YVJW8"(XUG( P5T!&.*A-.L*585,M<,):; &Q$AR)11\NA\;G+AU,"8U@#]
M#7ZB3\*+B_-MME_M.+Z^NDHLB)LS%KA,B;P,:9#5C P#,<8"A?%HHZCSVLT3
M>'QZE7[MWQAEW[WVF%"J,Z>X7._#ZY2,]QB)B>O->.9MBA26"]"U9$?5='3O
M"@/NL2AE$A?WD_AW@N.1)>9](FJ!C*GDV1DL+B[7RQLV2N(IQ]K[33D#BA4.
M=, ;8.A+-*D4$X=T#GUDB7D?<XX!BWWEV<$5Z3:M%S<7UV*Z!7<(,2BM(1E#
M7.@D2"@.03-'PBE*$"\MSLW=Y,S[*#,U@B84?0< NMX++\G777U#?(Y++(N+
MS0TWM<MC2=)1L& #<6-(-H9;\"%GCL)'5*(%D!XG:]XGFU: FE 5_0#K:F;5
MQ_ 7?F?$J82<27#%%CIY"0">MDQ]P. E^!0Q-+E9?I"B>9]W&L/I0 5T@*1M
M3/KSM<8--S(%JTQ1M"_B=LJ A! E Z<*RR8()T.3S,W'R9JW(44K3$VHB@Z
M]3 CI4B!6,?09R- E1(@)'(*HW.H9"RU&KBAB=H33LWZ2C0V40<JH.<&$J]>
MOWWV]L7KM[\^>__^V=M?7_[V\NW'?9ZB=W_.9%>% \B<Z+;O%XP7N^KLN;/(
MO ;CLZU3/B1%X\R#U+7E+9U)LLVKR6YR#IZ&^L.G?K]Z]SX(%3,'S9TG5*L"
M,;@ F$1![65.O(E9>8">F2=!'HZ$GZ:/3B#WGI\\=F[3O9]L'_NTMI:EX=/L
M ZA*EE'@G3PDI>B4LA0\.943:*&U) @XK9NT/&UC7[Z_]M7/O_>^AS((+E2&
M*(0$%>K%IK 66*B)R1)%+DV2Y1XCJDM+,P83#[^W'JB!#MS@[[S\%BXNUUL_
M[&HB8!W%M8,_9C/R:!)85V<E57-*3IX!%JVR,6D?8Y-6K&,)G?=!HRGJ&FCJ
MY Z^V^?K%ZOE9G6^R-N2"!+&Q;4P]G_6/VR]MH?G?FRW/5XE9LU*9& L*Z"2
M8^ +6HA,R,A2*$(TZ>'3SGU_O:3/NMP.C[LJF,YDQS4F*%%S4-$ZB,9&X,PK
M%]"ZR)M,J=E!2Y>'Z1@$['+;#Y%W!V?H"UIR<?$JI'J/\6W;MLEJ(YE)DLS[
M=FAN#! L5U"DX]I%Y4MJ\G3R,RGS ^8@[:XF%75W8+ENY9$#$XBH@3P"XL$)
M#E&K6JIC$VT>IJ5KXK;O(F9>P!RJX$?QLH>T.T#,>_QC=?['8OGI1V:NF[4$
MX5 I[D&FH$")D&JC701E7 R9=I?^/@Y^VHF>CU#5$X;V4?I/<SNGTD '<+KK
M+7ZD?W/59M!D0]LL@<3:Z =C@> \V>2<@ZHO.%XU2=W>1<S\D=N4)];!XNX0
M,C<-J'@V!J4%YK@%I70"K\@P<Q&MD3:%J)HX_KO)F=?F'*[F)W"SA\P[0,X'
M3)>U10<Q<6TM:2MAH",;DC2>3G/Z$K75$$3RO!BC;)MGD)\HZ0LO^ZCWIW:O
MA\BZ [#\<[GYB0558DB(I$[K#8669'5=D:4VV##9,\.2;!)Z[Z!EWG.I 6 .
ME7<'D/GQM-X:7:Z*4L60"!QWY(XA@M>9 \HH);/>F399BS^3,F_R]-2.S(&B
M[@XL;\.7FTW$#)W-4@9(-M?[*R,@Z(B02K)")^UE:9: L(N@GNYLQBOZ4=SL
M*?69BS >" !_N<3_O%PB:5=>F\\810[>>: HL';B<0G(G JRH:A"LLB,OW>1
ML[,B8^AZ/0%E7\VN&HMY9NC4Q[DWJ[!\_C,W^IH;)G)Q0=B:+ZG(*J< 3L<,
M=!*'[*SPRK !H'EZI9XBZPG@,K%H]P;*'[B.JT90>;OZ8\O)'9Z\U=RI.I8F
MUI:LF!AQ1R>YBEPDKC72*;\G7'Y>K2<?IA%D#A3QW,,1<+E8K:]CO[>K"]R8
M?VCV.ZX328RX^XTH^TRLB9O;2J6]24D",CK E0H6O.$>M+ EJ<R92T.,S<AE
MYZT"FQQ&+87>'9[L/]@.UM0U:X4IX=!;R%FZ^CI#6\4)#24CHK,4;BBY%YX>
M77;>(K CX&DZH?>$)TV[9,O>;K,K8E"FWEYDK@-MDV@AQE! ALR*]N3=W:_F
M>1I+CR\Y;_576QQ-*.R^,&3U#5O/+C]=;BZ(*7L3&&2+0:,$H6JO+E%H8XC:
MWY#.[&P-"H]#AL,,7G#>2J_6^)E(T+,[UE=L;7G1FMVQIS?Q)#?1%DO^7N0E
MU(ORVA')D[P81R&*]'I0?XVGUIFWD*L16B82:U<@<59OV?EVAQE9LDG<1HH$
MZC10OYV@+:KEE-RA2);G(0UZGEAF$$3\24+D4*'VA!!UC?>[O+!H,YV;$EA&
M<O)-)B=?B00YR<BL*'3$#KG[>WR583=^[!0!<JA,>\*'X:*"_=G7]>+\CL^E
M;,C:. ].VP0JVP!!UH*T'(1D(18Q(OA^9*%A*#F=B^%I)=N%-[MEQK,*^5\P
MW7?.I4K!J!K;15LS1U@"AS$#1LN#T\B<'PF4AY8:!I73N12>6KH=@>4'X)O;
M!_N4#'<9;!9T@J)""$DQX(S.5B&X,WGDJ;-SG6$P.9V+X$GEVM/)X[:GZ'^&
MY658?[L3L%%8AKD.?4!ML$Z+U.!<\*!3H7WB.$]IR*O!TRL-0\JIW?5.)MM^
M[(EE/W+C;BX72R+CF!CH+3?62'"2![#T%U9)+?F@-^RG5QJ&E%.[Q9U,MOT@
M13_ C69<*4;N.,O%D-/E&3AN16VM8+VP.8VY^W]LI6%(.;5[VLEDVP]2S/8L
M?85Q?<V.OWD!0T8.>ITY6Y@B$\DHD$-4X#EYZ"JC=G;(?.8!2PW#RJG=R4XG
MW7[ 8L7W"Z$;3J1F0@03013+ZT!042^$.!0LPC,98M)QY.'S\RK#('*2%[&'
MRK0?=.@M)[>&4;)K;HPJL920(<941QAPA%C?/BUA0!H9,9BQA\[NE8:AY#3O
M8B>0[<Q(N1K@<Z?[Q34+CF20@ZR=FTL-\+T$8HE!3D9*)U.Q0@R QP,?/RR#
M[G2N7Z>08G>9W6]NIY<['4@"AH&B$Q"4RP&<K3/O0L@EFJ*)D_:)W;?T])0%
M-75!P'Y"G_7F9#<C-ZV]WX<+_'!1^ZM<Y^&$3WB6L.AL% 5LB+:6QQ!O4B>0
MQA=A%,/0IM_L<!)[2@G?$Q./XFPR]70(O1=AO?ZV6'YZ]J7.KSLK'-')@&!8
M;24FHB*CKB*=QBQFZ1*SY0B53#\2U5,*>0MX':""#L[!NR?Y&>/$-2\"+-_.
M^HKD$W 4D%31]7_([]_X3E>>?4-$3^GCT\!E;Q%/UJEX&GC<-%O6QNH@44(@
MPTG!H:@/IZ17$0,6)41.KHF1V4%+3^[1]&#91^!=G%%WF7B[6J9K/B+*(KTQ
M()02=6)A@&@M SJ"K=;<9!6;M0SYF9R>$L*GQ\Z>8I\0/L?JZ_AB]0<N YW#
MJR]?SQ=AF7#B1HX/+]"V<^- QMJV:D1C40E'D&&9SBNF$D2*\,@_CA5..<3[
MER.GUJJ1%X_:\SK4I-2"/]IL,>H"UD<A+>,<59-V6*?2JG$, H:T:APC[PX<
MY!WMY83--IL4P ?IR<67Q O3"HP,S&NC=6K3OO046C6.TN[3K1K'B+H[L%S?
MM$9,+'*N(=CJ\D=;N:$?B72AH[$FRB-T]NRA3\2A"A[2JG&,M+MXNKJNG=G9
M*%"4S(R+$IS .B'),XC"</"9*\$P16^'5Q \LE!/L-A'CP\5)!TLU YLRN.M
M)(U+,FDRM<AJM7G)DIQ[+H%K"A8%6=X@FTS'.[R99[,KO\G@-+T&.H#30X%G
M9NB#]04TJY<,VC%PR3C@P>K@=2GL_B/Y_ ]?1VWI>8AG,X709SZL[EUZ7\>F
M5Y?>S_Z@L+0*Z=5J_1[I=Q:IOK*$;]L!ZV>RR.*4\J!M2!1!.$<R% F",-(S
M;[(;E*&S/P4]N<E[*G]U=$UTB;?O=R'7)_P;_ /7X1.^K^JL<P!5*G2T%U%?
M\Z+7X+VV8$S)/FN?@BE[(^WQM7LR6*TP-J'T3V]\S(-^Y0(W4X^.&;)6X[$Q
MH]EM>P]9+'II78:4ZB6VL19(A &L<$4+)K,534;4'^\>,M46&MQ*<BAJB5F@
MC>.<3*"=,X:8MJDT\>1/Y1YR# *&W$..D7<'?ON.NY-LM7 NU=$YGB(/:0U$
M9BF:U9RD8YBVILG-]2G<0X[2[M/WD&-$W1U8KD-@<O*TX5D#+[+.L]"1G#]9
M&\P7H14=THXW,:$G<0\Y2L%#[B''2+L#Q#Q^QR%*T,DQ5L>4D.V-68''[$"3
M!YE*5LG>+R[OY9;IN)>6HY0^ZI9IC 8Z@-,;O* />U>N>+GA00:3@B:B/6TO
M5:]1/)$'C&%4M1HVA2:YU;N(Z?"*\A#P'"SO#C"SHXMX*!78-81,KMZM*K+/
M.2EPVOO:<@%+:3(Z=L_._$>]CSS$PSE0U-V!Y4Y=BY I>FT2H-'UHI\1"Q$9
MH,I..LVX\$<(HSKNS#]*T4,[\X^1>K>OK@O<7%M.BU;)S Q0;%E L3H&QR<-
M3,JHBD:6U?":TD>7Z@D>^^IST.OK?L(]E2D.N<Z[L#8"F5[B*:<:.>0 IB2A
MZ-R6Z(;TH9UTBL/Q.S#MBYHF8NY_B@,GV<02,]A0-X)P%H*T#M"RE$,B%M60
MMBD337$X?B>F?>$RL6AG[\4T<,2 )'QSGB,DGVI"N#9T9B<.+CFEBHS9:[\G
M7/9L<WW\EDQ30N9 $7?@!/]76"]J+% K&[>^7;%>(K<!4O(,E'6E/O<E.E]]
MR3I$H7235,/[A/1D< Z/E@X2<V<PN=Y'R3M+6X;XQVQ .54;."@.Y(=9[IE.
M,C9)8?Z9E'D=X,-4^PA.]I!S!TAYA23N</[J<IDW+TO!=+'X S_\&;Y6EF[:
M3)F$,@4!H81:3B0=>!,D\,!+T"%ET>9.9@!M_6!I'_6OVNJB WB]O%RO\NK\
M/*QONE#E:'TH&D*N34BXS^ 9-Q"-8H)K+971+;!TGY!YXZF)@7.0E&>.FEZ$
M9<CA>5C^#WW<LY3PZT5--[H#^9)X08KU@&%MV^P5'>0A(>2$3FAM??1#4KR>
M7&A>%V8B2$POT@ZLR/.PN4N]<M&[)"1$%<EG3\[425D6K%6V6.F\BDTN?'\D
M8]YX:6(+<H"$9[8?-Y2_6_^^7GRYRX0-FGD1'9AH$91*'AQS@6RBCSE[;]C]
M(<\[[<:#"\Q;3CZAO9A&A#/B8+.^.'L?EI^N'/JD<^8Q!%",77=:CC(P\%JY
MX)%%\I(&F ?ZT#NF@7ZZ;Q9^6+6GVY/]X]_]!=F#]F\>P2TCCI6'P$.LB3V6
MG!]9)PIEAN3X9&-P4OW/&8H<H+'[.M]#?#-K_;?%<O'E\LN-L<J%9:\Y&2M!
MYH^L%00C/22530R&&36H2\T@O?^P\LR:WT=OJRF$.+?VPU]W"(_.1A,$ LJ*
M_Z@%.2^V0#'&V.2-X&R(4SA,^W=7GB>2G$S[>PNQ@[B@MK^YN&Y_\Y'^S=8&
M*DF.3Q("I(X4V]0)J"09 5XQJ\F?-8DUN>C<14Q/'8<.OQ4_6-P=0N;:=<[6
M9I\IPLG*U8"X9N*1<PLL>N$,%JYRDY!R-SGSWFH>KN8G<+.'S#M SG6*RYT&
MR)P76Q@6T%SIVJ6-K&6B>"OE$+.P64O7)+OU)TKZPLL^ZEU-*>L.P/+/Y>8G
M%H(0LOCB@&?-R/2B!.>1CFC!HF).A=3FVFH'+?/>?C< S*'R[@ R#Q7TRJR$
M$_55DG .BF<.H39PEZ9VY<XIDK_>/KWUS:@V#4>:LC-U6O1^0N\ .Y7PFU*
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M(@:*-94)><C\D:=7ZJD6=C+$3";:+@S-EAOMK"9V?@O?[LS<T38)@GD&+W0
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M?Y&V 8(HS'(2G#3WW\&F@=!#!/7TZC$-A"81_8FFJ_YXR]HD877W$L=(61W
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MH)D"(P>+M2N0/'!B"DQ:*JT 53 4$#H/,7$/')VTTK&0]%A+<H S<OPRF2F
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MJEZIC"">J4Q\P#4X+93E![!HACG[9Y^S:4]6#PXLOS1%#)0[G0EUGA-9DM!
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M:?'O<'V3/HZ_CQ<7DY/)!)VO]_BTQ4AF[EQI&&*I+K-#F"+.IC+L*^*1Z+P
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M\@]S>D8@K+5E>P< 3J36C(!"7GHNM?+::\,K)Q-WN)KC3BQN@>KMB<5]86,
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MD)D-PA!M?$F:I[Y4_U!B(6F:F,'E5:F%>Y&J?L_HSF3?#%,["&( J"HI9$C
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MU$DG*P(ZW5DC&,PR4(U'7$*,:%&ZD^LJP;0Z"JYT)EHG=Y2N[R^,>WF2^<,
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M!?42M&8R9BE#PF/3!")ECFB#V41R:9JEO)+I:0NSWR=HS5+,R23<H$;%4K#
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MTXH?)M#8MF=7-<^\"@K:M.YJ(Y+ZV2OK7Y0O'N;I_____A]02P,$%     @
M#XEC49H7T&6*"   YB8  !0   !E>&AI8FET,S$Q<3,R,#(P+FAT;>5:;5/C
M.!+^?K]"FZF;@:J\.0G#$!BJ0O 4;,T""^%F]].58LNQ#MOR2G9"[M??(\DF
M[TR890]V9JKPQ%)+:G4_W?W(]M%/IY?]P>]7+@FS.")7MR>?S_ND4FLTOK3[
MC<;IX)2<#7[Y3#KUID,&DB:*9UPD-&HTW(L*J819EG8;C<ED4I^TZT*.&H/K
MAIZJTXB$4*SN9W[E^$BWX,JH?_R/HY]J-7(JO#QF248\R6C&?)(KGHS(%Y^I
M.U*K%5)]D4XE'X49:35;3?)%R#L^IK8_XUG$CLMYCAKV_JAA%CD:"G]Z?.3S
M,>'^QPIO'1QT'!8$K<X^[00'P0?:.6C[K59[G[ZGPP[[MP,E&Q"W8U0VC=C'
M2LR36LCT^MWV^S0[G' _"[M.L_G/RJ(<E2.(#D66B1C]$"V:,I&:>\@'(LF@
ME\0Z]J==;F71C-UG-1KQ4=(U6R^&EMV>B(3LOFF:?X>ZIQ;0F$?3[KL!CYDB
M%VQ"KD5,DW=5!7?5%),\L(**_Y=9]<SMQ&YM'_-$/&'E5IV6WI]['_(ASTC;
MJ3N+&J_7U8,3F'PA9?ON]>#\TWF_-SB_O""7G\C@S"7]LW/W$W%_<_NW@_-_
MN6B&A'O]ZC=S=7M]<]N[&)#!);F^_>P2ITUK3F>'[KYZU7LWI'=Z>35P3\G<
M+C:JO10W+:SQ6G9RX_8UEMZ^<=XW#]O-5@FJF][U2>_"O:E=_O;9_9WT^@/T
M6*E6L]GZQJW^)U<9#Z9_^5X[:_=Z7B4_(U6G(>G7R15-:95X3&J%2!;2[.V;
MO0^'3]E82GT?R;P6L:!(G*M;M4T\\>'D;DT+O=#FG;KUWNKUG(1TS(AD8\XF
MJ%!9R!7Y(Z<2J(RF:$^%S(A(R"<A8SO$:=9^)2(@)S177DC.&(TR6%7$*4TX
M4\6\B5<G.UG(RL4^M%K-0RLT-7?.X2Z,?O#]&KVUT>@G5,'4,&H\)7>)F$3,
M'[&JM7UA<5] D42 .F =RA,"LY$\R63.L ^0"<,KX 5*8MQ)3B,24 ]-DH@8
M)2T35FY%(&$>4XK*J1:)Z1W#NG-S*K3Y4 9+1H:48 TMX'$)$@*Q!,.AB<\D
MF80< %"YOLS&3YADQ21Z S%7$=B*)CX3#J!(IE+F&07UO"E4$SZV.<8PGPRG
MQ@S63M86WS=*VD]'"2,!3^ '[=*9W:N ",31+>?Z>1(@<*FFL_CM1;F/.>';
M.:Q5@0NN@SV%:S2J--JB: :;PF-J:6D@TS<\N:HE\@@"P(J 0\URRNCC4162
M(!(350*IR &$ZA:K-%2LSH%!E9K,5/UQ\-#9B(?!S'CO5.'HHH3IX!)!P'%K
M#'I.J&3&;_ #'T9,FY@P@&48<15J<2T6(['HY*+O?:Z\2*@<XW3*D2*R#DRE
M\)B/9D5V:.$'GP$%UCGNO1?29,1(#R%]G4=E_C=T;F^'[>I)BJ8]WS:9-@P&
MO!*+([T<T1E@#E[6V5JU;U@W6%TWP+K:"@L8+&5T$?QS%&!_/=MY-;BB&W%U
MRA04AEE-(O\Z#JJZQG@H_ML/T<E^R(A?KF3+A\@E)D#,C[DR:012+#'S:$HV
M2T#S24RRB!I4%/6C<&6UR&ZZAR,301$E(NZ;8[?*AXK[G$JNM>>VQ)F<FNAI
M<J7+C@DH96J423H@B] &!VXS* 4CXEX>49THL2>CP:Q\880MAO,U'+^&#(+6
MS,AIF(3Y?RY]O7:8#;>$V=;1OX*V[?/&UJ #4,?<UPF3*I%0G2^I @XUUT'C
MB$J_]#?@Q^F01SR;ZH*V;ED-?0,-XW"+V@71.:YDTO)]L:$TERE0ITP!]CPA
M?:. 84TCEJ"N1@ ?>EBJ4:U%P CUDBGPZ/'49,'O&5W>1G2Y8QKE)MBUZ5D0
M@+#P,8RFEHF'/GPX^X=JF[1E;Y>XR,.A"$C"0&0=9>G.4.39YN6W2:ST09II
M+A<\PI!++88E2S3!P:P9H(\!@K4-5OEN$>%OSC?6WJM^TX6_( ^F9Q493T@Q
MNDX)S\NE=LU<79@1M5BH#"/T@QY,H3R,+\[7YGP\)QD 40CU):%"1Q!I9LY[
M^BB8Y ]:[%H=0JH>ZJ5.$@:!S#?9TVR]R&Q3G.KN6%0<_I;DJTNJ;VV'9P+;
M:^?F>\_#S<T3%[^$9W46PCJCS,-E%LW:\T\HF8O<Z '7%/PH$U(]E"C3@/GB
MF&<98YLRY5"@ NI.GT,S,\..D 6M 6G2V0__:Y)6XI_]D7-H;T"?)YXY$.[^
MJ R[A].T)B$<**!03)]C/,[@MJ+&/##=":-WNFA8$F#*AJ$OYK%.>;)^$A@*
M7FK/@VN2 /4Q4+&''+ >. 7C@3P  &)2M65+H6:I/(;G8">SDR+'KGT \8.4
MI,T4N(?*$T@$715>829)P*_F(5D!@*K-YCP9BVC,=$I/Z*AXUB>+O,+B-!)3
MAMY)*&PRH0OP AR62]M3DGE]2\_L+;X!W-OP8B,S?+J880CL,%F#*R*:*M8M
M?QPB':81G79Y8@QJ!AV.=09%+2RFQ"K%V\F##W6GW=(O*#.)/[^<OGAW63?O
M+AN9O]K7J;>=_8V]S;JSL>_163OU_=:W3?M87ZON=%K/K^P>;-#9:MJ&,:\U
M,5RE *6/E7:E'%"$9;>5WA-GT?TZ4I?]9W'SZ%OEEPA:\Z;[% &XICR5%GK&
MS;_$[BX0Z_$0X=ZNFH\,'C;Y]>TUB77*4T770N=]92D1S/Q.S.,:4MKB[V1=
M\[T#_MZ^Z:!8FBOY^?+&O3HS[QI[5[U78V_SJ<:S&?NQ.%ZLV<Y>?7_OQ8)[
M\<4O>7*(_T4^^3MAO!]2#AJ7E$>$$W,DT(RO'W(6$/>>>;E^Y$$N[5E'!\3.
ME7TN!7:QTK_[_XJ)AN$2:]C,_$=/J;"??'7MX^4QV_@95('PYFP('2*:\FSS
MD*]_.;7QBY"-WU(55_L%F/D6[?A_4$L#!!0    (  ^)8U'6NU'$DP@   DG
M   4    97AH:6)I=#,Q,G$S,C R,"YH=&WE6FUOVS@2_GZ_@NOBV@3PF_S2
MI$Y:P'4<U$#.R27.]?;3@1:IF!=)U)*2'>^OOX>D9#M^29-M]I)M"T2UR"$Y
MG'EFYJ&DXU].SGNC7R_Z9))&(;FX_GPVZ)%2I5;[VNS5:B>C$_)E](\STJK6
M/3)2--8B%3*F8:W6'Y9(:9*F2:=6F\UFU5FS*M5-;719,U.U:J&4FE=9RDJ?
MCDT+KIRR3W\[_J52(2?2SR(>I\17G*:<D4R+^(9\95S?DDHEE^K)9*[$S20E
MC7JC3KY*=2NFU/6G(@WYIV*>XYJ[/Z[918['DLT_'3,Q)8)]+(GQV#O\T*Y[
M[]G!0>O0;XZ;E+6;!Q\\U@X"VO#_XT')&L3=&)W.0_ZQ%(FX,N%F_4[S?9(>
MS01+)QVO7O][Z;X<53<0'<LTE1'Z(9HWI3*Q]Y /9)Q"+X5UW$^WW,:B*;]+
M*S04-W'';CT?6G3[,I2J\Z9N_QV9GDI (Q'..^]&(N*:#/F,7,J(QN_*&NZJ
M:*Y$X 2U^)T[]>SMS&WM /.$(N;%5KV&V5__;B+&(B5-K]JXK_%V77TX@:L7
M4K;7OQP-3@>][FAP/B3GIV3TI4]Z7P;]4W(Z&':'O4'W#,V0Z%^^^LU<7%]>
M77>'(S(Z)Y?79WWB-6G%:^W1_5>O>O>*=$_.+T;]$[*RBYUJK\5- VN\EIU<
M]7L&2V_?>._K1\UZHP#55??R<W?8OZJ<__NL_ROI]D;H<5*->GUWI#R\U?]F
M.A7!_$_?:VOK7@=E<D&SD%Q5R1>N>,PXC\O$Y\KH1-()3=^^:1\>/65O"64,
M^;P2\B#/G9N[=4T"R\5IIV*$7FC_7M4Y</,Z(!,ZY43QJ> S%*ET(C3Y+:,*
MP SG:$^D2HF,R:E4D1OBU2O_)#(@GVFF_0D,2L-T@D(6)3067.?SQGZ5[*43
M7BQVV&C4CYS0W-YY1_LP^H<?U^B-G4;_3#5,#:-&<W(;RUG(V0TO.]OG%F<2
MBL02[ 'K4!$3F(UD<:HRCGV 3UAJ 2]0$N%."1J2@/IH4D1&J&JI='(; C'W
MN=94S8U(1&\YUEV94Z.-01DL&5I>@C6,@"\4> C$8@R')HPK,IL( $!GYK(<
M/T.$Y9.8#41"AR LAOO,!("BN$ZX;Q4T\R9033)L<XIAC(SGU@S.3LX6/S9*
MFD]'"2>!B.$'X]*EW<N ",31K5;Z11P@<*EAM/CMAQG#G/#M"M;*P(4PP9[
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MHNED IK9&?:DRHD.:)3)A_C?T+8B(OAOF8#V-@"RV+<'Q?V?E7-W<<HVM$0
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M?C2R\W.K_.H^$K.?JWWZ'U!+ P04    "  /B6-1FB%76# &  !)&0  %
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M"V">#CYA*CD2/"H4%64U38( 4 TAX3&!$PFR(,J9EG]W?*!!+RM/L\,%I=)
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MDT/VX\?9/U!+ 0(4 Q0    (  ^)8U'X3\6@6[L$ *<)-0 0
M  "  0    !B:&,M,C R,# Y,S N:'1M4$L! A0#%     @ #XEC46@*!BK=
M'P  #%$! !               ( !B;L$ &)H8RTR,#(P,#DS,"YX<V102P$"
M% ,4    "  /B6-1 <3*B\0P  #/# ( %               @ &4VP0 8FAC
M+3(P,C P.3,P7V-A;"YX;6Q02P$"% ,4    "  /B6-1_T$?\ZFS  !+R0<
M%               @ &*# 4 8FAC+3(P,C P.3,P7V1E9BYX;6Q02P$"% ,4
M    "  /B6-1869&K'IG 0"#4PX %               @ %EP 4 8FAC+3(P
M,C P.3,P7VQA8BYX;6Q02P$"% ,4    "  /B6-1G[]2,VWH  !"<@H %
M            @ $1* < 8FAC+3(P,C P.3,P7W!R92YX;6Q02P$"% ,4
M"  /B6-1FA?098H(  #F)@  %               @ &P$ @ 97AH:6)I=#,Q
M,7$S,C R,"YH=&U02P$"% ,4    "  /B6-1UKM1Q),(   ))P  %
M        @ %L&0@ 97AH:6)I=#,Q,G$S,C R,"YH=&U02P$"% ,4    "  /
MB6-1FB%76# &  !)&0  %               @ $Q(@@ 97AH:6)I=#,R,7$S
M,C R,"YH=&U02P$"% ,4    "  /B6-1L^Z*'3@&  !7&0  %
M    @ &3* @ 97AH:6)I=#,R,G$S,C R,"YH=&U02P4&      H "@", @
&_2X(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
